<SEC-DOCUMENT>0000896262-21-000045.txt : 20210225
<SEC-HEADER>0000896262-21-000045.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225080216
ACCESSION NUMBER:		0000896262-21-000045
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		21676472

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>amed-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:267db984-3247-4ac4-9ea7-650da4f8e37e,g:25daadda-e66f-46f9-96fb-eec4b4d1abf0,d:d92bd70d620044018083957a908405c4--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:amed="http://www.amedisys.com/20201231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amed-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF80LTEtMS0xLTA_c9121a1b-34c9-4d72-bbec-df6b57697705">false</ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF81LTEtMS0xLTY5NzI_4b60d062-05b6-4ea6-bef3-e78771f7e890">true</ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF82LTEtMS0xLTA_0ab6f69d-d930-4a5e-a836-2183c5e06a43">2020</ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF83LTEtMS0xLTA_7fcd3045-8104-46e7-8b78-5e5897307420">FY</ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF8xMC0xLTEtMS0w_5a9cc02f-5afd-43b5-a493-7d241be908e2">0000896262</ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF8xMS0xLTEtMS0w_c0b6a394-4e2b-4328-8b31-1e2dd4e63f76">12/31</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="ic6f32ffb396941779dd01b141bf45abd_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83Ni9mcmFnOjZlODdjZDRiYWE3ZTQwODdiMTRmNjc4YzU1NjI2NWQ1L3RleHRyZWdpb246NmU4N2NkNGJhYTdlNDA4N2IxNGY2NzhjNTU2MjY1ZDVfMTA5OTUxMTYyNzg0Nw_913e7481-ca7c-47d9-8117-3eba76217ff0">3.0</ix:nonFraction><ix:nonNumeric contextRef="ib90ca7053c5a4eabba3431aecde330cb_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxNg_2ef6bf16-13c0-4b4a-ac9d-18652113e2f9">P2Y</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84Mi9mcmFnOjU0Y2E4ZGMwMmMyYTQxM2E5OWZlMTIyYTE5MTBmMDRiL3RhYmxlOjNiNzgzYTMzOTkwYTQ2OTc5OTY4NzBhNzY1MzNjMjMxL3RhYmxlcmFuZ2U6M2I3ODNhMzM5OTBhNDY5Nzk5Njg3MGE3NjUzM2MyMzFfMi0xLTEtMS0w_ee36c7f7-5838-440c-924b-bbf5cb8de338">83,357</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84OC9mcmFnOmRjYzRjYWEzZWQ0NTQ3YjViNmVmMTFhYmMzYmU1M2ZiL3RhYmxlOjdkY2MyOGM4NzZjNDQ5MDI5Yjg2M2I1MWY5MzFjNzNhL3RhYmxlcmFuZ2U6N2RjYzI4Yzg3NmM0NDkwMjliODYzYjUxZjkzMWM3M2FfNS0xLTEtMS0w_4915f472-a580-4e7d-85c5-3a187c94bc51">3.3</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84OC9mcmFnOmRjYzRjYWEzZWQ0NTQ3YjViNmVmMTFhYmMzYmU1M2ZiL3RhYmxlOjdkY2MyOGM4NzZjNDQ5MDI5Yjg2M2I1MWY5MzFjNzNhL3RhYmxlcmFuZ2U6N2RjYzI4Yzg3NmM0NDkwMjliODYzYjUxZjkzMWM3M2FfNi0xLTEtMS0w_a5305c69-38e6-4b93-a8ee-58f62f9545ff">8.2</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84OC9mcmFnOmRjYzRjYWEzZWQ0NTQ3YjViNmVmMTFhYmMzYmU1M2ZiL3RhYmxlOjdkY2MyOGM4NzZjNDQ5MDI5Yjg2M2I1MWY5MzFjNzNhL3RhYmxlcmFuZ2U6N2RjYzI4Yzg3NmM0NDkwMjliODYzYjUxZjkzMWM3M2FfNy0xLTEtMS03MjQ3_7339a1d1-c892-4718-b201-2c5594dafb4d">5.6</ix:nonFraction><ix:nonNumeric contextRef="i994f6975b70a49068c75d0139eb0bb9d_I20201231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzQyMg_e7798f55-1ce4-47ef-a7fb-73e95a0c87a0">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i6e1c460171b341758ee7f2c6f5213b5e_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDYvZnJhZzo3ZGM2N2YxOTljYjc0MmU2OGYyNDkzMTNiNzJhNWQ5OS90ZXh0cmVnaW9uOjdkYzY3ZjE5OWNiNzQyZTY4ZjI0OTMxM2I3MmE1ZDk5XzI4NQ_c103f721-fa67-4451-963f-a90665915d6c">Option for early termination of lease after one year</ix:nonNumeric><ix:nonNumeric contextRef="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDYvZnJhZzo3ZGM2N2YxOTljYjc0MmU2OGYyNDkzMTNiNzJhNWQ5OS90ZXh0cmVnaW9uOjdkYzY3ZjE5OWNiNzQyZTY4ZjI0OTMxM2I3MmE1ZDk5XzI4Ng_51164379-36eb-471f-bff8-b3a066d74467">Option for early termination of lease after three years</ix:nonNumeric><ix:nonNumeric contextRef="i82f050f262b84796a9b340b2d9129bc0_D20200101-20201231" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTIvZnJhZzpiZjI5MzIwM2RmMjg0MzA1ODZiMTdmZDBjNDMwNTQyZS90ZXh0cmVnaW9uOmJmMjkzMjAzZGYyODQzMDU4NmIxN2ZkMGM0MzA1NDJlXzU0Ng_5b605a84-b5ea-4aa3-ab84-82d539a3a0bf">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</ix:nonNumeric><ix:nonNumeric contextRef="ifcea2f99e9244669860fa34644e434d1_D20200101-20201231" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTIvZnJhZzpiZjI5MzIwM2RmMjg0MzA1ODZiMTdmZDBjNDMwNTQyZS90ZXh0cmVnaW9uOmJmMjkzMjAzZGYyODQzMDU4NmIxN2ZkMGM0MzA1NDJlXzU0Nw_3393369b-9281-44a4-9de7-3a3b0f626803">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTgvZnJhZzpiNTY1MjUyZjE5Mzk0MDQwOTViZDBhNzNlOWI4ODk2My90YWJsZTo2NTE0ZDg0ZmM3NDk0YTY3YWE5Y2RkYjJiZmFjNmY1NS90YWJsZXJhbmdlOjY1MTRkODRmYzc0OTRhNjdhYTljZGRiMmJmYWM2ZjU1XzItMS0xLTEtMA_719737e6-9d2a-41f6-830c-f538c4aa73e0">38,859</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTgvZnJhZzpiNTY1MjUyZjE5Mzk0MDQwOTViZDBhNzNlOWI4ODk2My90YWJsZTo2NTE0ZDg0ZmM3NDk0YTY3YWE5Y2RkYjJiZmFjNmY1NS90YWJsZXJhbmdlOjY1MTRkODRmYzc0OTRhNjdhYTljZGRiMmJmYWM2ZjU1XzMtMS0xLTEtMA_28210d95-2a8c-472c-9b89-b762e261b920">38,859</ix:nonFraction><ix:nonNumeric contextRef="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDMzMTE_132e2a63-3451-42de-8da7-d71ba010d03c">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="ifbd18b01890b461182b19c8a098912de_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MDY_02c412b8-41ea-4c92-b3c7-f45653d56560">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i15df4480ba24493cb5e3394c14dff135_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MTI_5f8948f7-2285-435f-ba9f-02ccda0ec48b">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i6e1c460171b341758ee7f2c6f5213b5e_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjQvZnJhZzo4ZWYxNDMxZTkzMWI0MDUzODA2ODY0NjkwZTMxYWVmYy90YWJsZTpkMWU5YzE1NjRmNmU0YzRkODdmNGUxZTlkZWUwOGNlMy90YWJsZXJhbmdlOmQxZTljMTU2NGY2ZTRjNGQ4N2Y0ZTFlOWRlZTA4Y2UzXzExLTEtMS0xLTA_7dbbbea9-c253-45af-94c0-d01e90ffd529">12</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTQvZnJhZzowYjFjYzk5NzNlMjQ0YTEwODMzNzhlMDc5MTQ0ZjZkZi90YWJsZTphMGEwZjQ5YzYyMWI0ZTE2YWY3ZTM0YmVlMzk3MmUwYi90YWJsZXJhbmdlOmEwYTBmNDljNjIxYjRlMTZhZjdlMzRiZWUzOTcyZTBiXzEtMS0xLTEtMA_a97d6b69-422e-491f-aff7-42972692e363">1,778,161</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTQvZnJhZzowYjFjYzk5NzNlMjQ0YTEwODMzNzhlMDc5MTQ0ZjZkZi90YWJsZTphMGEwZjQ5YzYyMWI0ZTE2YWY3ZTM0YmVlMzk3MmUwYi90YWJsZXJhbmdlOmEwYTBmNDljNjIxYjRlMTZhZjdlMzRiZWUzOTcyZTBiXzEtMi0xLTEtMA_23998f67-1672-442d-8217-c725361f0c8e">1,507,430</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amed-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2521c40c2e674edaba9586526c5b83a7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2b4abd4b7b654854b3d46e098ad305fe_I20210219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i767079f30664438f8d9be671a161fd0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia733ca32dbec4462ac0839915fc3b59a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d70551ae8f463895c999fdc4613768_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c73d7f291d449999ecc705771a35788_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9320162518845cd970162f4a4cb6a6c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f984b3dbe34af3aace209254870882_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c1a95136f914b75adc71c283c901b28_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ae973af03114509bb73f714dfe8c520_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idae5b781450b4b82a9efea9a6ab20171_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ead52e4a58e40af94f4cfcfabee33f3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11cb32ff042042599b56293d9c96b2de_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578f5d8892c542728c9f3d614bb9ae1c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75707ab7adca4f98a7ec345287bc457d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253841217f1446de87fdaaac95f8653f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c4c0651a104d48aa8b1906c357fbbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ccddfc560fe46b5b31297f960c4cdfa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c61e77ed93b41c1a04abf43c6726a45_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if901346fc21749c693ca795fa77431fb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b9b1d7d6085499cbd3f5b49680ccb64_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9317f7646da44eee93324b0a16fb1827_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0afee284554110852d7f9cc9a2bb52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47e4e9c01d44fe7b652556bb85a5f1b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed066fa0032452b960a5c28694f984d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3cb19d428214cf1b5d7b341146b4fbb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76be51b421be4511a94ed8e7e72c0652_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i822e34ba968444868d3c6943bd915b7c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic19c797f2e324b2eb967c2bce916b767_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77a7f6ef23f49b1b151e334930d121b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb85416bef844237937a8966fd006741_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a117d66ff846f2af342b27fd619eb3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d57dd850e241008b6b1e4d426681fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3c23c0c8b54e24b20b5c10ef9f270e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af783f565644361ab504f9908131fb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3defad69f61b4cf99c2daf1bee38aab8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b86cc0a4b0247b0be34b31af7783e22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bbb43da3d614bb0a07f82de8f66c0ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i556d9f2b4c0446a481203b0d721356f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8445bad575a44eaf8f8bf43b13576231_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0e73c8be1d6044ae94fdfbcfab376671_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5312e58d089a492e8f1b50eb41d38fe4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf84b9ba9e1d4509914b4659ae8cf76e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="care_center"><xbrli:measure>amed:care_center</xbrli:measure></xbrli:unit><xbrli:context id="i3f4d87d3f8c04768adb0d99598494f75_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7618d2cebdef436fa6e1ece2cb3e1a9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30daf9d0e928439bbf628952733e011b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>amed:state</xbrli:measure></xbrli:unit><xbrli:context id="i2914b051b7f649fbb23140dd91cafcdb_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eee69c4378245919523ef9c81dcd659_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">amed:NoncontrollingInterestSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6f32ffb396941779dd01b141bf45abd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:HeritageHealthcareInnovationFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e986e4e31c44d36a9f7a6664353fdce_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:HealthcareanalyticscompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9908f52af49414aaa4bba7ff6a04ea2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbdc95bff22c46c88b5ecb49ca013c65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa97deb735d340eca9b8cc590a5b1849_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f3ed78fd22d4d13a30267510435daf6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefef9d24cffa43e4a8689e876b718fdf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc080435d3fc4721a9440877edb75f0d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74323b930434bcdb3617ec041a4cfe6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdc0080330a7432e9027a57a221467c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf6f8b2217645d7a837564472c1641e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b9e3d120ed425ba59ad31de35d305d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd65f8b7a704689a2fe739ca3da0471_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib865129db50747ec9ba2b83c279bc869_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6389e8be7141058ce2e5865620a128_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6368cc1cda74803ab17d38cb452059b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c88b95605441ba8df42caa5d36162b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ebe30ad71fe49acad1f10623f51159b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c59d1d549d4f0b8e8a5cd6aa96ee72_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaa6c33dce254267aa5511c42c11f0c1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number_of_visits"><xbrli:measure>amed:Number_of_Visits</xbrli:measure></xbrli:unit><xbrli:context id="i1fd55beb3b4d4378b920094a5b091472_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6206325b4d4a58a46dff6013229b68_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5177b049f064d83bb0e48f33e3b2e58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca03328f124427a801b7d654ef05ff9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1910bccf75da421d95218682b6c0f049_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e4242100dce41a99f05af2e39618231_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b22800f018b4cb5b23b5e899cc8f26a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4486f034b52465db1934c0b02d4badf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i458e999686ec425fb89dcbbb0521682c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>amed:day</xbrli:measure></xbrli:unit><xbrli:context id="id56f149b375540d6ac65813b85c223fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d302a79021b4c4cbaf66726ebe127e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203914f8db684c668d2c7dac204ca2c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i640213bfd2f74b9a8e1dde58507eabc6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb00a1b56bb044c7ab5db9f625aec705_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e3297361534d9ebafe84913d07eb73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie624c24d63be42a88573abdf69aae516_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99cc7fb2614e43a78496b7db077072c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bde4b17d3e64e889a2b995dc1b96e0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33563aeb6c734c9b8f2b02515df00ee4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbdd825dcd9b4a34a7e7ee40b29823ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a14cc7e58784bbabd79f9688f678767_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcdf59b18c044a0586a45d15dd0cc388_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ef5f5295c143c4814a9cc4b7e9a2aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id32eea10fdea44f8b804df035c1d9f9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a0c5250e66540da9c9ee41bb6cc2a6b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90ca7053c5a4eabba3431aecde330cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf4b84d294244f4783317a7222e4e879_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c91ba472944f99a6daf60ac242bcb6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9e61c64a324dccb0426c5ca15ad0fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab41181582e84ce6a158eb40d3e43022_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0822cae609e455f8dabd64cd55ce112_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaceabeac78a43fa8dcdac6a349b0ed0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7919ceb133453abee391bfba5d166c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6001d3911d55430a8c080827cb5bcaff_I20200327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i372268bd3773442994730e4fe0e5ee44_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa49fd6f4b049c4852349a3f959f964_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e4a08657594a9e8a1641435acac59f_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9d23dde21e42c9a907136f7eeaf5e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i118a662ab55141c19f9cdf727c8817fe_I20200424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6134feb4f36f4032ba67f2372de0d569_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie67bc19fa2814c5abd3ff91ce96f6e90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityTaxesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic433fb8ffa524d98b4462b2bfdb4ca4a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9cafc4be2f5437d9ca0b72a01385735_D20200301-20200301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027e9e9fdcb3465e9e2a8e7763db61d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcad9ea4bad644b7aef096a89d73a367_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c82b6aabd174ab7b9b1bbd04c0e4f43_D20200418-20200418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-18</xbrli:startDate><xbrli:endDate>2020-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b5bde6cd03496eb965aaa99d46b4e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af9f0752744492d80892b57fe0eb43f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736c6f864f0c4f2f90cb716d504ad728_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28272584e8864b6eac538308aa55f7f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefb68536b309420b86b96f71d3be7002_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicarelicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4071912f29b1471a90316176f150bae0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac1ab93fa9c14e638c003d6efff17ec7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45609ba2476e4e52aa2321ed4c22caa4_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9861da3d84840e5b7b2f004402be77c_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1196979b4bd42e99e052738971c3d6d_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a1566846d62435ebae17d6c7c127850_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7182413ea774295b30d183d04b1cabd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dade9dfe7084bfbadf9e3614bbe33ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicarelicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1af67560f042a28a10f654e58775f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5098d5c55d8b4b1dbeee2d1d43a9b870_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6dbc8b680ea432483b0218a761a9ee4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50e918f9fa742aea3517c666077cbc2_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4caa862c918a45e6bc9f8e6f842d75f0_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i539b5ad7e9ee440ba81d9f4f4069b5e8_D20190201-20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000c57f033a6483d8bf707b4eb4e6f55_D20190201-20190201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if362ac0d7ade4dbe9a2f52099ec6f0e7_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a1575f31584575992abc74ced2bc65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i169c7364acc540578506213cd50aac76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i856c123c4c204fe38e4e036fd7752a96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6826cc9464ca4135b180f102528d6d44_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4483458942a649af981f192426433819_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2123af26c18b4412a49a520f6e2ab7c8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c3a57b90754fd780752ab5eaeb2119_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ca74d3eda644e30a68c80809f7fc57f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie88935582b014075a328bfa1b117396c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af8da337a3b49f3a113759b906bf9f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941dbf037dc148deb289e0c5c518ef5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3b8059d89b46389a5544b50a169658_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299a9ff0faaf4204a8a8ec39062247b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758a004b4fbe477aa6e2ef91789cb336_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i189835ae24ec4c70b6a717d5b08a421a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9aefbc5b7fb48c5b29a38dcb7a14868_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6192d3d4b0a84bfeaab23464bd0e6b9e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib187ff5463f54b85b4e3f4bc6ad8636c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i969ee2ebea1b499f906b31aa81ec4f31_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia87f788f2fe64b23944a430849785260_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe18e321548455c94c7d0cd77924cf8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d6b40ce5cc498eba1f0d3ec5483959_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83cdcc0f05d44f1d840709161ceb3440_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc65628a7dbf4a1da089fe655a7e819d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd0ee0b03f92409eb2ff67a774546a35_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9714b4cf7d7c4de1be0e59b0dd0e7085_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib383332f81cd4bfa9b1922280c354414_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided786cf36e844558e359485f224451e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7040a24f0754adc968817731ec50305_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f77e35787c46fe9512e728260f7095_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c25949461664d0aaec5b5040213f6b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e88ffd25ce42179e2ee5206728bafa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i994f6975b70a49068c75d0139eb0bb9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3998374665924f3aa61bd5813eecd5f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e380d81b95f448eab4c555d915ea5cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:LeaseTypeAxis">amed:FleetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e1c460171b341758ee7f2c6f5213b5e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90dece5459db457b9caee4a934044bae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7c937ebfcbb4487b42fa8461a09a162_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8de54dd0485448269d1eebf429a33e51_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2041f507eabe49338b0fd15b6f05a37a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ed331009f24a32b73120f18a9797f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7367ab708f42b39e9081b6c1bb9a02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f2b03850b34492e9f5c7baeadcdd170_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0024757aa534d409fcb4e8a79dad213_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8051bc5ccedc4458b6ff74abcdfd5b59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03a65bdf068041f2ba700f2afe87977d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4365d319b33f4857ae4bc38bf1acf0d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83398cda1ea54e6783c252370998336f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifedadb8035864252bc2a50fe50d27fb7_I20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55e3ad37975747ce85e5f9e56a387aeb_I20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib818b639b2fc470b9dfaf7a8a57d34aa_D20180629-20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-29</xbrli:startDate><xbrli:endDate>2018-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f987fd3c874bb7a0482a03ac02dd0a_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20973059f44430a8ea7527042093e66_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f050f262b84796a9b340b2d9129bc0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcea2f99e9244669860fa34644e434d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5550ca8a47443f914e49b80cf1c663_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449b5f09d3b34ec39a18a9cef526b9a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic46bf12be9614cdc9e2592966809f199_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4332b377849d47079522cdb966f405aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if009f649f525477986901bf87b9a8a8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663a0220bf1f4bde8453506f3ec8b0c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ce40c5da424eb1acc6a5a1cc10d1ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6dd35f3ef914c7b9e3b873612e24d07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2fdd832f78f447590dcea35096f588e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id875fdd2eb7148c4aa89a6f6d517e964_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd3a5e252c794510b621a8afd98a30af_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73c6064129945f89356c2e9781e2ff3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ac1b22c6f554e6db80a1dec5c335a03_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i327f7ac146d444c88f630645e8202d8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if363353766114727baf5a4aab4fe9ca4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef9e7a889a946cfba1e6124e81184a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3064d98b299543439b8d8a53616ccd96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6594991d717f452eb94882c394b94cea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d69adb19bc439892e8f7b86338bcb6_D20190204-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7328ca3b33b846ebb1d8865233054b79_D20200401-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f285d89c3194106bf7a283b287c5858_D20230401-20240204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b3d4329c9e413992649f97f3932f8e_D20190204-20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813d4685897443ab84f5078bedbc3eed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a9f227940024b9b9e6f47095fc1825c_D20190204-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-04</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd494e95d0b348dbbcf7c525e255735b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d03942e78784e909bcee19f2ae8dcad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7e72eca4bc4cf0b3983258ef075db8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68bc26784c984ab2b763317f0ea13821_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-10</xbrli:startDate><xbrli:endDate>2020-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e2a3b22027c46259ffb26bf610aae36_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061c5e4bcf0a48809b0f8aaa50b8d7f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a797cd8697149299906057726300694_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c55a72c359242999f6ad37fe6380c0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeOfIncomeTaxDeferralAxis">amed:SocialSecurityTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff4532176b44743aad3722dcd2582f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa1ce8651ce74253af7461cfa4722490_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">amed:StateTaxCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2bfa60d1a274089b775bff19975c6d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2268173c1609427b91285a18f7856aa8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsToMoreThanTenPercentOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic23e136463954fce97ebf07eaca62d49_I20120606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-06-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f87b9321c534dcfae4d2ce97fe4fc8b_I20120607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f247884db846bdb4821a221bbfe57c_D20120607-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-06-07</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i172263bdf66a4f008f59172cfb1d5640_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d88f9ec77c9452c8bb506759c530a16_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b760ab2443e4046941e64e3b50a2f09_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc731d16af2b4adb980e8754afe1b9f9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17ca81d5bf204e579790350d278411ad_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44d57dec79174a29a10a484c6e35ee00_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c385df453324adfaca85d0811925684_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3692bce7d32644e5b337cd5691239645_D20120607-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-06-07</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0967904d6aa443bda7b944783f5368a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b123e655fe43e190e185f8dbe56430_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5def5d90694943c991e6829f70fa6a4c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b8d67240ac466ba65b24c556a36122_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6fc63306454ed1ad46e51a0060949e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf88ad709fd64cffbbba3949d9877821_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1850298439a4c2f8d557340227845e9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d3940f86e248f5a619e4759d853c1e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic24c7c520697474487b3aceda222db5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbd18b01890b461182b19c8a098912de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15df4480ba24493cb5e3394c14dff135_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9934834a8a0c409b8d6d372c860f05c2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id48af308b58146e1a94f7cbf20c53001_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67aef9e5409443cc838400c94814e771_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6fba36dadd24151b9f0f7c470401177_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief02df4838c5483f9c1fee131227eb29_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i085cfa11bc6843488c86ab3d0a3da2ad_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a62c2d5f8ed48a78a320ddb584e246f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i521c7c89279e4c0aa844c60ec36a5f59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>amed:patient</xbrli:measure></xbrli:unit><xbrli:context id="i1560d4e370f847fb92bf3948fe2bd932_D20150521-20150521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-21</xbrli:startDate><xbrli:endDate>2015-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ce9e524eb0543eeae2df4f429cd9905_D20151103-20151103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-03</xbrli:startDate><xbrli:endDate>2015-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07641836ad0d4665b300523692960b1f_D20160627-20160627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-27</xbrli:startDate><xbrli:endDate>2016-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf11c6ccfd794c169a08d89e5cd17b31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92e1c7184a7449e846c859caeab4fbe_D20140423-20140423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:AmedisysCIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-23</xbrli:startDate><xbrli:endDate>2014-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if492da41859849a18fe046b7f1da314e_D20150130-20150130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:CompassionateCareHospiceCIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-30</xbrli:startDate><xbrli:endDate>2015-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="beneficiary"><xbrli:measure>amed:beneficiary</xbrli:measure></xbrli:unit><xbrli:context id="if3e4bf70e5d9479ebc20d004efd4f9e8_D20080101-20100331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2010-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7b09ab0a49d4b838fe8db28575066f2_D20110606-20110606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-06-06</xbrli:startDate><xbrli:endDate>2011-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92498864eda34c97bf3f44b5a1827b5b_I20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amed:claim</xbrli:measure></xbrli:unit><xbrli:context id="i44e23098929046f7af1cfe828afaec85_D20160118-20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-18</xbrli:startDate><xbrli:endDate>2016-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02eb19f870b48a0ac524cc591131f73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8979ada06f974ae48d397f54b6e49eda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80891250852448afbff7aef1c0666a33_I20190110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b988a539e7458e9ebc3dfab2f46a43_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5fc041d76e49a5983d00e207829170_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib558c962d6c04f40adef9ad76c074458_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f99d4d9f475438a97dba13e3a83c516_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa86f34e687461286bbecf374c1f96e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f2f005315e5492bb8fec7e5757a7e04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie45f729caf77486a9faad14454801668_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29dcf5be2ab240aa86b1d44b4274b48e_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib20172f07d6649a2a8664caf1f015ef2_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76464f5a074a42fc86111f27060e6a56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b9a36901674eb9a302469e2cac8ab9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf602ed6544f4e14998550bd3bc16290_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3800a96a7434d7f807e7946ac5ea7d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8e83cf1d9574cf69c223d04622768aa_I20201223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:A2021StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i982a73904c8843df8b8f14ae21909b06_D20201223-20201223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:A2021StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib40aceab8f864987a75d9c12fb66ae7e_I20190225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:A2019StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0bafbf9ffa74adb9775ae8c65c96711_D20190225-20190225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:A2019StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-25</xbrli:startDate><xbrli:endDate>2019-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:KKRShareRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-04</xbrli:startDate><xbrli:endDate>2018-06-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>amed:segment</xbrli:measure></xbrli:unit><xbrli:context id="i479834b49d53404d82becc11f229a75a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib96bea9253ac4d8d90b0d2f79b7e9bb6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d01c191f7b94742a8aedf3242104b2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce2a100b9be4e04b1c79c526dd5afe1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562b1925a10f47859b8528d0316b1f34_D20180604-20180604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:KKRShareRepurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:KKRConsultingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-04</xbrli:startDate><xbrli:endDate>2018-06-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id92bd70d620044018083957a908405c4_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTAy_97a9e86a-ceee-4fd0-a4d4-4dc00ae78823">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDkx_0150e72f-9015-48db-9082-ddfe2f2431cf">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended: <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8yMTk_85b6cf05-6ab7-4e65-97ae-e0811358a2c2">December&#160;31, 2020</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk2_577f87c5-72a3-4bd6-b7b2-d28005fd2047">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk3_954d43e3-a3b0-47f6-b631-aa16a6398995">0-24260</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><img src="amed-20201231_g1.jpg" alt="amed-20201231_g1.jpg" style="height:98px;margin-bottom:5pt;vertical-align:text-bottom;width:156px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTAz_36de1bfd-a136-4b22-96b6-ae7970d2bc44">AMEDISYS, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6YjNlMjIwYTMzNmQ2NDU3ZmIzYjE2ZWIwNGI2NzI3YWUvdGFibGVyYW5nZTpiM2UyMjBhMzM2ZDY0NTdmYjNiMTZlYjA0YjY3MjdhZV8wLTAtMS0xLTA_a8dce9d9-9239-449e-a182-9aeb08794128">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6YjNlMjIwYTMzNmQ2NDU3ZmIzYjE2ZWIwNGI2NzI3YWUvdGFibGVyYW5nZTpiM2UyMjBhMzM2ZDY0NTdmYjNiMTZlYjA0YjY3MjdhZV8wLTItMS0xLTA_d964f2eb-0868-43f4-946e-43512ec2dd90">11-3131700</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDky_a3bbdcd4-79b9-4aed-9930-720aeee7c42b">3854 American Way, Suite A,</ix:nonNumeric> <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTA0_6d66af9b-1ccb-43d1-b4c6-7096ea005827">Baton Rouge,</ix:nonNumeric> <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk4_c8d0a37e-aeb4-48d0-869a-0b2de471d772">LA</ix:nonNumeric> <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk0_f1c40600-c8e7-4b4b-bda3-4ad3aea9b24c">70816</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDkz_38017330-0ff7-4336-aeb2-16a6c04565d4">225</ix:nonNumeric>) <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk1_ab2431ba-bb43-4812-b8f6-d63927ce01a2">292-2031</ix:nonNumeric> or (800)&#160;467-2662</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:33.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6MzE5YmI4YjMwNTYxNDgxZmIyNTI4MTY1OTAxN2EzN2YvdGFibGVyYW5nZTozMTliYjhiMzA1NjE0ODFmYjI1MjgxNjU5MDE3YTM3Zl8xLTAtMS0xLTA_d03cbe71-f954-4df4-a3c2-6c7208050c5a">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6MzE5YmI4YjMwNTYxNDgxZmIyNTI4MTY1OTAxN2EzN2YvdGFibGVyYW5nZTozMTliYjhiMzA1NjE0ODFmYjI1MjgxNjU5MDE3YTM3Zl8xLTItMS0xLTA_b506299a-635e-4371-bf3b-61ee50b14f9e">AMED</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6MzE5YmI4YjMwNTYxNDgxZmIyNTI4MTY1OTAxN2EzN2YvdGFibGVyYW5nZTozMTliYjhiMzA1NjE0ODFmYjI1MjgxNjU5MDE3YTM3Zl8xLTQtMS0xLTA_0745ffe3-db41-431d-bb92-1e72380eced8">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTAw_bc45894e-3a83-4830-b4c7-7a35dfcdc1a8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk5_f8b4d197-a81f-4b11-83bf-c19f8ff9aecf">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTAx_a023b39f-0897-4173-a9eb-8fface96a18e">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDg5_90b276b6-80ea-4449-9898-8b004af21946">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6N2ZlOGRkMTU5YjBiNDExMmJjNzIxY2JmNGZmYTJmMTcvdGFibGVyYW5nZTo3ZmU4ZGQxNTliMGI0MTEyYmM3MjFjYmY0ZmZhMmYxN18wLTAtMS0xLTA_303f4693-446b-49c8-b58c-99b70d2aa008">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6N2ZlOGRkMTU5YjBiNDExMmJjNzIxY2JmNGZmYTJmMTcvdGFibGVyYW5nZTo3ZmU4ZGQxNTliMGI0MTEyYmM3MjFjYmY0ZmZhMmYxN18xLTQtMS0xLTA_b513f632-3339-44f8-aa51-3a7a6fccc22c">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6N2ZlOGRkMTU5YjBiNDExMmJjNzIxY2JmNGZmYTJmMTcvdGFibGVyYW5nZTo3ZmU4ZGQxNTliMGI0MTEyYmM3MjFjYmY0ZmZhMmYxN18yLTQtMS0xLTA_350c94fe-bb5c-436a-a582-0a52a62cd53c">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9745;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDkw_1a1112a3-4d9a-4db5-a34a-f6a6dacd77db">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant, based on the last sale price as quoted by the NASDAQ Global Select Market on June&#160;30, 2020 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was $<ix:nonFraction unitRef="usd" contextRef="i2521c40c2e674edaba9586526c5b83a7_I20200630" decimals="-8" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8yODIz_00aab844-6cf5-47df-85b9-05568f36d3c4">5.5</ix:nonFraction> billion. For purposes of this determination shares beneficially owned by executive officers, directors and ten percent stockholders have been excluded, which does not constitute a determination that such persons are affiliates.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;19, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i2b4abd4b7b654854b3d46e098ad305fe_I20210219" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zMDc1_bd91cdaa-08bb-4037-b227-50f7ff90db7a">32,848,547</ix:nonFraction>&#160;shares of Common Stock outstanding.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement for its 2021 Annual Meeting of Stockholders (the &#8220;2021 Proxy Statement&#8221;) to be filed pursuant to the Securities Exchange Act of 1934 with the Securities and Exchange Commission within 120 days of December&#160;31, 2020 are incorporated herein by reference into Part III of this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id92bd70d620044018083957a908405c4_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_10">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_10">1</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_13">PART I.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_16">ITEM&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_19">ITEM&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_19">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_19">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_22">ITEM&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_22">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_25">ITEM&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_25">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_25">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_28">ITEM&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_28">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_28">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_31">ITEM&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_31">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_31">29</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_34">PART II.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_37">ITEM&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_37">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_37">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_40">ITEM&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_40">SELECTED FINANCIAL DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_40">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_43">ITEM&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_43">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_43">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_46">ITEM&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_46">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_46">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_49">ITEM&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_49">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_49">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_169">ITEM&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_169">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_169">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_172">ITEM&#160;9A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_172">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_172">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_175">ITEM&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_175">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_175">102</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_178">PART III.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_181">ITEM&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_181">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_181">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_184">ITEM&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_184">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_184">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_187">ITEM&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_187">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT&#160;AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_187">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_190">ITEM&#160;13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_190">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_190">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_193">ITEM&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_193">PRINCIPAL ACCOUNT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_193">ANT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_193"> FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_193">102</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_196">PART IV.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_199">ITEM&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_199">EXHIBITS</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_199"> AND</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_199"> FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_199">103</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_202">ITEM&#160;16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_202">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_202">103</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_205">EXHIBIT INDEX</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_205">104</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_208">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id92bd70d620044018083957a908405c4_208">110</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id92bd70d620044018083957a908405c4_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">When included in this Annual Report on Form&#160;10-K, or in other documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) or in statements made by or on behalf of the Company, words like &#8220;believes,&#8221; &#8220;belief,&#8221; &#8220;expects,&#8221; &#8220;strategy,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; "could," &#8220;would,&#8221; &#8220;should&#8221; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control, and such other factors as discussed throughout Part I, Item 1A. "Risk Factors" of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&#160;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&#160;For a discussion of some of the factors discussed above as well as additional factors, see Part&#160;I, Item&#160;1A, &#8220;Risk Factors&#8221; and Part&#160;II, Item&#160;7, &#8220;Critical Accounting Estimates&#8221; within &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise provided, &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Amedisys, Inc. and our consolidated subsidiaries and when we refer to 2020, 2019 and 2018, we mean the twelve month period then ended December&#160;31, unless otherwise provided.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A copy of this Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 as filed with the SEC, including all exhibits, is available on our internet website at http://www.amedisys.com on the &#8220;Investors&#8221; page under the &#8220;SEC Filings&#8221; link.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="id92bd70d620044018083957a908405c4_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="id92bd70d620044018083957a908405c4_16"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;BUSINESS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc. is a leading healthcare services company committed to helping our patients age in place by providing clinically excellent care and support in the home. Our operations involve serving patients across the United States through our three operating divisions: home health, hospice and personal care. We deliver clinically distinct care that best suits our patients' needs, whether that is home-based recovery and rehabilitation after an operation or injury, care that empowers patients to manage a chronic disease, hospice care at the end of life or providing assistance with daily activities through our personal care division.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are among the largest providers of home health and hospice care in the United States, with approximately 21,000 employees in 514 care centers in 39&#160;states within the United States and the District of Columbia. Our&#160;employees deliver the highest quality care performing more than 11.5&#160;million visits for more than 418,000&#160;patients annually. Over 2,900&#160;hospitals and 78,000&#160;physicians nationwide have chosen us as a partner in post-acute care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the age demographics of our patient base, our services are primarily paid for by Medicare which has represented approximately 73% to 75% of our net service revenue over the last three years. We also remain focused on maintaining a profitable and strategically important managed care contract portfolio. We continuously work with our payors to structure innovative contracts which reward us for providing quality care to our patients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys is headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee. Our common stock is currently traded on the NASDAQ Global Select Market under the trading symbol &#8220;AMED.&#8221; Founded and incorporated in Louisiana in 1982, Amedisys was reincorporated as a Delaware corporation prior to becoming a publicly traded company in August 1994.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to be the best choice for care wherever our patients call home. We accomplish this by providing clinically distinct care, being the employer of choice and delivering operational excellence and efficiency, which when combined, drive growth. Our mission is to provide best-in-class home health, hospice and personal care services allowing our patients to maintain a sense of independence, quality of life and dignity while delivering industry leading outcomes. We believe that our unwavering dedication to clinical quality and constant focus on both our patients and our employees differentiates us from our competitors.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Our Home Health Segment:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys Home Health provides compassionate healthcare to help our patients recover from surgery or illness, live with chronic diseases and prevent avoidable hospital readmissions. Our home health footprint includes 320 care centers located in 33&#160;states within the United States and the District of Columbia. Within these care centers, we deploy our care teams which include skilled nurses who are trained, licensed and certified to administer medications, care for wounds, monitor vital signs and provide a wide range of other nursing services; rehabilitation therapists specialized in physical, speech and occupational therapy; and social workers and aides who assist our patients with completing important personal tasks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take an empowering approach to helping our patients and their families understand their medical conditions, how to manage them and how to maximize the quality of their lives while living with a chronic disease or other health condition. Our clinicians are trained to understand the whole patient &#8211; not just their medical diagnosis.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This commitment to clinical distinction is most evident in our clinical quality measures such as Star Ratings. In the Center for Medicare and Medicaid Services (&#8220;CMS&#8221;) reports for the October 2020 release, the Quality of Patient Care star average across all Amedisys providers is 4.33 with 92% of our providers at 4+ stars and 44 care centers rated at 5 stars. Our Patient Satisfaction average for the October 2020 release was 4.28, outperforming the industry average by 7%. CMS plans to hold the reported October 2020 release data constant until January 2022. Our goal is to have all care centers achieve a 4.0 Quality Star Rating, and we are implementing targeted action plans to continue to improve the quality of care we deliver for our patients and further our culture of quality.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Our Hospice Segment:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospice care is designed to provide comfort and support for those who are dealing with a terminal illness. It is a benevolent form of care that promotes dignity and affirms quality of life for the patient, family members and other loved ones. Individuals </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with a terminal illness such as cancer, heart disease, pulmonary disease or Alzheimer&#8217;s may be eligible for hospice care if they have a life expectancy of six months or less.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2019, we have acquired Compassionate Care Hospice ("CCH"), RoseRock Healthcare ("RoseRock"), Asana Hospice ("Asana") and AseraCare Hospice ("AseraCare"). With these acquisitions, Amedisys now owns and operates 180 hospice care centers in 35 states, providing care to more than 13,000 patients daily as the third largest hospice provider in the United States. Within these care centers, we deploy our care teams which include nurse practitioners and other skilled nurses, social workers, aides, bereavement counselors and chaplains.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on building and retaining an exceptional team, delivering the highest quality care and service to our patients and their families and establishing Amedisys as the preferred and preeminent hospice provider in each community we serve. In order to realize these goals, we invest in tailored training, development and recognition programs for our employees, including medical record training, employee skills training and leadership development. This has led to our team&#8217;s consistent achievement at or above the national average in family satisfaction results and quality scores, as well as the trust of the healthcare community.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another element of our approach is our outreach strategy to more fully engage the entire community of eligible patients.&#160;These outreach efforts have built our hospice patient population to more accurately represent the causes of death in the communities we serve, with a specific focus on heart disease, lung disease and dementia in order to address the historical underrepresentation of non-cancer diagnoses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By working to accept every eligible patient who seeks end-of-life care, we fulfill our hospice mission and strengthen our standing in the community. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Our Personal Care Segment:</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal care provides assistance with the essential activities of daily living. We believe that personal care services are highly synergistic with our core skilled home health and hospice businesses, and that by expanding these capabilities, we will be able to provide our patients and payor partners with a true continuum of care.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys acquired its first personal care company in 2016,&#160;an important step in executing our strategy of improving the continuity of care our patients receive as their clinical needs change. We continued our strategy to expand our personal care segment with four additional acquisitions. We currently operate 12 personal-care care centers in Massachusetts and one personal-care care center in each of Florida and Tennessee. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we signed an agreement with ClearCare, Inc. ("ClearCare"), the provider of the personal care industry&#8217;s leading software platform, representing 4,000 personal care agencies in every zip code in the United States. Our agreement with ClearCare creates an opportunity to establish a network partnership between Amedisys and the personal care agencies using ClearCare in order to better coordinate patient care. In August 2020, we signed a Care Coordination Agreement with BrightStar Care to add its agencies to the Amedisys personal care network, which helps facilitate the coordination of care between our home health and hospice care centers and a network of personal care partners. Long term, we believe these agreements will allow us to build a nation-wide network of personal care agencies and further our efforts to provide patients with a true care continuum in the home. These relationships will also help us as we continue to have innovative payment conversations with Medicare Advantage plans who have begun to recognize the value that combined home health, hospice and personal care services bring to their members and care delivery infrastructure.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Responding to the Changing Regulatory and Reimbursement Environment:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the government continues to seek opportunities to refine payment models, we believe that our strategy of becoming a leader in providing a range of services across the at-home continuum positions us well for the future. Our ability to provide quality home health, hospice and personal care allows us to partner with health systems and managed care organizations to improve care coordination, reduce hospitalizations and lower costs.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Innovations:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to build our aging-in-place services, we intend to innovate around our core businesses to deliver new home based care models such as skilled nursing facilities in the home ("SNF@Home"). Additional innovation initiatives include the expansion of palliative care and telehealth which will also allow us to expand our primary businesses and accelerate our differentiated care delivery model.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we acquired Asana Hospice, a hospice provider with eight locations in Pennsylvania, Ohio, Texas, Missouri and Kansas.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2020, we acquired the regulatory assets of a home health provider in Kentucky. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with 44 locations. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information for our home health, hospice and personal care segments can be found in our consolidated financial statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are critical to our vision to be the leading aging-in-place company. Taking care of our people is our top priority. Our success is directly correlated with our ability to continue to attract, develop and retain the most qualified and passionate employees. Our work is not just a job but a calling. Our workforce strategy emanates from our core values of SPIRIT - Service, Passion, Integrity, Respect, Innovation and Talent. We know that by taking care of our people, they can continue to provide industry leading patient care. Our mission has never been more important than has been demonstrated during this public health emergency.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;19, 2021, we employed approximately 21,000 people throughout the United States. We also utilize contract employees in the normal course of our business.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diversity and Inclusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diversity and inclusion is a business imperative. We endeavor to create a culture of caregiving where our employees feel as cared for every day as our patients do. Success means all team members feel a sense of belonging, support and empowerment to be their best selves personally and professionally. We have committed to giving our employees a voice and have instituted numerous formal listening programs - quarterly pulse surveys, focus groups and town halls - to routinely gather feedback from our employees and address any concerns. Our commitment to diversity and inclusion is also broadly reflected across our policies and people practices. During 2020, we established an employee-led Diversity and Inclusion Council to address company policies and procedures that will facilitate a supportive, positive and inclusive work environment for all employees at Amedisys, and we invested in inclusion training for all leaders in the company.  </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also committed to having a diverse Board of Directors. Women currently comprise over half of the directors on our Board, and in December 2020, we expanded the Board to add a woman of color.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Talent Acquisition, Retention and Development:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to hire, develop and retain top talent. The core of our care delivery model is dependent upon attracting high demand clinicians, predominately nurses. We compete for talent by offering a great culture, an opportunity to provide the highest quality clinical care and competitive market-based compensation. Our compensation plans are designed to deliver a competitive base pay as well as attractive incentive opportunities, primarily for leadership positions, but also to reward quality care. We provide significant opportunities for development and continuing education as we know that career development is a key component of attracting and retaining top talent. We continually monitor and assess employee metrics on hiring, retention and terminations to gain a deep understanding of our workforce and drive continuous improvement.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Health and Safety</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health and well-being of our employees is of utmost importance to us. We offer a comprehensive benefit package that provides employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs that support their physical and mental health by providing tools and resources to help them improve or maintain their health status. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus on the health and safety of our employees became even more critical during the novel coronavirus pandemic (&#8220;COVID-19&#8221;), and Amedisys took action to help protect, educate and care for our employees. Measures taken to provide support during this pandemic include: </span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developed clinical protocols for COVID-19 testing, proper usage of personal protective equipment ("PPE"), caring for COVID-positive patients and maintaining safety measures in our care centers;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created a COVID-19 Resource Center available 24 hours a day, seven days a week for employees to access educational materials, safety documents, policies, clinical protocols and operational metrics. Our focus is now on resources to help our clinicians get vaccinated as quickly and easily as possible in each of the states we serve;</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implemented up to 14 days of paid leave during any required quarantine periods;</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Awarded SPIRIT bonuses to our clinicians and caregivers who have seen patients during the pandemic;</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed an early cash pay-out of employee paid-time off;</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Instituted work-from-home arrangements for our corporate and administrative support employees;</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allowed employees to temporarily suspend any 401(k) plan loan deductions and offered employees the option of making a withdrawal from their 401(k) plan for coronavirus-related distributions without incurring the additional 10% early withdrawal penalty;</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Granted access to Teladoc services to all employees;</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provided access to COVID-19 self-test kits to all employees;</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Procured millions in PPE and created a centralized distribution center for all critical PPE, allowing us to flex our inventory on a care center by care center basis, based on need and demand as further described in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations: Overview - Novel Coronavirus Pandemic ("COVID-19")."</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment for Our Services</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived in large part from governmental third-party payors. Governmental payment programs are subject to statutory and regulatory changes, retroactive rate adjustments, administrative or executive orders and government funding restrictions, all of which may materially increase or decrease the rate of program payments to us for our services. It is possible that future budget cuts in Medicare and Medicaid may be enacted by Congress and implemented by CMS. Therefore, we cannot assure you that payments from governmental or private payors will remain at levels comparable to present levels or will, in the future, be sufficient to cover the costs allocable to patients eligible for reimbursement pursuant to such programs. See Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations: Overview - Payment" for additional information on the most recent regulations from CMS.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit is available both for patients who need home care following discharge from a hospital and patients who suffer from chronic conditions that require ongoing, but intermittent, care. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of participation under Medicare, beneficiaries must be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during COVID-19, CMS has relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their house because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to January 1, 2020, Medicare payment rates were based on the severity of the patient&#8217;s condition, his or her service needs and other factors relating to the cost of providing services and supplies, bundled into 60-day episodes of care. An episode starts with the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier. If a patient is still in treatment on the 60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day, a recertification assessment is undertaken to determine whether the patient needs additional care. If the patient&#8217;s physician determines that further care is necessary, another episode begins on the 61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day (regardless of whether a billable visit is rendered on that day) and ends 60 days later. The table below includes the 60-day base episode payment rates.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base&#160;Episode<br/>Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2018 through December 31, 2018</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2019 through December 31, 2019</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2020 through December 31, 2020 (only applies to episodes beginning on December 31, 2019 or prior)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, CMS implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adequate access to home health care. PDGM uses a 30-day period of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. The table below includes the base 30-day payment rates.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base 30-Day Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2020 through December 31, 2020 (only applies to episodes beginning on January 1, 2020 and thereafter)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2021 through December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case mix adjusted payment for a 30-day period of care may be adjusted up or down as a result of one or more of the following: (a)&#160;an outlier payment if our patient&#8217;s care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies, with limited exceptions, are now included in the 30-day payment rate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a Medicare provider, we are subject to periodic audits by the Medicare program, and that program has various rights and remedies against us if they assert that we have overcharged the program or failed to comply with program requirements. Home health providers are subject to pre- and post-payment reviews for compliance with Medicare coverage guidelines and medical necessity. Adjustments on this basis may include individual claims adjustments or overpayment determinations based on an extrapolated sample of claims. Medical necessity reviews evaluate whether services are clinically appropriate in terms of frequency, type, extent, site and duration. Technical billing and documentation reviews focus on documentation of services. Medicare and other payors may reject or deny claims for payment if the underlying paperwork does not support the medical necessity of services or fails to establish satisfaction of a coverage rule; such as if a provider is unable to perform periodic therapy assessments required by coverage criteria or cannot provide appropriate billing documentation, acceptable physician authorizations or face-to-face meeting documentation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can reopen previously filed and reviewed claims and deny coverage of the services and require us to repay any overcharges, as well as make deductions from future amounts due to us. In the ordinary course of business, we appeal the Medicare and Medicaid program's denial of claims that we believe are inappropriate in an effort to recover the denied claims.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health Non-Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from Medicaid and private insurance carriers are either a percentage of Medicare rates or per-visit rates depending upon the terms and conditions established with such payors. Reimbursements from our non-Medicare payors that are based on Medicare rates are paid in a similar manner and subject to the same adjustments as discussed above for Medicare; however, these rates can vary based upon negotiated terms which generally range from 90% to 100% of Medicare rates. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payment if we achieve certain quality or process metrics as defined in each contract.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare hospice benefit is available when a physician and specific clinical findings support a diagnosis of a terminal condition where the patient has a terminal diagnosis of six months or less. Hospice care is evaluated in benefit periods; two 90-day benefit periods followed by an unlimited number of 60-day benefit periods. Payments are based on daily rates for each day a beneficiary is enrolled in the hospice benefit. The daily payment rates are intended to cover costs that hospices incur in furnishing services identified in patients' care plans, based on specific levels of care. Payments are adjusted by a wage index to reflect health care labor costs across the country and are established annually through federal legislation. Payments are made according to a fee schedule that has four different levels of care: routine home care, continuous home care, inpatient respite care and general inpatient care.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare payment is provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, Medicare also reimburses for a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments for medical necessity and technical billing requirements may be made to Medicare revenue based on the same claims processing or medical necessity reviews described above for home health services when we find we are unable to obtain appropriate billing documentation, authorizations or face-to-face documentation and other reasons unrelated to credit risk.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two caps limit the amount of payment that any individual hospice provider number can receive in a single year. Generally, each hospice care center has its own provider number; however, where we have created branch care centers to help our parent care centers serve a geographic location, the parent and branch have the same provider number. </span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Inpatient Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inpatient cap limits the number of days of inpatient care an agency may provide to not more than 20 percent of its total patient care days. The daily Medicare payment rate for any inpatient days of service that exceed the cap is set at the routine home care rate, and the provider is required to reimburse Medicare for any amounts it receives in excess of the cap.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Payment Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall payment cap is an absolute dollar limit on the average annual payment per beneficiary a hospice agency can receive. This cap is calculated by the Medicare administrative contractor at the end of each hospice cap period to determine the maximum allowable payments per provider number. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our potential cap exposure using information available for both inpatient day limits as well as per beneficiary cap amounts. The total cap amount for each provider is calculated by multiplying the number of beneficiaries electing hospice care during the period by a statutory amount that is indexed for inflation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment rates for hospice care, the hospice cap amount and the hospice wage index are updated annually according to Section 1814(i)(1)(C)(ii)(VII) of the Social Security Act, which requires CMS to use the inpatient hospital market basket, adjusted for multifactor productivity and other adjustments as specified in the Social Security Act, to determine the hospice payment update percentage. The caps are subject to annual and retroactive adjustments, which can cause providers to be required to reimburse the Medicare program if such caps are exceeded. Our ability to stay within these caps depends on a number of factors, each determined on a provider number basis, including the average length of stay and mix in level of care.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-Medicare payors pay at rates that differ from established Medicare rates for hospice services, and are based on separate, negotiated agreements. We bill and are paid by these non-Medicare payors based on such negotiated agreements.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Non-Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal care payments are received from payor clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers, based on rates that are either contractual or fixed by legislation.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controls Over Our Business System Infrastructure</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We establish and maintain processes and controls over coding, clinical operations, billing, patient recertifications and compliance to help monitor and promote adherence with Medicare requirements.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Coding &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Specified international classification of disease ("ICD") diagnosis codes are assigned to each of our patients based on their particular health conditions (such as diabetes, coronary artery disease or congestive heart failure). Because coding regulations are complex and are subject to frequent change, we maintain controls surrounding our coding process. To reduce the associated risk of coding failures, we provide annual update training to clinical managers, as needed training to care center directors and clinical managers and training during orientation for new employees to ensure accurate information is gathered and provided to our coding team. In addition, our electronic medical records system (Homecare Homebase) includes automated edits for home health and hospice based on pre-defined compliance metrics. For home health, we also provide monthly specialized coding education, obtain outside expert coding instruction and have certified clinician coders review all patient outcome and assessment information sets (&#8220;OASIS&#8221;) and assign the appropriate ICD code. Additional training for our home health coders, clinicians, office staff and business development teams occurred throughout 2019 and 2020 in connection with the implementation of PDGM.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Clinical Operations &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We provide education on coverage criteria and conditions of participation and utilize outside expert regulatory services if necessary. Regulatory requirements allow patients to be eligible for home health care benefits if through a face-to-face visit with a physician, they are considered homebound and it is determined that skilled nursing, physical therapy or speech therapy services are required. These clinical services may include: educating the patient about their disease, assessment and observation of disease status, delivery of clinical skills such </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as wound care, administration of injections or intravenous fluids, management and evaluation of a patient&#8217;s plan of care, physical therapy services to assist patients with functional limitations and speech therapy services for speech or swallowing disorders. Patients eligible for hospice care are terminally ill (with a life expectancy of six months or less if the illness runs its normal course). Our hospice program provides care and support to our terminally ill patients with a 6-month prognosis and their families through services including medical care, counseling, spiritual care, pre-bereavement and bereavement support, medication management and needed equipment and supplies for the terminal illness and all related conditions. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Billing &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We maintain controls over our billing processes to help promote accurate and complete billing. We conduct annual billing compliance testing, use formalized billing attestations, limit access to billing systems, use automated daily billing operational indicators, and take prompt corrective action with employees who knowingly fail to follow our billing policies and procedures in accordance with a "zero tolerance" policy.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Patient Recertification &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to be recertified for an additional home health episode of care, a patient must continue to meet qualifying criteria and have a continuing medical need. Changes in the patient&#8217;s condition may require changes to the patient&#8217;s medical regimen or modified care protocols within the episode of care. The patient&#8217;s progress towards established goals is evaluated prior to recertification. As with the initial episode of care, a recertification requires orders from the patient&#8217;s physician. Before any employee recommends recertification to a physician, we conduct a care center level, multidisciplinary care team conference. Specific tools are used to ensure that the patient continues to meet coverage criteria prior to recertifying. Hospice recertification for additional benefit periods of care require continued demonstration of a terminal prognosis as determined by the hospice physician in collaboration with the attending physician and the interdisciplinary care team.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Compliance &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We develop, implement and maintain ethics and compliance programs as a component of the centralized corporate services provided to our home health, hospice and personal-care care centers. Our ethics and compliance program includes a Code of Conduct for our employees, officers, directors, contractors and affiliates and a disclosure program for reporting regulatory or ethical concerns to our compliance team through a confidential hotline, which is augmented by exit surveys of departing employees. We promote a culture of compliance within our company through educational presentations, regular newsletters and persistent messaging from our senior leadership to our employees stressing the importance of strict compliance with legal requirements and company policies and procedures.&#160;Additionally, we have mandatory compliance training and testing for all new employees upon hire and annually for all staff thereafter. We also maintain a robust compliance audit program focusing on key risk areas.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Regulatory Environment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly regulated by federal, state and local authorities. The healthcare industry is subject to numerous laws, regulations and rules including, among others, those related to government healthcare participation requirements, various licensure and accreditations, reimbursement for patient services, health information privacy and security rules, and Medicare and Medicaid fraud and abuse prohibitions (including, but not limited to, federal statutes and regulations prohibiting kickbacks and other illegal inducements to potential referral sources, self-referrals by physicians and false claims submitted to federal health care programs). Regulations and policies frequently change, and we monitor changes through our internal government affairs department, as well as multiple trade and governmental publications and associations. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health and hospice subsidiaries are certified by CMS and therefore are subject to the rules and regulations of the Medicare system. Additionally, all of our business lines are likewise subject to federal, state and local laws and regulations dealing with issues such as occupational safety, employment, medical leave, insurance, civil rights, discrimination, building codes, privacy and recordkeeping. We have set forth below a discussion of the regulations that we believe most significantly affect our home health and hospice businesses.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensure, Certificates of Need ("CON") and Permits of Approval ("POA")</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home health and hospice care centers operate under licenses granted by the health authorities of their respective states. Some states require health care providers (including hospice and home health agencies) to obtain prior state approval for the purchase, construction or expansion of health care locations, capital expenditures exceeding a prescribed amount, or changes in services. For those states that require a CON or POA, the provider must also complete a separate application process establishing a location and must receive required approvals.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states, including a number in which we operate, carefully restrict new entrants into the market based on demographic and/or demonstrative usage of additional providers. These states limit the entry of new providers or services and the expansion </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of existing providers or services in their markets through a CON process, which is periodically evaluated and updated as required by applicable state law. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we require a CON or other similar approvals to expand our operations, our expansion could be adversely affected by the inability to obtain the necessary approvals, changes in the standards applicable to those approvals and possible delays and expenses associated with obtaining those approvals.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In every state where required, our care centers possess a license and/or CON or POA issued by the state health authority that determines the local service area for the home health or hospice care centers. Currently, state health authorities in 18 states and the District of Columbia require a CON or, in the State of Arkansas, a POA, in order to establish and operate a home health care center, and state health authorities in 9 states and the District of Columbia require a CON to operate a hospice care center.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate 228 home health care centers and 48 hospice care centers in the following CON/POA states as listed below.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"></td><td style="width:41.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alabama</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arkansas (POA)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mississippi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rhode Island</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Virginia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington, DC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Care Centers in CON States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Participation: Licensing, Certification and Accreditation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our care centers must comply with regulations promulgated by the United States Department of Health and Human Services and CMS in order to participate in the Medicare program and receive Medicare payments. Sections 1861(o) and 1891 of the SSA, 42 CFR 484.1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et seq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., establish the conditions that a home health agency ("HHA") must meet in order to participate in the Medicare program. Section 1861(dd) of the SSA, 42 CFR 418.1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et seq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., establishes the conditions that a hospice provider must meet in order to participate in the Medicare program. Among other things, these regulations, applicable to HHAs and hospices, respectively, known as conditions of participation (&#8220;COPs&#8221;), relate to the type of facility, its personnel and its standards of medical care, as well as its compliance with federal, state and local laws and regulations. Additional COPs applicable to HHAs, which went into effect on January 13, 2018, focus on the safe delivery of quality care provided to patients and the impact of that care on patient outcomes through the protection and promotion of patients' rights, care planning, delivery and coordination of services and streamlining of regulatory requirements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has adopted alternative sanction enforcement options which allow CMS (i) to impose temporary management, direct plans of correction or direct training and (ii) to impose payment suspensions and civil monetary penalties in each case on providers out of compliance with the COPs. CMS engages or has engaged a number of third party contractors, including Recovery Audit Contractors (&#8220;RACs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors ("UPICs"), Medicaid Integrity Contractors (&#8220;MICs&#8221;) and Supplemental </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Review Contractors (&#8220;SMRCs&#8221;), to conduct extensive reviews of claims data and state and federal government health care program laws and regulations applicable to healthcare providers. These audits evaluate the appropriateness of billings submitted for payment. In addition to identifying overpayments, audit contractors can refer suspected violations of law to government enforcement authorities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All providers are subject to compliance with various federal, state and local statutes and regulations in the U.S. and receive periodic inspection by state licensing agencies to review standards of medical care, equipment and safety. We have dedicated internal resources and utilize external parties when necessary to monitor and ensure compliance with the various applicable federal, state and local laws, rules and regulations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable laws and regulations, we could be subjected to liabilities, including criminal penalties, civil penalties (including the loss of our licenses to operate one or more of our businesses) and exclusion of a facility from participation in the Medicare, Medicaid and other federal and state health care programs. If any of our facilities were to lose its accreditation or otherwise lose its certification under the Medicare and Medicaid programs, the facility may be unable to receive reimbursement from the Medicare and Medicaid programs and other payors. We believe our facilities are in substantial compliance with current applicable federal, state, local and independent review body regulations and standards. The requirements for licensure, certification and accreditation are subject to change and, in order to remain qualified, it may become necessary for us to make changes in our facilities, equipment, personnel and services in the future, which could have a material adverse impact on our operations.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Anti-Fraud and Anti-Kickback Laws</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a provider under the Medicare and Medicaid systems, we are subject to various anti-fraud and abuse laws, including the federal health care programs&#8217; anti-kickback statute and, where applicable, its state law counterparts. Affected government health care programs include any health care plans or programs that are funded by the United States government (other than certain federal employee health insurance benefits/programs), including certain state health care programs that receive federal funds, such as Medicaid.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, these laws prohibit any offer, payment, solicitation or receipt of any form of remuneration to induce or reward the referral of business payable under a government health care program or in return for the purchase, lease, order, arranging for, or recommendation of items or services covered under a government health care program. A related law forbids the offer or transfer of anything of value, including certain waivers of co-payment obligations and deductible amounts, to a beneficiary of Medicare or Medicaid that is likely to influence the beneficiary&#8217;s selection of health care providers, again, subject to certain exceptions. Violations of the federal anti-kickback statute can result in imprisonment, the imposition of penalties topping $100,000, plus three times the amount of the improper remuneration and potentially, exclusion from furnishing services under any government health care program. In addition, the states in which we operate generally have laws that prohibit certain direct or indirect payments or fee-splitting arrangements between health care providers where they are designed to obtain the referral of patients from a particular provider.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stark Law</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Social Security Act includes a provision commonly known as the &#8220;Stark Law.&#8221; This law prohibits physicians from referring Medicare and Medicaid patients to entities for the provision of designated health services with which they or any of their immediate family members have a financial relationship, unless an exception to the law's prohibition is met. These types of referrals are known as &#8220;self-referrals.&#8221; Sanctions for violating the Stark Law include civil penalties up to $25,820 for each violation, up to $172,137 for schemes to circumvent the Stark restrictions and up to $10,000 for each day an entity fails to report required information and exclusion from the federal health care programs. There are a number of exceptions to the self-referral prohibition, including employment contracts, leases, and recruitment agreements that adhere to certain enumerated requirements. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the Stark Law result in payment denials and may also trigger civil monetary penalties and federal program exclusion. Several of the states in which we conduct business have also enacted statutes similar in scope and purpose to the federal anti-fraud and abuse laws and the Stark Law. These state laws may mirror the federal Stark Law or may be different in scope. The available guidance and enforcement activity associated with such state laws vary considerably.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor all aspects of our business and have developed a comprehensive ethics and compliance program that is designed to ensure that Amedisys meets all applicable federal guidelines and industry standards. Nonetheless, because the law in this area is complex and constantly evolving, there can be no assurance that federal regulatory authorities will not determine that any of our arrangements with physicians violate the Stark Law. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Privacy and Security Laws</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, requires us to comply with standards for the exchange of health information within our company and with third parties, such as payors, business associates and patients. These include standards for common health care transactions, such as claims information, plan eligibility, payment information and the use of electronic signatures; unique identifiers for providers, employers, health plans and individuals; and security, privacy, breach notification and enforcement.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA transaction regulations establish form, format and data content requirements for most electronic health care transactions, such as health care claims that are submitted electronically. The HIPAA privacy regulations establish comprehensive requirements relating to the use and disclosure of protected health information. The HIPAA security regulations establish minimum standards for the protection of protected health information that is stored or transmitted electronically. The HIPAA breach notification regulations establish the applicable requirements for notifying individuals, the U.S. Department of Health and Human Services (HHS), and the media in the event of a data breach affecting protected health information. Violations of the privacy, security and breach notification regulations are punishable by civil and criminal penalties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Recovery and Economic Reinvestment Act of 2009 (&#8220;ARRA&#8221;) increased the amount of civil monetary penalties that can be imposed for violations of HIPAA, and the amounts are updated annually for inflation. For 2020, penalties for HIPAA violations can range from $119 to $1.785 million per violation with a maximum fine of $1.785 million for identical violations during a calendar year.  In 2018, a nation-wide health benefit company paid $16 million to HHS following a data breach. Prior to this record payment, the largest HIPAA fine was $5.55 million.  ARRA also authorized state attorneys general to bring civil enforcement actions under HIPAA, and attorneys general are actively engaged in enforcement. These penalties could be in addition to other penalties assessed by a state for a breach which would be considered reportable under the state&#8217;s data breach notification laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act was enacted in conjunction with ARRA. Among other things, the HITECH Act makes business associates of covered entities directly liable for compliance with certain HIPAA requirements, strengthens the limitations on the use and disclosure of protected health information without individual authorizations, and adopts the additional HITECH Act enhancements, including enforcement of noncompliance with HIPAA due to willful neglect. The changes to HIPAA enacted as part of ARRA reflect a Congressional intent that HIPAA&#8217;s privacy and security provisions be more strictly enforced. These changes have stimulated increased enforcement activity and enhanced the potential that health care providers will be subject to financial penalties for violations of HIPAA. In addition, the Secretary of HHS is required to perform periodic audits to ensure covered entities (and their business associates, as that term is defined under HIPAA) comply with the applicable HIPAA requirements, increasing the likelihood that a HIPAA violation will result in an enforcement action. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the federal HIPAA regulations, most states also have laws that protect the confidentiality of health information and other personal data. Certain of these laws grant individuals rights with respect to their information, and we may be required to expend significant resources to comply with these laws.  Further, all 50 states and the District of Columbia have adopted data breach notification laws that impose, in varying degrees, an obligation to notify affected persons and/or state regulators in the event of a data breach or compromise, including when their personal information has or may have been accessed by an unauthorized person. Some state breach notification laws may also impose physical and electronic security requirements regarding the safeguarding of personal information, such as social security numbers and bank and credit card account numbers. Violation of state privacy, security, and breach notification laws can trigger significant monetary penalties. In addition, certain states&#8217; privacy, security and data breach laws, including, for example, the California Consumer Privacy Act, include a private right of action that may expose us to private litigation regarding our privacy practices and significant damages awards or settlements in civil litigation.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The False Claims Act</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal False Claims Act ("FCA") prohibits false claims or requests for payment for health care services. Under the FCA, the government may penalize any person who knowingly submits, or participates in submitting, claims for payment to the Federal Government which are false or fraudulent, or which contain false or misleading information. Any person who knowingly makes or uses a false record or statement to avoid paying the Federal Government, or knowingly conceals or avoids an obligation to pay money to the Federal Government, may also be subject to fines under the FCA. Under the FCA, the term &#8220;person&#8221; means an individual, company or corporation. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Government has used the FCA to prosecute Medicare and other governmental program fraud in areas such as violations of the Federal anti-kickback statute or the Stark Laws, coding errors, billing for services not provided and submitting false cost reports. The FCA has also been used to prosecute people or entities that bill services at a higher reimbursement rate </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than is allowed and that bill for care that is not medically necessary. In addition to government enforcement, the FCA authorizes private citizens to bring qui tam or &#8220;whistleblower&#8221; lawsuits, greatly extending the practical reach of the FCA. In 2018, the Department of Justice ("DOJ") announced that the FCA penalties would once again be increasing. The per-claim penalty range is between $11,665 and $23,331 (last updated 2020).</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Fraud Enforcement and Recovery Act of 2009 (&#8220;FERA&#8221;) amended the FCA with the intent of enhancing the powers of government enforcement authorities and whistleblowers to bring FCA cases. In particular, FERA attempts to clarify that liability may be established not only for false claims submitted directly to the government, but also for claims submitted to government contractors and grantees. FERA also seeks to clarify that liability exists for attempts to avoid repayment of overpayments, including improper retention of federal funds. FERA also included amendments to FCA procedures, expanding the government&#8217;s ability to use the Civil Investigative Demand process to investigate defendants, and permitting government complaints and intervention to relate back to the filing of the whistleblower&#8217;s original complaint. FERA is likely to increase both the volume and liability exposure of FCA cases brought against health care providers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Patient Protection and Affordable Care Act, Congress enacted requirements related to identifying and returning overpayments made under Medicare and Medicaid. CMS finalized regulations regarding this so-called &#8220;60-day rule,&#8221; which requires providers to report and return Medicare and Medicaid overpayments within 60 days of identifying the overpayment. A provider who retains identified overpayments beyond 60 days may be liable under the FCA. &#8220;Identification&#8221; occurs when a person &#8220;has, or should have through the exercise of reasonable diligence,&#8221; identified and quantified the amount of an overpayment. The final rule also established a six-year lookback period, meaning overpayments must be reported and returned if a person identifies the overpayment within six years of the date the overpayment was received. Providers must report and return overpayments even if they did not cause the overpayment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FCA, the Federal Government may use several criminal statutes to prosecute the submission of false or fraudulent claims for payment to the Federal Government. Many states have similar false claims statutes that impose liability for the types of acts prohibited by the False Claims Act. As part of the Deficit Reduction Act of 2005 (the &#8220;DRA&#8221;), Congress provided states an incentive to adopt state false claims acts consistent with the federal FCA. Additionally, the DRA required providers who receive $5&#160;million or more annually from Medicaid to include information on federal and state false claims acts, whistleblower protections and the providers&#8217; own policies on detecting and preventing fraud in their written employee policies.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Regulation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (&#8220;FDA&#8221;) regulates medical device user facilities, which include home health care providers. FDA regulations require user facilities to report patient deaths and serious injuries to the FDA and/or the manufacturer of a device used by the facility if the device may have caused or contributed to the death or serious injury of any patient. FDA regulations also require user facilities to maintain files related to adverse events and to establish and implement appropriate procedures to ensure compliance with the above reporting and recordkeeping requirements. User facilities are subject to FDA inspection, and noncompliance with applicable requirements may result in warning letters or sanctions including civil monetary penalties, injunction, product seizure, criminal fines and/or imprisonment.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Improving Medicare Post-Acute Care Transformation Act</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the Improving Medicare Post-Acute Care Transformation Act (&#8220;IMPACT Act&#8221;)&#160;was signed into law requiring the reporting of standardized patient assessment data for quality improvement, payment and discharge planning purposes across the spectrum of post-acute care providers (&#8220;PACs&#8221;), including skilled nursing facilities and home health agencies. The IMPACT Act requires PACs to report: (1)&#160;standardized patient assessment data at admission and discharge; (2) quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls and patient preference regarding treatment and discharge; and (3)&#160;resource use measures, including Medicare spending per beneficiary, discharge to community and hospitalization rates of potentially preventable readmissions. Failure to report such data when required would subject a facility to a two percent reduction in market basket prices then in effect.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IMPACT Act further requires HHS and the Medicare Payment Advisory Commission (&#8220;MedPAC&#8221;), a commission chartered by Congress to advise it on Medicare payment issues, to study alternative PAC payment models, including payment based upon individual patient characteristics and not care setting, with corresponding Congressional reports required based on such analysis. The IMPACT Act also included provisions impacting Medicare-certified hospices, including: (1)&#160;increasing survey frequency for Medicare-certified hospices to once every 36 months; (2)&#160;imposing a medical review process for facilities with a high percentage of stays in excess of 180 days; and (3)&#160;updating the annual aggregate Medicare payment cap.</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Claim Review Demonstration for Home Health Services</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;8, 2016, CMS announced the implementation of a three-year Medicare pre-claim review ("PCR") demonstration for home health services provided to beneficiaries in the states of Illinois, Florida, Texas, Michigan and Massachusetts. The pre-claim review is a process through which a request for provisional affirmation of coverage is submitted for review before a final claim is submitted for payment. On April 1, 2017, CMS paused the PCR Demonstration for Home Health Services while CMS considered a number of changes. CMS revised the demonstration to incorporate more flexibility and choices for providers, as well as risk-based changes to reward providers who show compliance with Medicare home health policies.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2018, CMS issued a notice indicating its intention to re-launch an HHA pre-claim review demonstration project. The original program had drawn criticism that it created significant administrative burdens and reduced access to care. Now called the Review Choice Demonstration for Home Health Services ("RCD"), the revised demonstration will give HHAs in the demonstration states three options: pre-claim review of all claims, post-payment review of all claims, or minimal post-payment review with a 25% payment reduction for all home health services. Under the pre-claim review and post-payment review options, provider claims are reviewed for every episode of care until the appropriate claim approval rate (90% based on a minimum of ten pre-claim requests or claims submitted) is reached. Further, once the appropriate claim approval rate is reached, a provider can elect to opt-out of claim reviews except for a spot check of 5% of its claims to ensure continued compliance. The demonstration initially applies to HHA providers in Florida, Illinois, North Carolina, Ohio and Texas, with the option to expand after five years to other states in the Medicare Administrative Contractor Jurisdiction M (Palmetto). In April 2019, CMS announced a June 1, 2019 start date for RCD in Illinois. In July 2019, CMS announced a September 30, 2019 start date for RCD in Ohio. Thereafter, in an October 21, 2019 release, CMS announced that it will reschedule the next phase of its RCD to allow agencies in Texas, North Carolina and Florida time to transition to PDGM. Throughout the first few months of 2020, CMS made various announcements about new start dates for the remaining three states, including a March 2, 2020 start date in Texas and projected start date of May 4, 2020 for North Carolina and Florida. The Texas portion began as scheduled; however, due to the ongoing public health emergency, on March 31, 2020, CMS announced a voluntary pause of RCD for Illinois, Ohio and Texas and delay for beginning the demonstration in North Carolina and Florida. In July 2020, CMS announced its intention to resume the demonstration on August 30, 2020 for Illinois, Ohio and Texas and a voluntary phase-in for North Carolina and Florida. The voluntary phase-in was extended by CMS in October until January 1, 2021 and then again in December until March 31, 2021.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Home Health Value-Based Purchasing</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2016, CMS implemented Home Health Value-Based Purchasing ("HHVBP"). The HHVBP model was designed to give Medicare-certified home health agencies incentives or penalties, through payment bonuses, to provide higher quality and more efficient care. HHVBP was rolled out to nine pilot states: Arizona, Florida, Iowa, Maryland, Massachusetts, Nebraska, North Carolina, Tennessee and Washington, seven of which Amedisys currently has home health operations.&#160;Bonuses and penalties began in 2018 with the maximum of plus or minus 3% growing to plus or minus 8% by 2022.&#160;Payment adjustments are calculated based on performance in a variety of measures which include current Quality of Patient Care and Patient Satisfaction star measures, as well as measures based on submission of data to a CMS web portal. The measures used may be subject to modification or change by CMS.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the demonstration, agencies with higher performance receive bonuses, while those with lower scores receive lower payments relative to current levels. Agency performance is evaluated against separate improvement and attainment scores, with payment tied to the higher of these two scores. CMS used 2015 as the baseline year for performance, with 2016 as the first year for performance measurement. The first payment adjustment began January 1, 2018, based on 2016 performance data. Between 2018 and 2022, the payment adjustment varies (upward or downward) from 3 percent to 8 percent. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, CMS and the Center for Medicare and Medicaid Innovation announced its intention, through rulemaking, to expand HHVBP with an implementation date no earlier than January 2022.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Home Health Payment Reform</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2018, Congress passed the Bipartisan Budget Act of 2018 ("BBA of 2018"), which funded government operations, set two-year government spending limits and enacted a variety of healthcare related policies. Specific to home health, the BBA of 2018 provides for a targeted extension of the home health rural add-on payment, a reduction of the 2020 market basket update, modification of eligibility documentation requirements and reform to the Home Health Prospective Payment System ("HHPPS"). The HHPPS reform included the following parameters: for home health units of service beginning on January 1, 2020, a 30-day payment system is to be applied; the transition to the 30-day payment system was to be budget neutral; and CMS was to conduct at least one Technical Expert Panel during 2018, prior to any notice and comment rulemaking process, related to the design of any new case-mix adjustment model.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final HHA regulations introduced by CMS (CMS-1689-FC) updated the Medicare HHPPS and finalized the implementation of an alternative case-mix adjustment methodology, PDGM, that became effective on January 1, 2020. PDGM adjusts payments to home health agencies based on patient characteristics for 30-day periods of care and also eliminates the use of therapy visits in the determination of payments. While the changes were to be implemented in a budget neutral manner to the industry, the ultimate impact will vary by provider based on factors including patient mix and admission source. Additionally, CMS made assumptions about behavioral changes which were finalized in the Calendar Year 2020 Home Health Final Rule released on October 31, 2019 and resulted in a 4.36% reduction to reimbursement. The behavioral changes were related to coding practices, low utilization payment adjustment ("LUPA") management and co-morbidities. CMS is required by law to analyze data for calendar years 2020-2026, retrospectively, to determine the impact of the difference between assumed and actual behavior changes and to make any such payment changes as are necessary to offset or supplement the adjustments based on anticipated behavior. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in an effort to eliminate fraud risks, CMS reduced the upfront payment associated with requests for anticipated payment ("RAPs") to 20% in 2020 with the full elimination of RAPs in 2021. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase-Out of the Rural Add-On</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BBA of 2018 also mandated the implementation of a new methodology for applying rural add-on payments for home health services (&#8220;rural add-on&#8221;). Unlike previous rural add-ons, which were applied to all rural areas uniformly, the extension provided varying add-on amounts depending on the rural county (or equivalent area) classification by classifying each rural county (or equivalent area) into one of three distinct categories: (1) rural counties and equivalent areas in the highest quartile of all counties and equivalent areas based on the number of Medicare home health episodes furnished per 100 individuals who are entitled to, or enrolled for, benefits under Part A of Medicare or enrolled for benefits under Part B of Medicare only, but not enrolled in a Medicare Advantage plan under Part C of Medicare (the "high utilization" category); (2) rural counties and equivalent areas with a population density of 6 individuals or fewer per square mile of land area and are not included in the "high utilization" category (the "low population density" category); and (3) rural counties and equivalent areas not in either the "high utilization" or "low population density" categories (the "all other" category).</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Calendar Year ("CY") 2019 Home Health Final Rule, CMS finalized policies for the rural add-on payments for CY 2019 through CY 2022, in accordance with section 50208 of the BBA of 2018. The CY 2019 proposed rule (83 FR 32373) described the provisions of the rural add-on payments and the methodology for applying the new payments and outlined how to categorize rural counties (or equivalent areas) based on claims data, the Medicare beneficiary summary file and census data.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CY 2019 through CY 2022 rural add-on percentages outlined in the rule are shown in the table below.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rural Add-On Percentages, CYs 2019-2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CY 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CY 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CY 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CY 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High utilization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low population density</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Civil Monetary Penalties</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Department of Health and Human Services may impose civil monetary penalties ("CMP") for a variety of civil offenses related to federal health care programs. They may be imposed upon any person or entity who presents, or causes to be presented, certain ineligible claims for medical items or services, for providing improper inducements to beneficiaries to obtain services, for payments to limit services to patients, and for offenses related to relationships with excluded individuals, among other things. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximum CMP amounts have been increased significantly as a result of the Bipartisan Budget Act of 2018, which was signed into law on February 9, 2018. The maximum CMP has increased to $104,330 for knowingly making or causing to be made a false statement, omission or misrepresentation of a material fact in any application, bid or contract to participate or enroll as a provider or supplier and to $58,832 for making or using a false record or statement that is material to a false or fraudulent claim. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Competitors</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are few barriers to entry in the home health and hospice jurisdictions that do not require certificates of need or permits of approval.&#160;Our primary competition in these jurisdictions comes from local privately and publicly-owned and hospital-owned health care providers.&#160;We compete based on the quality of services, the availability of personnel, expertise of visiting staff, and, in certain instances, on the price of our services.&#160;In addition, we compete with a number of non-profit organizations that finance acquisitions and capital expenditures on a tax-exempt basis or receive charitable contributions that are unavailable to us.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.amedisys.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#8220;Investors&#8221; on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link &#8220;SEC Filings&#8221;), free of charge, our annual reports on Form&#160;10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link &#8220;Governance&#8221;). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our electronically filed reports can also be obtained on the SEC&#8217;s internet site at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The risks described below, and risks described elsewhere in this Form 10-K, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows and the actual outcome of matters as to which forward-looking statements are made in this Form&#160;10-K. The risk factors described below and elsewhere in this Form 10-K are not the only risks faced by Amedisys. Our business and consolidated financial condition, results of operations and cash flows may also be materially adversely affected by factors that are not currently known to us, by factors that we currently consider immaterial or by factors that are not specific to us, such as general economic conditions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If any of the following risks are actually realized, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected. In that case, the trading price of our common stock could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should refer to the explanation of the qualifications and limitations on forward-looking statements under &#8220;Special Caution Concerning Forward-Looking Statements.&#8221; All forward-looking statements made by us are qualified by the risk factors described below.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reimbursement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and state changes to reimbursement and other aspects of Medicare and Medicaid could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue is primarily derived from Medicare, which accounted for 75%, 74% and 73% of our revenue during 2020, 2019 and 2018, respectively. Payments received from Medicare are subject to changes made through federal legislation. When such changes are implemented, we must also modify our internal billing processes and procedures accordingly, which can require significant time and expense. These changes, as further detailed in Part I, Item 1, &#8220;Business: Payment for Our Services,&#8221; can include changes to base payments and adjustments for home health services, changes to cap limits and per diem rates for hospice services and changes to Medicare eligibility and documentation requirements or changes designed to restrict utilization. Any such changes, including retroactive adjustments, adopted in the future by the Center for Medicare and Medicaid Services (&#8220;CMS&#8221;) could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6407 of the Affordable Care Act, as implemented by 42 CFR &#167; 424.22,&#160;added new Medicare requirements for face-to-face encounters to support claims for home health services.&#160;The requirements for face-to-face encounters continue to be one of the most complex issues in the industry and can be the source of claims denials if not fulfilled. Section 6407(d) of the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affordable Care Act also provided that the requirements for face-to-face encounters in the provisions described above shall apply in the case of physicians making certifications for home health services under title XIX of the Act (Medicaid) in the same manner and to the same extent as such requirements apply&#160;under title XVIII &#160;(Medicare). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are continuing efforts to reform governmental health care programs that could result in major changes in the health care delivery and reimbursement system on a national and state level, including changes directly impacting the reimbursement systems for our home health and hospice care centers. Though we cannot predict what, if any, reform proposals will be adopted, health care reform and legislation may have a material adverse effect on our business and our financial condition, results of operations and cash flows through decreasing payments made for our services.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be affected adversely by the continuing efforts of governmental payors to contain health care costs. We cannot assure you that reimbursement payments under governmental payor programs, including Medicare supplemental insurance policies, will remain at levels comparable to present levels or will be sufficient to cover the costs allocable to patients eligible for reimbursement pursuant to these programs. Any such changes could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality reporting requirements may negatively impact Medicare reimbursement.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospice quality reporting was mandated by the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act ("PPACA"), which directs the Secretary to establish quality reporting requirements for hospice programs. Failure to submit required quality data will result in a 2% reduction to the market basket percentage increase for that fiscal year. This quality reporting program is currently &#8220;pay-for-reporting,&#8221; meaning it is the act of submitting data that determines compliance with program requirements.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, in the Calendar Year 2015 Home Health Final Rule, CMS proposed to establish a new &#8220;Pay-for-Reporting Performance Requirement&#8221; with which provider compliance with quality reporting program requirements can be measured. Home health agencies that do not submit quality measure data to CMS are subject to a 2% reduction in their annual home health payment update percentage. Currently, home health agencies are required to report prescribed quality assessment data for a minimum of 90% of all patients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Improving Medicare Post-Acute Care Transformation Act of 2014 (the &#8220;IMPACT Act&#8221;) requires the submission of standardized data by home health agencies and other providers. Specifically, the IMPACT Act requires, among other significant activities, the reporting of standardized patient assessment data with regard to quality measures, resource use, and other measures. Failure to report data as required will subject providers to a 2% reduction in market basket prices then in effect.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that all of our agencies will continue to meet quality reporting requirements in the future which may result in one or more of our agencies seeing a reduction in its Medicare reimbursements. Regardless, we, like other healthcare providers, are likely to incur additional expenses in an effort to comply with additional and changing quality reporting requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value-based purchasing may negatively impact Medicare reimbursement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both government and private payors are increasingly looking to value-based purchasing to contain costs. Value-based purchasing focuses on quality of outcomes and efficiency of care, rather than quantity of care. CMS currently has a pilot program for home health agencies in several states, which it may expand to other states. CMS may also create a similar plan for hospices in the future. Government and private payors&#8217; implementation of value-based purchasing requirements could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any economic downturn, deepening of an economic downturn, continued deficit spending by the Federal Government or state budget pressures may result in a reduction in payments and covered services.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse developments in the United States could lead to a reduction in Federal Government expenditures, including governmentally funded programs in which we participate, such as Medicare and Medicaid. In addition, if at any time the Federal Government is not able to meet its debt payments unless the federal debt ceiling is raised, and legislation increasing the debt ceiling is not enacted, the Federal Government may stop or delay making payments on its obligations, including funding for government programs in which we participate, such as Medicare and Medicaid. Failure of the government to make payments under these programs could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Further, any failure by the United States Congress to complete the federal budget process and fund government operations may result in a Federal Government shutdown, potentially causing us to incur substantial costs without reimbursement under the Medicare program, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. As an example, the failure of the 2011 Joint Select Committee to meet its Deficit Reduction goal resulted in an automatic reduction in Medicare home health and hospice payments of 2% beginning April&#160;1, 2013.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, state budget pressures have resulted in reductions in state spending. Given that Medicaid outlays are a significant component of state budgets, we can expect continuing cost containment pressures on Medicaid outlays for our services.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future cost containment initiatives undertaken by private third party payors may limit our future revenue and profitability.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-Medicare revenue and profitability are affected by continuing efforts of third party payors to maintain or reduce costs of health care by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. There can be no assurance that third party payors will make timely payments for our services, and there is no assurance that we will continue to maintain our current payor or revenue mix. We are continuing our efforts to develop our non-Medicare sources of revenue and any changes in payment levels from current or future third party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be materially adversely affected by the ongoing COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the COVID-19 pandemic has resulted in a general economic downturn and volatility in the stock market and has also caused and may continue to cause a decrease in our patient volumes and revenues, an increase in costs and an inability to access our patients and referral sources and could lead to staffing and medical supply shortages, any of which, or a combination of which, could have a material adverse effect on our business and financial results. The ultimate impact of COVID-19, including the impact on our liquidity, financial condition and results of operations, is uncertain and will depend on many factors and future developments, which are highly uncertain and cannot be predicted at this time, including the severity, scope and length of time that the pandemic continues, including regional surges in COVID-19 cases at various times, the impact of new variants of the virus, uncertainty regarding vaccine distribution timing and efficacy in slowing the spread of the virus, its impact on the national and global economy, its effect on the demand for our services, our ability to ensure the safety of our patients and employees and the actions taken by federal, state and local authorities to contain or treat the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A shortage of qualified registered nursing staff and other clinicians, such as therapists and nurse practitioners, could materially impact our ability to attract, train and retain qualified personnel and could increase operating costs.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete for qualified personnel with other healthcare providers. Our ability to attract and retain clinicians depends on several factors, including our ability to provide these personnel with attractive assignments and competitive salaries and benefits. We cannot be assured we will succeed in any of these areas. In addition, there are shortages of qualified health care personnel in some of our markets. As a result, we may face higher costs of attracting clinicians and providing them with attractive benefit packages than we originally anticipated which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. In addition, if we expand our operations into geographic areas where health care providers historically have been unionized, or if any of our care center employees become unionized, being subject to a collective bargaining agreement may have a negative impact on our ability to timely and successfully recruit qualified personnel and may increase our operating costs. Generally, if we are unable to attract and retain clinicians, the quality of our services may decline and we could lose patients and referral sources, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are limited in our ability to control rates received for our services, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected if we are not able to maintain or reduce our costs to provide such services.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Medicare is our primary payor and rates are established through federal legislation, we have to manage our costs of providing care to achieve a desired level of profitability. Additionally, non-Medicare rates are difficult for us to negotiate as such payors are under pressure to reduce their own costs. As a result, we manage our costs in order to achieve a desired level of profitability including, but not limited to, centralization of various processes, the use of technology and management of the number of employees utilized. If we are not able to continue to streamline our processes and reduce our costs, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to provide consistently high quality of care, our business will be adversely impacted.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. Clinical quality is becoming increasingly important within our industry. Effective October 2012, Medicare began to impose a financial penalty upon hospitals that have excessive rates of patient readmissions within 30 days from hospital discharge. We believe this regulation provides a competitive advantage to home health providers who can differentiate themselves based upon quality, particularly by achieving low patient acute care hospitalization readmission rates and by implementing disease management programs designed to be responsive to the needs of patients served by referring hospitals. We are focused intently upon improving our patient outcomes, particularly our patient acute care hospitalization readmission rates. If we should fail to attain our goals regarding acute care hospitalization readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Medicare has established consumer-facing websites, Home Health Compare and Hospice Compare, that present data regarding our performance on certain quality measures compared to state and national averages. Failure to achieve or exceed these averages may affect our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain relationships with existing patient referral sources, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on referrals from physicians, hospitals and other sources in the communities we serve and on our ability to maintain good relationships with existing referral sources. Our referral sources are not contractually obligated to refer patients to us and may refer their patients to other providers. Our growth and profitability depend, in part, on our ability to establish and maintain close working relationships with these patient referral sources and to increase awareness and acceptance of the benefits of home health and hospice care by our referral sources and their patients. Our loss of, or failure to maintain, existing relationships or our failure to develop new referral relationships could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Possible changes in the case mix of patients, as well as payor mix and payment methodologies, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is determined by a number of factors, including our mix of patients and the rates of payment among payors. Changes in the case mix of our patients, payment methodologies or the payor mix among Medicare, Medicaid and private payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to negotiate favorable managed care contracts, or our loss of existing favorable managed care contracts, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of our strategies is to diversify our payor sources by increasing the business we do with managed care companies, and we strive to put in place favorable contracts with managed care payors. However, we may not be successful in these efforts. Additionally, there is a risk that the favorable managed care contracts that we put in place may be terminated. Managed care contracts typically permit the payor to terminate the contract without cause, on very short notice, typically 60 days, which can provide payors leverage to reduce volume or obtain favorable pricing. Our failure to negotiate and put in place favorable managed care contracts, or our failure to maintain in place favorable managed care contracts, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our industry is highly competitive, with few barriers to entry in certain states.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are few barriers to entry in home health markets that do not require a CON or POA. Our primary competition comes from local privately-owned and hospital-owned health care providers. We compete based on the availability of personnel, the quality of services, expertise of visiting staff, and in certain instances, on the price of our services. Increased competition in the future may limit our ability to maintain or increase our market share.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the introduction of new and enhanced service offerings by others, in combination with industry consolidation and the development of strategic relationships by our competitors (including mergers of competitors with each other and with insurers), could cause a decline in revenue or loss of market acceptance of our services or make our services less attractive. Additionally, we compete with a number of non-profit organizations that can finance acquisitions and capital expenditures on a tax-exempt basis or receive charitable contributions that are unavailable to us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care organizations and other third party payors continue to consolidate, which enhances their ability to influence the delivery of health care services. Consequently, the health care needs of patients in the United States are increasingly served by a smaller number of managed care organizations. These organizations generally enter into service agreements with a limited number of providers. Our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected if these organizations terminate us as a provider and/or engage our competitors as a preferred or exclusive provider. In addition, should private payors, including managed care payors, seek to negotiate additional discounted fee structures or the assumption by health care providers of all or a portion of the financial risk through prepaid capitation arrangements, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to react competitively to new developments, our operating results may suffer. State CON or POA laws often limit the ability of competitors to enter into a given market, are not uniform throughout the United States and are frequently the subject of efforts to limit or repeal such laws. If states remove existing CONs or POAs, we could face increased competition in these states. There can be no assurances that other states will not seek to eliminate or limit their existing CON or POA programs, which could lead to increased competition in these states. Further, we cannot assure you that we will be able to compete successfully against current or future competitors, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends on our information systems. A cyber-attack, security breach or our inability to effectively integrate, manage and keep our information systems secure and operational could disrupt our operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most healthcare providers, including all who accept commercial insurance Medicare and Medicaid, must comply with the HIPAA regulations regarding the privacy and security of protected health information. All 50 states also maintain laws focused on the privacy, security and notification requirements with regard to personally identifiable information, including health information. The HIPAA regulations impose significant requirements on providers and our third party vendor business associates with regard to how such protected health information may be used and disclosed. Further, the regulations include extensive and complex regulations which require providers to establish reasonable and appropriate administrative, technical and physical safeguards to ensure the confidentiality, integrity and availability of protected health information. Providers are obligated under HIPAA and state law to notify individuals and the government if personal information is compromised as defined by the respective law. In addition to federal regulators, state attorneys general are also enforcing information security breaches. All 50 states have breach notification laws. In addition to state laws regarding confidentiality of medical information, several states are now focused on expanding state privacy laws regarding personal information. HIPAA directs the Secretary of HHS to provide for periodic audits to ensure covered entities (and their business associates, as that term is defined under HIPAA) comply with the applicable HIPAA requirements.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our networks, systems and devices store sensitive information, including intellectual property, proprietary business information and personally identifiable information of our patients, partners, and employees. We have installed privacy protection systems and devices on our network, systems and point of care tablets in an attempt to prevent unauthorized access to information created, received, transmitted and maintained by us. However, our technology may fail to adequately secure the protected health information and personally identifiable information we create, receive, transmit and maintain in our databases. In such circumstances, we may be held liable to our patients and regulators, which could result in fines, litigation or adverse publicity that could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Even if we are not held liable, any resulting negative publicity could harm our business and distract the attention of management.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on effective, secure and operational information systems which include systems provided by or hosted by external contractors, partners and other service providers. For example, our care centers depend upon our information systems </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and software for patient care, accounting, billing, collections, risk management, quality assurance, human resources, payroll and other information considered to be confidential. We believe that our subcontractors and vendors take precautionary measures to prevent problems that could affect our business operations as a result of failure or disruption to their information systems or networks. However, there is no guarantee such efforts will be successful in preventing a disruption, and it is possible that we may be impacted by information system failures. The occurrence of any information system failures could result in interruptions, delays, breaches of protected health information and personally identifiable information, loss or corruption of data and cessations or interruptions in the availability of these systems and the information they create, receive, transmit or maintain. All of these events or circumstances, among others, could have an adverse effect on our business and consolidated financial position, results of operations and cash flows, and they could harm our business reputation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, all information systems including those we host or have hosted by third parties are vulnerable to damage or interruption from fire, flood, power loss, telecommunications failure, human acts, break-ins and other intentional or unintentional events. Our business is at risk from and may be impacted by information security incidents, including ransomware, malware, viruses, phishing, social engineering, and other security events. Such incidents can range from individual attempts to gain unauthorized access to information technology systems to more sophisticated security threats. These events can also result from internal compromises, such as human error or malicious acts. These events can occur on our systems or on the systems of our partners and subcontractors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Problems with, or the failure of, our technology and systems or any system upgrades or programming changes associated with such technology and systems could have a material adverse effect on our operations, patient care, data capture and integrity, medical documentation, billing, collections, assessment of internal controls and management and reporting capabilities. If we experience a reduction in the performance, reliability, or availability of our information systems, our operations and ability to produce timely and accurate reports could be materially adversely affected.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information systems and applications also require continual maintenance, upgrading and enhancement to meet our operational and security needs. Our acquisition activity requires transitions and integration of various information systems. We regularly upgrade and expand our information systems&#8217; capabilities. If we experience difficulties with the transition and integration of information systems or are unable to implement, maintain, or expand our systems properly, we could suffer from, among other things, operational disruptions, regulatory investigations or audits and increases in administrative expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As cyber threats continue to evolve, we may be required to expend significant capital and other resources to protect against the threat of security breaches or to mitigate and alleviate problems caused by breaches, including unauthorized access to protected health information and personally identifiable information stored in our information systems, and the introduction of computer viruses or other malicious software programs to our systems. Our security measures may be inadequate to prevent security breaches and our business operations could be materially adversely affected by federal and state fines and penalties, legal claims or proceedings, cancellation of contracts and loss of patients if security breaches are not prevented. The healthcare industry is currently a target for cyber criminals and therefore experiencing increased attention on compliance with regulations designed to safeguard protected health information and mitigate cyber-attacks on entities. There are significant costs associated with a breach, including investigation costs, remediation and mitigation costs, notification costs, attorney fees, litigation and the potential for reputational harm and lost revenues due to a loss in confidence in the provider. We cannot predict the costs to comply with these laws or the costs associated with a potential breach of protected health information, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows, and our business reputation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are subject to cyber-attacks or security breaches in the future, this could result in harm to patients; business interruptions and delays; the loss, misappropriation, corruption or unauthorized access of data; litigation and potential liability under privacy, security and consumer protection laws or other applicable laws; reputational damage and federal and state governmental inquiries. Any such problems or failures and the costs incurred in correcting any such problems or failures, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Further, to the extent our external information technology contractors or other service providers have their own cyber-attack, security event or information technology failure, become insolvent or fail to support the software or systems we have licensed from them, our operations could be materially adversely affected. A failure to restore our information systems after the occurrence of any of these events could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Because of the protected health information we store and transmit, loss of electronically stored information for any reason could expose us to a risk of regulatory action and litigation and possible liability and loss.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have all the necessary licenses from third parties to use technology and software that we do not own. A third party could, however, allege that we are infringing its rights, which may deter our ability to obtain licenses on commercially </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable terms from the third party, if at all, or cause the third party to commence litigation against us. In addition, we may find it necessary to initiate litigation to protect our trade secrets, to enforce our intellectual property rights and to determine the scope and validity of any proprietary rights of others. Any such litigation, or the failure to obtain any necessary licenses or other rights, could materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance liability coverage may not be sufficient for our business needs.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of operating in the home health industry, our business entails an inherent risk of claims, losses and potential lawsuits alleging incidents involving our employees that are likely to occur in a patient&#8217;s home. We maintain professional liability insurance to provide coverage to us and our subsidiaries against these risks. However, we cannot assure you claims will not be made in the future in excess of the limits of our insurance, nor can we assure you that any such claims, if successful and in excess of such limits, will not have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Our insurance coverage also includes fire, property damage and general liability with varying limits. We cannot assure you that the insurance we maintain will satisfy claims made against us or that insurance coverage will continue to be available to us at commercially reasonable rates, in adequate amounts or on satisfactory terms. Any claims made against us, regardless of their merit or eventual outcome, could damage our reputation and business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to substantial malpractice or other similar claims.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The services we offer involve an inherent risk of professional liability and related substantial damage awards. As of February&#160;19, 2021, we have approximately 21,000&#160;employees (10,800 home health, 6,500 hospice, 2,700 personal care and 1,000 corporate employees). In addition, we employ direct care workers on a contractual basis to support our existing workforce. Due to the nature of our business, we, through our employees and caregivers who provide services on our behalf, may be the subject of medical malpractice claims. A court could find these individuals should be considered our agents, and, as a result, we could be held liable for their acts or omissions. We cannot predict the effect that any claims of this nature, regardless of&#160;their ultimate outcome, could have on our business or reputation or on our ability to attract and retain patients and employees. While we maintain malpractice liability coverage that we believe is appropriate given the nature and breadth of our operations, any claims against us in excess of insurance limits, or multiple claims requiring us to pay deductibles, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain our corporate reputation, our business may suffer.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our ability to maintain our corporate reputation, including our reputation for providing quality patient care and for compliance with Medicare requirements and the other laws to which we are subject. Adverse publicity surrounding any aspect of our business, including the death or disability of any of our patients due to our failure to provide proper care, or due to any failure on our part to comply with Medicare requirements or other laws to which we are subject, could negatively affect our Company&#8217;s overall reputation and the willingness of referral sources to refer patients to us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A write off of a significant amount of intangible assets or long-lived assets could have a material adverse effect on our consolidated financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant and sustained decline in our stock price and market capitalization, a significant decline in our expected future cash flows, a significant adverse change in the business climate or slower growth rates could result in the need to perform an impairment analysis under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350 &#8220;Intangibles &#8211; Goodwill and Other&#8221; in future periods in addition to our annual impairment test. If we were to conclude that a write down of goodwill is necessary, then we would record the appropriate charge, which could result in material charges that are adverse to our consolidated financial condition and results of operations. See Part II, Item&#160;8, Note 5 &#8211; Goodwill and Other Intangible Assets, Net to our consolidated financial statements for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have grown in part through acquisitions, goodwill and other acquired intangible assets represent a substantial portion of our assets. Goodwill was $932.7 million as of December&#160;31, 2020 and if we make additional acquisitions, it is likely that we will record additional goodwill and intangible assets in our consolidated financial statements. We also have long-lived assets consisting of property and equipment and other identifiable intangible assets of $97.9 million as of December&#160;31, 2020, which we review on a periodic basis as well as when events or circumstances indicate that the carrying amount of an asset may not be recoverable. If a determination that a significant impairment in value of our unamortized intangible assets or long-lived assets occurs, such determination could require us to write off a substantial portion of our assets. A write off of these assets could have a material adverse effect on our consolidated financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations could be impacted by natural disasters.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of natural disasters in the markets in which we operate could not only impact the day-to-day operations of our care centers, but could also disrupt our relationships with patients, employees and referral sources located in the affected areas and, in the case of our corporate office, our ability to provide administrative support services, including billing and collection services. In addition, any episode of care that is not completed due to the impact of a natural disaster will generally result in lower revenue for the episode. For example, our corporate office and a number of our care centers are located in the southeastern United States and the Gulf Coast Region, increasing our exposure to hurricanes and flooding. Future hurricanes or other natural disasters may have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Growth Strategies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth strategy depends on our ability to acquire additional care centers and integrate and operate these care centers effectively. If our growth strategy is unsuccessful or we are not able to successfully integrate newly acquired care centers into our existing operations, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to fully integrate the operations of our acquired businesses with our current business structure in an efficient and cost-effective manner. Acquisitions involve significant risks and uncertainties, including difficulties in recouping partial episode payments and other types of misdirected payments for services from the previous owners; difficulties integrating acquired personnel and business practices into our business; the potential loss of key employees, referral sources or patients of acquired care centers; the delay in payments associated with change in ownership, control and the internal processes of the Medicare administrative contractors; and the assumption of liabilities and exposure to unforeseen liabilities of acquired care centers. Further, the financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, improve the reputation of the acquired business in the community and control costs. The failure to accomplish any of these objectives or to effectively integrate any of these businesses could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the acquisition agreements by which we have acquired companies require the former owners to indemnify us against certain liabilities related to the operation of the acquired company before we acquired it. In most of these agreements, however, the liability of the former owners is limited, and certain former owners may be unable to meet their indemnification responsibilities. We cannot assure you that these indemnification provisions will protect us fully or at all, and as a result, we may face unexpected liabilities that could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State efforts to regulate the establishment or expansion of health care providers could impair our ability to expand our operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states require health care providers (including skilled nursing facilities, hospice care centers, home health care centers and assisted living facilities) to obtain prior approval, known as a CON or POA, in order to commence operations. See Part I, Item 1, &#8220;Our Regulatory Environment&#8221; for additional information on CONs and POAs. If we are not able to obtain such approvals, our ability to expand our operations could be impaired, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal regulation may impair our ability to consummate acquisitions or open new care centers.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in federal laws or regulations may materially adversely impact our ability to acquire care centers or open new start-up care centers. For example, the Social Security Act provides the Secretary with the authority to impose temporary moratoria on the enrollment of new Medicare providers, if deemed necessary to combat fraud, waste or abuse under government programs.&#160;While there are no active Medicare moratoria, there can be no assurance that CMS will not adopt a moratorium on new providers in the future.&#160; Additionally, in 2010, CMS implemented and amended a regulation known as the &#8220;36 Month Rule&#8221; that is applicable to home health care center acquisitions.&#160;Subject to certain exceptions, the 36 Month Rule prohibits buyers of certain home health care centers - those that either enrolled in Medicare or underwent a change in majority ownership fewer than 36 months prior to the acquisition - from assuming the Medicare billing privileges of the acquired care center. The 36 Month Rule may restrict bona fide transactions and potentially block new investments in home health agencies. These changes in federal laws and regulations, and similar future changes, may further increase competition for acquisition targets and could have a material detrimental impact on our acquisition strategy.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Laws and Government Regulations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive government regulation. Any changes to the laws and regulations governing our business, or to the interpretation and enforcement of those laws or regulations, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is subject to extensive federal and state laws and regulations. See Part I, Item 1, &#8220;Our Regulatory Environment&#8221; for additional information on such laws and regulations. Federal and state laws and regulations impact how we conduct our business, the services we offer and our interactions with patients, our employees and the public and impose certain requirements on us such as:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensure and certification;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequacy and quality of health care services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifications of health care and support personnel;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality and safety of medical equipment;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">confidentiality, maintenance and security associated with medical records and claims processing;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and other referral sources;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating policies and procedures;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">emergency preparedness risk assessments and policies and procedures;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">policies and procedures regarding employee relations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition of facilities and services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">billing for services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements for utilization of services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">documentation required for billing and patient care; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reporting and maintaining records regarding adverse events.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations, and their interpretations, are subject to change. Changes in existing laws and regulations, or their interpretations, or the enactment of new laws or regulations could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows by:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our administrative and other costs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing or decreasing mandated services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">causing us to abandon business opportunities we might have otherwise pursued;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreasing utilization of services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">forcing us to restructure our relationships with referral sources and providers; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring us to implement additional or different programs and systems.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are subject to various routine and non-routine reviews, audits and investigations by the Medicare and Medicaid programs and other federal and state governmental agencies, which have various rights and remedies against us if they establish that we have overcharged the programs or failed to comply with program requirements. We are also subject to potential lawsuits under the federal False Claims Act and other federal and state whistleblower statutes designed to combat fraud and abuse in our industry. Violation of the laws governing our operations, or changes in interpretations of those laws, could result in the imposition of fines, civil or criminal penalties, and the termination of our rights to participate in federal and state-sponsored programs and/or the suspension or revocation of our licenses. If we become subject to material fines, or if other sanctions or other corrective actions are imposed on us, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face periodic and routine reviews, audits and investigations under our contracts with federal and state government agencies and private payors, and these audits could have adverse findings that may negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our participation in the Medicare and Medicaid programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with these programs and applicable laws and regulations. We also are subject to audits under various federal and state government programs in which third party firms engaged by CMS, including the Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;) and Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;), conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare program. The Office of Inspector General-HHS ("OIG") also conducts audits and has included various home home health agency and hospice payment and quality issues in its current workplan. Additionally, private pay sources reserve the right to conduct audits. If billing errors are identified in the sample of reviewed claims, the billing error can be extrapolated to all claims filed which could result in a larger overpayment than originally identified in the sample of reviewed claims. Our costs to respond to and defend reviews, audits and investigations may be significant and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Moreover, an adverse review, audit or investigation could result in:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required refunding or retroactive adjustment of amounts we have been paid pursuant to the federal or state programs or from private payors;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state or federal agencies imposing fines, penalties and other sanctions on us;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of our right to participate in the Medicare program, state programs, or one or more private payor networks;&#160;or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our business and reputation in various markets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These results could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a care center fails to comply with the conditions of participation in the Medicare program, that care center could be subjected to sanctions or terminated from the Medicare program.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our care centers must comply with required conditions of participation in the Medicare program. If we fail to meet the conditions of participation at a care center, we may receive a notice of deficiency from the applicable state surveyor. If that care center then fails to institute an acceptable plan of correction to remediate the deficiency within the correction period provided by the state surveyor, that care center could be terminated from the Medicare program or subjected to alternative sanctions. CMS outlined its alternative sanction enforcement options for home health care centers through a regulation published in 2012; under the regulation, CMS may impose temporary management, direct a plan of correction, direct training or impose payment suspensions and civil monetary penalties, in each case, upon providers who fail to comply with the conditions of participation. Termination of one or more of our care centers from the Medicare program for failure to satisfy the program&#8217;s conditions of participation, or the imposition of alternative sanctions, could disrupt operations, require significant attention by management, or have a material adverse effect on our business and reputation and consolidated financial condition, results of operations and cash flows. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal and state laws that govern our financial relationships with physicians and other health care providers, including potential or current referral sources.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with federal and state laws, generally referred to as &#8220;anti-kickback laws,&#8221; that prohibit certain direct and indirect payments or other financial arrangements between health care providers that are designed to encourage the referral of patients to a particular provider for medical services. In addition to these anti-kickback laws, the Federal Government has enacted specific legislation, the physician self-referral prohibition, commonly known as the &#8220;Stark Law,&#8221; that prohibits certain financial relationships, specifically including ownership interests and compensation arrangements, between physicians (and the immediate family members of physicians) and providers of designated health services, such as home health care centers, to whom the physicians refer patients. Some of these same financial relationships are also subject to additional regulation by states. Although we believe we have structured our relationships with physicians and other actual or potential referral sources to comply with these laws where applicable, the laws are complex. It is possible that courts or regulatory agencies may interpret state and federal anti-kickback laws and/or the Stark Law and similar state laws regulating relationships between health care providers and physicians in ways that will adversely implicate our practices or that isolated instances of noncompliance may occur. Violations of federal or state Stark or anti-kickback laws could lead to criminal or civil fines or other sanctions, including repayment of federal health care program payments related to these arrangements, denials of government program reimbursement or even exclusion from participation in governmental health care programs, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. It is possible that a claim that results from a kickback or is made in violation of the Stark Law also may render it false or fraudulent, creating further potential liability under the federal False Claims Act, discussed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face significant uncertainty in the industry due to government health care reform.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care industry in the United States is subject to fundamental changes due to ongoing health care reform efforts and related political, economic and regulatory influences. In March&#160;2010, comprehensive health care reform legislation was signed into law in the United States through the passage of PPACA, which calls for a number of changes to Medicare payment rates and the rebasing of the home health payment system to be made over time. PPACA has had and will likely continue to have a significant impact upon the health care delivery system. Implementation of the regulations and related initiatives as required by PPACA may increase our costs, decrease our revenues, expose us to expanded liability or require us to revise the ways in which we conduct our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various health care reform proposals similar to the federal reforms have also emerged at the state level, including in several states in which we operate. We cannot predict with certainty what health care initiatives, if any, will be implemented at the state level, or what the ultimate effect of federal health care reform or any future legislation or regulation may have on us or on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to impacting our Medicare businesses, PPACA may also significantly affect our non-Medicare businesses. PPACA makes many changes to the underwriting and marketing practices of private payors. The resulting economic pressures could prompt these payors to seek to lower their rates of reimbursement for the services we provide. PPACA may continue to have residual effects on our non-Medicare business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, efforts to repeal or substantially modify provisions of the PPACA continue in Congress and in the courts. The ultimate outcomes of legislative efforts to repeal, substantially amend, eliminate or reduce funding for the PPACA is unknown. In addition to the prospect for legislative repeal or revision, administrative action, including revised regulation and other Executive Branch action, could impose changes on how the law is applied. The effect of any major modification or repeal of the PPACA on our business, operations or financial condition cannot be predicted, but could be materially adverse.</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in payment may cause liquidity problems.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is characterized by delays from the time we provide services to the time we receive payment for these services. If we have difficulty in obtaining documentation, such as physician orders, experience information system problems or experience other issues that arise with Medicare or other payors, we may encounter additional delays in our payment cycle.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, timing delays in billings and collections may cause working capital shortages. Working capital management, including prompt and diligent billing and collection, is an important factor in achieving our financial results and maintaining liquidity. It is possible that documentation support, system problems, Medicare or other payor issues or industry trends may extend our collection period, which may materially adversely affect our working capital, and our working capital management procedures may not successfully mitigate this risk.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2018, CMS issued a notice indicating its intention to re-launch a home health agency pre-claim review demonstration project. Now called the Review Choice Demonstration for Home Health Services, the revised demonstration will give home health agencies in the demonstration states three initial options: pre-claim review of all claims, post-payment review of all claims, or minimal post-payment review with a 25% payment reduction for all home health services. Reduced review options are available for home health agencies that demonstrate compliance. The demonstration initially applies to home health providers in Florida, Illinois, North Carolina, Ohio, and Texas, with staggered start dates beginning in 2019 and extending into 2021. Compliance with this process could result in increased administrative costs or delays in reimbursement for home health services in states subject to the demonstration.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice operations may experience payment delays. We have experienced payment delays when attempting to collect funds from state Medicaid programs in certain instances. Delays in receiving payments from these programs may also materially adversely affect our working capital.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in units of payment for home health agencies could reduce our Medicare home health reimbursement levels.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Bipartisan Budget Act of 2018 and final rules issued in October of 2019, PDGM changed the unit of payment for home health agencies from a 60-day episode of care to 30-day periods of care, effective January 1, 2020. Although this change was to be implemented in an overall budget neutral manner, the ultimate impact will vary by provider based on factors including patient mix and admission source. Additionally, CMS made assumptions about behavioral changes which resulted in a 4.36% reduction to reimbursement. Accordingly, the adoption of PDGM had a negative impact on our Medicare revenue per episode in 2020 and could negatively impact our rates of reimbursement in future years and have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. See Part I, Item 1, &#8220;Our Regulatory Environment - Home Health Payment Reform&#8221; for additional information on PDGM.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The volatility and disruption of the capital and credit markets and adverse changes in the United States and global economies could impact our ability to access both available and affordable financing, and without such financing, we may be unable to achieve our objectives for strategic acquisitions and internal growth.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we intend to finance strategic acquisitions and internal growth with cash flows from operations and borrowings under our revolving credit facility, we may require sources of capital in addition to those presently available to us. Uncertainty in the capital and credit markets may impact our ability to access capital on terms acceptable to us (i.e. at attractive/affordable rates) or at all, and this may result in our inability to achieve present objectives for strategic acquisitions and internal growth. Further, in the event we need additional funds, and we are unable to raise the necessary funds on acceptable terms, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could impact our financial condition and impair our ability to fulfill other obligations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had total outstanding indebtedness of approximately $215.1 million.&#160;Our level of indebtedness could have a material adverse effect on our business and consolidated financial position, results of operations and cash flows and could impair our ability to fulfill other obligations in several ways, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could require us to dedicate a portion of our cash flow from operations to payments on our indebtedness, which could reduce the availability of cash flow to fund acquisitions, start-ups, working capital, capital expenditures and other general corporate purposes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could limit our ability to borrow money or sell stock for working capital, capital expenditures, debt service requirements and other purposes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could limit our flexibility in planning for, and reacting to, changes in our industry or business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could make us more vulnerable to unfavorable economic or business conditions;&#160;and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could limit our ability to make acquisitions or take advantage of other business opportunities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we incur additional indebtedness, the risks described above could increase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The agreements governing our indebtedness contain various covenants that limit our discretion in the operation of our business and our failure to satisfy requirements in these agreements could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements governing our indebtedness (the &#8220;Debt Agreements&#8221;) contain certain obligations, including restrictive covenants that require us to comply with or maintain certain financial covenants and ratios and restrict our ability to:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional debt;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redeem or repurchase stock, pay dividends or make other distributions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain investments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create liens;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into transactions with affiliates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make acquisitions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into joint ventures;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">merge or consolidate;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invest in foreign subsidiaries;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amend acquisition documents;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into certain swap agreements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain restricted payments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfer, sell or leaseback assets; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make fundamental changes in our corporate existence and principal business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Debt Agreements also limit our ability to reinvest the net cash proceeds from asset sales or subordinated debt issuances in certain circumstances. For example, in the event we or any of our subsidiaries receive more than $5 million in net cash proceeds from an asset sale, disposition or involuntary disposition, our Debt Agreements require us to prepay our term loan facility and revolving credit facility with all of such net cash proceeds, unless we elect to reinvest the net cash proceeds in fixed or capital assets related to our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, events beyond our control could affect our ability to comply with the Debt Agreements. Any failure by us to comply with or maintain all applicable financial covenants and ratios and to comply with all other applicable covenants could result in an event of default with respect to the Debt Agreements.&#160;If we are unable to obtain a waiver from our lenders in the event of any non-compliance, our lenders could accelerate the maturity of any outstanding indebtedness and terminate the commitments to make further extensions of credit (including our ability to borrow under our revolving credit facility).&#160;Any failure to comply with these covenants could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The potential cessation or modification of LIBOR may increase our interest expense or otherwise adversely affect us.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our credit facility carries a floating interest rate which is tied to the Eurodollar rate (i.e., LIBOR) and the prime rate. On July&#160;27, 2017, the United Kingdom&#8217;s Financial Conduct Authority, which regulates LIBOR, announced that it intends to stop persuading or compelling banks to submit LIBOR quotations after 2021 (the &#8220;FCA Announcement&#8221;). The FCA Announcement indicates that the continuation of LIBOR on the current basis cannot and will not be assured after 2021, and LIBOR may cease to exist or otherwise be unsuitable for use as a benchmark. Recent proposals for LIBOR reforms may result in the establishment of new methods of calculating LIBOR or the establishment of one or more alternative benchmark rates. Although our credit facility provides for alternative base rates, some of those alternative base rates are related to LIBOR, and the consequences of any potential cessation, modification or other reform of LIBOR cannot be predicted at this time. If LIBOR ceases to exist, we most likely will need to amend the credit facility, and we cannot predict what alternative interest rate(s) will be negotiated with our counterparties. As a result, our interest expense may increase, our ability to refinance some or all of our existing indebtedness may be impacted and our available cash flow may be adversely affected.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price at which our common stock trades may be volatile. The stock market from time to time experiences significant price and volume fluctuations that impact the market prices of securities, particularly those of health care companies. The market price of our common stock may be influenced by many factors, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operating and financial performance;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variances in our quarterly financial results compared to research analyst expectations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the depth and liquidity of the market for our common stock;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future purchases or sales of common stock by the Company or large stockholders or the perception that such purchases or sales could occur;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investor, analyst and media perception of our business and our prospects;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to litigation or governmental investigations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or proposed changes in health care laws or regulations or enforcement of these laws and regulations, or announcements relating to these matters;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">departure of key personnel;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the Medicare, Medicaid and private insurance payment rates for home health and hospice;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the operating and stock price performance of other comparable companies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market and business conditions related to COVID-19;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and stock market conditions; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors described in this "Risk Factors" section and elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the NASDAQ Global Select Market (&#8220;NASDAQ&#8221;) in particular, has experienced price and volume fluctuations that we believe have often been unrelated or disproportionate to the operating performance of health care provider companies. These broad market and industry factors may materially reduce the market price of our common stock, regardless of our operating performance. Securities class-action cases have often been brought against companies following periods of volatility in the market price of their securities. Such litigation, if instituted against us, could result in substantial costs and a diversion of management's attention and resources.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities of short sellers could reduce the price or prevent increases in the price of our common stock. &#8220;Short sale&#8221; is defined as the sale of stock by an investor that the investor does not own. Typically, investors who sell short believe the price of the stock will fall, and anticipate selling shares at a higher price than the purchase price at which they will buy the stock. As of December&#160;31, 2020, investors held a short position of approximately 0.6 million&#160;shares of our common stock which represented 2% of our outstanding common stock. The anticipated downward pressure on our stock price due to actual or anticipated sales of our stock by some institutions or individuals who engage in short sales of our common stock could cause our stock price to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Board of Directors may use anti-takeover provisions or issue stock to discourage a change of control.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation currently authorizes us to issue up to 60,000,000&#160;shares of common stock and 5,000,000 shares of undesignated preferred stock. Our Board of Directors may cause us to issue additional stock to discourage an attempt to obtain control of our company. For example, shares of stock could be sold to purchasers who might support our Board of Directors in a control contest or to dilute the voting or other rights of a person seeking to obtain control. In addition, our Board of Directors could cause us to issue preferred stock entitling holders to vote separately on any proposed transaction, convert preferred stock into common stock, demand redemption at a specified price in connection with a change in control, or exercise other rights designed to impede a takeover.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of additional shares may, among other things, dilute the earnings and equity per share of our common stock and the voting rights of common stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented other anti-takeover provisions or provisions that could have an anti-takeover effect, including advance notice requirements for director nominations and stockholder proposals, no cumulative voting for directors, requirement that director vacancies are filled by remaining directors (including vacancies resulting from removal), and the number of directors is fixed by the Board of Directors, and the Board of Directors can increase or decrease the size of the Board of Directors without stockholder approval (within the range set forth in our Certificate of Incorporation and Bylaws). These provisions, and others that our Board of Directors may adopt hereafter, may discourage offers to acquire us and may permit our Board of Directors to choose not to entertain offers to purchase us, even if such offers include a substantial premium to the market price of our stock. Therefore, our stockholders may be deprived of opportunities to profit from a change of control.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_22"></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.  UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.  PROPERTIES</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive office is located in Nashville, Tennessee in a leased property consisting of 25,097 square feet; our corporate headquarters is located in Baton Rouge, Louisiana in a leased property consisting of 85,955 square feet. We believe we have adequate space to accommodate our corporate staff located in these locations for the foreseeable future.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our executive office and corporate headquarters, we also lease facilities for our home health, hospice and personal-care care centers.&#160;Generally, our leases have an initial term of five years, but range from one to ten years.&#160;Most of our leases also contain early termination options and renewal options. The following table shows the location of our 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and 14 personal-care care centers at December&#160;31, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.834%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alabama</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New Jersey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arkansas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nebraska</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arizona</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New York</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New Hampshire</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Connecticut</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">North Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ohio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oklahoma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oregon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Illinois</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indiana</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rhode Island</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Iowa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kansas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">South Dakota</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kentucky</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tennessee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Louisiana</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Virginia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Washington</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maryland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">West Virginia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michigan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wisconsin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minnesota</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Washington, D.C.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mississippi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Missouri</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 25.75pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.  LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item&#160;8, Note 11 &#8211; Commitments and Contingencies for information concerning our legal proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="id92bd70d620044018083957a908405c4_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="id92bd70d620044018083957a908405c4_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information and Holders</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the NASDAQ Global Select Market under the trading symbol &#8220;AMED.&#8221; As of February&#160;19, 2021, there were approximately 483&#160;holders of record of our common stock. This number of holders of record does not represent the actual number of beneficial owners of our common stock because shares are frequently held in &#8220;street name&#8221; by securities dealers and others for the benefit of individual owners who have the right to vote their shares.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our common stock or any other of our securities and do not expect to pay cash dividends for the foreseeable future. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. Future decisions concerning the payment of dividends will depend upon our results of operations, financial condition, capital expenditure plans and debt service requirements, as well as such other factors as our Board of Directors, in its sole discretion, may consider relevant. In addition, our outstanding indebtedness restricts, and we anticipate any additional future indebtedness may restrict, our ability to pay cash dividends; provided, however, that we may pay dividends (i) payable solely in our equity securities and (ii) if (1) no default or event of default under the Amended Credit Agreement shall have occurred and be continuing at the time of such dividend or would result therefrom, (2) we demonstrate that, upon giving pro forma effect to such dividend, our consolidated leverage ratio (as defined in the Amended Credit Agreement) is less than 2.0 to 1.0 and (3) we demonstrate a minimum liquidity of $50 million upon giving effect to such dividend.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended December&#160;31, 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)<br/>Total&#160;Number<br/>of&#160; Shares&#160;(or&#160;Units)<br/>Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)<br/>Average&#160;Price<br/>Paid&#160; per&#160;Share&#160;(or&#160;Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)<br/>Total&#160;Number&#160; of<br/>Shares&#160;(or&#160;Units)<br/>Purchased&#160;as&#160;Part&#160;of<br/>Publicly Announced<br/>Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(d)<br/>Maximum&#160;Number&#160; (or<br/>Approximate Dollar<br/>Value) of Shares (or<br/>Units)&#160;That&#160;May&#160;Yet&#160;Be<br/>Purchased Under the<br/>Plans or Programs (2)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2020 to October 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2020 to November 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2020 to December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.64&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.</span></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On December 23, 2020, we announced that our board of directors authorized a stock repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through December 31, 2021. We did not repurchase any shares pursuant to this stock repurchase program. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Performance Graph below compares the cumulative total stockholder return on our common stock, $0.001 par value per share, for the five-year period ended December&#160;31, 2020, with the cumulative total return on the NASDAQ composite index and an industry peer group over the same period (assuming the investment of $100 in our common stock, the NASDAQ composite index and the industry peer group on December&#160;31, 2015 and the reinvestment of dividends). The peer group we selected is comprised of: Addus Homecare Corporation ("ADUS"), Chemed Corporation ("CHE"), Encompass Health Corporation ("EHC"), LHC Group, Inc. (&#8220;LHCG&#8221;) and National Healthcare Corporation (&#8220;NHC&#8221;). The cumulative total stockholder return on the following graph is historical and is not necessarily indicative of future stock price performance. No cash dividends have been paid on our common stock.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><img src="amed-20201231_g2.jpg" alt="amed-20201231_g2.jpg" style="height:459px;margin-bottom:5pt;vertical-align:text-bottom;width:594px"/></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:24.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Composite</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Peer Group</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This stock performance information is &#8220;furnished&#8221; and shall not be deemed to be &#8220;soliciting material&#8221; or subject to Regulation 14A under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this report and irrespective of any general incorporation by reference language in any such filing, except to the extent we specifically incorporate the information by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="id92bd70d620044018083957a908405c4_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. SELECTED FINANCIAL DATA</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selected consolidated financial data presented below is derived from our audited consolidated financial statements for the five-year period ended December&#160;31, 2020. The financial data for the years ended December&#160;31, 2020, 2019 and 2018 should be read together with our consolidated financial statements and related notes included in Item&#160;8, &#8220;Financial Statements and Supplementary Data&#8221; and the information included in Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; herein.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 (1)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017 (2)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016 (3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Data:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,071,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,662,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,511,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,419,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. per basic share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. per diluted share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During 2020, we recorded a $24.0 million income tax benefit in connection with the stock option exercise by Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During 2017, we recorded charges related to the Securities Class Action Lawsuit settlement and related legal fees in the amount of $29.8&#160;million ($18.1&#160;million, net of tax). Additionally, we recorded a charge in the amount of $21.4 million as the result of H.R. 1 (Tax Cuts and Jobs Act) enacted on December 22, 2017.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During 2016, we recorded Homecare Homebase (&#8220;HCHB&#8221;) implementation costs in the amount of $8.4&#160;million ($5.1&#160;million, net of tax) and recognized a non-cash charge to write off assets as a result of our conversion to the HCHB platform in the amount of $4.4&#160;million ($2.7&#160;million, net of tax).</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.771%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Data:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,567,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,262,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">717,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt, including current portion</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Amedisys, Inc. stockholders&#8217; equity</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">809,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">515,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_43"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for 2020, 2019 and 2018. This discussion should be read in conjunction with our audited financial statements included in Item 8, &#8220;Financial Statements and Supplementary Data&#8221; and Part I, Item 1, &#8220;Business&#8221; of this Annual Report on Form 10-K. The following analysis contains forward-looking statements about our future revenues, operating results and expectations. See &#8220;Special Caution Concerning Forward-Looking Statements&#8221; for a discussion of the risks, assumptions and uncertainties affecting these statements as well as Part I, Item 1A, &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 75%, 74% and 73% of our revenue derived from Medicare for 2020, 2019 and 2018, respectively.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients assistance with the essential activities of daily living. As of December&#160;31, 2020, we owned and operated 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and 14 personal-care care centers, including unconsolidated joint ventures, in 39 states within the United States and the District of Columbia.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Centers Summary (Includes Unconsolidated Joint Ventures)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Start-Ups/Denovos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Start-Ups/Denovos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Start-Ups/Denovos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we refer to &#8220;same store business,&#8221; we mean home health, hospice and personal-care care centers that we have operated for at least the last twelve months and start-ups that are an expansion of a same store care center; when we refer to &#8220;acquisitions,&#8221; we mean home health, hospice and personal-care care centers that we acquired within the last twelve months; and when we refer to &#8220;denovos,&#8221; we mean home health, hospice and personal-care care centers opened by us in the last twelve months which are not an expansion of a same store care center. Once a care center has been in operation for a twelve month period, the results for that particular care center are included as part of our same store business from that date forward. </span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Developments</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achieved the highest Quality of Patient Care Star Score in the Home Health industry in the October 2020 Home Health Compare ("HHC") release of 4.33 stars with 95% of our care centers at 4+ Stars.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Outperformed the industry on all Hospice Item Set ("HIS") measures.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performed over 11.5 million visits.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquired and successfully integrated Asana Hospice ("Asana") and AseraCare Hospice ("AseraCare") making Amedisys the third largest hospice company in the United States, exceeding 13,000 in hospice average daily census.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successfully procured personal protective equipment ("PPE") and implemented protocols to ensure the safety of our employees and patients during the novel coronavirus pandemic as discussed in further detail under Novel Coronavirus Pandemic ("COVID-19") below.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ended the year with overall voluntary turnover of 18.3% and reduced our early exit rate by 6% over 2019, ending 2020 at 11.9%.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successfully piloted several tools and data analytics platforms of Medalogix, a predictive data and analytics company, helping to further optimize our current business and positioning us to work more closely with Medicare Advantage payors.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implemented pay practice changes and staffing model efficiencies to further drive operational excellence.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successfully navigated the transition to the Patient-Driven Groupings Model ("PDGM") while continuing to deliver operational efficiencies through margin expansion.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Executed a Care Coordination Agreement with BrightStar Care to facilitate the coordination of care between home health and hospice care centers and a network of personal care partners.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased operating income 24%.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded home health gross margin as a percentage of revenue by 320 basis points.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delivered $289 million in cash flow from operations.</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Strategy</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Further advance our industry leading Quality of Patient Care Star scores in home health. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drive best-in-class hospice quality while continuing to integrate acquired hospice assets. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance our culture and sense of belonging through diversity and inclusion initiatives. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Build a learning culture through world class leadership development.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduce turnover in critical clinician roles.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue our success in operating under PDGM.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expand our analytics capabilities internally and through our Medalogix investment.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deliver above industry average growth rates in all three lines of business. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pursue consolidations in the home health industry via a regional-based acquisition strategy.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Incrementally innovate around our core business to deliver new home based care models such as Skilled Nursing Facility ("SNF") at Home.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Performance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results for the year ended December&#160;31, 2020 were impacted by acquisitions, COVID-19, the suspension of sequestration and the transition to PDGM. On a consolidated basis, we increased operating income $42 million on a $116 million increase in net service revenue.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health care centers experienced growth in volumes and improvement in utilization and clinician mix which, combined with our variable cost structure and sequestration relief, mitigated a significant portion of our estimated COVID-19 impact and led to the segment delivering a $26 million increase in operating income.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice segment completed the acquisitions of Asana and AseraCare in 2020. These acquisitions contributed approximately $13 million in operating income to the hospice segment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personal care segment contributed approximately $6 million in operating income during 2020.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Economic and Industry Factors</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health, hospice and personal care segments operate in a highly fragmented and highly competitive industry. The degree of competitiveness varies based upon whether our care centers operate in states that require a certificate of need ("CON") or permit of approval ("POA"). In such states, expansion by existing providers or entry into the market by new providers is permitted only where determination is made by state health authorities that a given amount of unmet healthcare need exists. Currently, 71% and 27% of our home health and hospice care centers, respectively, operate in CON/POA states.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Federal government continues to debate a reduction in expenditures and a reform of the Medicare system, our industry continues to face reimbursement pressures. These reform efforts could result in major changes in the health care delivery and reimbursement system on a national and state level, including changes directly impacting the reimbursement systems for our home health and hospice care centers. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Hospice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 31, 2020, the Centers for Medicare and Medicaid Services ("CMS") issued a final rule to update hospice payment rates and the wage index for fiscal year 2021 effective for services provided beginning October 1, 2020. CMS estimates hospices serving Medicare beneficiaries would see an e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stimated 2.4% increase in payments. This increase is the result of a 2.4% market basket adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, "PPACA"). The rule also changed the hospice wage index by adopting the most recent Office </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of Management and Budget statistical area delineations with a five percent cap on wage index decreases. Finally, CMS  increased the aggregate cap amount by 2.4% to $30,684. Based on our analysis of the final rule, we expect our impact to be in line with the 2.4% increase.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Home Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, CMS issued the Calendar Year 2020 Home Health Final Rule, which confirmed the implementation of PDGM effective January 1, 2020 as well as a change in the unit of payment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from a 60-day episode of care to a 30-day period of care</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, in an effort to reduce fraud risks, CMS reduced requests for anticipated payment ("RAPs") for 2020 to 20% with the full elimination in 2021. CMS estimated that the final rule would result in a 1.3% increase in payments to home health providers. The increase is the result of a statutorily mandated 1.5% market basket increase pursuant to the Bipartisan Budget Act of 2018, reduced by 0.2% for the rural add-on. In calculating the impact, CMS also assumed that the industry would make certain behavioral changes related to coding practices, low utilization payment adjustment ("LUPA") management and co-morbidities. As a result, CMS reduced reimbursement by 4.36%. The impact of the final rule on us was a 2.8% reduction in revenue for 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 29, 2020, CMS issued the Home Health Final Rule for Medicare home health providers for calendar year 2021. CMS estimates that the final rule will result in a 1.9% increase in payments to home health providers. The increase is the result of a 2.0% market basket adjustment reduced by 0.1% for the rural add-on. Based on our analysis of the final rule, we expect our impact to be in line with th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e 1.9% increase. Ad</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ditionally, CMS made permanent the telehealth flexibilities that were announced in the Interim Final Rule (Emergency Rule) for COVID-19 in March 2020. These flexibilities allow home health agencies to provide certain care via telehealth if it is clinically appropriate and included in the plan of care. Telehealth visits still do not count as visits for purposes of patient eligibility or payment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following payment adjustments are effective for each of the years indicated based on CMS&#8217;s final rules:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market Basket Update</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rural Add-On Adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PPACA Adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Productivity Adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Behavioral Assumptions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Industry Impact Including Behavioral Assumptions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Company-Specific Impact </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Effective for services provided from October&#160;1, 2020 to September&#160;30, 2021.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our company-specific impact of the home health final rule could differ depending on differences in the wage index, our patient case mix and other factors, such as LUPAs or outliers, which are described in more detail under Critical Accounting Estimates below. Our company-specific impact of the hospice final rule could differ based on our mix of patients and differences in the wage index.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novel Coronavirus Pandemic ("COVID-19")</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial performance for the year ended December 31, 2020 have been impacted by COVID-19. The impacts on our operations began during the second week of March 2020, as we experienced declines in referral volumes and an increase in missed visits. Our home health segment experienced a referral low-point the week of April 5th. Since that time, we have seen a steady recovery in referral volumes and a corresponding drop in missed visits. In our hospice segment, our referrals hit their low-point the week of March 22nd. While hospice admission volumes have improved significantly, the slowdown in March has impacted our average daily census and has been most significant in our facility-based census. Additionally, we have seen a decline in our hospice average daily census as a result of a significant increase in deaths, an increase in the discharge rate of same-month admissions and a delay in the timing of patients coming onto service resulting in a shorter length of stay. The financial impacts of COVID-19 during the year ended December 31, 2020 are discussed in further detail under "Results of Operations" below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently believe that we have a reasonable view of operations, the uncertainty created by COVID-19 could alter our outlook of the pandemic's impact on our consolidated financial condition, results of operations or cash flows. The following factors could potentially impact our performance: the continued increase or decrease in the number of COVID-19 cases nationwide, the severity and impacts of new variants of the virus, uncertainty regarding vaccine distribution timing and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efficiency, the utilization of elective procedures, the return of patient confidence to enter a hospital or a doctor's office, the ability to have access to our patients in their homes and in facilities, cost normalization around PPE and any future or prolonged shelter-in-place orders and other federal, state and local requirements. Potential impacts of COVID-19 on our results include lower revenue, higher salary and wage expense related to quarantine pay and training and increased supply costs related to PPE and COVID-19 testing. The impacts to revenue may consist of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower volumes due to interruption of the operations of our referral sources, patients' unwillingness to accept services and restrictions on access to facilities for hospice services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower reimbursement due to missed visits resulting in an increase in LUPAs and lost billing periods; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower hospice average daily census due to a decline in average length of stay and an increase in deaths.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provides for the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare. Consistent with the terms and conditions for receipt of the payment, we are allowed to use the funds to cover lost revenues and health care costs related to COVID-19, and we are required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we have decided to only utilize PRF funds to the extent we have qualifying COVID-19 expenses, which totaled $33&#160;million for our home health and hospice segments during the year ended December 31, 2020. Accordingly, for our wholly-owned subsidiaries, we will not be using the funds to cover lost revenues resulting from COVID-19. In September 2020, HHS issued new guidance noting that PRF funds can be used through June 30, 2021. We do not believe that we will fully utilize the funds received; therefore, we have recorded a liability related to the funds that we do not expect to utilize totaling $60&#160;million which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. Funds that we intend to use in the future to cover COVID-19 expenses, which we have estimated to be approximately $12&#160;million, have been recorded to a deferred liability account within accrued expenses in our consolidated balance sheet. These estimates may change as our ability to utilize and retain the funds will depend on the magnitude, timing and nature of the impact of the pandemic. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1 through December 31, 2020. The impact was an increase to our 2020 net service revenue of approximately $23 million. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date. Fifty percent is due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, we have deferred approximately $55 million of social security tax which has increased our cash flow from operations by the same amount; approximately $28 million is reflected in each of payroll and employee benefits and other long-term obligations within our consolidated balance sheet.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The temporary suspension of Medicare patient coverage criteria and documentation and care requirements and the expansion of providing home health and hospice care to patients via telehealth.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability for non-physician practitioners to certify for home health, order home health services, establish and review plans of care and certify and recertify eligibility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The well-being of our employees has been one of our top priorities during this pandemic. We have taken the following steps to support our employees: implemented up to 14 days of paid leave during any required quarantine periods; awarded SPIRIT bonuses to our clinicians and caregivers who have seen patients during the pandemic; completed an early cash pay-out of employee paid-time-off; instituted work-from-home arrangements for our corporate and administrative support employees; allowed employees to temporarily suspend any 401(k) plan loan deductions and offered employees the option of making a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">withdrawal from their 401(k) plan for coronavirus-related distributions without incurring the additional 10% early withdrawal penalty; granted access to Teladoc services to all employees; provided access to COVID-19 self-test kits to all employees and created a COVID-19 Resource Center, available 24 hours a day, seven days a week for employees to access educational materials, safety documents, policies, clinical protocols and operational metrics. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety of our clinicians and patients has also been a focus, and as a result, we have made the following business changes: developed clinical protocols for COVID-19 testing, proper usage of PPE, caring for COVID-positive patients and maintaining safety measures in our care centers; researched each state's vaccination plan to develop a state by state protocol to work with local health departments and other health systems to obtain vaccine appointments for our clinical staff; implemented software enabling us to track staff that have been vaccinated; procured millions in PPE and created a centralized distribution center for all critical PPE, allowing us to flex our inventory on a care center by care center basis, based on need and demand. We have had success in utilizing both traditional and non-traditional suppliers for our PPE needs. While we were very fortunate to secure the supplies needed, we faced significantly higher per unit costs for the purchase of PPE. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Network Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we signed a Care Coordination Agreement with BrightStar Care to add its agencies to the Amedisys personal care network, which helps facilitate the coordination of care between our home health and hospice care centers and a network of personal care partners.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we signed an agreement with ClearCare, Inc. ("ClearCare"), the provider of the personal care industry&#8217;s leading software platform, representing 4,000 personal care agencies in every zip code in the United States. Our agreement with ClearCare creates an opportunity to establish a network partnership between Amedisys and personal care agencies using ClearCare in order to better coordinate patient care. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long term, we believe these agreements will allow us to build a nation-wide network of personal care agencies and further our efforts to provide patients with a true care continuum in the home. These relationships will also help us as we continue to have innovative payment conversations with Medicare Advantage plans who have begun to recognize the value that combined home health, hospice and personal care services bring to their members and care delivery infrastructure.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governmental Inquiries and Investigations and Other Litigation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 8, Note 11 &#8211; Commitments and Contingencies to our consolidated financial statements for additional information regarding the subpoena and civil investigative demands issued by the U.S. Department of Justice and the South Carolina and Florida Zone Program Integrity Contractor audits. No assurances can be given as to the timing or outcome of these items.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2020 Compared to the Year Ended December&#160;31, 2019 </span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, our operating income increased approximately $42 million on a revenue increase of $116 million.  COVID-19 resulted in significant impacts to all of our segments; however, we experienced a significant increase in our gross margin as a percentage of revenue which drove our improvement over 2019. Our results were also impacted by acquisitions, the suspension of sequestration, the transition to PDGM, a reduction in revenue adjustments, severance associated with reductions in staffing levels, primarily within our home health segment and an asset impairment charge related to our acquired names intangibles. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 results include the acquisitions of Asana and AseraCare, which contributed revenue of $88 million and an operating loss of $12 million, which is inclusive of acquisition and integration costs totaling $10 million and intangibles amortization totaling $9 million. Our results also reflect one additional month of revenue and operating income from Compassionate Care Hospice ("CCH"), which was acquired on February 1, 2019, and three additional months of revenue and operating income from RoseRock Healthcare ("RoseRock"), which was acquired on April 1, 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 disrupted both net service revenue and costs during 2020. The most significant impact occurred in the second quarter during which we experienced a $30 million decline in net service revenue over prior year due to COVID-19. Our variable cost structure helped us mitigate a significant portion of the revenue impact. Our home health segment, which was the most heavily impacted by COVID-19, recovered quickly and returned to year over year growth in volumes during the third and fourth quarters. Our hospice segment experienced declines in admissions during the second quarter but saw an overall slower decline in average daily census, which is the main driver of hospice revenue. While we have experienced strong admission growth during the third and fourth quarters, a significant increase in deaths, an increase in the discharge rate of same-month admissions and a delay in the timing of patients coming onto service has driven down our length of stay resulting in average daily census growth of only 1% year over year. Based on our current projections, we are anticipating a decline in average daily census early in 2021 despite strong growth in admissions. We expect that our length of stay will return to normal levels during 2021.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 operating results were positively impacted by the suspension of sequestration effective May 1, 2020, which resulted in an increase to net service revenue of approximately $23 million ($13 million home health, $10 million hospice) but negatively impacted by the change in reimbursement under PDGM, which resulted in a $23 million reduction in net service revenue. We were able to significantly mitigate the PDGM rate cut and expand margin in our home health segment by </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivering improvements in clinician utilization and discipline mix and by reducing our revenue adjustments. Additionally, we experienced an expansion in our hospice gross margin resulting from lower costs associated with a decline in visit volumes due to access restrictions imposed by facilities as well as a reduction in revenue adjustments; prior year results included a $7 million reduction to revenue related to settlement discussions with the U.S. Department of Justice (See Item 8, Note 11 &#8211; Commitments and Contingencies to our consolidated financial statements for additional information).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our segments incurred incremental costs related to COVID-19. As noted above, for our wholly-owned subsidiaries, we have elected to use the CARES Act Provider Relief Funds to cover COVID-19 expenses incurred by our home health and hospice segments which totaled $33 million during 2020. Our personal care segment received funds from the Mass Home Care ASAP COVID-19 Provider Sustainability Program totaling $1 million. We have used these funds to cover COVID-19 expenses as well. We have recorded income associated with both of these programs totaling $34 million in other operating income within our consolidated statement of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect a 1.2% increase in our other operating expenses as a percentage of revenue compared to prior year; this increase is due to the addition of resources to support growth (primarily business development employees), investments related to PDGM and planned wage increases, partially offset by overall reductions in spend during the pandemic and lower acquisition and integration costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Last, we recorded a $4 million asset impairment charge related to acquired names which are no longer in use (see Item 8, Note 5 &#8211; Goodwill and Other Intangible Assets, Net to our consolidated financial statements for additional information).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net includes the following items (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased $4&#160;million in 2020 from 2019 as a result of a decrease in borrowings under our Amended Credit Agreement (see Item 8, Note 8 &#8211; Long-Term Obligations to our consolidated financial statements for additional information regarding our Amended Credit Agreement). Miscellaneous, net includes a $3 million loss from the sale of our investment in the Heritage Healthcare Innovation Fund, LP during 2020 (see Item 8, Note 1 - Nature of Operations, Consolidation and Presentation of Financial Statements to our consolidated financial statements for additional information).</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2019 Compared to the Year Ended December&#160;31, 2018 </span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $22&#160;million on a revenue increase of $293 million. Our 2019 operating results include the acquisitions of CCH and RoseRock which contributed approximately $174 million in revenue and an operating loss of approximately $5 million, which is inclusive of $14 million in acquisition and integration costs and $6 million in intangibles amortization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our operating income was negatively impacted by a $7 million accrual related to settlement discussions with the U.S. Department of Justice (see Item 8, Note 11 - Commitments and Contingencies to our consolidated financial statements for additional information) and a $2 million asset impairment charge related to our acquired names (see Item 8, Note 5 - Goodwill and Other Intangible Assets, Net to our consolidated financial statements for additional information).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our year-to-date performance reflects growth and operating improvement in all three segments of our legacy operations. We expanded gross margin as a percentage of revenue in our home health and personal care segments. Both segments benefited from rate increases with home health also delivering improvements in clinician utilization and discipline mix. Our hospice segment's gross margin as a percentage of revenue decreased due to our acquisition activity. Additionally, our other operating expenses as a percentage of revenue increased only 1% compared to 2018; this increase is inclusive of approximately $16 million in acquisition and integration costs. Excluding the acquisition and integration costs, our other operating expenses as a percentage of revenue remained relatively flat compared to 2018 despite planned wage increases and the addition of resources to support growth. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net includes the following items (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $7&#160;million in 2019 from 2018 as a result of an increase in borrowings under our Amended Credit Agreement (see Item 8, Note 8 &#8211; Long-Term Obligations to our consolidated financial statements for additional information regarding our Amended Credit Agreement). Equity in earnings from equity method investments includes gains of $2 million and $5 million for 2019 and 2018, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health Division</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes (6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode (4) (6)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode (5) (6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting Clinician Cost per Visit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Manager Cost per Visit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cost per Visit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,388,549&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273,308&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,033,654&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total volume includes all admissions and recertifications.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total includes acquisitions and denovos.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode for the year ended December 31, 2020 reflects the transition to PDGM effective January 1, 2020 and the suspension of sequestration effective May 1, 2020. </span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Prior year amounts have been recast to conform to the current year calculation.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2020 Compared to the Year Ended December&#160;31, 2019 </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $26 million on a $7 million decrease in net service revenue. Our results for the year ended December 31, 2020 were impacted by COVID-19, the suspension of sequestration, the transition to PDGM, severance associated with reductions in staffing levels and a reduction in revenue adjustments. Despite the decrease in net service revenue, we saw significant improvement in our operating performance driven by improvements in our clinician utilization and discipline mix, both of which have contributed to year over year gross margin expansion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 resulted in disruption to our home health volumes beginning at the end of the first quarter through most of the second quarter and amplified the negative impact of the PDGM rate cut on our Medicare revenue per episode. Volumes significantly improved during the third and fourth quarters and our efforts to operationalize PDGM reduced the impact of the PDGM rate cut in the second half of the year. While we are very encouraged by the improvement in volumes and Medicare revenue per episode that we have experienced, we will continue to closely monitor COVID-19 cases and the potential impacts on our operating results. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results were also impacted by incremental costs totaling $20 million related to COVID-19, which were offset by the recognition of income totaling $20 million associated with the CARES Act Provider Relief Fund, and severance totaling $5 million related to reductions in staffing levels.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue decreased $7 million primarily due to the impacts of COVID-19 and the 2020 change in reimbursement under PDGM. The combination of these resulted in lower volumes than anticipated and lower Medicare revenue per episode for the year ended December 31, 2020. COVID-19 significantly increased the number of missed visits which increased the number of LUPA episodes and the number of episodes with lost billing periods (i.e. episodes with no visits during one of the 30-day billing periods), leading to a decline in our Medicare revenue per episode. Additionally, the implementation of PDGM resulted in a $23 million reduction in net service revenue during the year ended December 31, 2020. This reduction was partially offset by $13 million resulting from the suspension of sequestration effective May 1, 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have seen significant increases in both volumes and Medicare revenue per episode in the second half of the year as the impacts of COVID-19 have moderated and as we have been able to refocus our efforts on operationalizing PDGM. We have provided additional training, increased our focus on OASIS accuracy and coding and also completed the rollout of Medalogix Care to all of our home health care centers, all of which have resulted in higher case mix and functional impairment scores for our patients. Additionally, we have seen a reduction in our revenue adjustments year over year.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act Provider Relief Fund. In accordance with the terms and conditions, these funds can be used to cover lost revenues as well as costs directly attributable to COVID-19. For our wholly-owned subsidiaries, we have elected to utilize the funds to cover COVID-19 related costs only, and therefore, have recognized income equal to the amount of COVID-19 costs incurred to date totaling $20 million. These costs are associated with the purchase of personal protective equipment, bonuses paid to our clinicians, clinician training, quarantine pay and COVID-19 testing. Of the $20 million of COVID-19 costs incurred to date, $19 million has been recorded to cost of service and $1 million has been recorded to other operating expenses.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service decreased 3% on an 11% decrease in total visits. Lower costs associated with a decline in volumes driven by COVID-19, improvements in clinician utilization as evidenced by a decline of 2.1 visits per completed episode year over year and optimization of discipline mix were partially offset by an 8% increase in our total cost per visit, which was driven by planned wage increases, an increase in the utilization of contractors to supplement clinician visits in certain areas, new hire pay, a change in the mix of our visits, costs directly attributable to COVID-19 totaling approximately $19 million and severance totaling $5 million related to a reduction in staffing levels. While we compensate our clinicians on a per visit basis, there is a fixed cost component of our cost structure which resulted in an increase in our cost per visit as we had a significant decline in visits. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased approximately $10 million primarily due to planned wage increases, the addition of resources to support volume growth, investments related to PDGM and approximately $1 million of costs directly attributable to COVID-19. These increases were partially offset by a reduction in travel and training expense and an overall reduction in spend during the pandemic.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2019 Compared to the Year Ended December&#160;31, 2018 </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $27 million on an $82 million increase in net service revenue. Our gross margin as a percentage of revenue was positively impacted by the 2019 changes in reimbursement, growth in volumes, the acuity level of our patients, improved utilization and a focus on discipline mix. The impact of the 2019 change in reimbursement was an increase in net service revenue and gross margin of approximately $12 million. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue increased $82 million (7%) on a 5% increase in total volume and a 2% increase in Medicare revenue per episode. The volume growth was driven by a 7% increase in admissions offset by lower recertification volume. The increase in Medicare revenue per episode is the result of a 1.2% increase in reimbursement with the remainder due to an increase in the acuity level of our patients. Additionally, our non-Medicare (per visit and episodic) rates increased approximately 3% which is a combination of rate increases and increases in the acuity level of our patients. Revenue was also positively impacted by a reduction in our revenue adjustments.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service increased 4% on a 3% increase in total visits. Our total cost per visit increased approximately 1% as improvements in clinician utilization and optimization of discipline mix partially offset planned wage increases. Additionally, changes in our home health care center staffing resulted in a shift of some office staff from cost of service to other operating expenses totaling approximately $4 million.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased approximately $22 million primarily due to an increase in salaries and benefits expense as a result of the addition of resources to support volume growth, planned wage increases and the home health staffing shifts referenced above.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Division</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:55.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total includes acquisitions and denovos.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2020 Compared to the Year Ended December&#160;31, 2019 </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for 2020 include the results of the acquisition of Asana on January 1, 2020 (8 hospice care centers) and AseraCare on June 1, 2020 (44 hospice care centers). Acquisitions are included in our consolidated financial statements from their respective acquisition dates. As a result of our acquisitions, our hospice segment operating results for 2020 and 2019 are not fully comparable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $41 million on a $133&#160;million increase in net service revenue. Our 2020 results include the acquisitions of Asana and AseraCare, which contributed revenue of $88 million and operating income of $13 million. Our results also reflect one additional month of revenue and operating income from CCH and three additional months of revenue and operating income from RoseRock. Additionally, our operating results were favorably impacted by the following: 1% growth in average daily census, changes in reimbursement, which resulted in an increase in net service revenue and gross margin of approximately $6 million and $3 million, respectively, lower revenue adjustments, the suspension of sequestration effective May 1, 2020 and lower visit volumes due to facility access restrictions. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $133&#160;million, approximately $88 million of which is attributable to our Asana and AseraCare acquisitions during 2020. The remaining increase in net service revenue is the result of one additional month of revenue from our 2019 acquisition of CCH (approximately $15 million), three additional months of revenue from our 2019 acquisition of RoseRock (approximately $2 million), growth in our average daily census, the suspension of sequestration effective May 1, 2020 ($9 million excluding acquisitions), a 0.5% increase in reimbursement effective October 1, 2019 ($3 million), a 2.4% increase in reimbursement effective October 1, 2020 ($3 million, excluding acquisitions) and lower revenue adjustments as prior year results included a $7 million reduction to revenue related to settlement discussions with the U.S. Department of Justice (see Note 11 &#8211; Commitments and Contingencies to our consolidated financial statements for additional information). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While COVID-19 significantly impacted our admission volumes during the second quarter, our hospice admissions rebounded quickly, resulting in strong year over year growth in admissions during the third and fourth quarters. Our same store admissions growth was up 6% year over year; however, our average daily census, which is the main driver of hospice revenue, was up only 1%. Generally, changes in average daily census lag changes in admission volumes; however, we have not seen an increase in our average daily census growth due to a significant increase in the number of deaths, an increase in the discharge rate of same-month admissions and a delay in the timing of patients coming onto service resulting in a lower length of stay. This lower length of stay resulted in a declining census as we exited 2020. Based on our current projections, we expect this trend to continue into 2021.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act Provider Relief Fund. In accordance with the terms and conditions, these funds are intended to cover lost revenues as well as costs directly attributable to COVID-19. For our wholly-owned subsidiaries, we have elected to utilize the funds to cover COVID-19 related costs only, and therefore, have recognized income equal to the amount of COVID-19 costs incurred to date totaling $13 million. These costs are associated with the purchase of personal protective equipment, bonuses paid to our clinicians, clinician training, quarantine pay and COVID-19 testing. Of the $13 million of COVID-19 costs incurred to date, $12 million has been recorded to cost of service and $1 million has been recorded to other operating expenses.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased $66&#160;million, approximately $52 million of which is attributable to our Asana and AseraCare acquisitions during 2020. The remaining increase is primarily due to one additional month of costs from our 2019 acquisition of CCH, three additional months of costs from our 2019 acquistion of RoseRock, a 1% increase in average daily census, planned wage increases, COVID-19 costs totaling $12 million and an increase in our general inpatient and respite facility costs as the majority of the reimbursement increase, which became effective October 1, 2019, was passed through to these facilities. These increases were offset by a decline in visits performed by our hourly licensed practical nurses and hospice aides due to facility access restrictions as well as lower transportation costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $39&#160;million, approximately $25 million of which is related to our Asana and AseraCare acquisitions during 2020. The remaining increase is due to the addition of resources to support census growth and planned wage increases, partially offset by a decrease in travel and training expense.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2019 Compared to the Year Ended December&#160;31, 2018 </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2019, we acquired CCH, which owned and operated 53 hospice care centers. On April 1, 2019, we acquired RoseRock, which owned and operated one hospice care center. Acquisitions are included in our consolidated financial statements from their respective acquisition dates. As a result, our hospice segment operating results for 2019 and 2018 are not fully comparable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $30 million on a $206&#160;million increase in net service revenue. Our operating income was negatively impacted by a $7 million reduction to revenue and gross margin related to settlement discussions with the U.S. Department of Justice (see Item 8, Note 11 - Commitments and Contingencies to our consolidated financial statements for </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional information). Our operating results were positively impacted by changes in reimbursement, which resulted in an increase in net service revenue and gross margin of approximately $7 million and $6 million, respectively. The majority of the revenue increase associated with the 2020 change in reimbursement, which became effective October 1, 2019, was passed through to our general inpatient and respite facilities. Our operating results were also positively impacted by continued growth and by our acquisitions which contributed approximately $174 million in net service revenue and $22 million in operating income to our hospice segment's results for the year ended December 31, 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice revenue increased $206&#160;million; approximately $174 million of which is attributable to our acquisition activities. The remaining $32 million increase is the result of a 7% increase in our average daily census and increases in reimbursement totaling 1.6% and 0.5% effective for services provided from October 1, 2018 and October 1, 2019, respectively, partially offset by an increase in our revenue adjustments, which include a $7 million reduction to revenue and gross margin related to the U.S. Department of Justice matter noted above.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased $123&#160;million, approximately $110 million of which is attributable to our acquisition activity. The remaining $13 million increase is primarily due to a 7% increase in average daily census, planned wage increases and an increase in our general inpatient and respite facility costs as the majority of the reimbursement increase, which became effective October 1, 2019, was passed through to these facilities. Our cost of service per day increased 7%, largely driven by our acquisitions as our same store cost of service per day remained relatively flat. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $53&#160;million; approximately $42 million of the increase is related to our acquisition activity. The remaining $11 million increase is due to increases in other care center related expenses, primarily salaries and benefits expense due to the addition of resources to support census growth and planned wage increases, professional fees and travel and training expense.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Division</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total includes acquisitions.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2020 Compared to the Year Ended December&#160;31, 2019 </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment decreased approximately $3 million on a $10 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19 partially offset by rate increases. The impact of COVID-19 was mitigated by a reduction in costs as most of our personal care employees are paid on an hourly basis and rate increases which were intended to address market pressures and incremental costs related to the pandemic. Our personal care segment incurred approximately $2 million of COVID-19 costs related to the purchase of PPE, bonuses paid to our employees and quarantine pay. Additionally, our personal care segment received funds totaling $1 million under the Mass Home Care ASAP COVID-19 Provider Sustainability Program. These funds were used to cover COVID-19 related costs and are recorded to other operating income within our consolidated statement of operations.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2019 Compared to the Year Ended December&#160;31, 2018</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment increased $3 million on a $5 million increase in net service revenue. These results are inclusive of the acquisitions of East Tennessee Personal Care Services (May 2018) and Bring Care Home (October 2018). As a result, our personal care operating results for 2019 and 2018 are not fully comparable. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin as a percentage of revenue increased 170 basis points as the segment benefited from rate increases combined with operating cost controls. Additionally, other operating expenses decreased approximately $1 million resulting in an increase in operating income. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate expenses consist of costs relating to our executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2020 Compared to the Year Ended December&#160;31, 2019 </span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate total operating expenses increased approximately $22 million during the year ended December 31, 2020 compared to 2019. Our 2020 acquisitions of Asana and AseraCare added approximately $15 million which is inclusive of $9 million related to intangibles amortization. The remaining $7 million increase is primarily due to one additional month of corporate support costs from our 2019 acquisition of CCH, planned wage increases, the addition of corporate support staff, an increase in employer payroll taxes associated with employee stock option exercises, incentive compensation accruals, fees related to our ClearCare partnership and lower gains on the sale of fleet vehicles in 2020 as compared to 2019; these items were partially offset by decreases in travel and training expense and acquisition and integration costs.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2019 Compared to the Year Ended December&#160;31, 2018</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, corporate operating expenses increased $37 million; approximately $27 million of which is attributable to the CCH acquisition: $7 million relates to CCH corporate and administrative support functions, $6 million relates to CCH intangibles amortization and approximately $14 million relates to CCH acquisition and integration costs. Excluding the impact of the CCH acquisition, corporate operating expenses increased $10 million which represents 3% of our $293 million increase in revenue. This increase is primarily due to increases in salaries and benefits expense and information technology expense which were partially offset by decreases in professional fees and legal settlements as well as gains on the sale of fleet vehicles.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities for 2020, 2019 and 2018 have provided sufficient liquidity to finance our capital expenditures, both routine and non-routine, and acquisitions. Changes in our cash provided by operating activities during the past three years were primarily the result of fluctuations in our net income, the collections of our accounts receivable and the timing of payments of accrued expenses. Additionally, our cash provided by operating activities for 2020 also includes the deferral of payroll taxes as provided for in the CARES Act totaling $55.4 million and the receipt of Provider Relief Funds, which we expect to retain, totaling $38.5 million, partially offset by the payment of COVID-19 related expenses. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities primarily consists of the purchase of property and equipment, investments in equity method investees and acquisitions. Additionally, during 2020, our cash flows from investing activities includes proceeds from the sale of our investment in the Heritage Healthcare Innovation Fund, LP (see Item 8, Note 1 - Nature of Operations, Consolidation and Presentation of Financial Statements to our consolidated financial statements for additional information). Cash used in investing activities decreased $65.8 million during 2020 compared to 2019 as a result of a reduction in acquisition spend. Cash used in investing activities increased $330.7&#160;million during 2019 compared to 2018 primarily due to the acquisitions of CCH and RoseRock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing activities primarily consist of borrowings under our term loan and/or revolving credit facility, repayments of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation and proceeds related to the exercise of stock options and the purchase of stock under our employee stock purchase plan. Additionally, during 2020, our financing activities included the receipt of Provider Relief Funds, which we do not expect to retain, totaling $60 million (see Note 3 - Novel Coronavirus Pandemic ("COVID-19") to our consolidated financial statements for additional information). Cash used in financing activities totaled $15.0 milling during 2020 primarily due to repayments of borrowings and the remittance of tax withholding obligations related to non-cash compensation and stock option exercises (see Item 8, Note 10 - Capital Stock and Share-Based Compensation to our consolidated financial statements for additional information), partially offset by the receipt of Provider Relief Funds totaling $60.0 million. Cash provided by financing activities totaled $227.2 million during 2019 and is primarily related to our borrowings under our Amended Credit Agreement to fund acquisitions. Cash used in financing activities totaled $267.4 million in 2018 and is primarily related to our repurchase of company stock and the repayments of borrowings.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we spent $5.3&#160;million in capital expenditures compared to $7.9&#160;million and $6.6&#160;million during 2019 and 2018, respectively. Our capital expenditures for 2021 are expected to be approximately $6.0 million to $8.0&#160;million, excluding the impact of any future acquisitions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had $81.8 million in cash and cash equivalents and $470.2 million in availability under our $550.0&#160;million Revolving Credit Facility. Our cash and cash equivalents include $60.0 million related to CARES Act funds that we do not expect to utilize and have recorded as a liability within our consolidated balance sheet as of December 31, 2020.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable increased $17.5&#160;million from December&#160;31, 2019 to December&#160;31, 2020 due to our acquisition activity which added $19.6 million to accounts receivable and the reduction in RAP payments under PDGM, partially offset by a reduction in days revenue outstanding which decreased 0.7 days despite an estimated negative impact of 2.7 days related to the transition to PDGM. Our cash collection as a percentage of revenue was 106% and 105% for the twelve-month periods ended December&#160;31, 2020 and 2019, respectively. Our days revenue outstanding, net at December&#160;31, 2020 was 40.2 days which is a decrease of 0.7 days from December&#160;31, 2019. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable includes unbilled receivables and are aged based upon the initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the date the episode was completed, varies by state for Medicaid-reimbursable services and varies among insurance companies and other private payors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over&#160;365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over&#160;365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2019:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our calculation of days revenue outstanding, net is derived by dividing our ending net patient accounts receivable at December&#160;31, 2020 and 2019 by our average daily net patient service revenue for the three-month periods ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2019, we entered into the First Amendment to the Credit Agreement (as amended by the First Amendment, the &#8220;Amended Credit Agreement&#8221;). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes the $550.0 million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $175.0 million (the &#8220;Term Loan Facility&#8221; and collectively with the Revolving Credit Facility, the &#8220;Credit Facility&#8221;), which was added by the First Amendment.  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We borrowed the entire principal amount of the Term Loan Facility on February 4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 2.2% for the period ended December 31, 2020 and 3.8% for the period February 4, 2019 to December&#160;31, 2019. Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.2% for the period ended December 31, 2020 and 4.0% for the period ended December 31, 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our consolidated leverage ratio was 0.6, our consolidated interest coverage ratio was 25.6 and we are in compliance with our covenants under the Amended Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our availability under our $550.0&#160;million Revolving Credit Facility was $470.2 million as we have $51.0 million outstanding in borrowings and $28.8 million outstanding in letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 8, Note 8 - Long Term Obligations to our consolidated financial statements for additional details on our outstanding long-term obligations.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not repurchase any shares pursuant to this stock repurchase program during the year ended December 31, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100 million of our outstanding common stock through March 1, 2020. We did not repurchase any shares pursuant to this stock purchase program during 2019 or 2020. The stock repurchase plan expired on March 1, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Share Repurchase</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2018, we purchased 2,418,304 of our common shares from affiliates of KKR Credit Advisors (US) LLC ("KKR"), representing one-half of KKR's then current holdings in the Company and 7.1% of the aggregate outstanding shares of the Company's common stock for a total purchase price of $181.4 million including related direct costs. The Company repurchased the shares at $73.96 which represents 96% of the closing stock price of the Company's common stock on June 4, 2018. The repurchased shares are classified as treasury shares.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future contractual obligations at December&#160;31, 2020 were as follows (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After<br/>5&#160;Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on long-term obligations (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Interest on debt with variable rates was calculated using the current rate for that particular debt instrument at December&#160;31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Purchase obligations are primarily related to information technology contracts and software licenses.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, collectability of accounts receivable, reserves related to insurance and litigation, business combinations, goodwill, intangible assets, income taxes and contingencies. We base these estimates on our historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results experienced may vary materially and adversely from our estimates. To the extent there are material differences between our estimates and the actual results, our future results of operations may be affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the following critical accounting policies represent our most significant judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of the Company's consolidated net service revenue. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, CMS implemented a revised case-mix adjustment methodology, PDGM, to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient&#8217;s care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are now included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue and a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP") is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our consolidated balance sheets. CMS reduced the upfront payment for RAPs to 20% for 2020 and has fully eliminated payments associated with RAPs in 2021.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2020, 2019 and 2018, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28th of the following year. As of December&#160;31, 2020, we have settled our Medicare hospice reimbursements for all fiscal years through </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October&#160;31, 2013. As of December&#160;31, 2020, we have recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021; approximately $2.0 million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth and discount rates.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP allows for impairment testing to be done on either a quantitative or qualitative basis. During 2020, we utilized a qualitative analysis for our annual impairment test and determined that there were no triggering events that would indicate that it is "more likely than not" that the carrying values of our reporting units are higher than their respective fair values. As a result, we did not record any goodwill impairment charges and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October 31, 2020. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of certificates of need, licenses, acquired names and non-compete agreements. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which is generally two to three years for non-compete agreements and up to three years for acquired names. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. During 2020, we performed a qualitative assessment of our indefinite-lived intangible assets; as a result of this analysis, we wrote off approximately $4.2 million of acquired names that are no longer in use. There have been no material developments, events, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our remaining intangible assets would be less than their carrying amounts.</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from fluctuations in interest rates. Our Term Loan and Revolving Credit Facility carry a floating interest rate which is tied to the Eurodollar rate (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LIBOR) and the Prime Rate and therefore, our consolidated statements of operations and our consolidated statements of cash flows are exposed to changes in interest rates. As of December&#160;31, 2020, the total amount of outstanding debt subject to interest rate fluctuations was $215.1&#160;million. A 1.0% interest rate change would cause interest expense to change by approximately $2.2&#160;million annually, assuming the Company makes no principal repayments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="id92bd70d620044018083957a908405c4_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc.:</span></div><div><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Amedisys, Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 25, 2021 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Accounting Principle</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for leases as of January 1, 2019 due to the adoption of Accounting Standards Update (ASU) 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#894; ASU 2018-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Land Easement Practical Expedient for Transition to Topic 842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#894; ASU 2018-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842, Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#894; and ASU 2018-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Improvements (collectively, Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of AseraCare Hospice &#8211; Evaluation of the fair value of certain intangible assets</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 2 and 4 to the consolidated financial statements, the Company accounts for business combinations using the acquisition method of accounting. The Company acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice (AseraCare), on June 1, 2020. Intangible assets acquired in connection with this transaction included licenses, acquired names and non-compete agreements.  </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of the fair value of certain intangible assets, which consisted of licenses, acquired names, and non-compete agreements, acquired in the AseraCare transaction as a critical audit matter. Subjective auditor judgment was required to evaluate the identification of intangible assets acquired and significant assumptions used in the valuation of certain intangible assets. Specifically, the significant assumptions included projected revenue growth rates, projected earnings before interest, taxes, depreciation and amortization (EBITDA), and the weighted average cost of capital (WACC). Changes to these assumptions could have had a significant effect on the Company&#8217;s estimate of fair value of the intangible assets.  </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s acquisition accounting process, including controls over the identification of intangible assets acquired and the development of the significant assumptions used in the valuation of the intangible assets. We read the purchase agreement to identify the significant terms, conditions, and intangible assets acquired and compared them to the Company&#8217;s analysis of intangible assets acquired. We evaluated the Company&#8217;s projected revenue growth rates by comparing such assumptions to those of AseraCare&#8217;s peers and to industry reports.  We evaluated the Company&#8217;s projected EBITDA by comparing such assumptions to those of AseraCare&#8217;s peers.  Additionally, we compared the Company&#8217;s projected revenue growth rates and projected EBITDA to AseraCare&#8217;s and the Company&#8217;s historical actual results. We involved valuation professionals with specialized skills and knowledge, who assisted in:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating the Company&#8217;s identification of intangible assets acquired</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating the WACC, which was used by the Company to determine the discount rate, by comparing the Company's inputs to the WACC to publicly available data for comparable entities and assessing the resulting WACC.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of the non-contractual revenue adjustment estimates for Home Health and Hospice</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2 to the consolidated financial statements, the Company determines the transaction price for revenue contracts based on gross charges for services provided, reduced by contractual revenue adjustments and an estimate for non-contractual revenue adjustments. Non-contractual revenue adjustments are recorded for self-pay, uninsured patients, and other payors by major payor class based on historical collection experience, evaluated for current economic conditions. Adjustments resulting from payment reviews and adjustments arising from the inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation are factors that are relevant to the estimate of ultimate collection. The non-contractual revenue adjustments represent the difference between amounts billed and amounts the Company expects to collect based on its collection history with similar payors.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of the non-contractual revenue adjustment estimates noted above for the Home Health and Hospice segments as a critical audit matter. Subjective and complex auditor judgment was required to evaluate the method and historical collection experience used by the Company when developing the non-contractual revenue adjustment estimate. Specifically, the significant judgments related to evaluating the relevance of historical collection experience to the determination of the estimate, which included evaluation of current conditions, trends, historical adjustment experience, and other factors.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s revenue process, including controls over the method and significant judgments for estimating non-contractual revenue adjustments noted above. We assessed the outcome of the estimation of non-contractual revenue adjustments in the prior period to identify circumstances or conditions that are relevant to the determination of the current year estimate. To assess the current year method and the relevance of the historical collection experience, we also evaluated current conditions, trends, historical adjustment experience, and other factors relevant to the estimation of non-contractual revenue adjustments.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2002.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baton Rouge, Louisiana</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="id92bd70d620044018083957a908405c4_52"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNC0xLTEtMS0w_89be5005-f960-410e-a9fd-3a644ed5bbf9">81,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNC0zLTEtMS0w_96ada87b-bc19-4882-8e4d-706bf2f01151">30,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNS0xLTEtMS0w_ae122a05-7bc2-42e9-8e7e-aeb674f1a810">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNS0zLTEtMS0w_acbdd928-1834-4482-982d-e85d4cb1f191">66,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNi0xLTEtMS0w_8a321fa5-2c7f-4744-a74b-5dcc088df5c2">255,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNi0zLTEtMS0w_d4e0d80d-ac39-4655-9848-0d16d35f08be">237,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNy0xLTEtMS0w_ff9a1719-3b20-45b4-a89b-cff191a306a2">10,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNy0zLTEtMS0w_d6f3d14c-244b-447c-b8c5-fd97778008e7">8,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfOC0xLTEtMS0w_9541e0c0-cc2c-46e1-83bc-8b9357fc09e5">13,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfOC0zLTEtMS0w_b12ca590-c507-4e99-9ad1-bf08888e10ed">8,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfOS0xLTEtMS0w_0a27a623-fa0d-4a2b-abb2-0d4d6227e490">361,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfOS0zLTEtMS0w_680ec2b1-440a-498d-a67c-6d388a83a65d">350,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjNhZGU1ZTQzNWQ4MjQ2YmU4NGMwZjNiNmFjOGRjODY5XzEwOTk1MTE2Mjc4NjU_832966b8-83de-4588-8ee7-eeb9cc1e5ee4">95,024</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjNhZGU1ZTQzNWQ4MjQ2YmU4NGMwZjNiNmFjOGRjODY5XzEwOTk1MTE2Mjc4NzY_568b397a-c974-4dee-bcd4-e7ef08f0f256">96,137</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTAtMS0xLTEtMA_7030d057-ca89-4925-98ff-9bb3d0a23fd3">23,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTAtMy0xLTEtMA_e27993e6-6741-4489-8702-2e5dd24b852f">28,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTEtMS0xLTEtMA_ce026fe3-79e7-411a-84d5-b65a2279113a">93,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTEtMy0xLTEtMA_c9bdedb4-8cba-43f7-ae7a-9868ba4336d6">84,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTItMS0xLTEtMA_e8c717b7-2fb9-468f-b779-d934dd5aefc7">932,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTItMy0xLTEtMA_685d296e-5a64-410b-aeee-066db9e705cc">658,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjBkMDJmZjA4YThkMTRkZWQ4YjU2MGEyMzBjMGRjMWFmXzEwOTk1MTE2Mjc4NTc_058a5e4c-3862-47df-864b-7e63ceb486a0">22,973</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjBkMDJmZjA4YThkMTRkZWQ4YjU2MGEyMzBjMGRjMWFmXzEwOTk1MTE2Mjc4Njc_fc3f5914-d368-4d69-802c-4b110b9b76a3">7,044</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTMtMS0xLTEtMA_7cb066e3-f29c-4e2c-9b1f-1d31ab7c2fa8">74,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTMtMy0xLTEtMA_8dc8ee58-f171-4fef-908c-cb06d0a2b487">64,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTQtMS0xLTEtMA_3e0029be-ab95-4ee6-b007-157b4ae72858">47,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTQtMy0xLTEtMA_e2d140b4-1348-4866-8ae7-550e235ec2c8">21,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTUtMS0xLTEtMA_da987d4d-4edc-4c07-9e7a-e1a632774bbd">33,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTUtMy0xLTEtMA_d791da41-0040-426f-87fc-9b6cd2e50562">54,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTYtMS0xLTEtMA_241027d1-254e-418e-9b92-3cb755ce05ae">1,567,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTYtMy0xLTEtMA_e10e22f2-626b-4529-a5fc-5971e5e090a5">1,262,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTktMS0xLTEtMA_ad0fcf65-8321-443d-99e7-7dbb57870813">42,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTktMy0xLTEtMA_1c07e030-649d-42bc-b9bc-530cb2f4517d">31,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjAtMS0xLTEtMA_2e202f67-d0ae-4b8d-9c20-8394a2be5896">146,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjAtMy0xLTEtMA_2ed02273-bcd0-4809-b711-555935a6110c">120,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjEtMS0xLTEtMA_a30a7b42-2ec2-48f9-a751-6d4e6cabda5d">166,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjEtMy0xLTEtMA_cf5992f6-cbe0-4a48-84ad-0f20a121d7a4">137,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provider relief fund advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjItMS0xLTEtMTMx_ce5e3745-263d-4a32-99c2-dad5d5982c57">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:zerodash" name="amed:ProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjItMy0xLTEtMTMx_0285a0e9-bd19-41ea-af66-77b6bad19571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjItMS0xLTEtMA_f371c55e-4b56-4987-927f-797d081adec6">10,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjItMy0xLTEtMA_2ca543ee-bbc0-4536-815b-31a08557af80">9,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjMtMS0xLTEtMA_5e127385-8f2e-4706-bf30-b0053ca27796">30,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjMtMy0xLTEtMA_24815bb1-9c27-43fd-90c5-b45262fa5ba9">27,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjQtMS0xLTEtMA_6f2c828f-97f0-4392-b52c-00ed2f32db6c">456,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjQtMy0xLTEtMA_b4d4f35f-a31b-445c-8033-62ed2edbffbc">326,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjUtMS0xLTEtMA_56c231b9-39f7-4c7e-ab7b-6a093d7035fb">204,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjUtMy0xLTEtMA_523b6ec1-06ca-45a1-9d7d-ad9b7133dcb0">232,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjYtMS0xLTEtMA_bbaf02cd-e257-47e0-ba88-b03c969dd3aa">61,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjYtMy0xLTEtMA_d125fda1-add5-4bd4-b485-1ed84a82914b">56,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjctMS0xLTEtMA_110fe269-d117-4038-9f17-d6cb56b2a268">33,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjctMy0xLTEtMA_485fd6bd-9b80-4b58-a92b-be56c40dcd05">5,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjgtMS0xLTEtMA_fbde874c-7a99-42f7-bd63-2485cd12fbb8">756,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjgtMy0xLTEtMA_c76c4764-cb15-411c-acc9-d52bf85521c0">621,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and Contingencies &#8211; Note 11</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzAtMS0xLTEtNTcwMw_dae1c28b-294c-4c56-ae36-8c8de1e758b0"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzAtMy0xLTEtNTcwNQ_e0b862ab-0920-4b1b-b1b7-8f8bac4bea46"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4NzY_5c4989d4-1953-4998-a122-ae8fd2b7b08e"><ix:nonFraction unitRef="usdPerShare" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4NzY_94dfb867-38ea-4057-93ec-16792e5e755c">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTA_94b8158c-7162-4187-8a31-4a70615d6404"><ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTA_f19bd78c-de96-4ff7-ba67-3b60415ff2f1">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTU_0aa7c1b3-3887-40ba-b7b3-6315701ede1b"><ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTU_91ea7d90-05eb-4429-8e3b-6c98a0ad868c"><ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTU_92aef5c6-e2b9-495c-9ff2-706e445eb26a"><ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTU_d153d0f3-7cdc-4354-b8d0-98cc892739d1">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMS0xLTEtMA_1e9d9f23-569f-4b31-b6fc-e407a9d949fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMy0xLTEtMA_487d0b9d-76a7-4493-8f20-4b0d44e0facb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5Mzc_0fc0c6ee-2f76-4a31-954e-3b46f3b73400"><ix:nonFraction unitRef="usdPerShare" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5Mzc_1e71141a-89ed-4f35-adef-f3be87ab0a88">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5NTI_3119469b-0597-42e6-b582-9d3a8da40015"><ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5NTI_51f14b6f-614a-4ee0-a3ef-d927527edb99">60,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5NjU_ee21504d-59b8-4df8-8eb5-7b7966061865">37,470,212</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5Nzg_3b49fb8c-ba8c-4f30-a5b7-708c7344d5eb">36,638,021</ix:nonFraction> shares issued; and <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5OTE_7fed9cc8-632b-4d01-8314-78aac9fe63af">32,814,278</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2MjgwMDQ_1ad8ddfb-fb7e-42bb-ae2e-188e129a63d7">32,284,051</ix:nonFraction> shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMS0xLTEtMA_5e2a8b3b-0749-42b9-a0db-499e8d32eb64">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMy0xLTEtMA_9b16bee7-3aff-44d4-9dac-3edcdaf0e966">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzMtMS0xLTEtMA_320c9995-486a-479a-812b-742be46af145">698,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzMtMy0xLTEtMA_f8f4cecf-2c6d-4d4d-bca5-4c233867b362">645,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock at cost, <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmFmNGU3Yjk3NTNhZTQ1MGNhYTNkOTM1MTllZDA3ZGRmXzEwOTk1MTE2Mjc4NTg_4278215a-1eba-4667-a7c9-d060076c042c">4,655,934</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmFmNGU3Yjk3NTNhZTQ1MGNhYTNkOTM1MTllZDA3ZGRmXzEwOTk1MTE2Mjc4NzA_e5ac28f7-5cba-4ed0-8ee6-86bc3de800b0">4,353,970</ix:nonFraction> shares of common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzQtMS0xLTEtMA_a99e013a-88f7-4c10-a359-cc4cc20e7775">319,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzQtMy0xLTEtMA_13061900-9d40-4d6f-bbd0-0380624578e0">251,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzUtMS0xLTEtMA_4024bdc3-0601-4e90-90d8-bd0ca7852f49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzUtMy0xLTEtMA_35e2d76c-d01d-4eb9-930e-e283df328ac8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzYtMS0xLTEtMA_377a1d62-dc68-4a2a-8ba1-66b3a4256104">429,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzYtMy0xLTEtMA_7c4c2019-6df3-4125-8532-5fd2895e5381">246,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Amedisys, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzctMS0xLTEtMA_822298f6-f72f-4059-a9a9-095ef3f99f64">809,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzctMy0xLTEtMA_e12fc059-6d86-403f-aef5-34ecef7dd57e">640,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzgtMS0xLTEtMA_4ad478d1-37ba-4c81-b75e-37d6f7cd5a0f">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzgtMy0xLTEtMA_56634a66-8d39-44b7-8aed-44882c5e2567">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzktMS0xLTEtMA_ce3a4fd8-8d1f-4a0b-aecb-3f68f1b81513">810,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzktMy0xLTEtMA_7ed78f91-563e-4ff8-964a-79172cfaf026">641,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNDAtMS0xLTEtMA_2fc18390-8b17-44e5-a3b9-ced367aa6a85">1,567,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNDAtMy0xLTEtMA_c3ddcc94-5dd2-4e1c-9bb8-81f24568368e">1,262,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="id92bd70d620044018083957a908405c4_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMi0xLTEtMS0w_e8cd9444-15ff-4f24-a6d1-25ccc456f25b">2,071,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMi0zLTEtMS0w_5a0814b8-1448-4a63-b2c4-bd3857cf5926">1,955,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMi01LTEtMS0w_58627d3e-47dd-42f3-819e-c334316bdddc">1,662,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy0xLTEtMS0xMTY_fe22abac-18d6-484a-a377-02151d059a04">34,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy0zLTEtMS0xMTY_7cfbbec5-f543-47cc-969c-edc47bded682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy01LTEtMS0xMTY_25f59ea0-8f2d-4d58-8687-54d69e2b7308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy0xLTEtMS0w_74131688-daad-4999-ace9-2542f08b962c">1,185,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy0zLTEtMS0w_4dccd0fc-5bd3-4409-b45e-6f5c12f7b241">1,150,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy01LTEtMS0w_8640e4a1-8ef7-4944-8f28-532b64069533">992,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNS0xLTEtMS0w_8ef4c0ef-9238-46b1-a55e-67a18e2e1374">449,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNS0zLTEtMS0w_8bc11bb8-56dc-47fd-8311-f11e6c6c0e78">394,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNS01LTEtMS0w_4c180c2f-5aa9-4a23-93dc-43a851a15e3f">316,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNi0xLTEtMS0w_fc4fc771-4b54-43ff-a381-a41e1bf556bb">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNi0zLTEtMS0w_ff696e9b-f508-4ce0-971d-d18df98407f8">25,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNi01LTEtMS0w_c4facd15-6a18-4362-8b3d-ed5f327b67c0">17,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNy0xLTEtMS0w_61b90be4-f8f7-4c63-942a-464de0b616f7">192,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNy0zLTEtMS0w_61af3496-1efb-4ac7-94b3-0ac7fb7942ca">188,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNy01LTEtMS0w_4e4d1635-7a78-4861-a5e9-9df641def430">166,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOC0xLTEtMS0w_358d8379-18d7-4104-8074-6b6024b419b3">28,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOC0zLTEtMS0w_9adec4f0-e8ac-4508-9bdf-c1cd95977b80">18,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOC01LTEtMS0w_44b2fcb1-f9e1-4a66-b231-35a984b98dbb">13,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOS0xLTEtMS0w_76efed3b-bd7a-4e50-a58b-8d576ae4e6d0">4,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOS0zLTEtMS0w_572d0f3f-aae3-4a8e-a3d7-d2c6b9454abd">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOS01LTEtMS0w_346b4c38-de37-4efa-b601-fa5772f44d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTEtMS0xLTEtMA_22448eb8-e106-4914-afce-54279feea221">1,886,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTEtMy0xLTEtMA_39f67520-dabd-430e-89da-0e38c09e6dfa">1,778,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTEtNS0xLTEtMA_74f74626-4a03-4397-879c-d88cfaff1c81">1,507,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTItMS0xLTEtMA_6dfed0a5-5371-47a4-b638-3a8cc9fec303">219,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTItMy0xLTEtMA_721d7d5c-4314-4465-bd14-2621e9da6a33">177,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTItNS0xLTEtMA_57795e45-ee44-445f-a24a-f8741dcdc10e">155,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTQtMS0xLTEtMA_75eeca9b-e993-42d7-91a8-2b461785680a">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTQtMy0xLTEtMA_0f8bdd50-596a-4ca1-af44-404ec104bf77">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTQtNS0xLTEtMA_7208bfdb-de16-449e-8cbe-a8890e9e812f">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTUtMS0xLTEtMA_1b40232a-00db-4ed6-aa5b-154d39d6635b">11,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTUtMy0xLTEtMA_66ac51ee-9295-4c8a-bd75-31b5b486c75c">14,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTUtNS0xLTEtMA_8c494505-5d98-46da-94f6-27600bd280c1">7,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTYtMS0xLTEtMA_2e3313b9-44fc-46e9-a2af-0cefb14e1442">3,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTYtMy0xLTEtMA_390df1f8-6b29-4616-b83d-018a6583d0ef">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTYtNS0xLTEtMA_4270a3f7-5164-4980-8c5d-e610ae5d9a34">7,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTctMS0xLTEtMA_f30b69c3-585e-4338-9829-04fa130c0aa8">1,669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTctMy0xLTEtMA_1df1a143-41e9-4c8b-ab20-cca79a632f0e">2,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTctNS0xLTEtMA_b28bdbdf-d36c-4538-b428-93b66b663657">3,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTgtMS0xLTEtMA_1b554d2f-d96c-4d10-a1f4-ee5a3fc18983">8,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTgtMy0xLTEtMA_0e59892d-397e-4978-96e1-45a8384c5627">7,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTgtNS0xLTEtMA_a148e0d6-8f66-4c2f-8846-8f508abab1f3">3,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTktMS0xLTEtMA_5461f862-4e27-4b09-94a4-973ce3c7a247">210,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTktMy0xLTEtMA_15daf2bd-1140-4b22-a8e6-2ddc39860d53">170,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTktNS0xLTEtMA_afe7c0ec-f237-4f67-88c3-a66e80242662">158,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjAtMS0xLTEtMA_574775c5-4d72-499f-aa70-74544ea3cd31">25,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjAtMy0xLTEtMA_6ae35dc2-8ea0-4b53-b561-2857e75875bb">42,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjAtNS0xLTEtMA_45f1878d-f9ef-4cef-8d71-21e0243e99e2">38,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjEtMS0xLTEtMA_2547c2d5-007c-490d-a872-ed04a9b067c5">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjEtMy0xLTEtMA_1948e4e1-8ba0-4c09-8cf3-0c9c2b2f07fa">127,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjEtNS0xLTEtMA_68a0bc2c-8e4e-476c-84ae-67e1b2a5a33f">120,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjItMS0xLTEtMA_f8739ee7-b511-4b14-8f9c-3fcd168c7cf1">1,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjItMy0xLTEtMA_b095a3cd-818f-45c3-bbb5-be72fa6aee19">1,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjItNS0xLTEtMA_1de05818-729b-4d72-ac7d-564d39be5e75">783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjMtMS0xLTEtMA_584b819d-b75c-4011-918b-f6871616545d">183,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjMtMy0xLTEtMA_041e2056-4c5e-47da-8a6c-54e97411a36a">126,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjMtNS0xLTEtMA_bd38b183-9eae-410a-a494-e466936f0994">119,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjUtMS0xLTEtMA_fdad5e80-47a4-487f-97ee-73be1b9acfec">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjUtMy0xLTEtMA_85327035-9c5d-4895-826f-b0c73261a69c">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjUtNS0xLTEtMA_c2121ed9-c423-4b0d-87d0-7433a2595cfa">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjYtMS0xLTEtMA_e3c1aa4f-b09b-4cef-a9d9-7c01d36759f0">32,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjYtMy0xLTEtMA_51933a66-9de9-4878-8e2f-6847f704e857">32,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjYtNS0xLTEtMA_a25c79dc-688e-4867-8ed5-fcaa2b144b35">32,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjgtMS0xLTEtMA_4656d831-27d6-4426-b022-bd4dbb04aede">5.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjgtMy0xLTEtMA_f305d4ec-53e7-40e0-bd44-d8a668a7d364">3.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjgtNS0xLTEtMA_77e347cd-922d-4cbb-ab8a-5089a6cdbdc3">3.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjktMS0xLTEtMA_8daed060-b159-44d8-adb0-2acd0277acf6">33,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjktMy0xLTEtMA_32e69694-0b01-4c45-a83e-cf817350f259">32,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjktNS0xLTEtMA_c0805c3f-44c1-4aef-8e07-47763ac1aab2">33,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="id92bd70d620044018083957a908405c4_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMi0xLTEtMS0w_0fc8a03f-b28f-469e-8c0e-c87cb2e7d6e7">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMi0zLTEtMS0w_2d4eab19-8adb-4b3e-8090-9777813a5622">127,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMi01LTEtMS0w_69b86df7-742e-41fc-bfe3-6b202f4bbb55">120,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMy0xLTEtMS0w_357c6b84-5220-4d59-9d62-e759277783fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMy0zLTEtMS0w_e4d022e3-9347-457c-9766-5a020d5aa99f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMy01LTEtMS0w_3a2cb2ac-5dec-4cb6-b0fb-c4fd6dda71bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNC0xLTEtMS0w_709ad47d-5651-4e28-b4ba-22bc9a4bdfdb">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNC0zLTEtMS0w_90670e18-cfd0-4fd0-9e2c-488887a8bcb4">127,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNC01LTEtMS0w_9520c62d-91d5-4a59-b79a-ae47167af8c9">120,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNS0xLTEtMS0w_409bae2d-fec9-4fe2-a2be-2a6ec23a8172">1,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNS0zLTEtMS0w_ca54a8f0-1b0f-4394-85c9-2676d2107fe4">1,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNS01LTEtMS0w_a57d3830-e39a-4f18-91d6-ba72cdba01c5">783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNi0xLTEtMS0w_8505a99c-234c-4a1d-bcf1-b3df1c775c3b">183,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNi0zLTEtMS0w_73e7fdce-5713-4885-b72f-bc837b4d5cbc">126,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNi01LTEtMS0w_7ffcdfb8-73f1-4e78-826e-51f8e522563c">119,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:341pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="id92bd70d620044018083957a908405c4_64"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except common stock shares)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.213%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d70551ae8f463895c999fdc4613768_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0xLTEtMS0w_f877b520-afd9-47b0-820d-f72eef441a16">516,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c73d7f291d449999ecc705771a35788_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0zLTEtMS0w_1db2b74a-98c0-4200-8190-6b7b2f6eaf9d">35,747,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c73d7f291d449999ecc705771a35788_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi01LTEtMS0w_fcdf9d3f-f463-4bc6-b44c-8939d99f43cc">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9320162518845cd970162f4a4cb6a6c_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi03LTEtMS0w_6e8c8fa8-04be-442d-aef9-8d040e75afd5">568,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44f984b3dbe34af3aace209254870882_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi05LTEtMS0w_63bddf0e-b252-40d2-ad08-c5a3c90a0c72">53,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1a95136f914b75adc71c283c901b28_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0xMS0xLTEtMA_829d685f-1f3b-4c35-9cf5-d8e2dde6cc1d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae973af03114509bb73f714dfe8c520_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0xMy0xLTEtMA_2a8741b9-e37c-40de-820f-f5cefc27845f">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae5b781450b4b82a9efea9a6ab20171_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0xNS0xLTEtMA_4f981b3b-7255-4e3d-94e3-93de5af33ba8">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMy0xLTEtMS0w_8f3dd8ed-3cc3-4e7b-87d2-95d037a043b8">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMy0zLTEtMS0w_c13f4702-f61b-4005-993a-6f25ba4a8e72">38,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMy03LTEtMS0w_a3c670b4-7b10-487e-a22c-ba28447ccd66">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; 401(k) plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNC0xLTEtMS0w_1694084e-6be4-4611-80b9-7ce312e93481">9,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNC0zLTEtMS0w_f7ac0c3c-7945-4595-9e2b-13a25ac77656">129,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNC03LTEtMS0w_e1cdd6f2-4232-4783-958d-14752bf406e1">9,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNS0xLTEtMS0w_6f6813bb-50ea-48f1-b6ef-dd97e9ba592b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNS0zLTEtMS0w_a3ebc1ad-38d2-43b1-a668-99a49d3fe648">174,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNS01LTEtMS0w_c1384ff7-3b3a-4e18-acf3-06cf349dcc47">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNS03LTEtMS0w_7f2f8e77-98da-477f-9f7d-38c75ec797d6">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNi0xLTEtMS0w_05e43f05-7c9b-4a58-9cf7-c93e40801065">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNi0zLTEtMS0w_ee45a01e-67ad-46ae-b039-d5741d7a3eb6">162,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNi03LTEtMS0w_c6f45430-f0ad-4289-bb17-f19bf720606f">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNy0xLTEtMS0w_b61dea8e-88d6-4ea5-a266-c4f412dd749c">17,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNy03LTEtMS0w_327ccd2c-c233-45ce-9ed7-e60237da6783">17,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfOS0xLTEtMS0w_218bc850-de7f-490b-bfee-8ca891149633">6,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ead52e4a58e40af94f4cfcfabee33f3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfOS05LTEtMS0w_47d4584b-fd32-41d2-8b6a-48bca6e60079">6,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfOS0xLTEtMS0yMDM1_d86bac2b-fdf0-49fc-9330-04d3768b2290">181,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ead52e4a58e40af94f4cfcfabee33f3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfOS05LTEtMS0yMDM1_c6092b45-2d77-4808-9999-b2ece97195c1">181,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTAtMS0xLTEtMA_39eea4d4-82e4-49ef-8166-9bf16dc01b9e">1,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11cb32ff042042599b56293d9c96b2de_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTAtMTUtMS0xLTA_09f44c3d-0b25-43ac-933d-6ed5b02a8a76">1,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTEtMS0xLTEtMA_5c21d606-9b52-47f4-8ce0-73789b958f95">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231" decimals="-3" sign="-" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTEtNy0xLTEtMA_241c6385-4259-42eb-9bb7-7ea844c7600f">614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cb32ff042042599b56293d9c96b2de_D20180101-20181231" decimals="-3" name="amed:EquityImpactofRepurchaseofNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTEtMTUtMS0xLTA_43422597-43de-4726-95e5-0504fda6b0e0">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTItMS0xLTEtMA_23840014-c3b5-4eeb-a6d3-3ed11293f7e6">120,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578f5d8892c542728c9f3d614bb9ae1c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTItMTMtMS0xLTA_f1d430ef-54f7-441f-ac25-54ef88d6bdf5">119,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cb32ff042042599b56293d9c96b2de_D20180101-20181231" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTItMTUtMS0xLTA_3465c960-1319-4ddc-8065-2992d4456893">783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMS0xLTEtMA_2accdfe6-b537-4706-9870-75905134c846">482,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i253841217f1446de87fdaaac95f8653f_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMy0xLTEtMA_caf0d1a2-c2c1-4632-b63d-62e9a01ed375">36,252,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253841217f1446de87fdaaac95f8653f_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtNS0xLTEtMA_9602460e-4dec-497f-af65-39e79a45abda">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c4c0651a104d48aa8b1906c357fbbc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtNy0xLTEtMA_d9c9b7a5-9a99-4af3-a26a-dff56094166f">603,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ccddfc560fe46b5b31297f960c4cdfa_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtOS0xLTEtMA_bdc511df-8700-4395-95d9-1fd6152a8d48">241,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c61e77ed93b41c1a04abf43c6726a45_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMTEtMS0xLTA_7d464fbe-3a84-41b5-952d-a3b7e41a2431">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if901346fc21749c693ca795fa77431fb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMTMtMS0xLTA_8a6ca490-f4a9-4bf3-806a-558a2df9ee63">119,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9b1d7d6085499cbd3f5b49680ccb64_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMTUtMS0xLTA_6449f0fa-acb7-4073-adfe-2667029448e7">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTQtMS0xLTEtMA_765baf76-b226-48f0-bb68-86d50e7fa1a2">3,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTQtMy0xLTEtMA_c525ee1c-d740-45c0-88ad-b982eb53c31f">30,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTQtNy0xLTEtMA_5dc704fe-e93e-45be-b082-457f3f0104b7">3,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; 401(k) plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTUtMS0xLTEtMA_57916be0-ea43-4908-876d-ddf9525781b2">9,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTUtMy0xLTEtMA_74dc22d1-54ee-4d11-8239-74396a988691">79,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTUtNy0xLTEtMA_abdbf7c2-3034-48b0-9a2a-6a42378864cc">9,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTYtMS0xLTEtMA_cf74d297-79e8-4066-96da-894e6c9632d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTYtMy0xLTEtMA_66f3e6e4-66b7-4346-8cfb-5fc7b1e2d006">189,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTYtNS0xLTEtMA_f11a5983-1677-40bc-81d4-b51fca68e388">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTYtNy0xLTEtMA_c623b4aa-e752-4908-a9ca-65fe2f8bfcf4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTctMS0xLTEtMA_0e944420-111a-4c19-b81e-929bbb7656bc">3,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTctMy0xLTEtMA_9d1be081-ac95-4046-853f-32f2cb27ef8d">87,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTctNy0xLTEtMA_f92fd964-f370-42cf-a4f8-2fdd3e348976">3,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTgtMS0xLTEtMA_2c870922-8464-4197-8f54-52a98fa1b8c8">25,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTgtNy0xLTEtMA_c2bf7557-054c-4d38-82ba-78eb7cf1048f">25,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTktMS0xLTEtMA_9457995f-e99d-4808-b50d-9e844426716e">9,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9317f7646da44eee93324b0a16fb1827_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTktOS0xLTEtMA_fff53ac6-f626-40b6-85d1-d8c0c8a07cc0">9,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjEtMS0xLTEtMA_66302c70-3bf6-4f9c-b048-b94cece03c97">1,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida0afee284554110852d7f9cc9a2bb52_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjEtMTUtMS0xLTA_eccea3f4-38e4-4837-9086-b2018f3c8bbc">1,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjMtMS0xLTEtMA_5d010428-6ad8-4511-af7e-57316bd0b5a8">127,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47e4e9c01d44fe7b652556bb85a5f1b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjMtMTMtMS0xLTA_090af464-130c-43a3-93cb-b324c0511006">126,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0afee284554110852d7f9cc9a2bb52_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjMtMTUtMS0xLTA_152861c8-b726-4304-8423-319fe8166f39">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMS0xLTEtMA_469593ff-8016-4078-acab-2a9e272b545f">641,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaed066fa0032452b960a5c28694f984d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMy0xLTEtMA_8e7cfd71-f93c-451e-ba08-57b56025e73f">36,638,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed066fa0032452b960a5c28694f984d_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtNS0xLTEtMA_f5177166-1380-45b2-9308-f8c9e5bc5c09">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3cb19d428214cf1b5d7b341146b4fbb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtNy0xLTEtMA_6d6b56ee-9ecc-4ee2-851b-9b2832f9ab60">645,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76be51b421be4511a94ed8e7e72c0652_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtOS0xLTEtMA_1ec7bc56-b55d-4aae-b3ba-274eef03e114">251,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822e34ba968444868d3c6943bd915b7c_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMTEtMS0xLTA_4eefc977-6f86-4cc9-98dd-cf4c2178bd66">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19c797f2e324b2eb967c2bce916b767_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMTMtMS0xLTA_fe53f88b-2fc8-495e-b639-232d86377adf">246,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77a7f6ef23f49b1b151e334930d121b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMTUtMS0xLTA_97799d66-9e7d-4d41-8008-cc4e0a93faba">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjUtMS0xLTEtMA_b8f5c5ad-0b77-4622-9478-64d55263e307">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjUtMy0xLTEtMA_3127431e-0f06-43e8-a4cf-7202c576487d">21,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjUtNy0xLTEtMA_e4c896dd-0577-4d5f-8335-b459575e7cce">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; 401(k) plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjYtMS0xLTEtMA_50e9ae40-3e1f-47c8-ba45-fed33a4aaef6">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjYtMy0xLTEtMA_4f718d84-7fc0-418b-8589-7162da659755">18,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjYtNy0xLTEtMA_3ee7ec4e-17bc-46c7-8ff0-5f4be8f9012a">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjctMS0xLTEtMA_2d5c691b-bf30-47ff-b8e1-005fecad17ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjctMy0xLTEtMA_291e8c20-29b4-4ae6-a26a-98c22cfecc8b">169,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjgtMS0xLTEtMA_7aae0f88-5bd5-4a7c-ad0d-d8136b828f57">6,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjgtMy0xLTEtMA_3c1801c8-d0eb-4075-88c5-af439001fb87">622,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjgtNS0xLTEtMA_61d9566e-e091-4f54-8d3d-a6ec7ada64ca">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjgtNy0xLTEtMA_30cdc723-e3e5-4282-9be9-35b9eeef6f52">6,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjktMS0xLTEtMA_56014421-a6cd-41fb-99d7-28cbf2566bde">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjktNy0xLTEtMA_759a176d-2bab-409b-959c-a40f8533c868">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtMS0xLTEtMA_5a9cea8f-0893-460b-915e-ac2e254d9d01">54,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtNy0xLTEtMA_a3a93fbb-2f1e-44e3-8db5-5126bebfb648">13,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb85416bef844237937a8966fd006741_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtOS0xLTEtMA_3ece8204-474d-4b71-a118-01aa713a9951">67,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzEtMS0xLTEtMA_a057b31a-e1bd-4137-8d1e-c895577a6c89">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3a117d66ff846f2af342b27fd619eb3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzEtMTUtMS0xLTA_ea9b746c-fbc1-4fd9-8ba4-38c9f9166df8">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off of other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtMS0xLTEtMjA0MA_6ac972e2-34c9-417b-afe9-0022b237c889">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7d57dd850e241008b6b1e4d426681fb_D20200101-20201231" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtMTEtMS0xLTIwNDA_5cde4014-8d59-4e96-bcbd-ef5283a022b3">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzItMS0xLTEtMA_98efe178-c232-4722-8ab3-6abc03602a02">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3c23c0c8b54e24b20b5c10ef9f270e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzItMTMtMS0xLTA_0776f75f-16ec-450e-b391-3b85c3b19925">183,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a117d66ff846f2af342b27fd619eb3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzItMTUtMS0xLTA_24f34c10-7744-426d-a156-b663396b4671">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMS0xLTEtMA_d3cd5f06-ddb3-4337-9a24-9f277f25ec0c">810,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7af783f565644361ab504f9908131fb3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMy0xLTEtMA_6f6905fe-fc2c-4702-90ba-4f3555f0017c">37,470,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af783f565644361ab504f9908131fb3_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtNS0xLTEtMA_87104a64-3edf-4fd2-beaf-61571dcde8d9">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3defad69f61b4cf99c2daf1bee38aab8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtNy0xLTEtMA_3cd70ee3-e7ff-4b3c-9998-2140d32ed5fe">698,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b86cc0a4b0247b0be34b31af7783e22_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtOS0xLTEtMA_744f9563-b67e-4830-a764-86a6dffbb81b">319,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bbb43da3d614bb0a07f82de8f66c0ab_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMTEtMS0xLTA_b32ba8c3-a869-4a40-97a2-5e92b5b14856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i556d9f2b4c0446a481203b0d721356f2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMTMtMS0xLTA_7ef229c2-c959-45f3-bf69-d8e844fd37eb">429,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8445bad575a44eaf8f8bf43b13576231_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMTUtMS0xLTA_325145ba-7709-4295-b4a6-4daab4022575">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="id92bd70d620044018083957a908405c4_67"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMy0xLTEtMS0w_2f518a42-74d5-4d76-addd-a9d1f32fe819">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMy0zLTEtMS0w_173436a2-c1ed-4fc1-a35b-a82ae5c7c28b">127,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMy01LTEtMS0w_a80e86ca-49c5-4146-88d6-5d24f59df5fe">120,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNS0xLTEtMS0w_44e43f31-5a7b-4727-935a-1593fa36b7ae">28,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNS0zLTEtMS0w_a1facfd7-c140-4535-ab94-e0537190f915">18,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNS01LTEtMS0w_0c273d6e-a8dd-4773-8ede-d4ce991bf954">13,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNi0xLTEtMS0w_29d864d7-5f52-4380-9333-43f613ae0680">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNi0zLTEtMS0w_6809de29-a8bc-4a95-be95-641414b7f250">25,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNi01LTEtMS0w_685ca0f7-1339-4534-8706-d083843bb6c2">17,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash 401(k) employer match</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PensionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNy0xLTEtMS0w_5ec19c56-1d77-49e7-89c7-b2854150a7a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNy0zLTEtMS0w_27cb82f8-0297-405a-89a4-6faed43be664">10,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNy01LTEtMS0w_1276a4b7-4930-4b8b-a2ce-9c48c647b416">8,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of operating lease right of use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOC0xLTEtMS0w_8b9932d0-13a2-4e18-914a-2654069b84b1">39,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOC0zLTEtMS0w_6cd7d710-5534-4064-9d02-78f8ee10f767">35,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOC01LTEtMS0w_7bb48df8-3c3d-4157-8b14-1b9bd30e909a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOS0xLTEtMS0w_ff9f46e0-aab9-400e-9ea2-3a2eb7bd93a1">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOS0zLTEtMS0w_438a7a29-7a47-474e-8428-ce30b9ebc9f9">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOS01LTEtMS0w_f2b03353-577b-4ca8-a05d-1a4b6822b34a">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMS0xLTEtMzk0Mw_6c7c61ca-ceb0-4cef-9e92-c2cdfc7b4756">2,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMy0xLTEtMzk0Mw_7470f70f-9955-42f3-ab0c-0af623cb74a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:LossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtNS0xLTEtMzk0Mw_3ac84bfc-8344-447b-9b79-02f7104568e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off of other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMS0xLTEtMjA1Mg_0affd782-80bb-494e-9cf0-6a98269fcacf">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMy0xLTEtMjA1Mg_1b4cbd9d-ad51-4b1b-bd7f-ee840033004b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtNS0xLTEtMjA1Mg_f14bf62f-1224-4dd3-b3b3-5be1730cceec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMS0xLTEtMA_055b5a54-2701-43e8-91b2-76872dd21aa3">26,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMy0xLTEtMA_ea24df79-9929-44e2-b94a-e162bb6f1a9b">13,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtNS0xLTEtMA_68594d5e-f201-46fa-a005-f42bd4d07bbe">20,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTEtMS0xLTEtMA_20fe6de1-1ef0-4bae-a0b7-3d36f8191254">3,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTEtMy0xLTEtMA_37348d09-5926-42f8-a7c5-cb551efbc8b1">5,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTEtNS0xLTEtMA_3ce898bb-e630-4653-8daf-9565f299a800">7,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of deferred debt issuance costs/debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTItMS0xLTEtMA_fd6a8ab1-512d-4992-a2ce-b1706beb066e">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTItMy0xLTEtMA_11ab855c-4e74-4564-8c08-bbc6e61983cc">873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTItNS0xLTEtMA_140420f4-d2f3-4a47-9b09-5138a12d045d">797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Return on equity investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTMtMS0xLTEtMA_d254a641-bcd2-4a4d-9e26-ecc152897552">5,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTMtMy0xLTEtMA_da72b701-364a-44ca-b9a5-ccab3f1f6a7a">4,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTMtNS0xLTEtMA_d1847faf-c58e-4fd1-9947-c2aa2ca44324">6,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTQtMS0xLTEtMA_830459a1-435c-4b29-af6e-ad457f696ede">4,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTQtMy0xLTEtMA_192d799d-90d6-49ad-89ce-61111f67c3ed">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTQtNS0xLTEtMA_d56acaca-0549-48c1-acf0-852ba56138f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of impact of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTYtMS0xLTEtMA_96d7aa28-1b0b-42fb-bd4c-bbb14d4fd163">2,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTYtMy0xLTEtMA_2ae6f265-d982-4589-9013-f3b9cdbe91aa">24,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTYtNS0xLTEtMA_492c8520-db09-4926-aad0-f93143de3bfd">12,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTctMS0xLTEtMA_8f8c23b7-313a-431a-b567-22bf4d0bacaf">7,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTctMy0xLTEtMA_9a8f3009-4848-4109-a178-a881cbfc0e99">2,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTctNS0xLTEtMA_f21097ac-19c1-4e77-b010-0987f0dc3485">8,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTgtMS0xLTEtMA_730e033f-9785-4ac1-be1a-a2adf309820c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTgtMy0xLTEtMA_b7252915-0670-4f0f-a825-46c1229846a7">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTgtNS0xLTEtMA_c7e8de1f-1547-424d-86a8-ef9d9a27d128">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTktMS0xLTEtMA_f86dbd26-2a21-46ab-a563-1de18c7ee355">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTktMy0xLTEtMA_8a99fc2b-8c06-4afa-903c-598e0a48465f">11,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTktNS0xLTEtMA_5c0a0b89-cb09-4419-af20-a5f940ec7a5d">3,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjAtMS0xLTEtMA_608a6f41-5c27-424c-b51e-cb9cf4e95524">39,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjAtMy0xLTEtMA_8e0a1402-8fe1-45d8-a7a1-fb8b6d57a693">42,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjAtNS0xLTEtMA_fb4facb6-5b93-41c4-b440-71678c0cd0e6">13,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjEtMS0xLTEtMA_d91a66d7-c4fb-442a-8d1d-39891e4c3b96">27,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjEtMy0xLTEtMA_d35c5cc2-349f-445c-98ce-34889f1a6e0f">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjEtNS0xLTEtMA_7aaf28fd-100e-477f-ac9e-0c60ad64b493">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjItMS0xLTEtMA_5e0449a4-ac67-4400-bc66-420e7278daaf">34,695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjItMy0xLTEtMA_5a3e9520-27c1-445b-8aa9-db84a0e59a68">32,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjItNS0xLTEtMA_dd2daea4-c60e-4484-962b-c815c9141598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjMtMS0xLTEtMA_40adc0f2-9612-4c06-a689-8a5840aa59fd">3,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjMtMy0xLTEtMA_754997bf-8027-44d4-90c6-10b9cc8d6da0">3,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjMtNS0xLTEtMA_3af87394-0707-47f3-9f29-7f76af24a13f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjQtMS0xLTEtMA_0918747f-63b3-484d-bf66-fb5b4d1d4b90">288,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjQtMy0xLTEtMA_69b589b7-849e-4a96-a42a-209a09e866bf">202,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjQtNS0xLTEtMA_377e3b2a-9c44-4874-b0df-27195ab42d31">223,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of deferred compensation plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjYtMS0xLTEtMA_92fe4016-50f3-4609-98f6-36cd89debb44">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjYtMy0xLTEtMA_4b405826-3c2d-423d-971e-4b4b5eb4c4e5">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjYtNS0xLTEtMA_40e2d471-3ee8-4a8d-ad4e-59a2d20dedc5">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjctMS0xLTEtMA_ede7e5ce-b816-4926-afae-23fd59d21d30">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjctMy0xLTEtMA_ce60f97b-474c-4c8b-9b57-1a6a37671467">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjctNS0xLTEtMA_e119e0d9-6f34-4c12-81fb-f8d391d0d5b3">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjgtMS0xLTEtMA_374191cd-66c1-462a-a549-5162e7a5495d">5,332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjgtMy0xLTEtMA_79acf638-0ad6-43d6-b435-0a1429a9b0f4">7,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjgtNS0xLTEtMA_5705fc28-dfdb-454f-8222-93a30babe5b0">6,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjktMS0xLTEtMA_9d88442f-5808-4291-bb96-a36479a80dbc">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjktMy0xLTEtMA_d11141d5-7368-47c2-84bc-39da59ab9932">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjktNS0xLTEtMA_a0219325-be76-4014-9db2-6631b1cf334c">7,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzItMS0xLTEtMzk0Ng_c0a8b03c-8053-403f-91a1-617a5b58d353">17,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzItMy0xLTEtMzk0Ng_34a07725-1dc5-4253-ab3b-604b869ad3af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzItNS0xLTEtMzk0Ng_f002debf-2d9b-4342-9f6f-f4304d40c96d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzAtMS0xLTEtMA_eb5e44ae-a737-4150-b47e-c8ba03b6e038">298,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzAtMy0xLTEtMA_ba200c7c-17cd-464f-aec2-ff865d8085b5">345,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzAtNS0xLTEtMA_a13e24b6-b0b6-44d1-ad77-ab6f64ca850c">9,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzEtMS0xLTEtMA_34994f09-6cf4-44bc-92ee-c09584561083">287,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzEtMy0xLTEtMA_63d3de0c-ca0f-4683-8980-17fc4192548a">352,948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzEtNS0xLTEtMA_b222a29c-6572-478f-bedd-797b09673984">22,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzMtMS0xLTEtMA_5fb5f650-21bb-43be-a3e2-ceab9ed8d981">6,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzMtMy0xLTEtMA_08e388b0-c30b-477f-94b6-a1dcbcc8d560">3,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzMtNS0xLTEtMA_e098b4b1-d6bf-4daa-8149-c1812084c423">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of stock to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzQtMS0xLTEtMA_16f708fa-836e-4b66-8b02-eb77cd52fe82">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzQtMy0xLTEtMA_38bb3526-a3e9-4c80-b95e-ee2e20d154a0">3,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzQtNS0xLTEtMA_4d398674-4caf-4d49-9506-4234379bd059">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares withheld to pay taxes on non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzUtMS0xLTEtMA_44adc05a-30b9-4300-9883-1053ea1b3207">54,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzUtMy0xLTEtMA_5825ac8f-cfe8-4b31-befa-86f3c5d993a4">9,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzUtNS0xLTEtMA_3c501e94-68b5-427c-8e79-0400667fbc5b">6,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-controlling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzYtMS0xLTEtMA_aac644ab-3639-4fbf-ad1c-35216bbb512f">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzYtMy0xLTEtMA_33b2367c-5384-4136-a5f9-6a888ddb1b61">1,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzYtNS0xLTEtMA_544914f2-bca3-446a-98cf-9b109a632ca8">1,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="amed:ProceedsFromBorrowingsUnderTermLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzctMS0xLTEtMA_285641db-dc9c-4775-8aae-b2396e2821c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="amed:ProceedsFromBorrowingsUnderTermLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzctMy0xLTEtMA_1fe2b288-9207-47de-864d-b120305e4bf9">175,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="amed:ProceedsFromBorrowingsUnderTermLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzctNS0xLTEtMA_53057ebd-0d19-4da7-b27c-851d10b86dc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings under revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzgtMS0xLTEtMA_b994d746-0268-43ad-a698-2a7d9254541b">684,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzgtMy0xLTEtMA_fc6e7921-a197-4925-81de-448c600ebe62">262,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzgtNS0xLTEtMA_54e446f6-b71e-401a-a52f-3f22b96bf83f">138,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of borrowings under revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzktMS0xLTEtMA_04319a7a-bb61-4b23-98c3-3a8124556198">703,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzktMy0xLTEtMA_28b8bd31-03cb-4ae2-ac48-d9622e642fa2">200,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzktNS0xLTEtMA_a05cf35d-f6a9-40e1-8578-81c4f35e4bc8">130,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDAtMS0xLTEtMA_8914d04b-4d3f-4c73-8413-4cb50b8ff43c">10,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDAtMy0xLTEtMA_179ded9b-8e3e-4b45-8ffb-8b71aee338fa">5,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDAtNS0xLTEtMA_0045362b-1edf-4098-8243-7eb05767584a">91,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDEtMS0xLTEtMA_59d917bd-38eb-4b02-ba4b-a1937091d873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDEtMy0xLTEtMA_1360c0ac-8559-4ac9-a88b-b419ec62aa52">847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDEtNS0xLTEtMA_28e9bc78-9d39-49ae-b009-22ed5a324f6b">2,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provider relief fund advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="amed:FundsReceivedFromProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtMS0xLTEtMjA1Ng_224f140c-a05c-4c7c-87d1-ac0b7c756a20">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="amed:FundsReceivedFromProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtMy0xLTEtMjA1Ng_e7808089-4f54-432a-a7c3-43a5b13dfe4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="amed:FundsReceivedFromProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtNS0xLTEtMjA1Ng_cd451cb5-7872-4a5b-8b18-5aa0e057ef38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of company stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDItMS0xLTEtMA_4904c6c1-cc35-44ee-b984-c43743958762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDItMy0xLTEtMA_31c85b39-52df-47fc-8d1f-4d9375848f23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDItNS0xLTEtMA_a41d4ec7-88b2-45d8-890c-88af65105c58">181,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="amed:PaymentsForRepurchaseOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDMtMS0xLTEtMA_7ced0ded-07c5-4cdb-8481-c105dcc99912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="amed:PaymentsForRepurchaseOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDMtMy0xLTEtMA_982b6430-093c-4ad2-97e9-0cba23e98136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="amed:PaymentsForRepurchaseOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDMtNS0xLTEtMA_fafc18a9-77b9-4e4c-a4e7-da68e277a0f3">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtMS0xLTEtMA_a910a8bc-a4c7-420d-92ca-842bff51ea33">14,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtMy0xLTEtMA_7a94e287-db3a-413f-9079-3cd1a86324af">227,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtNS0xLTEtMA_de0433fe-40a5-4180-8425-a2928c9f8b7d">267,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDUtMS0xLTEtMA_f229810d-84fe-4064-a03f-5233c7f0b6eb">13,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDUtMy0xLTEtMA_78672655-aa9c-44a9-af95-f81285eeeb6d">76,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDUtNS0xLTEtMA_fd8121fe-207e-4fcb-8479-8154503f65b1">66,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDYtMS0xLTEtMA_838b00bb-c3c7-48ac-8d78-27d5507c6450">96,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDYtMy0xLTEtMA_e7d335a7-01b5-4e39-a7d9-761e94b445cd">20,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d70551ae8f463895c999fdc4613768_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDYtNS0xLTEtMA_3d7bdfae-19ce-4aef-ac8a-dad28d2b4cb4">86,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDctMS0xLTEtMA_4fa72778-2c5c-4a1d-a781-93f05e1f9cf0">83,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDctMy0xLTEtMA_c683732a-2317-4649-9c05-7b183b6ff2c4">96,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDctNS0xLTEtMA_761e9431-2e11-442a-ac7f-e373cd37f8cb">20,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDktMS0xLTEtMA_056b0323-8138-4049-828c-7915801c4c76">6,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDktMy0xLTEtMA_a90f862d-f537-4de7-8501-b247c70d8fbe">9,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDktNS0xLTEtMA_4c7f164e-0cdd-407c-a05c-ca193cde67e8">3,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes, net of refunds received</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTAtMS0xLTEtMA_1e0f0725-ea30-43ff-be9c-5fa0f6a493ab">50,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTAtMy0xLTEtMA_467f5deb-53d3-489e-932e-d8ddec1cf370">29,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTAtNS0xLTEtMA_1b909d53-d6d1-4ce0-97b3-6329a67cc2c2">14,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Financing Activity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Note payable issued for software licenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTItMS0xLTEtMA_9c8c8604-834e-487d-81fb-8590a1ff1d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTItMy0xLTEtMA_5eabcae9-0d83-4a14-b587-2c78104a08ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:NotesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTItNS0xLTEtMA_0e14e4e7-69bd-4557-af40-5f5e3f6c1e91">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="id92bd70d620044018083957a908405c4_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MTM_399d745c-42ae-43a2-b500-12d0fbb69f01" continuedAt="if8ec1542b6cc49eebdb3785486bf8f80" escape="true">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="if8ec1542b6cc49eebdb3785486bf8f80" continuedAt="ifdd55d8dbec94fc089449fcf6dc6c930"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice and personal care services with approximately <ix:nonFraction unitRef="number" contextRef="i0e73c8be1d6044ae94fdfbcfab376671_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMzIz_f92635cc-c2ea-4634-a169-fc95bf2a8fdf">75</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i5312e58d089a492e8f1b50eb41d38fe4_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMzI3_a88249be-7caa-418b-8824-915107859127">74</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ibf84b9ba9e1d4509914b4659ae8cf76e_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMzM0_a6bd1756-5dd8-48ef-be5a-31b9404c1e56">73</ix:nonFraction>% of our revenue derived from Medicare for 2020, 2019 and 2018, respectively. As of December&#160;31, 2020, we owned and operated <ix:nonFraction unitRef="care_center" contextRef="i3f4d87d3f8c04768adb0d99598494f75_I20201231" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfNDM5_e0de70c9-b3de-4f28-906f-7205ffff03c3">320</ix:nonFraction> Medicare-certified home health care centers, <ix:nonFraction unitRef="care_center" contextRef="i7618d2cebdef436fa6e1ece2cb3e1a9c_I20201231" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfNDg3_da92f4b9-9010-45bb-8827-9d20546f0aac">180</ix:nonFraction> Medicare-certified hospice care centers and <ix:nonFraction unitRef="care_center" contextRef="i30daf9d0e928439bbf628952733e011b_I20201231" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfNTM0_bf2a3112-f18c-4654-b6a3-32cf56f34beb">14</ix:nonFraction> personal-care care centers in <ix:nonFraction unitRef="state" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfNTY3_931e6e0c-72ba-48a7-8e74-e44bd78429bf">39</ix:nonFraction> states within the United States and the District of Columbia.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MTQ_83ebb70c-69a5-4391-801b-400eedc9ea1f" continuedAt="ic6d26693498246698afac1ab559e1377" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Accounting Standards Update ("ASU") 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes, enacts changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, the Company adopted Accounting Standards Codification ("ASC") 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using a modified retrospective transition approach, which requires the new standard to be applied to all leases existing at the date of initial application. Under ASC 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. We used the standard's effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019. The new standard provides several optional practical expedients that can be adopted at transition. We elected the "package of practical expedients," which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us. The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i2914b051b7f649fbb23140dd91cafcdb_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMjUzNg_ac9193f0-ae1f-4160-963c-1fa1e6e13271"><ix:nonFraction unitRef="usd" contextRef="i2914b051b7f649fbb23140dd91cafcdb_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMjUzNg_ea57d975-6a06-456a-aaf2-cca8354a2c21">80</ix:nonFraction></ix:nonFraction> million in operating leases liabilities with corresponding ROU assets of approximately the same amount. The new standard also provides practical expedients for an entity&#8217;s ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, the Company adopted ASU 2018-07,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Compensation - Stock Compensation (Topic 718): Improvements to Nonemployees Share-Based Payment Accounting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods or services. Our adoption of this standard did not have an effect on our consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the full retrospective method. ASC 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The standard supersedes existing revenue recognition requirements and eliminates most industry-specific guidance from U.S. Generally Accepted Accounting Principles ("U.S. GAAP"). The core principle of the revenue recognition standard is to require an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. As a result of the Company's adoption of ASC 606, the revenue and related estimated uncollectible amounts owed to us by non-Medicare payors that were historically classified as provision for doubtful accounts are now considered a revenue adjustment in determining net service revenue. Accordingly, the Company reports estimated uncollectible balances due from third-party payors and uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore, as a reduction in net service revenue (or as it relates to Hospice room and board, an increase in cost of service, excluding depreciation and amortization) when historically these amounts were classified as provision for doubtful accounts within operating expenses within our consolidated statements of operations. In addition, the adoption of ASC 606 resulted in increased disclosure, </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="ifdd55d8dbec94fc089449fcf6dc6c930" continuedAt="i0add01d97d6c4172a3c9f1d4f9942341"><ix:continuation id="ic6d26693498246698afac1ab559e1377" continuedAt="i0c06ed5d408340d8b99e7fb0f1c746dd"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2017-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition (or disposal) of assets or a business. We adopted this ASU on a prospective basis. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions as evaluated under the new framework.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. We adopted this ASU on a prospective basis and will apply this guidance to our future tests of goodwill impairment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2016-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December&#160;15, 2017. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. Our adoption of this standard using a retrospective transition method for each period presented did not have an effect on our consolidated financial statements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i0c06ed5d408340d8b99e7fb0f1c746dd" continuedAt="i9bf4c7ee780f44a2a5d562bfe44d1897"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9bf4c7ee780f44a2a5d562bfe44d1897">, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued, subject to meeting certain criteria. The amendments in this ASU were effective beginning on March 12, 2020 and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our consolidated financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MDM_9922a04f-8107-495f-be35-3eff0efa0b14" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MDg_7ae26679-ebe7-4687-bee0-ef9a060b0bab" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MDY_5ef0d3de-c0c2-42a7-bc84-521894db90b8" continuedAt="id32b8c284a2240e98bc523e4a8cb9656" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of <ix:nonFraction unitRef="number" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" name="amed:MinimumPercentOwnershipForControllingInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTA2Njk_0204eec3-c8d7-496b-a839-a90d3a1a8a30">50</ix:nonFraction>%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. During 2016, we sold a <ix:nonFraction unitRef="number" contextRef="i3eee69c4378245919523ef9c81dcd659_I20161231" decimals="1" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTA4NDQ_02e4b75e-f420-4b73-8752-99f2d0f04b3a">30</ix:nonFraction>% interest in one of our care centers while maintaining a controlling interest in the newly formed joint venture; we repurchased the <ix:nonFraction unitRef="number" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="1" name="amed:NoncontrollingInterestRepurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTA5Nzg_96ee3a46-8737-435f-9f76-517005b2d08c">30</ix:nonFraction>% interest during 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold <ix:nonFraction unitRef="number" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" name="amed:MaximumPercentOwnershipForEquityMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTExNDA_0e22f70d-460c-4a02-a322-028537472cf5">50</ix:nonFraction>% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $<ix:nonFraction unitRef="usd" contextRef="ic6f32ffb396941779dd01b141bf45abd_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTA5OTUxMTY0Mzc5Mw_c6798e38-9713-4f02-858e-22d787b39310">17.9</ix:nonFraction>&#160;million which resulted in a $3.0&#160;million loss which is reflected in miscellaneous, net within our consolidated statement of </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0add01d97d6c4172a3c9f1d4f9942341"><ix:continuation id="id32b8c284a2240e98bc523e4a8cb9656">operations for the year ended December 31, 2020.  The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund operations. During 2018, we made a $<ix:nonFraction unitRef="usd" contextRef="i3e986e4e31c44d36a9f7a6664353fdce_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTEyODQ_44d4cf03-64cb-41e9-948b-ae9ca6c99767">7.0</ix:nonFraction> million investment in a healthcare analytics company; this investment is accounted for under the equity method. The book value of investments that we account for under the equity method of accounting totaled $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE0ODc_dc4b0831-6c12-4bd4-9fc7-7d70238881a7">14.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE0OTQ_cde371a4-c7d3-43c0-8ca8-fbe4535b8cf4">35.7</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively, and is reflected in other assets within our consolidated balance sheets.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MzM_f82d9080-96d9-4d46-a30a-3c51403a0947" continuedAt="i960dbbcdd0884f3b971fde56a58c0e45" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i960dbbcdd0884f3b971fde56a58c0e45" continuedAt="i18a1cc5de9d448acb2bed489e7aa1094"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NjI_281422e0-bead-4d92-85f0-f34a9366de6d" continuedAt="i173fa3c9434f46a8a3f273554ef647ce" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately <ix:nonFraction unitRef="number" contextRef="i0e73c8be1d6044ae94fdfbcfab376671_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMzEyNw_d1cf3c4d-5a9b-4e5b-85ff-8fef3eec7be8">75</ix:nonFraction>% of the Company's consolidated net service revenue.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMzg5OQ_28bfd2a4-95bf-4a8c-99ed-a352035444ce">99</ix:nonFraction>% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i18a1cc5de9d448acb2bed489e7aa1094" continuedAt="ieb9932c0d3fb4803b2b98f4350440fdb"><ix:continuation id="i173fa3c9434f46a8a3f273554ef647ce" continuedAt="i16ff2b014af844e78224f4b8a996f901"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NDU_b2f66d1f-caa4-4e0e-a49f-81291204bd5d" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:59.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9908f52af49414aaa4bba7ff6a04ea2_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMy0xLTEtMS0w_5273682a-e496-48a2-acf7-7fe35e932518">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbdc95bff22c46c88b5ecb49ca013c65_D20190101-20191231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMy0zLTEtMS0w_6570ea84-4b54-4c25-b658-ad379b82e7c2">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa97deb735d340eca9b8cc590a5b1849_D20180101-20181231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMy01LTEtMS0w_4bba439c-3293-4845-b6ea-a4a02821f9a0">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare - Episodic-based</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f3ed78fd22d4d13a30267510435daf6_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNC0xLTEtMS0w_9d4c343e-7189-44b6-b5f6-89699450ee56">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iefef9d24cffa43e4a8689e876b718fdf_D20190101-20191231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNC0zLTEtMS0w_bfead795-b885-411c-b103-aa2f255471ef">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc080435d3fc4721a9440877edb75f0d_D20180101-20181231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNC01LTEtMS0w_36bd339d-cbef-4666-9a36-ae4bc94dfb24">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare - Non-episodic based</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia74323b930434bcdb3617ec041a4cfe6_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNS0xLTEtMS0w_60ab6664-963a-47a9-bf03-2d4473af5c20">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdc0080330a7432e9027a57a221467c0_D20190101-20191231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNS0zLTEtMS0w_a804a161-9527-4cbb-8e06-7e94d67a56ba">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifdf6f8b2217645d7a837564472c1641e_D20180101-20181231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNS01LTEtMS0w_82e96e3e-91e9-4470-8639-9b4058b84b1b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04b9e3d120ed425ba59ad31de35d305d_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNy0xLTEtMS0w_683a7569-9c87-4b49-8b45-d4dc240308ad">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1cd65f8b7a704689a2fe739ca3da0471_D20190101-20191231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNy0zLTEtMS0w_e324afc3-c866-4f3c-afb3-9263d66ff005">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib865129db50747ec9ba2b83c279bc869_D20180101-20181231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNy01LTEtMS0w_88931b55-c55a-4712-9803-68b2ccb628b6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae6389e8be7141058ce2e5865620a128_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOC0xLTEtMS0w_f0040a5c-db72-4c8d-8f3f-21ab76d87dd8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6368cc1cda74803ab17d38cb452059b_D20190101-20191231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOC0zLTEtMS0w_bc9cf1de-17af-4b46-bbf8-891812695b9c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c88b95605441ba8df42caa5d36162b_D20180101-20181231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOC01LTEtMS0w_7b069092-d3aa-4abd-84f9-56ba85cbe01a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ebe30ad71fe49acad1f10623f51159b_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOS0xLTEtMS0w_1798c32c-cc59-4a1c-8ac4-a15827ab9ee1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59c59d1d549d4f0b8e8a5cd6aa96ee72_D20190101-20191231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOS0zLTEtMS0w_801ab99e-3837-4388-93ac-599a633a5e4b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaaa6c33dce254267aa5511c42c11f0c1_D20180101-20181231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOS01LTEtMS0w_bfe6b320-4088-4711-b03e-5d0a2259b6f0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMTAtMS0xLTEtMA_ed0b751a-00b0-4ee2-a896-ccab9194f9cc">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMTAtMy0xLTEtMA_464c808c-fc1a-4075-874f-07bf9146b209">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMTAtNS0xLTEtMA_d7e6a3ad-f833-4413-944d-6a1f78338749">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare Hospice on June 1, 2020.</span></div></ix:nonNumeric><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY3NzgxMg_3e4ada10-2eb4-4c2a-8ed1-25600155f7bc">30</ix:nonNumeric>-day periods of care rather than <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:durday" name="amed:NetServiceRevenueEpisodePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY3NzgyMA_f21628fe-8720-4a88-b05d-c1eff4b89c87">60</ix:nonNumeric>-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjE2Nw_acbb89e7-d184-47a0-b923-34fa69316ec6">30</ix:nonNumeric>-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient&#8217;s care was unusually costly (capped at <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:PercentageOfTotalReimbursementOfOutlierPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfNDU2Ng_73c49494-bd3c-4234-a78f-44d7fe33b145">10</ix:nonFraction>% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from <ix:nonFraction unitRef="number_of_visits" contextRef="i1fd55beb3b4d4378b920094a5b091472_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjEwOQ_bda77063-9610-42cf-865e-841bef1740ce">two</ix:nonFraction> to <ix:nonFraction unitRef="number_of_visits" contextRef="i1f6206325b4d4a58a46dff6013229b68_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjExNw_dd7ed8a4-ce9c-45f5-838a-b2a4567108de">six</ix:nonFraction> visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are now included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="ib5177b049f064d83bb0e48f33e3b2e58_D20200101-20201231" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY3NTU2Mg_c09ef699-e511-4364-8444-d7211d155f33">99</ix:nonFraction>% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="ieb9932c0d3fb4803b2b98f4350440fdb" continuedAt="i5d3a413514c24011a8993e29b1aff3bc"><ix:continuation id="i16ff2b014af844e78224f4b8a996f901" continuedAt="if107fe7583a24724a0ba6b36ee584f0f"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. Any cash received from Medicare for a RAP for a <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODY4Nw_e0d57e05-d83d-482f-9765-92b4fb8f7e6e">30</ix:nonNumeric>-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our consolidated balance sheets. CMS reduced the upfront payment for RAPs to <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcyNw_6fc6c08e-0fed-46ad-b91d-4f1f8fd2e008">20</ix:nonFraction>% for 2020 and has fully eliminated payments associated with RAPs in 2021.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from <ix:nonFraction unitRef="number" contextRef="i1fd55beb3b4d4378b920094a5b091472_D20200101-20201231" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfODU4NA_9d25c32f-f28c-458d-8483-8c8d3d50687b">90</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1f6206325b4d4a58a46dff6013229b68_D20200101-20201231" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfODU5MA_8a6dabe7-4d3f-4183-b835-90b4b7cbc745">100</ix:nonFraction>% of Medicare rates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for <ix:nonFraction unitRef="number" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfOTc3OQ_6fe87bff-f908-4082-b89d-fee62040323e"><ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfOTc3OQ_ad9ca6b9-f063-4e8b-8414-ab173553eb90"><ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfOTc3OQ_d342a583-2ffb-40e8-a2df-43a60134cbe6">97</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of our total Medicare hospice service revenue for each of 2020, 2019 and 2018, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="icca03328f124427a801b7d654ef05ff9_D20200101-20201231" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA3OTQ_3c341f7e-7192-4f76-a528-5e2b78fe3056">99</ix:nonFraction>% on Medicare claims, and record it during the period services are rendered. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28th of the following year. As of December&#160;31, 2020, we have settled our Medicare hospice reimbursements for all fiscal years through October&#160;31, 2013. As of December&#160;31, 2020, we have recorded $<ix:nonFraction unitRef="usd" contextRef="i1910bccf75da421d95218682b6c0f049_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTE2OTI_408ce299-c3f4-49da-b56d-ea62c3f07ba3">9.3</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021; approximately $<ix:nonFraction unitRef="usd" contextRef="i8e4242100dce41a99f05af2e39618231_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTE4NDk_a8976377-5856-48a8-8237-b7d4f3ef2de2">2.0</ix:nonFraction> million of this balance was acquired with the AseraCare Hospice ("AseraCare") acquisition. As of December&#160;31, 2019, we had recorded $<ix:nonFraction unitRef="usd" contextRef="i2b22800f018b4cb5b23b5e899cc8f26a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTE5OTc_54459dbe-bba6-4c5e-afcc-e4b01d370e45">5.7</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i5d3a413514c24011a8993e29b1aff3bc" continuedAt="ie00f9deb655048d291b23987d465f0ad"><ix:continuation id="if107fe7583a24724a0ba6b36ee584f0f" continuedAt="i04885e0b43b644ba9aa49d857caa5e4f"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i04885e0b43b644ba9aa49d857caa5e4f">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA").</ix:continuation> </span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:GovernmentGrantsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODY5Mg_c514f13c-9676-449a-a091-808a7a61baa2" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div></ix:nonNumeric><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NTY_e143e317-1022-4107-8b9a-dfb8507dbffc" continuedAt="ie59629561a8943508714f54759a057a3" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie59629561a8943508714f54759a057a3">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased.</ix:continuation> Our cash balance as of December 31, 2020 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:CashBalanceAssociatedWithProviderReliefFund" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjE5NQ_5e8c89c2-5676-46a1-9a6a-483784cc6b40">77</ix:nonFraction>&#160;million associated with the CARES Act Provider Relief Fund ("PRF"). We separated the PRF funds into their own account and as of December 31, 2020, we have only transferred funds used during the nine-month period ended September 30, 2020 to our operating account. We will transfer funds used during the three-month period ended December  31, 2020 to our operating account in 2021. Restricted cash includes cash that is not available for ordinary business use. As of December 31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="ic4486f034b52465db1934c0b02d4badf_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjU5Mw_0b198c70-2e92-457b-b101-236d22b344b3">1.5</ix:nonFraction>&#160;million of restricted cash that was placed into an escrow account related to the indemnity provisions within the Asana Hospice purchase agreement. As of December 31, 2019, we had $<ix:nonFraction unitRef="usd" contextRef="i458e999686ec425fb89dcbbb0521682c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODY5NA_56c44a8b-24e1-4037-9de9-3c05b65c2bb6">66.2</ix:nonFraction>&#160;million of restricted cash that was placed into an escrow account to fund the acquisition of Asana Hospice on January 1, 2020. </span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxMA_a8389635-ffe2-4323-b49e-9fb890e9a7db" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:68.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfMi0xLTEtMS0w_0b9aa280-3bd2-430f-ae8b-61c192cff36f">81.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfMi0zLTEtMS0w_c5329c29-a3f3-433b-b8cd-8db93f6602a7">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfMy0xLTEtMS0w_078cbc85-31d1-42d7-bc86-48b911be6ea2">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfMy0zLTEtMS0w_68160c8a-90aa-4a86-b021-88849e033629">66.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfNC0zLTEtMS0w_f9c90896-1067-494a-8537-458875d849d2">96.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="ie00f9deb655048d291b23987d465f0ad" continuedAt="i3973fb741a9e4fca81fae4953c76031a"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NjE_6cb64a71-fd62-4977-b24e-c47dc8bcef69" continuedAt="i7211bc58022e452399bab07dd72c4f71" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:PercentageOfPatientReceivablesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTQ2NDU_cda13a63-2fdd-4770-ac0e-4da93f49957f">10</ix:nonFraction>% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="amed:PortionOfPatientAccountsReceivableDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTUxMTY_7102a0fc-fe7c-4297-a960-bb29718f45ca">64</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="2" name="amed:PortionOfPatientAccountsReceivableDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTUxMjM_03f052f5-5dae-483e-8604-6458b23eb438">58</ix:nonFraction>% of our net patient accounts receivable at December&#160;31, 2020 and 2019, respectively, is limited due to our historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTUyNTA_3fd25981-0350-4592-bb41-1aaceed2f160">99</ix:nonFraction>% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTU4Njc_741493ff-6de1-4c50-a6af-f58046d797aa">20</ix:nonFraction>% of our estimated payment for each 30-day period of care. The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of <ix:nonFraction unitRef="day" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTYzMDQ_2c47db8b-cfe7-4d40-9830-df2d5216f499">90</ix:nonFraction> days from the start of the 30-day period of care, or <ix:nonFraction unitRef="day" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTYzNDY_c040d2e4-33be-48bf-ac1e-ee8dcfc25699">60</ix:nonFraction> days from the date the RAP was paid, any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of all upfront payments associated with RAPs in 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, and Personal Care</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7211bc58022e452399bab07dd72c4f71">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</ix:continuation> </span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MTc_a0074009-c32f-4e77-a9dc-a101bb6b511d" continuedAt="i824d34b9974d463f99b551756ff51ad7" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#8217;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the extent or manner in which the long-lived asset group is being used.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the business climate that could affect the value of the long-lived asset group.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the market value of the assets included in the asset group.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i3973fb741a9e4fca81fae4953c76031a" continuedAt="i9d7cd44b456c45d0ac8abdad103aa41b"><ix:continuation id="i824d34b9974d463f99b551756ff51ad7"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4Mzk_d73b96a5-b4f2-4460-ae0d-74dac7fb47b0" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide for depreciation over the following estimated useful service lives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id56f149b375540d6ac65813b85c223fc_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfMS0xLTEtMS0w_ed7fae2e-bb8f-4a01-9312-f2ded0d2c212">39</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9d302a79021b4c4cbaf66726ebe127e1_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfMi0xLTEtMS0w_90835457-ef73-467f-aa2e-05508be252c7">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i203914f8db684c668d2c7dac204ca2c6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfMy0xLTEtMS0wL3RleHRyZWdpb246NTU2ZjM1NGMwZjJmNDBlYmE1MWFhYWZkZTE1NDBhODlfMTA5OTUxMTYyNzc4Nw_eb06ba6a-00f4-4e37-8c02-f99d4e055eef">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i640213bfd2f74b9a8e1dde58507eabc6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfMy0xLTEtMS0wL3RleHRyZWdpb246NTU2ZjM1NGMwZjJmNDBlYmE1MWFhYWZkZTE1NDBhODlfMTA5OTUxMTYyNzc5MQ_077d2e4d-b626-44ab-b010-b800dadb903a">7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibb00a1b56bb044c7ab5db9f625aec705_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfNC0xLTEtMS0w_09f5ff3f-b137-481e-b29a-931f76824c8f">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib5e3297361534d9ebafe84913d07eb73_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfNS0xLTEtMS0wL3RleHRyZWdpb246NzA1MTlhMTkwOGQyNDYxOGFmNjEzMjM4ODAwMzJkNmRfMTA5OTUxMTYyNzc4Nw_847cb6b9-d9b2-4a20-8547-e94aeebc547c">2</ix:nonNumeric> to <ix:nonNumeric contextRef="ie624c24d63be42a88573abdf69aae516_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfNS0xLTEtMS0wL3RleHRyZWdpb246NzA1MTlhMTkwOGQyNDYxOGFmNjEzMjM4ODAwMzJkNmRfMTA5OTUxMTYyNzc5MA_d4d2fa20-51be-4dae-b3cb-87d3e9256f8e">7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i99cc7fb2614e43a78496b7db077072c9_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfNi0xLTEtMS0w_06f801ff-ba4c-41d1-8e05-5941d2f29f6b">3</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MjQ_84f1b86f-9f4f-4576-a080-87f5ab8f32bf" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our property and equipment for 2020 and 2019 (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bde4b17d3e64e889a2b995dc1b96e0f_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfMi0xLTEtMS0w_652a99f8-6046-4e9d-85bb-233268fe36b1">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33563aeb6c734c9b8f2b02515df00ee4_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfMi0zLTEtMS0w_7086f4f7-1e22-4c3a-9124-9e1dd348d5ce">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdd825dcd9b4a34a7e7ee40b29823ce_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfMy0xLTEtMS0w_1142f5b8-8030-40bf-9806-55e2b8e7e7b9">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a14cc7e58784bbabd79f9688f678767_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfMy0zLTEtMS0w_4f524be9-ecea-4bcf-9c66-0af553b7130e">55.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcdf59b18c044a0586a45d15dd0cc388_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNC0xLTEtMS0w_d3828d72-b3e7-488e-abe1-8d0d145155de">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ef5f5295c143c4814a9cc4b7e9a2aa_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNC0zLTEtMS0w_a30ece44-b231-4869-94bd-7fc64e0d9ecf">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id32eea10fdea44f8b804df035c1d9f9d_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNS0xLTEtMS0w_02477846-28f8-4f45-9bb6-b3ca2e3cafca">50.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0c5250e66540da9c9ee41bb6cc2a6b_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNS0zLTEtMS0w_0f886c0a-d0b5-487c-93a5-8bef6b32789b">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNi0xLTEtMS0w_5560053f-5de3-44fc-96a3-ec0bc57b7f64">118.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNi0zLTEtMS0w_0f182591-8711-488c-9a4e-21fa42d9160a">124.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNy0xLTEtMS0w_c5283aac-da8e-45cd-8f80-32a64df015f6">95.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNy0zLTEtMS0w_f509e157-59ff-4034-b59f-3e74b883a4c5">96.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfOC0xLTEtMS0w_9024bc05-7edd-4bfb-8141-74ad75280b36">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfOC0zLTEtMS0w_1eed365a-d4c1-45b7-abe5-d8e82c2a3f11">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTk3NjU_429776ce-4f87-4301-a92d-6c788c26055b">12.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTk3Njk_b6b5c353-c6bd-4f3c-9607-6c6ece4161dc">11.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTk3NzY_5b26afe0-6a2e-4e5a-b1a5-e128ec38191f">10.8</ix:nonFraction> million, respectively.</span></div></ix:continuation><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2OTk5Mg_98f71342-ea32-4c69-bb9e-aedcdf5e18ba" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth and discount rates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NTc_721364bd-f108-403e-9d25-fcc7f1af37b8" continuedAt="i836d4cdddab34d619c2b0d2dcac63733" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our operating segments described in Note 14 &#8211; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and have also deemed each of them to be a single reporting unit.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i9d7cd44b456c45d0ac8abdad103aa41b" continuedAt="ia5217405249a4767adb8eebef9116cb3"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i836d4cdddab34d619c2b0d2dcac63733" continuedAt="i58c3f0ec96864381957961f569f6b20c">During 2020, we performed a qualitative assessment to determine if it is more likely than not that the fair value of the reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we did not record any goodwill impairment charges and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October&#160;31, 2020. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.</ix:continuation></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i58c3f0ec96864381957961f569f6b20c">Intangible assets consist of certificates of need, licenses, acquired names and non-compete agreements. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxNg_2ef6bf16-13c0-4b4a-ac9d-18652113e2f9">two</span> to <ix:nonNumeric contextRef="iaf4b84d294244f4783317a7222e4e879_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjIzODE_c0a7946d-172f-4735-b2e2-b5f1136a54e3">three years</ix:nonNumeric> for non-compete agreements and up to <ix:nonNumeric contextRef="id9c91ba472944f99a6daf60ac242bcb6_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjI0MjE_edeb8b28-dde6-45f9-9bfa-65be83b61bbe">three years</ix:nonNumeric> for acquired names. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount.</ix:continuation> During 2020, we performed a qualitative assessment of our indefinite-lived intangible assets; as a result of this analysis, we wrote off approximately $<ix:nonFraction unitRef="usd" contextRef="i8a9e61c64a324dccb0426c5ca15ad0fd_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NzY5Ng_eddbfe88-a000-4341-98e7-f655afd1f3a0">4.2</ix:nonFraction>&#160;million of acquired names that are no longer in use. During 2019, we also performed a qualitative assessment of our indefinite-lived intangible assets; as a result of this analysis, we wrote off approximately $<ix:nonFraction unitRef="usd" contextRef="iab41181582e84ce6a158eb40d3e43022_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjI4Njc_833d225c-4562-4e6e-8d0f-ca39bed6bdd4">1.5</ix:nonFraction> million of acquired names. There have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our remaining intangible assets would be less than their carrying amounts.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:DebtIssuanceCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MDk_918edb97-b538-446a-b7de-16a4009ced78" continuedAt="i7dee62ec8975448fbc69bfe1ca366548" escape="true">Debt Issuance Costs</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7dee62ec8975448fbc69bfe1ca366548">During 2019, we recorded $<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjMyNjU_6de76e6e-7efa-4533-855e-76bd5c0a962b">0.8</ix:nonFraction> million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 8 - Long-Term Obligations). As of December&#160;31, 2020 and 2019, we had unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjM1NTc_992f088f-0753-4c46-be9c-efea74f39da7">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjY2Ng_1035579c-639b-4f5d-93f8-5b1ff94255b8">3.5</ix:nonFraction> million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed.</ix:continuation> The unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjM5NDk_f567adad-7d6d-4ff9-bc70-b567cd1ddd45">2.7</ix:nonFraction> million at December&#160;31, 2020 will be amortized over a weighted-average amortization period of <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:duryear" name="amed:UnamortizedDebtIssuanceCostAmortizationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjQwMjM_307f5a6c-4344-4205-b0b0-ca74d3d2a801">3.1</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NzI_433c5d6d-7db7-4274-95ac-09bd9f5c3b8e" continuedAt="i9ea0de479ae340a4af13286bab70055d" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:FinancialInstrumentDetailsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcwOQ_2bd7b811-9260-47ff-b394-c3cda51cf5cc" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:24.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of<br/>December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DebtInstrumentCarryingAmountExcludingFinanceLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjQ4OTJlOTMyYjc1YzQ1NWViNzkyYmM3ZTA0MjJmNTVkL3RhYmxlcmFuZ2U6NDg5MmU5MzJiNzVjNDU1ZWI3OTJiYzdlMDQyMmY1NWRfMi0xLTEtMS0w_b1a6f057-9145-454f-921e-00fbb589730b">215.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0822cae609e455f8dabd64cd55ce112_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjQ4OTJlOTMyYjc1YzQ1NWViNzkyYmM3ZTA0MjJmNTVkL3RhYmxlcmFuZ2U6NDg5MmU5MzJiNzVjNDU1ZWI3OTJiYzdlMDQyMmY1NWRfMi0zLTEtMS0w_73b035c0-c1cc-4209-8583-35f25c5de3bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaceabeac78a43fa8dcdac6a349b0ed0_I20201231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjQ4OTJlOTMyYjc1YzQ1NWViNzkyYmM3ZTA0MjJmNTVkL3RhYmxlcmFuZ2U6NDg5MmU5MzJiNzVjNDU1ZWI3OTJiYzdlMDQyMmY1NWRfMi01LTEtMS0w_8944ba8e-48a7-498c-be83-9e44a62ab55e">217.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7919ceb133453abee391bfba5d166c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjQ4OTJlOTMyYjc1YzQ1NWViNzkyYmM3ZTA0MjJmNTVkL3RhYmxlcmFuZ2U6NDg5MmU5MzJiNzVjNDU1ZWI3OTJiYzdlMDQyMmY1NWRfMi03LTEtMS0w_aa128a58-a9ab-4fbb-85ca-c21fdfbb6a39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9ea0de479ae340a4af13286bab70055d">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="ia5217405249a4767adb8eebef9116cb3"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MjA_a77f6d58-f0ea-44ff-af7f-fa5dede90284" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2020 and 2019, our net deferred tax assets were $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjU5NjQ_86440867-be7b-4687-8c1e-3f552d710d34">48.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjU5NzE_40e1a277-36c7-412b-8c07-21ff3c98b9f2">21.4</ix:nonFraction> million, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#8217;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#8217;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.</span></div></ix:nonNumeric><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NDI_d3bef262-73c7-40b2-9c46-b9fb6cca2dfa" continuedAt="i81ec72def4ac49beac7d1a51102d890a" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i81ec72def4ac49beac7d1a51102d890a">We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award.</ix:continuation> Share-based compensation expense for 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcwNTI_65b95029-6e79-4ce8-aa28-11261736be9c">26.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcwNTY_128fcded-8b0f-4366-89ee-73de11349c19">25.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcwNjM_7cd7e965-26e0-420a-b36f-457f2d856bee">17.9</ix:nonFraction> million, respectively, and the total income tax benefit recognized for these expenses was $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcxNDg_322e9af8-acc3-4dca-9b04-195fa64178ad">4.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcxNTI_b630479f-8cbd-45ff-acf4-51c905e30c55">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcxNTk_99abd9ea-7506-4ab5-ac1e-1c04c03e92b6">4.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MTI_e21cdda4-6b22-4638-84f7-fa9657c977e2" continuedAt="i3009ef1f16604e599411582bb71538db" escape="true">Weighted-Average Shares Outstanding</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3009ef1f16604e599411582bb71538db">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</ix:continuation> <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4Mjg_efde11d5-c2d2-4248-8b25-59e0fa08bd2c" continuedAt="i7630e5db2cc7488b8c2ae4e115933b8a" escape="true">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i7630e5db2cc7488b8c2ae4e115933b8a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfMi0xLTEtMS0w_e92e5d8b-bb29-4aa0-a5a8-a6da7f3f0832">32,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfMi0zLTEtMS0w_b7af6c2d-fbef-4488-bdb8-98719f394fd4">32,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfMi01LTEtMS0w_946dd893-43ea-4c48-a7cd-28927d23dc24">32,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNC0xLTEtMS0w_9cbc3c1c-64ee-4ff5-bac8-04314d030be4">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNC0zLTEtMS0w_aedd51c3-05f3-4114-b4aa-e42a3509eb25">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNC01LTEtMS0w_f35876d8-b135-423c-a5e7-2df1f45bb0a8">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNS0xLTEtMS0w_fb7c6d2f-2d2a-4ca8-bf28-eb03219a20f4">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNS0zLTEtMS0w_c3837900-5615-4cca-964c-7af7ba9d93d2">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNS01LTEtMS0w_fbcaf209-8eb7-49ce-aa83-4eab9e20f374">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNi0xLTEtMS0w_b80cce68-a5f1-4475-9cd4-1facb48be4e7">33,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNi0zLTEtMS0w_5d843c6e-8066-48c7-ab8b-0265ace09023">32,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNi01LTEtMS0w_f5484076-2046-46f6-b1dc-a3e4981be3d7">33,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNy0xLTEtMS0w_7a15f30c-100c-42ab-b0aa-6034d6a05763">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNy0zLTEtMS0w_6c962031-611c-4630-b7b3-a805ce7eb949">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNy01LTEtMS0w_d187a644-4f36-4ca0-9bcc-1581122bdf14">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MDc_14b1c253-c997-4d93-a317-7e02267a4d5e" continuedAt="if35d00298abc4ae2bad3b2b31bd33af9" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if35d00298abc4ae2bad3b2b31bd33af9">We expense advertising costs as incurred.</ix:continuation> Advertising expense for 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc3Nzg_85a96ffb-7a56-4709-9a99-a858bc45660e">8.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc3ODI_37a9264c-c156-4496-b9d9-22b1ee5c4d65">8.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc3ODk_bc5c64ab-16af-45d3-a28b-c2e498011bba">7.0</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_1740"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:COVID19TextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjM1Mzky_f8340037-704d-427b-88b1-23673894d997" continuedAt="iab2e5e9fbbce41749277f3199cb503d6" escape="true">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</ix:nonNumeric></span></div><ix:continuation id="iab2e5e9fbbce41749277f3199cb503d6" continuedAt="i133f2c0c5fb94b258bd97a5bb75549dd"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provides for $<ix:nonFraction unitRef="usd" contextRef="i6001d3911d55430a8c080827cb5bcaff_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingForHealthcareProvidersIncludingHospitals" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNTUz_df8c6ffb-42f1-4581-bf69-dccb21f50de7">175</ix:nonFraction>&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $<ix:nonFraction unitRef="usd" contextRef="i6001d3911d55430a8c080827cb5bcaff_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNTY3_563db3ff-1cde-4e24-af82-e68bff8d0f21">30</ix:nonFraction>&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $<ix:nonFraction unitRef="usd" contextRef="i372268bd3773442994730e4fe0e5ee44_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNTgw_3cd90120-120d-4e4e-8df6-5316a95a896f">100</ix:nonFraction>&#160;million from the first $<ix:nonFraction unitRef="usd" contextRef="i6001d3911d55430a8c080827cb5bcaff_I20200327" decimals="-9" format="ixt:numdotdecimal" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjE4_f82cbefa-6dc8-4693-bee0-4e5bf69518b5">30</ix:nonFraction>&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $<ix:nonFraction unitRef="usd" contextRef="ibfa49fd6f4b049c4852349a3f959f964_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNTk0_555ee596-2ad0-417d-b083-9e3c08857a6f">2</ix:nonFraction>&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $<ix:nonFraction unitRef="usd" contextRef="i37e4a08657594a9e8a1641435acac59f_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjA2_f6f22fa0-8824-4dab-87f7-e47a8e126d8c">6</ix:nonFraction>&#160;million of PRF funds in </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i133f2c0c5fb94b258bd97a5bb75549dd" continuedAt="i9705061e36704dbea35258351d015ccd"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we are allowed to use the funds to cover lost revenues and health care costs related to COVID-19, and we are required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we have decided to only utilize PRF funds to the extent we have qualifying COVID-19 expenses, which totaled $<ix:nonFraction unitRef="usd" contextRef="i6b9d23dde21e42c9a907136f7eeaf5e9_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="amed:COVID19ExpensesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjMx_62189822-2b2c-462d-a5eb-df1ee7f33427">33</ix:nonFraction>&#160;million for our home health and hospice segments during the year ended December 31, 2020. Accordingly, for our wholly-owned subsidiaries, we will not be using PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred to date is reflected in other operating income within our consolidated statement of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HHS issued new guidance in September 2020 noting that PRF funds can be used towards lost revenues or expenses attributable to COVID-19 through June 30, 2021. We do not believe that we will fully utilize the funds received; therefore, we recorded a liability related to the funds that we do not expect to utilize totaling $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjU3_f7458c5f-69c1-4ff1-9397-694d0bb88a79">60</ix:nonFraction>&#160;million which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. Funds that we intend to use in the future to cover COVID-19 expenses, which we have estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:EstimatedFutureCOVID19RelatedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjcw_484faf4a-1777-408a-b0d8-b305d8a3e3bd">12</ix:nonFraction>&#160;million, have been recorded to a deferred liability account within accrued expenses in our consolidated balance sheet. These estimates may change as our ability to utilize and retain the funds will depend on the magnitude, timing and nature of the impact of the pandemic. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjM1Mzkz_d0f044ce-ec55-47ec-accb-701ed913a6bf" continuedAt="idf0902f221614a6095064fb387aa4937" escape="true">In summary, the total funds that we have received from the CARES Act PRF as of December 31, 2020 consist of the following (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="idf0902f221614a6095064fb387aa4937"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:74.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized during the year ended December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:CARESActProviderReliefFundsUtilized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV8xLTEtMS0xLTYxMTU_18cb3af6-2094-4503-8f54-2094c038cfcb">33.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be utilized January 2021 through June 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV8yLTEtMS0xLTYxMTg_36110b0e-e1e5-43e6-8cd7-73bd6160fab1">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be repaid to the government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV8zLTEtMS0xLTYxMjA_04eb37bb-a7d0-4fbf-87b8-e134d6a78072">60.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds received by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV80LTEtMS0xLTYxMjI_ad84a275-c074-4b5f-8496-ccded581927f">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:TotalCARESActProviderReliefFundsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV81LTEtMS0xLTYxMjQ_f416c0a1-6ccf-442d-800c-55291bdff2ed">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, HHS distributed an additional $<ix:nonFraction unitRef="usd" contextRef="i118a662ab55141c19f9cdf727c8817fe_I20200424" decimals="-9" format="ixt:numdotdecimal" name="amed:AdditionalFundingDistributedToHealthcareProviders" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjgz_1f6a7615-f6c6-451b-9f06-7c39d971f794">18</ix:nonFraction>&#160;billion in funds to healthcare providers. We did not receive, nor apply, for any additional funds from this second distribution. On October 1, 2020, HHS announced $<ix:nonFraction unitRef="usd" contextRef="i6134feb4f36f4032ba67f2372de0d569_I20201001" decimals="-9" format="ixt:numdotdecimal" name="amed:AdditionalFundingDistributedToHealthcareProviders" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjk2_c8d54a82-8951-45af-b882-3f20e3986ccb">20</ix:nonFraction>&#160;billion in new funding to healthcare providers under the Phase 3 general distribution. We did not apply for any additional funds from this distribution.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provides for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period May 1 through December 31, 2020 and the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, we have deferred $<ix:nonFraction unitRef="usd" contextRef="ie67bc19fa2814c5abd3ff91ce96f6e90_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:CARESActDeferralOfEmployerShareSocialSecurityTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNzA5_f2f2c341-e41f-4a5c-9dbb-85b83858c471">55</ix:nonFraction>&#160;million of social security taxes; approximately $<ix:nonFraction unitRef="usd" contextRef="ie67bc19fa2814c5abd3ff91ce96f6e90_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjM1Mzk1_50e86d34-4b4f-4bd4-a5d7-7ff711b80c8f"><ix:nonFraction unitRef="usd" contextRef="ie67bc19fa2814c5abd3ff91ce96f6e90_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjM1Mzk1_b6610127-3dee-4340-8634-601971bdc6c8">28</ix:nonFraction></ix:nonFraction>&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9705061e36704dbea35258351d015ccd">Our personal care segment did not receive funds under the CARES Act; however, they did receive funds from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which are intended to cover costs related to the public health emergency. The grant income associated with the funds received, which totaled $<ix:nonFraction unitRef="usd" contextRef="ic433fb8ffa524d98b4462b2bfdb4ca4a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNzI0_39330879-d049-41ed-aa48-9836aa23b5b2"><ix:nonFraction unitRef="usd" contextRef="ic433fb8ffa524d98b4462b2bfdb4ca4a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNzI0_b0e575fd-0cd0-4d6b-a8aa-189c538140ce">1</ix:nonFraction></ix:nonFraction>&#160;million during the year ended December 31, 2020, is reflected in other operating income within our consolidated statement of operations.</ix:continuation> </span></div><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDMyNA_430b4118-e8df-430f-b58e-bdc11b575466" continuedAt="i344d70aacd684bfe8fb2d23bfd325875" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i344d70aacd684bfe8fb2d23bfd325875" continuedAt="i17e01421d40042a69d8401fb1de8f1f0">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuation and liabilities assumed.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i17e01421d40042a69d8401fb1de8f1f0" continuedAt="i716cbfbc245243c9bc1d0665eb0d5852"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Acquisitions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Division</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="id9cafc4be2f5437d9ca0b72a01385735_D20200301-20200301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0Mjk4NA_ed5c5fa5-a984-45fb-bb91-e28e5df92708">3.0</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i027e9e9fdcb3465e9e2a8e7763db61d5_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0Mjk5OA_672cd652-fe4f-4db7-b6e4-442aa54b83ce">2.8</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="ibcad9ea4bad644b7aef096a89d73a367_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzAxMg_af26863c-9ff1-40c2-b0fe-a8781fe24040">0.2</ix:nonFraction>&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2020, we acquired the regulatory assets of a home health provider in Kentucky for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i2c82b6aabd174ab7b9b1bbd04c0e4f43_D20200418-20200418" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzAyNg_e3541a73-2057-486c-9d4e-9743dd512906">0.7</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="id6b5bde6cd03496eb965aaa99d46b4e1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA0MA_67eed7d6-bafe-4537-ad70-46c2463c8987">0.5</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="i8af9f0752744492d80892b57fe0eb43f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA1NA_1e94b377-2d31-474f-8851-cbb542c906ff">0.2</ix:nonFraction>&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Division</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with <ix:nonFraction unitRef="care_center" contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDM0NA_5f46b078-34df-4e29-a890-a4d87c2064f6">eight</ix:nonFraction> locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA2OA_727f834f-fec4-4f98-956c-83e70017aefb">66.3</ix:nonFraction>&#160;million, net of cash acquired of $<ix:nonFraction unitRef="usd" contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA4Mw_229ce4cf-35d4-455f-b5fa-1453e94eb8eb">0.7</ix:nonFraction>&#160;million. Under the purchase agreement, the purchase price was subject to a net working capital adjustment, whereby the purchase price would be adjusted to the extent the actual net working capital of Asana as of the closing differed from the required net working capital under the purchase agreement. The net working capital adjustment, which was finalized during the three-month period ended June 30, 2020, reduced the purchase price by $<ix:nonFraction unitRef="usd" contextRef="i736c6f864f0c4f2f90cb716d504ad728_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="amed:BusinessAcquisitionWorkingCapitalAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzEyNw_ad092eb1-1918-432e-921e-253238483f70">0.7</ix:nonFraction>&#160;million, from $<ix:nonFraction unitRef="usd" contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzExMg_2948f57d-3aec-4f06-9ba4-07d19025567b">66.3</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA5Nw_278f1e59-218e-4c4c-bea7-c31b503902a5">65.6</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI3OQ_156460af-d6de-4c83-a5ef-0cfab4849dcd" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired and liabilities assumed. The total estimated consideration of $65.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMS0xLTEtMS02NDM2_ee88b9fe-bf45-465b-a6e2-6b2e06037b96">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMi0xLTEtMS02NDM4_0a687a8b-8ac7-413b-a5af-4283f60e9ca5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMy0xLTEtMS02NDQw_a5cdafdb-eb2f-4cb8-a972-737f1957f2d5">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfNC0xLTEtMS02NDU3_4bea0f57-117d-4069-87db-e0698f53d771">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfNS0xLTEtMS02NDU5_e09c7ad5-7b1e-4714-b5e8-f204b6471c40">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfNi0xLTEtMS02NDYy_f3c40c8a-a3b5-4525-b288-abe8d71cd309">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfNy0xLTEtMS02NDY0_3ce4f452-ef7b-4a70-bde5-6e668d93c1d2">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfOC0xLTEtMS02NDY2_7aeeaafc-0dc1-436f-9358-e9c328f369dd">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfOS0xLTEtMS02NDY4_eafcae65-a6a0-4616-84fe-5527ffa487ae">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMTAtMS0xLTEtNjQ3NA_43394df3-82d6-4e9f-8d82-c39500694478">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMTEtMS0xLTEtNjQ3Ng_3c9b194c-365a-4dd6-ad9a-7386268c81de">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMTItMS0xLTEtNjQ3OA_cedabf65-f827-4229-847e-e0a73df5f21d">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMTMtMS0xLTEtNjQzMg_47aec421-eed2-4c40-bff7-3ca8c9c90c12">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses ($<ix:nonFraction unitRef="usd" contextRef="iefb68536b309420b86b96f71d3be7002_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzE1Ng_cd7e46e3-fe9e-4f30-a006-8e1aedcc2888">2.0</ix:nonFraction>&#160;million), acquired names ($<ix:nonFraction unitRef="usd" contextRef="i4071912f29b1471a90316176f150bae0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzE3MA_4563304f-d77c-4da6-8596-37acfabb8b45">1.3</ix:nonFraction>&#160;million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="iac1ab93fa9c14e638c003d6efff17ec7_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzE4NA_42ea746f-48de-4fb5-8852-49fc8b38d659">2.3</ix:nonFraction>&#160;million). The acquired names and non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i45609ba2476e4e52aa2321ed4c22caa4_D20200101-20200101" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzIwMg_7c470c3d-3fde-4abe-a161-1ae7985fc8e7"><ix:nonNumeric contextRef="ib9861da3d84840e5b7b2f004402be77c_D20200101-20200101" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzIwMg_c71af1dc-f341-4b8e-bee7-89f38e8f071d">2.0</ix:nonNumeric></ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asana contributed approximately $<ix:nonFraction unitRef="usd" contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzIyOA_66735b2b-8f97-4099-8d2e-4d4965ec0de2">23.4</ix:nonFraction>&#160;million in net service revenue and an operating loss of $3.3&#160;million (inclusive of acquisition and integration costs totaling $<ix:nonFraction unitRef="usd" contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzI0Mg_5b5383c4-95f2-4ab1-ae4b-5c4b5df25cd3">2.0</ix:nonFraction>&#160;million and intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzI1Ng_bc586718-1de7-4e6a-b6dc-7b30e77c9747">2.6</ix:nonFraction>&#160;million) during the year ended December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101" format="ixt-sec:duryear" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI5OQ_b4250f09-feda-405a-a967-52eb6d28c251">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with <ix:nonFraction unitRef="care_center" contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601" decimals="0" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzI4NA_f54142f4-1c12-4803-881d-ed3f81c49cad">44</ix:nonFraction> locations, for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzI4OA_2ce8600f-0a93-411e-9b09-79dc6d33e69d">230.4</ix:nonFraction>&#160;million, net of cash acquired and inclusive of a $<ix:nonFraction unitRef="usd" contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="amed:PaymentsRelatedToTaxAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzMwNA_fa608c57-7b6b-4f1e-a4d4-cf2f7ae8560a">32</ix:nonFraction>&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $<ix:nonFraction unitRef="usd" contextRef="ia1196979b4bd42e99e052738971c3d6d_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="amed:BusinessAcquisitionClosingPaymentAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzMxNw_60356b3e-6982-475a-beaf-3f96f8a53345">1.0</ix:nonFraction>&#160;million. The </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i716cbfbc245243c9bc1d0665eb0d5852" continuedAt="i613560607e8f4bfbb5e1bb5823212c6e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $<ix:nonFraction unitRef="usd" contextRef="i3a1566846d62435ebae17d6c7c127850_D20201001-20201001" decimals="-5" format="ixt:numdotdecimal" name="amed:BusinessAcquisitionClosingPaymentAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzMzMQ_b8ae7704-7577-45ed-b9fd-314b7f1729f7">0.8</ix:nonFraction>&#160;million, from $<ix:nonFraction unitRef="usd" contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzM0NQ_e4c19a81-0998-4d88-ae63-d6d2447e5206">230.4</ix:nonFraction>&#160;million&#160;to $<ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzM2MQ_9f28d038-6368-4125-9fdf-984e7b20d92e">229.6</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI4MA_eebb6f4d-8b4b-44a8-9144-7db9cec56bae" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. During the year ended December 31, 2020, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. The final valuation of the assets acquired and liabilities assumed was not complete as of December 31, 2020, but will be finalized within the allowable measurement period. Based on the Company's preliminary valuation, the total estimated consideration of $<ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzM3Nw_ba51408d-f43f-43b9-bcac-ef6293f45633">229.6</ix:nonFraction>&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMS0xLTEtMS02NTQ1_f5358027-4ea1-4dc7-bfae-f817109fb539">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMi0xLTEtMS02NTY5_1d7d3535-648a-4ed7-b395-c8baf0a4959a">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMy0xLTEtMS02NTQ3_dbab4a26-31da-49e3-b378-b9a1b13af998">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfNC0xLTEtMS02NTQ5_177d7b96-7b14-42e9-b296-74c2a1c92d13">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfNS0xLTEtMS02NTUx_45730ba9-9589-4ec0-9744-6885887c7d81">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfNi0xLTEtMS02NTcx_dbc9df35-ab19-479e-b82f-c4ac43daed03">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfNy0xLTEtMS02NTUz_fd86df4a-fdd9-4f1a-9134-9a4011a7f321">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfOC0xLTEtMS02NTU1_1c195320-4ccf-4c52-95d6-112fd21ff766">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfOS0xLTEtMS02NTU3_97bf14a4-b7e3-4f41-96ac-5710881f4afa">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTAtMS0xLTEtNjU1OQ_ae2fa6b0-25dc-4629-8aa8-d074fb214430">10.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTEtMS0xLTEtNjU2MQ_4c14eb03-86fb-408f-9f20-60891b1be40a">5.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTItMS0xLTEtNjU2Mw_f0f1ae34-6912-4b58-bc75-84f6245fa6d3">27.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTMtMS0xLTEtNjU2NQ_5f8c4266-c03a-4760-bb54-b183c192caea">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTQtMS0xLTEtNjU2Nw_0ab4feea-9a4c-4c73-86ed-8351ab769443">210.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTUtMS0xLTEtNjUwMQ_3ff51440-ed04-4b82-b392-21a694901a18">229.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses ($<ix:nonFraction unitRef="usd" contextRef="i6dade9dfe7084bfbadf9e3614bbe33ae_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzM5Mw_83c04c09-c9f2-4f46-b947-5357a5b7e0ea">8.7</ix:nonFraction>&#160;million), certificates of need ($<ix:nonFraction unitRef="usd" contextRef="i5f1af67560f042a28a10f654e58775f2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDQ5NA_fa5c072f-0e6b-444d-b034-40c8bbbe1962">0.7</ix:nonFraction>&#160;million), acquired names ($<ix:nonFraction unitRef="usd" contextRef="i5098d5c55d8b4b1dbeee2d1d43a9b870_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQwNw_aa9c0943-8ae6-46d0-b1d2-f8a0907e0891">5.7</ix:nonFraction>&#160;million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="ia6dbc8b680ea432483b0218a761a9ee4_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQyMQ_103b9c77-dbf4-47bb-a531-4e1a9ae908b0">9.2</ix:nonFraction>&#160;million). The acquired names will be amortized over a weighted-average period of <ix:nonNumeric contextRef="id50e918f9fa742aea3517c666077cbc2_D20200601-20200601" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQzNw_8a6aef4a-abdb-46d8-8d82-294d4d74d2e6">2.0</ix:nonNumeric> years and the non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i4caa862c918a45e6bc9f8e6f842d75f0_D20200601-20200601" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQ1OQ_291dccea-3e58-4474-b06f-ed6ba459135a">1.7</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AseraCare contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQ3OQ_524b08a9-4a1a-4c64-a16f-df38df49fac6">64.5</ix:nonFraction>&#160;million in net service revenue and an operating loss of $8.2&#160;million (inclusive of acquisition and integration costs totaling $<ix:nonFraction unitRef="usd" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzUyMg_abb5e0a9-2f28-48c0-ab98-f59edbcf6409">7.6</ix:nonFraction>&#160;million and intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzUwOA_8e6b1d09-4576-4279-9108-0c08ab67bb69">6.0</ix:nonFraction>&#160;million) during the year ended December 31, 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601" format="ixt-sec:duryear" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDMxOA_86e927fc-12e5-46f4-925a-e3bbf43b817b">15</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI4MQ_26cbe549-da8a-4d6d-8f53-029877db98f8" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2020 and 2019 assuming that the AseraCare acquisition closed on January 1, 2019 (amounts in millions, except per share data). The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.748%"><tr><td style="width:1.0%"></td><td style="width:61.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfMi0xLTEtMS02NTg4_3531af40-075d-4007-89a3-a975cce3f4cd">2,120.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfMi0zLTEtMS02NjEy_001f250d-b198-405c-b887-9fd080c45040">2,077.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="-5" name="amed:BusinessAcquisitionProFormaOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfMy0xLTEtMS02NTkx_901160e9-c7b0-41d0-9876-990430d25af5">218.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231" decimals="-5" name="amed:BusinessAcquisitionProFormaOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfMy0zLTEtMS02NjEy_7f5d0505-1be3-41ea-b0ff-5154169139a5">167.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys Inc. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNC0xLTEtMS02NTkz_5e7f00ee-110b-4e0c-9785-d49ec60f6481">180.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNC0zLTEtMS02NjEy_c6d9da47-86d8-4e7e-bffe-d5212e3cbfc0">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNS0xLTEtMS02NTk1_44688918-9cfb-44ef-a466-17064d0e359a">5.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNS0zLTEtMS02NjEy_1c2415bd-30e2-4ae2-93de-03127201a5fc">3.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNi0xLTEtMS02NTk1_557bbb85-6456-4b70-8faa-77ee2d4f139a">5.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNi0zLTEtMS02NjEy_b2d6852b-4ea6-402f-bdaa-985ef05ed847">3.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i613560607e8f4bfbb5e1bb5823212c6e" continuedAt="ifbf3c48aaaf14c7bbdd01e950afd8ca4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma information presented above includes adjustments for (i) amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the AseraCare acquisition, (iii) non-recurring transaction costs and (iv) income taxes based on the Company's statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Acquisitions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Division </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2019, we acquired Compassionate Care Hopsice ("CCH"), a national hospice care provider headquartered in New Jersey, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTM4NQ_6532eadc-7fff-4d89-b4a7-552839f120f1">327.9</ix:nonFraction> million, net of cash acquired of $<ix:nonFraction unitRef="usd" contextRef="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTQxMw_3f93fcb1-24e9-44b3-9dd3-4f8c5c0b33c7">6.7</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI4Mg_03b2cbdc-142a-40ec-99cd-65480beecbd5" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired and liabilities assumed. The total consideration of $<ix:nonFraction unitRef="usd" contextRef="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTUzMg_d961929b-44ec-4d2f-87fd-477094e4518b">327.9</ix:nonFraction> million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.481%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMS0xLTEtMS0w_c088112b-3274-4cf2-b524-403eadf8900b">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMi0xLTEtMS0w_2439b264-defb-48cd-9dfb-289fbd2ac645">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMy0xLTEtMS0w_c421f1cb-e13d-48fb-a52a-56b5c3b4ab2a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfNC0xLTEtMS0w_dc69cd73-2f3d-4ac1-8e29-35a0bddc8cb9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfNS0xLTEtMS0w_a52349a9-51b8-4957-a200-45b8f0f57ede">27.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfNi0xLTEtMS0w_fc5cfdb1-45c0-4eb3-9b61-0f614f4cc05b">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfNy0xLTEtMS0w_827e9b59-21b4-412f-ba80-152e442c2e71">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfOC0xLTEtMS0w_5d47ecb2-3440-4574-97c6-a1585bedcbb7">57.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfOS0xLTEtMS0w_d8b90ee1-bfce-417e-97a5-da0a9eb319cf">14.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTAtMS0xLTEtMA_154f5151-afe3-48f3-bbbe-4ecbf195c472">11.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTEtMS0xLTEtMA_7d48b993-534b-4d70-a910-6f26b97df103">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTItMS0xLTEtMA_e32292c7-4427-4c94-9705-00e3fffe36b5">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTMtMS0xLTEtMA_75891442-f346-49aa-9f3c-b359a513a636">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTQtMS0xLTEtMA_c63aa598-d815-4bb4-be14-4b73b43b27b8">42.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTUtMS0xLTEtMA_1e5ef673-d596-4feb-af40-bc8ff0385a8f">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTYtMS0xLTEtMA_5f03e711-2c11-48cc-8ead-fc9bc8c8b5d6">313.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTctMS0xLTEtMA_23c09c05-6a25-4b0b-b78a-c403e91e4893">327.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses, certificates of need, acquired names and non-compete agreements. The acquired names and non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i539b5ad7e9ee440ba81d9f4f4069b5e8_D20190201-20190201" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTg2OA_38be1478-6b52-40eb-85a0-5312b756b597">2.0</ix:nonNumeric> and <ix:nonNumeric contextRef="i000c57f033a6483d8bf707b4eb4e6f55_D20190201-20190201" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTg3NQ_9eb95fbd-99fa-4471-acb9-f008ac50d3b4">2.3</ix:nonNumeric> years, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CCH contributed approximately $<ix:nonFraction unitRef="usd" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTkyOQ_19bbf9d7-bacb-49bf-beb6-572caa661b5d">167.4</ix:nonFraction> million in net service revenue and an operating loss of $5.6 million (inclusive of acquisition and integration costs totaling $<ix:nonFraction unitRef="usd" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMjA0MA_85b19a95-db16-4e91-8c64-1c878160d891">14.5</ix:nonFraction> million) during the year ended December 31, 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect $<ix:nonFraction unitRef="usd" contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMjA5Ng_1efc86d7-af2b-4a8b-8d80-ee4a67e1b2c3">278.8</ix:nonFraction> million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201" format="ixt-sec:duryear" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMjIwMQ_7bc9d6db-3dbf-4a81-94a9-877041fa5ca0">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDM1NA_b4054bd5-9028-4f44-a77b-86d115c8aed5" continuedAt="id33ee34e01cc48d3bb661e3699845c5d" escape="true">The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="ifbf3c48aaaf14c7bbdd01e950afd8ca4"><div style="margin-top:5pt;text-align:center"><ix:continuation id="id33ee34e01cc48d3bb661e3699845c5d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"></td><td style="width:67.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years<br/>Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfMi0xLTEtMS0w_238b851d-4fe9-4b0b-a4e8-a01d7226ead6">1,971.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfMi0zLTEtMS0w_64a19e5b-9793-490c-be11-71108a3f3126">1,852.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="-5" name="amed:BusinessAcquisitionProFormaOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfMy0xLTEtMS0w_090020c2-4e55-4bd7-8827-a84d9da891ac">183.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231" decimals="-5" name="amed:BusinessAcquisitionProFormaOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfMy0zLTEtMS0w_7660a754-cf34-4ba9-a65b-9559bb371e2a">175.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNC0xLTEtMS0w_149b86f7-1373-4f2a-9c40-4ce53c5e469e">130.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNC0zLTEtMS0w_5dbb7aab-4e6e-449e-9613-ca8bce1ddc6a">124.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNS0xLTEtMS0w_4752ce7f-1219-49ce-8318-32e3a20412de">4.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNS0zLTEtMS0w_69594ee7-ad30-478c-8554-6af55848a47d">3.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNi0xLTEtMS0w_eca45657-3d91-4446-8358-c6de07176015">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231" decimals="2" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNi0zLTEtMS0w_ad5af61e-b2f3-4a1c-ad5b-e991626c99a9">3.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma information presented above includes adjustments for (i)&#160;amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the CCH acquisition, (iii) non-recurring transaction costs and (iv)&#160;income taxes based on the Company&#8217;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, we acquired RoseRock Healthcare ("RoseRock"), an Oklahoma based hospice provider, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="if362ac0d7ade4dbe9a2f52099ec6f0e7_D20190401-20190401" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzE2MA_229b31fa-8717-477f-a5f2-c7ccd9120605">17.5</ix:nonFraction> million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill ($<ix:nonFraction unitRef="usd" contextRef="i05a1575f31584575992abc74ced2bc65_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzMxNQ_24ad1898-faec-4dd0-9405-211e59fc2ca3">15.8</ix:nonFraction> million) and other intangibles including acquired names ($<ix:nonFraction unitRef="usd" contextRef="i169c7364acc540578506213cd50aac76_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzM2Nw_30193e4d-8fc7-4072-aa40-a22c6f72dba9">1.0</ix:nonFraction> million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="i856c123c4c204fe38e4e036fd7752a96_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzM5OQ_1246590c-e80a-457f-bbd5-829673076f78">0.7</ix:nonFraction> million). The acquired names and non-compete agreements will each be amortized over a weighted-average period of <ix:nonNumeric contextRef="i6826cc9464ca4135b180f102528d6d44_D20190401-20190401" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzUwNg_8e0389a3-c1ba-4cbd-b599-e166018a069d"><ix:nonNumeric contextRef="i4483458942a649af981f192426433819_D20190401-20190401" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzUwNg_ffbb2909-21af-4d65-99d8-4042eb70e4c0">3.0</ix:nonNumeric></ix:nonNumeric> years. RoseRock contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i05a1575f31584575992abc74ced2bc65_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzU1MQ_20632690-127f-4be1-9f82-2d6ca5d2a729">6.8</ix:nonFraction> million in net service revenue and $<ix:nonFraction unitRef="usd" contextRef="i05a1575f31584575992abc74ced2bc65_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzU4MQ_72aa1734-a642-4308-98fd-7a55a6c00ce4">0.8</ix:nonFraction> million in operating income for the year ended December 31, 2019. We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="if362ac0d7ade4dbe9a2f52099ec6f0e7_D20190401-20190401" format="ixt-sec:duryear" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzc3Mg_ce9f3c1b-0d10-4dc0-a4c2-eb986c916643">15</ix:nonNumeric> years.</span></div></ix:continuation><div id="id92bd70d620044018083957a908405c4_97"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMjA1OQ_8a11b737-1728-4713-890a-3f07d3e3d208" continuedAt="i79b98bbe9ff94db5b3c5eaf4db20fffc" escape="true">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</ix:nonNumeric></span></div><ix:continuation id="i79b98bbe9ff94db5b3c5eaf4db20fffc" continuedAt="iac8c66121d3f4ee387af0aac09e0c2c8"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October&#160;31st of each respective year (the date of our annual goodwill impairment test). Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts. </span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMjA0OA_35b153da-2199-4577-a172-d15f45ed3fc1" continuedAt="ib94b75a23b5a4d50a0f5a0abffc5a11f" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our goodwill for 2020 and 2019 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2018 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2123af26c18b4412a49a520f6e2ab7c8_I20181231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMi0xLTEtMS0w_356f1a51-cb7f-492d-9a51-b0aa3f25c141">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c3a57b90754fd780752ab5eaeb2119_I20181231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMi0zLTEtMS0w_7d79d7d7-498c-48b2-bb8f-e4e61d97e1c7">199.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca74d3eda644e30a68c80809f7fc57f_I20181231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMi01LTEtMS0w_e10d9cab-32b0-4fb9-9f5f-34ca32ddeab0">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMi03LTEtMS0w_c99ab789-0365-4bdb-b172-61efa5a77ec8">329.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88935582b014075a328bfa1b117396c_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMy0xLTEtMS0w_3e9322e7-fcf4-4f51-af09-5d4f08711650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af8da337a3b49f3a113759b906bf9f3_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMy0zLTEtMS0w_d8874dc9-7e3c-44b6-bcee-0ad8eb634ecc">329.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i941dbf037dc148deb289e0c5c518ef5d_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMy01LTEtMS0w_d1aafa8c-d3e5-4e50-b01e-7c3e1d1fc916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMy03LTEtMS0w_4d9f24fe-d136-4d4c-93d4-7ea388ece165">329.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3b8059d89b46389a5544b50a169658_I20191231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNC0xLTEtMS0w_017eb692-edb8-4ae4-96e7-5d251d9e8c8d">87.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299a9ff0faaf4204a8a8ec39062247b5_I20191231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNC0zLTEtMS0w_9c3aca7f-3071-4817-bc75-6e28ccc4d5de">528.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758a004b4fbe477aa6e2ef91789cb336_I20191231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNC01LTEtMS0w_587395d6-7ef7-42a6-9832-75285f78e0d8">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNC03LTEtMS0w_8c995155-ed6e-48e5-86c1-f0ef25346867">658.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5177b049f064d83bb0e48f33e3b2e58_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNS0xLTEtMS0w_e58a4d58-0d82-449b-bf3b-ba8c369dc848">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca03328f124427a801b7d654ef05ff9_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNS0zLTEtMS0w_535ff08d-2558-4490-938a-37ae51f33af1">270.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic433fb8ffa524d98b4462b2bfdb4ca4a_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNS01LTEtMS0w_d9dc2722-c8ca-42da-867b-6d812cc692b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNS03LTEtMS0w_14574bc9-22e3-4257-8075-df6f0996bd61">274.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f4d87d3f8c04768adb0d99598494f75_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNi0xLTEtMS0w_2f909cbc-30d2-4099-840c-181852ec91aa">90.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7618d2cebdef436fa6e1ece2cb3e1a9c_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNi0zLTEtMS0w_7cb97ef5-fbe5-410c-909f-2112400952b7">799.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30daf9d0e928439bbf628952733e011b_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNi01LTEtMS0w_7a7bcc6a-c983-4633-a6de-aed4a9834347">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNi03LTEtMS0w_4e26b60d-cd5b-4e80-9acc-beca83c14aaf">932.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated impairment losses of $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfODU2_15489553-39a3-4c50-967b-0b357a666dd0">733.7</ix:nonFraction> million, which is inclusive of write-offs related to the sale and closure of care centers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we recorded a non-cash other intangible assets impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i8a9e61c64a324dccb0426c5ca15ad0fd_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTA5OTUxMTYzMDQyNA_f6785961-1dd6-49ab-a3fe-fabcb230e441">4.2</ix:nonFraction>&#160;million related to acquired names which are no longer in use; additionally, we recorded amortization of $<ix:nonFraction unitRef="usd" contextRef="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTA5OTUxMTYzMDkwOA_c77c64f7-f524-41a5-ad3d-39015c187bc3">2.4</ix:nonFraction>&#160;million related to certificates of need and licenses associated with care centers that were closed. During 2019, we recorded a non-cash other intangible assets impairment charge of $<ix:nonFraction unitRef="usd" contextRef="iab41181582e84ce6a158eb40d3e43022_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTIzOQ_48288284-b286-4ebd-b9e2-5b83c7241768">1.5</ix:nonFraction> million related to acquired names which are no longer in use or are associated with care centers that were closed.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="iac8c66121d3f4ee387af0aac09e0c2c8"><ix:continuation id="ib94b75a23b5a4d50a0f5a0abffc5a11f"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our other intangible assets, net for 2020 and 2019 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Certificates of Need and Licenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Unamortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Amortizable (4)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Compete<br/>Agreements (4)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2018 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189835ae24ec4c70b6a717d5b08a421a_I20181231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi0xLTEtMS0w_3be58316-9391-4016-ae40-d62a905085eb">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9aefbc5b7fb48c5b29a38dcb7a14868_I20181231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi0zLTEtMS0w_a2581a4b-9379-4c03-a52a-c4b3ef213efe">19.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6192d3d4b0a84bfeaab23464bd0e6b9e_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi01LTEtMS0w_2e03611f-2738-40dc-9beb-37be03a870ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib187ff5463f54b85b4e3f4bc6ad8636c_I20181231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi03LTEtMS0w_7d5eeb8c-d19d-4220-88ed-81ca4bf2134d">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi05LTEtMS0w_e6aaa9ba-fa4b-4a4f-a219-0a1ade3d52c3">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969ee2ebea1b499f906b31aa81ec4f31_D20190101-20191231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy0xLTEtMS0w_1e99f6f0-50d6-4da9-9a65-db7b1d595b4c">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87f788f2fe64b23944a430849785260_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy0zLTEtMS0w_909bdae0-cfd9-4361-b707-f835d6bc830d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe18e321548455c94c7d0cd77924cf8_D20190101-20191231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy01LTEtMS0w_53a2667e-be4e-49a4-9a61-4ec57280dd69">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d6b40ce5cc498eba1f0d3ec5483959_D20190101-20191231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy03LTEtMS0w_08681ed6-f81b-4556-8444-347996caedfe">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy05LTEtMS0w_b719d1e9-22b5-423a-8a04-942aaf9d6269">28.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969ee2ebea1b499f906b31aa81ec4f31_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC0xLTEtMS05Mzc_99071c80-a792-4549-b467-59382c6b00b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia87f788f2fe64b23944a430849785260_D20190101-20191231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC0zLTEtMS05Mzc_70a599f4-c807-462d-84ea-3e81d0691d5b">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe18e321548455c94c7d0cd77924cf8_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC01LTEtMS05Mzc_a4e3415b-2beb-4701-a041-7a39c498dcba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d6b40ce5cc498eba1f0d3ec5483959_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC03LTEtMS05Mzc_0bb837ba-4937-4c14-aef4-cd9aa1ce8e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC05LTEtMS05Mzc_0eb5fb20-9395-437e-8e09-e442ccb0b457">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969ee2ebea1b499f906b31aa81ec4f31_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC0xLTEtMS0w_99d4cf79-467a-4da7-ae5a-036669e138e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87f788f2fe64b23944a430849785260_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC0zLTEtMS0w_4d6a33b3-83aa-4af0-9dae-089510bc42b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffe18e321548455c94c7d0cd77924cf8_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC01LTEtMS0w_e600148c-8540-4c1d-9276-61fdaf8e10dd">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6d6b40ce5cc498eba1f0d3ec5483959_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC03LTEtMS0w_86a6eee2-a766-48c6-b989-97d18b251fd5">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC05LTEtMS0w_638488e3-6773-4114-ac20-d5b8a321f307">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83cdcc0f05d44f1d840709161ceb3440_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS0xLTEtMS0w_e7505b9c-4f5b-4d71-a763-09220dbd74f7">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc65628a7dbf4a1da089fe655a7e819d_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS0zLTEtMS0w_cce1b442-663e-4f70-8ba8-6228ef52ba31">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd0ee0b03f92409eb2ff67a774546a35_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS01LTEtMS0w_feb9456c-67ae-4246-829d-9549908d7860">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9714b4cf7d7c4de1be0e59b0dd0e7085_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS03LTEtMS0w_22ff5650-ac15-4a75-ba49-75fe8269a013">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS05LTEtMS0w_0a1e23f5-79bc-4de0-90b4-5f776dc726c5">64.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi0xLTEtMS0w_d8bee06b-c7bf-434a-b7ed-73e6c42a6a02">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib383332f81cd4bfa9b1922280c354414_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi0zLTEtMS0w_9f7e2e58-ec8b-49d0-b83d-23a201d0d084">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided786cf36e844558e359485f224451e_D20200101-20201231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi01LTEtMS0w_945479b9-417c-4c49-9973-33be1e1defe7">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi03LTEtMS0w_2e084b71-6304-4975-9db9-12f1d7ab911f">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi05LTEtMS0w_63f2dd50-6a55-4217-a203-4c05679d1833">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy0xLTEtMS0w_ba5adfd8-0ba9-42b5-a8b7-e1f439f643a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib383332f81cd4bfa9b1922280c354414_D20200101-20201231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy0zLTEtMS0w_6dd136bd-27ee-474d-861a-b45e3d9904b2">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided786cf36e844558e359485f224451e_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy01LTEtMS0w_8aeb048c-0ce3-4ea6-8e5b-9f20faeea17d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy03LTEtMS0w_52ef2c1d-4ea8-4bff-805f-f51ff8f54ff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy05LTEtMS0w_fad116e7-1529-4fbc-9fd3-87d8b0e68b23">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC0xLTEtMS0w_b9b659d3-d7f6-4a58-bc2b-23c474dc55ac">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib383332f81cd4bfa9b1922280c354414_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC0zLTEtMS0w_6eae4ebe-9b64-4b42-820e-064b9841110a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided786cf36e844558e359485f224451e_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC01LTEtMS0w_a27d82f1-63e0-491c-a441-ffe06c6d09f9">7.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC03LTEtMS0w_989e86be-b762-4321-808c-c69ee6ce48f2">7.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC05LTEtMS0w_3eba02df-d2b5-40a6-8fcb-e378a107fac9">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7040a24f0754adc968817731ec50305_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS0xLTEtMS0w_157076ae-9688-458b-bba9-05c2a5d7e9ba">47.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f77e35787c46fe9512e728260f7095_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS0zLTEtMS0w_816bc434-bc67-4e8e-a213-9909343008ac">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c25949461664d0aaec5b5040213f6b7_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS01LTEtMS0w_05883d51-dde7-4774-923e-531ccd7203d1">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e88ffd25ce42179e2ee5206728bafa_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS03LTEtMS0w_68f72a35-1d31-4b82-8d32-7eddfffc179e">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS05LTEtMS0w_c6ac5629-7efa-4737-8210-8279303fd233">74.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i71e88ffd25ce42179e2ee5206728bafa_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTYxOA_a5fabc2d-bd33-4788-9a5c-593ef63e5428">0.7</ix:nonFraction> million for non-compete agreements. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Write-offs are related to our acquired names that are no longer in use or that were associated with care centers that are closed.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amortization of certificates of need and licenses is related to care centers that were closed during 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average remaining amortization period of our amortizable acquired names and non-compete agreements is <ix:nonNumeric contextRef="ided786cf36e844558e359485f224451e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTc2NQ_7f4727b5-9b9f-4aee-a6c6-325ae3f63a3f">1.3</ix:nonNumeric> years and <ix:nonNumeric contextRef="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTc3Mg_614b5156-ea5f-49a7-9c22-55c8b4231d26">1.2</ix:nonNumeric> years, respectively.</span></div></ix:continuation><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4 &#8211; Acquisitions for further details on additions to goodwill and other intangible assets, net.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMjA1Nw_fb561798-8e4a-4ef4-80ad-596642d07bac" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"><tr><td style="width:1.0%"></td><td style="width:72.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Asset Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfMS0xLTEtMS0w_21ce6b3f-b4c2-43e0-bd8c-c9f5e2f0e468">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfMi0xLTEtMS0w_6326e2a2-2429-4afe-b19c-4f54bc8f0336">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfMy0xLTEtMS0w_59c6ee16-d26f-4f06-81c9-55aef589a355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfNC0xLTEtMS0w_7c5cc3b8-10c0-494a-8061-08e0aed03d1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfNS0xLTEtMS0w_590e4654-664c-4627-bc3b-c96969464cff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfNi0xLTEtMS0w_dba1dde7-666f-4767-bea5-b0d8f4c67f3d">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="id92bd70d620044018083957a908405c4_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE2OQ_60c52f85-2c26-44b7-80d4-b4a26d5f0d07" continuedAt="i732fafdca66342529221bcf46c1b7395" escape="true">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</ix:nonNumeric></span></div><ix:continuation id="i732fafdca66342529221bcf46c1b7395"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE1Nw_fa57619d-68be-4aae-b37a-ebed9ba0dc46" escape="true"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE2MQ_2c07aaca-e426-437e-9e7c-563b316a566a" escape="true"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE2Ng_d6a781d4-0bc3-4b13-8fc6-cb9e1fb9261e" escape="true"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE3NQ_67fbf27a-8fd4-45a1-88d9-819dabba763b" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:PayrollTaxEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMtMS0xLTEtMA_83da2884-bf51-49d6-b4ce-d3af61ba2ded">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:PayrollTaxEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMtMy0xLTEtMA_522636d2-f789-4f71-aefe-f1987959905e">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzQtMS0xLTEtMA_f33a96f1-ef6f-4f1c-b44c-5f41140448a0">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzQtMy0xLTEtMA_03657134-74b5-4742-91a8-07c840ec7cf4">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DueFromJointVenturesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzUtMS0xLTEtMA_63cf7503-7b9d-45df-b150-98e2ab1281b1">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DueFromJointVenturesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzUtMy0xLTEtMA_2cd14529-b82f-437b-8956-85cc50d19efa">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzYtMS0xLTEtMA_622022ff-f461-48e6-8c8f-285c7232ded9">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzYtMy0xLTEtMA_1388a500-b37a-4338-9aa0-88f404576e4b">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzctMS0xLTEtMA_ef61d425-921b-4f94-b65c-e875cdd4da48">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzctMy0xLTEtMA_3b2ed129-49c3-4414-9b45-3c291782b27a">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:WorkersCompensationDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzktMS0xLTEtMA_0763443c-7d43-42d3-b8de-c0d35ba7f44d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:WorkersCompensationDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzktMy0xLTEtMA_37acbe5c-a43f-4ad9-99c9-3d81c3723afb">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:HealthInsuranceDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEwLTEtMS0xLTA_9d97bdd7-8ac5-49ce-b0fe-d0cfd9ca2825">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:HealthInsuranceDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEwLTMtMS0xLTA_8afb0085-616f-4d74-aba5-787736a274f7">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:OtherMiscellaneousDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzExLTEtMS0xLTA_5d739438-5d69-413c-afe5-81d1be8e7257">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:OtherMiscellaneousDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzExLTMtMS0xLTA_1501f09e-ce23-4f87-b699-8a90168e522c">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEyLTEtMS0xLTA_a20ebbda-11d9-4c63-8faf-b7d57adca109">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEyLTMtMS0xLTA_7830b209-942c-4a9e-96de-8b3fd512fba6">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEzLTEtMS0xLTA_eb642977-9fc8-45e1-9de7-f0e394dd6009">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEzLTMtMS0xLTA_2dbe2731-e3f3-46b1-b834-f5a582c049c2">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE0LTEtMS0xLTA_401f70fc-b351-45aa-aa91-1199d12d3aa2">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE0LTMtMS0xLTA_e39cdfd6-399c-4a38-9f77-fd92aeb7e6f9">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE1LTEtMS0xLTA_a06a347a-f2b1-4ce3-a79a-fe6a04a77be6">33.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE1LTMtMS0xLTA_866ab600-444a-45a8-bbd9-295b89213e92">54.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:AccruedInsuranceCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE3LTEtMS0xLTA_e0d878b2-3984-462e-9d05-673e7874ad4d">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:AccruedInsuranceCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE3LTMtMS0xLTA_6295e09b-bf25-4e34-82a4-4d873548cefb">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE4LTEtMS0xLTA_d79b18fe-2d60-4c2f-b2d2-9b2b316e1f31">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE4LTMtMS0xLTA_97a5f37e-e2ff-4270-b790-a415a10966af">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:ProvisionForLiabilityOnRegulatoryAudit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE5LTEtMS0xLTA_a22b74c1-a403-4471-82e1-4e368b1db613">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:ProvisionForLiabilityOnRegulatoryAudit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE5LTMtMS0xLTA_62750e36-8e9e-4d37-8ccd-5bb3ce1780ad">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:LegalAndOtherSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIwLTEtMS0xLTA_75a0694b-95cc-415b-8fe7-29bb81ce49f1">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:LegalAndOtherSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIwLTMtMS0xLTA_173b3271-20b5-425c-82b7-d835c86e9cd1">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIxLTEtMS0xLTA_d08a09dd-9c24-4c55-8c9f-0410fc25303c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIxLTMtMS0xLTA_f90925bd-921e-4d34-97a6-2b577b5dcee1">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:CharityCare" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIyLTEtMS0xLTA_70dc1c9d-120b-41bd-8940-a74eba58d1cf">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:CharityCare" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIyLTMtMS0xLTA_2d069fbb-d6bd-41a6-abda-6096960a3b60">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:EstimatedMedicareCapLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIzLTEtMS0xLTA_47e6f8d9-013c-4355-9a71-d40d9f09f2cf">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:EstimatedMedicareCapLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIzLTMtMS0xLTA_2a8c29e7-6160-491c-9795-86746e73f86c">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:HospiceAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI0LTEtMS0xLTA_b499ac20-da60-4080-8508-c2125623d49b">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:HospiceAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI0LTMtMS0xLTA_2808f211-8484-412f-9f70-cdef6f1ddbfb">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:PatientLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI2LTEtMS0xLTA_38357d64-155d-4d0b-8360-3c28b480cad5">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:PatientLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI2LTMtMS0xLTA_47f1c38c-d489-417c-96ea-a8387bd709b3">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred operating income (CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredOperatingIncomeCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI3LTEtMS0xLTM3OTE_29f13b75-5319-401f-b058-bd3ead56d73e">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:zerodash" name="amed:DeferredOperatingIncomeCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI3LTMtMS0xLTM3OTE_33c78da6-c1ed-4971-942c-2c2e7fcf58b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI3LTEtMS0xLTA_9c9d9b6d-26e3-441b-93da-e729f62cd776">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI3LTMtMS0xLTA_ffd2838d-f69c-41a0-916f-eb22a9ed05cf">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI4LTEtMS0xLTA_c50acc67-091f-4920-93de-51664181b3c4">166.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI4LTMtMS0xLTA_4d9b9b4f-da7b-48bf-90b5-0195853e4479">137.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:UncertainTaxBenefitsInLongTermObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMwLTEtMS0xLTA_e1acb673-8e6e-4e6e-8cdc-979acb2e996e">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:UncertainTaxBenefitsInLongTermObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMwLTMtMS0xLTA_0a021d83-c49c-4da5-b313-8bc9c183041a">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredCompensationPlanLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMxLTEtMS0xLTA_9176beef-8771-45d1-b481-ffd3434b85c1">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:DeferredCompensationPlanLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMxLTMtMS0xLTA_eea58fe8-5835-4f6e-8ca5-394caf0ceda5">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current social security taxes (deferred under CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMzLTEtMS0xLTM3OTk_b493fce1-e9d7-4dd3-819a-3102c7fc5c5d">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:zerodash" name="amed:NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMzLTMtMS0xLTM3OTk_37e2ccbb-74d3-4b38-aece-9e4610d9a041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMyLTEtMS0xLTA_ecaabe09-793a-4562-8870-262a69393a01">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMyLTMtMS0xLTA_20878d65-df3e-43e1-a419-541524655d75">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMzLTEtMS0xLTA_77cf895f-4bf3-4625-a904-c1f64efd65dd">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMzLTMtMS0xLTA_1e949937-cbcc-44d6-af71-1ab66007d6a6">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:LesseeLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE3OTk_750bb6f5-45da-4470-83f5-1eff7deaa386" continuedAt="ia1a93d840d5a42768a3110a5e54fb270" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ia1a93d840d5a42768a3110a5e54fb270" continuedAt="if4d19fa3ef004ef6bf671b2b4d9ded0c"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next <ix:nonNumeric contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzE3OA_95554468-067d-42cc-80e6-4d487465d003">eight years</ix:nonNumeric>. We also have finance leases covering certain office equipment that expire at various dates over the next <ix:nonNumeric contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzI4Nw_3eaf42fa-e653-43e2-a8c3-7de1cb515044">three years</ix:nonNumeric>. Our leases do not contain any restrictive covenants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our office leases generally contain renewal options for periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzQyMg_e7798f55-1ce4-47ef-a7fb-73e95a0c87a0">one</span> to <ix:nonNumeric contextRef="i3998374665924f3aa61bd5813eecd5f5_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzQyOA_b61464fb-9cf8-4c51-b866-5242e2f083af">five years</ix:nonNumeric>. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fleet leases include a term of <ix:nonNumeric contextRef="i6e380d81b95f448eab4c555d915ea5cd_I20201231" format="ixt-sec:durday" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzExMDU_9da2ec92-5d8e-4298-af9b-eb6c2504b045">367</ix:nonNumeric> days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#8220;TRAC&#8221;), which provide for a final rental payment adjustment at the end of the lease, typically based on the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="if4d19fa3ef004ef6bf671b2b4d9ded0c" continuedAt="ia1dadb38197440b7b7cbc55b32e2a0e1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDA_b9e2be00-1a83-45b5-9c19-7128d092051a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December 31, 2020 and 2019 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzMtMS0xLTEtMjY1Mw_57190ff1-d07a-4d1a-b0be-851afe8b269f">38.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzItMS0xLTEtMA_76799afe-d551-487a-adc1-c0fd12db75fd">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzQtMS0xLTEtMjY1Mw_02504e8e-2fb1-42e5-8adb-0f2b8a2604ab">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzMtMS0xLTEtMA_e0a9aa86-796f-45ec-b35a-ffaf8458eaa8">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzUtMS0xLTEtMjY1Mw_8b7dfdb7-f832-48bd-bef6-d49fc01a04ca">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzQtMS0xLTEtMA_c6017c2e-03a5-4948-b670-740f7a5db77f">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzgtMS0xLTEtMjY1Mw_983018ff-d3c0-4192-a1ad-752905357418">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzctMS0xLTEtMA_367475e5-de3a-417a-95c3-8fe0ddef0d69">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzktMS0xLTEtMjY1Mw_b8fd72b0-6f5b-49e4-bd6c-0fa6802188ef">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzgtMS0xLTEtMA_4f5e0cdb-6382-4a77-8d86-6c44f31670b7">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzEwLTEtMS0xLTI2NTM_0dd50916-2d32-4617-bf17-51812da2f24b">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzktMS0xLTEtMA_94901be4-08fe-4b34-bd62-5d2b471e778f">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzEyLTEtMS0xLTI2NTM_c5faaaf1-6f87-422a-8fd5-f2d8b1932b24">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzExLTEtMS0xLTA_5dad9093-53c4-4f19-bbf4-68996a7694e0">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzEzLTEtMS0xLTI2NTM_8984af59-2d1b-43aa-b8d8-8c0e0dce8d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzEyLTEtMS0xLTA_38ad81f0-f203-4de8-a0db-7f8ea7585ff0">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzE1LTEtMS0xLTI2NTM_358de26f-f6a5-4527-8858-b18e60870492">44.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzE0LTEtMS0xLTA_ac66fd53-cee0-42e0-b19f-f1f34b11f397">40.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:OperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDE_f6c9ca13-5fcf-4cf2-ad47-4c4bf75ad87c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for our operating leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzItMS0xLTEtMjY1Ng_ad8d43d9-123e-4167-a184-28df6039a22b">93.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzEtMS0xLTEtMA_58b79312-4bc4-4815-b0b4-054da3be8776">84.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzQtMS0xLTEtMjY1Ng_cd990c88-e31e-4297-8b10-e90ca04db313">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzMtMS0xLTEtMA_1363f7e9-b079-4e88-a0b6-1640d33b6394">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzUtMS0xLTEtMjY1Ng_9257f6d1-5d4e-492e-9814-056e6fdbd241">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzQtMS0xLTEtMA_6046cfa6-a22e-424f-9f15-66d7685a71e6">56.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzYtMS0xLTEtMjY1Ng_db5e1d0b-74ee-4a24-b48c-37f439c05e6e">92.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzUtMS0xLTEtMA_b12cfd40-d4c2-4f5e-848b-ce975fd13b01">83.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:FinanceLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDI_cc712a35-cea1-471f-ac3e-391d1042598a" continuedAt="iba7310391fb04a1a9093c01f75c72811" escape="true">Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="ia1dadb38197440b7b7cbc55b32e2a0e1" continuedAt="i41b68d5cac96438da00d0f7e16ae2859"><div style="margin-top:5pt;text-align:center"><ix:continuation id="iba7310391fb04a1a9093c01f75c72811"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzItMS0xLTEtMjY2MA_60d4484d-cffa-4a23-ab99-59144e885543">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzEtMS0xLTEtMA_16b466a5-af42-4a58-999e-ddd3f84d6afa">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzMtMS0xLTEtMjY2MA_700bab5a-a5af-4316-8729-40d73c1b62e4">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzItMS0xLTEtMA_3994ec0a-58c3-454f-9c96-154281c5d953">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzQtMS0xLTEtMjY2MA_210c801b-a737-4c75-bd70-20d6ebf1c886">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzMtMS0xLTEtMA_27262017-4916-4215-b73d-3d0177326e9e">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current installments of obligations under finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzYtMS0xLTEtMjY2MA_ba400cc3-4128-4d13-83d3-a70f6731e07d">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzUtMS0xLTEtMA_5096a403-9a4d-431d-a7ec-c7bfd65a710c">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzctMS0xLTEtMjY2MA_66e5fec4-dd74-455f-aa84-8f07e0b555c2">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzYtMS0xLTEtMA_3418e22a-788d-45bc-b049-30b85a1b7927">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzgtMS0xLTEtMjY2MA_c7218990-1ee6-4fed-8c2d-011948ef18a8">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzctMS0xLTEtMA_ad6f2700-9d7a-42b7-8d8c-3707e1f3832b">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDQ_9908595b-1e3e-48b1-91ed-8dc5c427ee14" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flow from operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzMtMS0xLTEtMjY2NA_1093b759-88fb-45c3-ae74-c03442e7ed2a">38.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzItMS0xLTEtMA_a283ca6e-0a5f-4668-b10e-87ca41f45686">35.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flow from finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzQtMS0xLTEtMjY2NA_47ef4541-91b5-4325-8631-b8270ac7fe32">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzMtMS0xLTEtMA_c9dd154f-9dca-4f7f-9e6a-8c6eea73c5ce">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzctMS0xLTEtMjY2NA_3e60d4a3-541e-44c1-ac41-643c7d054fc9">38.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzYtMS0xLTEtMA_d8252d90-ac19-4f92-8b3a-3f6166bd5e1d">116.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzgtMS0xLTEtMjY2NA_b355045f-5e92-4018-9217-4a1b52552611">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzctMS0xLTEtMA_4b168822-baa4-409a-8fd3-5a6ba65541c8">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to ROU assets resulting from reductions to lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" sign="-" name="amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzExLTEtMS0xLTI2NjQ_e8cd6562-0dde-4150-9249-37dafc5f2ffa">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" sign="-" name="amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzEwLTEtMS0xLTA_4570c8dc-7cc2-49a1-861a-7a5548aff51e">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzEyLTEtMS0xLTI2NjQ_b5e0c05c-cea8-4a8d-9c62-c268b904644d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzExLTEtMS0xLTA_11f33857-19e5-4542-9fcb-5da8a0fe1af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDU_344cdd63-8c31-485e-ae69-f370cc1ff049" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for our leases as of December 31, 2020 and 2019 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzItMS0xLTEtMA_6803a9ce-5938-41b3-9815-9e5bf06687c9">3.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzMtMy0xLTEtNzAwOQ_f7a88568-3d29-49f1-b80d-b19bcdc60ba0">3.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzMtMS0xLTEtMA_d19e62f1-1267-4e72-96cb-71c90b2bddfc">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzQtMy0xLTEtNzAwOQ_a5476bdb-e06f-4af5-8312-764b7273d499">2.1</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzYtMS0xLTEtMA_b22ec89d-c2cb-4f42-8aee-5ea0489991f0">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzctMy0xLTEtNzAwOQ_1a5daf1c-36d0-40e6-8ba3-94dc74eb573d">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzctMS0xLTEtMA_93efbb17-eedc-4798-8546-92caa2f14aa6">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzgtMy0xLTEtNzAwOQ_5224008a-9108-45b2-bfe2-8a1bd09bdff7">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i41b68d5cac96438da00d0f7e16ae2859"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:LeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDY_baa71f64-dc6b-45ef-a1be-23ea388261d7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:64.154%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzEtMS0xLTEtMA_35a0fd06-79fc-482d-ba19-577cc4063216">32.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzEtMy0xLTEtMA_cbeb7b62-79a4-430a-950b-811c9c5ed4c2">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzItMS0xLTEtMA_0732a198-c618-421a-af54-98fb9f526fb3">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzItMy0xLTEtMA_a4bf14ad-a316-4d55-a8a6-2087491f42b4">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzMtMS0xLTEtMA_987adac0-2cab-4eee-b7eb-a8e096479a99">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzMtMy0xLTEtMA_e685f473-4ee2-4fa4-a6ef-c599f354823e">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzQtMS0xLTEtMA_35aef244-5978-4ea2-85e5-dfa31a51c6fd">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzQtMy0xLTEtMA_663eacbc-56e9-45e5-95a1-210a7f651450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzUtMS0xLTEtMA_a2fa9ca0-f512-4901-bf27-ff3a474fe4f6">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzUtMy0xLTEtMA_1a77d43b-d174-40af-b0c6-0c7f0663228d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzYtMS0xLTEtMA_d89068d9-43b3-4b2c-a61c-e44f422ee262">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzYtMy0xLTEtMA_2191de62-9704-41f7-89da-6d4e60ee9e7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzctMS0xLTEtMA_55e78b47-05e0-4ef2-be86-efda37668337">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzctMy0xLTEtMA_d1e73fdc-91e4-4233-85ff-a1a5d2cd6161">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzgtMS0xLTEtMA_5100ae09-b26d-4639-bb11-f70faf1c9131">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzgtMy0xLTEtMA_1c1b5289-bfa1-4b85-8877-e84c8478cc94">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzktMS0xLTEtMA_996f7e19-2b5c-4327-8ebd-9c1282534da8">92.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzktMy0xLTEtMA_79fcf019-0adb-4d90-86c8-3f93eab3fc08">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:94.5pt;text-indent:-58.5pt"><span><br/></span></div><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzEwOTk1MTE2Mzk5OTI_8ead6c08-4a09-4c7c-b1a7-43897b3cd13c" continuedAt="i29d39d43d0ec4576b0913538dbfce6b9" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><ix:continuation id="i29d39d43d0ec4576b0913538dbfce6b9" continuedAt="i8c280ef75c09456cbdd6d443be40af73"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1MTE_da91df3e-88a5-446c-b2d7-fa8ce272238d" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i90dece5459db457b9caee4a934044bae_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmUzOWVkNDBiZWNjYzQwNjBiY2M3OGJmOTFhZjA1NmY2XzEwOTk1MTE2Mjc5NjE_e4fc27f3-650f-441f-b35f-1ddebe1fd548">175.0</ix:nonFraction> million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (<ix:nonFraction unitRef="number" contextRef="if7c937ebfcbb4487b42fa8461a09a162_I20201231" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmUzOWVkNDBiZWNjYzQwNjBiY2M3OGJmOTFhZjA1NmY2XzEwOTk1MTE2Mjc5NzA_5340293e-7289-4171-aee2-79d4bf0f92e0">1.7</ix:nonFraction>% at December 31, 2020); due <ix:nonNumeric contextRef="i8de54dd0485448269d1eebf429a33e51_D20200101-20201231" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmUzOWVkNDBiZWNjYzQwNjBiY2M3OGJmOTFhZjA1NmY2XzEwOTk1MTE2Mjc5ODk_bb6abeab-5bcc-4cc6-b0db-6d7bd03d6f81">February&#160;4, 2024</ix:nonNumeric></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90dece5459db457b9caee4a934044bae_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMS0xLTEtMA_c5bf183e-7050-4b2e-b37b-53c2b915ce6d">164.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2041f507eabe49338b0fd15b6f05a37a_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMy0xLTEtMA_e1cfd288-ef5f-4a00-9c58-84b599f6badd">171.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQzMzE4OTMzYTMwZDRhZDhiZGE1ZTNjZTdkODMyZTNhXzEwOTk1MTE2MjgwMDE_39baf939-5605-4b03-bda4-9d14cbc1554a">550.0</ix:nonFraction> million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (<ix:nonFraction unitRef="number" contextRef="i4a7367ab708f42b39e9081b6c1bb9a02_I20201231" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQzMzE4OTMzYTMwZDRhZDhiZGE1ZTNjZTdkODMyZTNhXzEwOTk1MTE2MjgwMTA_caa4230d-b7d2-4000-8fdb-4f607d8c3ac3">3.8</ix:nonFraction>% at December 31, 2020); due <ix:nonNumeric contextRef="i5f2b03850b34492e9f5c7baeadcdd170_D20200101-20201231" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQzMzE4OTMzYTMwZDRhZDhiZGE1ZTNjZTdkODMyZTNhXzEwOTk1MTE2MjgwMjk_426b85e5-d7fc-4d17-81a6-d04935f12554">February&#160;4, 2024</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMS0xLTEtMA_e9ead7ae-5bcc-47b5-ae07-c1e8ecb0bcbc">51.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0024757aa534d409fcb4e8a79dad213_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMy0xLTEtMA_295e5f44-afda-493b-9464-d0aa8670263f">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8051bc5ccedc4458b6ff74abcdfd5b59_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzQtMS0xLTEtMA_689e1122-d92c-4f85-9b5d-476b9b276a72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03a65bdf068041f2ba700f2afe87977d_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzQtMy0xLTEtMA_7201dd46-5f6f-4234-b00b-842e2662cd29">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4365d319b33f4857ae4bc38bf1acf0d9_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzUtMS0xLTEtMA_8ff5cdb6-7383-48f2-b7a7-0038d58c6c7e">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83398cda1ea54e6783c252370998336f_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzUtMy0xLTEtMA_fbaf17f3-9e63-4333-84f4-d1b9096db6a7">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzYtMS0xLTEtMA_30c3bf78-46d2-47f5-ae1a-d206639d664a">217.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzYtMy0xLTEtMA_2bf5e985-bfd6-4de5-ae46-68f4f263327c">245.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzctMS0xLTEtMA_3c9a5d7e-f743-4c7f-967a-ee1718ef384f">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzctMy0xLTEtMA_7567cf55-a9ea-47b9-85bc-0d7ca1f0bf74">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzgtMS0xLTEtMA_2e13d31a-4d39-45e7-8834-3e1fac21f4f6">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzgtMy0xLTEtMA_dc4bc95d-c6e3-41e6-bba6-960a790c140c">242.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzktMS0xLTEtMA_12a16149-afbd-4ab7-b02b-52d4ae688405">10.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzktMy0xLTEtMA_7f0b1612-9140-4df0-a8be-7ebb2ba8a4dc">9.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzEwLTEtMS0xLTA_47226288-07c5-4f98-9d22-21d434595622">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzEwLTMtMS0xLTA_16a5510b-0b10-4d64-bdef-7f533a03f094">232.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1MjA_204c9e39-744a-40a2-9d33-3215fa091844" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt as of December&#160;31, 2020 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"><tr><td style="width:1.0%"></td><td style="width:72.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.581%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzItMS0xLTEtMA_ffd52148-d3c8-402d-a801-1ed24cb10740">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzMtMS0xLTEtMA_5bcca680-786d-42e4-abc5-77a59b01df19">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzQtMS0xLTEtMA_c46fe5e3-46ee-40cc-9e4a-c14d3676eabd">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzUtMS0xLTEtMA_c7162a34-915e-4182-abc4-92801d6d6b4c">185.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzYtMS0xLTEtMA_f46c33d8-8bea-4231-9290-53bfb465d0cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzctMS0xLTEtMA_5dabbb07-e895-4ad9-88c2-60dcca2d7864">217.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2018, we entered into our Amended and Restated Credit Agreement ("Credit Agreement") which provided for a senior secured revolving credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzQxNQ_94f755e7-61b4-478e-a9a8-e9c5898ea326">550.0</ix:nonFraction> million (the "Revolving Credit Facility"). The Revolving Credit Facility provided for and included within its $<ix:nonFraction unitRef="usd" contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzUyMA_0c71929f-dfb6-4913-81d7-9f89dc7ba514">550.0</ix:nonFraction> million limit a $<ix:nonFraction unitRef="usd" contextRef="i55e3ad37975747ce85e5f9e56a387aeb_I20180629" decimals="-5" format="ixt:numdotdecimal" name="amed:SwingLineFacility" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzUzMQ_cad4ae4e-3a31-45f7-bf4c-c7185f3ec2dd">25.0</ix:nonFraction> million swingline facility and commitments for up to $<ix:nonFraction unitRef="usd" contextRef="i55e3ad37975747ce85e5f9e56a387aeb_I20180629" decimals="-5" format="ixt:numdotdecimal" name="amed:LettersofCreditmaximumcommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzU3OQ_30540e15-9574-415c-b330-e4a341cc2fb8">60.0</ix:nonFraction> million in letters of credit. Upon lender approval, we could increase the aggregate loan amount under the Revolving Credit Facility by $<ix:nonFraction unitRef="usd" contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629" decimals="-5" format="ixt:numdotdecimal" name="amed:LineOfCreditFacilityAdditionalBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcxNw_bdc430d7-f7a2-40e5-b3cf-b89d5dbafb49">125.0</ix:nonFraction> million plus an unlimited amount subject to a leverage limit of <ix:nonFraction unitRef="number" contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629" decimals="INF" name="amed:CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzc3OA_4a2a437a-7d93-4a4c-9fc4-3da3817b800a">0.5</ix:nonFraction>x under the maximum allowable consolidated leverage ratio which was <ix:nonFraction unitRef="number" contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629" decimals="0" name="amed:Creditfacilitymaximumallowableconsolidatedleverageratio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1Nw_50e9834c-5f23-4584-b779-666421bf635f">3.0</ix:nonFraction>x per the Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity of the Revolving Credit Facility was <ix:nonNumeric contextRef="ib818b639b2fc470b9dfaf7a8a57d34aa_D20180629-20180629" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzExNzE_707a0524-28b0-441c-85df-ffa8ab0d2548">June 29, 2023</ix:nonNumeric> and there was no mandatory amortization on the outstanding principal balances which were payable in full upon maturity. The Revolving Credit Facility was used to provide </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i8c280ef75c09456cbdd6d443be40af73" continuedAt="i03563d0e411244af8f7fcac134c27c17"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ongoing working capital and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2019, we entered into the First Amendment to the Credit Agreement (as amended by the First Amendment, the &#8220;Amended Credit Agreement&#8221;). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i90f987fd3c874bb7a0482a03ac02dd0a_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzE4NDM_72fbe17b-4de5-4e17-8db3-70748a632bd6">725.0</ix:nonFraction> million, which includes the $<ix:nonFraction unitRef="usd" contextRef="i90f987fd3c874bb7a0482a03ac02dd0a_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzE4NjY_be4ac504-ac76-4170-8342-99fa75b73053">550.0</ix:nonFraction> million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ic20973059f44430a8ea7527042093e66_I20190204" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzE5ODE_0eca1425-e2c7-4b84-aef9-a39aa1eb8548">175.0</ix:nonFraction> million (the &#8220;Term Loan Facility&#8221; and collectively with the Revolving Credit Facility, the &#8220;Credit Facility&#8221;), which was added by the First Amendment.  </span></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i)&#160;the Base Rate plus the Applicable Rate or (ii)&#160;the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzI3NDM_b675eb47-0db9-415e-8f67-8037e3600552">0.50</ix:nonFraction>% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate plus <ix:nonFraction unitRef="number" contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzI4NjI_488744f5-31af-48d1-9bc7-8858bbb15457">1</ix:nonFraction>% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the  London Interbank Offered Rate ("LIBOR") or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1MjE_c9685d84-edcd-4bda-946c-cc0f67992bf2" continuedAt="id8958541a5b841f0a41a1750a71217c0" escape="true">The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2020, the Applicable Rate is <ix:nonFraction unitRef="number" contextRef="i82f050f262b84796a9b340b2d9129bc0_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzMyNTk_28600be0-6aea-4564-9635-bf204f161a07">0.25</ix:nonFraction>% per annum for Base Rate Loans and <ix:nonFraction unitRef="number" contextRef="ifcea2f99e9244669860fa34644e434d1_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzMyOTY_12a9a7b0-9a6d-4040-83bf-c8d20a94813c">1.25</ix:nonFraction>% per annum for Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="id8958541a5b841f0a41a1750a71217c0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment<br/>Fee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter&#160;of<br/>Credit&#160;Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8805;&#160;<ix:nonFraction unitRef="number" contextRef="ifd5550ca8a47443f914e49b80cf1c663_D20200101-20201231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtMS0xLTEtMC90ZXh0cmVnaW9uOmQwYjljMDRmMzc4NTRmMTg4ZjAxYWQxNGZjNDYwZWE4XzEwOTk1MTE2Mjc4MTE_ac7fc809-29a9-4c03-89a7-b088d51cbe2a">3.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i449b5f09d3b34ec39a18a9cef526b9a6_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtMy0xLTEtMA_ba23b500-0ef6-43dc-9a59-a15a0209cd84">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic46bf12be9614cdc9e2592966809f199_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtNS0xLTEtMA_ddc1fe85-8f36-49fd-8a1e-3b5257d61f43">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4332b377849d47079522cdb966f405aa_D20200101-20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtNy0xLTEtMA_1ce788a2-4a28-4089-9b40-455f3f13aea5">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4332b377849d47079522cdb966f405aa_D20200101-20201231" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtOS0xLTEtMA_ffe65e05-9ef1-43ca-ac61-7fb4fd4619e3">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; <ix:nonFraction unitRef="number" contextRef="if009f649f525477986901bf87b9a8a8a_D20200101-20201231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItMS0xLTEtMC90ZXh0cmVnaW9uOmU1NzE2MThjZmYzMDQ3ZDNhNTcyZDA4ZmQ3ZTQxNGI3XzEwOTk1MTE2Mjc4NTQ_d2e9d40c-3dc0-4015-b136-47186ce5e760">3.00</ix:nonFraction> to 1.0 but &#8805;&#160;<ix:nonFraction unitRef="number" contextRef="i663a0220bf1f4bde8453506f3ec8b0c8_D20200101-20201231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItMS0xLTEtMC90ZXh0cmVnaW9uOmU1NzE2MThjZmYzMDQ3ZDNhNTcyZDA4ZmQ3ZTQxNGI3XzEwOTk1MTE2Mjc4NTk_d86072ec-9973-4674-ad70-ff539345c758">2.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58ce40c5da424eb1acc6a5a1cc10d1ae_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItMy0xLTEtMA_b92ce5ba-d6f9-46c4-9aca-00f82d9ead45">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6dd35f3ef914c7b9e3b873612e24d07_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItNS0xLTEtMA_c804012f-a6d8-4ab8-82c1-87427fc46a78">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2fdd832f78f447590dcea35096f588e_D20200101-20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItNy0xLTEtMA_5ee9eae0-fd99-4e9d-a716-d33a2217de3d">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2fdd832f78f447590dcea35096f588e_D20200101-20201231" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItOS0xLTEtMA_010cc7ba-46da-428a-a9dc-cbb89ad654c2">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; <ix:nonFraction unitRef="number" contextRef="id875fdd2eb7148c4aa89a6f6d517e964_D20200101-20201231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjI1ZjZiYmE2YWE0ODRkM2Y5YzFkNWMwZmRmMzc3ZTZiXzEwOTk1MTE2Mjc4NDk_12752c4c-3580-4755-b0a4-0757f5961d7f">2.00</ix:nonFraction> to 1.0 but &#8805;&#160;<ix:nonFraction unitRef="number" contextRef="ifd3a5e252c794510b621a8afd98a30af_D20200101-20201231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjI1ZjZiYmE2YWE0ODRkM2Y5YzFkNWMwZmRmMzc3ZTZiXzEwOTk1MTE2Mjc4NTQ_c664dff8-410b-4fe9-9708-b42dff895b32">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic73c6064129945f89356c2e9781e2ff3_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtMy0xLTEtMA_fc7ea5cb-7652-4bac-9652-08bdc74f446a">0.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ac1b22c6f554e6db80a1dec5c335a03_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtNS0xLTEtMA_441941e8-f79e-4b1b-8226-b1b088e7a73b">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i327f7ac146d444c88f630645e8202d8f_D20200101-20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtNy0xLTEtMA_a7763883-a938-4908-99b8-e60079fbfdb1">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i327f7ac146d444c88f630645e8202d8f_D20200101-20201231" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtOS0xLTEtMA_dc09fe25-a753-46d6-9bf2-f7bb58160a43">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; <ix:nonFraction unitRef="number" contextRef="if363353766114727baf5a4aab4fe9ca4_D20200101-20201231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjBjOWM4ZmM3ZDI5ZDRkNDE5ZDNkOTI4NTMzY2UzMzFkXzEwOTk1MTE2Mjc3OTc_add64549-5d72-44bc-9f5e-04fa819e900b">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ef9e7a889a946cfba1e6124e81184a0_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtMy0xLTEtMA_b36f1c7e-a76a-416d-b42e-60eb6764ed89">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3064d98b299543439b8d8a53616ccd96_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtNS0xLTEtMA_5e1d9197-c2a8-407b-bc39-d740e069faff">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6594991d717f452eb94882c394b94cea_D20200101-20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtNy0xLTEtMA_013d309e-771c-476b-9fbe-2c54d043cf68">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6594991d717f452eb94882c394b94cea_D20200101-20201231" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtOS0xLTEtMA_60b99ed9-25b4-47cf-820c-9668df929dd8">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Credit Facility is <ix:nonNumeric contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzM1MzY_758bcd70-050c-4008-9936-a0b56de048bd">February 4, 2024</ix:nonNumeric>. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) <ix:nonFraction unitRef="number" contextRef="ia7d69adb19bc439892e8f7b86338bcb6_D20190204-20200331" decimals="5" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzM3NDM_3a43e571-b077-49a4-ad4d-f3b1741dd522">0.625</ix:nonFraction>% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) <ix:nonFraction unitRef="number" contextRef="i7328ca3b33b846ebb1d8865233054b79_D20200401-20230331" decimals="5" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzM4Mjc_4af559b6-49d3-4bac-b827-da157b98e02a">1.250</ix:nonFraction>% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) <ix:nonFraction unitRef="number" contextRef="i5f285d89c3194106bf7a283b287c5858_D20230401-20240204" decimals="5" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzM5MTM_cba60a7a-20fa-4b34-bd0f-8dbb879cc64b">1.875</ix:nonFraction>% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="i81b3d4329c9e413992649f97f3932f8e_D20190204-20190204" decimals="-6" format="ixt:numdotdecimal" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzQ1MTU_1ac5bbbd-a689-4b88-b2a9-35cad6a5bcf6">5</ix:nonFraction> million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires maintenance of two financial covenants: (i)&#160;a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii)&#160;a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded $<ix:nonFraction unitRef="usd" contextRef="i813d4685897443ab84f5078bedbc3eed_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzU1NTY_25e79a93-2246-4932-b63d-3b84292281be">0.8</ix:nonFraction> million in deferred debt issuance costs as long-term obligations, less current portion within our consolidated balance sheet during the year ended December 31, 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i)&#160;provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204" decimals="2" name="amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzU5OTU_b2ee4ac8-77a4-40b8-b3c5-2aa33d38693f">95</ix:nonFraction>% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii)&#160;provide guarantees from subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204" decimals="2" name="amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzYxNzg_362706ea-e318-4246-b82d-6054b6a764e6">70</ix:nonFraction>% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i03563d0e411244af8f7fcac134c27c17"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="i90dece5459db457b9caee4a934044bae_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzYzMDU_76e0d7e5-7d1d-4fab-8a58-2ef167e739c1">175.0</ix:nonFraction> million Term Loan Facility was <ix:nonFraction unitRef="number" contextRef="i8de54dd0485448269d1eebf429a33e51_D20200101-20201231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzEwOTk1MTE2MzkyMTM_1111d1b9-6328-45e0-ac8a-c438af54e705">2.2</ix:nonFraction>% for the period ended December 31, 2020 and <ix:nonFraction unitRef="number" contextRef="i0a9f227940024b9b9e6f47095fc1825c_D20190204-20191231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzEwOTk1MTE2NDAwMjM_155d4ea7-a054-4366-864f-ef28e33178d3">3.8</ix:nonFraction>% for the period February 4, 2019 to December&#160;31, 2019. Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY0NDg_a33c854f-7faf-4206-9526-1ce83076d677">550.0</ix:nonFraction> million Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="i5f2b03850b34492e9f5c7baeadcdd170_D20200101-20201231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY0ODE_e5046265-4eda-4924-9e07-9e7d6ca90070">2.2</ix:nonFraction>% for the period ended December 31, 2020 and <ix:nonFraction unitRef="number" contextRef="ibd494e95d0b348dbbcf7c525e255735b_D20190101-20191231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY1Mjc_e5077704-1df8-408c-b609-2d5266997052">4.0</ix:nonFraction>% for the period ended December 31, 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our consolidated leverage ratio was <ix:nonFraction unitRef="number" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" name="amed:TotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY2Mjc_80fae559-1b42-405d-b6d2-97866d8edac1">0.6</ix:nonFraction>, our consolidated interest coverage ratio was <ix:nonFraction unitRef="number" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="1" name="amed:ConsolidatedInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY2NzY_4c9e0a50-8902-4664-8065-4392e40be7eb">25.6</ix:nonFraction> and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our availability under our $<ix:nonFraction unitRef="usd" contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcwNTQ_31ea170c-5272-4612-a12f-36c4a1a65fdd">550.0</ix:nonFraction> million Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcwODc_3470c79d-f4db-4b20-b617-a5bc313d1017">470.2</ix:nonFraction> million as we have $<ix:nonFraction unitRef="usd" contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcxMDE_01b138ed-ff32-43c7-85f4-7a67d36b9e09">51.0</ix:nonFraction> million outstanding in borrowings and $<ix:nonFraction unitRef="usd" contextRef="i3d03942e78784e909bcee19f2ae8dcad_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcxMzQ_2da99589-400f-4464-bc44-e25fc17c5191">28.8</ix:nonFraction> million outstanding in letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder,&#8221; and together with the CCH Joinder, the &#8220;Joinders&#8221;).  Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries and the AseraCare entities granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries and the AseraCare entities also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Amended Credit Agreement pursuant to the terms of the Joinders and the Amended Credit Agreement.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our finance leases outstanding of $<ix:nonFraction unitRef="usd" contextRef="i4365d319b33f4857ae4bc38bf1acf0d9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg0MzE_c3920efa-f5bc-42b8-a9a4-bcb84a3e964c">2.6</ix:nonFraction> million relate to leased equipment and bear interest rates ranging from <ix:nonFraction unitRef="number" contextRef="i3c7e72eca4bc4cf0b3983258ef075db8_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg0OTg_111f083a-0f58-4099-81d1-f6a658222eff">5.3</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i68bc26784c984ab2b763317f0ea13821_I20201231" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1MDQ_d3b6a726-d743-4de3-836a-30a12e2c080a">5.8</ix:nonFraction>%.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxODQ_460d8a7f-6e05-4b3a-9b22-f0bc3f76fc06" continuedAt="iee3c58a85d3343dfa1783ff339ac1397" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="iee3c58a85d3343dfa1783ff339ac1397" continuedAt="i84673b4535134754a759f1a354b1df46"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:ProvisionforIncomeTaxesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU3NjA_e77f3675-0075-4c99-9ce3-76ab2c461f82" continuedAt="i5e545ce40dbc49c8b2be52536113e5e0" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes attributable to continuing operations consist of the following (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzMtMS0xLTEtMA_49b4351f-796b-44b2-9615-dfc1b2e7671a">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzMtMy0xLTEtMA_1e0a888e-5d48-4c3d-ad76-1864ace3775e">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzMtNS0xLTEtMA_069c2d72-46a4-4828-aa08-12d1ca49579a">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzQtMS0xLTEtMA_29f1b7e4-9cfc-4ebf-9955-af5f77cfdebb">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzQtMy0xLTEtMA_5810f488-2bf2-46e5-91db-1174d56920e7">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzQtNS0xLTEtMA_e91b8775-0b99-4318-96a0-8d8cdacecc9d">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzUtMS0xLTEtMA_a858c630-8a3d-4f63-ad40-d58ae83f8457">52.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzUtMy0xLTEtMA_0b51887e-f9c7-47c3-8c84-f20f23b51cfe">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzUtNS0xLTEtMA_8cf50cd3-8e10-44b1-837b-24a5b5bfd539">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzctMS0xLTEtMA_084ef85e-474c-4e2f-96b3-0a7deb4d0ab5">22.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzctMy0xLTEtMA_7693dba8-13e9-4422-8662-693b4a23535d">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzctNS0xLTEtMA_359d74dc-ea74-4c06-9438-287463306400">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzgtMS0xLTEtMA_85853e48-2396-4914-8831-5af8326f4326">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzgtMy0xLTEtMA_6bbd4d92-7e5e-487f-9ea1-c17d69d46465">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzgtNS0xLTEtMA_a1724fbb-cdae-4e5c-bec9-84aedfce604b">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzktMS0xLTEtMA_c4c92bc0-1efd-49d9-89ef-973f8e745758">26.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzktMy0xLTEtMA_0d41af63-e182-4f21-bad6-3fa580c566f7">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzktNS0xLTEtMA_c108c7a0-d5d9-4922-b4e2-fca30c25db88">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzEwLTEtMS0xLTA_d3e4477c-e85a-4529-a417-bb6f00752aec">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzEwLTMtMS0xLTA_074fbe92-536a-4594-9462-6a90381443ad">42.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i84673b4535134754a759f1a354b1df46" continuedAt="ib8967ec69536426fb2d14b3f1eff0a70"><ix:continuation id="i5e545ce40dbc49c8b2be52536113e5e0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense for the years ended December&#160;31, 2020, 2019 and 2018 was allocated as follows (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzItMS0xLTEtMA_3454e0e6-c1bb-47f2-884b-9f7c4ed2fa6b">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzItMy0xLTEtMA_7a457af5-ed6c-47ce-b811-52bf91c092dc">42.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:IncomeTaxEffectsAllocatedToInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzMtMS0xLTEtMA_e62f80af-6d52-4424-9276-690ec0e7f040">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:IncomeTaxEffectsAllocatedToInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzMtMy0xLTEtMA_7f960515-647f-43ef-9dfa-9fdb01e219e0">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="amed:IncomeTaxEffectsAllocatedToInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzMtNS0xLTEtMA_287efd8b-aaf5-4d04-ade2-3ec73bd4f806">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="amed:IncomeTaxEffectsAllocatedToGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzUtMS0xLTEtMA_73ebc199-58a8-4ff5-87c8-79fa7114ecff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:IncomeTaxEffectsAllocatedToGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzUtMy0xLTEtMA_d1ee8f98-641c-4826-8081-95e555c1e821">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="amed:IncomeTaxEffectsAllocatedToGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzUtNS0xLTEtMA_634d8e3a-2982-49c5-b8b2-060cc41d9e5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzYtMS0xLTEtMA_14034154-6acf-48d5-83fe-e9551c132591">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzYtMy0xLTEtMA_0d9cfac8-b655-4924-a5d2-217f92ef8fe5">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzYtNS0xLTEtMA_98a397a1-8fe4-4490-b2b7-ec744c406c24">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU3NjQ_3a1f2f4e-c22b-4392-8113-0a61a373f615" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense at U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzItMS0xLTEtMA_b0405ae9-053c-4ca2-b87d-e4f65d9ef65d">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzItMy0xLTEtMA_eec32649-f85f-4e8e-9202-12c181aa7ca8">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzItNS0xLTEtMA_6d69be9d-b4b3-4ec9-b0e0-866ddbcfb695">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local income taxes, net of federal income tax benefit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzMtMS0xLTEtMA_9cdc9ac4-9d71-4499-b301-0b3ffd1d2266">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzMtMy0xLTEtMA_fde79fc1-1ead-4da4-bb24-755a4762bc9c">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzMtNS0xLTEtMA_68a401cf-34a6-4ae7-bead-45aaeb9af663">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Excess tax benefits from share-based compensation (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzQtMS0xLTEtMA_19e13656-c930-47f2-b94b-80c570247249">12.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzQtMy0xLTEtMA_eae9cd9e-b43c-49f2-b81b-61a3254e6bf6">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzQtNS0xLTEtMA_ac8754b3-9abc-48c1-bb80-09deaf11a533">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzUtMS0xLTEtMA_cf10aa80-3eaf-488e-9e5b-5c3383caddee">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzUtMy0xLTEtMA_084f8d31-a7fc-4ee9-bfbe-3934c5efd1fa">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzUtNS0xLTEtMA_ec5291e3-6bcd-43e6-9bfe-d47dc0e9fd2e">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other items, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzYtMS0xLTEtMA_451df2b0-1ca2-4d8f-8fef-23b775d5bba3">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzYtMy0xLTEtMA_6b1dba2e-3c51-4ff3-9e63-906529d95254">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzYtNS0xLTEtMA_59b7d3ef-82c5-4215-b490-90a67cd63d18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzctMS0xLTEtMA_52aa0765-9dbc-4575-8c8d-eb3556db0886">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzctMy0xLTEtMA_58ed6495-94ec-458b-b3cb-ba571500e08f">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzctNS0xLTEtMA_c61317a7-0798-4531-a520-eca72907a65a">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised <ix:nonFraction unitRef="shares" contextRef="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQyMTM_379add51-4341-486e-986f-d95d96f45e89">500,000</ix:nonFraction> stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $<ix:nonFraction unitRef="usd" contextRef="i5e2a3b22027c46259ffb26bf610aae36_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQwODQ_b3d3b48a-0e43-445b-af04-a4633989a417">92.1</ix:nonFraction>&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i061c5e4bcf0a48809b0f8aaa50b8d7f6_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQwOTk_a61e286a-f98a-4626-96ee-e7cd1f680da6">19.4</ix:nonFraction>&#160;million federal income tax benefit and a $<ix:nonFraction unitRef="usd" contextRef="i9a797cd8697149299906057726300694_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxMTQ_1b105219-273b-41e4-b6b2-b81a6d573d32">4.6</ix:nonFraction>&#160;million state and local income tax benefit for the year ended December 31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company had income taxes receivable of $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzE1MjI_197ca48a-80ac-4bf3-97f5-4c386c51b589">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzE1Mjk_aadcf908-0059-485a-8431-eeed0597cf1c">2.0</ix:nonFraction> million, respectively, included in other current assets within our consolidated balance sheets. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib8967ec69536426fb2d14b3f1eff0a70" continuedAt="i74ab3e7d7f73479d8878fd245e45fc83"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU3NjU_3a560798-d294-4e0f-8aef-f9a3d190bb84" continuedAt="i9480a4fbaae841bdbd508298fa72695e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities) consist of the following components (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued payroll&#160;&amp; employee benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzQtMS0xLTEtMA_6eef7c17-d0d9-46ee-93af-b1e5d4633b56">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzQtMy0xLTEtMA_bf64d918-7ffb-425e-9438-b6138ceded25">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzUtMS0xLTEtMA_6f7918c5-7aa9-404a-891c-885472152aee">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzUtMy0xLTEtMA_d808d3df-9f64-4485-a139-1e42307e519f">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzctMS0xLTEtMA_0af6115b-0318-4c6b-814c-5e584ab0b534">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzctMy0xLTEtMA_af27ad81-df6c-4dc3-a623-79454b21063c">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal &amp; compliance matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredTaxAssetsLegalAndComplianceMatters" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzgtMS0xLTEtMA_0bef4d61-0fef-4bef-94d4-cd9dea7f07d8">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:DeferredTaxAssetsLegalAndComplianceMatters" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzgtMy0xLTEtMA_6f87dfd0-e62a-435c-b7aa-c478bc5f5cf1">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredTaxAssetsLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzctMS0xLTEtNDEyNg_e9e8715b-b595-4f3c-8388-3a9e8f50dd3c">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:DeferredTaxAssetsLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzctMy0xLTEtNDEyNg_e0093904-4d8c-4c19-9ff3-eda7d2100960">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provider relief fund advance (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredTaxAssetsProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzgtMS0xLTEtNDEyNg_a6e73d89-8a7d-4fe8-bca7-0aae0a43f903">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:zerodash" name="amed:DeferredTaxAssetsProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzgtMy0xLTEtNDEyNg_40d40fd2-83ec-417b-93af-3c3b227184f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred social security taxes (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredTaxAssetDeferredSocialSecurityTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzktMS0xLTEtNDEyNg_3b1fe60d-9d11-42db-913e-866ff39ca8db">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:zerodash" name="amed:DeferredTaxAssetDeferredSocialSecurityTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzktMy0xLTEtNDEyNg_63f668c6-cebf-4ec2-be24-0f32da81f02f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzktMS0xLTEtMA_09d09782-8323-4e6f-9215-0013964367c7">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzktMy0xLTEtMA_8cf61f2d-317e-450f-991e-767dedf17e44">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEwLTEtMS0xLTA_021ce504-bba9-43aa-ac9e-fd10436b8003">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEwLTMtMS0xLTA_bcec71a5-c53b-4da9-8641-57c5ca23963f">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzExLTEtMS0xLTA_0fa16eb9-4148-49f3-8a7d-c5be60e34397">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzExLTMtMS0xLTA_4f773dc1-a742-4d3b-a609-6d71de45597c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEyLTEtMS0xLTA_36c15696-ef86-4039-9121-f0a139ae535e">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEyLTMtMS0xLTA_f882ace4-9024-475c-941b-b0095663e7e7">67.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEzLTEtMS0xLTA_0d6802b6-8b0f-4e2f-b77c-ddefb779db9a">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEzLTMtMS0xLTA_4e8f8db8-893a-4cd1-8dcc-5977820b9f5c">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE0LTEtMS0xLTA_639a9676-0554-40bd-be6b-ed44f0120f4b">98.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE0LTMtMS0xLTA_39f61516-513a-4a39-abc6-af1f2a689ea7">66.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE2LTEtMS0xLTA_9e84011c-7942-4b87-bf54-09c23530b4d2">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE2LTMtMS0xLTA_e422a30d-aaa0-4bca-90b9-beda2b2ffe5e">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE3LTEtMS0xLTA_7cd778ac-d0cf-40ea-afbd-a65e6cbf58d7">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE3LTMtMS0xLTA_d47d8b64-bec1-4c93-ae5c-01110c620465">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE4LTEtMS0xLTA_265a8e06-fb84-45f7-99cd-6a99ce87616a">9.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE4LTMtMS0xLTA_c6bd213b-e0bf-46fd-8afe-180bba70a26f">13.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE5LTEtMS0xLTA_1602a976-f930-4903-91d0-194e449cd382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE5LTMtMS0xLTA_f0564dde-068e-4c36-a200-031e49658679">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="amed:DeferredTaxLiabilitiesRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIxLTEtMS0xLTQxMjk_010ab809-6fe1-4b2e-b607-2c33608c2e15">24.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="amed:DeferredTaxLiabilitiesRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIxLTMtMS0xLTQxMjk_9dd7638a-3b4a-4ea2-b72b-18d83ea0cb0e">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIwLTEtMS0xLTA_1bc8f7ee-a409-44af-a7e0-5af6a0d0450d">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIwLTMtMS0xLTA_5e0649c4-d3ed-48bd-9e76-b91a8bce5910">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIxLTEtMS0xLTA_973b2d82-84f9-413c-aa9c-972474a7737f">50.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIxLTMtMS0xLTA_dbedcbe8-677b-41cb-b8b8-7dd7b3129a55">45.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIyLTEtMS0xLTA_8650fc31-cb2c-45b6-82bd-bc6f7e26efdd">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIyLTMtMS0xLTA_fef6e4ad-8970-411e-836b-f8f3331fa5e1">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">In April 2020, approximately $<ix:nonFraction unitRef="usd" contextRef="i372268bd3773442994730e4fe0e5ee44_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxOTk_86f450c9-623d-4604-b4ee-5538f9175ffb">100</ix:nonFraction>&#160;million was provided to the Company through the healthcare Provider Relief Fund established under the CARES Act. As of December 31, 2020, the Company recorded a liability related to the funds that we do not expect to utilize totaling $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxODY_b437ea1c-5920-47af-ae75-b76db66b122c">60</ix:nonFraction>&#160;million, which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. For income tax purposes, the Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:ProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxMjg_a2c37cff-6b97-4cc7-943c-6e3ae70e3b8a">60</ix:nonFraction>&#160;million as income upon receipt, resulting in a deferred tax asset as of December 31, 2020. The company will recognize an income tax deduction when the liability is paid during the year ended December 31, 2021.  </span></div></ix:nonNumeric><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i9480a4fbaae841bdbd508298fa72695e" continuedAt="i2a1753c4e75b4ee89e9108cded8c0959">(2)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"><ix:continuation id="i2a1753c4e75b4ee89e9108cded8c0959">The CARES Act provides for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, the Company has deferred $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:CARESActDeferralOfEmployerShareSocialSecurityTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxNDE_f34df0ab-3bd8-41c5-a46f-d1ed2f216270">55.4</ix:nonFraction>&#160;million of social security tax payments; $<ix:nonFraction unitRef="usd" contextRef="i4c55a72c359242999f6ad37fe6380c0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxNTY_8413f32d-4594-44ba-89f2-20c43fad4cc0"><ix:nonFraction unitRef="usd" contextRef="i4c55a72c359242999f6ad37fe6380c0f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxNTY_e4a2066b-61f2-4411-a32e-1bbc0de851f7">27.7</ix:nonFraction></ix:nonFraction>&#160;million of this amount is reflected in each payroll and employee benefits and other long-term obligations within our consolidated balance sheet. For income tax purposes, the deferred social security taxes will be deductible when paid on December 31, 2021 and December, 31, 2022, resulting in a deferred tax asset at December 31, 2020.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have state net operating loss ("NOL") carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i2ff4532176b44743aad3722dcd2582f0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzIwMzE_93a30817-81ad-412c-a964-308ea971dd01">47.5</ix:nonFraction> million that are available to reduce future taxable income and $<ix:nonFraction unitRef="usd" contextRef="iaa1ce8651ce74253af7461cfa4722490_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzIwODk_c88f4b53-c63d-46be-90e5-f5428db73302">3.7</ix:nonFraction> million of various state tax credits available to reduce future state income taxes. The state NOL and tax credit carryforwards expire at various times.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the valuation allowance for deferred tax assets, which is primarily related to certain state NOLs and state tax credit carryforwards, was $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzI0MDg_f556fda6-fca6-44aa-982a-b7feebb39af6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzI0MTU_62ce2a91-1d7c-4832-b4f1-a738a0170718">0.4</ix:nonFraction> million, respectively. The net change in the total valuation allowance for the years ended December 31, 2020 and 2019 was a decrease of $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzI1MzY_d143b74d-b102-4c8f-b6f6-72defefd471a"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzI1MzY_fa8719da-600c-41cc-b5e2-998dca12452d">0.3</ix:nonFraction></ix:nonFraction> million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i74ab3e7d7f73479d8878fd245e45fc83"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carryforwards governed by the tax code. Based on the current level of pretax earnings, the Company will generate the minimum amount of future taxable income needed to support the realization of the deferred tax assets. As a result, as of December&#160;31, 2020, management believes that it is more likely than not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU3Njc_865a99f6-5139-4868-a940-93fbbbf8f4ec" continuedAt="i45073b5b3a1e40aba57132320f0bcea9" escape="true">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><ix:continuation id="i45073b5b3a1e40aba57132320f0bcea9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzItMS0xLTEtMA_392461d7-1161-47b1-b327-86acf33db287">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzItMy0xLTEtMA_39d29e8a-cf9a-4db5-a4d1-fc49304f78df">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d70551ae8f463895c999fdc4613768_I20171231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzItNS0xLTEtMA_3928d3f8-c47d-4185-b841-3c08e8a36ad8">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzMtMS0xLTEtMA_67045844-606c-4141-b9de-5c4cc2ca953b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzMtMy0xLTEtMA_5ba7205b-d0e6-46d3-9787-71a5cd0efb87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzMtNS0xLTEtMA_640ad69f-913b-48aa-8914-16b1941d7865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions related to prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzQtMS0xLTEtMA_4f3bf6b3-2f1b-4cf6-8967-11824456b391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzQtMy0xLTEtMA_30894ad0-08a8-48c8-a7e4-15276507c710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzQtNS0xLTEtMA_d431a87d-d7f2-473e-b6cc-f82c4de45a4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reductions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzUtMS0xLTEtMA_bf023ecc-4bf2-4503-94d1-c01a3f973426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzUtMy0xLTEtMA_46fcbe58-7854-400d-ad97-7fefa37d89a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzUtNS0xLTEtMA_8af83839-cb38-45f7-af8c-81309af8705b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzYtMS0xLTEtMA_161dd5ba-8538-498e-9f23-5f4469449516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzYtMy0xLTEtMA_c8787777-6ed0-44e6-8a74-37db8c7213ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzYtNS0xLTEtMA_04a586e9-eb50-40c2-8c59-1510de804be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzgtMS0xLTEtMA_bba3bdc1-7c7f-4040-927c-7ba7d362a9fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzgtMy0xLTEtMA_279664b1-e53e-43e5-a6be-a68f4df54d57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzgtNS0xLTEtMA_ba6d955e-3a68-4d79-baf9-074bd7831651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzktMS0xLTEtMA_1226e71e-f007-483f-970b-65cd57c3e7bd">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzktMy0xLTEtMA_92142014-a196-42a5-a2c4-fec9eb44de6e">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzktNS0xLTEtMA_ce738fc9-badd-4d16-b16f-471b8ff73d8a">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, there is $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzQ1NDM_04ce5432-6720-47a0-ba12-8853b49f7fe0"><ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzQ1NDM_a0ce7e82-69a4-4550-b1a6-5e75edd4dcb7">2.7</ix:nonFraction></ix:nonFraction> million of unrecognized tax benefits recorded in other long-term obligations within the consolidated balance sheets that, if recognized in future periods, would impact our effective tax rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxNzE_0aa05bf9-2aa5-44f3-9a37-1f671235c2f3">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzQ3NDM_d361b703-1984-4bb3-8717-4552cfd059aa">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzQ3NTA_2fab7bb4-9210-432e-8915-9d21b53575c9">0.1</ix:nonFraction> million of interest as components of interest expense in connection with our reserve for uncertain tax positions during the years ended December 31, 2020, 2019 and 2018, respectively. Interest related to uncertain tax positions included in the consolidated balance sheets at December 31, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzUyNDE_4d1a7e3c-0075-4890-bc9f-d034b8979d91">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzUyNDg_de87083f-4d22-4feb-b857-9fb286f51528">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and in many individual states, with significant operations in Louisiana, South Carolina, Alabama, Georgia, Massachusetts and Tennessee. We are open to examination in the U.S. and in various individual states for tax years ended December&#160;31, 2014 through December&#160;31, 2020. We are also open to examination in various states for the years ended <ix:nonNumeric contextRef="i6e1c460171b341758ee7f2c6f5213b5e_D20200101-20201231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU2NTI_b978d601-64a0-4dde-926c-f30c41859b0c">2007</ix:nonNumeric> through <ix:nonNumeric contextRef="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU2NTc_f159cd4d-d2cc-4eed-abef-b2dca5dc4ec9">2020</ix:nonNumeric> resulting from NOLs generated and available for carryforward from those years.</span></div></ix:continuation><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0NzY_d08f290c-4a69-4724-8cd3-95925e0b6095" continuedAt="id0dd74b9b8ff453a8935b4707cb81375" escape="true">CAPITAL STOCK AND SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id0dd74b9b8ff453a8935b4707cb81375" continuedAt="i67528763fe39458f92c98ab7a5afbdbd">We are authorized by our Certificate of Incorporation to issue <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzExNA_d5265418-9943-4b5a-a0c2-246dfe28967d">60,000,000</ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzE0MQ_7854bee0-353e-4959-975a-45d2a391224b">0.001</ix:nonFraction> par value and <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzE1OA_f985c76d-912d-4ff5-89ee-6d5dbb4d4358">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzE4OA_d23dddc4-5551-4f5b-98bb-872ded5766c7">0.001</ix:nonFraction> par value. As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzIyMw_a8c91be6-65cf-4140-bc70-2a7e14e8a97b">37,470,212</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzIzMA_bd8105a9-b4b6-4496-99f6-023847e25e42">32,814,278</ix:nonFraction> shares of common stock issued and outstanding, respectively, and <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI5OA_61a91e14-9671-4e36-b1ea-6fba042b1fe5">no</ix:nonFraction> shares of preferred stock issued or outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i67528763fe39458f92c98ab7a5afbdbd" continuedAt="i22450502b235484faeaed03c61011340"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Awards</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2018, our Board of Directors and the Compensation Committee approved, subject to stockholder approval, the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (the &#8220;2018 Plan&#8221;). On June 6, 2018, our stockholders approved the 2018 Plan at the Company's annual meeting of stockholders. The 2018 Plan replaces our 2008 Omnibus Incentive Compensation Plan (the &#8220;2008 Plan&#8221;), which terminated on June 6, 2018 when the stockholders approved the 2018 Plan.  The 2018 Plan authorizes the grant of various types of equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:Percentageofownershipinsubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEyODY_eccaed08-a14e-43c6-8c99-f90781cc976b">50</ix:nonFraction>% or more owned subsidiaries, our non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our non-employee directors, continued service on the Board of Directors) and/or achievement of certain pre-determined performance goals. We refer to stock awards subject to service-based vesting conditions as &#8220;non-vested stock&#8221; and restricted stock units subject to service-based or a combination of service-based and performance-based vesting conditions as &#8220;non-vested stock units.&#8221; The 2018 Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the 2018 Plan, those eligible participants to whom, and the times at which, awards shall be granted. The Compensation Committee, in its discretion, may delegate its authority and duties under the 2018 Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzIzOTU_d2aac37b-76f0-4978-9ba9-37cdd68d2c6c">2.5</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock. We had approximately <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI0NDM_336a3610-530e-4961-9c7e-4817dddc447b">2.0</ix:nonFraction> million shares available at December&#160;31, 2020. The price per share for stock options shall be no less than the greater of (a) <ix:nonFraction unitRef="number" contextRef="if2bfa60d1a274089b775bff19975c6d2_D20200101-20201231" decimals="INF" name="amed:Fairvalueofshareofcommonstockpercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI1NDk_2490ae16-638b-4a28-8ae3-68b01aa4e622">100</ix:nonFraction>% of the fair value of a share of common stock on the date the option is granted or (b)&#160;the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI3NzY_c8f7e060-9a74-4cca-832b-31e36b8a152d">10</ix:nonFraction>% or more of the total combined voting power of us and our subsidiaries, the price is to be at least <ix:nonFraction unitRef="number" contextRef="i2268173c1609427b91285a18f7856aa8_D20200101-20201231" decimals="INF" name="amed:Fairvalueofshareofcommonstockpercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI4Nzg_09e47da5-4571-4762-b6b2-03d855638dfe">110</ix:nonFraction>% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a one year to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDMzMTE_132e2a63-3451-42de-8da7-d71ba010d03c">four</span> year period, with the exception of those issued under contractual arrangements that specify otherwise, and may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed <ix:nonNumeric contextRef="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzMzMzI_15ee7a71-0b81-409a-9398-4fdfbfb20536">ten years</ix:nonNumeric> from the date such option is granted. The Company analyzes historical data of forfeited awards to develop an estimated forfeiture rate that is applied to the Company's non-cash compensation expense; however, all non-cash compensation expense is adjusted to reflect actual vestings and forfeitures.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)                                                                                                                                                                        </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a plan whereby our eligible employees may purchase our common stock at <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzM5MjQ_22e44c0b-2fbf-4d04-be7d-35f89f11f374">85</ix:nonFraction>% of the market price at the time of purchase. On June&#160;7, 2012, our stockholders ratified an amendment adopted by our Board of Directors to increase the total number of shares of our common stock authorized for issuance under our ESPP from <ix:nonFraction unitRef="shares" contextRef="ic23e136463954fce97ebf07eaca62d49_I20120606" decimals="INF" format="ixt:numdotdecimal" name="amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQxNjU_2652985e-b787-4312-8371-b243009e9b42">2,500,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="i1f87b9321c534dcfae4d2ce97fe4fc8b_I20120607" decimals="INF" format="ixt:numdotdecimal" name="amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQxNzg_f2511418-7e04-419f-8420-75fdd30203e8">4,500,000</ix:nonFraction> shares, and as of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQyMTQ_0fab8bad-eb61-4581-a0f6-e2d6a58e5546">1,328,627</ix:nonFraction> shares available for future issuance. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0NjE_50059d33-f114-41af-8839-8094f9e0c9e9" continuedAt="i2c79fb424c8e419aaa04d28db1a74159" escape="true">The following is a detail of the purchases that were made under the plan:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i2c79fb424c8e419aaa04d28db1a74159"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018 and Prior</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4f247884db846bdb4821a221bbfe57c_D20120607-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzEtMS0xLTEtMA_ec858969-bd81-4496-a3ad-b3c14a1a5c8d">3,122,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzEtMy0xLTEtMA_b49cafe9-d780-4474-aee0-e41608175980">15.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January&#160;1, 2019 to March&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzItMS0xLTEtMA_68b0d041-c933-4815-a861-5146fed88c74">7,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i172263bdf66a4f008f59172cfb1d5640_I20190331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzItMy0xLTEtMA_7c4200d5-aca2-44d0-8d71-91ff5214fa85">104.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;1, 2019 to June&#160;30, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzMtMS0xLTEtMA_35016468-82cc-4c25-9d3c-2f524a010bbd">8,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d88f9ec77c9452c8bb506759c530a16_I20190630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzMtMy0xLTEtMA_fda3117d-3b9a-4071-af70-72aa9d8d44b5">103.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July&#160;1, 2019 to September&#160;30, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzQtMS0xLTEtMA_fac44995-c184-4f98-a3ef-0c049298c4f8">7,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b760ab2443e4046941e64e3b50a2f09_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzQtMy0xLTEtMA_ef1b7850-73e9-44cf-b1b3-8aaf80f5ae78">111.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October&#160;1, 2019 to December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzUtMS0xLTEtMA_440632a2-47e2-46cd-a5be-09e174964a22">6,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzUtMy0xLTEtMA_90331e1a-ef5b-42ba-b566-c2898f54a841">141.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January&#160;1, 2020 to March&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzYtMS0xLTEtMA_aac0ab84-d65b-4c00-a471-81a5aee5fa41">5,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc731d16af2b4adb980e8754afe1b9f9_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzYtMy0xLTEtMA_3cc517c9-7e60-4f86-8208-e4f66aa5260a">156.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;1, 2020 to June&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzctMS0xLTEtMA_b176c016-0200-4919-a046-ed000e08d2a4">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2521c40c2e674edaba9586526c5b83a7_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzctMy0xLTEtMA_12e19c18-5823-4d9d-b610-5a60a11c5472">168.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July&#160;1, 2020 to September&#160;30, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzgtMS0xLTEtMA_4c97a1e2-b928-4488-bc8c-370179bbd98e">4,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44d57dec79174a29a10a484c6e35ee00_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzgtMy0xLTEtMA_43729bb9-0f88-4514-828b-d4f5700fd57b">200.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October&#160;1, 2020 to December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzktMS0xLTEtMA_e867cac8-d53b-4d5c-8f67-4c2834cd8759">4,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzktMy0xLTEtMA_057afde8-9e6a-47f9-9879-6a97c4f24feb">249.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3692bce7d32644e5b337cd5691239645_D20120607-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzEwLTEtMS0xLTA_3ff81343-8f24-40b1-be47-d0d1e7f7259b">3,171,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP expense included in general and administrative expense in our accompanying consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ0NTM_8853c972-7140-475b-af46-c652cbf6a3ff">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ0NTc_3831a475-f66f-4d6b-bf20-bb1b4a72de57">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ0NjQ_eca60644-972b-47cb-9eb7-f5aae15c818d">0.5</ix:nonFraction> million for 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i22450502b235484faeaed03c61011340" continuedAt="i67a0e94c71e44c55a1e5f27d86ad93c2"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised <ix:nonFraction unitRef="shares" contextRef="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0NDM_860d1de8-c073-4af7-8f5a-1ce3de9cec1a">500,000</ix:nonFraction> stock options previously awarded to him under the 2008 Plan. In connection with the exercise, Mr. Kusserow surrendered <ix:nonFraction unitRef="shares" contextRef="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810" decimals="INF" format="ixt:numdotdecimal" name="amed:SurrenderedSharesInShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0NTI_82abf25b-6829-465e-8889-584792a32142">231,683</ix:nonFraction> shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net <ix:nonFraction unitRef="shares" contextRef="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0NjE_44285bd2-db8f-4ccb-a8a3-60582d65ec75">268,317</ix:nonFraction> shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $<ix:nonFraction unitRef="usd" contextRef="i5e2a3b22027c46259ffb26bf610aae36_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0NzA_83b0363f-a31b-48ed-a704-36e01ed71056">40.4</ix:nonFraction>&#160;million, reflected within financing activities in our consolidated statement of cashflows, related to the remittance of tax withholding obligations. In addition, Mr. Kusserow's stock option exercise resulted in a $<ix:nonFraction unitRef="usd" contextRef="i5e2a3b22027c46259ffb26bf610aae36_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0ODU_6a41099f-d9aa-42dd-b15c-94d1f6fd714d">24.0</ix:nonFraction>&#160;million income tax benefit that was recorded in our consolidated statement of operations during the year ended December 31, 2020. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were <ix:nonFraction unitRef="shares" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ2MzA_d2ee266e-5a28-4c78-ba71-a19b112d33d2">43,249</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ2MzQ_5c8af85d-4300-4f9f-b6b7-8c1352b07c24">142,122</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ2NDE_c6dcaea2-3284-4a7f-a129-48fe8ae125ca">163,666</ix:nonFraction> options granted during 2020, 2019 and 2018, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ4Mzk_df9e8222-17c9-4c34-81ba-c248275e772b">4.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ4NDM_d6e0e37c-6e78-4788-9ec7-b28f8083c56d">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ4NTA_418a23c1-c8ff-450d-bdf5-3fd6f5d784cd">5.7</ix:nonFraction> million for 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0OTA_4b928c70-4c97-4724-b84a-b85fd7053d4c" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the awards were estimated using the following assumptions for 2020, 2019 and 2018:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk Free Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItMS0xLTEtMC90ZXh0cmVnaW9uOmM2OGUyODIzOTNiNjQ4MjA4NTRhMGNiZmM4ZjJlZWE3XzEwOTk1MTE2Mjc3OTg_3e5a103f-7f2e-4693-9f55-e2e4d9a1d972">0.38</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItMS0xLTEtMC90ZXh0cmVnaW9uOmM2OGUyODIzOTNiNjQ4MjA4NTRhMGNiZmM4ZjJlZWE3XzEwOTk1MTE2Mjc4MDY_7ddacfaf-ed56-4c00-9390-23e5d0282680">1.51</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItMy0xLTEtMC90ZXh0cmVnaW9uOjgwYTBmZGZkMzQ0YTRhZjA4NGYzOGIyZDk1ZDk3ZGI5XzEwOTk1MTE2Mjc3OTg_bcd79e6b-e663-4ff6-a917-df8145072b74">1.44</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItMy0xLTEtMC90ZXh0cmVnaW9uOjgwYTBmZGZkMzQ0YTRhZjA4NGYzOGIyZDk1ZDk3ZGI5XzEwOTk1MTE2Mjc4MDY_1f82907e-43ed-4189-a40c-1bdc1fdf70be">2.53</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItNS0xLTEtMC90ZXh0cmVnaW9uOjgwZTQ1NDY2YjcxYTQ5M2JhNTY3MGUyMzcwN2JlOGRjXzEwOTk1MTE2Mjc3OTg_1cbb59b7-74f4-4eb3-8c8c-191ef5e014bb">2.56</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItNS0xLTEtMC90ZXh0cmVnaW9uOjgwZTQ1NDY2YjcxYTQ5M2JhNTY3MGUyMzcwN2JlOGRjXzEwOTk1MTE2Mjc4MDY_f13cc5f0-6b2e-453e-a3d8-e8c743e904ee">3.04</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtMS0xLTEtMC90ZXh0cmVnaW9uOmVlOTc1NzMwYjA5ZDQ2M2I4ZTgyNWQ4OGE0MWViZjg0XzEwOTk1MTE2Mjc4MDE_a33cf7e0-a7a2-4d89-9942-6d886b6c8ec9">40.15</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtMS0xLTEtMC90ZXh0cmVnaW9uOmVlOTc1NzMwYjA5ZDQ2M2I4ZTgyNWQ4OGE0MWViZjg0XzEwOTk1MTE2Mjc4MTA_cf368834-5c60-4856-af22-9d05be33511a">42.80</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjQ0ZmIxY2Q3NTkwODQ0MGFiMGRkZmI5N2ExMjg1NzRjXzEwOTk1MTE2Mjc4MDE_75fd796d-cbd6-4dcb-8f95-013b4a772a7b">42.46</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjQ0ZmIxY2Q3NTkwODQ0MGFiMGRkZmI5N2ExMjg1NzRjXzEwOTk1MTE2Mjc4MTA_0bdfb6f8-035e-4206-a102-f1683fa27a60">43.83</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtNS0xLTEtMC90ZXh0cmVnaW9uOmRjM2U3NTA3OTYyOTQ1ZTFiMGY4OWZjMTg3MzFjZDVmXzEwOTk1MTE2Mjc4MDE_e0d99713-cdd5-4422-a01c-3521d79312f3">42.00</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtNS0xLTEtMC90ZXh0cmVnaW9uOmRjM2U3NTA3OTYyOTQ1ZTFiMGY4OWZjMTg3MzFjZDVmXzEwOTk1MTE2Mjc4MTA_59100dcf-fb99-4466-8460-402d8842cacc">45.32</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtMS0xLTEtMA_91635e7f-1ba7-49e5-a250-2319399e300f">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0967904d6aa443bda7b944783f5368a3_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjI1MzI4N2FlYjI4MDQ0NDI4YTc2OWU3ZTc1ODE4MjZkXzEwOTk1MTE2Mjc4MDE_5a719d0b-9dc7-4673-b400-1c1e5d4bc9d0">6.00</ix:nonNumeric> - <ix:nonNumeric contextRef="i95b123e655fe43e190e185f8dbe56430_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjI1MzI4N2FlYjI4MDQ0NDI4YTc2OWU3ZTc1ODE4MjZkXzEwOTk1MTE2Mjc4MTQ_1883f750-9a2e-48e2-9734-e7a6183eca50">6.25</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5def5d90694943c991e6829f70fa6a4c_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtNS0xLTEtMC90ZXh0cmVnaW9uOjdiMGE0ODlmNTE1OTQ1NTRhZDdjYzM4ODQ4NDk4MzBjXzEwOTk1MTE2Mjc4MDE_e86414ff-b8c3-4be2-ad56-dce94af1b284">4.12</ix:nonNumeric> - <ix:nonNumeric contextRef="ie9b8d67240ac466ba65b24c556a36122_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtNS0xLTEtMC90ZXh0cmVnaW9uOjdiMGE0ODlmNTE1OTQ1NTRhZDdjYzM4ODQ4NDk4MzBjXzEwOTk1MTE2Mjc4MTQ_d44ba158-0196-4cc5-b38e-60e3158aad9b">6.25</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="2" name="amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzUtMS0xLTEtMA_16502246-4b02-4c0b-8e67-86798482ceb7">86.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="2" name="amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzUtMy0xLTEtMA_03538c62-4ab1-431a-9ac7-6713dd904172">54.42</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="2" name="amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzUtNS0xLTEtMA_8a9452e7-5f50-43b2-afd2-d2dd82b45dc6">42.48</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzYtMS0xLTEtMA_4516599e-7596-4910-93c2-fe9b6f5f1c28">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzYtMy0xLTEtMA_ac55953b-dff1-4917-877e-a535525b4e17">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzYtNS0xLTEtMA_94453808-a60f-4c2c-8cf3-a984d430166e">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the simplified method to estimate the expected term for the stock options granted during 2020, 2019 and 2018 as adequate historical experience is not available to provide a reasonable estimate.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0ODg_937bd9a1-ac52-4130-b614-3e2e4f897769" continuedAt="ie6289480732d4b478e39d9807c0ebcc2" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our stock option activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Contractual<br/>Life&#160;(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzEtMS0xLTEtMA_6b223924-c2d5-4c67-a152-cfca37eced37">875,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzEtMy0xLTEtMA_8bb0dc6b-b0e8-4b9f-bd8d-75918bb70935">49.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzEtNS0xLTEtMA_ffd991c7-a149-408b-a883-09ce29cda3ae">6.26</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzItMS0xLTEtMA_ba89f6c1-6196-4967-9d1d-a809ab3a71b5">43,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzItMy0xLTEtMA_8b03b6f4-3b94-42e4-9b8e-08d186e86106">209.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzMtMS0xLTEtMA_dbf4addd-9505-4c4a-9e01-9a19d4b69683">622,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzMtMy0xLTEtMA_9755b033-f903-4333-8892-a5668d8f4124">31.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzQtMS0xLTEtMA_7efbc824-2ad5-443d-95db-a745b73133ea">18,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzQtMy0xLTEtMA_11a366c9-566a-455d-8b70-83d47a959600">103.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzUtMS0xLTEtMA_cea6b4b1-be69-4892-9709-3a5b11cde775">278,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzUtMy0xLTEtMA_bc302672-095b-450d-b2b3-75a3b8a17321">111.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzUtNS0xLTEtMA_db604054-fbdb-4cfb-a507-79a13e99cb4e">7.68</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable options at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzYtMS0xLTEtMA_82586e2b-90fa-4b08-8961-60ee1dddbc85">89,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzYtMy0xLTEtMA_07a3f6c3-3fb8-45d4-8e54-b4e57077f17d">76.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzYtNS0xLTEtMA_ad275eba-77bb-4646-aea0-5ffa015ec826">6.75</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of our outstanding options and exercisable options at December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="iab6fc63306454ed1ad46e51a0060949e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzUzNDU_671c7359-2772-48e3-815d-9bab143f3f32">50.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iab6fc63306454ed1ad46e51a0060949e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzUzNTI_5aaf35af-71d7-49c4-ba8d-33c2f359e5d0">19.4</ix:nonFraction> million, respectively. Total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU0MTc_72974ef6-b25e-4ffc-8268-2b24c6a815fd">121.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU0MjE_ecd917c1-f1a5-4fb2-abe8-cbdd341fa2ac">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU0Mjg_ad0432be-72e3-4348-b073-0a82fbb1a6b0">9.7</ix:nonFraction> million for 2020, 2019 and 2018, respectively. The tax benefit from stock options exercised during the period amounted to $<ix:nonFraction unitRef="usd" contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU1NDU_d21a57b2-7694-4c40-a737-78408ecbfc98">27.9</ix:nonFraction> million,  $<ix:nonFraction unitRef="usd" contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU1NTA_c7be276d-837b-4080-99ee-f66cf91634a2">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU1NTc_d6f728df-6c14-41dd-8f7b-e9ab12d24781">1.6</ix:nonFraction> million for 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i67a0e94c71e44c55a1e5f27d86ad93c2" continuedAt="i76a238229e9346af9d109278f04b7145"><ix:continuation id="ie6289480732d4b478e39d9807c0ebcc2"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock option activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzEtMS0xLTEtMA_89eabb82-dc55-4161-a33c-ebf80e225b05">305,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzEtMy0xLTEtMA_4b1dc880-2895-4c48-86bf-29b5bf1e6f6b">41.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzItMS0xLTEtMA_1885663f-e989-471a-80ed-15204ccbd066">43,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzItMy0xLTEtMA_a36148de-25cd-4154-9107-488a007e3496">86.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzMtMS0xLTEtMA_8a789c46-17bc-4448-b996-15dcd00a0c34">142,233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzMtMy0xLTEtMA_ef8c9b83-a1c4-4894-8f5d-a63bd7860515">34.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzQtMS0xLTEtMA_6170cf81-11b3-48e4-8ca6-045ce498eb95">18,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzQtMy0xLTEtMA_f588ad3f-d714-4449-badf-f2ed05ec443b">47.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzUtMS0xLTEtMA_effd0961-b9ad-4bf5-a63b-10ebe003427e">188,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i767079f30664438f8d9be671a161fd0e_I20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzUtMy0xLTEtMA_27e5cc34-e9c7-471a-bab5-9b6a5ab3e2eb">56.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="iab6fc63306454ed1ad46e51a0060949e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU2OTI_85dc5afe-62f3-4e93-ad14-f2bd6614de55">4.8</ix:nonFraction> million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU4MjA_7463df5e-4c3f-411d-9c05-b82b9c5734a4">1.9</ix:nonNumeric> years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue shares of non-vested stock with a vesting term of <ix:nonNumeric contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDMyNjc_3afa2286-143c-4487-a124-c69f0f2ae36e">one year</ix:nonNumeric>. The compensation expense is determined based on the market price of our common stock at the date of grant applied to the total number of shares that are anticipated to fully vest. Non-vested stock compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzYyNDQ_cd260cae-9de2-4e1a-9cc2-b8a7fe917467">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idf88ad709fd64cffbbba3949d9877821_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzYyNDg_105e8baa-a8db-4276-918c-ba439a0a6e49">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic1850298439a4c2f8d557340227845e9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzYyNTU_a6ea3a65-f740-447c-896a-4d2a698b28a6">1.4</ix:nonFraction> million for 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0ODI_e4c414f5-bab6-4fe8-98fe-2b7476c1b7ee" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24d3940f86e248f5a619e4759d853c1e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzEtMS0xLTEtMA_f701a254-255c-4e26-984e-12631f009041">9,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24d3940f86e248f5a619e4759d853c1e_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzEtMy0xLTEtMA_7c740b69-c445-4b57-8f30-ab95d4014c62">119.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzItMS0xLTEtMA_3eb44969-02ee-413d-840c-190e563197e9">1,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzItMy0xLTEtMA_fe8dd41a-b2e7-4fe7-80f8-48f47a5cddfe">158.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzMtMS0xLTEtMA_abe6ec20-7898-4fe4-a8ea-c251f2717bd9">11,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzMtMy0xLTEtMA_289f5a0c-af9a-46ed-95a0-828f94d5bfd7">124.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzQtMS0xLTEtMA_26387739-afdf-4d9d-9c14-052426381da8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzQtMy0xLTEtMA_abd79082-1657-44e0-8ff3-aa6130d72c91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic24c7c520697474487b3aceda222db5c_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzUtMS0xLTEtMA_73181192-3700-4278-9e89-281a6bbb7766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic24c7c520697474487b3aceda222db5c_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzUtMy0xLTEtMA_071d4cb5-8eb7-4330-ac1e-5227a509c205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of non-vested stock granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY0MzU_64e8130d-5981-4cad-a620-7d7ffc020173">158.72</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="idf88ad709fd64cffbbba3949d9877821_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY0Mzk_0373e852-ff1d-429f-bda9-e198052269fa">119.12</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ic1850298439a4c2f8d557340227845e9_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY0NDY_2454905d-e522-4aef-8663-6707ea0a74a8">80.54</ix:nonFraction> in 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was no unrecognized compensation cost related to non-vested stock awards; we currently do not have any outstanding awards.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with vesting terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MDY_02c412b8-41ea-4c92-b3c7-f45653d56560">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MTI_5f8948f7-2285-435f-ba9f-02ccda0ec48b">four</span> years. Based on the terms and conditions of these awards, we determine if the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the total number of units that are anticipated to vest, unless the award specifies differently. We account for such awards similar to our non-vested stock awards; however, no shares of stock are issued to the recipient until the stock unit awards have vested and after the pre-determined delivery date has occurred.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units &#8211; Service-Based</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc2MDI_4c20d6c7-b638-4f86-ad89-92d3c43fc7f1">7.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9934834a8a0c409b8d6d372c860f05c2_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc2MDY_4222fe76-b97a-402d-a86e-553f09bb15c8">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id48af308b58146e1a94f7cbf20c53001_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc2MTM_4f1224db-bf9e-40c1-8861-da71cb2ad7e8">4.5</ix:nonFraction> million for 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i76a238229e9346af9d109278f04b7145"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0NzQ_66e1199f-4aea-4ef8-a8e5-27cf24f59807" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our service-based non-vested stock units activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67aef9e5409443cc838400c94814e771_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzEtMS0xLTEtMA_4f327d58-ef62-4621-9a6a-86daa7d75243">231,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67aef9e5409443cc838400c94814e771_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzEtMy0xLTEtMA_3bf2fde3-7f64-4332-b7a1-2dbb1048bfa5">91.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzItMS0xLTEtMA_b4e8c6c1-5c01-4316-9a56-e5ae921c70e5">34,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzItMy0xLTEtMA_4501a991-8ff2-458c-9e63-1c57b7e1404f">206.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzMtMS0xLTEtMA_30a24ee4-a5af-465a-b90a-230b2768a4a3">89,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzMtMy0xLTEtMA_071f8558-9e2f-48db-ba70-3601ad1f329f">78.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzQtMS0xLTEtMA_ad27758a-26ab-487a-9cf2-4063b7138626">19,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzQtMy0xLTEtMA_e3a00ab5-9f73-4d18-8e41-6fe6ab0fc8df">97.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6fba36dadd24151b9f0f7c470401177_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzUtMS0xLTEtMA_4e34efd7-c46d-46bc-897d-fd24fa7177b1">157,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if6fba36dadd24151b9f0f7c470401177_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzUtMy0xLTEtMA_828c8e55-1eeb-4391-81e8-4e80cf81bd70">123.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of service-based non-vested stock units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc4MzM_7239903c-fde7-4984-84b3-9509bb3e5431">206.10</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9934834a8a0c409b8d6d372c860f05c2_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc4Mzc_bb2de982-20a3-47c1-90a6-7b80add64715">123.70</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id48af308b58146e1a94f7cbf20c53001_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc4NDQ_3965f769-0cd7-40dc-9f2b-0be06538c211">95.14</ix:nonFraction> in 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="if6fba36dadd24151b9f0f7c470401177_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc4OTY_cc7c369c-3a6e-4488-9c7d-0b53bcaf68a1">9.3</ix:nonFraction> million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a weighted average period of <ix:nonNumeric contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzgwNTE_96eaf805-438d-4263-b25d-243ec4324116">1.8</ix:nonNumeric> years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units &#8211; Service-Based and Performance-Based Awards</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we awarded performance-based awards to certain employees. The target level established by the award, which is based on the Company&#8217;s 2020 adjusted earnings before interest, taxes, depreciation and amortization (&#8220;Adjusted EBITDA&#8221;), provided for the recipients to receive an aggregate of <ix:nonFraction unitRef="shares" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="amed:Performancebasedawardtargetshareamount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg0MDg_35f2d1f8-e58a-4e43-a22c-17a8b8f19527">81,183</ix:nonFraction> non-vested stock units if the target was achieved. For a select group of employees, if the target objective is surpassed to the point of achieving the projected maximum payout, the recipients will receive an additional aggregate of <ix:nonFraction unitRef="shares" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="amed:AdditionalPerformanceBasedAwardTargetShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg2MzA_ee35d8af-da79-4c94-af65-2c3cb41c527d">11,633</ix:nonFraction> non-vested stock units during the three-month period ending March 31, 2021. The target number of shares to be potentially awarded has been reduced by forfeitures as indicated in the table below. Performance-based non-vested stock units compensation expense included in general and administrative expenses in our consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg5ODc_1f716e95-6edf-4dc0-9539-11ad263bc71d">13.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ief02df4838c5483f9c1fee131227eb29_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg5OTE_46140637-97f6-42ab-90e7-6722c08deacd">8.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i085cfa11bc6843488c86ab3d0a3da2ad_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg5OTg_974d9a93-69af-4534-988c-bd82c1b2d911">5.8</ix:nonFraction> million for 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0Njg_1b102beb-0835-4ab4-b5a9-76895c3a1227" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our performance-based non-vested stock units activity for 2020:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a62c2d5f8ed48a78a320ddb584e246f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzEtMS0xLTEtMA_eb355876-7e8e-436f-8f26-41e56dd3b2f1">207,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a62c2d5f8ed48a78a320ddb584e246f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzEtMy0xLTEtMA_28d2806f-eb77-4faa-befa-10b312df8912">97.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzItMS0xLTEtMA_867be5a5-bf86-49c5-a679-ff4f87b949eb">85,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzItMy0xLTEtMA_323161c5-6d3e-49ff-a79d-c6a8daac7f1d">201.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzMtMS0xLTEtMA_f83cf70c-33c5-484d-92bd-95a446c08a76">78,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzMtMy0xLTEtMA_c5918f4e-4450-4145-8366-8dd3241ee96a">83.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzQtMS0xLTEtMA_8855e889-fa51-4e29-9e85-47a4e26e5659">18,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzQtMy0xLTEtMA_6b33951f-ed4b-45aa-b581-49611f8e54e4">101.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i521c7c89279e4c0aa844c60ec36a5f59_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzUtMS0xLTEtMA_dddf0559-5c50-49c8-929e-61fe2ebede6a">196,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i521c7c89279e4c0aa844c60ec36a5f59_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzUtMy0xLTEtMA_fc3b6a18-dc50-4564-b438-7ff2b84c089d">148.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of performance-based non-vested stock units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzkyMjY_592408a0-5140-4fa6-92d3-3d40c17c62e8">201.90</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ief02df4838c5483f9c1fee131227eb29_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzkyMzA_70b91f3d-869e-41f6-94ac-ecd3e2f7b020">128.89</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i085cfa11bc6843488c86ab3d0a3da2ad_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzkyMzc_fa9a8732-12af-4750-bf8d-e1f2e508e0f4">79.59</ix:nonFraction> in 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i521c7c89279e4c0aa844c60ec36a5f59_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzkyODk_76fdac73-daee-4313-8a83-9d9864fe35e1">17.3</ix:nonFraction> million in unrecognized compensation costs related to our performance-based non-vested stock units that we expect to be recognized over a weighted average period of <ix:nonNumeric contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0NDk_c6a7316d-67a0-4857-9357-df119874831a">1.8</ix:nonNumeric> years.</span></div></ix:continuation><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE3Mzg1_21dc1098-5ed8-4cb8-8f7d-42350b23b5ff" continuedAt="i34da10103ae34774ac358d1d490b7a6e" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i34da10103ae34774ac358d1d490b7a6e" continuedAt="i3cc51c425e1e4a8c934d4087c541942f"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings &#8211; Ongoing</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in the following legal actions:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#8220;Subpoena&#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding <ix:nonFraction unitRef="patient" contextRef="i1560d4e370f847fb92bf3948fe2bd932_D20150521-20150521" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzM3Ng_05b9eed9-f579-4a13-8e77-6e8b73206f55">53</ix:nonFraction> identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May 21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a civil investigative demand (&#8220;CID&#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i3cc51c425e1e4a8c934d4087c541942f" continuedAt="ib1543e5575374d8fbc98f7d75ac92554"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attorney&#8217;s Office for the Northern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="i3ce9e524eb0543eeae2df4f429cd9905_D20151103-20151103" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEyNDM_24e2acbf-6fdc-4551-bdaf-83550e104e90">66</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August&#160;31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="i07641836ad0d4665b300523692960b1f_D20160627-20160627" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE5Njk_73aa4039-bff6-4ce9-8bf2-d7434b018580">68</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of $<ix:nonFraction unitRef="usd" contextRef="iaf11c6ccfd794c169a08d89e5cd17b31_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzI0NzM_de630b2d-8ff4-4678-a0ba-f464d98c58bd">6.5</ix:nonFraction> million to accrued expenses in our consolidated balance sheets related to this matter. Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investigative Matters &#8211; Completed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Integrity Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2020, the Company received notice from the Office of Inspector General-HHS ("OIG") that the Company's five-year corporate integrity agreement ("CIA") with the OIG has been completed. On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a CIA with the OIG. The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization ("IRO") to perform certain audits and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically required that we report substantial overpayments that we discovered we had received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of <ix:nonNumeric contextRef="id92e1c7184a7449e846c859caeab4fbe_D20140423-20140423" format="ixt-sec:durwordsen" name="amed:CorporateIntegrityAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzc0NDM_a6ff3195-24f2-4e00-af9f-7c652f2c638b">five years</ix:nonNumeric> that ended on April 21, 2019. We filed our final annual report on July 19, 2019. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compassionate Care Hospice Corporate Integrity Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company received notice from the OIG that the Company's five-year CIA with the OIG has been completed. On January 30, 2015, CCH entered into a CIA with the OIG. The CIA required that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an IRO to complete claims review for hospice services rendered in New York. The OIG waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA required that CCH report substantial overpayments that CCH discovered it received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could have become liable for payment of certain stipulated penalties, or could have been excluded from participation in federal health care programs. The CIA had a term of <ix:nonNumeric contextRef="if492da41859849a18fe046b7f1da314e_D20150130-20150130" format="ixt-sec:durwordsen" name="amed:CorporateIntegrityAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTk1MTE2NTUyNTk_104a89c2-8557-42de-bcdf-7df1a5616911">five years</ix:nonNumeric> that ended on January 30, 2020. We filed our final annual report on March 25, 2020. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="ib1543e5575374d8fbc98f7d75ac92554" continuedAt="i77e0934d0f1f41df8b7ed8284b21d390"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits &#8211; Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;) and Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of <ix:nonFraction unitRef="beneficiary" contextRef="if3e4bf70e5d9479ebc20d004efd4f9e8_D20080101-20100331" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzk2NDI_edff2505-dedc-44b4-97e7-cd2ca2a012ba">30</ix:nonFraction> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for <ix:nonFraction unitRef="beneficiary" contextRef="ib7b09ab0a49d4b838fe8db28575066f2_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwMDg2_72bce81e-74c6-4d2a-9de0-a107f9b64741">16</ix:nonFraction> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor ("MAC") for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $<ix:nonFraction unitRef="usd" contextRef="i92498864eda34c97bf3f44b5a1827b5b_I20160118" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwODg5_3b8e08e9-f314-42a8-aa25-0df6fab052e2">3.7</ix:nonFraction> million with a balance owed of $<ix:nonFraction unitRef="usd" contextRef="i92498864eda34c97bf3f44b5a1827b5b_I20160118" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTE1_4d249208-083b-4339-b616-c282f98e1eb2">5.6</ix:nonFraction> million including interest based on <ix:nonFraction unitRef="claim" contextRef="i44e23098929046f7af1cfe828afaec85_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTQ2_dc2a9a79-5fea-4d30-8af2-fe99afdfda34">9</ix:nonFraction> disputed claims (originally <ix:nonFraction unitRef="beneficiary" contextRef="ib7b09ab0a49d4b838fe8db28575066f2_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTc3_72bce81e-74c6-4d2a-9de0-a107f9b64741">16</ix:nonFraction>). We filed an appeal to the Medicare Appeals Council on the remaining <ix:nonFraction unitRef="claim" contextRef="i44e23098929046f7af1cfe828afaec85_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzExMDUw_dc2a9a79-5fea-4d30-8af2-fe99afdfda34">9</ix:nonFraction> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of December 31, 2020, Medicare has withheld payments of $<ix:nonFraction unitRef="usd" contextRef="ib02eb19f870b48a0ac524cc591131f73_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzExMzEw_edec69e5-b01e-4859-9e12-60055652dbb6">5.7</ix:nonFraction> million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $<ix:nonFraction unitRef="usd" contextRef="i8979ada06f974ae48d397f54b6e49eda_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzExODE1_97003f80-217a-4fe9-a62b-f4665f489352"><ix:nonFraction unitRef="usd" contextRef="i80891250852448afbff7aef1c0666a33_I20190110" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzExODE1_c5dc920e-1ce1-467b-9978-74459401ac45">2.8</ix:nonFraction></ix:nonFraction> million. This amount is recorded as an indemnity receivable within other assets in our consolidated balance sheets.</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC (&#8220;Palmetto&#8221;) regarding Infinity Home Care of Lakeland, LLC, (&#8220;Lakeland Care Centers&#8221;) and Infinity Home Care of Pinellas, LLC, (&#8220;Clearwater Care Center&#8221;). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $<ix:nonFraction unitRef="usd" contextRef="i93b988a539e7458e9ebc3dfab2f46a43_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEyOTMw_ad586e04-0edb-4433-8069-ac98e8a5e902">34.0</ix:nonFraction> million for the Lakeland Care Centers on a universe of <ix:nonFraction unitRef="claim" contextRef="i1c5fc041d76e49a5983d00e207829170_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEyOTgw_84a200fd-a4b6-4b11-b94a-6aa2a3597df9">72</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="i93b988a539e7458e9ebc3dfab2f46a43_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:ActualClaimsPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMDA4_e9d2ef33-1932-4661-8e51-7e6f16c7d40f">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="i93b988a539e7458e9ebc3dfab2f46a43_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMDQ1_f50f80ce-73be-4d81-b8dd-db56c5da5f6d">100</ix:nonFraction>% error rate and an overpayment of $<ix:nonFraction unitRef="usd" contextRef="ib558c962d6c04f40adef9ad76c074458_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMDgx_6e2f39cc-7d33-4671-a941-d47f9ffccf98">4.8</ix:nonFraction> million for the Clearwater Care Center on a universe of <ix:nonFraction unitRef="claim" contextRef="i5f99d4d9f475438a97dba13e3a83c516_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMTMy_2449cfe9-f4e5-4947-b83c-b01f4b6be39f">70</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="ib558c962d6c04f40adef9ad76c074458_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:ActualClaimsPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMTYw_ddfa5412-24d6-423e-ab49-d657e5b58861">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="ib558c962d6c04f40adef9ad76c074458_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMTk3_c1677725-e54c-4c22-a177-f88382199c47">100</ix:nonFraction>% error rate. </span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $<ix:nonFraction unitRef="usd" contextRef="icaa86f34e687461286bbecf374c1f96e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzNTYz_67f64aa2-3bae-41f4-9928-13e024ebfb9c">26.0</ix:nonFraction> million and the alleged overpayment for the Clearwater Care Center has been reduced to $<ix:nonFraction unitRef="usd" contextRef="i6f2f005315e5492bb8fec7e5757a7e04_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzNjQ1_01c6005b-8a24-4536-9621-9039e6b7ef1d">3.3</ix:nonFraction> million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $<ix:nonFraction unitRef="usd" contextRef="ie45f729caf77486a9faad14454801668_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0MDA0_2af15e6c-8193-49ae-a0f5-829c0fd71c90">12.6</ix:nonFraction> million.</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $<ix:nonFraction unitRef="usd" contextRef="i29dcf5be2ab240aa86b1d44b4274b48e_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0MjQ2_0d591e66-25f0-4991-97b4-474c57f848c2">6.5</ix:nonFraction> million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $<ix:nonFraction unitRef="usd" contextRef="ib20172f07d6649a2a8664caf1f015ef2_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0NDky_9d4711d7-e6d9-425c-b711-9b11cc826f43">38.8</ix:nonFraction> million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which $<ix:nonFraction unitRef="usd" contextRef="ie45f729caf77486a9faad14454801668_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTk1MTE2NTYwNTY_e847815d-b8b9-4eec-afb9-a4d7b435449b">12.6</ix:nonFraction>&#160;million is subject to indemnification by the prior owners) to $<ix:nonFraction unitRef="usd" contextRef="i76464f5a074a42fc86111f27060e6a56_I20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0Njg5_8f356c01-62de-45c5-a070-942c9c036792">29.3</ix:nonFraction> million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="padding-left:2.25pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we have an accrued liability of approximately $<ix:nonFraction unitRef="usd" contextRef="if2b9a36901674eb9a302469e2cac8ab9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0ODc1_0d110874-254c-4907-9acc-7736c8a99959">17.4</ix:nonFraction> million related to this matter. We expect to be indemnified by the prior owners for approximately $<ix:nonFraction unitRef="usd" contextRef="if2b9a36901674eb9a302469e2cac8ab9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0OTY4_fd80f018-11db-47d9-b8dd-7943031c3794">10.9</ix:nonFraction> million of the total $<ix:nonFraction unitRef="usd" contextRef="ie45f729caf77486a9faad14454801668_I20170831" decimals="-5" format="ixt:numdotdecimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0OTg0_a66fe5af-87e7-42ff-bd28-95150bac6d53">12.6</ix:nonFraction> million available indemnification related to this matter and have recorded this amount within other assets in our consolidated balance sheets. The net of these two amounts, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i77e0934d0f1f41df8b7ed8284b21d390"><div style="padding-left:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="icf602ed6544f4e14998550bd3bc16290_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="amed:FloridaZpicRevenueReduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE1MTc1_6844ec84-bc81-4f0e-959f-605e3215f81e">6.5</ix:nonFraction> million, was recorded as a reduction in revenue in our consolidated statements of operations during 2017. As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ie3800a96a7434d7f807e7946ac5ea7d4_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE1MzAx_97be63bf-149b-4eb7-b9b3-73467c137709">1.5</ix:nonFraction> million of net receivables have been impacted by this payment suspension.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="amed:InsuranceProgramsTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE3Mzg4_caed7550-fcb4-4873-8534-b89a72dfded0" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our insurance programs, including amounts accrued for the periods indicated (amounts in millions) in accrued expenses in our consolidated balance sheets. The amounts accrued below represent our total estimated liability for individual claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"></td><td style="width:67.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Insurance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:HealthInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzItMS0xLTEtMA_81daad69-fce8-449a-a5b5-c65b89def725">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:HealthInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzItMy0xLTEtMA_9be861c7-4776-45cb-8189-a467987050fe">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:WokersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzMtMS0xLTEtMA_0db5bd8d-2ec3-4c05-9fa3-e5d8471763db">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:WokersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzMtMy0xLTEtMA_9d5935c5-c9e8-438a-b396-348e89dddf16">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:ProfessionalLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzQtMS0xLTEtMA_effafab5-da11-42a9-b056-ac357db5473a">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:ProfessionalLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzQtMy0xLTEtMA_40c83572-9145-4f70-9660-abfc892a8bcd">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:EstimatedInsuranceTotal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzUtMS0xLTEtMA_5305d8eb-7a7c-4313-8d81-baea5cea292c">55.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:EstimatedInsuranceTotal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzUtMy0xLTEtMA_5a164659-21e3-4e85-83f4-6f27caf2855f">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:EstimatedInsuranceLongTermPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzYtMS0xLTEtMA_f0e72bbb-2354-43c6-a6d2-010993ac0a97">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:EstimatedInsuranceLongTermPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzYtMy0xLTEtMA_fc4c7964-d3e7-4ba8-b332-851e791aad78">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:EstimatedInsuranceExcludingLongTermPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzctMS0xLTEtMA_1ba99c84-aaf4-4efb-9c8e-50e89c5f3a68">54.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:EstimatedInsuranceExcludingLongTermPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzctMy0xLTEtMA_ff07e7fb-f5ab-4c3d-b628-958a136404a9">53.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:HealthInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE2NTQz_44bed404-822b-44c1-86ba-6bbeeb0e5741">1.3</ix:nonFraction> million for any individual covered life. Our workers compensation insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:WorkersCompensationInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE2NjM5_789ae7f7-ba6a-4545-b57c-0e7afd137d7b">1.0</ix:nonFraction> million per incident and our professional liability insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="amed:ProfessionalLiabilityInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE2NzIx_c668516b-3b5e-473a-ba89-a07d8ee2c54d">0.3</ix:nonFraction> million per incident. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments related to our severance plans applicable to a number of our senior executives and senior management, as well as the employment agreement entered into with our Chief Executive Officer, all of which generally commit us to pay severance benefits under certain circumstances.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations and cash flows.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_133"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzE1Nzc_76bc12b8-d2ef-45a6-8a35-aebd554b2f84" continuedAt="i18192febd2d249afa7ac079bf673133b" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i18192febd2d249afa7ac079bf673133b" continuedAt="i991b96367e0e4409a54c316a489284ec"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Benefit Plan</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have reached 21 years of age, effective the first month after their hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue Service limits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our match of contributions to be made to each eligible employee contribution is $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:DefinedContributionPlanEmployerMatchingContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzQ2NA_64428aea-ffa2-4308-8caa-bb3cc8aff8b7">0.44</ix:nonFraction> for every $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzQ3Nw_884b58f4-a465-49e5-bdd2-6378a7c0d40f">1.00</ix:nonFraction> contributed up to the first <ix:nonFraction unitRef="number" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" name="amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzUwOA_4cefc6d9-b81d-4f83-9073-0e74e2fdbc21">6</ix:nonFraction>% of their salary. The match is discretionary and thus is subject to change at the discretion of management. Effective January 1, 2020, our match of contributions is made in the form of cash. During 2019 and 2018, matching contributions were made in the form of our common stock, valued based upon the fair value of the stock as of the end of each calendar quarter end. We expensed approximately $<ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzc5Ng_f451b4c6-4ed3-49cc-b8b1-1b23c2fc6a72">12.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzgwMA_fc77592b-f9a5-40f9-a24d-8ee7b8780d11">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzgwNw_eb2abfb8-71b6-4130-a225-0b841c2c18df">9.0</ix:nonFraction> million related to our 401(k) benefit plan for 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="i991b96367e0e4409a54c316a489284ec"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a Deferred Compensation Plan for additional tax-deferred savings for a select group of management or highly compensated employees. Amounts credited under the Deferred Compensation Plan were funded into a rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus, the assets are not necessarily reflective of the same investment choices that would have been made by the participants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2015, all prospective salary deferrals ceased. Participants will be allowed to make transactions with any remaining account balances as they wish per plan guidelines.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzE1MDk_00bede27-c178-4e4c-9dbb-effff1b51b1b" continuedAt="i81932d6ecd5548ac9247edaafc758fe6" escape="true">SHARE REPURCHASES </ix:nonNumeric></span></div><ix:continuation id="i81932d6ecd5548ac9247edaafc758fe6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ic8e83cf1d9574cf69c223d04622768aa_I20201223" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEwOTk1MTE2MzAzMzE_2e4278e9-e130-4792-8122-d10c5dadcc4b">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="i982a73904c8843df8b8f14ae21909b06_D20201223-20201223" format="ixt:datemonthdayyearen" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEwOTk1MTE2MzAzNDU_728bfb6f-a742-4592-b270-4cef511e61c1">December 31, 2021</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not repurchase any shares pursuant to this stock repurchase program during the year ended December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we could have repurchased up to $<ix:nonFraction unitRef="usd" contextRef="ib40aceab8f864987a75d9c12fb66ae7e_I20190225" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzE5NQ_ee572709-d56e-4267-9bfe-bb9888a6d0ed">100</ix:nonFraction> million of our outstanding common stock through <ix:nonNumeric contextRef="ia0bafbf9ffa74adb9775ae8c65c96711_D20190225-20190225" format="ixt:datemonthdayyearen" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzIzOA_a2db83b4-a62d-4874-b811-7821afd124ac">March 1, 2020</ix:nonNumeric>. We did not repurchase any shares pursuant to this stock repurchase program during 2019 or 2020. The stock repurchase program expired on March 1, 2020.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Share Repurchase</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2018, we purchased <ix:nonFraction unitRef="shares" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEwMjk_d6dba318-2d28-4e83-95d9-b0cf1354c294">2,418,304</ix:nonFraction> of our common shares from affiliates of KKR Credit Advisors (US) LLC ("KKR"), representing one-half of KKR's then current holdings in the Company and <ix:nonFraction unitRef="number" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="3" name="amed:PercentageofSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzExODI_3ac9189d-84fb-4983-8ec6-5a4f25ad1dd8">7.1</ix:nonFraction>% of the aggregate outstanding shares of the Company's common stock for a total purchase price of $<ix:nonFraction unitRef="usd" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEyODE_7485dd0d-c9be-4516-9aa2-3a9b67f51347">181.4</ix:nonFraction> million including related direct costs. The Company repurchased the shares at $<ix:nonFraction unitRef="usdPerShare" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="2" name="amed:DiscountedClosingStockPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEzNTQ_b56ca63c-aa34-47f6-93da-63ece4250d42">73.96</ix:nonFraction> which represents <ix:nonFraction unitRef="number" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="2" name="amed:PercentageofClosingStockPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEzNzQ_53dd7e0b-c3b9-4502-898d-087268757028">96</ix:nonFraction>% of the closing stock price of the Company's common stock on June 4, 2018. The repurchased shares are classified as treasury shares.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90ZXh0cmVnaW9uOjA1NzY1YWRjOTcxNjRhNDk5Mjc4YTE1YjAxYmQ0MzIyXzEzNjY_c8b99050-507b-4366-b469-41fd8b5aa7c1" continuedAt="i15efa258f06b47a481cb242bb136bb9a" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i15efa258f06b47a481cb242bb136bb9a" continuedAt="iea099e777e82445bbdd6c03227912018"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our <ix:nonFraction unitRef="segment" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90ZXh0cmVnaW9uOjA1NzY1YWRjOTcxNjRhNDk5Mjc4YTE1YjAxYmQ0MzIyXzgz_90cd8d0a-735f-43f3-a331-21740023d2ef">three</ix:nonFraction> reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90ZXh0cmVnaW9uOjA1NzY1YWRjOTcxNjRhNDk5Mjc4YTE1YjAxYmQ0MzIyXzEzNjk_949fa479-ffef-48c7-9d80-ed8916bff361" continuedAt="ia68c9e8be3794e01b951859e6a8afaff" escape="true">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><ix:continuation id="iea099e777e82445bbdd6c03227912018"><ix:continuation id="ia68c9e8be3794e01b951859e6a8afaff"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItMS0xLTEtMA_4331cd87-d735-4ae5-ae10-ec6a0899de85">1,249.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItMy0xLTEtMA_c68ff4ad-7ee8-47cb-985e-bc1e81a88587">750.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItNS0xLTEtMA_17043b08-1df0-4c16-b727-cb2b75d12833">72.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItNy0xLTEtMA_3cf5ee60-aca6-48df-925e-29b2ce356730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItOS0xLTEtMA_986c6f76-1637-4654-a087-107f4f1ed97b">2,071.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtMS0xLTEtMTEzNw_5d86b5bc-61e9-4ddb-aa9e-370c815b722c">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtMy0xLTEtMTEzNw_be17a688-a18f-40da-b7ee-bcd6815a93cb">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtNS0xLTEtMTEzNw_07158f5c-1f86-4f5e-a074-848fb63ae89f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtNy0xLTEtMTEzNw_38745171-c2ff-4b27-8f21-c835233768f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtOS0xLTEtMTEzNw_ddf6ec45-3c25-4b87-8c76-c85c4e7f5a2a">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtMS0xLTEtMA_83ce0ff8-9ad6-48bf-92a7-b622d3dd09b9">729.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtMy0xLTEtMA_55a3a72e-458b-456d-a6e2-e727312fd538">400.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtNS0xLTEtMA_d57d7d9b-24f7-49d9-bcc6-8c8b861221de">54.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtNy0xLTEtMA_c66112bc-0f9c-49e3-a33b-30e50f82401e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtOS0xLTEtMA_3d9a06e4-769f-450c-ac4d-2d2035039d54">1,185.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtMS0xLTEtMA_59a1cc27-3de6-42cc-9fb7-76cf4084bba0">307.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtMy0xLTEtMA_9ae6b0cd-a605-43f4-be42-4ddb7c82a174">175.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtNS0xLTEtMA_36517e02-37b5-4006-8414-4f9952f61211">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtNy0xLTEtMA_b22942a0-85ac-468c-84f9-b161c830beea">173.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtOS0xLTEtMA_e154a2b3-ea67-425e-9b6d-ab6e32875a4b">668.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtMS0xLTEtMA_4b705f64-5803-4892-96c5-26905b869123">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtMy0xLTEtMA_ed6d9cad-45d1-4a2c-9046-7510e03d655f">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtNS0xLTEtMA_63143ad9-52cd-4645-a4e5-b68d21e2202c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtNy0xLTEtMA_f7ef7b0a-651e-45f8-813f-03f5c2205d59">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtOS0xLTEtMA_fa1ca64d-15ab-4f5d-b0b0-93ac26997944">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctMS0xLTEtMzY1NQ_4597160b-c9f5-41c0-8f90-7797eae833b8">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctMy0xLTEtMzY1NQ_8584edae-efbb-465f-857a-8623e9060257">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctNS0xLTEtMzY1NQ_240699ff-0f9e-474a-8284-7f4b1d5fb4a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctNy0xLTEtMzY1NQ_96dee905-371f-4bf6-82b7-82f93870320e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctOS0xLTEtMzY1NQ_2f5f27d0-0b20-48b4-898a-ffb2e3df6ab0">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctMS0xLTEtMA_d300db32-883f-49f0-918c-cc3a38f31dfc">1,044.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctMy0xLTEtMA_909026d4-ae61-44f7-9d96-9ec34dad021b">579.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctNS0xLTEtMA_b31c0b81-d533-4e1d-9698-560032437b28">67.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctNy0xLTEtMA_f5420047-a201-4d0c-aea0-04d3a7376fb4">195.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctOS0xLTEtMA_a2b32bb1-17f0-4169-bea7-831299200f56">1,886.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtMS0xLTEtMA_a0b4813a-10c2-430b-b5fe-6ffe26cebc20">225.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtMy0xLTEtMA_9884b605-4626-40c8-8800-44def60d15b6">184.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtNS0xLTEtMA_174c2e22-f473-4ccc-a916-2d00f036ec68">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtNy0xLTEtMA_52f63433-bb42-46d4-b4af-9cfdeab58ced">195.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtOS0xLTEtMA_9e4931b1-bd7f-4c2d-afcc-3d5f561ae28e">219.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItMS0xLTEtMA_baa588a0-d597-43cd-8fe9-9ff35e3827e5">1,256.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItMy0xLTEtMA_f730a312-25cc-41c0-aa82-2315fa4684ab">617.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItNS0xLTEtMA_3170ab31-ed87-4111-a6f5-3605901a830d">82.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItNy0xLTEtMA_c71927ab-d49e-4d8a-a6df-9217358105b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItOS0xLTEtMA_b86cbc4a-37c7-46c2-a5f5-d563b2f4f2cf">1,955.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtMS0xLTEtMA_4164188d-8d75-436e-adc5-97a24d5809f0">754.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtMy0xLTEtMA_cb6608d7-7f6b-4dbc-b50b-fda6288c1e0d">335.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtNS0xLTEtMA_bc3a859e-502a-4e26-8ff6-4679e1e9bf0e">61.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtNy0xLTEtMA_4dfa08f0-b2ec-40eb-ad1b-db3ba50b53df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtOS0xLTEtMA_d8c8125c-d18c-4786-b52d-98f8a9fefbc6">1,150.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtMS0xLTEtMA_bac91c9c-675c-4f57-b565-903316309a36">297.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtMy0xLTEtMA_f6901840-056e-4001-9df0-e78350f57fed">137.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtNS0xLTEtMA_22b8ff5f-3a99-48dc-9eb3-a4d11d2ada79">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtNy0xLTEtMA_a40b9d37-7c2d-43a0-9c05-4315ec97af2f">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtOS0xLTEtMA_fcb9f16c-a3c0-49d0-92b3-e48f91855641">607.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtMS0xLTEtMA_161f9cf1-43b6-4647-905c-ef04f56b91fc">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtMy0xLTEtMA_3bdf65e5-532e-4d1f-a9ed-6ddd4ebacdfb">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtNS0xLTEtMA_00b528dc-8df4-434f-aa40-4fe0bd4f38c9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtNy0xLTEtMA_6df8be40-bc2b-454e-8dc0-bf4f9ecd4bcd">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtOS0xLTEtMA_3c378277-e212-4e5e-9646-582321137465">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtMS0xLTEtMTE0MA_d017406f-35cf-4de4-9873-d5033bebcf56">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtMy0xLTEtMTE0MA_70bc0cbc-57ff-4e47-8946-f93aa5de7696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtNS0xLTEtMTE0MA_e85e2035-55b6-489a-b6c9-02682df70237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtNy0xLTEtMTE0MA_3db8b369-4082-4b72-980f-828b5d4d7067">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtOS0xLTEtMTE0MA_3e2044aa-fde1-4d17-abce-a2bdf3f7bce4">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtMS0xLTEtMA_56b4d348-3461-40fe-9b78-33c2c325dac4">1,057.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtMy0xLTEtMA_55e0a94b-667a-4743-a794-7ea2a51403d4">474.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtNS0xLTEtMA_3bcd449d-815b-4ba4-a6b7-928d190b09ad">73.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtNy0xLTEtMA_247f0f89-4e95-4117-a970-7156fe6905c1">173.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,778.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctMS0xLTEtMA_4ead53c0-01f8-4af2-8d6c-61ebc0cb6093">199.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctMy0xLTEtMA_6e6bc946-a963-4685-bc39-479f4a292588">143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctNS0xLTEtMA_8c4862bb-fa9f-468f-a3f1-0c5a15bac546">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctNy0xLTEtMA_c10aebaf-615f-4f06-ae74-34289951ccd4">173.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctOS0xLTEtMA_c0fdc86e-2080-4dc0-8f9d-29517103ed08">177.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItMS0xLTEtMA_10dd4a1a-a247-4fb9-8478-0b657f532799">1,174.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItMy0xLTEtMA_8692af2b-e664-47a8-88ff-1a438f4b93a9">410.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItNS0xLTEtMA_8596a543-4520-4361-8aa1-bd0430baf335">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItNy0xLTEtMA_591eeb7a-2848-4793-b15e-34b00130bc1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItOS0xLTEtMA_b0146d63-fba0-42cf-8be4-8168818859e0">1,662.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtMS0xLTEtMA_e2009510-d459-49a1-a1e5-f5a552849491">722.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtMy0xLTEtMA_443909fe-b679-473b-8442-080181cde40c">212.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtNS0xLTEtMA_6e806810-fec7-41f4-884f-70eadc7bb242">58.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtNy0xLTEtMA_ede6ff85-f3d6-4c2b-92b3-52bd98ec64b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtOS0xLTEtMA_12fe898c-2ed8-42fe-a366-8de95d023755">992.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtMS0xLTEtMA_2edbe0ad-6ad2-4029-93ab-c7ee58eeef88">276.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtMy0xLTEtMA_f78b7129-835f-4075-8e3e-76611608a79c">84.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtNS0xLTEtMA_efcbd43c-db4b-40ed-bbc7-02db5479a9be">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtNy0xLTEtMA_da8a8b75-3a5c-4ba5-af3b-176371c00d61">127.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtOS0xLTEtMA_679e6aa9-4fa1-41d1-914d-fa1bacc0a39a">501.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtMS0xLTEtMA_710e527b-7535-4033-906a-847fe44be75a">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtMy0xLTEtMA_f41b03aa-2367-41cf-a733-964a9c724d8f">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtNS0xLTEtMA_733c301a-50da-45e5-9c28-1379feca5274">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtNy0xLTEtMA_a4a31460-ec78-463c-b804-79bdc10d0454">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtOS0xLTEtMA_8c3e23f3-d6ef-4e91-91c6-83b40ec5d2a1">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzgtMS0xLTEtMA_2f17d413-1dc4-46a9-a562-341adf53d002">1,001.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzgtMy0xLTEtMA_86a7fecc-5732-435f-b405-bbd5e57e276b">297.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzgtNS0xLTEtMA_9b2b00d6-7d80-4696-b794-17f190814031">71.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzgtNy0xLTEtMA_a4924e36-2c92-4bb0-94a4-8dcc81ca7856">136.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,507.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktMS0xLTEtMA_114653d9-29aa-4ba6-996c-7a98efd1723e">172.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktMy0xLTEtMA_288f3960-b279-42f7-a743-66aeb22f5eda">113.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktNS0xLTEtMA_11532ca5-a669-486d-92b3-d935d809321b">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktNy0xLTEtMA_19a80687-2501-4cd7-9361-ab048f774510">136.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktOS0xLTEtMA_d61e2683-85b5-418a-9634-54e40eefda68">155.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_157"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90ZXh0cmVnaW9uOmRjMjRhY2ZjMTI5YjRiNmQ4MGUwMTg5N2NkMmUxNjg4XzIzOA_e6b10f3d-6736-4521-8f3e-57f558c60209" continuedAt="i024259b90c3f424da9345b57c44c1e2b" escape="true">UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i024259b90c3f424da9345b57c44c1e2b"><ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90ZXh0cmVnaW9uOmRjMjRhY2ZjMTI5YjRiNmQ4MGUwMTg5N2NkMmUxNjg4XzIzMw_0b064104-ca11-40a5-94d7-f7de442ce79a" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Income<br/>Attributable to<br/>Amedisys, Inc.<br/>Common<br/>Stockholders&#160;(1)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Service Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Income<br/>Attributable to<br/>Amedisys, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1st Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzMtMS0xLTEtMA_fcd49d42-a416-47f2-9fd3-3da647f48d1b">491.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzMtMy0xLTEtMA_0942f24e-2d8f-4d54-b456-5be944777ec0">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzMtNS0xLTEtMA_80c7d5bf-049e-4269-9bb3-2259a1c45c26">0.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzMtNy0xLTEtMA_899a4aa4-69aa-4e48-9906-bc96239a7f86">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2nd Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzQtMS0xLTEtMA_2009fe09-efae-4d38-bf54-609229869323">485.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzQtMy0xLTEtMA_d70d0a35-3b5c-4e8c-af55-c19bcd9a6617">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzQtNS0xLTEtMA_4f7f5e4a-cb38-4205-91f8-f9f51a0d8d57">1.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzQtNy0xLTEtMA_9bd4d940-cf5f-4535-8a18-5381636f37fc">1.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3rd Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzUtMS0xLTEtMA_a6183644-9bce-40a5-8d21-b7f8466e194e">544.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzUtMy0xLTEtMA_c2aa963e-4e99-444a-b3f3-1b80094e9853">72.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzUtNS0xLTEtMA_2a178df1-05de-4430-95b2-9e1cd3643226">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzUtNy0xLTEtMA_af307368-6fac-45c0-a9ce-513ddf1fe243">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4th Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzYtMS0xLTEtMA_08292c5c-0aa9-4fc8-94c4-5ed47448c7d9">550.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzYtMy0xLTEtMA_f9ac343d-573f-41d6-98da-792eefec1d31">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzYtNS0xLTEtMA_5544b3c8-2fe8-4a92-a3c8-41b18b948659">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzYtNy0xLTEtMA_53c12b57-f86a-4d0d-8aac-7521a5bb9e3c">1.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzctMS0xLTEtMA_69748d08-d3bf-475d-80e2-b68081fc15ed">2,071.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzctMy0xLTEtMA_460b3c46-eb63-4959-9063-b14931b6565f">183.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzctNS0xLTEtMA_1fdae015-1603-4086-ba7f-68b03012a6e7">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzctNy0xLTEtMA_8ac4de69-919e-4589-870e-b147203f30fd">5.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1st Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzktMS0xLTEtMA_320212ee-53c4-4c35-9442-bb8aaf04b2bb">467.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzktMy0xLTEtMA_c06da9f0-70fe-43dd-9237-6890b30b2bff">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzktNS0xLTEtMA_fc91b041-61e2-41fc-be10-c5f33530ae18">0.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzktNy0xLTEtMA_58d861d6-a7b9-432e-bb1b-b6cbcbd101e9">0.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2nd Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEwLTEtMS0xLTA_2b4a2e17-b199-4866-81fc-31e5445a6db3">493.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEwLTMtMS0xLTA_3d3c18fa-f45a-4587-a249-8d541cd2d861">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEwLTUtMS0xLTA_f92c4670-5614-43ee-bb2f-46be707c38b6">1.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEwLTctMS0xLTA_26e94136-1b0f-4171-ab9e-ae23757b9ddb">1.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3rd Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzExLTEtMS0xLTA_b04307e2-89ae-433e-8f82-7de0498bbfe9">494.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzExLTMtMS0xLTA_36b0ed19-3eb2-4ead-bcef-83c757c51285">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzExLTUtMS0xLTA_6a60eb31-20bd-4c67-a84d-cf38c52281e5">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzExLTctMS0xLTA_a25b6a0b-1e38-4ff5-9fb5-4a271c3cdf02">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4th Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEyLTEtMS0xLTA_9e53112b-a080-4cd6-9180-6e3b9d776e45">500.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEyLTMtMS0xLTA_5ba3baf9-39c5-4398-b5c4-580a223f80f4">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEyLTUtMS0xLTA_e4fc7781-6b7f-440b-9c1a-d983592d4d0f">0.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEyLTctMS0xLTA_b3c44e60-86a9-49ac-be6b-3777cf679344">0.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEzLTEtMS0xLTA_23c1e2a2-b9fb-4798-8232-c1f8c89b0341">1,955.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEzLTMtMS0xLTA_c0e11fb6-7747-45b4-b1b0-b6862061490f">126.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEzLTUtMS0xLTA_3cb006ca-3dc5-4489-b4ab-53ad40072032">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEzLTctMS0xLTA_e4f1762d-c3ec-4b91-9814-a5961a6ed99c">3.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="id92bd70d620044018083957a908405c4_160"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020</span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;<ix:nonNumeric contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzEwNDE_98c142fb-710e-42eb-9daa-cdf2db26f115" continuedAt="i7cb7264f085b42dbb550c919752c350f" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="i7cb7264f085b42dbb550c919752c350f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we made a $<ix:nonFraction unitRef="usd" contextRef="ib96bea9253ac4d8d90b0d2f79b7e9bb6_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzU5_05a1996e-1382-437f-9859-6f7b7e062538">7.0</ix:nonFraction> million investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the years ended December 31, 2020 and 2019, we incurred costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i1d01c191f7b94742a8aedf3242104b2b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzEwOTk1MTE2Mjg5MDE_c4556014-8d11-4f63-989a-082ccb429edf">3.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6ce2a100b9be4e04b1c79c526dd5afe1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzI3Mw_06666703-ef19-40d8-b2b7-6b8894a1724a">0.5</ix:nonFraction> million, respectively, in connection with the usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm&#8217;s length.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2018, we purchased <ix:nonFraction unitRef="shares" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzQ3Mw_d6dba318-2d28-4e83-95d9-b0cf1354c294">2,418,304</ix:nonFraction> of our common shares from affiliates of KKR, representing one-half of KKR's holdings in the Company and <ix:nonFraction unitRef="number" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="3" name="amed:PercentageofSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzU4MA_3ac9189d-84fb-4983-8ec6-5a4f25ad1dd8">7.1</ix:nonFraction>% of the aggregate outstanding shares of the Company's common stock for a total purchase price of $<ix:nonFraction unitRef="usd" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzY3OQ_7485dd0d-c9be-4516-9aa2-3a9b67f51347">181.4</ix:nonFraction> million including related direct costs. The Company repurchased the shares at $<ix:nonFraction unitRef="usdPerShare" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="2" name="amed:DiscountedClosingStockPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4Xzc1Mg_b56ca63c-aa34-47f6-93da-63ece4250d42">73.96</ix:nonFraction> which represents <ix:nonFraction unitRef="number" contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604" decimals="2" name="amed:PercentageofClosingStockPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4Xzc3Mg_53dd7e0b-c3b9-4502-898d-087268757028">96</ix:nonFraction>% of the closing stock price of the Company's common stock on June 4, 2018. At the time of the transaction, KKR held approximately <ix:nonFraction unitRef="number" contextRef="i562b1925a10f47859b8528d0316b1f34_D20180604-20180604" decimals="3" name="amed:PercentageofSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzkwNA_ec1d2db0-f482-44f9-abc3-95dc4db48eab">14.2</ix:nonFraction>% of the Company's outstanding shares of common stock.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="id92bd70d620044018083957a908405c4_169"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC&#8217;s rules and forms. This information is also accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of this Annual Report on Form 10-K, as of December&#160;31, 2020, under the supervision and with the participation of our principal executive officer and principal financial officer, our management conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of December&#160;31, 2020, the end of the period covered by this Annual Report on Form 10-K.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Under the supervision and with the participation of our principal executive officer and our principal financial officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation under the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our management concluded our internal control over financial reporting was effective as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under guidelines established by the SEC, companies are allowed to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company. Accordingly, our assessment of internal controls excluded our acquisition of AseraCare Hospice ("AseraCare"), completed on June 1, 2020. See Item 8, Note 4 - Acquisitions to our consolidated financial statements for additional information on our acquisition of AseraCare. Operations from this acquisition represented approximately 3% of total assets and 3% of total revenue as of and for the year ended December 31, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KPMG LLP, the independent registered public accounting firm that audited our consolidated financial statements included in this Form 10-K, has issued a report on our internal control over financial reporting, which is included herein.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#8217; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of December 31, 2020, the end of the period covered by this Annual Report.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc.:</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Amedisys, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements), and our report dated February 25, 2021 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired Homecare Preferred Hospice, Inc., doing business as AseraCare Hospice during 2020, and management excluded from its assessment of the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2020, Homecare Preferred Hospice, Inc., doing business as AseraCare Hospice&#8217;s internal control over financial reporting associated with 3% of total assets and 3% of total revenues included in the consolidated financial statements of the Company as of and for the year ended December 31, 2020. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Homecare Preferred Hospice, Inc., doing business as AseraCare Hospice.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baton Rouge, Louisiana</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="id92bd70d620044018083957a908405c4_175"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B. OTHER INFORMATION</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id92bd70d620044018083957a908405c4_178"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:center"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2021 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2020.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct and Ethics</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. This code of ethics, which is entitled Code of Ethical Business Conduct, is posted at our internet website, http://www.amedisys.com. Any amendments to, or waivers of, the code of ethics will be disclosed on our website promptly following the date of such amendment or waiver.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11. EXECUTIVE COMPENSATION</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2021 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2021 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2021 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2021 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2020.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="id92bd70d620044018083957a908405c4_196"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:center"><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All financial statements are set forth under Part II, Item 8 of this report.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statement Schedules</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no financial statement schedules included in this report as they are either not applicable or included in the financial statements.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Exhibits are listed in the Exhibit Index required by Item&#160;601 of Regulation&#160;S-K preceding the signature page of this report.</span></td></tr></table></div><div><span><br/></span></div><div id="id92bd70d620044018083957a908405c4_202"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16. FORM 10-K SUMMARY</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="id92bd70d620044018083957a908405c4_205"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits marked with the cross symbol (&#8224;) are filed and the exhibits marked with a double cross (&#8224;&#8224;) are furnished with this Form 10-K. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item&#160;601(b)(10)(iii) of Regulation S-K. The registrant agrees to furnish to the Commission supplementally upon request a copy of any schedules or exhibits omitted pursuant to Item&#160;601(a)(5) of Regulation S-K of any exhibit set forth below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312516577422/d173200dex21.htm">Equity Purchase Agreement dated February 5, 2016, by and between the Company, as Purchaser, and Michael Trigilio, as Seller</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626218000008/amed-20183006xexx101.htm">First Amendment to Equity Purchase Agreement, dated May 18, 2018, by and among the Company, Amedisys Personal Care, LLC, Associated Home Care, LLC, Elder Home Options, LLC and Michael Trigilio</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518183451/d600655dex21.htm">Share Repurchase Agreement, dated as of June 4, 2018, by and among the Company and the selling stockholders set forth on Schedule I thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's current Report on Form 8-K filed on June 4, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626218000010/amed-20183009xexx21.htm">Stock Purchase Agreement, dated as of October 9, 2018, by and among Milton Heching, the Heching 2012 Exempt Irrevocable Trust, Amedisys Hospice, L.L.C., Compassionate Care Hospice Group, Inc., and solely for purposes of Sections 3.4, 4.3(a), 4.15 and Article VIII thereof, Amedisys, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312520119950/d882548dex21.htm">Securities Purchase Agreement, dated as of April 23, 2020, by and between Amedisys Hospice, L.L.C. and Golden Gate Ancillary LLC (Immaterial schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Current Report on Form 8-K filed on April 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507166703/dex31.htm">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&#160;14, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000014/amed-20193009xexx32.htm">Composite of By-Laws of the Company inclusive of all amendments through October 17, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507186003/dex48.htm">Common Stock Specimen</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Registration Statement on Form S-3 filed August&#160;20, 2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-145582</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626220000006/a201910-kexhibit42.htm">Description of Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312509031143/dex101.htm">Form of Director Indemnification Agreement dated February&#160;12, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2008</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312512264590/d366568dex101.htm">Amended and Restated Amedisys, Inc. Employee Stock Purchase Plan dated June&#160;7, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed June&#160;8, 2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626220000006/a201910-kexhibit103.htm">Composite Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan (inclusive of Plan amendments dated June&#160;7, 2012, October&#160;25, 2012, April&#160;23, 2015 and June&#160;4, 2015, January&#160;20, 2017,  February&#160;22, 2017 and September 25, 2018 and the full text of the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312508160163/dex103.htm">Form of Nonvested Stock Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2008</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312508160163/dex104.htm">Form of Restricted Stock Unit Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2008</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312515076564/d861886dex106.htm">Form of Stock Option Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312515076564/d861886dex107.htm">Form of Performance Stock Option Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312515076564/d861886dex108.htm">Form of Restricted Stock Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312515076564/d861886dex109.htm">Form of Restricted Performance Stock Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000004/a201810-kexhibit1010.htm">Form of Stock Option Award Agreement Issued under the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000004/a201810-kexhibit1011.htm">Form of Restricted Stock Unit Award Agreement Issued under the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000004/a201810-kexhibit1012.htm">Form of Performance Restricted Stock Unit Award Agreement Issued under the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518292066/d624008dex101.htm">Amended and Restated Employment Agreement dated as of September 27, 2018,  by and  among Amedisys, Inc., Amedisys Holding, L.L.C. and Paul B. Kusserow</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on October 3, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000014/amed-20193009xexx101.htm">Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Executive Officers dated as of July 25, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626218000005/amed-20183103xexx101.htm">Confidential Separation Agreement and General Release between the Company and Stephen E. Seim</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202010-kexhibit1016.htm">Composite Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (inclusive of Plan amendments dated September 25, 2018 and October 21, 2020 and the full text of the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518210472/d676917dex101.htm">Amended and Restated Credit Agreement dated as of June 29, 2018, among the Company and Amedisys Holding, L.L.C., as borrowers, certain subsidiaries of the Company party thereto as guarantors, Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, JPMorgan Chase Bank, N.A., as Syndication Agent, Capital One Bank National Association, Citizens Bank, N.A., Compass Bank, Fifth Third Bank, Hancock Whitney Bank, Regions Bank, and Wells Fargo Bank, National Association, as Co-Documentation Agents, the lenders party thereto, Merrill Lynch, Pierce Fenner&#160;&amp; Smith Incorporated, Citizens Bank N.A., Fifth Third Bank and JPMorgan Chase Bank, N.A., as Joint Lead Arrangers, and Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated and JPMorgan Chase Bank, N.A., as Joint Bookrunners</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s current Report on Form 8-K filed on July 2, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518210472/d676917dex102.htm">Amended and Restated Security Agreement, dated as of June 29, 2018, among the Company and Amedisys Holding, L.L.C., as borrowers, certain other parties identified as &#8220;grantors&#8221; on the signature pages thereto and Bank of America, N.A., in its capacity as Administrative Agent</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s current Report on Form 8-K filed on July 2, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518210472/d676917dex103.htm">Amended and Restated Pledge Agreement dated as of June 29, 2018, among the Company and Amedisys Holding, L.L.C., as borrowers, certain other parties identified as &#8220;pledgors&#8221; on the signature pages thereto, and Bank of America, N.A., in its capacity as Administrative Agent</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s current Report on Form 8-K filed on July 2, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312516498856/d38348dex1027.htm">Agreement and Plan of Merger dated October&#160;31, 2015 by and among Amedisys Health Care West, L.L.C., IHC Acquisitions, L.L.C., Infinity Home Care, L.L.C., Axiom HealthEquity Holdings Management, LLC, Infinity Healthcare Holdings, LLC, and Amedisys, Inc.</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312516498856/d38348dex1028.htm">Agreement of Purchase and Sale dated as of November&#160;25, 2015, between Amedisys, Inc., through its wholly-owned subsidiary, Amedisys Property, L.L.C., as seller and Franciscan Missionaries of Our Lady of the Lake Heath System, Inc., as purchaser.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312519026458/d699024dex101.htm">First Amendment to Amended and Restated Credit Agreement, dated as of February 4, 2019, by and among the Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, certain subsidiaries of the Company party thereto as guarantors, Bank of America, N.A., as the administrative agent, swingline lender and letter of credit issuer, JPMorganChase Bank, N.A., as syndication agent, Capital One Bank, National Association, Citizens Bank, N.A., Compass Bank, Fifth Third Bank, Hancock Whitney Bank, Regions Bank, and Wells Fargo Bank, National Association, as co-documentation agents, the lenders party thereto, Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, Citizens Bank, N.A., Fifth Third Bank and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated and JPMorgan Chase Bank, N.A., as joint bookrunners </a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on February 4, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:147pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312519026458/d699024dex102.htm">Joinder Agreement, dated as of February 4, 2019, by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, each of the new subsidiary guarantors party thereto, and Bank of America, N.A., as the administrative agent  </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on February 4, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312519043484/d709399dex101.htm">Retirement and Consulting Agreement, dated as of February 13, 2019, by and between Amedisys, Inc. and Linda J. Hall</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on February 19, 2019<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312520169361/d944425dex101.htm">Joinder Agreement, dated as of June 12, 2020, by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, each of the new subsidiary guarantors party thereto, and Bank of America, N.A., as the administrative agent (The schedules to the Joinder have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of the omitted schedules to the Securities and Exchange Commission upon request.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Current Report on Form 8-K filed on June 15, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202010-kexhibit1026.htm">Second Amendment to the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan, dated October 21, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202010-kexhibit211.htm">Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202010-kexhibit231.htm">Consent of KPMG LLP</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202010-kexhibit311.htm">Certification of Paul B. Kusserow, Chief Executive Officer (principal executive officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202010-kexhibit312.htm">Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202010-kexhibit321.htm">Certification of Paul B. Kusserow, Chief Executive Officer (principal executive officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202010-kexhibit322.htm">Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="id92bd70d620044018083957a908405c4_208"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.222%"><tr><td style="width:1.0%"></td><td style="width:8.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDISYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USSEROW&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paul B. Kusserow,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chief Executive Officer and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman of the Board</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;25, 2021 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:42.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USSEROW</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br/>and Chairman of the Board (Principal<br/>Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paul B. Kusserow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> G. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">INN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer (Principal<br/>Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:27pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scott G. Ginn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICKIE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">APPS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vickie L. Capps</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OLLY </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OYE, MD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molly Coye, MD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ULIE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LAPSTEIN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Julie D. Klapstein</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERESA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LINE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Teresa L. Kline</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHARD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ECHLEITER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lead Independent Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Richard A. Lechleiter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RUCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D. P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERKINS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bruce D. Perkins</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EFFREY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IDEOUT, MD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jeffrey A. Rideout, MD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;IVANETTA D. SAMUELS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ivanetta D. Samuels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>2
<FILENAME>a202010-kexhibit1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i095025c55e914baaa2b2efd93e9cfdea_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.16</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. 2018 OMNIBUS INCENTIVE COMPENSATION PLAN</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Inclusive of Plan amendments dated September 25, 2018 and October 21, 2020 and the full text of the Plan)</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">PURPOSE.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (the &#8220;Plan&#8221;) is to promote the interests of Amedisys, Inc., a Delaware corporation (the &#8220;Company&#8221;) and its stockholders by (i) attracting and retaining key officers, employees, and directors of, and consultants to, the Company and its Subsidiaries and Affiliates&#59; (ii) motivating such individuals by means of performance-related incentives to achieve long-range performance goals&#59; (iii) enabling such individuals to participate in the long-term growth and financial success of the Company&#59; (iv) encouraging ownership of stock in the Company by such individuals&#59; and (v) linking their compensation to the long-term interests of the Company and its stockholders. Toward this objective, the Committee may grant stock options, Stock Appreciation Rights (&#34;SARs&#34;), Stock Awards, cash bonuses and other incentive awards to Employees of the Company and its Subsidiaries and Affiliates on the terms and subject to the conditions set forth in the Plan. In addition, this Plan is intended to enable the Company to effectively attract, retain and reward Outside Directors by providing for grants of Outside Director Awards to Outside Directors. No Award under this Plan (or modification thereof) shall provide for deferral of compensation that does not comply with Section 409A of the Code unless the Committee, at the time of grant, specifically provides that the Award is not intended to comply with Section 409A of the Code. Notwithstanding any provision of this Plan to the contrary, if one or more of the payments or benefits received or to be received by a Participant pursuant to an Award would cause the Participant to incur any additional tax or interest under Section 409A of the Code, the Committee may reform such provision to maintain to the maximum extent practicable the original intent of the applicable provision without violating the provisions of Section 409A of the Code.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">DEFINITIONS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any entity (other than the Company and any Subsidiary) that is designated by the Board as a participating employer under the Plan, provided that the Company directly or indirectly owns at least 20% of the combined voting power of all classes of stock of that entity or at least 20% of the ownership interests in that entity.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">&#8220;Alternative Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has the meaning assigned to such term in Section 22, herein.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">&#8220;Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any form of Option, SAR, Stock Award, Restricted Share Unit, cash bonus or other incentive award granted under the Plan, whether singly, in combination, or in tandem, to a Participant by the Committee pursuant to terms, conditions, restrictions and limitations, if any, as the Committee may establish by the Award Notice or otherwise.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">&#8220;Award Notice&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a written notice from the Company to a Participant that establishes the terms, conditions, restrictions, and limitations applicable to an Award in addition to those established by the Plan and by the Committee&#8217;s exercise of its administrative powers. In the event of a conflict between the terms of the Plan and any Award Notice, the terms of the Plan shall prevail. The Committee shall, subject to applicable law, determine the date an Award is deemed to be granted. The Committee or, except to the extent prohibited under applicable law, its delegate(s) may establish the terms of agreements or other documents evidencing Awards under this Plan and may, but need not, require as a condition to any such agreement&#8217;s or document&#8217;s effectiveness that such agreement or document be executed by the Participant, including by electronic signature or other electronic indication of acceptance, and that such Participant agree to such further terms and conditions as specified in such agreement or document.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">&#8220;Board&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Board of Directors of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.17pt">&#8220;Cash Maximum&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means $5 million.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">&#8220;Cause&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, when used in connection with the termination of a Participant&#8217;s Employment, (i) if the Participant has an effective employment agreement with the Company or any Subsidiary or Affiliate as of the date an Award is granted, the definition used in such employment agreement as of such date, or (ii) if the Participant does not have an effective employment agreement with the Company or any Subsidiary or Affiliate as of the date an Award is granted, unless otherwise provided in the Participant&#8217;s Award Notice, matters which, in the judgment of the Committee, constitute any one or more of the following&#58; (i) default or breach of any of the provisions of any agreement that the Participant may have with the Company or any Affiliate or Subsidiary&#59; (ii) actions constituting fraud, abuse, dishonesty, embezzlement, destruction or theft of Company property, or breach of the duty of loyalty owed by the Participant to the Company&#59; (iii) violation of any applicable laws, rules or regulations (including, without limitation, all Medicare and other health care laws, rules and regulations pertaining to the provision of home health care, hospice or any other services provided by the Company)&#59; (iv) furnishing materially false, inaccurate, misleading or incomplete information to the Company&#59; (v) actions constituting a material breach of the Company&#8217;s Code of Ethical Business Conduct, the Company&#8217;s employee handbook or any other Company policy&#59; (vi) willful failure to follow reasonable and lawful directives of the Participant&#8217;s supervisor, or any of the Company&#8217;s senior executive officers, which are consistent with the Participant&#8217;s job responsibilities and performance&#59; or (vii) failure to satisfy the requirements of the Participant&#8217;s job, regardless whether or not such failure is willful, including the failure to satisfy the objectives of any action plan or performance improvement plan that the Participant may be under. Any determination of Cause for purposes of the Plan or any Award shall be made by the Committee in its sole discretion. Any such determination shall be final and binding on a Participant.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">&#8220;Change In Control&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the happening of any of the following&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-41.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">any person or entity, including a &#8220;group&#8221; as defined in Section 13(d)(3) of the Exchange Act or in Section 409A of the Code, other than the Company or a wholly-owned Subsidiary, or any employee benefit plan of the Company or any Subsidiary, becomes the beneficial owner of the Company&#8217;s securities having 50% or more of the combined voting power of the then outstanding securities of the Company that may be cast for the election of directors of the Company (other than as a result of an issuance of securities initiated by the Company in the ordinary course of business)&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-44.04pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">as the result of, or in connection with, any cash tender or exchange offer, merger or other business combination, sales of assets or contested election of directors, or any combination of the foregoing transactions, after the transaction less than a majority of the combined voting power of the then outstanding securities of the Company, or any successor corporation or cooperative or entity, entitled to vote generally in the election of the directors of the Company, or other successor corporation or other entity, are held in the aggregate by the holders of the Company&#8217;s securities who immediately prior to the transaction had been entitled to vote generally in the election of directors of the Company&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-46.81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">during any period of 12 consecutive months, individuals who at the beginning of the period constitute the Board cease for any reason to constitute at least a majority of the Board, unless the election, or the nomination for election by the Company&#8217;s stockholders, of each director of the Company first elected during the relevant 12 month period was approved by a vote of at least 2&#47;3 of the directors of the Company then still in office who were directors of the Company at the beginning of that period.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.73pt">&#8220;Change In Control Price&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the closing price (or, if the shares are not traded on an exchange, the last sale price or closing &#8220;asked&#8221; price) per share paid for the purchase of Common Stock in a national securities market on the date the Change In Control occurs.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.17pt">&#8220;Code&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Internal Revenue Code of 1986, as amended from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">&#8220;Committee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Compensation Committee of the Board, or any other committee designated by the Board, authorized to administer the Plan under Section 3 of this Plan. The Committee shall consist of not less than 2 members who shall be appointed by, and shall serve at the pleasure of, the Board. The directors appointed to serve on the Committee shall be&#58; (i) &#8220;independent&#8221; within the meaning of the listing standards of any securities exchange or automated quotation system upon which the Common Stock is listed or quoted&#59; (ii) &#8220;non-employee directors&#8221; (within the meaning of Rule 16b-3 under the Exchange Act)&#59; and (iii) &#8220;outside directors&#8221; (within the meaning of Code Section 162(m) and its related regulations). However, the mere fact that a Committee member fails to qualify under any of the foregoing requirements shall not invalidate any Award made by the Committee if the Award is otherwise validly made under the Plan.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.73pt">&#8220;Common Stock&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the $0.001 par value common stock of the Company.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.17pt">&#8220;Company&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means Amedisys, Inc. or any successor.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">n.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">&#8220;Consultant&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall mean any consultant to the Company or its Subsidiaries or Affiliates.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">o.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">&#8220;Covered Employee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an individual who is, with respect to the Company, an individual defined in Code Section 162(m)(3).</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">p.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">&#8220;Director&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an individual who is a member of the Board.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">&#8220;Disability&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has the same meaning as provided in the long-term disability plan or policy maintained by the Company or if applicable, most recently maintained, by the Company or if applicable, a Subsidiary or Affiliate, for the Participant, whether or not that Participant actually receives disability benefits under the plan or policy. If no long-term disability plan or policy was ever maintained on behalf of Participant or if the determination of Disability relates to an Incentive Stock Option, Disability means Permanent and Total Disability as defined in Section 22(e)(3) of the Code. In a dispute, the determination whether a Participant has suffered a Disability will be made by the Committee and may be supported by the advice of a physician competent in the area to which that Disability relates.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">r.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">&#8220;Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is defined in Section 6.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.61pt">&#8220;Employee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an employee or prospective employee of the Company, a Subsidiary or an Affiliate.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">t.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.17pt">&#8220;Employment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, except as otherwise required by Section 409A of the Code, continuous, uninterrupted full time employment with the Company or any Affiliate or Subsidiary, and shall include the provision of services as an Outside Director or Consultant for the Company or any Affiliate or Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that a change in a Participant&#8217;s status from an Employee or Outside Director to a Consultant shall constitute a termination of Employment as an Employee or Outside Director, as applicable, and shall constitute a new Employment as a Consultant, and for the avoidance of doubt, a change in a Participant&#8217;s status from a full time Employee to a part time Employee shall constitute a termination of Employment as an Employee under this Plan. A Participant&#8217;s Employment shall terminate on the date (i) the Participant&#8217;s status changes as set forth in the preceding sentence or (ii) the Participant is no longer employed by an entity that is at least one of the Company, an Affiliate or a Subsidiary as of such date. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall have a correlative meaning.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">u.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">&#8220;Exchange Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Securities and Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">&#8220;Exercise Price&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the purchase price payable to purchase one Share upon the exercise of an Option or the price by which the value of a SAR shall be determined upon exercise, pursuant to Section 2.37.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">w.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.28pt">&#8220;Fair Market Value&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to the Common Stock, as of any given date, unless otherwise determined by the Committee in good faith, means the reported closing sale price of a share of Common Stock on the automated quotation system or other market or exchange that is the principal trading market for the Common Stock, or if no sale of a share of Common Stock is so reported on that date, the fair market value of a share of Common Stock as determined by the Committee in good faith.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">x.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">&#8220;Fiscal Year&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the Company's fiscal year.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">y.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">&#8220;Good Reason&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall mean&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-41.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">If a Participant is a party to an employment agreement with the Company and such agreement provides for a definition of Good Reason, the definition contained in such agreement&#59; or </font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-44.04pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">If a Participant is a &#8220;Covered Executive&#8221; as defined in the Amedisys Holding, L.L.C. Severance Plan for Key Employees (the &#8220;Key Executive Severance Plan&#8221;), the definition of Good Reason contained in the Key Executive Severance Plan&#59; or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-46.81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">If no such employment agreement exists or if such agreement does not define Good Reason, and the Participant is not a &#8220;Covered Executive&#8221; under the Key Executive Severance Plan, the occurrence of one or more of the following without the Participant's express written consent&#58; (i) Participant suffers a material diminution in authority, responsibilities, or duties&#59; or (ii) Participant suffers a material reduction in base salary other than in connection with a proportionate reduction in the base salaries of all similarly situated senior officer-level employees. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">z.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">&#8220;Immediate Family&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, and includes adoptive relationships.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">aa.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.5pt">&#8220;Incentive Stock Option&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an option to purchase Common Stock from the Company that is granted under Section 8 of the Plan and that is intended to meet the requirements of Section 422 of the Code or any successor provision thereto. To the extent the aggregate Fair Market Value (determined at the time the Incentive Stock Option is granted) of the Common Stock with respect to which all Incentive Stock Options are exercisable for the first time by an Employee during any calendar year (under all plans described in subsection (d) of Section 422 of the Code of the Employee&#8217;s employer corporation and its parent and Subsidiaries) exceeds $100,000, such Options shall be treated as Non-Qualified Stock Options.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ab.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.94pt">&#8220;Non-Qualified Stock Option&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall mean an option to purchase Common Stock from the Company that is granted under Section 8 or 23 of the Plan and is not intended to be an Incentive Stock Option.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ac.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.07pt">&#8220;Option&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an Incentive Stock Option or a Non-Qualified Stock Option.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ad.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.94pt">&#8220;Outside Director&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a member of the Board who is not an officer or employee of the Company or any Subsidiary or Affiliate of the Company.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ae.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.07pt">&#8220;Outside Director Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means either a Director Option or a Director Stock Award or combination thereof awarded to an Outside Director under Section 23.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">af.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.17pt">&#8220;Participant&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any individual to whom an Award has been granted by the Committee under this Plan.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ag.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.5pt">&#8220;Performance-Based Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means (i) any Option or SAR granted under the Plan, or (ii) any other Award that is made subject to performance goals based on Performance Measures as set forth in Section 12.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ah.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.94pt">&#8220;Performance Measures&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means one or more of the performance measures listed in Section 12.1 upon which performance goals for certain Performance-Based Awards may be established by the Committee.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ai.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.73pt">&#8220;Qualifying Event&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means, with respect to a Participant, (i) a termination of such Participant&#8217;s Employment by the Company (and all then-Affiliates or Subsidiaries) without Cause following a Change in Control of the Company, (ii) a termination of such Participant&#8217;s Employment by the Participant for Good Reason following a Change in Control of the Company, or (iii) a relocation of the Participant&#8217;s principal place of employment by more than 50 miles. It is understood that a Participant shall not have a Qualifying Event pursuant to clause (i) above by virtue of ceasing to be Employed by an entity or its subsidiaries undergoing a Change in Control where, following such Change in Control, the Participant remains employed by an entity that is at least one of (i) the Company or (ii) any entity that was an Affiliate or Subsidiary undergoing a Change in Control immediately prior to such Change in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Control. Notwithstanding the foregoing, payments on account of a Participant&#8217;s Qualifying Event that constitute &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code shall not commence unless and until the Participant has also incurred a &#8220;separation from service&#8221; within the meaning of Code Section 409A.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">aj.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.17pt">&#8220;Restricted Share Unit&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a bookkeeping entry used by the Company to record and account for the grant of an Award of restricted Common Stocks under Section 10 of the Plan until the Award is paid, canceled, forfeited or terminated, as the case may be.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ak.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.94pt">&#8220;SAR&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an Award that shall entitle the recipient to receive, with respect to each share of Common Stock encompassed by the exercise of the SAR, a payment equal to the excess of the Fair Market Value on the date of exercise over the Fair Market Value on the date of grant.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">al.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15.73pt">&#8220;Section 162(m)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means Section 162(m) of the Code and the regulations promulgated thereunder and any successor provision thereto as in effect from time to time.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">am.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.17pt">&#8220;Section 16&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means Section 16 of the Exchange Act and the rules promulgated thereunder and any successor provision thereto as in effect from time to time.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">an.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.94pt">&#8220;Section 16 Insider&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a Participant who is subject to the reporting requirements of Section 16 as a result of the Participant&#8217;s position with the Company.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ao.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.5pt">&#8220;Stock Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means an Award granted pursuant to Section 10 in the form of shares of Common Stock or restricted shares of Common Stock.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ap.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.94pt">&#8220;Stockholder Approval Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the date on which this Plan is approved by the requisite vote of the stockholders of the Company.  </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">aq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.94pt">&#8220;Subsidiary&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means a corporation or other business entity in which the Company directly or indirectly has an ownership interest of 50% or more.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">ADMINISTRATION.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan shall be administered by the Committee. The Committee shall have the discretionary authority to&#58; (a) interpret the Plan&#59; (b) establish any rules and regulations it deems necessary for the proper operation and administration of the Plan&#59; (c) select persons to become Participants and receive Awards under the Plan&#59; (d) determine the form of an Award, whether an Option, SAR, Stock Award, cash bonus, or other incentive award established by the Committee, the number of shares subject to the Award, all the terms, conditions, restrictions and limitations, if any, of an Award, including the time and conditions of exercise or vesting, and the terms of any Award Notice&#59; (e) determine whether Awards should be granted singly, in combination or in tandem&#59; (f) grant waivers of Plan terms, conditions, restrictions and limitations&#59; (g) accelerate the vesting, exercise or payment of an Award or the performance period of an Award in the event of a Participant&#8217;s termination of employment or when that action or actions would be in the best interests of the Company, but only to the extent that such action would not violate the provisions of Section 409A of the Code&#59; (h) establish such other types of Awards, besides those specifically enumerated in Section 2.3, which the Committee determines are consistent with the Plan&#8217;s purpose&#59; and (i) take all other action it deems necessary or advisable for the proper operation or administration of the Plan. Subject to Section 20, the Committee also shall have the authority to grant Awards in replacement of Awards previously granted under the Plan or any other executive compensation plan of the Company or a Subsidiary. All determinations of the Committee shall be made by a majority of its members, and its determinations shall be final, binding and conclusive on all persons, including the Company and Participants. The Committee, in its discretion, may delegate its authority and duties under the Plan to the Chief Executive Officer or to other senior officers of the Company under conditions and limitations the Committee may establish&#59; however, only the Committee may select, grant, and establish the terms of Awards to Section 16 Insiders, and only the Board shall have the authority to grant and establish the terms of awards under Section 23.  Notwithstanding the foregoing, neither the Board, the Committee nor any of their respective delegates shall have the authority to reprice (or cancel and regrant) any Option or, if applicable, other Award at a lower exercise, base or purchase price, or cancel any Award with an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise, base or purchase price in exchange for cash, property or other Award, without first obtaining the approval of the Company's stockholders.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">ELIGIBILITY.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any Employee, Outside Director or Consultant shall be eligible to be designated a Participant&#59; provided, however, that Outside Directors shall only be eligible to receive Awards granted consistent with Section 23.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">NUMBER OF SHARES AVAILABLE.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Share Limits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Subject to adjustment as provided in Section 16 of the Plan, the maximum number of shares of Common Stock that shall be available for grant of Awards under the Plan (including incentive stock options) during its term shall not exceed 2,500,000 shares. The maximum number of shares of Common Stock subject to Awards granted during a single Fiscal Year to any Outside Director, together with any cash fees paid to such Outside Director during the Fiscal Year, shall not exceed a total value of $500,000 (calculating the value of any Awards based on the grant date fair value for financial reporting purposes).  Any shares of Common Stock related to Awards that are settled in cash in lieu of Common Stock shall be available again for grant under the Plan. Similarly, subject to Section 20(c), any shares of Common Stock related to Awards that terminate by expiration, forfeiture, cancellation or otherwise without the issuance of the related shares or are exchanged with the Committee&#8217;s permission for Awards not involving Common Stock, shall be available again for grant under the Plan. Any shares of Common Stock related to Awards that are cancelled on settlement of options or SARs in payment of the exercise price thereof and shares of Common Stock withheld to pay taxes shall not be available again for grant under the Plan. Finally, and notwithstanding the foregoing and subject to adjustment as provided in Section 16 of the Plan, the maximum number of shares of Common Stock with respect to which Awards may be granted under the Plan shall be increased by the number of shares of Common Stock with respect to which options or other awards were granted under the Company&#8217;s 2008 Omnibus Incentive Compensation Plan (the &#8220;2008 Plan&#8221;) as of the record date for the meeting of stockholders to approve this Plan, but which thereafter terminate, expire unexercised or are settled for cash, forfeited or cancelled without the delivery of Common Stock under the terms of the 2008 Plan (but excluding shares of Common Stock cancelled on settlement of options or SARs in payment of the exercise price thereof or shares of Common Stock withheld to pay taxes)&#59; and any such shares shall again be available for grant as Awards under this Plan. Notwithstanding any provision in the Plan to the contrary, and subject to adjustment as provided in Section 16 hereof, no Participant may receive Options, SARs, Stock Awards or Restricted Share Units under the Plan during any one calendar year under the Plan that, taken together, relate to more than 750,000 shares of Common Stock. For purposes of this limitation, forfeited, canceled or stockholder approved repriced shares granted to a Participant in any given calendar year shall continue to be counted against the maximum number of shares that may be granted to that Participant in that calendar year. The shares of Common Stock available for issuance under the Plan may be authorized and unissued shares. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Minimum Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With the exception of Performance-Based Awards, which are subject to a minimum one-year vesting period, effective for Awards issued on or after the Effective Date, no more than 5% of the total number of shares authorized for delivery under the Plan may be granted as SARs, Options, Stock Awards or Restricted Share Units which vest within one year after the date of grant. With respect to such Awards in excess of 5% of the Shares authorized for delivery under the Plan, the vesting period must be a minimum of one year from the date of grant. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">No Further Awards Under 2008 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  After the Stockholder Approval Date, no Awards may be granted under the 2008 Plan.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">EFFECTIVE DATE&#59; TERM.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan became effective upon adoption by the Board on March 29, 2018 (the &#8220;Effective Date&#8221;), subject to requisite approval by stockholders of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">PARTICIPATION.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee shall select, from time to time, Participants from those Employees, Directors and Consultants who, in the opinion of the Committee, can further the Plan&#8217;s purposes. Once a Participant is selected, the Committee shall determine the type or types of Awards to be made to the Participant and shall establish in the related Award Notices the terms, conditions, restrictions and limitations, if any, applicable to the Awards in addition to those set forth in the Plan and the administrative rules and regulations issued by the Committee.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">STOCK OPTIONS. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Grants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Awards may be granted in the form of Options. Options may be Incentive Stock Options, other tax-qualified stock options, or Non-Qualified Stock Options, or a combination of any of those.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Terms and Conditions of Options.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> An Option shall be exercisable in whole or in such installments and at the times determined by the Committee. The Committee also shall determine the performance or other conditions, if any, which must be satisfied before all or part of an Option may be exercised. The price at which Common Stock may be purchased upon exercise of a stock option shall be established by the Committee, but such price shall not be less than 110% of the Fair Market Value of the Common Stock on the date the Option is granted in the case of Incentive Stock Options when the Employee to whom the option is to be granted owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or of any of its Subsidiaries (a &#8220;Ten Percent Owner&#8221;), and in the case of all Options other than Incentive Stock Options, not less than 100% of the Fair Market Value of the Common Stock on the date the Option is granted. Each Option shall expire not later than 10 years (or, in the case of an Incentive Stock Option granted to a Ten Percent Owner, not later than 5 years) from its date of grant.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">Restrictions Relating to Incentive Stock Options.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Incentive Stock Options shall, in addition to being subject to all applicable terms, conditions, restrictions and limitations established by the Committee, comply with Section 422 of the Code. Accordingly, Incentive Stock Options may only be granted to Employees who are employees of the Company or a Subsidiary, and the aggregate market value (determined at the time the option was granted) of the Common Stock with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar year (under the Plan or any other plan of the Company or any of its Subsidiaries) shall not exceed $100,000 (or other limit required by the Code). Except with respect to Ten Percent Owners, each Incentive Stock Option shall expire not later than 10 years from its date of grant.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Additional Terms and Conditions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee may, by way of the Award Notice or otherwise, establish other terms, conditions, restrictions and limitations, if any, on any Option, provided they are not inconsistent with the Plan.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Committee shall determine the methods by which the Exercise Price of an Option may be paid, the form of payment, including, without limitation, cash, shares of Common Stock, or other property (including &#8220;cashless exercise&#8221; arrangements, so long as they do not in any way conflict with the requirements of applicable law), and the methods by which shares of Common Stock shall be delivered or deemed to be delivered by Participants. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:28.5pt">STOCK APPRECIATION RIGHTS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Grants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Awards may be granted in the form of SARs. The SAR may be granted in tandem with all or a portion of a related Option under the Plan (&#8220;Tandem SARs&#8221;), or may be granted separately (&#8220;Freestanding SARs&#8221;). A Tandem SAR may be granted either at the time of the grant of the related Option or at any time thereafter during the term of the Option. In the case of SARs granted in tandem with Options granted prior to the grant of the SARs, the appreciation in value is the difference between the option price of the related stock option and the Fair Market Value of the Common Stock on the date of exercise.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Terms and Conditions of Tandem SARs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A Tandem SAR shall be exercisable to the extent, and only to the extent, that the related Option is exercisable, and the &#8220;exercise price&#8221; of that SAR (the base from which the value </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the SAR is measured at its exercise) shall be the Exercise Price under the related Option. If a related Option is exercised as to some or all of the shares of Common Stock covered by the Award, the related Tandem SAR, if any, shall be canceled automatically to the extent of the number of shares of Common Stock covered by the Option exercise. Upon exercise of a Tandem SAR as to some or all of the shares of Common Stock covered by the Award, the related Option shall be canceled automatically to the extent of the number of shares of Common Stock covered by the exercise.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">Terms and Conditions of Freestanding SARs. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Freestanding SARs shall be exercisable in whole or in the installments and at the times determined by the Committee. Freestanding SARs shall have a term specified by the Committee, in no event to exceed 10 years. The Exercise Price of a Freestanding SAR shall also be determined by the Committee&#59; however, that price shall not be less than 100% of the Fair Market Value on the date of grant of the Freestanding SAR of the number of shares of Common Stock to which the Freestanding SAR relates. The Committee also shall determine the Performance Measures or other conditions, if any, that must be satisfied before all or part of a Freestanding SAR may be exercised.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Deemed Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Committee may provide that an SAR shall be deemed to be exercised at the close of business on the scheduled expiration date of the affected SAR if at that time the SAR by its terms remains exercisable and, if so exercised, would result in a payment to the holder of the SAR.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">Additional Terms and Conditions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee may, by way of the Award Notice or otherwise, determine such other terms, conditions, restrictions and limitations, if any, of any SAR Award, provided they are not inconsistent with the Plan.  </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">STOCK AWARDS AND RESTRICTED SHARE UNITS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Grants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Awards may be granted in the form of Stock Awards and Restricted Share Units. Stock Awards and Restricted Share Units shall be awarded in such numbers and at such times during the term of the Plan as the Committee shall determine. Stock Awards shall be made in actual shares of Common Stock.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Award Restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock Awards and Restricted Share Units shall be subject to terms, conditions, restrictions, and limitations, if any, the Committee deems appropriate including, without limitation, restrictions on transferability and continued Employment of the Participant. The Committee also shall determine the Performance Measures or other conditions, if any, that must be satisfied before all or part of the applicable restrictions lapse. The Committee may, at its discretion, waive all or any part of the restrictions applicable to any or all outstanding Stock Awards and Restricted Share Unit Awards.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">Rights as Stockholder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the period in which any restricted shares of Common Stock are subject to restrictions imposed pursuant to Section 10.2, (i) the Participant to whom restricted shares have been awarded shall have no right with respect to such Common Stock to vote such shares during the restricted period or to receive dividends which are declared with respect to such Common Stock with a record date during the restricted period&#59; (ii) the Participant shall not be entitled to delivery of the stock certificate until the expiration of the restricted period and the fulfillment of any other restrictive conditions set forth in the Award Notice with respect to such Common Stock&#59; (iii) none of the Common Stock represented by the Award may be sold, assigned, transferred, pledged, hypothecated or otherwise encumbered or disposed of during such restricted period or until after the fulfillment of any such other restrictive conditions&#59; and (iv) except as otherwise determined by the Committee at or after grant, all of the shares of Common Stock subject to the Award shall be forfeited and all rights of the Participant to such Common Stock shall terminate, without further obligation on the part of the Company, unless the Participant remains in the continuous Employment of the Company for the entire restricted period in relation to which such shares of Common Stock were granted and unless any other restrictive conditions relating to the restricted Share Award are met. Unless otherwise provided in the applicable Award Notice, any shares of Common Stock, any other securities of the Company and any other property (except for cash dividends) distributed with respect to the Common Stock subject to restricted Share Awards shall be subject to the same restrictions, terms and conditions as such restricted Share Award.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Evidence of Award. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to Section 10.5, any Stock Award granted under the Plan shall be evidenced by issuance of a stock certificate or certificates or, in the discretion of the Committee, through issuance of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instructions to the Company&#8217;s transfer agent to issue the shares of Common Stock subject to the Award in book-entry (uncertificated) form on the books and records of the transfer agent through the Direct Registration System (&#8220;DRS&#8221;) or any successor system. Any Restricted Share Unit shall be evidenced by an Award Notice that sets forth any other terms, conditions, restrictions and limitations, if any, established by the Committee with respect to any Restricted Share Unit Award that are consistent with the terms of the Plan.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">Delivery of Shares and Transfer Restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upon issuance of a certificate evidencing a restricted Share Award, such certificate shall be held by the Company or any custodian appointed by the Company for the account of the Participant subject to the terms and conditions of the Plan, and shall bear such a legend setting forth the restrictions imposed thereon as the Committee, in its discretion, may determine. Unless otherwise provided in the applicable Award Notice, the grantee shall have all rights of a stockholder with respect to the Restricted Shares Upon the issuance of a restricted Share Award in book entry form, the Company&#8217;s transfer agent shall be apprised of and shall duly note any restrictions such as those set forth above that are applicable to the restricted Share Award.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.17pt">Termination of Restrictions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the end of the restricted period and provided that any other restrictive conditions of the restricted Share Award are met, or at such earlier time as otherwise determined by the Committee, all restrictions set forth in the Award Notice relating to the restricted Share Award or in the Plan shall lapse as to the restricted shares of Common Stock subject thereto, and either&#58; (i) a stock certificate for the appropriate number of shares of Common Stock, free of the restrictions and restricted stock legend, shall be delivered to the Participant or the Participant&#8217;s beneficiary or estate, as the case may be&#59; or (ii) in the event the Share Award was evidenced in book entry form, the Company&#8217;s transfer agent shall be notified of the lapse and or termination of the restrictions and to remove all references thereto in its books and records.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Payment of Restricted Share Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each Restricted Share Unit shall have a value equal to the Fair Market Value of a share of Common Stock. Restricted Share Units shall be paid in cash, Shares, other securities or other property, as determined in the sole discretion of the Committee, upon the lapse of the restrictions applicable thereto, or otherwise in accordance with the applicable Award Notice. Unless otherwise provided in the applicable Award Notice, a Participant shall receive dividend rights in respect of any vested Restricted Share Units at the time of any payment of dividends to stockholders on the Common Stock. The amount of any such dividend right shall equal the amount that would be payable to the Participant as a stockholder in respect of a number of shares of Common Stock equal to the number of vested Restricted Share Units then credited to the Participant. Other than pursuant to Section 15 (but no transfers for consideration shall be permitted), Restricted Share Units may not be sold, assigned, transferred, pledged, hypothecated or otherwise encumbered or disposed of, and all Restricted Share Units and all rights of the grantee to such Restricted Share Units shall terminate, without further obligation on the part of the Company, unless the Participant remains in continuous Employment of the Company for the entire restricted period in relation to which such Restricted Share Units were granted and unless any other restrictive conditions relating to the Restricted Share Unit Award are met.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">PLAN CASH BONUSES.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While cash bonuses may be granted at any time outside this Plan, cash awards may also be granted in addition to other Awards granted under the Plan and in addition to cash awards made outside of the Plan. Subject to the provisions of the Plan, the Committee shall have authority to determine the persons to whom cash bonuses under the Plan shall be granted and the amount, terms and conditions of those cash bonuses. Notwithstanding anything to the contrary in this Plan, no Covered Employee shall be eligible to receive a cash bonus granted under the Plan in excess of the Cash Maximum in any fiscal year&#59; no cash bonus shall be granted pursuant to this Plan to any Covered Employee unless the cash bonus constitutes a Performance-Based Award, and no cash bonus awarded pursuant to the Plan shall be paid later than 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months after the end of the calendar year in which such bonus was earned.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">PERFORMANCE GOALS FOR CERTAIN AWARDS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Performance-Based Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When granting any Award, the Committee may designate the Award as a Performance-Based Award. If an Award is so designated, the Committee shall establish performance goals for the Award based on one or more of the following Performance Measures, which may be expressed in terms of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company-wide objectives or in terms of objectives that relate to the performance of a Subsidiary or a division, region, department or function within the Company or a Subsidiary&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">return on capital, equity, or assets (including economic value created),</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">productivity or operating efficiencies,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">cost improvements,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">cash flow,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">sales revenue growth,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">net income, earnings per share, or earnings from operations,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">quality,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">customer satisfaction,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">comparable store sales,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">stock price or total stockholder return,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">EBITDA or EBITDAR,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">after tax operating income,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">book value per Share,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">debt reduction,</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">strategic business objectives, consisting of one or more objectives based on meeting specified cost targets, business expansion goals and goals relating to acquisitions, retention or divestitures, or</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">any combination of the foregoing.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each goal may be expressed on an absolute and&#47;or relative basis, may be based on or otherwise employ comparisons based on internal targets, the past performance of the Company or any Subsidiary, operating unit, business segment or division of the Company and&#47;or the past or current performance of other companies, and in the case of earnings-based measures, may use or employ comparisons relating to capital, stockholders&#8217; equity and&#47;or Common Stock outstanding, or to assets or net assets. The Committee may appropriately adjust any evaluation of performance under criteria set forth in this Section 12.1 to exclude any of the following events that occurs during a performance period&#58; (i) asset write-downs, (ii) litigation or claim judgments or settlements, (iii) the effect of changes in tax law, accounting principles or other such laws or provisions affecting reported results, (iv) accruals for reorganization and restructuring programs, (v) acquisitions or divestitures, (vi)  </font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extraordinary, unusual or infrequently occurring items as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s financial statements or notes thereto appearing in the Company&#8217;s Annual Report on Form 10-K, and&#47;or in management&#8217;s discussion and analysis of financial condition and results of operations appearing in such Annual Report, and (vii) any other specific unusual or nonrecurring events, or objectively determinable category thereof. Measurement of the Company&#8217;s performance against the goals established by the Committee shall be objectively determinable, and to the extent goals are expressed in standard accounting terms, performance shall be measured according to generally accepted accounting principles as in existence on the date on which the performance goals are established and without regard to any changes in those principles after that date.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Performance Goal Conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each Performance-Based Award (other than an Option or SAR) shall be earned, vested and payable (as applicable) only upon the achievement of performance goals established by the Committee based upon one or more of the Performance Measures, together with the satisfaction of any other conditions, such as continued Employment, the Committee may determine to be appropriate&#59; however, (i) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Committee may provide, either in connection with the grant of an Award or by later amendment, that achievement of the performance goals will be waived upon the death or Disability of the Participant, and (ii) the provisions of Section 22 shall apply notwithstanding this sentence.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.07pt">Certification of Goal Achievement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Any payment of a Performance-Based Award granted with performance goals shall be conditioned on the written certification of the Committee in each case that the performance goals and any other material conditions were satisfied. Except as specifically provided in Section 12.2, no Performance-Based Award may be amended, nor may the Committee exercise any discretionary authority it may otherwise have under the Plan with respect to a Performance-Based Award, in any manner to waive the achievement of the applicable performance goal based on Performance Measures or to increase the amount payable under, or the value of, the Award.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">PAYMENT OF AWARDS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the discretion of the Committee, payment of Awards may be made in cash, Common Stock, a combination of cash and Common Stock, or any other form of property the Committee shall determine. In addition, payment of Awards may include terms, conditions, restrictions and limitations, if any, the Committee deems appropriate, including, in the case of Awards paid in the form of Common Stock, restrictions on transfer and forfeiture provisions.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">TERMINATION OF EMPLOYMENT.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms in this Section 14 describe a Participant&#8217;s rights upon termination of Employment with respect to Awards granted under the Plan, provided, however, that the terms provided in a Participant&#8217;s Award Notice may supplement or modify the results of termination of Employment under this Section 14 and, provided further, in the event of a Change in Control, the Participant&#8217;s rights under an Award will be determined in accordance with Section 22.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:18.5pt">Options.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of an Option that has become vested under the terms of an Award Notice or this Plan following termination of Employment, based on the conditions for such termination, shall be exercisable for the period described in this Section 14.1. Upon the expiration of such right to exercise the Option, the unexercised portion of the Option will be forfeited.</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-41.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">Death and Disability. If the Participant&#8217;s Employment is terminated due to death or Disability, the Option shall become fully vested. The right to exercise the Option will expire one year after death or Disability or, if sooner ten years after the Option was granted.</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-44.04pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">Termination for Cause. If the Participant&#8217;s employment is terminated for Cause, the Participant shall immediately forfeit the unexercised portion of the Option, whether vested or unvested.</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-46.81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">Other Termination of Employment. If the Participant&#8217;s Employment is terminated for any reason not described above in this Section 14.1, the Participant shall immediately forfeit any portion of the Option that is unvested as of the date of termination of Employment. The right to exercise the vested portion of the Option will expire 90 days following such termination of Employment or, if sooner ten years after the Grant Date.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.94pt">Other Awards.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Awards of Performance-Based Awards, Restricted Share Units, SARs, and Stock Awards that have not become vested under the terms of an Award Notice or this Plan will be forfeited upon the termination of the Participant&#8217;s Employment, except as described in this Section 14.2.</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-41.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">Time Vested Awards. With respect to Awards that condition vesting solely with respect to continued employment, upon termination of Employment that is due to death or Disability, the Participant&#8217;s rights under an Award that shall become fully vested.</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-44.04pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">Performance Vested Awards. With respect to Awards that condition vesting upon achievement of performance measures, which may be stated in the Award Notice, upon termination of Employment that is due to death or Disability, the Participant&#8217;s rights under an Award that shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become fully vested with respect to the portion of the Award that is earned by achievement of such performance measures on or prior to the date of death or Disability.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">NO ASSIGNMENT. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No Awards (other than unrestricted Stock Awards) or any other payment under the Plan shall be subject in any manner to alienation, anticipation, sale, transfer (except by will or the laws of descent and distribution), assignment, pledge, or encumbrance&#59; however, the Committee may (but need not) permit other transfers where the Committee concludes that transferability (i) does not result in accelerated taxation, (ii) does not cause any option intended to be an incentive stock option to fail to be described in Code Section 422(b), and (iii) is otherwise appropriate and desirable, taking into account any state or federal securities laws applicable to transferable Awards. During the lifetime of the Participant no Award shall be payable to or exercisable by anyone other than the Participant to whom it was granted, other than (a) the duly appointed conservator or other lawfully designated representative of the Participant in the case of a permanent Disability involving a mental incapacity or (b) the transferee in the case of an Award transferred in accordance with the preceding sentence.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">CAPITAL ADJUSTMENTS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number and price of shares of Common Stock covered by each Award and Outside Director Award and the total number of shares of Common Stock that may be awarded under the Plan shall be proportionately adjusted to reflect any stock dividend, stock split or share combination of the Common Stock or any recapitalization of the Company. In the event of any merger, consolidation, reorganization, liquidation or dissolution of the Company, or any exchange of shares involving the Common Stock, any Award or Outside Director Award granted under the Plan shall automatically be deemed to pertain to the securities and other property to which a holder of the number of shares of Common Stock covered by the Award or Outside Director Award would have been entitled to receive in connection with any such event. The Committee shall have the sole discretion to make all interpretations and determinations required under this section to the extent it deems equitable and appropriate. It is the intent of any such adjustment that the value of the Awards or Outside Director Awards held by the Participants or Outside Directors, as the case may be, immediately following the change is the same as that value immediately prior to the change.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">WITHHOLDING TAXES.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy Federal, state, and local taxes (including the Participant&#8217;s FICA obligations) required by law to be withheld with respect to any taxable event arising as a result of this Plan. With respect to withholding required upon any taxable event, the Company may elect in its discretion, and Participants may elect, subject to the approval of the Committee, to satisfy the withholding requirement, in whole or in part, by withholding or having the Company withhold shares of Common Stock having a Fair Market Value that is equal to the withholding. The Company shall determine the amount of the tax withholding in an amount that is not in excess of the maximum applicable tax rate.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">REGULATORY APPROVALS AND LISTINGS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding anything contained in the Plan to the contrary, the Company shall have no obligation to issue or deliver certificates of Common Stock evidencing Stock Awards or any other Award resulting in the payment of shares of Common Stock prior to (a) the obtaining of any approval from any governmental agency which the Company shall, in its sole discretion, determine to be necessary or advisable, (b) the admission of the shares to quotation or listing on the automated quotation system or stock exchange on which the Common Stock may be listed, and (c) the completion of any registration or other qualification of the shares under any State or Federal law or ruling of any governmental body that the Company shall, in its sole discretion, determine to be necessary or advisable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">PLAN AMENDMENT. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided in Section 22, the Board or the Committee may, at any time and from time to time, suspend, amend, modify, or terminate the Plan without stockholder approval&#59; however, if an amendment to the Plan would, in the reasonable opinion of the Board or the Committee, either (i) result in repricing stock options or SARs or otherwise increase the benefits accruing to Participants or Outside Directors, (ii) increase the number of shares of Common Stock issuable under the Plan, or (iii) modify the requirements for eligibility, then that amendment shall be subject to stockholder approval&#59; and, the Board or Committee may condition any amendment or modification on the approval of stockholders of the Company if that approval is necessary or deemed advisable to (i) permit Awards to be exempt from liability under Section 16(b), (ii) to comply with the listing or other requirements of an automated quotation system or stock exchange, or (iii) to satisfy any other tax, securities or other applicable laws, policies or regulations.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">AWARD AMENDMENTS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided in Section 22, the Committee may amend, modify or terminate any outstanding Award or Outside Director Award without approval of the Participant or Outside Director, as applicable&#59; however&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-41.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">subject to the terms of the applicable Award Notice, an amendment, modification or termination shall not, without the Participant&#8217;s or Outside Director&#8217;s consent, as applicable, reduce or diminish the value of the Award or Outside Director Award determined as if the Award or Outside Director Award had been exercised, vested, cashed in (at the spread value in the case of stock options or SARs) or otherwise settled on the date of that amendment or termination&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-44.04pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">the original term of any stock option or SAR may not be extended without the prior approval of the stockholders of the Company&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-46.81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">except as otherwise provided in Section 16 of the Plan, the exercise price of any outstanding stock option or SAR may not be reduced, directly or indirectly, and outstanding stock options or SARs may not be cancelled in exchange for cash or replaced by other awards or stock options or SARs with an exercise price that is less than the exercise price of the cancelled stock options or SARs, without the prior approval of the stockholders of the Company&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-46.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">no termination, amendment, or modification of the Plan shall adversely affect any Award or Outside Director Awards previously granted under the Plan, without the written consent of the affected Participant or Outside Director.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">GOVERNING LAW. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Plan shall be governed by and construed in accordance with the laws of the State of Delaware, except as superseded by applicable Federal law.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">CHANGE IN CONTROL.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the limitations set forth in this Section 22, in the event (i) a Participant has a Qualifying Event within two years following a Change in Control of the Company, or (ii) a Change in Control occurs in which outstanding Awards are not assumed or honored by the successor entity or corporation or replaced with an Alternative Award (as defined below), the following provisions shall apply to any Award which has not previously terminated or expired&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-41.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">any SAR and any Option or Outside Director Award awarded under this Plan that is not previously vested and exercisable shall become fully vested and exercisable&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-44.04pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">the restrictions applicable to any Award which are not already vested under the Plan shall lapse, and those existing shares and awards shall be deemed fully vested&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-46.81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">unless otherwise determined by the Board or by the Committee in its sole discretion prior to any Change in Control, the value of all vested outstanding Options, SARs, Outside Director Awards and other Awards, shall be cashed out on the basis of the Change in Control Price as of the date the Change in Control is determined to have occurred (or other date determined by the Board or Committee prior to the Change in Control)&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-46.27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">the Board or the Committee may impose additional conditions on the acceleration or valuation of any Award in any applicable Award Notice.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify as an &#8220;Alternative Award,&#8221; the Committee must determine that the existing Awards are to be assumed, honored or new rights substituted by the successor corporation or entity and further must&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">be based on shares of common stock that are traded on an established U.S. securities market or another public market&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">provide the Participant (or each Participant in a class of Participants) with rights and entitlements substantially equivalent to or better than the rights, terms and conditions applicable under such Award, including, but not limited to, an identical or better exercise or vesting schedule, identical or better timing and methods of payment and identical or better performance criteria for those awards that are performance based&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">have substantially equivalent economic value to such Award&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">contain terms and conditions which provide that in the event that the Participant&#8217;s employment is terminated for death or Disability or is terminated without Cause within two years following a Change of Control, any conditions on the Participant&#8217;s rights under, or any restrictions on transfer, vesting or exercisability applicable to, each such Award shall lapse&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">be on terms and conditions that do not result in adverse tax consequences to the Participant under Section 409A of the Code.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">AWARDS TO OUTSIDE DIRECTORS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.5pt">The independent members of the Board may provide that all or a portion of an Outside Director&#8217;s annual retainer, meeting fees and&#47;or other awards or compensation as determined by such independent members of the Board, be payable (either automatically or at the election of an Outside Director) in the form of Non-Qualified Stock Options, Restricted Shares, Restricted Share Units and&#47;or Other Stock-Based Awards, including unrestricted Shares. The Board shall determine the terms and conditions of any such Awards, including the terms and conditions which shall apply upon a termination of the Non-Employee Director&#8217;s service as a member of the Board, and shall have full power and authority in its discretion to administer such Awards, subject to the terms of the Plan and applicable law.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.94pt">The Board may also grant Awards to Outside Directors pursuant to the terms of the Plan, including any Award described in Sections 8, 9 and 10 above. With respect to such Awards, all references in the Plan to the Committee shall be deemed to be references to the independent members of the Board.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">NO RIGHT TO EMPLOYMENT OR PARTICIPATION.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant of an Award under this Plan shall not confer any rights upon the Participant holding such Award other than such terms, and subject to such conditions, as are specified in this Plan as being applicable to such type of Award (or to all Awards) or as are expressly set forth in the Award Notice or other document evidencing such Award. Participation in the Plan shall not give any Participant any right to remain in the employ, or to serve as a director, of the Company or any Subsidiary or Affiliate of the Company or, in the case of employment with a Subsidiary or Affiliate, the Subsidiary or Affiliate reserves the right to terminate the employment of any Participant at any time. Further, the adoption of this Plan shall not be deemed to give any Employee or any other individual any right to be selected as a Participant or to be granted an Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">NO RIGHT, TITLE OR INTEREST IN COMPANY ASSETS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan is intended to constitute an &#8220;unfunded&#8221; plan for incentive compensation. No Participant shall have any rights as a stockholder as a result of participation in the Plan until the date of issuance of a stock certificate in the Participant&#8217;s name, and, in the case of restricted shares of Common Stock, such rights are granted to the Participant under Section 10.3 hereof. To the extent any person acquires a right to receive payments from the Company under the Plan, those rights shall be no greater than the rights of an unsecured creditor of the Company. In its sole discretion, the Committee may authorize the creation of trusts or other arrangements to meet the obligations created under the Plan to deliver Common Stock or to make payments in lieu of, or with respect to, Plan awards. However, unless the Committee determines otherwise with the express consent of the affected Participant, the existence of any such trusts or other arrangements is consistent with this &#8220;unfunded&#8221; status of the Plan.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">DIVIDENDS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No dividends or dividend equivalents shall be paid to Participants with respect to any unvested Awards until such Awards vest.  Notwithstanding the foregoing, dividends may be accrued and paid only at such time, if any, as such unvested Awards become vested. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">SECURITIES LAWS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to Section 16 Insiders, transactions under this Plan are intended to comply with all applicable conditions of Rule 16b-3 or its successors under the Exchange Act. To the extent any provision of the Plan or action by the Committee fails so to comply, it shall be deemed null and void, to the extent permitted by law and deemed advisable by the Committee.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">REQUIRED WRITTEN REPRESENTATIONS.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee may require each person purchasing shares pursuant to a stock option or other award under the Plan to represent to and agree with the Company in writing that the optionee or Participant is acquiring any shares of Common Stock without a view to their distribution. The certificates for shares may include any legend which the Committee deems appropriate to reflect any restrictions on transfer. All certificates for shares of Common Stock or other securities delivered under the Plan shall be subject to stop transfer orders and other restrictions the Committee deems advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Common Stock is then listed, and any applicable Federal or state securities laws, and the Committee may cause a legend or legends to be put on any certificates to make appropriate reference to the applicable restrictions. Each Participant is responsible for fully complying with all applicable state and federal securities laws and rules and the Company assumes no responsibility for compliance with any such laws or rules pertaining to a Participant&#8217;s resale of any shares of Common Stock acquired pursuant to this Plan.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">NON-EXCLUSIVE ARRANGEMENT.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if required&#59; and those arrangements may be either generally applicable or applicable only in specific cases.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">LIMITS ON LIABILITY AND INDEMNIFICATION.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of the Committee and the Board shall not be liable to any employee or other person with respect to any determination made under the Plan in a manner that is not inconsistent with their legal obligations as members of the Board. In addition to all other rights of indemnification they may have as directors or as members of the Committee, the members of the Committee shall be indemnified by the Company against reasonable expenses, including attorneys&#8217; fees actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party because of any action taken or failure to act under or in connection with the Plan or any Award granted under it, and against all amounts paid by them in settlement (provided the settlement is approved by independent legal counsel selected by the Company) or paid to them in satisfaction of a judgment in that action, suit or proceeding, except in relation to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matters as to which it shall be adjudged in the action, suit or proceeding that the Committee member is liable for negligence or misconduct in the performance of his or her duties. Within 60 days after institution of any action, suit or proceeding covered by this Section 30, the Committee member must inform the Company in writing of the claim and offer the Company the opportunity, at its own expense, to handle and defend the matter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2826014-000031 04&#47;05&#47;2018&#34; &#34;&#34; </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>3
<FILENAME>a202010-kexhibit1026.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i001094500e954c6b82faa9b690eab7ce_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.26</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECOND AMENDMENT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amedisys, Inc. 2018 OMNIBUS Incentive COMPENSATION PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Second Amendment (this &#8220;Amendment&#8221;) to the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan, as amended (the &#8220;Plan&#8221;), is entered into this 21st day of October, 2020, by the Compensation Committee of the Board of Directors (the &#8220;Committee&#8221;) of Amedisys, Inc. (the &#8220;Company&#8221;), as authorized pursuant to Section 19 of the Plan.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company established and maintains the Plan, as it may be amended and&#47;or restated from time to time&#59; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Section 19 of the Plan permits the Committee to amend the Plan without stockholder approval as set forth therein&#59; and </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Committee now desires to amend the Plan to amend the definition of &#8220;Employment&#8221; to clarify the effect of a change in status of a Participant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, for Awards that vest or are granted on and after October 21, 2020, the Plan is hereby amended as follows&#58;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.20 of the Plan is hereby deleted in its entirety and replaced with the following&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;2.20&#160;&#160;&#160;&#160;&#8220;Employment&#8221; means, except as otherwise required by Section 409A of the Code, continuous, uninterrupted full time employment with the Company or any Affiliate or Subsidiary, and shall include the provision of services as an Outside Director or Consultant for the Company or any Affiliate or Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> that a change in a Participant&#8217;s status from an Employee or Outside Director to a Consultant shall constitute a termination of Employment as an Employee or Outside Director, as applicable, and shall constitute a new Employment as a Consultant, and for the avoidance of doubt, a change in a Participant&#8217;s status from a full time Employee to a part time Employee shall constitute a termination of Employment as an Employee under this Plan. A Participant&#8217;s Employment shall terminate on the date (i) the Participant&#8217;s status changes as set forth in the preceding sentence or (ii) the Participant is no longer employed by an entity that is at least one of the Company, an Affiliate or a Subsidiary as of such date. &#8220;Employed&#8221; shall have a correlative meaning.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Except as specifically set forth above, the terms of the Plan shall continue in full force and effect.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Committee has caused this Amendment to be adopted and executed effective October 21, 2020.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amedisys, Inc.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Julie D. Klapstein&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Julie D. Klapstein</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; Compensation Committee Chair</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>a202010-kexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if2faef0421e5402bbac67d24473936ed_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CORPORATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOSPICE DELAWARE, INC., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE, INC., a Pennsylvania corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE GROUP, INC., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA, INC., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF GWYNEDD, INC., a Pennsylvania corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER, INC., a Florida corporation </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND THE FLORIDA KEYS, INC., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HI-TECH CARE, INC., a Florida Corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOMECARE PREFERRED CHOICE, INC., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE OF EASTERN CAROLINA, INC., a North Carolina corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE PREFERRED CHOICE, INC., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE ACQUISITION CORP., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PEACEFUL DAYS HOSPICE, INC., a California corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">LIMITED LIABILITY COMPANIES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ACCUMED HEALTH SERVICES, L.L.C., a Texas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ACCUMED HOME HEALTH OF GEORGIA, L.L.C.., a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADVENTA HOSPICE, L.L.C., a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ALBERT GALLATIN HOME CARE AND HOSPICE SERVICES, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS ALABAMA, L.L.C., an Alabama limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS ARIZONA, L.L.C., an Arizona limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS ARKANSAS, LLC, an Arkansas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS BA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS DELAWARE, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS FLORIDA, L.L.C., a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS GEORGIA, L.L.C., a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HEALTH CARE WEST, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOLDING, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH OF ALABAMA, L.L.C. an Alabama limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH OF SOUTH CAROLINA, L.L.C. a South Carolina limied liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH OF VIRGINIA, L.L.C. a Virginia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOSPICE, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS IDAHO, L.L.C., an Idaho limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS ILLINOIS, L.L.C., an Illinois limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS INDIANA, L.L.C., an Indiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS KANSAS, L.L.C., a Kansas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS LA ACQUISITIONS, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS LOUISIANA, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS MAINE, P.L.L.C., a Maine professional limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS MARYLAND, L.L.C., a Maryland limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS MISSISSIPPI, L.L.C., a Mississippi limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS MISSOURI, L.L.C., a Missouri limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NEW HAMPSHIRE, L.L.C., a New Hampshire limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NEW JERSEY, L.L.C., a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NORTH CAROLINA, L.L.C., a North Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NORTHWEST, L.L.C., a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS OHIO, L.L.C., an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS OKLAHOMA, L.L.C., an Oklahoma limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS OREGON, L.L.C., an Oregon limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS PENNSYLVANIA, L.L.C., a Pennsylvania limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS PERSONAL CARE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS RHODE ISLAND, L.L.C., a Rhode Island limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SC, L.L.C., a South Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SPECIALIZED MEDICAL SERVICES, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SP-IN, L.L.C., an Indiana limited liability company</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SP-KY, L.L.C., a Kentucky limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SP-OH, L.L.C., an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SP-TN, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS TENNESSEE, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS TEXAS, L.L.C., a Texas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS TLC ACQUISITION, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS WASHINGTON, L.L.C., a Washington limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS WEST VIRGINIA, L.L.C., a West Virginia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS WISCONSIN, L.L.C., a Wisconsin limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ANGEL WATCH HOME CARE, L.L.C., a Florida limited liability company  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASANA HOSPICE CLEVELAND, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASANA PALLIATIVE CLEVELAND, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; DEMOPOLIS, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; HAMILTON, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; JACKSON, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; MONROEVILLE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; NEW HORIZONS, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; RUSSELLVILLE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; SENTOBIA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; TENNESSEE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASSOCIATED HOME CARE, L.L.C., a Massachusetts limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AT HOME PARTNERS, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVENIR VENTURES, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BEACON HOSPICE, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BEAUFORT HOME HEALTH PARTNERS, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CH HOLDINGS, LLC, a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF BRYAN TEXAS, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CENTRAL GEORGIA, LLC, a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CENTRAL LOUISIANA, LLC, a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CENTRAL TEXAS, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CLIFTON, LLC, a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF DELAWARE, LLC, a Delaware limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF HOUSTON, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF ILLINOIS, LLC, an Illinois limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF KANSAS CITY, LLC, a Kansas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MAINE, LLC, a Maine limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MARLTON, LLC, a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MASSACHUSETTS, LLC, a Massachusetts limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MICHIGAN, LLC, a Michigan limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MINNESOTA, LLC, a Minnesota limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NEW HAMPSHIRE, LLC, a New Hampshire limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NORTH TEXAS, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NORTHERN GEORGIA, LLC, a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NORTHERN NEW JERSEY, LLC, a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NORTHWESTERN PENNSYLVANIA, LLC, a Pennsylvania limited liability company COMPASSIONATE CARE HOSPICE OF OHIO, LLC, an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF PITTSBURG, LLC, a Pennsylvania limited liability company C</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SAN DIEGO, LLC, a California limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SAVANNAH, LLC, a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SOUTH CAROLINA, LLC, a South Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SOUTHEASTERN MASSACHUSETTS, LLC, a Massachusetts limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SOUTHEASTERN TEXAS, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SOUTHERN MISSISSIPPI, LLC, a Mississippi limited liability company COMPASSIONATE CARE HOSPICE OF THE CHESAPEAKE BAY, LLC, a Virginia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF THE DELMAR PENINSULA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF THE MIDWEST, LLC, a South Dakota limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF WISCONSIN, LLC, a Wisconsin limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE WEST, LLC, a California limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPREHENSIVE HOME HEALTHCARE SERVICES, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ELDER HOME OPTIONS, L.L.C., a Massachusetts limited liability company</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EMERALD CARE, L.L.C., a North Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FAMILY HOME HEALTH CARE, L.L.C., a Kentucky limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HHC, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOME HEALTH OF ALEXANDRIA, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOME HEALTH PARTNERSHIP OPERATING COMPANY, L.L.C., a Texas limited liability company (100% owned by UMC Home Health and Hospice, an Amedisys Partner, L.L.C. JV)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOME HOSPITALISTS OF AMERICA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HORIZONS HOSPICE CARE, L.L.C., an Alabama limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE HOLDINGS DFW, LLC, a Texas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE HOLDINGS HARRISBURG, LLC, a Pennsylvania Limited Liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE PARTNERSHIP OPERATING COMPANY, L.L.C., a Texas limited liability company (100% owned by UMC Home Health and Hospice, an Amedisys Partner, L.L.C. JV)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOUSECALL HOME HEALTH, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE, L.L.C., a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF BROWARD, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF JACKSONVILLE, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF LAKELAND, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF OCALA, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF PINELLAS, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF PORT CHARLOTTE, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOMECARE OF DISTRICT 9, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MISSOURI HOSPICE HOLDINGS, LLC, a Missouri limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NINE PALMS 1, L.L.C., a Virginia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NINE PALMS 2, LLC, a Mississippi limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OHIO HOSPICE HOLDINGS, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PATHWAYS TO COMPASSION, LLC, a Nebraska limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PATHWAYS TO COMPASSION, LLC, a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PATHWAYS TO COMPASSION OF CALIFORNIA, LLC, a California limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PENNSYLVANIA HOSPICE HOLDINGS, LLC, a Pennsylvania limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TAYLOR HOSPICE HOLDINGS, LLC, a Pennsylvania limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES INTERNATIONAL, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF BROWARD, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF ERIE NIAGARA, LLC, a New York limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF GEORGIA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF NASSAU SUFFOLK, LLC, a New York limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF NEW ENGLAND, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF WEST VIRGINIA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES SOUTHEAST, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES WESTERN, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TEXAS HOSPICE HOLDINGS, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TLC HOLDINGS I, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TLC HEALTH CARE SERVICES, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TUCSON HOME HEALTH, LLC, a Delaware limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WT HOSPICE HOLDINGS, LLC, a Pennsylvania limited liability company</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">JOINT VENTURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH, A LAWRENCE MEDICAL CENTER PARTNER, L.L.C, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(66.67% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AT INDIANAPOLIS HOME PARTNERS, L.L.C., a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GEORGETOWN HOSPITAL HOME HEALTH, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(70% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MARIETTA HOME HEALTH AND HOSPICE, L.L.C., an Ohio limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> (50% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MORGANTOWN HOSPICE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(80% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TRI-CITIES HOME HEALTH, LLC, a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> (50% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WENTWORTH HOME CARE AND HOSPICE, LLC, a New Hampshire limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> (50% ownership)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">UMC HOME HEALH AND HOSPICE, AN AMEDISYS PARTNER, L.L.C., a Texas limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(50% ownership)</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a202010-kexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i14440ae6663d4862882d5027c69b0972_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc.&#58;</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statement (Nos. 333-138255 and 333-145582) on Form&#160;S&#8209;3 and (Nos.&#160;333&#8209;60525, 333&#8209;51704, 333&#8209;53786, 333&#8209;143967, 333&#8209;152359, 333&#8209;182347, 333&#8209;205267, and 333-225461) on Form&#160;S&#8209;8 of Amedisys, Inc. of our reports dated February 25, 2021, with respect to the consolidated balance sheets of Amedisys, Inc. as of December&#160;31, 2020 and 2019, and the related consolidated statements of operations, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three&#8209;year period ended December&#160;31, 2020, and the related notes (collectively, the&#160;consolidated financial statements), and the effectiveness of internal control over financial reporting as of December&#160;31, 2020, which reports appear in the December&#160;31, 2020 annual report on Form&#160;10&#8209;K of Amedisys, Inc. Our report on the consolidated financial statements refers to a change in the method of accounting for leases.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baton Rouge, Louisiana</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 25, 2021</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>a202010-kexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iab4a8f09ca24402280c6cfa537ecd192_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul B. Kusserow, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2020, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47;&#160;Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>a202010-kexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0b10b79f7e304f39b930a818da56ccd6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott G. Ginn, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2020, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47;&#160;Scott G. Ginn</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>a202010-kexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iaba1d79684e6459caac3d752b9f29ac6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;Report&#8221;), I, Paul B. Kusserow, Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47;&#160;Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>a202010-kexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4d3003bd754e4edfbeed5eb6bd568f6c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;Report&#8221;), I, Scott G. Ginn, Executive Vice President and Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47;&#160;Scott G. Ginn</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>amed-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:267db984-3247-4ac4-9ea7-650da4f8e37e,g:25daadda-e66f-46f9-96fb-eec4b4d1abf0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amed="http://www.amedisys.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amedisys.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.amedisys.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
        <link:definition>2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails">
        <link:definition>2403402 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Recently Issued Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsPolicies" roleURI="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies">
        <link:definition>2204201 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2105102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2206202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2307301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails">
        <link:definition>2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
        <link:definition>2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails">
        <link:definition>2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails">
        <link:definition>2413408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails">
        <link:definition>2414409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails">
        <link:definition>2415410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails">
        <link:definition>2416411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19">
        <link:definition>2117103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Tables" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables">
        <link:definition>2318302 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Details" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details">
        <link:definition>2419412 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.amedisys.com/role/ACQUISITIONS">
        <link:definition>2120104 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.amedisys.com/role/ACQUISITIONSTables">
        <link:definition>2321303 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>2422413 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails">
        <link:definition>2423414 - Disclosure - ACQUISITIONS - Pro Forma Condensed Consolidated Statement of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNET" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET">
        <link:definition>2124105 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETTables" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables">
        <link:definition>2325304 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails">
        <link:definition>2426415 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails">
        <link:definition>2427416 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails">
        <link:definition>2428417 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails">
        <link:definition>2429418 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DETAILSOFCERTAINBALANCESHEETACCOUNTS" roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS">
        <link:definition>2130106 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables">
        <link:definition>2331305 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails">
        <link:definition>2432419 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.amedisys.com/role/LEASES">
        <link:definition>2133107 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.amedisys.com/role/LEASESTables">
        <link:definition>2334306 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCodificationTopic842Policies" roleURI="http://www.amedisys.com/role/LeasesCodificationTopic842Policies">
        <link:definition>2235203 - Disclosure - Leases, Codification Topic 842 (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESDetails" roleURI="http://www.amedisys.com/role/LEASESDetails">
        <link:definition>2436420 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostDetails" roleURI="http://www.amedisys.com/role/LEASESLeaseCostDetails">
        <link:definition>2437421 - Disclosure - LEASES - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseDetails" roleURI="http://www.amedisys.com/role/LEASESOperatingLeaseDetails">
        <link:definition>2438422 - Disclosure - LEASES - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESFinanceLeasesDetails" roleURI="http://www.amedisys.com/role/LEASESFinanceLeasesDetails">
        <link:definition>2439423 - Disclosure - LEASES - Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSupplementalCashflowInformationDetails" roleURI="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails">
        <link:definition>2440424 - Disclosure - LEASES - Supplemental Cashflow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESWeightedAverageRemainingTermandDiscountRateDetails" roleURI="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails">
        <link:definition>2441425 - Disclosure - LEASES- Weighted Average Remaining Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesDetails" roleURI="http://www.amedisys.com/role/LEASESMaturitiesDetails">
        <link:definition>2442426 - Disclosure - LEASES - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONS" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <link:definition>2143108 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSTables" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables">
        <link:definition>2344307 - Disclosure - LONG-TERM OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails">
        <link:definition>2445427 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1">
        <link:definition>2445427 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails">
        <link:definition>2446428 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSMaturitiesofDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails">
        <link:definition>2447429 - Disclosure - LONG-TERM OBLIGATIONS - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
        <link:definition>2448430 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails">
        <link:definition>2449431 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.amedisys.com/role/INCOMETAXES">
        <link:definition>2150109 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.amedisys.com/role/INCOMETAXESTables">
        <link:definition>2351308 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2452432 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails">
        <link:definition>2453433 - Disclosure - INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESIncomeTaxExpenseAllocationDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails">
        <link:definition>2454434 - Disclosure - INCOME TAXES - Income Tax Expense Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofEffectiveTaxRateDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails">
        <link:definition>2455435 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>2456436 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>2457437 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATION" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION">
        <link:definition>2158110 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables">
        <link:definition>2359309 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2460438 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails">
        <link:definition>2461439 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails">
        <link:definition>2462440 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails">
        <link:definition>2463441 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails">
        <link:definition>2464442 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails">
        <link:definition>2465443 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails">
        <link:definition>2466444 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2167111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>2368310 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>2469445 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails">
        <link:definition>2470446 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2171112 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSNarrativeDetails" roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails">
        <link:definition>2472447 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASE" roleURI="http://www.amedisys.com/role/SHAREREPURCHASE">
        <link:definition>2173113 - Disclosure - SHARE REPURCHASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASENarrativeDetails" roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails">
        <link:definition>2474448 - Disclosure - SHARE REPURCHASE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <link:definition>2175114 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <link:definition>2376311 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2477449 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
        <link:definition>2478450 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION">
        <link:definition>2179115 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables">
        <link:definition>2380312 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails" roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails">
        <link:definition>2481451 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION Operating Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2182116 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>2483452 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" abstract="true" name="FiveHundredFiftyMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HealthcareanalyticscompanyMember" abstract="true" name="HealthcareanalyticscompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NonVestedStockAndStockUnits" abstract="false" name="NonVestedStockAndStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_EpisodesInProgressThatBeginDuringReportingPeriod" abstract="false" name="EpisodesInProgressThatBeginDuringReportingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_Percentageofownershipinsubsidiaries" abstract="false" name="Percentageofownershipinsubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_MedicarelicensesMember" abstract="true" name="MedicarelicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FleetLeaseMember" abstract="true" name="FleetLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_WageAndHourLitigationMember" abstract="true" name="WageAndHourLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DeferredOperatingIncomeCARESAct" abstract="false" name="DeferredOperatingIncomeCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BuildingAndLeaseholdImprovementsMember" abstract="true" name="BuildingAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NumberOfBeneficiaries" abstract="false" name="NumberOfBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_SurrenderedSharesInShares" abstract="false" name="SurrenderedSharesInShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" abstract="true" name="ShareBasedAwardsToMoreThanTenPercentOwnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ConsolidatedLeverageRatio" abstract="false" name="ConsolidatedLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_WriteOffOfOtherComprehensiveIncome" abstract="false" name="WriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PersonalCareMember" abstract="true" name="PersonalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DepreciationAndAmortizationForContinuingOperations" abstract="false" name="DepreciationAndAmortizationForContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CertificatesOfNeedAndLicensesMember" abstract="true" name="CertificatesOfNeedAndLicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DeferredTaxAssetsLegalAndComplianceMatters" abstract="false" name="DeferredTaxAssetsLegalAndComplianceMatters" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" abstract="false" name="DebtInstrumentCarryingAmountExcludingFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" abstract="false" name="EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_InternalAuditComplianceReviewMember" abstract="true" name="InternalAuditComplianceReviewMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CompassionateCareHospiceCIAMember" abstract="true" name="CompassionateCareHospiceCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_WorkersCompensationDeposits" abstract="false" name="WorkersCompensationDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearDomain" abstract="true" name="CapYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_OperatingCareCenters" abstract="false" name="OperatingCareCenters" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_Performancebasedawardtargetshareamount" abstract="false" name="Performancebasedawardtargetshareamount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_EastTennesseePersonalCareMember" abstract="true" name="EastTennesseePersonalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_InsuranceProgramsTableTableTextBlock" abstract="false" name="InsuranceProgramsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_Fairvalueofshareofcommonstockpercentage" abstract="false" name="Fairvalueofshareofcommonstockpercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" abstract="false" name="FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" abstract="false" name="MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_WokersCompensation" abstract="false" name="WokersCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LeaseLiabilityMaturityTableTextBlock" abstract="false" name="LeaseLiabilityMaturityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" abstract="false" name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_SafeguardZoneProgramIntegrityContractorMember" abstract="true" name="SafeguardZoneProgramIntegrityContractorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NetServiceRevenueEpisodePaymentRateDuration" abstract="false" name="NetServiceRevenueEpisodePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_AssetImpairmentChargesNetOfIncomeTaxes" abstract="false" name="AssetImpairmentChargesNetOfIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForCostMethodPercent" abstract="false" name="MaximumPercentOwnershipForCostMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HospiceMedicareMember" abstract="true" name="HospiceMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LegalAndOtherSettlements" abstract="false" name="LegalAndOtherSettlements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AseraCareHospiceMember" abstract="true" name="AseraCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NonVestedStockUnitsServiceMember" abstract="true" name="NonVestedStockUnitsServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_OperatingLeaseTermYears" abstract="false" name="OperatingLeaseTermYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_NonVestedStockMember" abstract="true" name="NonVestedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_FrontierLitigationMember" abstract="true" name="FrontierLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_RevenueAdjustmentToMedicareRevenue" abstract="false" name="RevenueAdjustmentToMedicareRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" abstract="false" name="BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_TypeofEquityMethodInvestmentDomain" abstract="true" name="TypeofEquityMethodInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" abstract="false" name="PortionOfPatientAccountsReceivableDerivedFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="EpisodeOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_PercentageOfTotalReimbursementOfOutlierPayment" abstract="false" name="PercentageOfTotalReimbursementOfOutlierPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_MedalogixMember" abstract="true" name="MedalogixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MorgantownWestVirginiaMember" abstract="true" name="MorgantownWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LesseeLeasesTextBlock" abstract="false" name="LesseeLeasesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_Numberofpatients" abstract="false" name="Numberofpatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HistoricalCollectionRateFromMedicare" abstract="false" name="HistoricalCollectionRateFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_CashBalanceAssociatedWithProviderReliefFund" abstract="false" name="CashBalanceAssociatedWithProviderReliefFund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_KKRShareRepurchaseMember" abstract="true" name="KKRShareRepurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessAcquisitionProFormaOperatingIncomeLoss" abstract="false" name="BusinessAcquisitionProFormaOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DiscountedClosingStockPrice" abstract="false" name="DiscountedClosingStockPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_BringCareHomeMember" abstract="true" name="BringCareHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" abstract="false" name="NetServiceRevenuePeriodOfCarePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_AmedisysCIAMember" abstract="true" name="AmedisysCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageofClosingStockPrice" abstract="false" name="PercentageofClosingStockPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" abstract="false" name="CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_YearOfDeparture" abstract="false" name="YearOfDeparture" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="amed_WeightedAverageInterestRate" abstract="false" name="WeightedAverageInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HeritageHealthcareInnovationFundLPMember" abstract="true" name="HeritageHealthcareInnovationFundLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DeferredTaxAssetDeferredSocialSecurityTaxes" abstract="false" name="DeferredTaxAssetDeferredSocialSecurityTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NetOperatingLossMember" abstract="true" name="NetOperatingLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EstimatedMedicareCapLiability" abstract="false" name="EstimatedMedicareCapLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_InternallyDevelopedComputerSoftware" abstract="false" name="InternallyDevelopedComputerSoftware" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareNonEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareNonEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" abstract="false" name="GoodwillDeductibleForIncomeTaxPurposesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" abstract="false" name="LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" abstract="false" name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_PeriodOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="PeriodOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_ProceedsFromBorrowingsUnderTermLoan" abstract="false" name="ProceedsFromBorrowingsUnderTermLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessAcquisitionClosingPaymentAdjustment" abstract="false" name="BusinessAcquisitionClosingPaymentAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevolvingCreditFacilityTotal" abstract="false" name="RevolvingCreditFacilityTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ThirdThresholdOfTherapyServicesRequired" abstract="false" name="ThirdThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_RefundTaxYear" abstract="false" name="RefundTaxYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_EstimatedInsuranceLongTermPortion" abstract="false" name="EstimatedInsuranceLongTermPortion" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" abstract="false" name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeHealthAndHospiceMember" abstract="true" name="HomeHealthAndHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_UsDepartmentOfJusticeMember" abstract="true" name="UsDepartmentOfJusticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PaymentsRelatedToTaxAsset" abstract="false" name="PaymentsRelatedToTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HealthInsuranceDeposits" abstract="false" name="HealthInsuranceDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PayrollTaxEscrow" abstract="false" name="PayrollTaxEscrow" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentPeriodicPaymentPercentage" abstract="false" name="DebtInstrumentPeriodicPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_FundingReceivedFromCARESAct" abstract="false" name="FundingReceivedFromCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SwingLineLoanMember" abstract="true" name="SwingLineLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet" abstract="false" name="TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" abstract="false" name="ScheduleOfCaresActProviderReliefFundsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_OrganizationAndNatureOfOperationsTable" abstract="true" name="OrganizationAndNatureOfOperationsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_ExtrapolatedMember" abstract="true" name="ExtrapolatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EstimatedInsuranceTotal" abstract="false" name="EstimatedInsuranceTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="amed_SocialSecurityTaxMember" abstract="true" name="SocialSecurityTaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AsanaHospiceMember" abstract="true" name="AsanaHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LeaseTypeAxis" abstract="true" name="LeaseTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" abstract="false" name="WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IntercityHomeCareMember" abstract="true" name="IntercityHomeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" abstract="false" name="LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" abstract="false" name="AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AdditionalFundingDistributedToHealthcareProviders" abstract="false" name="AdditionalFundingDistributedToHealthcareProviders" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" abstract="false" name="CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes" abstract="false" name="BusinessAcquisitionTransactionCostsNetOfIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" abstract="false" name="SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_ShareRepurchaseTable" abstract="true" name="ShareRepurchaseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" abstract="false" name="UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmortizableAcquiredNamesMember" abstract="true" name="AmortizableAcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" abstract="false" name="LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TypeofEquityMethodInvestmentAxis" abstract="true" name="TypeofEquityMethodInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_NoncontrollingInterestSoldMember" abstract="true" name="NoncontrollingInterestSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_UnamortizedDebtIssuanceCostAmortizationPeriod" abstract="false" name="UnamortizedDebtIssuanceCostAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_HomeHealthMember" abstract="true" name="HomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NumberOfClaimsSubmittedBySubsidiary" abstract="false" name="NumberOfClaimsSubmittedBySubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NumberOfCareCentersSold" abstract="false" name="NumberOfCareCentersSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtIssuanceCostsPolicyPolicyTextBlock" abstract="false" name="DebtIssuanceCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" abstract="false" name="DeferredTaxAssetsGoodwillAndIntangibleAssets1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TotalCARESActProviderReliefFundsReceived" abstract="false" name="TotalCARESActProviderReliefFundsReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashDistributionToNoncontrollingInterest" abstract="false" name="CashDistributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CallPremiumPayment" abstract="false" name="CallPremiumPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" abstract="false" name="NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareRepurchaseDomain" abstract="true" name="ShareRepurchaseDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" abstract="false" name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_SwingLineFacility" abstract="false" name="SwingLineFacility" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PercentageofSharesOutstanding" abstract="false" name="PercentageofSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_UncertainTaxBenefitsInLongTermObligations" abstract="false" name="UncertainTaxBenefitsInLongTermObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsUtilized" abstract="false" name="CARESActProviderReliefFundsUtilized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LeaseTypeDomain" abstract="true" name="LeaseTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FirstThresholdOfTherapyServicesRequired" abstract="false" name="FirstThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_HomeHealthMedicareMember" abstract="true" name="HomeHealthMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_UnamortizableAcquiredNamesMember" abstract="true" name="UnamortizableAcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheThreeMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ProvisionforIncomeTaxesTableTextBlock" abstract="false" name="ProvisionforIncomeTaxesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_FinancialInstrumentDetailsTableTextBlock" abstract="false" name="FinancialInstrumentDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_WorkersCompensationInsuranceRetentionLimit" abstract="false" name="WorkersCompensationInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProfessionalLiability" abstract="false" name="ProfessionalLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TenetHealthcareMember" abstract="true" name="TenetHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CARESActDeferralOfEmployerShareSocialSecurityTax" abstract="false" name="CARESActDeferralOfEmployerShareSocialSecurityTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_AlternativeMinimumTaxCreditMember" abstract="true" name="AlternativeMinimumTaxCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TypeOfIncomeTaxDeferralDomain" abstract="true" name="TypeOfIncomeTaxDeferralDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AcquiredNamesMember" abstract="true" name="AcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" abstract="false" name="FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EstimatedInsuranceExcludingLongTermPortion" abstract="false" name="EstimatedInsuranceExcludingLongTermPortion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EquityImpactofRepurchaseofNoncontrollingInterest" abstract="false" name="EquityImpactofRepurchaseofNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProvisionForLiabilityOnRegulatoryAudit" abstract="false" name="ProvisionForLiabilityOnRegulatoryAudit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_KKRConsultingMember" abstract="true" name="KKRConsultingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_IndemnificationAmount" abstract="false" name="IndemnificationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ComputerInventoryAndDataSecurityReportingMember" abstract="true" name="ComputerInventoryAndDataSecurityReportingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentNumberOfPeriodicPayments" abstract="false" name="DebtInstrumentNumberOfPeriodicPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" abstract="true" name="NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TypeOfIncomeTaxDeferralAxis" abstract="true" name="TypeOfIncomeTaxDeferralAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_EstimatedFutureCOVID19RelatedExpenses" abstract="false" name="EstimatedFutureCOVID19RelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_COVID19TextBlock" abstract="false" name="COVID19TextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_FundingForHealthcareProvidersIncludingHospitals" abstract="false" name="FundingForHealthcareProvidersIncludingHospitals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearAxis" abstract="true" name="CapYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_ThresholdOfIndividualsInDataBreach" abstract="false" name="ThresholdOfIndividualsInDataBreach" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" abstract="false" name="EquityImpactOfWriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareBasedAwardsMember" abstract="true" name="ShareBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageOfPatientReceivablesOutstanding" abstract="false" name="PercentageOfPatientReceivablesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_OigSelfDisclosureMember" abstract="true" name="OigSelfDisclosureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_OrganizationAndNatureOfOperationsLineItems" abstract="true" name="OrganizationAndNatureOfOperationsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_LettersofCreditmaximumcommitment" abstract="false" name="LettersofCreditmaximumcommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareRepurchaseLineItems" abstract="true" name="ShareRepurchaseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_HospiceNonMedicareMember" abstract="true" name="HospiceNonMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DeferredTaxAssetsProviderReliefFundAdvance" abstract="false" name="DeferredTaxAssetsProviderReliefFundAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" abstract="false" name="Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_COVID19DeferralOfSocialSecurityTaxesMember" abstract="true" name="COVID19DeferralOfSocialSecurityTaxesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_UnrecognizedTaxBenefitsAxis" abstract="true" name="UnrecognizedTaxBenefitsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_FinanceLeasesTableTextBlock" abstract="false" name="FinanceLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_CompassionateCareHospiceMember" abstract="true" name="CompassionateCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheTwoMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" abstract="false" name="EstimatedCARESActProviderReliefFundAmountsToBeRepaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheOneMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_IncomeTaxEffectsAllocatedToGoodwill" abstract="false" name="IncomeTaxEffectsAllocatedToGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ErrorRatePercentage" abstract="false" name="ErrorRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" abstract="true" name="CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PayorClassAxis" abstract="true" name="PayorClassAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" abstract="true" name="OneHundredSeventyFiveMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CorporateIntegrityAgreementTerm" abstract="false" name="CorporateIntegrityAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_NoncontrollingInterestRepurchased" abstract="false" name="NoncontrollingInterestRepurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_OtherMiscellaneousDeposits" abstract="false" name="OtherMiscellaneousDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DefinedContributionPlanEmployerMatchingContribution" abstract="false" name="DefinedContributionPlanEmployerMatchingContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TaxCreditCarryforwardMember" abstract="true" name="TaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PatientLiability" abstract="false" name="PatientLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_ConsolidatedInterestCoverageRatio" abstract="false" name="ConsolidatedInterestCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_HealthInsuranceRetentionLimit" abstract="false" name="HealthInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DetailsOfCertainBalanceSheetAccountsAbstract" abstract="true" name="DetailsOfCertainBalanceSheetAccountsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentInterestRateatPeriodEnd" abstract="false" name="DebtInstrumentInterestRateatPeriodEnd" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_SecondThresholdOfServicesRequired" abstract="false" name="SecondThresholdOfServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ExecutiveStockOptionExerciseMember" abstract="true" name="ExecutiveStockOptionExerciseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitMember" abstract="true" name="SecuritiesClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ResearchAndDevelopmentTaxCreditMember" abstract="true" name="ResearchAndDevelopmentTaxCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HospiceAccruals" abstract="false" name="HospiceAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AssociatedHomecareMember" abstract="true" name="AssociatedHomecareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" abstract="false" name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ProceedsReceivedFromLoanPartyOfSubsidiary" abstract="false" name="ProceedsReceivedFromLoanPartyOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IdahoandWyomingSelfReportMember" abstract="true" name="IdahoandWyomingSelfReportMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" abstract="false" name="EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" abstract="false" name="MinimumDaysAccountsReceivableOutstandingFullyReserved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_TwoHundredMillionRevolvingCreditFacilityMember" abstract="true" name="TwoHundredMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EmploymentTaxCreditMember" abstract="true" name="EmploymentTaxCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CertificateOfNeedMember" abstract="true" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_IncomeTaxEffectsAllocatedToInterestExpense" abstract="false" name="IncomeTaxEffectsAllocatedToInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedicareRevenueMember" abstract="true" name="MedicareRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" abstract="false" name="Revenuebypayorclassasapercentageoftotalnetservicerevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_OtherIntangibleAssetsAdditions" abstract="false" name="OtherIntangibleAssetsAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ParkersburgWestVirginiaMember" abstract="true" name="ParkersburgWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" abstract="false" name="LowUtilizationPaymentAdjustmentNumberOfVisits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ActualClaimsPayment" abstract="false" name="ActualClaimsPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_UnrecognizedTaxBenefitsDomain" abstract="true" name="UnrecognizedTaxBenefitsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NumberOfIndividualStatesSubjectToIncomeTax" abstract="false" name="NumberOfIndividualStatesSubjectToIncomeTax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ClearwaterFloridaMember" abstract="true" name="ClearwaterFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_UnfavorableMember" abstract="true" name="UnfavorableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FundsReceivedFromProviderReliefFundAdvance" abstract="false" name="FundsReceivedFromProviderReliefFundAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PaymentsForRepurchaseOfNoncontrollingInterest" abstract="false" name="PaymentsForRepurchaseOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" abstract="false" name="DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Creditfacilitymaximumallowableconsolidatedleverageratio" abstract="false" name="Creditfacilitymaximumallowableconsolidatedleverageratio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_TotalLeverageRatio" abstract="false" name="TotalLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_RoseRockHealthcareMember" abstract="true" name="RoseRockHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" abstract="true" name="CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NonMedicareRevenueTermRates" abstract="false" name="NonMedicareRevenueTermRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CareInnovationsMember" abstract="true" name="CareInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_OtherLongTermObligationsMember" abstract="true" name="OtherLongTermObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DeferredCompensationPlanLiability" abstract="false" name="DeferredCompensationPlanLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MinimumPercentOwnershipForControllingInterestPercent" abstract="false" name="MinimumPercentOwnershipForControllingInterestPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForEquityMethodPercent" abstract="false" name="MaximumPercentOwnershipForEquityMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" abstract="false" name="HospiceMedicareRevenueRateAccountedForRoutineCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" abstract="false" name="DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_LegalFeesNetOfIncomeTaxes" abstract="false" name="LegalFeesNetOfIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AcquiredNameOfBusinessMember" abstract="true" name="AcquiredNameOfBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LetterOfCreditFee" abstract="false" name="LetterOfCreditFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ShareRepurchaseAxis" abstract="true" name="ShareRepurchaseAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_NonVestedStockUnitsMember" abstract="true" name="NonVestedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_InfinityHomeCareMember" abstract="true" name="InfinityHomeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AsanaHospiceAcquisitionMember" abstract="true" name="AsanaHospiceAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_GovernmentGrantsPolicyTextBlock" abstract="false" name="GovernmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_ChristianCareatHomeMember" abstract="true" name="ChristianCareatHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ProfessionalLiabilityInsuranceRetentionLimit" abstract="false" name="ProfessionalLiabilityInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OperatingLeasesTableTextBlock" abstract="false" name="OperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" abstract="false" name="CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_StateTaxCreditMember" abstract="true" name="StateTaxCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_SurrenderedShares" abstract="false" name="SurrenderedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FloridaZpicRevenueReduction" abstract="false" name="FloridaZpicRevenueReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" abstract="false" name="DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_EquipmentAndFurnitureMember" abstract="true" name="EquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessAcquisitionWorkingCapitalAdjustment" abstract="false" name="BusinessAcquisitionWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_A2019StockRepurchaseProgramMember" abstract="true" name="A2019StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CertificatesOfNeedMember" abstract="true" name="CertificatesOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheFourMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LakelandFloridaMember" abstract="true" name="LakelandFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" abstract="false" name="BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_AdditionalPerformanceBasedAwardTargetShareAmount" abstract="false" name="AdditionalPerformanceBasedAwardTargetShareAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_PayorClassDomain" abstract="true" name="PayorClassDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HealthInsurance" abstract="false" name="HealthInsurance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProviderReliefFundAdvance" abstract="false" name="ProviderReliefFundAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_A2021StockRepurchaseProgramMember" abstract="true" name="A2021StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment" abstract="false" name="EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeStaffLlcMember" abstract="true" name="HomeStaffLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CharityCare" abstract="false" name="CharityCare" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_COVID19ExpensesIncurred" abstract="false" name="COVID19ExpensesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>amed-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:267db984-3247-4ac4-9ea7-650da4f8e37e,g:25daadda-e66f-46f9-96fb-eec4b4d1abf0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="amed-20201231.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46176bbf-a882-42a0-aeac-e56c904bfd0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9d0692c7-1807-452b-8f18-2c9a3ee1f913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46176bbf-a882-42a0-aeac-e56c904bfd0a" xlink:to="loc_us-gaap_StockholdersEquity_9d0692c7-1807-452b-8f18-2c9a3ee1f913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0dbe6695-a80a-43df-a243-c943885d7085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_46176bbf-a882-42a0-aeac-e56c904bfd0a" xlink:to="loc_us-gaap_MinorityInterest_0dbe6695-a80a-43df-a243-c943885d7085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3fe6257f-4582-429f-9b23-bcf05c12ddea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_cb12fbf5-16f0-4630-9063-b8453ff312a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3fe6257f-4582-429f-9b23-bcf05c12ddea" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_cb12fbf5-16f0-4630-9063-b8453ff312a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_6ce66f48-5cac-41da-b102-55ee3798b0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3fe6257f-4582-429f-9b23-bcf05c12ddea" xlink:to="loc_us-gaap_CommonStockValueOutstanding_6ce66f48-5cac-41da-b102-55ee3798b0b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a5ba6bd8-2930-463b-bf29-ada18c1051b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3fe6257f-4582-429f-9b23-bcf05c12ddea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a5ba6bd8-2930-463b-bf29-ada18c1051b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b5928feb-7c40-46a0-9758-c0e61f2ac850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3fe6257f-4582-429f-9b23-bcf05c12ddea" xlink:to="loc_us-gaap_TreasuryStockValue_b5928feb-7c40-46a0-9758-c0e61f2ac850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9f75adc4-6a2f-455a-aa44-f499b5d7573b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3fe6257f-4582-429f-9b23-bcf05c12ddea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9f75adc4-6a2f-455a-aa44-f499b5d7573b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac2a7aff-fe1e-4e6b-8434-05e96453cdb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3fe6257f-4582-429f-9b23-bcf05c12ddea" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac2a7aff-fe1e-4e6b-8434-05e96453cdb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4fc64f8b-8d9a-4a2f-a89f-bf546307e70f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6434a4a9-012a-457c-be1e-0c7146b41101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4fc64f8b-8d9a-4a2f-a89f-bf546307e70f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6434a4a9-012a-457c-be1e-0c7146b41101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_55e945f8-65f3-477f-8e9c-f8f09cad3737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4fc64f8b-8d9a-4a2f-a89f-bf546307e70f" xlink:to="loc_us-gaap_RestrictedCash_55e945f8-65f3-477f-8e9c-f8f09cad3737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8258c78f-d8f4-4c5c-9fc7-c6317754f333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4fc64f8b-8d9a-4a2f-a89f-bf546307e70f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8258c78f-d8f4-4c5c-9fc7-c6317754f333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_0f8a2ec9-fde9-41a8-af86-07d142d139a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4fc64f8b-8d9a-4a2f-a89f-bf546307e70f" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_0f8a2ec9-fde9-41a8-af86-07d142d139a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8eb7c372-5d53-4c1a-a6d3-c98e5f1911e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4fc64f8b-8d9a-4a2f-a89f-bf546307e70f" xlink:to="loc_us-gaap_OtherAssetsCurrent_8eb7c372-5d53-4c1a-a6d3-c98e5f1911e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_baaec3a1-911e-4480-9dbd-fe60ae900279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d8762a0d-800e-4757-b648-243e82cf7a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_baaec3a1-911e-4480-9dbd-fe60ae900279" xlink:to="loc_us-gaap_AccountsPayableCurrent_d8762a0d-800e-4757-b648-243e82cf7a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_495afe99-3afa-4b35-9aa6-22de5886a8cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_baaec3a1-911e-4480-9dbd-fe60ae900279" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_495afe99-3afa-4b35-9aa6-22de5886a8cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d47469ba-9eb7-4488-9262-4414d9d2e9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_baaec3a1-911e-4480-9dbd-fe60ae900279" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d47469ba-9eb7-4488-9262-4414d9d2e9cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_31b96ba5-7a6d-470e-aeb2-5159c8c3da8f" xlink:href="amed-20201231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_baaec3a1-911e-4480-9dbd-fe60ae900279" xlink:to="loc_amed_ProviderReliefFundAdvance_31b96ba5-7a6d-470e-aeb2-5159c8c3da8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4af1726c-1c01-4445-9056-0ca275462002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_baaec3a1-911e-4480-9dbd-fe60ae900279" xlink:to="loc_us-gaap_LongTermDebtCurrent_4af1726c-1c01-4445-9056-0ca275462002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_422c6dcb-fb28-4a38-a7ba-fa4aa965c87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_baaec3a1-911e-4480-9dbd-fe60ae900279" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_422c6dcb-fb28-4a38-a7ba-fa4aa965c87c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4f644dad-4cc7-4e59-b3c5-b9a9cd1656c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d7070c8c-aeff-411f-a280-db6ec143f41a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4f644dad-4cc7-4e59-b3c5-b9a9cd1656c9" xlink:to="loc_us-gaap_Liabilities_d7070c8c-aeff-411f-a280-db6ec143f41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09ff0d77-7d97-4213-b7cd-f303e6f30205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4f644dad-4cc7-4e59-b3c5-b9a9cd1656c9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09ff0d77-7d97-4213-b7cd-f303e6f30205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c5d30d97-1795-45a9-9e6c-7da0438edb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6b58a84a-0be9-4e05-b41e-baacea2642ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c5d30d97-1795-45a9-9e6c-7da0438edb6a" xlink:to="loc_us-gaap_LiabilitiesCurrent_6b58a84a-0be9-4e05-b41e-baacea2642ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_152ae31c-e66a-4569-aea6-d1f2150ca3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c5d30d97-1795-45a9-9e6c-7da0438edb6a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_152ae31c-e66a-4569-aea6-d1f2150ca3df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_febb01ad-90e2-4807-83ce-42a4c0457509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c5d30d97-1795-45a9-9e6c-7da0438edb6a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_febb01ad-90e2-4807-83ce-42a4c0457509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_89623ca9-90bd-4931-8b0c-428018dc9960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c5d30d97-1795-45a9-9e6c-7da0438edb6a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_89623ca9-90bd-4931-8b0c-428018dc9960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_474a67ca-db67-4e88-b475-54273c7c1644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4c15fc1f-74da-4222-9562-e42a0eeb4f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_474a67ca-db67-4e88-b475-54273c7c1644" xlink:to="loc_us-gaap_AssetsCurrent_4c15fc1f-74da-4222-9562-e42a0eeb4f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19fed574-d191-4470-a8d0-158c7f981b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_474a67ca-db67-4e88-b475-54273c7c1644" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_19fed574-d191-4470-a8d0-158c7f981b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_064dc046-68c7-47f4-b5de-b6b6e4a9d0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_474a67ca-db67-4e88-b475-54273c7c1644" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_064dc046-68c7-47f4-b5de-b6b6e4a9d0be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d2e97e3e-8d7d-4a97-b446-7ce3bb573e8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_474a67ca-db67-4e88-b475-54273c7c1644" xlink:to="loc_us-gaap_Goodwill_d2e97e3e-8d7d-4a97-b446-7ce3bb573e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1092de93-512b-44b7-9098-c442449a407f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_474a67ca-db67-4e88-b475-54273c7c1644" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1092de93-512b-44b7-9098-c442449a407f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_dbbd6411-780a-41ac-ba30-21fe96427f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_474a67ca-db67-4e88-b475-54273c7c1644" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_dbbd6411-780a-41ac-ba30-21fe96427f8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_852bea68-86a3-42f2-9093-5d92dcb8b8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_474a67ca-db67-4e88-b475-54273c7c1644" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_852bea68-86a3-42f2-9093-5d92dcb8b8ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_337ac5b9-bab5-4275-bbc5-2c0dae7a9445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_47c59eae-cd92-4290-ba3a-f6ecb171e448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_337ac5b9-bab5-4275-bbc5-2c0dae7a9445" xlink:to="loc_us-gaap_ProfitLoss_47c59eae-cd92-4290-ba3a-f6ecb171e448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_42c830b6-a5f0-498a-ad05-633b4c10d1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_337ac5b9-bab5-4275-bbc5-2c0dae7a9445" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_42c830b6-a5f0-498a-ad05-633b4c10d1c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c2073721-8443-4b73-879b-d4864288d79c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_13cfecb6-caa4-4a68-a189-b7970067f0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c2073721-8443-4b73-879b-d4864288d79c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_13cfecb6-caa4-4a68-a189-b7970067f0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_5f0b1040-c38a-4b50-a22f-649e8fe26f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c2073721-8443-4b73-879b-d4864288d79c" xlink:to="loc_us-gaap_LaborAndRelatedExpense_5f0b1040-c38a-4b50-a22f-649e8fe26f7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c634ffe5-3933-4447-bfb4-143122dc1764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c2073721-8443-4b73-879b-d4864288d79c" xlink:to="loc_us-gaap_ShareBasedCompensation_c634ffe5-3933-4447-bfb4-143122dc1764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_5432f5b9-7bdf-441d-bfc1-205d44cc778b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c2073721-8443-4b73-879b-d4864288d79c" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_5432f5b9-7bdf-441d-bfc1-205d44cc778b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_476a6272-db3e-422f-a669-7f8e24b9168f" xlink:href="amed-20201231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c2073721-8443-4b73-879b-d4864288d79c" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_476a6272-db3e-422f-a669-7f8e24b9168f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_57b8dd2e-3fa4-4d1d-87b2-b8b53824f6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c2073721-8443-4b73-879b-d4864288d79c" xlink:to="loc_us-gaap_AssetImpairmentCharges_57b8dd2e-3fa4-4d1d-87b2-b8b53824f6d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_70424f8e-6376-427c-bbdb-43f4b163f30b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_35c8fe9d-ced7-4c5c-97cf-67ea941d5a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_70424f8e-6376-427c-bbdb-43f4b163f30b" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_35c8fe9d-ced7-4c5c-97cf-67ea941d5a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0a0f6872-f20a-42bb-8ea2-d7d8e149cb68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_70424f8e-6376-427c-bbdb-43f4b163f30b" xlink:to="loc_us-gaap_InterestExpense_0a0f6872-f20a-42bb-8ea2-d7d8e149cb68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9681096c-baf9-41bc-b73c-33606b8ac933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_70424f8e-6376-427c-bbdb-43f4b163f30b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9681096c-baf9-41bc-b73c-33606b8ac933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_743da26f-168a-44b1-a251-a6285907f222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_70424f8e-6376-427c-bbdb-43f4b163f30b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_743da26f-168a-44b1-a251-a6285907f222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_17d6f08b-3210-47e6-83e1-b1e2f4b41599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_75337c06-2133-4180-ba51-55ea5fb540f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_17d6f08b-3210-47e6-83e1-b1e2f4b41599" xlink:to="loc_us-gaap_OperatingIncomeLoss_75337c06-2133-4180-ba51-55ea5fb540f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_80c3b4e2-2cbf-45b2-8602-28cd56a9ab9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_17d6f08b-3210-47e6-83e1-b1e2f4b41599" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_80c3b4e2-2cbf-45b2-8602-28cd56a9ab9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_243f774f-7483-486f-9b16-8698ec374c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_7aea241c-fb4a-481d-a729-3a8ae11525c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_243f774f-7483-486f-9b16-8698ec374c7b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_7aea241c-fb4a-481d-a729-3a8ae11525c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_3e268c23-9c6b-46fc-b1a1-561ede4dca57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_243f774f-7483-486f-9b16-8698ec374c7b" xlink:to="loc_us-gaap_OtherOperatingIncome_3e268c23-9c6b-46fc-b1a1-561ede4dca57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0c70ecad-d4c3-4cfa-9dc8-c3fda6879757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_243f774f-7483-486f-9b16-8698ec374c7b" xlink:to="loc_us-gaap_CostsAndExpenses_0c70ecad-d4c3-4cfa-9dc8-c3fda6879757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1eb639d5-e213-4d4c-938b-ad46d4c4d356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15e5935e-8fda-43d4-bae9-17b86ad58072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1eb639d5-e213-4d4c-938b-ad46d4c4d356" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_15e5935e-8fda-43d4-bae9-17b86ad58072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5bff2f8f-ff0a-44f7-81bc-c73d1a50fa9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1eb639d5-e213-4d4c-938b-ad46d4c4d356" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5bff2f8f-ff0a-44f7-81bc-c73d1a50fa9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8890eb6b-1418-4e54-88c3-2bf94aeb2b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0e022dbd-4530-42b5-a7a7-a550a8efb8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8890eb6b-1418-4e54-88c3-2bf94aeb2b4d" xlink:to="loc_us-gaap_ProfitLoss_0e022dbd-4530-42b5-a7a7-a550a8efb8c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cabf1950-b62a-41fc-8924-3e379cba770c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8890eb6b-1418-4e54-88c3-2bf94aeb2b4d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cabf1950-b62a-41fc-8924-3e379cba770c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_10e0fc79-f414-45a7-a39f-77542a8584b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bc9f06b2-9489-4dfd-9e09-8e43ef5893f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_10e0fc79-f414-45a7-a39f-77542a8584b8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bc9f06b2-9489-4dfd-9e09-8e43ef5893f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_01b0bd24-da41-495a-838e-15bd7dd67770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_10e0fc79-f414-45a7-a39f-77542a8584b8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_01b0bd24-da41-495a-838e-15bd7dd67770" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826274ff-f2f6-4d2d-a47f-f4e788ae205c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1dc997c3-42c5-49e4-b6ce-a84f818898b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826274ff-f2f6-4d2d-a47f-f4e788ae205c" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1dc997c3-42c5-49e4-b6ce-a84f818898b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f82ba9b1-456c-4a28-b387-643791a75f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826274ff-f2f6-4d2d-a47f-f4e788ae205c" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f82ba9b1-456c-4a28-b387-643791a75f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_28ad0c3c-5fa4-4c5a-ada2-f641dde03933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826274ff-f2f6-4d2d-a47f-f4e788ae205c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_28ad0c3c-5fa4-4c5a-ada2-f641dde03933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d291f36c-aee6-4a50-a94a-8a1dad03826d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826274ff-f2f6-4d2d-a47f-f4e788ae205c" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d291f36c-aee6-4a50-a94a-8a1dad03826d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_6638dc58-d428-4d2c-ae69-7bce6a76624d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826274ff-f2f6-4d2d-a47f-f4e788ae205c" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_6638dc58-d428-4d2c-ae69-7bce6a76624d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d329b105-52f3-4f05-8444-45e499f05336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_826274ff-f2f6-4d2d-a47f-f4e788ae205c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d329b105-52f3-4f05-8444-45e499f05336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0f79ef61-2ceb-4e5d-8c33-da1a650aa1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ead0e6f4-3828-49f8-a444-77d762ed67a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0f79ef61-2ceb-4e5d-8c33-da1a650aa1c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ead0e6f4-3828-49f8-a444-77d762ed67a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3fd3f943-c244-4e98-ae62-1f15be7beb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0f79ef61-2ceb-4e5d-8c33-da1a650aa1c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3fd3f943-c244-4e98-ae62-1f15be7beb53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4a1021f-f34a-4498-9628-3ff5617e11b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0f79ef61-2ceb-4e5d-8c33-da1a650aa1c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4a1021f-f34a-4498-9628-3ff5617e11b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dc8d3917-3c0e-4ce8-a2a7-bf2bcd3618e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_ProfitLoss_dc8d3917-3c0e-4ce8-a2a7-bf2bcd3618e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b1edcc4d-d41f-4f5f-b713-7472f5eb75ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b1edcc4d-d41f-4f5f-b713-7472f5eb75ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_517866f3-e5e6-4d1a-802f-33b10f51efd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_ShareBasedCompensation_517866f3-e5e6-4d1a-802f-33b10f51efd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense_42fce8e6-3b56-4b80-b87e-2537d7a1afe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_PensionExpense_42fce8e6-3b56-4b80-b87e-2537d7a1afe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_4d6740a2-3c38-4c51-b139-46febde47264" xlink:href="amed-20201231.xsd#amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_4d6740a2-3c38-4c51-b139-46febde47264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_515e5ab1-2c3b-4db7-b9f7-2298342358de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_515e5ab1-2c3b-4db7-b9f7-2298342358de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnSaleOfInvestments_7fe2bf57-f737-4e24-825a-d5c8d6e6695f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnSaleOfInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_LossOnSaleOfInvestments_7fe2bf57-f737-4e24-825a-d5c8d6e6695f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_dcb70abb-4871-4c98-a983-be08ca50eae8" xlink:href="amed-20201231.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_dcb70abb-4871-4c98-a983-be08ca50eae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_44725c79-a1ae-401c-b569-dc81037f9ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_44725c79-a1ae-401c-b569-dc81037f9ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_65edb050-fd5f-4e75-babe-e01ee5afad1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_65edb050-fd5f-4e75-babe-e01ee5afad1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b2572da0-d440-45ce-85cd-47c7eb1719b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_b2572da0-d440-45ce-85cd-47c7eb1719b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_99cb8437-a7ed-4901-8867-4e6324a77d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_99cb8437-a7ed-4901-8867-4e6324a77d90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8eec9e0a-070d-4977-a5e9-c83282ac0dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_AssetImpairmentCharges_8eec9e0a-070d-4977-a5e9-c83282ac0dd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_60494d7a-90f4-4292-b2e9-e8f231d77d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_60494d7a-90f4-4292-b2e9-e8f231d77d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c6d2b559-d5d4-496f-a3d2-715b8357eaab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c6d2b559-d5d4-496f-a3d2-715b8357eaab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ccf70d69-e80d-4840-9b77-9c9f21173b8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ccf70d69-e80d-4840-9b77-9c9f21173b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c7de52d-95ec-4222-9a07-6b9619ae31b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c7de52d-95ec-4222-9a07-6b9619ae31b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9c70659c-ba7c-4435-a47b-331b13f16a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9c70659c-ba7c-4435-a47b-331b13f16a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f55af2b4-089c-4ef0-a395-cfebb60bcb8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f55af2b4-089c-4ef0-a395-cfebb60bcb8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_aeb98e21-ebe8-4eba-8c21-54625a365dea" xlink:href="amed-20201231.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_aeb98e21-ebe8-4eba-8c21-54625a365dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_ce6135fc-f26c-492f-a02d-feaa24323221" xlink:href="amed-20201231.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac6ca029-ca1c-456e-ba26-7975a76a7bff" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_ce6135fc-f26c-492f-a02d-feaa24323221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b336d3af-c6de-4ef7-8aab-0d2ee455bea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b336d3af-c6de-4ef7-8aab-0d2ee455bea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_8b4cf5bd-2c00-4536-a614-a0bc6e5bb993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_us-gaap_ProceedsFromStockPlans_8b4cf5bd-2c00-4536-a614-a0bc6e5bb993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a9444a34-b7be-437b-a436-5cbddabd995e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a9444a34-b7be-437b-a436-5cbddabd995e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_788f948d-4b74-4482-9d67-7d3b587cf8a4" xlink:href="amed-20201231.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_788f948d-4b74-4482-9d67-7d3b587cf8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_4ed912ac-15a7-41ed-ad86-67049ca032dc" xlink:href="amed-20201231.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_amed_ProceedsFromBorrowingsUnderTermLoan_4ed912ac-15a7-41ed-ad86-67049ca032dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_ff0197f9-bc17-439c-a035-febf00b57865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_ff0197f9-bc17-439c-a035-febf00b57865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_625bece2-60e7-4171-8b77-9e889a009c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_625bece2-60e7-4171-8b77-9e889a009c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2dae7ce1-8f57-4cc8-9327-428b9d230136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2dae7ce1-8f57-4cc8-9327-428b9d230136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_69038b49-79e7-4d0f-bb60-651aeb6a1206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_69038b49-79e7-4d0f-bb60-651aeb6a1206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_aa3cb835-7de5-46ea-bb89-fdb2471e9a72" xlink:href="amed-20201231.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_aa3cb835-7de5-46ea-bb89-fdb2471e9a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_997578e2-e9a2-4243-ae4e-89935208e1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_997578e2-e9a2-4243-ae4e-89935208e1cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_a12826da-f113-464a-b1be-6c29b32d11e7" xlink:href="amed-20201231.xsd#amed_PaymentsForRepurchaseOfNoncontrollingInterest"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ce727db-7960-44e9-b9ca-342679e71c52" xlink:to="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_a12826da-f113-464a-b1be-6c29b32d11e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="simple" xlink:href="amed-20201231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2a918c8-188e-46e9-9393-136c16c42d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a5722796-2ec6-4032-9cb6-1823caf60f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d2a918c8-188e-46e9-9393-136c16c42d63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a5722796-2ec6-4032-9cb6-1823caf60f55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2e600d37-317b-4d90-be72-2f5b8c6441ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_d2a918c8-188e-46e9-9393-136c16c42d63" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2e600d37-317b-4d90-be72-2f5b8c6441ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d6cb8ff-6496-4998-b2ae-5ea1ffc75ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05314157-6cfd-4d20-8e4a-3afcef30ee62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d6cb8ff-6496-4998-b2ae-5ea1ffc75ad9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05314157-6cfd-4d20-8e4a-3afcef30ee62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4a4e62f8-49da-4fd9-9492-7e8f1be9c70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d6cb8ff-6496-4998-b2ae-5ea1ffc75ad9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4a4e62f8-49da-4fd9-9492-7e8f1be9c70e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_e64ace82-d4b7-474e-a4ec-210858a84b57" xlink:href="amed-20201231.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d6cb8ff-6496-4998-b2ae-5ea1ffc75ad9" xlink:to="loc_amed_NonVestedStockAndStockUnits_e64ace82-d4b7-474e-a4ec-210858a84b57" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Tables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNET"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a98a16c-cff7-47e6-a31c-b8e293384c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_87ec1fec-25da-42b3-abd9-3789e2a8ed66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a98a16c-cff7-47e6-a31c-b8e293384c20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_87ec1fec-25da-42b3-abd9-3789e2a8ed66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d4d81f8f-9062-40e6-972f-460e58ac4f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a98a16c-cff7-47e6-a31c-b8e293384c20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d4d81f8f-9062-40e6-972f-460e58ac4f00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_21186c51-62ff-4d7a-b645-cf2061a21ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a98a16c-cff7-47e6-a31c-b8e293384c20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_21186c51-62ff-4d7a-b645-cf2061a21ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_00532566-e626-4107-9e5d-1e3a5affeb98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a98a16c-cff7-47e6-a31c-b8e293384c20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_00532566-e626-4107-9e5d-1e3a5affeb98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_41d954c8-74c8-4470-b39e-1d811620ddc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a98a16c-cff7-47e6-a31c-b8e293384c20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_41d954c8-74c8-4470-b39e-1d811620ddc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8faa111b-1265-4fcf-9ec0-2c9d47cf381a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UncertainTaxBenefitsInLongTermObligations_81e70b64-7204-46ba-acf3-25b031779927" xlink:href="amed-20201231.xsd#amed_UncertainTaxBenefitsInLongTermObligations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8faa111b-1265-4fcf-9ec0-2c9d47cf381a" xlink:to="loc_amed_UncertainTaxBenefitsInLongTermObligations_81e70b64-7204-46ba-acf3-25b031779927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredCompensationPlanLiability_db5fd1b6-bb66-49e7-a813-15b1be470394" xlink:href="amed-20201231.xsd#amed_DeferredCompensationPlanLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8faa111b-1265-4fcf-9ec0-2c9d47cf381a" xlink:to="loc_amed_DeferredCompensationPlanLiability_db5fd1b6-bb66-49e7-a813-15b1be470394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct_5b6e6f01-0710-45d4-a006-bda298deb93b" xlink:href="amed-20201231.xsd#amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8faa111b-1265-4fcf-9ec0-2c9d47cf381a" xlink:to="loc_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct_5b6e6f01-0710-45d4-a006-bda298deb93b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_e3e9b7d3-3ba0-4379-9ef8-c028fac123b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_8faa111b-1265-4fcf-9ec0-2c9d47cf381a" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_e3e9b7d3-3ba0-4379-9ef8-c028fac123b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f5995f65-e5db-4e8c-bacf-4b1594faa220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayrollTaxEscrow_d45a775e-de8f-4064-888b-3d2d471bfd25" xlink:href="amed-20201231.xsd#amed_PayrollTaxEscrow"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_f5995f65-e5db-4e8c-bacf-4b1594faa220" xlink:to="loc_amed_PayrollTaxEscrow_d45a775e-de8f-4064-888b-3d2d471bfd25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_d7860a97-1497-4242-bc64-5747623625ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_f5995f65-e5db-4e8c-bacf-4b1594faa220" xlink:to="loc_us-gaap_IncomeTaxesReceivable_d7860a97-1497-4242-bc64-5747623625ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromJointVenturesCurrent_3b269853-295b-4335-b15c-6dcdec9da8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromJointVenturesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_f5995f65-e5db-4e8c-bacf-4b1594faa220" xlink:to="loc_us-gaap_DueFromJointVenturesCurrent_3b269853-295b-4335-b15c-6dcdec9da8dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_3c8ac33b-85bb-4597-ba7f-2cc7bcb0e185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_f5995f65-e5db-4e8c-bacf-4b1594faa220" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_3c8ac33b-85bb-4597-ba7f-2cc7bcb0e185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_24c3c823-caad-45f9-93a1-2a87ee53cab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationDeposits_588cada1-4393-43f5-b9f5-a06327562f0f" xlink:href="amed-20201231.xsd#amed_WorkersCompensationDeposits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_24c3c823-caad-45f9-93a1-2a87ee53cab6" xlink:to="loc_amed_WorkersCompensationDeposits_588cada1-4393-43f5-b9f5-a06327562f0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceDeposits_a40293e1-1981-463d-b7b9-a241f8547203" xlink:href="amed-20201231.xsd#amed_HealthInsuranceDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_24c3c823-caad-45f9-93a1-2a87ee53cab6" xlink:to="loc_amed_HealthInsuranceDeposits_a40293e1-1981-463d-b7b9-a241f8547203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherMiscellaneousDeposits_6db072c0-b95c-4562-b63c-2ef6480d3b03" xlink:href="amed-20201231.xsd#amed_OtherMiscellaneousDeposits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_24c3c823-caad-45f9-93a1-2a87ee53cab6" xlink:to="loc_amed_OtherMiscellaneousDeposits_6db072c0-b95c-4562-b63c-2ef6480d3b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_e9e9c430-cf9c-4beb-a41b-48536a8bb96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_24c3c823-caad-45f9-93a1-2a87ee53cab6" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_e9e9c430-cf9c-4beb-a41b-48536a8bb96a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_5cd25129-13a9-432d-b34c-43348c2b1600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_24c3c823-caad-45f9-93a1-2a87ee53cab6" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_5cd25129-13a9-432d-b34c-43348c2b1600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_d2a345e7-48df-4a83-b3cf-6541a93d25dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_24c3c823-caad-45f9-93a1-2a87ee53cab6" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_d2a345e7-48df-4a83-b3cf-6541a93d25dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_62b58fea-7410-46c8-866b-011a54778a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_62b58fea-7410-46c8-866b-011a54778a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_8478c9e7-7d91-4bf2-8d70-a24b1c38ed5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_8478c9e7-7d91-4bf2-8d70-a24b1c38ed5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionForLiabilityOnRegulatoryAudit_98984e95-efef-456c-ba9c-fcca04a30c33" xlink:href="amed-20201231.xsd#amed_ProvisionForLiabilityOnRegulatoryAudit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_amed_ProvisionForLiabilityOnRegulatoryAudit_98984e95-efef-456c-ba9c-fcca04a30c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalAndOtherSettlements_16faa835-bfd8-4fc3-94da-a3195256989e" xlink:href="amed-20201231.xsd#amed_LegalAndOtherSettlements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_amed_LegalAndOtherSettlements_16faa835-bfd8-4fc3-94da-a3195256989e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_661a0e3c-105d-403d-b758-519a3ba6b80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_661a0e3c-105d-403d-b758-519a3ba6b80f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CharityCare_b849ba34-fcf7-41d1-92d6-84f7368606f9" xlink:href="amed-20201231.xsd#amed_CharityCare"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_amed_CharityCare_b849ba34-fcf7-41d1-92d6-84f7368606f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedMedicareCapLiability_86b98c39-d5b2-44d3-b010-96d58a2d1ac3" xlink:href="amed-20201231.xsd#amed_EstimatedMedicareCapLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_amed_EstimatedMedicareCapLiability_86b98c39-d5b2-44d3-b010-96d58a2d1ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceAccruals_601d4a0a-4db2-4fe1-a52f-ece13c22c152" xlink:href="amed-20201231.xsd#amed_HospiceAccruals"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_amed_HospiceAccruals_601d4a0a-4db2-4fe1-a52f-ece13c22c152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PatientLiability_c4c48b20-8c7c-4420-8a76-0c528d2464d3" xlink:href="amed-20201231.xsd#amed_PatientLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_amed_PatientLiability_c4c48b20-8c7c-4420-8a76-0c528d2464d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredOperatingIncomeCARESAct_490724c8-85ec-4748-86be-2bc2ccbe3a8c" xlink:href="amed-20201231.xsd#amed_DeferredOperatingIncomeCARESAct"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_amed_DeferredOperatingIncomeCARESAct_490724c8-85ec-4748-86be-2bc2ccbe3a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ec295c4a-2091-409f-a75a-053d190dff0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_be31f494-d4d5-476f-ab99-300a8015ad16" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ec295c4a-2091-409f-a75a-053d190dff0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASES" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASES"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesCodificationTopic842Policies" xlink:type="simple" xlink:href="amed-20201231.xsd#LeasesCodificationTopic842Policies"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LeasesCodificationTopic842Policies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASESLeaseCostDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESOperatingLeaseDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESOperatingLeaseDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASESOperatingLeaseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESSupplementalCashflowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_accf120f-58ba-4273-b212-4b88e33c06fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c48b7bc5-80fb-4bee-94c5-4eed37047d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_accf120f-58ba-4273-b212-4b88e33c06fa" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c48b7bc5-80fb-4bee-94c5-4eed37047d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6ede8096-2aad-4ac4-91da-747e05531522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_accf120f-58ba-4273-b212-4b88e33c06fa" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6ede8096-2aad-4ac4-91da-747e05531522" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_06037aa1-58f7-467a-8fd5-9b0d96ac1701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_66e6f7e1-a4b9-4ef8-b8a3-3411bbe82b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_06037aa1-58f7-467a-8fd5-9b0d96ac1701" xlink:to="loc_us-gaap_LongTermDebtCurrent_66e6f7e1-a4b9-4ef8-b8a3-3411bbe82b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4c0d7727-7d7a-4c13-9408-126c92dcde17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_06037aa1-58f7-467a-8fd5-9b0d96ac1701" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4c0d7727-7d7a-4c13-9408-126c92dcde17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSMaturitiesofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2f57a4bc-f893-43a8-aeb9-f370f965b7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fb0d068c-09dc-436d-9e29-8384bd622d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2f57a4bc-f893-43a8-aeb9-f370f965b7eb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fb0d068c-09dc-436d-9e29-8384bd622d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8ef4b081-787e-4665-b3ed-47073f58e87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2f57a4bc-f893-43a8-aeb9-f370f965b7eb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8ef4b081-787e-4665-b3ed-47073f58e87f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_21cba273-545b-44da-9b31-03918c3bbca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2f57a4bc-f893-43a8-aeb9-f370f965b7eb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_21cba273-545b-44da-9b31-03918c3bbca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_662f282b-8539-4244-93ff-423c4cc1085f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2f57a4bc-f893-43a8-aeb9-f370f965b7eb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_662f282b-8539-4244-93ff-423c4cc1085f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_87b3863e-5011-42a2-a202-11c644281f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_2f57a4bc-f893-43a8-aeb9-f370f965b7eb" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_87b3863e-5011-42a2-a202-11c644281f36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXES" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXES"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eacbbf92-1665-4782-bcf0-8a0df4d8998a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_84293f73-2976-45c9-bf81-f1810dce801d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eacbbf92-1665-4782-bcf0-8a0df4d8998a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_84293f73-2976-45c9-bf81-f1810dce801d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_22161bae-224c-4c9e-8f34-c698ad575344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eacbbf92-1665-4782-bcf0-8a0df4d8998a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_22161bae-224c-4c9e-8f34-c698ad575344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5590a924-849e-498a-bde4-21095a8e8a90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e8e38d49-cda0-4211-b561-0a8be0e9f758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5590a924-849e-498a-bde4-21095a8e8a90" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e8e38d49-cda0-4211-b561-0a8be0e9f758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6c951e49-29da-46ec-b547-8d7b11fede06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5590a924-849e-498a-bde4-21095a8e8a90" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6c951e49-29da-46ec-b547-8d7b11fede06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_28a02e62-8ac1-490a-85a9-0c22e752631d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_fdfa658b-24ed-4302-8329-7a02c88766c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_28a02e62-8ac1-490a-85a9-0c22e752631d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_fdfa658b-24ed-4302-8329-7a02c88766c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_953087d9-5e89-445d-9cf2-ff98adc74006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_28a02e62-8ac1-490a-85a9-0c22e752631d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_953087d9-5e89-445d-9cf2-ff98adc74006" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESIncomeTaxExpenseAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_07592380-b26d-4b3f-b1f4-e8fd5a63faab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5cd73621-9db1-48e7-8872-a26bac8a4ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_07592380-b26d-4b3f-b1f4-e8fd5a63faab" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5cd73621-9db1-48e7-8872-a26bac8a4ec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense_95d3ed85-32f1-47c4-bc2f-bc0bc5275d93" xlink:href="amed-20201231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_07592380-b26d-4b3f-b1f4-e8fd5a63faab" xlink:to="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense_95d3ed85-32f1-47c4-bc2f-bc0bc5275d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToGoodwill_e23fd7aa-a19e-471d-9e5d-fd1a8cddb0bd" xlink:href="amed-20201231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_07592380-b26d-4b3f-b1f4-e8fd5a63faab" xlink:to="loc_amed_IncomeTaxEffectsAllocatedToGoodwill_e23fd7aa-a19e-471d-9e5d-fd1a8cddb0bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESReconciliationofEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8fbb4b5-eaf8-498a-b59b-f365b4ac3887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_169b8583-6038-4881-a489-846a235cd12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8fbb4b5-eaf8-498a-b59b-f365b4ac3887" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_169b8583-6038-4881-a489-846a235cd12e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_aa3bd880-0a53-493d-b767-c28d5531c2d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8fbb4b5-eaf8-498a-b59b-f365b4ac3887" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_aa3bd880-0a53-493d-b767-c28d5531c2d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_66d51ac0-4405-4560-a812-eb4fdbccdbc3" xlink:href="amed-20201231.xsd#amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8fbb4b5-eaf8-498a-b59b-f365b4ac3887" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_66d51ac0-4405-4560-a812-eb4fdbccdbc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_2c248396-f719-4d6e-a875-62ce9b73fb10" xlink:href="amed-20201231.xsd#amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8fbb4b5-eaf8-498a-b59b-f365b4ac3887" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_2c248396-f719-4d6e-a875-62ce9b73fb10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d30b905b-7c96-4ec4-bd63-a9253aa04ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8fbb4b5-eaf8-498a-b59b-f365b4ac3887" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d30b905b-7c96-4ec4-bd63-a9253aa04ee6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5a325846-138b-4ade-addd-6533164cc83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3ca3dc6e-41c9-4263-983e-eaf205b08fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_5a325846-138b-4ade-addd-6533164cc83f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3ca3dc6e-41c9-4263-983e-eaf205b08fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_ed52b3a7-b60f-4c3d-8640-d428edd8da33" xlink:href="amed-20201231.xsd#amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_5a325846-138b-4ade-addd-6533164cc83f" xlink:to="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_ed52b3a7-b60f-4c3d-8640-d428edd8da33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_59275522-e25f-4a8b-b13f-bf8e02e7f97e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_5a325846-138b-4ade-addd-6533164cc83f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_59275522-e25f-4a8b-b13f-bf8e02e7f97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_e4d49c78-a009-4c62-b368-8048b62e784a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_5a325846-138b-4ade-addd-6533164cc83f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_e4d49c78-a009-4c62-b368-8048b62e784a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets_71b070d6-33b0-4b83-8a22-1fc2751a794d" xlink:href="amed-20201231.xsd#amed_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_5a325846-138b-4ade-addd-6533164cc83f" xlink:to="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets_71b070d6-33b0-4b83-8a22-1fc2751a794d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_c72acddb-0449-4f2c-8c53-570dc50fc636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_5a325846-138b-4ade-addd-6533164cc83f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_c72acddb-0449-4f2c-8c53-570dc50fc636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_a41cc8b8-56f2-4330-b9f0-2643ff248996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_a41cc8b8-56f2-4330-b9f0-2643ff248996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_9c88e2f7-8e75-4cb0-87ab-7e437f4ae257" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_9c88e2f7-8e75-4cb0-87ab-7e437f4ae257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_dfb40a5d-16dc-4498-86d0-2dd00b28543d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_dfb40a5d-16dc-4498-86d0-2dd00b28543d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters_9d05f19c-0479-4e0b-a1dc-8d896d0556b4" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsLegalAndComplianceMatters"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters_9d05f19c-0479-4e0b-a1dc-8d896d0556b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLeaseLiability_d49ec705-ff3b-464f-a064-ee38d858cb52" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_amed_DeferredTaxAssetsLeaseLiability_d49ec705-ff3b-464f-a064-ee38d858cb52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance_d113f45c-aa36-4ead-8b13-a89cafdc4551" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsProviderReliefFundAdvance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance_d113f45c-aa36-4ead-8b13-a89cafdc4551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_2a4926a1-ad89-40d2-8463-be062dac2ca4" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetDeferredSocialSecurityTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_2a4926a1-ad89-40d2-8463-be062dac2ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_69bf10b7-bb33-4293-95f1-e2470b725ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_69bf10b7-bb33-4293-95f1-e2470b725ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b463be02-9a16-44dd-9600-5b9d9b812cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b463be02-9a16-44dd-9600-5b9d9b812cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_147a57d0-1f90-4ac8-804d-861d09b72985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_02cc36d8-7280-4d7e-91dd-8251f0f3fb35" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_147a57d0-1f90-4ac8-804d-861d09b72985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5ffb2a28-b64c-4603-b7e6-865bc533f624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_708f57c1-8922-4d7c-8b53-a12f06d93989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5ffb2a28-b64c-4603-b7e6-865bc533f624" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_708f57c1-8922-4d7c-8b53-a12f06d93989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_67448b78-522b-421b-8d9f-26fc59df1604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5ffb2a28-b64c-4603-b7e6-865bc533f624" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_67448b78-522b-421b-8d9f-26fc59df1604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dd6d3c52-ff60-46d5-9ca2-589de8241f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2c24c9bd-ea17-4ccf-9499-2b5827fe5b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dd6d3c52-ff60-46d5-9ca2-589de8241f81" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2c24c9bd-ea17-4ccf-9499-2b5827fe5b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4185ea18-cc4e-4b29-9fc8-677d293df796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dd6d3c52-ff60-46d5-9ca2-589de8241f81" xlink:to="loc_us-gaap_DeferredTaxLiabilities_4185ea18-cc4e-4b29-9fc8-677d293df796" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceExcludingLongTermPortion_a33d841d-37ba-40c3-a9d0-817956f456b5" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceTotal_9ab93af4-19de-47b2-8d9a-e125f2971c9c" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceTotal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceExcludingLongTermPortion_a33d841d-37ba-40c3-a9d0-817956f456b5" xlink:to="loc_amed_EstimatedInsuranceTotal_9ab93af4-19de-47b2-8d9a-e125f2971c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceLongTermPortion_16babd81-f3d8-41a1-a3eb-9c4645960dec" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceLongTermPortion"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceExcludingLongTermPortion_a33d841d-37ba-40c3-a9d0-817956f456b5" xlink:to="loc_amed_EstimatedInsuranceLongTermPortion_16babd81-f3d8-41a1-a3eb-9c4645960dec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceTotal_8d07a905-cf3d-45fd-a36e-b024e5d69b64" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsurance_8092055a-abce-43f4-a2c3-ef3c652c6f3a" xlink:href="amed-20201231.xsd#amed_HealthInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceTotal_8d07a905-cf3d-45fd-a36e-b024e5d69b64" xlink:to="loc_amed_HealthInsurance_8092055a-abce-43f4-a2c3-ef3c652c6f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WokersCompensation_a2e12000-f072-45fb-af56-5ee8843d6742" xlink:href="amed-20201231.xsd#amed_WokersCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceTotal_8d07a905-cf3d-45fd-a36e-b024e5d69b64" xlink:to="loc_amed_WokersCompensation_a2e12000-f072-45fb-af56-5ee8843d6742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiability_debbd001-f485-4ab3-8423-d9da2706a416" xlink:href="amed-20201231.xsd#amed_ProfessionalLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceTotal_8d07a905-cf3d-45fd-a36e-b024e5d69b64" xlink:to="loc_amed_ProfessionalLiability_debbd001-f485-4ab3-8423-d9da2706a416" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="amed-20201231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#EMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20201231.xsd#SHAREREPURCHASE"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATION"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>amed-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:267db984-3247-4ac4-9ea7-650da4f8e37e,g:25daadda-e66f-46f9-96fb-eec4b4d1abf0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="amed-20201231.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/DocumentandEntityInformation" xlink:type="extended" id="i6297a4d695f34524af3a6c90372af943_DocumentandEntityInformation"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i56c7d5ca5ba243c481a25fd7ef0ff336_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="id37dec861a234f07810e9179fdc5ed3e_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ib049a8e43faf4fdfaba2e4e5699f5808_CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended" id="ib1b921984b014d56b55206d0ed0db993_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i2d4e93bf6a4f490fa73fe1dd0061c755_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4825ad54-a4f9-4129-ac05-0d260917c77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4825ad54-a4f9-4129-ac05-0d260917c77a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f35b3d09-04ed-43f2-a086-01f909637438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f35b3d09-04ed-43f2-a086-01f909637438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9a0d1e83-5e20-4f42-86f6-49d8b5384181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_SharesOutstanding_9a0d1e83-5e20-4f42-86f6-49d8b5384181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_56bba2bd-f926-4c10-bff6-285aaece09b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_56bba2bd-f926-4c10-bff6-285aaece09b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ddf6a130-a52b-4a04-9260-1435cd80a3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ddf6a130-a52b-4a04-9260-1435cd80a3c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_3c745f4a-816a-47f8-b562-1b2bb2919cc7" xlink:href="amed-20201231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_3c745f4a-816a-47f8-b562-1b2bb2919cc7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_c79b9ad9-e06c-402e-bf3a-a402a5abe554" xlink:href="amed-20201231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_c79b9ad9-e06c-402e-bf3a-a402a5abe554" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_991edac2-bc1a-44ec-b88f-21c48ca8a192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_991edac2-bc1a-44ec-b88f-21c48ca8a192" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16e36c66-dc1e-48fc-93e5-c1dbc59a0bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16e36c66-dc1e-48fc-93e5-c1dbc59a0bd0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3d833900-2cdb-4a7a-bff5-2b1637c78b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3d833900-2cdb-4a7a-bff5-2b1637c78b12" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7d634e6-2107-4a4c-885b-a0e8bb5f8d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7d634e6-2107-4a4c-885b-a0e8bb5f8d75" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_98492b48-04e8-4882-b270-ec02ed641975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_98492b48-04e8-4882-b270-ec02ed641975" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_b1eb4156-1961-438a-8091-4c04530cb997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_b1eb4156-1961-438a-8091-4c04530cb997" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_68f81bf8-9531-48cf-95f8-7dae5500c629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_68f81bf8-9531-48cf-95f8-7dae5500c629" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_698d7ac5-b4b8-42be-9450-3df58b4282ae" xlink:href="amed-20201231.xsd#amed_SurrenderedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_SurrenderedShares_698d7ac5-b4b8-42be-9450-3df58b4282ae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0c36e9a7-4f3b-4fa0-b80d-f62d55e1b703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0c36e9a7-4f3b-4fa0-b80d-f62d55e1b703" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d70a3692-00d3-4342-a119-3ef491e68da6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d70a3692-00d3-4342-a119-3ef491e68da6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_62d571dc-f911-4b75-bd9d-d9f1dd4cd142" xlink:href="amed-20201231.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_62d571dc-f911-4b75-bd9d-d9f1dd4cd142" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment_bb16bb4b-02f0-4e81-b377-9f97273cd6f4" xlink:href="amed-20201231.xsd#amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment_bb16bb4b-02f0-4e81-b377-9f97273cd6f4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_81d5c4fe-4c66-4794-8366-a7d07166de65" xlink:href="amed-20201231.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_81d5c4fe-4c66-4794-8366-a7d07166de65" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d181b8b8-c2aa-4e67-a363-cdca75e2d616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_ProfitLoss_d181b8b8-c2aa-4e67-a363-cdca75e2d616" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e560cd4-1abb-4f8a-9338-f59dd1d97d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_82304585-eb42-4a42-b65f-df7e8889db21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3c273bae-d864-4eb2-8009-25c1f1451600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4825ad54-a4f9-4129-ac05-0d260917c77a" xlink:to="loc_us-gaap_StatementTable_3c273bae-d864-4eb2-8009-25c1f1451600" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a6a52374-1948-48c9-9310-71294541f63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3c273bae-d864-4eb2-8009-25c1f1451600" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a6a52374-1948-48c9-9310-71294541f63c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6a52374-1948-48c9-9310-71294541f63c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6a52374-1948-48c9-9310-71294541f63c" xlink:to="loc_us-gaap_EquityComponentDomain_a6a52374-1948-48c9-9310-71294541f63c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6a52374-1948-48c9-9310-71294541f63c" xlink:to="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4163c6db-e048-47c9-b845-c863056253ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_CommonStockMember_4163c6db-e048-47c9-b845-c863056253ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a68ed7b2-e5d8-435c-b5fd-92e75bbcd13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a68ed7b2-e5d8-435c-b5fd-92e75bbcd13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_aad5c52c-0575-4380-b123-b827d18e8ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_TreasuryStockMember_aad5c52c-0575-4380-b123-b827d18e8ae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bdc1672a-8021-417f-a5a1-1906275852fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bdc1672a-8021-417f-a5a1-1906275852fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_607b2805-00e4-445b-9668-1c3238e09264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_RetainedEarningsMember_607b2805-00e4-445b-9668-1c3238e09264" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_db6ffb0d-12c2-4e06-ae95-be91c88974bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_db6ffb0d-12c2-4e06-ae95-be91c88974bf" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i3714a79a0efc4fc0848362c008cec6fb_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended" id="id2e6623eab334473a593082d94688b05_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended" id="id87e3cfa5b724b6084b81888ec33258d_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:href="amed-20201231.xsd#amed_OrganizationAndNatureOfOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f88b679a-a05f-43f5-bc72-e6e6111de1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f88b679a-a05f-43f5-bc72-e6e6111de1bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_0f1c053e-b035-44ff-9a21-9548c2a4f50a" xlink:href="amed-20201231.xsd#amed_OperatingCareCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_OperatingCareCenters_0f1c053e-b035-44ff-9a21-9548c2a4f50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_fb12e0a2-0620-4068-82b2-d060c8353fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_fb12e0a2-0620-4068-82b2-d060c8353fd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_61feca9a-e05a-47a5-9945-724894fe3817" xlink:href="amed-20201231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_61feca9a-e05a-47a5-9945-724894fe3817" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1db70a73-7ec3-4bfe-bed2-3d5d082b9317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1db70a73-7ec3-4bfe-bed2-3d5d082b9317" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestRepurchased_b45d37bc-5a70-41bf-a4ef-84504446434a" xlink:href="amed-20201231.xsd#amed_NoncontrollingInterestRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_NoncontrollingInterestRepurchased_b45d37bc-5a70-41bf-a4ef-84504446434a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_1f7f588b-3a29-49a0-afd8-b8babab7a756" xlink:href="amed-20201231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_1f7f588b-3a29-49a0-afd8-b8babab7a756" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b87400d0-c9d4-4320-bae8-5fb84f567c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b87400d0-c9d4-4320-bae8-5fb84f567c8d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_c30ea207-9fa6-454d-a4f3-c07cbba153a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_c30ea207-9fa6-454d-a4f3-c07cbba153a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_6861d055-78b1-4db7-9abd-c031a64877f3" xlink:href="amed-20201231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_6861d055-78b1-4db7-9abd-c031a64877f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8f06b3b9-d3c1-4358-bf17-152a356ffc96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8f06b3b9-d3c1-4358-bf17-152a356ffc96" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnSaleOfInvestments_52324fba-21b1-45ca-acb7-55c1005c029a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_LossOnSaleOfInvestments_52324fba-21b1-45ca-acb7-55c1005c029a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:href="amed-20201231.xsd#amed_OrganizationAndNatureOfOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_f0b1666d-8311-4d8a-9acc-330530732b14" xlink:href="amed-20201231.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_f0b1666d-8311-4d8a-9acc-330530732b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_f0b1666d-8311-4d8a-9acc-330530732b14_default" xlink:href="amed-20201231.xsd#amed_TypeofEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_f0b1666d-8311-4d8a-9acc-330530732b14" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_f0b1666d-8311-4d8a-9acc-330530732b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_8ee2efd8-7a2d-4c3b-b3fb-d92b9a03b95c" xlink:href="amed-20201231.xsd#amed_TypeofEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_f0b1666d-8311-4d8a-9acc-330530732b14" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_8ee2efd8-7a2d-4c3b-b3fb-d92b9a03b95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthcareanalyticscompanyMember_41f1c94e-8b12-47d9-9609-9f99f29d9288" xlink:href="amed-20201231.xsd#amed_HealthcareanalyticscompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_8ee2efd8-7a2d-4c3b-b3fb-d92b9a03b95c" xlink:to="loc_amed_HealthcareanalyticscompanyMember_41f1c94e-8b12-47d9-9609-9f99f29d9288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember_fe09510c-c26e-4da6-8977-7a53181ccd7d" xlink:href="amed-20201231.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_8ee2efd8-7a2d-4c3b-b3fb-d92b9a03b95c" xlink:to="loc_amed_HeritageHealthcareInnovationFundLPMember_fe09510c-c26e-4da6-8977-7a53181ccd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_57c1778a-7474-4e3c-a8f2-5397b608838a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_57c1778a-7474-4e3c-a8f2-5397b608838a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_57c1778a-7474-4e3c-a8f2-5397b608838a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_57c1778a-7474-4e3c-a8f2-5397b608838a" xlink:to="loc_us-gaap_SegmentDomain_57c1778a-7474-4e3c-a8f2-5397b608838a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_57c1778a-7474-4e3c-a8f2-5397b608838a" xlink:to="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_cabb8be6-b810-49be-84d8-43ea04feb1d0" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:to="loc_amed_HomeHealthMember_cabb8be6-b810-49be-84d8-43ea04feb1d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_98b03510-01e1-44c7-ac9b-4c7a1963135a" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:to="loc_amed_HospiceMember_98b03510-01e1-44c7-ac9b-4c7a1963135a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_736bb6b6-bef2-45ff-ba32-f187fa8442ec" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:to="loc_amed_PersonalCareMember_736bb6b6-bef2-45ff-ba32-f187fa8442ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d10843a7-5594-4dcf-b02d-9ac0cf745286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d10843a7-5594-4dcf-b02d-9ac0cf745286" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d10843a7-5594-4dcf-b02d-9ac0cf745286_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d10843a7-5594-4dcf-b02d-9ac0cf745286" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d10843a7-5594-4dcf-b02d-9ac0cf745286_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21197c6e-c479-441d-a891-1c7380c34013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d10843a7-5594-4dcf-b02d-9ac0cf745286" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21197c6e-c479-441d-a891-1c7380c34013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_58a22768-f60d-4bc5-b417-2bd0db538b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21197c6e-c479-441d-a891-1c7380c34013" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_58a22768-f60d-4bc5-b417-2bd0db538b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_cba7a450-788a-4b17-9154-061759d879e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_cba7a450-788a-4b17-9154-061759d879e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cba7a450-788a-4b17-9154-061759d879e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cba7a450-788a-4b17-9154-061759d879e7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cba7a450-788a-4b17-9154-061759d879e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_66b398d0-8df0-4906-b447-7666b5155119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cba7a450-788a-4b17-9154-061759d879e7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_66b398d0-8df0-4906-b447-7666b5155119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_c3a0459a-8a7e-446b-b5b1-07246bcf4296" xlink:href="amed-20201231.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_66b398d0-8df0-4906-b447-7666b5155119" xlink:to="loc_amed_MedicareRevenueMember_c3a0459a-8a7e-446b-b5b1-07246bcf4296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_81cbcc43-456c-4b1e-8a73-263a0e760a4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_srt_OwnershipAxis_81cbcc43-456c-4b1e-8a73-263a0e760a4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_81cbcc43-456c-4b1e-8a73-263a0e760a4d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_81cbcc43-456c-4b1e-8a73-263a0e760a4d" xlink:to="loc_srt_OwnershipDomain_81cbcc43-456c-4b1e-8a73-263a0e760a4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_dbc39fb9-4517-4b44-986a-f7eb4e30c0a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_81cbcc43-456c-4b1e-8a73-263a0e760a4d" xlink:to="loc_srt_OwnershipDomain_dbc39fb9-4517-4b44-986a-f7eb4e30c0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestSoldMember_1812209b-cf0d-4b08-a88e-905e6967cbda" xlink:href="amed-20201231.xsd#amed_NoncontrollingInterestSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_dbc39fb9-4517-4b44-986a-f7eb4e30c0a5" xlink:to="loc_amed_NoncontrollingInterestSoldMember_1812209b-cf0d-4b08-a88e-905e6967cbda" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="extended" id="i48efe390152345fa9e0336300c1a3566_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_87685c27-5659-497a-af10-dce3877bab07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d20ad609-2a50-4e83-b5e5-5d00eb0ce800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_87685c27-5659-497a-af10-dce3877bab07" xlink:to="loc_us-gaap_OperatingLeaseLiability_d20ad609-2a50-4e83-b5e5-5d00eb0ce800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_03e5ff66-bf5b-4ede-9fcb-a5f4d0804cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_87685c27-5659-497a-af10-dce3877bab07" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_03e5ff66-bf5b-4ede-9fcb-a5f4d0804cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_87685c27-5659-497a-af10-dce3877bab07" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b0a47f90-928d-4aeb-ac5a-fa6028cbe663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b0a47f90-928d-4aeb-ac5a-fa6028cbe663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b0a47f90-928d-4aeb-ac5a-fa6028cbe663_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b0a47f90-928d-4aeb-ac5a-fa6028cbe663" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b0a47f90-928d-4aeb-ac5a-fa6028cbe663_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_195338c0-fc7f-43fc-9a11-38a680d88ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b0a47f90-928d-4aeb-ac5a-fa6028cbe663" xlink:to="loc_us-gaap_TypeOfAdoptionMember_195338c0-fc7f-43fc-9a11-38a680d88ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_154c53b1-6ebd-4430-9f27-cee06974d6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_195338c0-fc7f-43fc-9a11-38a680d88ce3" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_154c53b1-6ebd-4430-9f27-cee06974d6c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_73d4b1bb-18ff-4645-98cc-5e8807aad0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_195338c0-fc7f-43fc-9a11-38a680d88ce3" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_73d4b1bb-18ff-4645-98cc-5e8807aad0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15c277f8-8f1d-4931-a918-c38b3ffeadb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15c277f8-8f1d-4931-a918-c38b3ffeadb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_15c277f8-8f1d-4931-a918-c38b3ffeadb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15c277f8-8f1d-4931-a918-c38b3ffeadb7" xlink:to="loc_us-gaap_EquityComponentDomain_15c277f8-8f1d-4931-a918-c38b3ffeadb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1635bb4-be5f-42cc-9ce6-8656e76372c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15c277f8-8f1d-4931-a918-c38b3ffeadb7" xlink:to="loc_us-gaap_EquityComponentDomain_a1635bb4-be5f-42cc-9ce6-8656e76372c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c6f3bc4e-97f1-45de-86f7-59abe2e19ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1635bb4-be5f-42cc-9ce6-8656e76372c9" xlink:to="loc_us-gaap_RetainedEarningsMember_c6f3bc4e-97f1-45de-86f7-59abe2e19ec8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_bf8f72b8-3ce1-407b-b187-8881cf7a09d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:to="loc_srt_RestatementAxis_bf8f72b8-3ce1-407b-b187-8881cf7a09d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_bf8f72b8-3ce1-407b-b187-8881cf7a09d5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_bf8f72b8-3ce1-407b-b187-8881cf7a09d5" xlink:to="loc_srt_RestatementDomain_bf8f72b8-3ce1-407b-b187-8881cf7a09d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_4064d734-91f4-40ac-8282-3821d7d599e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_bf8f72b8-3ce1-407b-b187-8881cf7a09d5" xlink:to="loc_srt_RestatementDomain_4064d734-91f4-40ac-8282-3821d7d599e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_d0007cb3-c55e-4544-89fa-3ea776a7fb94" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_4064d734-91f4-40ac-8282-3821d7d599e9" xlink:to="loc_srt_RestatementAdjustmentMember_d0007cb3-c55e-4544-89fa-3ea776a7fb94" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="simple" xlink:href="amed-20201231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="extended" id="i7fa4b0f781f44631b9d014008929b14b_OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i073f1fbf0a154ddd9d339963babaa2b6_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="i2daeec0d64db4e24b23d1264b5b75603_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended" id="i49faeabd854541f1ae826d3622d8cf7b_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="ia24bcd11ef4b4a9d99b33519085dfcf9_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_405e6e3f-55d4-4f22-ad67-0168bf57b05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_405e6e3f-55d4-4f22-ad67-0168bf57b05d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_78a67284-6c71-4be9-9484-500c0ffbda1f" xlink:href="amed-20201231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_78a67284-6c71-4be9-9484-500c0ffbda1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_b8e38a8b-6a63-400f-b389-9a05426eded9" xlink:href="amed-20201231.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_b8e38a8b-6a63-400f-b389-9a05426eded9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_13b19c0f-4753-461f-a394-5ebfc1f481d1" xlink:href="amed-20201231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_13b19c0f-4753-461f-a394-5ebfc1f481d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_75795298-a4ca-43fa-a37a-e19e66f941ce" xlink:href="amed-20201231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_75795298-a4ca-43fa-a37a-e19e66f941ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_dcf290f4-463a-45d0-b3d1-7555f6048b5f" xlink:href="amed-20201231.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_dcf290f4-463a-45d0-b3d1-7555f6048b5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_d197f20a-9a1a-4666-84d4-7733ac3a74b2" xlink:href="amed-20201231.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_SecondThresholdOfServicesRequired_d197f20a-9a1a-4666-84d4-7733ac3a74b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_1f0df632-8501-4582-90ea-4f49ead34df3" xlink:href="amed-20201231.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_1f0df632-8501-4582-90ea-4f49ead34df3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_44800955-4348-4951-bf1c-f26462f08247" xlink:href="amed-20201231.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_44800955-4348-4951-bf1c-f26462f08247" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodesInProgressThatBeginDuringReportingPeriod_38d80f68-8d96-4f14-81c9-82f9bbdab70e" xlink:href="amed-20201231.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_EpisodesInProgressThatBeginDuringReportingPeriod_38d80f68-8d96-4f14-81c9-82f9bbdab70e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_b450c6fa-7a24-4bda-b991-6fbf3f94008c" xlink:href="amed-20201231.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_NonMedicareRevenueTermRates_b450c6fa-7a24-4bda-b991-6fbf3f94008c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_047857f7-5572-40e4-8f7d-ba62c9f31024" xlink:href="amed-20201231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_047857f7-5572-40e4-8f7d-ba62c9f31024" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_dcf5b8fa-b4ef-477e-bb70-07d9a9e25efb" xlink:href="amed-20201231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_dcf5b8fa-b4ef-477e-bb70-07d9a9e25efb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_d309e4f8-30c1-49d8-9539-de7103edc886" xlink:href="amed-20201231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_d309e4f8-30c1-49d8-9539-de7103edc886" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_7ce2fb2e-49ce-479f-a4ba-9da99deaf328" xlink:href="amed-20201231.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_7ce2fb2e-49ce-479f-a4ba-9da99deaf328" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_db2cef53-aab6-41aa-bbb2-80ed0d54f060" xlink:href="amed-20201231.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_db2cef53-aab6-41aa-bbb2-80ed0d54f060" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_f8145bbc-51b6-4333-88c7-2173f5313528" xlink:href="amed-20201231.xsd#amed_CapYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_amed_CapYearAxis_f8145bbc-51b6-4333-88c7-2173f5313528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_f8145bbc-51b6-4333-88c7-2173f5313528_default" xlink:href="amed-20201231.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_CapYearAxis_f8145bbc-51b6-4333-88c7-2173f5313528" xlink:to="loc_amed_CapYearDomain_f8145bbc-51b6-4333-88c7-2173f5313528_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_4d5e33b2-9022-470d-bd81-54edc4c712e1" xlink:href="amed-20201231.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_CapYearAxis_f8145bbc-51b6-4333-88c7-2173f5313528" xlink:to="loc_amed_CapYearDomain_4d5e33b2-9022-470d-bd81-54edc4c712e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_425f77b4-699a-4ec1-a606-18925f9d3c07" xlink:href="amed-20201231.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_4d5e33b2-9022-470d-bd81-54edc4c712e1" xlink:to="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_425f77b4-699a-4ec1-a606-18925f9d3c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_017dea2c-dc48-4a57-ab58-055162d1ebeb" xlink:href="amed-20201231.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_4d5e33b2-9022-470d-bd81-54edc4c712e1" xlink:to="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_017dea2c-dc48-4a57-ab58-055162d1ebeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d42a55d-f0d3-4517-94ce-46497f5c6306" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_srt_RangeAxis_9d42a55d-f0d3-4517-94ce-46497f5c6306" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d42a55d-f0d3-4517-94ce-46497f5c6306_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9d42a55d-f0d3-4517-94ce-46497f5c6306" xlink:to="loc_srt_RangeMember_9d42a55d-f0d3-4517-94ce-46497f5c6306_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_127cc09a-e6d4-4c4e-8350-98fd5866f922" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9d42a55d-f0d3-4517-94ce-46497f5c6306" xlink:to="loc_srt_RangeMember_127cc09a-e6d4-4c4e-8350-98fd5866f922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22b00f78-af29-4bdc-beae-8d74613180ff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_127cc09a-e6d4-4c4e-8350-98fd5866f922" xlink:to="loc_srt_MinimumMember_22b00f78-af29-4bdc-beae-8d74613180ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_95d57ee1-0c6e-48b0-96d0-31e3ddb56c87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_127cc09a-e6d4-4c4e-8350-98fd5866f922" xlink:to="loc_srt_MaximumMember_95d57ee1-0c6e-48b0-96d0-31e3ddb56c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a327d3c0-48d9-46c1-91d7-54627b3de4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a327d3c0-48d9-46c1-91d7-54627b3de4bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a327d3c0-48d9-46c1-91d7-54627b3de4bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a327d3c0-48d9-46c1-91d7-54627b3de4bd" xlink:to="loc_us-gaap_SegmentDomain_a327d3c0-48d9-46c1-91d7-54627b3de4bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_708626aa-1a7a-4e42-a503-f482025174ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a327d3c0-48d9-46c1-91d7-54627b3de4bd" xlink:to="loc_us-gaap_SegmentDomain_708626aa-1a7a-4e42-a503-f482025174ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_dff5f045-ce54-4c3f-9d5d-5f058754dd64" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_708626aa-1a7a-4e42-a503-f482025174ef" xlink:to="loc_amed_HomeHealthMember_dff5f045-ce54-4c3f-9d5d-5f058754dd64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_2fa82c15-8ba6-49e0-8782-358b72875ac9" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_708626aa-1a7a-4e42-a503-f482025174ef" xlink:to="loc_amed_HospiceMember_2fa82c15-8ba6-49e0-8782-358b72875ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fa6921c6-15c2-47ff-a109-00c95b018ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fa6921c6-15c2-47ff-a109-00c95b018ffb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa6921c6-15c2-47ff-a109-00c95b018ffb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fa6921c6-15c2-47ff-a109-00c95b018ffb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fa6921c6-15c2-47ff-a109-00c95b018ffb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_faf3af93-99b3-4fbc-8d3e-f04ba0925818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fa6921c6-15c2-47ff-a109-00c95b018ffb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_faf3af93-99b3-4fbc-8d3e-f04ba0925818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1d658457-affb-44cd-9c44-29d48a8f2e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_faf3af93-99b3-4fbc-8d3e-f04ba0925818" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_1d658457-affb-44cd-9c44-29d48a8f2e4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_356dc0f1-d1d3-40d4-84d5-f010868cf0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_356dc0f1-d1d3-40d4-84d5-f010868cf0be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_356dc0f1-d1d3-40d4-84d5-f010868cf0be_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_356dc0f1-d1d3-40d4-84d5-f010868cf0be" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_356dc0f1-d1d3-40d4-84d5-f010868cf0be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7b95bd49-efbd-4593-8bf6-fd7a7d6bc505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_356dc0f1-d1d3-40d4-84d5-f010868cf0be" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7b95bd49-efbd-4593-8bf6-fd7a7d6bc505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_d5d59fef-dd80-404b-93f4-cad72f04eb61" xlink:href="amed-20201231.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7b95bd49-efbd-4593-8bf6-fd7a7d6bc505" xlink:to="loc_amed_MedicareRevenueMember_d5d59fef-dd80-404b-93f4-cad72f04eb61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_83402d1c-faae-4816-9e56-da80e914b6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_83402d1c-faae-4816-9e56-da80e914b6b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83402d1c-faae-4816-9e56-da80e914b6b2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_83402d1c-faae-4816-9e56-da80e914b6b2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83402d1c-faae-4816-9e56-da80e914b6b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05bf561e-d13e-4850-bd63-d0e2702c4618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_83402d1c-faae-4816-9e56-da80e914b6b2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05bf561e-d13e-4850-bd63-d0e2702c4618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_a945adbe-3c4b-471b-8d2e-fe7c359af154" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05bf561e-d13e-4850-bd63-d0e2702c4618" xlink:to="loc_amed_AseraCareHospiceMember_a945adbe-3c4b-471b-8d2e-fe7c359af154" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="extended" id="i5641360c8e3a4883b9c46217619276a7_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bebcfd93-126f-4ae5-a47d-082d5636d3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_7d46f561-1354-4d37-a1f7-ce65300b964b" xlink:href="amed-20201231.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bebcfd93-126f-4ae5-a47d-082d5636d3a1" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_7d46f561-1354-4d37-a1f7-ce65300b964b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_7a369ea6-39ae-4238-aeb3-c7b310399f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bebcfd93-126f-4ae5-a47d-082d5636d3a1" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_7a369ea6-39ae-4238-aeb3-c7b310399f66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7" xlink:href="amed-20201231.xsd#amed_PayorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_7a369ea6-39ae-4238-aeb3-c7b310399f66" xlink:to="loc_amed_PayorClassAxis_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7_default" xlink:href="amed-20201231.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorClassAxis_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7" xlink:to="loc_amed_PayorClassDomain_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:href="amed-20201231.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorClassAxis_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7" xlink:to="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_d9c41b72-7e3a-47f8-9a45-b066d2215596" xlink:href="amed-20201231.xsd#amed_HomeHealthMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HomeHealthMedicareMember_d9c41b72-7e3a-47f8-9a45-b066d2215596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_8ec30f3b-a25d-4596-8d5d-5b014ec8f862" xlink:href="amed-20201231.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_8ec30f3b-a25d-4596-8d5d-5b014ec8f862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_4a80181a-25dd-4f0e-a350-e16caf8ed434" xlink:href="amed-20201231.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_4a80181a-25dd-4f0e-a350-e16caf8ed434" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_55b8da12-9201-4455-9149-ec64c9b8c1f9" xlink:href="amed-20201231.xsd#amed_HospiceMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HospiceMedicareMember_55b8da12-9201-4455-9149-ec64c9b8c1f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_508125f6-069b-4e49-b979-b966f38c0afc" xlink:href="amed-20201231.xsd#amed_HospiceNonMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HospiceNonMedicareMember_508125f6-069b-4e49-b979-b966f38c0afc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_2c0d2a3d-8336-4f03-9cdd-3649ca43930e" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_PersonalCareMember_2c0d2a3d-8336-4f03-9cdd-3649ca43930e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i22fdd1697e92473aa6514e93d5ff1c70_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d77fe213-5e57-4fe2-bf65-0324161c916d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d77fe213-5e57-4fe2-bf65-0324161c916d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3a6c1780-ecc6-4adc-90b0-ae3c239da33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_us-gaap_RestrictedCash_3a6c1780-ecc6-4adc-90b0-ae3c239da33c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0e59c35-9add-49c1-a67d-6068b180ad6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0e59c35-9add-49c1-a67d-6068b180ad6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_f95f562b-4bd3-4233-be0b-917f2f925c95" xlink:href="amed-20201231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_f95f562b-4bd3-4233-be0b-917f2f925c95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_1428d5a1-2b13-4637-8bf7-fe9166a2f6ac" xlink:href="amed-20201231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9334adbe-f052-4d02-8a37-31c378ced81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9334adbe-f052-4d02-8a37-31c378ced81e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b53747ab-bfd0-45ef-9659-c2259b0966ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9334adbe-f052-4d02-8a37-31c378ced81e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b53747ab-bfd0-45ef-9659-c2259b0966ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b53747ab-bfd0-45ef-9659-c2259b0966ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b53747ab-bfd0-45ef-9659-c2259b0966ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b53747ab-bfd0-45ef-9659-c2259b0966ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a5ddc00-728c-41de-becb-90708417ea33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b53747ab-bfd0-45ef-9659-c2259b0966ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a5ddc00-728c-41de-becb-90708417ea33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAcquisitionMember_458b0cf2-cad8-48d7-a45c-b2090a5559a1" xlink:href="amed-20201231.xsd#amed_AsanaHospiceAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a5ddc00-728c-41de-becb-90708417ea33" xlink:to="loc_amed_AsanaHospiceAcquisitionMember_458b0cf2-cad8-48d7-a45c-b2090a5559a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended" id="iae9127c91e864d579498cf1f57a4c6a0_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="extended" id="i795043c58afb451e8b481a32f1dc67fb_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_37146c18-2641-4afe-b364-5d3093129951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1f0bbe05-232c-4d5e-9da0-0345d4fcccb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_37146c18-2641-4afe-b364-5d3093129951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1f0bbe05-232c-4d5e-9da0-0345d4fcccb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a5dd4426-d6b0-487d-b088-d8de571cb581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_37146c18-2641-4afe-b364-5d3093129951" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a5dd4426-d6b0-487d-b088-d8de571cb581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_37146c18-2641-4afe-b364-5d3093129951" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_537ff168-5f97-47b9-be16-d0d0bbe0fea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_537ff168-5f97-47b9-be16-d0d0bbe0fea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_537ff168-5f97-47b9-be16-d0d0bbe0fea5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_537ff168-5f97-47b9-be16-d0d0bbe0fea5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_537ff168-5f97-47b9-be16-d0d0bbe0fea5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646a5ce4-14fd-4002-9eab-4cb541b6cb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_537ff168-5f97-47b9-be16-d0d0bbe0fea5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646a5ce4-14fd-4002-9eab-4cb541b6cb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_4fd837d9-ea42-4030-a4ef-00a8573f95ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646a5ce4-14fd-4002-9eab-4cb541b6cb99" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_4fd837d9-ea42-4030-a4ef-00a8573f95ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_2548f513-3a1c-490b-83b2-290301c86468" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646a5ce4-14fd-4002-9eab-4cb541b6cb99" xlink:to="loc_amed_AcquiredNamesMember_2548f513-3a1c-490b-83b2-290301c86468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a398b56a-36d9-4323-93a3-4966d30a44c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:to="loc_srt_RangeAxis_a398b56a-36d9-4323-93a3-4966d30a44c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a398b56a-36d9-4323-93a3-4966d30a44c6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a398b56a-36d9-4323-93a3-4966d30a44c6" xlink:to="loc_srt_RangeMember_a398b56a-36d9-4323-93a3-4966d30a44c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7dcd71e-6977-42b9-9996-cddc5f50e615" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a398b56a-36d9-4323-93a3-4966d30a44c6" xlink:to="loc_srt_RangeMember_a7dcd71e-6977-42b9-9996-cddc5f50e615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f5d5fe44-65d0-43a0-8498-1cadbf866cf3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a7dcd71e-6977-42b9-9996-cddc5f50e615" xlink:to="loc_srt_MinimumMember_f5d5fe44-65d0-43a0-8498-1cadbf866cf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aacb5f50-f870-475a-9e41-05b3b4f9f8b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a7dcd71e-6977-42b9-9996-cddc5f50e615" xlink:to="loc_srt_MaximumMember_aacb5f50-f870-475a-9e41-05b3b4f9f8b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ddb01b66-ffec-4047-b62a-8c72906a2b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ddb01b66-ffec-4047-b62a-8c72906a2b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_d95878f5-6b25-46af-888a-9702404f775b" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ddb01b66-ffec-4047-b62a-8c72906a2b01" xlink:to="loc_amed_AcquiredNamesMember_d95878f5-6b25-46af-888a-9702404f775b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended" id="i576b0372a18d4317a8fb51c461a85625_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e9bad50a-4852-42f8-b6c5-d0f845778d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_105625d2-5ce6-4488-94cb-7d7d2b0b1936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e9bad50a-4852-42f8-b6c5-d0f845778d98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_105625d2-5ce6-4488-94cb-7d7d2b0b1936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_ccb24608-9dcb-44f5-ba30-341bc474fca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e9bad50a-4852-42f8-b6c5-d0f845778d98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_ccb24608-9dcb-44f5-ba30-341bc474fca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e9bad50a-4852-42f8-b6c5-d0f845778d98" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ad07651-9091-44f3-afb7-858779335964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ad07651-9091-44f3-afb7-858779335964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ad07651-9091-44f3-afb7-858779335964_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ad07651-9091-44f3-afb7-858779335964" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4ad07651-9091-44f3-afb7-858779335964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ad07651-9091-44f3-afb7-858779335964" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_1ee3d570-68f9-49cf-8a59-dbe814d753a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_BuildingMember_1ee3d570-68f9-49cf-8a59-dbe814d753a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fdbe821d-e659-4eff-b8a3-d3dee0e72e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fdbe821d-e659-4eff-b8a3-d3dee0e72e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember_d8ca72e2-7488-40cd-9e7a-40ba6907f1b1" xlink:href="amed-20201231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_amed_EquipmentAndFurnitureMember_d8ca72e2-7488-40cd-9e7a-40ba6907f1b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_12436909-238f-47c5-88be-c387dc823e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_VehiclesMember_12436909-238f-47c5-88be-c387dc823e2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c43c4cbf-a9d2-4c8f-9696-ccf2b36f2ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c43c4cbf-a9d2-4c8f-9696-ccf2b36f2ec8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_9942ceae-2714-4a6d-b7e8-092347faf160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_9942ceae-2714-4a6d-b7e8-092347faf160" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e402e614-6cc1-42be-8166-9d2ae2e9d9bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:to="loc_srt_RangeAxis_e402e614-6cc1-42be-8166-9d2ae2e9d9bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e402e614-6cc1-42be-8166-9d2ae2e9d9bb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e402e614-6cc1-42be-8166-9d2ae2e9d9bb" xlink:to="loc_srt_RangeMember_e402e614-6cc1-42be-8166-9d2ae2e9d9bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd252531-8442-455f-946a-c924951f753c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e402e614-6cc1-42be-8166-9d2ae2e9d9bb" xlink:to="loc_srt_RangeMember_dd252531-8442-455f-946a-c924951f753c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2af98f8a-e661-4a73-b536-27df62836d2d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dd252531-8442-455f-946a-c924951f753c" xlink:to="loc_srt_MinimumMember_2af98f8a-e661-4a73-b536-27df62836d2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40b3addf-7fff-44ee-9ea9-eccc7f7dcd72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dd252531-8442-455f-946a-c924951f753c" xlink:to="loc_srt_MaximumMember_40b3addf-7fff-44ee-9ea9-eccc7f7dcd72" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="extended" id="id45433544ced412cb43d186597e22eaa_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_89c18ecb-8c6a-44b2-ba39-6e201805ae9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_89c18ecb-8c6a-44b2-ba39-6e201805ae9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b78e13fc-cc78-4ea6-a603-3b23f9bc08a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b78e13fc-cc78-4ea6-a603-3b23f9bc08a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5c1689e-d972-463e-b121-b505f52feaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5c1689e-d972-463e-b121-b505f52feaf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_672ed4d7-5c2c-4cfe-a934-a09897fe4090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_672ed4d7-5c2c-4cfe-a934-a09897fe4090" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_672ed4d7-5c2c-4cfe-a934-a09897fe4090" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BuildingAndLeaseholdImprovementsMember_4c7693c3-535d-43c7-bf88-a2d56b2e4964" xlink:href="amed-20201231.xsd#amed_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:to="loc_amed_BuildingAndLeaseholdImprovementsMember_4c7693c3-535d-43c7-bf88-a2d56b2e4964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember_186d7cf4-203e-484d-a2b2-e18493846db1" xlink:href="amed-20201231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:to="loc_amed_EquipmentAndFurnitureMember_186d7cf4-203e-484d-a2b2-e18493846db1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_652c7081-4b79-49a2-8d4f-5c0ac27229ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:to="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_652c7081-4b79-49a2-8d4f-5c0ac27229ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bc218fe7-60a6-4415-bee8-b201bc74ad02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bc218fe7-60a6-4415-bee8-b201bc74ad02" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="extended" id="i39680c914fde4e20bb52feff5d6ad0f3_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ea25437-cbf8-48b0-a9b7-cfe7b13d8d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_01071552-5942-4129-a9d1-e594739fc769" xlink:href="amed-20201231.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ea25437-cbf8-48b0-a9b7-cfe7b13d8d35" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_01071552-5942-4129-a9d1-e594739fc769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_487bda22-3595-4d5b-8f99-2adb4cded5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ea25437-cbf8-48b0-a9b7-cfe7b13d8d35" xlink:to="loc_us-gaap_LongTermDebtFairValue_487bda22-3595-4d5b-8f99-2adb4cded5ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0541bb9-029b-464b-8193-ec23b8ba2fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ea25437-cbf8-48b0-a9b7-cfe7b13d8d35" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0541bb9-029b-464b-8193-ec23b8ba2fcb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136b6da7-55eb-4c15-a2cc-28462658c85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0541bb9-029b-464b-8193-ec23b8ba2fcb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136b6da7-55eb-4c15-a2cc-28462658c85a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_136b6da7-55eb-4c15-a2cc-28462658c85a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136b6da7-55eb-4c15-a2cc-28462658c85a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_136b6da7-55eb-4c15-a2cc-28462658c85a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136b6da7-55eb-4c15-a2cc-28462658c85a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ccd97af1-50a9-4d86-bea8-97c2a81394f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ccd97af1-50a9-4d86-bea8-97c2a81394f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c3a73014-b9ea-4981-8c24-b4f109d1c0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c3a73014-b9ea-4981-8c24-b4f109d1c0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6df159d2-b0c2-4333-a01e-3ea7d17a5eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6df159d2-b0c2-4333-a01e-3ea7d17a5eca" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended" id="i88f359dcbabf41c28d0e38c15bb2c2af_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="extended" id="if15264b785174dcdbd9928d6ee39fa59_NOVELCORONAVIRUSPANDEMICCOVID19"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Tables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="extended" id="i3125e626f9274815aa1241ffa4c88c76_NOVELCORONAVIRUSPANDEMICCOVID19Tables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended" id="i2be9148e6a88447bb070cdf8eda3089c_NOVELCORONAVIRUSPANDEMICCOVID19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_ffa59745-5f9e-49d8-b0db-d28ee1f5f932" xlink:href="amed-20201231.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_ffa59745-5f9e-49d8-b0db-d28ee1f5f932" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_4de9d007-a08c-4a60-905d-e01400ed6977" xlink:href="amed-20201231.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_4de9d007-a08c-4a60-905d-e01400ed6977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_b2f742cc-f614-496c-b630-81608f0d13ad" xlink:href="amed-20201231.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_FundingReceivedFromCARESAct_b2f742cc-f614-496c-b630-81608f0d13ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred_0b1adfaf-005f-4428-8103-1d90c57d4b04" xlink:href="amed-20201231.xsd#amed_COVID19ExpensesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_COVID19ExpensesIncurred_0b1adfaf-005f-4428-8103-1d90c57d4b04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_f4a46746-6670-4efa-8a5d-2ff89a34b263" xlink:href="amed-20201231.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_f4a46746-6670-4efa-8a5d-2ff89a34b263" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_f93f7e4c-1f29-4790-b146-0c2f306f651f" xlink:href="amed-20201231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_f93f7e4c-1f29-4790-b146-0c2f306f651f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c1aa2577-e18b-469e-8302-89aec6f43f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c1aa2577-e18b-469e-8302-89aec6f43f87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a6043cca-0ec2-4c4a-a863-ee345f9fd2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a6043cca-0ec2-4c4a-a863-ee345f9fd2a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_afc3f254-f8bf-4a1a-aec4-826d8e47d651" xlink:href="amed-20201231.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_afc3f254-f8bf-4a1a-aec4-826d8e47d651" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_37f839ac-25b9-41ae-8497-a52e2951aa85" xlink:href="amed-20201231.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_37f839ac-25b9-41ae-8497-a52e2951aa85" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_b81f00c0-8d6e-4170-b755-a7f97b269902" xlink:href="amed-20201231.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_b81f00c0-8d6e-4170-b755-a7f97b269902" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_4c7ccdf6-cebf-4a08-ac57-a1bec80b9185" xlink:href="amed-20201231.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_4c7ccdf6-cebf-4a08-ac57-a1bec80b9185" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_0ce39a2e-c9f3-43d8-9476-2816213b800a" xlink:href="amed-20201231.xsd#amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_0ce39a2e-c9f3-43d8-9476-2816213b800a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_8282e780-2bbd-49e0-9bdb-350b5c07a14e" xlink:href="amed-20201231.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_8282e780-2bbd-49e0-9bdb-350b5c07a14e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_3627a9af-9b06-4784-9701-ea8c3c2e342a" xlink:href="amed-20201231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_ProviderReliefFundAdvance_3627a9af-9b06-4784-9701-ea8c3c2e342a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses_a2c0142b-2c5b-428b-8123-917f72bcbaba" xlink:href="amed-20201231.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_EstimatedFutureCOVID19RelatedExpenses_a2c0142b-2c5b-428b-8123-917f72bcbaba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_27092aad-ae11-45c5-8ac2-421134e18103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_us-gaap_OtherOperatingIncome_27092aad-ae11-45c5-8ac2-421134e18103" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ad11f965-c035-4883-93de-797b9f87034a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ad11f965-c035-4883-93de-797b9f87034a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ad11f965-c035-4883-93de-797b9f87034a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ad11f965-c035-4883-93de-797b9f87034a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ad11f965-c035-4883-93de-797b9f87034a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2bf7b5f1-2128-4857-a750-e89e7e62efdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ad11f965-c035-4883-93de-797b9f87034a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2bf7b5f1-2128-4857-a750-e89e7e62efdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_23147150-9254-44c0-b840-425b2bf4d348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2bf7b5f1-2128-4857-a750-e89e7e62efdb" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_23147150-9254-44c0-b840-425b2bf4d348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4a118d45-ac47-4c67-b707-7ee699446d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4a118d45-ac47-4c67-b707-7ee699446d50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a118d45-ac47-4c67-b707-7ee699446d50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4a118d45-ac47-4c67-b707-7ee699446d50" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a118d45-ac47-4c67-b707-7ee699446d50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_508085a0-234a-4e89-a1fb-69ad75b186c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4a118d45-ac47-4c67-b707-7ee699446d50" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_508085a0-234a-4e89-a1fb-69ad75b186c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_89e19e44-818e-4d81-a606-6e8c3af89367" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_508085a0-234a-4e89-a1fb-69ad75b186c7" xlink:to="loc_amed_AseraCareHospiceMember_89e19e44-818e-4d81-a606-6e8c3af89367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_85afc7dd-255f-4020-a1e0-406dbe379764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_85afc7dd-255f-4020-a1e0-406dbe379764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_85afc7dd-255f-4020-a1e0-406dbe379764_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_85afc7dd-255f-4020-a1e0-406dbe379764" xlink:to="loc_us-gaap_SegmentDomain_85afc7dd-255f-4020-a1e0-406dbe379764_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ac756648-efbc-477d-8251-c6a152d6ca75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_85afc7dd-255f-4020-a1e0-406dbe379764" xlink:to="loc_us-gaap_SegmentDomain_ac756648-efbc-477d-8251-c6a152d6ca75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_88ae568d-a282-4c70-a104-a0e8bd07d2ad" xlink:href="amed-20201231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ac756648-efbc-477d-8251-c6a152d6ca75" xlink:to="loc_amed_HomeHealthAndHospiceMember_88ae568d-a282-4c70-a104-a0e8bd07d2ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_9993e2ab-e267-4732-87f4-d3846b9a9640" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ac756648-efbc-477d-8251-c6a152d6ca75" xlink:to="loc_amed_PersonalCareMember_9993e2ab-e267-4732-87f4-d3846b9a9640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_1a9c4823-25f9-499e-a5d5-27d64a5e9226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_1a9c4823-25f9-499e-a5d5-27d64a5e9226" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_1a9c4823-25f9-499e-a5d5-27d64a5e9226_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_1a9c4823-25f9-499e-a5d5-27d64a5e9226" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_1a9c4823-25f9-499e-a5d5-27d64a5e9226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_f97990a6-52b0-4692-8de7-c7da3cee3f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_1a9c4823-25f9-499e-a5d5-27d64a5e9226" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_f97990a6-52b0-4692-8de7-c7da3cee3f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_0969b020-a455-4360-8485-efc67350d17f" xlink:href="amed-20201231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_f97990a6-52b0-4692-8de7-c7da3cee3f7d" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_0969b020-a455-4360-8485-efc67350d17f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended" id="i743442a6a90e4831b19ea9906557a6d1_ACQUISITIONS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended" id="i9c8f6fb1efbd44829ea443e7c45b0571_ACQUISITIONSTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="icadfc83237714fb590812fee3f0a9db8_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_8aec151c-5a0f-4a9d-a40f-50c00ef23da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_8aec151c-5a0f-4a9d-a40f-50c00ef23da2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_177eb0a1-26c3-4ad3-8017-ca3296b5c3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_177eb0a1-26c3-4ad3-8017-ca3296b5c3a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_471f7ede-2eb9-469b-8c2d-14a2907fa119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_NotesPayable_471f7ede-2eb9-469b-8c2d-14a2907fa119" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_8685bdbd-42d9-4476-86f7-b6a07a61febc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_8685bdbd-42d9-4476-86f7-b6a07a61febc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_81f028f9-d148-4925-9121-0f03d0443951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_81f028f9-d148-4925-9121-0f03d0443951" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_cda8101b-9d71-4392-95eb-cf7a1e635c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_cda8101b-9d71-4392-95eb-cf7a1e635c6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_6141c5c1-f8c3-4e11-9026-fc70ed2c6d70" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_6141c5c1-f8c3-4e11-9026-fc70ed2c6d70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a39cb1d0-df08-48e1-975a-49864f14dd90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a39cb1d0-df08-48e1-975a-49864f14dd90" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_15f0c8f9-690d-42b2-85bf-ffc7449a5a98" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_15f0c8f9-690d-42b2-85bf-ffc7449a5a98" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_e2d8d880-80f6-41b2-bd7e-40f5ac5fe6a9" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_e2d8d880-80f6-41b2-bd7e-40f5ac5fe6a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_710a5f8d-dbc2-4564-b6a9-fef588e656fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_710a5f8d-dbc2-4564-b6a9-fef588e656fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_0a4a7d81-34e2-4b19-9bc4-8763210dacca" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_0a4a7d81-34e2-4b19-9bc4-8763210dacca" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_53aeb0c7-62a5-42e0-91db-181950b02671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_53aeb0c7-62a5-42e0-91db-181950b02671" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_616e2837-b7c6-4acc-a4f3-aa146b45821d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_616e2837-b7c6-4acc-a4f3-aa146b45821d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_af100bb0-03dd-432d-8097-2ea0bb4b8925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_af100bb0-03dd-432d-8097-2ea0bb4b8925" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c24fe6ca-8257-4015-a796-4a2e643899df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c24fe6ca-8257-4015-a796-4a2e643899df" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_d9c6a5c2-5f9b-427a-90ac-84db83166001" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_d9c6a5c2-5f9b-427a-90ac-84db83166001" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_6ce02af2-d99b-4f41-b193-251766709417" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_6ce02af2-d99b-4f41-b193-251766709417" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3efc6290-e1ac-4c7c-a891-d1f6a9b04435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3efc6290-e1ac-4c7c-a891-d1f6a9b04435" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_dc6dbff8-20dc-4019-8c07-4c5371474c0a" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_dc6dbff8-20dc-4019-8c07-4c5371474c0a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_647d90ca-89fd-4c96-86e4-93000ec451e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_647d90ca-89fd-4c96-86e4-93000ec451e4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5538905c-870e-4a09-aeed-98ed68787e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5538905c-870e-4a09-aeed-98ed68787e26" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2cb7e568-bcf3-446a-9b87-de1b92f0ac31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2cb7e568-bcf3-446a-9b87-de1b92f0ac31" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3dbe8db0-a6b0-45d6-aa0d-eda299b60d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3dbe8db0-a6b0-45d6-aa0d-eda299b60d34" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_c15b02ef-f9bf-48d1-b9d7-2a201cc9d0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_EscrowDeposit_c15b02ef-f9bf-48d1-b9d7-2a201cc9d0da" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_6041f122-698d-43d8-9388-578de8321546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_6041f122-698d-43d8-9388-578de8321546" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_06c69e2f-98c6-4aca-9771-5007eb703657" xlink:href="amed-20201231.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_06c69e2f-98c6-4aca-9771-5007eb703657" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_ef12cbff-8616-4bb1-9bf9-09e24db12e17" xlink:href="amed-20201231.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_ef12cbff-8616-4bb1-9bf9-09e24db12e17" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_5b36d843-03f6-49d6-a03a-64d4f152edf1" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_5b36d843-03f6-49d6-a03a-64d4f152edf1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a26d774f-074a-4a7f-b09f-e3959b944220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a26d774f-074a-4a7f-b09f-e3959b944220" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_fb2f1476-8ea3-428f-8ac5-e8289796123f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_fb2f1476-8ea3-428f-8ac5-e8289796123f" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f1e2484-6d56-4445-a171-874d6a6b956e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f1e2484-6d56-4445-a171-874d6a6b956e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_595e5b5e-090b-4034-afb9-4c2012a6fe5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_595e5b5e-090b-4034-afb9-4c2012a6fe5b" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_8a00a770-1700-4fd2-b492-f13d5ac518c7" xlink:href="amed-20201231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_8a00a770-1700-4fd2-b492-f13d5ac518c7" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ea34eb98-ad1b-4174-9203-d417bfcbdd86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ea34eb98-ad1b-4174-9203-d417bfcbdd86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea34eb98-ad1b-4174-9203-d417bfcbdd86_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ea34eb98-ad1b-4174-9203-d417bfcbdd86" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ea34eb98-ad1b-4174-9203-d417bfcbdd86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ea34eb98-ad1b-4174-9203-d417bfcbdd86" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ChristianCareatHomeMember_24e96347-0f05-4630-ae18-358f8cbdf124" xlink:href="amed-20201231.xsd#amed_ChristianCareatHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_ChristianCareatHomeMember_24e96347-0f05-4630-ae18-358f8cbdf124" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EastTennesseePersonalCareMember_4355ed23-345b-406e-81db-3b628ee8d11c" xlink:href="amed-20201231.xsd#amed_EastTennesseePersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_EastTennesseePersonalCareMember_4355ed23-345b-406e-81db-3b628ee8d11c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BringCareHomeMember_807fdab7-9801-47e6-bb23-2bb5fd6d1ed0" xlink:href="amed-20201231.xsd#amed_BringCareHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_BringCareHomeMember_807fdab7-9801-47e6-bb23-2bb5fd6d1ed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeStaffLlcMember_c643226f-67be-4ce0-b59c-f7144ceef208" xlink:href="amed-20201231.xsd#amed_HomeStaffLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_HomeStaffLlcMember_c643226f-67be-4ce0-b59c-f7144ceef208" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IntercityHomeCareMember_00df4aa2-0dc7-46c2-83ed-c9c1a2e7930b" xlink:href="amed-20201231.xsd#amed_IntercityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_IntercityHomeCareMember_00df4aa2-0dc7-46c2-83ed-c9c1a2e7930b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TenetHealthcareMember_4a86ee0d-5a09-483d-bf09-96d0b8432d73" xlink:href="amed-20201231.xsd#amed_TenetHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_TenetHealthcareMember_4a86ee0d-5a09-483d-bf09-96d0b8432d73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssociatedHomecareMember_a2075c72-5edb-44d7-956f-b55154b05e10" xlink:href="amed-20201231.xsd#amed_AssociatedHomecareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_AssociatedHomecareMember_a2075c72-5edb-44d7-956f-b55154b05e10" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_d7337f2f-65c0-4297-9f44-eec3266e0b0b" xlink:href="amed-20201231.xsd#amed_InfinityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_InfinityHomeCareMember_d7337f2f-65c0-4297-9f44-eec3266e0b0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_bb0ca1ce-2d52-4a84-863e-b60000ad1c2d" xlink:href="amed-20201231.xsd#amed_AsanaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_AsanaHospiceMember_bb0ca1ce-2d52-4a84-863e-b60000ad1c2d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_460d731c-a83d-49d9-97eb-bdc32ddabbdb" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_AseraCareHospiceMember_460d731c-a83d-49d9-97eb-bdc32ddabbdb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RoseRockHealthcareMember_8219d7d2-cb21-4961-a80b-6613c1ca1192" xlink:href="amed-20201231.xsd#amed_RoseRockHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_RoseRockHealthcareMember_8219d7d2-cb21-4961-a80b-6613c1ca1192" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_ead9bcb8-11b7-4924-bc6e-314abab71507" xlink:href="amed-20201231.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_CompassionateCareHospiceMember_ead9bcb8-11b7-4924-bc6e-314abab71507" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d4c7f48a-e69c-4293-845a-a8b5d703b29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d4c7f48a-e69c-4293-845a-a8b5d703b29c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d4c7f48a-e69c-4293-845a-a8b5d703b29c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d4c7f48a-e69c-4293-845a-a8b5d703b29c" xlink:to="loc_us-gaap_SegmentDomain_d4c7f48a-e69c-4293-845a-a8b5d703b29c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d4c7f48a-e69c-4293-845a-a8b5d703b29c" xlink:to="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_b47de168-8e62-4956-bf47-1f22021090a6" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:to="loc_amed_HomeHealthMember_b47de168-8e62-4956-bf47-1f22021090a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_52e43775-8120-4098-ae68-46db5093ae8c" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:to="loc_amed_HospiceMember_52e43775-8120-4098-ae68-46db5093ae8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_27122a38-6f66-43e0-88b6-dcfd481241a7" xlink:href="amed-20201231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:to="loc_amed_HomeHealthAndHospiceMember_27122a38-6f66-43e0-88b6-dcfd481241a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_9b2c427b-4893-4fbc-a72c-9b4027a80726" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:to="loc_amed_PersonalCareMember_9b2c427b-4893-4fbc-a72c-9b4027a80726" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_72259706-fcd8-4570-9d48-6dfffdda5260" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_srt_StatementGeographicalAxis_72259706-fcd8-4570-9d48-6dfffdda5260" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_72259706-fcd8-4570-9d48-6dfffdda5260_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_72259706-fcd8-4570-9d48-6dfffdda5260" xlink:to="loc_srt_SegmentGeographicalDomain_72259706-fcd8-4570-9d48-6dfffdda5260_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_72259706-fcd8-4570-9d48-6dfffdda5260" xlink:to="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_5f6d5af6-300c-43c0-91f6-b1fed2a92968" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_MA_5f6d5af6-300c-43c0-91f6-b1fed2a92968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_16830f18-adf8-4b76-b9a2-c967ca67dc46" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_IL_16830f18-adf8-4b76-b9a2-c967ca67dc46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_ee419fd1-c08e-4283-afc3-5485a1c2c14d" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_TX_ee419fd1-c08e-4283-afc3-5485a1c2c14d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AZ_a360e312-d7dc-4a9e-8b74-82e182bffabd" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_AZ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_AZ_a360e312-d7dc-4a9e-8b74-82e182bffabd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_cee86de0-caf5-41d3-a1c4-725c2726cc08" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_TN_cee86de0-caf5-41d3-a1c4-725c2726cc08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_6125c5b5-1a16-4523-9aef-8f7ef05c402f" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_FL_6125c5b5-1a16-4523-9aef-8f7ef05c402f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_ad8bc1d7-4c33-49ee-abaf-6bbd85eda126" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_WA_ad8bc1d7-4c33-49ee-abaf-6bbd85eda126" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_fcbaa61f-6bf2-4876-94bf-7170d1cf2fae" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_KY_fcbaa61f-6bf2-4876-94bf-7170d1cf2fae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_995a6100-b8dc-4e81-830b-a646024f77a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_995a6100-b8dc-4e81-830b-a646024f77a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_995a6100-b8dc-4e81-830b-a646024f77a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_995a6100-b8dc-4e81-830b-a646024f77a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_995a6100-b8dc-4e81-830b-a646024f77a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_995a6100-b8dc-4e81-830b-a646024f77a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_81d21e77-d0d3-43f8-8ce9-4dd50535434c" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_CertificatesOfNeedMember_81d21e77-d0d3-43f8-8ce9-4dd50535434c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_2c6d5d9f-fc36-46ac-a3f0-ee0c58f32181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_2c6d5d9f-fc36-46ac-a3f0-ee0c58f32181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicarelicensesMember_9925667e-2d3a-434d-9f5c-23a0c21945cb" xlink:href="amed-20201231.xsd#amed_MedicarelicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_MedicarelicensesMember_9925667e-2d3a-434d-9f5c-23a0c21945cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNameOfBusinessMember_b461fd7e-6406-4796-a67c-0c9aee550f0b" xlink:href="amed-20201231.xsd#amed_AcquiredNameOfBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_AcquiredNameOfBusinessMember_b461fd7e-6406-4796-a67c-0c9aee550f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_cbc96d49-c24c-4a47-ba99-0b80c33c5122" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_cbc96d49-c24c-4a47-ba99-0b80c33c5122" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_0fff87c6-2eef-423b-86b4-4ef660e1225b" xlink:href="amed-20201231.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_CertificateOfNeedMember_0fff87c6-2eef-423b-86b4-4ef660e1225b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_4268ba29-98bc-4f74-98c3-863a6d71d303" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_AcquiredNamesMember_4268ba29-98bc-4f74-98c3-863a6d71d303" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_84423732-a966-4852-b2b6-9b71a7dafb38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_84423732-a966-4852-b2b6-9b71a7dafb38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_84423732-a966-4852-b2b6-9b71a7dafb38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_84423732-a966-4852-b2b6-9b71a7dafb38" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_84423732-a966-4852-b2b6-9b71a7dafb38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_759d9f46-875d-44d1-ae62-629cb0d264d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_84423732-a966-4852-b2b6-9b71a7dafb38" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_759d9f46-875d-44d1-ae62-629cb0d264d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_9d683eb2-5557-42d9-93df-fa0dc96c9aac" xlink:href="amed-20201231.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_759d9f46-875d-44d1-ae62-629cb0d264d1" xlink:to="loc_amed_PromissoryNotesMember_9d683eb2-5557-42d9-93df-fa0dc96c9aac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_srt_RangeAxis_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1" xlink:to="loc_srt_RangeMember_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db1d2351-0149-4d6b-9cc2-3f758d7c2ac8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1" xlink:to="loc_srt_RangeMember_db1d2351-0149-4d6b-9cc2-3f758d7c2ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79c31ebb-03e7-4ccc-b972-c35e85ccc27a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_db1d2351-0149-4d6b-9cc2-3f758d7c2ac8" xlink:to="loc_srt_MaximumMember_79c31ebb-03e7-4ccc-b972-c35e85ccc27a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="extended" id="ie3ad7618e8b7461f845bf0166010692a_ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_b899d8e7-8724-4634-9bc4-c18440447dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_b899d8e7-8724-4634-9bc4-c18440447dce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_2e7a2175-a348-4233-ac81-d21930aaf39b" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_2e7a2175-a348-4233-ac81-d21930aaf39b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f7501c8e-bff4-432e-af10-21d8b6308e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f7501c8e-bff4-432e-af10-21d8b6308e88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_7070f2c2-974b-416a-92f4-945d5665cfc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_7070f2c2-974b-416a-92f4-945d5665cfc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_1fd10b10-7497-4175-8ce8-8d5b18b398fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_1fd10b10-7497-4175-8ce8-8d5b18b398fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c360320-2dac-44a1-94b2-f04e9f575d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c360320-2dac-44a1-94b2-f04e9f575d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_f90f849a-b424-43f6-9bcd-37a657aab362" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c360320-2dac-44a1-94b2-f04e9f575d8e" xlink:to="loc_amed_AseraCareHospiceMember_f90f849a-b424-43f6-9bcd-37a657aab362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_da8af327-c3bc-41f8-a658-5a7ea9292722" xlink:href="amed-20201231.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c360320-2dac-44a1-94b2-f04e9f575d8e" xlink:to="loc_amed_CompassionateCareHospiceMember_da8af327-c3bc-41f8-a658-5a7ea9292722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_296d2255-3b7b-42b3-aee3-2ba3bf1f620e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_296d2255-3b7b-42b3-aee3-2ba3bf1f620e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_296d2255-3b7b-42b3-aee3-2ba3bf1f620e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_296d2255-3b7b-42b3-aee3-2ba3bf1f620e" xlink:to="loc_us-gaap_SegmentDomain_296d2255-3b7b-42b3-aee3-2ba3bf1f620e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a977f65d-701f-40f2-8525-8900c38dbe53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_296d2255-3b7b-42b3-aee3-2ba3bf1f620e" xlink:to="loc_us-gaap_SegmentDomain_a977f65d-701f-40f2-8525-8900c38dbe53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_955fb7b6-7d7b-42c8-bab4-cad0b7d24e6b" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a977f65d-701f-40f2-8525-8900c38dbe53" xlink:to="loc_amed_HospiceMember_955fb7b6-7d7b-42c8-bab4-cad0b7d24e6b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNET"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="extended" id="ia4d33863fa6f42f9bc7e94a3a2e00071_GOODWILLANDOTHERINTANGIBLEASSETSNET"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="extended" id="i16c14bc9666b4001bf5617f42cb95056_GOODWILLANDOTHERINTANGIBLEASSETSNETTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="extended" id="ibf696ece02f04a7eb98ad7b5be6992be_GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_dcda30c2-b88b-48c2-a4e9-011726bda1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fc88cd9e-996e-4085-8bcb-d74c7edb4570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_dcda30c2-b88b-48c2-a4e9-011726bda1a5" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fc88cd9e-996e-4085-8bcb-d74c7edb4570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_dcda30c2-b88b-48c2-a4e9-011726bda1a5" xlink:to="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c28463d2-a63d-420d-99a3-457ce540cf13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:to="loc_us-gaap_Goodwill_c28463d2-a63d-420d-99a3-457ce540cf13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_e1067608-8e9c-4b80-852f-a5bba51682ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_e1067608-8e9c-4b80-852f-a5bba51682ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_49f9a5bd-2270-49a9-98f5-47fba7f74129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_49f9a5bd-2270-49a9-98f5-47fba7f74129" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_18092c0c-6035-4882-b30e-12896d108a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_53cf1b48-d8ed-4372-93f6-a1744981ddd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_dcda30c2-b88b-48c2-a4e9-011726bda1a5" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_53cf1b48-d8ed-4372-93f6-a1744981ddd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ee74b808-b543-47ad-92de-87580e1da0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_53cf1b48-d8ed-4372-93f6-a1744981ddd1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ee74b808-b543-47ad-92de-87580e1da0d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ee74b808-b543-47ad-92de-87580e1da0d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee74b808-b543-47ad-92de-87580e1da0d7" xlink:to="loc_us-gaap_SegmentDomain_ee74b808-b543-47ad-92de-87580e1da0d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee74b808-b543-47ad-92de-87580e1da0d7" xlink:to="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_605c9cd2-19ca-450d-9470-dac6408bf79f" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:to="loc_amed_HomeHealthMember_605c9cd2-19ca-450d-9470-dac6408bf79f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_6fbf8d4a-7790-49e3-ad3f-6f734803e23e" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:to="loc_amed_HospiceMember_6fbf8d4a-7790-49e3-ad3f-6f734803e23e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_1d284c50-d8d5-433d-a686-c5045f295517" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:to="loc_amed_PersonalCareMember_1d284c50-d8d5-433d-a686-c5045f295517" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="extended" id="i33b57191d20f4fbaaf1a2e3415ddcc86_GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_bf9f50c5-4793-4f72-8262-3a1c199937b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4f369822-a5f2-4362-8dbb-9aa284f85025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_bf9f50c5-4793-4f72-8262-3a1c199937b1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4f369822-a5f2-4362-8dbb-9aa284f85025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1abbfde3-defd-4922-87e3-4957320ebcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_bf9f50c5-4793-4f72-8262-3a1c199937b1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1abbfde3-defd-4922-87e3-4957320ebcfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_d87521ef-04f6-4ee2-ab10-193264c3797f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_bf9f50c5-4793-4f72-8262-3a1c199937b1" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_d87521ef-04f6-4ee2-ab10-193264c3797f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_286afcba-3b1f-4572-b957-f92a48a3783c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_d87521ef-04f6-4ee2-ab10-193264c3797f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_286afcba-3b1f-4572-b957-f92a48a3783c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_286afcba-3b1f-4572-b957-f92a48a3783c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_286afcba-3b1f-4572-b957-f92a48a3783c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_286afcba-3b1f-4572-b957-f92a48a3783c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cabd80ce-c486-41b7-8acd-6beda326dbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_286afcba-3b1f-4572-b957-f92a48a3783c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cabd80ce-c486-41b7-8acd-6beda326dbd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_fa948fd2-ae40-4389-a4a9-f607b45fa5b1" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cabd80ce-c486-41b7-8acd-6beda326dbd1" xlink:to="loc_amed_AcquiredNamesMember_fa948fd2-ae40-4389-a4a9-f607b45fa5b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_14147638-a971-40b4-a9b7-5acb5a14bbd9" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cabd80ce-c486-41b7-8acd-6beda326dbd1" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_14147638-a971-40b4-a9b7-5acb5a14bbd9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="extended" id="if639223c36344593882885e7ea60dfcb_GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_20c973be-74e4-495c-8ce3-46c3c1a7c2f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_20c973be-74e4-495c-8ce3-46c3c1a7c2f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_de0d3720-c0fd-4bc9-a139-52214d09aded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_de0d3720-c0fd-4bc9-a139-52214d09aded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e0bac79b-6800-40de-9626-08c1a87dc351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e0bac79b-6800-40de-9626-08c1a87dc351" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_47d9e89d-8daf-4a38-96f1-209d77d461ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_47d9e89d-8daf-4a38-96f1-209d77d461ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherIntangibleAssetsAdditions_942f84aa-4bfb-4616-ab15-3c5e40654ce8" xlink:href="amed-20201231.xsd#amed_OtherIntangibleAssetsAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:to="loc_amed_OtherIntangibleAssetsAdditions_942f84aa-4bfb-4616-ab15-3c5e40654ce8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7096eb62-8597-4ee5-8d1c-b6071da7ad06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_33e83a6e-3413-45c8-905e-3966cc9b32d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_33e83a6e-3413-45c8-905e-3966cc9b32d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc09550c-88b3-4da3-8eb0-e370ed28e460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d008f76e-7e2d-4182-95df-e13c7918030d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d008f76e-7e2d-4182-95df-e13c7918030d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d008f76e-7e2d-4182-95df-e13c7918030d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d008f76e-7e2d-4182-95df-e13c7918030d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d008f76e-7e2d-4182-95df-e13c7918030d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14fe08a9-d901-4142-aaf2-34528270b610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d008f76e-7e2d-4182-95df-e13c7918030d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14fe08a9-d901-4142-aaf2-34528270b610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_417abd32-65b3-4e23-baf6-071782f99482" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14fe08a9-d901-4142-aaf2-34528270b610" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_417abd32-65b3-4e23-baf6-071782f99482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember_34a69b72-d7c5-4cb5-83bc-145d8eb161b6" xlink:href="amed-20201231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14fe08a9-d901-4142-aaf2-34528270b610" xlink:to="loc_amed_UnamortizableAcquiredNamesMember_34a69b72-d7c5-4cb5-83bc-145d8eb161b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d721e9b4-e27d-4ed4-9fe3-b0509742c25e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d721e9b4-e27d-4ed4-9fe3-b0509742c25e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d721e9b4-e27d-4ed4-9fe3-b0509742c25e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d721e9b4-e27d-4ed4-9fe3-b0509742c25e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d721e9b4-e27d-4ed4-9fe3-b0509742c25e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b887c9b7-5930-4d51-b9a5-4134b0d5a682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d721e9b4-e27d-4ed4-9fe3-b0509742c25e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b887c9b7-5930-4d51-b9a5-4134b0d5a682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember_e05f5cf4-32b9-476d-95d6-5dea741a9225" xlink:href="amed-20201231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b887c9b7-5930-4d51-b9a5-4134b0d5a682" xlink:to="loc_amed_AmortizableAcquiredNamesMember_e05f5cf4-32b9-476d-95d6-5dea741a9225" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_2d31cf59-5930-465f-a602-659e6208f8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b887c9b7-5930-4d51-b9a5-4134b0d5a682" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_2d31cf59-5930-465f-a602-659e6208f8e0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="extended" id="i845c144b7d4a4dd2980b1440c7032193_GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="extended" id="i9a0816228c3147b6aa0611fd93486248_DETAILSOFCERTAINBALANCESHEETACCOUNTS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="extended" id="i76038bec4e5743999447cf7ff9cec8b0_DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="extended" id="i3f271a9535f24e6dad304361e8f68254_DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASES" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASES"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASES" xlink:type="extended" id="ie22f6940585c40368e8134476c75b995_LEASES"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESTables" xlink:type="extended" id="ibdafb40c9dee4fa2b5ef06145cefabad_LEASESTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesCodificationTopic842Policies" xlink:type="simple" xlink:href="amed-20201231.xsd#LeasesCodificationTopic842Policies"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LeasesCodificationTopic842Policies" xlink:type="extended" id="icb1134b4de3e4cdab8c4eefdebe8a731_LeasesCodificationTopic842Policies"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESDetails" xlink:type="extended" id="i7a3dcb4fd3cc47f2bbaa1cbab162b78c_LEASESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0fc23744-dc8a-4d15-9d74-cd3ddca43caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0fc23744-dc8a-4d15-9d74-cd3ddca43caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_9444e7f3-315c-4a45-98af-2494b6352bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_9444e7f3-315c-4a45-98af-2494b6352bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_411915c1-a755-48fc-8f44-37b03a7aedba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_411915c1-a755-48fc-8f44-37b03a7aedba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fdad7085-3e91-4b0c-85b6-5916d9d8f0ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fdad7085-3e91-4b0c-85b6-5916d9d8f0ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bec6c524-4fce-4086-821e-61adf50e0df5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:to="loc_srt_RangeAxis_bec6c524-4fce-4086-821e-61adf50e0df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bec6c524-4fce-4086-821e-61adf50e0df5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bec6c524-4fce-4086-821e-61adf50e0df5" xlink:to="loc_srt_RangeMember_bec6c524-4fce-4086-821e-61adf50e0df5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79871b89-f785-4b9a-ae04-de9f0431efb0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bec6c524-4fce-4086-821e-61adf50e0df5" xlink:to="loc_srt_RangeMember_79871b89-f785-4b9a-ae04-de9f0431efb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0cdfbf43-92af-4ef0-97ce-1dd946230be1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79871b89-f785-4b9a-ae04-de9f0431efb0" xlink:to="loc_srt_MinimumMember_0cdfbf43-92af-4ef0-97ce-1dd946230be1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_39871b70-1702-4c07-af4e-75597dcb665b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79871b89-f785-4b9a-ae04-de9f0431efb0" xlink:to="loc_srt_MaximumMember_39871b70-1702-4c07-af4e-75597dcb665b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeAxis_52067d8d-f117-4f32-85ba-f4d2165100ed" xlink:href="amed-20201231.xsd#amed_LeaseTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:to="loc_amed_LeaseTypeAxis_52067d8d-f117-4f32-85ba-f4d2165100ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeDomain_52067d8d-f117-4f32-85ba-f4d2165100ed_default" xlink:href="amed-20201231.xsd#amed_LeaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_LeaseTypeAxis_52067d8d-f117-4f32-85ba-f4d2165100ed" xlink:to="loc_amed_LeaseTypeDomain_52067d8d-f117-4f32-85ba-f4d2165100ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeDomain_89d1e104-f576-471b-b3f3-dc701f7ed154" xlink:href="amed-20201231.xsd#amed_LeaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_LeaseTypeAxis_52067d8d-f117-4f32-85ba-f4d2165100ed" xlink:to="loc_amed_LeaseTypeDomain_89d1e104-f576-471b-b3f3-dc701f7ed154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetLeaseMember_fac73f22-3bf8-4d2c-b5c7-3b5959d98f50" xlink:href="amed-20201231.xsd#amed_FleetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_LeaseTypeDomain_89d1e104-f576-471b-b3f3-dc701f7ed154" xlink:to="loc_amed_FleetLeaseMember_fac73f22-3bf8-4d2c-b5c7-3b5959d98f50" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESLeaseCostDetails" xlink:type="extended" id="ic4b4cc43ee3147688e09d52a112bb90f_LEASESLeaseCostDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESOperatingLeaseDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESOperatingLeaseDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESOperatingLeaseDetails" xlink:type="extended" id="iff165ed8df6d4d97a46442a621fc7e41_LEASESOperatingLeaseDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESFinanceLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="extended" id="ic2258bbeeb8c45c3a97a395ad1be8614_LEASESFinanceLeasesDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESSupplementalCashflowInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails" xlink:type="extended" id="ic01c8047d4c140b2b39d6b9ed29ec005_LEASESSupplementalCashflowInformationDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="extended" id="i3c58d38b09b749338606fd260d0292e8_LEASESWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="extended" id="i9323df4a3a274954862321ecba13f5d7_LEASESMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended" id="if2edfa79b5bd4927869c8be3f30172d2_LONGTERMOBLIGATIONS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="extended" id="i62c45286290f4e859fdb9090fd9adbe4_LONGTERMOBLIGATIONSTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="extended" id="iee898f36206440d4afccad04550915dd_LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3677cdae-ddef-402e-8ac7-3ea6e4d40417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3677cdae-ddef-402e-8ac7-3ea6e4d40417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c5e7c55e-d580-4d7b-967a-ee89c5a77d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c5e7c55e-d580-4d7b-967a-ee89c5a77d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0411606d-b1d7-42a0-9355-942731a3ec60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_LongTermDebt_0411606d-b1d7-42a0-9355-942731a3ec60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7b371b5f-e9e8-4785-83cc-dbc5bc93a0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_LongTermDebtCurrent_7b371b5f-e9e8-4785-83cc-dbc5bc93a0e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6d9dc1bf-b566-427f-ac87-eb8fbe89048e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6d9dc1bf-b566-427f-ac87-eb8fbe89048e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e9601518-48f8-4ea8-8c73-b5678d90c2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e9601518-48f8-4ea8-8c73-b5678d90c2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e9601518-48f8-4ea8-8c73-b5678d90c2ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9601518-48f8-4ea8-8c73-b5678d90c2ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e9601518-48f8-4ea8-8c73-b5678d90c2ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9601518-48f8-4ea8-8c73-b5678d90c2ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_2d4c8f15-2c92-48fe-a5fe-3dd208b21574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:to="loc_us-gaap_LoansPayableMember_2d4c8f15-2c92-48fe-a5fe-3dd208b21574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f5cd5999-ca08-49ec-9c52-1d351ea1d305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f5cd5999-ca08-49ec-9c52-1d351ea1d305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_c81377bb-b749-4673-b1d1-d8b6992809d6" xlink:href="amed-20201231.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:to="loc_amed_PromissoryNotesMember_c81377bb-b749-4673-b1d1-d8b6992809d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_4bd22fa0-dfba-4151-8c6c-987c24bbde23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_4bd22fa0-dfba-4151-8c6c-987c24bbde23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5f480349-54bf-485c-8751-be5e51dcc47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:to="loc_us-gaap_DebtInstrumentAxis_5f480349-54bf-485c-8751-be5e51dcc47b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f480349-54bf-485c-8751-be5e51dcc47b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f480349-54bf-485c-8751-be5e51dcc47b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f480349-54bf-485c-8751-be5e51dcc47b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2727993d-6fe2-452f-ac67-31154765f528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f480349-54bf-485c-8751-be5e51dcc47b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2727993d-6fe2-452f-ac67-31154765f528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_881c81e1-b935-490c-81a4-c7d0ceb37154" xlink:href="amed-20201231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2727993d-6fe2-452f-ac67-31154765f528" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_881c81e1-b935-490c-81a4-c7d0ceb37154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_7e6a9b4f-ee6b-4c62-9c0b-d4a50f56585a" xlink:href="amed-20201231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2727993d-6fe2-452f-ac67-31154765f528" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_7e6a9b4f-ee6b-4c62-9c0b-d4a50f56585a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_300e0b41-710a-4e48-9e14-7c5cbb95f9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:to="loc_us-gaap_VariableRateAxis_300e0b41-710a-4e48-9e14-7c5cbb95f9b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_300e0b41-710a-4e48-9e14-7c5cbb95f9b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_300e0b41-710a-4e48-9e14-7c5cbb95f9b6" xlink:to="loc_us-gaap_VariableRateDomain_300e0b41-710a-4e48-9e14-7c5cbb95f9b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_138ca48f-96b1-4a2b-847d-f9b36c312fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_300e0b41-710a-4e48-9e14-7c5cbb95f9b6" xlink:to="loc_us-gaap_VariableRateDomain_138ca48f-96b1-4a2b-847d-f9b36c312fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_9868cbb7-9817-4eaf-9e63-b4fc74525c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_138ca48f-96b1-4a2b-847d-f9b36c312fa8" xlink:to="loc_us-gaap_EurodollarMember_9868cbb7-9817-4eaf-9e63-b4fc74525c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_fdd57426-e1ab-4091-a637-f4f6eeafe4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_138ca48f-96b1-4a2b-847d-f9b36c312fa8" xlink:to="loc_us-gaap_BaseRateMember_fdd57426-e1ab-4091-a637-f4f6eeafe4ce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i994fd3a218b1404f9765868eeb0824c3_LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5f5adba1-eae4-47fb-87ec-562a1fd5d9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5f5adba1-eae4-47fb-87ec-562a1fd5d9b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_64555735-8bf7-49ab-a22b-d74dbf4707ca" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_64555735-8bf7-49ab-a22b-d74dbf4707ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_ab0c9d09-cc5d-498c-8d92-d056fa3e7695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_ab0c9d09-cc5d-498c-8d92-d056fa3e7695" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:to="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9f73ae4e-3854-4aa5-bbd4-6d09a449e155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9f73ae4e-3854-4aa5-bbd4-6d09a449e155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f73ae4e-3854-4aa5-bbd4-6d09a449e155_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f73ae4e-3854-4aa5-bbd4-6d09a449e155" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f73ae4e-3854-4aa5-bbd4-6d09a449e155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_90e10576-4546-4215-b79e-9f27577b6151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f73ae4e-3854-4aa5-bbd4-6d09a449e155" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_90e10576-4546-4215-b79e-9f27577b6151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_4cea99d9-f604-45ac-9e25-1e85b88a1555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_90e10576-4546-4215-b79e-9f27577b6151" xlink:to="loc_us-gaap_LoansPayableMember_4cea99d9-f604-45ac-9e25-1e85b88a1555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_584586e7-0833-443b-8192-cb532e49dce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_90e10576-4546-4215-b79e-9f27577b6151" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_584586e7-0833-443b-8192-cb532e49dce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:to="loc_us-gaap_DebtInstrumentAxis_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_53d6c875-f71c-4fba-8844-565906b0e149" xlink:href="amed-20201231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_53d6c875-f71c-4fba-8844-565906b0e149" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_63938f81-dfed-415b-b736-9fe2675cd261" xlink:href="amed-20201231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_63938f81-dfed-415b-b736-9fe2675cd261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_f9c05567-f36d-46d2-9597-22eaed157e19" xlink:href="amed-20201231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_f9c05567-f36d-46d2-9597-22eaed157e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_050b5b62-2ba0-476b-98e2-62c466f632f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:to="loc_us-gaap_VariableRateAxis_050b5b62-2ba0-476b-98e2-62c466f632f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_050b5b62-2ba0-476b-98e2-62c466f632f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_050b5b62-2ba0-476b-98e2-62c466f632f6" xlink:to="loc_us-gaap_VariableRateDomain_050b5b62-2ba0-476b-98e2-62c466f632f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_07887c3a-ec91-442c-8584-870f85346a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_050b5b62-2ba0-476b-98e2-62c466f632f6" xlink:to="loc_us-gaap_VariableRateDomain_07887c3a-ec91-442c-8584-870f85346a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_9b142f41-8c27-4ed4-be61-f380fca0a42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_07887c3a-ec91-442c-8584-870f85346a38" xlink:to="loc_us-gaap_EurodollarMember_9b142f41-8c27-4ed4-be61-f380fca0a42a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_de364782-121c-4a83-aa24-e78d4a2f9c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_07887c3a-ec91-442c-8584-870f85346a38" xlink:to="loc_us-gaap_BaseRateMember_de364782-121c-4a83-aa24-e78d4a2f9c0b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSMaturitiesofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="extended" id="i55f9b71dd4c54ac5a7cc1ddce109a4f9_LONGTERMOBLIGATIONSMaturitiesofDebtDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended" id="icbd39038fb034712806779b3edee74f8_LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_a276435c-095f-4780-b86c-78346c75baf5" xlink:href="amed-20201231.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_amed_ConsolidatedLeverageRatio_a276435c-095f-4780-b86c-78346c75baf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2fac99cb-fa61-464d-83e2-e68bdffe3d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2fac99cb-fa61-464d-83e2-e68bdffe3d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_673fff6f-6b63-43d9-976f-fec555f4ed8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_673fff6f-6b63-43d9-976f-fec555f4ed8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_02d79846-2999-46e3-9731-8b6ec94202d1" xlink:href="amed-20201231.xsd#amed_LetterOfCreditFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_amed_LetterOfCreditFee_02d79846-2999-46e3-9731-8b6ec94202d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca352b12-37f0-4d59-8b9e-06855c050282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca352b12-37f0-4d59-8b9e-06855c050282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ca352b12-37f0-4d59-8b9e-06855c050282_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca352b12-37f0-4d59-8b9e-06855c050282" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ca352b12-37f0-4d59-8b9e-06855c050282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca352b12-37f0-4d59-8b9e-06855c050282" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_17f7f06c-0e5a-4e75-a30a-439a00673e17" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_17f7f06c-0e5a-4e75-a30a-439a00673e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_970b36c2-da90-4f78-9cc3-c0e41bb8d047" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_970b36c2-da90-4f78-9cc3-c0e41bb8d047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_2fd37b35-0c1e-4b34-8774-0925a139189f" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_2fd37b35-0c1e-4b34-8774-0925a139189f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_bd4a3ec0-0429-4869-9137-2202698cd35f" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_bd4a3ec0-0429-4869-9137-2202698cd35f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e63a2232-7862-48a6-aecc-8b8dedac899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:to="loc_us-gaap_VariableRateAxis_e63a2232-7862-48a6-aecc-8b8dedac899f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e63a2232-7862-48a6-aecc-8b8dedac899f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_e63a2232-7862-48a6-aecc-8b8dedac899f" xlink:to="loc_us-gaap_VariableRateDomain_e63a2232-7862-48a6-aecc-8b8dedac899f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_aeb28866-cebd-4ed1-baca-e98c424956b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_e63a2232-7862-48a6-aecc-8b8dedac899f" xlink:to="loc_us-gaap_VariableRateDomain_aeb28866-cebd-4ed1-baca-e98c424956b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_7900e493-ea14-4dc5-aadb-7b7b214a3661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_aeb28866-cebd-4ed1-baca-e98c424956b5" xlink:to="loc_us-gaap_BaseRateMember_7900e493-ea14-4dc5-aadb-7b7b214a3661" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_bbcbffc6-4163-4c52-80a7-2c7c27a47a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_aeb28866-cebd-4ed1-baca-e98c424956b5" xlink:to="loc_us-gaap_EurodollarMember_bbcbffc6-4163-4c52-80a7-2c7c27a47a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a44e66a9-8069-4709-95e6-b26ccf792fe9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:to="loc_srt_RangeAxis_a44e66a9-8069-4709-95e6-b26ccf792fe9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a44e66a9-8069-4709-95e6-b26ccf792fe9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a44e66a9-8069-4709-95e6-b26ccf792fe9" xlink:to="loc_srt_RangeMember_a44e66a9-8069-4709-95e6-b26ccf792fe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe36880d-a9b6-4ffb-bf03-2d7258f541c3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a44e66a9-8069-4709-95e6-b26ccf792fe9" xlink:to="loc_srt_RangeMember_fe36880d-a9b6-4ffb-bf03-2d7258f541c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_39b7e85e-66f3-4878-a7ed-09b52dcb78e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe36880d-a9b6-4ffb-bf03-2d7258f541c3" xlink:to="loc_srt_MaximumMember_39b7e85e-66f3-4878-a7ed-09b52dcb78e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eed08bac-411d-4386-95b5-c8f303bf846c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe36880d-a9b6-4ffb-bf03-2d7258f541c3" xlink:to="loc_srt_MinimumMember_eed08bac-411d-4386-95b5-c8f303bf846c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended" id="id6da5be2117746f48ec79a49d3e92e78_LONGTERMOBLIGATIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_479bddde-029b-4373-a0ba-b96b8bbdb906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_479bddde-029b-4373-a0ba-b96b8bbdb906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1da6606-cff4-4a89-b68e-cff94c0e1286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1da6606-cff4-4a89-b68e-cff94c0e1286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_8bdca899-1580-43f9-8cdb-9a49d67dfcd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_8bdca899-1580-43f9-8cdb-9a49d67dfcd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_9b699c4d-7f92-45f7-aa1a-0a39b32be293" xlink:href="amed-20201231.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_RevolvingCreditFacilityTotal_9b699c4d-7f92-45f7-aa1a-0a39b32be293" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_996b2432-2f3b-497a-b643-4032178e7e65" xlink:href="amed-20201231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_996b2432-2f3b-497a-b643-4032178e7e65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_efa748eb-3dab-4275-8475-ec1bb051fcbb" xlink:href="amed-20201231.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_efa748eb-3dab-4275-8475-ec1bb051fcbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_02ef70b8-7175-41c6-a6e5-b50da2e47c25" xlink:href="amed-20201231.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_02ef70b8-7175-41c6-a6e5-b50da2e47c25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ca193603-ceaf-40e3-a4eb-6617b6523d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ca193603-ceaf-40e3-a4eb-6617b6523d84" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_d914a627-ad63-4d26-92f0-4ccf5e00b18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_d914a627-ad63-4d26-92f0-4ccf5e00b18e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentNumberOfPeriodicPayments_46c62684-ffbb-447b-b6f9-690193017836" xlink:href="amed-20201231.xsd#amed_DebtInstrumentNumberOfPeriodicPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_DebtInstrumentNumberOfPeriodicPayments_46c62684-ffbb-447b-b6f9-690193017836" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_c2bd2f62-bc28-47dc-84be-390520c9268f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_c2bd2f62-bc28-47dc-84be-390520c9268f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16725fda-e211-4e85-9dc6-2306034c1a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16725fda-e211-4e85-9dc6-2306034c1a6c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_d6bcf231-3bae-4a7e-9545-d4dd4e581bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_d6bcf231-3bae-4a7e-9545-d4dd4e581bec" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_3603d228-86a7-4728-acf3-f55a12741fbd" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_3603d228-86a7-4728-acf3-f55a12741fbd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_89b15f01-f2d1-4054-bd10-684f388ebb1b" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_89b15f01-f2d1-4054-bd10-684f388ebb1b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c7c0bb7e-6b35-4800-b75e-a64dbeb52d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c7c0bb7e-6b35-4800-b75e-a64dbeb52d6b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WeightedAverageInterestRate_a8a36eb8-c1fa-4e2e-aa84-e41f730e4167" xlink:href="amed-20201231.xsd#amed_WeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_WeightedAverageInterestRate_a8a36eb8-c1fa-4e2e-aa84-e41f730e4167" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_15daff0c-018c-4ec0-9987-e8f4340b471e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_15daff0c-018c-4ec0-9987-e8f4340b471e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_de3c9458-e161-4f5c-9608-526ee2a461e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_de3c9458-e161-4f5c-9608-526ee2a461e6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_68a5d845-07d8-4ab1-86f9-53dfea976713" xlink:href="amed-20201231.xsd#amed_TotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_TotalLeverageRatio_68a5d845-07d8-4ab1-86f9-53dfea976713" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_7dbf6c2e-9972-4927-b860-6b57295c8739" xlink:href="amed-20201231.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_7dbf6c2e-9972-4927-b860-6b57295c8739" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_cc5e7eec-00c6-47b1-8097-ca140dcfad5a" xlink:href="amed-20201231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_cc5e7eec-00c6-47b1-8097-ca140dcfad5a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_4343e9f8-329a-415d-8760-59ede76cfdce" xlink:href="amed-20201231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_4343e9f8-329a-415d-8760-59ede76cfdce" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CallPremiumPayment_ee6c7e55-cf53-4c42-a16b-7e2c01a710dd" xlink:href="amed-20201231.xsd#amed_CallPremiumPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_CallPremiumPayment_ee6c7e55-cf53-4c42-a16b-7e2c01a710dd" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_a7d687f7-07ef-4a96-b811-5de1759f4599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_a7d687f7-07ef-4a96-b811-5de1759f4599" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_080c62c7-384f-4f3e-824e-addd517bfed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_080c62c7-384f-4f3e-824e-addd517bfed2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0d85a1a6-135e-4c79-a586-8de90dde847a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0d85a1a6-135e-4c79-a586-8de90dde847a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fdf3373c-46ec-46c5-9d8a-33fefd6e9556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fdf3373c-46ec-46c5-9d8a-33fefd6e9556" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_565606f3-1b65-4b3c-8c75-461cca2ba0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_565606f3-1b65-4b3c-8c75-461cca2ba0bf" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_82022428-d846-4937-8689-87c39da6fa28" xlink:href="amed-20201231.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_82022428-d846-4937-8689-87c39da6fa28" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_2eb4c38b-8caa-4639-82e1-832826c10533" xlink:href="amed-20201231.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_2eb4c38b-8caa-4639-82e1-832826c10533" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineFacility_9886b2b1-1599-4277-9a5e-9de6e7bfc38a" xlink:href="amed-20201231.xsd#amed_SwingLineFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_SwingLineFacility_9886b2b1-1599-4277-9a5e-9de6e7bfc38a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LettersofCreditmaximumcommitment_cf82847e-27b6-48d8-b9af-6ea7a1882c77" xlink:href="amed-20201231.xsd#amed_LettersofCreditmaximumcommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_LettersofCreditmaximumcommitment_cf82847e-27b6-48d8-b9af-6ea7a1882c77" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_540981a3-cbf3-4a61-87b9-0ff99c8f4090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_DebtInstrumentAxis_540981a3-cbf3-4a61-87b9-0ff99c8f4090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_540981a3-cbf3-4a61-87b9-0ff99c8f4090_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_540981a3-cbf3-4a61-87b9-0ff99c8f4090" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_540981a3-cbf3-4a61-87b9-0ff99c8f4090_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c8dd6894-cc11-4bec-915d-891c0f665cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_540981a3-cbf3-4a61-87b9-0ff99c8f4090" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c8dd6894-cc11-4bec-915d-891c0f665cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_29d3361d-3f5c-4db5-aa92-e76c361ab818" xlink:href="amed-20201231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c8dd6894-cc11-4bec-915d-891c0f665cb5" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_29d3361d-3f5c-4db5-aa92-e76c361ab818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_0e04ea9a-5a3b-4ceb-93dd-bd0979dca92a" xlink:href="amed-20201231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c8dd6894-cc11-4bec-915d-891c0f665cb5" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_0e04ea9a-5a3b-4ceb-93dd-bd0979dca92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f5ade106-3468-4c91-914c-337b90c7f5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f5ade106-3468-4c91-914c-337b90c7f5e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f5ade106-3468-4c91-914c-337b90c7f5e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5ade106-3468-4c91-914c-337b90c7f5e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f5ade106-3468-4c91-914c-337b90c7f5e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5ade106-3468-4c91-914c-337b90c7f5e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_b4d3368b-1e94-4fe9-8642-996fba435128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_LoansPayableMember_b4d3368b-1e94-4fe9-8642-996fba435128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_91a64ba1-d517-49e0-9ba6-2f21f25cf760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_91a64ba1-d517-49e0-9ba6-2f21f25cf760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b6c00ef0-75b6-4e3c-a0be-add91a08a03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_LineOfCreditMember_b6c00ef0-75b6-4e3c-a0be-add91a08a03e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_a69da4d3-dbf1-4bba-a334-278da5209028" xlink:href="amed-20201231.xsd#amed_SwingLineLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_amed_SwingLineLoanMember_a69da4d3-dbf1-4bba-a334-278da5209028" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_e7627a0d-9bb4-4351-9eeb-cc92ac788550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_LetterOfCreditMember_e7627a0d-9bb4-4351-9eeb-cc92ac788550" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditAgreementMember_159a67d6-83b2-4736-bc94-6110f5e581ce" xlink:href="amed-20201231.xsd#amed_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_amed_CreditAgreementMember_159a67d6-83b2-4736-bc94-6110f5e581ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_b0ca543d-f954-48f0-bfae-1cdebf54c61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_b0ca543d-f954-48f0-bfae-1cdebf54c61e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_03ab0c5d-fdaf-4342-bde1-6adc1458c8e8" xlink:href="amed-20201231.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_amed_AmendedCreditAgreementMember_03ab0c5d-fdaf-4342-bde1-6adc1458c8e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fe876760-046b-4fd6-b00b-1e9c4b1a9da7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_srt_StatementScenarioAxis_fe876760-046b-4fd6-b00b-1e9c4b1a9da7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fe876760-046b-4fd6-b00b-1e9c4b1a9da7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_fe876760-046b-4fd6-b00b-1e9c4b1a9da7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fe876760-046b-4fd6-b00b-1e9c4b1a9da7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2231a162-b34e-413e-ad4c-da5709183abd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_fe876760-046b-4fd6-b00b-1e9c4b1a9da7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2231a162-b34e-413e-ad4c-da5709183abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_63884c10-59e3-4038-a917-6e1b19ae6fd6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2231a162-b34e-413e-ad4c-da5709183abd" xlink:to="loc_srt_ScenarioForecastMember_63884c10-59e3-4038-a917-6e1b19ae6fd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6b55a351-e9fb-4566-8362-4c498b773f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_VariableRateAxis_6b55a351-e9fb-4566-8362-4c498b773f8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6b55a351-e9fb-4566-8362-4c498b773f8c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_6b55a351-e9fb-4566-8362-4c498b773f8c" xlink:to="loc_us-gaap_VariableRateDomain_6b55a351-e9fb-4566-8362-4c498b773f8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_67704889-35fd-47b4-aab6-d0ed9f99ddd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_6b55a351-e9fb-4566-8362-4c498b773f8c" xlink:to="loc_us-gaap_VariableRateDomain_67704889-35fd-47b4-aab6-d0ed9f99ddd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_a74f5c9f-2c52-4aa6-923b-963c170a07a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_67704889-35fd-47b4-aab6-d0ed9f99ddd2" xlink:to="loc_us-gaap_BaseRateMember_a74f5c9f-2c52-4aa6-923b-963c170a07a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_5f434a27-caf9-46f3-a385-c8dec25dfc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_67704889-35fd-47b4-aab6-d0ed9f99ddd2" xlink:to="loc_us-gaap_EurodollarMember_5f434a27-caf9-46f3-a385-c8dec25dfc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c3d51fb-881d-4a9c-a39c-ecffb3b876be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_srt_RangeAxis_4c3d51fb-881d-4a9c-a39c-ecffb3b876be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c3d51fb-881d-4a9c-a39c-ecffb3b876be_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c3d51fb-881d-4a9c-a39c-ecffb3b876be" xlink:to="loc_srt_RangeMember_4c3d51fb-881d-4a9c-a39c-ecffb3b876be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc4b5d13-e322-46be-92f1-95d4ed50a57d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c3d51fb-881d-4a9c-a39c-ecffb3b876be" xlink:to="loc_srt_RangeMember_fc4b5d13-e322-46be-92f1-95d4ed50a57d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_57f5773d-563b-4955-b65d-f70b6bf85e67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc4b5d13-e322-46be-92f1-95d4ed50a57d" xlink:to="loc_srt_MinimumMember_57f5773d-563b-4955-b65d-f70b6bf85e67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ed22931-7ba2-42e8-83d0-c65c7ad08e56" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc4b5d13-e322-46be-92f1-95d4ed50a57d" xlink:to="loc_srt_MaximumMember_5ed22931-7ba2-42e8-83d0-c65c7ad08e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8f3b1e22-f6a5-473c-8918-a3e3c575b8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8f3b1e22-f6a5-473c-8918-a3e3c575b8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cb59ad44-6ee8-44f7-b6d8-06c1c4eb01ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8f3b1e22-f6a5-473c-8918-a3e3c575b8a7" xlink:to="loc_us-gaap_SubsequentEventMember_cb59ad44-6ee8-44f7-b6d8-06c1c4eb01ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXES" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXES"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXES" xlink:type="extended" id="i801721c07ced43c0a85251e7661f273f_INCOMETAXES"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="extended" id="i6923b3307bc940e39286f0cbd8bd4960_INCOMETAXESTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="ibbf93a6ef8e845279c2449feaba4127e_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_721064b4-fcb6-4647-9e89-e4df651cc3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_721064b4-fcb6-4647-9e89-e4df651cc3c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_53e68f8d-64d1-4b87-9f5a-de207611011a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_IncomeTaxesReceivable_53e68f8d-64d1-4b87-9f5a-de207611011a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_e8a3a007-4b98-4333-b139-31f2ae2f0cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_e8a3a007-4b98-4333-b139-31f2ae2f0cf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RefundTaxYear_b1b0bf77-e390-49d1-8d4a-75a0717dee66" xlink:href="amed-20201231.xsd#amed_RefundTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_RefundTaxYear_b1b0bf77-e390-49d1-8d4a-75a0717dee66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_2c21947f-c41e-4ddb-9394-8856abb806d4" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_2c21947f-c41e-4ddb-9394-8856abb806d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e932177d-6913-48d7-9d57-a8e53eb2b74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e932177d-6913-48d7-9d57-a8e53eb2b74c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a95e6b91-aec4-49b9-b82c-da0919b186f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a95e6b91-aec4-49b9-b82c-da0919b186f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55a6434a-61da-407f-8ed9-63462c0c6b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55a6434a-61da-407f-8ed9-63462c0c6b54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_81584958-66d0-487a-bb9b-b98c8e408f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_81584958-66d0-487a-bb9b-b98c8e408f25" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ae113a12-fc6e-4fd3-9fd1-3121e2d0e758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ae113a12-fc6e-4fd3-9fd1-3121e2d0e758" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7d8f12a6-629d-498c-b6ed-fbaf66abb33f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7d8f12a6-629d-498c-b6ed-fbaf66abb33f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfIndividualStatesSubjectToIncomeTax_066df8b5-b11f-4ed8-bb6d-7f7d4f7dbbde" xlink:href="amed-20201231.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_NumberOfIndividualStatesSubjectToIncomeTax_066df8b5-b11f-4ed8-bb6d-7f7d4f7dbbde" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_6d10562b-6667-4495-b5b8-b138b34cde81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_OpenTaxYear_6d10562b-6667-4495-b5b8-b138b34cde81" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_3852b089-6966-4960-bbca-92c4eba64005" xlink:href="amed-20201231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_3852b089-6966-4960-bbca-92c4eba64005" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ac98c5cd-1075-493f-a5af-801fca8a2c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ac98c5cd-1075-493f-a5af-801fca8a2c26" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_631f0ebd-c1b7-40d7-9855-d73d092f8518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_631f0ebd-c1b7-40d7-9855-d73d092f8518" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_49eb0638-ef55-4f7a-b2b0-49ba900cd6a6" xlink:href="amed-20201231.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_FundingReceivedFromCARESAct_49eb0638-ef55-4f7a-b2b0-49ba900cd6a6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_ba8b2419-8485-4320-be02-592311328f18" xlink:href="amed-20201231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_ProviderReliefFundAdvance_ba8b2419-8485-4320-be02-592311328f18" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4c3bb62b-eaf0-488e-94a0-971342130181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4c3bb62b-eaf0-488e-94a0-971342130181" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_381225de-3d0e-4ef1-b904-fb138f10cd60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_381225de-3d0e-4ef1-b904-fb138f10cd60" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0ac651b0-388f-4ad2-b31a-efa5df08df86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0ac651b0-388f-4ad2-b31a-efa5df08df86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0ac651b0-388f-4ad2-b31a-efa5df08df86_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0ac651b0-388f-4ad2-b31a-efa5df08df86" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0ac651b0-388f-4ad2-b31a-efa5df08df86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d8de5028-d31f-4c4c-8cb3-99d77b2f0cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0ac651b0-388f-4ad2-b31a-efa5df08df86" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d8de5028-d31f-4c4c-8cb3-99d77b2f0cce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_7e22aa46-9d4e-4095-9576-5538dedcf186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d8de5028-d31f-4c4c-8cb3-99d77b2f0cce" xlink:to="loc_us-gaap_DomesticCountryMember_7e22aa46-9d4e-4095-9576-5538dedcf186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1a75f967-0f91-47a4-ae8a-f87685969ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d8de5028-d31f-4c4c-8cb3-99d77b2f0cce" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1a75f967-0f91-47a4-ae8a-f87685969ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AlternativeMinimumTaxCreditMember_99bcd906-c18c-4b59-bf0d-7e00f4b1e15e" xlink:href="amed-20201231.xsd#amed_AlternativeMinimumTaxCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:to="loc_amed_AlternativeMinimumTaxCreditMember_99bcd906-c18c-4b59-bf0d-7e00f4b1e15e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ResearchAndDevelopmentTaxCreditMember_6c8e2ea4-6732-4267-857a-1f5b2572c052" xlink:href="amed-20201231.xsd#amed_ResearchAndDevelopmentTaxCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:to="loc_amed_ResearchAndDevelopmentTaxCreditMember_6c8e2ea4-6732-4267-857a-1f5b2572c052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EmploymentTaxCreditMember_975049ec-a785-448d-a99e-b5dbede4c68d" xlink:href="amed-20201231.xsd#amed_EmploymentTaxCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:to="loc_amed_EmploymentTaxCreditMember_975049ec-a785-448d-a99e-b5dbede4c68d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StateTaxCreditMember_9cc83d94-a028-4c04-ad6f-22aa342a6117" xlink:href="amed-20201231.xsd#amed_StateTaxCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:to="loc_amed_StateTaxCreditMember_9cc83d94-a028-4c04-ad6f-22aa342a6117" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsAxis_3bfb9838-4277-4d1a-adea-0a6f54d522c2" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_amed_UnrecognizedTaxBenefitsAxis_3bfb9838-4277-4d1a-adea-0a6f54d522c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDomain_3bfb9838-4277-4d1a-adea-0a6f54d522c2_default" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_UnrecognizedTaxBenefitsAxis_3bfb9838-4277-4d1a-adea-0a6f54d522c2" xlink:to="loc_amed_UnrecognizedTaxBenefitsDomain_3bfb9838-4277-4d1a-adea-0a6f54d522c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDomain_c2a79c3f-d08c-454c-9a26-a59d6929a98d" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_UnrecognizedTaxBenefitsAxis_3bfb9838-4277-4d1a-adea-0a6f54d522c2" xlink:to="loc_amed_UnrecognizedTaxBenefitsDomain_c2a79c3f-d08c-454c-9a26-a59d6929a98d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetOperatingLossMember_080ba5ed-40f8-4a95-a5da-59054f990828" xlink:href="amed-20201231.xsd#amed_NetOperatingLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain_c2a79c3f-d08c-454c-9a26-a59d6929a98d" xlink:to="loc_amed_NetOperatingLossMember_080ba5ed-40f8-4a95-a5da-59054f990828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCreditCarryforwardMember_678a8c9d-0416-4572-9f49-40856d15777c" xlink:href="amed-20201231.xsd#amed_TaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain_c2a79c3f-d08c-454c-9a26-a59d6929a98d" xlink:to="loc_amed_TaxCreditCarryforwardMember_678a8c9d-0416-4572-9f49-40856d15777c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7a22496e-6302-4107-8ff0-145c3ede40a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7a22496e-6302-4107-8ff0-145c3ede40a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7a22496e-6302-4107-8ff0-145c3ede40a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a22496e-6302-4107-8ff0-145c3ede40a6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7a22496e-6302-4107-8ff0-145c3ede40a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_986ee3c8-1f8a-4960-a4b4-6683be8588c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a22496e-6302-4107-8ff0-145c3ede40a6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_986ee3c8-1f8a-4960-a4b4-6683be8588c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherLongTermObligationsMember_5e6c4966-7d5a-4ff6-ac10-b624468f4ec1" xlink:href="amed-20201231.xsd#amed_OtherLongTermObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_986ee3c8-1f8a-4960-a4b4-6683be8588c4" xlink:to="loc_amed_OtherLongTermObligationsMember_5e6c4966-7d5a-4ff6-ac10-b624468f4ec1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c44b7bc3-5f4c-4c72-9a09-26adee529ff0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_srt_RangeAxis_c44b7bc3-5f4c-4c72-9a09-26adee529ff0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c44b7bc3-5f4c-4c72-9a09-26adee529ff0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c44b7bc3-5f4c-4c72-9a09-26adee529ff0" xlink:to="loc_srt_RangeMember_c44b7bc3-5f4c-4c72-9a09-26adee529ff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ed93b5f-7704-47eb-8b09-0b4200183b67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c44b7bc3-5f4c-4c72-9a09-26adee529ff0" xlink:to="loc_srt_RangeMember_4ed93b5f-7704-47eb-8b09-0b4200183b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_958f4f21-4bd2-4695-9510-a44059cfbd91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4ed93b5f-7704-47eb-8b09-0b4200183b67" xlink:to="loc_srt_MinimumMember_958f4f21-4bd2-4695-9510-a44059cfbd91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56d72996-434f-46d8-a758-b1a1798c65f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4ed93b5f-7704-47eb-8b09-0b4200183b67" xlink:to="loc_srt_MaximumMember_56d72996-434f-46d8-a758-b1a1798c65f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_04e24541-e77a-436f-b421-3864e31484b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_04e24541-e77a-436f-b421-3864e31484b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_04e24541-e77a-436f-b421-3864e31484b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_04e24541-e77a-436f-b421-3864e31484b1" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_04e24541-e77a-436f-b421-3864e31484b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_07fb0c95-98df-4f54-af5a-d91644e82bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_04e24541-e77a-436f-b421-3864e31484b1" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_07fb0c95-98df-4f54-af5a-d91644e82bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_a5dbadb5-b9dc-4a13-95ab-ffd5d262ed7c" xlink:href="amed-20201231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_07fb0c95-98df-4f54-af5a-d91644e82bb9" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_a5dbadb5-b9dc-4a13-95ab-ffd5d262ed7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60707324-5efc-41b6-8b2a-9fff0048b11b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_AwardTypeAxis_60707324-5efc-41b6-8b2a-9fff0048b11b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60707324-5efc-41b6-8b2a-9fff0048b11b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_60707324-5efc-41b6-8b2a-9fff0048b11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60707324-5efc-41b6-8b2a-9fff0048b11b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26b154bf-916e-4927-a687-749b2ad15124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_60707324-5efc-41b6-8b2a-9fff0048b11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26b154bf-916e-4927-a687-749b2ad15124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_e0821be5-b9f6-4091-a61e-1cba54cb8a43" xlink:href="amed-20201231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26b154bf-916e-4927-a687-749b2ad15124" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_e0821be5-b9f6-4091-a61e-1cba54cb8a43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralAxis_aca38489-7ffa-4452-bf0c-1243826c768c" xlink:href="amed-20201231.xsd#amed_TypeOfIncomeTaxDeferralAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_amed_TypeOfIncomeTaxDeferralAxis_aca38489-7ffa-4452-bf0c-1243826c768c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralDomain_aca38489-7ffa-4452-bf0c-1243826c768c_default" xlink:href="amed-20201231.xsd#amed_TypeOfIncomeTaxDeferralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeOfIncomeTaxDeferralAxis_aca38489-7ffa-4452-bf0c-1243826c768c" xlink:to="loc_amed_TypeOfIncomeTaxDeferralDomain_aca38489-7ffa-4452-bf0c-1243826c768c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralDomain_069b3eb0-eaa0-49e7-9db4-8ced8613a948" xlink:href="amed-20201231.xsd#amed_TypeOfIncomeTaxDeferralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeOfIncomeTaxDeferralAxis_aca38489-7ffa-4452-bf0c-1243826c768c" xlink:to="loc_amed_TypeOfIncomeTaxDeferralDomain_069b3eb0-eaa0-49e7-9db4-8ced8613a948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SocialSecurityTaxMember_c8ca8d9d-ce56-4d07-b79f-1f22d30e1189" xlink:href="amed-20201231.xsd#amed_SocialSecurityTaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfIncomeTaxDeferralDomain_069b3eb0-eaa0-49e7-9db4-8ced8613a948" xlink:to="loc_amed_SocialSecurityTaxMember_c8ca8d9d-ce56-4d07-b79f-1f22d30e1189" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="extended" id="i314cea2f3c6640e290adea0ee64dc956_INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESIncomeTaxExpenseAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="extended" id="i3254c85793094a2180ef216aae569d29_INCOMETAXESIncomeTaxExpenseAllocationDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESReconciliationofEffectiveTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="extended" id="i4f319bf239c447ee9b5201ede3b3c8a4_INCOMETAXESReconciliationofEffectiveTaxRateDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended" id="iec39376ec3e84ad7987c78a4c2084890_INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="ib78064525f864c118c8900e2dd0a4bed_INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="extended" id="id1de3a4fa7834130b97f446386123d96_CAPITALSTOCKANDSHAREBASEDCOMPENSATION"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="extended" id="ic1bd65546e1c4c1ba0cdb31129ee0fd7_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i5555324c42c148178dbd011544784e62_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3e03f08e-f437-438a-bcc4-20144e351345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3e03f08e-f437-438a-bcc4-20144e351345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7570fe85-c3f1-4fb7-9781-17ee8ca18b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7570fe85-c3f1-4fb7-9781-17ee8ca18b98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_48c737b1-0a9a-469a-9757-e187e00829a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_48c737b1-0a9a-469a-9757-e187e00829a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d895de99-f0f0-4845-98b4-c7c18d1ab314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d895de99-f0f0-4845-98b4-c7c18d1ab314" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ff16b232-6be2-438c-a3dd-5d6740d3049c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_CommonStockSharesIssued_ff16b232-6be2-438c-a3dd-5d6740d3049c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_071250fe-9db8-4137-a4b3-916958632ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_071250fe-9db8-4137-a4b3-916958632ba2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_63d8914b-08e2-4780-8693-7f1df88b0ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_PreferredStockSharesIssued_63d8914b-08e2-4780-8693-7f1df88b0ba4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofownershipinsubsidiaries_616dada6-f3a3-4c73-a040-6dce1a529f92" xlink:href="amed-20201231.xsd#amed_Percentageofownershipinsubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_Percentageofownershipinsubsidiaries_616dada6-f3a3-4c73-a040-6dce1a529f92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bacd8e2-8400-4987-9fb8-41f37bf794e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bacd8e2-8400-4987-9fb8-41f37bf794e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f2d4c2a6-9e05-4888-80d1-74a1f20c55be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f2d4c2a6-9e05-4888-80d1-74a1f20c55be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Fairvalueofshareofcommonstockpercentage_b44c6e4e-b157-47bd-8eee-36dd5cbddeb2" xlink:href="amed-20201231.xsd#amed_Fairvalueofshareofcommonstockpercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_Fairvalueofshareofcommonstockpercentage_b44c6e4e-b157-47bd-8eee-36dd5cbddeb2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_9d81621c-f4ec-47ec-92fb-09c2af17e308" xlink:href="amed-20201231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_9d81621c-f4ec-47ec-92fb-09c2af17e308" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_d477b0b3-c10b-4c55-93c5-926de7350aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_d477b0b3-c10b-4c55-93c5-926de7350aea" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_468f06db-de4e-4c3f-8339-762c85572ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_468f06db-de4e-4c3f-8339-762c85572ea2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_2ae7e299-b257-4297-9b3f-30ab54c69662" xlink:href="amed-20201231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_2ae7e299-b257-4297-9b3f-30ab54c69662" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_99797255-1bd2-4ea4-905a-30c362899142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_99797255-1bd2-4ea4-905a-30c362899142" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c539e7a7-19cc-4f12-9c73-b9f322f8c079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c539e7a7-19cc-4f12-9c73-b9f322f8c079" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_304552a8-97ca-4b4f-b041-a81ab40e84d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_304552a8-97ca-4b4f-b041-a81ab40e84d1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_2d83c7a0-5eb1-4768-b236-ccc7807da053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_2d83c7a0-5eb1-4768-b236-ccc7807da053" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0d7cb474-1127-4d23-9fb8-f8dcf78e3deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0d7cb474-1127-4d23-9fb8-f8dcf78e3deb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_846d49db-6992-410d-8c48-0d1f4cda4095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_846d49db-6992-410d-8c48-0d1f4cda4095" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ec9506b2-3608-4aa9-a562-e530e44e4c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ec9506b2-3608-4aa9-a562-e530e44e4c15" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_52417ab6-bf73-4c2e-a8e5-9f14335e10f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_52417ab6-bf73-4c2e-a8e5-9f14335e10f9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b497cfe1-22f3-4179-92c3-c446ec39e4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b497cfe1-22f3-4179-92c3-c446ec39e4ff" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6724bb02-272f-434a-8e89-2fa9ad4927d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6724bb02-272f-434a-8e89-2fa9ad4927d4" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2d321a57-74f7-41f4-b4a4-fffb9462228a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2d321a57-74f7-41f4-b4a4-fffb9462228a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Performancebasedawardtargetshareamount_d0fe0f45-8850-4c88-a478-b560d2249a35" xlink:href="amed-20201231.xsd#amed_Performancebasedawardtargetshareamount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_Performancebasedawardtargetshareamount_d0fe0f45-8850-4c88-a478-b560d2249a35" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c53b43cc-3f09-4218-b751-7275945b069b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:to="loc_us-gaap_AwardTypeAxis_c53b43cc-3f09-4218-b751-7275945b069b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c53b43cc-3f09-4218-b751-7275945b069b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c53b43cc-3f09-4218-b751-7275945b069b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c53b43cc-3f09-4218-b751-7275945b069b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c53b43cc-3f09-4218-b751-7275945b069b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsMember_3a7a8f24-71df-4a79-bdbf-1c3612c51ae2" xlink:href="amed-20201231.xsd#amed_ShareBasedAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_amed_ShareBasedAwardsMember_3a7a8f24-71df-4a79-bdbf-1c3612c51ae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_4e93415e-498b-46ed-8b3f-cd05a0c3ef82" xlink:href="amed-20201231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_4e93415e-498b-46ed-8b3f-cd05a0c3ef82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24d38fd4-cf02-4f1f-b6e5-794fabeff8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24d38fd4-cf02-4f1f-b6e5-794fabeff8ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockMember_69123405-7b5c-4215-bf84-b7867f2956ce" xlink:href="amed-20201231.xsd#amed_NonVestedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_amed_NonVestedStockMember_69123405-7b5c-4215-bf84-b7867f2956ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember_9f9f1eb4-1c9e-4aa0-a39a-5a1e6a33e8b2" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_amed_NonVestedStockUnitsMember_9f9f1eb4-1c9e-4aa0-a39a-5a1e6a33e8b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember_f71bb311-79d0-466a-b1b1-4edbda10d135" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_NonVestedStockUnitsMember_9f9f1eb4-1c9e-4aa0-a39a-5a1e6a33e8b2" xlink:to="loc_amed_NonVestedStockUnitsServiceMember_f71bb311-79d0-466a-b1b1-4edbda10d135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_ec73fa0e-470b-4b3a-b354-299452b82007" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_NonVestedStockUnitsMember_9f9f1eb4-1c9e-4aa0-a39a-5a1e6a33e8b2" xlink:to="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_ec73fa0e-470b-4b3a-b354-299452b82007" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_938c6d46-90c3-4665-85db-f565fc63be7a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:to="loc_srt_RangeAxis_938c6d46-90c3-4665-85db-f565fc63be7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_938c6d46-90c3-4665-85db-f565fc63be7a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_938c6d46-90c3-4665-85db-f565fc63be7a" xlink:to="loc_srt_RangeMember_938c6d46-90c3-4665-85db-f565fc63be7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcab1a5e-5c47-4bd0-822d-4fba85c7f1d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_938c6d46-90c3-4665-85db-f565fc63be7a" xlink:to="loc_srt_RangeMember_fcab1a5e-5c47-4bd0-822d-4fba85c7f1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2e787853-c15d-40d2-bdc7-1917a24ff484" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcab1a5e-5c47-4bd0-822d-4fba85c7f1d9" xlink:to="loc_srt_MaximumMember_2e787853-c15d-40d2-bdc7-1917a24ff484" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_649d9c3d-2d28-4f8b-81ba-f5a559740be4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcab1a5e-5c47-4bd0-822d-4fba85c7f1d9" xlink:to="loc_srt_MinimumMember_649d9c3d-2d28-4f8b-81ba-f5a559740be4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" xlink:type="extended" id="i954a5c93b5574e9482b65e4ebfb9567b_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="extended" id="i2cf7a8e36e5e4aef984bdde337e776bf_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_588e31a3-2217-4069-8326-41504d9b2825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_588e31a3-2217-4069-8326-41504d9b2825" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fb17edf1-7388-4b7f-b128-2084e4428387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fb17edf1-7388-4b7f-b128-2084e4428387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b9e26ac3-e6eb-48c2-b4d7-b82f9156411f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b9e26ac3-e6eb-48c2-b4d7-b82f9156411f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3232c7ee-a51d-48aa-bbcc-1761c8a141ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3232c7ee-a51d-48aa-bbcc-1761c8a141ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a0adbb4a-0c85-4c7a-9894-174cbea062ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a0adbb4a-0c85-4c7a-9894-174cbea062ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_bd94ca8b-3fd4-4053-bc6d-ae966ed600a4" xlink:href="amed-20201231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_bd94ca8b-3fd4-4053-bc6d-ae966ed600a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1bd61bd9-aef7-4e17-81f8-bedc3391e5cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1bd61bd9-aef7-4e17-81f8-bedc3391e5cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_037d2949-18ef-493c-b73c-0c515925e88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:to="loc_us-gaap_AwardTypeAxis_037d2949-18ef-493c-b73c-0c515925e88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_037d2949-18ef-493c-b73c-0c515925e88f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_037d2949-18ef-493c-b73c-0c515925e88f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_037d2949-18ef-493c-b73c-0c515925e88f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9662745a-73d3-40a6-b742-fa9e0c9985db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_037d2949-18ef-493c-b73c-0c515925e88f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9662745a-73d3-40a6-b742-fa9e0c9985db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29ebd2a6-89f6-4d81-8284-2839b158d7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9662745a-73d3-40a6-b742-fa9e0c9985db" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29ebd2a6-89f6-4d81-8284-2839b158d7fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46eaf731-629a-44f9-8753-13393c30b0be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:to="loc_srt_RangeAxis_46eaf731-629a-44f9-8753-13393c30b0be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46eaf731-629a-44f9-8753-13393c30b0be_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_46eaf731-629a-44f9-8753-13393c30b0be" xlink:to="loc_srt_RangeMember_46eaf731-629a-44f9-8753-13393c30b0be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d28158f8-5e9e-4be5-8c00-265f87608c3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_46eaf731-629a-44f9-8753-13393c30b0be" xlink:to="loc_srt_RangeMember_d28158f8-5e9e-4be5-8c00-265f87608c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fe338e94-d5bd-44e3-aab4-c3f76f7c79c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d28158f8-5e9e-4be5-8c00-265f87608c3e" xlink:to="loc_srt_MinimumMember_fe338e94-d5bd-44e3-aab4-c3f76f7c79c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_994e5860-33b9-4ac4-a58f-5e99c90ff3c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d28158f8-5e9e-4be5-8c00-265f87608c3e" xlink:to="loc_srt_MaximumMember_994e5860-33b9-4ac4-a58f-5e99c90ff3c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended" id="i081fa84da7c6428381291c18e881f8a7_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_53d438e2-6020-4b12-9132-7e95af5f50ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_53d438e2-6020-4b12-9132-7e95af5f50ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares_dce594b7-7f8f-45c1-929f-d291cd6d331f" xlink:href="amed-20201231.xsd#amed_SurrenderedSharesInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_amed_SurrenderedSharesInShares_dce594b7-7f8f-45c1-929f-d291cd6d331f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c846f198-92ab-43f9-b45f-14252d47b0b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c846f198-92ab-43f9-b45f-14252d47b0b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_20a95916-b4cd-4c93-a7f2-c438b8baa556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_20a95916-b4cd-4c93-a7f2-c438b8baa556" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9d6ca5ea-bfe2-4637-8c29-a2b4e4b08518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9d6ca5ea-bfe2-4637-8c29-a2b4e4b08518" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af3484bd-3c8b-4b94-87c1-b7dd4c48c1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af3484bd-3c8b-4b94-87c1-b7dd4c48c1a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a153abd-35e0-46fa-a847-c6d71a9dc91d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af3484bd-3c8b-4b94-87c1-b7dd4c48c1a0" xlink:to="loc_us-gaap_AwardTypeAxis_2a153abd-35e0-46fa-a847-c6d71a9dc91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a153abd-35e0-46fa-a847-c6d71a9dc91d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2a153abd-35e0-46fa-a847-c6d71a9dc91d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a153abd-35e0-46fa-a847-c6d71a9dc91d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89f16e56-907f-4a19-9c19-92c0c0a8f9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2a153abd-35e0-46fa-a847-c6d71a9dc91d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89f16e56-907f-4a19-9c19-92c0c0a8f9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_6f5a4233-685a-4d1f-a904-17c680245d40" xlink:href="amed-20201231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89f16e56-907f-4a19-9c19-92c0c0a8f9f4" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_6f5a4233-685a-4d1f-a904-17c680245d40" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" xlink:type="extended" id="i6f04ee1d63ef4342b6b15189138e77eb_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="extended" id="i71faa905faef4f569e3e3998f1f84bb7_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab9c99ba-0ecd-4e1e-a02d-b28ece0ea88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab9c99ba-0ecd-4e1e-a02d-b28ece0ea88c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f00701b8-0d68-44d7-bc9d-87e498d4ff1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f00701b8-0d68-44d7-bc9d-87e498d4ff1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a137aad8-ebb8-4aae-a9fb-76f68e82e93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a137aad8-ebb8-4aae-a9fb-76f68e82e93a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_306f094d-0627-4093-aab4-472fcba50613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_306f094d-0627-4093-aab4-472fcba50613" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e8c7622e-6486-4555-b11d-56ad4873fcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e8c7622e-6486-4555-b11d-56ad4873fcf2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02c9a59e-25a1-4462-87f6-21a06d4bfe9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab9c99ba-0ecd-4e1e-a02d-b28ece0ea88c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3c125f9e-ac59-4e34-8130-15fc99abd8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3c125f9e-ac59-4e34-8130-15fc99abd8d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e85000cb-52c3-42a9-8f4f-2454ff4d4f68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e85000cb-52c3-42a9-8f4f-2454ff4d4f68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c40fddcf-860c-4689-ae74-0960715d5e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c40fddcf-860c-4689-ae74-0960715d5e08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fdfc2173-2797-42fa-abce-85ab93149644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fdfc2173-2797-42fa-abce-85ab93149644" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a642ae7b-6375-42be-8587-5b2ebc7b3ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab9c99ba-0ecd-4e1e-a02d-b28ece0ea88c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1935d94d-5330-4892-b7be-e1c59be322e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:to="loc_us-gaap_AwardTypeAxis_1935d94d-5330-4892-b7be-e1c59be322e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1935d94d-5330-4892-b7be-e1c59be322e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1935d94d-5330-4892-b7be-e1c59be322e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1935d94d-5330-4892-b7be-e1c59be322e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43aeb497-f302-49f7-ac3c-f1fb5d3eabd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1935d94d-5330-4892-b7be-e1c59be322e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43aeb497-f302-49f7-ac3c-f1fb5d3eabd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockMember_6e3833d1-d83f-4983-81ad-082512db5714" xlink:href="amed-20201231.xsd#amed_NonVestedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43aeb497-f302-49f7-ac3c-f1fb5d3eabd6" xlink:to="loc_amed_NonVestedStockMember_6e3833d1-d83f-4983-81ad-082512db5714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember_06c37ce1-2f05-4f82-8fc9-6c7ee0cb8aaf" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43aeb497-f302-49f7-ac3c-f1fb5d3eabd6" xlink:to="loc_amed_NonVestedStockUnitsMember_06c37ce1-2f05-4f82-8fc9-6c7ee0cb8aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5ce8541-8d27-468b-891e-fcb64707e7c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:to="loc_srt_RangeAxis_b5ce8541-8d27-468b-891e-fcb64707e7c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b5ce8541-8d27-468b-891e-fcb64707e7c0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b5ce8541-8d27-468b-891e-fcb64707e7c0" xlink:to="loc_srt_RangeMember_b5ce8541-8d27-468b-891e-fcb64707e7c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_10a76e4f-662b-434a-bd32-ea3f822e2fc3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b5ce8541-8d27-468b-891e-fcb64707e7c0" xlink:to="loc_srt_RangeMember_10a76e4f-662b-434a-bd32-ea3f822e2fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ef328a0-43c7-4c61-aac9-6e4299d97939" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10a76e4f-662b-434a-bd32-ea3f822e2fc3" xlink:to="loc_srt_MinimumMember_8ef328a0-43c7-4c61-aac9-6e4299d97939" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="extended" id="i042132bc1cea4a6b881425f58c5a8eaf_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5bad771e-38d7-4c53-a49b-c9b1e0f586f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5bad771e-38d7-4c53-a49b-c9b1e0f586f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82f92877-3a33-449b-a22d-1edafcdf54af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82f92877-3a33-449b-a22d-1edafcdf54af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1e81e42-b5de-4826-8a33-a3c485a399b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1e81e42-b5de-4826-8a33-a3c485a399b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3e873c97-bd34-4217-8738-e9a914a77ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3e873c97-bd34-4217-8738-e9a914a77ff7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_db7f757c-1022-445b-8367-db7508180157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5fd51da-c6e1-4b26-b5b1-97852fad56fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5fd51da-c6e1-4b26-b5b1-97852fad56fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff6a99d2-7f03-40e2-bb54-d6a623b68256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff6a99d2-7f03-40e2-bb54-d6a623b68256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd6e8bcc-68aa-420f-ae4b-7838a9e4705a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd6e8bcc-68aa-420f-ae4b-7838a9e4705a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9461c839-4f07-41fd-bce7-8503c29d24f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9461c839-4f07-41fd-bce7-8503c29d24f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c2c831f-3995-41d5-9fa6-0c84222cce7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount_d3038b69-59e1-416f-8946-4a6520633a97" xlink:href="amed-20201231.xsd#amed_AdditionalPerformanceBasedAwardTargetShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:to="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount_d3038b69-59e1-416f-8946-4a6520633a97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe050280-e635-4931-923c-4594c8f681b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe050280-e635-4931-923c-4594c8f681b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe050280-e635-4931-923c-4594c8f681b0" xlink:to="loc_us-gaap_AwardTypeAxis_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3fd8904-fe12-4527-9845-6767ae27938d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3fd8904-fe12-4527-9845-6767ae27938d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember_9660980b-9681-478b-afd0-8b092488a3c9" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3fd8904-fe12-4527-9845-6767ae27938d" xlink:to="loc_amed_NonVestedStockUnitsServiceMember_9660980b-9681-478b-afd0-8b092488a3c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_13c90351-c157-498c-ba36-89dbc7ac527c" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3fd8904-fe12-4527-9845-6767ae27938d" xlink:to="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_13c90351-c157-498c-ba36-89dbc7ac527c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="i9a0c49a0cc3a4e78bb5cb25aca11fdb1_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended" id="i9fe2ea344029472a84cf2389e047f15b_COMMITMENTSANDCONTINGENCIESTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="ifa43e2e9e0f4482cb03f98b45b371369_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_8e09ee59-15a9-405e-bd3a-c868d9715220" xlink:href="amed-20201231.xsd#amed_Numberofpatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_Numberofpatients_8e09ee59-15a9-405e-bd3a-c868d9715220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_accc6032-1bfb-4032-96e1-64e200b2e43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_accc6032-1bfb-4032-96e1-64e200b2e43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_29c42aff-d3bb-4f8b-882c-48e45a5fe2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_29c42aff-d3bb-4f8b-882c-48e45a5fe2c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_61e02bdf-042c-47fa-907d-ca9f372bd368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_61e02bdf-042c-47fa-907d-ca9f372bd368" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_2e297345-407e-4987-a9c8-a08f7268c1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_2e297345-407e-4987-a9c8-a08f7268c1c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersSold_9c5ca6ed-5984-44ab-bb3f-173ab0d70a16" xlink:href="amed-20201231.xsd#amed_NumberOfCareCentersSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_NumberOfCareCentersSold_9c5ca6ed-5984-44ab-bb3f-173ab0d70a16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_42830b7b-7f93-4bbc-9922-4733fa30f767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_42830b7b-7f93-4bbc-9922-4733fa30f767" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_89c832ba-3de2-44e2-96f7-e174da79b9e0" xlink:href="amed-20201231.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_89c832ba-3de2-44e2-96f7-e174da79b9e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThresholdOfIndividualsInDataBreach_475ec4d1-1e8d-41db-a482-b6fdcc6e5a52" xlink:href="amed-20201231.xsd#amed_ThresholdOfIndividualsInDataBreach"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_ThresholdOfIndividualsInDataBreach_475ec4d1-1e8d-41db-a482-b6fdcc6e5a52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_YearOfDeparture_9fd4a9c5-932d-4aff-a39b-81993d6fbe72" xlink:href="amed-20201231.xsd#amed_YearOfDeparture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_YearOfDeparture_9fd4a9c5-932d-4aff-a39b-81993d6fbe72" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_2987a8f3-145f-43b5-b530-c76602300027" xlink:href="amed-20201231.xsd#amed_NumberOfBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_NumberOfBeneficiaries_2987a8f3-145f-43b5-b530-c76602300027" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_b2d2d7b5-39ed-4fd4-852b-35e24a885ffd" xlink:href="amed-20201231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_b2d2d7b5-39ed-4fd4-852b-35e24a885ffd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_88276c94-de1a-4a5d-b3b3-148a690afb4a" xlink:href="amed-20201231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_88276c94-de1a-4a5d-b3b3-148a690afb4a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_efd02c33-8907-46de-8fc3-23c07ff86f6c" xlink:href="amed-20201231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_efd02c33-8907-46de-8fc3-23c07ff86f6c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_14f382c9-3e0f-4b88-8269-d6904d5da8d7" xlink:href="amed-20201231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_14f382c9-3e0f-4b88-8269-d6904d5da8d7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_6777a225-baf1-4cbc-8cd3-1e052a53665b" xlink:href="amed-20201231.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_6777a225-baf1-4cbc-8cd3-1e052a53665b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_3a97455a-7afe-4d8b-a060-375187e637ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_3a97455a-7afe-4d8b-a060-375187e637ce" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_b3accc15-b131-4d48-8abc-5c09bbfe5189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_b3accc15-b131-4d48-8abc-5c09bbfe5189" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_f73d3dc0-aaf3-42ba-bae0-b52bac5ba1d3" xlink:href="amed-20201231.xsd#amed_ActualClaimsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_ActualClaimsPayment_f73d3dc0-aaf3-42ba-bae0-b52bac5ba1d3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_0964f4d4-af0e-4f8c-9b1e-e111f386aaf7" xlink:href="amed-20201231.xsd#amed_ErrorRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_ErrorRatePercentage_0964f4d4-af0e-4f8c-9b1e-e111f386aaf7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_2dd69b8a-c45b-4faf-bddb-ce86603dd490" xlink:href="amed-20201231.xsd#amed_IndemnificationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_IndemnificationAmount_2dd69b8a-c45b-4faf-bddb-ce86603dd490" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_84956ac0-1c5c-493b-a625-e38e3a3ea09d" xlink:href="amed-20201231.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_FloridaZpicRevenueReduction_84956ac0-1c5c-493b-a625-e38e3a3ea09d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a715c6cb-c5a0-45c9-b1fb-8acde9f949a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a715c6cb-c5a0-45c9-b1fb-8acde9f949a7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeaseTermYears_f696d541-5f3f-4fc7-a87f-bc23d2c499b0" xlink:href="amed-20201231.xsd#amed_OperatingLeaseTermYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_OperatingLeaseTermYears_f696d541-5f3f-4fc7-a87f-bc23d2c499b0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7f066c46-da4d-40af-ba16-9718f55a6c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LeaseAndRentalExpense_7f066c46-da4d-40af-ba16-9718f55a6c80" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_fe82237e-9af0-429d-952c-f0389d921ea8" xlink:href="amed-20201231.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_HealthInsuranceRetentionLimit_fe82237e-9af0-429d-952c-f0389d921ea8" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_00b155e1-4370-446f-ab48-909628b9090c" xlink:href="amed-20201231.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_00b155e1-4370-446f-ab48-909628b9090c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_59797d70-cac7-4908-93bc-615b759d6719" xlink:href="amed-20201231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_59797d70-cac7-4908-93bc-615b759d6719" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_11e1ac2d-3850-48be-836e-8f0f51812f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_11e1ac2d-3850-48be-836e-8f0f51812f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11e1ac2d-3850-48be-836e-8f0f51812f7a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11e1ac2d-3850-48be-836e-8f0f51812f7a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11e1ac2d-3850-48be-836e-8f0f51812f7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3d7158f0-8363-4ccd-abcc-4cd7f003dc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11e1ac2d-3850-48be-836e-8f0f51812f7a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3d7158f0-8363-4ccd-abcc-4cd7f003dc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2af8bad4-4542-49f1-8828-8b9e29c6de12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3d7158f0-8363-4ccd-abcc-4cd7f003dc3c" xlink:to="loc_us-gaap_SubsequentEventMember_2af8bad4-4542-49f1-8828-8b9e29c6de12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3727d33a-7986-4449-8ba6-88c2cff7e637" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_srt_LitigationCaseAxis_3727d33a-7986-4449-8ba6-88c2cff7e637" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3727d33a-7986-4449-8ba6-88c2cff7e637_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3727d33a-7986-4449-8ba6-88c2cff7e637" xlink:to="loc_srt_LitigationCaseTypeDomain_3727d33a-7986-4449-8ba6-88c2cff7e637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3727d33a-7986-4449-8ba6-88c2cff7e637" xlink:to="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_5f4f595e-8604-4eef-bd9a-e940432610ed" xlink:href="amed-20201231.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_UsDepartmentOfJusticeMember_5f4f595e-8604-4eef-bd9a-e940432610ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WageAndHourLitigationMember_1af647e9-c465-452a-8791-75bf7d893f68" xlink:href="amed-20201231.xsd#amed_WageAndHourLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_WageAndHourLitigationMember_1af647e9-c465-452a-8791-75bf7d893f68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FrontierLitigationMember_03d7e797-0f0d-41e4-a7b3-cca64bbe0c90" xlink:href="amed-20201231.xsd#amed_FrontierLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_FrontierLitigationMember_03d7e797-0f0d-41e4-a7b3-cca64bbe0c90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_cbf40cfe-a3c2-4af7-ace3-815cafce3e20" xlink:href="amed-20201231.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_cbf40cfe-a3c2-4af7-ace3-815cafce3e20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IdahoandWyomingSelfReportMember_7f971430-7539-4741-9ba2-b20c14b7faa6" xlink:href="amed-20201231.xsd#amed_IdahoandWyomingSelfReportMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_IdahoandWyomingSelfReportMember_7f971430-7539-4741-9ba2-b20c14b7faa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ComputerInventoryAndDataSecurityReportingMember_3ca6d530-62dd-444f-9d3b-95da8be5ff7a" xlink:href="amed-20201231.xsd#amed_ComputerInventoryAndDataSecurityReportingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_ComputerInventoryAndDataSecurityReportingMember_3ca6d530-62dd-444f-9d3b-95da8be5ff7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OigSelfDisclosureMember_053db9c1-c58c-43f6-ae40-4b20dff7ff53" xlink:href="amed-20201231.xsd#amed_OigSelfDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_OigSelfDisclosureMember_053db9c1-c58c-43f6-ae40-4b20dff7ff53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_89a6d641-3a0b-4a23-a149-e645579a221a" xlink:href="amed-20201231.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_89a6d641-3a0b-4a23-a149-e645579a221a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_12ba5c1f-aee2-4662-ac42-bef393f25bee" xlink:href="amed-20201231.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_InternalAuditComplianceReviewMember_12ba5c1f-aee2-4662-ac42-bef393f25bee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_c246f3b6-04c6-4ebf-a1f6-be62c25104fd" xlink:href="amed-20201231.xsd#amed_AmedisysCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_AmedisysCIAMember_c246f3b6-04c6-4ebf-a1f6-be62c25104fd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_faeb4b3a-37d9-4807-b325-6bb57bd7255f" xlink:href="amed-20201231.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_faeb4b3a-37d9-4807-b325-6bb57bd7255f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4ba5f574-2e77-491c-92b4-027ad8484656" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_srt_StatementGeographicalAxis_4ba5f574-2e77-491c-92b4-027ad8484656" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4ba5f574-2e77-491c-92b4-027ad8484656_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4ba5f574-2e77-491c-92b4-027ad8484656" xlink:to="loc_srt_SegmentGeographicalDomain_4ba5f574-2e77-491c-92b4-027ad8484656_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4ba5f574-2e77-491c-92b4-027ad8484656" xlink:to="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_261694a5-3da8-40d9-942e-970fe245ec3a" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_MA_261694a5-3da8-40d9-942e-970fe245ec3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_ac5d0427-adfa-42cc-a906-5a07c92e0e2c" xlink:href="amed-20201231.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_amed_MorgantownWestVirginiaMember_ac5d0427-adfa-42cc-a906-5a07c92e0e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_efdec0dc-6dab-4fa5-a121-eb655bd295af" xlink:href="amed-20201231.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_amed_ParkersburgWestVirginiaMember_efdec0dc-6dab-4fa5-a121-eb655bd295af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_7c081519-6805-4551-964d-5083e1bced74" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_CT_7c081519-6805-4551-964d-5083e1bced74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_59ae2694-eee8-4088-bba5-b8c246231ac9" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_IL_59ae2694-eee8-4088-bba5-b8c246231ac9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_d8f738b7-b43a-4f38-a5f8-4d560412d7be" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_SC_d8f738b7-b43a-4f38-a5f8-4d560412d7be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_9b16453b-d22c-4fe4-a66e-0e545f01b29e" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_FL_9b16453b-d22c-4fe4-a66e-0e545f01b29e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_c8a07f17-a93a-4a74-ad61-a3cac447edf8" xlink:href="amed-20201231.xsd#amed_LakelandFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_9b16453b-d22c-4fe4-a66e-0e545f01b29e" xlink:to="loc_amed_LakelandFloridaMember_c8a07f17-a93a-4a74-ad61-a3cac447edf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_2bc97c06-3293-4cc3-9f4a-945b17b28c1a" xlink:href="amed-20201231.xsd#amed_ClearwaterFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_9b16453b-d22c-4fe4-a66e-0e545f01b29e" xlink:to="loc_amed_ClearwaterFloridaMember_2bc97c06-3293-4cc3-9f4a-945b17b28c1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9965dff5-52e3-4a5f-b131-7e7091d48893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9965dff5-52e3-4a5f-b131-7e7091d48893" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9965dff5-52e3-4a5f-b131-7e7091d48893_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9965dff5-52e3-4a5f-b131-7e7091d48893" xlink:to="loc_us-gaap_SegmentDomain_9965dff5-52e3-4a5f-b131-7e7091d48893_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f4d585d5-6b30-4208-8ec3-0e62aa850245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9965dff5-52e3-4a5f-b131-7e7091d48893" xlink:to="loc_us-gaap_SegmentDomain_f4d585d5-6b30-4208-8ec3-0e62aa850245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_0480725c-5072-453f-845f-0cda487c6605" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f4d585d5-6b30-4208-8ec3-0e62aa850245" xlink:to="loc_amed_HospiceMember_0480725c-5072-453f-845f-0cda487c6605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_7340fcd9-ee52-442e-9645-dcab85f61d98" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f4d585d5-6b30-4208-8ec3-0e62aa850245" xlink:to="loc_amed_HomeHealthMember_7340fcd9-ee52-442e-9645-dcab85f61d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0e4159fc-7bf7-44e7-afe9-e6923e1dd785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0e4159fc-7bf7-44e7-afe9-e6923e1dd785" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e4159fc-7bf7-44e7-afe9-e6923e1dd785_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0e4159fc-7bf7-44e7-afe9-e6923e1dd785" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0e4159fc-7bf7-44e7-afe9-e6923e1dd785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae53b96-c706-459d-b58a-ffb5d41929f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0e4159fc-7bf7-44e7-afe9-e6923e1dd785" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae53b96-c706-459d-b58a-ffb5d41929f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_0335ef1a-d1e2-4d32-8ead-40e5b58cd0fd" xlink:href="amed-20201231.xsd#amed_InfinityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae53b96-c706-459d-b58a-ffb5d41929f0" xlink:to="loc_amed_InfinityHomeCareMember_0335ef1a-d1e2-4d32-8ead-40e5b58cd0fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d228ee85-1280-465a-88bc-14dc2170cafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d228ee85-1280-465a-88bc-14dc2170cafc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_65b988fb-63e3-4df7-bed6-866f8f728eff" xlink:href="amed-20201231.xsd#amed_ExtrapolatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d228ee85-1280-465a-88bc-14dc2170cafc" xlink:to="loc_amed_ExtrapolatedMember_65b988fb-63e3-4df7-bed6-866f8f728eff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_9be63318-bb71-42bb-9812-1aa47e986e22" xlink:href="amed-20201231.xsd#amed_UnfavorableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d228ee85-1280-465a-88bc-14dc2170cafc" xlink:to="loc_amed_UnfavorableMember_9be63318-bb71-42bb-9812-1aa47e986e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_431670a0-aa94-42a8-bb15-d2ddf13a0612" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_srt_RangeAxis_431670a0-aa94-42a8-bb15-d2ddf13a0612" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_431670a0-aa94-42a8-bb15-d2ddf13a0612_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_431670a0-aa94-42a8-bb15-d2ddf13a0612" xlink:to="loc_srt_RangeMember_431670a0-aa94-42a8-bb15-d2ddf13a0612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a656acf4-60cb-4d53-b694-2ae3df0d34bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_431670a0-aa94-42a8-bb15-d2ddf13a0612" xlink:to="loc_srt_RangeMember_a656acf4-60cb-4d53-b694-2ae3df0d34bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ac89a94e-7e18-4bcf-ba7c-6ce6cea97bd9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a656acf4-60cb-4d53-b694-2ae3df0d34bb" xlink:to="loc_srt_MinimumMember_ac89a94e-7e18-4bcf-ba7c-6ce6cea97bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e0011cf-e59e-4e5d-b99a-976e301dceda" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a656acf4-60cb-4d53-b694-2ae3df0d34bb" xlink:to="loc_srt_MaximumMember_7e0011cf-e59e-4e5d-b99a-976e301dceda" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="extended" id="i56e4dc6f802e401fbe71634b68be8598_COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="amed-20201231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended" id="i6e49d55c1d6e4ef085e573ace70f13d5_EMPLOYEEBENEFITPLANS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#EMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended" id="i74a05548c72e41ab932dd7d412073e73_EMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20201231.xsd#SHAREREPURCHASE"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASE" xlink:type="extended" id="i6b1c556fb0364e20a4956e2538da4a78_SHAREREPURCHASE"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended" id="i7f73dbf02368488882b5a767c1f44771_SHAREREPURCHASENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_eef8adf2-10ff-493b-9fe5-abc29a674bf7" xlink:href="amed-20201231.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_amed_PercentageofSharesOutstanding_eef8adf2-10ff-493b-9fe5-abc29a674bf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_258eca30-6de1-42ed-8c47-851e497e17bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_258eca30-6de1-42ed-8c47-851e497e17bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DiscountedClosingStockPrice_a1722aaa-641e-4577-bcc8-42e4bd68bf38" xlink:href="amed-20201231.xsd#amed_DiscountedClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_amed_DiscountedClosingStockPrice_a1722aaa-641e-4577-bcc8-42e4bd68bf38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofClosingStockPrice_0145418d-4b9e-454d-80a4-c187297097e2" xlink:href="amed-20201231.xsd#amed_PercentageofClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_amed_PercentageofClosingStockPrice_0145418d-4b9e-454d-80a4-c187297097e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_257be23e-c799-41dc-9608-86c62a8fc374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_257be23e-c799-41dc-9608-86c62a8fc374" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_4c8e6aed-7816-4602-8a50-f80ac8b52558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_4c8e6aed-7816-4602-8a50-f80ac8b52558" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8c1c172c-3575-4a02-b341-6013816be015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8c1c172c-3575-4a02-b341-6013816be015" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f23a718e-5bdd-42fb-ab73-f8374d71e76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f23a718e-5bdd-42fb-ab73-f8374d71e76b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_976423fa-113b-4a65-8825-2f9f8c71a8c3" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_amed_ShareRepurchaseTable_976423fa-113b-4a65-8825-2f9f8c71a8c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseAxis_404454d0-e601-4d94-b920-e3b67b245db5" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_976423fa-113b-4a65-8825-2f9f8c71a8c3" xlink:to="loc_amed_ShareRepurchaseAxis_404454d0-e601-4d94-b920-e3b67b245db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_404454d0-e601-4d94-b920-e3b67b245db5_default" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_ShareRepurchaseAxis_404454d0-e601-4d94-b920-e3b67b245db5" xlink:to="loc_amed_ShareRepurchaseDomain_404454d0-e601-4d94-b920-e3b67b245db5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_ShareRepurchaseAxis_404454d0-e601-4d94-b920-e3b67b245db5" xlink:to="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021StockRepurchaseProgramMember_85879b9f-2ceb-4a70-bd0e-f20fe6c10d08" xlink:href="amed-20201231.xsd#amed_A2021StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:to="loc_amed_A2021StockRepurchaseProgramMember_85879b9f-2ceb-4a70-bd0e-f20fe6c10d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019StockRepurchaseProgramMember_baffba43-b49f-40d3-9889-745def1487dc" xlink:href="amed-20201231.xsd#amed_A2019StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:to="loc_amed_A2019StockRepurchaseProgramMember_baffba43-b49f-40d3-9889-745def1487dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRShareRepurchaseMember_06ba22a4-2169-411e-8a71-6dc39af71ca7" xlink:href="amed-20201231.xsd#amed_KKRShareRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:to="loc_amed_KKRShareRepurchaseMember_06ba22a4-2169-411e-8a71-6dc39af71ca7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATION"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended" id="i287dc53097944149a11541ba4f84e56d_SEGMENTINFORMATION"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended" id="i41893848c61448bb9b95cd29ce98ff5d_SEGMENTINFORMATIONTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="i94e51f06ae7e4147b61526ac7a70d159_SEGMENTINFORMATIONNarrativeDetails"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended" id="i6663086805e444d6996bb10772e069d1_SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_754bdb6e-52b8-4977-a711-52b2d629069e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_754bdb6e-52b8-4977-a711-52b2d629069e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_4f9f2ea5-0400-47e6-81f1-daf774ae2efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_OtherOperatingIncome_4f9f2ea5-0400-47e6-81f1-daf774ae2efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ec6f1007-07c7-4695-a439-2d24a6767244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ec6f1007-07c7-4695-a439-2d24a6767244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_89bef1ef-47ea-4c24-813b-04d007bcff07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_89bef1ef-47ea-4c24-813b-04d007bcff07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_4d9839b2-a65d-41e5-a951-114b5b0468d7" xlink:href="amed-20201231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_4d9839b2-a65d-41e5-a951-114b5b0468d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_216c4a13-c529-426b-af04-7442213ced0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_AssetImpairmentCharges_216c4a13-c529-426b-af04-7442213ced0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a3c44578-4baa-4c3a-8d34-4c48563a425e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_CostsAndExpenses_a3c44578-4baa-4c3a-8d34-4c48563a425e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d462d1b4-54f8-443a-bad1-52b1cc1cea67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_OperatingIncomeLoss_d462d1b4-54f8-443a-bad1-52b1cc1cea67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0026f1f4-ded6-495a-923b-ca7935df4826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0026f1f4-ded6-495a-923b-ca7935df4826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0026f1f4-ded6-495a-923b-ca7935df4826_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0026f1f4-ded6-495a-923b-ca7935df4826" xlink:to="loc_us-gaap_SegmentDomain_0026f1f4-ded6-495a-923b-ca7935df4826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0026f1f4-ded6-495a-923b-ca7935df4826" xlink:to="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_0cca14f2-56aa-4419-9aa4-7abddde2aff2" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:to="loc_amed_HomeHealthMember_0cca14f2-56aa-4419-9aa4-7abddde2aff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_1a38ef85-c6cb-43c1-8413-22d69ff11ebb" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:to="loc_amed_HospiceMember_1a38ef85-c6cb-43c1-8413-22d69ff11ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_d2180fc5-4e7c-464a-8663-31a69d85f89c" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:to="loc_amed_PersonalCareMember_d2180fc5-4e7c-464a-8663-31a69d85f89c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember_b60e9e0b-dfd4-4ce5-8aeb-c2fb04df5d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:to="loc_us-gaap_CorporateMember_b60e9e0b-dfd4-4ce5-8aeb-c2fb04df5d95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_041713ba-91f0-46c0-95d2-9e35722759c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:to="loc_srt_ConsolidationItemsAxis_041713ba-91f0-46c0-95d2-9e35722759c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_041713ba-91f0-46c0-95d2-9e35722759c9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_041713ba-91f0-46c0-95d2-9e35722759c9" xlink:to="loc_srt_ConsolidationItemsDomain_041713ba-91f0-46c0-95d2-9e35722759c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_16772197-89b2-463f-922d-362b44c133a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_041713ba-91f0-46c0-95d2-9e35722759c9" xlink:to="loc_srt_ConsolidationItemsDomain_16772197-89b2-463f-922d-362b44c133a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0cb677b9-07d5-48ee-ad0d-664bcbc94261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_16772197-89b2-463f-922d-362b44c133a8" xlink:to="loc_us-gaap_OperatingSegmentsMember_0cb677b9-07d5-48ee-ad0d-664bcbc94261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_9deee5b9-41df-4a8f-8301-e11bcd06f7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_16772197-89b2-463f-922d-362b44c133a8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_9deee5b9-41df-4a8f-8301-e11bcd06f7ce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" xlink:type="extended" id="i1af1c9776ec841fc986b994af6fdda10_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" xlink:type="extended" id="i25da493982544b0e911d14c0fd63c5ff_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails" xlink:type="extended" id="iaf3eecd4de50481aa353b9dc81b1b05e_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalFeesNetOfIncomeTaxes_8f213719-12a8-4190-83ef-9dae94c3472e" xlink:href="amed-20201231.xsd#amed_LegalFeesNetOfIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_amed_LegalFeesNetOfIncomeTaxes_8f213719-12a8-4190-83ef-9dae94c3472e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes_94c14bb3-eac4-47cc-bb59-e48f56347e0d" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes_94c14bb3-eac4-47cc-bb59-e48f56347e0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet_0aabbb04-4d21-4af5-9c83-62a1037c3e21" xlink:href="amed-20201231.xsd#amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet_0aabbb04-4d21-4af5-9c83-62a1037c3e21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssetImpairmentChargesNetOfIncomeTaxes_dbb6968c-935b-4263-b698-2ff6e9297061" xlink:href="amed-20201231.xsd#amed_AssetImpairmentChargesNetOfIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_amed_AssetImpairmentChargesNetOfIncomeTaxes_dbb6968c-935b-4263-b698-2ff6e9297061" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6f674673-4285-4abb-a62d-086c82ad6218" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:to="loc_srt_LitigationCaseAxis_6f674673-4285-4abb-a62d-086c82ad6218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6f674673-4285-4abb-a62d-086c82ad6218_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_6f674673-4285-4abb-a62d-086c82ad6218" xlink:to="loc_srt_LitigationCaseTypeDomain_6f674673-4285-4abb-a62d-086c82ad6218_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d5db93bc-28f8-4331-9479-f9414a9b85b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_6f674673-4285-4abb-a62d-086c82ad6218" xlink:to="loc_srt_LitigationCaseTypeDomain_d5db93bc-28f8-4331-9479-f9414a9b85b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_27cbbfac-0752-4e7b-b526-26d16621eb29" xlink:href="amed-20201231.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d5db93bc-28f8-4331-9479-f9414a9b85b6" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_27cbbfac-0752-4e7b-b526-26d16621eb29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30165702-252c-4b1e-871c-dfe382c916f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30165702-252c-4b1e-871c-dfe382c916f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30165702-252c-4b1e-871c-dfe382c916f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30165702-252c-4b1e-871c-dfe382c916f0" xlink:to="loc_us-gaap_SegmentDomain_30165702-252c-4b1e-871c-dfe382c916f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e1b2a0e5-667f-4afa-9117-65b258aeec4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30165702-252c-4b1e-871c-dfe382c916f0" xlink:to="loc_us-gaap_SegmentDomain_e1b2a0e5-667f-4afa-9117-65b258aeec4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_f903bfbe-528c-4574-9b04-ee4d75977faf" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e1b2a0e5-667f-4afa-9117-65b258aeec4c" xlink:to="loc_amed_HomeHealthMember_f903bfbe-528c-4574-9b04-ee4d75977faf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended" id="ib3676deae93440eabfd4f8cc20bad963_RELATEDPARTYTRANSACTIONS"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="ia10ad9b0b67548ab8ee21ef85017db02_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_2a8271ed-139e-418a-9df1-bd1656603aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_2a8271ed-139e-418a-9df1-bd1656603aa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c3fd5d7b-aaac-4550-8428-0e84a6352551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c3fd5d7b-aaac-4550-8428-0e84a6352551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_881e27dd-6cbe-467c-aea3-01812a0ba554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_881e27dd-6cbe-467c-aea3-01812a0ba554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_a34a7672-ef15-47a1-8c22-45e2d161a2de" xlink:href="amed-20201231.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_amed_PercentageofSharesOutstanding_a34a7672-ef15-47a1-8c22-45e2d161a2de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1345eff1-6913-405e-aad5-eb92fca6a6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1345eff1-6913-405e-aad5-eb92fca6a6cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DiscountedClosingStockPrice_fee6d3e4-b602-4816-909d-37cf6d3c6100" xlink:href="amed-20201231.xsd#amed_DiscountedClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_amed_DiscountedClosingStockPrice_fee6d3e4-b602-4816-909d-37cf6d3c6100" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofClosingStockPrice_77d9a328-4000-46e1-a114-a588a1740420" xlink:href="amed-20201231.xsd#amed_PercentageofClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_amed_PercentageofClosingStockPrice_77d9a328-4000-46e1-a114-a588a1740420" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_427e128d-9f04-41a8-8073-eb354f0dbbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_427e128d-9f04-41a8-8073-eb354f0dbbbb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseAxis_587eba7a-d721-4462-9c38-91e6e4f47147" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:to="loc_amed_ShareRepurchaseAxis_587eba7a-d721-4462-9c38-91e6e4f47147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_587eba7a-d721-4462-9c38-91e6e4f47147_default" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_ShareRepurchaseAxis_587eba7a-d721-4462-9c38-91e6e4f47147" xlink:to="loc_amed_ShareRepurchaseDomain_587eba7a-d721-4462-9c38-91e6e4f47147_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_5021bb89-b2fe-40ed-9250-a33423de4ca6" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_ShareRepurchaseAxis_587eba7a-d721-4462-9c38-91e6e4f47147" xlink:to="loc_amed_ShareRepurchaseDomain_5021bb89-b2fe-40ed-9250-a33423de4ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRShareRepurchaseMember_4c74ddd0-62f8-4133-bdfe-bef0a7d2edf4" xlink:href="amed-20201231.xsd#amed_KKRShareRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseDomain_5021bb89-b2fe-40ed-9250-a33423de4ca6" xlink:to="loc_amed_KKRShareRepurchaseMember_4c74ddd0-62f8-4133-bdfe-bef0a7d2edf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_66f32a78-6d38-47fd-a92c-199bc19fcd95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_66f32a78-6d38-47fd-a92c-199bc19fcd95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_66f32a78-6d38-47fd-a92c-199bc19fcd95_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_66f32a78-6d38-47fd-a92c-199bc19fcd95" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_66f32a78-6d38-47fd-a92c-199bc19fcd95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_66f32a78-6d38-47fd-a92c-199bc19fcd95" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRConsultingMember_78f5650e-5a44-4339-8516-2ab60862131f" xlink:href="amed-20201231.xsd#amed_KKRConsultingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:to="loc_amed_KKRConsultingMember_78f5650e-5a44-4339-8516-2ab60862131f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CareInnovationsMember_7aba62b6-829b-4b48-b45d-5d014e8f3b5d" xlink:href="amed-20201231.xsd#amed_CareInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:to="loc_amed_CareInnovationsMember_7aba62b6-829b-4b48-b45d-5d014e8f3b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_4978a135-900c-4584-b256-b21e63e623f4" xlink:href="amed-20201231.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:to="loc_amed_MedalogixMember_4978a135-900c-4584-b256-b21e63e623f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34aa864b-e6e7-43e8-a873-2dd3f77c3318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34aa864b-e6e7-43e8-a873-2dd3f77c3318" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_34aa864b-e6e7-43e8-a873-2dd3f77c3318_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34aa864b-e6e7-43e8-a873-2dd3f77c3318" xlink:to="loc_us-gaap_RelatedPartyDomain_34aa864b-e6e7-43e8-a873-2dd3f77c3318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1be6965d-d3b4-4b53-9652-6cbb1323865c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34aa864b-e6e7-43e8-a873-2dd3f77c3318" xlink:to="loc_us-gaap_RelatedPartyDomain_1be6965d-d3b4-4b53-9652-6cbb1323865c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c6e842f3-58b9-41db-ac74-ef874794690f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1be6965d-d3b4-4b53-9652-6cbb1323865c" xlink:to="loc_srt_AffiliatedEntityMember_c6e842f3-58b9-41db-ac74-ef874794690f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_ce5e3c12-e997-48b1-ad27-b513e2b82fc8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1be6965d-d3b4-4b53-9652-6cbb1323865c" xlink:to="loc_srt_ManagementMember_ce5e3c12-e997-48b1-ad27-b513e2b82fc8" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>amed-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:267db984-3247-4ac4-9ea7-650da4f8e37e,g:25daadda-e66f-46f9-96fb-eec4b4d1abf0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d0666ba5-2dfa-44ce-a403-b2e1ce8838b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_fd11efda-ac3c-4b52-91e4-474cd442ac2e_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase (decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="amed-20201231.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_96aeb565-ccae-49fb-b300-4f8b850eb858_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_913b6cd8-00ad-4a22-bedb-10cfa873f10a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OigSelfDisclosureMember_a9cb5717-1de7-4076-9247-61be798d8b08_terseLabel_en-US" xlink:label="lab_amed_OigSelfDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OIG Self-Disclosure [Member]</link:label>
    <link:label id="lab_amed_OigSelfDisclosureMember_label_en-US" xlink:label="lab_amed_OigSelfDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OIG Self-Disclosure [Member]</link:label>
    <link:label id="lab_amed_OigSelfDisclosureMember_documentation_en-US" xlink:label="lab_amed_OigSelfDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OIG Self-Disclosure matters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OigSelfDisclosureMember" xlink:href="amed-20201231.xsd#amed_OigSelfDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OigSelfDisclosureMember" xlink:to="lab_amed_OigSelfDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bac36b93-f25f-4290-b7ff-0aed40c19576_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d7702418-743f-447d-a9d5-195b3050c454_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e6f1d479-c7bc-4ff7-8e5d-64d72562fa78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_75b835fe-2b31-49b9-9443-4c024d97d8cd_negatedTerseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_e62942f7-00c5-4bdc-b77b-29ee4ed419b2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_f5aa0bd4-edba-4290-a13e-98114fe6c4f9_terseLabel_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_label_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember" xlink:href="amed-20201231.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MorgantownWestVirginiaMember" xlink:to="lab_amed_MorgantownWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_86a79ae1-e6fa-4ec7-b9e8-3f5fbf7a5328_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c73e1f2c-0f85-40dc-8388-232831671479_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eebceecc-dd57-4457-990b-9f264e4121d2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98fb2a5c-4c1e-4f6a-8be2-e233c586daf1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_ce08ec46-62a8-4cea-bbe3-513cfd272196_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d9f4dd29-848e-433a-832f-694168cc21ae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_8ed704bd-9daf-485f-af49-17e4030be377_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b28a6697-c5da-472d-8d96-ea7a2da384b0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_d932231a-a255-4baa-8e2a-f2c9bf89549f_terseLabel_en-US" xlink:label="lab_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum days for accounts receivable outstanding to be fully reserved</link:label>
    <link:label id="lab_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_label_en-US" xlink:label="lab_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Days Accounts Receivable Outstanding Fully Reserved</link:label>
    <link:label id="lab_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_documentation_en-US" xlink:label="lab_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of days required before a patient accounts receivable must be outstanding to be fully reserved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:href="amed-20201231.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:to="lab_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedInsuranceExcludingLongTermPortion_e7100810-c463-4298-8e16-03c7fc3f4768_totalLabel_en-US" xlink:label="lab_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Excluding Long Term Portion</link:label>
    <link:label id="lab_amed_EstimatedInsuranceExcludingLongTermPortion_label_en-US" xlink:label="lab_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Excluding Long Term Portion</link:label>
    <link:label id="lab_amed_EstimatedInsuranceExcludingLongTermPortion_documentation_en-US" xlink:label="lab_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated insurance liability, excluding long-term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:to="lab_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_1721bbe0-351c-483f-bfe7-a9914f174716_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_332bb6f9-6eea-4bbb-8c1f-659c29581e06_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio" xlink:href="amed-20201231.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedLeverageRatio" xlink:to="lab_amed_ConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_82e2a589-25c0-4a94-8d5b-13d121f09b2c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_f2fed42a-0ff7-4322-9396-0cfe5186c71a_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_c4323394-9474-4809-92ff-6d41704c3a01_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_2498164b-6d2e-4677-96f3-f4fdbac23efc_negatedTerseLabel_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_label_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Repurchase Of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow during the period for redemption of noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:href="amed-20201231.xsd#amed_PaymentsForRepurchaseOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:to="lab_amed_PaymentsForRepurchaseOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f67eed0a-bbb3-4934-900c-320d48770988_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_489ff662-5382-44c0-8d09-ef547ad559f1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_27c0fc51-e4ea-4fda-9477-c7849da723da_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InternallyDevelopedComputerSoftware_a59f3331-3fdb-4b80-b39e-339b00e2bb74_terseLabel_en-US" xlink:label="lab_amed_InternallyDevelopedComputerSoftware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed computer software</link:label>
    <link:label id="lab_amed_InternallyDevelopedComputerSoftware_label_en-US" xlink:label="lab_amed_InternallyDevelopedComputerSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally Developed Computer Software</link:label>
    <link:label id="lab_amed_InternallyDevelopedComputerSoftware_documentation_en-US" xlink:label="lab_amed_InternallyDevelopedComputerSoftware" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed AMS3 computer software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternallyDevelopedComputerSoftware" xlink:href="amed-20201231.xsd#amed_InternallyDevelopedComputerSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternallyDevelopedComputerSoftware" xlink:to="lab_amed_InternallyDevelopedComputerSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_cf65a59a-2d85-478e-8850-17e2116fd5dd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_d64f1401-e4e7-4271-8d2c-3738952e6da1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_49b0a564-f720-4345-a994-5771d5df1907_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1a7e0248-0728-4dee-9e12-e65690d1db6b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizableAcquiredNamesMember_5dbf4e13-b698-4b27-b407-ad4b739f084e_terseLabel_en-US" xlink:label="lab_amed_AmortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired names [Member]</link:label>
    <link:label id="lab_amed_AmortizableAcquiredNamesMember_label_en-US" xlink:label="lab_amed_AmortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired names [Member]</link:label>
    <link:label id="lab_amed_AmortizableAcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_AmortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember" xlink:href="amed-20201231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizableAcquiredNamesMember" xlink:to="lab_amed_AmortizableAcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e5d94568-54c4-447c-b64b-d21444d3de77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_0668e1a4-929c-44f9-b5e1-329d58b761ac_terseLabel_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_label_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Patient Receivables Outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:href="amed-20201231.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:to="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_e5750d3b-836b-4500-adb6-de0bcecd5dbc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_45c1b17e-7b90-4330-b480-76f94018b477_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_bf0e539a-2b2c-4e54-b1fe-8a53ed30f8d5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageofownershipinsubsidiaries_cef0ef9f-63ed-49a8-9327-5412cab72ed7_terseLabel_en-US" xlink:label="lab_amed_Percentageofownershipinsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership in subsidiaries</link:label>
    <link:label id="lab_amed_Percentageofownershipinsubsidiaries_label_en-US" xlink:label="lab_amed_Percentageofownershipinsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentageofownershipinsubsidiaries</link:label>
    <link:label id="lab_amed_Percentageofownershipinsubsidiaries_documentation_en-US" xlink:label="lab_amed_Percentageofownershipinsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership in subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofownershipinsubsidiaries" xlink:href="amed-20201231.xsd#amed_Percentageofownershipinsubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageofownershipinsubsidiaries" xlink:to="lab_amed_Percentageofownershipinsubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_0a74011e-1089-453b-853d-c203c804a7c7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_095eb963-c7df-49e5-ba48-bd6796fb451c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flow from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_d24abdc2-98f3-4bd9-9d1a-6b5dff184ea3_terseLabel_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_label_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical Collection Rate From Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_documentation_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare" xlink:href="amed-20201231.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HistoricalCollectionRateFromMedicare" xlink:to="lab_amed_HistoricalCollectionRateFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_258a4558-0b56-4d8c-b3c8-fc1a8c0fb3e0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_c920ce64-c594-4242-bc8a-6f8f4d790a3a_negatedLabel_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest distribution</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Distribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends or other distributions to noncontrolling interest holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest" xlink:href="amed-20201231.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashDistributionToNoncontrollingInterest" xlink:to="lab_amed_CashDistributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_88da852d-d507-405b-8056-9c552573c18b_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6044aaae-ec7d-4c5f-b108-fc117263b849_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b7f9956-7dbd-4d40-b76f-2447178593df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_59ec722a-f4fa-4fd4-8a37-fecf7babc978_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_57334292-79d0-4dfc-bf77-5cb9be3b4a81_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_23f89341-f5cf-452e-8489-84a4e84ffa3c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4c2628fe-5f52-4ddc-b9f1-6067087adcf7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1c7a86b7-ebc7-40a7-b9d3-8e1a390171a6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_b81aed10-a661-4a38-9913-05b5703880bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock options exercised and restricted stock vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1d71b028-8978-4a6c-872e-ba36e34b460a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_62273300-bb71-492d-8204-547387e088de_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_7b7354ca-c47c-450a-bc55-34a8fc9e85db_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_9ca243f9-ff31-4e13-8fe6-80b22892dddb_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare revenue rate accounted for routine care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_label_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_documentation_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:href="amed-20201231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:to="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_a11151eb-ca17-4c3c-9e03-88477de6247d_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2b5b4681-04da-49e5-bc77-e18607be74c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_48361986-e86c-4da2-9d59-725a7ad177ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_408099c8-f69c-4991-91e4-af486bd590b9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_09a67153-b6da-4e9e-9782-9281655e7d79_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_56a8fef1-ba2b-4d14-a778-30acb9586291_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d7151eb5-0721-455c-a391-e99b811695b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_4c39029e-95c9-4115-9b15-8081c572d8e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flow from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StateTaxCreditMember_07058526-3aa2-4bac-97a0-5abfcaf23991_terseLabel_en-US" xlink:label="lab_amed_StateTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Tax Credit [Member]</link:label>
    <link:label id="lab_amed_StateTaxCreditMember_label_en-US" xlink:label="lab_amed_StateTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Tax Credit [Member]</link:label>
    <link:label id="lab_amed_StateTaxCreditMember_documentation_en-US" xlink:label="lab_amed_StateTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Tax Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StateTaxCreditMember" xlink:href="amed-20201231.xsd#amed_StateTaxCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StateTaxCreditMember" xlink:to="lab_amed_StateTaxCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMember_dc83d330-51a3-4086-9f30-7d15d1d6d8b9_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_label_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMember" xlink:to="lab_amed_HomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_834d7aca-9cc2-497e-8f65-4ec10e6e5943_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction, amount of transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_fcf85c25-34d0-4313-b83a-c2a4e46d5f90_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:href="amed-20201231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_38b4a1fb-47aa-4a14-b0bd-462c073ada34_terseLabel_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low utilization payment adjustment, maximum number of visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_label_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Utilization Payment Adjustment Number Of Visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_documentation_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the visit threshold for a low utilization payment adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:href="amed-20201231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:to="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_cf24be49-d751-485b-846a-399d8ff2aebf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_bd91b6d4-c872-494b-8e53-c49b2a4f934c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net services revenue provided by Medicare</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_616de8a2-09ff-4c92-9674-b4b5fffccf2c_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected To Be Utilized</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected To Be Utilized</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected To Be Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:href="amed-20201231.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_e8b6c3fe-61d7-4f92-a102-dd40bf2f019d_terseLabel_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_label_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants [Policy Text Block]</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policy disclosure text block for government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:href="amed-20201231.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:to="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9315c1ab-156c-41e8-8682-ec7a4071f7e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_04c8504e-1583-485f-ad88-64da4806e9bc_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_42839c0a-406f-4dcb-8db6-3a530a2fbccc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4742ee17-a2b6-4724-a14e-ab7ee5546026_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_bb19ab83-6336-4432-95e1-72a0ea28da43_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax rate change</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_2e96a725-84ec-41b1-90e3-9b2256e46a48_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:href="amed-20201231.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_8a9662a1-79b8-4281-9048-0a0575aceb2e_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_label_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:href="amed-20201231.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:to="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_a4c31265-4425-4a0f-b85d-5566114abd99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_624bdc1c-70c1-4648-8918-c2cbaceaea90_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_33cc6053-e0fc-4886-aad5-29c40f2a3f1d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Numberofpatients_e861c0ef-8a0f-49bc-829c-dbb03699e1eb_terseLabel_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_label_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_documentation_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients" xlink:href="amed-20201231.xsd#amed_Numberofpatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Numberofpatients" xlink:to="lab_amed_Numberofpatients" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_75662430-b6db-4fd6-b27c-cb729aef61e6_terseLabel_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health And Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_label_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health And Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_documentation_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health And Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember" xlink:href="amed-20201231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthAndHospiceMember" xlink:to="lab_amed_HomeHealthAndHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_1648dae4-b569-46be-80a5-7ace251db2d1_negatedTerseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_51097482-f07f-475b-ad7a-55f6f8e59b81_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b6ce73a-d7de-4867-beae-4e3946b07c97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_4fe5ff78-4353-4afe-8f15-272433b39af2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_833aecab-2187-4aaa-92ee-52eb87bcd5a2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedInsuranceTotal_fa432208-5aa9-4b70-8696-c349ead079a4_totalLabel_en-US" xlink:label="lab_amed_EstimatedInsuranceTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Total</link:label>
    <link:label id="lab_amed_EstimatedInsuranceTotal_label_en-US" xlink:label="lab_amed_EstimatedInsuranceTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Total</link:label>
    <link:label id="lab_amed_EstimatedInsuranceTotal_documentation_en-US" xlink:label="lab_amed_EstimatedInsuranceTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated insurance, total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceTotal" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedInsuranceTotal" xlink:to="lab_amed_EstimatedInsuranceTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ThresholdOfIndividualsInDataBreach_0d2cc47c-1dc5-45e5-a584-94e6fad0b5e4_terseLabel_en-US" xlink:label="lab_amed_ThresholdOfIndividualsInDataBreach" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of individuals in data breach</link:label>
    <link:label id="lab_amed_ThresholdOfIndividualsInDataBreach_label_en-US" xlink:label="lab_amed_ThresholdOfIndividualsInDataBreach" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of Individuals in Data Breach</link:label>
    <link:label id="lab_amed_ThresholdOfIndividualsInDataBreach_documentation_en-US" xlink:label="lab_amed_ThresholdOfIndividualsInDataBreach" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of number of individuals involved in a data breach</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThresholdOfIndividualsInDataBreach" xlink:href="amed-20201231.xsd#amed_ThresholdOfIndividualsInDataBreach"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThresholdOfIndividualsInDataBreach" xlink:to="lab_amed_ThresholdOfIndividualsInDataBreach" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8662f807-6aa5-493c-b76d-68e6da7fc7c4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_485ec5ec-dddf-474a-ba40-9632487c776e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties accrued related to uncertain income tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_24f52a57-eed4-4a2a-9aed-fb346a8969f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6e7648d2-7ec1-4c7a-a97e-20e90ab5513b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based awards, number of shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_948b38e4-0642-4deb-abc2-13bfad477cf1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segment [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareRevenueMember_fb0b2b86-727a-42bc-aaf9-024d18745055_terseLabel_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_label_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_documentation_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember" xlink:href="amed-20201231.xsd#amed_MedicareRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareRevenueMember" xlink:to="lab_amed_MedicareRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_311d83d3-8fcd-4983-be28-3feab2a4a65f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based awards, shares available for grant (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_e303db47-5dfe-4dfd-bd49-cf18cd2eca98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_c7a4e69b-0174-4c90-80be-804eff91a5cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses:</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_5a6e9ca5-f451-4f6c-8861-690328683102_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_5b0b1443-463d-408c-9ecd-aa762db19fcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Purchase Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_3064fd05-fc94-4ae0-aba3-d3f1cddb8da6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_8825547f-2d12-4ad9-a0ba-26790dc60d2b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_00fd9cf4-cba1-4b5f-9c52-e50bd85f2ed5_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cares Act Provider Relief Funds</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cares Act Provider Relief Funds [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:href="amed-20201231.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:to="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LeaseTypeAxis_e4ecefdd-d159-4677-b676-4c15445344b1_terseLabel_en-US" xlink:label="lab_amed_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease type [Axis]</link:label>
    <link:label id="lab_amed_LeaseTypeAxis_label_en-US" xlink:label="lab_amed_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease type [Axis]</link:label>
    <link:label id="lab_amed_LeaseTypeAxis_documentation_en-US" xlink:label="lab_amed_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeAxis" xlink:href="amed-20201231.xsd#amed_LeaseTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LeaseTypeAxis" xlink:to="lab_amed_LeaseTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_d4bd52fd-e6b7-46a2-9473-1d1945bdca67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0feba11b-61d8-486c-9ddd-584eeca33890_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineFacility_de52cab9-f832-4692-9616-c8e1b67f4430_terseLabel_en-US" xlink:label="lab_amed_SwingLineFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Facility</link:label>
    <link:label id="lab_amed_SwingLineFacility_label_en-US" xlink:label="lab_amed_SwingLineFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Facility</link:label>
    <link:label id="lab_amed_SwingLineFacility_documentation_en-US" xlink:label="lab_amed_SwingLineFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Facility included within Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineFacility" xlink:href="amed-20201231.xsd#amed_SwingLineFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineFacility" xlink:to="lab_amed_SwingLineFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_df2a3e9c-5a2a-4480-92fc-b5860edc16bc_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than Equal to 3.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f6d8eac-30f3-4f67-b5b4-c4354cd58692_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedCreditAgreementMember_d561f6e1-5ed3-4583-b7d6-2fb37cca0094_terseLabel_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember" xlink:href="amed-20201231.xsd#amed_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedCreditAgreementMember" xlink:to="lab_amed_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_8d1794b9-8658-4aea-9eb0-8990ae13892e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Financing Activity:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7a384969-1c1d-4acf-b105-f893306774e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_26be5db8-1d2a-4c71-8722-8bbc5bc2bdee_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fc56a485-2f66-4f06-a0d6-42a7bd8d0a0e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredOperatingIncomeCARESAct_d00e8a6c-eaba-4b3d-b401-a31001da23b7_terseLabel_en-US" xlink:label="lab_amed_DeferredOperatingIncomeCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred operating income (CARES Act)</link:label>
    <link:label id="lab_amed_DeferredOperatingIncomeCARESAct_label_en-US" xlink:label="lab_amed_DeferredOperatingIncomeCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Operating Income (CARES Act)</link:label>
    <link:label id="lab_amed_DeferredOperatingIncomeCARESAct_documentation_en-US" xlink:label="lab_amed_DeferredOperatingIncomeCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred operating income as a result of the CARES Act in relation to the Novel Coronavirus Pandemic ("COVID-19")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredOperatingIncomeCARESAct" xlink:href="amed-20201231.xsd#amed_DeferredOperatingIncomeCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredOperatingIncomeCARESAct" xlink:to="lab_amed_DeferredOperatingIncomeCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DefinedContributionPlanEmployerMatchingContribution_3b5eb698-9852-47e6-b2ba-a07fbf7cb246_terseLabel_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer match amount</link:label>
    <link:label id="lab_amed_DefinedContributionPlanEmployerMatchingContribution_label_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Employer Matching Contribution</link:label>
    <link:label id="lab_amed_DefinedContributionPlanEmployerMatchingContribution_documentation_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan employer matching contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:href="amed-20201231.xsd#amed_DefinedContributionPlanEmployerMatchingContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:to="lab_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_07c0d66c-804d-4a21-a936-52060a64deb4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3057cc8b-574d-400f-841c-a61e678be278_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_64229012-853a-4dc5-95c8-0d0e90f63c7c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_bc14c63e-d51c-49b7-85fa-83b8ec4a61da_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RoseRockHealthcareMember_867a8d16-ca36-479a-8799-c52c9e9c06be_terseLabel_en-US" xlink:label="lab_amed_RoseRockHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:label id="lab_amed_RoseRockHealthcareMember_label_en-US" xlink:label="lab_amed_RoseRockHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:label id="lab_amed_RoseRockHealthcareMember_documentation_en-US" xlink:label="lab_amed_RoseRockHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoseRock Healthcare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RoseRockHealthcareMember" xlink:href="amed-20201231.xsd#amed_RoseRockHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RoseRockHealthcareMember" xlink:to="lab_amed_RoseRockHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ec36d77d-19cc-4751-acb4-89d7eb0f8cd0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39bc256b-f9e4-4cb9-90d0-bad8745e9bc0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateMember_bade4974-9211-4f82-a94e-155da709c292_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateMember_label_en-US" xlink:label="lab_us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateMember" xlink:to="lab_us-gaap_CorporateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e3194b70-3832-4e69-b32e-488dc7409104_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b66144f1-e9cd-4570-8d54-e34a69df64fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_c78b3cd5-78aa-4e67-a8e5-db999408c154_terseLabel_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_label_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details [Table Text Block]</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details, table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:href="amed-20201231.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:to="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_cd14e767-a501-43dc-a8bc-69a1cfdff003_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_a8424e81-131e-4fb4-85fb-87ab5ea3013f_terseLabel_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_label_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_documentation_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:href="amed-20201231.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:to="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_53b3a397-4146-4ae9-949c-773cf6db0747_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ComputerInventoryAndDataSecurityReportingMember_41ecd33a-75a8-4e12-a31d-28e5cf94603d_terseLabel_en-US" xlink:label="lab_amed_ComputerInventoryAndDataSecurityReportingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Inventory And Data Security Reporting [Member]</link:label>
    <link:label id="lab_amed_ComputerInventoryAndDataSecurityReportingMember_label_en-US" xlink:label="lab_amed_ComputerInventoryAndDataSecurityReportingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Inventory And Data Security Reporting [Member]</link:label>
    <link:label id="lab_amed_ComputerInventoryAndDataSecurityReportingMember_documentation_en-US" xlink:label="lab_amed_ComputerInventoryAndDataSecurityReportingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Inventory And Data Security Reporting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ComputerInventoryAndDataSecurityReportingMember" xlink:href="amed-20201231.xsd#amed_ComputerInventoryAndDataSecurityReportingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ComputerInventoryAndDataSecurityReportingMember" xlink:to="lab_amed_ComputerInventoryAndDataSecurityReportingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_d9730de9-b5c5-4898-8599-a24e3efd41b7_terseLabel_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_label_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claims Submitted By Subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_documentation_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:href="amed-20201231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:to="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0a821f88-8f5f-4223-9e80-cb8e85eb58b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_KKRShareRepurchaseMember_c1cae59d-2e21-49a8-9290-a79416103ffa_terseLabel_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKR Share Repurchase [Member]</link:label>
    <link:label id="lab_amed_KKRShareRepurchaseMember_label_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKR Share Repurchase [Member]</link:label>
    <link:label id="lab_amed_KKRShareRepurchaseMember_documentation_en-US" xlink:label="lab_amed_KKRShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKR Share Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRShareRepurchaseMember" xlink:href="amed-20201231.xsd#amed_KKRShareRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_KKRShareRepurchaseMember" xlink:to="lab_amed_KKRShareRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4d120049-9240-4826-99e0-2e8fb03028b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b55ba66-b4e7-4b96-9cd0-b30696088c0f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_b72642b6-f28e-43bf-bd41-1be901003dd5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_25b3cf22-a8f8-48aa-961b-d7c5b369b1f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct_fc7c3b98-4558-423a-8d35-c6cd27d0dd3c_terseLabel_en-US" xlink:label="lab_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current social security taxes (deferred under CARES Act)</link:label>
    <link:label id="lab_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct_label_en-US" xlink:label="lab_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current Social Security Taxes (deferred under CARES Act)</link:label>
    <link:label id="lab_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct_documentation_en-US" xlink:label="lab_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The non-current portion of Social Security Taxes deferred under the CARES Act as a result of the Novel Coronavirus Pandemic ("COVID-19")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" xlink:href="amed-20201231.xsd#amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" xlink:to="lab_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_f5d84a78-56ec-434b-bc9c-993c14ee944c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with facilities</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ee474ee7-2832-4fbc-b679-26d829b02e9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_35a96ede-377f-4d80-927f-f4570aeb354e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in total valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_92b204b8-9a27-4571-bd3d-66356a89303d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2016-09 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201609Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201609Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_939da7a3-186e-4178-87f6-b6913008ad4c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_af3ee635-0ea8-43df-a520-1b6e6e9013fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockUnitsMember_dbf064f7-28e1-4620-b339-18b03629ec81_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Units [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockUnitsMember_label_en-US" xlink:label="lab_amed_NonVestedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock Units [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockUnitsMember_documentation_en-US" xlink:label="lab_amed_NonVestedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockUnitsMember" xlink:to="lab_amed_NonVestedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_c6d9511e-d24d-4d39-a72a-79a521304606_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_97e76685-c09a-4ad0-bb9a-5a57c58df9d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_451c78f8-3393-458e-ab92-ea18bc900a94_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_c77ad631-a9c1-467e-aacd-cf38c0e4f6ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_985cedc8-d04f-421b-9899-7670619fc764_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_d6630198-16be-4f56-a56c-400dd0709f99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f6b56d00-b053-4a69-8f4b-bb4beb759cb7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_99e5244a-6e3e-4fc2-b691-f814831fbc5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_c0e8084c-03a7-46c2-8b61-d421e8247874_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_20fe4a30-20a2-4aa8-9bdc-6845714a4790_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareMember_ef05aa54-0dc4-4258-967d-32c610179b8d_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_label_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember" xlink:href="amed-20201231.xsd#amed_HospiceMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareMember" xlink:to="lab_amed_HospiceMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_b631d364-53ed-4c89-99c5-1a7c4119beae_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:to="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_9d84c4fd-7727-465b-9389-ed1e52de00e5_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock and stock units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_label_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock And Stock Units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_documentation_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non vested stock and stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits" xlink:href="amed-20201231.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockAndStockUnits" xlink:to="lab_amed_NonVestedStockAndStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToGoodwill_625685c3-8bc8-47b5-94f4-fb656d00e162_terseLabel_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToGoodwill_label_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Effects Allocated To Goodwill</link:label>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToGoodwill_documentation_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Effects Allocated To Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:href="amed-20201231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:to="lab_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageofSharesOutstanding_d47ce95c-5be6-41aa-94ab-229bfe4937aa_terseLabel_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_label_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding" xlink:href="amed-20201231.xsd#amed_PercentageofSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofSharesOutstanding" xlink:to="lab_amed_PercentageofSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_f125e504-d8ee-4ce0-a77d-2ef7e4d95811_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0aba1546-5d72-448f-a27e-26c9c4d8b050_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4e9ab2d3-7d55-46bf-a87b-4410fd0cf403_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb8e8a8d-d0a3-409d-8d6e-5efd9e6deea8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_49ea9759-3225-45c8-9834-b9b99000aef6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_53c232d0-3924-4055-9a80-7c3d89ee2601_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e07935f4-bc6d-4ee1-b402-a5f29837ac53_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_74edd34b-1ac5-4f14-a81d-d3907aff2a01_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_87de2e7a-4f5c-4fbe-9175-d53ee754b84e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ab4209f2-f8de-49b4-b37b-dabe50aa1df7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProvisionForLiabilityOnRegulatoryAudit_fa7f174e-d18c-4a58-9e6a-5bf204c81fe7_terseLabel_en-US" xlink:label="lab_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida ZPIC audit, gross liability</link:label>
    <link:label id="lab_amed_ProvisionForLiabilityOnRegulatoryAudit_label_en-US" xlink:label="lab_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Liability On Regulatory Audit</link:label>
    <link:label id="lab_amed_ProvisionForLiabilityOnRegulatoryAudit_documentation_en-US" xlink:label="lab_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Liability On Regulatory Audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:href="amed-20201231.xsd#amed_ProvisionForLiabilityOnRegulatoryAudit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:to="lab_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ddf99299-f8d0-4330-97c6-204128fb5efa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Income of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_d824fa89-ce84-4eec-a6ea-ded00e168e51_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f3b16af8-1b8a-457c-baef-68275756d98e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_427165ff-3601-4ba9-a64a-bc2748887047_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_d860b44b-3f6d-43db-85a5-79f5a5398b67_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for the initial period of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:href="amed-20201231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NoncontrollingInterestSoldMember_6c0ac782-4088-4e80-982a-8fe54b5c9221_terseLabel_en-US" xlink:label="lab_amed_NoncontrollingInterestSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest sold [Member]</link:label>
    <link:label id="lab_amed_NoncontrollingInterestSoldMember_label_en-US" xlink:label="lab_amed_NoncontrollingInterestSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest sold [Member]</link:label>
    <link:label id="lab_amed_NoncontrollingInterestSoldMember_documentation_en-US" xlink:label="lab_amed_NoncontrollingInterestSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestSoldMember" xlink:href="amed-20201231.xsd#amed_NoncontrollingInterestSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NoncontrollingInterestSoldMember" xlink:to="lab_amed_NoncontrollingInterestSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_a7db4834-7470-404a-bfb5-bf824bd8516a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ab3fd009-e1cb-4de5-8239-717975ea9ee4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_c609d4e9-a400-4935-bc7b-38928358a677_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_label_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct" xlink:href="amed-20201231.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromCARESAct" xlink:to="lab_amed_FundingReceivedFromCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_11e3d62a-0e4a-4f91-8b0b-3ca894229687_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralAxis_0b9ef241-9fb4-4e6c-be3b-85e49767bd34_terseLabel_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral [Axis]</link:label>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralAxis_label_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral [Axis]</link:label>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralAxis_documentation_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralAxis" xlink:href="amed-20201231.xsd#amed_TypeOfIncomeTaxDeferralAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfIncomeTaxDeferralAxis" xlink:to="lab_amed_TypeOfIncomeTaxDeferralAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_956f894d-17d2-4c4f-88af-ff10e57c1004_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_87409889-0dac-4d0d-8b85-ce6cf411ae74_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:href="amed-20201231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_46f68173-accf-4fde-b265-4317b964028b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_YearOfDeparture_c303735f-d71f-4d86-9a32-3be7457f033f_terseLabel_en-US" xlink:label="lab_amed_YearOfDeparture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year of departure</link:label>
    <link:label id="lab_amed_YearOfDeparture_label_en-US" xlink:label="lab_amed_YearOfDeparture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year of Departure</link:label>
    <link:label id="lab_amed_YearOfDeparture_documentation_en-US" xlink:label="lab_amed_YearOfDeparture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year of departure from the company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_YearOfDeparture" xlink:href="amed-20201231.xsd#amed_YearOfDeparture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_YearOfDeparture" xlink:to="lab_amed_YearOfDeparture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_75637710-a1ff-495b-b147-929ab62640ba_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software [Member]</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_ff5b6829-b53d-414e-bd75-e15cbadec626_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OtherIntangibleAssetsAdditions_249594ba-8a87-4d1c-8253-5e06d919ce4d_terseLabel_en-US" xlink:label="lab_amed_OtherIntangibleAssetsAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_amed_OtherIntangibleAssetsAdditions_label_en-US" xlink:label="lab_amed_OtherIntangibleAssetsAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets Additions</link:label>
    <link:label id="lab_amed_OtherIntangibleAssetsAdditions_documentation_en-US" xlink:label="lab_amed_OtherIntangibleAssetsAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to Other Intangible Assets that occurred during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherIntangibleAssetsAdditions" xlink:href="amed-20201231.xsd#amed_OtherIntangibleAssetsAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OtherIntangibleAssetsAdditions" xlink:to="lab_amed_OtherIntangibleAssetsAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingLeaseTermYears_e1ef6b30-7664-40ec-9bfc-95196e5aca1e_terseLabel_en-US" xlink:label="lab_amed_OperatingLeaseTermYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term (years)</link:label>
    <link:label id="lab_amed_OperatingLeaseTermYears_label_en-US" xlink:label="lab_amed_OperatingLeaseTermYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Term Years</link:label>
    <link:label id="lab_amed_OperatingLeaseTermYears_documentation_en-US" xlink:label="lab_amed_OperatingLeaseTermYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term, years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeaseTermYears" xlink:href="amed-20201231.xsd#amed_OperatingLeaseTermYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingLeaseTermYears" xlink:to="lab_amed_OperatingLeaseTermYears" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember_2d0c5b16-eadd-4852-92f8-c898b1b1f28d_terseLabel_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security Taxes [Member]</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember_label_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security Taxes [Member]</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember_documentation_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:href="amed-20201231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:to="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_c66f8850-0701-4541-8cc1-05d616359622_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested Performance-based Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_3d63dc7d-d357-4535-8676-8b3fc1ce25d9_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_e75c79bc-bc3a-46f2-9ec9-fb08a2f453e8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6ec5c3cb-6836-4121-8259-6c80a62a4448_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_130a1901-659e-408f-90f6-246e5cc137d8_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareBasedAwardsMember_c4f295b8-6582-4aab-a60b-467a7b02ba51_terseLabel_en-US" xlink:label="lab_amed_ShareBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Awards [Member]</link:label>
    <link:label id="lab_amed_ShareBasedAwardsMember_label_en-US" xlink:label="lab_amed_ShareBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Awards [Member]</link:label>
    <link:label id="lab_amed_ShareBasedAwardsMember_documentation_en-US" xlink:label="lab_amed_ShareBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsMember" xlink:href="amed-20201231.xsd#amed_ShareBasedAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareBasedAwardsMember" xlink:to="lab_amed_ShareBasedAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_830a2bb1-2627-45f8-a745-4ebdd6d36eab_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_5e9db7ca-4858-442b-ad87-29f0fb2f8637_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceAccruals_e517bec6-84ac-459e-b7af-22212f5932d4_terseLabel_en-US" xlink:label="lab_amed_HospiceAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice accruals (room and board, general in-patient and other)</link:label>
    <link:label id="lab_amed_HospiceAccruals_label_en-US" xlink:label="lab_amed_HospiceAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice accruals</link:label>
    <link:label id="lab_amed_HospiceAccruals_documentation_en-US" xlink:label="lab_amed_HospiceAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to Hospice room and board, general in-patient and other expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceAccruals" xlink:href="amed-20201231.xsd#amed_HospiceAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceAccruals" xlink:to="lab_amed_HospiceAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3a50d241-e332-4524-9045-7578ccd27b91_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_f37986cf-c2e7-49af-ba9b-166551e94a88_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcquiredNamesMember_2434d0a3-c77f-443d-86ec-ed982eb0ab1c_terseLabel_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_label_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcquiredNamesMember" xlink:to="lab_amed_AcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_48c76103-313a-4b12-9b12-4854b4f31845_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_3a6e8ce7-2cc1-44de-8adf-8e9898ed5395_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_accc6952-6c43-4ca6-b959-9664be9e6236_terseLabel_en-US" xlink:label="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term and Discount Rate</link:label>
    <link:label id="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_label_en-US" xlink:label="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_documentation_en-US" xlink:label="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term and discount rate Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:href="amed-20201231.xsd#amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8cbcd37e-a522-435c-9552-e9dd2384c2da_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d4a9063b-da7f-4ed6-bc69-3fdbaf62f118_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_37c3747a-6c19-488a-843e-5f04b93fed06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_cd861894-22a5-4062-99dd-8042fcc2e564_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4f960090-eef5-4c10-82fe-277975b8ceac_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld to pay taxes on non-cash compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7537c9e0-6e10-4d60-b3cb-6ddecdf35e09_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_04bd07e9-f66e-4d66-b0cb-004868be62d9_terseLabel_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_label_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_documentation_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:href="amed-20201231.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:to="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DocumentAndEntityInformationAbstract_4170a837-7c31-4f5e-a1d0-e6c6dc883746_terseLabel_en-US" xlink:label="lab_amed_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_amed_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_amed_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_amed_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_amed_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DocumentAndEntityInformationAbstract" xlink:href="amed-20201231.xsd#amed_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DocumentAndEntityInformationAbstract" xlink:to="lab_amed_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_ffd8dd00-3128-458e-88ce-58644adf283d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recorded during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_ed7ae1d4-124d-4ab7-bc58-78cd4153180e_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_e9e35b14-6930-4392-80c0-e068365faf65_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock_436ac472-1c71-4611-9727-49e5ab0fae67_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Financial Information, Compassionate Care Hospice</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock_label_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information, Compassionate Care Hospice [Table Text Block]</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of pro forma results of operations for the Compassionate Care Hospice acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" xlink:to="lab_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_96171eb9-20ba-4da3-a7e1-140fcf34f3ca_terseLabel_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed To Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_label_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed To Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_documentation_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:href="amed-20201231.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:to="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8dd3d583-4d77-45c6-b15f-519d0703dd5f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_9acd5e91-7fa3-4bd7-87eb-05313a4a1fad_terseLabel_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-medicare revenue term rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_label_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_documentation_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates" xlink:href="amed-20201231.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonMedicareRevenueTermRates" xlink:to="lab_amed_NonMedicareRevenueTermRates" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OrganizationAndNatureOfOperationsTable_f35f68aa-b755-4a90-9c5d-609606858c77_terseLabel_en-US" xlink:label="lab_amed_OrganizationAndNatureOfOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Nature Of Operations [Table]</link:label>
    <link:label id="lab_amed_OrganizationAndNatureOfOperationsTable_label_en-US" xlink:label="lab_amed_OrganizationAndNatureOfOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Nature Of Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsTable" xlink:href="amed-20201231.xsd#amed_OrganizationAndNatureOfOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable" xlink:to="lab_amed_OrganizationAndNatureOfOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_5aea9519-223e-4ebe-bd9a-5b8d06c26794_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_8b96acf5-ac65-46ec-8f66-3c08b1d179c4_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_83e33106-5d61-4310-8566-f6338d809217_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_a8e6ac8d-04e2-4cc3-aea9-0104f2044fa3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_de64b2d8-c94d-40aa-80a3-e571c9b254d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of share-based award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_7e654180-481a-40db-a9cf-e73de2f70e0f_terseLabel_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_label_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_documentation_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:href="amed-20201231.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:to="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_3b99c373-5067-4b49-a966-475000a99e00_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IntercityHomeCareMember_69dc2de2-a633-446c-bf6d-d4b5e941d6e4_terseLabel_en-US" xlink:label="lab_amed_IntercityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercity Home Care [Member]</link:label>
    <link:label id="lab_amed_IntercityHomeCareMember_label_en-US" xlink:label="lab_amed_IntercityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercity Home Care [Member]</link:label>
    <link:label id="lab_amed_IntercityHomeCareMember_documentation_en-US" xlink:label="lab_amed_IntercityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercity Home Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IntercityHomeCareMember" xlink:href="amed-20201231.xsd#amed_IntercityHomeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IntercityHomeCareMember" xlink:to="lab_amed_IntercityHomeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_f3544749-3520-418e-99ba-84a0dab74e1e_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance retention limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Retention Limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit" xlink:href="amed-20201231.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceRetentionLimit" xlink:to="lab_amed_HealthInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a89cf07a-7d41-4b2d-8366-28da28113e6c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8f6c6903-575a-4f0a-a669-380b820f61d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_162e041b-3630-4b1a-a036-0b7957b467c0_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance retention limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability Insurance Retention Limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:href="amed-20201231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:to="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_5a4c1513-6b23-458d-90b4-a5d3226b9f4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2e50d8ea-e47b-478d-9951-cf948e4430a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_7a64cdf6-85b6-405c-a9aa-7b4047f657e4_terseLabel_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the third threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:href="amed-20201231.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:to="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_16276a92-48b7-4ac1-8ee8-2d4c190aeff2_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment_ac8fc3ea-36a7-4265-8056-962a07b6009a_terseLabel_en-US" xlink:label="lab_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets contributed to equity investment</link:label>
    <link:label id="lab_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment_label_en-US" xlink:label="lab_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact Of Increase Decrease In Assets Of Equity Method Investment</link:label>
    <link:label id="lab_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment_documentation_en-US" xlink:label="lab_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact Of Increase Decrease In Assets Of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:href="amed-20201231.xsd#amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:to="lab_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_42a8e5e4-f4b1-4051-b5a2-725423e83b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_18704df5-2f86-450c-af2b-bc5fe5824c73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_346b1ab0-39de-4ffb-a204-ade255962ce8_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Federal Fund rate (percent)</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_97149612-14e4-4cd7-9d92-aeb08ae9c5a3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ff0e1916-e3f0-44d8-87ba-b5a2d6c4c143_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f0959aab-b765-4a01-8a14-a95bd18adf22_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassAxis_2c263fa8-52fd-43da-ade9-3d1a68948e64_terseLabel_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_label_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_documentation_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis" xlink:href="amed-20201231.xsd#amed_PayorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassAxis" xlink:to="lab_amed_PayorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_3568f8c4-5599-499b-8990-5f789eb1b067_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_232e5d73-4285-4cad-9856-f3a836e2c946_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_ac3ed8ca-699d-47fb-948b-1cd002e46cc3_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions, Asana Hospice</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions Asana Hospice [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the Asana business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:href="amed-20201231.xsd#amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_1d45310e-b55d-4969-b742-bbdacccbb8f2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_d154c4a7-24ea-47ec-ac79-fd84d00593f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CareInnovationsMember_d831b0c0-ddb2-44bb-b31a-b293d6fd98f1_terseLabel_en-US" xlink:label="lab_amed_CareInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Care Innovations [Member]</link:label>
    <link:label id="lab_amed_CareInnovationsMember_label_en-US" xlink:label="lab_amed_CareInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Care Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CareInnovationsMember" xlink:href="amed-20201231.xsd#amed_CareInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CareInnovationsMember" xlink:to="lab_amed_CareInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_73ab9c09-3ee4-4722-962a-cdbeb73fc542_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average&#160;Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_752ca09d-a701-4508-9b1b-b0c62622f3b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_8b394b88-3b73-433a-aa67-8ecc429d6756_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax years open to examination</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_3bd19cf4-cbc7-428d-9905-96e3395dcbac_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_23b5604e-885c-4778-9204-bc12c903b5ec_terseLabel_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total reimbursement of outlier payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_label_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Reimbursement Of Outlier Payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_documentation_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:href="amed-20201231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:to="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8d999ed3-0a7f-428f-b27c-625b71e69125_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_d9dbed23-267a-462c-8dde-a38401061da4_terseLabel_en-US" xlink:label="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized for issuance under Employee Stock Purchase Plan (shares)</link:label>
    <link:label id="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan</link:label>
    <link:label id="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for issuance to the Company's employee stock purchase plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:href="amed-20201231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:to="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_5f583790-48cd-480f-8d6f-fb14162fbb53_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE REPURCHASE</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters_99d2c633-0c90-4843-ba5f-ad6ee1206da9_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal &amp; compliance matters</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Legal and Compliance Matters</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from legal and compliance matters.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsLegalAndComplianceMatters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:to="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_bb337af7-97b6-4404-acf3-aa51485f7748_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_cac5f887-1bcf-48aa-be21-17b020bc230c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, expiration date</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:to="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_64a8cca6-8306-4224-aff1-2032a3a73aab_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c5e4acf4-aa77-4222-a17d-4515a4940624_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ErrorRatePercentage_58de4e46-b353-4e83-9126-0f861a617fb7_terseLabel_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error rate (percent)</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_label_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_documentation_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage" xlink:href="amed-20201231.xsd#amed_ErrorRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ErrorRatePercentage" xlink:to="lab_amed_ErrorRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_a36cf06e-dc6b-4de1-949d-33c0ebac4601_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_99b32a6b-9d2b-431a-89f0-07f35211c3e8_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_0b96beac-b1c6-480b-b60a-f0035c15e3b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_25ec3e20-6fc6-47eb-8227-0860e821a8cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_5955ec74-a9a2-4ccb-93f4-fdfb1e285d77_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember" xlink:href="amed-20201231.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitMember" xlink:to="lab_amed_SecuritiesClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_26501302-ee09-4c8a-b46e-dcd9f9abf55f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_d5ffbab1-be06-4ee6-8d62-7bc177e22fc3_terseLabel_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_label_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_documentation_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:href="amed-20201231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:to="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f082dd39-b402-4a87-bd99-6e22b68817ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_3a8c6db2-9f65-413c-b305-306cf9e91ac6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_27a9bf11-0b90-4844-8727-59dd7b29ffb5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_301dbc1e-8040-43b2-8fb2-d41a6e87f4ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_98064555-1423-45a2-aede-418cc8cc8f1a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_f802448e-5e1b-4ac3-8b0c-157624af54e9_terseLabel_en-US" xlink:label="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_label_en-US" xlink:label="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Property And Equipment [Text Block]</link:label>
    <link:label id="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_documentation_en-US" xlink:label="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">stimated Useful Lives Of Property And Equipment, table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:href="amed-20201231.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:to="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_46d9db6d-5251-4f7e-9301-56c84c452925_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Goodwill and Other Intangible Assets Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_054687c7-a3eb-4bb5-a05b-e0ec5b4182f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_f59dd4e3-cfdd-45b6-8c41-ca3e736fb363_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_d9e0f930-270e-45e0-83e5-27eae3e17109_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Aggregate Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_46bf983b-3b91-4386-a097-6e76574c2fbe_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f151ec6-2eca-43e1-9c19-750c21de6f6b_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding &#8211; diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_c46f0c63-e023-4bfb-96f4-7bdf05f98c26_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5104b204-f278-4a7a-8e06-01185e92ee79_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited or expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_442a4f03-257d-4999-8059-4931c7d98d5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_eb2704cf-ad5f-48da-aedb-db7178a1e51e_terseLabel_en-US" xlink:label="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</link:label>
    <link:label id="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of Certain Balance Sheet Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:href="amed-20201231.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:to="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_dbc03fbe-c023-4ff1-85ab-fc5b6a6a0309_terseLabel_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated With Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_label_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated With Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_documentation_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with the CARES Act Provider Relief Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:href="amed-20201231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:to="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6d06ae3f-6291-4a62-bd73-4aec0ac5f75d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs/debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_66685918-9e96-49ab-8575-3abb787e748c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_d67bc884-43ae-4f30-932b-3d0d5adc84a4_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_930a7ecb-2196-4faa-b3cb-4122e92a0b42_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayrollTaxEscrow_f9288c01-a8b8-4822-b321-fd114cfb0707_terseLabel_en-US" xlink:label="lab_amed_PayrollTaxEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax escrow</link:label>
    <link:label id="lab_amed_PayrollTaxEscrow_label_en-US" xlink:label="lab_amed_PayrollTaxEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax escrow</link:label>
    <link:label id="lab_amed_PayrollTaxEscrow_documentation_en-US" xlink:label="lab_amed_PayrollTaxEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayrollTaxEscrow" xlink:href="amed-20201231.xsd#amed_PayrollTaxEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayrollTaxEscrow" xlink:to="lab_amed_PayrollTaxEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19TextBlock_6e9b8176-5c8e-4a32-be64-a5d1180e7a2e_terseLabel_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</link:label>
    <link:label id="lab_amed_COVID19TextBlock_label_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID19 [Text Block]</link:label>
    <link:label id="lab_amed_COVID19TextBlock_documentation_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock" xlink:href="amed-20201231.xsd#amed_COVID19TextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19TextBlock" xlink:to="lab_amed_COVID19TextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_02a60ae6-2fb2-4f4f-bcb1-26f510000135_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax benefits accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c67d1b5b-2b59-48a8-a187-d9028bc9bb5d_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax benefits, beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_08b3c41e-46a9-486a-989e-c0f788396c5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax benefits, ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_4d897a98-2bd9-4a9f-b242-dcb62605aad5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9f38e03d-a486-42bf-8bc6-76c475d3c4b9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5e113f31-a601-43b7-b934-3fd9044c185c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_113e9a39-c9d9-44a5-b08a-cd7ae430ac53_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e322151a-dc08-428a-a55e-dd2431af03fa_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_7ba6d235-0bb7-4644-aa99-f120a41ccdf7_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ed77ad37-8ab2-409c-9fbd-80e56bd9c284_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_07d70785-5c7a-4c49-98ac-e1c251c6afd9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_1b7c3f76-46a0-41c6-ae1d-6e956b567592_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLeverageRatio_7873eeae-8962-4197-9671-fd83f99123f7_terseLabel_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_label_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Leverage Ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_documentation_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio" xlink:href="amed-20201231.xsd#amed_TotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLeverageRatio" xlink:to="lab_amed_TotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_18fd97b6-f5d3-440c-a9b6-f5f797c7e8b2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_55155876-8754-4a09-bdd7-c1f450cb8924_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_27b6a6c8-d32c-46c0-be0e-6ab04bbd847e_terseLabel_en-US" xlink:label="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of employee salary eligible for employer match (percent)</link:label>
    <link:label id="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_label_en-US" xlink:label="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defind Contribution Plan Maximum Annual Match Per Employee Salary Percentage</link:label>
    <link:label id="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_documentation_en-US" xlink:label="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percentage of Employee Salary Eligible for Employer Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:href="amed-20201231.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:to="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CallPremiumPayment_e77bce5f-3a71-43d8-baaf-59584238cab9_terseLabel_en-US" xlink:label="lab_amed_CallPremiumPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call premium payment</link:label>
    <link:label id="lab_amed_CallPremiumPayment_label_en-US" xlink:label="lab_amed_CallPremiumPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Premium Payment</link:label>
    <link:label id="lab_amed_CallPremiumPayment_documentation_en-US" xlink:label="lab_amed_CallPremiumPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call premium paid during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CallPremiumPayment" xlink:href="amed-20201231.xsd#amed_CallPremiumPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CallPremiumPayment" xlink:to="lab_amed_CallPremiumPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c362f6a9-54a7-4357-8f27-839860f55f4a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_aafebcc4-cd04-4ec2-b253-7e84a315a800_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicarelicensesMember_fe74b970-4046-4b9e-9bca-21564a5b6593_terseLabel_en-US" xlink:label="lab_amed_MedicarelicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Licenses [Member]</link:label>
    <link:label id="lab_amed_MedicarelicensesMember_label_en-US" xlink:label="lab_amed_MedicarelicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare licenses [Member]</link:label>
    <link:label id="lab_amed_MedicarelicensesMember_documentation_en-US" xlink:label="lab_amed_MedicarelicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare licenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicarelicensesMember" xlink:href="amed-20201231.xsd#amed_MedicarelicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicarelicensesMember" xlink:to="lab_amed_MedicarelicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7506cbe8-dc74-4f8d-a304-0c2304d0fad2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c1d75399-2f7b-434c-a514-f375e29c2078_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_93f968ff-b903-42f6-8724-1dc61f4a9b1e_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_486f05f1-7f67-48fa-9735-1edd75e2bff3_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Net of Patient Service Revenue Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmedisysCIAMember_6c925eb2-21d6-4418-b987-71cd3fbb4810_terseLabel_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_label_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_documentation_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember" xlink:href="amed-20201231.xsd#amed_AmedisysCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmedisysCIAMember" xlink:to="lab_amed_AmedisysCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_08e7ec7f-1edb-472f-af6c-86bd96518493_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_c5483a1e-822a-421c-8302-b77f118d523c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_fbf22d3d-5580-42ab-a155-f789830756f8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_37e9f623-28fb-47e0-90ff-609c60eeb057_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UncertainTaxBenefitsInLongTermObligations_c0b2e2fb-1839-4be9-be92-656a4b2ed627_terseLabel_en-US" xlink:label="lab_amed_UncertainTaxBenefitsInLongTermObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for uncertain tax positions</link:label>
    <link:label id="lab_amed_UncertainTaxBenefitsInLongTermObligations_label_en-US" xlink:label="lab_amed_UncertainTaxBenefitsInLongTermObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Benefits In Long Term Obligations</link:label>
    <link:label id="lab_amed_UncertainTaxBenefitsInLongTermObligations_documentation_en-US" xlink:label="lab_amed_UncertainTaxBenefitsInLongTermObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Benefits In Long Term Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UncertainTaxBenefitsInLongTermObligations" xlink:href="amed-20201231.xsd#amed_UncertainTaxBenefitsInLongTermObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UncertainTaxBenefitsInLongTermObligations" xlink:to="lab_amed_UncertainTaxBenefitsInLongTermObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_75f985eb-fd5b-44ce-8114-7cc5e2ecdaec_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_label_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_documentation_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:href="amed-20201231.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:to="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bbe00b06-347a-4da4-af85-ee9143a1dfe4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_07edcae6-0fc6-496f-af82-4ec42c744d62_negatedTerseLabel_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:href="amed-20201231.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_91db9ec3-af03-4525-89c2-b7b4e84447d3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amedisys, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_fb1df7fc-ee90-4950-b992-20d12e688d84_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a5791d86-5c34-4f22-89dc-83e58eb2a17d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_eb890f2d-bb76-4d16-824c-405acbccec71_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable issued in acquisition</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f3e4a5ba-02da-488d-b2f9-8c86611d6192_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b51622d4-ce9d-4dcc-9aff-81efd06254ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrentAbstract_0cdb4e02-8da8-42df-b5a1-9229e0517f3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets:</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ddd78849-ffd5-4fbd-b2bd-1dbc121a2f9c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_3147be06-f34f-49c8-a922-f72468a7e293_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralDomain_201cb2cf-7216-41cc-b835-c2f69fc4294e_terseLabel_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral [Domain]</link:label>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralDomain_label_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral [Domain]</link:label>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralDomain_documentation_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralDomain" xlink:href="amed-20201231.xsd#amed_TypeOfIncomeTaxDeferralDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfIncomeTaxDeferralDomain" xlink:to="lab_amed_TypeOfIncomeTaxDeferralDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_85b6b80c-14ce-4144-b166-945c0d3540c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cd591098-3d0d-4fb2-adc9-3a437149464d_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2eb1750f-5b0c-41a8-bb4e-64f86ca67f0c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_bfc3aca2-2689-4d5c-a04b-f5e55f879dbb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6cee8f38-284a-4550-a5b8-4c96481a51f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e6a9a8c1-62a0-4564-b04e-4a49078adc59_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WageAndHourLitigationMember_30060bd2-1f6e-44d0-b1d5-2e59c5dec103_terseLabel_en-US" xlink:label="lab_amed_WageAndHourLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wage and Hour Litigation [Member]</link:label>
    <link:label id="lab_amed_WageAndHourLitigationMember_label_en-US" xlink:label="lab_amed_WageAndHourLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wage And Hour Litigation [Member]</link:label>
    <link:label id="lab_amed_WageAndHourLitigationMember_documentation_en-US" xlink:label="lab_amed_WageAndHourLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wage And Hour Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WageAndHourLitigationMember" xlink:href="amed-20201231.xsd#amed_WageAndHourLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WageAndHourLitigationMember" xlink:to="lab_amed_WageAndHourLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_ad7e4aa7-05b3-449a-80be-c61a90143286_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of obligations under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_9d9c2b5e-af4a-4703-922a-0f7bb8521bad_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_label_en-US" xlink:label="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:to="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5e7c803e-fc17-4608-9df9-055771ac259b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageofClosingStockPrice_bb2088e0-5a67-408d-97d6-4b53b2d8260f_terseLabel_en-US" xlink:label="lab_amed_PercentageofClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Closing Stock Price</link:label>
    <link:label id="lab_amed_PercentageofClosingStockPrice_label_en-US" xlink:label="lab_amed_PercentageofClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Closing Stock Price</link:label>
    <link:label id="lab_amed_PercentageofClosingStockPrice_documentation_en-US" xlink:label="lab_amed_PercentageofClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Closing Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofClosingStockPrice" xlink:href="amed-20201231.xsd#amed_PercentageofClosingStockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofClosingStockPrice" xlink:to="lab_amed_PercentageofClosingStockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IdahoandWyomingSelfReportMember_bf9574fd-c704-46ce-bfe4-84d1d3109497_terseLabel_en-US" xlink:label="lab_amed_IdahoandWyomingSelfReportMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idaho and Wyoming Self Report [Member]</link:label>
    <link:label id="lab_amed_IdahoandWyomingSelfReportMember_label_en-US" xlink:label="lab_amed_IdahoandWyomingSelfReportMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idaho and Wyoming Self Report [Member]</link:label>
    <link:label id="lab_amed_IdahoandWyomingSelfReportMember_documentation_en-US" xlink:label="lab_amed_IdahoandWyomingSelfReportMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idaho and Wyoming Self Report [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IdahoandWyomingSelfReportMember" xlink:href="amed-20201231.xsd#amed_IdahoandWyomingSelfReportMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IdahoandWyomingSelfReportMember" xlink:to="lab_amed_IdahoandWyomingSelfReportMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FleetLeaseMember_f4656cda-8133-4dac-b432-36fff45c9256_terseLabel_en-US" xlink:label="lab_amed_FleetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fleet Lease [Member]</link:label>
    <link:label id="lab_amed_FleetLeaseMember_label_en-US" xlink:label="lab_amed_FleetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fleet Lease [Member]</link:label>
    <link:label id="lab_amed_FleetLeaseMember_documentation_en-US" xlink:label="lab_amed_FleetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fleet Lease Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetLeaseMember" xlink:href="amed-20201231.xsd#amed_FleetLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FleetLeaseMember" xlink:to="lab_amed_FleetLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1ef047a1-4f0e-46a6-8b49-99e7dd6af0e1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8b848558-a02b-45c2-ae7e-926478e303c8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f93558e9-0bcb-40c6-9fe4-e6401697ba5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_d60ecf5a-1a3e-460c-8f33-35515aa0b8ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7c35fa42-9343-4f87-a375-3a8a28caff19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet_04424a42-0a4b-4266-81f0-5a8dbc838c67_terseLabel_en-US" xlink:label="lab_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Tax Cuts and Jobs Act of 2017, net of income taxes</link:label>
    <link:label id="lab_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet_label_en-US" xlink:label="lab_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Transition Tax Expense (Benefit), Net</link:label>
    <link:label id="lab_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet_documentation_en-US" xlink:label="lab_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Transition Tax Expense (Benefit), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet" xlink:href="amed-20201231.xsd#amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet" xlink:to="lab_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_21c2f9c6-e120-4e1d-b46c-f7c2d1866fa5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income taxes, net of federal income tax benefit (1)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_5722be64-c6fe-4f97-ac9e-681587863789_terseLabel_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_label_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_documentation_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember" xlink:href="amed-20201231.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UsDepartmentOfJusticeMember" xlink:to="lab_amed_UsDepartmentOfJusticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseTable_88d2fb79-14c9-425a-8984-00fe4aacd6af_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_label_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseTable" xlink:to="lab_amed_ShareRepurchaseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_8a60c07f-d7cd-4bff-9db8-25c4667d00bf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EastTennesseePersonalCareMember_ee2dfb9e-6f82-4f08-9ebc-27c96934617d_terseLabel_en-US" xlink:label="lab_amed_EastTennesseePersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">East Tennessee Personal Care [Member]</link:label>
    <link:label id="lab_amed_EastTennesseePersonalCareMember_label_en-US" xlink:label="lab_amed_EastTennesseePersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">East Tennessee Personal Care [Member]</link:label>
    <link:label id="lab_amed_EastTennesseePersonalCareMember_documentation_en-US" xlink:label="lab_amed_EastTennesseePersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">East Tennessee Personal Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EastTennesseePersonalCareMember" xlink:href="amed-20201231.xsd#amed_EastTennesseePersonalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EastTennesseePersonalCareMember" xlink:to="lab_amed_EastTennesseePersonalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionExpense_46c29d68-6515-4006-a2b9-3dc7dbd760e4_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash 401(k) employer match</link:label>
    <link:label id="lab_us-gaap_PensionExpense_label_en-US" xlink:label="lab_us-gaap_PensionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense" xlink:to="lab_us-gaap_PensionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_855f159c-613f-4bf1-b75a-c1f1a33a3b04_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c3df4094-d89b-42f2-8819-93224e6d1b34_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock_91f03dc1-bf02-4831-b424-de526c319755_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions Compassionate Care Hospice</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions Compassionate Care Hospice [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of Compassionate Care business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" xlink:href="amed-20201231.xsd#amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_f2f52298-92d9-489d-a7bb-2739f3eb6bb2_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated interest coverage ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Interest Coverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio" xlink:href="amed-20201231.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedInterestCoverageRatio" xlink:to="lab_amed_ConsolidatedInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_a266709c-7ba6-4ad7-8b37-b49321b94516_terseLabel_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic revenue reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_label_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic Revenue Reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_documentation_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in revenue as a result of the Florida ZPIC audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction" xlink:href="amed-20201231.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FloridaZpicRevenueReduction" xlink:to="lab_amed_FloridaZpicRevenueReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_a9bdb96f-9d26-455c-b682-19106c32e03a_terseLabel_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">200 Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:href="amed-20201231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_f057b053-655b-418e-a88e-b151dc6f6769_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsAxis_155241cd-7617-450a-9c63-a79f0957ff52_terseLabel_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Axis]</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsAxis_label_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Axis]</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsAxis_documentation_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsAxis" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnrecognizedTaxBenefitsAxis" xlink:to="lab_amed_UnrecognizedTaxBenefitsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_0fafb44e-3e10-45b3-9c40-0a0dd367024c_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401 (k) plan (shares)</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:href="amed-20201231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingCareCenters_ab755e9c-b5a5-40a3-a31a-51e2eb527358_terseLabel_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of owned and operated care centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_label_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Care Centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_documentation_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters" xlink:href="amed-20201231.xsd#amed_OperatingCareCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingCareCenters" xlink:to="lab_amed_OperatingCareCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_3c872f37-ab7f-4916-942b-91bfe67eef34_terseLabel_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contribution amount</link:label>
    <link:label id="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_label_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Employee Contribution For Employee Matching Program</link:label>
    <link:label id="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_documentation_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Employee Contribution For Employer Matching Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:href="amed-20201231.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:to="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_248931b3-bdec-47c9-a240-11c552fde77b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_48bdd1e4-968c-432f-874d-a0b0d8dddea3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7e713e6c-86a5-472b-9fab-bdceb5a61c9c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_b45277f7-8f05-42a0-b446-fa6d3c43ffe9_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Overpayment Made To Subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:href="amed-20201231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationDeposits_7f0850ef-3f9d-4750-93cc-e99498876e0d_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation deposits</link:label>
    <link:label id="lab_amed_WorkersCompensationDeposits_label_en-US" xlink:label="lab_amed_WorkersCompensationDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Deposits</link:label>
    <link:label id="lab_amed_WorkersCompensationDeposits_documentation_en-US" xlink:label="lab_amed_WorkersCompensationDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationDeposits" xlink:href="amed-20201231.xsd#amed_WorkersCompensationDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationDeposits" xlink:to="lab_amed_WorkersCompensationDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_90e8eec2-5ed7-436e-8403-bcfaa5b6802d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) expense recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_0b721a35-a9e5-4a7f-93f8-0c4af790d0a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedShares_bdad33d1-06a7-49e3-bbfe-dea1a8eb8b60_terseLabel_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_label_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_documentation_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares" xlink:href="amed-20201231.xsd#amed_SurrenderedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedShares" xlink:to="lab_amed_SurrenderedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedInsuranceLongTermPortion_72219750-3b28-41f5-a473-8e07713ffdc0_negatedTerseLabel_en-US" xlink:label="lab_amed_EstimatedInsuranceLongTermPortion" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: long-term portion</link:label>
    <link:label id="lab_amed_EstimatedInsuranceLongTermPortion_label_en-US" xlink:label="lab_amed_EstimatedInsuranceLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Long Term Portion</link:label>
    <link:label id="lab_amed_EstimatedInsuranceLongTermPortion_documentation_en-US" xlink:label="lab_amed_EstimatedInsuranceLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term portion of estimated insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceLongTermPortion" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceLongTermPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedInsuranceLongTermPortion" xlink:to="lab_amed_EstimatedInsuranceLongTermPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_79859f39-510d-46e8-aea5-33fc7aaefd6f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfBeneficiaries_d74a736b-ac3f-476d-8579-1a61fb27d703_terseLabel_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_label_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_documentation_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries who received services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries" xlink:href="amed-20201231.xsd#amed_NumberOfBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfBeneficiaries" xlink:to="lab_amed_NumberOfBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_0480563d-db31-49ea-8398-d7e8a200aab5_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_45b8b06a-19df-4fef-8cf6-37742e5d9267_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_16fb57b9-7953-453f-a375-afdccfa57ac5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets_3f5b5ad3-00bd-48f2-8447-334fe5cc7bdb_negatedTerseLabel_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right of Use Assets</link:label>
    <link:label id="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="amed-20201231.xsd#amed_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_0703411f-ab4c-47d5-8f15-5a8f9be4c8ef_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_7b396811-36f2-44b3-96f3-de37ddef68a1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_e2e5bbc9-2d83-4f9f-a9e9-d0b8488db0c1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_1f3107c2-f9a9-485c-8528-9e8d346fe2d1_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:href="amed-20201231.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:to="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd5e082e-52f7-444f-906b-29e6abae124e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b78ef8c0-ee9e-45d7-bf5f-cab4663cf464_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_d3974a0b-235c-4c10-91d6-e886bcd872d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_90747997-d4e0-4c19-8c04-0d2cd671b911_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_707f1cf6-134c-475e-9c17-cc57765de503_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_c4c1f1b6-0f46-4c8e-8228-2b372c5ec8b1_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember" xlink:href="amed-20201231.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceCIAMember" xlink:to="lab_amed_CompassionateCareHospiceCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5be6c932-98ea-4bc9-b0a8-9bdce4b31428_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_10374bde-dae1-4513-87bb-152b9216e2c6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_a82e57de-2552-452f-ad36-8dc5f3657bb0_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2013 Through 2020 [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Thirteen Through Two Thousand Twenty [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Thirteen Through Two Thousand Twenty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:href="amed-20201231.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:to="lab_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_5b3d7894-de5a-48fe-9c0c-debdf1d5a463_terseLabel_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate integrity agreement term (years)</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_label_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_documentation_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm" xlink:href="amed-20201231.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CorporateIntegrityAgreementTerm" xlink:to="lab_amed_CorporateIntegrityAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9751a60d-62f0-45f3-af52-a847ae285567_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ab0238b2-4f9e-4401-b72e-4b849e361934_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_caf0130c-a227-4816-b889-2caf0ae39371_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_715c5c34-a703-44c7-a65b-19350a44ef5a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_56885815-2324-4c7b-9cd6-7bfc6a6075a2_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401 (k) plan</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:href="amed-20201231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SocialSecurityTaxMember_32c0d2ef-5e9e-4eb6-9f31-597854038c91_terseLabel_en-US" xlink:label="lab_amed_SocialSecurityTaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax [Member]</link:label>
    <link:label id="lab_amed_SocialSecurityTaxMember_label_en-US" xlink:label="lab_amed_SocialSecurityTaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax [Member]</link:label>
    <link:label id="lab_amed_SocialSecurityTaxMember_documentation_en-US" xlink:label="lab_amed_SocialSecurityTaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SocialSecurityTaxMember" xlink:href="amed-20201231.xsd#amed_SocialSecurityTaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SocialSecurityTaxMember" xlink:to="lab_amed_SocialSecurityTaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditAgreementMember_4d535c82-46b2-4603-8c12-dc7b45b936b0_terseLabel_en-US" xlink:label="lab_amed_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_CreditAgreementMember_label_en-US" xlink:label="lab_amed_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_CreditAgreementMember_documentation_en-US" xlink:label="lab_amed_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditAgreementMember" xlink:href="amed-20201231.xsd#amed_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditAgreementMember" xlink:to="lab_amed_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_81b12699-de5c-4567-b37e-f333ee892992_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations, Fiscal Year Maturity</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_99f50bd9-af3c-43bb-a612-deaaf24e4071_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6923bed2-97f0-4d1e-98e5-2ae779531d8b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0f33d4c-72b6-4069-be92-3eb937520373_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_689ac00c-73a5-493a-a48a-7bd6431ee8b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f6b4be46-0bb2-4812-8f64-7b1f28c08b38_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_57a9af8d-ea37-4c80-8e16-a7e535529f18_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_8139c7d2-56c5-4edf-86ac-9484fa5c4359_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense allocation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Intraperiod Tax Allocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificatesOfNeedMember_96bf86b6-8cd9-4778-873a-9620ecef63c9_terseLabel_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_label_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificatesOfNeedMember" xlink:to="lab_amed_CertificatesOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_f2447636-c7f4-4e6c-a6da-bd60b54a08b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_e6a5eb10-d812-4338-84bb-0ea4c9f458bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3189c39d-9c9c-4782-9418-e6c09e3e1e02_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impairment charge for write-off of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4c681e4e-2cb5-4931-8834-c09fe2c92be6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_e7e2586a-0928-40b0-8a67-8086c8ee4621_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1404d6e1-2a7d-44ee-a9b6-29c051e0653c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1cfadafc-ce05-45ec-9bab-04fcaaded120_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_820acf86-82eb-41d7-89c8-db1bedad76af_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b576f512-80f8-4952-8a4c-661265e2ceba_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6c4d71b5-1679-4b68-81b2-116f6d79234c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders - diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_69a28c4b-17ac-443f-b278-20ec51351e02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Uncertain Tax Positions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_04c426ea-2245-4b6f-ad29-f67f2f5d2f3d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of deferred compensation plan assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_fb3ffb3a-1f93-4d03-8587-4e4d8936b0f6_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:href="amed-20201231.xsd#amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:to="lab_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_606e6634-6fc5-4a2c-a6c8-fde520284fc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f3db5294-d100-4c9e-9ee8-79b90018609b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_98a02150-45b1-4f85-bf9b-ddb900e29bcc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_64c35a5f-488c-4c65-868d-cba26e183ce0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LeaseTypeDomain_ed8e864c-99a8-4ea1-b74f-d25cdda8a5d1_terseLabel_en-US" xlink:label="lab_amed_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type [Domain]</link:label>
    <link:label id="lab_amed_LeaseTypeDomain_label_en-US" xlink:label="lab_amed_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type [Domain]</link:label>
    <link:label id="lab_amed_LeaseTypeDomain_documentation_en-US" xlink:label="lab_amed_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeDomain" xlink:href="amed-20201231.xsd#amed_LeaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LeaseTypeDomain" xlink:to="lab_amed_LeaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_dda1b94e-4794-4c7f-b43f-59beea7397ea_terseLabel_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental CashFlow Information and NonCash Activity for Leases</link:label>
    <link:label id="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_label_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental CashFlow Information and NonCash Activity for Leases [Table Text Block]</link:label>
    <link:label id="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_documentation_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental CashFlow Information and NonCash Activity for Leases Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:href="amed-20201231.xsd#amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:to="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8b7dc1f5-a096-4dba-add6-75eef147bdad_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AlternativeMinimumTaxCreditMember_3f40f810-0c06-47b7-8002-6796307adbcd_terseLabel_en-US" xlink:label="lab_amed_AlternativeMinimumTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Minimum Tax Credit [Member]</link:label>
    <link:label id="lab_amed_AlternativeMinimumTaxCreditMember_label_en-US" xlink:label="lab_amed_AlternativeMinimumTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Minimum Tax Credit [Member]</link:label>
    <link:label id="lab_amed_AlternativeMinimumTaxCreditMember_documentation_en-US" xlink:label="lab_amed_AlternativeMinimumTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Minimum Tax Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AlternativeMinimumTaxCreditMember" xlink:href="amed-20201231.xsd#amed_AlternativeMinimumTaxCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AlternativeMinimumTaxCreditMember" xlink:to="lab_amed_AlternativeMinimumTaxCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_b3e29585-75cb-4b2d-8222-fad5012f5627_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0bb6dd95-225e-4736-8c54-e924a1610c86_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a5ca6da5-86a1-4375-ad64-b8238edaa97f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_8210d93d-a267-44ca-9b41-2634ae1d78cc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets:</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e67aa197-ad6d-4911-acb8-6a52ae0e155f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_0d892e97-f44d-4bfd-8fde-34c61ab42e31_terseLabel_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_label_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Threshold Of Services Required</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_documentation_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the second threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired" xlink:href="amed-20201231.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondThresholdOfServicesRequired" xlink:to="lab_amed_SecondThresholdOfServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8de881e8-3edf-4222-b6f6-37a317d8120c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_329b2534-b3a9-4449-b55b-9fce28cb3a7d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_8b7e98df-b773-4369-9058-9f27d6dba48b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll&#160;&amp; employee benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_56fa185a-34b3-46b0-8b73-b1482d9f8773_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c405485c-5d0b-4259-9707-2980768728c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_96c8500b-35b9-46d1-a6a9-a5b821d08228_terseLabel_en-US" xlink:label="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of operating lease right of use assets</link:label>
    <link:label id="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:href="amed-20201231.xsd#amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_bd79ed34-f63a-44e2-b93b-ddfc715db838_terseLabel_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the first threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:href="amed-20201231.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:to="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34f25998-992a-4cf0-a364-1fc1aec6dab7_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ddaa2cd0-4f56-4565-953a-9b16894fd652_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7def522e-5d2b-4c5e-95d3-b8e5c5fd9b36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcquiredNameOfBusinessMember_532c578e-666f-468e-bc98-ca919a57da8f_terseLabel_en-US" xlink:label="lab_amed_AcquiredNameOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Name of Business [Member]</link:label>
    <link:label id="lab_amed_AcquiredNameOfBusinessMember_label_en-US" xlink:label="lab_amed_AcquiredNameOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Name Of Business [Member]</link:label>
    <link:label id="lab_amed_AcquiredNameOfBusinessMember_documentation_en-US" xlink:label="lab_amed_AcquiredNameOfBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Name Of Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNameOfBusinessMember" xlink:href="amed-20201231.xsd#amed_AcquiredNameOfBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcquiredNameOfBusinessMember" xlink:to="lab_amed_AcquiredNameOfBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4c8ff5a4-4d24-41ae-8d02-b23c80fa29b6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_7a004898-0be4-4f27-8958-836ae1fb1cfe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_ab775fb7-4c8a-4869-8c80-cb230a8a9915_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized" xlink:href="amed-20201231.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsUtilized" xlink:to="lab_amed_CARESActProviderReliefFundsUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_058ba9c4-d866-4b28-8c51-05e04e6e0c0e_terseLabel_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum allowable consolidated leverage ratio multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_label_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_documentation_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:href="amed-20201231.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:to="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42603c02-51ba-4877-b625-22995bf7a285_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cb09293a-fb4a-4b3d-adbb-c49faf5aa70f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_bdf254fd-47b2-4123-a811-5aa56c09cc5c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_03ae1f1e-0bc6-4b32-88e4-83c99ceff1bd_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_bba50822-db36-431d-b83a-144bf0f6e246_terseLabel_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral Of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_label_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral Of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_documentation_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The deferral of the employer's share social security tax provided by the CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:href="amed-20201231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:to="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_74b092f0-3269-4573-a679-f96041225dfd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c2e214de-baba-475d-a2ab-61f7e8b81d85_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_664a4c53-8ca6-4722-a283-689ed80667f0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:to="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_bd8d5c00-b89b-4476-895b-348efdaaf71f_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue Period Of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue Period Of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:href="amed-20201231.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_b0a1dcd5-3a0f-4415-96a0-9cd2abddbee0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7a900c60-86a3-4503-bccf-43acc2396db5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ClearwaterFloridaMember_1ca84bd4-23c0-402b-af9b-ac6ef52b7aa6_terseLabel_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_label_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_documentation_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember" xlink:href="amed-20201231.xsd#amed_ClearwaterFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ClearwaterFloridaMember" xlink:to="lab_amed_ClearwaterFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_7afe5ec1-a03e-4da4-b01e-5a9ff37f2b2a_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Carolina [Member]</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_5ac0569d-796a-4dac-bf71-7d1224f3f957_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_848a2ad4-6fc2-4e7b-90e3-b5205a067aa5_terseLabel_en-US" xlink:label="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total combined voting power of the Company and subsidiaries</link:label>
    <link:label id="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_label_en-US" xlink:label="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries</link:label>
    <link:label id="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_documentation_en-US" xlink:label="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total combined voting power of the Company and our subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:href="amed-20201231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:to="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6b2b9005-fd1f-4e3d-b98c-1f7d24bf0f51_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_661739fd-1e77-48e4-b726-f39f7ccec4a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_d7853317-e1a0-4867-8d36-e56263a88399_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_1984d1b3-d1ee-4183-96da-3187c44aada8_terseLabel_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health period of care using PDGM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20201231.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_4e24ec05-5a5b-47af-8b8f-54efca77a67d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_facf1b13-d0f2-4129-a27c-0a2fffbd2853_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3cf3c0bf-4cf9-4ac9-9371-50ef4c7e9de2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_a21cc039-251f-47d6-a4ff-97c49141e5fd_terseLabel_en-US" xlink:label="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_label_en-US" xlink:label="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_documentation_en-US" xlink:label="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:href="amed-20201231.xsd#amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:to="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4b46385b-0b1d-4a17-8fc1-2e6fa2ecae0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_bc6cec65-46fb-4380-80f3-c89e355841f8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost incurred in related party transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_f3bd562b-c9c3-4edb-b42d-86bf44c0d8a4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_585b0e72-f16f-425c-acd3-efd8f017bbe5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5665def2-c343-4a80-aac4-dfae60157c46_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization of $22,973 and $7,044</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4692359e-d0b3-4a8a-a827-c16d0dfbf33b_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8ea392b-b3a4-4594-ac73-70222c0de682_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_cbc722a5-0829-4081-b9ce-137bed4e4d14_terseLabel_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_label_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_documentation_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:href="amed-20201231.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:to="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_59fb2cac-bcad-4b39-ac14-90bdf7fc9643_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of intangible assets and the basis of intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:to="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_94a73347-e603-422d-a208-b23edc129fda_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_7e260238-2787-48c9-857a-93b90c00a39c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of market value for purchases under Employee Stock Purchase Program (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_769343c0-20a8-45de-8b35-e3f9d46afd2f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_de899228-319f-4ec0-8f14-a5996e2be3cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_1b0194c8-f03f-4043-8b6d-7f8fe0d7749c_terseLabel_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percent ownership for controlling interest (percent)</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_label_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percent Ownership For Controlling Interest Percent</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_documentation_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:href="amed-20201231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:to="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OtherLongTermObligationsMember_894dcd19-3840-4aae-b9b1-5556ea536053_terseLabel_en-US" xlink:label="lab_amed_OtherLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations [Member]</link:label>
    <link:label id="lab_amed_OtherLongTermObligationsMember_label_en-US" xlink:label="lab_amed_OtherLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations [Member]</link:label>
    <link:label id="lab_amed_OtherLongTermObligationsMember_documentation_en-US" xlink:label="lab_amed_OtherLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherLongTermObligationsMember" xlink:href="amed-20201231.xsd#amed_OtherLongTermObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OtherLongTermObligationsMember" xlink:to="lab_amed_OtherLongTermObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_0c531891-20c3-4102-b630-d695a9ebd1c1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9c3aac63-a6fc-4a9e-8867-d929d02235d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1812f230-b74a-4c1b-8893-937be0b6456b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersSold_c3c013d4-b01a-4155-8da4-bdcb7940c6c0_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers sold</link:label>
    <link:label id="lab_amed_NumberOfCareCentersSold_label_en-US" xlink:label="lab_amed_NumberOfCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Care Centers Sold</link:label>
    <link:label id="lab_amed_NumberOfCareCentersSold_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersSold" xlink:href="amed-20201231.xsd#amed_NumberOfCareCentersSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersSold" xlink:to="lab_amed_NumberOfCareCentersSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_cfe3412e-c459-47db-a316-ea17fd824a75_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_ff3cc4d9-bfba-46cf-a9f4-ab6adb93f404_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_597060af-cfe7-4309-aca6-7561b93b9f36_verboseLabel_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_label_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:href="amed-20201231.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:to="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9e5cb49d-9c9a-4498-8809-fa607876e350_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of equity-based awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bdc7fd9f-0375-410f-a683-de2dd5473cc6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FrontierLitigationMember_61136ce6-eabf-40f2-88dd-3c85bd28c1bd_terseLabel_en-US" xlink:label="lab_amed_FrontierLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frontier Litigation [Member]</link:label>
    <link:label id="lab_amed_FrontierLitigationMember_label_en-US" xlink:label="lab_amed_FrontierLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frontier Litigation [Member]</link:label>
    <link:label id="lab_amed_FrontierLitigationMember_documentation_en-US" xlink:label="lab_amed_FrontierLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frontier Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FrontierLitigationMember" xlink:href="amed-20201231.xsd#amed_FrontierLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FrontierLitigationMember" xlink:to="lab_amed_FrontierLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4ae6a595-32d4-4abf-b019-5af1807cc848_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe92d511-e157-44d6-842f-aed8e33d612d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_486c0450-2996-47ae-8132-8a5dec2efa9f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_70a4cb35-7bec-4643-854a-5a78bf024f81_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a62b46e3-2791-48b8-99b8-8e6167999d13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_e6384634-e248-4ba2-90fb-c4d13c3c6e6c_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract_67e888d9-82cd-4b04-ae8c-a5e1fe161de5_terseLabel_en-US" xlink:label="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details Of Certain Balance Sheet Accounts [Abstract]</link:label>
    <link:label id="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract_label_en-US" xlink:label="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details Of Certain Balance Sheet Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:href="amed-20201231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:to="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_b02a2db4-c466-4116-bda7-d5788a87c472_terseLabel_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode of care as episodic-based revenue, days</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health episode of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20201231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d869563b-cfb6-4b98-a705-6c3d3e21fa00_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_7824bdf7-937b-47a8-9ca3-3b50e0fdc2e2_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="amed-20201231.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_13236b24-83d8-4032-b99c-8e8601b672cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e58562bc-ef04-4b58-b5b6-fc512423824d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_04e3b2f4-9a3b-422c-a796-c251eb4cc39f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per Employee Stock Purchase Plan share issued (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_15ed51eb-906e-437c-ae07-8c79a1009251_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_271d420c-f564-46f9-acda-1220d673d899_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:href="amed-20201231.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_c9ba16ee-0bdb-4e93-a547-e4e31ccc31f1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearDomain_824f62bf-dbb0-4581-ba7b-c155f139bd30_terseLabel_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_label_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_documentation_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain" xlink:href="amed-20201231.xsd#amed_CapYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearDomain" xlink:to="lab_amed_CapYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_872ff56c-3a2f-4849-b775-70aa47b4158c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_d1d2e738-f536-423b-b700-57d8c97d4edb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a95be2da-d5b9-4ba8-8e1c-2a93a4e01ed3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember_ae22eda6-3b13-4f93-b656-5a83cd4a62e7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases [Member]</link:label>
    <link:label id="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember_label_en-US" xlink:label="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held under Capital Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:to="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AssociatedHomecareMember_dee609c8-56dc-4f8a-9daa-b772a27e61e2_terseLabel_en-US" xlink:label="lab_amed_AssociatedHomecareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associated Homecare [Member]</link:label>
    <link:label id="lab_amed_AssociatedHomecareMember_label_en-US" xlink:label="lab_amed_AssociatedHomecareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associated Homecare [Member]</link:label>
    <link:label id="lab_amed_AssociatedHomecareMember_documentation_en-US" xlink:label="lab_amed_AssociatedHomecareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Associated Homecare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssociatedHomecareMember" xlink:href="amed-20201231.xsd#amed_AssociatedHomecareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AssociatedHomecareMember" xlink:to="lab_amed_AssociatedHomecareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_40dda909-641c-415e-b4a0-496de0a420b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7392ed9d-26cc-4223-bd00-0c1acc1ec931_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3654e754-f58e-4979-8af4-c07fc3c691e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_06dad8dd-9e1d-450d-a6a6-ff30cc948719_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_915b0ba5-952a-4d91-a089-9c3e00e5f3a0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_ec288c75-0642-40d5-8b51-6b47099badff_terseLabel_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:href="amed-20201231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProviderReliefFundAdvance_d1a53cd1-66a2-4c92-8603-eccff4399844_terseLabel_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Relief Fund Advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable related to funds received from the government related to COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance" xlink:href="amed-20201231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProviderReliefFundAdvance" xlink:to="lab_amed_ProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_089ea5ca-6e29-4c4a-930d-b3f096ce00cf_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_43dbcd2d-6a96-4828-8558-6463515cea1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited or expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_7fae547d-f365-402a-b9a3-b5eb66056085_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_908b1319-0ac1-4d83-aec5-63a1ac6ba7a6_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred social security taxes (2)</link:label>
    <link:label id="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_label_en-US" xlink:label="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Deferred Social Security Taxes</link:label>
    <link:label id="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred social security taxes which are the result of the novel coronavirus pandemic ("COVID-19").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetDeferredSocialSecurityTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:to="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_93c61535-ef86-4af7-8efc-306c30fa63d6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7e3d8115-b69d-4149-8d46-de3fcea159db_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LegalFeesNetOfIncomeTaxes_1c4b097f-ae3c-48f0-b72e-0a5ebdeb6dd4_terseLabel_en-US" xlink:label="lab_amed_LegalFeesNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal fees, net of income taxes</link:label>
    <link:label id="lab_amed_LegalFeesNetOfIncomeTaxes_label_en-US" xlink:label="lab_amed_LegalFeesNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees, Net Of Income Taxes</link:label>
    <link:label id="lab_amed_LegalFeesNetOfIncomeTaxes_documentation_en-US" xlink:label="lab_amed_LegalFeesNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees, Net Of Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalFeesNetOfIncomeTaxes" xlink:href="amed-20201231.xsd#amed_LegalFeesNetOfIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LegalFeesNetOfIncomeTaxes" xlink:to="lab_amed_LegalFeesNetOfIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_01876e86-3612-402b-a4e3-6c4837cb08b6_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Fairvalueofshareofcommonstockpercentage_feba4685-c86a-497a-a2e7-cfdadc31f2e9_terseLabel_en-US" xlink:label="lab_amed_Fairvalueofshareofcommonstockpercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of share of common stock (percent)</link:label>
    <link:label id="lab_amed_Fairvalueofshareofcommonstockpercentage_label_en-US" xlink:label="lab_amed_Fairvalueofshareofcommonstockpercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fairvalueofshareofcommonstockpercentage</link:label>
    <link:label id="lab_amed_Fairvalueofshareofcommonstockpercentage_documentation_en-US" xlink:label="lab_amed_Fairvalueofshareofcommonstockpercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of a share of common stock, percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Fairvalueofshareofcommonstockpercentage" xlink:href="amed-20201231.xsd#amed_Fairvalueofshareofcommonstockpercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Fairvalueofshareofcommonstockpercentage" xlink:to="lab_amed_Fairvalueofshareofcommonstockpercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_18a707c6-fb9c-4f6a-a545-da21c062215b_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InfinityHomeCareMember_6629eeb1-daca-4e55-b522-9f7d2e644a26_terseLabel_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_label_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_documentation_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember" xlink:href="amed-20201231.xsd#amed_InfinityHomeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InfinityHomeCareMember" xlink:to="lab_amed_InfinityHomeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_ccb531fb-ebd0-41f3-961a-e20a7b114c59_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_b4f0b80c-3f98-4e7c-8586-c2cc4a0b2474_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_dddf0aea-13ab-4260-925f-1df9ec46e53a_terseLabel_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:href="amed-20201231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:to="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent_dc1d3004-a812-43f8-b098-e898c740cea4_terseLabel_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent_label_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Adjustment, Percent</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent_documentation_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit Adjustment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent" xlink:href="amed-20201231.xsd#amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent" xlink:to="lab_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LettersofCreditmaximumcommitment_d3d1c5f3-27a9-4209-8969-1b7482628f84_terseLabel_en-US" xlink:label="lab_amed_LettersofCreditmaximumcommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit, maximum commitment</link:label>
    <link:label id="lab_amed_LettersofCreditmaximumcommitment_label_en-US" xlink:label="lab_amed_LettersofCreditmaximumcommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LettersofCreditmaximumcommitment</link:label>
    <link:label id="lab_amed_LettersofCreditmaximumcommitment_documentation_en-US" xlink:label="lab_amed_LettersofCreditmaximumcommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit, maximum commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LettersofCreditmaximumcommitment" xlink:href="amed-20201231.xsd#amed_LettersofCreditmaximumcommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LettersofCreditmaximumcommitment" xlink:to="lab_amed_LettersofCreditmaximumcommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_591000f3-7cc6-4a15-9f03-e027ff998382_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_8b536f9a-0d59-4665-8c9a-1287047ded2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Long-Term Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_fdcd22a8-680f-4722-bd5f-0cd4aac9f87b_terseLabel_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under term loan</link:label>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_label_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Borrowings Under Term Loan</link:label>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_documentation_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from borrowings under the term loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:href="amed-20201231.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:to="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_b13815d8-88e0-4c24-ae88-c161f2e9733e_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4a20123b-dce6-4404-bd73-865ad738537b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_c2d2c1cc-3c1b-47ca-bd1a-e685e5687135_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_a45fd04a-8571-44fe-9b97-98ed02a34690_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_856797f9-17e2-4905-a0be-b0064fc1f219_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeStaffLlcMember_47dd3f3c-23ae-4328-b234-8dfca4bca4fa_terseLabel_en-US" xlink:label="lab_amed_HomeStaffLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Staff LLC [Member]</link:label>
    <link:label id="lab_amed_HomeStaffLlcMember_label_en-US" xlink:label="lab_amed_HomeStaffLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Staff LLC [Member]</link:label>
    <link:label id="lab_amed_HomeStaffLlcMember_documentation_en-US" xlink:label="lab_amed_HomeStaffLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Staff LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeStaffLlcMember" xlink:href="amed-20201231.xsd#amed_HomeStaffLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeStaffLlcMember" xlink:to="lab_amed_HomeStaffLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_fce1c073-ad9c-41e3-ad35-d39c47f9c156_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5176a19d-771e-48a2-a0b0-5a96233ea4bd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted average contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockUnitsServiceMember_257787ac-14bc-4b9a-be09-2b10b98c7c11_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockUnitsServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Units - Service-Based [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockUnitsServiceMember_label_en-US" xlink:label="lab_amed_NonVestedStockUnitsServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock Units Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockUnitsServiceMember" xlink:to="lab_amed_NonVestedStockUnitsServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a136ad64-a4dc-4684-8b12-9cb60f6fee67_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromJointVenturesCurrent_60681376-b579-4692-be8c-69256f7943d1_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromJointVenturesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from joint ventures</link:label>
    <link:label id="lab_us-gaap_DueFromJointVenturesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromJointVenturesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Joint Ventures, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromJointVenturesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromJointVenturesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromJointVenturesCurrent" xlink:to="lab_us-gaap_DueFromJointVenturesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_520b90bb-a3a6-47b1-9ce0-d0e18a11acb4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NoncontrollingInterestRepurchased_37a8f0a9-bab7-4a7f-bcdf-9b6586926c99_terseLabel_en-US" xlink:label="lab_amed_NoncontrollingInterestRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Repurchased</link:label>
    <link:label id="lab_amed_NoncontrollingInterestRepurchased_label_en-US" xlink:label="lab_amed_NoncontrollingInterestRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Repurchased</link:label>
    <link:label id="lab_amed_NoncontrollingInterestRepurchased_documentation_en-US" xlink:label="lab_amed_NoncontrollingInterestRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestRepurchased" xlink:href="amed-20201231.xsd#amed_NoncontrollingInterestRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NoncontrollingInterestRepurchased" xlink:to="lab_amed_NoncontrollingInterestRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DiscountedClosingStockPrice_173de10d-0bef-42d5-a15c-7f5983eb4675_terseLabel_en-US" xlink:label="lab_amed_DiscountedClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Closing Stock Price</link:label>
    <link:label id="lab_amed_DiscountedClosingStockPrice_label_en-US" xlink:label="lab_amed_DiscountedClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Closing Stock Price</link:label>
    <link:label id="lab_amed_DiscountedClosingStockPrice_documentation_en-US" xlink:label="lab_amed_DiscountedClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Closing Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DiscountedClosingStockPrice" xlink:href="amed-20201231.xsd#amed_DiscountedClosingStockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DiscountedClosingStockPrice" xlink:to="lab_amed_DiscountedClosingStockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_f8db8689-8e44-4f64-b16e-3b7dc6061164_terseLabel_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum additional borrowing capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="amed-20201231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TX_4c1953fa-49cf-4167-b198-8183ee33c7f8_terseLabel_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Texas [Member]</link:label>
    <link:label id="lab_stpr_TX_label_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEXAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_6f25890c-ff4b-4cd2-be17-f6c0ba19f088_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_152f55e1-42be-4cec-9a2e-7433d4fc0226_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_64ef32f7-080a-4b19-a214-c3d722772356_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations:</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d6878635-7ae8-4fa1-ab89-ff1ddf19c4d0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_2e5be08f-4cc6-4f1b-9692-3f829c71ac1d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4e247630-32ad-43f2-a711-d06b312352a7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6f1e54bb-29ed-482d-a147-6fa4f381ca2e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PatientLiability_2a98c5e6-87c2-4958-a65e-92f805bd37d3_terseLabel_en-US" xlink:label="lab_amed_PatientLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient liability</link:label>
    <link:label id="lab_amed_PatientLiability_label_en-US" xlink:label="lab_amed_PatientLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Liability</link:label>
    <link:label id="lab_amed_PatientLiability_documentation_en-US" xlink:label="lab_amed_PatientLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to Patient liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PatientLiability" xlink:href="amed-20201231.xsd#amed_PatientLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PatientLiability" xlink:to="lab_amed_PatientLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TN_013f708a-f8b8-4287-8b23-b9a2ebd90c69_terseLabel_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_label_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN" xlink:to="lab_stpr_TN" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_314f25bc-acd3-4893-9949-5270be604d34_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_890f773e-410e-4872-8282-179400136ce7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnamortizableAcquiredNamesMember_1c0faf52-577e-437e-8c03-73b5417a6fd0_terseLabel_en-US" xlink:label="lab_amed_UnamortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortizable acquired names [Member]</link:label>
    <link:label id="lab_amed_UnamortizableAcquiredNamesMember_label_en-US" xlink:label="lab_amed_UnamortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortizable acquired names [Member]</link:label>
    <link:label id="lab_amed_UnamortizableAcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_UnamortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortizable acquired names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember" xlink:href="amed-20201231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnamortizableAcquiredNamesMember" xlink:to="lab_amed_UnamortizableAcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_ba8010b5-bff3-4017-89c2-fac01bf2840f_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit for indemnification purposes and working capital price adjustments</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_ffc61651-917f-48bc-a296-6b01d2f67777_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_352b71f6-83a9-45c6-8e33-09c9fb20430f_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_79fe4ad3-f2ca-4096-a847-d4310fab24d5_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OrganizationAndNatureOfOperationsLineItems_b3002684-5041-4800-ae58-1eb437095784_terseLabel_en-US" xlink:label="lab_amed_OrganizationAndNatureOfOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Nature Of Operations [Line Items]</link:label>
    <link:label id="lab_amed_OrganizationAndNatureOfOperationsLineItems_label_en-US" xlink:label="lab_amed_OrganizationAndNatureOfOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Nature Of Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsLineItems" xlink:href="amed-20201231.xsd#amed_OrganizationAndNatureOfOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems" xlink:to="lab_amed_OrganizationAndNatureOfOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_e0cd8143-7fd5-42b3-82e5-c66b262e432e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_09409464-b6d4-4e33-94c3-d6d8b77cc85c_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:to="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_19107ef4-0ff8-4e49-8ae5-314236f09313_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the start of period of care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Start Of Period of Care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:href="amed-20201231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4513dc32-040b-4506-978b-cf5661eef692_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_7f2bfbaa-49b2-47c8-abc1-d3b1c41e92aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys Inc.</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f2d6a03d-8f0d-45b9-a551-ef63d79b1b82_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_f8045293-b0ee-40a7-ae25-595d2d13b0f8_terseLabel_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs, weighted average amortization period, years</link:label>
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_label_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Cost Amortization Period</link:label>
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_documentation_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization period of debt issuance cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:href="amed-20201231.xsd#amed_UnamortizedDebtIssuanceCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:to="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_de8abe22-bf3b-470d-84e5-8f730604c47c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitment Fee Under Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedMedicareCapLiability_48067b8e-fe60-41de-8631-c35ef2fc70f9_terseLabel_en-US" xlink:label="lab_amed_EstimatedMedicareCapLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Medicare cap liability</link:label>
    <link:label id="lab_amed_EstimatedMedicareCapLiability_label_en-US" xlink:label="lab_amed_EstimatedMedicareCapLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Medicare Cap Liability</link:label>
    <link:label id="lab_amed_EstimatedMedicareCapLiability_documentation_en-US" xlink:label="lab_amed_EstimatedMedicareCapLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to the estimated Medicare CAP liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedMedicareCapLiability" xlink:href="amed-20201231.xsd#amed_EstimatedMedicareCapLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedMedicareCapLiability" xlink:to="lab_amed_EstimatedMedicareCapLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b738183d-74a0-405b-a244-f18845a1ac47_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_1e0907a3-c53c-4615-9cbe-e0b1eb79eee2_terseLabel_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time goodwill is expected to be deductible for income tax purposes</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_label_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Deductible For Income Tax Purposes, Period</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_documentation_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Deductible For Income Tax Purposes, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:href="amed-20201231.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:to="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4f17daec-2fa7-420c-b981-a5d4710a4b77_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased, weighted average price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4f672712-6a17-40a5-a701-bde9b58ae07e_negatedTerseLabel_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact Of Write Off Of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact Of Write Off Of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:href="amed-20201231.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_33768147-99a7-4c9d-a741-315dd6c27153_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_9f94df5e-e718-4344-b6c6-1c995789b5f1_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions, AseraCare Hospice</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions AseraCare Hospice [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:href="amed-20201231.xsd#amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7c9fbe06-1ba2-48b2-a8f4-ef5c7d4d37c4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_69e9e540-4d4b-4848-83af-c5d5c12d329c_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_e7cf4653-45a1-4389-a4ed-df6b2b0544f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_81327b2f-9679-4bfd-b611-c921ba9dfe63_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_bde86ad9-22ed-41eb-867a-c206948e0505_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0d575aaa-c9a3-41b0-89ea-4ed056584edc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_92c88efe-6ae5-49aa-a95c-391fc01d27bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_db90999d-8683-4532-ac45-e3e187f2220b_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2021StockRepurchaseProgramMember_dba7580b-6f4b-4ecc-81ac-13bfb01c7ed0_terseLabel_en-US" xlink:label="lab_amed_A2021StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2021StockRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2021StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2021StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2021StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Stock Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021StockRepurchaseProgramMember" xlink:href="amed-20201231.xsd#amed_A2021StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2021StockRepurchaseProgramMember" xlink:to="lab_amed_A2021StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_d4d4289f-ba62-49ca-8158-803e5d7953dc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinanceLeasesTableTextBlock_2e6ca4c9-d8cd-423c-b196-d6ddcb486d1c_terseLabel_en-US" xlink:label="lab_amed_FinanceLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finance Leases</link:label>
    <link:label id="lab_amed_FinanceLeasesTableTextBlock_label_en-US" xlink:label="lab_amed_FinanceLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases [Table Text Block]</link:label>
    <link:label id="lab_amed_FinanceLeasesTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinanceLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinanceLeasesTableTextBlock" xlink:href="amed-20201231.xsd#amed_FinanceLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinanceLeasesTableTextBlock" xlink:to="lab_amed_FinanceLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_bcbae8a0-5116-4da4-ac6a-91410b879dec_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5920e233-d6b9-447d-bab9-a0becde03b6e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f633ce46-fadf-4625-b115-d46ea791eea1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_babad497-813d-4683-8e49-a813caad09f4_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TenetHealthcareMember_3a7d0ce0-71a9-4095-94f3-bd7835461b69_terseLabel_en-US" xlink:label="lab_amed_TenetHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenet Healthcare [Member]</link:label>
    <link:label id="lab_amed_TenetHealthcareMember_label_en-US" xlink:label="lab_amed_TenetHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenet Healthcare [Member]</link:label>
    <link:label id="lab_amed_TenetHealthcareMember_documentation_en-US" xlink:label="lab_amed_TenetHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenet Healthcare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TenetHealthcareMember" xlink:href="amed-20201231.xsd#amed_TenetHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TenetHealthcareMember" xlink:to="lab_amed_TenetHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8dc5f1a1-ada0-4492-bddd-4d6bab4f65b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_f8bc1d15-bb44-439b-ac6e-21159cdbfcdd_terseLabel_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable related to amounts withheld prior to August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_label_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_documentation_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:href="amed-20201231.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:to="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_bb737023-a93c-49e5-be99-59e45dfb5d67_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_895cd18f-c1ef-4eff-b412-cd31cd8d1649_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illinois [Member]</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_1b9a828e-5a69-4521-9e5f-5fd0c3aa2266_terseLabel_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revolving credit facility</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_label_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal" xlink:href="amed-20201231.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevolvingCreditFacilityTotal" xlink:to="lab_amed_RevolvingCreditFacilityTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedMember_f4443909-1a21-43a1-9707-e2a566400ff0_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember" xlink:href="amed-20201231.xsd#amed_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedMember" xlink:to="lab_amed_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_11e81c7f-71d4-4d80-85b1-cf6d2ca0af39_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan expense</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5d1670da-bcb5-4d93-b52f-2a07ada8b275_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedalogixMember_2fe1600d-6c5e-43f9-ab50-fc2b488da517_terseLabel_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix</link:label>
    <link:label id="lab_amed_MedalogixMember_label_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_documentation_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember" xlink:href="amed-20201231.xsd#amed_MedalogixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedalogixMember" xlink:to="lab_amed_MedalogixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4e59efe9-c3be-4d20-863a-c0ac31681686_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_714a4012-5cb3-4de8-8a09-4a22c2beeb92_terseLabel_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_label_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_documentation_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember" xlink:href="amed-20201231.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternalAuditComplianceReviewMember" xlink:to="lab_amed_InternalAuditComplianceReviewMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e97363eb-dc2a-44da-82de-8e68ffedc6bd_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_b35acb18-5d68-4149-a72c-3a3a17ff7672_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by noncontrolling owners (percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsLeaseLiability_10736ef3-3abd-4089-9186-d59a6c499a6a_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLeaseLiability" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsLeaseLiability" xlink:to="lab_amed_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_0af4132c-6dfb-4212-b5a4-c2e543ccee0a_terseLabel_en-US" xlink:label="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Awards to More Than Ten Percent Owner [Member]</link:label>
    <link:label id="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_label_en-US" xlink:label="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Awards To More Than Ten Percent Owner [Member]</link:label>
    <link:label id="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_documentation_en-US" xlink:label="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards to any owner of 10% or more of our total combined voting power of us and our subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:href="amed-20201231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:to="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsurance_17fb7ded-63b7-4761-b01e-8ae00b9a5bd0_terseLabel_en-US" xlink:label="lab_amed_HealthInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance</link:label>
    <link:label id="lab_amed_HealthInsurance_label_en-US" xlink:label="lab_amed_HealthInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance</link:label>
    <link:label id="lab_amed_HealthInsurance_documentation_en-US" xlink:label="lab_amed_HealthInsurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance, estimated liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsurance" xlink:href="amed-20201231.xsd#amed_HealthInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsurance" xlink:to="lab_amed_HealthInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_445e324d-0a9d-4d24-8c28-d108a80098a8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense weighted-average period for recognitions (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0af17d20-9418-4e0d-84c9-834a421cf4c6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LegalAndOtherSettlements_fe72b175-a76f-4636-b502-df5de1256711_terseLabel_en-US" xlink:label="lab_amed_LegalAndOtherSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and other audits</link:label>
    <link:label id="lab_amed_LegalAndOtherSettlements_label_en-US" xlink:label="lab_amed_LegalAndOtherSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Other Settlements</link:label>
    <link:label id="lab_amed_LegalAndOtherSettlements_documentation_en-US" xlink:label="lab_amed_LegalAndOtherSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to legal and other settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalAndOtherSettlements" xlink:href="amed-20201231.xsd#amed_LegalAndOtherSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LegalAndOtherSettlements" xlink:to="lab_amed_LegalAndOtherSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificatesOfNeedAndLicensesMember_aad4b041-a0f7-470e-952c-4a61cce1588f_terseLabel_en-US" xlink:label="lab_amed_CertificatesOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Need and Licenses [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedAndLicensesMember_label_en-US" xlink:label="lab_amed_CertificatesOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need And Licenses [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedAndLicensesMember_documentation_en-US" xlink:label="lab_amed_CertificatesOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need And Licenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificatesOfNeedAndLicensesMember" xlink:to="lab_amed_CertificatesOfNeedAndLicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_de058b4d-11d5-48ed-9367-b920792470f5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LakelandFloridaMember_1cc0f04d-3f24-430a-b239-f2085081b989_terseLabel_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_label_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_documentation_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember" xlink:href="amed-20201231.xsd#amed_LakelandFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LakelandFloridaMember" xlink:to="lab_amed_LakelandFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_06e54f56-9360-4009-bde7-91472ac1b18b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ac53ae0-e7f4-460a-971b-d932a46f57e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_39a8e356-65e6-42b2-88c4-c377aa568c50_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_8c09d260-b1cf-4f95-81b3-5467c684a126_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frequency of periodic payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c1c532c6-9d10-422e-93fc-04edfdf40df7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_bca4ec5e-d5a0-4914-9d20-fb72686cfd73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unaudited Summarized Quarterly Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_d7c73253-2392-4fee-a653-abfa69879d5a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Business Segments [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_dea60f0e-31d1-4db5-b43b-0111d62ee228_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_187ef840-96aa-4bf0-8530-0a15359de50a_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f149b443-bacc-4631-b97b-f0e4a5a6c9a6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_a9bbe58b-0eb6-408e-8325-fba0e8ac21e5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_76d50758-9238-4758-a391-ba07660d86f1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_0f7fcf81-b47b-4a6c-9f95-1948d03b31a1_terseLabel_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future COVID19 Related Expenses</link:label>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_label_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future COVID19 Related Expenses</link:label>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_documentation_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated expenses as a result of the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:href="amed-20201231.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:to="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_81593811-cce1-4faf-8a61-4174ede03b92_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_53dbcf68-feac-4520-a7d8-ab066fcb428e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedSharesInShares_04eebf99-ff39-4c7a-bdb0-6f626e427af5_terseLabel_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares In Shares</link:label>
    <link:label id="lab_amed_SurrenderedSharesInShares_label_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares In Shares</link:label>
    <link:label id="lab_amed_SurrenderedSharesInShares_documentation_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares In Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares" xlink:href="amed-20201231.xsd#amed_SurrenderedSharesInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedSharesInShares" xlink:to="lab_amed_SurrenderedSharesInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TaxCreditCarryforwardMember_195ccefb-1f56-46b6-ada3-b9e3d76b7650_terseLabel_en-US" xlink:label="lab_amed_TaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_amed_TaxCreditCarryforwardMember_label_en-US" xlink:label="lab_amed_TaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_amed_TaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_amed_TaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCreditCarryforwardMember" xlink:href="amed-20201231.xsd#amed_TaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TaxCreditCarryforwardMember" xlink:to="lab_amed_TaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EpisodesInProgressThatBeginDuringReportingPeriod_f261390e-575f-40b0-a176-1ab75e32c55c_terseLabel_en-US" xlink:label="lab_amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episodes in progress that begin during reporting period, days</link:label>
    <link:label id="lab_amed_EpisodesInProgressThatBeginDuringReportingPeriod_label_en-US" xlink:label="lab_amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episodes In Progress That Begin During Reporting Period</link:label>
    <link:label id="lab_amed_EpisodesInProgressThatBeginDuringReportingPeriod_documentation_en-US" xlink:label="lab_amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in an episode of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:href="amed-20201231.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:to="lab_amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_bc39c6db-0c34-4554-a64e-3b03aadcfbb6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_52d01563-92f0-4d59-a50f-04feebd1aa7c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_61c03b91-ddc6-4b00-9611-3fdb62644a9e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_274fc970-65fe-43dc-970a-8789060966f2_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_cbfb75ff-3221-46e4-980c-8dfec432a849_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_6fda2604-183c-48c2-85b4-042fb19916c9_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Liability</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="amed-20201231.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_dba20c7b-2a9f-4f88-b437-7dd97ddff55b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiability_45de2428-cbc2-4bd1-960e-7a89281ec017_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability</link:label>
    <link:label id="lab_amed_ProfessionalLiability_label_en-US" xlink:label="lab_amed_ProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability</link:label>
    <link:label id="lab_amed_ProfessionalLiability_documentation_en-US" xlink:label="lab_amed_ProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance, estimated liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiability" xlink:href="amed-20201231.xsd#amed_ProfessionalLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiability" xlink:to="lab_amed_ProfessionalLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_981e4ac7-f849-40b1-aa7c-395edae78925_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_87beacb5-4ec2-4759-8e2f-bd570284d0e1_terseLabel_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amounts due back to Medicare</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_label_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:href="amed-20201231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:to="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PersonalCareMember_b5ce9514-efa2-42aa-afb0-7622383c9f5c_terseLabel_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_label_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_documentation_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PersonalCareMember" xlink:to="lab_amed_PersonalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cd810775-4f41-4ae3-b077-571308754db5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_77fcfac4-a69b-4437-a862-25c2e98917d0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_fa5376fb-d28b-47f0-8362-56430db40100_terseLabel_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_label_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember" xlink:href="amed-20201231.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ParkersburgWestVirginiaMember" xlink:to="lab_amed_ParkersburgWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_bb00a0cd-87e9-404c-b1ed-6e5bc0c86f22_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_aa719eaf-7768-4f1e-81e2-8e2c7cc21b9e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_80fb54f5-f6ed-4f69-973d-1cd6a8da1073_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill deductible for income tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_e6007597-4703-4811-bb37-1aecbf76dd26_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized share-based compensation tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassDomain_a149ef9e-3fd2-4788-be55-776d8c472e84_terseLabel_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_label_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_documentation_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain" xlink:href="amed-20201231.xsd#amed_PayorClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassDomain" xlink:to="lab_amed_PayorClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_42f27533-1128-4950-91c2-f3873ae8160f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6e962005-0e32-48fc-8c01-d25f3b866747_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_23c17a1b-bba5-4505-b97b-98d59064c0ed_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_295b761e-9d7f-4849-8df1-612e95b938d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4ec4fb69-48f6-415d-a2b4-60c4876298ef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b5864d66-ed73-4998-9bd2-1998b945eab7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Sources of Tax Effects</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c546006a-86ee-4216-983b-e36ec42889fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_83d65688-7e67-4de6-ab74-9aace73c0feb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax deficit from stock options exercised and restricted stock vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_23f928fc-3346-4c21-9c8f-2e0c6c590e99_terseLabel_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Liability Maturity</link:label>
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability Maturity [Table Text Block]</link:label>
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_documentation_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability Maturity Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseLiabilityMaturityTableTextBlock" xlink:href="amed-20201231.xsd#amed_LeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LeaseLiabilityMaturityTableTextBlock" xlink:to="lab_amed_LeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_bb987beb-64d3-4395-8e1d-e494b631b37d_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts [Member]</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1c309721-d254-46c0-92dc-911c3d748285_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_0d0351bd-cad1-4abf-8d9e-a91736196ee2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b07b2544-0983-425e-a790-7c8b8a681b98_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WorkersCompensationLiabilityCurrent_7d7c1487-6a7a-46ee-b411-3b5407c60aed_terseLabel_en-US" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_us-gaap_WorkersCompensationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMember_c688e823-238a-4509-99f1-4130363e1366_terseLabel_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_label_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_documentation_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMember" xlink:to="lab_amed_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceDeposits_005cf906-52df-432e-9ebe-b26dfb2a2fc5_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance deposits</link:label>
    <link:label id="lab_amed_HealthInsuranceDeposits_label_en-US" xlink:label="lab_amed_HealthInsuranceDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Deposits</link:label>
    <link:label id="lab_amed_HealthInsuranceDeposits_documentation_en-US" xlink:label="lab_amed_HealthInsuranceDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceDeposits" xlink:href="amed-20201231.xsd#amed_HealthInsuranceDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceDeposits" xlink:to="lab_amed_HealthInsuranceDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_0dc94aaa-a3cc-4c37-bf75-7d30959b117c_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Financial Information, AseraCare</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_label_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information, AseraCare [Table Text Block]</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of pro forma results of operations for a the AseraCare acquisition .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:to="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9b92046b-2dd3-4b66-a1cb-df41c343ca3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_015966a1-a0da-4def-9386-675752255422_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock options beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_e43d6b3d-5ad6-4255-a8be-27be60940597_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock options ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_1b55cad0-c4fc-4a33-89bf-274ed3dd7453_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_79b3177b-81d0-4602-ad3e-c73eddac5bea_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_bd61ab57-3dfc-4cc6-a554-397621ef00f5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_f7a484af-3d81-4b0f-90dd-b02fe2452245_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_17fef369-d5ac-4686-9998-d1be52b4eab0_negatedTerseLabel_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Amortization of Intangible Assets</link:label>
    <link:label id="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_documentation_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from amortization of intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:href="amed-20201231.xsd#amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:to="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_f3d582cf-d898-4f5e-88ba-33277a76cdcb_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ac8dd846-9fe3-4e07-94e7-effca2ef5b6d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2e094d03-82b0-47f2-aa53-c5a703872510_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_74c862ec-fb1f-4582-ab53-b3e9e5c76e2e_terseLabel_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_label_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:label id="lab_amed_HealthcareanalyticscompanyMember_documentation_en-US" xlink:label="lab_amed_HealthcareanalyticscompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare analytics company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthcareanalyticscompanyMember" xlink:href="amed-20201231.xsd#amed_HealthcareanalyticscompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthcareanalyticscompanyMember" xlink:to="lab_amed_HealthcareanalyticscompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ActualClaimsPayment_fe74a144-6666-47aa-a38c-92473aa02105_terseLabel_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual claims payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_label_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_documentation_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment" xlink:href="amed-20201231.xsd#amed_ActualClaimsPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ActualClaimsPayment" xlink:to="lab_amed_ActualClaimsPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_492926ec-6e89-40d7-94bb-b615998f09c4_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2014 Through 2021 [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Fourteen Through Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Fourteen Through Two Thousand Twenty One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:href="amed-20201231.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:to="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_5db2f0f6-d74e-4260-9cd9-b0f7ca14a9ac_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_f0453434-e597-4448-916d-0450a1330700_verboseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_fb84d500-fb08-4fe6-a835-44b274cd5b8f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_6db83aee-a65f-4fee-8656-6d3e7c1befda_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_16c57947-b446-4c7e-9385-1ab987b37322_terseLabel_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible executive compensation</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_label_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_documentation_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:href="amed-20201231.xsd#amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:to="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_KY_e1f7e08d-d46c-4b5d-843d-ce1a85ce3d13_terseLabel_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:label id="lab_stpr_KY_label_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_KY" xlink:to="lab_stpr_KY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_f9eb9b43-a8c4-4232-9e3a-9b5df4f0e50e_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PromissoryNotesMember_ba2b360b-24a0-4546-b809-001f657316f8_terseLabel_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_label_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_documentation_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember" xlink:href="amed-20201231.xsd#amed_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PromissoryNotesMember" xlink:to="lab_amed_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetOperatingLossMember_585bfd7d-3238-48c2-b1f7-2c888e71eb5e_terseLabel_en-US" xlink:label="lab_amed_NetOperatingLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss [Member]</link:label>
    <link:label id="lab_amed_NetOperatingLossMember_label_en-US" xlink:label="lab_amed_NetOperatingLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss [Member]</link:label>
    <link:label id="lab_amed_NetOperatingLossMember_documentation_en-US" xlink:label="lab_amed_NetOperatingLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetOperatingLossMember" xlink:href="amed-20201231.xsd#amed_NetOperatingLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetOperatingLossMember" xlink:to="lab_amed_NetOperatingLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_80ee96e6-9493-4914-a6ef-04e955b39e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_01923b90-5367-40b2-824e-48b02e9393ad_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_6b077d5a-be4e-49e6-bdc9-0e4ace0880d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_595e7d86-e37c-4212-8c52-82c6595c182d_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2afc57ec-a327-40f7-afb1-7dd45db370b8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4042ee39-4a23-41d4-a67b-b849759f7422_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_da8a3443-6c34-4901-aa31-a0e0354bd657_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_17d1dcef-f19e-4b1c-b4cf-9876d45856ac_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ChristianCareatHomeMember_9fb066d6-c65d-4c0e-acfd-f92a57c93cc3_terseLabel_en-US" xlink:label="lab_amed_ChristianCareatHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christian Care at Home [Member]</link:label>
    <link:label id="lab_amed_ChristianCareatHomeMember_label_en-US" xlink:label="lab_amed_ChristianCareatHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christian Care at Home [Member]</link:label>
    <link:label id="lab_amed_ChristianCareatHomeMember_documentation_en-US" xlink:label="lab_amed_ChristianCareatHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christian Care at Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ChristianCareatHomeMember" xlink:href="amed-20201231.xsd#amed_ChristianCareatHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ChristianCareatHomeMember" xlink:to="lab_amed_ChristianCareatHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_95bcb14c-d6ed-43c9-8623-6c92fd38b910_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5faebf72-9e6a-4b4f-862f-9cb52ae5314c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_38a094a1-afab-4bb2-9ad8-0c685f79ce43_terseLabel_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_label_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_documentation_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:href="amed-20201231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:to="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_5c5ca3f8-e03c-40c1-a279-28ef24edecf1_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtrapolatedMember_221ef698-f539-44c1-b992-9ce47606b128_terseLabel_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_label_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_documentation_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember" xlink:href="amed-20201231.xsd#amed_ExtrapolatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtrapolatedMember" xlink:to="lab_amed_ExtrapolatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IndemnificationAmount_6d0aa523-3ddc-4776-85cd-be63fc2b0bd1_terseLabel_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_label_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_documentation_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount to be reimbursed if and when certain assumed liabilities are paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount" xlink:href="amed-20201231.xsd#amed_IndemnificationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IndemnificationAmount" xlink:to="lab_amed_IndemnificationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1df9a2da-6bde-442b-a045-8e3532817f0f_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMedicareMember_aa80562c-0d5b-42a2-b93a-0c8e142a6d5e_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_label_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember" xlink:href="amed-20201231.xsd#amed_HomeHealthMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMedicareMember" xlink:to="lab_amed_HomeHealthMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_e2a8ef94-4357-433a-acb2-de6d3e3138a9_terseLabel_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for debt issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:href="amed-20201231.xsd#amed_DebtIssuanceCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:to="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance_e0220d5e-6752-4b2e-b4a0-681f54a1aa69_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance (1)</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Provider Relief Fund Advance</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the Provider Relief Fund Advance set up as a result of the novel coronavirus pandemic ("COVID-19").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:to="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_01db8d41-27a6-49ca-8850-38844e2f8e54_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2e421618-c318-4cc2-898b-ab9ec5d07204_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_AZ_cf2f73b1-0cd5-45c1-b4e0-371978ee681f_terseLabel_en-US" xlink:label="lab_stpr_AZ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arizona [Member]</link:label>
    <link:label id="lab_stpr_AZ_label_en-US" xlink:label="lab_stpr_AZ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARIZONA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AZ" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_AZ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_AZ" xlink:to="lab_stpr_AZ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a0ebf67e-8602-4853-aeb6-bb0c688eecb0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e1953a13-32aa-432e-be5b-9461c32b25a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_ee86a77d-875f-484a-966d-739484f23a58_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount_80a78631-8f88-432a-8d88-dcabfa0efadc_terseLabel_en-US" xlink:label="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Performance Based Award Target share Amount</link:label>
    <link:label id="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount_label_en-US" xlink:label="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Performance Based Award Target share Amount</link:label>
    <link:label id="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount_documentation_en-US" xlink:label="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional stock units authorized for achievement of targeted performance if target objective is surpassed to the point of achieving the projected maximum payout</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:href="amed-20201231.xsd#amed_AdditionalPerformanceBasedAwardTargetShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:to="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6dabeddd-6ce4-4d29-a6ab-2a355fa4e455_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseDomain_9f2d030c-39eb-4683-9f21-3344d8a76cdb_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Domain]</link:label>
    <link:label id="lab_amed_ShareRepurchaseDomain_label_en-US" xlink:label="lab_amed_ShareRepurchaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Domain]</link:label>
    <link:label id="lab_amed_ShareRepurchaseDomain_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Share Repurchase [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseDomain" xlink:to="lab_amed_ShareRepurchaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_d22901d8-7372-44b0-ae5e-b7809f4e9a45_terseLabel_en-US" xlink:label="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value</link:label>
    <link:label id="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_label_en-US" xlink:label="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value</link:label>
    <link:label id="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_documentation_en-US" xlink:label="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The calculated fair value of a stock-based compensation award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:href="amed-20201231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:to="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_3eaf74d2-babf-4f1d-8d76-cc279f3857f8_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_193a4095-5975-43e6-a8ae-fd4b625370d1_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_b4b263f5-fb9d-483e-a942-482412a77089_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for equity method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Equity Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:href="amed-20201231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_5a524178-82ab-4e73-9bf9-dd499d8f5ac7_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock options beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4f21e5b8-fb92-4308-8214-92f673106ce2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock options ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BringCareHomeMember_a610d958-abf4-4720-9ed3-45694a1cc2ad_terseLabel_en-US" xlink:label="lab_amed_BringCareHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bring Care Home [Member]</link:label>
    <link:label id="lab_amed_BringCareHomeMember_label_en-US" xlink:label="lab_amed_BringCareHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bring Care Home [Member]</link:label>
    <link:label id="lab_amed_BringCareHomeMember_documentation_en-US" xlink:label="lab_amed_BringCareHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bring Care Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BringCareHomeMember" xlink:href="amed-20201231.xsd#amed_BringCareHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BringCareHomeMember" xlink:to="lab_amed_BringCareHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b6fe6763-64f5-41eb-a060-a7c5e8bcedab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_a3499321-fec8-469e-bfd2-840feb5aabda_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceNonMedicareMember_0f0ad9e3-1e76-4fcf-b747-e205953d1f95_terseLabel_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_label_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember" xlink:href="amed-20201231.xsd#amed_HospiceNonMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceNonMedicareMember" xlink:to="lab_amed_HospiceNonMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_492ccb64-73f6-4d71-a8d6-bc460f171f3a_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8e346c7e-84bb-446f-9842-e738f1d9b928_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_013c0dcc-b595-4a53-8180-dd944ed76255_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RefundTaxYear_f375d849-2f89-45b7-b90e-c46b4de650c1_terseLabel_en-US" xlink:label="lab_amed_RefundTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund tax year</link:label>
    <link:label id="lab_amed_RefundTaxYear_label_en-US" xlink:label="lab_amed_RefundTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund Tax Year</link:label>
    <link:label id="lab_amed_RefundTaxYear_documentation_en-US" xlink:label="lab_amed_RefundTaxYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RefundTaxYear" xlink:href="amed-20201231.xsd#amed_RefundTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RefundTaxYear" xlink:to="lab_amed_RefundTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceMember_899de701-21ff-43cd-8c78-4a0fd0323dd6_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_label_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember" xlink:href="amed-20201231.xsd#amed_AsanaHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceMember" xlink:to="lab_amed_AsanaHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_83b75799-8240-48e7-a395-2902df0e9534_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:to="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes_f3151c14-5d25-4443-b089-79d9cd537d93_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction-related expenses for acquisitions, net of income taxes</link:label>
    <link:label id="lab_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes_label_en-US" xlink:label="lab_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs, Net Of Income Taxes</link:label>
    <link:label id="lab_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs, Net Of Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes" xlink:to="lab_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_9a88489d-2558-4610-8cb9-96a7126dfaf4_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_581b19b8-e1cf-4b81-bcc4-6b5a597e42a0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_16643ff4-f736-4ebc-8184-3db17a58f744_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EmploymentTaxCreditMember_39008f54-9a4c-463a-9396-a427fa8e64dc_terseLabel_en-US" xlink:label="lab_amed_EmploymentTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Tax Credit [Member]</link:label>
    <link:label id="lab_amed_EmploymentTaxCreditMember_label_en-US" xlink:label="lab_amed_EmploymentTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Tax Credit [Member]</link:label>
    <link:label id="lab_amed_EmploymentTaxCreditMember_documentation_en-US" xlink:label="lab_amed_EmploymentTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Tax Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EmploymentTaxCreditMember" xlink:href="amed-20201231.xsd#amed_EmploymentTaxCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EmploymentTaxCreditMember" xlink:to="lab_amed_EmploymentTaxCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9287bbf3-fe01-49fa-8c1b-baa295086636_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_06beeaa6-8b5d-4c4f-b795-9154384c9fc5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7aca0482-c77e-49d8-a1d3-b458f30ab0dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a2811876-a0dd-41cb-9a0c-2f728021c66b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_86fcd05f-5fd5-4ecf-9451-a0a234eb4b8f_terseLabel_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding For Healthcare Providers Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_label_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding For Healthcare Providers Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_documentation_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:href="amed-20201231.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:to="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_0f190623-dc0f-4a17-ab99-50540f1ae7ad_terseLabel_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:href="amed-20201231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:to="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_df3e91dd-3f32-4c98-9180-d95cb0d00e78_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_39cc6bb9-b12c-42e1-a1b3-f41671d4f3b5_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OtherMiscellaneousDeposits_d4dfa915-a278-4306-83a1-3b20a3ccb8b8_terseLabel_en-US" xlink:label="lab_amed_OtherMiscellaneousDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other miscellaneous deposits</link:label>
    <link:label id="lab_amed_OtherMiscellaneousDeposits_label_en-US" xlink:label="lab_amed_OtherMiscellaneousDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Deposits</link:label>
    <link:label id="lab_amed_OtherMiscellaneousDeposits_documentation_en-US" xlink:label="lab_amed_OtherMiscellaneousDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherMiscellaneousDeposits" xlink:href="amed-20201231.xsd#amed_OtherMiscellaneousDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OtherMiscellaneousDeposits" xlink:to="lab_amed_OtherMiscellaneousDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_def53911-57da-4141-b9fe-361b9161e622_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:href="amed-20201231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_c4503ac5-4685-41db-bfc5-70c4f1f87fb4_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue episode payment rate</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Episode Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:href="amed-20201231.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_94b5b620-90e0-49d2-baad-188dac01da2c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquipmentAndFurnitureMember_3d2a2d75-a6db-4122-9b4a-b3d7ca68628f_terseLabel_en-US" xlink:label="lab_amed_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and Furniture [Member]</link:label>
    <link:label id="lab_amed_EquipmentAndFurnitureMember_label_en-US" xlink:label="lab_amed_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment And Furniture [Member]</link:label>
    <link:label id="lab_amed_EquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_amed_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment And Furniture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember" xlink:href="amed-20201231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquipmentAndFurnitureMember" xlink:to="lab_amed_EquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_367a7249-1ab8-4bf5-abc5-f921e1a6b76d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_bd7710b5-1afc-4f87-8ced-587ca3a8b5cc_negatedTerseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_327b6918-ea6a-418a-97d5-ef146219dc09_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock option exercise</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_790bb17d-1d37-47af-a893-7a0c0d802717_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense/(benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAssumed1_a3791e63-5e80-4b91-90af-929bff6b8070_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable issued for software licenses</link:label>
    <link:label id="lab_us-gaap_NotesAssumed1_label_en-US" xlink:label="lab_us-gaap_NotesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAssumed1" xlink:to="lab_us-gaap_NotesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1bb7aaab-6c4f-4ebf-ab35-35c9ff8bf463_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5dcc5192-ad4f-48f7-a35a-939ff43d05ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5d08e977-5342-4e83-b7c2-270869bd7487_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense/(benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19ExpensesIncurred_81125072-e89a-4ecb-9a20-75eead7c1172_terseLabel_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID19 Expenses Incurred</link:label>
    <link:label id="lab_amed_COVID19ExpensesIncurred_label_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID19 Expenses Incurred</link:label>
    <link:label id="lab_amed_COVID19ExpensesIncurred_documentation_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred as a result of the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred" xlink:href="amed-20201231.xsd#amed_COVID19ExpensesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19ExpensesIncurred" xlink:to="lab_amed_COVID19ExpensesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_7803135f-ab67-46d2-b6c0-205d04809b04_terseLabel_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_label_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_documentation_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:href="amed-20201231.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:to="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Performancebasedawardtargetshareamount_d7b9ff00-11dc-4725-aef3-34669eb1cef2_terseLabel_en-US" xlink:label="lab_amed_Performancebasedawardtargetshareamount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based award, target number of units to be received (shares)</link:label>
    <link:label id="lab_amed_Performancebasedawardtargetshareamount_label_en-US" xlink:label="lab_amed_Performancebasedawardtargetshareamount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Award Target Share Amount</link:label>
    <link:label id="lab_amed_Performancebasedawardtargetshareamount_documentation_en-US" xlink:label="lab_amed_Performancebasedawardtargetshareamount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock units authorized for achievement of targeted performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Performancebasedawardtargetshareamount" xlink:href="amed-20201231.xsd#amed_Performancebasedawardtargetshareamount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Performancebasedawardtargetshareamount" xlink:to="lab_amed_Performancebasedawardtargetshareamount" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_a7e027cf-209f-4e0e-bc08-22e256497688_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida [Member]</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2019StockRepurchaseProgramMember_62205c24-2c20-4765-aa65-e1a0ce248b50_terseLabel_en-US" xlink:label="lab_amed_A2019StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2019StockRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2019StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2019StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2019StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019StockRepurchaseProgramMember" xlink:href="amed-20201231.xsd#amed_A2019StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2019StockRepurchaseProgramMember" xlink:to="lab_amed_A2019StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0d023862-c0b6-48e9-82b0-85686225ecf9_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_6c6c7ef1-08fa-4952-b874-5177ab7a5f9a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ba88a9fb-66c5-4e8e-9022-5fbc24c220cd_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_26d6c22b-e673-4aa7-a5f5-16cbda37346d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders - basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceMember_dc362f3f-a0ba-4545-9990-b3aa3b0caec5_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember" xlink:href="amed-20201231.xsd#amed_CompassionateCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceMember" xlink:to="lab_amed_CompassionateCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingLeasesTableTextBlock_07603881-8c57-466c-b755-adce65ed8d6b_terseLabel_en-US" xlink:label="lab_amed_OperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases</link:label>
    <link:label id="lab_amed_OperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_amed_OperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases [Table Text Block]</link:label>
    <link:label id="lab_amed_OperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_amed_OperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeasesTableTextBlock" xlink:href="amed-20201231.xsd#amed_OperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingLeasesTableTextBlock" xlink:to="lab_amed_OperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_517a4b79-ace8-4ee4-a282-d5f2f607fdaa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dfe94326-3cc7-4002-8289-c1a4cbf9a851_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_da2558bc-d88e-45a3-b559-ca7d2d6584ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDomain_e15995c6-2e3e-4802-901d-01170f2be5d5_terseLabel_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Domain]</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDomain_label_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Domain]</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDomain_documentation_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDomain" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain" xlink:to="lab_amed_UnrecognizedTaxBenefitsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_d1fa7f18-79fd-439f-a8c5-b680d7ca8ebe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,470,212 and 36,638,021 shares issued; and 32,814,278 and 32,284,051 shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfIndividualStatesSubjectToIncomeTax_fd35c602-ad0f-49d6-9c8e-5ecb37aa3a4b_terseLabel_en-US" xlink:label="lab_amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual states subject to income taxes</link:label>
    <link:label id="lab_amed_NumberOfIndividualStatesSubjectToIncomeTax_label_en-US" xlink:label="lab_amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Individual States Subject To Income Tax</link:label>
    <link:label id="lab_amed_NumberOfIndividualStatesSubjectToIncomeTax_documentation_en-US" xlink:label="lab_amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual states subject to income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:href="amed-20201231.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:to="lab_amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AssetImpairmentChargesNetOfIncomeTaxes_681f06e1-c5d4-4a49-9b9e-189982172030_terseLabel_en-US" xlink:label="lab_amed_AssetImpairmentChargesNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charge, net of income taxes</link:label>
    <link:label id="lab_amed_AssetImpairmentChargesNetOfIncomeTaxes_label_en-US" xlink:label="lab_amed_AssetImpairmentChargesNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges, Net Of Income Taxes</link:label>
    <link:label id="lab_amed_AssetImpairmentChargesNetOfIncomeTaxes_documentation_en-US" xlink:label="lab_amed_AssetImpairmentChargesNetOfIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges, Net Of Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssetImpairmentChargesNetOfIncomeTaxes" xlink:href="amed-20201231.xsd#amed_AssetImpairmentChargesNetOfIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AssetImpairmentChargesNetOfIncomeTaxes" xlink:to="lab_amed_AssetImpairmentChargesNetOfIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d9440406-058b-4e68-9066-4dc6be16560a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_41546371-5e42-4dbd-9400-6f82b2ad3ea4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of former employees who filled a putative collective and class action complaint</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b2b5cf44-d366-4f6c-9e4b-8eed5ccb5e26_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_61c92de5-41b5-4013-91ff-f8c9e0111120_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_900149c3-991e-419b-99ea-3d99b6fcde26_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ResearchAndDevelopmentTaxCreditMember_8ca2a7b8-7791-4970-8dc4-75c61d923f51_terseLabel_en-US" xlink:label="lab_amed_ResearchAndDevelopmentTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit [Member]</link:label>
    <link:label id="lab_amed_ResearchAndDevelopmentTaxCreditMember_label_en-US" xlink:label="lab_amed_ResearchAndDevelopmentTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit [Member]</link:label>
    <link:label id="lab_amed_ResearchAndDevelopmentTaxCreditMember_documentation_en-US" xlink:label="lab_amed_ResearchAndDevelopmentTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ResearchAndDevelopmentTaxCreditMember" xlink:href="amed-20201231.xsd#amed_ResearchAndDevelopmentTaxCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ResearchAndDevelopmentTaxCreditMember" xlink:to="lab_amed_ResearchAndDevelopmentTaxCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_347f0416-19a5-4385-9ed8-b515128ef9ae_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense_ef211be9-5914-4db3-ba53-8daf940a9cbb_terseLabel_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense_label_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Effects Allocated to Interest Expense</link:label>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense_documentation_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect of items occuring during the period that have been charged or credited directly to interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:href="amed-20201231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:to="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_54fe1476-69a9-42da-b603-a10dcb73e5d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exerciseable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_feccde90-9c88-48a4-9b17-784efc40e1b0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, tax benefit recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a2fe0c94-33b1-4171-99e4-9c661d15df30_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineLoanMember_1c762ead-6150-4654-8d11-fcbae4102d8e_terseLabel_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_label_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_documentation_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember" xlink:href="amed-20201231.xsd#amed_SwingLineLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineLoanMember" xlink:to="lab_amed_SwingLineLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_491fd83e-aa10-45fc-94ad-c3863ccf01fa_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f9881841-b7fe-41b3-903c-b0c8c294ba9e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e6bc5144-b1fb-4a8a-8855-8beb20808184_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_9968f22a-4b0c-4860-a1ed-7d309d1ea2a3_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd4c661d-f7f3-4503-9b79-017d9d397820_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock granted, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6b0d68c6-7d8c-477b-8002-f28154776538_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_971eb47a-4a9f-4624-b959-4d02984002f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_38152e4b-7bfc-4c80-8178-56daf126f199_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in partnerships</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b333b917-ef4d-414d-8720-80082dcd4653_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_17cf0eed-2b03-42f2-890f-a9a3d12df50d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_72cf0832-cce5-476c-aa7c-26d150858cd0_terseLabel_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in uncertain tax positions from change in enacted tax rate</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_5239d3fa-535b-4e51-b2e4-d5dffd4c2151_negatedTerseLabel_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in statutory tax rate (1)</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_label_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Decreases Resulting From Change In Statutory Tax Rate</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_documentation_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Decreases Resulting From Change In Statutory Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:to="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CT_b6263ea8-e09a-4d49-adaa-44d27299669d_terseLabel_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Connecticut [Member]</link:label>
    <link:label id="lab_stpr_CT_label_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONNECTICUT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CT" xlink:to="lab_stpr_CT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1ed91301-d431-480e-9a02-0273a602e8cc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseAxis_5b2112ad-0f91-4680-9596-609458290406_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:label id="lab_amed_ShareRepurchaseAxis_label_en-US" xlink:label="lab_amed_ShareRepurchaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:label id="lab_amed_ShareRepurchaseAxis_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseAxis" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseAxis" xlink:to="lab_amed_ShareRepurchaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdad2492-edce-4ca2-aa97-d6893349459f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProvisionforIncomeTaxesTableTextBlock_5c3b6003-ce15-4221-9c7f-1dd4e1a43f43_terseLabel_en-US" xlink:label="lab_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Provision</link:label>
    <link:label id="lab_amed_ProvisionforIncomeTaxesTableTextBlock_label_en-US" xlink:label="lab_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes [Table Text Block]</link:label>
    <link:label id="lab_amed_ProvisionforIncomeTaxesTableTextBlock_documentation_en-US" xlink:label="lab_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:href="amed-20201231.xsd#amed_ProvisionforIncomeTaxesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:to="lab_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_3fae7529-b80b-4eee-911b-708b83581d6e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_091144b1-1bee-4ec6-a717-1819582e8465_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_32ceb37f-7b10-48fb-80fb-fbc3f9cbf47b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_80034229-bc93-411c-941d-d94352523174_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, number of care centers acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_420d5d5f-5e1a-4da4-a4bc-28066ccf8887_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_cf516e39-55e4-47b6-8c09-bec38815b13f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BuildingAndLeaseholdImprovementsMember_3fd4d27a-b627-46b1-9e7a-ef0c05513d5d_terseLabel_en-US" xlink:label="lab_amed_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements [Member]</link:label>
    <link:label id="lab_amed_BuildingAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_amed_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_amed_BuildingAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_amed_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building And Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BuildingAndLeaseholdImprovementsMember" xlink:href="amed-20201231.xsd#amed_BuildingAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BuildingAndLeaseholdImprovementsMember" xlink:to="lab_amed_BuildingAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_86de5289-a76b-4c99-9004-3c3c5032901b_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_b9be8954-8d83-4043-aed3-cebc55ebf80f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_362465cf-ce53-471c-aa65-2eb3e8659ccc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3a1eadac-bafd-4879-a97c-da58a7bb6db8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_04f5edf7-227f-48b6-8086-eff4adba0909_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d237be1b-da8d-45d5-8906-860dcf59d125_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_f0302597-0470-4b4c-9bc1-978e3e6c3e57_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_c04a8a78-4b38-43b9-9c22-8774980d5e7f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_e646d6b8-1348-4453-8162-db521a9568a4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_811fd6bc-67ce-4675-90a4-22e96f0f25f9_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_label_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_documentation_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:href="amed-20201231.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:to="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4a9f2f30-c3ce-481e-b896-45e88e904dad_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_32a0bb3c-bcf9-42c1-9dbc-736cea8760fe_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5ff75bae-424a-4a11-97f9-11e2ba1c55b1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_07731cf5-d610-468b-b46c-f8bae6292fd6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_ab04bfec-7f13-4244-ad1e-ec60f4333e72_terseLabel_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:href="amed-20201231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:to="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d8baf97d-b902-4888-89a9-9473432a439a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $95,024 and $96,137</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b1481c5a-3696-4ed8-b6c4-e2067aadbe15_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0f32022e-c21f-48c7-a4cd-1031ab724887_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c4b91917-ad8f-41cd-8ba9-3bb2cc8ee6a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9ebfead1-2b4e-4647-b119-88a42f7d9c9a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAPITAL SOCK AND SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e9aed392-1fd4-4206-852a-11dadbea936f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_037ee451-c63d-4b3e-84ab-1671c567523d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_17ef264a-c498-46e6-be64-5f9a4e5d8d2c_terseLabel_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund LP [Member]</link:label>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_label_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund LP [Member]</link:label>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_documentation_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund LP Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember" xlink:href="amed-20201231.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HeritageHealthcareInnovationFundLPMember" xlink:to="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cfc96113-359c-46e7-9a8c-0d3796213fb5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_98564002-beca-49e3-97ac-9db7d3a62ffa_terseLabel_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise [Member]</link:label>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_label_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise [Member]</link:label>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_documentation_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember" xlink:href="amed-20201231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExecutiveStockOptionExerciseMember" xlink:to="lab_amed_ExecutiveStockOptionExerciseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnfavorableMember_8d039ccb-61dd-4c44-92cd-073844171120_terseLabel_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:label id="lab_amed_UnfavorableMember_label_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember" xlink:href="amed-20201231.xsd#amed_UnfavorableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnfavorableMember" xlink:to="lab_amed_UnfavorableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WokersCompensation_48862d0e-b678-45c4-9f4a-d086fc0bcf82_terseLabel_en-US" xlink:label="lab_amed_WokersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_amed_WokersCompensation_label_en-US" xlink:label="lab_amed_WokersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wokers Compensation</link:label>
    <link:label id="lab_amed_WokersCompensation_documentation_en-US" xlink:label="lab_amed_WokersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation insurance, estimated liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WokersCompensation" xlink:href="amed-20201231.xsd#amed_WokersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WokersCompensation" xlink:to="lab_amed_WokersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_07527eb7-2fce-449f-8733-068d47c8ff23_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement amount to be paid by Company's insurance carriers</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableCurrent" xlink:to="lab_us-gaap_LossContingencyReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_46c82d25-89dd-487c-a717-81cd558c36be_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_434b1ae0-6b35-4bdf-b520-65691a598eb7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearAxis_ec0cb85b-4fbf-4d50-92c2-645ffcddf087_terseLabel_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_label_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_documentation_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis" xlink:href="amed-20201231.xsd#amed_CapYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearAxis" xlink:to="lab_amed_CapYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_c82eb680-e440-475d-aa44-9b5672c4c012_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, ROU Asset, Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_97f85c21-be2b-4eef-abd0-043fd4b155b6_terseLabel_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue adjustment to Medicare revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_label_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Adjustment To Medicare Revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_documentation_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:href="amed-20201231.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:to="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_df31b620-f1c0-459c-bfbe-02a89a846987_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, other intangibles recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredCompensationPlanLiability_36486a83-225e-47cf-a751-a08797f942b9_terseLabel_en-US" xlink:label="lab_amed_DeferredCompensationPlanLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan liability</link:label>
    <link:label id="lab_amed_DeferredCompensationPlanLiability_label_en-US" xlink:label="lab_amed_DeferredCompensationPlanLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Liability</link:label>
    <link:label id="lab_amed_DeferredCompensationPlanLiability_documentation_en-US" xlink:label="lab_amed_DeferredCompensationPlanLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredCompensationPlanLiability" xlink:href="amed-20201231.xsd#amed_DeferredCompensationPlanLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredCompensationPlanLiability" xlink:to="lab_amed_DeferredCompensationPlanLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c3704102-c731-48ee-b04d-f8fc72c88fa9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7f452290-c6f6-471b-ac4f-6df7292fdd32_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_e32707d2-f0de-41ac-aaf7-9b1a8cf1eaea_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:href="amed-20201231.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AseraCareHospiceMember_90accf5d-37b7-4a98-a953-4f06eb5fa45d_terseLabel_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_label_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_documentation_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AseraCareHospiceMember" xlink:to="lab_amed_AseraCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnSaleOfInvestments_fc7453c6-d552-4b35-a999-01d7ad3ab983_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_LossOnSaleOfInvestments_5bd299d9-36b7-425c-92e3-39ae5ebf2bdb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_LossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_LossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnSaleOfInvestments" xlink:to="lab_us-gaap_LossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_8a4f0f30-2373-471a-8f19-9268eb390731_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceAcquisitionMember_d903d0bb-c6b2-4e28-a924-f6cefa6f94ea_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Acquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAcquisitionMember_label_en-US" xlink:label="lab_amed_AsanaHospiceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Acquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAcquisitionMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAcquisitionMember" xlink:href="amed-20201231.xsd#amed_AsanaHospiceAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceAcquisitionMember" xlink:to="lab_amed_AsanaHospiceAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_b003fd7f-b356-4729-b11e-21129c10e0b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0e5c081c-514e-4001-a2db-8b498a523b83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_092f1fc3-58aa-4242-8bca-b8df3489839a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseLineItems_f29ed33e-ceed-49f8-9498-e60b3bb460fe_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_label_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseLineItems" xlink:to="lab_amed_ShareRepurchaseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InsuranceProgramsTableTableTextBlock_71ec1297-aec8-4c3f-aff1-2cd7c1d2df6b_terseLabel_en-US" xlink:label="lab_amed_InsuranceProgramsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Insurance Programs</link:label>
    <link:label id="lab_amed_InsuranceProgramsTableTableTextBlock_label_en-US" xlink:label="lab_amed_InsuranceProgramsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Programs Table [Table Text Block]</link:label>
    <link:label id="lab_amed_InsuranceProgramsTableTableTextBlock_documentation_en-US" xlink:label="lab_amed_InsuranceProgramsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Programs Details, Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InsuranceProgramsTableTableTextBlock" xlink:href="amed-20201231.xsd#amed_InsuranceProgramsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InsuranceProgramsTableTableTextBlock" xlink:to="lab_amed_InsuranceProgramsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_e21a5ac2-bb02-4508-b975-f8ed27b41df8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_3ed9ec7d-91d2-4900-8507-bb3925a39647_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, aggregate cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2bb89cbb-6915-4afa-9b36-2b515317e34c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_27fc5efa-a820-41f0-b117-83c5475e1f71_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_5f0cdbcb-6656-47a5-a512-571b65ba71e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6abb475f-6449-4332-b376-d346a59573fc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LetterOfCreditFee_cea1d28c-62f8-45c6-9c0f-0add63ef16bd_terseLabel_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_label_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_documentation_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee" xlink:href="amed-20201231.xsd#amed_LetterOfCreditFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LetterOfCreditFee" xlink:to="lab_amed_LetterOfCreditFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_420fb889-4082-4ae5-8e01-14f29a2aad23_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_748b1a56-1558-49d2-9f2e-f8260d1f23df_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_b7094628-f8a9-4570-8d3a-a84fa6495dcf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic principal payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e7ff48a1-9974-48a4-9c22-0a15b8b7f561_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_85bcdf41-ea8a-494e-9b64-121766b84f94_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under the revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_f8ca73ae-f955-4a24-a40e-4b20997d645c_terseLabel_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_label_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_documentation_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:href="amed-20201231.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:to="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1630da69-3187-4dc3-9766-591321147933_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8599b5c2-77aa-42db-bfa8-543a3083ab82_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_b42621df-562c-413f-bd51-3043fb6b0afa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_28de8ac6-e588-43dc-a18f-14f0f1bb8270_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Interest Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_54601544-aff5-4826-a757-7989adf44bec_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_79522bf8-1652-4b30-9842-8325df7766c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_5c4cf5b7-fcad-408a-b4a3-94775f0b111e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease ROU assets, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_136b8426-de8f-473a-8ce8-e695dda30e4e_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_da6cff3d-afcc-4a52-9138-9bb8fcd899d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Payor Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentNumberOfPeriodicPayments_cf18943f-7227-48c0-b130-9ba9d4699ad8_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentNumberOfPeriodicPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly installments</link:label>
    <link:label id="lab_amed_DebtInstrumentNumberOfPeriodicPayments_label_en-US" xlink:label="lab_amed_DebtInstrumentNumberOfPeriodicPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Number Of Periodic Payments</link:label>
    <link:label id="lab_amed_DebtInstrumentNumberOfPeriodicPayments_documentation_en-US" xlink:label="lab_amed_DebtInstrumentNumberOfPeriodicPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, number of quarterly installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentNumberOfPeriodicPayments" xlink:href="amed-20201231.xsd#amed_DebtInstrumentNumberOfPeriodicPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentNumberOfPeriodicPayments" xlink:to="lab_amed_DebtInstrumentNumberOfPeriodicPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_4714b100-2765-45a2-8b25-d62f6a647b49_terseLabel_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_label_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_documentation_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset" xlink:href="amed-20201231.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsRelatedToTaxAsset" xlink:to="lab_amed_PaymentsRelatedToTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_8c862ac4-2246-4508-aabe-8404372d43ef_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets tax deferred expense compensation and benefits workers compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:to="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b98b9787-8a4d-45a3-96e4-7da714ccbd17_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6d77534e-6c96-497e-a466-23fe3b26dc9a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding &#8211; basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_909e6b6d-6b1e-4c8d-b491-97140fe70768_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Margin on Loans</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4e112667-2c2e-4cac-a7e7-3d70f4bb11be_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_c5e8974b-2716-4eb7-bbf6-7eb77ea04ac8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_5f5a90f0-a55b-442c-8e8c-4c487ee6c8ea_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_bc88a38a-26db-4e2a-9ba4-f0fb37772d1a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_fd4bf2ee-53b6-4aeb-91ba-8ed00afef083_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Commitments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_39f6ba44-af9c-4c21-9281-89c1e694c3d2_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Eurodollar Rate (percent)</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_a3f8efb2-77ab-4d13-a59a-d193799d0991_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2a9ddb49-7eb0-4aa3-8816-3cd9a522e775_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_c399012d-f9e2-49d2-a746-fc6973437ecd_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for cost method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Cost Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:href="amed-20201231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_85fb3a68-df80-4f16-953a-e2da2db2585b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_197bf444-8ca9-4e46-a130-b713eab0ddf6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a953df57-b770-422a-bce3-dd7a9662b0b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_07f5f463-6c1c-4262-bb9b-40d509018625_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_20c9901d-26f5-4f12-b0f7-4c765207961d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a36f50af-a6c8-4fb3-bf94-c6991f7aa380_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e391ba5-5c5e-48c9-9ec2-d24e760f9eec_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_247751a9-1bd6-4932-a723-ac67d1fedfd2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4688fb87-fab7-4351-b217-49f5aa0302c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_cfc2d680-887a-4d4a-b920-87b8975da72c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7925bd3a-0411-4131-8f9e-689fa19c0135_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_b54908cb-5be7-42e2-98c7-d6a755daf5f2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current installments of obligations under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_af3f5ab7-e908-4df6-babb-d162c62823d1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_115815a4-0a30-4562-b73b-7e03bec9773b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c4b0577a-1d50-45db-9a7f-12f0da025982_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised during the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_c6794556-b3d2-437d-a7bb-7fd06eba5898_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_621749e3-f9f2-493d-b03b-f5fe8852a190_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_fa51d040-d0c4-4654-a462-80ef49f94e28_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_41d8ab4b-56ae-41be-b194-898e716801a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_a6ba98bd-29a0-4d39-b35a-c82e48a3347e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_005dc213-f040-4cda-a386-085fbae65a8e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_604fd945-35d1-42ba-a43c-36702d87b733_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinanceLeaseCost_532d0bdd-5dbb-48d2-acb4-7729294fc47d_terseLabel_en-US" xlink:label="lab_amed_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:label id="lab_amed_FinanceLeaseCost_label_en-US" xlink:label="lab_amed_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:label id="lab_amed_FinanceLeaseCost_documentation_en-US" xlink:label="lab_amed_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of finance lease cost including amortization of ROU asset and interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinanceLeaseCost" xlink:href="amed-20201231.xsd#amed_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinanceLeaseCost" xlink:to="lab_amed_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ece9bce1-5508-4f09-856d-29c0b9aeacf6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_49adc421-1553-442a-92d7-b10adee33e2e_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_1af40546-2b5e-4f13-a3a0-ba2c13d5cf24_terseLabel_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_label_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_documentation_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:href="amed-20201231.xsd#amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:to="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7c405e11-ce81-4c77-85e1-5183a645be3e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_423717a7-baaf-4467-b791-164cb2d0b6a5_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' compensation insurance retention limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Insurance Retention Limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:href="amed-20201231.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:to="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cda2e683-94dd-4a1d-b5cd-3370d70cc692_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1a6221dd-b568-441d-a092-5c5d82aab0af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockMember_06ae2724-20ec-4147-bee1-6be0878e39f6_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockMember_label_en-US" xlink:label="lab_amed_NonVestedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockMember_documentation_en-US" xlink:label="lab_amed_NonVestedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Non-Vested Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockMember" xlink:href="amed-20201231.xsd#amed_NonVestedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockMember" xlink:to="lab_amed_NonVestedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_6c9b51b3-0922-48e0-bbf8-cf320547f2a9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_df5cd014-5c81-43e1-aea2-365b08d84edd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_f2fa2de8-ad6e-4d1d-bbc4-9beee578936c_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentDomain_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain" xlink:href="amed-20201231.xsd#amed_TypeofEquityMethodInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain" xlink:to="lab_amed_TypeofEquityMethodInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_74a325de-4908-4698-bec5-1dbefbf4306f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WeightedAverageInterestRate_cb339c29-dc81-411f-8524-4e8eb2415c77_terseLabel_en-US" xlink:label="lab_amed_WeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average interest rate for five year Term Loan (percent)</link:label>
    <link:label id="lab_amed_WeightedAverageInterestRate_label_en-US" xlink:label="lab_amed_WeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WeightedAverageInterestRate" xlink:href="amed-20201231.xsd#amed_WeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WeightedAverageInterestRate" xlink:to="lab_amed_WeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_c2ac7763-3d41-4e96-b8fc-406e45c7e21e_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_label_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:to="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1986bbd0-d147-4cba-a955-b53127033a24_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6c45447a-93a5-4e68-beae-3a9e642ecc02_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_e357d9d0-3174-4206-b2c8-e0872b6aa7fe_negatedTerseLabel_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax benefits from share-based compensation (1)</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_label_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_documentation_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:href="amed-20201231.xsd#amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:to="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CharityCare_5d5f1974-5961-4b75-a2ec-f87435381038_terseLabel_en-US" xlink:label="lab_amed_CharityCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charity care</link:label>
    <link:label id="lab_amed_CharityCare_label_en-US" xlink:label="lab_amed_CharityCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charity Care</link:label>
    <link:label id="lab_amed_CharityCare_documentation_en-US" xlink:label="lab_amed_CharityCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to charity care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CharityCare" xlink:href="amed-20201231.xsd#amed_CharityCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CharityCare" xlink:to="lab_amed_CharityCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_85ba0b60-db72-454c-b65e-e4f0ea48c575_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f13efd72-0956-425a-81b1-3abfb87e8a6d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_7aabc1bd-3e2e-4b60-bfaa-d940eb770ae3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_6aa07592-7a59-4706-a2dd-7c62f4c3e6c2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17f9dddd-90d8-41eb-bf36-e8a37a1d03c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average&#160;Contractual Life&#160;(Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_8cf35564-3996-425b-9371-ef233b4a38d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_5d841a49-184e-43d6-8308-7b289829fcae_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_518fcef2-0857-4c3b-97a1-31c466e7fbd7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted average contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b51fc7ec-409f-4980-96e6-96f0552f55f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_2b2e5eb2-64bd-4b6d-926a-e1e77e9f6974_terseLabel_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds Received From Provider Relief Fund Advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:href="amed-20201231.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:to="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_5a7304f1-0552-420d-b016-f58a090fe5da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_e0be222f-e8f6-4b8a-be0d-55f8372229b4_terseLabel_en-US" xlink:label="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of accounts receivable derived from Medicare</link:label>
    <link:label id="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_label_en-US" xlink:label="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion Of Patient Accounts Receivable Derived From Medicare</link:label>
    <link:label id="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_documentation_en-US" xlink:label="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:href="amed-20201231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:to="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dc06a768-0321-48f5-8ad7-baa9b7675308_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_KKRConsultingMember_08fca45a-d6be-4d0e-9d76-339981edfe56_terseLabel_en-US" xlink:label="lab_amed_KKRConsultingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKR Consulting [Member]</link:label>
    <link:label id="lab_amed_KKRConsultingMember_label_en-US" xlink:label="lab_amed_KKRConsultingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKR Consulting [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRConsultingMember" xlink:href="amed-20201231.xsd#amed_KKRConsultingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_KKRConsultingMember" xlink:to="lab_amed_KKRConsultingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_81e797e9-6eb5-4269-9e1c-03471f793252_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost, 4,655,934 and 4,353,970 shares of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_55185de7-0b4f-45b8-a3e4-6a018849dd43_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net (2)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeLeasesTextBlock_a4c77f40-cf0a-4a99-bbb1-4655cb914813_terseLabel_en-US" xlink:label="lab_amed_LesseeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_amed_LesseeLeasesTextBlock_label_en-US" xlink:label="lab_amed_LesseeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Text Block]</link:label>
    <link:label id="lab_amed_LesseeLeasesTextBlock_documentation_en-US" xlink:label="lab_amed_LesseeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of operating and finance lease and maturity analysis of operating and finance lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeLeasesTextBlock" xlink:href="amed-20201231.xsd#amed_LesseeLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeLeasesTextBlock" xlink:to="lab_amed_LesseeLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e3391724-6b86-4d13-9409-90b85ff32b1f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3674d644-5c5d-4afb-a06e-0461e2423dc5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense at U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a7777bda-8171-4392-98ef-f7535f663959_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2aa517c3-2c28-486a-9ef0-3dc25042580f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_0b7da0f9-25c2-4fbe-b516-4afdf40b64c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>amed-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:267db984-3247-4ac4-9ea7-650da4f8e37e,g:25daadda-e66f-46f9-96fb-eec4b4d1abf0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="amed-20201231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:href="amed-20201231.xsd#amed_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_21b87fcb-d642-411b-bece-48cded07a956" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_DocumentType_21b87fcb-d642-411b-bece-48cded07a956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9d8ab8c0-63f1-44d6-956f-b4a2456564af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_DocumentAnnualReport_9d8ab8c0-63f1-44d6-956f-b4a2456564af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_88ba6476-af02-4e8b-ab54-c2285b0f8b3c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_DocumentPeriodEndDate_88ba6476-af02-4e8b-ab54-c2285b0f8b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b2c08fd3-1329-42c3-9871-be9fbf41596c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_DocumentTransitionReport_b2c08fd3-1329-42c3-9871-be9fbf41596c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cdadf7d7-d026-46a9-8ec3-e0f6e8314b21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityFileNumber_cdadf7d7-d026-46a9-8ec3-e0f6e8314b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a5f11300-2248-4da6-9334-63bfdf5d0c4c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityRegistrantName_a5f11300-2248-4da6-9334-63bfdf5d0c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6998d739-e281-4e90-b973-817a632f7ee5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6998d739-e281-4e90-b973-817a632f7ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5a7b689c-2f61-4a74-8049-aca19ec72133" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityTaxIdentificationNumber_5a7b689c-2f61-4a74-8049-aca19ec72133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_822bf004-26d3-425e-9e1d-fbcecce9e353" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityAddressAddressLine1_822bf004-26d3-425e-9e1d-fbcecce9e353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a452388a-606b-4a1f-8279-db419f83e8cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityAddressCityOrTown_a452388a-606b-4a1f-8279-db419f83e8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_088c1f4a-6de7-441b-897a-657e136b97cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityAddressStateOrProvince_088c1f4a-6de7-441b-897a-657e136b97cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_69459d3e-5a52-417a-8d0c-aac579dd1350" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityAddressPostalZipCode_69459d3e-5a52-417a-8d0c-aac579dd1350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_01b25a86-c5de-4f47-9dbf-c34a861aa410" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_CityAreaCode_01b25a86-c5de-4f47-9dbf-c34a861aa410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ac132ee0-f0f8-410e-a127-56d6079ff3e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_LocalPhoneNumber_ac132ee0-f0f8-410e-a127-56d6079ff3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c881c350-56a4-4012-a7b6-6381e4619269" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_Security12bTitle_c881c350-56a4-4012-a7b6-6381e4619269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_234e09a6-5fa1-4a7f-b3a4-812bffbe8025" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_SecurityExchangeName_234e09a6-5fa1-4a7f-b3a4-812bffbe8025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e69d6a5a-6211-4726-b83f-fdbbe8e6b5be" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e69d6a5a-6211-4726-b83f-fdbbe8e6b5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_bc6fccbb-90ea-481a-8acf-1368fa86fb37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityVoluntaryFilers_bc6fccbb-90ea-481a-8acf-1368fa86fb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_970686b9-b7ae-41bc-8ffb-ef7dad3d9209" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityCurrentReportingStatus_970686b9-b7ae-41bc-8ffb-ef7dad3d9209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_90e808e3-2d8f-402c-a1fc-53d0a0801fef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityInteractiveDataCurrent_90e808e3-2d8f-402c-a1fc-53d0a0801fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1a3b3a5d-18e3-42ee-a957-94b887ba0cee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityFilerCategory_1a3b3a5d-18e3-42ee-a957-94b887ba0cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_36d2205a-4e7f-427f-a929-4c0db9667115" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntitySmallBusiness_36d2205a-4e7f-427f-a929-4c0db9667115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6c602550-2999-419a-b386-6ea07f9e803b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityEmergingGrowthCompany_6c602550-2999-419a-b386-6ea07f9e803b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1474620d-5fbd-4f60-ace5-d366ca178273" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1474620d-5fbd-4f60-ace5-d366ca178273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ee858319-7eed-4ef6-a7be-ca14bc8cc9ca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityShellCompany_ee858319-7eed-4ef6-a7be-ca14bc8cc9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f43fd1be-1cba-4b92-a035-cd1f8e5d76b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityPublicFloat_f43fd1be-1cba-4b92-a035-cd1f8e5d76b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d1a0a9d2-5bda-4edb-a764-f5b5fdf6a461" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d1a0a9d2-5bda-4edb-a764-f5b5fdf6a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_11d09fb9-e529-4932-aeaa-427569564b35" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_AmendmentFlag_11d09fb9-e529-4932-aeaa-427569564b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ecbe4123-ccb7-41d3-b05a-441c5b5ea3f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_DocumentFiscalYearFocus_ecbe4123-ccb7-41d3-b05a-441c5b5ea3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e1d63fa0-3eb3-4e7d-81ca-d019c5388954" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e1d63fa0-3eb3-4e7d-81ca-d019c5388954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ad0d1c14-0f34-4871-b9fa-6b68ce3d63f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_TradingSymbol_ad0d1c14-0f34-4871-b9fa-6b68ce3d63f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_325180e4-43c0-48d5-b97f-96fdd4f2e05a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_EntityCentralIndexKey_325180e4-43c0-48d5-b97f-96fdd4f2e05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d508dc78-4cc4-4f8d-8061-a4734503663e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_aad64165-137c-4826-bd03-74e432d84030" xlink:to="loc_dei_CurrentFiscalYearEndDate_d508dc78-4cc4-4f8d-8061-a4734503663e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_12edcd3f-fbef-46cb-ae0f-eabe9476d09c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12edcd3f-fbef-46cb-ae0f-eabe9476d09c" xlink:to="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c94a7b8d-c731-478a-9c16-5c7ee21e5787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c94a7b8d-c731-478a-9c16-5c7ee21e5787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_691347a0-a7e9-4be6-bd5b-e45773962862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c94a7b8d-c731-478a-9c16-5c7ee21e5787" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_691347a0-a7e9-4be6-bd5b-e45773962862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_ef52aaa2-ad23-4b28-b367-506fcd7a7ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c94a7b8d-c731-478a-9c16-5c7ee21e5787" xlink:to="loc_us-gaap_RestrictedCash_ef52aaa2-ad23-4b28-b367-506fcd7a7ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_008b8b57-57c2-4a7e-837f-8ba75aef2880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c94a7b8d-c731-478a-9c16-5c7ee21e5787" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_008b8b57-57c2-4a7e-837f-8ba75aef2880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_440d77d7-a5a8-44be-bd46-b75fe0aa4f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c94a7b8d-c731-478a-9c16-5c7ee21e5787" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_440d77d7-a5a8-44be-bd46-b75fe0aa4f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_018f1ca2-2260-4378-9b3d-6a849dbd2d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c94a7b8d-c731-478a-9c16-5c7ee21e5787" xlink:to="loc_us-gaap_OtherAssetsCurrent_018f1ca2-2260-4378-9b3d-6a849dbd2d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_df58769d-eb64-4663-992d-2af7d4e3a256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c94a7b8d-c731-478a-9c16-5c7ee21e5787" xlink:to="loc_us-gaap_AssetsCurrent_df58769d-eb64-4663-992d-2af7d4e3a256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_faa1e910-3a43-4329-9eef-c888cc92261d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_faa1e910-3a43-4329-9eef-c888cc92261d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_00f46db4-df2c-4354-a9cd-647244144315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_00f46db4-df2c-4354-a9cd-647244144315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_81a406ba-acf8-4fd0-b289-b563882d6262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:to="loc_us-gaap_Goodwill_81a406ba-acf8-4fd0-b289-b563882d6262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_31cf2b20-95ea-4b88-889c-f953764eb2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_31cf2b20-95ea-4b88-889c-f953764eb2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_d364cf12-9660-48c0-82da-dae947b82712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_d364cf12-9660-48c0-82da-dae947b82712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6ac6d17d-f303-414f-9cf9-8851b2b88f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6ac6d17d-f303-414f-9cf9-8851b2b88f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_01112c8c-fdf3-4495-9b6c-1433f3eaac7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_796f78f1-0e7e-49d3-94df-e207dc95da8b" xlink:to="loc_us-gaap_Assets_01112c8c-fdf3-4495-9b6c-1433f3eaac7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12edcd3f-fbef-46cb-ae0f-eabe9476d09c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b460e4b4-7ec8-4600-b18c-6ecc210b48a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:to="loc_us-gaap_AccountsPayableCurrent_b460e4b4-7ec8-4600-b18c-6ecc210b48a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6981f437-8fc5-4848-9f7b-1bd75dc7f383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6981f437-8fc5-4848-9f7b-1bd75dc7f383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b9fb8898-9174-4b98-a077-1f9896f7232a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b9fb8898-9174-4b98-a077-1f9896f7232a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_e4baa1dd-7a5b-4b71-824a-14b109d862cc" xlink:href="amed-20201231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:to="loc_amed_ProviderReliefFundAdvance_e4baa1dd-7a5b-4b71-824a-14b109d862cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_af9aff64-e262-4ae8-9944-ddae9508ca5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:to="loc_us-gaap_LongTermDebtCurrent_af9aff64-e262-4ae8-9944-ddae9508ca5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_84c96e8d-692d-40b4-983f-e9fd5c2f34c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_84c96e8d-692d-40b4-983f-e9fd5c2f34c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_16db45e4-0384-4e2a-82e4-fca51416c01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3f6a03e3-7f2b-4aeb-9f19-7ec826b37938" xlink:to="loc_us-gaap_LiabilitiesCurrent_16db45e4-0384-4e2a-82e4-fca51416c01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_383fd84a-4b01-4888-8dd8-71457e53cbc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_383fd84a-4b01-4888-8dd8-71457e53cbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e65e5258-f696-4fab-87a5-980be82f96f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e65e5258-f696-4fab-87a5-980be82f96f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_eb95866f-bb53-4458-b69b-2d1926dd6e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_eb95866f-bb53-4458-b69b-2d1926dd6e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_14468b13-f0b5-43ad-8720-964ecabf615d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:to="loc_us-gaap_Liabilities_14468b13-f0b5-43ad-8720-964ecabf615d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e2e5feb8-4269-4681-8bb0-262739013f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e2e5feb8-4269-4681-8bb0-262739013f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_65ff24db-d992-46fd-8fb2-94cddb25218d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_65ff24db-d992-46fd-8fb2-94cddb25218d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1fbcb333-0ba6-457f-afa9-4ec738e82d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_CommonStockValueOutstanding_1fbcb333-0ba6-457f-afa9-4ec738e82d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_610ae990-1905-491f-ab16-a942a7405025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_610ae990-1905-491f-ab16-a942a7405025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_ddf9d2e8-776a-4f6b-b2c5-ce7ec67cd321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_TreasuryStockValue_ddf9d2e8-776a-4f6b-b2c5-ce7ec67cd321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e94dd22b-57d8-43bf-b562-b10efd2eaef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e94dd22b-57d8-43bf-b562-b10efd2eaef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21bf5334-03b5-4bfa-b258-15b55cff2276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21bf5334-03b5-4bfa-b258-15b55cff2276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8338a70d-4b87-4043-8f76-e0c01ab24db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_StockholdersEquity_8338a70d-4b87-4043-8f76-e0c01ab24db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a78e51ac-4afb-4a43-aa9a-7356729c9b97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_MinorityInterest_a78e51ac-4afb-4a43-aa9a-7356729c9b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37714c06-51a3-4598-a401-1d950e0c1717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_fb6052b5-cfc0-443d-bf11-b06c096b5e2c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37714c06-51a3-4598-a401-1d950e0c1717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5d998772-33be-46b7-936d-c87b23ee22ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdd62b-db05-424d-9790-f313f3bc0fe5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5d998772-33be-46b7-936d-c87b23ee22ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fc0af05-bda2-41e4-9873-be776d68ceac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fc0af05-bda2-41e4-9873-be776d68ceac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_72cd09bb-aebb-40bc-b04d-a5e6a6521ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_72cd09bb-aebb-40bc-b04d-a5e6a6521ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_33ce7f46-5c5f-4dd2-b632-66627f25e198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_33ce7f46-5c5f-4dd2-b632-66627f25e198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c08d9f5d-9d14-4c1b-964a-fed7a7ff60f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c08d9f5d-9d14-4c1b-964a-fed7a7ff60f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_08395d1d-02e6-46e4-b8fc-0f0d6eb4ead1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_08395d1d-02e6-46e4-b8fc-0f0d6eb4ead1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2abfd316-0cf0-40d8-8f63-1cd545411695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2abfd316-0cf0-40d8-8f63-1cd545411695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f392ac88-5c50-4deb-a905-98ed104e3c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f392ac88-5c50-4deb-a905-98ed104e3c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ec6ecaf1-0bad-46ce-8914-450dbcf66980" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ec6ecaf1-0bad-46ce-8914-450dbcf66980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_447922c8-2366-4915-8904-a9dd0836d4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_CommonStockSharesIssued_447922c8-2366-4915-8904-a9dd0836d4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_73b93960-ede2-4d61-ad01-14724ca14324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_73b93960-ede2-4d61-ad01-14724ca14324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_5023531f-35dd-4965-94ae-6ad74030960a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2d0bf11-a24c-45b4-b741-1ead6f0cbc6c" xlink:to="loc_us-gaap_TreasuryStockShares_5023531f-35dd-4965-94ae-6ad74030960a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_be018ba2-afce-4e58-92e1-f31a3b467538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_be018ba2-afce-4e58-92e1-f31a3b467538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_23fad142-ed9d-485d-a0f7-b0ba609a9419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_OtherOperatingIncome_23fad142-ed9d-485d-a0f7-b0ba609a9419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9cc8b339-a4c7-4aac-996d-5ff0a140d10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9cc8b339-a4c7-4aac-996d-5ff0a140d10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_9a11da3b-59d5-4608-8560-a26a9ee93def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_9a11da3b-59d5-4608-8560-a26a9ee93def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_ca11aba5-09a4-426e-9f85-985986c7fc9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_9a11da3b-59d5-4608-8560-a26a9ee93def" xlink:to="loc_us-gaap_LaborAndRelatedExpense_ca11aba5-09a4-426e-9f85-985986c7fc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1dace15d-459c-4957-bbf1-3d156036e53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_9a11da3b-59d5-4608-8560-a26a9ee93def" xlink:to="loc_us-gaap_ShareBasedCompensation_1dace15d-459c-4957-bbf1-3d156036e53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_03ef8297-c941-44c4-b165-300d391bdb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_9a11da3b-59d5-4608-8560-a26a9ee93def" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_03ef8297-c941-44c4-b165-300d391bdb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_d18ff680-b948-4355-89ad-a2e4a915d181" xlink:href="amed-20201231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_d18ff680-b948-4355-89ad-a2e4a915d181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d1b72f23-d925-4245-97ff-f21e3d6021c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_AssetImpairmentCharges_d1b72f23-d925-4245-97ff-f21e3d6021c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2cca8748-b35f-430a-9dba-1b6ba594725d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_CostsAndExpenses_2cca8748-b35f-430a-9dba-1b6ba594725d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ebd48d42-9c30-4fd7-b7db-3223ef942fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_OperatingIncomeLoss_ebd48d42-9c30-4fd7-b7db-3223ef942fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac1a52b2-8f34-4dd1-9b95-2c79b03180ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac1a52b2-8f34-4dd1-9b95-2c79b03180ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_44a61cc9-0c3d-45c6-88e5-078aea0c1af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac1a52b2-8f34-4dd1-9b95-2c79b03180ce" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_44a61cc9-0c3d-45c6-88e5-078aea0c1af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_987e50f5-51f3-40b5-a469-4cb5f2b5517e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac1a52b2-8f34-4dd1-9b95-2c79b03180ce" xlink:to="loc_us-gaap_InterestExpense_987e50f5-51f3-40b5-a469-4cb5f2b5517e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a77bce53-2dad-48ef-9370-8fe4a70049b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac1a52b2-8f34-4dd1-9b95-2c79b03180ce" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a77bce53-2dad-48ef-9370-8fe4a70049b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_838d4d14-1f04-4e6e-8b6d-ebced69aae6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac1a52b2-8f34-4dd1-9b95-2c79b03180ce" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_838d4d14-1f04-4e6e-8b6d-ebced69aae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_59a9dfd5-a9c0-4e81-86a3-c79f8dd997a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ac1a52b2-8f34-4dd1-9b95-2c79b03180ce" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_59a9dfd5-a9c0-4e81-86a3-c79f8dd997a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1533b6d4-95f0-4a1d-ba3c-57524f553897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1533b6d4-95f0-4a1d-ba3c-57524f553897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5d3e14f9-fff3-44f0-8485-4656c6fb2db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5d3e14f9-fff3-44f0-8485-4656c6fb2db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_51fc7b70-997e-4b2e-bca3-b0e5d73cecee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_ProfitLoss_51fc7b70-997e-4b2e-bca3-b0e5d73cecee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_907de01e-1cca-4942-80fd-ee8d63265591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_907de01e-1cca-4942-80fd-ee8d63265591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f297aace-60b7-4891-b324-e67103a6d279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_NetIncomeLoss_f297aace-60b7-4891-b324-e67103a6d279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_d51b6eca-9381-4023-a186-6def50110267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_d51b6eca-9381-4023-a186-6def50110267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f3ce6279-232f-4b11-818e-d961c9a74dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_d51b6eca-9381-4023-a186-6def50110267" xlink:to="loc_us-gaap_EarningsPerShareBasic_f3ce6279-232f-4b11-818e-d961c9a74dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_300c9956-ebc4-434d-ad9b-1b40c7f3dad8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_d51b6eca-9381-4023-a186-6def50110267" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_300c9956-ebc4-434d-ad9b-1b40c7f3dad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_12737502-1b4b-41f6-9a37-f55a169d0c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_48bcbe3f-8178-4ec8-809a-d0b47eb6903a" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_12737502-1b4b-41f6-9a37-f55a169d0c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3e45193c-2440-4384-ba44-66bad9e17403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_12737502-1b4b-41f6-9a37-f55a169d0c96" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3e45193c-2440-4384-ba44-66bad9e17403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_244653e7-2f6c-4527-9847-1fd0fa45aed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_12737502-1b4b-41f6-9a37-f55a169d0c96" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_244653e7-2f6c-4527-9847-1fd0fa45aed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2c5d17b-8d01-46ed-9571-f36e90b04ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7db8700f-bb91-4430-83bc-f6bec55d3cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2c5d17b-8d01-46ed-9571-f36e90b04ec1" xlink:to="loc_us-gaap_ProfitLoss_7db8700f-bb91-4430-83bc-f6bec55d3cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_144ce7f2-e376-4649-8475-03067790a7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2c5d17b-8d01-46ed-9571-f36e90b04ec1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_144ce7f2-e376-4649-8475-03067790a7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_817dd616-d165-4b7e-a2e1-6c4c95c908e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2c5d17b-8d01-46ed-9571-f36e90b04ec1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_817dd616-d165-4b7e-a2e1-6c4c95c908e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1fc99119-7c39-45d9-ab62-edf1e2126065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2c5d17b-8d01-46ed-9571-f36e90b04ec1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1fc99119-7c39-45d9-ab62-edf1e2126065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ecc7fd10-adb5-4c67-9e76-cec24e316f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b2c5d17b-8d01-46ed-9571-f36e90b04ec1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ecc7fd10-adb5-4c67-9e76-cec24e316f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_43e807b8-c32a-4c19-abeb-02da3e8c084b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3c273bae-d864-4eb2-8009-25c1f1451600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_43e807b8-c32a-4c19-abeb-02da3e8c084b" xlink:to="loc_us-gaap_StatementTable_3c273bae-d864-4eb2-8009-25c1f1451600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a6a52374-1948-48c9-9310-71294541f63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3c273bae-d864-4eb2-8009-25c1f1451600" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a6a52374-1948-48c9-9310-71294541f63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a6a52374-1948-48c9-9310-71294541f63c" xlink:to="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4163c6db-e048-47c9-b845-c863056253ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_CommonStockMember_4163c6db-e048-47c9-b845-c863056253ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a68ed7b2-e5d8-435c-b5fd-92e75bbcd13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a68ed7b2-e5d8-435c-b5fd-92e75bbcd13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_aad5c52c-0575-4380-b123-b827d18e8ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_TreasuryStockMember_aad5c52c-0575-4380-b123-b827d18e8ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bdc1672a-8021-417f-a5a1-1906275852fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bdc1672a-8021-417f-a5a1-1906275852fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_607b2805-00e4-445b-9668-1c3238e09264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_RetainedEarningsMember_607b2805-00e4-445b-9668-1c3238e09264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_db6ffb0d-12c2-4e06-ae95-be91c88974bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ee1d736-4f18-49b1-9496-73049829c08f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_db6ffb0d-12c2-4e06-ae95-be91c88974bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4825ad54-a4f9-4129-ac05-0d260917c77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3c273bae-d864-4eb2-8009-25c1f1451600" xlink:to="loc_us-gaap_StatementLineItems_4825ad54-a4f9-4129-ac05-0d260917c77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4825ad54-a4f9-4129-ac05-0d260917c77a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f35b3d09-04ed-43f2-a086-01f909637438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f35b3d09-04ed-43f2-a086-01f909637438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9a0d1e83-5e20-4f42-86f6-49d8b5384181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_SharesOutstanding_9a0d1e83-5e20-4f42-86f6-49d8b5384181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_56bba2bd-f926-4c10-bff6-285aaece09b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_56bba2bd-f926-4c10-bff6-285aaece09b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ddf6a130-a52b-4a04-9260-1435cd80a3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ddf6a130-a52b-4a04-9260-1435cd80a3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_3c745f4a-816a-47f8-b562-1b2bb2919cc7" xlink:href="amed-20201231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_3c745f4a-816a-47f8-b562-1b2bb2919cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_c79b9ad9-e06c-402e-bf3a-a402a5abe554" xlink:href="amed-20201231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_c79b9ad9-e06c-402e-bf3a-a402a5abe554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_991edac2-bc1a-44ec-b88f-21c48ca8a192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_991edac2-bc1a-44ec-b88f-21c48ca8a192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16e36c66-dc1e-48fc-93e5-c1dbc59a0bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_16e36c66-dc1e-48fc-93e5-c1dbc59a0bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3d833900-2cdb-4a7a-bff5-2b1637c78b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3d833900-2cdb-4a7a-bff5-2b1637c78b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7d634e6-2107-4a4c-885b-a0e8bb5f8d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7d634e6-2107-4a4c-885b-a0e8bb5f8d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_98492b48-04e8-4882-b270-ec02ed641975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_98492b48-04e8-4882-b270-ec02ed641975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_b1eb4156-1961-438a-8091-4c04530cb997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_b1eb4156-1961-438a-8091-4c04530cb997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_68f81bf8-9531-48cf-95f8-7dae5500c629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_68f81bf8-9531-48cf-95f8-7dae5500c629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_698d7ac5-b4b8-42be-9450-3df58b4282ae" xlink:href="amed-20201231.xsd#amed_SurrenderedShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_SurrenderedShares_698d7ac5-b4b8-42be-9450-3df58b4282ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0c36e9a7-4f3b-4fa0-b80d-f62d55e1b703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0c36e9a7-4f3b-4fa0-b80d-f62d55e1b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d70a3692-00d3-4342-a119-3ef491e68da6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d70a3692-00d3-4342-a119-3ef491e68da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_62d571dc-f911-4b75-bd9d-d9f1dd4cd142" xlink:href="amed-20201231.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_62d571dc-f911-4b75-bd9d-d9f1dd4cd142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment_bb16bb4b-02f0-4e81-b377-9f97273cd6f4" xlink:href="amed-20201231.xsd#amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment_bb16bb4b-02f0-4e81-b377-9f97273cd6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_81d5c4fe-4c66-4794-8366-a7d07166de65" xlink:href="amed-20201231.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_81d5c4fe-4c66-4794-8366-a7d07166de65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d181b8b8-c2aa-4e67-a363-cdca75e2d616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_ProfitLoss_d181b8b8-c2aa-4e67-a363-cdca75e2d616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e560cd4-1abb-4f8a-9338-f59dd1d97d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7e560cd4-1abb-4f8a-9338-f59dd1d97d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_82304585-eb42-4a42-b65f-df7e8889db21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_68a03ad5-ce81-4b59-845d-94034ad43292" xlink:to="loc_us-gaap_SharesOutstanding_82304585-eb42-4a42-b65f-df7e8889db21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20201231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08377ddd-e5f6-4dd4-826b-32f078777427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08377ddd-e5f6-4dd4-826b-32f078777427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_67f47680-3165-47c0-a85f-6a51a01d99b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08377ddd-e5f6-4dd4-826b-32f078777427" xlink:to="loc_us-gaap_ProfitLoss_67f47680-3165-47c0-a85f-6a51a01d99b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08377ddd-e5f6-4dd4-826b-32f078777427" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_673873d2-b623-4cbb-984f-90ad469eaa42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_673873d2-b623-4cbb-984f-90ad469eaa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ec2bd3a4-9df5-49c2-9d85-2b937399cbda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_ShareBasedCompensation_ec2bd3a4-9df5-49c2-9d85-2b937399cbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense_6f36c960-510c-4a0c-930c-caac93d9d052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_PensionExpense_6f36c960-510c-4a0c-930c-caac93d9d052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_6cc94e13-6894-4f79-a67a-e6721cc8fb78" xlink:href="amed-20201231.xsd#amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_6cc94e13-6894-4f79-a67a-e6721cc8fb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8643321d-e992-437f-802e-be9d9f86ead4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8643321d-e992-437f-802e-be9d9f86ead4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnSaleOfInvestments_4dc86459-0ba4-47e4-a229-4f9879e679fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnSaleOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_LossOnSaleOfInvestments_4dc86459-0ba4-47e4-a229-4f9879e679fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_a0c52443-af5a-4908-aec8-04f2bfcb147a" xlink:href="amed-20201231.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_a0c52443-af5a-4908-aec8-04f2bfcb147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_62e4a676-3475-4c2f-923f-f568a9fc4ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_62e4a676-3475-4c2f-923f-f568a9fc4ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1867532a-370f-425d-9c23-28cdab280cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1867532a-370f-425d-9c23-28cdab280cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_863e751a-a492-4041-8d3f-f473583c2460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_863e751a-a492-4041-8d3f-f473583c2460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_1bbc6334-bd5c-4106-a1eb-dbdddcf1f469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_1bbc6334-bd5c-4106-a1eb-dbdddcf1f469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6a734671-1f22-418c-a757-59679fc64b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_AssetImpairmentCharges_6a734671-1f22-418c-a757-59679fc64b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e0982ca8-564c-4e3c-b027-842914dcd564" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b79a4955-173c-48b7-96de-1bb3288a8d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b79a4955-173c-48b7-96de-1bb3288a8d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4706edeb-ed5c-4a61-98fc-d8634c8c8cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4706edeb-ed5c-4a61-98fc-d8634c8c8cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1b75da94-cd2c-433e-a758-48704e0e569a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1b75da94-cd2c-433e-a758-48704e0e569a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bf7583ec-60e9-4ab6-9099-a8fc9c0bb49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bf7583ec-60e9-4ab6-9099-a8fc9c0bb49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3c9cfd08-1e49-4668-99df-857967344b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3c9cfd08-1e49-4668-99df-857967344b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_789c5dbf-8edd-4628-81a9-c6520e33e5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_789c5dbf-8edd-4628-81a9-c6520e33e5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_0e37fb74-c121-460a-8f74-9eb9575fa9ae" xlink:href="amed-20201231.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_0e37fb74-c121-460a-8f74-9eb9575fa9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_008e0dae-c854-42b6-89da-948d5e077026" xlink:href="amed-20201231.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c3048e24-9821-4847-bdf6-f77779815585" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_008e0dae-c854-42b6-89da-948d5e077026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ee3addd-394f-4e77-9cdd-ae5172e70726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08377ddd-e5f6-4dd4-826b-32f078777427" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ee3addd-394f-4e77-9cdd-ae5172e70726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_dcc79cff-87ee-40b9-aade-2a8dd8b6ed4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_dcc79cff-87ee-40b9-aade-2a8dd8b6ed4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3a848ffd-f5ed-498f-9379-5366a2dfcc32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3a848ffd-f5ed-498f-9379-5366a2dfcc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_129536dd-9438-4134-acbe-894627f18bde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_129536dd-9438-4134-acbe-894627f18bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_06f029e1-9bcf-47dc-aeba-1e02da553240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_06f029e1-9bcf-47dc-aeba-1e02da553240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_52cfaf22-ffd2-469c-ac64-025f733b7a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_52cfaf22-ffd2-469c-ac64-025f733b7a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6ceed992-953f-4c9b-878c-cd91a93d68a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6ceed992-953f-4c9b-878c-cd91a93d68a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc741774-f61a-40c7-8d62-1ffc9f902180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_80b75664-57be-42b8-b9f6-d96252aada12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc741774-f61a-40c7-8d62-1ffc9f902180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0af257dd-8b94-417a-93d7-7171836ade01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0af257dd-8b94-417a-93d7-7171836ade01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b2fc8c36-a536-45a2-b2d2-e0442fb8d2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b2fc8c36-a536-45a2-b2d2-e0442fb8d2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fff50d6a-40a4-450a-b7ca-ce09d655ea4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fff50d6a-40a4-450a-b7ca-ce09d655ea4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_b4af1928-6d6e-4707-9cd4-0f5307042a01" xlink:href="amed-20201231.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_b4af1928-6d6e-4707-9cd4-0f5307042a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_5f781897-bdd8-4452-bfd6-5e34b9914c91" xlink:href="amed-20201231.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_amed_ProceedsFromBorrowingsUnderTermLoan_5f781897-bdd8-4452-bfd6-5e34b9914c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_c9a5437b-eee2-4053-bf10-bc823f4905e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_c9a5437b-eee2-4053-bf10-bc823f4905e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b5143595-52bc-48b2-b79e-ae75c37fae81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b5143595-52bc-48b2-b79e-ae75c37fae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a9815206-159d-431d-bd51-9de72d5217fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a9815206-159d-431d-bd51-9de72d5217fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_37ef8466-b148-450d-810a-78871d78c544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_37ef8466-b148-450d-810a-78871d78c544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_a16123fa-5e03-4ed6-b6f1-487ca162caf8" xlink:href="amed-20201231.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_a16123fa-5e03-4ed6-b6f1-487ca162caf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f81e37db-fc51-4aca-8289-3ce19cd484f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f81e37db-fc51-4aca-8289-3ce19cd484f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_17286975-d003-4663-9191-e6b7cacce1f0" xlink:href="amed-20201231.xsd#amed_PaymentsForRepurchaseOfNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_amed_PaymentsForRepurchaseOfNoncontrollingInterest_17286975-d003-4663-9191-e6b7cacce1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df829226-a6b0-4edd-8d1e-f9636d41be32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d242f62f-2772-4630-8f55-20a2fd307f21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df829226-a6b0-4edd-8d1e-f9636d41be32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1c3687eb-20a1-427a-b70b-41c6f1ca0e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1c3687eb-20a1-427a-b70b-41c6f1ca0e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8de7eaf4-01e7-450b-99e4-8546166b64a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8de7eaf4-01e7-450b-99e4-8546166b64a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f90b1af0-e162-4e59-9afc-aea1266610f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f90b1af0-e162-4e59-9afc-aea1266610f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fe5f36a-98af-46d7-a89e-5aaa96af4679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fe5f36a-98af-46d7-a89e-5aaa96af4679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a91a00b1-e105-4c6b-af26-9bf6023d29e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fe5f36a-98af-46d7-a89e-5aaa96af4679" xlink:to="loc_us-gaap_InterestPaidNet_a91a00b1-e105-4c6b-af26-9bf6023d29e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_e8bb32b7-287d-44b9-9547-0b1c6bf9b95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fe5f36a-98af-46d7-a89e-5aaa96af4679" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_e8bb32b7-287d-44b9-9547-0b1c6bf9b95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_b633ffb3-a480-4b0d-aea3-96493619e94c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8c239fb7-be5f-4798-b930-2a2b1ed18d3b" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_b633ffb3-a480-4b0d-aea3-96493619e94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAssumed1_6020eec9-d230-4c45-a766-af61a459cf48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAssumed1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_b633ffb3-a480-4b0d-aea3-96493619e94c" xlink:to="loc_us-gaap_NotesAssumed1_6020eec9-d230-4c45-a766-af61a459cf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29e0004b-55f4-4734-9859-e9ed07716ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5a872ee8-d169-48f2-98d9-46d4ceba0e93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_29e0004b-55f4-4734-9859-e9ed07716ef8" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5a872ee8-d169-48f2-98d9-46d4ceba0e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c9bbef9-f418-4414-8150-63b74514dd63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:href="amed-20201231.xsd#amed_OrganizationAndNatureOfOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c9bbef9-f418-4414-8150-63b74514dd63" xlink:to="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_f0b1666d-8311-4d8a-9acc-330530732b14" xlink:href="amed-20201231.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_f0b1666d-8311-4d8a-9acc-330530732b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentDomain_8ee2efd8-7a2d-4c3b-b3fb-d92b9a03b95c" xlink:href="amed-20201231.xsd#amed_TypeofEquityMethodInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_f0b1666d-8311-4d8a-9acc-330530732b14" xlink:to="loc_amed_TypeofEquityMethodInvestmentDomain_8ee2efd8-7a2d-4c3b-b3fb-d92b9a03b95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthcareanalyticscompanyMember_41f1c94e-8b12-47d9-9609-9f99f29d9288" xlink:href="amed-20201231.xsd#amed_HealthcareanalyticscompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_8ee2efd8-7a2d-4c3b-b3fb-d92b9a03b95c" xlink:to="loc_amed_HealthcareanalyticscompanyMember_41f1c94e-8b12-47d9-9609-9f99f29d9288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember_fe09510c-c26e-4da6-8977-7a53181ccd7d" xlink:href="amed-20201231.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentDomain_8ee2efd8-7a2d-4c3b-b3fb-d92b9a03b95c" xlink:to="loc_amed_HeritageHealthcareInnovationFundLPMember_fe09510c-c26e-4da6-8977-7a53181ccd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_57c1778a-7474-4e3c-a8f2-5397b608838a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_57c1778a-7474-4e3c-a8f2-5397b608838a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_57c1778a-7474-4e3c-a8f2-5397b608838a" xlink:to="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_cabb8be6-b810-49be-84d8-43ea04feb1d0" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:to="loc_amed_HomeHealthMember_cabb8be6-b810-49be-84d8-43ea04feb1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_98b03510-01e1-44c7-ac9b-4c7a1963135a" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:to="loc_amed_HospiceMember_98b03510-01e1-44c7-ac9b-4c7a1963135a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_736bb6b6-bef2-45ff-ba32-f187fa8442ec" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d8e8215e-466a-4a46-be19-859f6f0ac7c9" xlink:to="loc_amed_PersonalCareMember_736bb6b6-bef2-45ff-ba32-f187fa8442ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d10843a7-5594-4dcf-b02d-9ac0cf745286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d10843a7-5594-4dcf-b02d-9ac0cf745286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21197c6e-c479-441d-a891-1c7380c34013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d10843a7-5594-4dcf-b02d-9ac0cf745286" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21197c6e-c479-441d-a891-1c7380c34013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_58a22768-f60d-4bc5-b417-2bd0db538b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21197c6e-c479-441d-a891-1c7380c34013" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_58a22768-f60d-4bc5-b417-2bd0db538b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_cba7a450-788a-4b17-9154-061759d879e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_cba7a450-788a-4b17-9154-061759d879e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_66b398d0-8df0-4906-b447-7666b5155119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cba7a450-788a-4b17-9154-061759d879e7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_66b398d0-8df0-4906-b447-7666b5155119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_c3a0459a-8a7e-446b-b5b1-07246bcf4296" xlink:href="amed-20201231.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_66b398d0-8df0-4906-b447-7666b5155119" xlink:to="loc_amed_MedicareRevenueMember_c3a0459a-8a7e-446b-b5b1-07246bcf4296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_81cbcc43-456c-4b1e-8a73-263a0e760a4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_srt_OwnershipAxis_81cbcc43-456c-4b1e-8a73-263a0e760a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_dbc39fb9-4517-4b44-986a-f7eb4e30c0a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_81cbcc43-456c-4b1e-8a73-263a0e760a4d" xlink:to="loc_srt_OwnershipDomain_dbc39fb9-4517-4b44-986a-f7eb4e30c0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestSoldMember_1812209b-cf0d-4b08-a88e-905e6967cbda" xlink:href="amed-20201231.xsd#amed_NoncontrollingInterestSoldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_dbc39fb9-4517-4b44-986a-f7eb4e30c0a5" xlink:to="loc_amed_NoncontrollingInterestSoldMember_1812209b-cf0d-4b08-a88e-905e6967cbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:href="amed-20201231.xsd#amed_OrganizationAndNatureOfOperationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_11885dd9-c986-4666-a13b-7f3b06779760" xlink:to="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f88b679a-a05f-43f5-bc72-e6e6111de1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f88b679a-a05f-43f5-bc72-e6e6111de1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_0f1c053e-b035-44ff-9a21-9548c2a4f50a" xlink:href="amed-20201231.xsd#amed_OperatingCareCenters"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_OperatingCareCenters_0f1c053e-b035-44ff-9a21-9548c2a4f50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_fb12e0a2-0620-4068-82b2-d060c8353fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_fb12e0a2-0620-4068-82b2-d060c8353fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_61feca9a-e05a-47a5-9945-724894fe3817" xlink:href="amed-20201231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_61feca9a-e05a-47a5-9945-724894fe3817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1db70a73-7ec3-4bfe-bed2-3d5d082b9317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1db70a73-7ec3-4bfe-bed2-3d5d082b9317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestRepurchased_b45d37bc-5a70-41bf-a4ef-84504446434a" xlink:href="amed-20201231.xsd#amed_NoncontrollingInterestRepurchased"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_NoncontrollingInterestRepurchased_b45d37bc-5a70-41bf-a4ef-84504446434a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_1f7f588b-3a29-49a0-afd8-b8babab7a756" xlink:href="amed-20201231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_1f7f588b-3a29-49a0-afd8-b8babab7a756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b87400d0-c9d4-4320-bae8-5fb84f567c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b87400d0-c9d4-4320-bae8-5fb84f567c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_c30ea207-9fa6-454d-a4f3-c07cbba153a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_c30ea207-9fa6-454d-a4f3-c07cbba153a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_6861d055-78b1-4db7-9abd-c031a64877f3" xlink:href="amed-20201231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_6861d055-78b1-4db7-9abd-c031a64877f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8f06b3b9-d3c1-4358-bf17-152a356ffc96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8f06b3b9-d3c1-4358-bf17-152a356ffc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnSaleOfInvestments_52324fba-21b1-45ca-acb7-55c1005c029a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnSaleOfInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_616996c1-42ef-4721-915d-d2a30210d943" xlink:to="loc_us-gaap_LossOnSaleOfInvestments_52324fba-21b1-45ca-acb7-55c1005c029a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d61608ce-765c-418a-8b93-ad63e78a7e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d61608ce-765c-418a-8b93-ad63e78a7e6f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b0a47f90-928d-4aeb-ac5a-fa6028cbe663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b0a47f90-928d-4aeb-ac5a-fa6028cbe663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_195338c0-fc7f-43fc-9a11-38a680d88ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b0a47f90-928d-4aeb-ac5a-fa6028cbe663" xlink:to="loc_us-gaap_TypeOfAdoptionMember_195338c0-fc7f-43fc-9a11-38a680d88ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_154c53b1-6ebd-4430-9f27-cee06974d6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_195338c0-fc7f-43fc-9a11-38a680d88ce3" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_154c53b1-6ebd-4430-9f27-cee06974d6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_73d4b1bb-18ff-4645-98cc-5e8807aad0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_195338c0-fc7f-43fc-9a11-38a680d88ce3" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_73d4b1bb-18ff-4645-98cc-5e8807aad0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15c277f8-8f1d-4931-a918-c38b3ffeadb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15c277f8-8f1d-4931-a918-c38b3ffeadb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1635bb4-be5f-42cc-9ce6-8656e76372c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15c277f8-8f1d-4931-a918-c38b3ffeadb7" xlink:to="loc_us-gaap_EquityComponentDomain_a1635bb4-be5f-42cc-9ce6-8656e76372c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c6f3bc4e-97f1-45de-86f7-59abe2e19ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1635bb4-be5f-42cc-9ce6-8656e76372c9" xlink:to="loc_us-gaap_RetainedEarningsMember_c6f3bc4e-97f1-45de-86f7-59abe2e19ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_bf8f72b8-3ce1-407b-b187-8881cf7a09d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:to="loc_srt_RestatementAxis_bf8f72b8-3ce1-407b-b187-8881cf7a09d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_4064d734-91f4-40ac-8282-3821d7d599e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_bf8f72b8-3ce1-407b-b187-8881cf7a09d5" xlink:to="loc_srt_RestatementDomain_4064d734-91f4-40ac-8282-3821d7d599e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_d0007cb3-c55e-4544-89fa-3ea776a7fb94" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_4064d734-91f4-40ac-8282-3821d7d599e9" xlink:to="loc_srt_RestatementAdjustmentMember_d0007cb3-c55e-4544-89fa-3ea776a7fb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_87685c27-5659-497a-af10-dce3877bab07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_99c28aeb-eb93-4068-a4dd-803a755ac559" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_87685c27-5659-497a-af10-dce3877bab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d20ad609-2a50-4e83-b5e5-5d00eb0ce800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_87685c27-5659-497a-af10-dce3877bab07" xlink:to="loc_us-gaap_OperatingLeaseLiability_d20ad609-2a50-4e83-b5e5-5d00eb0ce800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_03e5ff66-bf5b-4ede-9fcb-a5f4d0804cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_87685c27-5659-497a-af10-dce3877bab07" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_03e5ff66-bf5b-4ede-9fcb-a5f4d0804cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="simple" xlink:href="amed-20201231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff9379fc-4b31-4f34-8066-60baa4d4e7e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b409030b-f7d8-401e-9df1-dadc9a9d3da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e66b3b96-cc72-4bca-8b1e-423a7fd993d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b409030b-f7d8-401e-9df1-dadc9a9d3da1" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e66b3b96-cc72-4bca-8b1e-423a7fd993d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_00c19c42-e3d1-42f5-9b69-3ea719bbfe88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_00c19c42-e3d1-42f5-9b69-3ea719bbfe88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3a1c29b9-0a46-4993-8314-445338fea5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_UseOfEstimates_3a1c29b9-0a46-4993-8314-445338fea5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ad5aae9a-4603-450a-95bc-e12e606706d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ad5aae9a-4603-450a-95bc-e12e606706d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_9eed7ffd-5231-41b1-9301-9c1460a7c5a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_9eed7ffd-5231-41b1-9301-9c1460a7c5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_07806e8a-6960-4dfd-b242-aaddd31bfc8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_07806e8a-6960-4dfd-b242-aaddd31bfc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock_45766af0-b1e7-4c01-90d9-907934b291e3" xlink:href="amed-20201231.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_amed_GovernmentGrantsPolicyTextBlock_45766af0-b1e7-4c01-90d9-907934b291e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7bcf830e-0b7b-43b0-b928-8686a7e50880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7bcf830e-0b7b-43b0-b928-8686a7e50880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_6c8ee26d-15fd-47d2-8fd9-7934d16a10ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_6c8ee26d-15fd-47d2-8fd9-7934d16a10ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9bff5e4f-0936-4451-b53f-e18040fdfb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9bff5e4f-0936-4451-b53f-e18040fdfb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_c1826898-7887-4647-93e9-886453b1503d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_c1826898-7887-4647-93e9-886453b1503d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_29f95db7-eae4-4b94-bd85-9f37e31b2cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_29f95db7-eae4-4b94-bd85-9f37e31b2cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_1dc66eb4-9b4f-43e2-8fa4-73576e10bd11" xlink:href="amed-20201231.xsd#amed_DebtIssuanceCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_1dc66eb4-9b4f-43e2-8fa4-73576e10bd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ccc94f85-955c-42a8-b638-bc36bb542090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_ccc94f85-955c-42a8-b638-bc36bb542090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1a2ccc41-3b5f-4a65-b325-5238c8a4276e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1a2ccc41-3b5f-4a65-b325-5238c8a4276e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fb00d215-9308-4496-937e-9a758c8a6e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fb00d215-9308-4496-937e-9a758c8a6e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_695ec8a0-8c9d-4583-b168-07da113d2ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_695ec8a0-8c9d-4583-b168-07da113d2ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_59ac267d-fb5f-4f44-a955-65b404b9e29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ecfbc1b-33df-45fe-9bc9-dc987826de1c" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_59ac267d-fb5f-4f44-a955-65b404b9e29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d30e81e4-5209-42bd-8177-4d425f21840d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_e3916284-1339-4816-a78f-d738aa70def8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d30e81e4-5209-42bd-8177-4d425f21840d" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_e3916284-1339-4816-a78f-d738aa70def8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_4b2a4a2a-a43c-4ce8-97db-f2b9060e8c95" xlink:href="amed-20201231.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d30e81e4-5209-42bd-8177-4d425f21840d" xlink:to="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_4b2a4a2a-a43c-4ce8-97db-f2b9060e8c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_aa579768-7de8-4b4d-95bf-e62075766735" xlink:href="amed-20201231.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d30e81e4-5209-42bd-8177-4d425f21840d" xlink:to="loc_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_aa579768-7de8-4b4d-95bf-e62075766735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78964f5e-a152-4db7-9a8e-9e41df659717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d30e81e4-5209-42bd-8177-4d425f21840d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_78964f5e-a152-4db7-9a8e-9e41df659717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_fb324920-f809-4cfb-a9b2-cdd59aed6f5e" xlink:href="amed-20201231.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d30e81e4-5209-42bd-8177-4d425f21840d" xlink:to="loc_amed_FinancialInstrumentDetailsTableTextBlock_fb324920-f809-4cfb-a9b2-cdd59aed6f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_bf430ada-3500-4a5b-ac84-1ae27bc7a6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d30e81e4-5209-42bd-8177-4d425f21840d" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_bf430ada-3500-4a5b-ac84-1ae27bc7a6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_af2b8122-bd46-473e-8c2b-453f9388bad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af2b8122-bd46-473e-8c2b-453f9388bad0" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_f8145bbc-51b6-4333-88c7-2173f5313528" xlink:href="amed-20201231.xsd#amed_CapYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_amed_CapYearAxis_f8145bbc-51b6-4333-88c7-2173f5313528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_4d5e33b2-9022-470d-bd81-54edc4c712e1" xlink:href="amed-20201231.xsd#amed_CapYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearAxis_f8145bbc-51b6-4333-88c7-2173f5313528" xlink:to="loc_amed_CapYearDomain_4d5e33b2-9022-470d-bd81-54edc4c712e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_425f77b4-699a-4ec1-a606-18925f9d3c07" xlink:href="amed-20201231.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_4d5e33b2-9022-470d-bd81-54edc4c712e1" xlink:to="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_425f77b4-699a-4ec1-a606-18925f9d3c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_017dea2c-dc48-4a57-ab58-055162d1ebeb" xlink:href="amed-20201231.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_4d5e33b2-9022-470d-bd81-54edc4c712e1" xlink:to="loc_amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember_017dea2c-dc48-4a57-ab58-055162d1ebeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d42a55d-f0d3-4517-94ce-46497f5c6306" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_srt_RangeAxis_9d42a55d-f0d3-4517-94ce-46497f5c6306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_127cc09a-e6d4-4c4e-8350-98fd5866f922" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9d42a55d-f0d3-4517-94ce-46497f5c6306" xlink:to="loc_srt_RangeMember_127cc09a-e6d4-4c4e-8350-98fd5866f922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22b00f78-af29-4bdc-beae-8d74613180ff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_127cc09a-e6d4-4c4e-8350-98fd5866f922" xlink:to="loc_srt_MinimumMember_22b00f78-af29-4bdc-beae-8d74613180ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_95d57ee1-0c6e-48b0-96d0-31e3ddb56c87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_127cc09a-e6d4-4c4e-8350-98fd5866f922" xlink:to="loc_srt_MaximumMember_95d57ee1-0c6e-48b0-96d0-31e3ddb56c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a327d3c0-48d9-46c1-91d7-54627b3de4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a327d3c0-48d9-46c1-91d7-54627b3de4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_708626aa-1a7a-4e42-a503-f482025174ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a327d3c0-48d9-46c1-91d7-54627b3de4bd" xlink:to="loc_us-gaap_SegmentDomain_708626aa-1a7a-4e42-a503-f482025174ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_dff5f045-ce54-4c3f-9d5d-5f058754dd64" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_708626aa-1a7a-4e42-a503-f482025174ef" xlink:to="loc_amed_HomeHealthMember_dff5f045-ce54-4c3f-9d5d-5f058754dd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_2fa82c15-8ba6-49e0-8782-358b72875ac9" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_708626aa-1a7a-4e42-a503-f482025174ef" xlink:to="loc_amed_HospiceMember_2fa82c15-8ba6-49e0-8782-358b72875ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fa6921c6-15c2-47ff-a109-00c95b018ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fa6921c6-15c2-47ff-a109-00c95b018ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_faf3af93-99b3-4fbc-8d3e-f04ba0925818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fa6921c6-15c2-47ff-a109-00c95b018ffb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_faf3af93-99b3-4fbc-8d3e-f04ba0925818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1d658457-affb-44cd-9c44-29d48a8f2e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_faf3af93-99b3-4fbc-8d3e-f04ba0925818" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_1d658457-affb-44cd-9c44-29d48a8f2e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_356dc0f1-d1d3-40d4-84d5-f010868cf0be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_356dc0f1-d1d3-40d4-84d5-f010868cf0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7b95bd49-efbd-4593-8bf6-fd7a7d6bc505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_356dc0f1-d1d3-40d4-84d5-f010868cf0be" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7b95bd49-efbd-4593-8bf6-fd7a7d6bc505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_d5d59fef-dd80-404b-93f4-cad72f04eb61" xlink:href="amed-20201231.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_7b95bd49-efbd-4593-8bf6-fd7a7d6bc505" xlink:to="loc_amed_MedicareRevenueMember_d5d59fef-dd80-404b-93f4-cad72f04eb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_83402d1c-faae-4816-9e56-da80e914b6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_83402d1c-faae-4816-9e56-da80e914b6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05bf561e-d13e-4850-bd63-d0e2702c4618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_83402d1c-faae-4816-9e56-da80e914b6b2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05bf561e-d13e-4850-bd63-d0e2702c4618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_a945adbe-3c4b-471b-8d2e-fe7c359af154" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05bf561e-d13e-4850-bd63-d0e2702c4618" xlink:to="loc_amed_AseraCareHospiceMember_a945adbe-3c4b-471b-8d2e-fe7c359af154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_dd1a9b00-7a25-4e5d-96cf-f04375a6c799" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_405e6e3f-55d4-4f22-ad67-0168bf57b05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_405e6e3f-55d4-4f22-ad67-0168bf57b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_78a67284-6c71-4be9-9484-500c0ffbda1f" xlink:href="amed-20201231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_78a67284-6c71-4be9-9484-500c0ffbda1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_b8e38a8b-6a63-400f-b389-9a05426eded9" xlink:href="amed-20201231.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_b8e38a8b-6a63-400f-b389-9a05426eded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_13b19c0f-4753-461f-a394-5ebfc1f481d1" xlink:href="amed-20201231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_13b19c0f-4753-461f-a394-5ebfc1f481d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_75795298-a4ca-43fa-a37a-e19e66f941ce" xlink:href="amed-20201231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_75795298-a4ca-43fa-a37a-e19e66f941ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_dcf290f4-463a-45d0-b3d1-7555f6048b5f" xlink:href="amed-20201231.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_dcf290f4-463a-45d0-b3d1-7555f6048b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_d197f20a-9a1a-4666-84d4-7733ac3a74b2" xlink:href="amed-20201231.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_SecondThresholdOfServicesRequired_d197f20a-9a1a-4666-84d4-7733ac3a74b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_1f0df632-8501-4582-90ea-4f49ead34df3" xlink:href="amed-20201231.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_1f0df632-8501-4582-90ea-4f49ead34df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_44800955-4348-4951-bf1c-f26462f08247" xlink:href="amed-20201231.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_44800955-4348-4951-bf1c-f26462f08247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodesInProgressThatBeginDuringReportingPeriod_38d80f68-8d96-4f14-81c9-82f9bbdab70e" xlink:href="amed-20201231.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_EpisodesInProgressThatBeginDuringReportingPeriod_38d80f68-8d96-4f14-81c9-82f9bbdab70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_b450c6fa-7a24-4bda-b991-6fbf3f94008c" xlink:href="amed-20201231.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_NonMedicareRevenueTermRates_b450c6fa-7a24-4bda-b991-6fbf3f94008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_047857f7-5572-40e4-8f7d-ba62c9f31024" xlink:href="amed-20201231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_047857f7-5572-40e4-8f7d-ba62c9f31024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_dcf5b8fa-b4ef-477e-bb70-07d9a9e25efb" xlink:href="amed-20201231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_dcf5b8fa-b4ef-477e-bb70-07d9a9e25efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_d309e4f8-30c1-49d8-9539-de7103edc886" xlink:href="amed-20201231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_d309e4f8-30c1-49d8-9539-de7103edc886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_7ce2fb2e-49ce-479f-a4ba-9da99deaf328" xlink:href="amed-20201231.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_7ce2fb2e-49ce-479f-a4ba-9da99deaf328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_db2cef53-aab6-41aa-bbb2-80ed0d54f060" xlink:href="amed-20201231.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_91a01be3-b3a9-40fa-9160-06b7a8cfa5da" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_db2cef53-aab6-41aa-bbb2-80ed0d54f060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_89832680-8869-4c89-9ba8-680a9afe1ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_7a369ea6-39ae-4238-aeb3-c7b310399f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_89832680-8869-4c89-9ba8-680a9afe1ca2" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_7a369ea6-39ae-4238-aeb3-c7b310399f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7" xlink:href="amed-20201231.xsd#amed_PayorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_7a369ea6-39ae-4238-aeb3-c7b310399f66" xlink:to="loc_amed_PayorClassAxis_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:href="amed-20201231.xsd#amed_PayorClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassAxis_b991df3d-9ba1-48f8-be72-1cbf6d2a0bb7" xlink:to="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_d9c41b72-7e3a-47f8-9a45-b066d2215596" xlink:href="amed-20201231.xsd#amed_HomeHealthMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HomeHealthMedicareMember_d9c41b72-7e3a-47f8-9a45-b066d2215596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_8ec30f3b-a25d-4596-8d5d-5b014ec8f862" xlink:href="amed-20201231.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_8ec30f3b-a25d-4596-8d5d-5b014ec8f862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_4a80181a-25dd-4f0e-a350-e16caf8ed434" xlink:href="amed-20201231.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_4a80181a-25dd-4f0e-a350-e16caf8ed434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_55b8da12-9201-4455-9149-ec64c9b8c1f9" xlink:href="amed-20201231.xsd#amed_HospiceMedicareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HospiceMedicareMember_55b8da12-9201-4455-9149-ec64c9b8c1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_508125f6-069b-4e49-b979-b966f38c0afc" xlink:href="amed-20201231.xsd#amed_HospiceNonMedicareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_HospiceNonMedicareMember_508125f6-069b-4e49-b979-b966f38c0afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_2c0d2a3d-8336-4f03-9cdd-3649ca43930e" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_6a3b3614-a20b-4696-9fd4-b22b731b084e" xlink:to="loc_amed_PersonalCareMember_2c0d2a3d-8336-4f03-9cdd-3649ca43930e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bebcfd93-126f-4ae5-a47d-082d5636d3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_7a369ea6-39ae-4238-aeb3-c7b310399f66" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bebcfd93-126f-4ae5-a47d-082d5636d3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_7d46f561-1354-4d37-a1f7-ce65300b964b" xlink:href="amed-20201231.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_bebcfd93-126f-4ae5-a47d-082d5636d3a1" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_7d46f561-1354-4d37-a1f7-ce65300b964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2f7cebac-18fe-4f45-afb7-f07a49bba48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9334adbe-f052-4d02-8a37-31c378ced81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f7cebac-18fe-4f45-afb7-f07a49bba48a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9334adbe-f052-4d02-8a37-31c378ced81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b53747ab-bfd0-45ef-9659-c2259b0966ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9334adbe-f052-4d02-8a37-31c378ced81e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b53747ab-bfd0-45ef-9659-c2259b0966ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a5ddc00-728c-41de-becb-90708417ea33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b53747ab-bfd0-45ef-9659-c2259b0966ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a5ddc00-728c-41de-becb-90708417ea33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAcquisitionMember_458b0cf2-cad8-48d7-a45c-b2090a5559a1" xlink:href="amed-20201231.xsd#amed_AsanaHospiceAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a5ddc00-728c-41de-becb-90708417ea33" xlink:to="loc_amed_AsanaHospiceAcquisitionMember_458b0cf2-cad8-48d7-a45c-b2090a5559a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9334adbe-f052-4d02-8a37-31c378ced81e" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d77fe213-5e57-4fe2-bf65-0324161c916d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d77fe213-5e57-4fe2-bf65-0324161c916d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3a6c1780-ecc6-4adc-90b0-ae3c239da33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_us-gaap_RestrictedCash_3a6c1780-ecc6-4adc-90b0-ae3c239da33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0e59c35-9add-49c1-a67d-6068b180ad6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0e59c35-9add-49c1-a67d-6068b180ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_f95f562b-4bd3-4233-be0b-917f2f925c95" xlink:href="amed-20201231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_38754566-c99e-4f51-8b9e-9dc86735e926" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_f95f562b-4bd3-4233-be0b-917f2f925c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_1428d5a1-2b13-4637-8bf7-fe9166a2f6ac" xlink:href="amed-20201231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_dccfb36c-91f4-49e7-a3bf-bafb3e62a4e3" xlink:href="amed-20201231.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_PercentageOfPatientReceivablesOutstanding_dccfb36c-91f4-49e7-a3bf-bafb3e62a4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_f4f83efd-ca3c-4d58-9a01-65203d38d4a2" xlink:href="amed-20201231.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_f4f83efd-ca3c-4d58-9a01-65203d38d4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_7dbfa816-1a18-47da-bd85-bfed20e3ff30" xlink:href="amed-20201231.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_7dbfa816-1a18-47da-bd85-bfed20e3ff30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_f25637b9-03fe-4c95-a99f-2508e16decca" xlink:href="amed-20201231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_f25637b9-03fe-4c95-a99f-2508e16decca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue_14f6fc6d-6f37-4b2c-b795-d931459a18ca" xlink:href="amed-20201231.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_RevenueAdjustmentToMedicareRevenue_14f6fc6d-6f37-4b2c-b795-d931459a18ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_9f78bba3-285b-4a59-9480-cbf5e8243bf9" xlink:href="amed-20201231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_9f78bba3-285b-4a59-9480-cbf5e8243bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_911d210b-7be9-46bb-ba79-0ac0067b54b4" xlink:href="amed-20201231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_911d210b-7be9-46bb-ba79-0ac0067b54b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_72a7a673-45ed-40d3-bc0a-e61dc35df492" xlink:href="amed-20201231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_72a7a673-45ed-40d3-bc0a-e61dc35df492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_2f582c7f-a418-4e3d-bb2a-08e4a9295877" xlink:href="amed-20201231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_668ff94e-8cdf-4745-a0fb-67548ef5fa7b" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_2f582c7f-a418-4e3d-bb2a-08e4a9295877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_98518963-00df-4f3f-8a9c-dd84e25996ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_98518963-00df-4f3f-8a9c-dd84e25996ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_2a4c0545-058d-4c58-86b0-a20146ba8e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_2a4c0545-058d-4c58-86b0-a20146ba8e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternallyDevelopedComputerSoftware_639dd356-2044-48ef-938d-4bda6e8c2892" xlink:href="amed-20201231.xsd#amed_InternallyDevelopedComputerSoftware"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_amed_InternallyDevelopedComputerSoftware_639dd356-2044-48ef-938d-4bda6e8c2892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_64d53fef-19dc-45d7-b400-123212131977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_AssetImpairmentCharges_64d53fef-19dc-45d7-b400-123212131977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_25a4fdee-7492-4a6c-8051-5a9768a5c35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_Depreciation_25a4fdee-7492-4a6c-8051-5a9768a5c35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_d810e5ad-ee6a-4bf3-b5a5-12ef27ddd833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_d810e5ad-ee6a-4bf3-b5a5-12ef27ddd833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_9103809b-82e1-4f8f-ad98-586c4fec788e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_9103809b-82e1-4f8f-ad98-586c4fec788e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_3fd96ad4-71a7-417e-9102-029caae190f5" xlink:href="amed-20201231.xsd#amed_UnamortizedDebtIssuanceCostAmortizationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_3fd96ad4-71a7-417e-9102-029caae190f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_75463c31-04e0-49b8-9746-2d8095f927fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_75463c31-04e0-49b8-9746-2d8095f927fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2c9aa1f0-c817-42ca-9dd2-b6abd5afea63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_ShareBasedCompensation_2c9aa1f0-c817-42ca-9dd2-b6abd5afea63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_84aba7f1-c3cc-44e1-9808-45986622a40f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_84aba7f1-c3cc-44e1-9808-45986622a40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_b9c41ce3-96be-43eb-a8ef-60beda358842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_AdvertisingExpense_b9c41ce3-96be-43eb-a8ef-60beda358842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c3b7b26-4bdf-43e0-b0f9-8e470ddf2fdd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_537ff168-5f97-47b9-be16-d0d0bbe0fea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_537ff168-5f97-47b9-be16-d0d0bbe0fea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646a5ce4-14fd-4002-9eab-4cb541b6cb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_537ff168-5f97-47b9-be16-d0d0bbe0fea5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646a5ce4-14fd-4002-9eab-4cb541b6cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_4fd837d9-ea42-4030-a4ef-00a8573f95ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646a5ce4-14fd-4002-9eab-4cb541b6cb99" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_4fd837d9-ea42-4030-a4ef-00a8573f95ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_2548f513-3a1c-490b-83b2-290301c86468" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_646a5ce4-14fd-4002-9eab-4cb541b6cb99" xlink:to="loc_amed_AcquiredNamesMember_2548f513-3a1c-490b-83b2-290301c86468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a398b56a-36d9-4323-93a3-4966d30a44c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:to="loc_srt_RangeAxis_a398b56a-36d9-4323-93a3-4966d30a44c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7dcd71e-6977-42b9-9996-cddc5f50e615" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a398b56a-36d9-4323-93a3-4966d30a44c6" xlink:to="loc_srt_RangeMember_a7dcd71e-6977-42b9-9996-cddc5f50e615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f5d5fe44-65d0-43a0-8498-1cadbf866cf3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a7dcd71e-6977-42b9-9996-cddc5f50e615" xlink:to="loc_srt_MinimumMember_f5d5fe44-65d0-43a0-8498-1cadbf866cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aacb5f50-f870-475a-9e41-05b3b4f9f8b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a7dcd71e-6977-42b9-9996-cddc5f50e615" xlink:to="loc_srt_MaximumMember_aacb5f50-f870-475a-9e41-05b3b4f9f8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ddb01b66-ffec-4047-b62a-8c72906a2b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d05b0d23-2e9c-40ee-9a9d-25b8c496bf64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ddb01b66-ffec-4047-b62a-8c72906a2b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_d95878f5-6b25-46af-888a-9702404f775b" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ddb01b66-ffec-4047-b62a-8c72906a2b01" xlink:to="loc_amed_AcquiredNamesMember_d95878f5-6b25-46af-888a-9702404f775b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_37146c18-2641-4afe-b364-5d3093129951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e1826e5-f61b-4759-9de2-9b63a746ba20" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_37146c18-2641-4afe-b364-5d3093129951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1f0bbe05-232c-4d5e-9da0-0345d4fcccb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_37146c18-2641-4afe-b364-5d3093129951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1f0bbe05-232c-4d5e-9da0-0345d4fcccb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a5dd4426-d6b0-487d-b088-d8de571cb581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_37146c18-2641-4afe-b364-5d3093129951" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a5dd4426-d6b0-487d-b088-d8de571cb581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e80d7c45-eea1-42c0-aaeb-6b40ed353150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e80d7c45-eea1-42c0-aaeb-6b40ed353150" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ad07651-9091-44f3-afb7-858779335964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ad07651-9091-44f3-afb7-858779335964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4ad07651-9091-44f3-afb7-858779335964" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_1ee3d570-68f9-49cf-8a59-dbe814d753a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_BuildingMember_1ee3d570-68f9-49cf-8a59-dbe814d753a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fdbe821d-e659-4eff-b8a3-d3dee0e72e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fdbe821d-e659-4eff-b8a3-d3dee0e72e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember_d8ca72e2-7488-40cd-9e7a-40ba6907f1b1" xlink:href="amed-20201231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_amed_EquipmentAndFurnitureMember_d8ca72e2-7488-40cd-9e7a-40ba6907f1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_12436909-238f-47c5-88be-c387dc823e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_VehiclesMember_12436909-238f-47c5-88be-c387dc823e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c43c4cbf-a9d2-4c8f-9696-ccf2b36f2ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c43c4cbf-a9d2-4c8f-9696-ccf2b36f2ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_9942ceae-2714-4a6d-b7e8-092347faf160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60615af7-1296-4e05-a648-cdf2d61eb889" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_9942ceae-2714-4a6d-b7e8-092347faf160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e402e614-6cc1-42be-8166-9d2ae2e9d9bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:to="loc_srt_RangeAxis_e402e614-6cc1-42be-8166-9d2ae2e9d9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd252531-8442-455f-946a-c924951f753c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e402e614-6cc1-42be-8166-9d2ae2e9d9bb" xlink:to="loc_srt_RangeMember_dd252531-8442-455f-946a-c924951f753c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2af98f8a-e661-4a73-b536-27df62836d2d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dd252531-8442-455f-946a-c924951f753c" xlink:to="loc_srt_MinimumMember_2af98f8a-e661-4a73-b536-27df62836d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40b3addf-7fff-44ee-9ea9-eccc7f7dcd72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dd252531-8442-455f-946a-c924951f753c" xlink:to="loc_srt_MaximumMember_40b3addf-7fff-44ee-9ea9-eccc7f7dcd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e9bad50a-4852-42f8-b6c5-d0f845778d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_97cfc62a-5b5e-4bd9-ac4a-64b878833c28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e9bad50a-4852-42f8-b6c5-d0f845778d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_105625d2-5ce6-4488-94cb-7d7d2b0b1936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e9bad50a-4852-42f8-b6c5-d0f845778d98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_105625d2-5ce6-4488-94cb-7d7d2b0b1936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_ccb24608-9dcb-44f5-ba30-341bc474fca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e9bad50a-4852-42f8-b6c5-d0f845778d98" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_ccb24608-9dcb-44f5-ba30-341bc474fca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dbbf3101-925c-45e8-b467-02d5cc80a4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_672ed4d7-5c2c-4cfe-a934-a09897fe4090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dbbf3101-925c-45e8-b467-02d5cc80a4a0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_672ed4d7-5c2c-4cfe-a934-a09897fe4090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_672ed4d7-5c2c-4cfe-a934-a09897fe4090" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cbd5f3a5-4348-4ba6-ba0f-acd6ca02ac0f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BuildingAndLeaseholdImprovementsMember_4c7693c3-535d-43c7-bf88-a2d56b2e4964" xlink:href="amed-20201231.xsd#amed_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:to="loc_amed_BuildingAndLeaseholdImprovementsMember_4c7693c3-535d-43c7-bf88-a2d56b2e4964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember_186d7cf4-203e-484d-a2b2-e18493846db1" xlink:href="amed-20201231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:to="loc_amed_EquipmentAndFurnitureMember_186d7cf4-203e-484d-a2b2-e18493846db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_652c7081-4b79-49a2-8d4f-5c0ac27229ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:to="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_652c7081-4b79-49a2-8d4f-5c0ac27229ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bc218fe7-60a6-4415-bee8-b201bc74ad02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a91936c0-8031-4350-85c9-62ffd9ef013a" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_bc218fe7-60a6-4415-bee8-b201bc74ad02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_672ed4d7-5c2c-4cfe-a934-a09897fe4090" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_89c18ecb-8c6a-44b2-ba39-6e201805ae9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_89c18ecb-8c6a-44b2-ba39-6e201805ae9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b78e13fc-cc78-4ea6-a603-3b23f9bc08a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b78e13fc-cc78-4ea6-a603-3b23f9bc08a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5c1689e-d972-463e-b121-b505f52feaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ec71c510-8617-408d-96b8-d6684f00f831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5c1689e-d972-463e-b121-b505f52feaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4a70cb0d-caaf-4bdf-8f6e-ba1cf6f143b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0541bb9-029b-464b-8193-ec23b8ba2fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a70cb0d-caaf-4bdf-8f6e-ba1cf6f143b3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0541bb9-029b-464b-8193-ec23b8ba2fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136b6da7-55eb-4c15-a2cc-28462658c85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0541bb9-029b-464b-8193-ec23b8ba2fcb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136b6da7-55eb-4c15-a2cc-28462658c85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136b6da7-55eb-4c15-a2cc-28462658c85a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ccd97af1-50a9-4d86-bea8-97c2a81394f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ccd97af1-50a9-4d86-bea8-97c2a81394f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c3a73014-b9ea-4981-8c24-b4f109d1c0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c3a73014-b9ea-4981-8c24-b4f109d1c0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6df159d2-b0c2-4333-a01e-3ea7d17a5eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f7e188b2-f67d-4434-80b0-455039edae6e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6df159d2-b0c2-4333-a01e-3ea7d17a5eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ea25437-cbf8-48b0-a9b7-cfe7b13d8d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0541bb9-029b-464b-8193-ec23b8ba2fcb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ea25437-cbf8-48b0-a9b7-cfe7b13d8d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_01071552-5942-4129-a9d1-e594739fc769" xlink:href="amed-20201231.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ea25437-cbf8-48b0-a9b7-cfe7b13d8d35" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_01071552-5942-4129-a9d1-e594739fc769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_487bda22-3595-4d5b-8f99-2adb4cded5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3ea25437-cbf8-48b0-a9b7-cfe7b13d8d35" xlink:to="loc_us-gaap_LongTermDebtFairValue_487bda22-3595-4d5b-8f99-2adb4cded5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_db20ca73-eb71-481b-a7e3-365017d1b305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3abe5346-ea74-4c8e-a1ae-c015d041f9d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db20ca73-eb71-481b-a7e3-365017d1b305" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3abe5346-ea74-4c8e-a1ae-c015d041f9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c77a10db-45f6-4a3f-bdf6-f0e8e60d4f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db20ca73-eb71-481b-a7e3-365017d1b305" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c77a10db-45f6-4a3f-bdf6-f0e8e60d4f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d07d705c-5d1f-4785-a00b-768fe2822f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c77a10db-45f6-4a3f-bdf6-f0e8e60d4f0e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d07d705c-5d1f-4785-a00b-768fe2822f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_326b81a5-b00a-4212-8334-0ed4847d6e1f" xlink:href="amed-20201231.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c77a10db-45f6-4a3f-bdf6-f0e8e60d4f0e" xlink:to="loc_amed_NonVestedStockAndStockUnits_326b81a5-b00a-4212-8334-0ed4847d6e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f0efa75-8412-4bf5-8818-bceae3abb353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db20ca73-eb71-481b-a7e3-365017d1b305" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f0efa75-8412-4bf5-8818-bceae3abb353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_666f411b-93f1-427c-8cf7-bca8757aa1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db20ca73-eb71-481b-a7e3-365017d1b305" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_666f411b-93f1-427c-8cf7-bca8757aa1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_1ea3a062-4e48-41d4-8db0-0d7ef07b4d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock_392f747a-9f66-4f39-afb3-38a1bb0a99a1" xlink:href="amed-20201231.xsd#amed_COVID19TextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_1ea3a062-4e48-41d4-8db0-0d7ef07b4d0b" xlink:to="loc_amed_COVID19TextBlock_392f747a-9f66-4f39-afb3-38a1bb0a99a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Tables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_f03bd80f-7ca5-4537-8efa-acc8af0237dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_994a6e6b-a6b8-4c19-9c99-09d3b708f437" xlink:href="amed-20201231.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_f03bd80f-7ca5-4537-8efa-acc8af0237dd" xlink:to="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_994a6e6b-a6b8-4c19-9c99-09d3b708f437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20201231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_0c4351f2-e635-4a69-aae6-e2bfb2e0ba58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_0c4351f2-e635-4a69-aae6-e2bfb2e0ba58" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ad11f965-c035-4883-93de-797b9f87034a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ad11f965-c035-4883-93de-797b9f87034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2bf7b5f1-2128-4857-a750-e89e7e62efdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ad11f965-c035-4883-93de-797b9f87034a" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2bf7b5f1-2128-4857-a750-e89e7e62efdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_23147150-9254-44c0-b840-425b2bf4d348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2bf7b5f1-2128-4857-a750-e89e7e62efdb" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_23147150-9254-44c0-b840-425b2bf4d348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4a118d45-ac47-4c67-b707-7ee699446d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4a118d45-ac47-4c67-b707-7ee699446d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_508085a0-234a-4e89-a1fb-69ad75b186c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4a118d45-ac47-4c67-b707-7ee699446d50" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_508085a0-234a-4e89-a1fb-69ad75b186c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_89e19e44-818e-4d81-a606-6e8c3af89367" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_508085a0-234a-4e89-a1fb-69ad75b186c7" xlink:to="loc_amed_AseraCareHospiceMember_89e19e44-818e-4d81-a606-6e8c3af89367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_85afc7dd-255f-4020-a1e0-406dbe379764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_85afc7dd-255f-4020-a1e0-406dbe379764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ac756648-efbc-477d-8251-c6a152d6ca75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_85afc7dd-255f-4020-a1e0-406dbe379764" xlink:to="loc_us-gaap_SegmentDomain_ac756648-efbc-477d-8251-c6a152d6ca75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_88ae568d-a282-4c70-a104-a0e8bd07d2ad" xlink:href="amed-20201231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ac756648-efbc-477d-8251-c6a152d6ca75" xlink:to="loc_amed_HomeHealthAndHospiceMember_88ae568d-a282-4c70-a104-a0e8bd07d2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_9993e2ab-e267-4732-87f4-d3846b9a9640" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ac756648-efbc-477d-8251-c6a152d6ca75" xlink:to="loc_amed_PersonalCareMember_9993e2ab-e267-4732-87f4-d3846b9a9640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_1a9c4823-25f9-499e-a5d5-27d64a5e9226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_1a9c4823-25f9-499e-a5d5-27d64a5e9226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_f97990a6-52b0-4692-8de7-c7da3cee3f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_1a9c4823-25f9-499e-a5d5-27d64a5e9226" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_f97990a6-52b0-4692-8de7-c7da3cee3f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_0969b020-a455-4360-8485-efc67350d17f" xlink:href="amed-20201231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_f97990a6-52b0-4692-8de7-c7da3cee3f7d" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_0969b020-a455-4360-8485-efc67350d17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_f1a85bd8-d85a-447f-98a4-6ed8abe66dae" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_ffa59745-5f9e-49d8-b0db-d28ee1f5f932" xlink:href="amed-20201231.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_ffa59745-5f9e-49d8-b0db-d28ee1f5f932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_4de9d007-a08c-4a60-905d-e01400ed6977" xlink:href="amed-20201231.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_4de9d007-a08c-4a60-905d-e01400ed6977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_b2f742cc-f614-496c-b630-81608f0d13ad" xlink:href="amed-20201231.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_FundingReceivedFromCARESAct_b2f742cc-f614-496c-b630-81608f0d13ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred_0b1adfaf-005f-4428-8103-1d90c57d4b04" xlink:href="amed-20201231.xsd#amed_COVID19ExpensesIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_COVID19ExpensesIncurred_0b1adfaf-005f-4428-8103-1d90c57d4b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_f4a46746-6670-4efa-8a5d-2ff89a34b263" xlink:href="amed-20201231.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_f4a46746-6670-4efa-8a5d-2ff89a34b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_f93f7e4c-1f29-4790-b146-0c2f306f651f" xlink:href="amed-20201231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_f93f7e4c-1f29-4790-b146-0c2f306f651f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c1aa2577-e18b-469e-8302-89aec6f43f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c1aa2577-e18b-469e-8302-89aec6f43f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a6043cca-0ec2-4c4a-a863-ee345f9fd2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a6043cca-0ec2-4c4a-a863-ee345f9fd2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_afc3f254-f8bf-4a1a-aec4-826d8e47d651" xlink:href="amed-20201231.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_afc3f254-f8bf-4a1a-aec4-826d8e47d651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_37f839ac-25b9-41ae-8497-a52e2951aa85" xlink:href="amed-20201231.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_37f839ac-25b9-41ae-8497-a52e2951aa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_b81f00c0-8d6e-4170-b755-a7f97b269902" xlink:href="amed-20201231.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_b81f00c0-8d6e-4170-b755-a7f97b269902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_4c7ccdf6-cebf-4a08-ac57-a1bec80b9185" xlink:href="amed-20201231.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_4c7ccdf6-cebf-4a08-ac57-a1bec80b9185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_0ce39a2e-c9f3-43d8-9476-2816213b800a" xlink:href="amed-20201231.xsd#amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures_0ce39a2e-c9f3-43d8-9476-2816213b800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_8282e780-2bbd-49e0-9bdb-350b5c07a14e" xlink:href="amed-20201231.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_8282e780-2bbd-49e0-9bdb-350b5c07a14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_3627a9af-9b06-4784-9701-ea8c3c2e342a" xlink:href="amed-20201231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_ProviderReliefFundAdvance_3627a9af-9b06-4784-9701-ea8c3c2e342a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses_a2c0142b-2c5b-428b-8123-917f72bcbaba" xlink:href="amed-20201231.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_amed_EstimatedFutureCOVID19RelatedExpenses_a2c0142b-2c5b-428b-8123-917f72bcbaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_27092aad-ae11-45c5-8ac2-421134e18103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_a3d5b033-d879-4977-baf3-e02dd3baef7f" xlink:to="loc_us-gaap_OtherOperatingIncome_27092aad-ae11-45c5-8ac2-421134e18103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_98fe3dcf-d64b-4869-8d8b-6115229fe52a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ee052c4b-9345-4c61-8bc0-4ecda4dc2b04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_98fe3dcf-d64b-4869-8d8b-6115229fe52a" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_ee052c4b-9345-4c61-8bc0-4ecda4dc2b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a8b0c12b-4ed0-4428-8816-dcaf8a5793fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_8a1d482f-815d-404a-b792-a330a7656406" xlink:href="amed-20201231.xsd#amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a8b0c12b-4ed0-4428-8816-dcaf8a5793fd" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_8a1d482f-815d-404a-b792-a330a7656406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_d4f8cf97-4f7c-4893-b0db-9accb3f271c1" xlink:href="amed-20201231.xsd#amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a8b0c12b-4ed0-4428-8816-dcaf8a5793fd" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_d4f8cf97-4f7c-4893-b0db-9accb3f271c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_ee634e26-71af-4144-aa8d-8f9c891d745d" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a8b0c12b-4ed0-4428-8816-dcaf8a5793fd" xlink:to="loc_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_ee634e26-71af-4144-aa8d-8f9c891d745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock_69659591-a8ae-413c-865a-d84c3d5c5fa4" xlink:href="amed-20201231.xsd#amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a8b0c12b-4ed0-4428-8816-dcaf8a5793fd" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock_69659591-a8ae-413c-865a-d84c3d5c5fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock_6fb41e1b-a747-409f-ae29-6916e6d5a157" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a8b0c12b-4ed0-4428-8816-dcaf8a5793fd" xlink:to="loc_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock_6fb41e1b-a747-409f-ae29-6916e6d5a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8663e96e-74bc-4c02-9a79-20996b1e929a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8663e96e-74bc-4c02-9a79-20996b1e929a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ea34eb98-ad1b-4174-9203-d417bfcbdd86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ea34eb98-ad1b-4174-9203-d417bfcbdd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ea34eb98-ad1b-4174-9203-d417bfcbdd86" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ChristianCareatHomeMember_24e96347-0f05-4630-ae18-358f8cbdf124" xlink:href="amed-20201231.xsd#amed_ChristianCareatHomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_ChristianCareatHomeMember_24e96347-0f05-4630-ae18-358f8cbdf124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EastTennesseePersonalCareMember_4355ed23-345b-406e-81db-3b628ee8d11c" xlink:href="amed-20201231.xsd#amed_EastTennesseePersonalCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_EastTennesseePersonalCareMember_4355ed23-345b-406e-81db-3b628ee8d11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BringCareHomeMember_807fdab7-9801-47e6-bb23-2bb5fd6d1ed0" xlink:href="amed-20201231.xsd#amed_BringCareHomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_BringCareHomeMember_807fdab7-9801-47e6-bb23-2bb5fd6d1ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeStaffLlcMember_c643226f-67be-4ce0-b59c-f7144ceef208" xlink:href="amed-20201231.xsd#amed_HomeStaffLlcMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_HomeStaffLlcMember_c643226f-67be-4ce0-b59c-f7144ceef208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IntercityHomeCareMember_00df4aa2-0dc7-46c2-83ed-c9c1a2e7930b" xlink:href="amed-20201231.xsd#amed_IntercityHomeCareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_IntercityHomeCareMember_00df4aa2-0dc7-46c2-83ed-c9c1a2e7930b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TenetHealthcareMember_4a86ee0d-5a09-483d-bf09-96d0b8432d73" xlink:href="amed-20201231.xsd#amed_TenetHealthcareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_TenetHealthcareMember_4a86ee0d-5a09-483d-bf09-96d0b8432d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssociatedHomecareMember_a2075c72-5edb-44d7-956f-b55154b05e10" xlink:href="amed-20201231.xsd#amed_AssociatedHomecareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_AssociatedHomecareMember_a2075c72-5edb-44d7-956f-b55154b05e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_d7337f2f-65c0-4297-9f44-eec3266e0b0b" xlink:href="amed-20201231.xsd#amed_InfinityHomeCareMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_InfinityHomeCareMember_d7337f2f-65c0-4297-9f44-eec3266e0b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_bb0ca1ce-2d52-4a84-863e-b60000ad1c2d" xlink:href="amed-20201231.xsd#amed_AsanaHospiceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_AsanaHospiceMember_bb0ca1ce-2d52-4a84-863e-b60000ad1c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_460d731c-a83d-49d9-97eb-bdc32ddabbdb" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_AseraCareHospiceMember_460d731c-a83d-49d9-97eb-bdc32ddabbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RoseRockHealthcareMember_8219d7d2-cb21-4961-a80b-6613c1ca1192" xlink:href="amed-20201231.xsd#amed_RoseRockHealthcareMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_RoseRockHealthcareMember_8219d7d2-cb21-4961-a80b-6613c1ca1192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_ead9bcb8-11b7-4924-bc6e-314abab71507" xlink:href="amed-20201231.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e10a36c-1556-4d53-b94e-c8de46f0fe76" xlink:to="loc_amed_CompassionateCareHospiceMember_ead9bcb8-11b7-4924-bc6e-314abab71507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d4c7f48a-e69c-4293-845a-a8b5d703b29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d4c7f48a-e69c-4293-845a-a8b5d703b29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d4c7f48a-e69c-4293-845a-a8b5d703b29c" xlink:to="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_b47de168-8e62-4956-bf47-1f22021090a6" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:to="loc_amed_HomeHealthMember_b47de168-8e62-4956-bf47-1f22021090a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_52e43775-8120-4098-ae68-46db5093ae8c" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:to="loc_amed_HospiceMember_52e43775-8120-4098-ae68-46db5093ae8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_27122a38-6f66-43e0-88b6-dcfd481241a7" xlink:href="amed-20201231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:to="loc_amed_HomeHealthAndHospiceMember_27122a38-6f66-43e0-88b6-dcfd481241a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_9b2c427b-4893-4fbc-a72c-9b4027a80726" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_134de31d-6461-45aa-bf51-774add514f3b" xlink:to="loc_amed_PersonalCareMember_9b2c427b-4893-4fbc-a72c-9b4027a80726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_72259706-fcd8-4570-9d48-6dfffdda5260" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_srt_StatementGeographicalAxis_72259706-fcd8-4570-9d48-6dfffdda5260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_72259706-fcd8-4570-9d48-6dfffdda5260" xlink:to="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_5f6d5af6-300c-43c0-91f6-b1fed2a92968" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_MA_5f6d5af6-300c-43c0-91f6-b1fed2a92968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_16830f18-adf8-4b76-b9a2-c967ca67dc46" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_IL_16830f18-adf8-4b76-b9a2-c967ca67dc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_ee419fd1-c08e-4283-afc3-5485a1c2c14d" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TX"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_TX_ee419fd1-c08e-4283-afc3-5485a1c2c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AZ_a360e312-d7dc-4a9e-8b74-82e182bffabd" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_AZ"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_AZ_a360e312-d7dc-4a9e-8b74-82e182bffabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_cee86de0-caf5-41d3-a1c4-725c2726cc08" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_TN_cee86de0-caf5-41d3-a1c4-725c2726cc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_6125c5b5-1a16-4523-9aef-8f7ef05c402f" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_FL_6125c5b5-1a16-4523-9aef-8f7ef05c402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_ad8bc1d7-4c33-49ee-abaf-6bbd85eda126" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_WA_ad8bc1d7-4c33-49ee-abaf-6bbd85eda126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_fcbaa61f-6bf2-4876-94bf-7170d1cf2fae" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f64890b-df2d-4caa-87d6-b239d4db0b41" xlink:to="loc_stpr_KY_fcbaa61f-6bf2-4876-94bf-7170d1cf2fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_995a6100-b8dc-4e81-830b-a646024f77a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_995a6100-b8dc-4e81-830b-a646024f77a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_995a6100-b8dc-4e81-830b-a646024f77a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_81d21e77-d0d3-43f8-8ce9-4dd50535434c" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_CertificatesOfNeedMember_81d21e77-d0d3-43f8-8ce9-4dd50535434c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_2c6d5d9f-fc36-46ac-a3f0-ee0c58f32181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_2c6d5d9f-fc36-46ac-a3f0-ee0c58f32181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicarelicensesMember_9925667e-2d3a-434d-9f5c-23a0c21945cb" xlink:href="amed-20201231.xsd#amed_MedicarelicensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_MedicarelicensesMember_9925667e-2d3a-434d-9f5c-23a0c21945cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNameOfBusinessMember_b461fd7e-6406-4796-a67c-0c9aee550f0b" xlink:href="amed-20201231.xsd#amed_AcquiredNameOfBusinessMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_AcquiredNameOfBusinessMember_b461fd7e-6406-4796-a67c-0c9aee550f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_cbc96d49-c24c-4a47-ba99-0b80c33c5122" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_cbc96d49-c24c-4a47-ba99-0b80c33c5122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_0fff87c6-2eef-423b-86b4-4ef660e1225b" xlink:href="amed-20201231.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_CertificateOfNeedMember_0fff87c6-2eef-423b-86b4-4ef660e1225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_4268ba29-98bc-4f74-98c3-863a6d71d303" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_460d4544-1304-41aa-96d3-d256cc371902" xlink:to="loc_amed_AcquiredNamesMember_4268ba29-98bc-4f74-98c3-863a6d71d303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_84423732-a966-4852-b2b6-9b71a7dafb38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_84423732-a966-4852-b2b6-9b71a7dafb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_759d9f46-875d-44d1-ae62-629cb0d264d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_84423732-a966-4852-b2b6-9b71a7dafb38" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_759d9f46-875d-44d1-ae62-629cb0d264d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_9d683eb2-5557-42d9-93df-fa0dc96c9aac" xlink:href="amed-20201231.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_759d9f46-875d-44d1-ae62-629cb0d264d1" xlink:to="loc_amed_PromissoryNotesMember_9d683eb2-5557-42d9-93df-fa0dc96c9aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_srt_RangeAxis_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db1d2351-0149-4d6b-9cc2-3f758d7c2ac8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_75e7e8d2-833e-4ff2-86da-dcc9e7056fe1" xlink:to="loc_srt_RangeMember_db1d2351-0149-4d6b-9cc2-3f758d7c2ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79c31ebb-03e7-4ccc-b972-c35e85ccc27a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_db1d2351-0149-4d6b-9cc2-3f758d7c2ac8" xlink:to="loc_srt_MaximumMember_79c31ebb-03e7-4ccc-b972-c35e85ccc27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8269a6f4-3401-4f8f-baee-336ed564c6d9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_8aec151c-5a0f-4a9d-a40f-50c00ef23da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_8aec151c-5a0f-4a9d-a40f-50c00ef23da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_177eb0a1-26c3-4ad3-8017-ca3296b5c3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_177eb0a1-26c3-4ad3-8017-ca3296b5c3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_471f7ede-2eb9-469b-8c2d-14a2907fa119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_NotesPayable_471f7ede-2eb9-469b-8c2d-14a2907fa119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_8685bdbd-42d9-4476-86f7-b6a07a61febc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_8685bdbd-42d9-4476-86f7-b6a07a61febc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_81f028f9-d148-4925-9121-0f03d0443951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_81f028f9-d148-4925-9121-0f03d0443951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_cda8101b-9d71-4392-95eb-cf7a1e635c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_cda8101b-9d71-4392-95eb-cf7a1e635c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_6141c5c1-f8c3-4e11-9026-fc70ed2c6d70" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_6141c5c1-f8c3-4e11-9026-fc70ed2c6d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a39cb1d0-df08-48e1-975a-49864f14dd90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a39cb1d0-df08-48e1-975a-49864f14dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_15f0c8f9-690d-42b2-85bf-ffc7449a5a98" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_15f0c8f9-690d-42b2-85bf-ffc7449a5a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_e2d8d880-80f6-41b2-bd7e-40f5ac5fe6a9" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_e2d8d880-80f6-41b2-bd7e-40f5ac5fe6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_710a5f8d-dbc2-4564-b6a9-fef588e656fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_710a5f8d-dbc2-4564-b6a9-fef588e656fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_0a4a7d81-34e2-4b19-9bc4-8763210dacca" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_0a4a7d81-34e2-4b19-9bc4-8763210dacca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_53aeb0c7-62a5-42e0-91db-181950b02671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_53aeb0c7-62a5-42e0-91db-181950b02671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_616e2837-b7c6-4acc-a4f3-aa146b45821d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_616e2837-b7c6-4acc-a4f3-aa146b45821d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_af100bb0-03dd-432d-8097-2ea0bb4b8925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_af100bb0-03dd-432d-8097-2ea0bb4b8925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c24fe6ca-8257-4015-a796-4a2e643899df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c24fe6ca-8257-4015-a796-4a2e643899df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_d9c6a5c2-5f9b-427a-90ac-84db83166001" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_d9c6a5c2-5f9b-427a-90ac-84db83166001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_6ce02af2-d99b-4f41-b193-251766709417" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_6ce02af2-d99b-4f41-b193-251766709417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3efc6290-e1ac-4c7c-a891-d1f6a9b04435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3efc6290-e1ac-4c7c-a891-d1f6a9b04435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_dc6dbff8-20dc-4019-8c07-4c5371474c0a" xlink:href="amed-20201231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_dc6dbff8-20dc-4019-8c07-4c5371474c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_647d90ca-89fd-4c96-86e4-93000ec451e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_647d90ca-89fd-4c96-86e4-93000ec451e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5538905c-870e-4a09-aeed-98ed68787e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5538905c-870e-4a09-aeed-98ed68787e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2cb7e568-bcf3-446a-9b87-de1b92f0ac31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2cb7e568-bcf3-446a-9b87-de1b92f0ac31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3dbe8db0-a6b0-45d6-aa0d-eda299b60d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3dbe8db0-a6b0-45d6-aa0d-eda299b60d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_c15b02ef-f9bf-48d1-b9d7-2a201cc9d0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_EscrowDeposit_c15b02ef-f9bf-48d1-b9d7-2a201cc9d0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_6041f122-698d-43d8-9388-578de8321546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_6041f122-698d-43d8-9388-578de8321546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_06c69e2f-98c6-4aca-9771-5007eb703657" xlink:href="amed-20201231.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_06c69e2f-98c6-4aca-9771-5007eb703657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_ef12cbff-8616-4bb1-9bf9-09e24db12e17" xlink:href="amed-20201231.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_ef12cbff-8616-4bb1-9bf9-09e24db12e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_5b36d843-03f6-49d6-a03a-64d4f152edf1" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_5b36d843-03f6-49d6-a03a-64d4f152edf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a26d774f-074a-4a7f-b09f-e3959b944220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a26d774f-074a-4a7f-b09f-e3959b944220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_fb2f1476-8ea3-428f-8ac5-e8289796123f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_fb2f1476-8ea3-428f-8ac5-e8289796123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f1e2484-6d56-4445-a171-874d6a6b956e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f1e2484-6d56-4445-a171-874d6a6b956e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_595e5b5e-090b-4034-afb9-4c2012a6fe5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_595e5b5e-090b-4034-afb9-4c2012a6fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_8a00a770-1700-4fd2-b492-f13d5ac518c7" xlink:href="amed-20201231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7f02de95-cda5-44f0-bf43-70fc3b46c5b2" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_8a00a770-1700-4fd2-b492-f13d5ac518c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_97e3c3af-4fc0-4a47-9f5c-3f3675e403a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_97e3c3af-4fc0-4a47-9f5c-3f3675e403a3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c360320-2dac-44a1-94b2-f04e9f575d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_868e4712-db8f-47c8-a1b3-0e12d7ba6ff0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c360320-2dac-44a1-94b2-f04e9f575d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_f90f849a-b424-43f6-9bcd-37a657aab362" xlink:href="amed-20201231.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c360320-2dac-44a1-94b2-f04e9f575d8e" xlink:to="loc_amed_AseraCareHospiceMember_f90f849a-b424-43f6-9bcd-37a657aab362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_da8af327-c3bc-41f8-a658-5a7ea9292722" xlink:href="amed-20201231.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8c360320-2dac-44a1-94b2-f04e9f575d8e" xlink:to="loc_amed_CompassionateCareHospiceMember_da8af327-c3bc-41f8-a658-5a7ea9292722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_296d2255-3b7b-42b3-aee3-2ba3bf1f620e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_296d2255-3b7b-42b3-aee3-2ba3bf1f620e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a977f65d-701f-40f2-8525-8900c38dbe53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_296d2255-3b7b-42b3-aee3-2ba3bf1f620e" xlink:to="loc_us-gaap_SegmentDomain_a977f65d-701f-40f2-8525-8900c38dbe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_955fb7b6-7d7b-42c8-bab4-cad0b7d24e6b" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a977f65d-701f-40f2-8525-8900c38dbe53" xlink:to="loc_amed_HospiceMember_955fb7b6-7d7b-42c8-bab4-cad0b7d24e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7db8616e-e387-42fe-97f4-ccc2ea1e321b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_b899d8e7-8724-4634-9bc4-c18440447dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_b899d8e7-8724-4634-9bc4-c18440447dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_2e7a2175-a348-4233-ac81-d21930aaf39b" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_2e7a2175-a348-4233-ac81-d21930aaf39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f7501c8e-bff4-432e-af10-21d8b6308e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_f7501c8e-bff4-432e-af10-21d8b6308e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_7070f2c2-974b-416a-92f4-945d5665cfc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_7070f2c2-974b-416a-92f4-945d5665cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_1fd10b10-7497-4175-8ce8-8d5b18b398fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d6a5775d-728c-4ded-923e-b568c719b568" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_1fd10b10-7497-4175-8ce8-8d5b18b398fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNET"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_704b2417-300f-4dc2-b277-b3501a29cd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b156c78e-6af8-4fb6-88a1-9ab57fd7b4ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_704b2417-300f-4dc2-b277-b3501a29cd41" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b156c78e-6af8-4fb6-88a1-9ab57fd7b4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ef017905-141f-4899-9749-611db85d85af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b87bb549-2e84-49eb-8991-16b7087930fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ef017905-141f-4899-9749-611db85d85af" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b87bb549-2e84-49eb-8991-16b7087930fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_57c9e4f7-e2f5-4dc6-ae1c-7b4441202856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ef017905-141f-4899-9749-611db85d85af" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_57c9e4f7-e2f5-4dc6-ae1c-7b4441202856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8cf2662-42cc-4497-bd0b-9cba5dd7440b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_53cf1b48-d8ed-4372-93f6-a1744981ddd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8cf2662-42cc-4497-bd0b-9cba5dd7440b" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_53cf1b48-d8ed-4372-93f6-a1744981ddd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ee74b808-b543-47ad-92de-87580e1da0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_53cf1b48-d8ed-4372-93f6-a1744981ddd1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ee74b808-b543-47ad-92de-87580e1da0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ee74b808-b543-47ad-92de-87580e1da0d7" xlink:to="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_605c9cd2-19ca-450d-9470-dac6408bf79f" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:to="loc_amed_HomeHealthMember_605c9cd2-19ca-450d-9470-dac6408bf79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_6fbf8d4a-7790-49e3-ad3f-6f734803e23e" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:to="loc_amed_HospiceMember_6fbf8d4a-7790-49e3-ad3f-6f734803e23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_1d284c50-d8d5-433d-a686-c5045f295517" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_88d974c2-40af-4b49-8286-e398d423da29" xlink:to="loc_amed_PersonalCareMember_1d284c50-d8d5-433d-a686-c5045f295517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_dcda30c2-b88b-48c2-a4e9-011726bda1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_53cf1b48-d8ed-4372-93f6-a1744981ddd1" xlink:to="loc_us-gaap_GoodwillLineItems_dcda30c2-b88b-48c2-a4e9-011726bda1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fc88cd9e-996e-4085-8bcb-d74c7edb4570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_dcda30c2-b88b-48c2-a4e9-011726bda1a5" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fc88cd9e-996e-4085-8bcb-d74c7edb4570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_dcda30c2-b88b-48c2-a4e9-011726bda1a5" xlink:to="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c28463d2-a63d-420d-99a3-457ce540cf13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:to="loc_us-gaap_Goodwill_c28463d2-a63d-420d-99a3-457ce540cf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_e1067608-8e9c-4b80-852f-a5bba51682ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_e1067608-8e9c-4b80-852f-a5bba51682ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_49f9a5bd-2270-49a9-98f5-47fba7f74129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_49f9a5bd-2270-49a9-98f5-47fba7f74129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_18092c0c-6035-4882-b30e-12896d108a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ebfa205b-adee-41f4-bc84-70cd2fb52bc7" xlink:to="loc_us-gaap_Goodwill_18092c0c-6035-4882-b30e-12896d108a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_35cbeae1-566f-44b4-b2ea-bac1eda647e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_d87521ef-04f6-4ee2-ab10-193264c3797f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_35cbeae1-566f-44b4-b2ea-bac1eda647e3" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_d87521ef-04f6-4ee2-ab10-193264c3797f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_286afcba-3b1f-4572-b957-f92a48a3783c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_d87521ef-04f6-4ee2-ab10-193264c3797f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_286afcba-3b1f-4572-b957-f92a48a3783c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cabd80ce-c486-41b7-8acd-6beda326dbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_286afcba-3b1f-4572-b957-f92a48a3783c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cabd80ce-c486-41b7-8acd-6beda326dbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_fa948fd2-ae40-4389-a4a9-f607b45fa5b1" xlink:href="amed-20201231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cabd80ce-c486-41b7-8acd-6beda326dbd1" xlink:to="loc_amed_AcquiredNamesMember_fa948fd2-ae40-4389-a4a9-f607b45fa5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_14147638-a971-40b4-a9b7-5acb5a14bbd9" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cabd80ce-c486-41b7-8acd-6beda326dbd1" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_14147638-a971-40b4-a9b7-5acb5a14bbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_bf9f50c5-4793-4f72-8262-3a1c199937b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_d87521ef-04f6-4ee2-ab10-193264c3797f" xlink:to="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_bf9f50c5-4793-4f72-8262-3a1c199937b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4f369822-a5f2-4362-8dbb-9aa284f85025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_bf9f50c5-4793-4f72-8262-3a1c199937b1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4f369822-a5f2-4362-8dbb-9aa284f85025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1abbfde3-defd-4922-87e3-4957320ebcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_bf9f50c5-4793-4f72-8262-3a1c199937b1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1abbfde3-defd-4922-87e3-4957320ebcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2d44b417-b089-4f9c-9c01-6a1062f42cff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2d44b417-b089-4f9c-9c01-6a1062f42cff" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d008f76e-7e2d-4182-95df-e13c7918030d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d008f76e-7e2d-4182-95df-e13c7918030d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14fe08a9-d901-4142-aaf2-34528270b610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d008f76e-7e2d-4182-95df-e13c7918030d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14fe08a9-d901-4142-aaf2-34528270b610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_417abd32-65b3-4e23-baf6-071782f99482" xlink:href="amed-20201231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14fe08a9-d901-4142-aaf2-34528270b610" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_417abd32-65b3-4e23-baf6-071782f99482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember_34a69b72-d7c5-4cb5-83bc-145d8eb161b6" xlink:href="amed-20201231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14fe08a9-d901-4142-aaf2-34528270b610" xlink:to="loc_amed_UnamortizableAcquiredNamesMember_34a69b72-d7c5-4cb5-83bc-145d8eb161b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d721e9b4-e27d-4ed4-9fe3-b0509742c25e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d721e9b4-e27d-4ed4-9fe3-b0509742c25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b887c9b7-5930-4d51-b9a5-4134b0d5a682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d721e9b4-e27d-4ed4-9fe3-b0509742c25e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b887c9b7-5930-4d51-b9a5-4134b0d5a682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember_e05f5cf4-32b9-476d-95d6-5dea741a9225" xlink:href="amed-20201231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b887c9b7-5930-4d51-b9a5-4134b0d5a682" xlink:to="loc_amed_AmortizableAcquiredNamesMember_e05f5cf4-32b9-476d-95d6-5dea741a9225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_2d31cf59-5930-465f-a602-659e6208f8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b887c9b7-5930-4d51-b9a5-4134b0d5a682" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_2d31cf59-5930-465f-a602-659e6208f8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_3c10b662-66cd-4382-b5ca-439111281f5a" xlink:to="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_20c973be-74e4-495c-8ce3-46c3c1a7c2f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_20c973be-74e4-495c-8ce3-46c3c1a7c2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_de0d3720-c0fd-4bc9-a139-52214d09aded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_de0d3720-c0fd-4bc9-a139-52214d09aded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e0bac79b-6800-40de-9626-08c1a87dc351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e0bac79b-6800-40de-9626-08c1a87dc351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_48ee60c2-3e7a-4175-b652-f6299b6b2071" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_47d9e89d-8daf-4a38-96f1-209d77d461ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_47d9e89d-8daf-4a38-96f1-209d77d461ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherIntangibleAssetsAdditions_942f84aa-4bfb-4616-ab15-3c5e40654ce8" xlink:href="amed-20201231.xsd#amed_OtherIntangibleAssetsAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:to="loc_amed_OtherIntangibleAssetsAdditions_942f84aa-4bfb-4616-ab15-3c5e40654ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7096eb62-8597-4ee5-8d1c-b6071da7ad06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7096eb62-8597-4ee5-8d1c-b6071da7ad06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_33e83a6e-3413-45c8-905e-3966cc9b32d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_33e83a6e-3413-45c8-905e-3966cc9b32d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc09550c-88b3-4da3-8eb0-e370ed28e460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d4e165f3-18ea-4b0e-a0c2-d0c552453986" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc09550c-88b3-4da3-8eb0-e370ed28e460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9db3d7f0-7d9a-4e53-aea2-ce348c2406b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e8aeb824-4562-48b7-a6c7-e9b00d7dc842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9db3d7f0-7d9a-4e53-aea2-ce348c2406b1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e8aeb824-4562-48b7-a6c7-e9b00d7dc842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_584539ae-61c0-49de-a2d4-0dea6784382a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e8aeb824-4562-48b7-a6c7-e9b00d7dc842" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_584539ae-61c0-49de-a2d4-0dea6784382a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e9da91a2-8b90-49fa-a80b-c7e50238d8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e8aeb824-4562-48b7-a6c7-e9b00d7dc842" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e9da91a2-8b90-49fa-a80b-c7e50238d8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_68740dbd-65b7-4941-94bf-703bff13bcd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e8aeb824-4562-48b7-a6c7-e9b00d7dc842" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_68740dbd-65b7-4941-94bf-703bff13bcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_42f98e80-3467-4791-8b05-fea980acf33a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e8aeb824-4562-48b7-a6c7-e9b00d7dc842" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_42f98e80-3467-4791-8b05-fea980acf33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6f83531c-4333-4cbf-bfcc-216bb8d0abda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e8aeb824-4562-48b7-a6c7-e9b00d7dc842" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6f83531c-4333-4cbf-bfcc-216bb8d0abda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2fcf38c1-c04f-4dff-a136-c09d9cc3a135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e8aeb824-4562-48b7-a6c7-e9b00d7dc842" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2fcf38c1-c04f-4dff-a136-c09d9cc3a135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_535cc60a-3575-4256-bc27-f351f1428ef6" xlink:href="amed-20201231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_1e861363-1f67-4839-af64-7b8618d3d7c5" xlink:href="amed-20201231.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_535cc60a-3575-4256-bc27-f351f1428ef6" xlink:to="loc_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_1e861363-1f67-4839-af64-7b8618d3d7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_d2751409-8a28-4560-b70b-f3895e64a5c8" xlink:href="amed-20201231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_b94a1b11-3c85-422b-a283-3df0d4366001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_d2751409-8a28-4560-b70b-f3895e64a5c8" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_b94a1b11-3c85-422b-a283-3df0d4366001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_0ae085b7-6a44-4605-a771-03078d9b3984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_d2751409-8a28-4560-b70b-f3895e64a5c8" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_0ae085b7-6a44-4605-a771-03078d9b3984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7132f606-c368-4c09-833e-450d1ed95f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_d2751409-8a28-4560-b70b-f3895e64a5c8" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7132f606-c368-4c09-833e-450d1ed95f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_d566f9b3-a874-44dd-bfd9-afad8241c430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_d2751409-8a28-4560-b70b-f3895e64a5c8" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_d566f9b3-a874-44dd-bfd9-afad8241c430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_b56812ac-d931-425c-98d0-0ae2d520d422" xlink:href="amed-20201231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_9e698b28-7b67-4ce3-89e0-355cc5b261fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_b56812ac-d931-425c-98d0-0ae2d520d422" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_9e698b28-7b67-4ce3-89e0-355cc5b261fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayrollTaxEscrow_51a6cfc2-904b-499e-b836-9dd2e3c8d410" xlink:href="amed-20201231.xsd#amed_PayrollTaxEscrow"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_9e698b28-7b67-4ce3-89e0-355cc5b261fa" xlink:to="loc_amed_PayrollTaxEscrow_51a6cfc2-904b-499e-b836-9dd2e3c8d410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a2717f9c-df93-429c-b44c-7aad00548918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_9e698b28-7b67-4ce3-89e0-355cc5b261fa" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a2717f9c-df93-429c-b44c-7aad00548918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromJointVenturesCurrent_640a782d-3650-49a0-b236-e3015f057a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromJointVenturesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_9e698b28-7b67-4ce3-89e0-355cc5b261fa" xlink:to="loc_us-gaap_DueFromJointVenturesCurrent_640a782d-3650-49a0-b236-e3015f057a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_0e9d164d-3ea0-49a5-96e8-b41a5ee47310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_9e698b28-7b67-4ce3-89e0-355cc5b261fa" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_0e9d164d-3ea0-49a5-96e8-b41a5ee47310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_da58e41f-ea23-436f-83f5-ab7433a67b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_9e698b28-7b67-4ce3-89e0-355cc5b261fa" xlink:to="loc_us-gaap_OtherAssetsCurrent_da58e41f-ea23-436f-83f5-ab7433a67b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_b56812ac-d931-425c-98d0-0ae2d520d422" xlink:to="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationDeposits_aacf49f8-5044-41b5-88db-410ecd9c55cc" xlink:href="amed-20201231.xsd#amed_WorkersCompensationDeposits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:to="loc_amed_WorkersCompensationDeposits_aacf49f8-5044-41b5-88db-410ecd9c55cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceDeposits_d33ab8c2-ec64-4178-b541-9610c84e9762" xlink:href="amed-20201231.xsd#amed_HealthInsuranceDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:to="loc_amed_HealthInsuranceDeposits_d33ab8c2-ec64-4178-b541-9610c84e9762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherMiscellaneousDeposits_998794d6-91b3-4cb1-8fe5-46475ed9bc15" xlink:href="amed-20201231.xsd#amed_OtherMiscellaneousDeposits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:to="loc_amed_OtherMiscellaneousDeposits_998794d6-91b3-4cb1-8fe5-46475ed9bc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_20603660-3b8c-4e08-9206-04fbbd081ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_20603660-3b8c-4e08-9206-04fbbd081ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6777ad7b-f003-4555-9f76-ce74377c438d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6777ad7b-f003-4555-9f76-ce74377c438d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_2d1372b8-8bfc-4d8c-8db6-f01665eae0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_2d1372b8-8bfc-4d8c-8db6-f01665eae0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_803dd3aa-5921-4cc8-9719-6be9a701c395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3131f327-716e-4ff2-b64c-e5f8da786d11" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_803dd3aa-5921-4cc8-9719-6be9a701c395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_b56812ac-d931-425c-98d0-0ae2d520d422" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_613cd6d4-d5a9-4f90-9cae-684ba8727c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_613cd6d4-d5a9-4f90-9cae-684ba8727c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_7bef2504-99e2-47c6-b419-49deaa4c8ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_7bef2504-99e2-47c6-b419-49deaa4c8ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionForLiabilityOnRegulatoryAudit_ce3c8502-b99b-4874-8bfd-556dce7ce300" xlink:href="amed-20201231.xsd#amed_ProvisionForLiabilityOnRegulatoryAudit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_amed_ProvisionForLiabilityOnRegulatoryAudit_ce3c8502-b99b-4874-8bfd-556dce7ce300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalAndOtherSettlements_7032163e-e275-4680-852b-6d561fe0df3f" xlink:href="amed-20201231.xsd#amed_LegalAndOtherSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_amed_LegalAndOtherSettlements_7032163e-e275-4680-852b-6d561fe0df3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_867c161c-1130-4882-ac52-b4ebad271ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_867c161c-1130-4882-ac52-b4ebad271ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CharityCare_ea50cda3-8bea-401c-a7e3-9fafc8481a9f" xlink:href="amed-20201231.xsd#amed_CharityCare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_amed_CharityCare_ea50cda3-8bea-401c-a7e3-9fafc8481a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedMedicareCapLiability_f08abab1-e6d5-42f0-8062-f4c153f248ff" xlink:href="amed-20201231.xsd#amed_EstimatedMedicareCapLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_amed_EstimatedMedicareCapLiability_f08abab1-e6d5-42f0-8062-f4c153f248ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceAccruals_7b801e96-ec66-4244-8a7f-5e90119de5f4" xlink:href="amed-20201231.xsd#amed_HospiceAccruals"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_amed_HospiceAccruals_7b801e96-ec66-4244-8a7f-5e90119de5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PatientLiability_dcaad829-9a4e-4469-b6ed-15928bb15448" xlink:href="amed-20201231.xsd#amed_PatientLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_amed_PatientLiability_dcaad829-9a4e-4469-b6ed-15928bb15448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredOperatingIncomeCARESAct_4e7c7bf9-b669-4c58-95b8-578c2de1a17d" xlink:href="amed-20201231.xsd#amed_DeferredOperatingIncomeCARESAct"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_amed_DeferredOperatingIncomeCARESAct_4e7c7bf9-b669-4c58-95b8-578c2de1a17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b606943a-1dcb-4f0b-a4ea-fd9c708e9208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b606943a-1dcb-4f0b-a4ea-fd9c708e9208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e7c38505-7603-4c46-b478-b7fda2896b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_bf91ed24-000f-4975-a2bb-51a3d5bd9f7d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e7c38505-7603-4c46-b478-b7fda2896b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7af8b6f9-4d69-4b47-9af9-8ba31af70ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_b56812ac-d931-425c-98d0-0ae2d520d422" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7af8b6f9-4d69-4b47-9af9-8ba31af70ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UncertainTaxBenefitsInLongTermObligations_f9bff164-5a06-4aa5-94a9-ad389de4df42" xlink:href="amed-20201231.xsd#amed_UncertainTaxBenefitsInLongTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7af8b6f9-4d69-4b47-9af9-8ba31af70ba5" xlink:to="loc_amed_UncertainTaxBenefitsInLongTermObligations_f9bff164-5a06-4aa5-94a9-ad389de4df42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredCompensationPlanLiability_2ea37c00-4d05-4c9a-825b-1172a0b8c86f" xlink:href="amed-20201231.xsd#amed_DeferredCompensationPlanLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7af8b6f9-4d69-4b47-9af9-8ba31af70ba5" xlink:to="loc_amed_DeferredCompensationPlanLiability_2ea37c00-4d05-4c9a-825b-1172a0b8c86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct_d959b1d4-3270-4462-a8be-803bd2552c6e" xlink:href="amed-20201231.xsd#amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7af8b6f9-4d69-4b47-9af9-8ba31af70ba5" xlink:to="loc_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct_d959b1d4-3270-4462-a8be-803bd2552c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_213cf14e-58aa-44be-a73b-b4627fcdc513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7af8b6f9-4d69-4b47-9af9-8ba31af70ba5" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_213cf14e-58aa-44be-a73b-b4627fcdc513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_52695136-d8b9-4fdd-82e5-440709b0460f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7af8b6f9-4d69-4b47-9af9-8ba31af70ba5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_52695136-d8b9-4fdd-82e5-440709b0460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASES" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2f25a842-bad2-453c-923d-468892ff8ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeLeasesTextBlock_00411cda-df1e-428c-aa2d-3f4a8bde2b00" xlink:href="amed-20201231.xsd#amed_LesseeLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f25a842-bad2-453c-923d-468892ff8ff3" xlink:to="loc_amed_LesseeLeasesTextBlock_00411cda-df1e-428c-aa2d-3f4a8bde2b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9fa390a7-18b0-4a1f-926c-f0d1ca6afa74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_545bd091-2fa2-41ef-b5b6-4c28e959381e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9fa390a7-18b0-4a1f-926c-f0d1ca6afa74" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_545bd091-2fa2-41ef-b5b6-4c28e959381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeasesTableTextBlock_c94faf66-327f-43ad-95da-d1227635f8c9" xlink:href="amed-20201231.xsd#amed_OperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9fa390a7-18b0-4a1f-926c-f0d1ca6afa74" xlink:to="loc_amed_OperatingLeasesTableTextBlock_c94faf66-327f-43ad-95da-d1227635f8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinanceLeasesTableTextBlock_882403c9-6863-4856-b21a-bd7af430b9ac" xlink:href="amed-20201231.xsd#amed_FinanceLeasesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9fa390a7-18b0-4a1f-926c-f0d1ca6afa74" xlink:to="loc_amed_FinanceLeasesTableTextBlock_882403c9-6863-4856-b21a-bd7af430b9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_128ea752-fdff-4680-9c16-320e74130c66" xlink:href="amed-20201231.xsd#amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9fa390a7-18b0-4a1f-926c-f0d1ca6afa74" xlink:to="loc_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_128ea752-fdff-4680-9c16-320e74130c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_b2443483-a0fb-4c2e-9dc9-72912c42debc" xlink:href="amed-20201231.xsd#amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9fa390a7-18b0-4a1f-926c-f0d1ca6afa74" xlink:to="loc_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_b2443483-a0fb-4c2e-9dc9-72912c42debc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseLiabilityMaturityTableTextBlock_41df91fb-6cb4-4e5f-b6b6-d61e64692577" xlink:href="amed-20201231.xsd#amed_LeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9fa390a7-18b0-4a1f-926c-f0d1ca6afa74" xlink:to="loc_amed_LeaseLiabilityMaturityTableTextBlock_41df91fb-6cb4-4e5f-b6b6-d61e64692577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesCodificationTopic842Policies" xlink:type="simple" xlink:href="amed-20201231.xsd#LeasesCodificationTopic842Policies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesCodificationTopic842Policies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fab7b06c-86d3-4190-842c-872e70f88e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fbadc053-b2e3-4333-afc6-930b2d094908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fbadc053-b2e3-4333-afc6-930b2d094908" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bec6c524-4fce-4086-821e-61adf50e0df5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:to="loc_srt_RangeAxis_bec6c524-4fce-4086-821e-61adf50e0df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79871b89-f785-4b9a-ae04-de9f0431efb0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bec6c524-4fce-4086-821e-61adf50e0df5" xlink:to="loc_srt_RangeMember_79871b89-f785-4b9a-ae04-de9f0431efb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0cdfbf43-92af-4ef0-97ce-1dd946230be1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79871b89-f785-4b9a-ae04-de9f0431efb0" xlink:to="loc_srt_MinimumMember_0cdfbf43-92af-4ef0-97ce-1dd946230be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_39871b70-1702-4c07-af4e-75597dcb665b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79871b89-f785-4b9a-ae04-de9f0431efb0" xlink:to="loc_srt_MaximumMember_39871b70-1702-4c07-af4e-75597dcb665b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeAxis_52067d8d-f117-4f32-85ba-f4d2165100ed" xlink:href="amed-20201231.xsd#amed_LeaseTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:to="loc_amed_LeaseTypeAxis_52067d8d-f117-4f32-85ba-f4d2165100ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeDomain_89d1e104-f576-471b-b3f3-dc701f7ed154" xlink:href="amed-20201231.xsd#amed_LeaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_LeaseTypeAxis_52067d8d-f117-4f32-85ba-f4d2165100ed" xlink:to="loc_amed_LeaseTypeDomain_89d1e104-f576-471b-b3f3-dc701f7ed154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetLeaseMember_fac73f22-3bf8-4d2c-b5c7-3b5959d98f50" xlink:href="amed-20201231.xsd#amed_FleetLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_LeaseTypeDomain_89d1e104-f576-471b-b3f3-dc701f7ed154" xlink:to="loc_amed_FleetLeaseMember_fac73f22-3bf8-4d2c-b5c7-3b5959d98f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_2c3c2a13-e4f1-461a-83d8-16ab53d17177" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0fc23744-dc8a-4d15-9d74-cd3ddca43caf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0fc23744-dc8a-4d15-9d74-cd3ddca43caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_9444e7f3-315c-4a45-98af-2494b6352bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_9444e7f3-315c-4a45-98af-2494b6352bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_411915c1-a755-48fc-8f44-37b03a7aedba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_411915c1-a755-48fc-8f44-37b03a7aedba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fdad7085-3e91-4b0c-85b6-5916d9d8f0ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55b4937f-f0a5-4b43-9080-92ef2a07e282" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_fdad7085-3e91-4b0c-85b6-5916d9d8f0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_41e889cd-5234-488d-a030-591b4de44ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_us-gaap_OperatingLeaseExpense_41e889cd-5234-488d-a030-591b4de44ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_feeec292-343b-494b-918a-94a4fbad70fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_feeec292-343b-494b-918a-94a4fbad70fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d4315e17-cb9b-4b21-8779-e16f6f06c4ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_us-gaap_OperatingLeaseCost_d4315e17-cb9b-4b21-8779-e16f6f06c4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_167b1ec7-a422-4607-91ee-f16907fd3906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_167b1ec7-a422-4607-91ee-f16907fd3906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_f149c9e6-ee25-43b2-83ac-31ce42ec070b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_f149c9e6-ee25-43b2-83ac-31ce42ec070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinanceLeaseCost_90a84214-4410-4486-88f7-6e90e628270d" xlink:href="amed-20201231.xsd#amed_FinanceLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_amed_FinanceLeaseCost_90a84214-4410-4486-88f7-6e90e628270d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_92116fe2-fa34-4db7-aada-bb1255584b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_us-gaap_VariableLeaseCost_92116fe2-fa34-4db7-aada-bb1255584b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_6955ce6d-c58a-4148-9a5b-7919a3309d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_us-gaap_ShortTermLeaseCost_6955ce6d-c58a-4148-9a5b-7919a3309d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_59de2b19-ab4f-41b1-9d72-8504021e14a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af3520fd-ba94-400d-8ab6-207c3b533c10" xlink:to="loc_us-gaap_LeaseCost_59de2b19-ab4f-41b1-9d72-8504021e14a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESOperatingLeaseDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8b281361-4c01-4933-a059-5ec9fabc860b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9f99baff-e94a-4d55-97f3-039cac50f769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b281361-4c01-4933-a059-5ec9fabc860b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9f99baff-e94a-4d55-97f3-039cac50f769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffad3411-2b7e-4d7d-9b5d-3894e72f72f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b281361-4c01-4933-a059-5ec9fabc860b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffad3411-2b7e-4d7d-9b5d-3894e72f72f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d95d0260-5350-487f-8d27-1677e4d79720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b281361-4c01-4933-a059-5ec9fabc860b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d95d0260-5350-487f-8d27-1677e4d79720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d724ebe7-3167-4e48-aef9-8ea5201fa93d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b281361-4c01-4933-a059-5ec9fabc860b" xlink:to="loc_us-gaap_OperatingLeaseLiability_d724ebe7-3167-4e48-aef9-8ea5201fa93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d1d693c2-e907-4eff-b9eb-cef22caf9720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_9e569b80-ef51-47a5-b509-d88690865ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1d693c2-e907-4eff-b9eb-cef22caf9720" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_9e569b80-ef51-47a5-b509-d88690865ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_75ab32f3-f7a4-4f59-9fb2-45937a50927e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1d693c2-e907-4eff-b9eb-cef22caf9720" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_75ab32f3-f7a4-4f59-9fb2-45937a50927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_6c02610c-b8b3-4cf3-8bfe-efe639c3a6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1d693c2-e907-4eff-b9eb-cef22caf9720" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_6c02610c-b8b3-4cf3-8bfe-efe639c3a6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_7f200905-e837-4c91-8c82-2a33d3f94630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1d693c2-e907-4eff-b9eb-cef22caf9720" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_7f200905-e837-4c91-8c82-2a33d3f94630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_33f406af-8589-4003-9ead-5889c82cf3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1d693c2-e907-4eff-b9eb-cef22caf9720" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_33f406af-8589-4003-9ead-5889c82cf3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_032ff731-e7f6-48aa-8bbe-67b3b0cabfc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d1d693c2-e907-4eff-b9eb-cef22caf9720" xlink:to="loc_us-gaap_FinanceLeaseLiability_032ff731-e7f6-48aa-8bbe-67b3b0cabfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESSupplementalCashflowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9abdfbd7-8a4e-4357-a296-da3ec5ecf537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ee953743-5709-44ae-ab1a-3e68a8ebe37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9abdfbd7-8a4e-4357-a296-da3ec5ecf537" xlink:to="loc_us-gaap_OperatingLeasePayments_ee953743-5709-44ae-ab1a-3e68a8ebe37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_49d7619b-e7d2-476f-8a0e-d5e21ca1f9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9abdfbd7-8a4e-4357-a296-da3ec5ecf537" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_49d7619b-e7d2-476f-8a0e-d5e21ca1f9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_24d67d5f-e79a-4558-b874-54b8465c8596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9abdfbd7-8a4e-4357-a296-da3ec5ecf537" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_24d67d5f-e79a-4558-b874-54b8465c8596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e08f1f7c-0eaa-4f1d-90e9-ab5b3ba168e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9abdfbd7-8a4e-4357-a296-da3ec5ecf537" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e08f1f7c-0eaa-4f1d-90e9-ab5b3ba168e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_b898d727-6011-4f6d-892f-3dcccd3e930f" xlink:href="amed-20201231.xsd#amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9abdfbd7-8a4e-4357-a296-da3ec5ecf537" xlink:to="loc_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_b898d727-6011-4f6d-892f-3dcccd3e930f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_a1437e41-ae27-4190-abea-86a32e6bcb5c" xlink:href="amed-20201231.xsd#amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9abdfbd7-8a4e-4357-a296-da3ec5ecf537" xlink:to="loc_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_a1437e41-ae27-4190-abea-86a32e6bcb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_85a1390f-ddd6-48d9-b6fd-826087189e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f178ee8a-369b-4272-b42a-89402edcf522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85a1390f-ddd6-48d9-b6fd-826087189e09" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f178ee8a-369b-4272-b42a-89402edcf522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_46aa401c-9276-4cfe-b9b9-ed067f61a56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85a1390f-ddd6-48d9-b6fd-826087189e09" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_46aa401c-9276-4cfe-b9b9-ed067f61a56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_47341cc9-b849-4cb0-9bc8-09208f6b8b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85a1390f-ddd6-48d9-b6fd-826087189e09" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_47341cc9-b849-4cb0-9bc8-09208f6b8b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_71454256-0f40-48b4-b9a4-48e793d15188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85a1390f-ddd6-48d9-b6fd-826087189e09" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_71454256-0f40-48b4-b9a4-48e793d15188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LEASESMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4d4e4a5b-4e18-4932-8461-a7d11395fffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4d4e4a5b-4e18-4932-8461-a7d11395fffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0b72f0a4-d0e7-496d-9514-983cad077a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0b72f0a4-d0e7-496d-9514-983cad077a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a2fcae3a-014c-471c-b872-bc7fc1f58b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a2fcae3a-014c-471c-b872-bc7fc1f58b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_62dab48a-9e0e-4af5-9117-34a8e37af879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_62dab48a-9e0e-4af5-9117-34a8e37af879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_48bcb337-3df7-4c10-a169-454bf7ad16b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_48bcb337-3df7-4c10-a169-454bf7ad16b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_989da4bf-5c20-437a-ba5d-e54ece1fb713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_989da4bf-5c20-437a-ba5d-e54ece1fb713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6ffae00-0782-469b-86d1-2812c3201ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b6ffae00-0782-469b-86d1-2812c3201ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e9b86c5-28ad-4462-896d-d19ef73fb0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e9b86c5-28ad-4462-896d-d19ef73fb0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2bb54a5f-6b4e-4e31-9e15-d04160df5cea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_OperatingLeaseLiability_2bb54a5f-6b4e-4e31-9e15-d04160df5cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_8ff06ddf-d3d3-451e-9d8a-8370d9a7d7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_8ff06ddf-d3d3-451e-9d8a-8370d9a7d7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8dd43d83-0ca1-4328-91a6-3975ff7e1598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8dd43d83-0ca1-4328-91a6-3975ff7e1598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_e09f62df-4a99-4105-88f7-bfa53b05d3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_e09f62df-4a99-4105-88f7-bfa53b05d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_af489710-c20a-4297-8230-9c829841063b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_af489710-c20a-4297-8230-9c829841063b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f8acd5b3-71ce-45a7-b0b3-c1a533a1522d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f8acd5b3-71ce-45a7-b0b3-c1a533a1522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_317de469-b2f3-434d-9dae-450019bf68bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_317de469-b2f3-434d-9dae-450019bf68bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b449109b-c251-4e09-bf42-41fcbe743b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b449109b-c251-4e09-bf42-41fcbe743b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_be8c4123-8388-489c-84de-406a2b276f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_be8c4123-8388-489c-84de-406a2b276f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_399fd415-6190-451f-bc05-230362310906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b86392b6-3746-4cba-a61f-186fcf90daaa" xlink:to="loc_us-gaap_FinanceLeaseLiability_399fd415-6190-451f-bc05-230362310906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_78338c34-8d7c-4bc8-8dc8-72822bfcf319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_128f13a8-ece6-4b44-b816-66cf2533172f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_78338c34-8d7c-4bc8-8dc8-72822bfcf319" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_128f13a8-ece6-4b44-b816-66cf2533172f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fd97ba03-4ab2-46fb-9ecc-fbacf88025bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_72b9cbe1-8c76-4526-9c21-16727e3ed38f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd97ba03-4ab2-46fb-9ecc-fbacf88025bb" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_72b9cbe1-8c76-4526-9c21-16727e3ed38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9ecb3240-863c-48ca-b558-53d9c440c34e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd97ba03-4ab2-46fb-9ecc-fbacf88025bb" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9ecb3240-863c-48ca-b558-53d9c440c34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_7746ddf2-7907-4e52-ab62-bb37f2a39f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd97ba03-4ab2-46fb-9ecc-fbacf88025bb" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_7746ddf2-7907-4e52-ab62-bb37f2a39f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b339d10d-3824-4199-937e-b0e0481f231f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b339d10d-3824-4199-937e-b0e0481f231f" xlink:to="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e9601518-48f8-4ea8-8c73-b5678d90c2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e9601518-48f8-4ea8-8c73-b5678d90c2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9601518-48f8-4ea8-8c73-b5678d90c2ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_2d4c8f15-2c92-48fe-a5fe-3dd208b21574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:to="loc_us-gaap_LoansPayableMember_2d4c8f15-2c92-48fe-a5fe-3dd208b21574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f5cd5999-ca08-49ec-9c52-1d351ea1d305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f5cd5999-ca08-49ec-9c52-1d351ea1d305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_c81377bb-b749-4673-b1d1-d8b6992809d6" xlink:href="amed-20201231.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:to="loc_amed_PromissoryNotesMember_c81377bb-b749-4673-b1d1-d8b6992809d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_4bd22fa0-dfba-4151-8c6c-987c24bbde23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b8f71677-c5e1-41bb-a1f5-2821dcedcdbd" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_4bd22fa0-dfba-4151-8c6c-987c24bbde23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5f480349-54bf-485c-8751-be5e51dcc47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:to="loc_us-gaap_DebtInstrumentAxis_5f480349-54bf-485c-8751-be5e51dcc47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2727993d-6fe2-452f-ac67-31154765f528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f480349-54bf-485c-8751-be5e51dcc47b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2727993d-6fe2-452f-ac67-31154765f528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_881c81e1-b935-490c-81a4-c7d0ceb37154" xlink:href="amed-20201231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2727993d-6fe2-452f-ac67-31154765f528" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_881c81e1-b935-490c-81a4-c7d0ceb37154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_7e6a9b4f-ee6b-4c62-9c0b-d4a50f56585a" xlink:href="amed-20201231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2727993d-6fe2-452f-ac67-31154765f528" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_7e6a9b4f-ee6b-4c62-9c0b-d4a50f56585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_300e0b41-710a-4e48-9e14-7c5cbb95f9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:to="loc_us-gaap_VariableRateAxis_300e0b41-710a-4e48-9e14-7c5cbb95f9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_138ca48f-96b1-4a2b-847d-f9b36c312fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_300e0b41-710a-4e48-9e14-7c5cbb95f9b6" xlink:to="loc_us-gaap_VariableRateDomain_138ca48f-96b1-4a2b-847d-f9b36c312fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_9868cbb7-9817-4eaf-9e63-b4fc74525c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_138ca48f-96b1-4a2b-847d-f9b36c312fa8" xlink:to="loc_us-gaap_EurodollarMember_9868cbb7-9817-4eaf-9e63-b4fc74525c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_fdd57426-e1ab-4091-a637-f4f6eeafe4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_138ca48f-96b1-4a2b-847d-f9b36c312fa8" xlink:to="loc_us-gaap_BaseRateMember_fdd57426-e1ab-4091-a637-f4f6eeafe4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3603c990-b7ac-47d6-bc03-bcbbb4fe7770" xlink:to="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3677cdae-ddef-402e-8ac7-3ea6e4d40417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3677cdae-ddef-402e-8ac7-3ea6e4d40417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c5e7c55e-d580-4d7b-967a-ee89c5a77d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c5e7c55e-d580-4d7b-967a-ee89c5a77d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0411606d-b1d7-42a0-9355-942731a3ec60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_LongTermDebt_0411606d-b1d7-42a0-9355-942731a3ec60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7b371b5f-e9e8-4785-83cc-dbc5bc93a0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_LongTermDebtCurrent_7b371b5f-e9e8-4785-83cc-dbc5bc93a0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6d9dc1bf-b566-427f-ac87-eb8fbe89048e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_324b80b7-458f-4d39-ae7e-d01e8f3cb346" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6d9dc1bf-b566-427f-ac87-eb8fbe89048e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0b1d784e-fe8d-4f36-93e0-682832b53ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0b1d784e-fe8d-4f36-93e0-682832b53ab4" xlink:to="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9f73ae4e-3854-4aa5-bbd4-6d09a449e155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9f73ae4e-3854-4aa5-bbd4-6d09a449e155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_90e10576-4546-4215-b79e-9f27577b6151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f73ae4e-3854-4aa5-bbd4-6d09a449e155" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_90e10576-4546-4215-b79e-9f27577b6151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_4cea99d9-f604-45ac-9e25-1e85b88a1555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_90e10576-4546-4215-b79e-9f27577b6151" xlink:to="loc_us-gaap_LoansPayableMember_4cea99d9-f604-45ac-9e25-1e85b88a1555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_584586e7-0833-443b-8192-cb532e49dce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_90e10576-4546-4215-b79e-9f27577b6151" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_584586e7-0833-443b-8192-cb532e49dce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:to="loc_us-gaap_DebtInstrumentAxis_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e2367b9d-d8a1-4f35-b83d-810a7cb8bd0c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_53d6c875-f71c-4fba-8844-565906b0e149" xlink:href="amed-20201231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_53d6c875-f71c-4fba-8844-565906b0e149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_63938f81-dfed-415b-b736-9fe2675cd261" xlink:href="amed-20201231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_63938f81-dfed-415b-b736-9fe2675cd261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_f9c05567-f36d-46d2-9597-22eaed157e19" xlink:href="amed-20201231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_685c7138-5942-49f1-9337-18aa560f8e9f" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_f9c05567-f36d-46d2-9597-22eaed157e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_050b5b62-2ba0-476b-98e2-62c466f632f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:to="loc_us-gaap_VariableRateAxis_050b5b62-2ba0-476b-98e2-62c466f632f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_07887c3a-ec91-442c-8584-870f85346a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_050b5b62-2ba0-476b-98e2-62c466f632f6" xlink:to="loc_us-gaap_VariableRateDomain_07887c3a-ec91-442c-8584-870f85346a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_9b142f41-8c27-4ed4-be61-f380fca0a42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_07887c3a-ec91-442c-8584-870f85346a38" xlink:to="loc_us-gaap_EurodollarMember_9b142f41-8c27-4ed4-be61-f380fca0a42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_de364782-121c-4a83-aa24-e78d4a2f9c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_07887c3a-ec91-442c-8584-870f85346a38" xlink:to="loc_us-gaap_BaseRateMember_de364782-121c-4a83-aa24-e78d4a2f9c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_491e0984-ee71-4522-973b-6292159947e9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5f5adba1-eae4-47fb-87ec-562a1fd5d9b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5f5adba1-eae4-47fb-87ec-562a1fd5d9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_64555735-8bf7-49ab-a22b-d74dbf4707ca" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_64555735-8bf7-49ab-a22b-d74dbf4707ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_ab0c9d09-cc5d-498c-8d92-d056fa3e7695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a452de7b-0f8a-49ff-aabf-d1cbd701894a" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_ab0c9d09-cc5d-498c-8d92-d056fa3e7695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSMaturitiesofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0797c945-1f71-4d9a-9dde-764c1c07b421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_5e7b83fa-a7e0-4887-a8ef-c0b6c6eb4616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0797c945-1f71-4d9a-9dde-764c1c07b421" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_5e7b83fa-a7e0-4887-a8ef-c0b6c6eb4616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a92d9a11-079f-42e1-86e1-26badbea4237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5e7b83fa-a7e0-4887-a8ef-c0b6c6eb4616" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a92d9a11-079f-42e1-86e1-26badbea4237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e59f8248-dd07-4b7b-97cb-17b181635a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5e7b83fa-a7e0-4887-a8ef-c0b6c6eb4616" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e59f8248-dd07-4b7b-97cb-17b181635a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_21884b57-5edf-4ebc-b766-64b65c2e39f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5e7b83fa-a7e0-4887-a8ef-c0b6c6eb4616" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_21884b57-5edf-4ebc-b766-64b65c2e39f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ba241cfc-9d4c-4eea-9b14-ef09e88a52e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5e7b83fa-a7e0-4887-a8ef-c0b6c6eb4616" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ba241cfc-9d4c-4eea-9b14-ef09e88a52e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3b2394e9-60b7-4b69-8b2f-ae311cca5714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5e7b83fa-a7e0-4887-a8ef-c0b6c6eb4616" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3b2394e9-60b7-4b69-8b2f-ae311cca5714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2e655644-ec02-483e-ba34-55b130928bba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_5e7b83fa-a7e0-4887-a8ef-c0b6c6eb4616" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2e655644-ec02-483e-ba34-55b130928bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_91c12596-1bf7-414c-ad84-7aba820052ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_91c12596-1bf7-414c-ad84-7aba820052ec" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca352b12-37f0-4d59-8b9e-06855c050282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca352b12-37f0-4d59-8b9e-06855c050282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca352b12-37f0-4d59-8b9e-06855c050282" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_17f7f06c-0e5a-4e75-a30a-439a00673e17" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_17f7f06c-0e5a-4e75-a30a-439a00673e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_970b36c2-da90-4f78-9cc3-c0e41bb8d047" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_970b36c2-da90-4f78-9cc3-c0e41bb8d047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_2fd37b35-0c1e-4b34-8774-0925a139189f" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_2fd37b35-0c1e-4b34-8774-0925a139189f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_bd4a3ec0-0429-4869-9137-2202698cd35f" xlink:href="amed-20201231.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0f5a3cf-66d0-45a6-b06c-ce5df302e286" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_bd4a3ec0-0429-4869-9137-2202698cd35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e63a2232-7862-48a6-aecc-8b8dedac899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:to="loc_us-gaap_VariableRateAxis_e63a2232-7862-48a6-aecc-8b8dedac899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_aeb28866-cebd-4ed1-baca-e98c424956b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_e63a2232-7862-48a6-aecc-8b8dedac899f" xlink:to="loc_us-gaap_VariableRateDomain_aeb28866-cebd-4ed1-baca-e98c424956b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_7900e493-ea14-4dc5-aadb-7b7b214a3661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_aeb28866-cebd-4ed1-baca-e98c424956b5" xlink:to="loc_us-gaap_BaseRateMember_7900e493-ea14-4dc5-aadb-7b7b214a3661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_bbcbffc6-4163-4c52-80a7-2c7c27a47a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_aeb28866-cebd-4ed1-baca-e98c424956b5" xlink:to="loc_us-gaap_EurodollarMember_bbcbffc6-4163-4c52-80a7-2c7c27a47a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a44e66a9-8069-4709-95e6-b26ccf792fe9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:to="loc_srt_RangeAxis_a44e66a9-8069-4709-95e6-b26ccf792fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe36880d-a9b6-4ffb-bf03-2d7258f541c3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a44e66a9-8069-4709-95e6-b26ccf792fe9" xlink:to="loc_srt_RangeMember_fe36880d-a9b6-4ffb-bf03-2d7258f541c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_39b7e85e-66f3-4878-a7ed-09b52dcb78e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe36880d-a9b6-4ffb-bf03-2d7258f541c3" xlink:to="loc_srt_MaximumMember_39b7e85e-66f3-4878-a7ed-09b52dcb78e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eed08bac-411d-4386-95b5-c8f303bf846c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe36880d-a9b6-4ffb-bf03-2d7258f541c3" xlink:to="loc_srt_MinimumMember_eed08bac-411d-4386-95b5-c8f303bf846c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_4d8e0975-3da3-423e-b18b-dcd279436271" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_a276435c-095f-4780-b86c-78346c75baf5" xlink:href="amed-20201231.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_amed_ConsolidatedLeverageRatio_a276435c-095f-4780-b86c-78346c75baf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2fac99cb-fa61-464d-83e2-e68bdffe3d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_2fac99cb-fa61-464d-83e2-e68bdffe3d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_673fff6f-6b63-43d9-976f-fec555f4ed8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_673fff6f-6b63-43d9-976f-fec555f4ed8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_02d79846-2999-46e3-9731-8b6ec94202d1" xlink:href="amed-20201231.xsd#amed_LetterOfCreditFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_68ca18db-24fc-44f0-8a3c-d47d4c902be3" xlink:to="loc_amed_LetterOfCreditFee_02d79846-2999-46e3-9731-8b6ec94202d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ca49451e-dfe7-434b-a928-8ba3ba730158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ca49451e-dfe7-434b-a928-8ba3ba730158" xlink:to="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_540981a3-cbf3-4a61-87b9-0ff99c8f4090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_DebtInstrumentAxis_540981a3-cbf3-4a61-87b9-0ff99c8f4090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c8dd6894-cc11-4bec-915d-891c0f665cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_540981a3-cbf3-4a61-87b9-0ff99c8f4090" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c8dd6894-cc11-4bec-915d-891c0f665cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_29d3361d-3f5c-4db5-aa92-e76c361ab818" xlink:href="amed-20201231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c8dd6894-cc11-4bec-915d-891c0f665cb5" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_29d3361d-3f5c-4db5-aa92-e76c361ab818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_0e04ea9a-5a3b-4ceb-93dd-bd0979dca92a" xlink:href="amed-20201231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c8dd6894-cc11-4bec-915d-891c0f665cb5" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_0e04ea9a-5a3b-4ceb-93dd-bd0979dca92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f5ade106-3468-4c91-914c-337b90c7f5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f5ade106-3468-4c91-914c-337b90c7f5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f5ade106-3468-4c91-914c-337b90c7f5e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_b4d3368b-1e94-4fe9-8642-996fba435128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_LoansPayableMember_b4d3368b-1e94-4fe9-8642-996fba435128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_91a64ba1-d517-49e0-9ba6-2f21f25cf760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_91a64ba1-d517-49e0-9ba6-2f21f25cf760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_b6c00ef0-75b6-4e3c-a0be-add91a08a03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_LineOfCreditMember_b6c00ef0-75b6-4e3c-a0be-add91a08a03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_a69da4d3-dbf1-4bba-a334-278da5209028" xlink:href="amed-20201231.xsd#amed_SwingLineLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_amed_SwingLineLoanMember_a69da4d3-dbf1-4bba-a334-278da5209028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_e7627a0d-9bb4-4351-9eeb-cc92ac788550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_LetterOfCreditMember_e7627a0d-9bb4-4351-9eeb-cc92ac788550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditAgreementMember_159a67d6-83b2-4736-bc94-6110f5e581ce" xlink:href="amed-20201231.xsd#amed_CreditAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_amed_CreditAgreementMember_159a67d6-83b2-4736-bc94-6110f5e581ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_b0ca543d-f954-48f0-bfae-1cdebf54c61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_b0ca543d-f954-48f0-bfae-1cdebf54c61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_03ab0c5d-fdaf-4342-bde1-6adc1458c8e8" xlink:href="amed-20201231.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_089c4132-a099-44c0-9238-fca92075352f" xlink:to="loc_amed_AmendedCreditAgreementMember_03ab0c5d-fdaf-4342-bde1-6adc1458c8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fe876760-046b-4fd6-b00b-1e9c4b1a9da7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_srt_StatementScenarioAxis_fe876760-046b-4fd6-b00b-1e9c4b1a9da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2231a162-b34e-413e-ad4c-da5709183abd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_fe876760-046b-4fd6-b00b-1e9c4b1a9da7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2231a162-b34e-413e-ad4c-da5709183abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_63884c10-59e3-4038-a917-6e1b19ae6fd6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2231a162-b34e-413e-ad4c-da5709183abd" xlink:to="loc_srt_ScenarioForecastMember_63884c10-59e3-4038-a917-6e1b19ae6fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_6b55a351-e9fb-4566-8362-4c498b773f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_VariableRateAxis_6b55a351-e9fb-4566-8362-4c498b773f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_67704889-35fd-47b4-aab6-d0ed9f99ddd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_6b55a351-e9fb-4566-8362-4c498b773f8c" xlink:to="loc_us-gaap_VariableRateDomain_67704889-35fd-47b4-aab6-d0ed9f99ddd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_a74f5c9f-2c52-4aa6-923b-963c170a07a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_67704889-35fd-47b4-aab6-d0ed9f99ddd2" xlink:to="loc_us-gaap_BaseRateMember_a74f5c9f-2c52-4aa6-923b-963c170a07a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_5f434a27-caf9-46f3-a385-c8dec25dfc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_67704889-35fd-47b4-aab6-d0ed9f99ddd2" xlink:to="loc_us-gaap_EurodollarMember_5f434a27-caf9-46f3-a385-c8dec25dfc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c3d51fb-881d-4a9c-a39c-ecffb3b876be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_srt_RangeAxis_4c3d51fb-881d-4a9c-a39c-ecffb3b876be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc4b5d13-e322-46be-92f1-95d4ed50a57d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c3d51fb-881d-4a9c-a39c-ecffb3b876be" xlink:to="loc_srt_RangeMember_fc4b5d13-e322-46be-92f1-95d4ed50a57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_57f5773d-563b-4955-b65d-f70b6bf85e67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc4b5d13-e322-46be-92f1-95d4ed50a57d" xlink:to="loc_srt_MinimumMember_57f5773d-563b-4955-b65d-f70b6bf85e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5ed22931-7ba2-42e8-83d0-c65c7ad08e56" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc4b5d13-e322-46be-92f1-95d4ed50a57d" xlink:to="loc_srt_MaximumMember_5ed22931-7ba2-42e8-83d0-c65c7ad08e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8f3b1e22-f6a5-473c-8918-a3e3c575b8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_588f1e69-d0ea-45d9-a1a5-d89c6e3c69df" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8f3b1e22-f6a5-473c-8918-a3e3c575b8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cb59ad44-6ee8-44f7-b6d8-06c1c4eb01ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8f3b1e22-f6a5-473c-8918-a3e3c575b8a7" xlink:to="loc_us-gaap_SubsequentEventMember_cb59ad44-6ee8-44f7-b6d8-06c1c4eb01ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f20a8759-371f-4439-ac70-7bd1708a2199" xlink:to="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_479bddde-029b-4373-a0ba-b96b8bbdb906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_479bddde-029b-4373-a0ba-b96b8bbdb906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e1da6606-cff4-4a89-b68e-cff94c0e1286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e1da6606-cff4-4a89-b68e-cff94c0e1286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_8bdca899-1580-43f9-8cdb-9a49d67dfcd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_8bdca899-1580-43f9-8cdb-9a49d67dfcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_9b699c4d-7f92-45f7-aa1a-0a39b32be293" xlink:href="amed-20201231.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_RevolvingCreditFacilityTotal_9b699c4d-7f92-45f7-aa1a-0a39b32be293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_996b2432-2f3b-497a-b643-4032178e7e65" xlink:href="amed-20201231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_996b2432-2f3b-497a-b643-4032178e7e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_efa748eb-3dab-4275-8475-ec1bb051fcbb" xlink:href="amed-20201231.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_efa748eb-3dab-4275-8475-ec1bb051fcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_02ef70b8-7175-41c6-a6e5-b50da2e47c25" xlink:href="amed-20201231.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_02ef70b8-7175-41c6-a6e5-b50da2e47c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ca193603-ceaf-40e3-a4eb-6617b6523d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ca193603-ceaf-40e3-a4eb-6617b6523d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_d914a627-ad63-4d26-92f0-4ccf5e00b18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_d914a627-ad63-4d26-92f0-4ccf5e00b18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentNumberOfPeriodicPayments_46c62684-ffbb-447b-b6f9-690193017836" xlink:href="amed-20201231.xsd#amed_DebtInstrumentNumberOfPeriodicPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_DebtInstrumentNumberOfPeriodicPayments_46c62684-ffbb-447b-b6f9-690193017836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_c2bd2f62-bc28-47dc-84be-390520c9268f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_c2bd2f62-bc28-47dc-84be-390520c9268f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16725fda-e211-4e85-9dc6-2306034c1a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_16725fda-e211-4e85-9dc6-2306034c1a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_d6bcf231-3bae-4a7e-9545-d4dd4e581bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_d6bcf231-3bae-4a7e-9545-d4dd4e581bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_3603d228-86a7-4728-acf3-f55a12741fbd" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_3603d228-86a7-4728-acf3-f55a12741fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_89b15f01-f2d1-4054-bd10-684f388ebb1b" xlink:href="amed-20201231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_89b15f01-f2d1-4054-bd10-684f388ebb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c7c0bb7e-6b35-4800-b75e-a64dbeb52d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c7c0bb7e-6b35-4800-b75e-a64dbeb52d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WeightedAverageInterestRate_a8a36eb8-c1fa-4e2e-aa84-e41f730e4167" xlink:href="amed-20201231.xsd#amed_WeightedAverageInterestRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_WeightedAverageInterestRate_a8a36eb8-c1fa-4e2e-aa84-e41f730e4167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_15daff0c-018c-4ec0-9987-e8f4340b471e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_15daff0c-018c-4ec0-9987-e8f4340b471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_de3c9458-e161-4f5c-9608-526ee2a461e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_de3c9458-e161-4f5c-9608-526ee2a461e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_68a5d845-07d8-4ab1-86f9-53dfea976713" xlink:href="amed-20201231.xsd#amed_TotalLeverageRatio"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_TotalLeverageRatio_68a5d845-07d8-4ab1-86f9-53dfea976713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_7dbf6c2e-9972-4927-b860-6b57295c8739" xlink:href="amed-20201231.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_7dbf6c2e-9972-4927-b860-6b57295c8739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_cc5e7eec-00c6-47b1-8097-ca140dcfad5a" xlink:href="amed-20201231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_cc5e7eec-00c6-47b1-8097-ca140dcfad5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_4343e9f8-329a-415d-8760-59ede76cfdce" xlink:href="amed-20201231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_4343e9f8-329a-415d-8760-59ede76cfdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CallPremiumPayment_ee6c7e55-cf53-4c42-a16b-7e2c01a710dd" xlink:href="amed-20201231.xsd#amed_CallPremiumPayment"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_CallPremiumPayment_ee6c7e55-cf53-4c42-a16b-7e2c01a710dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_a7d687f7-07ef-4a96-b811-5de1759f4599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_a7d687f7-07ef-4a96-b811-5de1759f4599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_080c62c7-384f-4f3e-824e-addd517bfed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_080c62c7-384f-4f3e-824e-addd517bfed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0d85a1a6-135e-4c79-a586-8de90dde847a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0d85a1a6-135e-4c79-a586-8de90dde847a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fdf3373c-46ec-46c5-9d8a-33fefd6e9556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fdf3373c-46ec-46c5-9d8a-33fefd6e9556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_565606f3-1b65-4b3c-8c75-461cca2ba0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_565606f3-1b65-4b3c-8c75-461cca2ba0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_82022428-d846-4937-8689-87c39da6fa28" xlink:href="amed-20201231.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_82022428-d846-4937-8689-87c39da6fa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_2eb4c38b-8caa-4639-82e1-832826c10533" xlink:href="amed-20201231.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_2eb4c38b-8caa-4639-82e1-832826c10533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineFacility_9886b2b1-1599-4277-9a5e-9de6e7bfc38a" xlink:href="amed-20201231.xsd#amed_SwingLineFacility"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_SwingLineFacility_9886b2b1-1599-4277-9a5e-9de6e7bfc38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LettersofCreditmaximumcommitment_cf82847e-27b6-48d8-b9af-6ea7a1882c77" xlink:href="amed-20201231.xsd#amed_LettersofCreditmaximumcommitment"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21f61a04-7d34-4c3c-b1bf-cead9945c5cb" xlink:to="loc_amed_LettersofCreditmaximumcommitment_cf82847e-27b6-48d8-b9af-6ea7a1882c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXES" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2f80769c-1d5d-470c-ba79-d69e0a33face" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a831c2e3-da17-4e8f-8e2d-2e78d74255e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2f80769c-1d5d-470c-ba79-d69e0a33face" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a831c2e3-da17-4e8f-8e2d-2e78d74255e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_920068d2-cd28-42a6-bd98-3e1e981e9250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionforIncomeTaxesTableTextBlock_4431f96a-e32a-4fc6-b44a-e8bbb1f886cf" xlink:href="amed-20201231.xsd#amed_ProvisionforIncomeTaxesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_920068d2-cd28-42a6-bd98-3e1e981e9250" xlink:to="loc_amed_ProvisionforIncomeTaxesTableTextBlock_4431f96a-e32a-4fc6-b44a-e8bbb1f886cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_80e36810-4215-48c9-9195-2652e39b61de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_920068d2-cd28-42a6-bd98-3e1e981e9250" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_80e36810-4215-48c9-9195-2652e39b61de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d133a817-6dd7-4257-b264-b2051c4963c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_920068d2-cd28-42a6-bd98-3e1e981e9250" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d133a817-6dd7-4257-b264-b2051c4963c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_8b29877b-0e9b-47e0-ac75-17fac9f07ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_920068d2-cd28-42a6-bd98-3e1e981e9250" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_8b29877b-0e9b-47e0-ac75-17fac9f07ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40ecf812-2366-4fe7-9afc-025f1fa6a787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ecf812-2366-4fe7-9afc-025f1fa6a787" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0ac651b0-388f-4ad2-b31a-efa5df08df86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0ac651b0-388f-4ad2-b31a-efa5df08df86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d8de5028-d31f-4c4c-8cb3-99d77b2f0cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0ac651b0-388f-4ad2-b31a-efa5df08df86" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d8de5028-d31f-4c4c-8cb3-99d77b2f0cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_7e22aa46-9d4e-4095-9576-5538dedcf186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d8de5028-d31f-4c4c-8cb3-99d77b2f0cce" xlink:to="loc_us-gaap_DomesticCountryMember_7e22aa46-9d4e-4095-9576-5538dedcf186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1a75f967-0f91-47a4-ae8a-f87685969ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d8de5028-d31f-4c4c-8cb3-99d77b2f0cce" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1a75f967-0f91-47a4-ae8a-f87685969ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5d6f8b3e-66d6-4c5c-8f81-102ef64f2520" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AlternativeMinimumTaxCreditMember_99bcd906-c18c-4b59-bf0d-7e00f4b1e15e" xlink:href="amed-20201231.xsd#amed_AlternativeMinimumTaxCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:to="loc_amed_AlternativeMinimumTaxCreditMember_99bcd906-c18c-4b59-bf0d-7e00f4b1e15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ResearchAndDevelopmentTaxCreditMember_6c8e2ea4-6732-4267-857a-1f5b2572c052" xlink:href="amed-20201231.xsd#amed_ResearchAndDevelopmentTaxCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:to="loc_amed_ResearchAndDevelopmentTaxCreditMember_6c8e2ea4-6732-4267-857a-1f5b2572c052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EmploymentTaxCreditMember_975049ec-a785-448d-a99e-b5dbede4c68d" xlink:href="amed-20201231.xsd#amed_EmploymentTaxCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:to="loc_amed_EmploymentTaxCreditMember_975049ec-a785-448d-a99e-b5dbede4c68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StateTaxCreditMember_9cc83d94-a028-4c04-ad6f-22aa342a6117" xlink:href="amed-20201231.xsd#amed_StateTaxCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f2199d15-a02b-40f1-9eae-ceb423ca3c0c" xlink:to="loc_amed_StateTaxCreditMember_9cc83d94-a028-4c04-ad6f-22aa342a6117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsAxis_3bfb9838-4277-4d1a-adea-0a6f54d522c2" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_amed_UnrecognizedTaxBenefitsAxis_3bfb9838-4277-4d1a-adea-0a6f54d522c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDomain_c2a79c3f-d08c-454c-9a26-a59d6929a98d" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_UnrecognizedTaxBenefitsAxis_3bfb9838-4277-4d1a-adea-0a6f54d522c2" xlink:to="loc_amed_UnrecognizedTaxBenefitsDomain_c2a79c3f-d08c-454c-9a26-a59d6929a98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetOperatingLossMember_080ba5ed-40f8-4a95-a5da-59054f990828" xlink:href="amed-20201231.xsd#amed_NetOperatingLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain_c2a79c3f-d08c-454c-9a26-a59d6929a98d" xlink:to="loc_amed_NetOperatingLossMember_080ba5ed-40f8-4a95-a5da-59054f990828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCreditCarryforwardMember_678a8c9d-0416-4572-9f49-40856d15777c" xlink:href="amed-20201231.xsd#amed_TaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain_c2a79c3f-d08c-454c-9a26-a59d6929a98d" xlink:to="loc_amed_TaxCreditCarryforwardMember_678a8c9d-0416-4572-9f49-40856d15777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7a22496e-6302-4107-8ff0-145c3ede40a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7a22496e-6302-4107-8ff0-145c3ede40a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_986ee3c8-1f8a-4960-a4b4-6683be8588c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7a22496e-6302-4107-8ff0-145c3ede40a6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_986ee3c8-1f8a-4960-a4b4-6683be8588c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherLongTermObligationsMember_5e6c4966-7d5a-4ff6-ac10-b624468f4ec1" xlink:href="amed-20201231.xsd#amed_OtherLongTermObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_986ee3c8-1f8a-4960-a4b4-6683be8588c4" xlink:to="loc_amed_OtherLongTermObligationsMember_5e6c4966-7d5a-4ff6-ac10-b624468f4ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c44b7bc3-5f4c-4c72-9a09-26adee529ff0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_srt_RangeAxis_c44b7bc3-5f4c-4c72-9a09-26adee529ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ed93b5f-7704-47eb-8b09-0b4200183b67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c44b7bc3-5f4c-4c72-9a09-26adee529ff0" xlink:to="loc_srt_RangeMember_4ed93b5f-7704-47eb-8b09-0b4200183b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_958f4f21-4bd2-4695-9510-a44059cfbd91" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4ed93b5f-7704-47eb-8b09-0b4200183b67" xlink:to="loc_srt_MinimumMember_958f4f21-4bd2-4695-9510-a44059cfbd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56d72996-434f-46d8-a758-b1a1798c65f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4ed93b5f-7704-47eb-8b09-0b4200183b67" xlink:to="loc_srt_MaximumMember_56d72996-434f-46d8-a758-b1a1798c65f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_04e24541-e77a-436f-b421-3864e31484b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_04e24541-e77a-436f-b421-3864e31484b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_07fb0c95-98df-4f54-af5a-d91644e82bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_04e24541-e77a-436f-b421-3864e31484b1" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_07fb0c95-98df-4f54-af5a-d91644e82bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_a5dbadb5-b9dc-4a13-95ab-ffd5d262ed7c" xlink:href="amed-20201231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_07fb0c95-98df-4f54-af5a-d91644e82bb9" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_a5dbadb5-b9dc-4a13-95ab-ffd5d262ed7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60707324-5efc-41b6-8b2a-9fff0048b11b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_AwardTypeAxis_60707324-5efc-41b6-8b2a-9fff0048b11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26b154bf-916e-4927-a687-749b2ad15124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_60707324-5efc-41b6-8b2a-9fff0048b11b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26b154bf-916e-4927-a687-749b2ad15124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_e0821be5-b9f6-4091-a61e-1cba54cb8a43" xlink:href="amed-20201231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26b154bf-916e-4927-a687-749b2ad15124" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_e0821be5-b9f6-4091-a61e-1cba54cb8a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralAxis_aca38489-7ffa-4452-bf0c-1243826c768c" xlink:href="amed-20201231.xsd#amed_TypeOfIncomeTaxDeferralAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_amed_TypeOfIncomeTaxDeferralAxis_aca38489-7ffa-4452-bf0c-1243826c768c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralDomain_069b3eb0-eaa0-49e7-9db4-8ced8613a948" xlink:href="amed-20201231.xsd#amed_TypeOfIncomeTaxDeferralDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfIncomeTaxDeferralAxis_aca38489-7ffa-4452-bf0c-1243826c768c" xlink:to="loc_amed_TypeOfIncomeTaxDeferralDomain_069b3eb0-eaa0-49e7-9db4-8ced8613a948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SocialSecurityTaxMember_c8ca8d9d-ce56-4d07-b79f-1f22d30e1189" xlink:href="amed-20201231.xsd#amed_SocialSecurityTaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfIncomeTaxDeferralDomain_069b3eb0-eaa0-49e7-9db4-8ced8613a948" xlink:to="loc_amed_SocialSecurityTaxMember_c8ca8d9d-ce56-4d07-b79f-1f22d30e1189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_129c9f16-557b-49ca-a180-e8e218809a7c" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_721064b4-fcb6-4647-9e89-e4df651cc3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_721064b4-fcb6-4647-9e89-e4df651cc3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_53e68f8d-64d1-4b87-9f5a-de207611011a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_IncomeTaxesReceivable_53e68f8d-64d1-4b87-9f5a-de207611011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_e8a3a007-4b98-4333-b139-31f2ae2f0cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_e8a3a007-4b98-4333-b139-31f2ae2f0cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RefundTaxYear_b1b0bf77-e390-49d1-8d4a-75a0717dee66" xlink:href="amed-20201231.xsd#amed_RefundTaxYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_RefundTaxYear_b1b0bf77-e390-49d1-8d4a-75a0717dee66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_2c21947f-c41e-4ddb-9394-8856abb806d4" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_2c21947f-c41e-4ddb-9394-8856abb806d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e932177d-6913-48d7-9d57-a8e53eb2b74c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e932177d-6913-48d7-9d57-a8e53eb2b74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a95e6b91-aec4-49b9-b82c-da0919b186f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a95e6b91-aec4-49b9-b82c-da0919b186f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55a6434a-61da-407f-8ed9-63462c0c6b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55a6434a-61da-407f-8ed9-63462c0c6b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_81584958-66d0-487a-bb9b-b98c8e408f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_81584958-66d0-487a-bb9b-b98c8e408f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ae113a12-fc6e-4fd3-9fd1-3121e2d0e758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ae113a12-fc6e-4fd3-9fd1-3121e2d0e758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7d8f12a6-629d-498c-b6ed-fbaf66abb33f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7d8f12a6-629d-498c-b6ed-fbaf66abb33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfIndividualStatesSubjectToIncomeTax_066df8b5-b11f-4ed8-bb6d-7f7d4f7dbbde" xlink:href="amed-20201231.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_NumberOfIndividualStatesSubjectToIncomeTax_066df8b5-b11f-4ed8-bb6d-7f7d4f7dbbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_6d10562b-6667-4495-b5b8-b138b34cde81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_OpenTaxYear_6d10562b-6667-4495-b5b8-b138b34cde81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_3852b089-6966-4960-bbca-92c4eba64005" xlink:href="amed-20201231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_3852b089-6966-4960-bbca-92c4eba64005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ac98c5cd-1075-493f-a5af-801fca8a2c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ac98c5cd-1075-493f-a5af-801fca8a2c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_631f0ebd-c1b7-40d7-9855-d73d092f8518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_631f0ebd-c1b7-40d7-9855-d73d092f8518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_49eb0638-ef55-4f7a-b2b0-49ba900cd6a6" xlink:href="amed-20201231.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_FundingReceivedFromCARESAct_49eb0638-ef55-4f7a-b2b0-49ba900cd6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_ba8b2419-8485-4320-be02-592311328f18" xlink:href="amed-20201231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_amed_ProviderReliefFundAdvance_ba8b2419-8485-4320-be02-592311328f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4c3bb62b-eaf0-488e-94a0-971342130181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4c3bb62b-eaf0-488e-94a0-971342130181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_381225de-3d0e-4ef1-b904-fb138f10cd60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_6328dfeb-98ad-4f48-ac79-32f2274fdb79" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_381225de-3d0e-4ef1-b904-fb138f10cd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_387ce993-a98a-4fba-90ed-c955d0800c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3e388b2a-3d3e-4b08-9829-8c6f75829b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_387ce993-a98a-4fba-90ed-c955d0800c76" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3e388b2a-3d3e-4b08-9829-8c6f75829b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_dd4bad60-f232-4b2a-9413-149f9c3fc8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3e388b2a-3d3e-4b08-9829-8c6f75829b8f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_dd4bad60-f232-4b2a-9413-149f9c3fc8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_134296d3-56cc-4722-9d6b-2c0654dbf94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3e388b2a-3d3e-4b08-9829-8c6f75829b8f" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_134296d3-56cc-4722-9d6b-2c0654dbf94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2b0a3e5a-8387-4d9c-a98e-0278403e8467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3e388b2a-3d3e-4b08-9829-8c6f75829b8f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2b0a3e5a-8387-4d9c-a98e-0278403e8467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e672e52f-e710-407a-95f9-eeecdb062490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_387ce993-a98a-4fba-90ed-c955d0800c76" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e672e52f-e710-407a-95f9-eeecdb062490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_336956fe-702f-4133-a3ba-9656765a2f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e672e52f-e710-407a-95f9-eeecdb062490" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_336956fe-702f-4133-a3ba-9656765a2f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a08fc17b-64b5-4def-a355-75a2118c0792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e672e52f-e710-407a-95f9-eeecdb062490" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a08fc17b-64b5-4def-a355-75a2118c0792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_442c382e-a2df-4a60-a6b8-5148819513ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e672e52f-e710-407a-95f9-eeecdb062490" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_442c382e-a2df-4a60-a6b8-5148819513ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_934af4b1-0a0e-4589-b739-dbd003abb564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_387ce993-a98a-4fba-90ed-c955d0800c76" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_934af4b1-0a0e-4589-b739-dbd003abb564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESIncomeTaxExpenseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bd4bf3ed-7f24-4e33-bed8-0b35583e43e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a82445bf-c5c6-429a-ae7c-c42b30a5b56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd4bf3ed-7f24-4e33-bed8-0b35583e43e2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a82445bf-c5c6-429a-ae7c-c42b30a5b56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense_e75ed4d7-cb6b-453f-bea9-bc1f7bb55bad" xlink:href="amed-20201231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd4bf3ed-7f24-4e33-bed8-0b35583e43e2" xlink:to="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense_e75ed4d7-cb6b-453f-bea9-bc1f7bb55bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToGoodwill_05fc1ec4-3279-4534-8631-335e42b13f55" xlink:href="amed-20201231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd4bf3ed-7f24-4e33-bed8-0b35583e43e2" xlink:to="loc_amed_IncomeTaxEffectsAllocatedToGoodwill_05fc1ec4-3279-4534-8631-335e42b13f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_9369ec7d-13ef-47ae-8b5a-a490dfda24d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd4bf3ed-7f24-4e33-bed8-0b35583e43e2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_9369ec7d-13ef-47ae-8b5a-a490dfda24d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESReconciliationofEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6e8a9c76-ee15-47c2-a5f2-968fe92e9f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6e8a9c76-ee15-47c2-a5f2-968fe92e9f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_80e2957b-ba0d-41c6-859c-0a9e6e418420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_80e2957b-ba0d-41c6-859c-0a9e6e418420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_c9aab31a-e249-4ab1-b90f-626e7034f5c6" xlink:href="amed-20201231.xsd#amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_c9aab31a-e249-4ab1-b90f-626e7034f5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_ccd0b1e1-522c-48d9-9d3c-32fd16f00d56" xlink:href="amed-20201231.xsd#amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_ccd0b1e1-522c-48d9-9d3c-32fd16f00d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3adce8b0-3e9a-413f-9598-7c3fbfc18117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_3adce8b0-3e9a-413f-9598-7c3fbfc18117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bb566f23-a7b9-42ff-be80-6e1eb1699a26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bb566f23-a7b9-42ff-be80-6e1eb1699a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent_0df6b226-f100-446e-a4f6-81a9ed445140" xlink:href="amed-20201231.xsd#amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent_0df6b226-f100-446e-a4f6-81a9ed445140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1904cec3-5c06-475e-9cb8-ea0bdc8a90df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1904cec3-5c06-475e-9cb8-ea0bdc8a90df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7be6c7cb-c077-4cb3-99f4-6945a3562984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7be6c7cb-c077-4cb3-99f4-6945a3562984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_eca5aaa8-b274-47e8-9947-a919ae44efeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_eca5aaa8-b274-47e8-9947-a919ae44efeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1280c81e-e297-4b80-a0a6-c705ba310e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fae8ab72-180c-4b78-b1a5-ec391b9fd464" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1280c81e-e297-4b80-a0a6-c705ba310e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f7810f15-db98-4680-8497-2c3ed02305dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f7810f15-db98-4680-8497-2c3ed02305dc" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_8f52fea3-6a7f-4465-99d5-d5617788e915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_8f52fea3-6a7f-4465-99d5-d5617788e915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_69ea4c86-6fde-45f0-a4b5-ac63a6bc5639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_69ea4c86-6fde-45f0-a4b5-ac63a6bc5639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_af1d2f93-6b40-4733-b43d-8fc6065f7dfc" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_af1d2f93-6b40-4733-b43d-8fc6065f7dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_2df27963-194c-466a-a16f-78c5033e410b" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_2df27963-194c-466a-a16f-78c5033e410b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_07d28beb-32d3-4f46-95eb-d2b62e1754c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_07d28beb-32d3-4f46-95eb-d2b62e1754c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters_e25df739-cd95-4bd8-b752-74251cb248c2" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsLegalAndComplianceMatters"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters_e25df739-cd95-4bd8-b752-74251cb248c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLeaseLiability_5facafc4-8ed0-4ef0-9fd3-c665f38176a2" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_amed_DeferredTaxAssetsLeaseLiability_5facafc4-8ed0-4ef0-9fd3-c665f38176a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance_24eceadf-6f86-4414-908c-1722a58cfd09" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetsProviderReliefFundAdvance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance_24eceadf-6f86-4414-908c-1722a58cfd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_5dc87f8c-b3ce-466f-8f41-8adb5f3cfe72" xlink:href="amed-20201231.xsd#amed_DeferredTaxAssetDeferredSocialSecurityTaxes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_5dc87f8c-b3ce-466f-8f41-8adb5f3cfe72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_30b04659-e92b-45b6-b273-7e304ba7a472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_30b04659-e92b-45b6-b273-7e304ba7a472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4979c911-00cf-4809-b4fb-654909f2418d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4979c911-00cf-4809-b4fb-654909f2418d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3fa2bd5f-5a9c-4e4d-b484-c0f7aa4e61e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3fa2bd5f-5a9c-4e4d-b484-c0f7aa4e61e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_deba165f-91ed-4978-b6d9-8fffd2b8e7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_deba165f-91ed-4978-b6d9-8fffd2b8e7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_479d2e0e-ad82-4c68-b704-027558df1f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_479d2e0e-ad82-4c68-b704-027558df1f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_dcb2f04e-24d0-4244-aa86-35a2d6e52cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_992e3c31-7836-48ef-8891-0262747f4c81" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_dcb2f04e-24d0-4244-aa86-35a2d6e52cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f7810f15-db98-4680-8497-2c3ed02305dc" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5d1e32e8-6913-4455-a942-89f217fd9c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5d1e32e8-6913-4455-a942-89f217fd9c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_405cb869-9333-4092-b6eb-e5d8ca585314" xlink:href="amed-20201231.xsd#amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:to="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_405cb869-9333-4092-b6eb-e5d8ca585314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_4f6506e2-656f-4796-867b-0b5464ddf283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_4f6506e2-656f-4796-867b-0b5464ddf283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_2186777e-c2b6-4b96-afc6-6babdc1ec8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_2186777e-c2b6-4b96-afc6-6babdc1ec8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets_0ecc466f-9d4e-48a4-8cb6-7170ab68d3fb" xlink:href="amed-20201231.xsd#amed_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:to="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets_0ecc466f-9d4e-48a4-8cb6-7170ab68d3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_76e8393b-6e33-4d72-b1c6-c1382699d16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_76e8393b-6e33-4d72-b1c6-c1382699d16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7769c0ef-1590-4309-b644-feb5e16697ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_86bbc33a-c4af-4761-821e-bb2743d36374" xlink:to="loc_us-gaap_DeferredTaxLiabilities_7769c0ef-1590-4309-b644-feb5e16697ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6d756ddf-8f50-4bb4-b212-fc0d5314fa4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f7810f15-db98-4680-8497-2c3ed02305dc" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6d756ddf-8f50-4bb4-b212-fc0d5314fa4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2f0886ef-0d9b-40c1-a83d-e54ad84c964d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2f0886ef-0d9b-40c1-a83d-e54ad84c964d" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1d429207-9515-494f-9be3-7dcfda9ffde1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1d429207-9515-494f-9be3-7dcfda9ffde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f481b0a1-9e59-44c7-8047-cd336e03c656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f481b0a1-9e59-44c7-8047-cd336e03c656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5dda8712-20f8-4fd6-a3b0-f4e00a6ea5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5dda8712-20f8-4fd6-a3b0-f4e00a6ea5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_fdf02c11-06a6-4801-843f-16f6cad56152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_fdf02c11-06a6-4801-843f-16f6cad56152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_aad1d3ee-c13d-4133-a40e-c5e0128af194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_aad1d3ee-c13d-4133-a40e-c5e0128af194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_5c78f54d-e478-4027-8c53-01c1cba46d50" xlink:href="amed-20201231.xsd#amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:to="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_5c78f54d-e478-4027-8c53-01c1cba46d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e40fbed3-df04-44ef-ad9b-6bf26c82a48b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e40fbed3-df04-44ef-ad9b-6bf26c82a48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f97e9b97-efb5-4d18-a5bf-b63f5ebf427f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be7fb32a-717f-4b4c-bb41-0e6d948859d1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f97e9b97-efb5-4d18-a5bf-b63f5ebf427f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_086d9629-b83c-42eb-93aa-c018a66f1676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_711ee77d-bf2e-4a2c-8950-3c8a49226901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_086d9629-b83c-42eb-93aa-c018a66f1676" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_711ee77d-bf2e-4a2c-8950-3c8a49226901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a398ddeb-398a-4959-a363-815410a5a3e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_9e90983b-b7ad-45ad-a318-173936479e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a398ddeb-398a-4959-a363-815410a5a3e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_9e90983b-b7ad-45ad-a318-173936479e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_813920ee-ad2e-4d66-8701-24bb2d56f0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a398ddeb-398a-4959-a363-815410a5a3e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_813920ee-ad2e-4d66-8701-24bb2d56f0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a2ccc2bd-822d-43fb-ae53-b6586fe91849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a398ddeb-398a-4959-a363-815410a5a3e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a2ccc2bd-822d-43fb-ae53-b6586fe91849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_e62c8e60-711f-4065-a84d-3621165692b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a398ddeb-398a-4959-a363-815410a5a3e4" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_e62c8e60-711f-4065-a84d-3621165692b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8e770aad-b92b-49ea-ba57-9a6a2fbd74d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a398ddeb-398a-4959-a363-815410a5a3e4" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8e770aad-b92b-49ea-ba57-9a6a2fbd74d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_9e5007df-cb1b-4364-9120-08821a47f445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a398ddeb-398a-4959-a363-815410a5a3e4" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_9e5007df-cb1b-4364-9120-08821a47f445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76d57c8d-c51f-453c-8757-720cb115e315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76d57c8d-c51f-453c-8757-720cb115e315" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c53b43cc-3f09-4218-b751-7275945b069b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:to="loc_us-gaap_AwardTypeAxis_c53b43cc-3f09-4218-b751-7275945b069b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c53b43cc-3f09-4218-b751-7275945b069b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsMember_3a7a8f24-71df-4a79-bdbf-1c3612c51ae2" xlink:href="amed-20201231.xsd#amed_ShareBasedAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_amed_ShareBasedAwardsMember_3a7a8f24-71df-4a79-bdbf-1c3612c51ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_4e93415e-498b-46ed-8b3f-cd05a0c3ef82" xlink:href="amed-20201231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_4e93415e-498b-46ed-8b3f-cd05a0c3ef82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24d38fd4-cf02-4f1f-b6e5-794fabeff8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24d38fd4-cf02-4f1f-b6e5-794fabeff8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockMember_69123405-7b5c-4215-bf84-b7867f2956ce" xlink:href="amed-20201231.xsd#amed_NonVestedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_amed_NonVestedStockMember_69123405-7b5c-4215-bf84-b7867f2956ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember_9f9f1eb4-1c9e-4aa0-a39a-5a1e6a33e8b2" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d3ec735-a997-4445-963c-b3063d4fda3d" xlink:to="loc_amed_NonVestedStockUnitsMember_9f9f1eb4-1c9e-4aa0-a39a-5a1e6a33e8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember_f71bb311-79d0-466a-b1b1-4edbda10d135" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_NonVestedStockUnitsMember_9f9f1eb4-1c9e-4aa0-a39a-5a1e6a33e8b2" xlink:to="loc_amed_NonVestedStockUnitsServiceMember_f71bb311-79d0-466a-b1b1-4edbda10d135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_ec73fa0e-470b-4b3a-b354-299452b82007" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_NonVestedStockUnitsMember_9f9f1eb4-1c9e-4aa0-a39a-5a1e6a33e8b2" xlink:to="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_ec73fa0e-470b-4b3a-b354-299452b82007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_938c6d46-90c3-4665-85db-f565fc63be7a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:to="loc_srt_RangeAxis_938c6d46-90c3-4665-85db-f565fc63be7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcab1a5e-5c47-4bd0-822d-4fba85c7f1d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_938c6d46-90c3-4665-85db-f565fc63be7a" xlink:to="loc_srt_RangeMember_fcab1a5e-5c47-4bd0-822d-4fba85c7f1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2e787853-c15d-40d2-bdc7-1917a24ff484" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcab1a5e-5c47-4bd0-822d-4fba85c7f1d9" xlink:to="loc_srt_MaximumMember_2e787853-c15d-40d2-bdc7-1917a24ff484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_649d9c3d-2d28-4f8b-81ba-f5a559740be4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcab1a5e-5c47-4bd0-822d-4fba85c7f1d9" xlink:to="loc_srt_MinimumMember_649d9c3d-2d28-4f8b-81ba-f5a559740be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0aaeafc2-268c-43d5-9660-8a199c7cfde6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3e03f08e-f437-438a-bcc4-20144e351345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3e03f08e-f437-438a-bcc4-20144e351345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7570fe85-c3f1-4fb7-9781-17ee8ca18b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7570fe85-c3f1-4fb7-9781-17ee8ca18b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_48c737b1-0a9a-469a-9757-e187e00829a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_48c737b1-0a9a-469a-9757-e187e00829a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d895de99-f0f0-4845-98b4-c7c18d1ab314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d895de99-f0f0-4845-98b4-c7c18d1ab314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ff16b232-6be2-438c-a3dd-5d6740d3049c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_CommonStockSharesIssued_ff16b232-6be2-438c-a3dd-5d6740d3049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_071250fe-9db8-4137-a4b3-916958632ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_071250fe-9db8-4137-a4b3-916958632ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_63d8914b-08e2-4780-8693-7f1df88b0ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_PreferredStockSharesIssued_63d8914b-08e2-4780-8693-7f1df88b0ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofownershipinsubsidiaries_616dada6-f3a3-4c73-a040-6dce1a529f92" xlink:href="amed-20201231.xsd#amed_Percentageofownershipinsubsidiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_Percentageofownershipinsubsidiaries_616dada6-f3a3-4c73-a040-6dce1a529f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bacd8e2-8400-4987-9fb8-41f37bf794e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2bacd8e2-8400-4987-9fb8-41f37bf794e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f2d4c2a6-9e05-4888-80d1-74a1f20c55be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f2d4c2a6-9e05-4888-80d1-74a1f20c55be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Fairvalueofshareofcommonstockpercentage_b44c6e4e-b157-47bd-8eee-36dd5cbddeb2" xlink:href="amed-20201231.xsd#amed_Fairvalueofshareofcommonstockpercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_Fairvalueofshareofcommonstockpercentage_b44c6e4e-b157-47bd-8eee-36dd5cbddeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_9d81621c-f4ec-47ec-92fb-09c2af17e308" xlink:href="amed-20201231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_9d81621c-f4ec-47ec-92fb-09c2af17e308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_d477b0b3-c10b-4c55-93c5-926de7350aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_d477b0b3-c10b-4c55-93c5-926de7350aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_468f06db-de4e-4c3f-8339-762c85572ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_468f06db-de4e-4c3f-8339-762c85572ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_2ae7e299-b257-4297-9b3f-30ab54c69662" xlink:href="amed-20201231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_2ae7e299-b257-4297-9b3f-30ab54c69662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_99797255-1bd2-4ea4-905a-30c362899142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_99797255-1bd2-4ea4-905a-30c362899142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c539e7a7-19cc-4f12-9c73-b9f322f8c079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c539e7a7-19cc-4f12-9c73-b9f322f8c079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_304552a8-97ca-4b4f-b041-a81ab40e84d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_304552a8-97ca-4b4f-b041-a81ab40e84d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_2d83c7a0-5eb1-4768-b236-ccc7807da053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_2d83c7a0-5eb1-4768-b236-ccc7807da053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0d7cb474-1127-4d23-9fb8-f8dcf78e3deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0d7cb474-1127-4d23-9fb8-f8dcf78e3deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_846d49db-6992-410d-8c48-0d1f4cda4095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_846d49db-6992-410d-8c48-0d1f4cda4095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ec9506b2-3608-4aa9-a562-e530e44e4c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ec9506b2-3608-4aa9-a562-e530e44e4c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_52417ab6-bf73-4c2e-a8e5-9f14335e10f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_52417ab6-bf73-4c2e-a8e5-9f14335e10f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b497cfe1-22f3-4179-92c3-c446ec39e4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b497cfe1-22f3-4179-92c3-c446ec39e4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6724bb02-272f-434a-8e89-2fa9ad4927d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6724bb02-272f-434a-8e89-2fa9ad4927d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2d321a57-74f7-41f4-b4a4-fffb9462228a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2d321a57-74f7-41f4-b4a4-fffb9462228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Performancebasedawardtargetshareamount_d0fe0f45-8850-4c88-a478-b560d2249a35" xlink:href="amed-20201231.xsd#amed_Performancebasedawardtargetshareamount"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_241ea70d-aec1-4cb0-86f5-4e7ed741f1aa" xlink:to="loc_amed_Performancebasedawardtargetshareamount_d0fe0f45-8850-4c88-a478-b560d2249a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c39e8aa-1977-439d-bcd7-9290961abaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a95aec58-fcb3-4e16-94e2-ea2e2a8b73e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c39e8aa-1977-439d-bcd7-9290961abaa1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a95aec58-fcb3-4e16-94e2-ea2e2a8b73e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_40b07d2f-b6c6-47be-bb29-a3ed77732ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c39e8aa-1977-439d-bcd7-9290961abaa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_40b07d2f-b6c6-47be-bb29-a3ed77732ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31b599aa-2e72-4954-a1d5-ab30014ba33c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31b599aa-2e72-4954-a1d5-ab30014ba33c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_037d2949-18ef-493c-b73c-0c515925e88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:to="loc_us-gaap_AwardTypeAxis_037d2949-18ef-493c-b73c-0c515925e88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9662745a-73d3-40a6-b742-fa9e0c9985db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_037d2949-18ef-493c-b73c-0c515925e88f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9662745a-73d3-40a6-b742-fa9e0c9985db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_29ebd2a6-89f6-4d81-8284-2839b158d7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9662745a-73d3-40a6-b742-fa9e0c9985db" xlink:to="loc_us-gaap_EmployeeStockOptionMember_29ebd2a6-89f6-4d81-8284-2839b158d7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46eaf731-629a-44f9-8753-13393c30b0be" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:to="loc_srt_RangeAxis_46eaf731-629a-44f9-8753-13393c30b0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d28158f8-5e9e-4be5-8c00-265f87608c3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_46eaf731-629a-44f9-8753-13393c30b0be" xlink:to="loc_srt_RangeMember_d28158f8-5e9e-4be5-8c00-265f87608c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fe338e94-d5bd-44e3-aab4-c3f76f7c79c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d28158f8-5e9e-4be5-8c00-265f87608c3e" xlink:to="loc_srt_MinimumMember_fe338e94-d5bd-44e3-aab4-c3f76f7c79c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_994e5860-33b9-4ac4-a58f-5e99c90ff3c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d28158f8-5e9e-4be5-8c00-265f87608c3e" xlink:to="loc_srt_MaximumMember_994e5860-33b9-4ac4-a58f-5e99c90ff3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dfc878e-c18c-4ff1-ba39-f3d9cb495c1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_588e31a3-2217-4069-8326-41504d9b2825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_588e31a3-2217-4069-8326-41504d9b2825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fb17edf1-7388-4b7f-b128-2084e4428387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fb17edf1-7388-4b7f-b128-2084e4428387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b9e26ac3-e6eb-48c2-b4d7-b82f9156411f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b9e26ac3-e6eb-48c2-b4d7-b82f9156411f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3232c7ee-a51d-48aa-bbcc-1761c8a141ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3232c7ee-a51d-48aa-bbcc-1761c8a141ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a0adbb4a-0c85-4c7a-9894-174cbea062ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a0adbb4a-0c85-4c7a-9894-174cbea062ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_bd94ca8b-3fd4-4053-bc6d-ae966ed600a4" xlink:href="amed-20201231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_bd94ca8b-3fd4-4053-bc6d-ae966ed600a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1bd61bd9-aef7-4e17-81f8-bedc3391e5cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2494373a-0ade-483c-8f2f-34c84f496037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1bd61bd9-aef7-4e17-81f8-bedc3391e5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f59931bb-a293-4e29-b694-1cd64167e9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec0d16d7-c763-49b5-9128-8a01e2c6066c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f59931bb-a293-4e29-b694-1cd64167e9b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec0d16d7-c763-49b5-9128-8a01e2c6066c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c469ca1-e197-478f-abdc-40bf4d193bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec0d16d7-c763-49b5-9128-8a01e2c6066c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c469ca1-e197-478f-abdc-40bf4d193bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a1696b64-356d-4031-bd58-a9e6bce961ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec0d16d7-c763-49b5-9128-8a01e2c6066c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a1696b64-356d-4031-bd58-a9e6bce961ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9d930ada-b322-4e9e-9647-c04aa20c6451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec0d16d7-c763-49b5-9128-8a01e2c6066c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9d930ada-b322-4e9e-9647-c04aa20c6451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0513f2b7-8cfa-4d8b-bc52-40d644dbfcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec0d16d7-c763-49b5-9128-8a01e2c6066c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0513f2b7-8cfa-4d8b-bc52-40d644dbfcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51b5b5a0-ba5b-4a9e-8bda-40cba74a9a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec0d16d7-c763-49b5-9128-8a01e2c6066c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51b5b5a0-ba5b-4a9e-8bda-40cba74a9a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c05c2c37-d928-4cee-9d12-f20d22cc33a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec0d16d7-c763-49b5-9128-8a01e2c6066c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c05c2c37-d928-4cee-9d12-f20d22cc33a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2a123be-6090-419f-95b9-e428575357ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f59931bb-a293-4e29-b694-1cd64167e9b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2a123be-6090-419f-95b9-e428575357ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_abc129b5-882c-4dec-82cb-2821580b113a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2a123be-6090-419f-95b9-e428575357ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_abc129b5-882c-4dec-82cb-2821580b113a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eef622f2-854d-4c1b-a78c-013e623c617b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2a123be-6090-419f-95b9-e428575357ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eef622f2-854d-4c1b-a78c-013e623c617b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f6e9fb8d-e3cf-4f41-80f0-2bd218f5c5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2a123be-6090-419f-95b9-e428575357ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f6e9fb8d-e3cf-4f41-80f0-2bd218f5c5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_82c70883-2192-454d-8b9d-d1d10faf899a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2a123be-6090-419f-95b9-e428575357ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_82c70883-2192-454d-8b9d-d1d10faf899a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_260853a9-75fb-4875-b8be-bfda3a18c842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2a123be-6090-419f-95b9-e428575357ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_260853a9-75fb-4875-b8be-bfda3a18c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_549f870e-bed7-47fa-a400-8114371011a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c2a123be-6090-419f-95b9-e428575357ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_549f870e-bed7-47fa-a400-8114371011a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68e83b5f-8922-4c89-a509-8a32fc5adc28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f59931bb-a293-4e29-b694-1cd64167e9b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68e83b5f-8922-4c89-a509-8a32fc5adc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6590107b-a0b3-4a86-8989-f62ec4ad2e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68e83b5f-8922-4c89-a509-8a32fc5adc28" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6590107b-a0b3-4a86-8989-f62ec4ad2e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_97852101-e21d-4fe5-8ef2-9d51386654b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68e83b5f-8922-4c89-a509-8a32fc5adc28" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_97852101-e21d-4fe5-8ef2-9d51386654b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af3484bd-3c8b-4b94-87c1-b7dd4c48c1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f59931bb-a293-4e29-b694-1cd64167e9b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af3484bd-3c8b-4b94-87c1-b7dd4c48c1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2a153abd-35e0-46fa-a847-c6d71a9dc91d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af3484bd-3c8b-4b94-87c1-b7dd4c48c1a0" xlink:to="loc_us-gaap_AwardTypeAxis_2a153abd-35e0-46fa-a847-c6d71a9dc91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89f16e56-907f-4a19-9c19-92c0c0a8f9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2a153abd-35e0-46fa-a847-c6d71a9dc91d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89f16e56-907f-4a19-9c19-92c0c0a8f9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_6f5a4233-685a-4d1f-a904-17c680245d40" xlink:href="amed-20201231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89f16e56-907f-4a19-9c19-92c0c0a8f9f4" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_6f5a4233-685a-4d1f-a904-17c680245d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af3484bd-3c8b-4b94-87c1-b7dd4c48c1a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_53d438e2-6020-4b12-9132-7e95af5f50ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_53d438e2-6020-4b12-9132-7e95af5f50ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares_dce594b7-7f8f-45c1-929f-d291cd6d331f" xlink:href="amed-20201231.xsd#amed_SurrenderedSharesInShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_amed_SurrenderedSharesInShares_dce594b7-7f8f-45c1-929f-d291cd6d331f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c846f198-92ab-43f9-b45f-14252d47b0b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c846f198-92ab-43f9-b45f-14252d47b0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_20a95916-b4cd-4c93-a7f2-c438b8baa556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_20a95916-b4cd-4c93-a7f2-c438b8baa556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9d6ca5ea-bfe2-4637-8c29-a2b4e4b08518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19dc3d02-8e31-48eb-b7cc-6aa64dcd2da4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9d6ca5ea-bfe2-4637-8c29-a2b4e4b08518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c6a9ef4-1738-4d7f-a73f-674c0a3b574c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_62801eaa-5418-40d1-869a-fcf93d29de20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c6a9ef4-1738-4d7f-a73f-674c0a3b574c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_62801eaa-5418-40d1-869a-fcf93d29de20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_ff2956ca-b1ff-4f54-9419-9d90b66d3e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_62801eaa-5418-40d1-869a-fcf93d29de20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_ff2956ca-b1ff-4f54-9419-9d90b66d3e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8b1178d-12d0-47e2-82c9-9fcc4f5850e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_62801eaa-5418-40d1-869a-fcf93d29de20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8b1178d-12d0-47e2-82c9-9fcc4f5850e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_92c18a0d-8e52-4317-8da8-afaaac881f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_62801eaa-5418-40d1-869a-fcf93d29de20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_92c18a0d-8e52-4317-8da8-afaaac881f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_7d4a9364-3efb-4a35-b0c8-59d1975fdf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_62801eaa-5418-40d1-869a-fcf93d29de20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_7d4a9364-3efb-4a35-b0c8-59d1975fdf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_9f73422b-f7e4-49e1-81af-82d04964395a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_62801eaa-5418-40d1-869a-fcf93d29de20" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_9f73422b-f7e4-49e1-81af-82d04964395a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_49c4db91-2bb5-4867-bbc7-17360a6366f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c6a9ef4-1738-4d7f-a73f-674c0a3b574c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_49c4db91-2bb5-4867-bbc7-17360a6366f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_269e2485-4c12-4614-96ab-7aec38dad7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_49c4db91-2bb5-4867-bbc7-17360a6366f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_269e2485-4c12-4614-96ab-7aec38dad7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c6f591f-5943-4b48-b794-89555b42376d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_49c4db91-2bb5-4867-bbc7-17360a6366f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c6f591f-5943-4b48-b794-89555b42376d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4276350e-13ef-4390-b4bf-25de77af175b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_49c4db91-2bb5-4867-bbc7-17360a6366f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4276350e-13ef-4390-b4bf-25de77af175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e3cac7fa-671b-447b-970f-141151d49f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_49c4db91-2bb5-4867-bbc7-17360a6366f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_e3cac7fa-671b-447b-970f-141151d49f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2fa2372f-82f6-4470-9615-1844b2ddf009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_49c4db91-2bb5-4867-bbc7-17360a6366f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2fa2372f-82f6-4470-9615-1844b2ddf009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a688bc96-0c3e-4765-916f-1d27fb0f113d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a688bc96-0c3e-4765-916f-1d27fb0f113d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1935d94d-5330-4892-b7be-e1c59be322e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:to="loc_us-gaap_AwardTypeAxis_1935d94d-5330-4892-b7be-e1c59be322e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43aeb497-f302-49f7-ac3c-f1fb5d3eabd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1935d94d-5330-4892-b7be-e1c59be322e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43aeb497-f302-49f7-ac3c-f1fb5d3eabd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockMember_6e3833d1-d83f-4983-81ad-082512db5714" xlink:href="amed-20201231.xsd#amed_NonVestedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43aeb497-f302-49f7-ac3c-f1fb5d3eabd6" xlink:to="loc_amed_NonVestedStockMember_6e3833d1-d83f-4983-81ad-082512db5714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember_06c37ce1-2f05-4f82-8fc9-6c7ee0cb8aaf" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43aeb497-f302-49f7-ac3c-f1fb5d3eabd6" xlink:to="loc_amed_NonVestedStockUnitsMember_06c37ce1-2f05-4f82-8fc9-6c7ee0cb8aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5ce8541-8d27-468b-891e-fcb64707e7c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:to="loc_srt_RangeAxis_b5ce8541-8d27-468b-891e-fcb64707e7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_10a76e4f-662b-434a-bd32-ea3f822e2fc3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b5ce8541-8d27-468b-891e-fcb64707e7c0" xlink:to="loc_srt_RangeMember_10a76e4f-662b-434a-bd32-ea3f822e2fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ef328a0-43c7-4c61-aac9-6e4299d97939" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10a76e4f-662b-434a-bd32-ea3f822e2fc3" xlink:to="loc_srt_MinimumMember_8ef328a0-43c7-4c61-aac9-6e4299d97939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab9c99ba-0ecd-4e1e-a02d-b28ece0ea88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a6df38c-ece6-4760-b3bd-ca984e6949d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab9c99ba-0ecd-4e1e-a02d-b28ece0ea88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab9c99ba-0ecd-4e1e-a02d-b28ece0ea88c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f00701b8-0d68-44d7-bc9d-87e498d4ff1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f00701b8-0d68-44d7-bc9d-87e498d4ff1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a137aad8-ebb8-4aae-a9fb-76f68e82e93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a137aad8-ebb8-4aae-a9fb-76f68e82e93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_306f094d-0627-4093-aab4-472fcba50613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_306f094d-0627-4093-aab4-472fcba50613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e8c7622e-6486-4555-b11d-56ad4873fcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e8c7622e-6486-4555-b11d-56ad4873fcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02c9a59e-25a1-4462-87f6-21a06d4bfe9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82c2d818-76ac-4787-88f9-47302c3bf9fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02c9a59e-25a1-4462-87f6-21a06d4bfe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab9c99ba-0ecd-4e1e-a02d-b28ece0ea88c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3c125f9e-ac59-4e34-8130-15fc99abd8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3c125f9e-ac59-4e34-8130-15fc99abd8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e85000cb-52c3-42a9-8f4f-2454ff4d4f68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e85000cb-52c3-42a9-8f4f-2454ff4d4f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c40fddcf-860c-4689-ae74-0960715d5e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c40fddcf-860c-4689-ae74-0960715d5e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fdfc2173-2797-42fa-abce-85ab93149644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fdfc2173-2797-42fa-abce-85ab93149644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a642ae7b-6375-42be-8587-5b2ebc7b3ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1d740410-079b-4fda-b6af-55128e395719" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a642ae7b-6375-42be-8587-5b2ebc7b3ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_809f1c05-be9f-495b-8a1f-8604012d38a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe050280-e635-4931-923c-4594c8f681b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_809f1c05-be9f-495b-8a1f-8604012d38a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe050280-e635-4931-923c-4594c8f681b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe050280-e635-4931-923c-4594c8f681b0" xlink:to="loc_us-gaap_AwardTypeAxis_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3fd8904-fe12-4527-9845-6767ae27938d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3186ecdc-5107-4e3c-90d7-7a795fbd0eaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3fd8904-fe12-4527-9845-6767ae27938d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember_9660980b-9681-478b-afd0-8b092488a3c9" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3fd8904-fe12-4527-9845-6767ae27938d" xlink:to="loc_amed_NonVestedStockUnitsServiceMember_9660980b-9681-478b-afd0-8b092488a3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_13c90351-c157-498c-ba36-89dbc7ac527c" xlink:href="amed-20201231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3fd8904-fe12-4527-9845-6767ae27938d" xlink:to="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_13c90351-c157-498c-ba36-89dbc7ac527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe050280-e635-4931-923c-4594c8f681b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5bad771e-38d7-4c53-a49b-c9b1e0f586f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5bad771e-38d7-4c53-a49b-c9b1e0f586f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82f92877-3a33-449b-a22d-1edafcdf54af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82f92877-3a33-449b-a22d-1edafcdf54af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1e81e42-b5de-4826-8a33-a3c485a399b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1e81e42-b5de-4826-8a33-a3c485a399b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3e873c97-bd34-4217-8738-e9a914a77ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3e873c97-bd34-4217-8738-e9a914a77ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_db7f757c-1022-445b-8367-db7508180157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_32ef7b9f-ff95-465d-8544-f622bef6f63b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_db7f757c-1022-445b-8367-db7508180157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5fd51da-c6e1-4b26-b5b1-97852fad56fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f5fd51da-c6e1-4b26-b5b1-97852fad56fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff6a99d2-7f03-40e2-bb54-d6a623b68256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff6a99d2-7f03-40e2-bb54-d6a623b68256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd6e8bcc-68aa-420f-ae4b-7838a9e4705a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd6e8bcc-68aa-420f-ae4b-7838a9e4705a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9461c839-4f07-41fd-bce7-8503c29d24f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9461c839-4f07-41fd-bce7-8503c29d24f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c2c831f-3995-41d5-9fa6-0c84222cce7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b5e459-20dd-4723-83e9-451f6d98fc05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c2c831f-3995-41d5-9fa6-0c84222cce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount_d3038b69-59e1-416f-8946-4a6520633a97" xlink:href="amed-20201231.xsd#amed_AdditionalPerformanceBasedAwardTargetShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07aa1938-6ff5-482c-8c77-89c0efbea18f" xlink:to="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount_d3038b69-59e1-416f-8946-4a6520633a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e4fbe111-03f2-4eaf-9d99-4b3fd936f295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2767db58-4e00-41aa-bd2f-fd23147b6bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e4fbe111-03f2-4eaf-9d99-4b3fd936f295" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2767db58-4e00-41aa-bd2f-fd23147b6bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7fdd746-df55-4142-8cfa-8ae3c6ec67fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_85db3b64-0c2c-4056-b16d-3a19ef2cc639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7fdd746-df55-4142-8cfa-8ae3c6ec67fa" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_85db3b64-0c2c-4056-b16d-3a19ef2cc639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InsuranceProgramsTableTableTextBlock_f18d8dce-714e-4bbc-b378-80e222ca3f5b" xlink:href="amed-20201231.xsd#amed_InsuranceProgramsTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d7fdd746-df55-4142-8cfa-8ae3c6ec67fa" xlink:to="loc_amed_InsuranceProgramsTableTableTextBlock_f18d8dce-714e-4bbc-b378-80e222ca3f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_45841988-38f1-4384-9e02-e3d48c9f6241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_45841988-38f1-4384-9e02-e3d48c9f6241" xlink:to="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_11e1ac2d-3850-48be-836e-8f0f51812f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_11e1ac2d-3850-48be-836e-8f0f51812f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3d7158f0-8363-4ccd-abcc-4cd7f003dc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11e1ac2d-3850-48be-836e-8f0f51812f7a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3d7158f0-8363-4ccd-abcc-4cd7f003dc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2af8bad4-4542-49f1-8828-8b9e29c6de12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3d7158f0-8363-4ccd-abcc-4cd7f003dc3c" xlink:to="loc_us-gaap_SubsequentEventMember_2af8bad4-4542-49f1-8828-8b9e29c6de12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3727d33a-7986-4449-8ba6-88c2cff7e637" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_srt_LitigationCaseAxis_3727d33a-7986-4449-8ba6-88c2cff7e637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3727d33a-7986-4449-8ba6-88c2cff7e637" xlink:to="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_5f4f595e-8604-4eef-bd9a-e940432610ed" xlink:href="amed-20201231.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_UsDepartmentOfJusticeMember_5f4f595e-8604-4eef-bd9a-e940432610ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WageAndHourLitigationMember_1af647e9-c465-452a-8791-75bf7d893f68" xlink:href="amed-20201231.xsd#amed_WageAndHourLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_WageAndHourLitigationMember_1af647e9-c465-452a-8791-75bf7d893f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FrontierLitigationMember_03d7e797-0f0d-41e4-a7b3-cca64bbe0c90" xlink:href="amed-20201231.xsd#amed_FrontierLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_FrontierLitigationMember_03d7e797-0f0d-41e4-a7b3-cca64bbe0c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_cbf40cfe-a3c2-4af7-ace3-815cafce3e20" xlink:href="amed-20201231.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_cbf40cfe-a3c2-4af7-ace3-815cafce3e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IdahoandWyomingSelfReportMember_7f971430-7539-4741-9ba2-b20c14b7faa6" xlink:href="amed-20201231.xsd#amed_IdahoandWyomingSelfReportMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_IdahoandWyomingSelfReportMember_7f971430-7539-4741-9ba2-b20c14b7faa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ComputerInventoryAndDataSecurityReportingMember_3ca6d530-62dd-444f-9d3b-95da8be5ff7a" xlink:href="amed-20201231.xsd#amed_ComputerInventoryAndDataSecurityReportingMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_ComputerInventoryAndDataSecurityReportingMember_3ca6d530-62dd-444f-9d3b-95da8be5ff7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OigSelfDisclosureMember_053db9c1-c58c-43f6-ae40-4b20dff7ff53" xlink:href="amed-20201231.xsd#amed_OigSelfDisclosureMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_OigSelfDisclosureMember_053db9c1-c58c-43f6-ae40-4b20dff7ff53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_89a6d641-3a0b-4a23-a149-e645579a221a" xlink:href="amed-20201231.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_89a6d641-3a0b-4a23-a149-e645579a221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_12ba5c1f-aee2-4662-ac42-bef393f25bee" xlink:href="amed-20201231.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_InternalAuditComplianceReviewMember_12ba5c1f-aee2-4662-ac42-bef393f25bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_c246f3b6-04c6-4ebf-a1f6-be62c25104fd" xlink:href="amed-20201231.xsd#amed_AmedisysCIAMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_AmedisysCIAMember_c246f3b6-04c6-4ebf-a1f6-be62c25104fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_faeb4b3a-37d9-4807-b325-6bb57bd7255f" xlink:href="amed-20201231.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b3bf6965-89dd-436b-9626-9536fdae4693" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_faeb4b3a-37d9-4807-b325-6bb57bd7255f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4ba5f574-2e77-491c-92b4-027ad8484656" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_srt_StatementGeographicalAxis_4ba5f574-2e77-491c-92b4-027ad8484656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4ba5f574-2e77-491c-92b4-027ad8484656" xlink:to="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_261694a5-3da8-40d9-942e-970fe245ec3a" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_MA_261694a5-3da8-40d9-942e-970fe245ec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_ac5d0427-adfa-42cc-a906-5a07c92e0e2c" xlink:href="amed-20201231.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_amed_MorgantownWestVirginiaMember_ac5d0427-adfa-42cc-a906-5a07c92e0e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_efdec0dc-6dab-4fa5-a121-eb655bd295af" xlink:href="amed-20201231.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_amed_ParkersburgWestVirginiaMember_efdec0dc-6dab-4fa5-a121-eb655bd295af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_7c081519-6805-4551-964d-5083e1bced74" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CT"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_CT_7c081519-6805-4551-964d-5083e1bced74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_59ae2694-eee8-4088-bba5-b8c246231ac9" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_IL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_IL_59ae2694-eee8-4088-bba5-b8c246231ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_d8f738b7-b43a-4f38-a5f8-4d560412d7be" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_SC_d8f738b7-b43a-4f38-a5f8-4d560412d7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_9b16453b-d22c-4fe4-a66e-0e545f01b29e" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_019c3120-3667-4b77-b91c-3281b548d971" xlink:to="loc_stpr_FL_9b16453b-d22c-4fe4-a66e-0e545f01b29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_c8a07f17-a93a-4a74-ad61-a3cac447edf8" xlink:href="amed-20201231.xsd#amed_LakelandFloridaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_9b16453b-d22c-4fe4-a66e-0e545f01b29e" xlink:to="loc_amed_LakelandFloridaMember_c8a07f17-a93a-4a74-ad61-a3cac447edf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_2bc97c06-3293-4cc3-9f4a-945b17b28c1a" xlink:href="amed-20201231.xsd#amed_ClearwaterFloridaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_9b16453b-d22c-4fe4-a66e-0e545f01b29e" xlink:to="loc_amed_ClearwaterFloridaMember_2bc97c06-3293-4cc3-9f4a-945b17b28c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9965dff5-52e3-4a5f-b131-7e7091d48893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9965dff5-52e3-4a5f-b131-7e7091d48893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f4d585d5-6b30-4208-8ec3-0e62aa850245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9965dff5-52e3-4a5f-b131-7e7091d48893" xlink:to="loc_us-gaap_SegmentDomain_f4d585d5-6b30-4208-8ec3-0e62aa850245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_0480725c-5072-453f-845f-0cda487c6605" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f4d585d5-6b30-4208-8ec3-0e62aa850245" xlink:to="loc_amed_HospiceMember_0480725c-5072-453f-845f-0cda487c6605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_7340fcd9-ee52-442e-9645-dcab85f61d98" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f4d585d5-6b30-4208-8ec3-0e62aa850245" xlink:to="loc_amed_HomeHealthMember_7340fcd9-ee52-442e-9645-dcab85f61d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0e4159fc-7bf7-44e7-afe9-e6923e1dd785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0e4159fc-7bf7-44e7-afe9-e6923e1dd785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae53b96-c706-459d-b58a-ffb5d41929f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0e4159fc-7bf7-44e7-afe9-e6923e1dd785" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae53b96-c706-459d-b58a-ffb5d41929f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_0335ef1a-d1e2-4d32-8ead-40e5b58cd0fd" xlink:href="amed-20201231.xsd#amed_InfinityHomeCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ae53b96-c706-459d-b58a-ffb5d41929f0" xlink:to="loc_amed_InfinityHomeCareMember_0335ef1a-d1e2-4d32-8ead-40e5b58cd0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d228ee85-1280-465a-88bc-14dc2170cafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_bb2d65ad-3bf7-4241-8152-b75d5cbc02bb" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d228ee85-1280-465a-88bc-14dc2170cafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_65b988fb-63e3-4df7-bed6-866f8f728eff" xlink:href="amed-20201231.xsd#amed_ExtrapolatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d228ee85-1280-465a-88bc-14dc2170cafc" xlink:to="loc_amed_ExtrapolatedMember_65b988fb-63e3-4df7-bed6-866f8f728eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_9be63318-bb71-42bb-9812-1aa47e986e22" xlink:href="amed-20201231.xsd#amed_UnfavorableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_d228ee85-1280-465a-88bc-14dc2170cafc" xlink:to="loc_amed_UnfavorableMember_9be63318-bb71-42bb-9812-1aa47e986e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_431670a0-aa94-42a8-bb15-d2ddf13a0612" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_srt_RangeAxis_431670a0-aa94-42a8-bb15-d2ddf13a0612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a656acf4-60cb-4d53-b694-2ae3df0d34bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_431670a0-aa94-42a8-bb15-d2ddf13a0612" xlink:to="loc_srt_RangeMember_a656acf4-60cb-4d53-b694-2ae3df0d34bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ac89a94e-7e18-4bcf-ba7c-6ce6cea97bd9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a656acf4-60cb-4d53-b694-2ae3df0d34bb" xlink:to="loc_srt_MinimumMember_ac89a94e-7e18-4bcf-ba7c-6ce6cea97bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e0011cf-e59e-4e5d-b99a-976e301dceda" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a656acf4-60cb-4d53-b694-2ae3df0d34bb" xlink:to="loc_srt_MaximumMember_7e0011cf-e59e-4e5d-b99a-976e301dceda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_29704b90-6625-4a14-a387-dfdebf48b8b5" xlink:to="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_8e09ee59-15a9-405e-bd3a-c868d9715220" xlink:href="amed-20201231.xsd#amed_Numberofpatients"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_Numberofpatients_8e09ee59-15a9-405e-bd3a-c868d9715220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_accc6032-1bfb-4032-96e1-64e200b2e43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_accc6032-1bfb-4032-96e1-64e200b2e43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_29c42aff-d3bb-4f8b-882c-48e45a5fe2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_29c42aff-d3bb-4f8b-882c-48e45a5fe2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_61e02bdf-042c-47fa-907d-ca9f372bd368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_61e02bdf-042c-47fa-907d-ca9f372bd368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_2e297345-407e-4987-a9c8-a08f7268c1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_2e297345-407e-4987-a9c8-a08f7268c1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersSold_9c5ca6ed-5984-44ab-bb3f-173ab0d70a16" xlink:href="amed-20201231.xsd#amed_NumberOfCareCentersSold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_NumberOfCareCentersSold_9c5ca6ed-5984-44ab-bb3f-173ab0d70a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_42830b7b-7f93-4bbc-9922-4733fa30f767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_42830b7b-7f93-4bbc-9922-4733fa30f767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_89c832ba-3de2-44e2-96f7-e174da79b9e0" xlink:href="amed-20201231.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_89c832ba-3de2-44e2-96f7-e174da79b9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThresholdOfIndividualsInDataBreach_475ec4d1-1e8d-41db-a482-b6fdcc6e5a52" xlink:href="amed-20201231.xsd#amed_ThresholdOfIndividualsInDataBreach"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_ThresholdOfIndividualsInDataBreach_475ec4d1-1e8d-41db-a482-b6fdcc6e5a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_YearOfDeparture_9fd4a9c5-932d-4aff-a39b-81993d6fbe72" xlink:href="amed-20201231.xsd#amed_YearOfDeparture"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_YearOfDeparture_9fd4a9c5-932d-4aff-a39b-81993d6fbe72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_2987a8f3-145f-43b5-b530-c76602300027" xlink:href="amed-20201231.xsd#amed_NumberOfBeneficiaries"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_NumberOfBeneficiaries_2987a8f3-145f-43b5-b530-c76602300027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_b2d2d7b5-39ed-4fd4-852b-35e24a885ffd" xlink:href="amed-20201231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_b2d2d7b5-39ed-4fd4-852b-35e24a885ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_88276c94-de1a-4a5d-b3b3-148a690afb4a" xlink:href="amed-20201231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_88276c94-de1a-4a5d-b3b3-148a690afb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_efd02c33-8907-46de-8fc3-23c07ff86f6c" xlink:href="amed-20201231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_efd02c33-8907-46de-8fc3-23c07ff86f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_14f382c9-3e0f-4b88-8269-d6904d5da8d7" xlink:href="amed-20201231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_14f382c9-3e0f-4b88-8269-d6904d5da8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_6777a225-baf1-4cbc-8cd3-1e052a53665b" xlink:href="amed-20201231.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_6777a225-baf1-4cbc-8cd3-1e052a53665b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_3a97455a-7afe-4d8b-a060-375187e637ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_3a97455a-7afe-4d8b-a060-375187e637ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_b3accc15-b131-4d48-8abc-5c09bbfe5189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_b3accc15-b131-4d48-8abc-5c09bbfe5189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_f73d3dc0-aaf3-42ba-bae0-b52bac5ba1d3" xlink:href="amed-20201231.xsd#amed_ActualClaimsPayment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_ActualClaimsPayment_f73d3dc0-aaf3-42ba-bae0-b52bac5ba1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_0964f4d4-af0e-4f8c-9b1e-e111f386aaf7" xlink:href="amed-20201231.xsd#amed_ErrorRatePercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_ErrorRatePercentage_0964f4d4-af0e-4f8c-9b1e-e111f386aaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_2dd69b8a-c45b-4faf-bddb-ce86603dd490" xlink:href="amed-20201231.xsd#amed_IndemnificationAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_IndemnificationAmount_2dd69b8a-c45b-4faf-bddb-ce86603dd490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_84956ac0-1c5c-493b-a625-e38e3a3ea09d" xlink:href="amed-20201231.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_FloridaZpicRevenueReduction_84956ac0-1c5c-493b-a625-e38e3a3ea09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a715c6cb-c5a0-45c9-b1fb-8acde9f949a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a715c6cb-c5a0-45c9-b1fb-8acde9f949a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeaseTermYears_f696d541-5f3f-4fc7-a87f-bc23d2c499b0" xlink:href="amed-20201231.xsd#amed_OperatingLeaseTermYears"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_OperatingLeaseTermYears_f696d541-5f3f-4fc7-a87f-bc23d2c499b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7f066c46-da4d-40af-ba16-9718f55a6c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_us-gaap_LeaseAndRentalExpense_7f066c46-da4d-40af-ba16-9718f55a6c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_fe82237e-9af0-429d-952c-f0389d921ea8" xlink:href="amed-20201231.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_HealthInsuranceRetentionLimit_fe82237e-9af0-429d-952c-f0389d921ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_00b155e1-4370-446f-ab48-909628b9090c" xlink:href="amed-20201231.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_00b155e1-4370-446f-ab48-909628b9090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_59797d70-cac7-4908-93bc-615b759d6719" xlink:href="amed-20201231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_a7d98db8-1971-4552-aaba-8e247f11bf7f" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_59797d70-cac7-4908-93bc-615b759d6719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54788aa3-9e56-459a-ad2f-65be7f7bcd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsurance_d418e8c6-6559-46d0-9986-2cb49022bd62" xlink:href="amed-20201231.xsd#amed_HealthInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54788aa3-9e56-459a-ad2f-65be7f7bcd5b" xlink:to="loc_amed_HealthInsurance_d418e8c6-6559-46d0-9986-2cb49022bd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WokersCompensation_8e36f235-25b5-44a4-b9b1-91ff29c9969d" xlink:href="amed-20201231.xsd#amed_WokersCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54788aa3-9e56-459a-ad2f-65be7f7bcd5b" xlink:to="loc_amed_WokersCompensation_8e36f235-25b5-44a4-b9b1-91ff29c9969d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiability_beffede5-29ac-4544-8755-6ea98e518afe" xlink:href="amed-20201231.xsd#amed_ProfessionalLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54788aa3-9e56-459a-ad2f-65be7f7bcd5b" xlink:to="loc_amed_ProfessionalLiability_beffede5-29ac-4544-8755-6ea98e518afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceTotal_44d552b6-9a58-411d-9214-7f82f22edde1" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceTotal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54788aa3-9e56-459a-ad2f-65be7f7bcd5b" xlink:to="loc_amed_EstimatedInsuranceTotal_44d552b6-9a58-411d-9214-7f82f22edde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceLongTermPortion_5524b1bb-9ed9-4491-b63d-0f1eb6480ea2" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceLongTermPortion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54788aa3-9e56-459a-ad2f-65be7f7bcd5b" xlink:to="loc_amed_EstimatedInsuranceLongTermPortion_5524b1bb-9ed9-4491-b63d-0f1eb6480ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceExcludingLongTermPortion_fed1f601-b7b0-404b-a4c4-ad2bc4e39685" xlink:href="amed-20201231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_54788aa3-9e56-459a-ad2f-65be7f7bcd5b" xlink:to="loc_amed_EstimatedInsuranceExcludingLongTermPortion_fed1f601-b7b0-404b-a4c4-ad2bc4e39685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="amed-20201231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a8367ec-25c3-4bbc-b6f8-e6391a6513ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_86080f26-e8d7-4349-a234-975889287e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a8367ec-25c3-4bbc-b6f8-e6391a6513ae" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_86080f26-e8d7-4349-a234-975889287e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#EMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b7f30475-3646-4295-b547-abe675ead48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefinedContributionPlanEmployerMatchingContribution_d9eacf8b-32c8-434a-b050-eb2d96add2fa" xlink:href="amed-20201231.xsd#amed_DefinedContributionPlanEmployerMatchingContribution"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b7f30475-3646-4295-b547-abe675ead48a" xlink:to="loc_amed_DefinedContributionPlanEmployerMatchingContribution_d9eacf8b-32c8-434a-b050-eb2d96add2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_ab5acdfc-1a18-4169-9c11-1167e3690e8f" xlink:href="amed-20201231.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b7f30475-3646-4295-b547-abe675ead48a" xlink:to="loc_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_ab5acdfc-1a18-4169-9c11-1167e3690e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_042c122b-7791-42af-bffc-63d2ba3302d8" xlink:href="amed-20201231.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b7f30475-3646-4295-b547-abe675ead48a" xlink:to="loc_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_042c122b-7791-42af-bffc-63d2ba3302d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_39368f53-8b55-4b60-81b1-bd6a73e53969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b7f30475-3646-4295-b547-abe675ead48a" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_39368f53-8b55-4b60-81b1-bd6a73e53969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20201231.xsd#SHAREREPURCHASE"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a05b921a-799f-4b1c-96b3-baabcd1de22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_94ef3fae-3410-4913-a713-5f3a62cdb4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a05b921a-799f-4b1c-96b3-baabcd1de22c" xlink:to="loc_us-gaap_TreasuryStockTextBlock_94ef3fae-3410-4913-a713-5f3a62cdb4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4dc63295-01a1-4d93-b5fa-d71ab4c9a9f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_976423fa-113b-4a65-8825-2f9f8c71a8c3" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4dc63295-01a1-4d93-b5fa-d71ab4c9a9f2" xlink:to="loc_amed_ShareRepurchaseTable_976423fa-113b-4a65-8825-2f9f8c71a8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseAxis_404454d0-e601-4d94-b920-e3b67b245db5" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_976423fa-113b-4a65-8825-2f9f8c71a8c3" xlink:to="loc_amed_ShareRepurchaseAxis_404454d0-e601-4d94-b920-e3b67b245db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseAxis_404454d0-e601-4d94-b920-e3b67b245db5" xlink:to="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021StockRepurchaseProgramMember_85879b9f-2ceb-4a70-bd0e-f20fe6c10d08" xlink:href="amed-20201231.xsd#amed_A2021StockRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:to="loc_amed_A2021StockRepurchaseProgramMember_85879b9f-2ceb-4a70-bd0e-f20fe6c10d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019StockRepurchaseProgramMember_baffba43-b49f-40d3-9889-745def1487dc" xlink:href="amed-20201231.xsd#amed_A2019StockRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:to="loc_amed_A2019StockRepurchaseProgramMember_baffba43-b49f-40d3-9889-745def1487dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRShareRepurchaseMember_06ba22a4-2169-411e-8a71-6dc39af71ca7" xlink:href="amed-20201231.xsd#amed_KKRShareRepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseDomain_237e33a9-a079-440a-960e-f5d8819729ec" xlink:to="loc_amed_KKRShareRepurchaseMember_06ba22a4-2169-411e-8a71-6dc39af71ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_976423fa-113b-4a65-8825-2f9f8c71a8c3" xlink:to="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_eef8adf2-10ff-493b-9fe5-abc29a674bf7" xlink:href="amed-20201231.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_amed_PercentageofSharesOutstanding_eef8adf2-10ff-493b-9fe5-abc29a674bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_258eca30-6de1-42ed-8c47-851e497e17bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_258eca30-6de1-42ed-8c47-851e497e17bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DiscountedClosingStockPrice_a1722aaa-641e-4577-bcc8-42e4bd68bf38" xlink:href="amed-20201231.xsd#amed_DiscountedClosingStockPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_amed_DiscountedClosingStockPrice_a1722aaa-641e-4577-bcc8-42e4bd68bf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofClosingStockPrice_0145418d-4b9e-454d-80a4-c187297097e2" xlink:href="amed-20201231.xsd#amed_PercentageofClosingStockPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_amed_PercentageofClosingStockPrice_0145418d-4b9e-454d-80a4-c187297097e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_257be23e-c799-41dc-9608-86c62a8fc374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_257be23e-c799-41dc-9608-86c62a8fc374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_4c8e6aed-7816-4602-8a50-f80ac8b52558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_4c8e6aed-7816-4602-8a50-f80ac8b52558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8c1c172c-3575-4a02-b341-6013816be015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8c1c172c-3575-4a02-b341-6013816be015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f23a718e-5bdd-42fb-ab73-f8374d71e76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_a9374c87-67e3-47b2-8f5c-77f72cfb1f6f" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f23a718e-5bdd-42fb-ab73-f8374d71e76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6042b4f4-4a45-4e7f-991e-478a6eab8a4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_970b012e-7560-483d-891a-32ce138b6724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6042b4f4-4a45-4e7f-991e-478a6eab8a4f" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_970b012e-7560-483d-891a-32ce138b6724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d7ccdfc0-26d2-43dd-95ab-2035655f5cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ccf0a920-8789-4d19-ab8e-0d4c5f05edc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d7ccdfc0-26d2-43dd-95ab-2035655f5cc2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ccf0a920-8789-4d19-ab8e-0d4c5f05edc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f72246fa-8c30-4340-a684-e61696864ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e415ec3e-7d7d-4649-8111-41c7825fcdeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f72246fa-8c30-4340-a684-e61696864ff8" xlink:to="loc_us-gaap_NumberOfReportableSegments_e415ec3e-7d7d-4649-8111-41c7825fcdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_576a3e09-0d44-4a4e-9503-b80f98edea6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_576a3e09-0d44-4a4e-9503-b80f98edea6b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0026f1f4-ded6-495a-923b-ca7935df4826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0026f1f4-ded6-495a-923b-ca7935df4826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0026f1f4-ded6-495a-923b-ca7935df4826" xlink:to="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_0cca14f2-56aa-4419-9aa4-7abddde2aff2" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:to="loc_amed_HomeHealthMember_0cca14f2-56aa-4419-9aa4-7abddde2aff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_1a38ef85-c6cb-43c1-8413-22d69ff11ebb" xlink:href="amed-20201231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:to="loc_amed_HospiceMember_1a38ef85-c6cb-43c1-8413-22d69ff11ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_d2180fc5-4e7c-464a-8663-31a69d85f89c" xlink:href="amed-20201231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:to="loc_amed_PersonalCareMember_d2180fc5-4e7c-464a-8663-31a69d85f89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember_b60e9e0b-dfd4-4ce5-8aeb-c2fb04df5d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d90ed64f-184b-4b34-a339-10dc2802ba18" xlink:to="loc_us-gaap_CorporateMember_b60e9e0b-dfd4-4ce5-8aeb-c2fb04df5d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_041713ba-91f0-46c0-95d2-9e35722759c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:to="loc_srt_ConsolidationItemsAxis_041713ba-91f0-46c0-95d2-9e35722759c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_16772197-89b2-463f-922d-362b44c133a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_041713ba-91f0-46c0-95d2-9e35722759c9" xlink:to="loc_srt_ConsolidationItemsDomain_16772197-89b2-463f-922d-362b44c133a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0cb677b9-07d5-48ee-ad0d-664bcbc94261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_16772197-89b2-463f-922d-362b44c133a8" xlink:to="loc_us-gaap_OperatingSegmentsMember_0cb677b9-07d5-48ee-ad0d-664bcbc94261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_9deee5b9-41df-4a8f-8301-e11bcd06f7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_16772197-89b2-463f-922d-362b44c133a8" xlink:to="loc_us-gaap_CorporateNonSegmentMember_9deee5b9-41df-4a8f-8301-e11bcd06f7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6e19c271-2531-4e6a-8c23-8fdf29b50a20" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_754bdb6e-52b8-4977-a711-52b2d629069e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_754bdb6e-52b8-4977-a711-52b2d629069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_4f9f2ea5-0400-47e6-81f1-daf774ae2efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_OtherOperatingIncome_4f9f2ea5-0400-47e6-81f1-daf774ae2efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ec6f1007-07c7-4695-a439-2d24a6767244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ec6f1007-07c7-4695-a439-2d24a6767244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_89bef1ef-47ea-4c24-813b-04d007bcff07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_89bef1ef-47ea-4c24-813b-04d007bcff07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_4d9839b2-a65d-41e5-a951-114b5b0468d7" xlink:href="amed-20201231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_4d9839b2-a65d-41e5-a951-114b5b0468d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_216c4a13-c529-426b-af04-7442213ced0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_AssetImpairmentCharges_216c4a13-c529-426b-af04-7442213ced0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a3c44578-4baa-4c3a-8d34-4c48563a425e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_CostsAndExpenses_a3c44578-4baa-4c3a-8d34-4c48563a425e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d462d1b4-54f8-443a-bad1-52b1cc1cea67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_04213a35-f1d3-4af6-903a-40920965270b" xlink:to="loc_us-gaap_OperatingIncomeLoss_d462d1b4-54f8-443a-bad1-52b1cc1cea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4bd33eda-64b6-4e87-bea8-db703523a06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_2b0778d4-30b2-4b6b-8e0f-e5409a7b51e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4bd33eda-64b6-4e87-bea8-db703523a06e" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_2b0778d4-30b2-4b6b-8e0f-e5409a7b51e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3295b17e-e141-455f-8e83-c111ea834a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_75aeb75d-a05e-4abe-b8e8-94b2c11fa1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3295b17e-e141-455f-8e83-c111ea834a27" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_75aeb75d-a05e-4abe-b8e8-94b2c11fa1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_774091cb-4207-4cb3-8ab5-5407dd5ba3e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_8e4dc245-0b5e-465d-abc1-5a7a8f2a4acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_774091cb-4207-4cb3-8ab5-5407dd5ba3e8" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_8e4dc245-0b5e-465d-abc1-5a7a8f2a4acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8cba404-06dd-4a55-bc76-ea8fcb88da9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_774091cb-4207-4cb3-8ab5-5407dd5ba3e8" xlink:to="loc_us-gaap_NetIncomeLoss_a8cba404-06dd-4a55-bc76-ea8fcb88da9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6add67f9-9da0-421d-bad4-6a86bedb1d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_774091cb-4207-4cb3-8ab5-5407dd5ba3e8" xlink:to="loc_us-gaap_EarningsPerShareBasic_6add67f9-9da0-421d-bad4-6a86bedb1d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e02df92e-2420-41cc-ae43-bf7b2e9a06b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_774091cb-4207-4cb3-8ab5-5407dd5ba3e8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e02df92e-2420-41cc-ae43-bf7b2e9a06b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_774091cb-4207-4cb3-8ab5-5407dd5ba3e8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6f674673-4285-4abb-a62d-086c82ad6218" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:to="loc_srt_LitigationCaseAxis_6f674673-4285-4abb-a62d-086c82ad6218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d5db93bc-28f8-4331-9479-f9414a9b85b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_6f674673-4285-4abb-a62d-086c82ad6218" xlink:to="loc_srt_LitigationCaseTypeDomain_d5db93bc-28f8-4331-9479-f9414a9b85b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_27cbbfac-0752-4e7b-b526-26d16621eb29" xlink:href="amed-20201231.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d5db93bc-28f8-4331-9479-f9414a9b85b6" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_27cbbfac-0752-4e7b-b526-26d16621eb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_30165702-252c-4b1e-871c-dfe382c916f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_30165702-252c-4b1e-871c-dfe382c916f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e1b2a0e5-667f-4afa-9117-65b258aeec4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_30165702-252c-4b1e-871c-dfe382c916f0" xlink:to="loc_us-gaap_SegmentDomain_e1b2a0e5-667f-4afa-9117-65b258aeec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_f903bfbe-528c-4574-9b04-ee4d75977faf" xlink:href="amed-20201231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e1b2a0e5-667f-4afa-9117-65b258aeec4c" xlink:to="loc_amed_HomeHealthMember_f903bfbe-528c-4574-9b04-ee4d75977faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_81ad14df-cdcf-43b9-8000-9263f2e4acf6" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalFeesNetOfIncomeTaxes_8f213719-12a8-4190-83ef-9dae94c3472e" xlink:href="amed-20201231.xsd#amed_LegalFeesNetOfIncomeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_amed_LegalFeesNetOfIncomeTaxes_8f213719-12a8-4190-83ef-9dae94c3472e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes_94c14bb3-eac4-47cc-bb59-e48f56347e0d" xlink:href="amed-20201231.xsd#amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes_94c14bb3-eac4-47cc-bb59-e48f56347e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet_0aabbb04-4d21-4af5-9c83-62a1037c3e21" xlink:href="amed-20201231.xsd#amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet_0aabbb04-4d21-4af5-9c83-62a1037c3e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssetImpairmentChargesNetOfIncomeTaxes_dbb6968c-935b-4263-b698-2ff6e9297061" xlink:href="amed-20201231.xsd#amed_AssetImpairmentChargesNetOfIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c4fd32c-cf56-4be9-ad34-b1a397263b11" xlink:to="loc_amed_AssetImpairmentChargesNetOfIncomeTaxes_dbb6968c-935b-4263-b698-2ff6e9297061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20201231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_da280135-6e50-4178-8d89-30026339ccfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_44c6504b-0d6e-4b36-acbc-1eae29440024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_da280135-6e50-4178-8d89-30026339ccfe" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_44c6504b-0d6e-4b36-acbc-1eae29440024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20201231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b0f29491-fc70-43cb-807a-ac4e716e5e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b0f29491-fc70-43cb-807a-ac4e716e5e08" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseAxis_587eba7a-d721-4462-9c38-91e6e4f47147" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:to="loc_amed_ShareRepurchaseAxis_587eba7a-d721-4462-9c38-91e6e4f47147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseDomain_5021bb89-b2fe-40ed-9250-a33423de4ca6" xlink:href="amed-20201231.xsd#amed_ShareRepurchaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseAxis_587eba7a-d721-4462-9c38-91e6e4f47147" xlink:to="loc_amed_ShareRepurchaseDomain_5021bb89-b2fe-40ed-9250-a33423de4ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRShareRepurchaseMember_4c74ddd0-62f8-4133-bdfe-bef0a7d2edf4" xlink:href="amed-20201231.xsd#amed_KKRShareRepurchaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseDomain_5021bb89-b2fe-40ed-9250-a33423de4ca6" xlink:to="loc_amed_KKRShareRepurchaseMember_4c74ddd0-62f8-4133-bdfe-bef0a7d2edf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_66f32a78-6d38-47fd-a92c-199bc19fcd95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_66f32a78-6d38-47fd-a92c-199bc19fcd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_66f32a78-6d38-47fd-a92c-199bc19fcd95" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_KKRConsultingMember_78f5650e-5a44-4339-8516-2ab60862131f" xlink:href="amed-20201231.xsd#amed_KKRConsultingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:to="loc_amed_KKRConsultingMember_78f5650e-5a44-4339-8516-2ab60862131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CareInnovationsMember_7aba62b6-829b-4b48-b45d-5d014e8f3b5d" xlink:href="amed-20201231.xsd#amed_CareInnovationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:to="loc_amed_CareInnovationsMember_7aba62b6-829b-4b48-b45d-5d014e8f3b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_4978a135-900c-4584-b256-b21e63e623f4" xlink:href="amed-20201231.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f9ff863-8b6a-4834-a8ba-3d23049486d4" xlink:to="loc_amed_MedalogixMember_4978a135-900c-4584-b256-b21e63e623f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34aa864b-e6e7-43e8-a873-2dd3f77c3318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34aa864b-e6e7-43e8-a873-2dd3f77c3318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1be6965d-d3b4-4b53-9652-6cbb1323865c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34aa864b-e6e7-43e8-a873-2dd3f77c3318" xlink:to="loc_us-gaap_RelatedPartyDomain_1be6965d-d3b4-4b53-9652-6cbb1323865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c6e842f3-58b9-41db-ac74-ef874794690f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1be6965d-d3b4-4b53-9652-6cbb1323865c" xlink:to="loc_srt_AffiliatedEntityMember_c6e842f3-58b9-41db-ac74-ef874794690f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_ce5e3c12-e997-48b1-ad27-b513e2b82fc8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ManagementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1be6965d-d3b4-4b53-9652-6cbb1323865c" xlink:to="loc_srt_ManagementMember_ce5e3c12-e997-48b1-ad27-b513e2b82fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fa6cf24f-6efd-4023-87c6-443db088a8a5" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_2a8271ed-139e-418a-9df1-bd1656603aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_2a8271ed-139e-418a-9df1-bd1656603aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c3fd5d7b-aaac-4550-8428-0e84a6352551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_c3fd5d7b-aaac-4550-8428-0e84a6352551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_881e27dd-6cbe-467c-aea3-01812a0ba554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_881e27dd-6cbe-467c-aea3-01812a0ba554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_a34a7672-ef15-47a1-8c22-45e2d161a2de" xlink:href="amed-20201231.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_amed_PercentageofSharesOutstanding_a34a7672-ef15-47a1-8c22-45e2d161a2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1345eff1-6913-405e-aad5-eb92fca6a6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1345eff1-6913-405e-aad5-eb92fca6a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DiscountedClosingStockPrice_fee6d3e4-b602-4816-909d-37cf6d3c6100" xlink:href="amed-20201231.xsd#amed_DiscountedClosingStockPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_amed_DiscountedClosingStockPrice_fee6d3e4-b602-4816-909d-37cf6d3c6100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofClosingStockPrice_77d9a328-4000-46e1-a114-a588a1740420" xlink:href="amed-20201231.xsd#amed_PercentageofClosingStockPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_amed_PercentageofClosingStockPrice_77d9a328-4000-46e1-a114-a588a1740420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_427e128d-9f04-41a8-8073-eb354f0dbbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f2fb5cb2-e186-4e03-8dab-822a32288279" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_427e128d-9f04-41a8-8073-eb354f0dbbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>amed-20201231_g1.jpg
<TEXT>
begin 644 amed-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !> )4# 2(  A$! Q$!_\0
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M^YF#Q=5Q=2-K))V]5??_ (!TV@?M6>!O$OB>+2;75V\^Y?RK>:6UECM[ELX
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M:RHTY-2DE=!1116IH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>amed-20201231_g2.jpg
<TEXT>
begin 644 amed-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" '+ E(# 2(  A$! Q$!_\0
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M>:7?Q5UC4-;U2S\ >";CQ/;:1*;>\O?M\=I'YPSE(]P/F8QSCG..,%2:NO\
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M&3Q7H=% 'A?@OQQI'PACUSPQX_%QI=PFI3W=G<?99)([^)SD-&R@\\8.< 9
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MJP#'./E)'K]% 'A;>#;[4=(N?[9T&ZN)+?PE<KIZ7$+2-!)Y\K6Z+UQ.L9C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F?\(WHO_"2?
M\)!_9=K_ &OY?E?;?*'F[<8QN^G&>N..E:=% &3!X5\/6UI>6MMH.F0V]\<W
M<,=G&J7'^^H&&ZGKGK3I?#&@SV=G:3Z)ILEM8L&M(7M(REN1T**1A3],5J44
M %9VA_\ (/E_Z_+K_P!'R5HUG:'_ ,@^7_K\NO\ T?)0!HT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBFRRI#$\LSK'&BEG=S@*!U)/84
M -GGBM;>2XN94AAB4O)([!510,DDGH *X2X\,VWQ+U2VUG7H+F'1[2-TTVW2
M>6WEN S(YFD*,K!=T491>ORACR0!IP1OXXN([RZ1D\-Q.'M;=Q@ZBP.1+(/^
M>0/*J?O<,>-HKK* ,C1O#&FZ#=7-U8?;'N+I(XY9;R_GNG94+E%!E=B #(YP
M,?>-:]%% !1110 4444 %%%% !1110 5F?\ "-Z+_P ))_PD']EVO]K^7Y7V
MWRAYNW&,;OIQGKCCI6G10!2.BZ6=)DTLZ;9G3Y-V^T\A?*;<Q9LIC!RQ)/')
M)-02^&-!GL[.TGT339+:Q8-:0O:1E+<CH44C"GZ8K4HH *SM#_Y!\O\ U^77
M_H^2M&L[0_\ D'R_]?EU_P"CY* -&BBB@ HHHH **** "BBB@ HHHH ****
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M^\1C?L+"UTO3X;'3X$M[:! D<2# 44 +965MIMC#96$$=O;6Z".*&-=JHH&
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M8;#3H5@MH%VHB]NY)/4DG))/)))-6:** "BBB@ HHHH **** "BBB@ HHHH
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M$HOW-JJ W6I+O0-:CM-6NI=%U*:UUG3]=MM-MTLY'>"2ZN5>#?'C,.Y1G+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK<TS2=/T:S%KI-E;V4 .?+@C" GU..I]SS5NB@ HHHH **** "BBB@ HHHH
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M':1Z<Z![?[$JB$JW(*[>,'.<BKM !1110 4444 %%%% !1110 4444 %%%%
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M8]2?<\U>HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*SM#_P"0?+_U^77_ */DK1K.T/\ Y!\O_7Y=?^CY* -&BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***I:AK.EZ0H.JZE:6(89!N9UCR/\ @1%
M%VBL?3?%WAW6+[['I&N:??W&TMY=K<I*<#K]TFJNM^.=&T">>+4/M^ZW4-*\
M6G3R1(#TS*$V#_OKVH Z*BN:TKQ[HVJW%O"K36K7:JUG]I4+]J![Q@$DCWP!
MS69+X^U:5M1&E>"]4N%L)?++7*M )OF*@I\C%QQGY<X'7% '<5G_ -O:/_;'
M]D_VK8_VCC/V/[2GG=,_<SNZ<]*PH_&%_%:VW]KZ/#ITURI9G.HPM%:@]/,W
MF-]WJ%0@>I-?+2>*=2U?PRVHBXM4U?3X?,M;*UTZ6265=Q>>[DDWX1MVV0OR
M<PH<*,Y /M*L/5O%EAIE[_9UNDVIZJ5!73[%0\H!Z%^0L:G^\Y4>]<K!;>/?
M%-AI<>J30Z3I=Q C74FEZ@!>$X!W>8(]H!](\'!^]VHTSX>V6E6=Z8O"[221
MS"2""379Y5N26Y=@WRJ>_(.>] &GJ$-W=6XN?'6N6VA::YP-/M;OR0_M+<':
MS<=53:/=A5[0?$GA#=;Z/X7O+*2,96.+34WQ+CK\R J.G4FKDTEY<WFGBZ\/
M1RHR!Y9FGC;[(Y'( (RWU&*5=4U46=W(WAVX$D#!8(4N82;@$XR"6 7 YPV/
M:@!=6UNZTZZ6"TT#4]49DW;K3R50<D8+22(,\4NDZAK-[</_ &GH8TRW"Y1G
MO%ED9LC@J@( QWW'ITIXU2_^TV4;:#>!+A TTHF@*VK?W7'F9./50PJ)=:OS
M:WDK>&=45[=@L</FVI:Z!."T?[[  ')WE3CH">* (;VS\5W%Y*+/6=+LK0M^
M[']FO+,![L9@N?\ @-7])L;ZRMW34M6FU.1VR))(8XM@QT4(!Q]<GWJ,:M<_
M:K*%M$U!5NHP[RYA*VQ_NR8DSD?[(8>]1C7IOLMY,^AZHIM7"B(QQEY\G&4
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M-10!C^&O#J>&K"XM8]0O+_[1=273278B!5Y#E@!&B* 6RW3JS5L444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9VA_\@^7_K\NO_1\E:-9VA_\@^7_
M *_+K_T?)0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP[3_ )ZW_P#X,)__ (NC^P[3_GK?_P#@PG_^+H T:*SO[#M/^>M__P"#"?\
M^+H_L.T_YZW_ /X,)_\ XN@#1HK._L.T_P">M_\ ^#"?_P"+H_L.T_YZW_\
MX,)__BZ -&F":-IVA# R(JNR]P"2 ?\ QT_E5'^P[3_GK?\ _@PG_P#BZ:/#
M]B)6D#7HD90K/]OGR0,X&=_09/YF@#3HK._L.T_YZW__ (,)_P#XNC^P[3_G
MK?\ _@PG_P#BZ -&BL[^P[3_ )ZW_P#X,)__ (NC^P[3_GK?_P#@PG_^+H T
M:*SO[#M/^>M__P"#"?\ ^+H_L.T_YZW_ /X,)_\ XN@#1HK._L.T_P">M_\
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M_GK?_P#@PG_^+H T:9+-' @>5@BEE0$^K$*!^)(%4?[#M/\ GK?_ /@PG_\
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M_BZ/[#M/^>M__P"#"?\ ^+H T:*SO[#M/^>M_P#^#"?_ .+H_L.T_P">M_\
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MV)F>TN)XIY;$[<EV0. ZKUSD XS7D</Q'\5WKZ^=,URXDTK2=.N]4TW4I[.
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M9MJ#)PJX STH VZ*** "BBB@#@;O4_$NA_$)+2741J5OJ-I=S65A+#' DDJ
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M+D2NNYL.X9AG@]* .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"0TK1HPB& 3ER. 3TK2O=:TS3M$DUB]OH(=-CB$S71D'E[#T8'OG(QCKD8H
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M9-%\6:UX@T+S;KQA90VEZ\\MW?\ ]C;8!]FF0%1"K$L6D5<%2,,QX(!'7?\
M"+ZO_P!#WX@_[\:?_P#(M=)10!D6-E=:':7=Q?:UJFM@)O"7$,!=-H)(188D
M+$^AST&,<Y\A\,Z+XOTG6O#GC'4M V3ZEJ,[:H+>662Y$5WC:)8?)&Q8MD6?
MG.-O0=O=:* / ]*\!M/K>BS:CX:FD\_Q1J9OI)[-CNM3YAC$A(_U);! /RDG
MODYYS3?"7BAM*LH=6L-3A*V)@TE_[%FNY[*5;V4CRCYL:VS[?)822$*4 YP*
M^GZ* /!O&WAV_G\0>(#>:%J&I:M/JFF2Z?J$%C)(@M$,>]1(H*H P<LF022&
MP0-PDU'POJ-YX.UNVNK?5+,-XVN[U"FD&]22(L=C26Y^:6$D@Y4-S@X(&1[K
M10!\Y)H6L+'X;T671?[*C\86RZ=?V<<DI$,=I<>;YF)29%#6[2*%8Y48'&,5
MT7B#P_J,'QN@U?3M+N]1+7UH!#<Z=(B6T2IM:6"]B;:J ;MT,FT,2?E8E37L
M']DZ=_:_]J_8+7^T?*\G[9Y*^=Y><[-^-VW/.,XJW0!Q'BK4V\5?##QG;:7I
M]]]IMX;W3A \/[R:1$(RBJ265L@KW((XYKSWQ;X0O=5GO))M NKMH?A_##:D
MVC/LO%D<A4X_UPSP!\P!/K7NL%M!:QF.UACA1G>0K&@4%G8LS8'<LQ)/<DGO
M4E 'CVF:8%\;7=YXP\-ZQJ>JSSV$FE7MO;2GR(A"H8>>"%A"OYA=&9=V2<-N
MY]1TG5O[66\/V"^LOLMW):XO(?+,VPX\Q.3NC;JK=Q6A10 4444 %%%% !11
M10 4444 8JZ%J"Z?/;'Q5J[2RN&2Z,5IYD0'\*@0;,'_ &E)]Q5'Q19>(K;1
MY;SPYJ6I7E_#:^3#8!;01W$A^7S7+HIR-V\A70'9@ 9P>HHH \O\#>%]=T>;
M4-'MO^$DT?2;B*.>*]O9-.DFBN%PCJH3S%(= A)9,Y1B26;-=\-+NQJ-K<G7
M=0,4$022U,=OY=P<$;W/E;PQSGY64<#C&0=*B@#C_&6D7X^%/B:P2\O];NY]
M/N1%YL49E8M&0(U6*-0>>G!//4UYCX8\,Z_X)\?:$3I>H7?A_3])N[ZV\JW=
MVMY)H4:2UP <-YB,57J3)CDU[]10!X;X1T+Q;X>U[PMXFU30PLNJW%Q'J[VL
MLLLY%V?-0S1>4/*6-E12=[8[X[6_#VG:SHOQ,EC\+1Z[!H6ISW<FK:5JU@PA
MM) &(E@GY1@[D85&)(//3Y?9Z* /$/"]IJ&H_#_P!X:CT?5K;4=*U.WO+Y[O
M39[>.VCA=G;]Y(BJQ8$* I).X]@:J'3/%S:@?B(WAV03#Q +M8PTWV_[ /\
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M(].N;"9K*W:XDM)'9&63RE#,P.PKE5;'&1C-<5JT'BGQ7X%U6WU2VUN_M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>amed-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amed="http://www.amedisys.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amed-20201231.xsd" xlink:type="simple"/>
    <context id="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2521c40c2e674edaba9586526c5b83a7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2b4abd4b7b654854b3d46e098ad305fe_I20210219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-02-19</instant>
        </period>
    </context>
    <context id="i767079f30664438f8d9be671a161fd0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia733ca32dbec4462ac0839915fc3b59a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i71d70551ae8f463895c999fdc4613768_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2c73d7f291d449999ecc705771a35788_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id9320162518845cd970162f4a4cb6a6c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i44f984b3dbe34af3aace209254870882_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7c1a95136f914b75adc71c283c901b28_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3ae973af03114509bb73f714dfe8c520_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idae5b781450b4b82a9efea9a6ab20171_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0ead52e4a58e40af94f4cfcfabee33f3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i11cb32ff042042599b56293d9c96b2de_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i578f5d8892c542728c9f3d614bb9ae1c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i75707ab7adca4f98a7ec345287bc457d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i253841217f1446de87fdaaac95f8653f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib7c4c0651a104d48aa8b1906c357fbbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8ccddfc560fe46b5b31297f960c4cdfa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1c61e77ed93b41c1a04abf43c6726a45_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if901346fc21749c693ca795fa77431fb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3b9b1d7d6085499cbd3f5b49680ccb64_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9317f7646da44eee93324b0a16fb1827_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida0afee284554110852d7f9cc9a2bb52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib47e4e9c01d44fe7b652556bb85a5f1b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaed066fa0032452b960a5c28694f984d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id3cb19d428214cf1b5d7b341146b4fbb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i76be51b421be4511a94ed8e7e72c0652_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i822e34ba968444868d3c6943bd915b7c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic19c797f2e324b2eb967c2bce916b767_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie77a7f6ef23f49b1b151e334930d121b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb85416bef844237937a8966fd006741_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3a117d66ff846f2af342b27fd619eb3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7d57dd850e241008b6b1e4d426681fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf3c23c0c8b54e24b20b5c10ef9f270e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7af783f565644361ab504f9908131fb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3defad69f61b4cf99c2daf1bee38aab8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b86cc0a4b0247b0be34b31af7783e22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2bbb43da3d614bb0a07f82de8f66c0ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i556d9f2b4c0446a481203b0d721356f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8445bad575a44eaf8f8bf43b13576231_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e73c8be1d6044ae94fdfbcfab376671_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5312e58d089a492e8f1b50eb41d38fe4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibf84b9ba9e1d4509914b4659ae8cf76e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3f4d87d3f8c04768adb0d99598494f75_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7618d2cebdef436fa6e1ece2cb3e1a9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30daf9d0e928439bbf628952733e011b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2914b051b7f649fbb23140dd91cafcdb_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i3eee69c4378245919523ef9c81dcd659_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">amed:NoncontrollingInterestSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ic6f32ffb396941779dd01b141bf45abd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:HeritageHealthcareInnovationFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e986e4e31c44d36a9f7a6664353fdce_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:HealthcareanalyticscompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia9908f52af49414aaa4bba7ff6a04ea2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icbdc95bff22c46c88b5ecb49ca013c65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa97deb735d340eca9b8cc590a5b1849_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0f3ed78fd22d4d13a30267510435daf6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iefef9d24cffa43e4a8689e876b718fdf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc080435d3fc4721a9440877edb75f0d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia74323b930434bcdb3617ec041a4cfe6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icdc0080330a7432e9027a57a221467c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifdf6f8b2217645d7a837564472c1641e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i04b9e3d120ed425ba59ad31de35d305d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cd65f8b7a704689a2fe739ca3da0471_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib865129db50747ec9ba2b83c279bc869_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iae6389e8be7141058ce2e5865620a128_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6368cc1cda74803ab17d38cb452059b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8c88b95605441ba8df42caa5d36162b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0ebe30ad71fe49acad1f10623f51159b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59c59d1d549d4f0b8e8a5cd6aa96ee72_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaaa6c33dce254267aa5511c42c11f0c1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1fd55beb3b4d4378b920094a5b091472_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f6206325b4d4a58a46dff6013229b68_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5177b049f064d83bb0e48f33e3b2e58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icca03328f124427a801b7d654ef05ff9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1910bccf75da421d95218682b6c0f049_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e4242100dce41a99f05af2e39618231_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b22800f018b4cb5b23b5e899cc8f26a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandThirteenThroughTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4486f034b52465db1934c0b02d4badf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i458e999686ec425fb89dcbbb0521682c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id56f149b375540d6ac65813b85c223fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d302a79021b4c4cbaf66726ebe127e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i203914f8db684c668d2c7dac204ca2c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i640213bfd2f74b9a8e1dde58507eabc6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb00a1b56bb044c7ab5db9f625aec705_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5e3297361534d9ebafe84913d07eb73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie624c24d63be42a88573abdf69aae516_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99cc7fb2614e43a78496b7db077072c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bde4b17d3e64e889a2b995dc1b96e0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33563aeb6c734c9b8f2b02515df00ee4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibbdd825dcd9b4a34a7e7ee40b29823ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a14cc7e58784bbabd79f9688f678767_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idcdf59b18c044a0586a45d15dd0cc388_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89ef5f5295c143c4814a9cc4b7e9a2aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id32eea10fdea44f8b804df035c1d9f9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a0c5250e66540da9c9ee41bb6cc2a6b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib90ca7053c5a4eabba3431aecde330cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf4b84d294244f4783317a7222e4e879_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9c91ba472944f99a6daf60ac242bcb6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8a9e61c64a324dccb0426c5ca15ad0fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab41181582e84ce6a158eb40d3e43022_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0822cae609e455f8dabd64cd55ce112_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icaceabeac78a43fa8dcdac6a349b0ed0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a7919ceb133453abee391bfba5d166c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6001d3911d55430a8c080827cb5bcaff_I20200327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="i372268bd3773442994730e4fe0e5ee44_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ibfa49fd6f4b049c4852349a3f959f964_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i37e4a08657594a9e8a1641435acac59f_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i6b9d23dde21e42c9a907136f7eeaf5e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i118a662ab55141c19f9cdf727c8817fe_I20200424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="i6134feb4f36f4032ba67f2372de0d569_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="ie67bc19fa2814c5abd3ff91ce96f6e90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic433fb8ffa524d98b4462b2bfdb4ca4a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9cafc4be2f5437d9ca0b72a01385735_D20200301-20200301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-01</endDate>
        </period>
    </context>
    <context id="i027e9e9fdcb3465e9e2a8e7763db61d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcad9ea4bad644b7aef096a89d73a367_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c82b6aabd174ab7b9b1bbd04c0e4f43_D20200418-20200418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-18</startDate>
            <endDate>2020-04-18</endDate>
        </period>
    </context>
    <context id="id6b5bde6cd03496eb965aaa99d46b4e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8af9f0752744492d80892b57fe0eb43f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:KY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i736c6f864f0c4f2f90cb716d504ad728_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i28272584e8864b6eac538308aa55f7f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iefb68536b309420b86b96f71d3be7002_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicarelicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4071912f29b1471a90316176f150bae0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac1ab93fa9c14e638c003d6efff17ec7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45609ba2476e4e52aa2321ed4c22caa4_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="ib9861da3d84840e5b7b2f004402be77c_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AsanaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="ia1196979b4bd42e99e052738971c3d6d_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i3a1566846d62435ebae17d6c7c127850_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="ia7182413ea774295b30d183d04b1cabd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6dade9dfe7084bfbadf9e3614bbe33ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicarelicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f1af67560f042a28a10f654e58775f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5098d5c55d8b4b1dbeee2d1d43a9b870_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6dbc8b680ea432483b0218a761a9ee4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id50e918f9fa742aea3517c666077cbc2_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i4caa862c918a45e6bc9f8e6f842d75f0_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="i7f9f9514c4b747218bdb73b2a59513b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i539b5ad7e9ee440ba81d9f4f4069b5e8_D20190201-20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="i000c57f033a6483d8bf707b4eb4e6f55_D20190201-20190201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-01</endDate>
        </period>
    </context>
    <context id="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:CompassionateCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if362ac0d7ade4dbe9a2f52099ec6f0e7_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i05a1575f31584575992abc74ced2bc65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i169c7364acc540578506213cd50aac76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i856c123c4c204fe38e4e036fd7752a96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6826cc9464ca4135b180f102528d6d44_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i4483458942a649af981f192426433819_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:RoseRockHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i2123af26c18b4412a49a520f6e2ab7c8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i14c3a57b90754fd780752ab5eaeb2119_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3ca74d3eda644e30a68c80809f7fc57f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie88935582b014075a328bfa1b117396c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5af8da337a3b49f3a113759b906bf9f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i941dbf037dc148deb289e0c5c518ef5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b3b8059d89b46389a5544b50a169658_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i299a9ff0faaf4204a8a8ec39062247b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i758a004b4fbe477aa6e2ef91789cb336_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i189835ae24ec4c70b6a717d5b08a421a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib9aefbc5b7fb48c5b29a38dcb7a14868_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6192d3d4b0a84bfeaab23464bd0e6b9e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib187ff5463f54b85b4e3f4bc6ad8636c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i969ee2ebea1b499f906b31aa81ec4f31_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia87f788f2fe64b23944a430849785260_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iffe18e321548455c94c7d0cd77924cf8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6d6b40ce5cc498eba1f0d3ec5483959_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83cdcc0f05d44f1d840709161ceb3440_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc65628a7dbf4a1da089fe655a7e819d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd0ee0b03f92409eb2ff67a774546a35_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9714b4cf7d7c4de1be0e59b0dd0e7085_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib383332f81cd4bfa9b1922280c354414_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ided786cf36e844558e359485f224451e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7040a24f0754adc968817731ec50305_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80f77e35787c46fe9512e728260f7095_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c25949461664d0aaec5b5040213f6b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71e88ffd25ce42179e2ee5206728bafa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i994f6975b70a49068c75d0139eb0bb9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3998374665924f3aa61bd5813eecd5f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e380d81b95f448eab4c555d915ea5cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:LeaseTypeAxis">amed:FleetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e1c460171b341758ee7f2c6f5213b5e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90dece5459db457b9caee4a934044bae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7c937ebfcbb4487b42fa8461a09a162_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8de54dd0485448269d1eebf429a33e51_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2041f507eabe49338b0fd15b6f05a37a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie2ed331009f24a32b73120f18a9797f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a7367ab708f42b39e9081b6c1bb9a02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f2b03850b34492e9f5c7baeadcdd170_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0024757aa534d409fcb4e8a79dad213_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8051bc5ccedc4458b6ff74abcdfd5b59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03a65bdf068041f2ba700f2afe87977d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4365d319b33f4857ae4bc38bf1acf0d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83398cda1ea54e6783c252370998336f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifedadb8035864252bc2a50fe50d27fb7_I20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="i55e3ad37975747ce85e5f9e56a387aeb_I20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="ib818b639b2fc470b9dfaf7a8a57d34aa_D20180629-20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="i90f987fd3c874bb7a0482a03ac02dd0a_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="ic20973059f44430a8ea7527042093e66_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="i82f050f262b84796a9b340b2d9129bc0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifcea2f99e9244669860fa34644e434d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd5550ca8a47443f914e49b80cf1c663_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i449b5f09d3b34ec39a18a9cef526b9a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic46bf12be9614cdc9e2592966809f199_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4332b377849d47079522cdb966f405aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if009f649f525477986901bf87b9a8a8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i663a0220bf1f4bde8453506f3ec8b0c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58ce40c5da424eb1acc6a5a1cc10d1ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6dd35f3ef914c7b9e3b873612e24d07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2fdd832f78f447590dcea35096f588e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id875fdd2eb7148c4aa89a6f6d517e964_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd3a5e252c794510b621a8afd98a30af_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic73c6064129945f89356c2e9781e2ff3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ac1b22c6f554e6db80a1dec5c335a03_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i327f7ac146d444c88f630645e8202d8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if363353766114727baf5a4aab4fe9ca4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ef9e7a889a946cfba1e6124e81184a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3064d98b299543439b8d8a53616ccd96_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6594991d717f452eb94882c394b94cea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7d69adb19bc439892e8f7b86338bcb6_D20190204-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7328ca3b33b846ebb1d8865233054b79_D20200401-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5f285d89c3194106bf7a283b287c5858_D20230401-20240204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-02-04</endDate>
        </period>
    </context>
    <context id="i81b3d4329c9e413992649f97f3932f8e_D20190204-20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-02-04</endDate>
        </period>
    </context>
    <context id="i813d4685897443ab84f5078bedbc3eed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a9f227940024b9b9e6f47095fc1825c_D20190204-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-04</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibd494e95d0b348dbbcf7c525e255735b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d03942e78784e909bcee19f2ae8dcad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c7e72eca4bc4cf0b3983258ef075db8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68bc26784c984ab2b763317f0ea13821_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-10</startDate>
            <endDate>2020-08-10</endDate>
        </period>
    </context>
    <context id="i5e2a3b22027c46259ffb26bf610aae36_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i061c5e4bcf0a48809b0f8aaa50b8d7f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a797cd8697149299906057726300694_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c55a72c359242999f6ad37fe6380c0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeOfIncomeTaxDeferralAxis">amed:SocialSecurityTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ff4532176b44743aad3722dcd2582f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa1ce8651ce74253af7461cfa4722490_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">amed:StateTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2bfa60d1a274089b775bff19975c6d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2268173c1609427b91285a18f7856aa8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsToMoreThanTenPercentOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic23e136463954fce97ebf07eaca62d49_I20120606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-06-06</instant>
        </period>
    </context>
    <context id="i1f87b9321c534dcfae4d2ce97fe4fc8b_I20120607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-06-07</instant>
        </period>
    </context>
    <context id="ia4f247884db846bdb4821a221bbfe57c_D20120607-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2012-06-07</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i172263bdf66a4f008f59172cfb1d5640_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1d88f9ec77c9452c8bb506759c530a16_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9b760ab2443e4046941e64e3b50a2f09_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifc731d16af2b4adb980e8754afe1b9f9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i17ca81d5bf204e579790350d278411ad_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44d57dec79174a29a10a484c6e35ee00_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5c385df453324adfaca85d0811925684_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3692bce7d32644e5b337cd5691239645_D20120607-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2012-06-07</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0967904d6aa443bda7b944783f5368a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95b123e655fe43e190e185f8dbe56430_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5def5d90694943c991e6829f70fa6a4c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie9b8d67240ac466ba65b24c556a36122_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iab6fc63306454ed1ad46e51a0060949e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf88ad709fd64cffbbba3949d9877821_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic1850298439a4c2f8d557340227845e9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i24d3940f86e248f5a619e4759d853c1e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic24c7c520697474487b3aceda222db5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbd18b01890b461182b19c8a098912de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15df4480ba24493cb5e3394c14dff135_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9934834a8a0c409b8d6d372c860f05c2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id48af308b58146e1a94f7cbf20c53001_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i67aef9e5409443cc838400c94814e771_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6fba36dadd24151b9f0f7c470401177_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief02df4838c5483f9c1fee131227eb29_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i085cfa11bc6843488c86ab3d0a3da2ad_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9a62c2d5f8ed48a78a320ddb584e246f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i521c7c89279e4c0aa844c60ec36a5f59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1560d4e370f847fb92bf3948fe2bd932_D20150521-20150521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-21</startDate>
            <endDate>2015-05-21</endDate>
        </period>
    </context>
    <context id="i3ce9e524eb0543eeae2df4f429cd9905_D20151103-20151103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-03</startDate>
            <endDate>2015-11-03</endDate>
        </period>
    </context>
    <context id="i07641836ad0d4665b300523692960b1f_D20160627-20160627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-27</startDate>
            <endDate>2016-06-27</endDate>
        </period>
    </context>
    <context id="iaf11c6ccfd794c169a08d89e5cd17b31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id92e1c7184a7449e846c859caeab4fbe_D20140423-20140423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:AmedisysCIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-04-23</startDate>
            <endDate>2014-04-23</endDate>
        </period>
    </context>
    <context id="if492da41859849a18fe046b7f1da314e_D20150130-20150130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:CompassionateCareHospiceCIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-30</startDate>
            <endDate>2015-01-30</endDate>
        </period>
    </context>
    <context id="if3e4bf70e5d9479ebc20d004efd4f9e8_D20080101-20100331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="ib7b09ab0a49d4b838fe8db28575066f2_D20110606-20110606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-06-06</startDate>
            <endDate>2011-06-06</endDate>
        </period>
    </context>
    <context id="i92498864eda34c97bf3f44b5a1827b5b_I20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-18</instant>
        </period>
    </context>
    <context id="i44e23098929046f7af1cfe828afaec85_D20160118-20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-18</startDate>
            <endDate>2016-01-18</endDate>
        </period>
    </context>
    <context id="ib02eb19f870b48a0ac524cc591131f73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8979ada06f974ae48d397f54b6e49eda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80891250852448afbff7aef1c0666a33_I20190110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-10</instant>
        </period>
    </context>
    <context id="i93b988a539e7458e9ebc3dfab2f46a43_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i1c5fc041d76e49a5983d00e207829170_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="ib558c962d6c04f40adef9ad76c074458_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i5f99d4d9f475438a97dba13e3a83c516_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="icaa86f34e687461286bbecf374c1f96e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f2f005315e5492bb8fec7e5757a7e04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie45f729caf77486a9faad14454801668_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i29dcf5be2ab240aa86b1d44b4274b48e_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ib20172f07d6649a2a8664caf1f015ef2_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i76464f5a074a42fc86111f27060e6a56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2b9a36901674eb9a302469e2cac8ab9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf602ed6544f4e14998550bd3bc16290_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie3800a96a7434d7f807e7946ac5ea7d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8e83cf1d9574cf69c223d04622768aa_I20201223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:A2021StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="i982a73904c8843df8b8f14ae21909b06_D20201223-20201223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:A2021StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="ib40aceab8f864987a75d9c12fb66ae7e_I20190225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:A2019StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="ia0bafbf9ffa74adb9775ae8c65c96711_D20190225-20190225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:A2019StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-25</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:KKRShareRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-04</startDate>
            <endDate>2018-06-04</endDate>
        </period>
    </context>
    <context id="i479834b49d53404d82becc11f229a75a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib96bea9253ac4d8d90b0d2f79b7e9bb6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1d01c191f7b94742a8aedf3242104b2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ce2a100b9be4e04b1c79c526dd5afe1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i562b1925a10f47859b8528d0316b1f34_D20180604-20180604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:KKRConsultingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:ShareRepurchaseAxis">amed:KKRShareRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-04</startDate>
            <endDate>2018-06-04</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="care_center">
        <measure>amed:care_center</measure>
    </unit>
    <unit id="state">
        <measure>amed:state</measure>
    </unit>
    <unit id="number_of_visits">
        <measure>amed:Number_of_Visits</measure>
    </unit>
    <unit id="day">
        <measure>amed:day</measure>
    </unit>
    <unit id="patient">
        <measure>amed:patient</measure>
    </unit>
    <unit id="beneficiary">
        <measure>amed:beneficiary</measure>
    </unit>
    <unit id="claim">
        <measure>amed:claim</measure>
    </unit>
    <unit id="segment">
        <measure>amed:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF80LTEtMS0xLTA_c9121a1b-34c9-4d72-bbec-df6b57697705">false</dei:AmendmentFlag>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF81LTEtMS0xLTY5NzI_4b60d062-05b6-4ea6-bef3-e78771f7e890">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF82LTEtMS0xLTA_0ab6f69d-d930-4a5e-a836-2183c5e06a43">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF83LTEtMS0xLTA_7fcd3045-8104-46e7-8b78-5e5897307420">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF8xMC0xLTEtMS0w_5a9cc02f-5afd-43b5-a493-7d241be908e2">0000896262</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF80L2ZyYWc6NDc3ZTI4NmFmOGMzNDUzNmE5MmEwOTJkNjJiNDU4MGMvdGFibGU6NTZkNWY1ODkzNTNmNDUxNmIyMzNiZjUxMzVjM2E4YjgvdGFibGVyYW5nZTo1NmQ1ZjU4OTM1M2Y0NTE2YjIzM2JmNTEzNWMzYThiOF8xMS0xLTEtMS0w_c0b6a394-4e2b-4328-8b31-1e2dd4e63f76">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="ic6f32ffb396941779dd01b141bf45abd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83Ni9mcmFnOjZlODdjZDRiYWE3ZTQwODdiMTRmNjc4YzU1NjI2NWQ1L3RleHRyZWdpb246NmU4N2NkNGJhYTdlNDA4N2IxNGY2NzhjNTU2MjY1ZDVfMTA5OTUxMTYyNzg0Nw_913e7481-ca7c-47d9-8117-3eba76217ff0"
      unitRef="usd">3000000.0</us-gaap:LossOnSaleOfInvestments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib90ca7053c5a4eabba3431aecde330cb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxNg_2ef6bf16-13c0-4b4a-ac9d-18652113e2f9">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84Mi9mcmFnOjU0Y2E4ZGMwMmMyYTQxM2E5OWZlMTIyYTE5MTBmMDRiL3RhYmxlOjNiNzgzYTMzOTkwYTQ2OTc5OTY4NzBhNzY1MzNjMjMxL3RhYmxlcmFuZ2U6M2I3ODNhMzM5OTBhNDY5Nzk5Njg3MGE3NjUzM2MyMzFfMi0xLTEtMS0w_ee36c7f7-5838-440c-924b-bbf5cb8de338"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OperatingIncomeLoss
      contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84OC9mcmFnOmRjYzRjYWEzZWQ0NTQ3YjViNmVmMTFhYmMzYmU1M2ZiL3RhYmxlOjdkY2MyOGM4NzZjNDQ5MDI5Yjg2M2I1MWY5MzFjNzNhL3RhYmxlcmFuZ2U6N2RjYzI4Yzg3NmM0NDkwMjliODYzYjUxZjkzMWM3M2FfNS0xLTEtMS0w_4915f472-a580-4e7d-85c5-3a187c94bc51"
      unitRef="usd">-3300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84OC9mcmFnOmRjYzRjYWEzZWQ0NTQ3YjViNmVmMTFhYmMzYmU1M2ZiL3RhYmxlOjdkY2MyOGM4NzZjNDQ5MDI5Yjg2M2I1MWY5MzFjNzNhL3RhYmxlcmFuZ2U6N2RjYzI4Yzg3NmM0NDkwMjliODYzYjUxZjkzMWM3M2FfNi0xLTEtMS0w_a5305c69-38e6-4b93-a8ee-58f62f9545ff"
      unitRef="usd">-8200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84OC9mcmFnOmRjYzRjYWEzZWQ0NTQ3YjViNmVmMTFhYmMzYmU1M2ZiL3RhYmxlOjdkY2MyOGM4NzZjNDQ5MDI5Yjg2M2I1MWY5MzFjNzNhL3RhYmxlcmFuZ2U6N2RjYzI4Yzg3NmM0NDkwMjliODYzYjUxZjkzMWM3M2FfNy0xLTEtMS03MjQ3_7339a1d1-c892-4718-b201-2c5594dafb4d"
      unitRef="usd">-5600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i994f6975b70a49068c75d0139eb0bb9d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzQyMg_e7798f55-1ce4-47ef-a7fb-73e95a0c87a0">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="i6e1c460171b341758ee7f2c6f5213b5e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDYvZnJhZzo3ZGM2N2YxOTljYjc0MmU2OGYyNDkzMTNiNzJhNWQ5OS90ZXh0cmVnaW9uOjdkYzY3ZjE5OWNiNzQyZTY4ZjI0OTMxM2I3MmE1ZDk5XzI4NQ_c103f721-fa67-4451-963f-a90665915d6c">Option for early termination of lease after one year</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDYvZnJhZzo3ZGM2N2YxOTljYjc0MmU2OGYyNDkzMTNiNzJhNWQ5OS90ZXh0cmVnaW9uOjdkYzY3ZjE5OWNiNzQyZTY4ZjI0OTMxM2I3MmE1ZDk5XzI4Ng_51164379-36eb-471f-bff8-b3a066d74467">Option for early termination of lease after three years</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i82f050f262b84796a9b340b2d9129bc0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTIvZnJhZzpiZjI5MzIwM2RmMjg0MzA1ODZiMTdmZDBjNDMwNTQyZS90ZXh0cmVnaW9uOmJmMjkzMjAzZGYyODQzMDU4NmIxN2ZkMGM0MzA1NDJlXzU0Ng_5b605a84-b5ea-4aa3-ab84-82d539a3a0bf">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="ifcea2f99e9244669860fa34644e434d1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTIvZnJhZzpiZjI5MzIwM2RmMjg0MzA1ODZiMTdmZDBjNDMwNTQyZS90ZXh0cmVnaW9uOmJmMjkzMjAzZGYyODQzMDU4NmIxN2ZkMGM0MzA1NDJlXzU0Nw_3393369b-9281-44a4-9de7-3a3b0f626803">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTgvZnJhZzpiNTY1MjUyZjE5Mzk0MDQwOTViZDBhNzNlOWI4ODk2My90YWJsZTo2NTE0ZDg0ZmM3NDk0YTY3YWE5Y2RkYjJiZmFjNmY1NS90YWJsZXJhbmdlOjY1MTRkODRmYzc0OTRhNjdhYTljZGRiMmJmYWM2ZjU1XzItMS0xLTEtMA_719737e6-9d2a-41f6-830c-f538c4aa73e0"
      unitRef="usd">38859000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTgvZnJhZzpiNTY1MjUyZjE5Mzk0MDQwOTViZDBhNzNlOWI4ODk2My90YWJsZTo2NTE0ZDg0ZmM3NDk0YTY3YWE5Y2RkYjJiZmFjNmY1NS90YWJsZXJhbmdlOjY1MTRkODRmYzc0OTRhNjdhYTljZGRiMmJmYWM2ZjU1XzMtMS0xLTEtMA_28210d95-2a8c-472c-9b89-b762e261b920"
      unitRef="usd">38859000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDMzMTE_132e2a63-3451-42de-8da7-d71ba010d03c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifbd18b01890b461182b19c8a098912de_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MDY_02c412b8-41ea-4c92-b3c7-f45653d56560">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i15df4480ba24493cb5e3394c14dff135_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MTI_5f8948f7-2285-435f-ba9f-02ccda0ec48b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6e1c460171b341758ee7f2c6f5213b5e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjQvZnJhZzo4ZWYxNDMxZTkzMWI0MDUzODA2ODY0NjkwZTMxYWVmYy90YWJsZTpkMWU5YzE1NjRmNmU0YzRkODdmNGUxZTlkZWUwOGNlMy90YWJsZXJhbmdlOmQxZTljMTU2NGY2ZTRjNGQ4N2Y0ZTFlOWRlZTA4Y2UzXzExLTEtMS0xLTA_7dbbbea9-c253-45af-94c0-d01e90ffd529">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CostsAndExpenses
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTQvZnJhZzowYjFjYzk5NzNlMjQ0YTEwODMzNzhlMDc5MTQ0ZjZkZi90YWJsZTphMGEwZjQ5YzYyMWI0ZTE2YWY3ZTM0YmVlMzk3MmUwYi90YWJsZXJhbmdlOmEwYTBmNDljNjIxYjRlMTZhZjdlMzRiZWUzOTcyZTBiXzEtMS0xLTEtMA_a97d6b69-422e-491f-aff7-42972692e363"
      unitRef="usd">1778161000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTQvZnJhZzowYjFjYzk5NzNlMjQ0YTEwODMzNzhlMDc5MTQ0ZjZkZi90YWJsZTphMGEwZjQ5YzYyMWI0ZTE2YWY3ZTM0YmVlMzk3MmUwYi90YWJsZXJhbmdlOmEwYTBmNDljNjIxYjRlMTZhZjdlMzRiZWUzOTcyZTBiXzEtMi0xLTEtMA_23998f67-1672-442d-8217-c725361f0c8e"
      unitRef="usd">1507430000</us-gaap:CostsAndExpenses>
    <dei:DocumentType
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTAy_97a9e86a-ceee-4fd0-a4d4-4dc00ae78823">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDkx_0150e72f-9015-48db-9082-ddfe2f2431cf">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8yMTk_85b6cf05-6ab7-4e65-97ae-e0811358a2c2">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk2_577f87c5-72a3-4bd6-b7b2-d28005fd2047">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk3_954d43e3-a3b0-47f6-b631-aa16a6398995">0-24260</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTAz_36de1bfd-a136-4b22-96b6-ae7970d2bc44">AMEDISYS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6YjNlMjIwYTMzNmQ2NDU3ZmIzYjE2ZWIwNGI2NzI3YWUvdGFibGVyYW5nZTpiM2UyMjBhMzM2ZDY0NTdmYjNiMTZlYjA0YjY3MjdhZV8wLTAtMS0xLTA_a8dce9d9-9239-449e-a182-9aeb08794128">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6YjNlMjIwYTMzNmQ2NDU3ZmIzYjE2ZWIwNGI2NzI3YWUvdGFibGVyYW5nZTpiM2UyMjBhMzM2ZDY0NTdmYjNiMTZlYjA0YjY3MjdhZV8wLTItMS0xLTA_d964f2eb-0868-43f4-946e-43512ec2dd90">11-3131700</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDky_a3bbdcd4-79b9-4aed-9930-720aeee7c42b">3854 American Way, Suite A,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTA0_6d66af9b-1ccb-43d1-b4c6-7096ea005827">Baton Rouge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk4_c8d0a37e-aeb4-48d0-869a-0b2de471d772">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk0_f1c40600-c8e7-4b4b-bda3-4ad3aea9b24c">70816</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDkz_38017330-0ff7-4336-aeb2-16a6c04565d4">225</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk1_ab2431ba-bb43-4812-b8f6-d63927ce01a2">292-2031</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6MzE5YmI4YjMwNTYxNDgxZmIyNTI4MTY1OTAxN2EzN2YvdGFibGVyYW5nZTozMTliYjhiMzA1NjE0ODFmYjI1MjgxNjU5MDE3YTM3Zl8xLTAtMS0xLTA_d03cbe71-f954-4df4-a3c2-6c7208050c5a">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6MzE5YmI4YjMwNTYxNDgxZmIyNTI4MTY1OTAxN2EzN2YvdGFibGVyYW5nZTozMTliYjhiMzA1NjE0ODFmYjI1MjgxNjU5MDE3YTM3Zl8xLTItMS0xLTA_b506299a-635e-4371-bf3b-61ee50b14f9e">AMED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6MzE5YmI4YjMwNTYxNDgxZmIyNTI4MTY1OTAxN2EzN2YvdGFibGVyYW5nZTozMTliYjhiMzA1NjE0ODFmYjI1MjgxNjU5MDE3YTM3Zl8xLTQtMS0xLTA_0745ffe3-db41-431d-bb92-1e72380eced8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTAw_bc45894e-3a83-4830-b4c7-7a35dfcdc1a8">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDk5_f8b4d197-a81f-4b11-83bf-c19f8ff9aecf">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNTAx_a023b39f-0897-4173-a9eb-8fface96a18e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDg5_90b276b6-80ea-4449-9898-8b004af21946">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6N2ZlOGRkMTU5YjBiNDExMmJjNzIxY2JmNGZmYTJmMTcvdGFibGVyYW5nZTo3ZmU4ZGQxNTliMGI0MTEyYmM3MjFjYmY0ZmZhMmYxN18wLTAtMS0xLTA_303f4693-446b-49c8-b58c-99b70d2aa008">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6N2ZlOGRkMTU5YjBiNDExMmJjNzIxY2JmNGZmYTJmMTcvdGFibGVyYW5nZTo3ZmU4ZGQxNTliMGI0MTEyYmM3MjFjYmY0ZmZhMmYxN18xLTQtMS0xLTA_b513f632-3339-44f8-aa51-3a7a6fccc22c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGFibGU6N2ZlOGRkMTU5YjBiNDExMmJjNzIxY2JmNGZmYTJmMTcvdGFibGVyYW5nZTo3ZmU4ZGQxNTliMGI0MTEyYmM3MjFjYmY0ZmZhMmYxN18yLTQtMS0xLTA_350c94fe-bb5c-436a-a582-0a52a62cd53c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zNDkw_1a1112a3-4d9a-4db5-a34a-f6a6dacd77db">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i2521c40c2e674edaba9586526c5b83a7_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8yODIz_00aab844-6cf5-47df-85b9-05568f36d3c4"
      unitRef="usd">5500000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2b4abd4b7b654854b3d46e098ad305fe_I20210219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xL2ZyYWc6MDFkMWI4NzhhNDdkNGEzZWJiNGVmMTRhN2NhNDU3ZmQvdGV4dHJlZ2lvbjowMWQxYjg3OGE0N2Q0YTNlYmI0ZWYxNGE3Y2E0NTdmZF8zMDc1_bd91cdaa-08bb-4037-b227-50f7ff90db7a"
      unitRef="shares">32848547</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNC0xLTEtMS0w_89be5005-f960-410e-a9fd-3a644ed5bbf9"
      unitRef="usd">81808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNC0zLTEtMS0w_96ada87b-bc19-4882-8e4d-706bf2f01151"
      unitRef="usd">30294000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNS0xLTEtMS0w_ae122a05-7bc2-42e9-8e7e-aeb674f1a810"
      unitRef="usd">1549000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNS0zLTEtMS0w_acbdd928-1834-4482-982d-e85d4cb1f191"
      unitRef="usd">66196000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNi0xLTEtMS0w_8a321fa5-2c7f-4744-a74b-5dcc088df5c2"
      unitRef="usd">255145000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNi0zLTEtMS0w_d4e0d80d-ac39-4655-9848-0d16d35f08be"
      unitRef="usd">237596000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNy0xLTEtMS0w_ff9a1719-3b20-45b4-a89b-cff191a306a2"
      unitRef="usd">10217000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNy0zLTEtMS0w_d6f3d14c-244b-447c-b8c5-fd97778008e7"
      unitRef="usd">8243000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfOC0xLTEtMS0w_9541e0c0-cc2c-46e1-83bc-8b9357fc09e5"
      unitRef="usd">13265000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfOC0zLTEtMS0w_b12ca590-c507-4e99-9ad1-bf08888e10ed"
      unitRef="usd">8225000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfOS0xLTEtMS0w_0a27a623-fa0d-4a2b-abb2-0d4d6227e490"
      unitRef="usd">361984000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfOS0zLTEtMS0w_680ec2b1-440a-498d-a67c-6d388a83a65d"
      unitRef="usd">350554000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjNhZGU1ZTQzNWQ4MjQ2YmU4NGMwZjNiNmFjOGRjODY5XzEwOTk1MTE2Mjc4NjU_832966b8-83de-4588-8ee7-eeb9cc1e5ee4"
      unitRef="usd">95024000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjNhZGU1ZTQzNWQ4MjQ2YmU4NGMwZjNiNmFjOGRjODY5XzEwOTk1MTE2Mjc4NzY_568b397a-c974-4dee-bcd4-e7ef08f0f256"
      unitRef="usd">96137000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTAtMS0xLTEtMA_7030d057-ca89-4925-98ff-9bb3d0a23fd3"
      unitRef="usd">23719000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTAtMy0xLTEtMA_e27993e6-6741-4489-8702-2e5dd24b852f"
      unitRef="usd">28113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTEtMS0xLTEtMA_ce026fe3-79e7-411a-84d5-b65a2279113a"
      unitRef="usd">93440000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTEtMy0xLTEtMA_c9bdedb4-8cba-43f7-ae7a-9868ba4336d6"
      unitRef="usd">84791000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTItMS0xLTEtMA_e8c717b7-2fb9-468f-b779-d934dd5aefc7"
      unitRef="usd">932685000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTItMy0xLTEtMA_685d296e-5a64-410b-aeee-066db9e705cc"
      unitRef="usd">658500000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjBkMDJmZjA4YThkMTRkZWQ4YjU2MGEyMzBjMGRjMWFmXzEwOTk1MTE2Mjc4NTc_058a5e4c-3862-47df-864b-7e63ceb486a0"
      unitRef="usd">22973000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjBkMDJmZjA4YThkMTRkZWQ4YjU2MGEyMzBjMGRjMWFmXzEwOTk1MTE2Mjc4Njc_fc3f5914-d368-4d69-802c-4b110b9b76a3"
      unitRef="usd">7044000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTMtMS0xLTEtMA_7cb066e3-f29c-4e2c-9b1f-1d31ab7c2fa8"
      unitRef="usd">74183000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTMtMy0xLTEtMA_8dc8ee58-f171-4fef-908c-cb06d0a2b487"
      unitRef="usd">64748000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTQtMS0xLTEtMA_3e0029be-ab95-4ee6-b007-157b4ae72858"
      unitRef="usd">47987000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTQtMy0xLTEtMA_e2d140b4-1348-4866-8ae7-550e235ec2c8"
      unitRef="usd">21427000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTUtMS0xLTEtMA_da987d4d-4edc-4c07-9e7a-e1a632774bbd"
      unitRef="usd">33200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTUtMy0xLTEtMA_d791da41-0040-426f-87fc-9b6cd2e50562"
      unitRef="usd">54612000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTYtMS0xLTEtMA_241027d1-254e-418e-9b92-3cb755ce05ae"
      unitRef="usd">1567198000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTYtMy0xLTEtMA_e10e22f2-626b-4529-a5fc-5971e5e090a5"
      unitRef="usd">1262745000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTktMS0xLTEtMA_ad0fcf65-8321-443d-99e7-7dbb57870813"
      unitRef="usd">42674000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMTktMy0xLTEtMA_1c07e030-649d-42bc-b9bc-530cb2f4517d"
      unitRef="usd">31259000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjAtMS0xLTEtMA_2e202f67-d0ae-4b8d-9c20-8394a2be5896"
      unitRef="usd">146929000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjAtMy0xLTEtMA_2ed02273-bcd0-4809-b711-555935a6110c"
      unitRef="usd">120877000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjEtMS0xLTEtMA_a30a7b42-2ec2-48f9-a751-6d4e6cabda5d"
      unitRef="usd">166192000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjEtMy0xLTEtMA_cf5992f6-cbe0-4a48-84ad-0f20a121d7a4"
      unitRef="usd">137111000</us-gaap:AccruedLiabilitiesCurrent>
    <amed:ProviderReliefFundAdvance
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjItMS0xLTEtMTMx_ce5e3745-263d-4a32-99c2-dad5d5982c57"
      unitRef="usd">60000000</amed:ProviderReliefFundAdvance>
    <amed:ProviderReliefFundAdvance
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjItMy0xLTEtMTMx_0285a0e9-bd19-41ea-af66-77b6bad19571"
      unitRef="usd">0</amed:ProviderReliefFundAdvance>
    <us-gaap:LongTermDebtCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjItMS0xLTEtMA_f371c55e-4b56-4987-927f-797d081adec6"
      unitRef="usd">10496000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjItMy0xLTEtMA_2ca543ee-bbc0-4536-815b-31a08557af80"
      unitRef="usd">9927000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjMtMS0xLTEtMA_5e127385-8f2e-4706-bf30-b0053ca27796"
      unitRef="usd">30046000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjMtMy0xLTEtMA_24815bb1-9c27-43fd-90c5-b45262fa5ba9"
      unitRef="usd">27769000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjQtMS0xLTEtMA_6f2c828f-97f0-4392-b52c-00ed2f32db6c"
      unitRef="usd">456337000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjQtMy0xLTEtMA_b4d4f35f-a31b-445c-8033-62ed2edbffbc"
      unitRef="usd">326943000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjUtMS0xLTEtMA_56c231b9-39f7-4c7e-ab7b-6a093d7035fb"
      unitRef="usd">204511000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjUtMy0xLTEtMA_523b6ec1-06ca-45a1-9d7d-ad9b7133dcb0"
      unitRef="usd">232256000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjYtMS0xLTEtMA_bbaf02cd-e257-47e0-ba88-b03c969dd3aa"
      unitRef="usd">61987000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjYtMy0xLTEtMA_d125fda1-add5-4bd4-b485-1ed84a82914b"
      unitRef="usd">56128000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjctMS0xLTEtMA_110fe269-d117-4038-9f17-d6cb56b2a268"
      unitRef="usd">33622000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjctMy0xLTEtMA_485fd6bd-9b80-4b58-a92b-be56c40dcd05"
      unitRef="usd">5905000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjgtMS0xLTEtMA_fbde874c-7a99-42f7-bd63-2485cd12fbb8"
      unitRef="usd">756457000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMjgtMy0xLTEtMA_c76c4764-cb15-411c-acc9-d52bf85521c0"
      unitRef="usd">621232000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzAtMS0xLTEtNTcwMw_dae1c28b-294c-4c56-ae36-8c8de1e758b0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzAtMy0xLTEtNTcwNQ_e0b862ab-0920-4b1b-b1b7-8f8bac4bea46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4NzY_5c4989d4-1953-4998-a122-ae8fd2b7b08e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4NzY_94dfb867-38ea-4057-93ec-16792e5e755c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTA_94b8158c-7162-4187-8a31-4a70615d6404"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTA_f19bd78c-de96-4ff7-ba67-3b60415ff2f1"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTU_0aa7c1b3-3887-40ba-b7b3-6315701ede1b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTU_91ea7d90-05eb-4429-8e3b-6c98a0ad868c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTU_92aef5c6-e2b9-495c-9ff2-706e445eb26a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjBiYjEwNjAwNTA3ODRjNTFiY2IwNzY5ZDkwZjc4YTU0XzEwOTk1MTE2Mjc4OTU_d153d0f3-7cdc-4354-b8d0-98cc892739d1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMS0xLTEtMA_1e9d9f23-569f-4b31-b6fc-e407a9d949fe"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzEtMy0xLTEtMA_487d0b9d-76a7-4493-8f20-4b0d44e0facb"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5Mzc_0fc0c6ee-2f76-4a31-954e-3b46f3b73400"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5Mzc_1e71141a-89ed-4f35-adef-f3be87ab0a88"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5NTI_3119469b-0597-42e6-b582-9d3a8da40015"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5NTI_51f14b6f-614a-4ee0-a3ef-d927527edb99"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5NjU_ee21504d-59b8-4df8-8eb5-7b7966061865"
      unitRef="shares">37470212</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5Nzg_3b49fb8c-ba8c-4f30-a5b7-708c7344d5eb"
      unitRef="shares">36638021</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2Mjc5OTE_7fed9cc8-632b-4d01-8314-78aac9fe63af"
      unitRef="shares">32814278</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjNlM2I3YmM1ZmY3OTQ2NmU4M2VjMjBkMzlhNzY3NTFjXzEwOTk1MTE2MjgwMDQ_1ad8ddfb-fb7e-42bb-ae2e-188e129a63d7"
      unitRef="shares">32284051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMS0xLTEtMA_5e2a8b3b-0749-42b9-a0db-499e8d32eb64"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzItMy0xLTEtMA_9b16bee7-3aff-44d4-9dac-3edcdaf0e966"
      unitRef="usd">37000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzMtMS0xLTEtMA_320c9995-486a-479a-812b-742be46af145"
      unitRef="usd">698287000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzMtMy0xLTEtMA_f8f4cecf-2c6d-4d4d-bca5-4c233867b362"
      unitRef="usd">645256000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmFmNGU3Yjk3NTNhZTQ1MGNhYTNkOTM1MTllZDA3ZGRmXzEwOTk1MTE2Mjc4NTg_4278215a-1eba-4667-a7c9-d060076c042c"
      unitRef="shares">4655934</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmFmNGU3Yjk3NTNhZTQ1MGNhYTNkOTM1MTllZDA3ZGRmXzEwOTk1MTE2Mjc4NzA_e5ac28f7-5cba-4ed0-8ee6-86bc3de800b0"
      unitRef="shares">4353970</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzQtMS0xLTEtMA_a99e013a-88f7-4c10-a359-cc4cc20e7775"
      unitRef="usd">319092000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzQtMy0xLTEtMA_13061900-9d40-4d6f-bbd0-0380624578e0"
      unitRef="usd">251241000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzUtMS0xLTEtMA_4024bdc3-0601-4e90-90d8-bd0ca7852f49"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzUtMy0xLTEtMA_35e2d76c-d01d-4eb9-930e-e283df328ac8"
      unitRef="usd">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzYtMS0xLTEtMA_377a1d62-dc68-4a2a-8ba1-66b3a4256104"
      unitRef="usd">429991000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzYtMy0xLTEtMA_7c4c2019-6df3-4125-8532-5fd2895e5381"
      unitRef="usd">246383000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzctMS0xLTEtMA_822298f6-f72f-4059-a9a9-095ef3f99f64"
      unitRef="usd">809224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzctMy0xLTEtMA_e12fc059-6d86-403f-aef5-34ecef7dd57e"
      unitRef="usd">640450000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzgtMS0xLTEtMA_4ad478d1-37ba-4c81-b75e-37d6f7cd5a0f"
      unitRef="usd">1517000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzgtMy0xLTEtMA_56634a66-8d39-44b7-8aed-44882c5e2567"
      unitRef="usd">1063000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzktMS0xLTEtMA_ce3a4fd8-8d1f-4a0b-aecb-3f68f1b81513"
      unitRef="usd">810741000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfMzktMy0xLTEtMA_7ed78f91-563e-4ff8-964a-79172cfaf026"
      unitRef="usd">641513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNDAtMS0xLTEtMA_2fc18390-8b17-44e5-a3b9-ced367aa6a85"
      unitRef="usd">1567198000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81Mi9mcmFnOjhhZjFhMGVmZTY2ODQxNDJhMjc4ZmZhM2UzYmQyM2FkL3RhYmxlOmE1YjNjOWM5ZjA1MDQ3NzM5ZjU1MDA5NjU5ZTM5ZWZiL3RhYmxlcmFuZ2U6YTViM2M5YzlmMDUwNDc3MzlmNTUwMDk2NTllMzllZmJfNDAtMy0xLTEtMA_c3ddcc94-5dd2-4e1c-9bb8-81f24568368e"
      unitRef="usd">1262745000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMi0xLTEtMS0w_e8cd9444-15ff-4f24-a6d1-25ccc456f25b"
      unitRef="usd">2071519000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMi0zLTEtMS0w_5a0814b8-1448-4a63-b2c4-bd3857cf5926"
      unitRef="usd">1955633000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMi01LTEtMS0w_58627d3e-47dd-42f3-819e-c334316bdddc"
      unitRef="usd">1662578000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy0xLTEtMS0xMTY_fe22abac-18d6-484a-a377-02151d059a04"
      unitRef="usd">34372000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy0zLTEtMS0xMTY_7cfbbec5-f543-47cc-969c-edc47bded682"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy01LTEtMS0xMTY_25f59ea0-8f2d-4d58-8687-54d69e2b7308"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy0xLTEtMS0w_74131688-daad-4999-ace9-2542f08b962c"
      unitRef="usd">1185369000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy0zLTEtMS0w_4dccd0fc-5bd3-4409-b45e-6f5c12f7b241"
      unitRef="usd">1150337000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMy01LTEtMS0w_8640e4a1-8ef7-4944-8f28-532b64069533"
      unitRef="usd">992863000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNS0xLTEtMS0w_8ef4c0ef-9238-46b1-a55e-67a18e2e1374"
      unitRef="usd">449448000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNS0zLTEtMS0w_8bc11bb8-56dc-47fd-8311-f11e6c6c0e78"
      unitRef="usd">394452000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNS01LTEtMS0w_4c180c2f-5aa9-4a23-93dc-43a851a15e3f"
      unitRef="usd">316522000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNi0xLTEtMS0w_fc4fc771-4b54-43ff-a381-a41e1bf556bb"
      unitRef="usd">26730000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNi0zLTEtMS0w_ff696e9b-f508-4ce0-971d-d18df98407f8"
      unitRef="usd">25040000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNi01LTEtMS0w_c4facd15-6a18-4362-8b3d-ed5f327b67c0"
      unitRef="usd">17887000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNy0xLTEtMS0w_61b90be4-f8f7-4c63-942a-464de0b616f7"
      unitRef="usd">192122000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNy0zLTEtMS0w_61af3496-1efb-4ac7-94b3-0ac7fb7942ca"
      unitRef="usd">188434000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfNy01LTEtMS0w_4e4d1635-7a78-4861-a5e9-9df641def430"
      unitRef="usd">166897000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOC0xLTEtMS0w_358d8379-18d7-4104-8074-6b6024b419b3"
      unitRef="usd">28802000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOC0zLTEtMS0w_9adec4f0-e8ac-4508-9bdf-c1cd95977b80"
      unitRef="usd">18428000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOC01LTEtMS0w_44b2fcb1-f9e1-4a66-b231-35a984b98dbb"
      unitRef="usd">13261000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:AssetImpairmentCharges
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOS0xLTEtMS0w_76efed3b-bd7a-4e50-a58b-8d576ae4e6d0"
      unitRef="usd">4152000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOS0zLTEtMS0w_572d0f3f-aae3-4a8e-a3d7-d2c6b9454abd"
      unitRef="usd">1470000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfOS01LTEtMS0w_346b4c38-de37-4efa-b601-fa5772f44d08"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTEtMS0xLTEtMA_22448eb8-e106-4914-afce-54279feea221"
      unitRef="usd">1886623000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTEtMy0xLTEtMA_39f67520-dabd-430e-89da-0e38c09e6dfa"
      unitRef="usd">1778161000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTEtNS0xLTEtMA_74f74626-4a03-4397-879c-d88cfaff1c81"
      unitRef="usd">1507430000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTItMS0xLTEtMA_6dfed0a5-5371-47a4-b638-3a8cc9fec303"
      unitRef="usd">219268000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTItMy0xLTEtMA_721d7d5c-4314-4465-bd14-2621e9da6a33"
      unitRef="usd">177472000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTItNS0xLTEtMA_57795e45-ee44-445f-a24a-f8741dcdc10e"
      unitRef="usd">155148000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTQtMS0xLTEtMA_75eeca9b-e993-42d7-91a8-2b461785680a"
      unitRef="usd">292000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTQtMy0xLTEtMA_0f8bdd50-596a-4ca1-af44-404ec104bf77"
      unitRef="usd">78000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTQtNS0xLTEtMA_7208bfdb-de16-449e-8cbe-a8890e9e812f"
      unitRef="usd">278000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTUtMS0xLTEtMA_1b40232a-00db-4ed6-aa5b-154d39d6635b"
      unitRef="usd">11038000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTUtMy0xLTEtMA_66ac51ee-9295-4c8a-bd75-31b5b486c75c"
      unitRef="usd">14515000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTUtNS0xLTEtMA_8c494505-5d98-46da-94f6-27600bd280c1"
      unitRef="usd">7370000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTYtMS0xLTEtMA_2e3313b9-44fc-46e9-a2af-0cefb14e1442"
      unitRef="usd">3966000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTYtMy0xLTEtMA_390df1f8-6b29-4616-b83d-018a6583d0ef"
      unitRef="usd">5338000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTYtNS0xLTEtMA_4270a3f7-5164-4980-8c5d-e610ae5d9a34"
      unitRef="usd">7692000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTctMS0xLTEtMA_f30b69c3-585e-4338-9829-04fa130c0aa8"
      unitRef="usd">-1669000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTctMy0xLTEtMA_1df1a143-41e9-4c8b-ab20-cca79a632f0e"
      unitRef="usd">2037000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTctNS0xLTEtMA_b28bdbdf-d36c-4538-b428-93b66b663657"
      unitRef="usd">3240000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTgtMS0xLTEtMA_1b554d2f-d96c-4d10-a1f4-ee5a3fc18983"
      unitRef="usd">-8449000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTgtMy0xLTEtMA_0e59892d-397e-4978-96e1-45a8384c5627"
      unitRef="usd">-7062000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTgtNS0xLTEtMA_a148e0d6-8f66-4c2f-8846-8f508abab1f3"
      unitRef="usd">3840000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTktMS0xLTEtMA_5461f862-4e27-4b09-94a4-973ce3c7a247"
      unitRef="usd">210819000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTktMy0xLTEtMA_15daf2bd-1140-4b22-a8e6-2ddc39860d53"
      unitRef="usd">170410000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMTktNS0xLTEtMA_afe7c0ec-f237-4f67-88c3-a66e80242662"
      unitRef="usd">158988000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjAtMS0xLTEtMA_574775c5-4d72-499f-aa70-74544ea3cd31"
      unitRef="usd">25635000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjAtMy0xLTEtMA_6ae35dc2-8ea0-4b53-b561-2857e75875bb"
      unitRef="usd">42503000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjAtNS0xLTEtMA_45f1878d-f9ef-4cef-8d71-21e0243e99e2"
      unitRef="usd">38859000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjEtMS0xLTEtMA_2547c2d5-007c-490d-a872-ed04a9b067c5"
      unitRef="usd">185184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjEtMy0xLTEtMA_1948e4e1-8ba0-4c09-8cf3-0c9c2b2f07fa"
      unitRef="usd">127907000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjEtNS0xLTEtMA_68a0bc2c-8e4e-476c-84ae-67e1b2a5a33f"
      unitRef="usd">120129000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjItMS0xLTEtMA_f8739ee7-b511-4b14-8f9c-3fcd168c7cf1"
      unitRef="usd">1576000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjItMy0xLTEtMA_b095a3cd-818f-45c3-bbb5-be72fa6aee19"
      unitRef="usd">1074000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjItNS0xLTEtMA_1de05818-729b-4d72-ac7d-564d39be5e75"
      unitRef="usd">783000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjMtMS0xLTEtMA_584b819d-b75c-4011-918b-f6871616545d"
      unitRef="usd">183608000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjMtMy0xLTEtMA_041e2056-4c5e-47da-8a6c-54e97411a36a"
      unitRef="usd">126833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjMtNS0xLTEtMA_bd38b183-9eae-410a-a494-e466936f0994"
      unitRef="usd">119346000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjUtMS0xLTEtMA_fdad5e80-47a4-487f-97ee-73be1b9acfec"
      unitRef="usdPerShare">5.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjUtMy0xLTEtMA_85327035-9c5d-4895-826f-b0c73261a69c"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjUtNS0xLTEtMA_c2121ed9-c423-4b0d-87d0-7433a2595cfa"
      unitRef="usdPerShare">3.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjYtMS0xLTEtMA_e3c1aa4f-b09b-4cef-a9d9-7c01d36759f0"
      unitRef="shares">32559000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjYtMy0xLTEtMA_51933a66-9de9-4878-8e2f-6847f704e857"
      unitRef="shares">32142000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjYtNS0xLTEtMA_a25c79dc-688e-4867-8ed5-fcaa2b144b35"
      unitRef="shares">32791000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjgtMS0xLTEtMA_4656d831-27d6-4426-b022-bd4dbb04aede"
      unitRef="usdPerShare">5.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjgtMy0xLTEtMA_f305d4ec-53e7-40e0-bd44-d8a668a7d364"
      unitRef="usdPerShare">3.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjgtNS0xLTEtMA_77e347cd-922d-4cbb-ab8a-5089a6cdbdc3"
      unitRef="usdPerShare">3.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjktMS0xLTEtMA_8daed060-b159-44d8-adb0-2acd0277acf6"
      unitRef="shares">33268000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjktMy0xLTEtMA_32e69694-0b01-4c45-a83e-cf817350f259"
      unitRef="shares">32990000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF81OC9mcmFnOmNjMzU3NDZjMzUwMjQ4MDVhMTgyMWUyOWRmOTFhNDg4L3RhYmxlOjA2YzljMDM5ODllNDQxMzRhOTc0YjQ1MmZkN2RkYTllL3RhYmxlcmFuZ2U6MDZjOWMwMzk4OWU0NDEzNGE5NzRiNDUyZmQ3ZGRhOWVfMjktNS0xLTEtMA_c0805c3f-44c1-4aef-8e07-47763ac1aab2"
      unitRef="shares">33609000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMi0xLTEtMS0w_0fc8a03f-b28f-469e-8c0e-c87cb2e7d6e7"
      unitRef="usd">185184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMi0zLTEtMS0w_2d4eab19-8adb-4b3e-8090-9777813a5622"
      unitRef="usd">127907000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMi01LTEtMS0w_69b86df7-742e-41fc-bfe3-6b202f4bbb55"
      unitRef="usd">120129000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMy0xLTEtMS0w_357c6b84-5220-4d59-9d62-e759277783fa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMy0zLTEtMS0w_e4d022e3-9347-457c-9766-5a020d5aa99f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfMy01LTEtMS0w_3a2cb2ac-5dec-4cb6-b0fb-c4fd6dda71bc"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNC0xLTEtMS0w_709ad47d-5651-4e28-b4ba-22bc9a4bdfdb"
      unitRef="usd">185184000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNC0zLTEtMS0w_90670e18-cfd0-4fd0-9e2c-488887a8bcb4"
      unitRef="usd">127907000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNC01LTEtMS0w_9520c62d-91d5-4a59-b79a-ae47167af8c9"
      unitRef="usd">120129000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNS0xLTEtMS0w_409bae2d-fec9-4fe2-a2be-2a6ec23a8172"
      unitRef="usd">1576000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNS0zLTEtMS0w_ca54a8f0-1b0f-4394-85c9-2676d2107fe4"
      unitRef="usd">1074000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNS01LTEtMS0w_a57d3830-e39a-4f18-91d6-ba72cdba01c5"
      unitRef="usd">783000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNi0xLTEtMS0w_8505a99c-234c-4a1d-bcf1-b3df1c775c3b"
      unitRef="usd">183608000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNi0zLTEtMS0w_73e7fdce-5713-4885-b72f-bc837b4d5cbc"
      unitRef="usd">126833000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82MS9mcmFnOjc5NThmYzYyNzdmNzRhNTc5YmQzMTY0NTY3NDZlMWQ4L3RhYmxlOjFkMzE3OWYzYjBkNDRlYjVhNTgzZTgzZjU3ZWEyNDg1L3RhYmxlcmFuZ2U6MWQzMTc5ZjNiMGQ0NGViNWE1ODNlODNmNTdlYTI0ODVfNi01LTEtMS0w_7ffcdfb8-73f1-4e78-826e-51f8e522563c"
      unitRef="usd">119346000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71d70551ae8f463895c999fdc4613768_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0xLTEtMS0w_f877b520-afd9-47b0-820d-f72eef441a16"
      unitRef="usd">516426000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i2c73d7f291d449999ecc705771a35788_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0zLTEtMS0w_1db2b74a-98c0-4200-8190-6b7b2f6eaf9d"
      unitRef="shares">35747134</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c73d7f291d449999ecc705771a35788_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi01LTEtMS0w_fcdf9d3f-f463-4bc6-b44c-8939d99f43cc"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9320162518845cd970162f4a4cb6a6c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi03LTEtMS0w_6e8c8fa8-04be-442d-aef9-8d040e75afd5"
      unitRef="usd">568780000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44f984b3dbe34af3aace209254870882_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi05LTEtMS0w_63bddf0e-b252-40d2-ad08-c5a3c90a0c72"
      unitRef="usd">-53713000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c1a95136f914b75adc71c283c901b28_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0xMS0xLTEtMA_829d685f-1f3b-4c35-9cf5-d8e2dde6cc1d"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ae973af03114509bb73f714dfe8c520_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0xMy0xLTEtMA_2a8741b9-e37c-40de-820f-f5cefc27845f"
      unitRef="usd">204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idae5b781450b4b82a9efea9a6ab20171_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMi0xNS0xLTEtMA_4f981b3b-7255-4e3d-94e3-93de5af33ba8"
      unitRef="usd">1105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMy0xLTEtMS0w_8f3dd8ed-3cc3-4e7b-87d2-95d037a043b8"
      unitRef="usd">2429000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMy0zLTEtMS0w_c13f4702-f61b-4005-993a-6f25ba4a8e72"
      unitRef="shares">38961</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMy03LTEtMS0w_a3c670b4-7b10-487e-a22c-ba28447ccd66"
      unitRef="usd">2429000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNC0xLTEtMS0w_1694084e-6be4-4611-80b9-7ce312e93481"
      unitRef="usd">9232000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNC0zLTEtMS0w_f7ac0c3c-7945-4595-9e2b-13a25ac77656"
      unitRef="shares">129451</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNC03LTEtMS0w_e1cdd6f2-4232-4783-958d-14752bf406e1"
      unitRef="usd">9232000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNS0xLTEtMS0w_6f6813bb-50ea-48f1-b6ef-dd97e9ba592b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNS0zLTEtMS0w_a3ebc1ad-38d2-43b1-a668-99a49d3fe648"
      unitRef="shares">174044</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNS01LTEtMS0w_c1384ff7-3b3a-4e18-acf3-06cf349dcc47"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNS03LTEtMS0w_7f2f8e77-98da-477f-9f7d-38c75ec797d6"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNi0xLTEtMS0w_05e43f05-7c9b-4a58-9cf7-c93e40801065"
      unitRef="usd">5953000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8886d92bd4ac41d59f43d9c9ecf8db1d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNi0zLTEtMS0w_ee45a01e-67ad-46ae-b039-d5741d7a3eb6"
      unitRef="shares">162690</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNi03LTEtMS0w_c6f45430-f0ad-4289-bb17-f19bf720606f"
      unitRef="usd">5953000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNy0xLTEtMS0w_b61dea8e-88d6-4ea5-a266-c4f412dd749c"
      unitRef="usd">17887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfNy03LTEtMS0w_327ccd2c-c233-45ce-9ed7-e60237da6783"
      unitRef="usd">17887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfOS0xLTEtMS0w_218bc850-de7f-490b-bfee-8ca891149633"
      unitRef="usd">-6570000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i0ead52e4a58e40af94f4cfcfabee33f3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfOS05LTEtMS0w_47d4584b-fd32-41d2-8b6a-48bca6e60079"
      unitRef="usd">-6570000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfOS0xLTEtMS0yMDM1_d86bac2b-fdf0-49fc-9330-04d3768b2290"
      unitRef="usd">181402000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0ead52e4a58e40af94f4cfcfabee33f3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfOS05LTEtMS0yMDM1_c6092b45-2d77-4808-9999-b2ece97195c1"
      unitRef="usd">181402000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTAtMS0xLTEtMA_39eea4d4-82e4-49ef-8166-9bf16dc01b9e"
      unitRef="usd">1090000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i11cb32ff042042599b56293d9c96b2de_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTAtMTUtMS0xLTA_09f44c3d-0b25-43ac-933d-6ed5b02a8a76"
      unitRef="usd">1090000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTEtMS0xLTEtMA_5c21d606-9b52-47f4-8ce0-73789b958f95"
      unitRef="usd">-361000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="i5b96d63e5a134e3ca007085adf33769d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTEtNy0xLTEtMA_241c6385-4259-42eb-9bb7-7ea844c7600f"
      unitRef="usd">-614000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <amed:EquityImpactofRepurchaseofNoncontrollingInterest
      contextRef="i11cb32ff042042599b56293d9c96b2de_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTEtMTUtMS0xLTA_43422597-43de-4726-95e5-0504fda6b0e0"
      unitRef="usd">253000</amed:EquityImpactofRepurchaseofNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTItMS0xLTEtMA_23840014-c3b5-4eeb-a6d3-3ed11293f7e6"
      unitRef="usd">120129000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i578f5d8892c542728c9f3d614bb9ae1c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTItMTMtMS0xLTA_f1d430ef-54f7-441f-ac25-54ef88d6bdf5"
      unitRef="usd">119346000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i11cb32ff042042599b56293d9c96b2de_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTItMTUtMS0xLTA_3465c960-1319-4ddc-8065-2992d4456893"
      unitRef="usd">783000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMS0xLTEtMA_2accdfe6-b537-4706-9870-75905134c846"
      unitRef="usd">482633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i253841217f1446de87fdaaac95f8653f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMy0xLTEtMA_caf0d1a2-c2c1-4632-b63d-62e9a01ed375"
      unitRef="shares">36252280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i253841217f1446de87fdaaac95f8653f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtNS0xLTEtMA_9602460e-4dec-497f-af65-39e79a45abda"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7c4c0651a104d48aa8b1906c357fbbc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtNy0xLTEtMA_d9c9b7a5-9a99-4af3-a26a-dff56094166f"
      unitRef="usd">603666000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ccddfc560fe46b5b31297f960c4cdfa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtOS0xLTEtMA_bdc511df-8700-4395-95d9-1fd6152a8d48"
      unitRef="usd">-241685000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c61e77ed93b41c1a04abf43c6726a45_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMTEtMS0xLTA_7d464fbe-3a84-41b5-952d-a3b7e41a2431"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if901346fc21749c693ca795fa77431fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMTMtMS0xLTA_8a6ca490-f4a9-4bf3-806a-558a2df9ee63"
      unitRef="usd">119550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b9b1d7d6085499cbd3f5b49680ccb64_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTMtMTUtMS0xLTA_6449f0fa-acb7-4073-adfe-2667029448e7"
      unitRef="usd">1051000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTQtMS0xLTEtMA_765baf76-b226-48f0-bb68-86d50e7fa1a2"
      unitRef="usd">3187000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTQtMy0xLTEtMA_c525ee1c-d740-45c0-88ad-b982eb53c31f"
      unitRef="shares">30483</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTQtNy0xLTEtMA_5dc704fe-e93e-45be-b082-457f3f0104b7"
      unitRef="usd">3187000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTUtMS0xLTEtMA_57916be0-ea43-4908-876d-ddf9525781b2"
      unitRef="usd">9753000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTUtMy0xLTEtMA_74dc22d1-54ee-4d11-8239-74396a988691"
      unitRef="shares">79056</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTUtNy0xLTEtMA_abdbf7c2-3034-48b0-9a2a-6a42378864cc"
      unitRef="usd">9753000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTYtMS0xLTEtMA_cf74d297-79e8-4066-96da-894e6c9632d4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTYtMy0xLTEtMA_66f3e6e4-66b7-4346-8cfb-5fc7b1e2d006"
      unitRef="shares">189134</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTYtNS0xLTEtMA_f11a5983-1677-40bc-81d4-b51fca68e388"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTYtNy0xLTEtMA_c623b4aa-e752-4908-a9ca-65fe2f8bfcf4"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTctMS0xLTEtMA_0e944420-111a-4c19-b81e-929bbb7656bc"
      unitRef="usd">3611000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i84c1b899fc9b4a2390b3aa2a0c028650_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTctMy0xLTEtMA_9d1be081-ac95-4046-853f-32f2cb27ef8d"
      unitRef="shares">87068</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTctNy0xLTEtMA_f92fd964-f370-42cf-a4f8-2fdd3e348976"
      unitRef="usd">3611000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTgtMS0xLTEtMA_2c870922-8464-4197-8f54-52a98fa1b8c8"
      unitRef="usd">25040000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic3608a53a9964d29a2db4cd5c1b3210d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTgtNy0xLTEtMA_c2bf7557-054c-4d38-82ba-78eb7cf1048f"
      unitRef="usd">25040000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTktMS0xLTEtMA_9457995f-e99d-4808-b50d-9e844426716e"
      unitRef="usd">-9556000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i9317f7646da44eee93324b0a16fb1827_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMTktOS0xLTEtMA_fff53ac6-f626-40b6-85d1-d8c0c8a07cc0"
      unitRef="usd">-9556000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjEtMS0xLTEtMA_66302c70-3bf6-4f9c-b048-b94cece03c97"
      unitRef="usd">1062000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ida0afee284554110852d7f9cc9a2bb52_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjEtMTUtMS0xLTA_eccea3f4-38e4-4837-9086-b2018f3c8bbc"
      unitRef="usd">1062000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjMtMS0xLTEtMA_5d010428-6ad8-4511-af7e-57316bd0b5a8"
      unitRef="usd">127907000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib47e4e9c01d44fe7b652556bb85a5f1b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjMtMTMtMS0xLTA_090af464-130c-43a3-93cb-b324c0511006"
      unitRef="usd">126833000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ida0afee284554110852d7f9cc9a2bb52_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjMtMTUtMS0xLTA_152861c8-b726-4304-8423-319fe8166f39"
      unitRef="usd">1074000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMS0xLTEtMA_469593ff-8016-4078-acab-2a9e272b545f"
      unitRef="usd">641513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iaed066fa0032452b960a5c28694f984d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMy0xLTEtMA_8e7cfd71-f93c-451e-ba08-57b56025e73f"
      unitRef="shares">36638021</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaed066fa0032452b960a5c28694f984d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtNS0xLTEtMA_f5177166-1380-45b2-9308-f8c9e5bc5c09"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3cb19d428214cf1b5d7b341146b4fbb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtNy0xLTEtMA_6d6b56ee-9ecc-4ee2-851b-9b2832f9ab60"
      unitRef="usd">645256000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76be51b421be4511a94ed8e7e72c0652_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtOS0xLTEtMA_1ec7bc56-b55d-4aae-b3ba-274eef03e114"
      unitRef="usd">-251241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i822e34ba968444868d3c6943bd915b7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMTEtMS0xLTA_4eefc977-6f86-4cc9-98dd-cf4c2178bd66"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic19c797f2e324b2eb967c2bce916b767_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMTMtMS0xLTA_fe53f88b-2fc8-495e-b639-232d86377adf"
      unitRef="usd">246383000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie77a7f6ef23f49b1b151e334930d121b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjQtMTUtMS0xLTA_97799d66-9e7d-4d41-8008-cc4e0a93faba"
      unitRef="usd">1063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjUtMS0xLTEtMA_b8f5c5ad-0b77-4622-9478-64d55263e307"
      unitRef="usd">3562000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjUtMy0xLTEtMA_3127431e-0f06-43e8-a4cf-7202c576487d"
      unitRef="shares">21561</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjUtNy0xLTEtMA_e4c896dd-0577-4d5f-8335-b459575e7cce"
      unitRef="usd">3562000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjYtMS0xLTEtMA_50e9ae40-3e1f-47c8-ba45-fed33a4aaef6"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjYtMy0xLTEtMA_4f718d84-7fc0-418b-8589-7162da659755"
      unitRef="shares">18312</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjYtNy0xLTEtMA_3ee7ec4e-17bc-46c7-8ff0-5f4be8f9012a"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjctMS0xLTEtMA_2d5c691b-bf30-47ff-b8e1-005fecad17ec"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjctMy0xLTEtMA_291e8c20-29b4-4ae6-a26a-98c22cfecc8b"
      unitRef="shares">169489</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjgtMS0xLTEtMA_7aae0f88-5bd5-4a7c-ad0d-d8136b828f57"
      unitRef="usd">6325000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjgtMy0xLTEtMA_3c1801c8-d0eb-4075-88c5-af439001fb87"
      unitRef="shares">622829</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ide5ad634bcd74f9a90dffc0433b09b34_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjgtNS0xLTEtMA_61d9566e-e091-4f54-8d3d-a6ec7ada64ca"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjgtNy0xLTEtMA_30cdc723-e3e5-4282-9be9-35b9eeef6f52"
      unitRef="usd">6324000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjktMS0xLTEtMA_56014421-a6cd-41fb-99d7-28cbf2566bde"
      unitRef="usd">26730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMjktNy0xLTEtMA_759a176d-2bab-409b-959c-a40f8533c868"
      unitRef="usd">26730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtMS0xLTEtMA_5a9cea8f-0893-460b-915e-ac2e254d9d01"
      unitRef="usd">-54493000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i4bd15bdefbd54a8bb968fc68fd237ff6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtNy0xLTEtMA_a3a93fbb-2f1e-44e3-8db5-5126bebfb648"
      unitRef="usd">13358000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="idb85416bef844237937a8966fd006741_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtOS0xLTEtMA_3ece8204-474d-4b71-a118-01aa713a9951"
      unitRef="usd">-67851000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzEtMS0xLTEtMA_a057b31a-e1bd-4137-8d1e-c895577a6c89"
      unitRef="usd">1122000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib3a117d66ff846f2af342b27fd619eb3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzEtMTUtMS0xLTA_ea9b746c-fbc1-4fd9-8ba4-38c9f9166df8"
      unitRef="usd">1122000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtMS0xLTEtMjA0MA_6ac972e2-34c9-417b-afe9-0022b237c889"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="id7d57dd850e241008b6b1e4d426681fb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzAtMTEtMS0xLTIwNDA_5cde4014-8d59-4e96-bcbd-ef5283a022b3"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <us-gaap:ProfitLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzItMS0xLTEtMA_98efe178-c232-4722-8ab3-6abc03602a02"
      unitRef="usd">185184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icf3c23c0c8b54e24b20b5c10ef9f270e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzItMTMtMS0xLTA_0776f75f-16ec-450e-b391-3b85c3b19925"
      unitRef="usd">183608000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib3a117d66ff846f2af342b27fd619eb3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzItMTUtMS0xLTA_24f34c10-7744-426d-a156-b663396b4671"
      unitRef="usd">1576000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMS0xLTEtMA_d3cd5f06-ddb3-4337-9a24-9f277f25ec0c"
      unitRef="usd">810741000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i7af783f565644361ab504f9908131fb3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMy0xLTEtMA_6f6905fe-fc2c-4702-90ba-4f3555f0017c"
      unitRef="shares">37470212</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7af783f565644361ab504f9908131fb3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtNS0xLTEtMA_87104a64-3edf-4fd2-beaf-61571dcde8d9"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3defad69f61b4cf99c2daf1bee38aab8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtNy0xLTEtMA_3cd70ee3-e7ff-4b3c-9998-2140d32ed5fe"
      unitRef="usd">698287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b86cc0a4b0247b0be34b31af7783e22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtOS0xLTEtMA_744f9563-b67e-4830-a764-86a6dffbb81b"
      unitRef="usd">-319092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2bbb43da3d614bb0a07f82de8f66c0ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMTEtMS0xLTA_b32ba8c3-a869-4a40-97a2-5e92b5b14856"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i556d9f2b4c0446a481203b0d721356f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMTMtMS0xLTA_7ef229c2-c959-45f3-bf69-d8e844fd37eb"
      unitRef="usd">429991000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8445bad575a44eaf8f8bf43b13576231_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82NC9mcmFnOjBiMzI0NDQ0NmNiZDQ1YTg5NWEwZTU4NmVhYWUxNmZmL3RhYmxlOjgwNGQwNGU1YjVmODQyNWE4NGJjMDBiMTIwMzY0MzdlL3RhYmxlcmFuZ2U6ODA0ZDA0ZTViNWY4NDI1YTg0YmMwMGIxMjAzNjQzN2VfMzMtMTUtMS0xLTA_325145ba-7709-4295-b4a6-4daab4022575"
      unitRef="usd">1517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMy0xLTEtMS0w_2f518a42-74d5-4d76-addd-a9d1f32fe819"
      unitRef="usd">185184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMy0zLTEtMS0w_173436a2-c1ed-4fc1-a35b-a82ae5c7c28b"
      unitRef="usd">127907000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMy01LTEtMS0w_a80e86ca-49c5-4146-88d6-5d24f59df5fe"
      unitRef="usd">120129000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNS0xLTEtMS0w_44e43f31-5a7b-4727-935a-1593fa36b7ae"
      unitRef="usd">28802000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNS0zLTEtMS0w_a1facfd7-c140-4535-ab94-e0537190f915"
      unitRef="usd">18428000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNS01LTEtMS0w_0c273d6e-a8dd-4773-8ede-d4ce991bf954"
      unitRef="usd">13261000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNi0xLTEtMS0w_29d864d7-5f52-4380-9333-43f613ae0680"
      unitRef="usd">26730000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNi0zLTEtMS0w_6809de29-a8bc-4a95-be95-641414b7f250"
      unitRef="usd">25040000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNi01LTEtMS0w_685ca0f7-1339-4534-8706-d083843bb6c2"
      unitRef="usd">17887000</us-gaap:ShareBasedCompensation>
    <us-gaap:PensionExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNy0xLTEtMS0w_5ec19c56-1d77-49e7-89c7-b2854150a7a6"
      unitRef="usd">0</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNy0zLTEtMS0w_27cb82f8-0297-405a-89a4-6faed43be664"
      unitRef="usd">10509000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNy01LTEtMS0w_1276a4b7-4930-4b8b-a2ce-9c48c647b416"
      unitRef="usd">8976000</us-gaap:PensionExpense>
    <amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOC0xLTEtMS0w_8b9932d0-13a2-4e18-914a-2654069b84b1"
      unitRef="usd">39140000</amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset>
    <amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOC0zLTEtMS0w_6cd7d710-5534-4064-9d02-78f8ee10f767"
      unitRef="usd">35905000</amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset>
    <amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOC01LTEtMS0w_7bb48df8-3c3d-4157-8b14-1b9bd30e909a"
      unitRef="usd">0</amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOS0xLTEtMS0w_ff9f46e0-aab9-400e-9ea2-3a2eb7bd93a1"
      unitRef="usd">30000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOS0zLTEtMS0w_438a7a29-7a47-474e-8428-ce30b9ebc9f9"
      unitRef="usd">-141000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfOS01LTEtMS0w_f2b03353-577b-4ca8-a05d-1a4b6822b34a"
      unitRef="usd">-714000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMS0xLTEtMzk0Mw_6c7c61ca-ceb0-4cef-9e92-c2cdfc7b4756"
      unitRef="usd">2980000</us-gaap:LossOnSaleOfInvestments>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMy0xLTEtMzk0Mw_7470f70f-9955-42f3-ab0c-0af623cb74a0"
      unitRef="usd">0</us-gaap:LossOnSaleOfInvestments>
    <us-gaap:LossOnSaleOfInvestments
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtNS0xLTEtMzk0Mw_3ac84bfc-8344-447b-9b79-02f7104568e7"
      unitRef="usd">0</us-gaap:LossOnSaleOfInvestments>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMS0xLTEtMjA1Mg_0affd782-80bb-494e-9cf0-6a98269fcacf"
      unitRef="usd">15000</amed:WriteOffOfOtherComprehensiveIncome>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMy0xLTEtMjA1Mg_1b4cbd9d-ad51-4b1b-bd7f-ee840033004b"
      unitRef="usd">0</amed:WriteOffOfOtherComprehensiveIncome>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtNS0xLTEtMjA1Mg_f14bf62f-1224-4dd3-b3b3-5be1730cceec"
      unitRef="usd">0</amed:WriteOffOfOtherComprehensiveIncome>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMS0xLTEtMA_055b5a54-2701-43e8-91b2-76872dd21aa3"
      unitRef="usd">-26560000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtMy0xLTEtMA_ea24df79-9929-44e2-b94a-e162bb6f1a9b"
      unitRef="usd">13466000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTAtNS0xLTEtMA_68594d5e-f201-46fa-a005-f42bd4d07bbe"
      unitRef="usd">20271000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTEtMS0xLTEtMA_20fe6de1-1ef0-4bae-a0b7-3d36f8191254"
      unitRef="usd">3966000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTEtMy0xLTEtMA_37348d09-5926-42f8-a7c5-cb551efbc8b1"
      unitRef="usd">5338000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTEtNS0xLTEtMA_3ce898bb-e630-4653-8daf-9565f299a800"
      unitRef="usd">7692000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTItMS0xLTEtMA_fd6a8ab1-512d-4992-a2ce-b1706beb066e"
      unitRef="usd">869000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTItMy0xLTEtMA_11ab855c-4e74-4564-8c08-bbc6e61983cc"
      unitRef="usd">873000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTItNS0xLTEtMA_140420f4-d2f3-4a47-9b09-5138a12d045d"
      unitRef="usd">797000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTMtMS0xLTEtMA_d254a641-bcd2-4a4d-9e26-ecc152897552"
      unitRef="usd">5444000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTMtMy0xLTEtMA_da72b701-364a-44ca-b9a5-ccab3f1f6a7a"
      unitRef="usd">4955000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTMtNS0xLTEtMA_d1847faf-c58e-4fd1-9947-c2aa2ca44324"
      unitRef="usd">6158000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:AssetImpairmentCharges
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTQtMS0xLTEtMA_830459a1-435c-4b29-af6e-ad457f696ede"
      unitRef="usd">4152000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTQtMy0xLTEtMA_192d799d-90d6-49ad-89ce-61111f67c3ed"
      unitRef="usd">1470000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTQtNS0xLTEtMA_d56acaca-0549-48c1-acf0-852ba56138f3"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTYtMS0xLTEtMA_96d7aa28-1b0b-42fb-bd4c-bbb14d4fd163"
      unitRef="usd">-2114000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTYtMy0xLTEtMA_2ae6f265-d982-4589-9013-f3b9cdbe91aa"
      unitRef="usd">24146000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTYtNS0xLTEtMA_492c8520-db09-4926-aad0-f93143de3bfd"
      unitRef="usd">-12224000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTctMS0xLTEtMA_8f8c23b7-313a-431a-b567-22bf4d0bacaf"
      unitRef="usd">7181000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTctMy0xLTEtMA_9a8f3009-4848-4109-a178-a881cbfc0e99"
      unitRef="usd">2682000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTctNS0xLTEtMA_f21097ac-19c1-4e77-b010-0987f0dc3485"
      unitRef="usd">-8679000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTgtMS0xLTEtMA_730e033f-9785-4ac1-be1a-a2adf309820c"
      unitRef="usd">-31000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTgtMy0xLTEtMA_b7252915-0670-4f0f-a825-46c1229846a7"
      unitRef="usd">-832000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTgtNS0xLTEtMA_c7e8de1f-1547-424d-86a8-ef9d9a27d128"
      unitRef="usd">-2947000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTktMS0xLTEtMA_f86dbd26-2a21-46ab-a563-1de18c7ee355"
      unitRef="usd">1941000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTktMy0xLTEtMA_8a99fc2b-8c06-4afa-903c-598e0a48465f"
      unitRef="usd">-11329000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMTktNS0xLTEtMA_5c0a0b89-cb09-4419-af20-a5f940ec7a5d"
      unitRef="usd">3165000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjAtMS0xLTEtMA_608a6f41-5c27-424c-b51e-cb9cf4e95524"
      unitRef="usd">39839000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjAtMy0xLTEtMA_8e0a1402-8fe1-45d8-a7a1-fb8b6d57a693"
      unitRef="usd">42096000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjAtNS0xLTEtMA_fb4facb6-5b93-41c4-b440-71678c0cd0e6"
      unitRef="usd">13524000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjEtMS0xLTEtMA_d91a66d7-c4fb-442a-8d1d-39891e4c3b96"
      unitRef="usd">27717000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjEtMy0xLTEtMA_d35c5cc2-349f-445c-98ce-34889f1a6e0f"
      unitRef="usd">-329000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjEtNS0xLTEtMA_7aaf28fd-100e-477f-ac9e-0c60ad64b493"
      unitRef="usd">2443000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjItMS0xLTEtMA_5e0449a4-ac67-4400-bc66-420e7278daaf"
      unitRef="usd">-34695000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjItMy0xLTEtMA_5a3e9520-27c1-445b-8aa9-db84a0e59a68"
      unitRef="usd">-32295000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjItNS0xLTEtMA_dd2daea4-c60e-4484-962b-c815c9141598"
      unitRef="usd">0</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjMtMS0xLTEtMA_40adc0f2-9612-4c06-a689-8a5840aa59fd"
      unitRef="usd">-3544000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjMtMy0xLTEtMA_754997bf-8027-44d4-90c6-10b9cc8d6da0"
      unitRef="usd">-3503000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjMtNS0xLTEtMA_3af87394-0707-47f3-9f29-7f76af24a13f"
      unitRef="usd">0</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjQtMS0xLTEtMA_0918747f-63b3-484d-bf66-fb5b4d1d4b90"
      unitRef="usd">288952000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjQtMy0xLTEtMA_69b589b7-849e-4a96-a42a-209a09e866bf"
      unitRef="usd">202000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjQtNS0xLTEtMA_377e3b2a-9c44-4874-b0df-27195ab42d31"
      unitRef="usd">223483000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjYtMS0xLTEtMA_92fe4016-50f3-4609-98f6-36cd89debb44"
      unitRef="usd">101000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjYtMy0xLTEtMA_4b405826-3c2d-423d-971e-4b4b5eb4c4e5"
      unitRef="usd">448000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjYtNS0xLTEtMA_40e2d471-3ee8-4a8d-ad4e-59a2d20dedc5"
      unitRef="usd">715000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjctMS0xLTEtMA_ede7e5ce-b816-4926-afae-23fd59d21d30"
      unitRef="usd">80000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjctMy0xLTEtMA_ce60f97b-474c-4c8b-9b57-1a6a37671467"
      unitRef="usd">162000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjctNS0xLTEtMA_e119e0d9-6f34-4c12-81fb-f8d391d0d5b3"
      unitRef="usd">54000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjgtMS0xLTEtMA_374191cd-66c1-462a-a549-5162e7a5495d"
      unitRef="usd">5332000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjgtMy0xLTEtMA_79acf638-0ad6-43d6-b435-0a1429a9b0f4"
      unitRef="usd">7888000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjgtNS0xLTEtMA_5705fc28-dfdb-454f-8222-93a30babe5b0"
      unitRef="usd">6558000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjktMS0xLTEtMA_9d88442f-5808-4291-bb96-a36479a80dbc"
      unitRef="usd">875000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjktMy0xLTEtMA_d11141d5-7368-47c2-84bc-39da59ab9932"
      unitRef="usd">210000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMjktNS0xLTEtMA_a0219325-be76-4014-9db2-6631b1cf334c"
      unitRef="usd">7144000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzItMS0xLTEtMzk0Ng_c0a8b03c-8053-403f-91a1-617a5b58d353"
      unitRef="usd">17876000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzItMy0xLTEtMzk0Ng_34a07725-1dc5-4253-ab3b-604b869ad3af"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzItNS0xLTEtMzk0Ng_f002debf-2d9b-4342-9f6f-f4304d40c96d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzAtMS0xLTEtMA_eb5e44ae-a737-4150-b47e-c8ba03b6e038"
      unitRef="usd">298958000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzAtMy0xLTEtMA_ba200c7c-17cd-464f-aec2-ff865d8085b5"
      unitRef="usd">345460000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzAtNS0xLTEtMA_a13e24b6-b0b6-44d1-ad77-ab6f64ca850c"
      unitRef="usd">9260000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzEtMS0xLTEtMA_34994f09-6cf4-44bc-92ee-c09584561083"
      unitRef="usd">-287108000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzEtMy0xLTEtMA_63d3de0c-ca0f-4683-8980-17fc4192548a"
      unitRef="usd">-352948000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzEtNS0xLTEtMA_b222a29c-6572-478f-bedd-797b09673984"
      unitRef="usd">-22193000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzMtMS0xLTEtMA_5fb5f650-21bb-43be-a3e2-ceab9ed8d981"
      unitRef="usd">6325000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzMtMy0xLTEtMA_08e388b0-c30b-477f-94b6-a1dcbcc8d560"
      unitRef="usd">3611000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzMtNS0xLTEtMA_e098b4b1-d6bf-4daa-8149-c1812084c423"
      unitRef="usd">5953000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzQtMS0xLTEtMA_16f708fa-836e-4b66-8b02-eb77cd52fe82"
      unitRef="usd">3562000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzQtMy0xLTEtMA_38bb3526-a3e9-4c80-b95e-ee2e20d154a0"
      unitRef="usd">3187000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzQtNS0xLTEtMA_4d398674-4caf-4d49-9506-4234379bd059"
      unitRef="usd">2429000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzUtMS0xLTEtMA_44adc05a-30b9-4300-9883-1053ea1b3207"
      unitRef="usd">54493000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzUtMy0xLTEtMA_5825ac8f-cfe8-4b31-befa-86f3c5d993a4"
      unitRef="usd">9556000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzUtNS0xLTEtMA_3c501e94-68b5-427c-8e79-0400667fbc5b"
      unitRef="usd">6570000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzYtMS0xLTEtMA_aac644ab-3639-4fbf-ad1c-35216bbb512f"
      unitRef="usd">1122000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzYtMy0xLTEtMA_33b2367c-5384-4136-a5f9-6a888ddb1b61"
      unitRef="usd">1062000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzYtNS0xLTEtMA_544914f2-bca3-446a-98cf-9b109a632ca8"
      unitRef="usd">1090000</amed:CashDistributionToNoncontrollingInterest>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzctMS0xLTEtMA_285641db-dc9c-4775-8aae-b2396e2821c3"
      unitRef="usd">0</amed:ProceedsFromBorrowingsUnderTermLoan>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzctMy0xLTEtMA_1fe2b288-9207-47de-864d-b120305e4bf9"
      unitRef="usd">175000000</amed:ProceedsFromBorrowingsUnderTermLoan>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzctNS0xLTEtMA_53057ebd-0d19-4da7-b27c-851d10b86dc9"
      unitRef="usd">0</amed:ProceedsFromBorrowingsUnderTermLoan>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzgtMS0xLTEtMA_b994d746-0268-43ad-a698-2a7d9254541b"
      unitRef="usd">684200000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzgtMy0xLTEtMA_fc6e7921-a197-4925-81de-448c600ebe62"
      unitRef="usd">262500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzgtNS0xLTEtMA_54e446f6-b71e-401a-a52f-3f22b96bf83f"
      unitRef="usd">138000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzktMS0xLTEtMA_04319a7a-bb61-4b23-98c3-3a8124556198"
      unitRef="usd">703200000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzktMy0xLTEtMA_28b8bd31-03cb-4ae2-ac48-d9622e642fa2"
      unitRef="usd">200000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfMzktNS0xLTEtMA_a05cf35d-f6a9-40e1-8578-81c4f35e4bc8"
      unitRef="usd">130500000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDAtMS0xLTEtMA_8914d04b-4d3f-4c73-8413-4cb50b8ff43c"
      unitRef="usd">10249000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDAtMy0xLTEtMA_179ded9b-8e3e-4b45-8ffb-8b71aee338fa"
      unitRef="usd">5624000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDAtNS0xLTEtMA_0045362b-1edf-4098-8243-7eb05767584a"
      unitRef="usd">91450000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDEtMS0xLTEtMA_59d917bd-38eb-4b02-ba4b-a1937091d873"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDEtMy0xLTEtMA_1360c0ac-8559-4ac9-a88b-b419ec62aa52"
      unitRef="usd">847000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDEtNS0xLTEtMA_28e9bc78-9d39-49ae-b009-22ed5a324f6b"
      unitRef="usd">2433000</us-gaap:PaymentsOfFinancingCosts>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtMS0xLTEtMjA1Ng_224f140c-a05c-4c7c-87d1-ac0b7c756a20"
      unitRef="usd">60000000</amed:FundsReceivedFromProviderReliefFundAdvance>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtMy0xLTEtMjA1Ng_e7808089-4f54-432a-a7c3-43a5b13dfe4e"
      unitRef="usd">0</amed:FundsReceivedFromProviderReliefFundAdvance>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtNS0xLTEtMjA1Ng_cd451cb5-7872-4a5b-8b18-5aa0e057ef38"
      unitRef="usd">0</amed:FundsReceivedFromProviderReliefFundAdvance>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDItMS0xLTEtMA_4904c6c1-cc35-44ee-b984-c43743958762"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDItMy0xLTEtMA_31c85b39-52df-47fc-8d1f-4d9375848f23"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDItNS0xLTEtMA_a41d4ec7-88b2-45d8-890c-88af65105c58"
      unitRef="usd">181402000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <amed:PaymentsForRepurchaseOfNoncontrollingInterest
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDMtMS0xLTEtMA_7ced0ded-07c5-4cdb-8481-c105dcc99912"
      unitRef="usd">0</amed:PaymentsForRepurchaseOfNoncontrollingInterest>
    <amed:PaymentsForRepurchaseOfNoncontrollingInterest
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDMtMy0xLTEtMA_982b6430-093c-4ad2-97e9-0cba23e98136"
      unitRef="usd">0</amed:PaymentsForRepurchaseOfNoncontrollingInterest>
    <amed:PaymentsForRepurchaseOfNoncontrollingInterest
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDMtNS0xLTEtMA_fafc18a9-77b9-4e4c-a4e7-da68e277a0f3"
      unitRef="usd">361000</amed:PaymentsForRepurchaseOfNoncontrollingInterest>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtMS0xLTEtMA_a910a8bc-a4c7-420d-92ca-842bff51ea33"
      unitRef="usd">-14977000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtMy0xLTEtMA_7a94e287-db3a-413f-9079-3cd1a86324af"
      unitRef="usd">227209000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDQtNS0xLTEtMA_de0433fe-40a5-4180-8425-a2928c9f8b7d"
      unitRef="usd">-267424000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDUtMS0xLTEtMA_f229810d-84fe-4064-a03f-5233c7f0b6eb"
      unitRef="usd">-13133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDUtMy0xLTEtMA_78672655-aa9c-44a9-af95-f81285eeeb6d"
      unitRef="usd">76261000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDUtNS0xLTEtMA_fd8121fe-207e-4fcb-8479-8154503f65b1"
      unitRef="usd">-66134000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDYtMS0xLTEtMA_838b00bb-c3c7-48ac-8d78-27d5507c6450"
      unitRef="usd">96490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDYtMy0xLTEtMA_e7d335a7-01b5-4e39-a7d9-761e94b445cd"
      unitRef="usd">20229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i71d70551ae8f463895c999fdc4613768_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDYtNS0xLTEtMA_3d7bdfae-19ce-4aef-ac8a-dad28d2b4cb4"
      unitRef="usd">86363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDctMS0xLTEtMA_4fa72778-2c5c-4a1d-a781-93f05e1f9cf0"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDctMy0xLTEtMA_c683732a-2317-4649-9c05-7b183b6ff2c4"
      unitRef="usd">96490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDctNS0xLTEtMA_761e9431-2e11-442a-ac7f-e373cd37f8cb"
      unitRef="usd">20229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDktMS0xLTEtMA_056b0323-8138-4049-828c-7915801c4c76"
      unitRef="usd">6207000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDktMy0xLTEtMA_a90f862d-f537-4de7-8501-b247c70d8fbe"
      unitRef="usd">9628000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNDktNS0xLTEtMA_4c7f164e-0cdd-407c-a05c-ca193cde67e8"
      unitRef="usd">3522000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTAtMS0xLTEtMA_1e0f0725-ea30-43ff-be9c-5fa0f6a493ab"
      unitRef="usd">50721000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTAtMy0xLTEtMA_467f5deb-53d3-489e-932e-d8ddec1cf370"
      unitRef="usd">29522000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTAtNS0xLTEtMA_1b909d53-d6d1-4ce0-97b3-6329a67cc2c2"
      unitRef="usd">14278000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NotesAssumed1
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTItMS0xLTEtMA_9c8c8604-834e-487d-81fb-8590a1ff1d6d"
      unitRef="usd">0</us-gaap:NotesAssumed1>
    <us-gaap:NotesAssumed1
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTItMy0xLTEtMA_5eabcae9-0d83-4a14-b587-2c78104a08ab"
      unitRef="usd">0</us-gaap:NotesAssumed1>
    <us-gaap:NotesAssumed1
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF82Ny9mcmFnOjc2YzM1YzBmNDM5YzQzMjNiNzUxY2Y2MmVlZGM1ZTFhL3RhYmxlOmI5NmFlMmMxZGFiZjQ3ZDdiOWM2MDA1ZDc4MTczOTg4L3RhYmxlcmFuZ2U6Yjk2YWUyYzFkYWJmNDdkN2I5YzYwMDVkNzgxNzM5ODhfNTItNS0xLTEtMA_0e14e4e7-69bd-4557-af40-5f5e3f6c1e91"
      unitRef="usd">418000</us-gaap:NotesAssumed1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MTM_399d745c-42ae-43a2-b500-12d0fbb69f01">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#x201c;Amedisys,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;), is a multi-state provider of home health, hospice and personal care services with approximately 75%, 74% and 73% of our revenue derived from Medicare for 2020, 2019 and 2018, respectively. As of December&#160;31, 2020, we owned and operated 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and 14 personal-care care centers in 39 states within the United States and the District of Columbia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, the Company adopted Accounting Standards Update ("ASU") 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020, the Company adopted ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes, enacts changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, the Company adopted Accounting Standards Codification ("ASC") 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using a modified retrospective transition approach, which requires the new standard to be applied to all leases existing at the date of initial application. Under ASC 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. We used the standard's effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019. The new standard provides several optional practical expedients that can be adopted at transition. We elected the "package of practical expedients," which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us. The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately $80 million in operating leases liabilities with corresponding ROU assets of approximately the same amount. The new standard also provides practical expedients for an entity&#x2019;s ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, the Company adopted ASU 2018-07,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Compensation - Stock Compensation (Topic 718): Improvements to Nonemployees Share-Based Payment Accounting, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods or services. Our adoption of this standard did not have an effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using the full retrospective method. ASC 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The standard supersedes existing revenue recognition requirements and eliminates most industry-specific guidance from U.S. Generally Accepted Accounting Principles ("U.S. GAAP"). The core principle of the revenue recognition standard is to require an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. As a result of the Company's adoption of ASC 606, the revenue and related estimated uncollectible amounts owed to us by non-Medicare payors that were historically classified as provision for doubtful accounts are now considered a revenue adjustment in determining net service revenue. Accordingly, the Company reports estimated uncollectible balances due from third-party payors and uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore, as a reduction in net service revenue (or as it relates to Hospice room and board, an increase in cost of service, excluding depreciation and amortization) when historically these amounts were classified as provision for doubtful accounts within operating expenses within our consolidated statements of operations. In addition, the adoption of ASC 606 resulted in increased disclosure, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASU 2017-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition (or disposal) of assets or a business. We adopted this ASU on a prospective basis. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions as evaluated under the new framework.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASU 2017-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. We adopted this ASU on a prospective basis and will apply this guidance to our future tests of goodwill impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASU 2016-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December&#160;15, 2017. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. Our adoption of this standard using a retrospective transition method for each period presented did not have an effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 12, 2020, the FASB issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued, subject to meeting certain criteria. The amendments in this ASU were effective beginning on March 12, 2020 and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. During 2016, we sold a 30% interest in one of our care centers while maintaining a controlling interest in the newly formed joint venture; we repurchased the 30% interest during 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0&#160;million loss which is reflected in miscellaneous, net within our consolidated statement of &lt;/span&gt;&lt;/div&gt;operations for the year ended December 31, 2020.  The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund operations. During 2018, we made a $7.0 million investment in a healthcare analytics company; this investment is accounted for under the equity method. The book value of investments that we account for under the equity method of accounting totaled $14.2 million and $35.7 million as of December&#160;31, 2020 and 2019, respectively, and is reflected in other assets within our consolidated balance sheets.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e73c8be1d6044ae94fdfbcfab376671_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMzIz_f92635cc-c2ea-4634-a169-fc95bf2a8fdf"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5312e58d089a492e8f1b50eb41d38fe4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMzI3_a88249be-7caa-418b-8824-915107859127"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibf84b9ba9e1d4509914b4659ae8cf76e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMzM0_a6bd1756-5dd8-48ef-be5a-31b9404c1e56"
      unitRef="number">0.73</us-gaap:ConcentrationRiskPercentage1>
    <amed:OperatingCareCenters
      contextRef="i3f4d87d3f8c04768adb0d99598494f75_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfNDM5_e0de70c9-b3de-4f28-906f-7205ffff03c3"
      unitRef="care_center">320</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i7618d2cebdef436fa6e1ece2cb3e1a9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfNDg3_da92f4b9-9010-45bb-8827-9d20546f0aac"
      unitRef="care_center">180</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i30daf9d0e928439bbf628952733e011b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfNTM0_bf2a3112-f18c-4654-b6a3-32cf56f34beb"
      unitRef="care_center">14</amed:OperatingCareCenters>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfNTY3_931e6e0c-72ba-48a7-8e74-e44bd78429bf"
      unitRef="state">39</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MTQ_83ebb70c-69a5-4391-801b-400eedc9ea1f">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, the Company adopted Accounting Standards Update ("ASU") 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020, the Company adopted ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes, enacts changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, the Company adopted Accounting Standards Codification ("ASC") 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using a modified retrospective transition approach, which requires the new standard to be applied to all leases existing at the date of initial application. Under ASC 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. We used the standard's effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019. The new standard provides several optional practical expedients that can be adopted at transition. We elected the "package of practical expedients," which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us. The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately $80 million in operating leases liabilities with corresponding ROU assets of approximately the same amount. The new standard also provides practical expedients for an entity&#x2019;s ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, the Company adopted ASU 2018-07,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Compensation - Stock Compensation (Topic 718): Improvements to Nonemployees Share-Based Payment Accounting, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods or services. Our adoption of this standard did not have an effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using the full retrospective method. ASC 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The standard supersedes existing revenue recognition requirements and eliminates most industry-specific guidance from U.S. Generally Accepted Accounting Principles ("U.S. GAAP"). The core principle of the revenue recognition standard is to require an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. As a result of the Company's adoption of ASC 606, the revenue and related estimated uncollectible amounts owed to us by non-Medicare payors that were historically classified as provision for doubtful accounts are now considered a revenue adjustment in determining net service revenue. Accordingly, the Company reports estimated uncollectible balances due from third-party payors and uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore, as a reduction in net service revenue (or as it relates to Hospice room and board, an increase in cost of service, excluding depreciation and amortization) when historically these amounts were classified as provision for doubtful accounts within operating expenses within our consolidated statements of operations. In addition, the adoption of ASC 606 resulted in increased disclosure, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASU 2017-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition (or disposal) of assets or a business. We adopted this ASU on a prospective basis. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions as evaluated under the new framework.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASU 2017-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. We adopted this ASU on a prospective basis and will apply this guidance to our future tests of goodwill impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2018, the Company adopted ASU 2016-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December&#160;15, 2017. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. Our adoption of this standard using a retrospective transition method for each period presented did not have an effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 12, 2020, the FASB issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued, subject to meeting certain criteria. The amendments in this ASU were effective beginning on March 12, 2020 and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2914b051b7f649fbb23140dd91cafcdb_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMjUzNg_ac9193f0-ae1f-4160-963c-1fa1e6e13271"
      unitRef="usd">80000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2914b051b7f649fbb23140dd91cafcdb_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMjUzNg_ea57d975-6a06-456a-aaf2-cca8354a2c21"
      unitRef="usd">80000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:UseOfEstimates
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MDM_9922a04f-8107-495f-be35-3eff0efa0b14">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MDg_7ae26679-ebe7-4687-bee0-ef9a060b0bab">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE2MDY_5ef0d3de-c0c2-42a7-bc84-521894db90b8">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. During 2016, we sold a 30% interest in one of our care centers while maintaining a controlling interest in the newly formed joint venture; we repurchased the 30% interest during 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0&#160;million loss which is reflected in miscellaneous, net within our consolidated statement of &lt;/span&gt;&lt;/div&gt;operations for the year ended December 31, 2020.  The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund operations. During 2018, we made a $7.0 million investment in a healthcare analytics company; this investment is accounted for under the equity method. The book value of investments that we account for under the equity method of accounting totaled $14.2 million and $35.7 million as of December&#160;31, 2020 and 2019, respectively, and is reflected in other assets within our consolidated balance sheets.</us-gaap:EquityMethodInvestmentsPolicy>
    <amed:MinimumPercentOwnershipForControllingInterestPercent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTA2Njk_0204eec3-c8d7-496b-a839-a90d3a1a8a30"
      unitRef="number">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i3eee69c4378245919523ef9c81dcd659_I20161231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTA4NDQ_02e4b75e-f420-4b73-8752-99f2d0f04b3a"
      unitRef="number">0.30</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <amed:NoncontrollingInterestRepurchased
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTA5Nzg_96ee3a46-8737-435f-9f76-517005b2d08c"
      unitRef="number">0.30</amed:NoncontrollingInterestRepurchased>
    <amed:MaximumPercentOwnershipForEquityMethodPercent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTExNDA_0e22f70d-460c-4a02-a322-028537472cf5"
      unitRef="number">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ic6f32ffb396941779dd01b141bf45abd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTA5OTUxMTY0Mzc5Mw_c6798e38-9713-4f02-858e-22d787b39310"
      unitRef="usd">17900000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i3e986e4e31c44d36a9f7a6664353fdce_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTEyODQ_44d4cf03-64cb-41e9-948b-ae9ca6c99767"
      unitRef="usd">7000000.0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE0ODc_dc4b0831-6c12-4bd4-9fc7-7d70238881a7"
      unitRef="usd">14200000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83My9mcmFnOjVhNGFkNTBiOTE2NjQxMzRhOWI1NjJlODRjOGU4NDE4L3RleHRyZWdpb246NWE0YWQ1MGI5MTY2NDEzNGE5YjU2MmU4NGM4ZTg0MThfMTE0OTQ_cde371a4-c7d3-43c0-8ca8-fbe4535b8cf4"
      unitRef="usd">35700000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MzM_f82d9080-96d9-4d46-a30a-3c51403a0947">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of the Company's consolidated net service revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare Hospice on June 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient&#x2019;s care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are now included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our consolidated balance sheets. CMS reduced the upfront payment for RAPs to 20% for 2020 and has fully eliminated payments associated with RAPs in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2020, 2019 and 2018, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28th of the following year. As of December&#160;31, 2020, we have settled our Medicare hospice reimbursements for all fiscal years through October&#160;31, 2013. As of December&#160;31, 2020, we have recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021; approximately $2.0 million of this balance was acquired with the AseraCare Hospice ("AseraCare") acquisition. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of December 31, 2020 includes approximately $77&#160;million associated with the CARES Act Provider Relief Fund ("PRF"). We separated the PRF funds into their own account and as of December 31, 2020, we have only transferred funds used during the nine-month period ended September 30, 2020 to our operating account. We will transfer funds used during the three-month period ended December  31, 2020 to our operating account in 2021. Restricted cash includes cash that is not available for ordinary business use. As of December 31, 2020, we had $1.5&#160;million of restricted cash that was placed into an escrow account related to the indemnity provisions within the Asana Hospice purchase agreement. As of December 31, 2019, we had $66.2&#160;million of restricted cash that was placed into an escrow account to fund the acquisition of Asana Hospice on January 1, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 64% and 58% of our net patient accounts receivable at December&#160;31, 2020 and 2019, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid, any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of all upfront payments associated with RAPs in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, and Personal Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#x2019;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the extent or manner in which the long-lived asset group is being used.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the business climate that could affect the value of the long-lived asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the market value of the assets included in the asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide for depreciation over the following estimated useful service lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our property and equipment for 2020 and 2019 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for 2020, 2019 and 2018 was $12.1 million, $11.6 million and $10.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth and discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of our operating segments described in Note 14 &#x2013; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and have also deemed each of them to be a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we performed a qualitative assessment to determine if it is more likely than not that the fair value of the reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we did not record any goodwill impairment charges and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October&#160;31, 2020. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of certificates of need, licenses, acquired names and non-compete agreements. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxNg_2ef6bf16-13c0-4b4a-ac9d-18652113e2f9"&gt;two&lt;/span&gt; to three years for non-compete agreements and up to three years for acquired names. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. During 2020, we performed a qualitative assessment of our indefinite-lived intangible assets; as a result of this analysis, we wrote off approximately $4.2&#160;million of acquired names that are no longer in use. During 2019, we also performed a qualitative assessment of our indefinite-lived intangible assets; as a result of this analysis, we wrote off approximately $1.5 million of acquired names. There have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our remaining intangible assets would be less than their carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, we recorded $0.8 million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 8 - Long-Term Obligations). As of December&#160;31, 2020 and 2019, we had unamortized debt issuance costs of $2.7 million and $3.5 million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. The unamortized debt issuance costs of $2.7 million at December&#160;31, 2020 will be amortized over a weighted-average amortization period of 3.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2020 and 2019, our net deferred tax assets were $48.0 million and $21.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#x2019;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#x2019;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award. Share-based compensation expense for 2020, 2019 and 2018 was $26.7 million, $25.0 million and $17.9 million, respectively, and the total income tax benefit recognized for these expenses was $4.7 million, $4.6 million and $4.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense advertising costs as incurred. Advertising expense for 2020, 2019 and 2018 was $8.0 million, $8.5 million and $7.0 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NjI_281422e0-bead-4d92-85f0-f34a9366de6d">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of the Company's consolidated net service revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare Hospice on June 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient&#x2019;s care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are now included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our consolidated balance sheets. CMS reduced the upfront payment for RAPs to 20% for 2020 and has fully eliminated payments associated with RAPs in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2020, 2019 and 2018, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28th of the following year. As of December&#160;31, 2020, we have settled our Medicare hospice reimbursements for all fiscal years through October&#160;31, 2013. As of December&#160;31, 2020, we have recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021; approximately $2.0 million of this balance was acquired with the AseraCare Hospice ("AseraCare") acquisition. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA").</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e73c8be1d6044ae94fdfbcfab376671_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMzEyNw_d1cf3c4d-5a9b-4e5b-85ff-8fef3eec7be8"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMzg5OQ_28bfd2a4-95bf-4a8c-99ed-a352035444ce"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NDU_b2f66d1f-caa4-4e0e-a49f-81291204bd5d">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice (1):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare Hospice on June 1, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ia9908f52af49414aaa4bba7ff6a04ea2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMy0xLTEtMS0w_5273682a-e496-48a2-acf7-7fe35e932518"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="icbdc95bff22c46c88b5ecb49ca013c65_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMy0zLTEtMS0w_6570ea84-4b54-4c25-b658-ad379b82e7c2"
      unitRef="number">0.44</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iaa97deb735d340eca9b8cc590a5b1849_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMy01LTEtMS0w_4bba439c-3293-4845-b6ea-a4a02821f9a0"
      unitRef="number">0.50</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i0f3ed78fd22d4d13a30267510435daf6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNC0xLTEtMS0w_9d4c343e-7189-44b6-b5f6-89699450ee56"
      unitRef="number">0.07</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iefef9d24cffa43e4a8689e876b718fdf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNC0zLTEtMS0w_bfead795-b885-411c-b103-aa2f255471ef"
      unitRef="number">0.09</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="idc080435d3fc4721a9440877edb75f0d_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNC01LTEtMS0w_36bd339d-cbef-4666-9a36-ae4bc94dfb24"
      unitRef="number">0.09</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ia74323b930434bcdb3617ec041a4cfe6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNS0xLTEtMS0w_60ab6664-963a-47a9-bf03-2d4473af5c20"
      unitRef="number">0.13</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="icdc0080330a7432e9027a57a221467c0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNS0zLTEtMS0w_a804a161-9527-4cbb-8e06-7e94d67a56ba"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ifdf6f8b2217645d7a837564472c1641e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNS01LTEtMS0w_82e96e3e-91e9-4470-8639-9b4058b84b1b"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i04b9e3d120ed425ba59ad31de35d305d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNy0xLTEtMS0w_683a7569-9c87-4b49-8b45-d4dc240308ad"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i1cd65f8b7a704689a2fe739ca3da0471_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNy0zLTEtMS0w_e324afc3-c866-4f3c-afb3-9263d66ff005"
      unitRef="number">0.30</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ib865129db50747ec9ba2b83c279bc869_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfNy01LTEtMS0w_88931b55-c55a-4712-9803-68b2ccb628b6"
      unitRef="number">0.23</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iae6389e8be7141058ce2e5865620a128_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOC0xLTEtMS0w_f0040a5c-db72-4c8d-8f3f-21ab76d87dd8"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ib6368cc1cda74803ab17d38cb452059b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOC0zLTEtMS0w_bc9cf1de-17af-4b46-bbf8-891812695b9c"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="if8c88b95605441ba8df42caa5d36162b_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOC01LTEtMS0w_7b069092-d3aa-4abd-84f9-56ba85cbe01a"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i0ebe30ad71fe49acad1f10623f51159b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOS0xLTEtMS0w_1798c32c-cc59-4a1c-8ac4-a15827ab9ee1"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i59c59d1d549d4f0b8e8a5cd6aa96ee72_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOS0zLTEtMS0w_801ab99e-3837-4388-93ac-599a633a5e4b"
      unitRef="number">0.04</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iaaa6c33dce254267aa5511c42c11f0c1_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfOS01LTEtMS0w_bfe6b320-4088-4711-b03e-5d0a2259b6f0"
      unitRef="number">0.05</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMTAtMS0xLTEtMA_ed0b751a-00b0-4ee2-a896-ccab9194f9cc"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMTAtMy0xLTEtMA_464c808c-fc1a-4075-874f-07bf9146b209"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmUzMDYwNzZmYTA1MTRhMTk4ZGQ4ZjYyMDcxMzE2M2RkL3RhYmxlcmFuZ2U6ZTMwNjA3NmZhMDUxNGExOThkZDhmNjIwNzEzMTYzZGRfMTAtNS0xLTEtMA_d7e6a3ad-f833-4413-944d-6a1f78338749"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY3NzgxMg_3e4ada10-2eb4-4c2a-8ed1-25600155f7bc">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY3NzgyMA_f21628fe-8720-4a88-b05d-c1eff4b89c87">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjE2Nw_acbb89e7-d184-47a0-b923-34fa69316ec6">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:PercentageOfTotalReimbursementOfOutlierPayment
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfNDU2Ng_73c49494-bd3c-4234-a78f-44d7fe33b145"
      unitRef="number">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i1fd55beb3b4d4378b920094a5b091472_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjEwOQ_bda77063-9610-42cf-865e-841bef1740ce"
      unitRef="number_of_visits">2</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i1f6206325b4d4a58a46dff6013229b68_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjExNw_dd7ed8a4-ce9c-45f5-838a-b2a4567108de"
      unitRef="number_of_visits">6</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="ib5177b049f064d83bb0e48f33e3b2e58_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY3NTU2Mg_c09ef699-e511-4364-8444-d7211d155f33"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODY4Nw_e0d57e05-d83d-482f-9765-92b4fb8f7e6e">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcyNw_6fc6c08e-0fed-46ad-b91d-4f1f8fd2e008"
      unitRef="number">0.20</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare>
    <amed:NonMedicareRevenueTermRates
      contextRef="i1fd55beb3b4d4378b920094a5b091472_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfODU4NA_9d25c32f-f28c-458d-8483-8c8d3d50687b"
      unitRef="number">0.90</amed:NonMedicareRevenueTermRates>
    <amed:NonMedicareRevenueTermRates
      contextRef="i1f6206325b4d4a58a46dff6013229b68_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfODU5MA_8a6dabe7-4d3f-4183-b835-90b4b7cbc745"
      unitRef="number">1</amed:NonMedicareRevenueTermRates>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfOTc3OQ_6fe87bff-f908-4082-b89d-fee62040323e"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfOTc3OQ_ad9ca6b9-f063-4e8b-8414-ab173553eb90"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfOTc3OQ_d342a583-2ffb-40e8-a2df-43a60134cbe6"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="icca03328f124427a801b7d654ef05ff9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA3OTQ_3c341f7e-7192-4f76-a528-5e2b78fe3056"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i1910bccf75da421d95218682b6c0f049_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTE2OTI_408ce299-c3f4-49da-b56d-ea62c3f07ba3"
      unitRef="usd">9300000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i8e4242100dce41a99f05af2e39618231_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTE4NDk_a8976377-5856-48a8-8237-b7d4f3ef2de2"
      unitRef="usd">2000000.0</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i2b22800f018b4cb5b23b5e899cc8f26a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTE5OTc_54459dbe-bba6-4c5e-afcc-e4b01d370e45"
      unitRef="usd">5700000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:GovernmentGrantsPolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODY5Mg_c514f13c-9676-449a-a091-808a7a61baa2">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.&lt;/span&gt;&lt;/div&gt;</amed:GovernmentGrantsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NTY_e143e317-1022-4107-8b9a-dfb8507dbffc">Cash, Cash Equivalents and Restricted CashCash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <amed:CashBalanceAssociatedWithProviderReliefFund
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjE5NQ_5e8c89c2-5676-46a1-9a6a-483784cc6b40"
      unitRef="usd">77000000</amed:CashBalanceAssociatedWithProviderReliefFund>
    <us-gaap:RestrictedCash
      contextRef="ic4486f034b52465db1934c0b02d4badf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjU5Mw_0b198c70-2e92-457b-b101-236d22b344b3"
      unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i458e999686ec425fb89dcbbb0521682c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODY5NA_56c44a8b-24e1-4037-9de9-3c05b65c2bb6"
      unitRef="usd">66200000</us-gaap:RestrictedCash>
    <amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxMA_a8389635-ffe2-4323-b49e-9fb890e9a7db">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfMi0xLTEtMS0w_0b9aa280-3bd2-430f-ae8b-61c192cff36f"
      unitRef="usd">81800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfMi0zLTEtMS0w_c5329c29-a3f3-433b-b8cd-8db93f6602a7"
      unitRef="usd">30300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfMy0xLTEtMS0w_078cbc85-31d1-42d7-bc86-48b911be6ea2"
      unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfMy0zLTEtMS0w_68160c8a-90aa-4a86-b021-88849e033629"
      unitRef="usd">66200000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOmRhNWMzODEyZTc2YjRmYmJiNTk0MWYzNjhjMzcyOWViL3RhYmxlcmFuZ2U6ZGE1YzM4MTJlNzZiNGZiYmI1OTQxZjM2OGMzNzI5ZWJfNC0zLTEtMS0w_f9c90896-1067-494a-8537-458875d849d2"
      unitRef="usd">96500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NjE_6cb64a71-fd62-4977-b24e-c47dc8bcef69">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 64% and 58% of our net patient accounts receivable at December&#160;31, 2020 and 2019, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid, any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of all upfront payments associated with RAPs in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, and Personal Care&lt;/span&gt;&lt;/div&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <amed:PercentageOfPatientReceivablesOutstanding
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTQ2NDU_cda13a63-2fdd-4770-ac0e-4da93f49957f"
      unitRef="number">0.10</amed:PercentageOfPatientReceivablesOutstanding>
    <amed:PortionOfPatientAccountsReceivableDerivedFromMedicare
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTUxMTY_7102a0fc-fe7c-4297-a960-bb29718f45ca"
      unitRef="number">0.64</amed:PortionOfPatientAccountsReceivableDerivedFromMedicare>
    <amed:PortionOfPatientAccountsReceivableDerivedFromMedicare
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTUxMjM_03f052f5-5dae-483e-8604-6458b23eb438"
      unitRef="number">0.58</amed:PortionOfPatientAccountsReceivableDerivedFromMedicare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTUyNTA_3fd25981-0350-4592-bb41-1aaceed2f160"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTU4Njc_741493ff-6de1-4c50-a6af-f58046d797aa"
      unitRef="number">0.20</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare>
    <amed:MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTYzMDQ_2c47db8b-cfe7-4d40-9830-df2d5216f499"
      unitRef="day">90</amed:MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare>
    <amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTYzNDY_c040d2e4-33be-48bf-ac1e-ee8dcfc25699"
      unitRef="day">60</amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MTc_a0074009-c32f-4e77-a9dc-a101bb6b511d">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#x2019;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the extent or manner in which the long-lived asset group is being used.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the business climate that could affect the value of the long-lived asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the market value of the assets included in the asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide for depreciation over the following estimated useful service lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our property and equipment for 2020 and 2019 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for 2020, 2019 and 2018 was $12.1 million, $11.6 million and $10.8 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4Mzk_d73b96a5-b4f2-4460-ae0d-74dac7fb47b0">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide for depreciation over the following estimated useful service lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id56f149b375540d6ac65813b85c223fc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfMS0xLTEtMS0w_ed7fae2e-bb8f-4a01-9312-f2ded0d2c212">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i9d302a79021b4c4cbaf66726ebe127e1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfMi0xLTEtMS0w_90835457-ef73-467f-aa2e-05508be252c7">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i203914f8db684c668d2c7dac204ca2c6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfMy0xLTEtMS0wL3RleHRyZWdpb246NTU2ZjM1NGMwZjJmNDBlYmE1MWFhYWZkZTE1NDBhODlfMTA5OTUxMTYyNzc4Nw_eb06ba6a-00f4-4e37-8c02-f99d4e055eef">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i640213bfd2f74b9a8e1dde58507eabc6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfMy0xLTEtMS0wL3RleHRyZWdpb246NTU2ZjM1NGMwZjJmNDBlYmE1MWFhYWZkZTE1NDBhODlfMTA5OTUxMTYyNzc5MQ_077d2e4d-b626-44ab-b010-b800dadb903a">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibb00a1b56bb044c7ab5db9f625aec705_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfNC0xLTEtMS0w_09f5ff3f-b137-481e-b29a-931f76824c8f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib5e3297361534d9ebafe84913d07eb73_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfNS0xLTEtMS0wL3RleHRyZWdpb246NzA1MTlhMTkwOGQyNDYxOGFmNjEzMjM4ODAwMzJkNmRfMTA5OTUxMTYyNzc4Nw_847cb6b9-d9b2-4a20-8547-e94aeebc547c">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie624c24d63be42a88573abdf69aae516_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfNS0xLTEtMS0wL3RleHRyZWdpb246NzA1MTlhMTkwOGQyNDYxOGFmNjEzMjM4ODAwMzJkNmRfMTA5OTUxMTYyNzc5MA_d4d2fa20-51be-4dae-b3cb-87d3e9256f8e">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i99cc7fb2614e43a78496b7db077072c9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjY3MTI3ZTM5Yjc5MTRiNTE5Nzc5YjY0Y2U1MTAzYjU2L3RhYmxlcmFuZ2U6NjcxMjdlMzliNzkxNGI1MTk3NzliNjRjZTUxMDNiNTZfNi0xLTEtMS0w_06f801ff-ba4c-41d1-8e05-5941d2f29f6b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MjQ_84f1b86f-9f4f-4576-a080-87f5ab8f32bf">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our property and equipment for 2020 and 2019 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Building and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9bde4b17d3e64e889a2b995dc1b96e0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfMi0xLTEtMS0w_652a99f8-6046-4e9d-85bb-233268fe36b1"
      unitRef="usd">9000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i33563aeb6c734c9b8f2b02515df00ee4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfMi0zLTEtMS0w_7086f4f7-1e22-4c3a-9124-9e1dd348d5ce"
      unitRef="usd">8700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibbdd825dcd9b4a34a7e7ee40b29823ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfMy0xLTEtMS0w_1142f5b8-8030-40bf-9806-55e2b8e7e7b9"
      unitRef="usd">53100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8a14cc7e58784bbabd79f9688f678767_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfMy0zLTEtMS0w_4f524be9-ecea-4bcf-9c66-0af553b7130e"
      unitRef="usd">55600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idcdf59b18c044a0586a45d15dd0cc388_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNC0xLTEtMS0w_d3828d72-b3e7-488e-abe1-8d0d145155de"
      unitRef="usd">5900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i89ef5f5295c143c4814a9cc4b7e9a2aa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNC0zLTEtMS0w_a30ece44-b231-4869-94bd-7fc64e0d9ecf"
      unitRef="usd">5200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id32eea10fdea44f8b804df035c1d9f9d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNS0xLTEtMS0w_02477846-28f8-4f45-9bb6-b3ca2e3cafca"
      unitRef="usd">50700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0a0c5250e66540da9c9ee41bb6cc2a6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNS0zLTEtMS0w_0f886c0a-d0b5-487c-93a5-8bef6b32789b"
      unitRef="usd">54700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNi0xLTEtMS0w_5560053f-5de3-44fc-96a3-ec0bc57b7f64"
      unitRef="usd">118700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNi0zLTEtMS0w_0f182591-8711-488c-9a4e-21fa42d9160a"
      unitRef="usd">124200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNy0xLTEtMS0w_c5283aac-da8e-45cd-8f80-32a64df015f6"
      unitRef="usd">95000000.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfNy0zLTEtMS0w_f509e157-59ff-4034-b59f-3e74b883a4c5"
      unitRef="usd">96100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfOC0xLTEtMS0w_9024bc05-7edd-4bfb-8141-74ad75280b36"
      unitRef="usd">23700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjVlYzY1MTQ1OTE2NjQ3MzA4YWRmOTAzNzQ2YjA0ODQxL3RhYmxlcmFuZ2U6NWVjNjUxNDU5MTY2NDczMDhhZGY5MDM3NDZiMDQ4NDFfOC0zLTEtMS0w_1eed365a-d4c1-45b7-abe5-d8e82c2a3f11"
      unitRef="usd">28100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTk3NjU_429776ce-4f87-4301-a92d-6c788c26055b"
      unitRef="usd">12100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTk3Njk_b6b5c353-c6bd-4f3c-9607-6c6ece4161dc"
      unitRef="usd">11600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTk3NzY_5b26afe0-6a2e-4e5a-b1a5-e128ec38191f"
      unitRef="usd">10800000</us-gaap:Depreciation>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2OTk5Mg_98f71342-ea32-4c69-bb9e-aedcdf5e18ba">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth and discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NTc_721364bd-f108-403e-9d25-fcc7f1af37b8">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of our operating segments described in Note 14 &#x2013; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and have also deemed each of them to be a single reporting unit.&lt;/span&gt;&lt;/div&gt;During 2020, we performed a qualitative assessment to determine if it is more likely than not that the fair value of the reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we did not record any goodwill impairment charges and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October&#160;31, 2020. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.Intangible assets consist of certificates of need, licenses, acquired names and non-compete agreements. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxNg_2ef6bf16-13c0-4b4a-ac9d-18652113e2f9"&gt;two&lt;/span&gt; to three years for non-compete agreements and up to three years for acquired names. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iaf4b84d294244f4783317a7222e4e879_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjIzODE_c0a7946d-172f-4735-b2e2-b5f1136a54e3">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id9c91ba472944f99a6daf60ac242bcb6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjI0MjE_edeb8b28-dde6-45f9-9bfa-65be83b61bbe">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i8a9e61c64a324dccb0426c5ca15ad0fd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NzY5Ng_eddbfe88-a000-4341-98e7-f655afd1f3a0"
      unitRef="usd">4200000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iab41181582e84ce6a158eb40d3e43022_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjI4Njc_833d225c-4562-4e6e-8d0f-ca39bed6bdd4"
      unitRef="usd">1500000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <amed:DebtIssuanceCostsPolicyPolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MDk_918edb97-b538-446a-b7de-16a4009ced78">Debt Issuance CostsDuring 2019, we recorded $0.8 million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 8 - Long-Term Obligations). As of December&#160;31, 2020 and 2019, we had unamortized debt issuance costs of $2.7 million and $3.5 million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed.</amed:DebtIssuanceCostsPolicyPolicyTextBlock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjMyNjU_6de76e6e-7efa-4533-855e-76bd5c0a962b"
      unitRef="usd">800000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjM1NTc_992f088f-0753-4c46-be9c-efea74f39da7"
      unitRef="usd">2700000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2NjY2Ng_1035579c-639b-4f5d-93f8-5b1ff94255b8"
      unitRef="usd">3500000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjM5NDk_f567adad-7d6d-4ff9-bc70-b567cd1ddd45"
      unitRef="usd">2700000</us-gaap:UnamortizedDebtIssuanceExpense>
    <amed:UnamortizedDebtIssuanceCostAmortizationPeriod
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjQwMjM_307f5a6c-4344-4205-b0b0-ca74d3d2a801">P3Y1M6D</amed:UnamortizedDebtIssuanceCostAmortizationPeriod>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NzI_433c5d6d-7db7-4274-95ac-09bd9f5c3b8e">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amed:FinancialInstrumentDetailsTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcwOQ_2bd7b811-9260-47ff-b394-c3cda51cf5cc">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTableTextBlock>
    <amed:DebtInstrumentCarryingAmountExcludingFinanceLeases
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjQ4OTJlOTMyYjc1YzQ1NWViNzkyYmM3ZTA0MjJmNTVkL3RhYmxlcmFuZ2U6NDg5MmU5MzJiNzVjNDU1ZWI3OTJiYzdlMDQyMmY1NWRfMi0xLTEtMS0w_b1a6f057-9145-454f-921e-00fbb589730b"
      unitRef="usd">215100000</amed:DebtInstrumentCarryingAmountExcludingFinanceLeases>
    <us-gaap:LongTermDebtFairValue
      contextRef="id0822cae609e455f8dabd64cd55ce112_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjQ4OTJlOTMyYjc1YzQ1NWViNzkyYmM3ZTA0MjJmNTVkL3RhYmxlcmFuZ2U6NDg5MmU5MzJiNzVjNDU1ZWI3OTJiYzdlMDQyMmY1NWRfMi0zLTEtMS0w_73b035c0-c1cc-4209-8583-35f25c5de3bc"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="icaceabeac78a43fa8dcdac6a349b0ed0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjQ4OTJlOTMyYjc1YzQ1NWViNzkyYmM3ZTA0MjJmNTVkL3RhYmxlcmFuZ2U6NDg5MmU5MzJiNzVjNDU1ZWI3OTJiYzdlMDQyMmY1NWRfMi01LTEtMS0w_8944ba8e-48a7-498c-be83-9e44a62ab55e"
      unitRef="usd">217700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7a7919ceb133453abee391bfba5d166c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjQ4OTJlOTMyYjc1YzQ1NWViNzkyYmM3ZTA0MjJmNTVkL3RhYmxlcmFuZ2U6NDg5MmU5MzJiNzVjNDU1ZWI3OTJiYzdlMDQyMmY1NWRfMi03LTEtMS0w_aa128a58-a9ab-4fbb-85ca-c21fdfbb6a39"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MjA_a77f6d58-f0ea-44ff-af7f-fa5dede90284">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2020 and 2019, our net deferred tax assets were $48.0 million and $21.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#x2019;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#x2019;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjU5NjQ_86440867-be7b-4687-8c1e-3f552d710d34"
      unitRef="usd">48000000.0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjU5NzE_40e1a277-36c7-412b-8c07-21ff3c98b9f2"
      unitRef="usd">21400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4NDI_d3bef262-73c7-40b2-9c46-b9fb6cca2dfa">Share-Based CompensationWe record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensation
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcwNTI_65b95029-6e79-4ce8-aa28-11261736be9c"
      unitRef="usd">26700000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcwNTY_128fcded-8b0f-4366-89ee-73de11349c19"
      unitRef="usd">25000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcwNjM_7cd7e965-26e0-420a-b36f-457f2d856bee"
      unitRef="usd">17900000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcxNDg_322e9af8-acc3-4dca-9b04-195fa64178ad"
      unitRef="usd">4700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcxNTI_b630479f-8cbd-45ff-acf4-51c905e30c55"
      unitRef="usd">4600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjcxNTk_99abd9ea-7506-4ab5-ac1e-1c04c03e92b6"
      unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MTI_e21cdda4-6b22-4638-84f7-fa9657c977e2">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4Mjg_efde11d5-c2d2-4248-8b25-59e0fa08bd2c">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfMi0xLTEtMS0w_e92e5d8b-bb29-4aa0-a5a8-a6da7f3f0832"
      unitRef="shares">32559000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfMi0zLTEtMS0w_b7af6c2d-fbef-4488-bdb8-98719f394fd4"
      unitRef="shares">32142000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfMi01LTEtMS0w_946dd893-43ea-4c48-a7cd-28927d23dc24"
      unitRef="shares">32791000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNC0xLTEtMS0w_9cbc3c1c-64ee-4ff5-bac8-04314d030be4"
      unitRef="shares">420000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNC0zLTEtMS0w_aedd51c3-05f3-4114-b4aa-e42a3509eb25"
      unitRef="shares">545000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNC01LTEtMS0w_f35876d8-b135-423c-a5e7-2df1f45bb0a8"
      unitRef="shares">502000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <amed:NonVestedStockAndStockUnits
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNS0xLTEtMS0w_fb7c6d2f-2d2a-4ca8-bf28-eb03219a20f4"
      unitRef="shares">289000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNS0zLTEtMS0w_c3837900-5615-4cca-964c-7af7ba9d93d2"
      unitRef="shares">303000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNS01LTEtMS0w_fbcaf209-8eb7-49ce-aa83-4eab9e20f374"
      unitRef="shares">316000</amed:NonVestedStockAndStockUnits>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNi0xLTEtMS0w_b80cce68-a5f1-4475-9cd4-1facb48be4e7"
      unitRef="shares">33268000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNi0zLTEtMS0w_5d843c6e-8066-48c7-ab8b-0265ace09023"
      unitRef="shares">32990000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNi01LTEtMS0w_f5484076-2046-46f6-b1dc-a3e4981be3d7"
      unitRef="shares">33609000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNy0xLTEtMS0w_7a15f30c-100c-42ab-b0aa-6034d6a05763"
      unitRef="shares">25000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNy0zLTEtMS0w_6c962031-611c-4630-b7b3-a805ce7eb949"
      unitRef="shares">117000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RhYmxlOjI5NTk3ODc5Mzc1ZDQ1MGViMzc1ZDg1ZTcxZDE3NmZhL3RhYmxlcmFuZ2U6Mjk1OTc4NzkzNzVkNDUwZWIzNzVkODVlNzFkMTc2ZmFfNy01LTEtMS0w_d187a644-4f36-4ca0-9bcc-1581122bdf14"
      unitRef="shares">50000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc4MDc_14b1c253-c997-4d93-a317-7e02267a4d5e">Advertising CostsWe expense advertising costs as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc3Nzg_85a96ffb-7a56-4709-9a99-a858bc45660e"
      unitRef="usd">8000000.0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc3ODI_37a9264c-c156-4496-b9d9-22b1ee5c4d65"
      unitRef="usd">8500000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMjc3ODk_bc5c64ab-16af-45d3-a28b-c2e498011bba"
      unitRef="usd">7000000.0</us-gaap:AdvertisingExpense>
    <amed:COVID19TextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjM1Mzky_f8340037-704d-427b-88b1-23673894d997">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provides for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we are allowed to use the funds to cover lost revenues and health care costs related to COVID-19, and we are required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our wholly-owned subsidiaries, we have decided to only utilize PRF funds to the extent we have qualifying COVID-19 expenses, which totaled $33&#160;million for our home health and hospice segments during the year ended December 31, 2020. Accordingly, for our wholly-owned subsidiaries, we will not be using PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred to date is reflected in other operating income within our consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HHS issued new guidance in September 2020 noting that PRF funds can be used towards lost revenues or expenses attributable to COVID-19 through June 30, 2021. We do not believe that we will fully utilize the funds received; therefore, we recorded a liability related to the funds that we do not expect to utilize totaling $60&#160;million which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. Funds that we intend to use in the future to cover COVID-19 expenses, which we have estimated to be approximately $12&#160;million, have been recorded to a deferred liability account within accrued expenses in our consolidated balance sheet. These estimates may change as our ability to utilize and retain the funds will depend on the magnitude, timing and nature of the impact of the pandemic. In summary, the total funds that we have received from the CARES Act PRF as of December 31, 2020 consist of the following (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized during the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated funds to be utilized January 2021 through June 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated funds to be repaid to the government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds received by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 24, 2020, HHS distributed an additional $18&#160;billion in funds to healthcare providers. We did not receive, nor apply, for any additional funds from this second distribution. On October 1, 2020, HHS announced $20&#160;billion in new funding to healthcare providers under the Phase 3 general distribution. We did not apply for any additional funds from this distribution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act also provides for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period May 1 through December 31, 2020 and the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, we have deferred $55&#160;million of social security taxes; approximately $28&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021.&lt;/span&gt;&lt;/div&gt;Our personal care segment did not receive funds under the CARES Act; however, they did receive funds from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which are intended to cover costs related to the public health emergency. The grant income associated with the funds received, which totaled $1&#160;million during the year ended December 31, 2020, is reflected in other operating income within our consolidated statement of operations.</amed:COVID19TextBlock>
    <amed:FundingForHealthcareProvidersIncludingHospitals
      contextRef="i6001d3911d55430a8c080827cb5bcaff_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNTUz_df8c6ffb-42f1-4581-bf69-dccb21f50de7"
      unitRef="usd">175000000000</amed:FundingForHealthcareProvidersIncludingHospitals>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i6001d3911d55430a8c080827cb5bcaff_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNTY3_563db3ff-1cde-4e24-af82-e68bff8d0f21"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i372268bd3773442994730e4fe0e5ee44_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNTgw_3cd90120-120d-4e4e-8df6-5316a95a896f"
      unitRef="usd">100000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i6001d3911d55430a8c080827cb5bcaff_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjE4_f82cbefa-6dc8-4693-bee0-4e5bf69518b5"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="ibfa49fd6f4b049c4852349a3f959f964_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNTk0_555ee596-2ad0-417d-b083-9e3c08857a6f"
      unitRef="usd">2000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingReceivedFromCARESAct
      contextRef="i37e4a08657594a9e8a1641435acac59f_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjA2_f6f22fa0-8824-4dab-87f7-e47a8e126d8c"
      unitRef="usd">6000000</amed:FundingReceivedFromCARESAct>
    <amed:COVID19ExpensesIncurred
      contextRef="i6b9d23dde21e42c9a907136f7eeaf5e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjMx_62189822-2b2c-462d-a5eb-df1ee7f33427"
      unitRef="usd">33000000</amed:COVID19ExpensesIncurred>
    <amed:ProviderReliefFundAdvance
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjU3_f7458c5f-69c1-4ff1-9397-694d0bb88a79"
      unitRef="usd">60000000</amed:ProviderReliefFundAdvance>
    <amed:EstimatedFutureCOVID19RelatedExpenses
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjcw_484faf4a-1777-408a-b0d8-b305d8a3e3bd"
      unitRef="usd">12000000</amed:EstimatedFutureCOVID19RelatedExpenses>
    <amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjM1Mzkz_d0f044ce-ec55-47ec-accb-701ed913a6bf">In summary, the total funds that we have received from the CARES Act PRF as of December 31, 2020 consist of the following (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized during the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated funds to be utilized January 2021 through June 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated funds to be repaid to the government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds received by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock>
    <amed:CARESActProviderReliefFundsUtilized
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV8xLTEtMS0xLTYxMTU_18cb3af6-2094-4503-8f54-2094c038cfcb"
      unitRef="usd">33300000</amed:CARESActProviderReliefFundsUtilized>
    <amed:EstimatedCARESActProviderReliefFundsExpectedToBeUtilized
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV8yLTEtMS0xLTYxMTg_36110b0e-e1e5-43e6-8cd7-73bd6160fab1"
      unitRef="usd">11600000</amed:EstimatedCARESActProviderReliefFundsExpectedToBeUtilized>
    <amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV8zLTEtMS0xLTYxMjA_04eb37bb-a7d0-4fbf-87b8-e134d6a78072"
      unitRef="usd">60000000.0</amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid>
    <amed:CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV80LTEtMS0xLTYxMjI_ad84a275-c074-4b5f-8496-ccded581927f"
      unitRef="usd">1900000</amed:CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures>
    <amed:TotalCARESActProviderReliefFundsReceived
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGFibGU6Nzc4ZDZjMWFkNzRhNDE5NmFkOWQ2ZjUxMDgxZjg4YWEvdGFibGVyYW5nZTo3NzhkNmMxYWQ3NGE0MTk2YWQ5ZDZmNTEwODFmODhhYV81LTEtMS0xLTYxMjQ_f416c0a1-6ccf-442d-800c-55291bdff2ed"
      unitRef="usd">106800000</amed:TotalCARESActProviderReliefFundsReceived>
    <amed:AdditionalFundingDistributedToHealthcareProviders
      contextRef="i118a662ab55141c19f9cdf727c8817fe_I20200424"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjgz_1f6a7615-f6c6-451b-9f06-7c39d971f794"
      unitRef="usd">18000000000</amed:AdditionalFundingDistributedToHealthcareProviders>
    <amed:AdditionalFundingDistributedToHealthcareProviders
      contextRef="i6134feb4f36f4032ba67f2372de0d569_I20201001"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNjk2_c8d54a82-8951-45af-b882-3f20e3986ccb"
      unitRef="usd">20000000000</amed:AdditionalFundingDistributedToHealthcareProviders>
    <amed:CARESActDeferralOfEmployerShareSocialSecurityTax
      contextRef="ie67bc19fa2814c5abd3ff91ce96f6e90_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNzA5_f2f2c341-e41f-4a5c-9dbb-85b83858c471"
      unitRef="usd">55000000</amed:CARESActDeferralOfEmployerShareSocialSecurityTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie67bc19fa2814c5abd3ff91ce96f6e90_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjM1Mzk1_50e86d34-4b4f-4bd4-a5d7-7ff711b80c8f"
      unitRef="usd">28000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie67bc19fa2814c5abd3ff91ce96f6e90_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjM1Mzk1_b6610127-3dee-4340-8634-601971bdc6c8"
      unitRef="usd">28000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherOperatingIncome
      contextRef="ic433fb8ffa524d98b4462b2bfdb4ca4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNzI0_39330879-d049-41ed-aa48-9836aa23b5b2"
      unitRef="usd">1000000</us-gaap:OtherOperatingIncome>
    <amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram
      contextRef="ic433fb8ffa524d98b4462b2bfdb4ca4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNzQwL2ZyYWc6ODIxNzIwZmUwOTBhNGZjYWEzMzE1MTM1NDRmYmY3YjUvdGV4dHJlZ2lvbjo4MjE3MjBmZTA5MGE0ZmNhYTMzMTUxMzU0NGZiZjdiNV8xMDk5NTExNjMzNzI0_b0e575fd-0cd0-4d6b-a8aa-189c538140ce"
      unitRef="usd">1000000</amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDMyNA_430b4118-e8df-430f-b58e-bdc11b575466">ACQUISITIONSWe complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuation and liabilities assumed.&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Division&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $3.0&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $2.8&#160;million and other intangibles (certificate of need) of $0.2&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2020, we acquired the regulatory assets of a home health provider in Kentucky for a purchase price of $0.7&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $0.5&#160;million and other intangibles (certificate of need) of $0.2&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Division&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with eight locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $66.3&#160;million, net of cash acquired of $0.7&#160;million. Under the purchase agreement, the purchase price was subject to a net working capital adjustment, whereby the purchase price would be adjusted to the extent the actual net working capital of Asana as of the closing differed from the required net working capital under the purchase agreement. The net working capital adjustment, which was finalized during the three-month period ended June 30, 2020, reduced the purchase price by $0.7&#160;million, from $66.3&#160;million to $65.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has finalized its valuation of the assets acquired and liabilities assumed. The total estimated consideration of $65.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total estimated consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired include licenses ($2.0&#160;million), acquired names ($1.3&#160;million) and non-compete agreements ($2.3&#160;million). The acquired names and non-compete agreements will be amortized over a weighted-average period of 2.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asana contributed approximately $23.4&#160;million in net service revenue and an operating loss of $3.3&#160;million (inclusive of acquisition and integration costs totaling $2.0&#160;million and intangibles amortization totaling $2.6&#160;million) during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with 44 locations, for an estimated purchase price of $230.4&#160;million, net of cash acquired and inclusive of a $32&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $1.0&#160;million. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $0.8&#160;million, from $230.4&#160;million&#160;to $229.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. During the year ended December 31, 2020, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. The final valuation of the assets acquired and liabilities assumed was not complete as of December 31, 2020, but will be finalized within the allowable measurement period. Based on the Company's preliminary valuation, the total estimated consideration of $229.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total estimated consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired include licenses ($8.7&#160;million), certificates of need ($0.7&#160;million), acquired names ($5.7&#160;million) and non-compete agreements ($9.2&#160;million). The acquired names will be amortized over a weighted-average period of 2.0 years and the non-compete agreements will be amortized over a weighted-average period of 1.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AseraCare contributed approximately $64.5&#160;million in net service revenue and an operating loss of $8.2&#160;million (inclusive of acquisition and integration costs totaling $7.6&#160;million and intangibles amortization totaling $6.0&#160;million) during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2020 and 2019 assuming that the AseraCare acquisition closed on January 1, 2019 (amounts in millions, except per share data). The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.748%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,077.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Amedisys Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pro forma information presented above includes adjustments for (i) amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the AseraCare acquisition, (iii) non-recurring transaction costs and (iv) income taxes based on the Company's statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Division &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2019, we acquired Compassionate Care Hopsice ("CCH"), a national hospice care provider headquartered in New Jersey, for a purchase price of $327.9 million, net of cash acquired of $6.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has finalized its valuation of the assets acquired and liabilities assumed. The total consideration of $327.9 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total estimated consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired include licenses, certificates of need, acquired names and non-compete agreements. The acquired names and non-compete agreements will be amortized over a weighted-average period of 2.0 and 2.3 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CCH contributed approximately $167.4 million in net service revenue and an operating loss of $5.6 million (inclusive of acquisition and integration costs totaling $14.5 million) during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect $278.8 million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years&lt;br/&gt;Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,971.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Amedisys, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pro forma information presented above includes adjustments for (i)&#160;amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the CCH acquisition, (iii) non-recurring transaction costs and (iv)&#160;income taxes based on the Company&#x2019;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2019, we acquired RoseRock Healthcare ("RoseRock"), an Oklahoma based hospice provider, for a purchase price of $17.5 million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill ($15.8 million) and other intangibles including acquired names ($1.0 million) and non-compete agreements ($0.7 million). The acquired names and non-compete agreements will each be amortized over a weighted-average period of 3.0 years. RoseRock contributed approximately $6.8 million in net service revenue and $0.8 million in operating income for the year ended December 31, 2019. We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id9cafc4be2f5437d9ca0b72a01385735_D20200301-20200301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0Mjk4NA_ed5c5fa5-a984-45fb-bb91-e28e5df92708"
      unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i027e9e9fdcb3465e9e2a8e7763db61d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0Mjk5OA_672cd652-fe4f-4db7-b6e4-442aa54b83ce"
      unitRef="usd">2800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ibcad9ea4bad644b7aef096a89d73a367_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzAxMg_af26863c-9ff1-40c2-b0fe-a8781fe24040"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i2c82b6aabd174ab7b9b1bbd04c0e4f43_D20200418-20200418"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzAyNg_e3541a73-2057-486c-9d4e-9743dd512906"
      unitRef="usd">700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id6b5bde6cd03496eb965aaa99d46b4e1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA0MA_67eed7d6-bafe-4537-ad70-46c2463c8987"
      unitRef="usd">500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8af9f0752744492d80892b57fe0eb43f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA1NA_1e94b377-2d31-474f-8851-cbb542c906ff"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDM0NA_5f46b078-34df-4e29-a890-a4d87c2064f6"
      unitRef="care_center">8</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA2OA_727f834f-fec4-4f98-956c-83e70017aefb"
      unitRef="usd">66300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA4Mw_229ce4cf-35d4-455f-b5fa-1453e94eb8eb"
      unitRef="usd">700000</us-gaap:CashAcquiredFromAcquisition>
    <amed:BusinessAcquisitionWorkingCapitalAdjustment
      contextRef="i736c6f864f0c4f2f90cb716d504ad728_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzEyNw_ad092eb1-1918-432e-921e-253238483f70"
      unitRef="usd">700000</amed:BusinessAcquisitionWorkingCapitalAdjustment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzExMg_2948f57d-3aec-4f06-9ba4-07d19025567b"
      unitRef="usd">66300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzA5Nw_278f1e59-218e-4c4c-bea7-c31b503902a5"
      unitRef="usd">65600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <amed:ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI3OQ_156460af-d6de-4c83-a5ef-0cfab4849dcd">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has finalized its valuation of the assets acquired and liabilities assumed. The total estimated consideration of $65.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total estimated consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMS0xLTEtMS02NDM2_ee88b9fe-bf45-465b-a6e2-6b2e06037b96"
      unitRef="usd">4600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMi0xLTEtMS02NDM4_0a687a8b-8ac7-413b-a5af-4283f60e9ca5"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMy0xLTEtMS02NDQw_a5cdafdb-eb2f-4cb8-a972-737f1957f2d5"
      unitRef="usd">900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfNC0xLTEtMS02NDU3_4bea0f57-117d-4069-87db-e0698f53d771"
      unitRef="usd">5600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfNS0xLTEtMS02NDU5_e09c7ad5-7b1e-4714-b5e8-f204b6471c40"
      unitRef="usd">11300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfNi0xLTEtMS02NDYy_f3c40c8a-a3b5-4525-b288-abe8d71cd309"
      unitRef="usd">3200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfNy0xLTEtMS02NDY0_3ce4f452-ef7b-4a70-bde5-6e668d93c1d2"
      unitRef="usd">1500000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfOC0xLTEtMS02NDY2_7aeeaafc-0dc1-436f-9358-e9c328f369dd"
      unitRef="usd">500000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfOS0xLTEtMS02NDY4_eafcae65-a6a0-4616-84fe-5527ffa487ae"
      unitRef="usd">900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMTAtMS0xLTEtNjQ3NA_43394df3-82d6-4e9f-8d82-c39500694478"
      unitRef="usd">6100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMTEtMS0xLTEtNjQ3Ng_3c9b194c-365a-4dd6-ad9a-7386268c81de"
      unitRef="usd">5200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMTItMS0xLTEtNjQ3OA_cedabf65-f827-4229-847e-e0a73df5f21d"
      unitRef="usd">60400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i28272584e8864b6eac538308aa55f7f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOmFmN2U0NjczNDM5MTQ4MjFiZTVmZWNlOTg1OWZmODdkL3RhYmxlcmFuZ2U6YWY3ZTQ2NzM0MzkxNDgyMWJlNWZlY2U5ODU5ZmY4N2RfMTMtMS0xLTEtNjQzMg_47aec421-eed2-4c40-bff7-3ca8c9c90c12"
      unitRef="usd">65600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iefb68536b309420b86b96f71d3be7002_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzE1Ng_cd7e46e3-fe9e-4f30-a006-8e1aedcc2888"
      unitRef="usd">2000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4071912f29b1471a90316176f150bae0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzE3MA_4563304f-d77c-4da6-8596-37acfabb8b45"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="iac1ab93fa9c14e638c003d6efff17ec7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzE4NA_42ea746f-48de-4fb5-8852-49fc8b38d659"
      unitRef="usd">2300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i45609ba2476e4e52aa2321ed4c22caa4_D20200101-20200101"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzIwMg_7c470c3d-3fde-4abe-a161-1ae7985fc8e7">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib9861da3d84840e5b7b2f004402be77c_D20200101-20200101"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzIwMg_c71af1dc-f341-4b8e-bee7-89f38e8f071d">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzIyOA_66735b2b-8f97-4099-8d2e-4d4965ec0de2"
      unitRef="usd">23400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzI0Mg_5b5383c4-95f2-4ab1-ae4b-5c4b5df25cd3"
      unitRef="usd">2000000.0</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="idfb88ea78c4b42fcb70a9e117f41c8b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzI1Ng_bc586718-1de7-4e6a-b6dc-7b30e77c9747"
      unitRef="usd">2600000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i6511ef347af14b75b3b9c9a4fad441a2_D20200101-20200101"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI5OQ_b4250f09-feda-405a-a967-52eb6d28c251">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzI4NA_f54142f4-1c12-4803-881d-ed3f81c49cad"
      unitRef="care_center">44</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzI4OA_2ce8600f-0a93-411e-9b09-79dc6d33e69d"
      unitRef="usd">230400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amed:PaymentsRelatedToTaxAsset
      contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzMwNA_fa608c57-7b6b-4f1e-a4d4-cf2f7ae8560a"
      unitRef="usd">32000000</amed:PaymentsRelatedToTaxAsset>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="ia1196979b4bd42e99e052738971c3d6d_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzMxNw_60356b3e-6982-475a-beaf-3f96f8a53345"
      unitRef="usd">1000000.0</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i3a1566846d62435ebae17d6c7c127850_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzMzMQ_b8ae7704-7577-45ed-b9fd-314b7f1729f7"
      unitRef="usd">800000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzM0NQ_e4c19a81-0998-4d88-ae63-d6d2447e5206"
      unitRef="usd">230400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzM2MQ_9f28d038-6368-4125-9fdf-984e7b20d92e"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <amed:ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI4MA_eebb6f4d-8b4b-44a8-9144-7db9cec56bae">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. During the year ended December 31, 2020, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. The final valuation of the assets acquired and liabilities assumed was not complete as of December 31, 2020, but will be finalized within the allowable measurement period. Based on the Company's preliminary valuation, the total estimated consideration of $229.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total estimated consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzM3Nw_ba51408d-f43f-43b9-bcac-ef6293f45633"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMS0xLTEtMS02NTQ1_f5358027-4ea1-4dc7-bfae-f817109fb539"
      unitRef="usd">15000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMi0xLTEtMS02NTY5_1d7d3535-648a-4ed7-b395-c8baf0a4959a"
      unitRef="usd">700000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMy0xLTEtMS02NTQ3_dbab4a26-31da-49e3-b378-b9a1b13af998"
      unitRef="usd">600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfNC0xLTEtMS02NTQ5_177d7b96-7b14-42e9-b296-74c2a1c92d13"
      unitRef="usd">5900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfNS0xLTEtMS02NTUx_45730ba9-9589-4ec0-9744-6885887c7d81"
      unitRef="usd">24300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfNi0xLTEtMS02NTcx_dbc9df35-ab19-479e-b82f-c4ac43daed03"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfNy0xLTEtMS02NTUz_fd86df4a-fdd9-4f1a-9134-9a4011a7f321"
      unitRef="usd">46600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfOC0xLTEtMS02NTU1_1c195320-4ccf-4c52-95d6-112fd21ff766"
      unitRef="usd">5800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfOS0xLTEtMS02NTU3_97bf14a4-b7e3-4f41-96ac-5710881f4afa"
      unitRef="usd">5900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTAtMS0xLTEtNjU1OQ_ae2fa6b0-25dc-4629-8aa8-d074fb214430"
      unitRef="usd">10400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTEtMS0xLTEtNjU2MQ_4c14eb03-86fb-408f-9f20-60891b1be40a"
      unitRef="usd">5400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTItMS0xLTEtNjU2Mw_f0f1ae34-6912-4b58-bc75-84f6245fa6d3"
      unitRef="usd">27500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTMtMS0xLTEtNjU2NQ_5f8c4266-c03a-4760-bb54-b183c192caea"
      unitRef="usd">19100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTQtMS0xLTEtNjU2Nw_0ab4feea-9a4c-4c73-86ed-8351ab769443"
      unitRef="usd">210500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ia7182413ea774295b30d183d04b1cabd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjYyZjJjYWY0ZmU5ZjQyZTQ5ODlmMmFlYTZiOWRhN2UwL3RhYmxlcmFuZ2U6NjJmMmNhZjRmZTlmNDJlNDk4OWYyYWVhNmI5ZGE3ZTBfMTUtMS0xLTEtNjUwMQ_3ff51440-ed04-4b82-b392-21a694901a18"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i6dade9dfe7084bfbadf9e3614bbe33ae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzM5Mw_83c04c09-c9f2-4f46-b947-5357a5b7e0ea"
      unitRef="usd">8700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i5f1af67560f042a28a10f654e58775f2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDQ5NA_fa5c072f-0e6b-444d-b034-40c8bbbe1962"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i5098d5c55d8b4b1dbeee2d1d43a9b870_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQwNw_aa9c0943-8ae6-46d0-b1d2-f8a0907e0891"
      unitRef="usd">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ia6dbc8b680ea432483b0218a761a9ee4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQyMQ_103b9c77-dbf4-47bb-a531-4e1a9ae908b0"
      unitRef="usd">9200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id50e918f9fa742aea3517c666077cbc2_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQzNw_8a6aef4a-abdb-46d8-8d82-294d4d74d2e6">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4caa862c918a45e6bc9f8e6f842d75f0_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQ1OQ_291dccea-3e58-4474-b06f-ed6ba459135a">P1Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzQ3OQ_524b08a9-4a1a-4c64-a16f-df38df49fac6"
      unitRef="usd">64500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzUyMg_abb5e0a9-2f28-48c0-ab98-f59edbcf6409"
      unitRef="usd">7600000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0MzUwOA_8e6b1d09-4576-4279-9108-0c08ab67bb69"
      unitRef="usd">6000000.0</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i7fdfab940e394753aa8fd715d167990e_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDMxOA_86e927fc-12e5-46f4-925a-e3bbf43b817b">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <amed:BusinessAcquisitionProFormaInformationAseraCareTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI4MQ_26cbe549-da8a-4d6d-8f53-029877db98f8">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2020 and 2019 assuming that the AseraCare acquisition closed on January 1, 2019 (amounts in millions, except per share data). The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.748%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,077.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Amedisys Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:BusinessAcquisitionProFormaInformationAseraCareTableTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfMi0xLTEtMS02NTg4_3531af40-075d-4007-89a3-a975cce3f4cd"
      unitRef="usd">2120100000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfMi0zLTEtMS02NjEy_001f250d-b198-405c-b887-9fd080c45040"
      unitRef="usd">2077000000.0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <amed:BusinessAcquisitionProFormaOperatingIncomeLoss
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfMy0xLTEtMS02NTkx_901160e9-c7b0-41d0-9876-990430d25af5"
      unitRef="usd">218000000.0</amed:BusinessAcquisitionProFormaOperatingIncomeLoss>
    <amed:BusinessAcquisitionProFormaOperatingIncomeLoss
      contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfMy0zLTEtMS02NjEy_7f5d0505-1be3-41ea-b0ff-5154169139a5"
      unitRef="usd">167500000</amed:BusinessAcquisitionProFormaOperatingIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNC0xLTEtMS02NTkz_5e7f00ee-110b-4e0c-9785-d49ec60f6481"
      unitRef="usd">180600000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNC0zLTEtMS02NjEy_c6d9da47-86d8-4e7e-bffe-d5212e3cbfc0"
      unitRef="usd">112300000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNS0xLTEtMS02NTk1_44688918-9cfb-44ef-a466-17064d0e359a"
      unitRef="usdPerShare">5.55</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNS0zLTEtMS02NjEy_1c2415bd-30e2-4ae2-93de-03127201a5fc"
      unitRef="usdPerShare">3.49</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNi0xLTEtMS02NTk1_557bbb85-6456-4b70-8faa-77ee2d4f139a"
      unitRef="usdPerShare">5.43</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i7cbf70654c0e42faa3b45c1fb3d4d0f3_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjM3ZjdjYzcyZTBlYTQxYjc5NWE0YzA4ZmVkOTA5OWVhL3RhYmxlcmFuZ2U6MzdmN2NjNzJlMGVhNDFiNzk1YTRjMDhmZWQ5MDk5ZWFfNi0zLTEtMS02NjEy_b2d6852b-4ea6-402f-bdaa-985ef05ed847"
      unitRef="usdPerShare">3.40</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTM4NQ_6532eadc-7fff-4d89-b4a7-552839f120f1"
      unitRef="usd">327900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTQxMw_3f93fcb1-24e9-44b3-9dd3-4f8c5c0b33c7"
      unitRef="usd">6700000</us-gaap:CashAcquiredFromAcquisition>
    <amed:ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDI4Mg_03b2cbdc-142a-40ec-99cd-65480beecbd5">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has finalized its valuation of the assets acquired and liabilities assumed. The total consideration of $327.9 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total estimated consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTUzMg_d961929b-44ec-4d2f-87fd-477094e4518b"
      unitRef="usd">327900000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMS0xLTEtMS0w_c088112b-3274-4cf2-b524-403eadf8900b"
      unitRef="usd">24500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMi0xLTEtMS0w_2439b264-defb-48cd-9dfb-289fbd2ac645"
      unitRef="usd">800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMy0xLTEtMS0w_c421f1cb-e13d-48fb-a52a-56b5c3b4ab2a"
      unitRef="usd">100000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfNC0xLTEtMS0w_dc69cd73-2f3d-4ac1-8e29-35a0bddc8cb9"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfNS0xLTEtMS0w_a52349a9-51b8-4957-a200-45b8f0f57ede"
      unitRef="usd">27200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfNi0xLTEtMS0w_fc5cfdb1-45c0-4eb3-9b61-0f614f4cc05b"
      unitRef="usd">3400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfNy0xLTEtMS0w_827e9b59-21b4-412f-ba80-152e442c2e71"
      unitRef="usd">1100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfOC0xLTEtMS0w_5d47ecb2-3440-4574-97c6-a1585bedcbb7"
      unitRef="usd">57300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfOS0xLTEtMS0w_d8b90ee1-bfce-417e-97a5-da0a9eb319cf"
      unitRef="usd">14900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTAtMS0xLTEtMA_154f5151-afe3-48f3-bbbe-4ecbf195c472"
      unitRef="usd">11700000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTEtMS0xLTEtMA_7d48b993-534b-4d70-a910-6f26b97df103"
      unitRef="usd">11700000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTItMS0xLTEtMA_e32292c7-4427-4c94-9705-00e3fffe36b5"
      unitRef="usd">900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTMtMS0xLTEtMA_75891442-f346-49aa-9f3c-b359a513a636"
      unitRef="usd">3400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTQtMS0xLTEtMA_c63aa598-d815-4bb4-be14-4b73b43b27b8"
      unitRef="usd">42600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTUtMS0xLTEtMA_1e5ef673-d596-4feb-af40-bc8ff0385a8f"
      unitRef="usd">14700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTYtMS0xLTEtMA_5f03e711-2c11-48cc-8ead-fc9bc8c8b5d6"
      unitRef="usd">313200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjZlZjk1ZmQwMmMyNDQ4OTBhNjk1MTM5ZmM1ZjQwZTFjL3RhYmxlcmFuZ2U6NmVmOTVmZDAyYzI0NDg5MGE2OTUxMzlmYzVmNDBlMWNfMTctMS0xLTEtMA_23c09c05-6a25-4b0b-b78a-c403e91e4893"
      unitRef="usd">327900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i539b5ad7e9ee440ba81d9f4f4069b5e8_D20190201-20190201"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTg2OA_38be1478-6b52-40eb-85a0-5312b756b597">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i000c57f033a6483d8bf707b4eb4e6f55_D20190201-20190201"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTg3NQ_9eb95fbd-99fa-4471-acb9-f008ac50d3b4">P2Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTkyOQ_19bbf9d7-bacb-49bf-beb6-572caa661b5d"
      unitRef="usd">167400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMjA0MA_85b19a95-db16-4e91-8c64-1c878160d891"
      unitRef="usd">14500000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i7f9f9514c4b747218bdb73b2a59513b4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMjA5Ng_1efc86d7-af2b-4a8b-8d80-ee4a67e1b2c3"
      unitRef="usd">278800000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i60f50b78741b4d0baab1bb940013a458_D20190201-20190201"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMjIwMQ_7bc9d6db-3dbf-4a81-94a9-877041fa5ca0">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <amed:BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMTA5OTUxMTY0NDM1NA_b4054bd5-9028-4f44-a77b-86d115c8aed5">The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years&lt;br/&gt;Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,971.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Amedisys, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfMi0xLTEtMS0w_238b851d-4fe9-4b0b-a4e8-a01d7226ead6"
      unitRef="usd">1971700000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfMi0zLTEtMS0w_64a19e5b-9793-490c-be11-71108a3f3126"
      unitRef="usd">1852800000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <amed:BusinessAcquisitionProFormaOperatingIncomeLoss
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfMy0xLTEtMS0w_090020c2-4e55-4bd7-8827-a84d9da891ac"
      unitRef="usd">183800000</amed:BusinessAcquisitionProFormaOperatingIncomeLoss>
    <amed:BusinessAcquisitionProFormaOperatingIncomeLoss
      contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfMy0zLTEtMS0w_7660a754-cf34-4ba9-a65b-9559bb371e2a"
      unitRef="usd">175700000</amed:BusinessAcquisitionProFormaOperatingIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNC0xLTEtMS0w_149b86f7-1373-4f2a-9c40-4ce53c5e469e"
      unitRef="usd">130500000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNC0zLTEtMS0w_5dbb7aab-4e6e-449e-9613-ca8bce1ddc6a"
      unitRef="usd">124600000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNS0xLTEtMS0w_4752ce7f-1219-49ce-8318-32e3a20412de"
      unitRef="usdPerShare">4.06</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNS0zLTEtMS0w_69594ee7-ad30-478c-8554-6af55848a47d"
      unitRef="usdPerShare">3.80</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="ib56bd603e1b64ac382aa04658acd4bdb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNi0xLTEtMS0w_eca45657-3d91-4446-8358-c6de07176015"
      unitRef="usdPerShare">3.96</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i48f0fc128a27442ea084e393c1b190af_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RhYmxlOjllZGZlMWFkZDE4NTRhYWM5MTdlMThiOTE0OTE2ODQ2L3RhYmxlcmFuZ2U6OWVkZmUxYWRkMTg1NGFhYzkxN2UxOGI5MTQ5MTY4NDZfNi0zLTEtMS0w_ad5af61e-b2f3-4a1c-ad5b-e991626c99a9"
      unitRef="usdPerShare">3.71</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if362ac0d7ade4dbe9a2f52099ec6f0e7_D20190401-20190401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzE2MA_229b31fa-8717-477f-a5f2-c7ccd9120605"
      unitRef="usd">17500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i05a1575f31584575992abc74ced2bc65_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzMxNQ_24ad1898-faec-4dd0-9405-211e59fc2ca3"
      unitRef="usd">15800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i169c7364acc540578506213cd50aac76_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzM2Nw_30193e4d-8fc7-4072-aa40-a22c6f72dba9"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i856c123c4c204fe38e4e036fd7752a96_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzM5OQ_1246590c-e80a-457f-bbd5-829673076f78"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6826cc9464ca4135b180f102528d6d44_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzUwNg_8e0389a3-c1ba-4cbd-b599-e166018a069d">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4483458942a649af981f192426433819_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzUwNg_ffbb2909-21af-4d65-99d8-4042eb70e4c0">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i05a1575f31584575992abc74ced2bc65_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzU1MQ_20632690-127f-4be1-9f82-2d6ca5d2a729"
      unitRef="usd">6800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OperatingIncomeLoss
      contextRef="i05a1575f31584575992abc74ced2bc65_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzU4MQ_72aa1734-a642-4308-98fd-7a55a6c00ce4"
      unitRef="usd">800000</us-gaap:OperatingIncomeLoss>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="if362ac0d7ade4dbe9a2f52099ec6f0e7_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF84NS9mcmFnOjk2NWVhYTY1MWQ2MTRjYjk5NTNjODM5MWJmNjQ0MmQ0L3RleHRyZWdpb246OTY1ZWFhNjUxZDYxNGNiOTk1M2M4MzkxYmY2NDQyZDRfMzc3Mg_ce9f3c1b-0d10-4dc0-a4c2-eb986c916643">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMjA1OQ_8a11b737-1728-4713-890a-3f07d3e3d208">GOODWILL AND OTHER INTANGIBLE ASSETS, NET&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 2019 and 2018, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October&#160;31st of each respective year (the date of our annual goodwill impairment test). Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our goodwill for 2020 and 2019 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2018 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;528.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;658.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;274.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;932.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net of prior years' accumulated impairment losses of $733.7 million, which is inclusive of write-offs related to the sale and closure of care centers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we recorded a non-cash other intangible assets impairment charge of $4.2&#160;million related to acquired names which are no longer in use; additionally, we recorded amortization of $2.4&#160;million related to certificates of need and licenses associated with care centers that were closed. During 2019, we recorded a non-cash other intangible assets impairment charge of $1.5 million related to acquired names which are no longer in use or are associated with care centers that were closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our other intangible assets, net for 2020 and 2019 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Certificates of Need and Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;br/&gt;Names -Unamortizable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;br/&gt;Names -Amortizable (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Compete&lt;br/&gt;Agreements (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2018 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Write-off (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Write-off (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net of prior years' accumulated amortization of $0.7 million for non-compete agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Write-offs are related to our acquired names that are no longer in use or that were associated with care centers that are closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Amortization of certificates of need and licenses is related to care centers that were closed during 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The weighted average remaining amortization period of our amortizable acquired names and non-compete agreements is 1.3 years and 1.2 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 4 &#x2013; Acquisitions for further details on additions to goodwill and other intangible assets, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible Asset Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMjA0OA_35b153da-2199-4577-a172-d15f45ed3fc1">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our goodwill for 2020 and 2019 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2018 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;528.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;658.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;274.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;932.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net of prior years' accumulated impairment losses of $733.7 million, which is inclusive of write-offs related to the sale and closure of care centers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we recorded a non-cash other intangible assets impairment charge of $4.2&#160;million related to acquired names which are no longer in use; additionally, we recorded amortization of $2.4&#160;million related to certificates of need and licenses associated with care centers that were closed. During 2019, we recorded a non-cash other intangible assets impairment charge of $1.5 million related to acquired names which are no longer in use or are associated with care centers that were closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our other intangible assets, net for 2020 and 2019 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Certificates of Need and Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;br/&gt;Names -Unamortizable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;br/&gt;Names -Amortizable (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Compete&lt;br/&gt;Agreements (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2018 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Write-off (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Write-off (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net of prior years' accumulated amortization of $0.7 million for non-compete agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Write-offs are related to our acquired names that are no longer in use or that were associated with care centers that are closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Amortization of certificates of need and licenses is related to care centers that were closed during 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The weighted average remaining amortization period of our amortizable acquired names and non-compete agreements is 1.3 years and 1.2 years, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="i2123af26c18b4412a49a520f6e2ab7c8_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMi0xLTEtMS0w_356f1a51-cb7f-492d-9a51-b0aa3f25c141"
      unitRef="usd">87100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i14c3a57b90754fd780752ab5eaeb2119_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMi0zLTEtMS0w_7d79d7d7-498c-48b2-bb8f-e4e61d97e1c7"
      unitRef="usd">199300000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3ca74d3eda644e30a68c80809f7fc57f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMi01LTEtMS0w_e10d9cab-32b0-4fb9-9f5f-34ca32ddeab0"
      unitRef="usd">43100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMi03LTEtMS0w_c99ab789-0365-4bdb-b172-61efa5a77ec8"
      unitRef="usd">329500000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie88935582b014075a328bfa1b117396c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMy0xLTEtMS0w_3e9322e7-fcf4-4f51-af09-5d4f08711650"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i5af8da337a3b49f3a113759b906bf9f3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMy0zLTEtMS0w_d8874dc9-7e3c-44b6-bcee-0ad8eb634ecc"
      unitRef="usd">329000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i941dbf037dc148deb289e0c5c518ef5d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMy01LTEtMS0w_d1aafa8c-d3e5-4e50-b01e-7c3e1d1fc916"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfMy03LTEtMS0w_4d9f24fe-d136-4d4c-93d4-7ea388ece165"
      unitRef="usd">329000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i4b3b8059d89b46389a5544b50a169658_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNC0xLTEtMS0w_017eb692-edb8-4ae4-96e7-5d251d9e8c8d"
      unitRef="usd">87100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i299a9ff0faaf4204a8a8ec39062247b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNC0zLTEtMS0w_9c3aca7f-3071-4817-bc75-6e28ccc4d5de"
      unitRef="usd">528300000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i758a004b4fbe477aa6e2ef91789cb336_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNC01LTEtMS0w_587395d6-7ef7-42a6-9832-75285f78e0d8"
      unitRef="usd">43100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNC03LTEtMS0w_8c995155-ed6e-48e5-86c1-f0ef25346867"
      unitRef="usd">658500000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib5177b049f064d83bb0e48f33e3b2e58_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNS0xLTEtMS0w_e58a4d58-0d82-449b-bf3b-ba8c369dc848"
      unitRef="usd">3300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="icca03328f124427a801b7d654ef05ff9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNS0zLTEtMS0w_535ff08d-2558-4490-938a-37ae51f33af1"
      unitRef="usd">270900000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic433fb8ffa524d98b4462b2bfdb4ca4a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNS01LTEtMS0w_d9dc2722-c8ca-42da-867b-6d812cc692b4"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNS03LTEtMS0w_14574bc9-22e3-4257-8075-df6f0996bd61"
      unitRef="usd">274200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i3f4d87d3f8c04768adb0d99598494f75_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNi0xLTEtMS0w_2f909cbc-30d2-4099-840c-181852ec91aa"
      unitRef="usd">90400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7618d2cebdef436fa6e1ece2cb3e1a9c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNi0zLTEtMS0w_7cb97ef5-fbe5-410c-909f-2112400952b7"
      unitRef="usd">799200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i30daf9d0e928439bbf628952733e011b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNi01LTEtMS0w_7a7bcc6a-c983-4633-a6de-aed4a9834347"
      unitRef="usd">43100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjgyMTkxNjZlYTllODQ5NjY4OGI4MThiNzlhNzcxYjc5L3RhYmxlcmFuZ2U6ODIxOTE2NmVhOWU4NDk2Njg4YjgxOGI3OWE3NzFiNzlfNi03LTEtMS0w_4e26b60d-cd5b-4e80-9acc-beca83c14aaf"
      unitRef="usd">932700000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfODU2_15489553-39a3-4c50-967b-0b357a666dd0"
      unitRef="usd">733700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i8a9e61c64a324dccb0426c5ca15ad0fd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTA5OTUxMTYzMDQyNA_f6785961-1dd6-49ab-a3fe-fabcb230e441"
      unitRef="usd">4200000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTA5OTUxMTYzMDkwOA_c77c64f7-f524-41a5-ad3d-39015c187bc3"
      unitRef="usd">2400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iab41181582e84ce6a158eb40d3e43022_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTIzOQ_48288284-b286-4ebd-b9e2-5b83c7241768"
      unitRef="usd">1500000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i189835ae24ec4c70b6a717d5b08a421a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi0xLTEtMS0w_3be58316-9391-4016-ae40-d62a905085eb"
      unitRef="usd">23900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib9aefbc5b7fb48c5b29a38dcb7a14868_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi0zLTEtMS0w_a2581a4b-9379-4c03-a52a-c4b3ef213efe"
      unitRef="usd">19600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6192d3d4b0a84bfeaab23464bd0e6b9e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi01LTEtMS0w_2e03611f-2738-40dc-9beb-37be03a870ca"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib187ff5463f54b85b4e3f4bc6ad8636c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi03LTEtMS0w_7d5eeb8c-d19d-4220-88ed-81ca4bf2134d"
      unitRef="usd">600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMi05LTEtMS0w_e6aaa9ba-fa4b-4a4f-a219-0a1ade3d52c3"
      unitRef="usd">44100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i969ee2ebea1b499f906b31aa81ec4f31_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy0xLTEtMS0w_1e99f6f0-50d6-4da9-9a65-db7b1d595b4c"
      unitRef="usd">13700000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ia87f788f2fe64b23944a430849785260_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy0zLTEtMS0w_909bdae0-cfd9-4361-b707-f835d6bc830d"
      unitRef="usd">0</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="iffe18e321548455c94c7d0cd77924cf8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy01LTEtMS0w_53a2667e-be4e-49a4-9a61-4ec57280dd69"
      unitRef="usd">10000000.0</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ib6d6b40ce5cc498eba1f0d3ec5483959_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy03LTEtMS0w_08681ed6-f81b-4556-8444-347996caedfe"
      unitRef="usd">5200000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfMy05LTEtMS0w_b719d1e9-22b5-423a-8a04-942aaf9d6269"
      unitRef="usd">28900000</amed:OtherIntangibleAssetsAdditions>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i969ee2ebea1b499f906b31aa81ec4f31_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC0xLTEtMS05Mzc_99071c80-a792-4549-b467-59382c6b00b4"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ia87f788f2fe64b23944a430849785260_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC0zLTEtMS05Mzc_70a599f4-c807-462d-84ea-3e81d0691d5b"
      unitRef="usd">1500000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iffe18e321548455c94c7d0cd77924cf8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC01LTEtMS05Mzc_a4e3415b-2beb-4701-a041-7a39c498dcba"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ib6d6b40ce5cc498eba1f0d3ec5483959_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC03LTEtMS05Mzc_0bb837ba-4937-4c14-aef4-cd9aa1ce8e1c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC05LTEtMS05Mzc_0eb5fb20-9395-437e-8e09-e442ccb0b457"
      unitRef="usd">1500000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i969ee2ebea1b499f906b31aa81ec4f31_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC0xLTEtMS0w_99d4cf79-467a-4da7-ae5a-036669e138e9"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia87f788f2fe64b23944a430849785260_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC0zLTEtMS0w_4d6a33b3-83aa-4af0-9dae-089510bc42b1"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iffe18e321548455c94c7d0cd77924cf8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC01LTEtMS0w_e600148c-8540-4c1d-9276-61fdaf8e10dd"
      unitRef="usd">4400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib6d6b40ce5cc498eba1f0d3ec5483959_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC03LTEtMS0w_86a6eee2-a766-48c6-b989-97d18b251fd5"
      unitRef="usd">2400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNC05LTEtMS0w_638488e3-6773-4114-ac20-d5b8a321f307"
      unitRef="usd">6800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i83cdcc0f05d44f1d840709161ceb3440_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS0xLTEtMS0w_e7505b9c-4f5b-4d71-a763-09220dbd74f7"
      unitRef="usd">37600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idc65628a7dbf4a1da089fe655a7e819d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS0zLTEtMS0w_cce1b442-663e-4f70-8ba8-6228ef52ba31"
      unitRef="usd">18100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idd0ee0b03f92409eb2ff67a774546a35_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS01LTEtMS0w_feb9456c-67ae-4246-829d-9549908d7860"
      unitRef="usd">5600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9714b4cf7d7c4de1be0e59b0dd0e7085_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS03LTEtMS0w_22ff5650-ac15-4a75-ba49-75fe8269a013"
      unitRef="usd">3400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNS05LTEtMS0w_0a1e23f5-79bc-4de0-90b4-5f776dc726c5"
      unitRef="usd">64700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi0xLTEtMS0w_d8bee06b-c7bf-434a-b7ed-73e6c42a6a02"
      unitRef="usd">11800000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ib383332f81cd4bfa9b1922280c354414_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi0zLTEtMS0w_9f7e2e58-ec8b-49d0-b83d-23a201d0d084"
      unitRef="usd">0</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ided786cf36e844558e359485f224451e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi01LTEtMS0w_945479b9-417c-4c49-9973-33be1e1defe7"
      unitRef="usd">7000000.0</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi03LTEtMS0w_2e084b71-6304-4975-9db9-12f1d7ab911f"
      unitRef="usd">11500000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNi05LTEtMS0w_63f2dd50-6a55-4217-a203-4c05679d1833"
      unitRef="usd">30300000</amed:OtherIntangibleAssetsAdditions>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy0xLTEtMS0w_ba5adfd8-0ba9-42b5-a8b7-e1f439f643a2"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ib383332f81cd4bfa9b1922280c354414_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy0zLTEtMS0w_6dd136bd-27ee-474d-861a-b45e3d9904b2"
      unitRef="usd">4200000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ided786cf36e844558e359485f224451e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy01LTEtMS0w_8aeb048c-0ce3-4ea6-8e5b-9f20faeea17d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy03LTEtMS0w_52ef2c1d-4ea8-4bff-805f-f51ff8f54ff5"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfNy05LTEtMS0w_fad116e7-1529-4fbc-9fd3-87d8b0e68b23"
      unitRef="usd">4200000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id8164c75b07043e69778d67d94bcb6d7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC0xLTEtMS0w_b9b659d3-d7f6-4a58-bc2b-23c474dc55ac"
      unitRef="usd">2400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib383332f81cd4bfa9b1922280c354414_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC0zLTEtMS0w_6eae4ebe-9b64-4b42-820e-064b9841110a"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ided786cf36e844558e359485f224451e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC01LTEtMS0w_a27d82f1-63e0-491c-a441-ffe06c6d09f9"
      unitRef="usd">7100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC03LTEtMS0w_989e86be-b762-4321-808c-c69ee6ce48f2"
      unitRef="usd">7100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOC05LTEtMS0w_3eba02df-d2b5-40a6-8fcb-e378a107fac9"
      unitRef="usd">16600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie7040a24f0754adc968817731ec50305_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS0xLTEtMS0w_157076ae-9688-458b-bba9-05c2a5d7e9ba"
      unitRef="usd">47000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i80f77e35787c46fe9512e728260f7095_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS0zLTEtMS0w_816bc434-bc67-4e8e-a213-9909343008ac"
      unitRef="usd">13900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5c25949461664d0aaec5b5040213f6b7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS01LTEtMS0w_05883d51-dde7-4774-923e-531ccd7203d1"
      unitRef="usd">5500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i71e88ffd25ce42179e2ee5206728bafa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS03LTEtMS0w_68f72a35-1d31-4b82-8d32-7eddfffc179e"
      unitRef="usd">7800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOjkyMWZkNjk4YmRmMjRlNGRhZjEwZDZlODkxZGRiYjIwL3RhYmxlcmFuZ2U6OTIxZmQ2OThiZGYyNGU0ZGFmMTBkNmU4OTFkZGJiMjBfOS05LTEtMS0w_c6ac5629-7efa-4737-8210-8279303fd233"
      unitRef="usd">74200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i71e88ffd25ce42179e2ee5206728bafa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTYxOA_a5fabc2d-bd33-4788-9a5c-593ef63e5428"
      unitRef="usd">700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ided786cf36e844558e359485f224451e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTc2NQ_7f4727b5-9b9f-4aee-a6c6-325ae3f63a3f">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i01dc522fa61b48829fc16c85b9d09824_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMTc3Mg_614b5156-ea5f-49a7-9c22-55c8b4231d26">P1Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RleHRyZWdpb246ZjZhMzVhN2Q0NGU1NGY5MWJiNjU2ZjUyNTY5NmY5ZWVfMjA1Nw_fb561798-8e4a-4ef4-80ad-596642d07bac">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible Asset Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfMS0xLTEtMS0w_21ce6b3f-b4c2-43e0-bd8c-c9f5e2f0e468"
      unitRef="usd">10600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfMi0xLTEtMS0w_6326e2a2-2429-4afe-b19c-4f54bc8f0336"
      unitRef="usd">2700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfMy0xLTEtMS0w_59c6ee16-d26f-4f06-81c9-55aef589a355"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfNC0xLTEtMS0w_7c5cc3b8-10c0-494a-8061-08e0aed03d1e"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfNS0xLTEtMS0w_590e4654-664c-4627-bc3b-c96969464cff"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF85Ny9mcmFnOmY2YTM1YTdkNDRlNTRmOTFiYjY1NmY1MjU2OTZmOWVlL3RhYmxlOmE1NGQxMGM5YjIwNDRjMDBiZWI3ZTQwY2RlOWQyNzBlL3RhYmxlcmFuZ2U6YTU0ZDEwYzliMjA0NGMwMGJlYjdlNDBjZGU5ZDI3MGVfNi0xLTEtMS0w_dba1dde7-666f-4767-bea5-b0d8f4c67f3d"
      unitRef="usd">13300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE2OQ_60c52f85-2c26-44b7-80d4-b4a26d5f0d07">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred operating income (CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current social security taxes (deferred under CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE1Nw_fa57619d-68be-4aae-b37a-ebed9ba0dc46">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred operating income (CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current social security taxes (deferred under CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE2MQ_2c07aaca-e426-437e-9e7c-563b316a566a">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred operating income (CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current social security taxes (deferred under CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE2Ng_d6a781d4-0bc3-4b13-8fc6-cb9e1fb9261e">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred operating income (CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current social security taxes (deferred under CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90ZXh0cmVnaW9uOjI1NmU4OWVmYmNlZTRiMWZiOGQ3ZmNlNTQ4MTQ1M2FjXzE3NQ_67fbf27a-8fd4-45a1-88d9-819dabba763b">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred operating income (CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current social security taxes (deferred under CARES Act)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <amed:PayrollTaxEscrow
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMtMS0xLTEtMA_83da2884-bf51-49d6-b4ce-d3af61ba2ded"
      unitRef="usd">6300000</amed:PayrollTaxEscrow>
    <amed:PayrollTaxEscrow
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMtMy0xLTEtMA_522636d2-f789-4f71-aefe-f1987959905e"
      unitRef="usd">1500000</amed:PayrollTaxEscrow>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzQtMS0xLTEtMA_f33a96f1-ef6f-4f1c-b44c-5f41140448a0"
      unitRef="usd">200000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzQtMy0xLTEtMA_03657134-74b5-4742-91a8-07c840ec7cf4"
      unitRef="usd">2000000.0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:DueFromJointVenturesCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzUtMS0xLTEtMA_63cf7503-7b9d-45df-b150-98e2ab1281b1"
      unitRef="usd">2300000</us-gaap:DueFromJointVenturesCurrent>
    <us-gaap:DueFromJointVenturesCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzUtMy0xLTEtMA_2cd14529-b82f-437b-8956-85cc50d19efa"
      unitRef="usd">2000000.0</us-gaap:DueFromJointVenturesCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzYtMS0xLTEtMA_622022ff-f461-48e6-8c8f-285c7232ded9"
      unitRef="usd">4500000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzYtMy0xLTEtMA_1388a500-b37a-4338-9aa0-88f404576e4b"
      unitRef="usd">2700000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzctMS0xLTEtMA_ef61d425-921b-4f94-b65c-e875cdd4da48"
      unitRef="usd">13300000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzctMy0xLTEtMA_3b2ed129-49c3-4414-9b45-3c291782b27a"
      unitRef="usd">8200000</us-gaap:OtherAssetsCurrent>
    <amed:WorkersCompensationDeposits
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzktMS0xLTEtMA_0763443c-7d43-42d3-b8de-c0d35ba7f44d"
      unitRef="usd">300000</amed:WorkersCompensationDeposits>
    <amed:WorkersCompensationDeposits
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzktMy0xLTEtMA_37acbe5c-a43f-4ad9-99c9-3d81c3723afb"
      unitRef="usd">200000</amed:WorkersCompensationDeposits>
    <amed:HealthInsuranceDeposits
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEwLTEtMS0xLTA_9d97bdd7-8ac5-49ce-b0fe-d0cfd9ca2825"
      unitRef="usd">500000</amed:HealthInsuranceDeposits>
    <amed:HealthInsuranceDeposits
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEwLTMtMS0xLTA_8afb0085-616f-4d74-aba5-787736a274f7"
      unitRef="usd">500000</amed:HealthInsuranceDeposits>
    <amed:OtherMiscellaneousDeposits
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzExLTEtMS0xLTA_5d739438-5d69-413c-afe5-81d1be8e7257"
      unitRef="usd">1200000</amed:OtherMiscellaneousDeposits>
    <amed:OtherMiscellaneousDeposits
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzExLTMtMS0xLTA_1501f09e-ce23-4f87-b699-8a90168e522c"
      unitRef="usd">1000000.0</amed:OtherMiscellaneousDeposits>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEyLTEtMS0xLTA_a20ebbda-11d9-4c63-8faf-b7d57adca109"
      unitRef="usd">13600000</us-gaap:LossContingencyReceivableNoncurrent>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEyLTMtMS0xLTA_7830b209-942c-4a9e-96de-8b3fd512fba6"
      unitRef="usd">13600000</us-gaap:LossContingencyReceivableNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEzLTEtMS0xLTA_eb642977-9fc8-45e1-9de7-f0e394dd6009"
      unitRef="usd">14200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzEzLTMtMS0xLTA_2dbe2731-e3f3-46b1-b834-f5a582c049c2"
      unitRef="usd">35700000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE0LTEtMS0xLTA_401f70fc-b351-45aa-aa91-1199d12d3aa2"
      unitRef="usd">3400000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE0LTMtMS0xLTA_e39cdfd6-399c-4a38-9f77-fd92aeb7e6f9"
      unitRef="usd">3600000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE1LTEtMS0xLTA_a06a347a-f2b1-4ce3-a79a-fe6a04a77be6"
      unitRef="usd">33200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE1LTMtMS0xLTA_866ab600-444a-45a8-bbd9-295b89213e92"
      unitRef="usd">54600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE3LTEtMS0xLTA_e0d878b2-3984-462e-9d05-673e7874ad4d"
      unitRef="usd">15100000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE3LTMtMS0xLTA_6295e09b-bf25-4e34-82a4-4d873548cefb"
      unitRef="usd">15800000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE4LTEtMS0xLTA_d79b18fe-2d60-4c2f-b2d2-9b2b316e1f31"
      unitRef="usd">35800000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE4LTMtMS0xLTA_97a5f37e-e2ff-4270-b790-a415a10966af"
      unitRef="usd">33400000</us-gaap:WorkersCompensationLiabilityCurrent>
    <amed:ProvisionForLiabilityOnRegulatoryAudit
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE5LTEtMS0xLTA_a22b74c1-a403-4471-82e1-4e368b1db613"
      unitRef="usd">17400000</amed:ProvisionForLiabilityOnRegulatoryAudit>
    <amed:ProvisionForLiabilityOnRegulatoryAudit
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzE5LTMtMS0xLTA_62750e36-8e9e-4d37-8ccd-5bb3ce1780ad"
      unitRef="usd">17400000</amed:ProvisionForLiabilityOnRegulatoryAudit>
    <amed:LegalAndOtherSettlements
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIwLTEtMS0xLTA_75a0694b-95cc-415b-8fe7-29bb81ce49f1"
      unitRef="usd">24400000</amed:LegalAndOtherSettlements>
    <amed:LegalAndOtherSettlements
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIwLTMtMS0xLTA_173b3271-20b5-425c-82b7-d835c86e9cd1"
      unitRef="usd">19000000.0</amed:LegalAndOtherSettlements>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIxLTEtMS0xLTA_d08a09dd-9c24-4c55-8c9f-0410fc25303c"
      unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIxLTMtMS0xLTA_f90925bd-921e-4d34-97a6-2b577b5dcee1"
      unitRef="usd">500000</us-gaap:AccruedIncomeTaxesCurrent>
    <amed:CharityCare
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIyLTEtMS0xLTA_70dc1c9d-120b-41bd-8940-a74eba58d1cf"
      unitRef="usd">3600000</amed:CharityCare>
    <amed:CharityCare
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIyLTMtMS0xLTA_2d069fbb-d6bd-41a6-abda-6096960a3b60"
      unitRef="usd">2700000</amed:CharityCare>
    <amed:EstimatedMedicareCapLiability
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIzLTEtMS0xLTA_47e6f8d9-013c-4355-9a71-d40d9f09f2cf"
      unitRef="usd">9300000</amed:EstimatedMedicareCapLiability>
    <amed:EstimatedMedicareCapLiability
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzIzLTMtMS0xLTA_2a8c29e7-6160-491c-9795-86746e73f86c"
      unitRef="usd">5700000</amed:EstimatedMedicareCapLiability>
    <amed:HospiceAccruals
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI0LTEtMS0xLTA_b499ac20-da60-4080-8508-c2125623d49b"
      unitRef="usd">29200000</amed:HospiceAccruals>
    <amed:HospiceAccruals
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI0LTMtMS0xLTA_2808f211-8484-412f-9f70-cdef6f1ddbfb"
      unitRef="usd">24400000</amed:HospiceAccruals>
    <amed:PatientLiability
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI2LTEtMS0xLTA_38357d64-155d-4d0b-8360-3c28b480cad5"
      unitRef="usd">8400000</amed:PatientLiability>
    <amed:PatientLiability
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI2LTMtMS0xLTA_47f1c38c-d489-417c-96ea-a8387bd709b3"
      unitRef="usd">9400000</amed:PatientLiability>
    <amed:DeferredOperatingIncomeCARESAct
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI3LTEtMS0xLTM3OTE_29f13b75-5319-401f-b058-bd3ead56d73e"
      unitRef="usd">11600000</amed:DeferredOperatingIncomeCARESAct>
    <amed:DeferredOperatingIncomeCARESAct
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI3LTMtMS0xLTM3OTE_33c78da6-c1ed-4971-942c-2c2e7fcf58b9"
      unitRef="usd">0</amed:DeferredOperatingIncomeCARESAct>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI3LTEtMS0xLTA_9c9d9b6d-26e3-441b-93da-e729f62cd776"
      unitRef="usd">11400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI3LTMtMS0xLTA_ffd2838d-f69c-41a0-916f-eb22a9ed05cf"
      unitRef="usd">8800000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI4LTEtMS0xLTA_c50acc67-091f-4920-93de-51664181b3c4"
      unitRef="usd">166200000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzI4LTMtMS0xLTA_4d9b9b4f-da7b-48bf-90b5-0195853e4479"
      unitRef="usd">137100000</us-gaap:AccruedLiabilitiesCurrent>
    <amed:UncertainTaxBenefitsInLongTermObligations
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMwLTEtMS0xLTA_e1acb673-8e6e-4e6e-8cdc-979acb2e996e"
      unitRef="usd">3300000</amed:UncertainTaxBenefitsInLongTermObligations>
    <amed:UncertainTaxBenefitsInLongTermObligations
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMwLTMtMS0xLTA_0a021d83-c49c-4da5-b313-8bc9c183041a"
      unitRef="usd">3100000</amed:UncertainTaxBenefitsInLongTermObligations>
    <amed:DeferredCompensationPlanLiability
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMxLTEtMS0xLTA_9176beef-8771-45d1-b481-ffd3434b85c1"
      unitRef="usd">1000000.0</amed:DeferredCompensationPlanLiability>
    <amed:DeferredCompensationPlanLiability
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMxLTMtMS0xLTA_eea58fe8-5835-4f6e-8ca5-394caf0ceda5"
      unitRef="usd">1000000.0</amed:DeferredCompensationPlanLiability>
    <amed:NonCurrentSocialSecurityTaxesDeferredUnderCARESAct
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMzLTEtMS0xLTM3OTk_b493fce1-e9d7-4dd3-819a-3102c7fc5c5d"
      unitRef="usd">27700000</amed:NonCurrentSocialSecurityTaxesDeferredUnderCARESAct>
    <amed:NonCurrentSocialSecurityTaxesDeferredUnderCARESAct
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMzLTMtMS0xLTM3OTk_37e2ccbb-74d3-4b38-aece-9e4610d9a041"
      unitRef="usd">0</amed:NonCurrentSocialSecurityTaxesDeferredUnderCARESAct>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMyLTEtMS0xLTA_ecaabe09-793a-4562-8870-262a69393a01"
      unitRef="usd">1600000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMyLTMtMS0xLTA_20878d65-df3e-43e1-a419-541524655d75"
      unitRef="usd">1800000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMzLTEtMS0xLTA_77cf895f-4bf3-4625-a904-c1f64efd65dd"
      unitRef="usd">33600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDAvZnJhZzoyNTZlODllZmJjZWU0YjFmYjhkN2ZjZTU0ODE0NTNhYy90YWJsZTpiNDBhYWNiNzY3MzU0ZmEyYTA1ZDhiMTg4OWNlNTNhZi90YWJsZXJhbmdlOmI0MGFhY2I3NjczNTRmYTJhMDVkOGIxODg5Y2U1M2FmXzMzLTMtMS0xLTA_1e949937-cbcc-44d6-af71-1ab66007d6a6"
      unitRef="usd">5900000</us-gaap:OtherLiabilitiesNoncurrent>
    <amed:LesseeLeasesTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE3OTk_750bb6f5-45da-4470-83f5-1eff7deaa386">LEASES&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next eight years. We also have finance leases covering certain office equipment that expire at various dates over the next three years. Our leases do not contain any restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our office leases generally contain renewal options for periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzQyMg_e7798f55-1ce4-47ef-a7fb-73e95a0c87a0"&gt;one&lt;/span&gt; to five years. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fleet leases include a term of 367 days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#x201c;TRAC&#x201d;), which provide for a final rental payment adjustment at the end of the lease, typically based on the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended December 31, 2020 and 2019 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for our operating leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease ROU assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current installments of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities and ROU assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions to ROU assets resulting from reductions to lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates for our leases as of December 31, 2020 and 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2020 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:LesseeLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzE3OA_95554468-067d-42cc-80e6-4d487465d003">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzI4Nw_3eaf42fa-e653-43e2-a8c3-7de1cb515044">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i3998374665924f3aa61bd5813eecd5f5_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzQyOA_b61464fb-9cf8-4c51-b866-5242e2f083af">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6e380d81b95f448eab4c555d915ea5cd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzExMDU_9da2ec92-5d8e-4298-af9b-eb6c2504b045">P367D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDA_b9e2be00-1a83-45b5-9c19-7128d092051a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended December 31, 2020 and 2019 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzMtMS0xLTEtMjY1Mw_57190ff1-d07a-4d1a-b0be-851afe8b269f"
      unitRef="usd">38600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzItMS0xLTEtMA_76799afe-d551-487a-adc1-c0fd12db75fd"
      unitRef="usd">35000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzQtMS0xLTEtMjY1Mw_02504e8e-2fb1-42e5-8adb-0f2b8a2604ab"
      unitRef="usd">500000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzMtMS0xLTEtMA_e0a9aa86-796f-45ec-b35a-ffaf8458eaa8"
      unitRef="usd">900000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseCost
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzUtMS0xLTEtMjY1Mw_8b7dfdb7-f832-48bd-bef6-d49fc01a04ca"
      unitRef="usd">39100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzQtMS0xLTEtMA_c6017c2e-03a5-4948-b670-740f7a5db77f"
      unitRef="usd">35900000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzgtMS0xLTEtMjY1Mw_983018ff-d3c0-4192-a1ad-752905357418"
      unitRef="usd">2000000.0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzctMS0xLTEtMA_367475e5-de3a-417a-95c3-8fe0ddef0d69"
      unitRef="usd">1700000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzktMS0xLTEtMjY1Mw_b8fd72b0-6f5b-49e4-bd6c-0fa6802188ef"
      unitRef="usd">200000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzgtMS0xLTEtMA_4f5e0cdb-6382-4a77-8d86-6c44f31670b7"
      unitRef="usd">200000</us-gaap:FinanceLeaseInterestExpense>
    <amed:FinanceLeaseCost
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzEwLTEtMS0xLTI2NTM_0dd50916-2d32-4617-bf17-51812da2f24b"
      unitRef="usd">2200000</amed:FinanceLeaseCost>
    <amed:FinanceLeaseCost
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzktMS0xLTEtMA_94901be4-08fe-4b34-bd62-5d2b471e778f"
      unitRef="usd">1900000</amed:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzEyLTEtMS0xLTI2NTM_c5faaaf1-6f87-422a-8fd5-f2d8b1932b24"
      unitRef="usd">3000000.0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzExLTEtMS0xLTA_5dad9093-53c4-4f19-bbf4-68996a7694e0"
      unitRef="usd">2600000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzEzLTEtMS0xLTI2NTM_8984af59-2d1b-43aa-b8d8-8c0e0dce8d73"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzEyLTEtMS0xLTA_38ad81f0-f203-4de8-a0db-7f8ea7585ff0"
      unitRef="usd">200000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzE1LTEtMS0xLTI2NTM_358de26f-f6a5-4527-8858-b18e60870492"
      unitRef="usd">44300000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo4YzViYmNhZmEyNmU0NjEwOGJjYjI4NTk0ZTk4NTQ5ZS90YWJsZXJhbmdlOjhjNWJiY2FmYTI2ZTQ2MTA4YmNiMjg1OTRlOTg1NDllXzE0LTEtMS0xLTA_ac66fd53-cee0-42e0-b19f-f1f34b11f397"
      unitRef="usd">40600000</us-gaap:LeaseCost>
    <amed:OperatingLeasesTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDE_f6c9ca13-5fcf-4cf2-ad47-4c4bf75ad87c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for our operating leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:OperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzItMS0xLTEtMjY1Ng_ad8d43d9-123e-4167-a184-28df6039a22b"
      unitRef="usd">93400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzEtMS0xLTEtMA_58b79312-4bc4-4815-b0b4-054da3be8776"
      unitRef="usd">84800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzQtMS0xLTEtMjY1Ng_cd990c88-e31e-4297-8b10-e90ca04db313"
      unitRef="usd">30000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzMtMS0xLTEtMA_1363f7e9-b079-4e88-a0b6-1640d33b6394"
      unitRef="usd">27800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzUtMS0xLTEtMjY1Ng_9257f6d1-5d4e-492e-9814-056e6fdbd241"
      unitRef="usd">62000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzQtMS0xLTEtMA_6046cfa6-a22e-424f-9f15-66d7685a71e6"
      unitRef="usd">56100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzYtMS0xLTEtMjY1Ng_db5e1d0b-74ee-4a24-b48c-37f439c05e6e"
      unitRef="usd">92000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTpmODM2MGIxYTU1M2M0MzhiOTY3MmQ1NWI3NGEyMWI0My90YWJsZXJhbmdlOmY4MzYwYjFhNTUzYzQzOGI5NjcyZDU1Yjc0YTIxYjQzXzUtMS0xLTEtMA_b12cfd40-d4c2-4f5e-848b-ce975fd13b01"
      unitRef="usd">83900000</us-gaap:OperatingLeaseLiability>
    <amed:FinanceLeasesTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDI_cc712a35-cea1-471f-ac3e-391d1042598a">Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease ROU assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current installments of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:FinanceLeasesTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzItMS0xLTEtMjY2MA_60d4484d-cffa-4a23-ab99-59144e885543"
      unitRef="usd">5900000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzEtMS0xLTEtMA_16b466a5-af42-4a58-999e-ddd3f84d6afa"
      unitRef="usd">5200000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzMtMS0xLTEtMjY2MA_700bab5a-a5af-4316-8729-40d73c1b62e4"
      unitRef="usd">3300000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzItMS0xLTEtMA_3994ec0a-58c3-454f-9c96-154281c5d953"
      unitRef="usd">1800000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzQtMS0xLTEtMjY2MA_210c801b-a737-4c75-bd70-20d6ebf1c886"
      unitRef="usd">2600000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzMtMS0xLTEtMA_27262017-4916-4215-b73d-3d0177326e9e"
      unitRef="usd">3400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzYtMS0xLTEtMjY2MA_ba400cc3-4128-4d13-83d3-a70f6731e07d"
      unitRef="usd">1700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzUtMS0xLTEtMA_5096a403-9a4d-431d-a7ec-c7bfd65a710c"
      unitRef="usd">1700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzctMS0xLTEtMjY2MA_66e5fec4-dd74-455f-aa84-8f07e0b555c2"
      unitRef="usd">900000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzYtMS0xLTEtMA_3418e22a-788d-45bc-b049-30b85a1b7927"
      unitRef="usd">1700000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzgtMS0xLTEtMjY2MA_c7218990-1ee6-4fed-8c2d-011948ef18a8"
      unitRef="usd">2600000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo5ZDM0MzA1MmRlYTY0NjMwYmM0OTQ2NzViYmJhZDc0My90YWJsZXJhbmdlOjlkMzQzMDUyZGVhNjQ2MzBiYzQ5NDY3NWJiYmFkNzQzXzctMS0xLTEtMA_ad6f2700-9d7a-42b7-8d8c-3707e1f3832b"
      unitRef="usd">3400000</us-gaap:FinanceLeaseLiability>
    <amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDQ_9908595b-1e3e-48b1-91ed-8dc5c427ee14">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities and ROU assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions to ROU assets resulting from reductions to lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzMtMS0xLTEtMjY2NA_1093b759-88fb-45c3-ae74-c03442e7ed2a"
      unitRef="usd">38200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzItMS0xLTEtMA_a283ca6e-0a5f-4668-b10e-87ca41f45686"
      unitRef="usd">35800000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzQtMS0xLTEtMjY2NA_47ef4541-91b5-4325-8631-b8270ac7fe32"
      unitRef="usd">2000000.0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzMtMS0xLTEtMA_c9dd154f-9dca-4f7f-9e6a-8c6eea73c5ce"
      unitRef="usd">1700000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzctMS0xLTEtMjY2NA_3e60d4a3-541e-44c1-ac41-643c7d054fc9"
      unitRef="usd">38500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzYtMS0xLTEtMA_d8252d90-ac19-4f92-8b3a-3f6166bd5e1d"
      unitRef="usd">116000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzgtMS0xLTEtMjY2NA_b355045f-5e92-4018-9217-4a1b52552611"
      unitRef="usd">1200000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzctMS0xLTEtMA_4b168822-baa4-409a-8fd3-5a6ba65541c8"
      unitRef="usd">2900000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzExLTEtMS0xLTI2NjQ_e8cd6562-0dde-4150-9249-37dafc5f2ffa"
      unitRef="usd">-1100000</amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations>
    <amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzEwLTEtMS0xLTA_4570c8dc-7cc2-49a1-861a-7a5548aff51e"
      unitRef="usd">-1700000</amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations>
    <amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzEyLTEtMS0xLTI2NjQ_b5e0c05c-cea8-4a8d-9c62-c268b904644d"
      unitRef="usd">0</amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations>
    <amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTplNzliYTc4Mzg0ZmI0ZWJhODExMWRlNzc1Nzc5ZWJjNC90YWJsZXJhbmdlOmU3OWJhNzgzODRmYjRlYmE4MTExZGU3NzU3NzllYmM0XzExLTEtMS0xLTA_11f33857-19e5-4542-9fcb-5da8a0fe1af3"
      unitRef="usd">0</amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations>
    <amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDU_344cdd63-8c31-485e-ae69-f370cc1ff049">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates for our leases as of December 31, 2020 and 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzItMS0xLTEtMA_6803a9ce-5938-41b3-9815-9e5bf06687c9">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzMtMy0xLTEtNzAwOQ_f7a88568-3d29-49f1-b80d-b19bcdc60ba0">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzMtMS0xLTEtMA_d19e62f1-1267-4e72-96cb-71c90b2bddfc">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzQtMy0xLTEtNzAwOQ_a5476bdb-e06f-4af5-8312-764b7273d499">P2Y1M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzYtMS0xLTEtMA_b22ec89d-c2cb-4f42-8aee-5ea0489991f0"
      unitRef="number">0.031</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzctMy0xLTEtNzAwOQ_1a5daf1c-36d0-40e6-8ba3-94dc74eb573d"
      unitRef="number">0.039</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzctMS0xLTEtMA_93efbb17-eedc-4798-8546-92caa2f14aa6"
      unitRef="number">0.053</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTo2NjkyMDFiNTc3M2E0YTI3OTQyYzdlODc0NTI4MTVhYy90YWJsZXJhbmdlOjY2OTIwMWI1NzczYTRhMjc5NDJjN2U4NzQ1MjgxNWFjXzgtMy0xLTEtNzAwOQ_5224008a-9108-45b2-bfe2-8a1bd09bdff7"
      unitRef="number">0.053</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <amed:LeaseLiabilityMaturityTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzEwOTk1MTE2MzE4MDY_baa71f64-dc6b-45ef-a1be-23ea388261d7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2020 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:LeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzEtMS0xLTEtMA_35a0fd06-79fc-482d-ba19-577cc4063216"
      unitRef="usd">32200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzEtMy0xLTEtMA_cbeb7b62-79a4-430a-950b-811c9c5ed4c2"
      unitRef="usd">1800000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzItMS0xLTEtMA_0732a198-c618-421a-af54-98fb9f526fb3"
      unitRef="usd">25300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzItMy0xLTEtMA_a4bf14ad-a316-4d55-a8a6-2087491f42b4"
      unitRef="usd">700000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzMtMS0xLTEtMA_987adac0-2cab-4eee-b7eb-a8e096479a99"
      unitRef="usd">17600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzMtMy0xLTEtMA_e685f473-4ee2-4fa4-a6ef-c599f354823e"
      unitRef="usd">200000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzQtMS0xLTEtMA_35aef244-5978-4ea2-85e5-dfa31a51c6fd"
      unitRef="usd">11700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzQtMy0xLTEtMA_663eacbc-56e9-45e5-95a1-210a7f651450"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzUtMS0xLTEtMA_a2fa9ca0-f512-4901-bf27-ff3a474fe4f6"
      unitRef="usd">6200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzUtMy0xLTEtMA_1a77d43b-d174-40af-b0c6-0c7f0663228d"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzYtMS0xLTEtMA_d89068d9-43b3-4b2c-a61c-e44f422ee262"
      unitRef="usd">4600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzYtMy0xLTEtMA_2191de62-9704-41f7-89da-6d4e60ee9e7c"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzctMS0xLTEtMA_55e78b47-05e0-4ef2-be86-efda37668337"
      unitRef="usd">97600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzctMy0xLTEtMA_d1e73fdc-91e4-4233-85ff-a1a5d2cd6161"
      unitRef="usd">2700000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzgtMS0xLTEtMA_5100ae09-b26d-4639-bb11-f70faf1c9131"
      unitRef="usd">5600000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzgtMy0xLTEtMA_1c1b5289-bfa1-4b85-8877-e84c8478cc94"
      unitRef="usd">100000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzktMS0xLTEtMA_996f7e19-2b5c-4327-8ebd-9c1282534da8"
      unitRef="usd">92000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90YWJsZTozYWY3NGEzOTg0MDY0MzNjODI1YjgyMDNiZDhhODVkNi90YWJsZXJhbmdlOjNhZjc0YTM5ODQwNjQzM2M4MjViODIwM2JkOGE4NWQ2XzktMy0xLTEtMA_79fcf019-0adb-4d90-86c8-3f93eab3fc08"
      unitRef="usd">2600000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzEwOTk1MTE2Mzk5OTI_8ead6c08-4a09-4c7c-b1a7-43897b3cd13c">LONG-TERM OBLIGATIONS&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (1.7% at December 31, 2020); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (3.8% at December 31, 2020); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt as of December&#160;31, 2020 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;br/&gt;obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2018, we entered into our Amended and Restated Credit Agreement ("Credit Agreement") which provided for a senior secured revolving credit facility in an initial aggregate principal amount of up to $550.0 million (the "Revolving Credit Facility"). The Revolving Credit Facility provided for and included within its $550.0 million limit a $25.0 million swingline facility and commitments for up to $60.0 million in letters of credit. Upon lender approval, we could increase the aggregate loan amount under the Revolving Credit Facility by $125.0 million plus an unlimited amount subject to a leverage limit of 0.5x under the maximum allowable consolidated leverage ratio which was 3.0x per the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity of the Revolving Credit Facility was June 29, 2023 and there was no mandatory amortization on the outstanding principal balances which were payable in full upon maturity. The Revolving Credit Facility was used to provide &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ongoing working capital and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;First Amendment to Amended and Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 4, 2019, we entered into the First Amendment to the Credit Agreement (as amended by the First Amendment, the &#x201c;Amended Credit Agreement&#x201d;). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes the $550.0 million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $175.0 million (the &#x201c;Term Loan Facility&#x201d; and collectively with the Revolving Credit Facility, the &#x201c;Credit Facility&#x201d;), which was added by the First Amendment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i)&#160;the Base Rate plus the Applicable Rate or (ii)&#160;the Eurodollar Rate plus the Applicable Rate. The &#x201c;Base Rate&#x201d; means a fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate plus 1% per annum. The &#x201c;Eurodollar Rate&#x201d; means the quoted rate per annum equal to the  London Interbank Offered Rate ("LIBOR") or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2020, the Applicable Rate is 0.25% per annum for Base Rate Loans and 1.25% per annum for Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment&lt;br/&gt;Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter&#160;of&lt;br/&gt;Credit&#160;Fee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2265;&#160;3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&amp;lt; 3.00 to 1.0 but &#x2265;&#160;2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&amp;lt; 2.00 to 1.0 but &#x2265;&#160;0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&amp;lt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity date of the Credit Facility is February 4, 2024. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) 1.250% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) 1.875% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement requires maintenance of two financial covenants: (i)&#160;a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii)&#160;a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded $0.8 million in deferred debt issuance costs as long-term obligations, less current portion within our consolidated balance sheet during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i)&#160;provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii)&#160;provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 2.2% for the period ended December 31, 2020 and 3.8% for the period February 4, 2019 to December&#160;31, 2019. Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.2% for the period ended December 31, 2020 and 4.0% for the period ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, our consolidated leverage ratio was 0.6, our consolidated interest coverage ratio was 25.6 and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, our availability under our $550.0 million Revolving Credit Facility was $470.2 million as we have $51.0 million outstanding in borrowings and $28.8 million outstanding in letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joinder Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#x201c;CCH Joinder&#x201d;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Security Agreement&#x201d;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Pledge Agreement&#x201d;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;AseraCare Joinder,&#x201d; and together with the CCH Joinder, the &#x201c;Joinders&#x201d;).  Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries and the AseraCare entities granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries and the AseraCare entities also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Amended Credit Agreement pursuant to the terms of the Joinders and the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our finance leases outstanding of $2.6 million relate to leased equipment and bear interest rates ranging from 5.3% to 5.8%.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1MTE_da91df3e-88a5-446c-b2d7-fa8ce272238d">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (1.7% at December 31, 2020); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (3.8% at December 31, 2020); due February&#160;4, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i90dece5459db457b9caee4a934044bae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmUzOWVkNDBiZWNjYzQwNjBiY2M3OGJmOTFhZjA1NmY2XzEwOTk1MTE2Mjc5NjE_e4fc27f3-650f-441f-b35f-1ddebe1fd548"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="if7c937ebfcbb4487b42fa8461a09a162_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmUzOWVkNDBiZWNjYzQwNjBiY2M3OGJmOTFhZjA1NmY2XzEwOTk1MTE2Mjc5NzA_5340293e-7289-4171-aee2-79d4bf0f92e0"
      unitRef="number">0.017</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i8de54dd0485448269d1eebf429a33e51_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMC0xLTEtMC90ZXh0cmVnaW9uOmUzOWVkNDBiZWNjYzQwNjBiY2M3OGJmOTFhZjA1NmY2XzEwOTk1MTE2Mjc5ODk_bb6abeab-5bcc-4cc6-b0db-6d7bd03d6f81">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i90dece5459db457b9caee4a934044bae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMS0xLTEtMA_c5bf183e-7050-4b2e-b37b-53c2b915ce6d"
      unitRef="usd">164100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2041f507eabe49338b0fd15b6f05a37a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzItMy0xLTEtMA_e1cfd288-ef5f-4a00-9c58-84b599f6badd"
      unitRef="usd">171700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQzMzE4OTMzYTMwZDRhZDhiZGE1ZTNjZTdkODMyZTNhXzEwOTk1MTE2MjgwMDE_39baf939-5605-4b03-bda4-9d14cbc1554a"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="i4a7367ab708f42b39e9081b6c1bb9a02_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQzMzE4OTMzYTMwZDRhZDhiZGE1ZTNjZTdkODMyZTNhXzEwOTk1MTE2MjgwMTA_caa4230d-b7d2-4000-8fdb-4f607d8c3ac3"
      unitRef="number">0.038</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i5f2b03850b34492e9f5c7baeadcdd170_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMC0xLTEtMC90ZXh0cmVnaW9uOjQzMzE4OTMzYTMwZDRhZDhiZGE1ZTNjZTdkODMyZTNhXzEwOTk1MTE2MjgwMjk_426b85e5-d7fc-4d17-81a6-d04935f12554">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMS0xLTEtMA_e9ead7ae-5bcc-47b5-ae07-c1e8ecb0bcbc"
      unitRef="usd">51000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia0024757aa534d409fcb4e8a79dad213_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzMtMy0xLTEtMA_295e5f44-afda-493b-9464-d0aa8670263f"
      unitRef="usd">70000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8051bc5ccedc4458b6ff74abcdfd5b59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzQtMS0xLTEtMA_689e1122-d92c-4f85-9b5d-476b9b276a72"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i03a65bdf068041f2ba700f2afe87977d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzQtMy0xLTEtMA_7201dd46-5f6f-4234-b00b-842e2662cd29"
      unitRef="usd">600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4365d319b33f4857ae4bc38bf1acf0d9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzUtMS0xLTEtMA_8ff5cdb6-7383-48f2-b7a7-0038d58c6c7e"
      unitRef="usd">2600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i83398cda1ea54e6783c252370998336f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzUtMy0xLTEtMA_fbaf17f3-9e63-4333-84f4-d1b9096db6a7"
      unitRef="usd">3400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzYtMS0xLTEtMA_30c3bf78-46d2-47f5-ae1a-d206639d664a"
      unitRef="usd">217700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzYtMy0xLTEtMA_2bf5e985-bfd6-4de5-ae46-68f4f263327c"
      unitRef="usd">245700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzctMS0xLTEtMA_3c9a5d7e-f743-4c7f-967a-ee1718ef384f"
      unitRef="usd">2700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzctMy0xLTEtMA_7567cf55-a9ea-47b9-85bc-0d7ca1f0bf74"
      unitRef="usd">3500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzgtMS0xLTEtMA_2e13d31a-4d39-45e7-8834-3e1fac21f4f6"
      unitRef="usd">215000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzgtMy0xLTEtMA_dc4bc95d-c6e3-41e6-bba6-960a790c140c"
      unitRef="usd">242200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzktMS0xLTEtMA_12a16149-afbd-4ab7-b02b-52d4ae688405"
      unitRef="usd">10500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzktMy0xLTEtMA_7f0b1612-9140-4df0-a8be-7ebb2ba8a4dc"
      unitRef="usd">9900000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzEwLTEtMS0xLTA_47226288-07c5-4f98-9d22-21d434595622"
      unitRef="usd">204500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTplMmU2M2Q4NGMwNTE0ZjJhOTBmMTJlMjJhM2MzODc5OS90YWJsZXJhbmdlOmUyZTYzZDg0YzA1MTRmMmE5MGYxMmUyMmEzYzM4Nzk5XzEwLTMtMS0xLTA_16a5510b-0b10-4d64-bdef-7f533a03f094"
      unitRef="usd">232300000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1MjA_204c9e39-744a-40a2-9d33-3215fa091844">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt as of December&#160;31, 2020 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term&lt;br/&gt;obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzItMS0xLTEtMA_ffd52148-d3c8-402d-a801-1ed24cb10740"
      unitRef="usd">10500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzMtMS0xLTEtMA_5bcca680-786d-42e4-abc5-77a59b01df19"
      unitRef="usd">9400000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzQtMS0xLTEtMA_c46fe5e3-46ee-40cc-9e4a-c14d3676eabd"
      unitRef="usd">12300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzUtMS0xLTEtMA_c7162a34-915e-4182-abc4-92801d6d6b4c"
      unitRef="usd">185500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzYtMS0xLTEtMA_f46c33d8-8bea-4231-9290-53bfb465d0cb"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZToyNmNiNGEyZmUzMGM0MTE2YWE3YmU0MTljYzVlZDU0My90YWJsZXJhbmdlOjI2Y2I0YTJmZTMwYzQxMTZhYTdiZTQxOWNjNWVkNTQzXzctMS0xLTEtMA_5dabbb07-e895-4ad9-88c2-60dcca2d7864"
      unitRef="usd">217700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzQxNQ_94f755e7-61b4-478e-a9a8-e9c5898ea326"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzUyMA_0c71929f-dfb6-4913-81d7-9f89dc7ba514"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:SwingLineFacility
      contextRef="i55e3ad37975747ce85e5f9e56a387aeb_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzUzMQ_cad4ae4e-3a31-45f7-bf4c-c7185f3ec2dd"
      unitRef="usd">25000000.0</amed:SwingLineFacility>
    <amed:LettersofCreditmaximumcommitment
      contextRef="i55e3ad37975747ce85e5f9e56a387aeb_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzU3OQ_30540e15-9574-415c-b330-e4a341cc2fb8"
      unitRef="usd">60000000.0</amed:LettersofCreditmaximumcommitment>
    <amed:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcxNw_bdc430d7-f7a2-40e5-b3cf-b89d5dbafb49"
      unitRef="usd">125000000.0</amed:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <amed:CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple
      contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzc3OA_4a2a437a-7d93-4a4c-9fc4-3da3817b800a"
      unitRef="number">0.5</amed:CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple>
    <amed:Creditfacilitymaximumallowableconsolidatedleverageratio
      contextRef="ifedadb8035864252bc2a50fe50d27fb7_I20180629"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1Nw_50e9834c-5f23-4584-b779-666421bf635f"
      unitRef="number">3.0</amed:Creditfacilitymaximumallowableconsolidatedleverageratio>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="ib818b639b2fc470b9dfaf7a8a57d34aa_D20180629-20180629"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzExNzE_707a0524-28b0-441c-85df-ffa8ab0d2548">2023-06-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i90f987fd3c874bb7a0482a03ac02dd0a_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzE4NDM_72fbe17b-4de5-4e17-8db3-70748a632bd6"
      unitRef="usd">725000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i90f987fd3c874bb7a0482a03ac02dd0a_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzE4NjY_be4ac504-ac76-4170-8342-99fa75b73053"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic20973059f44430a8ea7527042093e66_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzE5ODE_0eca1425-e2c7-4b84-aef9-a39aa1eb8548"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate
      contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzI3NDM_b675eb47-0db9-415e-8f67-8037e3600552"
      unitRef="number">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
    <amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate
      contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzI4NjI_488744f5-31af-48d1-9bc7-8858bbb15457"
      unitRef="number">0.01</amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1MjE_c9685d84-edcd-4bda-946c-cc0f67992bf2">The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2020, the Applicable Rate is 0.25% per annum for Base Rate Loans and 1.25% per annum for Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment&lt;br/&gt;Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter&#160;of&lt;br/&gt;Credit&#160;Fee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2265;&#160;3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&amp;lt; 3.00 to 1.0 but &#x2265;&#160;2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&amp;lt; 2.00 to 1.0 but &#x2265;&#160;0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&amp;lt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i82f050f262b84796a9b340b2d9129bc0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzMyNTk_28600be0-6aea-4564-9635-bf204f161a07"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifcea2f99e9244669860fa34644e434d1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzMyOTY_12a9a7b0-9a6d-4040-83bf-c8d20a94813c"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="ifd5550ca8a47443f914e49b80cf1c663_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtMS0xLTEtMC90ZXh0cmVnaW9uOmQwYjljMDRmMzc4NTRmMTg4ZjAxYWQxNGZjNDYwZWE4XzEwOTk1MTE2Mjc4MTE_ac7fc809-29a9-4c03-89a7-b088d51cbe2a"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i449b5f09d3b34ec39a18a9cef526b9a6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtMy0xLTEtMA_ba23b500-0ef6-43dc-9a59-a15a0209cd84"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic46bf12be9614cdc9e2592966809f199_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtNS0xLTEtMA_ddc1fe85-8f36-49fd-8a1e-3b5257d61f43"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i4332b377849d47079522cdb966f405aa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtNy0xLTEtMA_1ce788a2-4a28-4089-9b40-455f3f13aea5"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i4332b377849d47079522cdb966f405aa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzEtOS0xLTEtMA_ffe65e05-9ef1-43ca-ac61-7fb4fd4619e3"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="if009f649f525477986901bf87b9a8a8a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItMS0xLTEtMC90ZXh0cmVnaW9uOmU1NzE2MThjZmYzMDQ3ZDNhNTcyZDA4ZmQ3ZTQxNGI3XzEwOTk1MTE2Mjc4NTQ_d2e9d40c-3dc0-4015-b136-47186ce5e760"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i663a0220bf1f4bde8453506f3ec8b0c8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItMS0xLTEtMC90ZXh0cmVnaW9uOmU1NzE2MThjZmYzMDQ3ZDNhNTcyZDA4ZmQ3ZTQxNGI3XzEwOTk1MTE2Mjc4NTk_d86072ec-9973-4674-ad70-ff539345c758"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i58ce40c5da424eb1acc6a5a1cc10d1ae_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItMy0xLTEtMA_b92ce5ba-d6f9-46c4-9aca-00f82d9ead45"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib6dd35f3ef914c7b9e3b873612e24d07_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItNS0xLTEtMA_c804012f-a6d8-4ab8-82c1-87427fc46a78"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ib2fdd832f78f447590dcea35096f588e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItNy0xLTEtMA_5ee9eae0-fd99-4e9d-a716-d33a2217de3d"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ib2fdd832f78f447590dcea35096f588e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzItOS0xLTEtMA_010cc7ba-46da-428a-a9dc-cbb89ad654c2"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="id875fdd2eb7148c4aa89a6f6d517e964_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjI1ZjZiYmE2YWE0ODRkM2Y5YzFkNWMwZmRmMzc3ZTZiXzEwOTk1MTE2Mjc4NDk_12752c4c-3580-4755-b0a4-0757f5961d7f"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="ifd3a5e252c794510b621a8afd98a30af_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjI1ZjZiYmE2YWE0ODRkM2Y5YzFkNWMwZmRmMzc3ZTZiXzEwOTk1MTE2Mjc4NTQ_c664dff8-410b-4fe9-9708-b42dff895b32"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic73c6064129945f89356c2e9781e2ff3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtMy0xLTEtMA_fc7ea5cb-7652-4bac-9652-08bdc74f446a"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1ac1b22c6f554e6db80a1dec5c335a03_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtNS0xLTEtMA_441941e8-f79e-4b1b-8226-b1b088e7a73b"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i327f7ac146d444c88f630645e8202d8f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtNy0xLTEtMA_a7763883-a938-4908-99b8-e60079fbfdb1"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i327f7ac146d444c88f630645e8202d8f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzMtOS0xLTEtMA_dc09fe25-a753-46d6-9bf2-f7bb58160a43"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="if363353766114727baf5a4aab4fe9ca4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjBjOWM4ZmM3ZDI5ZDRkNDE5ZDNkOTI4NTMzY2UzMzFkXzEwOTk1MTE2Mjc3OTc_add64549-5d72-44bc-9f5e-04fa819e900b"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6ef9e7a889a946cfba1e6124e81184a0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtMy0xLTEtMA_b36f1c7e-a76a-416d-b42e-60eb6764ed89"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3064d98b299543439b8d8a53616ccd96_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtNS0xLTEtMA_5e1d9197-c2a8-407b-bc39-d740e069faff"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i6594991d717f452eb94882c394b94cea_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtNy0xLTEtMA_013d309e-771c-476b-9fbe-2c54d043cf68"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i6594991d717f452eb94882c394b94cea_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90YWJsZTpmMTRiMmMwMTViY2I0ZmIzYjFmOTRlODYxMDZjZTNiNC90YWJsZXJhbmdlOmYxNGIyYzAxNWJjYjRmYjNiMWY5NGU4NjEwNmNlM2I0XzQtOS0xLTEtMA_60b99ed9-25b4-47cf-820c-9668df929dd8"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzM1MzY_758bcd70-050c-4008-9936-a0b56de048bd">2024-02-04</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="ia7d69adb19bc439892e8f7b86338bcb6_D20190204-20200331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzM3NDM_3a43e571-b077-49a4-ad4d-f3b1741dd522"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i7328ca3b33b846ebb1d8865233054b79_D20200401-20230331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzM4Mjc_4af559b6-49d3-4bac-b827-da157b98e02a"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i5f285d89c3194106bf7a283b287c5858_D20230401-20240204"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzM5MTM_cba60a7a-20fa-4b34-bd0f-8dbb879cc64b"
      unitRef="number">0.01875</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="i81b3d4329c9e413992649f97f3932f8e_D20190204-20190204"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzQ1MTU_1ac5bbbd-a689-4b88-b2a9-35cad6a5bcf6"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i813d4685897443ab84f5078bedbc3eed_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzU1NTY_25e79a93-2246-4932-b63d-3b84292281be"
      unitRef="usd">800000</us-gaap:PaymentsOfFinancingCosts>
    <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries
      contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzU5OTU_b2ee4ac8-77a4-40b8-b3c5-2aa33d38693f"
      unitRef="number">0.95</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
    <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries
      contextRef="i2ae208d27e6a4a389b37e530116743ab_D20190204-20190204"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzYxNzg_362706ea-e318-4246-b82d-6054b6a764e6"
      unitRef="number">0.70</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i90dece5459db457b9caee4a934044bae_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzYzMDU_76e0d7e5-7d1d-4fab-8a58-2ef167e739c1"
      unitRef="usd">175000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i8de54dd0485448269d1eebf429a33e51_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzEwOTk1MTE2MzkyMTM_1111d1b9-6328-45e0-ac8a-c438af54e705"
      unitRef="number">0.022</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i0a9f227940024b9b9e6f47095fc1825c_D20190204-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzEwOTk1MTE2NDAwMjM_155d4ea7-a054-4366-864f-ef28e33178d3"
      unitRef="number">0.038</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY0NDg_a33c854f-7faf-4206-9526-1ce83076d677"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i5f2b03850b34492e9f5c7baeadcdd170_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY0ODE_e5046265-4eda-4924-9e07-9e7d6ca90070"
      unitRef="number">0.022</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ibd494e95d0b348dbbcf7c525e255735b_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY1Mjc_e5077704-1df8-408c-b609-2d5266997052"
      unitRef="number">0.040</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <amed:TotalLeverageRatio
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY2Mjc_80fae559-1b42-405d-b6d2-97866d8edac1"
      unitRef="number">0.6</amed:TotalLeverageRatio>
    <amed:ConsolidatedInterestCoverageRatio
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzY2NzY_4c9e0a50-8902-4664-8065-4392e40be7eb"
      unitRef="number">25.6</amed:ConsolidatedInterestCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcwNTQ_31ea170c-5272-4612-a12f-36c4a1a65fdd"
      unitRef="usd">550000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcwODc_3470c79d-f4db-4b20-b617-a5bc313d1017"
      unitRef="usd">470200000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie2ed331009f24a32b73120f18a9797f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcxMDE_01b138ed-ff32-43c7-85f4-7a67d36b9e09"
      unitRef="usd">51000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i3d03942e78784e909bcee19f2ae8dcad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4XzcxMzQ_2da99589-400f-4464-bc44-e25fc17c5191"
      unitRef="usd">28800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4365d319b33f4857ae4bc38bf1acf0d9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg0MzE_c3920efa-f5bc-42b8-a9a4-bcb84a3e964c"
      unitRef="usd">2600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3c7e72eca4bc4cf0b3983258ef075db8_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg0OTg_111f083a-0f58-4099-81d1-f6a658222eff"
      unitRef="number">0.053</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i68bc26784c984ab2b763317f0ea13821_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDkvZnJhZzpjNDg3NDA0YjdmM2Y0MmE2OTFmYzQ5ODlkZjVkNTA3OC90ZXh0cmVnaW9uOmM0ODc0MDRiN2YzZjQyYTY5MWZjNDk4OWRmNWQ1MDc4Xzg1MDQ_d3b6a726-d743-4de3-836a-30a12e2c080a"
      unitRef="number">0.058</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxODQ_460d8a7f-6e05-4b3a-9b22-f0bc3f76fc06">INCOME TAXES&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes attributable to continuing operations consist of the following (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current income tax expense/(benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income tax expense/(benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense for the years ended December&#160;31, 2020, 2019 and 2018 was allocated as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense at U.S. federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local income taxes, net of federal income tax benefit (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Excess tax benefits from share-based compensation (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other items, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Compensation: Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $92.1&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $19.4&#160;million federal income tax benefit and a $4.6&#160;million state and local income tax benefit for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company had income taxes receivable of $0.2 million and $2.0 million, respectively, included in other current assets within our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets (liabilities) consist of the following components (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued payroll&#160;&amp;amp; employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal &amp;amp; compliance matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provider relief fund advance (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred social security taxes (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;In April 2020, approximately $100&#160;million was provided to the Company through the healthcare Provider Relief Fund established under the CARES Act. As of December 31, 2020, the Company recorded a liability related to the funds that we do not expect to utilize totaling $60&#160;million, which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. For income tax purposes, the Company recognized the $60&#160;million as income upon receipt, resulting in a deferred tax asset as of December 31, 2020. The company will recognize an income tax deduction when the liability is paid during the year ended December 31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;The CARES Act provides for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, the Company has deferred $55.4&#160;million of social security tax payments; $27.7&#160;million of this amount is reflected in each payroll and employee benefits and other long-term obligations within our consolidated balance sheet. For income tax purposes, the deferred social security taxes will be deductible when paid on December 31, 2021 and December, 31, 2022, resulting in a deferred tax asset at December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, we have state net operating loss ("NOL") carryforwards of $47.5 million that are available to reduce future taxable income and $3.7 million of various state tax credits available to reduce future state income taxes. The state NOL and tax credit carryforwards expire at various times.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 and 2019, the valuation allowance for deferred tax assets, which is primarily related to certain state NOLs and state tax credit carryforwards, was $0.1 million and $0.4 million, respectively. The net change in the total valuation allowance for the years ended December 31, 2020 and 2019 was a decrease of $0.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carryforwards governed by the tax code. Based on the current level of pretax earnings, the Company will generate the minimum amount of future taxable income needed to support the realization of the deferred tax assets. As a result, as of December&#160;31, 2020, management believes that it is more likely than not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020 and 2019, there is $2.7 million of unrecognized tax benefits recorded in other long-term obligations within the consolidated balance sheets that, if recognized in future periods, would impact our effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized $0.2&#160;million, $0.3 million and $0.1 million of interest as components of interest expense in connection with our reserve for uncertain tax positions during the years ended December 31, 2020, 2019 and 2018, respectively. Interest related to uncertain tax positions included in the consolidated balance sheets at December 31, 2020 and 2019 was $0.6 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to income taxes in the U.S. and in many individual states, with significant operations in Louisiana, South Carolina, Alabama, Georgia, Massachusetts and Tennessee. We are open to examination in the U.S. and in various individual states for tax years ended December&#160;31, 2014 through December&#160;31, 2020. We are also open to examination in various states for the years ended 2007 through 2020 resulting from NOLs generated and available for carryforward from those years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <amed:ProvisionforIncomeTaxesTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU3NjA_e77f3675-0075-4c99-9ce3-76ab2c461f82">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes attributable to continuing operations consist of the following (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current income tax expense/(benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income tax expense/(benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense for the years ended December&#160;31, 2020, 2019 and 2018 was allocated as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ProvisionforIncomeTaxesTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzMtMS0xLTEtMA_49b4351f-796b-44b2-9615-dfc1b2e7671a"
      unitRef="usd">41600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzMtMy0xLTEtMA_1e0a888e-5d48-4c3d-ad76-1864ace3775e"
      unitRef="usd">24200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzMtNS0xLTEtMA_069c2d72-46a4-4828-aa08-12d1ca49579a"
      unitRef="usd">16400000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzQtMS0xLTEtMA_29f1b7e4-9cfc-4ebf-9955-af5f77cfdebb"
      unitRef="usd">10600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzQtMy0xLTEtMA_5810f488-2bf2-46e5-91db-1174d56920e7"
      unitRef="usd">4800000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzQtNS0xLTEtMA_e91b8775-0b99-4318-96a0-8d8cdacecc9d"
      unitRef="usd">2100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzUtMS0xLTEtMA_a858c630-8a3d-4f63-ad40-d58ae83f8457"
      unitRef="usd">52200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzUtMy0xLTEtMA_0b51887e-f9c7-47c3-8c84-f20f23b51cfe"
      unitRef="usd">29000000.0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzUtNS0xLTEtMA_8cf50cd3-8e10-44b1-837b-24a5b5bfd539"
      unitRef="usd">18500000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzctMS0xLTEtMA_084ef85e-474c-4e2f-96b3-0a7deb4d0ab5"
      unitRef="usd">-22500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzctMy0xLTEtMA_7693dba8-13e9-4422-8662-693b4a23535d"
      unitRef="usd">9500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzctNS0xLTEtMA_359d74dc-ea74-4c06-9438-287463306400"
      unitRef="usd">14500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzgtMS0xLTEtMA_85853e48-2396-4914-8831-5af8326f4326"
      unitRef="usd">-4100000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzgtMy0xLTEtMA_6bbd4d92-7e5e-487f-9ea1-c17d69d46465"
      unitRef="usd">4000000.0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzgtNS0xLTEtMA_a1724fbb-cdae-4e5c-bec9-84aedfce604b"
      unitRef="usd">5800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzktMS0xLTEtMA_c4c92bc0-1efd-49d9-89ef-973f8e745758"
      unitRef="usd">-26600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzktMy0xLTEtMA_0d41af63-e182-4f21-bad6-3fa580c566f7"
      unitRef="usd">13500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzktNS0xLTEtMA_c108c7a0-d5d9-4922-b4e2-fca30c25db88"
      unitRef="usd">20300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzEwLTEtMS0xLTA_d3e4477c-e85a-4529-a417-bb6f00752aec"
      unitRef="usd">25600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo1MzQ3MzViYTlmNTM0OGY2OGFjYjdiM2Y1MTliODcyNS90YWJsZXJhbmdlOjUzNDczNWJhOWY1MzQ4ZjY4YWNiN2IzZjUxOWI4NzI1XzEwLTMtMS0xLTA_074fbe92-536a-4594-9462-6a90381443ad"
      unitRef="usd">42500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzItMS0xLTEtMA_3454e0e6-c1bb-47f2-884b-9f7c4ed2fa6b"
      unitRef="usd">25600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzItMy0xLTEtMA_7a457af5-ed6c-47ce-b811-52bf91c092dc"
      unitRef="usd">42500000</us-gaap:IncomeTaxExpenseBenefit>
    <amed:IncomeTaxEffectsAllocatedToInterestExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzMtMS0xLTEtMA_e62f80af-6d52-4424-9276-690ec0e7f040"
      unitRef="usd">200000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
    <amed:IncomeTaxEffectsAllocatedToInterestExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzMtMy0xLTEtMA_7f960515-647f-43ef-9dfa-9fdb01e219e0"
      unitRef="usd">300000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
    <amed:IncomeTaxEffectsAllocatedToInterestExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzMtNS0xLTEtMA_287efd8b-aaf5-4d04-ade2-3ec73bd4f806"
      unitRef="usd">100000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
    <amed:IncomeTaxEffectsAllocatedToGoodwill
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzUtMS0xLTEtMA_73ebc199-58a8-4ff5-87c8-79fa7114ecff"
      unitRef="usd">0</amed:IncomeTaxEffectsAllocatedToGoodwill>
    <amed:IncomeTaxEffectsAllocatedToGoodwill
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzUtMy0xLTEtMA_d1ee8f98-641c-4826-8081-95e555c1e821"
      unitRef="usd">900000</amed:IncomeTaxEffectsAllocatedToGoodwill>
    <amed:IncomeTaxEffectsAllocatedToGoodwill
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzUtNS0xLTEtMA_634d8e3a-2982-49c5-b8b2-060cc41d9e5f"
      unitRef="usd">0</amed:IncomeTaxEffectsAllocatedToGoodwill>
    <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzYtMS0xLTEtMA_14034154-6acf-48d5-83fe-e9551c132591"
      unitRef="usd">25800000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
    <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzYtMy0xLTEtMA_0d9cfac8-b655-4924-a5d2-217f92ef8fe5"
      unitRef="usd">43700000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
    <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTo5ODI1ZDg0N2VkZmY0ZTc1OWFkYmU5MjZmMzBhODQ1MC90YWJsZXJhbmdlOjk4MjVkODQ3ZWRmZjRlNzU5YWRiZTkyNmYzMGE4NDUwXzYtNS0xLTEtMA_98a397a1-8fe4-4490-b2b7-ec744c406c24"
      unitRef="usd">38900000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU3NjQ_3a1f2f4e-c22b-4392-8113-0a61a373f615">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense at U.S. federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local income taxes, net of federal income tax benefit (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Excess tax benefits from share-based compensation (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other items, net (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Compensation: Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $92.1&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $19.4&#160;million federal income tax benefit and a $4.6&#160;million state and local income tax benefit for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzItMS0xLTEtMA_b0405ae9-053c-4ca2-b87d-e4f65d9ef65d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzItMy0xLTEtMA_eec32649-f85f-4e8e-9202-12c181aa7ca8"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzItNS0xLTEtMA_6d69be9d-b4b3-4ec9-b0e0-866ddbcfb695"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzMtMS0xLTEtMA_9cdc9ac4-9d71-4499-b301-0b3ffd1d2266"
      unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzMtMy0xLTEtMA_fde79fc1-1ead-4da4-bb24-755a4762bc9c"
      unitRef="number">0.048</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzMtNS0xLTEtMA_68a401cf-34a6-4ae7-bead-45aaeb9af663"
      unitRef="number">0.048</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzQtMS0xLTEtMA_19e13656-c930-47f2-b94b-80c570247249"
      unitRef="number">0.127</amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzQtMy0xLTEtMA_eae9cd9e-b43c-49f2-b81b-61a3254e6bf6"
      unitRef="number">0.022</amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzQtNS0xLTEtMA_ac8754b3-9abc-48c1-bb80-09deaf11a533"
      unitRef="number">0.018</amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzUtMS0xLTEtMA_cf10aa80-3eaf-488e-9e5b-5c3383caddee"
      unitRef="number">0.021</amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzUtMy0xLTEtMA_084f8d31-a7fc-4ee9-bfbe-3934c5efd1fa"
      unitRef="number">0.016</amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzUtNS0xLTEtMA_ec5291e3-6bcd-43e6-9bfe-d47dc0e9fd2e"
      unitRef="number">0.004</amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzYtMS0xLTEtMA_451df2b0-1ca2-4d8f-8fef-23b775d5bba3"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzYtMy0xLTEtMA_6b1dba2e-3c51-4ff3-9e63-906529d95254"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzYtNS0xLTEtMA_59b7d3ef-82c5-4215-b490-90a67cd63d18"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzctMS0xLTEtMA_52aa0765-9dbc-4575-8c8d-eb3556db0886"
      unitRef="number">0.122</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzctMy0xLTEtMA_58ed6495-94ec-458b-b3cb-ba571500e08f"
      unitRef="number">0.249</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTphNjA4NTgxZWVhMTc0YTAxOGEyOGMxZTc1OGIyNjZkZS90YWJsZXJhbmdlOmE2MDg1ODFlZWExNzRhMDE4YTI4YzFlNzU4YjI2NmRlXzctNS0xLTEtMA_c61317a7-0798-4531-a520-eca72907a65a"
      unitRef="number">0.244</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQyMTM_379add51-4341-486e-986f-d95d96f45e89"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i5e2a3b22027c46259ffb26bf610aae36_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQwODQ_b3d3b48a-0e43-445b-af04-a4633989a417"
      unitRef="usd">92100000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i061c5e4bcf0a48809b0f8aaa50b8d7f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQwOTk_a61e286a-f98a-4626-96ee-e7cd1f680da6"
      unitRef="usd">19400000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i9a797cd8697149299906057726300694_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxMTQ_1b105219-273b-41e4-b6b2-b81a6d573d32"
      unitRef="usd">4600000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzE1MjI_197ca48a-80ac-4bf3-97f5-4c386c51b589"
      unitRef="usd">200000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzE1Mjk_aadcf908-0059-485a-8431-eeed0597cf1c"
      unitRef="usd">2000000.0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU3NjU_3a560798-d294-4e0f-8aef-f9a3d190bb84">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets (liabilities) consist of the following components (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued payroll&#160;&amp;amp; employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal &amp;amp; compliance matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provider relief fund advance (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred social security taxes (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investment in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;In April 2020, approximately $100&#160;million was provided to the Company through the healthcare Provider Relief Fund established under the CARES Act. As of December 31, 2020, the Company recorded a liability related to the funds that we do not expect to utilize totaling $60&#160;million, which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. For income tax purposes, the Company recognized the $60&#160;million as income upon receipt, resulting in a deferred tax asset as of December 31, 2020. The company will recognize an income tax deduction when the liability is paid during the year ended December 31, 2021.  &lt;/span&gt;&lt;/div&gt;(2)The CARES Act provides for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, the Company has deferred $55.4&#160;million of social security tax payments; $27.7&#160;million of this amount is reflected in each payroll and employee benefits and other long-term obligations within our consolidated balance sheet. For income tax purposes, the deferred social security taxes will be deductible when paid on December 31, 2021 and December, 31, 2022, resulting in a deferred tax asset at December 31, 2020.</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzQtMS0xLTEtMA_6eef7c17-d0d9-46ee-93af-b1e5d4633b56"
      unitRef="usd">15900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzQtMy0xLTEtMA_bf64d918-7ffb-425e-9438-b6138ceded25"
      unitRef="usd">15100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzUtMS0xLTEtMA_6f7918c5-7aa9-404a-891c-885472152aee"
      unitRef="usd">9600000</amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation>
    <amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzUtMy0xLTEtMA_d808d3df-9f64-4485-a139-1e42307e519f"
      unitRef="usd">9000000.0</amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzctMS0xLTEtMA_0af6115b-0318-4c6b-814c-5e584ab0b534"
      unitRef="usd">5100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzctMy0xLTEtMA_af27ad81-df6c-4dc3-a623-79454b21063c"
      unitRef="usd">7900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <amed:DeferredTaxAssetsLegalAndComplianceMatters
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzgtMS0xLTEtMA_0bef4d61-0fef-4bef-94d4-cd9dea7f07d8"
      unitRef="usd">7000000.0</amed:DeferredTaxAssetsLegalAndComplianceMatters>
    <amed:DeferredTaxAssetsLegalAndComplianceMatters
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzgtMy0xLTEtMA_6f87dfd0-e62a-435c-b7aa-c478bc5f5cf1"
      unitRef="usd">4800000</amed:DeferredTaxAssetsLegalAndComplianceMatters>
    <amed:DeferredTaxAssetsLeaseLiability
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzctMS0xLTEtNDEyNg_e9e8715b-b595-4f3c-8388-3a9e8f50dd3c"
      unitRef="usd">25200000</amed:DeferredTaxAssetsLeaseLiability>
    <amed:DeferredTaxAssetsLeaseLiability
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzctMy0xLTEtNDEyNg_e0093904-4d8c-4c19-9ff3-eda7d2100960"
      unitRef="usd">23100000</amed:DeferredTaxAssetsLeaseLiability>
    <amed:DeferredTaxAssetsProviderReliefFundAdvance
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzgtMS0xLTEtNDEyNg_a6e73d89-8a7d-4fe8-bca7-0aae0a43f903"
      unitRef="usd">15600000</amed:DeferredTaxAssetsProviderReliefFundAdvance>
    <amed:DeferredTaxAssetsProviderReliefFundAdvance
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzgtMy0xLTEtNDEyNg_40d40fd2-83ec-417b-93af-3c3b227184f3"
      unitRef="usd">0</amed:DeferredTaxAssetsProviderReliefFundAdvance>
    <amed:DeferredTaxAssetDeferredSocialSecurityTaxes
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzktMS0xLTEtNDEyNg_3b1fe60d-9d11-42db-913e-866ff39ca8db"
      unitRef="usd">14300000</amed:DeferredTaxAssetDeferredSocialSecurityTaxes>
    <amed:DeferredTaxAssetDeferredSocialSecurityTaxes
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzktMy0xLTEtNDEyNg_63f668c6-cebf-4ec2-be24-0f32da81f02f"
      unitRef="usd">0</amed:DeferredTaxAssetDeferredSocialSecurityTaxes>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzktMS0xLTEtMA_09d09782-8323-4e6f-9215-0013964367c7"
      unitRef="usd">2400000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzktMy0xLTEtMA_8cf61f2d-317e-450f-991e-767dedf17e44"
      unitRef="usd">3700000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEwLTEtMS0xLTA_021ce504-bba9-43aa-ac9e-fd10436b8003"
      unitRef="usd">2900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEwLTMtMS0xLTA_bcec71a5-c53b-4da9-8641-57c5ca23963f"
      unitRef="usd">3100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzExLTEtMS0xLTA_0fa16eb9-4148-49f3-8a7d-c5be60e34397"
      unitRef="usd">600000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzExLTMtMS0xLTA_4f773dc1-a742-4d3b-a609-6d71de45597c"
      unitRef="usd">500000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEyLTEtMS0xLTA_36c15696-ef86-4039-9121-f0a139ae535e"
      unitRef="usd">98600000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEyLTMtMS0xLTA_f882ace4-9024-475c-941b-b0095663e7e7"
      unitRef="usd">67200000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEzLTEtMS0xLTA_0d6802b6-8b0f-4e2f-b77c-ddefb779db9a"
      unitRef="usd">100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzEzLTMtMS0xLTA_4e8f8db8-893a-4cd1-8dcc-5977820b9f5c"
      unitRef="usd">400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE0LTEtMS0xLTA_639a9676-0554-40bd-be6b-ed44f0120f4b"
      unitRef="usd">98500000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE0LTMtMS0xLTA_39f61516-513a-4a39-abc6-af1f2a689ea7"
      unitRef="usd">66800000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE2LTEtMS0xLTA_9e84011c-7942-4b87-bf54-09c23530b4d2"
      unitRef="usd">3800000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE2LTMtMS0xLTA_e422a30d-aaa0-4bca-90b9-beda2b2ffe5e"
      unitRef="usd">4300000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE3LTEtMS0xLTA_7cd778ac-d0cf-40ea-afbd-a65e6cbf58d7"
      unitRef="usd">11800000</amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets>
    <amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE3LTMtMS0xLTA_d47d8b64-bec1-4c93-ae5c-01110c620465"
      unitRef="usd">300000</amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE4LTEtMS0xLTA_265a8e06-fb84-45f7-99cd-6a99ce87616a"
      unitRef="usd">9000000.0</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE4LTMtMS0xLTA_c6bd213b-e0bf-46fd-8afe-180bba70a26f"
      unitRef="usd">13500000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE5LTEtMS0xLTA_1602a976-f930-4903-91d0-194e449cd382"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzE5LTMtMS0xLTA_f0564dde-068e-4c36-a200-031e49658679"
      unitRef="usd">3300000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <amed:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIxLTEtMS0xLTQxMjk_010ab809-6fe1-4b2e-b607-2c33608c2e15"
      unitRef="usd">24900000</amed:DeferredTaxLiabilitiesRightOfUseAssets>
    <amed:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIxLTMtMS0xLTQxMjk_9dd7638a-3b4a-4ea2-b72b-18d83ea0cb0e"
      unitRef="usd">22800000</amed:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIwLTEtMS0xLTA_1bc8f7ee-a409-44af-a7e0-5af6a0d0450d"
      unitRef="usd">1000000.0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIwLTMtMS0xLTA_5e0649c4-d3ed-48bd-9e76-b91a8bce5910"
      unitRef="usd">1200000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIxLTEtMS0xLTA_973b2d82-84f9-413c-aa9c-972474a7737f"
      unitRef="usd">50500000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIxLTMtMS0xLTA_dbedcbe8-677b-41cb-b8b8-7dd7b3129a55"
      unitRef="usd">45400000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIyLTEtMS0xLTA_8650fc31-cb2c-45b6-82bd-bc6f7e26efdd"
      unitRef="usd">48000000.0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTplN2M0YmU0MjM5Y2I0M2MxOWNiZTFjY2ZiNDA3NjdjNC90YWJsZXJhbmdlOmU3YzRiZTQyMzljYjQzYzE5Y2JlMWNjZmI0MDc2N2M0XzIyLTMtMS0xLTA_fef6e4ad-8970-411e-836b-f8f3331fa5e1"
      unitRef="usd">21400000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <amed:FundingReceivedFromCARESAct
      contextRef="i372268bd3773442994730e4fe0e5ee44_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxOTk_86f450c9-623d-4604-b4ee-5538f9175ffb"
      unitRef="usd">100000000</amed:FundingReceivedFromCARESAct>
    <amed:ProviderReliefFundAdvance
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxODY_b437ea1c-5920-47af-ae75-b76db66b122c"
      unitRef="usd">60000000</amed:ProviderReliefFundAdvance>
    <amed:ProviderReliefFundAdvance
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxMjg_a2c37cff-6b97-4cc7-943c-6e3ae70e3b8a"
      unitRef="usd">60000000</amed:ProviderReliefFundAdvance>
    <amed:CARESActDeferralOfEmployerShareSocialSecurityTax
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxNDE_f34df0ab-3bd8-41c5-a46f-d1ed2f216270"
      unitRef="usd">55400000</amed:CARESActDeferralOfEmployerShareSocialSecurityTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4c55a72c359242999f6ad37fe6380c0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxNTY_8413f32d-4594-44ba-89f2-20c43fad4cc0"
      unitRef="usd">27700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4c55a72c359242999f6ad37fe6380c0f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxNTY_e4a2066b-61f2-4411-a32e-1bbc0de851f7"
      unitRef="usd">27700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2ff4532176b44743aad3722dcd2582f0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzIwMzE_93a30817-81ad-412c-a964-308ea971dd01"
      unitRef="usd">47500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="iaa1ce8651ce74253af7461cfa4722490_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzIwODk_c88f4b53-c63d-46be-90e5-f5428db73302"
      unitRef="usd">3700000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzI0MDg_f556fda6-fca6-44aa-982a-b7feebb39af6"
      unitRef="usd">100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzI0MTU_62ce2a91-1d7c-4832-b4f1-a738a0170718"
      unitRef="usd">400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzI1MzY_d143b74d-b102-4c8f-b6f6-72defefd471a"
      unitRef="usd">300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzI1MzY_fa8719da-600c-41cc-b5e2-998dca12452d"
      unitRef="usd">300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU3Njc_865a99f6-5139-4868-a940-93fbbbf8f4ec">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzItMS0xLTEtMA_392461d7-1161-47b1-b327-86acf33db287"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzItMy0xLTEtMA_39d29e8a-cf9a-4db5-a4d1-fc49304f78df"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i71d70551ae8f463895c999fdc4613768_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzItNS0xLTEtMA_3928d3f8-c47d-4185-b841-3c08e8a36ad8"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzMtMS0xLTEtMA_67045844-606c-4141-b9de-5c4cc2ca953b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzMtMy0xLTEtMA_5ba7205b-d0e6-46d3-9787-71a5cd0efb87"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzMtNS0xLTEtMA_640ad69f-913b-48aa-8914-16b1941d7865"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzQtMS0xLTEtMA_4f3bf6b3-2f1b-4cf6-8967-11824456b391"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzQtMy0xLTEtMA_30894ad0-08a8-48c8-a7e4-15276507c710"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzQtNS0xLTEtMA_d431a87d-d7f2-473e-b6cc-f82c4de45a4c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzUtMS0xLTEtMA_bf023ecc-4bf2-4503-94d1-c01a3f973426"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzUtMy0xLTEtMA_46fcbe58-7854-400d-ad97-7fefa37d89a8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzUtNS0xLTEtMA_8af83839-cb38-45f7-af8c-81309af8705b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzYtMS0xLTEtMA_161dd5ba-8538-498e-9f23-5f4469449516"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzYtMy0xLTEtMA_c8787777-6ed0-44e6-8a74-37db8c7213ba"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzYtNS0xLTEtMA_04a586e9-eb50-40c2-8c59-1510de804be5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzgtMS0xLTEtMA_bba3bdc1-7c7f-4040-927c-7ba7d362a9fb"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzgtMy0xLTEtMA_279664b1-e53e-43e5-a6be-a68f4df54d57"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzgtNS0xLTEtMA_ba6d955e-3a68-4d79-baf9-074bd7831651"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzktMS0xLTEtMA_1226e71e-f007-483f-970b-65cd57c3e7bd"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzktMy0xLTEtMA_92142014-a196-42a5-a2c4-fec9eb44de6e"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90YWJsZTozMjFmYWJmZjRlOWI0YWRmYWI2ZjI5ODkyMmZkZTc5Zi90YWJsZXJhbmdlOjMyMWZhYmZmNGU5YjRhZGZhYjZmMjk4OTIyZmRlNzlmXzktNS0xLTEtMA_ce738fc9-badd-4d16-b16f-471b8ff73d8a"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzQ1NDM_04ce5432-6720-47a0-ba12-8853b49f7fe0"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzQ1NDM_a0ce7e82-69a4-4550-b1a6-5e75edd4dcb7"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzEwOTk1MTE2NDQxNzE_0aa05bf9-2aa5-44f3-9a37-1f671235c2f3"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzQ3NDM_d361b703-1984-4bb3-8717-4552cfd059aa"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzQ3NTA_2fab7bb4-9210-432e-8915-9d21b53575c9"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzUyNDE_4d1a7e3c-0075-4890-bc9f-d034b8979d91"
      unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzUyNDg_de87083f-4d22-4feb-b857-9fb286f51528"
      unitRef="usd">400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:OpenTaxYear
      contextRef="i6e1c460171b341758ee7f2c6f5213b5e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU2NTI_b978d601-64a0-4dde-926c-f30c41859b0c">2007</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMTUvZnJhZzowNjk4MGQzMmQzZDE0MmNmODk0NzcwMTY2ZjIyMDkzMi90ZXh0cmVnaW9uOjA2OTgwZDMyZDNkMTQyY2Y4OTQ3NzAxNjZmMjIwOTMyXzU2NTc_f159cd4d-d2cc-4eed-abef-b2dca5dc4ec9">2020</us-gaap:OpenTaxYear>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0NzY_d08f290c-4a69-4724-8cd3-95925e0b6095">CAPITAL STOCK AND SHARE-BASED COMPENSATIONWe are authorized by our Certificate of Incorporation to issue 60,000,000 shares of common stock, $0.001 par value and 5,000,000 shares of preferred stock, $0.001 par value. As of December&#160;31, 2020, there were 37,470,212 and 32,814,278 shares of common stock issued and outstanding, respectively, and no shares of preferred stock issued or outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock.&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 29, 2018, our Board of Directors and the Compensation Committee approved, subject to stockholder approval, the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (the &#x201c;2018 Plan&#x201d;). On June 6, 2018, our stockholders approved the 2018 Plan at the Company's annual meeting of stockholders. The 2018 Plan replaces our 2008 Omnibus Incentive Compensation Plan (the &#x201c;2008 Plan&#x201d;), which terminated on June 6, 2018 when the stockholders approved the 2018 Plan.  The 2018 Plan authorizes the grant of various types of equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our 50% or more owned subsidiaries, our non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our non-employee directors, continued service on the Board of Directors) and/or achievement of certain pre-determined performance goals. We refer to stock awards subject to service-based vesting conditions as &#x201c;non-vested stock&#x201d; and restricted stock units subject to service-based or a combination of service-based and performance-based vesting conditions as &#x201c;non-vested stock units.&#x201d; The 2018 Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the 2018 Plan, those eligible participants to whom, and the times at which, awards shall be granted. The Compensation Committee, in its discretion, may delegate its authority and duties under the 2018 Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.5 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of common stock. We had approximately 2.0 million shares available at December&#160;31, 2020. The price per share for stock options shall be no less than the greater of (a) 100% of the fair value of a share of common stock on the date the option is granted or (b)&#160;the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of 10% or more of the total combined voting power of us and our subsidiaries, the price is to be at least 110% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a one year to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDMzMTE_132e2a63-3451-42de-8da7-d71ba010d03c"&gt;four&lt;/span&gt; year period, with the exception of those issued under contractual arrangements that specify otherwise, and may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed ten years from the date such option is granted. The Company analyzes historical data of forfeited awards to develop an estimated forfeiture rate that is applied to the Company's non-cash compensation expense; however, all non-cash compensation expense is adjusted to reflect actual vestings and forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)                                                                                                                                                                        &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a plan whereby our eligible employees may purchase our common stock at 85% of the market price at the time of purchase. On June&#160;7, 2012, our stockholders ratified an amendment adopted by our Board of Directors to increase the total number of shares of our common stock authorized for issuance under our ESPP from 2,500,000 shares to 4,500,000 shares, and as of December&#160;31, 2020, there were 1,328,627 shares available for future issuance. The following is a detail of the purchases that were made under the plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018 and Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,122,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January&#160;1, 2019 to March&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April&#160;1, 2019 to June&#160;30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July&#160;1, 2019 to September&#160;30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October&#160;1, 2019 to December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January&#160;1, 2020 to March&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April&#160;1, 2020 to June&#160;30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July&#160;1, 2020 to September&#160;30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October&#160;1, 2020 to December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,171,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ESPP expense included in general and administrative expense in our accompanying consolidated statements of operations was $0.6 million, $0.6 million and $0.5 million for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under the 2008 Plan. In connection with the exercise, Mr. Kusserow surrendered 231,683 shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net 268,317 shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $40.4&#160;million, reflected within financing activities in our consolidated statement of cashflows, related to the remittance of tax withholding obligations. In addition, Mr. Kusserow's stock option exercise resulted in a $24.0&#160;million income tax benefit that was recorded in our consolidated statement of operations during the year ended December 31, 2020. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation: Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 43,249, 142,122 and 163,666 options granted during 2020, 2019 and 2018, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $4.3 million, $6.2 million and $5.7 million for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the awards were estimated using the following assumptions for 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk Free Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.38% - 1.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.44% - 2.53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.56% - 3.04%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.15% - 42.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.46% - 43.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.00% - 45.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.00 - 6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.12 - 6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$86.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$54.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$42.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the simplified method to estimate the expected term for the stock options granted during 2020, 2019 and 2018 as adequate historical experience is not available to provide a reasonable estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our stock option activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Contractual&lt;br/&gt;Life&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding options at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(622,829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding options at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;278,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable options at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of our outstanding options and exercisable options at December&#160;31, 2020 was $50.6 million and $19.4 million, respectively. Total intrinsic value of options exercised was $121.1 million, $7.3 million and $9.7 million for 2020, 2019 and 2018, respectively. The tax benefit from stock options exercised during the period amounted to $27.9 million,  $1.3 million and $1.6 million for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our non-vested stock option activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock options at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(142,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock options at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, there was $4.8 million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of 1.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Vested Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue shares of non-vested stock with a vesting term of one year. The compensation expense is determined based on the market price of our common stock at the date of grant applied to the total number of shares that are anticipated to fully vest. Non-vested stock compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $0.8 million, $1.2 million and $1.4 million for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our non-vested stock activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of non-vested stock granted was $158.72, $119.12 and $80.54 in 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, there was no unrecognized compensation cost related to non-vested stock awards; we currently do not have any outstanding awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Vested Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with vesting terms ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MDY_02c412b8-41ea-4c92-b3c7-f45653d56560"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MTI_5f8948f7-2285-435f-ba9f-02ccda0ec48b"&gt;four&lt;/span&gt; years. Based on the terms and conditions of these awards, we determine if the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the total number of units that are anticipated to vest, unless the award specifies differently. We account for such awards similar to our non-vested stock awards; however, no shares of stock are issued to the recipient until the stock unit awards have vested and after the pre-determined delivery date has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Vested Stock Units &#x2013; Service-Based&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $7.5 million, $8.7 million and $4.5 million for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our service-based non-vested stock units activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(89,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of service-based non-vested stock units granted was $206.10, $123.70 and $95.14 in 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, there was $9.3 million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a weighted average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Vested Stock Units &#x2013; Service-Based and Performance-Based Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we awarded performance-based awards to certain employees. The target level established by the award, which is based on the Company&#x2019;s 2020 adjusted earnings before interest, taxes, depreciation and amortization (&#x201c;Adjusted EBITDA&#x201d;), provided for the recipients to receive an aggregate of 81,183 non-vested stock units if the target was achieved. For a select group of employees, if the target objective is surpassed to the point of achieving the projected maximum payout, the recipients will receive an additional aggregate of 11,633 non-vested stock units during the three-month period ending March 31, 2021. The target number of shares to be potentially awarded has been reduced by forfeitures as indicated in the table below. Performance-based non-vested stock units compensation expense included in general and administrative expenses in our consolidated statements of operations was $13.5 million, $8.4 million and $5.8 million for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our performance-based non-vested stock units activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of performance-based non-vested stock units granted was $201.90, $128.89 and $79.59 in 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, there was $17.3 million in unrecognized compensation costs related to our performance-based non-vested stock units that we expect to be recognized over a weighted average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzExNA_d5265418-9943-4b5a-a0c2-246dfe28967d"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzE0MQ_7854bee0-353e-4959-975a-45d2a391224b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzE1OA_f985c76d-912d-4ff5-89ee-6d5dbb4d4358"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzE4OA_d23dddc4-5551-4f5b-98bb-872ded5766c7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzIyMw_a8c91be6-65cf-4140-bc70-2a7e14e8a97b"
      unitRef="shares">37470212</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzIzMA_bd8105a9-b4b6-4496-99f6-023847e25e42"
      unitRef="shares">32814278</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI5OA_61a91e14-9671-4e36-b1ea-6fba042b1fe5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <amed:Percentageofownershipinsubsidiaries
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEyODY_eccaed08-a14e-43c6-8c99-f90781cc976b"
      unitRef="number">0.50</amed:Percentageofownershipinsubsidiaries>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzIzOTU_d2aac37b-76f0-4978-9ba9-37cdd68d2c6c"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI0NDM_336a3610-530e-4961-9c7e-4817dddc447b"
      unitRef="shares">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <amed:Fairvalueofshareofcommonstockpercentage
      contextRef="if2bfa60d1a274089b775bff19975c6d2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI1NDk_2490ae16-638b-4a28-8ae3-68b01aa4e622"
      unitRef="number">1</amed:Fairvalueofshareofcommonstockpercentage>
    <amed:Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI3NzY_c8f7e060-9a74-4cca-832b-31e36b8a152d"
      unitRef="number">0.10</amed:Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries>
    <amed:Fairvalueofshareofcommonstockpercentage
      contextRef="i2268173c1609427b91285a18f7856aa8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzI4Nzg_09e47da5-4571-4762-b6b2-03d855638dfe"
      unitRef="number">1.10</amed:Fairvalueofshareofcommonstockpercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="icccd23fa40c94bddb05d0c94db005351_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzMzMzI_15ee7a71-0b81-409a-9398-4fdfbfb20536">ten years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzM5MjQ_22e44c0b-2fbf-4d04-be7d-35f89f11f374"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan
      contextRef="ic23e136463954fce97ebf07eaca62d49_I20120606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQxNjU_2652985e-b787-4312-8371-b243009e9b42"
      unitRef="shares">2500000</amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan>
    <amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan
      contextRef="i1f87b9321c534dcfae4d2ce97fe4fc8b_I20120607"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQxNzg_f2511418-7e04-419f-8420-75fdd30203e8"
      unitRef="shares">4500000</amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan>
    <amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQyMTQ_0fab8bad-eb61-4581-a0f6-e2d6a58e5546"
      unitRef="shares">1328627</amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0NjE_50059d33-f114-41af-8839-8094f9e0c9e9">The following is a detail of the purchases that were made under the plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2018 and Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,122,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January&#160;1, 2019 to March&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April&#160;1, 2019 to June&#160;30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July&#160;1, 2019 to September&#160;30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October&#160;1, 2019 to December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January&#160;1, 2020 to March&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April&#160;1, 2020 to June&#160;30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July&#160;1, 2020 to September&#160;30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October&#160;1, 2020 to December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,171,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia4f247884db846bdb4821a221bbfe57c_D20120607-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzEtMS0xLTEtMA_ec858969-bd81-4496-a3ad-b3c14a1a5c8d"
      unitRef="shares">3122983</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i75707ab7adca4f98a7ec345287bc457d_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzEtMy0xLTEtMA_b49cafe9-d780-4474-aee0-e41608175980"
      unitRef="usdPerShare">15.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzItMS0xLTEtMA_68b0d041-c933-4815-a861-5146fed88c74"
      unitRef="shares">7181</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i172263bdf66a4f008f59172cfb1d5640_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzItMy0xLTEtMA_7c4200d5-aca2-44d0-8d71-91ff5214fa85"
      unitRef="usdPerShare">104.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzMtMS0xLTEtMA_35016468-82cc-4c25-9d3c-2f524a010bbd"
      unitRef="shares">8230</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i1d88f9ec77c9452c8bb506759c530a16_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzMtMy0xLTEtMA_fda3117d-3b9a-4071-af70-72aa9d8d44b5"
      unitRef="usdPerShare">103.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzQtMS0xLTEtMA_fac44995-c184-4f98-a3ef-0c049298c4f8"
      unitRef="shares">7216</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i9b760ab2443e4046941e64e3b50a2f09_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzQtMy0xLTEtMA_ef1b7850-73e9-44cf-b1b3-8aaf80f5ae78"
      unitRef="usdPerShare">111.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzUtMS0xLTEtMA_440632a2-47e2-46cd-a5be-09e174964a22"
      unitRef="shares">6063</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzUtMy0xLTEtMA_90331e1a-ef5b-42ba-b566-c2898f54a841"
      unitRef="usdPerShare">141.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzYtMS0xLTEtMA_aac0ab84-d65b-4c00-a471-81a5aee5fa41"
      unitRef="shares">5295</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="ifc731d16af2b4adb980e8754afe1b9f9_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzYtMy0xLTEtMA_3cc517c9-7e60-4f86-8208-e4f66aa5260a"
      unitRef="usdPerShare">156.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzctMS0xLTEtMA_b176c016-0200-4919-a046-ed000e08d2a4"
      unitRef="shares">5414</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i2521c40c2e674edaba9586526c5b83a7_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzctMy0xLTEtMA_12e19c18-5823-4d9d-b610-5a60a11c5472"
      unitRef="usdPerShare">168.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzgtMS0xLTEtMA_4c97a1e2-b928-4488-bc8c-370179bbd98e"
      unitRef="shares">4789</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i44d57dec79174a29a10a484c6e35ee00_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzgtMy0xLTEtMA_43729bb9-0f88-4514-828b-d4f5700fd57b"
      unitRef="usdPerShare">200.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzktMS0xLTEtMA_e867cac8-d53b-4d5c-8f67-4c2834cd8759"
      unitRef="shares">4202</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzktMy0xLTEtMA_057afde8-9e6a-47f9-9879-6a97c4f24feb"
      unitRef="usdPerShare">249.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i3692bce7d32644e5b337cd5691239645_D20120607-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmZDBmNDMzZDA1OWM0MWViODI3MzE4OGYwOTQ3NTQzZS90YWJsZXJhbmdlOmZkMGY0MzNkMDU5YzQxZWI4MjczMTg4ZjA5NDc1NDNlXzEwLTEtMS0xLTA_3ff81343-8f24-40b1-be47-d0d1e7f7259b"
      unitRef="shares">3171373</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ0NTM_8853c972-7140-475b-af46-c652cbf6a3ff"
      unitRef="usd">600000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ0NTc_3831a475-f66f-4d6b-bf20-bb1b4a72de57"
      unitRef="usd">600000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ0NjQ_eca60644-972b-47cb-9eb7-f5aae15c818d"
      unitRef="usd">500000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0NDM_860d1de8-c073-4af7-8f5a-1ce3de9cec1a"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <amed:SurrenderedSharesInShares
      contextRef="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0NTI_82abf25b-6829-465e-8889-584792a32142"
      unitRef="shares">231683</amed:SurrenderedSharesInShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i0075cef12e724763a07cf4e20abcc198_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0NjE_44285bd2-db8f-4ccb-a8a3-60582d65ec75"
      unitRef="shares">268317</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5e2a3b22027c46259ffb26bf610aae36_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0NzA_83b0363f-a31b-48ed-a704-36e01ed71056"
      unitRef="usd">40400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i5e2a3b22027c46259ffb26bf610aae36_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDI0ODU_6a41099f-d9aa-42dd-b15c-94d1f6fd714d"
      unitRef="usd">24000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ2MzA_d2ee266e-5a28-4c78-ba71-a19b112d33d2"
      unitRef="shares">43249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ2MzQ_5c8af85d-4300-4f9f-b6b7-8c1352b07c24"
      unitRef="shares">142122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ2NDE_c6dcaea2-3284-4a7f-a129-48fe8ae125ca"
      unitRef="shares">163666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ4Mzk_df9e8222-17c9-4c34-81ba-c248275e772b"
      unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ4NDM_d6e0e37c-6e78-4788-9ec7-b28f8083c56d"
      unitRef="usd">6200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzQ4NTA_418a23c1-c8ff-450d-bdf5-3fd6f5d784cd"
      unitRef="usd">5700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0OTA_4b928c70-4c97-4724-b84a-b85fd7053d4c">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the awards were estimated using the following assumptions for 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk Free Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.38% - 1.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.44% - 2.53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.56% - 3.04%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.15% - 42.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.46% - 43.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.00% - 45.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.00 - 6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.12 - 6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$86.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$54.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$42.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItMS0xLTEtMC90ZXh0cmVnaW9uOmM2OGUyODIzOTNiNjQ4MjA4NTRhMGNiZmM4ZjJlZWE3XzEwOTk1MTE2Mjc3OTg_3e5a103f-7f2e-4693-9f55-e2e4d9a1d972"
      unitRef="number">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItMS0xLTEtMC90ZXh0cmVnaW9uOmM2OGUyODIzOTNiNjQ4MjA4NTRhMGNiZmM4ZjJlZWE3XzEwOTk1MTE2Mjc4MDY_7ddacfaf-ed56-4c00-9390-23e5d0282680"
      unitRef="number">0.0151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItMy0xLTEtMC90ZXh0cmVnaW9uOjgwYTBmZGZkMzQ0YTRhZjA4NGYzOGIyZDk1ZDk3ZGI5XzEwOTk1MTE2Mjc3OTg_bcd79e6b-e663-4ff6-a917-df8145072b74"
      unitRef="number">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItMy0xLTEtMC90ZXh0cmVnaW9uOjgwYTBmZGZkMzQ0YTRhZjA4NGYzOGIyZDk1ZDk3ZGI5XzEwOTk1MTE2Mjc4MDY_1f82907e-43ed-4189-a40c-1bdc1fdf70be"
      unitRef="number">0.0253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItNS0xLTEtMC90ZXh0cmVnaW9uOjgwZTQ1NDY2YjcxYTQ5M2JhNTY3MGUyMzcwN2JlOGRjXzEwOTk1MTE2Mjc3OTg_1cbb59b7-74f4-4eb3-8c8c-191ef5e014bb"
      unitRef="number">0.0256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzItNS0xLTEtMC90ZXh0cmVnaW9uOjgwZTQ1NDY2YjcxYTQ5M2JhNTY3MGUyMzcwN2JlOGRjXzEwOTk1MTE2Mjc4MDY_f13cc5f0-6b2e-453e-a3d8-e8c743e904ee"
      unitRef="number">0.0304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtMS0xLTEtMC90ZXh0cmVnaW9uOmVlOTc1NzMwYjA5ZDQ2M2I4ZTgyNWQ4OGE0MWViZjg0XzEwOTk1MTE2Mjc4MDE_a33cf7e0-a7a2-4d89-9942-6d886b6c8ec9"
      unitRef="number">0.4015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtMS0xLTEtMC90ZXh0cmVnaW9uOmVlOTc1NzMwYjA5ZDQ2M2I4ZTgyNWQ4OGE0MWViZjg0XzEwOTk1MTE2Mjc4MTA_cf368834-5c60-4856-af22-9d05be33511a"
      unitRef="number">0.4280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjQ0ZmIxY2Q3NTkwODQ0MGFiMGRkZmI5N2ExMjg1NzRjXzEwOTk1MTE2Mjc4MDE_75fd796d-cbd6-4dcb-8f95-013b4a772a7b"
      unitRef="number">0.4246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjQ0ZmIxY2Q3NTkwODQ0MGFiMGRkZmI5N2ExMjg1NzRjXzEwOTk1MTE2Mjc4MTA_0bdfb6f8-035e-4206-a102-f1683fa27a60"
      unitRef="number">0.4383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtNS0xLTEtMC90ZXh0cmVnaW9uOmRjM2U3NTA3OTYyOTQ1ZTFiMGY4OWZjMTg3MzFjZDVmXzEwOTk1MTE2Mjc4MDE_e0d99713-cdd5-4422-a01c-3521d79312f3"
      unitRef="number">0.4200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzMtNS0xLTEtMC90ZXh0cmVnaW9uOmRjM2U3NTA3OTYyOTQ1ZTFiMGY4OWZjMTg3MzFjZDVmXzEwOTk1MTE2Mjc4MTA_59100dcf-fb99-4466-8460-402d8842cacc"
      unitRef="number">0.4532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtMS0xLTEtMA_91635e7f-1ba7-49e5-a250-2319399e300f">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0967904d6aa443bda7b944783f5368a3_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjI1MzI4N2FlYjI4MDQ0NDI4YTc2OWU3ZTc1ODE4MjZkXzEwOTk1MTE2Mjc4MDE_5a719d0b-9dc7-4673-b400-1c1e5d4bc9d0">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i95b123e655fe43e190e185f8dbe56430_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjI1MzI4N2FlYjI4MDQ0NDI4YTc2OWU3ZTc1ODE4MjZkXzEwOTk1MTE2Mjc4MTQ_1883f750-9a2e-48e2-9734-e7a6183eca50">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5def5d90694943c991e6829f70fa6a4c_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtNS0xLTEtMC90ZXh0cmVnaW9uOjdiMGE0ODlmNTE1OTQ1NTRhZDdjYzM4ODQ4NDk4MzBjXzEwOTk1MTE2Mjc4MDE_e86414ff-b8c3-4be2-ad56-dce94af1b284">P4Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie9b8d67240ac466ba65b24c556a36122_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzQtNS0xLTEtMC90ZXh0cmVnaW9uOjdiMGE0ODlmNTE1OTQ1NTRhZDdjYzM4ODQ4NDk4MzBjXzEwOTk1MTE2Mjc4MTQ_d44ba158-0196-4cc5-b38e-60e3158aad9b">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzUtMS0xLTEtMA_16502246-4b02-4c0b-8e67-86798482ceb7"
      unitRef="usdPerShare">86.72</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue>
    <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzUtMy0xLTEtMA_03538c62-4ab1-431a-9ac7-6713dd904172"
      unitRef="usdPerShare">54.42</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue>
    <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzUtNS0xLTEtMA_8a9452e7-5f50-43b2-afd2-d2dd82b45dc6"
      unitRef="usdPerShare">42.48</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzYtMS0xLTEtMA_4516599e-7596-4910-93c2-fe9b6f5f1c28"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzYtMy0xLTEtMA_ac55953b-dff1-4917-877e-a535525b4e17"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2MDdlMTU5YTQwMDM0NmI2YTBlODViMzgxNTRlN2Y2OS90YWJsZXJhbmdlOjYwN2UxNTlhNDAwMzQ2YjZhMGU4NWIzODE1NGU3ZjY5XzYtNS0xLTEtMA_94453808-a60f-4c2c-8cf3-a984d430166e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0ODg_937bd9a1-ac52-4130-b614-3e2e4f897769">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our stock option activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Contractual&lt;br/&gt;Life&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding options at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(622,829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding options at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;278,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable options at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our non-vested stock option activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock options at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(142,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock options at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzEtMS0xLTEtMA_6b223924-c2d5-4c67-a152-cfca37eced37"
      unitRef="shares">875974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzEtMy0xLTEtMA_8bb0dc6b-b0e8-4b9f-bd8d-75918bb70935"
      unitRef="usdPerShare">49.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzEtNS0xLTEtMA_ffd991c7-a149-408b-a883-09ce29cda3ae">P6Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzItMS0xLTEtMA_ba89f6c1-6196-4967-9d1d-a809ab3a71b5"
      unitRef="shares">43249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzItMy0xLTEtMA_8b03b6f4-3b94-42e4-9b8e-08d186e86106"
      unitRef="usdPerShare">209.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzMtMS0xLTEtMA_dbf4addd-9505-4c4a-9e01-9a19d4b69683"
      unitRef="shares">622829</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzMtMy0xLTEtMA_9755b033-f903-4333-8892-a5668d8f4124"
      unitRef="usdPerShare">31.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzQtMS0xLTEtMA_7efbc824-2ad5-443d-95db-a745b73133ea"
      unitRef="shares">18353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzQtMy0xLTEtMA_11a366c9-566a-455d-8b70-83d47a959600"
      unitRef="usdPerShare">103.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzUtMS0xLTEtMA_cea6b4b1-be69-4892-9709-3a5b11cde775"
      unitRef="shares">278041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzUtMy0xLTEtMA_bc302672-095b-450d-b2b3-75a3b8a17321"
      unitRef="usdPerShare">111.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzUtNS0xLTEtMA_db604054-fbdb-4cfb-a507-79a13e99cb4e">P7Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzYtMS0xLTEtMA_82586e2b-90fa-4b08-8961-60ee1dddbc85"
      unitRef="shares">89429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzYtMy0xLTEtMA_07a3f6c3-3fb8-45d4-8e54-b4e57077f17d"
      unitRef="usdPerShare">76.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTowYjUyZjViNzAzOTg0MzgxYjk3NDlkNzE5N2YyNjFkMi90YWJsZXJhbmdlOjBiNTJmNWI3MDM5ODQzODFiOTc0OWQ3MTk3ZjI2MWQyXzYtNS0xLTEtMA_ad275eba-77bb-4646-aea0-5ffa015ec826">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iab6fc63306454ed1ad46e51a0060949e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzUzNDU_671c7359-2772-48e3-815d-9bab143f3f32"
      unitRef="usd">50600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iab6fc63306454ed1ad46e51a0060949e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzUzNTI_5aaf35af-71d7-49c4-ba8d-33c2f359e5d0"
      unitRef="usd">19400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU0MTc_72974ef6-b25e-4ffc-8268-2b24c6a815fd"
      unitRef="usd">121100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU0MjE_ecd917c1-f1a5-4fb2-abe8-cbdd341fa2ac"
      unitRef="usd">7300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU0Mjg_ad0432be-72e3-4348-b073-0a82fbb1a6b0"
      unitRef="usd">9700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU1NDU_d21a57b2-7694-4c40-a737-78408ecbfc98"
      unitRef="usd">27900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i9a4d59f5d2394093b29d637764752d1f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU1NTA_c7be276d-837b-4080-99ee-f66cf91634a2"
      unitRef="usd">1300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i3895fa23f4064247ba2a2bba602cfdde_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU1NTc_d6f728df-6c14-41dd-8f7b-e9ab12d24781"
      unitRef="usd">1600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzEtMS0xLTEtMA_89eabb82-dc55-4161-a33c-ebf80e225b05"
      unitRef="shares">305750</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia733ca32dbec4462ac0839915fc3b59a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzEtMy0xLTEtMA_4b1dc880-2895-4c48-86bf-29b5bf1e6f6b"
      unitRef="usdPerShare">41.66</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzItMS0xLTEtMA_1885663f-e989-471a-80ed-15204ccbd066"
      unitRef="shares">43249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzItMy0xLTEtMA_a36148de-25cd-4154-9107-488a007e3496"
      unitRef="usdPerShare">86.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzMtMS0xLTEtMA_8a789c46-17bc-4448-b996-15dcd00a0c34"
      unitRef="shares">142233</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzMtMy0xLTEtMA_ef8c9b83-a1c4-4894-8f5d-a63bd7860515"
      unitRef="usdPerShare">34.84</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzQtMS0xLTEtMA_6170cf81-11b3-48e4-8ca6-045ce498eb95"
      unitRef="shares">18154</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzQtMy0xLTEtMA_f588ad3f-d714-4449-badf-f2ed05ec443b"
      unitRef="usdPerShare">47.66</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzUtMS0xLTEtMA_effd0961-b9ad-4bf5-a63b-10ebe003427e"
      unitRef="shares">188612</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i767079f30664438f8d9be671a161fd0e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmYzhhMTg3NzEwZTQ0MjcyYjgyYTA1ZTA2YmFhNTFhMS90YWJsZXJhbmdlOmZjOGExODc3MTBlNDQyNzJiODJhMDVlMDZiYWE1MWExXzUtMy0xLTEtMA_27e5cc34-e9c7-471a-bab5-9b6a5ab3e2eb"
      unitRef="usdPerShare">56.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iab6fc63306454ed1ad46e51a0060949e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU2OTI_85dc5afe-62f3-4e93-ad14-f2bd6614de55"
      unitRef="usd">4800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzU4MjA_7463df5e-4c3f-411d-9c05-b82b9c5734a4">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDMyNjc_3afa2286-143c-4487-a124-c69f0f2ae36e">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzYyNDQ_cd260cae-9de2-4e1a-9cc2-b8a7fe917467"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf88ad709fd64cffbbba3949d9877821_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzYyNDg_105e8baa-a8db-4276-918c-ba439a0a6e49"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1850298439a4c2f8d557340227845e9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzYyNTU_a6ea3a65-f740-447c-896a-4d2a698b28a6"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0ODI_e4c414f5-bab6-4fe8-98fe-2b7476c1b7ee">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our non-vested stock activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i24d3940f86e248f5a619e4759d853c1e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzEtMS0xLTEtMA_f701a254-255c-4e26-984e-12631f009041"
      unitRef="shares">9859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i24d3940f86e248f5a619e4759d853c1e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzEtMy0xLTEtMA_7c740b69-c445-4b57-8f30-ab95d4014c62"
      unitRef="usdPerShare">119.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzItMS0xLTEtMA_3eb44969-02ee-413d-840c-190e563197e9"
      unitRef="shares">1560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzItMy0xLTEtMA_fe8dd41a-b2e7-4fe7-80f8-48f47a5cddfe"
      unitRef="usdPerShare">158.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzMtMS0xLTEtMA_abe6ec20-7898-4fe4-a8ea-c251f2717bd9"
      unitRef="shares">11419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzMtMy0xLTEtMA_289f5a0c-af9a-46ed-95a0-828f94d5bfd7"
      unitRef="usdPerShare">124.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzQtMS0xLTEtMA_26387739-afdf-4d9d-9c14-052426381da8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzQtMy0xLTEtMA_abd79082-1657-44e0-8ff3-aa6130d72c91"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic24c7c520697474487b3aceda222db5c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzUtMS0xLTEtMA_73181192-3700-4278-9e89-281a6bbb7766"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic24c7c520697474487b3aceda222db5c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTpmNDBlOGZmOTYyOWE0MWJhOGEwOTkzYjZmNThkMDgzNC90YWJsZXJhbmdlOmY0MGU4ZmY5NjI5YTQxYmE4YTA5OTNiNmY1OGQwODM0XzUtMy0xLTEtMA_071d4cb5-8eb7-4330-ac1e-5227a509c205"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY0MzU_64e8130d-5981-4cad-a620-7d7ffc020173"
      unitRef="usdPerShare">158.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idf88ad709fd64cffbbba3949d9877821_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY0Mzk_0373e852-ff1d-429f-bda9-e198052269fa"
      unitRef="usdPerShare">119.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic1850298439a4c2f8d557340227845e9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY0NDY_2454905d-e522-4aef-8663-6707ea0a74a8"
      unitRef="usdPerShare">80.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc2MDI_4c20d6c7-b638-4f86-ad89-92d3c43fc7f1"
      unitRef="usd">7500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9934834a8a0c409b8d6d372c860f05c2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc2MDY_4222fe76-b97a-402d-a86e-553f09bb15c8"
      unitRef="usd">8700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id48af308b58146e1a94f7cbf20c53001_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc2MTM_4f1224db-bf9e-40c1-8861-da71cb2ad7e8"
      unitRef="usd">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0NzQ_66e1199f-4aea-4ef8-a8e5-27cf24f59807">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our service-based non-vested stock units activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(89,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i67aef9e5409443cc838400c94814e771_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzEtMS0xLTEtMA_4f327d58-ef62-4621-9a6a-86daa7d75243"
      unitRef="shares">231418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i67aef9e5409443cc838400c94814e771_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzEtMy0xLTEtMA_3bf2fde3-7f64-4332-b7a1-2dbb1048bfa5"
      unitRef="usdPerShare">91.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzItMS0xLTEtMA_b4e8c6c1-5c01-4316-9a56-e5ae921c70e5"
      unitRef="shares">34429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzItMy0xLTEtMA_4501a991-8ff2-458c-9e63-1c57b7e1404f"
      unitRef="usdPerShare">206.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzMtMS0xLTEtMA_30a24ee4-a5af-465a-b90a-230b2768a4a3"
      unitRef="shares">89074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzMtMy0xLTEtMA_071f8558-9e2f-48db-ba70-3601ad1f329f"
      unitRef="usdPerShare">78.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzQtMS0xLTEtMA_ad27758a-26ab-487a-9cf2-4063b7138626"
      unitRef="shares">19227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzQtMy0xLTEtMA_e3a00ab5-9f73-4d18-8e41-6fe6ab0fc8df"
      unitRef="usdPerShare">97.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if6fba36dadd24151b9f0f7c470401177_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzUtMS0xLTEtMA_4e34efd7-c46d-46bc-897d-fd24fa7177b1"
      unitRef="shares">157546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if6fba36dadd24151b9f0f7c470401177_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo1OWExNjRmYTQ1YWI0OWZkYmQwNjczZDg1YmVjZjY3MC90YWJsZXJhbmdlOjU5YTE2NGZhNDVhYjQ5ZmRiZDA2NzNkODViZWNmNjcwXzUtMy0xLTEtMA_828c8e55-1eeb-4391-81e8-4e80cf81bd70"
      unitRef="usdPerShare">123.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc4MzM_7239903c-fde7-4984-84b3-9509bb3e5431"
      unitRef="usdPerShare">206.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9934834a8a0c409b8d6d372c860f05c2_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc4Mzc_bb2de982-20a3-47c1-90a6-7b80add64715"
      unitRef="usdPerShare">123.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id48af308b58146e1a94f7cbf20c53001_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc4NDQ_3965f769-0cd7-40dc-9f2b-0be06538c211"
      unitRef="usdPerShare">95.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="if6fba36dadd24151b9f0f7c470401177_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzc4OTY_cc7c369c-3a6e-4488-9c7d-0b53bcaf68a1"
      unitRef="usd">9300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzgwNTE_96eaf805-438d-4263-b25d-243ec4324116">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <amed:Performancebasedawardtargetshareamount
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg0MDg_35f2d1f8-e58a-4e43-a22c-17a8b8f19527"
      unitRef="shares">81183</amed:Performancebasedawardtargetshareamount>
    <amed:AdditionalPerformanceBasedAwardTargetShareAmount
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg2MzA_ee35d8af-da79-4c94-af65-2c3cb41c527d"
      unitRef="shares">11633</amed:AdditionalPerformanceBasedAwardTargetShareAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg5ODc_1f716e95-6edf-4dc0-9539-11ad263bc71d"
      unitRef="usd">13500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief02df4838c5483f9c1fee131227eb29_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg5OTE_46140637-97f6-42ab-90e7-6722c08deacd"
      unitRef="usd">8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i085cfa11bc6843488c86ab3d0a3da2ad_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzg5OTg_974d9a93-69af-4534-988c-bd82c1b2d911"
      unitRef="usd">5800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0Njg_1b102beb-0835-4ab4-b5a9-76895c3a1227">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our performance-based non-vested stock units activity for 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;207,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9a62c2d5f8ed48a78a320ddb584e246f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzEtMS0xLTEtMA_eb355876-7e8e-436f-8f26-41e56dd3b2f1"
      unitRef="shares">207424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9a62c2d5f8ed48a78a320ddb584e246f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzEtMy0xLTEtMA_28d2806f-eb77-4faa-befa-10b312df8912"
      unitRef="usdPerShare">97.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzItMS0xLTEtMA_867be5a5-bf86-49c5-a679-ff4f87b949eb"
      unitRef="shares">85727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzItMy0xLTEtMA_323161c5-6d3e-49ff-a79d-c6a8daac7f1d"
      unitRef="usdPerShare">201.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzMtMS0xLTEtMA_f83cf70c-33c5-484d-92bd-95a446c08a76"
      unitRef="shares">78856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzMtMy0xLTEtMA_c5918f4e-4450-4145-8366-8dd3241ee96a"
      unitRef="usdPerShare">83.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzQtMS0xLTEtMA_8855e889-fa51-4e29-9e85-47a4e26e5659"
      unitRef="shares">18008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzQtMy0xLTEtMA_6b33951f-ed4b-45aa-b581-49611f8e54e4"
      unitRef="usdPerShare">101.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i521c7c89279e4c0aa844c60ec36a5f59_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzUtMS0xLTEtMA_dddf0559-5c50-49c8-929e-61fe2ebede6a"
      unitRef="shares">196287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i521c7c89279e4c0aa844c60ec36a5f59_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90YWJsZTo2OTBkYzVkMzY0Nzk0ZjM0YjM2ODY2NmI1NDNkNzVlYi90YWJsZXJhbmdlOjY5MGRjNWQzNjQ3OTRmMzRiMzY4NjY2YjU0M2Q3NWViXzUtMy0xLTEtMA_fc3b6a18-dc50-4564-b438-7ff2b84c089d"
      unitRef="usdPerShare">148.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzkyMjY_592408a0-5140-4fa6-92d3-3d40c17c62e8"
      unitRef="usdPerShare">201.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief02df4838c5483f9c1fee131227eb29_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzkyMzA_70b91f3d-869e-41f6-94ac-ecd3e2f7b020"
      unitRef="usdPerShare">128.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i085cfa11bc6843488c86ab3d0a3da2ad_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzkyMzc_fa9a8732-12af-4750-bf8d-e1f2e508e0f4"
      unitRef="usdPerShare">79.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i521c7c89279e4c0aa844c60ec36a5f59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzkyODk_76fdac73-daee-4313-8a83-9d9864fe35e1"
      unitRef="usd">17300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i953feb11d2d34475860f3ad2148d3c58_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5Xzk0NDk_c6a7316d-67a0-4857-9357-df119874831a">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE3Mzg1_21dc1098-5ed8-4cb8-8f7d-42350b23b5ff">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &#x2013; Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in the following legal actions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#x201c;Subpoena&#x201d;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney&#x2019;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May 21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;3, 2015, we received a civil investigative demand (&#x201c;CID&#x201d;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Attorney&#x2019;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August&#160;31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#x2019;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of $6.5 million to accrued expenses in our consolidated balance sheets related to this matter. Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees related to all legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Investigative Matters &#x2013; Completed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Corporate Integrity Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2020, the Company received notice from the Office of Inspector General-HHS ("OIG") that the Company's five-year corporate integrity agreement ("CIA") with the OIG has been completed. On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a CIA with the OIG. The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization ("IRO") to perform certain audits and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically required that we report substantial overpayments that we discovered we had received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of five years that ended on April 21, 2019. We filed our final annual report on July 19, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compassionate Care Hospice Corporate Integrity Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company received notice from the OIG that the Company's five-year CIA with the OIG has been completed. On January 30, 2015, CCH entered into a CIA with the OIG. The CIA required that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an IRO to complete claims review for hospice services rendered in New York. The OIG waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA required that CCH report substantial overpayments that CCH discovered it received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could have become liable for payment of certain stipulated penalties, or could have been excluded from participation in federal health care programs. The CIA had a term of five years that ended on January 30, 2020. We filed our final annual report on March 25, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Third Party Audits &#x2013; Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#x201c;RACs&#x201d;), Zone Program Integrity Contractors (&#x201c;ZPICs&#x201d;), Uniform Program Integrity Contractors (&#x201c;UPICs&#x201d;), Program Safeguard Contractors (&#x201c;PSCs&#x201d;), Medicaid Integrity Contractors (&#x201c;MICs&#x201d;) and Supplemental Medical Review Contractors (&#x201c;SMRCs&#x201d;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#x201c;Review Period&#x201d;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#x2019;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor ("MAC") for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of December 31, 2020, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#x201c;SafeGuard&#x201d;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC (&#x201c;Palmetto&#x201d;) regarding Infinity Home Care of Lakeland, LLC, (&#x201c;Lakeland Care Centers&#x201d;) and Infinity Home Care of Pinellas, LLC, (&#x201c;Clearwater Care Center&#x201d;). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which $12.6&#160;million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:2.25pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:2.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our consolidated balance sheets. The net of these two amounts, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:2.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.5 million, was recorded as a reduction in revenue in our consolidated statements of operations during 2017. As of December 31, 2020, $1.5 million of net receivables have been impacted by this payment suspension.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of our insurance programs, including amounts accrued for the periods indicated (amounts in millions) in accrued expenses in our consolidated balance sheets. The amounts accrued below represent our total estimated liability for individual claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Professional liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Severance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have commitments related to our severance plans applicable to a number of our senior executives and senior management, as well as the employment agreement entered into with our Chief Executive Officer, all of which generally commit us to pay severance benefits under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <amed:Numberofpatients
      contextRef="i1560d4e370f847fb92bf3948fe2bd932_D20150521-20150521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzM3Ng_05b9eed9-f579-4a13-8e77-6e8b73206f55"
      unitRef="patient">53</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="i3ce9e524eb0543eeae2df4f429cd9905_D20151103-20151103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEyNDM_24e2acbf-6fdc-4551-bdaf-83550e104e90"
      unitRef="patient">66</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="i07641836ad0d4665b300523692960b1f_D20160627-20160627"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE5Njk_73aa4039-bff6-4ce9-8bf2-d7434b018580"
      unitRef="patient">68</amed:Numberofpatients>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="iaf11c6ccfd794c169a08d89e5cd17b31_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzI0NzM_de630b2d-8ff4-4678-a0ba-f464d98c58bd"
      unitRef="usd">6500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:CorporateIntegrityAgreementTerm
      contextRef="id92e1c7184a7449e846c859caeab4fbe_D20140423-20140423"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzc0NDM_a6ff3195-24f2-4e00-af9f-7c652f2c638b">P5Y</amed:CorporateIntegrityAgreementTerm>
    <amed:CorporateIntegrityAgreementTerm
      contextRef="if492da41859849a18fe046b7f1da314e_D20150130-20150130"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTk1MTE2NTUyNTk_104a89c2-8557-42de-bcdf-7df1a5616911">P5Y</amed:CorporateIntegrityAgreementTerm>
    <amed:NumberOfBeneficiaries
      contextRef="if3e4bf70e5d9479ebc20d004efd4f9e8_D20080101-20100331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzk2NDI_edff2505-dedc-44b4-97e7-cd2ca2a012ba"
      unitRef="beneficiary">30</amed:NumberOfBeneficiaries>
    <amed:NumberOfBeneficiaries
      contextRef="ib7b09ab0a49d4b838fe8db28575066f2_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwMDg2_72bce81e-74c6-4d2a-9de0-a107f9b64741"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i92498864eda34c97bf3f44b5a1827b5b_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwODg5_3b8e08e9-f314-42a8-aa25-0df6fab052e2"
      unitRef="usd">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest
      contextRef="i92498864eda34c97bf3f44b5a1827b5b_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTE1_4d249208-083b-4339-b616-c282f98e1eb2"
      unitRef="usd">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i44e23098929046f7af1cfe828afaec85_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTQ2_dc2a9a79-5fea-4d30-8af2-fe99afdfda34"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:NumberOfBeneficiaries
      contextRef="ib7b09ab0a49d4b838fe8db28575066f2_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTc3_72bce81e-74c6-4d2a-9de0-a107f9b64741"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i44e23098929046f7af1cfe828afaec85_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzExMDUw_dc2a9a79-5fea-4d30-8af2-fe99afdfda34"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld
      contextRef="ib02eb19f870b48a0ac524cc591131f73_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzExMzEw_edec69e5-b01e-4859-9e12-60055652dbb6"
      unitRef="usd">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i8979ada06f974ae48d397f54b6e49eda_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzExODE1_97003f80-217a-4fe9-a62b-f4665f489352"
      unitRef="usd">2800000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="i80891250852448afbff7aef1c0666a33_I20190110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzExODE1_c5dc920e-1ce1-467b-9978-74459401ac45"
      unitRef="usd">2800000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i93b988a539e7458e9ebc3dfab2f46a43_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEyOTMw_ad586e04-0edb-4433-8069-ac98e8a5e902"
      unitRef="usd">34000000.0</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i1c5fc041d76e49a5983d00e207829170_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEyOTgw_84a200fd-a4b6-4b11-b94a-6aa2a3597df9"
      unitRef="claim">72</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="i93b988a539e7458e9ebc3dfab2f46a43_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMDA4_e9d2ef33-1932-4661-8e51-7e6f16c7d40f"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="i93b988a539e7458e9ebc3dfab2f46a43_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMDQ1_f50f80ce-73be-4d81-b8dd-db56c5da5f6d"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ib558c962d6c04f40adef9ad76c074458_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMDgx_6e2f39cc-7d33-4671-a941-d47f9ffccf98"
      unitRef="usd">4800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i5f99d4d9f475438a97dba13e3a83c516_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMTMy_2449cfe9-f4e5-4947-b83c-b01f4b6be39f"
      unitRef="claim">70</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="ib558c962d6c04f40adef9ad76c074458_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMTYw_ddfa5412-24d6-423e-ab49-d657e5b58861"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="ib558c962d6c04f40adef9ad76c074458_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzMTk3_c1677725-e54c-4c22-a177-f88382199c47"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="icaa86f34e687461286bbecf374c1f96e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzNTYz_67f64aa2-3bae-41f4-9928-13e024ebfb9c"
      unitRef="usd">26000000.0</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i6f2f005315e5492bb8fec7e5757a7e04_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEzNjQ1_01c6005b-8a24-4536-9621-9039e6b7ef1d"
      unitRef="usd">3300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="ie45f729caf77486a9faad14454801668_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0MDA0_2af15e6c-8193-49ae-a0f5-829c0fd71c90"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i29dcf5be2ab240aa86b1d44b4274b48e_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0MjQ2_0d591e66-25f0-4991-97b4-474c57f848c2"
      unitRef="usd">6500000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ib20172f07d6649a2a8664caf1f015ef2_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0NDky_9d4711d7-e6d9-425c-b711-9b11cc826f43"
      unitRef="usd">38800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="ie45f729caf77486a9faad14454801668_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzEwOTk1MTE2NTYwNTY_e847815d-b8b9-4eec-afb9-a4d7b435449b"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i76464f5a074a42fc86111f27060e6a56_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0Njg5_8f356c01-62de-45c5-a070-942c9c036792"
      unitRef="usd">29300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="if2b9a36901674eb9a302469e2cac8ab9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0ODc1_0d110874-254c-4907-9acc-7736c8a99959"
      unitRef="usd">17400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="if2b9a36901674eb9a302469e2cac8ab9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0OTY4_fd80f018-11db-47d9-b8dd-7943031c3794"
      unitRef="usd">10900000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="ie45f729caf77486a9faad14454801668_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE0OTg0_a66fe5af-87e7-42ff-bd28-95150bac6d53"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:FloridaZpicRevenueReduction
      contextRef="icf602ed6544f4e14998550bd3bc16290_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE1MTc1_6844ec84-bc81-4f0e-959f-605e3215f81e"
      unitRef="usd">6500000</amed:FloridaZpicRevenueReduction>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie3800a96a7434d7f807e7946ac5ea7d4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE1MzAx_97be63bf-149b-4eb7-b9b3-73467c137709"
      unitRef="usd">1500000</us-gaap:AccountsReceivableNetCurrent>
    <amed:InsuranceProgramsTableTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE3Mzg4_caed7550-fcb4-4873-8534-b89a72dfded0">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of our insurance programs, including amounts accrued for the periods indicated (amounts in millions) in accrued expenses in our consolidated balance sheets. The amounts accrued below represent our total estimated liability for individual claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Professional liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:InsuranceProgramsTableTableTextBlock>
    <amed:HealthInsurance
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzItMS0xLTEtMA_81daad69-fce8-449a-a5b5-c65b89def725"
      unitRef="usd">15100000</amed:HealthInsurance>
    <amed:HealthInsurance
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzItMy0xLTEtMA_9be861c7-4776-45cb-8189-a467987050fe"
      unitRef="usd">15800000</amed:HealthInsurance>
    <amed:WokersCompensation
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzMtMS0xLTEtMA_0db5bd8d-2ec3-4c05-9fa3-e5d8471763db"
      unitRef="usd">35800000</amed:WokersCompensation>
    <amed:WokersCompensation
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzMtMy0xLTEtMA_9d5935c5-c9e8-438a-b396-348e89dddf16"
      unitRef="usd">33400000</amed:WokersCompensation>
    <amed:ProfessionalLiability
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzQtMS0xLTEtMA_effafab5-da11-42a9-b056-ac357db5473a"
      unitRef="usd">4900000</amed:ProfessionalLiability>
    <amed:ProfessionalLiability
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzQtMy0xLTEtMA_40c83572-9145-4f70-9660-abfc892a8bcd"
      unitRef="usd">5100000</amed:ProfessionalLiability>
    <amed:EstimatedInsuranceTotal
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzUtMS0xLTEtMA_5305d8eb-7a7c-4313-8d81-baea5cea292c"
      unitRef="usd">55800000</amed:EstimatedInsuranceTotal>
    <amed:EstimatedInsuranceTotal
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzUtMy0xLTEtMA_5a164659-21e3-4e85-83f4-6f27caf2855f"
      unitRef="usd">54300000</amed:EstimatedInsuranceTotal>
    <amed:EstimatedInsuranceLongTermPortion
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzYtMS0xLTEtMA_f0e72bbb-2354-43c6-a6d2-010993ac0a97"
      unitRef="usd">1200000</amed:EstimatedInsuranceLongTermPortion>
    <amed:EstimatedInsuranceLongTermPortion
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzYtMy0xLTEtMA_fc4c7964-d3e7-4ba8-b332-851e791aad78"
      unitRef="usd">1300000</amed:EstimatedInsuranceLongTermPortion>
    <amed:EstimatedInsuranceExcludingLongTermPortion
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzctMS0xLTEtMA_1ba99c84-aaf4-4efb-9c8e-50e89c5f3a68"
      unitRef="usd">54600000</amed:EstimatedInsuranceExcludingLongTermPortion>
    <amed:EstimatedInsuranceExcludingLongTermPortion
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90YWJsZTo3YzdhMGMxNDRiYWE0MjMxOGMxZTgzZDM5ZDZjNWY2Zi90YWJsZXJhbmdlOjdjN2EwYzE0NGJhYTQyMzE4YzFlODNkMzlkNmM1ZjZmXzctMy0xLTEtMA_ff07e7fb-f5ab-4c3d-b628-958a136404a9"
      unitRef="usd">53000000.0</amed:EstimatedInsuranceExcludingLongTermPortion>
    <amed:HealthInsuranceRetentionLimit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE2NTQz_44bed404-822b-44c1-86ba-6bbeeb0e5741"
      unitRef="usd">1300000</amed:HealthInsuranceRetentionLimit>
    <amed:WorkersCompensationInsuranceRetentionLimit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE2NjM5_789ae7f7-ba6a-4545-b57c-0e7afd137d7b"
      unitRef="usd">1000000.0</amed:WorkersCompensationInsuranceRetentionLimit>
    <amed:ProfessionalLiabilityInsuranceRetentionLimit
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjcvZnJhZzo2OWJiOGFjYjVjMjE0MmM4OTI5ZGFlN2U3ZWZkYzQwZS90ZXh0cmVnaW9uOjY5YmI4YWNiNWMyMTQyYzg5MjlkYWU3ZTdlZmRjNDBlXzE2NzIx_c668516b-3b5e-473a-ba89-a07d8ee2c54d"
      unitRef="usd">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzE1Nzc_76bc12b8-d2ef-45a6-8a35-aebd554b2f84">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;401(k) Benefit Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have reached 21 years of age, effective the first month after their hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue Service limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our match of contributions to be made to each eligible employee contribution is $0.44 for every $1.00 contributed up to the first 6% of their salary. The match is discretionary and thus is subject to change at the discretion of management. Effective January 1, 2020, our match of contributions is made in the form of cash. During 2019 and 2018, matching contributions were made in the form of our common stock, valued based upon the fair value of the stock as of the end of each calendar quarter end. We expensed approximately $12.9 million, $10.5 million and $9.0 million related to our 401(k) benefit plan for 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Compensation Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had a Deferred Compensation Plan for additional tax-deferred savings for a select group of management or highly compensated employees. Amounts credited under the Deferred Compensation Plan were funded into a rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus, the assets are not necessarily reflective of the same investment choices that would have been made by the participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2015, all prospective salary deferrals ceased. Participants will be allowed to make transactions with any remaining account balances as they wish per plan guidelines.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <amed:DefinedContributionPlanEmployerMatchingContribution
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzQ2NA_64428aea-ffa2-4308-8caa-bb3cc8aff8b7"
      unitRef="usd">0.44</amed:DefinedContributionPlanEmployerMatchingContribution>
    <amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzQ3Nw_884b58f4-a465-49e5-bdd2-6378a7c0d40f"
      unitRef="usd">1.00</amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram>
    <amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzUwOA_4cefc6d9-b81d-4f83-9073-0e74e2fdbc21"
      unitRef="number">0.06</amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzc5Ng_f451b4c6-4ed3-49cc-b8b1-1b23c2fc6a72"
      unitRef="usd">12900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzgwMA_fc77592b-f9a5-40f9-a24d-8ee7b8780d11"
      unitRef="usd">10500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzMvZnJhZzpmOTdjZTBiMzM0NzA0Y2M4YmFiMWU4MzI2NTkzNTAzYi90ZXh0cmVnaW9uOmY5N2NlMGIzMzQ3MDRjYzhiYWIxZTgzMjY1OTM1MDNiXzgwNw_eb2abfb8-71b6-4130-a225-0b841c2c18df"
      unitRef="usd">9000000.0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:TreasuryStockTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzE1MDk_00bede27-c178-4e4c-9dbb-effff1b51b1b">SHARE REPURCHASES &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not repurchase any shares pursuant to this stock repurchase program during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we could have repurchased up to $100 million of our outstanding common stock through March 1, 2020. We did not repurchase any shares pursuant to this stock repurchase program during 2019 or 2020. The stock repurchase program expired on March 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Share Repurchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2018, we purchased 2,418,304 of our common shares from affiliates of KKR Credit Advisors (US) LLC ("KKR"), representing one-half of KKR's then current holdings in the Company and 7.1% of the aggregate outstanding shares of the Company's common stock for a total purchase price of $181.4 million including related direct costs. The Company repurchased the shares at $73.96 which represents 96% of the closing stock price of the Company's common stock on June 4, 2018. The repurchased shares are classified as treasury shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ic8e83cf1d9574cf69c223d04622768aa_I20201223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEwOTk1MTE2MzAzMzE_2e4278e9-e130-4792-8122-d10c5dadcc4b"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i982a73904c8843df8b8f14ae21909b06_D20201223-20201223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEwOTk1MTE2MzAzNDU_728bfb6f-a742-4592-b270-4cef511e61c1">2021-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ib40aceab8f864987a75d9c12fb66ae7e_I20190225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzE5NQ_ee572709-d56e-4267-9bfe-bb9888a6d0ed"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="ia0bafbf9ffa74adb9775ae8c65c96711_D20190225-20190225"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzIzOA_a2db83b4-a62d-4874-b811-7821afd124ac">2020-03-01</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEwMjk_d6dba318-2d28-4e83-95d9-b0cf1354c294"
      unitRef="shares">2418304</us-gaap:TreasuryStockSharesAcquired>
    <amed:PercentageofSharesOutstanding
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzExODI_3ac9189d-84fb-4983-8ec6-5a4f25ad1dd8"
      unitRef="number">0.071</amed:PercentageofSharesOutstanding>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEyODE_7485dd0d-c9be-4516-9aa2-3a9b67f51347"
      unitRef="usd">181400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <amed:DiscountedClosingStockPrice
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEzNTQ_b56ca63c-aa34-47f6-93da-63ece4250d42"
      unitRef="usdPerShare">73.96</amed:DiscountedClosingStockPrice>
    <amed:PercentageofClosingStockPrice
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMzkvZnJhZzo3YWJhYWIzY2M1Mzc0ZTFjODBmYjcxOWQwNzIxNGM0Yi90ZXh0cmVnaW9uOjdhYmFhYjNjYzUzNzRlMWM4MGZiNzE5ZDA3MjE0YzRiXzEzNzQ_53dd7e0b-c3b9-4502-898d-087268757028"
      unitRef="number">0.96</amed:PercentageofClosingStockPrice>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90ZXh0cmVnaW9uOjA1NzY1YWRjOTcxNjRhNDk5Mjc4YTE1YjAxYmQ0MzIyXzEzNjY_c8b99050-507b-4366-b469-41fd8b5aa7c1">SEGMENT INFORMATION&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#x201c;other&#x201d; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,249.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,071.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;729.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,886.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(195.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,256.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;617.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,955.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;754.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,057.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,778.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(173.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,174.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,662.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;992.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,507.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90ZXh0cmVnaW9uOjA1NzY1YWRjOTcxNjRhNDk5Mjc4YTE1YjAxYmQ0MzIyXzgz_90cd8d0a-735f-43f3-a331-21740023d2ef"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90ZXh0cmVnaW9uOjA1NzY1YWRjOTcxNjRhNDk5Mjc4YTE1YjAxYmQ0MzIyXzEzNjk_949fa479-ffef-48c7-9d80-ed8916bff361">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,249.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,071.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;729.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,886.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(195.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,256.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;617.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,955.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;754.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;335.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,057.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,778.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(173.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,174.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,662.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;992.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,507.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItMS0xLTEtMA_4331cd87-d735-4ae5-ae10-ec6a0899de85"
      unitRef="usd">1249200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItMy0xLTEtMA_c68ff4ad-7ee8-47cb-985e-bc1e81a88587"
      unitRef="usd">750100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItNS0xLTEtMA_17043b08-1df0-4c16-b727-cb2b75d12833"
      unitRef="usd">72200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItNy0xLTEtMA_3cf5ee60-aca6-48df-925e-29b2ce356730"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzItOS0xLTEtMA_986c6f76-1637-4654-a087-107f4f1ed97b"
      unitRef="usd">2071500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtMS0xLTEtMTEzNw_5d86b5bc-61e9-4ddb-aa9e-370c815b722c"
      unitRef="usd">20200000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtMy0xLTEtMTEzNw_be17a688-a18f-40da-b7ee-bcd6815a93cb"
      unitRef="usd">13100000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtNS0xLTEtMTEzNw_07158f5c-1f86-4f5e-a074-848fb63ae89f"
      unitRef="usd">1100000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtNy0xLTEtMTEzNw_38745171-c2ff-4b27-8f21-c835233768f3"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtOS0xLTEtMTEzNw_ddf6ec45-3c25-4b87-8c76-c85c4e7f5a2a"
      unitRef="usd">34400000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtMS0xLTEtMA_83ce0ff8-9ad6-48bf-92a7-b622d3dd09b9"
      unitRef="usd">729900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtMy0xLTEtMA_55a3a72e-458b-456d-a6e2-e727312fd538"
      unitRef="usd">400600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtNS0xLTEtMA_d57d7d9b-24f7-49d9-bcc6-8c8b861221de"
      unitRef="usd">54900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtNy0xLTEtMA_c66112bc-0f9c-49e3-a33b-30e50f82401e"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzMtOS0xLTEtMA_3d9a06e4-769f-450c-ac4d-2d2035039d54"
      unitRef="usd">1185400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtMS0xLTEtMA_59a1cc27-3de6-42cc-9fb7-76cf4084bba0"
      unitRef="usd">307200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtMy0xLTEtMA_9ae6b0cd-a605-43f4-be42-4ddb7c82a174"
      unitRef="usd">175400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtNS0xLTEtMA_36517e02-37b5-4006-8414-4f9952f61211"
      unitRef="usd">12400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtNy0xLTEtMA_b22942a0-85ac-468c-84f9-b161c830beea"
      unitRef="usd">173200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzQtOS0xLTEtMA_e154a2b3-ea67-425e-9b6d-ab6e32875a4b"
      unitRef="usd">668200000</us-gaap:GeneralAndAdministrativeExpense>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtMS0xLTEtMA_4b705f64-5803-4892-96c5-26905b869123"
      unitRef="usd">3900000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtMy0xLTEtMA_ed6d9cad-45d1-4a2c-9046-7510e03d655f"
      unitRef="usd">2200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtNS0xLTEtMA_63143ad9-52cd-4645-a4e5-b68d21e2202c"
      unitRef="usd">200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtNy0xLTEtMA_f7ef7b0a-651e-45f8-813f-03f5c2205d59"
      unitRef="usd">22500000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzUtOS0xLTEtMA_fa1ca64d-15ab-4f5d-b0b0-93ac26997944"
      unitRef="usd">28800000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:AssetImpairmentCharges
      contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctMS0xLTEtMzY1NQ_4597160b-c9f5-41c0-8f90-7797eae833b8"
      unitRef="usd">3400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctMy0xLTEtMzY1NQ_8584edae-efbb-465f-857a-8623e9060257"
      unitRef="usd">800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctNS0xLTEtMzY1NQ_240699ff-0f9e-474a-8284-7f4b1d5fb4a0"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctNy0xLTEtMzY1NQ_96dee905-371f-4bf6-82b7-82f93870320e"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctOS0xLTEtMzY1NQ_2f5f27d0-0b20-48b4-898a-ffb2e3df6ab0"
      unitRef="usd">4200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctMS0xLTEtMA_d300db32-883f-49f0-918c-cc3a38f31dfc"
      unitRef="usd">1044400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctMy0xLTEtMA_909026d4-ae61-44f7-9d96-9ec34dad021b"
      unitRef="usd">579000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctNS0xLTEtMA_b31c0b81-d533-4e1d-9698-560032437b28"
      unitRef="usd">67500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctNy0xLTEtMA_f5420047-a201-4d0c-aea0-04d3a7376fb4"
      unitRef="usd">195700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzctOS0xLTEtMA_a2b32bb1-17f0-4169-bea7-831299200f56"
      unitRef="usd">1886600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i479834b49d53404d82becc11f229a75a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtMS0xLTEtMA_a0b4813a-10c2-430b-b5fe-6ffe26cebc20"
      unitRef="usd">225000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i79a7ee99944446af9b6e6c448ed12461_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtMy0xLTEtMA_9884b605-4626-40c8-8800-44def60d15b6"
      unitRef="usd">184200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7c1fbc68f40542d1aac93c854dc37e0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtNS0xLTEtMA_174c2e22-f473-4ccc-a916-2d00f036ec68"
      unitRef="usd">5800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i050db7aef3bf413db186117cc5fedff5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtNy0xLTEtMA_52f63433-bb42-46d4-b4af-9cfdeab58ced"
      unitRef="usd">-195700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplZWM2OTExYTU0N2M0ZWU1YTJkYWFjNmU5MWM4ZmIxNC90YWJsZXJhbmdlOmVlYzY5MTFhNTQ3YzRlZTVhMmRhYWM2ZTkxYzhmYjE0XzgtOS0xLTEtMA_9e4931b1-bd7f-4c2d-afcc-3d5f561ae28e"
      unitRef="usd">219300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItMS0xLTEtMA_baa588a0-d597-43cd-8fe9-9ff35e3827e5"
      unitRef="usd">1256400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItMy0xLTEtMA_f730a312-25cc-41c0-aa82-2315fa4684ab"
      unitRef="usd">617200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItNS0xLTEtMA_3170ab31-ed87-4111-a6f5-3605901a830d"
      unitRef="usd">82000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItNy0xLTEtMA_c71927ab-d49e-4d8a-a6df-9217358105b4"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzItOS0xLTEtMA_b86cbc4a-37c7-46c2-a5f5-d563b2f4f2cf"
      unitRef="usd">1955600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtMS0xLTEtMA_4164188d-8d75-436e-adc5-97a24d5809f0"
      unitRef="usd">754100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtMy0xLTEtMA_cb6608d7-7f6b-4dbc-b50b-fda6288c1e0d"
      unitRef="usd">335100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtNS0xLTEtMA_bc3a859e-502a-4e26-8ff6-4679e1e9bf0e"
      unitRef="usd">61100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtNy0xLTEtMA_4dfa08f0-b2ec-40eb-ad1b-db3ba50b53df"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzMtOS0xLTEtMA_d8c8125c-d18c-4786-b52d-98f8a9fefbc6"
      unitRef="usd">1150300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtMS0xLTEtMA_bac91c9c-675c-4f57-b565-903316309a36"
      unitRef="usd">297200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtMy0xLTEtMA_f6901840-056e-4001-9df0-e78350f57fed"
      unitRef="usd">137500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtNS0xLTEtMA_22b8ff5f-3a99-48dc-9eb3-a4d11d2ada79"
      unitRef="usd">12300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtNy0xLTEtMA_a40b9d37-7c2d-43a0-9c05-4315ec97af2f"
      unitRef="usd">160900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzQtOS0xLTEtMA_fcb9f16c-a3c0-49d0-92b3-e48f91855641"
      unitRef="usd">607900000</us-gaap:GeneralAndAdministrativeExpense>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtMS0xLTEtMA_161f9cf1-43b6-4647-905c-ef04f56b91fc"
      unitRef="usd">4200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtMy0xLTEtMA_3bdf65e5-532e-4d1f-a9ed-6ddd4ebacdfb"
      unitRef="usd">1600000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtNS0xLTEtMA_00b528dc-8df4-434f-aa40-4fe0bd4f38c9"
      unitRef="usd">200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtNy0xLTEtMA_6df8be40-bc2b-454e-8dc0-bf4f9ecd4bcd"
      unitRef="usd">12400000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzUtOS0xLTEtMA_3c378277-e212-4e5e-9646-582321137465"
      unitRef="usd">18400000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:AssetImpairmentCharges
      contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtMS0xLTEtMTE0MA_d017406f-35cf-4de4-9873-d5033bebcf56"
      unitRef="usd">1500000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtMy0xLTEtMTE0MA_70bc0cbc-57ff-4e47-8946-f93aa5de7696"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtNS0xLTEtMTE0MA_e85e2035-55b6-489a-b6c9-02682df70237"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtNy0xLTEtMTE0MA_3db8b369-4082-4b72-980f-828b5d4d7067"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtOS0xLTEtMTE0MA_3e2044aa-fde1-4d17-abce-a2bdf3f7bce4"
      unitRef="usd">1500000</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtMS0xLTEtMA_56b4d348-3461-40fe-9b78-33c2c325dac4"
      unitRef="usd">1057000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtMy0xLTEtMA_55e0a94b-667a-4743-a794-7ea2a51403d4"
      unitRef="usd">474200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtNS0xLTEtMA_3bcd449d-815b-4ba4-a6b7-928d190b09ad"
      unitRef="usd">73600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzYtNy0xLTEtMA_247f0f89-4e95-4117-a970-7156fe6905c1"
      unitRef="usd">173300000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i00d577144da34d1288319b6ca2a053e2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctMS0xLTEtMA_4ead53c0-01f8-4af2-8d6c-61ebc0cb6093"
      unitRef="usd">199400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie7e033440c104ab6897499e4db6acb53_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctMy0xLTEtMA_6e6bc946-a963-4685-bc39-479f4a292588"
      unitRef="usd">143000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i809ba827dcff4fcfbccd73861c6dd76f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctNS0xLTEtMA_8c4862bb-fa9f-468f-a3f1-0c5a15bac546"
      unitRef="usd">8400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i34fb6391aec446d3b4c4cc6866eed306_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctNy0xLTEtMA_c10aebaf-615f-4f06-ae74-34289951ccd4"
      unitRef="usd">-173300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTplNWJmMDkyOTQzNmI0ZTc5ODJlMGEyYzg3MjlmZWI2Ny90YWJsZXJhbmdlOmU1YmYwOTI5NDM2YjRlNzk4MmUwYTJjODcyOWZlYjY3XzctOS0xLTEtMA_c0fdc86e-2080-4dc0-8f9d-29517103ed08"
      unitRef="usd">177500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItMS0xLTEtMA_10dd4a1a-a247-4fb9-8478-0b657f532799"
      unitRef="usd">1174500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItMy0xLTEtMA_8692af2b-e664-47a8-88ff-1a438f4b93a9"
      unitRef="usd">410900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItNS0xLTEtMA_8596a543-4520-4361-8aa1-bd0430baf335"
      unitRef="usd">77200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItNy0xLTEtMA_591eeb7a-2848-4793-b15e-34b00130bc1a"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzItOS0xLTEtMA_b0146d63-fba0-42cf-8be4-8168818859e0"
      unitRef="usd">1662600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtMS0xLTEtMA_e2009510-d459-49a1-a1e5-f5a552849491"
      unitRef="usd">722100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtMy0xLTEtMA_443909fe-b679-473b-8442-080181cde40c"
      unitRef="usd">212000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtNS0xLTEtMA_6e806810-fec7-41f4-884f-70eadc7bb242"
      unitRef="usd">58800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtNy0xLTEtMA_ede6ff85-f3d6-4c2b-92b3-52bd98ec64b6"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzMtOS0xLTEtMA_12fe898c-2ed8-42fe-a366-8de95d023755"
      unitRef="usd">992900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtMS0xLTEtMA_2edbe0ad-6ad2-4029-93ab-c7ee58eeef88"
      unitRef="usd">276300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtMy0xLTEtMA_f78b7129-835f-4075-8e3e-76611608a79c"
      unitRef="usd">84600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtNS0xLTEtMA_efcbd43c-db4b-40ed-bbc7-02db5479a9be"
      unitRef="usd">12800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtNy0xLTEtMA_da8a8b75-3a5c-4ba5-af3b-176371c00d61"
      unitRef="usd">127600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzQtOS0xLTEtMA_679e6aa9-4fa1-41d1-914d-fa1bacc0a39a"
      unitRef="usd">501300000</us-gaap:GeneralAndAdministrativeExpense>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtMS0xLTEtMA_710e527b-7535-4033-906a-847fe44be75a"
      unitRef="usd">3500000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtMy0xLTEtMA_f41b03aa-2367-41cf-a733-964a9c724d8f"
      unitRef="usd">1100000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtNS0xLTEtMA_733c301a-50da-45e5-9c28-1379feca5274"
      unitRef="usd">300000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtNy0xLTEtMA_a4a31460-ec78-463c-b804-79bdc10d0454"
      unitRef="usd">8400000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzUtOS0xLTEtMA_8c3e23f3-d6ef-4e91-91c6-83b40ec5d2a1"
      unitRef="usd">13300000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:CostsAndExpenses
      contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzgtMS0xLTEtMA_2f17d413-1dc4-46a9-a562-341adf53d002"
      unitRef="usd">1001900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzgtMy0xLTEtMA_86a7fecc-5732-435f-b405-bbd5e57e276b"
      unitRef="usd">297700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzgtNS0xLTEtMA_9b2b00d6-7d80-4696-b794-17f190814031"
      unitRef="usd">71900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzgtNy0xLTEtMA_a4924e36-2c92-4bb0-94a4-8dcc81ca7856"
      unitRef="usd">136000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifb44f003fe4b4d4bb25832374ec1fe17_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktMS0xLTEtMA_114653d9-29aa-4ba6-996c-7a98efd1723e"
      unitRef="usd">172600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib8c4f78e62274c9aa887dfd3af314cba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktMy0xLTEtMA_288f3960-b279-42f7-a743-66aeb22f5eda"
      unitRef="usd">113200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i90acbb30d8234be9a56dc61ec20415a7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktNS0xLTEtMA_11532ca5-a669-486d-92b3-d935d809321b"
      unitRef="usd">5300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ide8f328de51840c7a0e4878cfcae96cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktNy0xLTEtMA_19a80687-2501-4cd7-9361-ab048f774510"
      unitRef="usd">-136000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia010b61c8e9745908fbf1f096d7f0217_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTEvZnJhZzowNTc2NWFkYzk3MTY0YTQ5OTI3OGExNWIwMWJkNDMyMi90YWJsZTo0ODY2OWMyOTM3ZTk0OWIzYjQwNTU0NjRhODE4NmUwNy90YWJsZXJhbmdlOjQ4NjY5YzI5MzdlOTQ5YjNiNDA1NTQ2NGE4MTg2ZTA3XzktOS0xLTEtMA_d61e2683-85b5-418a-9634-54e40eefda68"
      unitRef="usd">155100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90ZXh0cmVnaW9uOmRjMjRhY2ZjMTI5YjRiNmQ4MGUwMTg5N2NkMmUxNjg4XzIzOA_e6b10f3d-6736-4521-8f3e-57f558c60209">UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&#160;Income&lt;br/&gt;Attributable to&lt;br/&gt;Amedisys, Inc.&lt;br/&gt;Common&lt;br/&gt;Stockholders&#160;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&#160;Income&lt;br/&gt;Attributable to&lt;br/&gt;Amedisys, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1st Quarter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2nd Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3rd Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4th Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,071.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1st Quarter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;467.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2nd Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3rd Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4th Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,955.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90ZXh0cmVnaW9uOmRjMjRhY2ZjMTI5YjRiNmQ4MGUwMTg5N2NkMmUxNjg4XzIzMw_0b064104-ca11-40a5-94d7-f7de442ce79a">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&#160;Income&lt;br/&gt;Attributable to&lt;br/&gt;Amedisys, Inc.&lt;br/&gt;Common&lt;br/&gt;Stockholders&#160;(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&#160;Income&lt;br/&gt;Attributable to&lt;br/&gt;Amedisys, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1st Quarter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;491.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2nd Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3rd Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4th Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,071.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1st Quarter&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;467.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2nd Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3rd Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4th Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,955.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzMtMS0xLTEtMA_fcd49d42-a416-47f2-9fd3-3da647f48d1b"
      unitRef="usd">491700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzMtMy0xLTEtMA_0942f24e-2d8f-4d54-b456-5be944777ec0"
      unitRef="usd">31800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzMtNS0xLTEtMA_80c7d5bf-049e-4269-9bb3-2259a1c45c26"
      unitRef="usdPerShare">0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8576c75a0ab74587b47085306a8fcff3_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzMtNy0xLTEtMA_899a4aa4-69aa-4e48-9906-bc96239a7f86"
      unitRef="usdPerShare">0.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzQtMS0xLTEtMA_2009fe09-efae-4d38-bf54-609229869323"
      unitRef="usd">485000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzQtMy0xLTEtMA_d70d0a35-3b5c-4e8c-af55-c19bcd9a6617"
      unitRef="usd">34700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzQtNS0xLTEtMA_4f7f5e4a-cb38-4205-91f8-f9f51a0d8d57"
      unitRef="usdPerShare">1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i17ca81d5bf204e579790350d278411ad_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzQtNy0xLTEtMA_9bd4d940-cf5f-4535-8a18-5381636f37fc"
      unitRef="usdPerShare">1.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzUtMS0xLTEtMA_a6183644-9bce-40a5-8d21-b7f8466e194e"
      unitRef="usd">544100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzUtMy0xLTEtMA_c2aa963e-4e99-444a-b3f3-1b80094e9853"
      unitRef="usd">72000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzUtNS0xLTEtMA_2a178df1-05de-4430-95b2-9e1cd3643226"
      unitRef="usdPerShare">2.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i98e7dc6b4c2d4387860e90187a3ad5cd_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzUtNy0xLTEtMA_af307368-6fac-45c0-a9ce-513ddf1fe243"
      unitRef="usdPerShare">2.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzYtMS0xLTEtMA_08292c5c-0aa9-4fc8-94c4-5ed47448c7d9"
      unitRef="usd">550700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzYtMy0xLTEtMA_f9ac343d-573f-41d6-98da-792eefec1d31"
      unitRef="usd">45100000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzYtNS0xLTEtMA_5544b3c8-2fe8-4a92-a3c8-41b18b948659"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5c385df453324adfaca85d0811925684_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzYtNy0xLTEtMA_53c12b57-f86a-4d0d-8aac-7521a5bb9e3c"
      unitRef="usdPerShare">1.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzctMS0xLTEtMA_69748d08-d3bf-475d-80e2-b68081fc15ed"
      unitRef="usd">2071500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzctMy0xLTEtMA_460b3c46-eb63-4959-9063-b14931b6565f"
      unitRef="usd">183600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzctNS0xLTEtMA_1fdae015-1603-4086-ba7f-68b03012a6e7"
      unitRef="usdPerShare">5.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzctNy0xLTEtMA_8ac4de69-919e-4589-870e-b147203f30fd"
      unitRef="usdPerShare">5.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzktMS0xLTEtMA_320212ee-53c4-4c35-9442-bb8aaf04b2bb"
      unitRef="usd">467300000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzktMy0xLTEtMA_c06da9f0-70fe-43dd-9237-6890b30b2bff"
      unitRef="usd">31300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzktNS0xLTEtMA_fc91b041-61e2-41fc-be10-c5f33530ae18"
      unitRef="usdPerShare">0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1b35d98e0d9446ada1fc8732b81d6add_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzktNy0xLTEtMA_58d861d6-a7b9-432e-bb1b-b6cbcbd101e9"
      unitRef="usdPerShare">0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEwLTEtMS0xLTA_2b4a2e17-b199-4866-81fc-31e5445a6db3"
      unitRef="usd">493000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEwLTMtMS0xLTA_3d3c18fa-f45a-4587-a249-8d541cd2d861"
      unitRef="usd">33700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEwLTUtMS0xLTA_f92c4670-5614-43ee-bb2f-46be707c38b6"
      unitRef="usdPerShare">1.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i95c9f62d38c6407e82a32e05c335e657_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEwLTctMS0xLTA_26e94136-1b0f-4171-ab9e-ae23757b9ddb"
      unitRef="usdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzExLTEtMS0xLTA_b04307e2-89ae-433e-8f82-7de0498bbfe9"
      unitRef="usd">494600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzExLTMtMS0xLTA_36b0ed19-3eb2-4ead-bcef-83c757c51285"
      unitRef="usd">34100000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzExLTUtMS0xLTA_6a60eb31-20bd-4c67-a84d-cf38c52281e5"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9a761a3cacb142669ac765f62fd92122_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzExLTctMS0xLTA_a25b6a0b-1e38-4ff5-9fb5-4a271c3cdf02"
      unitRef="usdPerShare">1.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEyLTEtMS0xLTA_9e53112b-a080-4cd6-9180-6e3b9d776e45"
      unitRef="usd">500700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEyLTMtMS0xLTA_5ba3baf9-39c5-4398-b5c4-580a223f80f4"
      unitRef="usd">27700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEyLTUtMS0xLTA_e4fc7781-6b7f-440b-9c1a-d983592d4d0f"
      unitRef="usdPerShare">0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id6e1cf4ed4d24953aee9f61d4699b272_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEyLTctMS0xLTA_b3c44e60-86a9-49ac-be6b-3777cf679344"
      unitRef="usdPerShare">0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEzLTEtMS0xLTA_23c1e2a2-b9fb-4798-8232-c1f8c89b0341"
      unitRef="usd">1955600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:NetIncomeLoss
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEzLTMtMS0xLTA_c0e11fb6-7747-45b4-b1b0-b6862061490f"
      unitRef="usd">126800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEzLTUtMS0xLTA_3cb006ca-3dc5-4489-b4ab-53ad40072032"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifbc02f06e2a44416b56e2e0be0f727a8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNTcvZnJhZzpkYzI0YWNmYzEyOWI0YjZkODBlMDE4OTdjZDJlMTY4OC90YWJsZTpmYjYzMWRiYWVlOGU0NTU2OWFiYWNiZDdhZGEwYTBjOS90YWJsZXJhbmdlOmZiNjMxZGJhZWU4ZTQ1NTY5YWJhY2JkN2FkYTBhMGM5XzEzLTctMS0xLTA_e4f1762d-c3ec-4b91-9814-a5961a6ed99c"
      unitRef="usdPerShare">3.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzEwNDE_98c142fb-710e-42eb-9daa-cdf2db26f115">RELATED PARTY TRANSACTIONS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2018, we made a $7.0 million investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the years ended December 31, 2020 and 2019, we incurred costs of approximately $3.9&#160;million and $0.5 million, respectively, in connection with the usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm&#x2019;s length.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2018, we purchased 2,418,304 of our common shares from affiliates of KKR, representing one-half of KKR's holdings in the Company and 7.1% of the aggregate outstanding shares of the Company's common stock for a total purchase price of $181.4 million including related direct costs. The Company repurchased the shares at $73.96 which represents 96% of the closing stock price of the Company's common stock on June 4, 2018. At the time of the transaction, KKR held approximately 14.2% of the Company's outstanding shares of common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ib96bea9253ac4d8d90b0d2f79b7e9bb6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzU5_05a1996e-1382-437f-9859-6f7b7e062538"
      unitRef="usd">7000000.0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i1d01c191f7b94742a8aedf3242104b2b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzEwOTk1MTE2Mjg5MDE_c4556014-8d11-4f63-989a-082ccb429edf"
      unitRef="usd">3900000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i6ce2a100b9be4e04b1c79c526dd5afe1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzI3Mw_06666703-ef19-40d8-b2b7-6b8894a1724a"
      unitRef="usd">500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzQ3Mw_d6dba318-2d28-4e83-95d9-b0cf1354c294"
      unitRef="shares">2418304</us-gaap:TreasuryStockSharesAcquired>
    <amed:PercentageofSharesOutstanding
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzU4MA_3ac9189d-84fb-4983-8ec6-5a4f25ad1dd8"
      unitRef="number">0.071</amed:PercentageofSharesOutstanding>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzY3OQ_7485dd0d-c9be-4516-9aa2-3a9b67f51347"
      unitRef="usd">181400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <amed:DiscountedClosingStockPrice
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4Xzc1Mg_b56ca63c-aa34-47f6-93da-63ece4250d42"
      unitRef="usdPerShare">73.96</amed:DiscountedClosingStockPrice>
    <amed:PercentageofClosingStockPrice
      contextRef="i85004fc8e04e4e8995b9dba1a27222bc_D20180604-20180604"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4Xzc3Mg_53dd7e0b-c3b9-4502-898d-087268757028"
      unitRef="number">0.96</amed:PercentageofClosingStockPrice>
    <amed:PercentageofSharesOutstanding
      contextRef="i562b1925a10f47859b8528d0316b1f34_D20180604-20180604"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xNjAvZnJhZzoyNTIwZjFkZjU1N2E0MDY0OWNjOWM0ODgyYTc0ZjJkOC90ZXh0cmVnaW9uOjI1MjBmMWRmNTU3YTQwNjQ5Y2M5YzQ4ODJhNzRmMmQ4XzkwNA_ec1d2db0-f482-44f9-abc3-95dc4db48eab"
      unitRef="number">0.142</amed:PercentageofSharesOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399058265320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3131700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3854 American Way, Suite A,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baton Rouge,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,848,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399058268168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,808<span></span>
</td>
<td class="nump">$ 30,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">66,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">255,145<span></span>
</td>
<td class="nump">237,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">10,217<span></span>
</td>
<td class="nump">8,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">13,265<span></span>
</td>
<td class="nump">8,225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">361,984<span></span>
</td>
<td class="nump">350,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $95,024 and $96,137</a></td>
<td class="nump">23,719<span></span>
</td>
<td class="nump">28,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">93,440<span></span>
</td>
<td class="nump">84,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">932,685<span></span>
</td>
<td class="nump">658,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $22,973 and $7,044</a></td>
<td class="nump">74,183<span></span>
</td>
<td class="nump">64,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">47,987<span></span>
</td>
<td class="nump">21,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">33,200<span></span>
</td>
<td class="nump">54,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,567,198<span></span>
</td>
<td class="nump">1,262,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">42,674<span></span>
</td>
<td class="nump">31,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">146,929<span></span>
</td>
<td class="nump">120,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">166,192<span></span>
</td>
<td class="nump">137,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">10,496<span></span>
</td>
<td class="nump">9,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">30,046<span></span>
</td>
<td class="nump">27,769<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">456,337<span></span>
</td>
<td class="nump">326,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">204,511<span></span>
</td>
<td class="nump">232,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">61,987<span></span>
</td>
<td class="nump">56,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">33,622<span></span>
</td>
<td class="nump">5,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">756,457<span></span>
</td>
<td class="nump">621,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,470,212 and 36,638,021 shares issued; and 32,814,278 and 32,284,051 shares outstanding</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">698,287<span></span>
</td>
<td class="nump">645,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost, 4,655,934 and 4,353,970 shares of common stock</a></td>
<td class="num">(319,092)<span></span>
</td>
<td class="num">(251,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">429,991<span></span>
</td>
<td class="nump">246,383<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders&#8217; equity</a></td>
<td class="nump">809,224<span></span>
</td>
<td class="nump">640,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">810,741<span></span>
</td>
<td class="nump">641,513<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,567,198<span></span>
</td>
<td class="nump">$ 1,262,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable related to funds received from the government related to COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398963047352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 95,024<span></span>
</td>
<td class="nump">$ 96,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 22,973<span></span>
</td>
<td class="nump">$ 7,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,470,212<span></span>
</td>
<td class="nump">36,638,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,814,278<span></span>
</td>
<td class="nump">32,284,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost (shares)</a></td>
<td class="nump">4,655,934<span></span>
</td>
<td class="nump">4,353,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399052419816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 2,071,519<span></span>
</td>
<td class="nump">$ 1,955,633<span></span>
</td>
<td class="nump">$ 1,662,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">34,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">1,185,369<span></span>
</td>
<td class="nump">1,150,337<span></span>
</td>
<td class="nump">992,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">449,448<span></span>
</td>
<td class="nump">394,452<span></span>
</td>
<td class="nump">316,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">26,730<span></span>
</td>
<td class="nump">25,040<span></span>
</td>
<td class="nump">17,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">192,122<span></span>
</td>
<td class="nump">188,434<span></span>
</td>
<td class="nump">166,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">28,802<span></span>
</td>
<td class="nump">18,428<span></span>
</td>
<td class="nump">13,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="nump">4,152<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">1,886,623<span></span>
</td>
<td class="nump">1,778,161<span></span>
</td>
<td class="nump">1,507,430<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">219,268<span></span>
</td>
<td class="nump">177,472<span></span>
</td>
<td class="nump">155,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(11,038)<span></span>
</td>
<td class="num">(14,515)<span></span>
</td>
<td class="num">(7,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="nump">3,966<span></span>
</td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="num">(1,669)<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">3,240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(8,449)<span></span>
</td>
<td class="num">(7,062)<span></span>
</td>
<td class="nump">3,840<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">210,819<span></span>
</td>
<td class="nump">170,410<span></span>
</td>
<td class="nump">158,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(25,635)<span></span>
</td>
<td class="num">(42,503)<span></span>
</td>
<td class="num">(38,859)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">185,184<span></span>
</td>
<td class="nump">127,907<span></span>
</td>
<td class="nump">120,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(1,576)<span></span>
</td>
<td class="num">(1,074)<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 183,608<span></span>
</td>
<td class="nump">$ 126,833<span></span>
</td>
<td class="nump">$ 119,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders (usd per share)</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 3.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding (shares)</a></td>
<td class="nump">32,559<span></span>
</td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">32,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders (usd per share)</a></td>
<td class="nump">$ 5.52<span></span>
</td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (shares)</a></td>
<td class="nump">33,268<span></span>
</td>
<td class="nump">32,990<span></span>
</td>
<td class="nump">33,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399037384792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 185,184<span></span>
</td>
<td class="nump">$ 127,907<span></span>
</td>
<td class="nump">$ 120,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">185,184<span></span>
</td>
<td class="nump">127,907<span></span>
</td>
<td class="nump">120,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to non-controlling interests</a></td>
<td class="num">(1,576)<span></span>
</td>
<td class="num">(1,074)<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 183,608<span></span>
</td>
<td class="nump">$ 126,833<span></span>
</td>
<td class="nump">$ 119,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039980552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2017</a></td>
<td class="nump">$ 516,426<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 568,780<span></span>
</td>
<td class="num">$ (53,713)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,747,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">2,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan</a></td>
<td class="nump">9,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">5,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">17,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(6,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(181,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(1,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EquityImpactofRepurchaseofNoncontrollingInterest', window );">Repurchase of noncontrolling interest</a></td>
<td class="num">(361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">120,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,346<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2018</a></td>
<td class="nump">482,633<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">603,666<span></span>
</td>
<td class="num">(241,685)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">119,550<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,252,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">3,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan</a></td>
<td class="nump">9,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">25,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(9,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(1,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">127,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,833<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2019</a></td>
<td class="nump">641,513<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">645,256<span></span>
</td>
<td class="num">(251,241)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">246,383<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,638,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">3,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan</a></td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 6,325<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">622,829<span></span>
</td>
<td class="nump">622,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">$ 26,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(54,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,358<span></span>
</td>
<td class="num">(67,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(1,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">185,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,608<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2020</a></td>
<td class="nump">$ 810,741<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 698,287<span></span>
</td>
<td class="num">$ (319,092)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 429,991<span></span>
</td>
<td class="nump">$ 1,517<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,470,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Impact Of Write Off Of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EquityImpactofRepurchaseofNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Impact of Repurchase of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EquityImpactofRepurchaseofNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039250232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 185,184<span></span>
</td>
<td class="nump">$ 127,907<span></span>
</td>
<td class="nump">$ 120,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">28,802<span></span>
</td>
<td class="nump">18,428<span></span>
</td>
<td class="nump">13,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">26,730<span></span>
</td>
<td class="nump">25,040<span></span>
</td>
<td class="nump">17,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Non-cash 401(k) employer match</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,509<span></span>
</td>
<td class="nump">8,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset', window );">Amortization and impairment of operating lease right of use assets</a></td>
<td class="nump">39,140<span></span>
</td>
<td class="nump">35,905<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on disposal of property and equipment</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnSaleOfInvestments', window );">Loss on sale of equity method investment</a></td>
<td class="nump">2,980<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(26,560)<span></span>
</td>
<td class="nump">13,466<span></span>
</td>
<td class="nump">20,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="num">(3,966)<span></span>
</td>
<td class="num">(5,338)<span></span>
</td>
<td class="num">(7,692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="nump">869<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity investment</a></td>
<td class="nump">5,444<span></span>
</td>
<td class="nump">4,955<span></span>
</td>
<td class="nump">6,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="nump">4,152<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="nump">2,114<span></span>
</td>
<td class="num">(24,146)<span></span>
</td>
<td class="nump">12,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="num">(7,181)<span></span>
</td>
<td class="num">(2,682)<span></span>
</td>
<td class="nump">8,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="num">(11,329)<span></span>
</td>
<td class="nump">3,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">39,839<span></span>
</td>
<td class="nump">42,096<span></span>
</td>
<td class="nump">13,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="nump">27,717<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(34,695)<span></span>
</td>
<td class="num">(32,295)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="num">(3,544)<span></span>
</td>
<td class="num">(3,503)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">288,952<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="nump">223,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of deferred compensation plan assets</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,332)<span></span>
</td>
<td class="num">(7,888)<span></span>
</td>
<td class="num">(6,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investments in equity method investees</a></td>
<td class="num">(875)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="num">(7,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">17,876<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(298,958)<span></span>
</td>
<td class="num">(345,460)<span></span>
</td>
<td class="num">(9,260)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(287,108)<span></span>
</td>
<td class="num">(352,948)<span></span>
</td>
<td class="num">(22,193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options</a></td>
<td class="nump">6,325<span></span>
</td>
<td class="nump">3,611<span></span>
</td>
<td class="nump">5,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">3,562<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on non-cash compensation</a></td>
<td class="num">(54,493)<span></span>
</td>
<td class="num">(9,556)<span></span>
</td>
<td class="num">(6,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Non-controlling interest distribution</a></td>
<td class="num">(1,122)<span></span>
</td>
<td class="num">(1,062)<span></span>
</td>
<td class="num">(1,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsFromBorrowingsUnderTermLoan', window );">Proceeds from borrowings under term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings under revolving line of credit</a></td>
<td class="nump">684,200<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of borrowings under revolving line of credit</a></td>
<td class="num">(703,200)<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="num">(130,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(10,249)<span></span>
</td>
<td class="num">(5,624)<span></span>
</td>
<td class="num">(91,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="num">(2,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundsReceivedFromProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(181,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PaymentsForRepurchaseOfNoncontrollingInterest', window );">Repurchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(14,977)<span></span>
</td>
<td class="nump">227,209<span></span>
</td>
<td class="num">(267,424)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(13,133)<span></span>
</td>
<td class="nump">76,261<span></span>
</td>
<td class="num">(66,134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">96,490<span></span>
</td>
<td class="nump">20,229<span></span>
</td>
<td class="nump">86,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">83,357<span></span>
</td>
<td class="nump">96,490<span></span>
</td>
<td class="nump">20,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,207<span></span>
</td>
<td class="nump">9,628<span></span>
</td>
<td class="nump">3,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">50,721<span></span>
</td>
<td class="nump">29,522<span></span>
</td>
<td class="nump">14,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Financing Activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAssumed1', window );">Note payable issued for software licenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundsReceivedFromProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundsReceivedFromProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PaymentsForRepurchaseOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PaymentsForRepurchaseOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsFromBorrowingsUnderTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings under the term loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsFromBorrowingsUnderTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off Of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398964825432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice and personal care services with approximately 75%, 74% and 73% of our revenue derived from Medicare for 2020, 2019 and 2018, respectively. As of December&#160;31, 2020, we owned and operated 320 Medicare-certified home health care centers, 180 Medicare-certified hospice care centers and 14 personal-care care centers in 39 states within the United States and the District of Columbia.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Accounting Standards Update ("ASU") 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes, enacts changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, the Company adopted Accounting Standards Codification ("ASC") 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using a modified retrospective transition approach, which requires the new standard to be applied to all leases existing at the date of initial application. Under ASC 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. We used the standard's effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019. The new standard provides several optional practical expedients that can be adopted at transition. We elected the "package of practical expedients," which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us. The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately $80 million in operating leases liabilities with corresponding ROU assets of approximately the same amount. The new standard also provides practical expedients for an entity&#8217;s ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, the Company adopted ASU 2018-07,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Compensation - Stock Compensation (Topic 718): Improvements to Nonemployees Share-Based Payment Accounting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods or services. Our adoption of this standard did not have an effect on our consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the full retrospective method. ASC 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The standard supersedes existing revenue recognition requirements and eliminates most industry-specific guidance from U.S. Generally Accepted Accounting Principles ("U.S. GAAP"). The core principle of the revenue recognition standard is to require an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. As a result of the Company's adoption of ASC 606, the revenue and related estimated uncollectible amounts owed to us by non-Medicare payors that were historically classified as provision for doubtful accounts are now considered a revenue adjustment in determining net service revenue. Accordingly, the Company reports estimated uncollectible balances due from third-party payors and uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore, as a reduction in net service revenue (or as it relates to Hospice room and board, an increase in cost of service, excluding depreciation and amortization) when historically these amounts were classified as provision for doubtful accounts within operating expenses within our consolidated statements of operations. In addition, the adoption of ASC 606 resulted in increased disclosure, </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2017-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition (or disposal) of assets or a business. We adopted this ASU on a prospective basis. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions as evaluated under the new framework.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. We adopted this ASU on a prospective basis and will apply this guidance to our future tests of goodwill impairment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2016-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December&#160;15, 2017. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. Our adoption of this standard using a retrospective transition method for each period presented did not have an effect on our consolidated financial statements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued, subject to meeting certain criteria. The amendments in this ASU were effective beginning on March 12, 2020 and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our consolidated financial statements. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. During 2016, we sold a 30% interest in one of our care centers while maintaining a controlling interest in the newly formed joint venture; we repurchased the 30% interest during 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0&#160;million loss which is reflected in miscellaneous, net within our consolidated statement of </span></div>operations for the year ended December 31, 2020.  The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund operations. During 2018, we made a $7.0 million investment in a healthcare analytics company; this investment is accounted for under the equity method. The book value of investments that we account for under the equity method of accounting totaled $14.2 million and $35.7 million as of December&#160;31, 2020 and 2019, respectively, and is reflected in other assets within our consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398965132168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of the Company's consolidated net service revenue.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:59.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare - Episodic-based</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare - Non-episodic based</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare Hospice on June 1, 2020.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient&#8217;s care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are now included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our consolidated balance sheets. CMS reduced the upfront payment for RAPs to 20% for 2020 and has fully eliminated payments associated with RAPs in 2021.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2020, 2019 and 2018, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28th of the following year. As of December&#160;31, 2020, we have settled our Medicare hospice reimbursements for all fiscal years through October&#160;31, 2013. As of December&#160;31, 2020, we have recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021; approximately $2.0 million of this balance was acquired with the AseraCare Hospice ("AseraCare") acquisition. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of December 31, 2020 includes approximately $77&#160;million associated with the CARES Act Provider Relief Fund ("PRF"). We separated the PRF funds into their own account and as of December 31, 2020, we have only transferred funds used during the nine-month period ended September 30, 2020 to our operating account. We will transfer funds used during the three-month period ended December  31, 2020 to our operating account in 2021. Restricted cash includes cash that is not available for ordinary business use. As of December 31, 2020, we had $1.5&#160;million of restricted cash that was placed into an escrow account related to the indemnity provisions within the Asana Hospice purchase agreement. As of December 31, 2019, we had $66.2&#160;million of restricted cash that was placed into an escrow account to fund the acquisition of Asana Hospice on January 1, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:68.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 64% and 58% of our net patient accounts receivable at December&#160;31, 2020 and 2019, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid, any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of all upfront payments associated with RAPs in 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, and Personal Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#8217;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the extent or manner in which the long-lived asset group is being used.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the business climate that could affect the value of the long-lived asset group.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the market value of the assets included in the asset group.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide for depreciation over the following estimated useful service lives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our property and equipment for 2020 and 2019 (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2020, 2019 and 2018 was $12.1 million, $11.6 million and $10.8 million, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth and discount rates.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our operating segments described in Note 14 &#8211; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and have also deemed each of them to be a single reporting unit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we performed a qualitative assessment to determine if it is more likely than not that the fair value of the reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we did not record any goodwill impairment charges and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October&#160;31, 2020. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of certificates of need, licenses, acquired names and non-compete agreements. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxNg_2ef6bf16-13c0-4b4a-ac9d-18652113e2f9">two</span> to three years for non-compete agreements and up to three years for acquired names. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. During 2020, we performed a qualitative assessment of our indefinite-lived intangible assets; as a result of this analysis, we wrote off approximately $4.2&#160;million of acquired names that are no longer in use. During 2019, we also performed a qualitative assessment of our indefinite-lived intangible assets; as a result of this analysis, we wrote off approximately $1.5 million of acquired names. There have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our remaining intangible assets would be less than their carrying amounts.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we recorded $0.8 million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 8 - Long-Term Obligations). As of December&#160;31, 2020 and 2019, we had unamortized debt issuance costs of $2.7 million and $3.5 million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. The unamortized debt issuance costs of $2.7 million at December&#160;31, 2020 will be amortized over a weighted-average amortization period of 3.1 years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of<br/>December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2020 and 2019, our net deferred tax assets were $48.0 million and $21.4 million, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#8217;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#8217;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award. Share-based compensation expense for 2020, 2019 and 2018 was $26.7 million, $25.0 million and $17.9 million, respectively, and the total income tax benefit recognized for these expenses was $4.7 million, $4.6 million and $4.3 million, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Shares Outstanding</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense advertising costs as incurred. Advertising expense for 2020, 2019 and 2018 was $8.0 million, $8.5 million and $7.0 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966149704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19")<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_COVID19TextBlock', window );">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</a></td>
<td class="text">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provides for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we are allowed to use the funds to cover lost revenues and health care costs related to COVID-19, and we are required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we have decided to only utilize PRF funds to the extent we have qualifying COVID-19 expenses, which totaled $33&#160;million for our home health and hospice segments during the year ended December 31, 2020. Accordingly, for our wholly-owned subsidiaries, we will not be using PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred to date is reflected in other operating income within our consolidated statement of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HHS issued new guidance in September 2020 noting that PRF funds can be used towards lost revenues or expenses attributable to COVID-19 through June 30, 2021. We do not believe that we will fully utilize the funds received; therefore, we recorded a liability related to the funds that we do not expect to utilize totaling $60&#160;million which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. Funds that we intend to use in the future to cover COVID-19 expenses, which we have estimated to be approximately $12&#160;million, have been recorded to a deferred liability account within accrued expenses in our consolidated balance sheet. These estimates may change as our ability to utilize and retain the funds will depend on the magnitude, timing and nature of the impact of the pandemic. In summary, the total funds that we have received from the CARES Act PRF as of December 31, 2020 consist of the following (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:74.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized during the year ended December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be utilized January 2021 through June 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be repaid to the government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds received by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, HHS distributed an additional $18&#160;billion in funds to healthcare providers. We did not receive, nor apply, for any additional funds from this second distribution. On October 1, 2020, HHS announced $20&#160;billion in new funding to healthcare providers under the Phase 3 general distribution. We did not apply for any additional funds from this distribution.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provides for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period May 1 through December 31, 2020 and the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, we have deferred $55&#160;million of social security taxes; approximately $28&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021.</span></div>Our personal care segment did not receive funds under the CARES Act; however, they did receive funds from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which are intended to cover costs related to the public health emergency. The grant income associated with the funds received, which totaled $1&#160;million during the year ended December 31, 2020, is reflected in other operating income within our consolidated statement of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_COVID19TextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_COVID19TextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966284616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONSWe complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuation and liabilities assumed.<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Acquisitions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Division</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $3.0&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $2.8&#160;million and other intangibles (certificate of need) of $0.2&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2020, we acquired the regulatory assets of a home health provider in Kentucky for a purchase price of $0.7&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $0.5&#160;million and other intangibles (certificate of need) of $0.2&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Division</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with eight locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $66.3&#160;million, net of cash acquired of $0.7&#160;million. Under the purchase agreement, the purchase price was subject to a net working capital adjustment, whereby the purchase price would be adjusted to the extent the actual net working capital of Asana as of the closing differed from the required net working capital under the purchase agreement. The net working capital adjustment, which was finalized during the three-month period ended June 30, 2020, reduced the purchase price by $0.7&#160;million, from $66.3&#160;million to $65.6&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired and liabilities assumed. The total estimated consideration of $65.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses ($2.0&#160;million), acquired names ($1.3&#160;million) and non-compete agreements ($2.3&#160;million). The acquired names and non-compete agreements will be amortized over a weighted-average period of 2.0 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asana contributed approximately $23.4&#160;million in net service revenue and an operating loss of $3.3&#160;million (inclusive of acquisition and integration costs totaling $2.0&#160;million and intangibles amortization totaling $2.6&#160;million) during the year ended December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with 44 locations, for an estimated purchase price of $230.4&#160;million, net of cash acquired and inclusive of a $32&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $1.0&#160;million. The </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $0.8&#160;million, from $230.4&#160;million&#160;to $229.6&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. During the year ended December 31, 2020, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. The final valuation of the assets acquired and liabilities assumed was not complete as of December 31, 2020, but will be finalized within the allowable measurement period. Based on the Company's preliminary valuation, the total estimated consideration of $229.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses ($8.7&#160;million), certificates of need ($0.7&#160;million), acquired names ($5.7&#160;million) and non-compete agreements ($9.2&#160;million). The acquired names will be amortized over a weighted-average period of 2.0 years and the non-compete agreements will be amortized over a weighted-average period of 1.7 years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AseraCare contributed approximately $64.5&#160;million in net service revenue and an operating loss of $8.2&#160;million (inclusive of acquisition and integration costs totaling $7.6&#160;million and intangibles amortization totaling $6.0&#160;million) during the year ended December 31, 2020. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2020 and 2019 assuming that the AseraCare acquisition closed on January 1, 2019 (amounts in millions, except per share data). The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.748%"><tr><td style="width:1.0%"/><td style="width:61.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys Inc. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma information presented above includes adjustments for (i) amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the AseraCare acquisition, (iii) non-recurring transaction costs and (iv) income taxes based on the Company's statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Acquisitions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Division </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2019, we acquired Compassionate Care Hopsice ("CCH"), a national hospice care provider headquartered in New Jersey, for a purchase price of $327.9 million, net of cash acquired of $6.7 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired and liabilities assumed. The total consideration of $327.9 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.481%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses, certificates of need, acquired names and non-compete agreements. The acquired names and non-compete agreements will be amortized over a weighted-average period of 2.0 and 2.3 years, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CCH contributed approximately $167.4 million in net service revenue and an operating loss of $5.6 million (inclusive of acquisition and integration costs totaling $14.5 million) during the year ended December 31, 2019.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect $278.8 million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"/><td style="width:67.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years<br/>Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma information presented above includes adjustments for (i)&#160;amortization of identifiable intangible assets, (ii) interest on additional debt required to fund the CCH acquisition, (iii) non-recurring transaction costs and (iv)&#160;income taxes based on the Company&#8217;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, we acquired RoseRock Healthcare ("RoseRock"), an Oklahoma based hospice provider, for a purchase price of $17.5 million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill ($15.8 million) and other intangibles including acquired names ($1.0 million) and non-compete agreements ($0.7 million). The acquired names and non-compete agreements will each be amortized over a weighted-average period of 3.0 years. RoseRock contributed approximately $6.8 million in net service revenue and $0.8 million in operating income for the year ended December 31, 2019. We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398965090456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</a></td>
<td class="text">GOODWILL AND OTHER INTANGIBLE ASSETS, NET<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October&#160;31st of each respective year (the date of our annual goodwill impairment test). Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our goodwill for 2020 and 2019 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2018 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">658.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated impairment losses of $733.7 million, which is inclusive of write-offs related to the sale and closure of care centers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we recorded a non-cash other intangible assets impairment charge of $4.2&#160;million related to acquired names which are no longer in use; additionally, we recorded amortization of $2.4&#160;million related to certificates of need and licenses associated with care centers that were closed. During 2019, we recorded a non-cash other intangible assets impairment charge of $1.5 million related to acquired names which are no longer in use or are associated with care centers that were closed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our other intangible assets, net for 2020 and 2019 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Certificates of Need and Licenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Unamortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Amortizable (4)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Compete<br/>Agreements (4)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2018 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated amortization of $0.7 million for non-compete agreements. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Write-offs are related to our acquired names that are no longer in use or that were associated with care centers that are closed.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amortization of certificates of need and licenses is related to care centers that were closed during 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average remaining amortization period of our amortizable acquired names and non-compete agreements is 1.3 years and 1.2 years, respectively.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4 &#8211; Acquisitions for further details on additions to goodwill and other intangible assets, net.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"><tr><td style="width:1.0%"/><td style="width:72.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Asset Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966421848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock', window );">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</a></td>
<td class="text">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred operating income (CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current social security taxes (deferred under CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399059217592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next eight years. We also have finance leases covering certain office equipment that expire at various dates over the next three years. Our leases do not contain any restrictive covenants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our office leases generally contain renewal options for periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMDMvZnJhZzpjOGI2ZjkwYTFmM2M0ZmUyOThmZGE1ZWExZTViZWJhMy90ZXh0cmVnaW9uOmM4YjZmOTBhMWYzYzRmZTI5OGZkYTVlYTFlNWJlYmEzXzQyMg_e7798f55-1ce4-47ef-a7fb-73e95a0c87a0">one</span> to five years. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fleet leases include a term of 367 days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#8220;TRAC&#8221;), which provide for a final rental payment adjustment at the end of the lease, typically based on the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December 31, 2020 and 2019 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for our operating leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current installments of obligations under finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flow from operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flow from finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to ROU assets resulting from reductions to lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for our leases as of December 31, 2020 and 2019 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:64.154%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of operating and finance lease and maturity analysis of operating and finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398965116232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (1.7% at December 31, 2020); due February&#160;4, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (3.8% at December 31, 2020); due February&#160;4, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt as of December&#160;31, 2020 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"><tr><td style="width:1.0%"/><td style="width:72.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.581%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2018, we entered into our Amended and Restated Credit Agreement ("Credit Agreement") which provided for a senior secured revolving credit facility in an initial aggregate principal amount of up to $550.0 million (the "Revolving Credit Facility"). The Revolving Credit Facility provided for and included within its $550.0 million limit a $25.0 million swingline facility and commitments for up to $60.0 million in letters of credit. Upon lender approval, we could increase the aggregate loan amount under the Revolving Credit Facility by $125.0 million plus an unlimited amount subject to a leverage limit of 0.5x under the maximum allowable consolidated leverage ratio which was 3.0x per the Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity of the Revolving Credit Facility was June 29, 2023 and there was no mandatory amortization on the outstanding principal balances which were payable in full upon maturity. The Revolving Credit Facility was used to provide </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ongoing working capital and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2019, we entered into the First Amendment to the Credit Agreement (as amended by the First Amendment, the &#8220;Amended Credit Agreement&#8221;). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes the $550.0 million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $175.0 million (the &#8220;Term Loan Facility&#8221; and collectively with the Revolving Credit Facility, the &#8220;Credit Facility&#8221;), which was added by the First Amendment.  </span></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i)&#160;the Base Rate plus the Applicable Rate or (ii)&#160;the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate plus 1% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the  London Interbank Offered Rate ("LIBOR") or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2020, the Applicable Rate is 0.25% per annum for Base Rate Loans and 1.25% per annum for Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment<br/>Fee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter&#160;of<br/>Credit&#160;Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8805;&#160;3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; 3.00 to 1.0 but &#8805;&#160;2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; 2.00 to 1.0 but &#8805;&#160;0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Credit Facility is February 4, 2024. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) 1.250% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) 1.875% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires maintenance of two financial covenants: (i)&#160;a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii)&#160;a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded $0.8 million in deferred debt issuance costs as long-term obligations, less current portion within our consolidated balance sheet during the year ended December 31, 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i)&#160;provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii)&#160;provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 2.2% for the period ended December 31, 2020 and 3.8% for the period February 4, 2019 to December&#160;31, 2019. Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.2% for the period ended December 31, 2020 and 4.0% for the period ended December 31, 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our consolidated leverage ratio was 0.6, our consolidated interest coverage ratio was 25.6 and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our availability under our $550.0 million Revolving Credit Facility was $470.2 million as we have $51.0 million outstanding in borrowings and $28.8 million outstanding in letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder,&#8221; and together with the CCH Joinder, the &#8220;Joinders&#8221;).  Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries and the AseraCare entities granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries and the AseraCare entities also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Amended Credit Agreement pursuant to the terms of the Joinders and the Amended Credit Agreement.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our finance leases outstanding of $2.6 million relate to leased equipment and bear interest rates ranging from 5.3% to 5.8%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398964837528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes attributable to continuing operations consist of the following (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense for the years ended December&#160;31, 2020, 2019 and 2018 was allocated as follows (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense at U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local income taxes, net of federal income tax benefit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Excess tax benefits from share-based compensation (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other items, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $92.1&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $19.4&#160;million federal income tax benefit and a $4.6&#160;million state and local income tax benefit for the year ended December 31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company had income taxes receivable of $0.2 million and $2.0 million, respectively, included in other current assets within our consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities) consist of the following components (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued payroll&#160;&amp; employee benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal &amp; compliance matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provider relief fund advance (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred social security taxes (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">In April 2020, approximately $100&#160;million was provided to the Company through the healthcare Provider Relief Fund established under the CARES Act. As of December 31, 2020, the Company recorded a liability related to the funds that we do not expect to utilize totaling $60&#160;million, which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. For income tax purposes, the Company recognized the $60&#160;million as income upon receipt, resulting in a deferred tax asset as of December 31, 2020. The company will recognize an income tax deduction when the liability is paid during the year ended December 31, 2021.  </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">The CARES Act provides for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, the Company has deferred $55.4&#160;million of social security tax payments; $27.7&#160;million of this amount is reflected in each payroll and employee benefits and other long-term obligations within our consolidated balance sheet. For income tax purposes, the deferred social security taxes will be deductible when paid on December 31, 2021 and December, 31, 2022, resulting in a deferred tax asset at December 31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have state net operating loss ("NOL") carryforwards of $47.5 million that are available to reduce future taxable income and $3.7 million of various state tax credits available to reduce future state income taxes. The state NOL and tax credit carryforwards expire at various times.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the valuation allowance for deferred tax assets, which is primarily related to certain state NOLs and state tax credit carryforwards, was $0.1 million and $0.4 million, respectively. The net change in the total valuation allowance for the years ended December 31, 2020 and 2019 was a decrease of $0.3 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income, and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carryforwards governed by the tax code. Based on the current level of pretax earnings, the Company will generate the minimum amount of future taxable income needed to support the realization of the deferred tax assets. As a result, as of December&#160;31, 2020, management believes that it is more likely than not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions related to prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reductions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, there is $2.7 million of unrecognized tax benefits recorded in other long-term obligations within the consolidated balance sheets that, if recognized in future periods, would impact our effective tax rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $0.2&#160;million, $0.3 million and $0.1 million of interest as components of interest expense in connection with our reserve for uncertain tax positions during the years ended December 31, 2020, 2019 and 2018, respectively. Interest related to uncertain tax positions included in the consolidated balance sheets at December 31, 2020 and 2019 was $0.6 million and $0.4 million, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and in many individual states, with significant operations in Louisiana, South Carolina, Alabama, Georgia, Massachusetts and Tennessee. We are open to examination in the U.S. and in various individual states for tax years ended December&#160;31, 2014 through December&#160;31, 2020. We are also open to examination in various states for the years ended 2007 through 2020 resulting from NOLs generated and available for carryforward from those years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399052543320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">CAPITAL SOCK AND SHARE-BASED COMPENSATION</a></td>
<td class="text">CAPITAL STOCK AND SHARE-BASED COMPENSATIONWe are authorized by our Certificate of Incorporation to issue 60,000,000 shares of common stock, $0.001 par value and 5,000,000 shares of preferred stock, $0.001 par value. As of December&#160;31, 2020, there were 37,470,212 and 32,814,278 shares of common stock issued and outstanding, respectively, and no shares of preferred stock issued or outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock.<div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Awards</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2018, our Board of Directors and the Compensation Committee approved, subject to stockholder approval, the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (the &#8220;2018 Plan&#8221;). On June 6, 2018, our stockholders approved the 2018 Plan at the Company's annual meeting of stockholders. The 2018 Plan replaces our 2008 Omnibus Incentive Compensation Plan (the &#8220;2008 Plan&#8221;), which terminated on June 6, 2018 when the stockholders approved the 2018 Plan.  The 2018 Plan authorizes the grant of various types of equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our 50% or more owned subsidiaries, our non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our non-employee directors, continued service on the Board of Directors) and/or achievement of certain pre-determined performance goals. We refer to stock awards subject to service-based vesting conditions as &#8220;non-vested stock&#8221; and restricted stock units subject to service-based or a combination of service-based and performance-based vesting conditions as &#8220;non-vested stock units.&#8221; The 2018 Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the 2018 Plan, those eligible participants to whom, and the times at which, awards shall be granted. The Compensation Committee, in its discretion, may delegate its authority and duties under the 2018 Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock. We had approximately 2.0 million shares available at December&#160;31, 2020. The price per share for stock options shall be no less than the greater of (a) 100% of the fair value of a share of common stock on the date the option is granted or (b)&#160;the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of 10% or more of the total combined voting power of us and our subsidiaries, the price is to be at least 110% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a one year to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzEwOTk1MTE2NDMzMTE_132e2a63-3451-42de-8da7-d71ba010d03c">four</span> year period, with the exception of those issued under contractual arrangements that specify otherwise, and may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed ten years from the date such option is granted. The Company analyzes historical data of forfeited awards to develop an estimated forfeiture rate that is applied to the Company's non-cash compensation expense; however, all non-cash compensation expense is adjusted to reflect actual vestings and forfeitures.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)                                                                                                                                                                        </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a plan whereby our eligible employees may purchase our common stock at 85% of the market price at the time of purchase. On June&#160;7, 2012, our stockholders ratified an amendment adopted by our Board of Directors to increase the total number of shares of our common stock authorized for issuance under our ESPP from 2,500,000 shares to 4,500,000 shares, and as of December&#160;31, 2020, there were 1,328,627 shares available for future issuance. The following is a detail of the purchases that were made under the plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018 and Prior</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,122,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January&#160;1, 2019 to March&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;1, 2019 to June&#160;30, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July&#160;1, 2019 to September&#160;30, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October&#160;1, 2019 to December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January&#160;1, 2020 to March&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;1, 2020 to June&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July&#160;1, 2020 to September&#160;30, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October&#160;1, 2020 to December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,171,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP expense included in general and administrative expense in our accompanying consolidated statements of operations was $0.6 million, $0.6 million and $0.5 million for 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under the 2008 Plan. In connection with the exercise, Mr. Kusserow surrendered 231,683 shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net 268,317 shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $40.4&#160;million, reflected within financing activities in our consolidated statement of cashflows, related to the remittance of tax withholding obligations. In addition, Mr. Kusserow's stock option exercise resulted in a $24.0&#160;million income tax benefit that was recorded in our consolidated statement of operations during the year ended December 31, 2020. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 43,249, 142,122 and 163,666 options granted during 2020, 2019 and 2018, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $4.3 million, $6.2 million and $5.7 million for 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the awards were estimated using the following assumptions for 2020, 2019 and 2018:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk Free Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.38% - 1.51%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.44% - 2.53%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.56% - 3.04%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.15% - 42.80%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.46% - 43.83%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.00% - 45.32%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.00 - 6.25 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.12 - 6.25 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$86.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$54.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$42.48</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the simplified method to estimate the expected term for the stock options granted during 2020, 2019 and 2018 as adequate historical experience is not available to provide a reasonable estimate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our stock option activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Contractual<br/>Life&#160;(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(622,829)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.68</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable options at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.75</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of our outstanding options and exercisable options at December&#160;31, 2020 was $50.6 million and $19.4 million, respectively. Total intrinsic value of options exercised was $121.1 million, $7.3 million and $9.7 million for 2020, 2019 and 2018, respectively. The tax benefit from stock options exercised during the period amounted to $27.9 million,  $1.3 million and $1.6 million for 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock option activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $4.8 million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of 1.9 years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue shares of non-vested stock with a vesting term of one year. The compensation expense is determined based on the market price of our common stock at the date of grant applied to the total number of shares that are anticipated to fully vest. Non-vested stock compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $0.8 million, $1.2 million and $1.4 million for 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of non-vested stock granted was $158.72, $119.12 and $80.54 in 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was no unrecognized compensation cost related to non-vested stock awards; we currently do not have any outstanding awards.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with vesting terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MDY_02c412b8-41ea-4c92-b3c7-f45653d56560">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF8xMjEvZnJhZzo2NWQyOWM4NTJlMDI0NWZkOTg3NzUzMTZmYWIwNDQ5OS90ZXh0cmVnaW9uOjY1ZDI5Yzg1MmUwMjQ1ZmQ5ODc3NTMxNmZhYjA0NDk5XzY4MTI_5f8948f7-2285-435f-ba9f-02ccda0ec48b">four</span> years. Based on the terms and conditions of these awards, we determine if the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the total number of units that are anticipated to vest, unless the award specifies differently. We account for such awards similar to our non-vested stock awards; however, no shares of stock are issued to the recipient until the stock unit awards have vested and after the pre-determined delivery date has occurred.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units &#8211; Service-Based</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $7.5 million, $8.7 million and $4.5 million for 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our service-based non-vested stock units activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(89,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of service-based non-vested stock units granted was $206.10, $123.70 and $95.14 in 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $9.3 million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a weighted average period of 1.8 years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units &#8211; Service-Based and Performance-Based Awards</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we awarded performance-based awards to certain employees. The target level established by the award, which is based on the Company&#8217;s 2020 adjusted earnings before interest, taxes, depreciation and amortization (&#8220;Adjusted EBITDA&#8221;), provided for the recipients to receive an aggregate of 81,183 non-vested stock units if the target was achieved. For a select group of employees, if the target objective is surpassed to the point of achieving the projected maximum payout, the recipients will receive an additional aggregate of 11,633 non-vested stock units during the three-month period ending March 31, 2021. The target number of shares to be potentially awarded has been reduced by forfeitures as indicated in the table below. Performance-based non-vested stock units compensation expense included in general and administrative expenses in our consolidated statements of operations was $13.5 million, $8.4 million and $5.8 million for 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our performance-based non-vested stock units activity for 2020:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of performance-based non-vested stock units granted was $201.90, $128.89 and $79.59 in 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, there was $17.3 million in unrecognized compensation costs related to our performance-based non-vested stock units that we expect to be recognized over a weighted average period of 1.8 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398965056472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings &#8211; Ongoing</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in the following legal actions:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena Duces Tecum (&#8220;Subpoena&#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&#160;1, 2011 through May 21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a civil investigative demand (&#8220;CID&#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attorney&#8217;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January&#160;1, 2009 through August&#160;31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&#160;1, 2011 through June&#160;20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of $6.5 million to accrued expenses in our consolidated balance sheets related to this matter. Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investigative Matters &#8211; Completed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Integrity Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2020, the Company received notice from the Office of Inspector General-HHS ("OIG") that the Company's five-year corporate integrity agreement ("CIA") with the OIG has been completed. On April&#160;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a CIA with the OIG. The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization ("IRO") to perform certain audits and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically required that we report substantial overpayments that we discovered we had received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of five years that ended on April 21, 2019. We filed our final annual report on July 19, 2019. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compassionate Care Hospice Corporate Integrity Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company received notice from the OIG that the Company's five-year CIA with the OIG has been completed. On January 30, 2015, CCH entered into a CIA with the OIG. The CIA required that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs;&#160;establish a compliance committee that contains both a Compliance Officer and a&#160;Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an IRO to complete claims review for hospice services rendered in New York. The OIG waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA required that CCH report substantial overpayments that CCH discovered it received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could have become liable for payment of certain stipulated penalties, or could have been excluded from participation in federal health care programs. The CIA had a term of five years that ended on January 30, 2020. We filed our final annual report on March 25, 2020. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits &#8211; Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;) and Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor ("MAC") for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of December 31, 2020, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our consolidated balance sheets.</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC (&#8220;Palmetto&#8221;) regarding Infinity Home Care of Lakeland, LLC, (&#8220;Lakeland Care Centers&#8221;) and Infinity Home Care of Pinellas, LLC, (&#8220;Clearwater Care Center&#8221;). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate. </span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which $12.6&#160;million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="padding-left:2.25pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our consolidated balance sheets. The net of these two amounts, </span></div><div style="padding-left:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.5 million, was recorded as a reduction in revenue in our consolidated statements of operations during 2017. As of December 31, 2020, $1.5 million of net receivables have been impacted by this payment suspension.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our insurance programs, including amounts accrued for the periods indicated (amounts in millions) in accrued expenses in our consolidated balance sheets. The amounts accrued below represent our total estimated liability for individual claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"/><td style="width:67.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Insurance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments related to our severance plans applicable to a number of our senior executives and senior management, as well as the employment agreement entered into with our Chief Executive Officer, all of which generally commit us to pay severance benefits under certain circumstances.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398964799896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Benefit Plan</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have reached 21 years of age, effective the first month after their hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue Service limits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our match of contributions to be made to each eligible employee contribution is $0.44 for every $1.00 contributed up to the first 6% of their salary. The match is discretionary and thus is subject to change at the discretion of management. Effective January 1, 2020, our match of contributions is made in the form of cash. During 2019 and 2018, matching contributions were made in the form of our common stock, valued based upon the fair value of the stock as of the end of each calendar quarter end. We expensed approximately $12.9 million, $10.5 million and $9.0 million related to our 401(k) benefit plan for 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a Deferred Compensation Plan for additional tax-deferred savings for a select group of management or highly compensated employees. Amounts credited under the Deferred Compensation Plan were funded into a rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus, the assets are not necessarily reflective of the same investment choices that would have been made by the participants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2015, all prospective salary deferrals ceased. Participants will be allowed to make transactions with any remaining account balances as they wish per plan guidelines.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398965147448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">SHARE REPURCHASE</a></td>
<td class="text">SHARE REPURCHASES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not repurchase any shares pursuant to this stock repurchase program during the year ended December 31, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we could have repurchased up to $100 million of our outstanding common stock through March 1, 2020. We did not repurchase any shares pursuant to this stock repurchase program during 2019 or 2020. The stock repurchase program expired on March 1, 2020.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Share Repurchase</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2018, we purchased 2,418,304 of our common shares from affiliates of KKR Credit Advisors (US) LLC ("KKR"), representing one-half of KKR's then current holdings in the Company and 7.1% of the aggregate outstanding shares of the Company's common stock for a total purchase price of $181.4 million including related direct costs. The Company repurchased the shares at $73.96 which represents 96% of the closing stock price of the Company's common stock on June 4, 2018. The repurchased shares are classified as treasury shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399035097944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,071.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(195.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,256.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">617.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,778.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(173.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,174.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,662.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">992.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,507.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966348984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</a></td>
<td class="text">UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Income<br/>Attributable to<br/>Amedisys, Inc.<br/>Common<br/>Stockholders&#160;(1)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Service Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Income<br/>Attributable to<br/>Amedisys, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1st Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2nd Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3rd Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4th Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,071.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1st Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">467.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2nd Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3rd Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4th Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966384056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we made a $7.0 million investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the years ended December 31, 2020 and 2019, we incurred costs of approximately $3.9&#160;million and $0.5 million, respectively, in connection with the usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm&#8217;s length.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2018, we purchased 2,418,304 of our common shares from affiliates of KKR, representing one-half of KKR's holdings in the Company and 7.1% of the aggregate outstanding shares of the Company's common stock for a total purchase price of $181.4 million including related direct costs. The Company repurchased the shares at $73.96 which represents 96% of the closing stock price of the Company's common stock on June 4, 2018. At the time of the transaction, KKR held approximately 14.2% of the Company's outstanding shares of common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399036244584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, the Company adopted Accounting Standards Update ("ASU") 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes, enacts changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, the Company adopted Accounting Standards Codification ("ASC") 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using a modified retrospective transition approach, which requires the new standard to be applied to all leases existing at the date of initial application. Under ASC 842, lessees are required to recognize a lease liability and right-of-use asset ("ROU asset") for all leases with a term greater than twelve months and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. We used the standard's effective date as our date of initial application. Consequently, our financial information was not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019. The new standard provides several optional practical expedients that can be adopted at transition. We elected the "package of practical expedients," which allows us to not reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter not being applicable to us. The most significant effects related to this adoption relate to (1) the recognition of new ROU assets and lease liabilities on our balance sheet for our real estate and fleet operating leases; and (2) significant new disclosures about our leasing activities. Upon adoption, we recognized approximately $80 million in operating leases liabilities with corresponding ROU assets of approximately the same amount. The new standard also provides practical expedients for an entity&#8217;s ongoing accounting. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, the Company adopted ASU 2018-07,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Compensation - Stock Compensation (Topic 718): Improvements to Nonemployees Share-Based Payment Accounting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which expands the scope of Topic 718 to include share-based payments issued to nonemployees for goods or services. Our adoption of this standard did not have an effect on our consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the full retrospective method. ASC 606 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers. The standard supersedes existing revenue recognition requirements and eliminates most industry-specific guidance from U.S. Generally Accepted Accounting Principles ("U.S. GAAP"). The core principle of the revenue recognition standard is to require an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. As a result of the Company's adoption of ASC 606, the revenue and related estimated uncollectible amounts owed to us by non-Medicare payors that were historically classified as provision for doubtful accounts are now considered a revenue adjustment in determining net service revenue. Accordingly, the Company reports estimated uncollectible balances due from third-party payors and uncollectible balances associated with patient responsibility as a reduction of the transaction price and therefore, as a reduction in net service revenue (or as it relates to Hospice room and board, an increase in cost of service, excluding depreciation and amortization) when historically these amounts were classified as provision for doubtful accounts within operating expenses within our consolidated statements of operations. In addition, the adoption of ASC 606 resulted in increased disclosure, </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2017-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Clarifying the Definition of a Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition (or disposal) of assets or a business. We adopted this ASU on a prospective basis. The impact on our consolidated financial statements and related disclosures will depend on the facts and circumstances of any specific future transactions as evaluated under the new framework.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other (Topic 350) - Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge (Step 2 of the goodwill impairment test). Instead, impairment will be measured using the difference between the carrying amount and the fair value of the reporting unit. The ASU is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. We adopted this ASU on a prospective basis and will apply this guidance to our future tests of goodwill impairment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, the Company adopted ASU 2016-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December&#160;15, 2017. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. Our adoption of this standard using a retrospective transition method for each period presented did not have an effect on our consolidated financial statements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span>, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued, subject to meeting certain criteria. The amendments in this ASU were effective beginning on March 12, 2020 and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. During 2016, we sold a 30% interest in one of our care centers while maintaining a controlling interest in the newly formed joint venture; we repurchased the 30% interest during 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0&#160;million loss which is reflected in miscellaneous, net within our consolidated statement of </span></div>operations for the year ended December 31, 2020.  The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund operations. During 2018, we made a $7.0 million investment in a healthcare analytics company; this investment is accounted for under the equity method. The book value of investments that we account for under the equity method of accounting totaled $14.2 million and $35.7 million as of December&#160;31, 2020 and 2019, respectively, and is reflected in other assets within our consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of the Company's consolidated net service revenue.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:59.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare - Episodic-based</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare - Non-episodic based</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare Hospice on June 1, 2020.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient&#8217;s care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are now included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our consolidated balance sheets. CMS reduced the upfront payment for RAPs to 20% for 2020 and has fully eliminated payments associated with RAPs in 2021.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2020, 2019 and 2018, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28th of the following year. As of December&#160;31, 2020, we have settled our Medicare hospice reimbursements for all fiscal years through October&#160;31, 2013. As of December&#160;31, 2020, we have recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021; approximately $2.0 million of this balance was acquired with the AseraCare Hospice ("AseraCare") acquisition. As of December&#160;31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2013 through September 30, 2020.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div>We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA").<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashCash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 64% and 58% of our net patient accounts receivable at December&#160;31, 2020 and 2019, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid, any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of all upfront payments associated with RAPs in 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, and Personal Care</span></div>For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#8217;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the extent or manner in which the long-lived asset group is being used.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the business climate that could affect the value of the long-lived asset group.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the market value of the assets included in the asset group.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide for depreciation over the following estimated useful service lives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our property and equipment for 2020 and 2019 (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2020, 2019 and 2018 was $12.1 million, $11.6 million and $10.8 million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, future growth and discount rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our operating segments described in Note 14 &#8211; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and have also deemed each of them to be a single reporting unit.</span></div>During 2020, we performed a qualitative assessment to determine if it is more likely than not that the fair value of the reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we did not record any goodwill impairment charges and none of the goodwill associated with our various reporting units was considered at risk of impairment as of October&#160;31, 2020. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.Intangible assets consist of certificates of need, licenses, acquired names and non-compete agreements. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ5MmJkNzBkNjIwMDQ0MDE4MDgzOTU3YTkwODQwNWM0L3NlYzpkOTJiZDcwZDYyMDA0NDAxODA4Mzk1N2E5MDg0MDVjNF83OS9mcmFnOmIxN2VjYWIyNTU2ODQwNjE5YzgxOTE2Zjg4NTgwMDZhL3RleHRyZWdpb246YjE3ZWNhYjI1NTY4NDA2MTljODE5MTZmODg1ODAwNmFfMTA5OTUxMTY2ODcxNg_2ef6bf16-13c0-4b4a-ac9d-18652113e2f9">two</span> to three years for non-compete agreements and up to three years for acquired names. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtIssuanceCostsPolicyPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text">Debt Issuance CostsDuring 2019, we recorded $0.8 million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Amended Credit Agreement (See Note 8 - Long-Term Obligations). As of December&#160;31, 2020 and 2019, we had unamortized debt issuance costs of $2.7 million and $3.5 million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of<br/>December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div>Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2020 and 2019, our net deferred tax assets were $48.0 million and $21.4 million, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#8217;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#8217;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based CompensationWe record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsWe expense advertising costs as incurred.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtIssuanceCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtIssuanceCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy disclosure text block for government grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039018568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Schedule of Revenue by Payor Class</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:59.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare - Episodic-based</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare - Non-episodic based</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice (1):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Medicare</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare Hospice on June 1, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Cash Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:68.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide for depreciation over the following estimated useful service lives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our property and equipment for 2020 and 2019 (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(96.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of<br/>December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted-Average Shares Outstanding</a></td>
<td class="text">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>stimated Useful Lives Of Property And Equipment, table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instrument Details, table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Cash Equivalents and Restricted Cash Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398965070008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock', window );">Schedule Of Cares Act Provider Relief Funds</a></td>
<td class="text">In summary, the total funds that we have received from the CARES Act PRF as of December 31, 2020 consist of the following (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:74.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized during the year ended December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be utilized January 2021 through June 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated funds to be repaid to the government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds received by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cares Act Provider Relief Funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038400792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock', window );">Schedule Of Business Acquisitions, Asana Hospice</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired and liabilities assumed. The total estimated consideration of $65.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock', window );">Schedule Of Business Acquisitions, AseraCare Hospice</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. During the year ended December 31, 2020, we recorded measurement period adjustments based on changes to management's estimates and assumptions related to the assets acquired and liabilities assumed. The final valuation of the assets acquired and liabilities assumed was not complete as of December 31, 2020, but will be finalized within the allowable measurement period. Based on the Company's preliminary valuation, the total estimated consideration of $229.6&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock', window );">Schedule of Pro Forma Financial Information, AseraCare</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2020 and 2019 assuming that the AseraCare acquisition closed on January 1, 2019 (amounts in millions, except per share data). The pro forma financial information includes various assumptions, including those related to the preliminary purchase price allocation of assets acquired and liabilities assumed. The pro forma financial information may vary in future quarters based on the final valuations and analysis of the fair value of the assets acquired and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.748%"><tr><td style="width:1.0%"/><td style="width:61.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys Inc. </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock', window );">Schedule Of Business Acquisitions Compassionate Care Hospice</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired and liabilities assumed. The total consideration of $327.9 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"><tr><td style="width:1.0%"/><td style="width:76.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.481%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total estimated consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock', window );">Schedule of Pro Forma Financial Information, Compassionate Care Hospice</a></td>
<td class="text">The following table contains unaudited pro forma condensed consolidated statement of operations information for the years ended December 31, 2019 and 2018 assuming that the CCH acquisition closed on January 1, 2018 (amounts in millions, except per share data):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"/><td style="width:67.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years<br/>Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a the AseraCare acquisition .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for the Compassionate Care Hospice acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the Asana business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Compassionate Care business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966260792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of Activity Related to Goodwill and Other Intangible Assets Net</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our goodwill for 2020 and 2019 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2018 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">658.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated impairment losses of $733.7 million, which is inclusive of write-offs related to the sale and closure of care centers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we recorded a non-cash other intangible assets impairment charge of $4.2&#160;million related to acquired names which are no longer in use; additionally, we recorded amortization of $2.4&#160;million related to certificates of need and licenses associated with care centers that were closed. During 2019, we recorded a non-cash other intangible assets impairment charge of $1.5 million related to acquired names which are no longer in use or are associated with care centers that were closed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our other intangible assets, net for 2020 and 2019 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:31.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Certificates of Need and Licenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Unamortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Amortizable (4)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Compete<br/>Agreements (4)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2018 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated amortization of $0.7 million for non-compete agreements. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Write-offs are related to our acquired names that are no longer in use or that were associated with care centers that are closed.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amortization of certificates of need and licenses is related to care centers that were closed during 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average remaining amortization period of our amortizable acquired names and non-compete agreements is 1.3 years and 1.2 years, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Aggregate Future Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"><tr><td style="width:1.0%"/><td style="width:72.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Asset Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966366792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred operating income (CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current social security taxes (deferred under CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred operating income (CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current social security taxes (deferred under CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred operating income (CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current social security taxes (deferred under CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock', window );">Schedule of Other Long-Term Obligations</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred operating income (CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current social security taxes (deferred under CARES Act)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039167320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December 31, 2020 and 2019 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingLeasesTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for our operating leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinanceLeasesTableTextBlock', window );">Schedule of Finance Leases</a></td>
<td class="text">Amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current installments of obligations under finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock', window );">Schedule of Supplemental CashFlow Information and NonCash Activity for Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flow from operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flow from finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to ROU assets resulting from reductions to lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Term and Discount Rate</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for our leases as of December 31, 2020 and 2019 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Liability Maturity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2020 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:64.154%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinanceLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance leases Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinanceLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Maturity Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental CashFlow Information and NonCash Activity for Leases Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term and discount rate Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039611416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (1.7% at December 31, 2020); due February&#160;4, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus the Applicable Rate (3.8% at December 31, 2020); due February&#160;4, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt as of December&#160;31, 2020 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"><tr><td style="width:1.0%"/><td style="width:72.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.581%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term<br/>obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2020, the Applicable Rate is 0.25% per annum for Base Rate Loans and 1.25% per annum for Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment<br/>Fee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter&#160;of<br/>Credit&#160;Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8805;&#160;3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; 3.00 to 1.0 but &#8805;&#160;2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; 2.00 to 1.0 but &#8805;&#160;0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&lt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966443352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionforIncomeTaxesTableTextBlock', window );">Schedule of Income Tax Provision</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes attributable to continuing operations consist of the following (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense for the years ended December&#160;31, 2020, 2019 and 2018 was allocated as follows (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Sources of Tax Effects</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense at U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local income taxes, net of federal income tax benefit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Excess tax benefits from share-based compensation (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other items, net (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $92.1&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $19.4&#160;million federal income tax benefit and a $4.6&#160;million state and local income tax benefit for the year ended December 31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities) consist of the following components (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued payroll&#160;&amp; employee benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal &amp; compliance matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provider relief fund advance (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred social security taxes (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in partnerships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">In April 2020, approximately $100&#160;million was provided to the Company through the healthcare Provider Relief Fund established under the CARES Act. As of December 31, 2020, the Company recorded a liability related to the funds that we do not expect to utilize totaling $60&#160;million, which is reflected in the Provider Relief Fund Advance account in current liabilities within our consolidated balance sheet. For income tax purposes, the Company recognized the $60&#160;million as income upon receipt, resulting in a deferred tax asset as of December 31, 2020. The company will recognize an income tax deduction when the liability is paid during the year ended December 31, 2021.  </span></div>(2)The CARES Act provides for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2020, the Company has deferred $55.4&#160;million of social security tax payments; $27.7&#160;million of this amount is reflected in each payroll and employee benefits and other long-term obligations within our consolidated balance sheet. For income tax purposes, the deferred social security taxes will be deductible when paid on December 31, 2021 and December, 31, 2022, resulting in a deferred tax asset at December 31, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Uncertain Tax Positions</a></td>
<td class="text">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions related to prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reductions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionforIncomeTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision for Income Taxes Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionforIncomeTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039190664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Employee Stock Purchase Plan Activity</a></td>
<td class="text">The following is a detail of the purchases that were made under the plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018 and Prior</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,122,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January&#160;1, 2019 to March&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;1, 2019 to June&#160;30, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July&#160;1, 2019 to September&#160;30, 2019</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October&#160;1, 2019 to December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January&#160;1, 2020 to March&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&#160;1, 2020 to June&#160;30, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July&#160;1, 2020 to September&#160;30, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October&#160;1, 2020 to December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,171,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the awards were estimated using the following assumptions for 2020, 2019 and 2018:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk Free Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.38% - 1.51%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.44% - 2.53%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.56% - 3.04%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.15% - 42.80%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.46% - 43.83%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.00% - 45.32%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.00 - 6.25 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.12 - 6.25 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$86.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$54.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$42.48</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our stock option activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Contractual<br/>Life&#160;(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(622,829)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.68</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable options at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.75</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock option activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Non-Vested Stock Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-Vested Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our service-based non-vested stock units activity for 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(89,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Non-Vested Performance-based Units Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our performance-based non-vested stock units activity for 2020:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398964838664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_InsuranceProgramsTableTableTextBlock', window );">Schedule of Insurance Programs</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our insurance programs, including amounts accrued for the periods indicated (amounts in millions) in accrued expenses in our consolidated balance sheets. The amounts accrued below represent our total estimated liability for individual claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"/><td style="width:67.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Insurance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_InsuranceProgramsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Programs Details, Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_InsuranceProgramsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966292312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Income of Reportable Segments</a></td>
<td class="text">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,071.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(195.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,256.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">617.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,778.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(173.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,174.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,662.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">992.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,507.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966361944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Unaudited Summarized Quarterly Financial Information</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Income<br/>Attributable to<br/>Amedisys, Inc.<br/>Common<br/>Stockholders&#160;(1)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Service Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net&#160;Income<br/>Attributable to<br/>Amedisys, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1st Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">491.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2nd Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3rd Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4th Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,071.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1st Quarter</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">467.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2nd Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3rd Quarter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4th Quarter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399041998392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>care_center </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states with facilities | state</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum percent ownership for controlling interest (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NoncontrollingInterestRepurchased', window );">Noncontrolling Interest Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum ownership percentage for equity method investment (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Equity Investments</a></td>
<td class="nump">$ 875<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 7,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment, aggregate cost</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">17,876<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnSaleOfInvestments', window );">Loss on sale of equity method investment</a></td>
<td class="num">$ (2,980)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=amed_NoncontrollingInterestSoldMember', window );">Noncontrolling interest sold [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest, ownership percentage by noncontrolling owners (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue provided by Medicare</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeofEquityMethodInvestmentAxis=amed_HealthcareanalyticscompanyMember', window );">Healthcare analytics company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Equity Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember', window );">Heritage Healthcare Innovation Fund LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnSaleOfInvestments', window );">Loss on sale of equity method investment</a></td>
<td class="num">$ (3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NoncontrollingInterestRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest Repurchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NoncontrollingInterestRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OrganizationAndNatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OrganizationAndNatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=amed_NoncontrollingInterestSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=amed_NoncontrollingInterestSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeofEquityMethodInvestmentAxis=amed_HealthcareanalyticscompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeofEquityMethodInvestmentAxis=amed_HealthcareanalyticscompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039453016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Recently Issued Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="nump">$ 83,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">$ 93,440<span></span>
</td>
<td class="nump">$ 84,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039022264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Number_of_Visits</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare', window );">Rate of request for anticipated payment submitted for the initial period of care</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net Service Revenue Period Of Care Payment Rate Duration</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark [Member] | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue provided by Medicare</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | Number_of_Visits</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-medicare revenue term rates</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | Number_of_Visits</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-medicare revenue term rates</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember', window );">Cap Year 2014 Through 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember', window );">Cap Year 2014 Through 2021 [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember', window );">Cap Year 2013 Through 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenueEpisodePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenueEpisodePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonMedicareRevenueTermRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonMedicareRevenueTermRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399047281128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember', window );">Home Health Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember', window );">Home Health Non-Medicare - Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember', window );">Home Health Non-Medicare - Non-Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceMedicareMember', window );">Hospice Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember', window );">Hospice Non-Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue by payor class as a percentage of total net service revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceNonMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399058271192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,808<span></span>
</td>
<td class="nump">$ 30,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">66,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">83,357<span></span>
</td>
<td class="nump">96,490<span></span>
</td>
<td class="nump">$ 20,229<span></span>
</td>
<td class="nump">$ 86,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashBalanceAssociatedWithProviderReliefFund', window );">Cash Balance Associated With Provider Relief Fund</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceAcquisitionMember', window );">Asana Hospice Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 66,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashBalanceAssociatedWithProviderReliefFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Balance Associated with the CARES Act Provider Relief Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashBalanceAssociatedWithProviderReliefFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399037343448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details) - day<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare', window );">Portion of accounts receivable derived from Medicare</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare', window );">Rate of request for anticipated payment submitted for the initial period of care</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare', window );">Maximum days to submit final bill from the start of period of care</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid', window );">Maximum days to submit final bill from the date the request for anticipated payment was paid</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PortionOfPatientAccountsReceivableDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399041932344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
<td class="nump">$ 2,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="nump">4,152<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">12,100<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_UnamortizedDebtIssuanceCostAmortizationPeriod', window );">Unamortized debt issuance costs, weighted average amortization period, years</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">$ 47,987<span></span>
</td>
<td class="nump">21,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">26,730<span></span>
</td>
<td class="nump">25,040<span></span>
</td>
<td class="nump">17,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share-based compensation, tax benefit recognized</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember', window );">Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember', window );">Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UnamortizedDebtIssuanceCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected amortization period of debt issuance cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UnamortizedDebtIssuanceCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038771880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">39 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Useful Life</a></td>
<td class="text">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember', window );">Equipment and Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember', window );">Equipment and Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399052424232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 118,700<span></span>
</td>
<td class="nump">$ 124,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(95,024)<span></span>
</td>
<td class="num">(96,137)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">23,719<span></span>
</td>
<td class="nump">28,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_BuildingAndLeaseholdImprovementsMember', window );">Building and Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember', window );">Equipment and Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">53,100<span></span>
</td>
<td class="nump">55,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 50,700<span></span>
</td>
<td class="nump">$ 54,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399036825496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases', window );">Debt Instrument Carrying Amount Excluding Finance Leases</a></td>
<td class="nump">$ 215.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term obligations, fair value</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term obligations, fair value</a></td>
<td class="nump">217.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term obligations, fair value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Carrying Amount Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentCarryingAmountExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966480904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding &#8211; basic</a></td>
<td class="nump">32,559<span></span>
</td>
<td class="nump">32,142<span></span>
</td>
<td class="nump">32,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding &#8211; diluted</a></td>
<td class="nump">33,268<span></span>
</td>
<td class="nump">32,990<span></span>
</td>
<td class="nump">33,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399040495896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingForHealthcareProvidersIncludingHospitals', window );">Funding For Healthcare Providers Including Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements', window );">Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral Of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,929<span></span>
</td>
<td class="nump">$ 120,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,622<span></span>
</td>
<td class="nump">5,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AdditionalFundingDistributedToHealthcareProviders', window );">Additional Funding Distributed To Healthcare Providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsUtilized', window );">CARES Act Provider Relief Funds Utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized', window );">Estimated CARES Act Provider Relief Funds Expected To Be Utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid', window );">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures', window );">CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalCARESActProviderReliefFundsReceived', window );">Total CARES Act Provider Relief Funds Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedFutureCOVID19RelatedExpenses', window );">Estimated Future COVID19 Related Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,372<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember', window );">COVID-19 Deferral of Social Security Taxes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral Of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember', window );">Home Health And Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_COVID19ExpensesIncurred', window );">COVID19 Expenses Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram', window );">Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity Method Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AdditionalFundingDistributedToHealthcareProviders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AdditionalFundingDistributedToHealthcareProviders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The deferral of the employer's share social security tax provided by the CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActDeferralOfEmployerShareSocialSecurityTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Utilized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_COVID19ExpensesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred as a result of the Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_COVID19ExpensesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated CARES Act Provider Relief Fund Amounts to be Repaid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated CARES Act Provider Relief Funds Expected To Be Utilized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedFutureCOVID19RelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated expenses as a result of the Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedFutureCOVID19RelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingForHealthcareProvidersIncludingHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingForHealthcareProvidersIncludingHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable related to funds received from the government related to COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalCARESActProviderReliefFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total CARES Act Provider Relief Funds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalCARESActProviderReliefFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398951354808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($) </div>
<div>care_center</div>
</th>
<th class="th">
<div>Apr. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($) </div>
<div>care_center</div>
</th>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,200<span></span>
</td>
<td class="nump">$ 329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,700<span></span>
</td>
<td class="nump">$ 544,100<span></span>
</td>
<td class="nump">$ 485,000<span></span>
</td>
<td class="nump">$ 491,700<span></span>
</td>
<td class="nump">$ 500,700<span></span>
</td>
<td class="nump">$ 494,600<span></span>
</td>
<td class="nump">$ 493,000<span></span>
</td>
<td class="nump">$ 467,300<span></span>
</td>
<td class="nump">2,071,519<span></span>
</td>
<td class="nump">1,955,633<span></span>
</td>
<td class="nump">$ 1,662,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,268<span></span>
</td>
<td class="nump">177,472<span></span>
</td>
<td class="nump">155,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,802<span></span>
</td>
<td class="nump">18,428<span></span>
</td>
<td class="nump">$ 13,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | WASHINGTON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | WASHINGTON | Certificate of Need [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | KENTUCKY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | KENTUCKY | Certificate of Need [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,900<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember', window );">Asana Hospice [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash Acquired from Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionWorkingCapitalAdjustment', window );">Business Acquisition Working Capital Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">Period of time goodwill is expected to be deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Business Combination, Integration Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember', window );">Asana Hospice [Member] | Hospice [Member] | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember', window );">Asana Hospice [Member] | Hospice [Member] | Medicare Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember', window );">Asana Hospice [Member] | Hospice [Member] | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">Period of time goodwill is expected to be deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PaymentsRelatedToTaxAsset', window );">Payments related to tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Business Combination, Integration Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member] | Hospice [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member] | Hospice [Member] | Certificates Of Need [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member] | Hospice [Member] | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member] | Hospice [Member] | Medicare Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member] | Hospice [Member] | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_RoseRockHealthcareMember', window );">RoseRock Healthcare [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">Period of time goodwill is expected to be deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_RoseRockHealthcareMember', window );">RoseRock Healthcare [Member] | Hospice [Member] | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_RoseRockHealthcareMember', window );">RoseRock Healthcare [Member] | Hospice [Member] | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember', window );">Compassionate Care Hospice [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash Acquired from Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset', window );">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Current Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">Period of time goodwill is expected to be deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Business Combination, Integration Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember', window );">Compassionate Care Hospice [Member] | Hospice [Member] | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember', window );">Compassionate Care Hospice [Member] | Hospice [Member] | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionClosingPaymentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Closing Payment Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionClosingPaymentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Working Capital Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Deductible For Income Tax Purposes, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillDeductibleForIncomeTaxPurposesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PaymentsRelatedToTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to tax asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PaymentsRelatedToTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_KY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_KY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AsanaHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicarelicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicarelicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_RoseRockHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_RoseRockHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399037152200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Pro Forma Condensed Consolidated Statement of Income (Details) - Hospice [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net service revenue</a></td>
<td class="nump">$ 2,120.1<span></span>
</td>
<td class="nump">$ 2,077.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionProFormaOperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">218.0<span></span>
</td>
<td class="nump">167.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income attributable to Amedisys Inc.</a></td>
<td class="nump">$ 180.6<span></span>
</td>
<td class="nump">$ 112.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic earnings per share</a></td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted earnings per share</a></td>
<td class="nump">$ 5.43<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember', window );">Compassionate Care Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,971.7<span></span>
</td>
<td class="nump">$ 1,852.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionProFormaOperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.8<span></span>
</td>
<td class="nump">175.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income attributable to Amedisys Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130.5<span></span>
</td>
<td class="nump">$ 124.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.06<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="nump">$ 3.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionProFormaOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionProFormaOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_CompassionateCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399052470248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="nump">$ 733,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">658,500<span></span>
</td>
<td class="nump">$ 329,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">274,200<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">932,685<span></span>
</td>
<td class="nump">658,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">87,100<span></span>
</td>
<td class="nump">87,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">90,400<span></span>
</td>
<td class="nump">87,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">528,300<span></span>
</td>
<td class="nump">199,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">270,900<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">799,200<span></span>
</td>
<td class="nump">528,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">43,100<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 43,100<span></span>
</td>
<td class="nump">$ 43,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038185528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember', window );">Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember', window );">Certificates of Need and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039650168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">22,973<span></span>
</td>
<td class="nump">7,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">64,748<span></span>
</td>
<td class="nump">44,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">30,300<span></span>
</td>
<td class="nump">28,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write-off</a></td>
<td class="num">(4,200)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(16,600)<span></span>
</td>
<td class="num">(6,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">74,183<span></span>
</td>
<td class="nump">64,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember', window );">Amortizable acquired names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write-off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(7,100)<span></span>
</td>
<td class="num">(4,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write-off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(7,100)<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember', window );">Certificates of Need and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">37,600<span></span>
</td>
<td class="nump">23,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">11,800<span></span>
</td>
<td class="nump">13,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write-off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(2,400)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">37,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_UnamortizableAcquiredNamesMember', window );">Unamortizable acquired names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Non-cash impairment charge for write-off of intangible assets</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">18,100<span></span>
</td>
<td class="nump">19,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write-off</a></td>
<td class="num">(4,200)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="nump">$ 18,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherIntangibleAssetsAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions to Other Intangible Assets that occurred during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherIntangibleAssetsAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_UnamortizableAcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_UnamortizableAcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038627880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 10.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 13.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399041940520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayrollTaxEscrow', window );">Payroll tax escrow</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromJointVenturesCurrent', window );">Due from joint ventures</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">13,265<span></span>
</td>
<td class="nump">8,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationDeposits', window );">Workers&#8217; compensation deposits</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceDeposits', window );">Health insurance deposits</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherMiscellaneousDeposits', window );">Other miscellaneous deposits</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investments</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">35,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">33,200<span></span>
</td>
<td class="nump">54,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Health insurance</a></td>
<td class="nump">15,100<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Workers&#8217; compensation</a></td>
<td class="nump">35,800<span></span>
</td>
<td class="nump">33,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForLiabilityOnRegulatoryAudit', window );">Florida ZPIC audit, gross liability</a></td>
<td class="nump">17,400<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LegalAndOtherSettlements', window );">Legal settlements and other audits</a></td>
<td class="nump">24,400<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CharityCare', window );">Charity care</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedMedicareCapLiability', window );">Estimated Medicare cap liability</a></td>
<td class="nump">9,300<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceAccruals', window );">Hospice accruals (room and board, general in-patient and other)</a></td>
<td class="nump">29,200<span></span>
</td>
<td class="nump">24,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PatientLiability', window );">Patient liability</a></td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredOperatingIncomeCARESAct', window );">Deferred operating income (CARES Act)</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">11,400<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">166,192<span></span>
</td>
<td class="nump">137,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other long-term obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_UncertainTaxBenefitsInLongTermObligations', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredCompensationPlanLiability', window );">Deferred compensation plan liability</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct', window );">Non-current social security taxes (deferred under CARES Act)</a></td>
<td class="nump">27,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">$ 33,622<span></span>
</td>
<td class="nump">$ 5,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CharityCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to charity care</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CharityCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredCompensationPlanLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Plan Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredCompensationPlanLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredOperatingIncomeCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred operating income as a result of the CARES Act in relation to the Novel Coronavirus Pandemic ("COVID-19")</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredOperatingIncomeCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedMedicareCapLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to the estimated Medicare CAP liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedMedicareCapLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Insurance Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to Hospice room and board, general in-patient and other expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LegalAndOtherSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to legal and other settlements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LegalAndOtherSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of Social Security Taxes deferred under the CARES Act as a result of the Novel Coronavirus Pandemic ("COVID-19")</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherMiscellaneousDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherMiscellaneousDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PatientLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to Patient liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PatientLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayrollTaxEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll tax escrow</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayrollTaxEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionForLiabilityOnRegulatoryAudit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Liability On Regulatory Audit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionForLiabilityOnRegulatoryAudit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UncertainTaxBenefitsInLongTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Benefits In Long Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UncertainTaxBenefitsInLongTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Workers Compensation Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromJointVenturesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from an entity in which the reporting entity shares joint control with another party or group, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromJointVenturesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038894104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, Finance Lease, Term of Contract</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LeaseTypeAxis=amed_FleetLeaseMember', window );">Fleet Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">367 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lessee, Operating Lease, Option to Terminate</a></td>
<td class="text">Option for early termination of lease after one year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lessee, Operating Lease, Option to Terminate</a></td>
<td class="text">Option for early termination of lease after three years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LeaseTypeAxis=amed_FleetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LeaseTypeAxis=amed_FleetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399058737944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 38.6<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of operating lease ROU assets</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">39.1<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance Lease, Interest Expense</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinanceLeaseCost', window );">Finance Lease Cost</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 44.3<span></span>
</td>
<td class="nump">$ 40.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of finance lease cost including amortization of ROU asset and interest expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398964941128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 93,440<span></span>
</td>
<td class="nump">$ 84,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">30,046<span></span>
</td>
<td class="nump">27,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">61,987<span></span>
</td>
<td class="nump">56,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="nump">$ 83,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399042000264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Finance Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease ROU assets</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance Lease, ROU Asset, Accumulated Amortization</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease ROU assets, net</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current installments of obligations under finance leases</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of obligations under finance leases</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399047285400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Supplemental Cashflow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow from operating leases</a></td>
<td class="num">$ (38.2)<span></span>
</td>
<td class="num">$ (35.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow from finance leases</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">38.5<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations', window );">Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations', window );">Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399043878760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES- Weighted Average Remaining Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039307112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Lease - 2021</a></td>
<td class="nump">$ 32.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Lease - 2022</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating Lease - 2023</a></td>
<td class="nump">17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating Lease - 2024</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Operating Lease - 2025</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Operating Lease - Thereafter</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating Lease - Total undiscounted lease payments</a></td>
<td class="nump">97.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Lease - Less: Imputed Interest</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">92.0<span></span>
</td>
<td class="nump">$ 83.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Lease - 2021</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Lease - 2022</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Finance Lease - 2023</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Finance Lease - 2024</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">Finance Lease - 2025</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Finance Lease - Thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance Lease - Total undiscounted lease payments</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Lease - Less: Imputed Interest</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399078246856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 217,700<span></span>
</td>
<td class="nump">$ 245,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(2,700)<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term obligations, including current portion</a></td>
<td class="nump">215,000<span></span>
</td>
<td class="nump">242,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(10,496)<span></span>
</td>
<td class="num">(9,927)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">204,511<span></span>
</td>
<td class="nump">232,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">164,100<span></span>
</td>
<td class="nump">171,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038034680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="nump">$ 175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | One Hundred Seventy Five Million Term Loan Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="nump">$ 550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">3.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398964892696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Maturities of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Obligations, Fiscal Year Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">185.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 217.7<span></span>
</td>
<td class="nump">$ 245.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399036198632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal to 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal to 3.00 to 1.0 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal to 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than Equal to 3.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039805032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 04, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 04, 2024</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,249<span></span>
</td>
<td class="nump">$ 5,624<span></span>
</td>
<td class="nump">$ 91,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedInterestCoverageRatio', window );">Consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,700<span></span>
</td>
<td class="nump">$ 217,700<span></span>
</td>
<td class="nump">245,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">847<span></span>
</td>
<td class="nump">$ 2,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SwingLineFacility', window );">Swing Line Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LettersofCreditmaximumcommitment', window );">Letters of Credit, maximum commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Additional interest rate above Federal Fund rate (percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate', window );">Additional interest rate above Eurodollar Rate (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted Average Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability under the revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Credit facility, maximum additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple', window );">Credit facility, maximum allowable consolidated leverage ratio multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Creditfacilitymaximumallowableconsolidatedleverageratio', window );">Credit facility maximum allowable consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 29,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember', window );">One Hundred Seventy Five Million Term Loan Facility [Member] | Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted Average Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,700<span></span>
</td>
<td class="nump">$ 164,100<span></span>
</td>
<td class="nump">$ 171,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember', window );">One Hundred Seventy Five Million Term Loan Facility [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember', window );">One Hundred Seventy Five Million Term Loan Facility [Member] | Amended Credit Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Creditfacilitymaximumallowableconsolidatedleverageratio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Creditfacilitymaximumallowableconsolidatedleverageratio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LettersofCreditmaximumcommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letters of Credit, maximum commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LettersofCreditmaximumcommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SwingLineFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Swing Line Facility included within Revolving Credit Facility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SwingLineFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039965912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in total valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued related to uncertain income tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral Of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,622<span></span>
</td>
<td class="nump">5,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,929<span></span>
</td>
<td class="nump">120,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,635<span></span>
</td>
<td class="nump">$ 42,503<span></span>
</td>
<td class="nump">$ 38,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeOfIncomeTaxDeferralAxis=amed_SocialSecurityTaxMember', window );">Social Security Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember', window );">Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Recognized share-based compensation tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember', window );">COVID-19 Deferral of Social Security Taxes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral Of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years open to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years open to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember', window );">State Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Recognized share-based compensation tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Recognized share-based compensation tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Net Operating Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The deferral of the employer's share social security tax provided by the CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActDeferralOfEmployerShareSocialSecurityTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable related to funds received from the government related to COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeOfIncomeTaxDeferralAxis=amed_SocialSecurityTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeOfIncomeTaxDeferralAxis=amed_SocialSecurityTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UnrecognizedTaxBenefitsAxis=amed_NetOperatingLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UnrecognizedTaxBenefitsAxis=amed_NetOperatingLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399047270136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Tax Provision by Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax expense/(benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 41,600<span></span>
</td>
<td class="nump">$ 24,200<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">10,600<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="nump">52,200<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax expense/(benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(22,500)<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(4,100)<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="num">(26,560)<span></span>
</td>
<td class="nump">13,466<span></span>
</td>
<td class="nump">20,271<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 25,635<span></span>
</td>
<td class="nump">$ 42,503<span></span>
</td>
<td class="nump">$ 38,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038402808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Income Tax Expense Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income from continuing operations</a></td>
<td class="nump">$ 25,635<span></span>
</td>
<td class="nump">$ 42,503<span></span>
</td>
<td class="nump">$ 38,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxEffectsAllocatedToInterestExpense', window );">Interest expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxEffectsAllocatedToGoodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Total income tax expense allocation</a></td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="nump">$ 43,700<span></span>
</td>
<td class="nump">$ 38,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncomeTaxEffectsAllocatedToGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Effects Allocated To Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncomeTaxEffectsAllocatedToGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncomeTaxEffectsAllocatedToInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect of items occuring during the period that have been charged or credited directly to interest expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncomeTaxEffectsAllocatedToInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for continuing operations, discontinued operations, other comprehensive income, and items charged (credited) directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399037343448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes, net of federal income tax benefit (1)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent', window );">Excess tax benefits from share-based compensation (1)</a></td>
<td class="num">(12.70%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent', window );">Non-deductible executive compensation</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other items, net (2)</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">24.90%<span></span>
</td>
<td class="nump">24.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038054904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">Accrued payroll&#160;&amp; employee benefits</a></td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation', window );">Workers&#8217; compensation</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxAssetsLegalAndComplianceMatters', window );">Legal &amp; compliance matters</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxAssetsProviderReliefFundAdvance', window );">Provider relief fund advance (1)</a></td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxAssetDeferredSocialSecurityTaxes', window );">Deferred social security taxes (2)</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">67.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">98.5<span></span>
</td>
<td class="nump">66.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(3.8)<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="num">(11.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Deferred revenue</a></td>
<td class="num">(9.0)<span></span>
</td>
<td class="num">(13.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Investment in partnerships</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use asset</a></td>
<td class="num">(24.9)<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other liabilities</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(50.5)<span></span>
</td>
<td class="num">(45.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 48.0<span></span>
</td>
<td class="nump">$ 21.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetDeferredSocialSecurityTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred social security taxes which are the result of the novel coronavirus pandemic ("COVID-19").</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetDeferredSocialSecurityTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsLegalAndComplianceMatters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from legal and compliance matters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsLegalAndComplianceMatters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the Provider Relief Fund Advance set up as a result of the novel coronavirus pandemic ("COVID-19").</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and benefits workers compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from amortization of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038189240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits, beginning balance</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to current year</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions related to prior year</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions related to prior years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits, ending balance</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398951312232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 07, 2012</div></th>
<th class="th"><div>Jun. 06, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,470,212<span></span>
</td>
<td class="nump">36,638,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,814,278<span></span>
</td>
<td class="nump">32,284,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Percentageofownershipinsubsidiaries', window );">Percentage of ownership in subsidiaries</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Equity-based awards, number of shares authorized (shares)</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Equity-based awards, shares available for grant (shares)</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries', window );">Percentage of total combined voting power of the Company and subsidiaries</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Percentage of market value for purchases under Employee Stock Purchase Program (percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan', window );">Common stock authorized for issuance under Employee Stock Purchase Plan (shares)</a></td>
<td class="nump">1,328,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Employee Stock Purchase Plan expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (shares)</a></td>
<td class="nump">43,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Contractual term of share-based award</a></td>
<td class="text">ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan', window );">Common stock authorized for issuance under Employee Stock Purchase Plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember', window );">Share-Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Fairvalueofshareofcommonstockpercentage', window );">Fair value of share of common stock (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember', window );">Share Based Awards to More Than Ten Percent Owner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Fairvalueofshareofcommonstockpercentage', window );">Fair value of share of common stock (percent)</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (shares)</a></td>
<td class="nump">43,249<span></span>
</td>
<td class="nump">142,122<span></span>
</td>
<td class="nump">163,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit from stock option exercise</a></td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exerciseable</a></td>
<td class="nump">19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised during the period</a></td>
<td class="nump">121.1<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognitions (years)</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember', window );">Non-Vested Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested stock granted, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 158.72<span></span>
</td>
<td class="nump">$ 119.12<span></span>
</td>
<td class="nump">$ 80.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsMember', window );">Non-Vested Stock Units [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsMember', window );">Non-Vested Stock Units [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember', window );">Non-Vested Stock Units - Service-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognitions (years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested stock granted, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 206.10<span></span>
</td>
<td class="nump">$ 123.70<span></span>
</td>
<td class="nump">$ 95.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember', window );">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 17.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognitions (years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested stock granted, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 201.90<span></span>
</td>
<td class="nump">$ 128.89<span></span>
</td>
<td class="nump">$ 79.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Performancebasedawardtargetshareamount', window );">Performance-based award, target number of units to be received (shares)</a></td>
<td class="nump">81,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance to the Company's employee stock purchase plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Fairvalueofshareofcommonstockpercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of a share of common stock, percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Fairvalueofshareofcommonstockpercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Percentageofownershipinsubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership in subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Percentageofownershipinsubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of total combined voting power of the Company and our subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Performancebasedawardtargetshareamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock units authorized for achievement of targeted performance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Performancebasedawardtargetshareamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038193576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1">79 Months Ended</th>
<th class="th" colspan="1">103 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee Stock Purchase Plan shares issued (shares)</a></td>
<td class="nump">4,202<span></span>
</td>
<td class="nump">4,789<span></span>
</td>
<td class="nump">5,414<span></span>
</td>
<td class="nump">5,295<span></span>
</td>
<td class="nump">6,063<span></span>
</td>
<td class="nump">7,216<span></span>
</td>
<td class="nump">8,230<span></span>
</td>
<td class="nump">7,181<span></span>
</td>
<td class="nump">3,122,983<span></span>
</td>
<td class="nump">3,171,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Price per Employee Stock Purchase Plan share issued (usd per share)</a></td>
<td class="nump">$ 249.33<span></span>
</td>
<td class="nump">$ 200.97<span></span>
</td>
<td class="nump">$ 168.76<span></span>
</td>
<td class="nump">$ 156.01<span></span>
</td>
<td class="nump">$ 141.88<span></span>
</td>
<td class="nump">$ 111.36<span></span>
</td>
<td class="nump">$ 103.20<span></span>
</td>
<td class="nump">$ 104.77<span></span>
</td>
<td class="nump">$ 15.92<span></span>
</td>
<td class="nump">$ 249.33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399037987560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details) - Stock Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk Free Rate, minimum</a></td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">1.44%<span></span>
</td>
<td class="nump">2.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk Free Rate, maximum</a></td>
<td class="nump">1.51%<span></span>
</td>
<td class="nump">2.53%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected Volatility, minimum</a></td>
<td class="nump">40.15%<span></span>
</td>
<td class="nump">42.46%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected Volatility, maximum</a></td>
<td class="nump">42.80%<span></span>
</td>
<td class="nump">43.83%<span></span>
</td>
<td class="nump">45.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue', window );">Weighted Average Fair Value</a></td>
<td class="nump">$ 86.72<span></span>
</td>
<td class="nump">$ 54.42<span></span>
</td>
<td class="nump">$ 42.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The calculated fair value of a stock-based compensation award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399052503480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled, forfeited or expired (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,041<span></span>
</td>
<td class="nump">875,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average&#160;Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled, forfeited or expired (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.27<span></span>
</td>
<td class="nump">$ 49.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average&#160;Contractual Life&#160;(Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
<td class="text">6 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments Related to Tax Withholding for Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,493<span></span>
</td>
<td class="nump">$ 9,556<span></span>
</td>
<td class="nump">$ 6,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember', window );">Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="nump">268,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedSharesInShares', window );">Surrendered Shares In Shares</a></td>
<td class="nump">231,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit from stock option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments Related to Tax Withholding for Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedSharesInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Surrendered Shares In Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedSharesInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399054581496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock options beginning balance (shares) | shares</a></td>
<td class="nump">305,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares) | shares</a></td>
<td class="nump">43,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (shares) | shares</a></td>
<td class="num">(142,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited (shares) | shares</a></td>
<td class="num">(18,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock options ending balance (shares) | shares</a></td>
<td class="nump">188,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted&#160;Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested stock options beginning balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 41.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share) | $ / shares</a></td>
<td class="nump">86.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (usd per share) | $ / shares</a></td>
<td class="nump">34.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (usd per share) | $ / shares</a></td>
<td class="nump">47.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested stock options ending balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 56.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398963650648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Activity (Details) - Non-Vested Stock [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, beginning balance (shares)</a></td>
<td class="nump">9,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(11,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled, forfeited or expired (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, ending balance (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, beginning balance (usd per share)</a></td>
<td class="nump">$ 119.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">158.72<span></span>
</td>
<td class="nump">$ 119.12<span></span>
</td>
<td class="nump">$ 80.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share)</a></td>
<td class="nump">124.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled, forfeited or expired (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, ending balance (usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 119.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399041966584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember', window );">Non-Vested Stock Units - Service-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, beginning balance (shares)</a></td>
<td class="nump">231,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">34,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(89,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled, forfeited or expired (shares)</a></td>
<td class="num">(19,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, ending balance (shares)</a></td>
<td class="nump">157,546<span></span>
</td>
<td class="nump">231,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, beginning balance (usd per share)</a></td>
<td class="nump">$ 91.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">206.10<span></span>
</td>
<td class="nump">$ 123.70<span></span>
</td>
<td class="nump">$ 95.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share)</a></td>
<td class="nump">78.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled, forfeited or expired (usd per share)</a></td>
<td class="nump">97.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, ending balance (usd per share)</a></td>
<td class="nump">$ 123.92<span></span>
</td>
<td class="nump">$ 91.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember', window );">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, beginning balance (shares)</a></td>
<td class="nump">207,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">85,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(78,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled, forfeited or expired (shares)</a></td>
<td class="num">(18,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, ending balance (shares)</a></td>
<td class="nump">196,287<span></span>
</td>
<td class="nump">207,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, beginning balance (usd per share)</a></td>
<td class="nump">$ 97.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">201.90<span></span>
</td>
<td class="nump">$ 128.89<span></span>
</td>
<td class="nump">$ 79.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share)</a></td>
<td class="nump">83.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled, forfeited or expired (usd per share)</a></td>
<td class="nump">101.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, ending balance (usd per share)</a></td>
<td class="nump">$ 148.16<span></span>
</td>
<td class="nump">$ 97.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AdditionalPerformanceBasedAwardTargetShareAmount', window );">Additional Performance Based Award Target share Amount</a></td>
<td class="nump">11,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AdditionalPerformanceBasedAwardTargetShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional stock units authorized for achievement of targeted performance if target objective is surpassed to the point of achieving the projected maximum payout</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AdditionalPerformanceBasedAwardTargetShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398962526872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 27, 2016 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Nov. 03, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>May 21, 2015 </div>
<div>patient</div>
</th>
<th class="th"><div>Jan. 30, 2015</div></th>
<th class="th"><div>Apr. 23, 2014</div></th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Jan. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,122<span></span>
</td>
<td class="nump">188,434<span></span>
</td>
<td class="nump">$ 166,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,145<span></span>
</td>
<td class="nump">$ 237,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers' compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina [Member] | Hospice [Member] | Extrapolated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina [Member] | Hospice [Member] | Unfavorable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice [Member] | Massachusetts [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice [Member] | Morgantown, West Virginia [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice [Member] | Parkersburg, West Virginia [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Florida [Member] | Infinity HomeCare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Florida [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FloridaZpicRevenueReduction', window );">Florida Zpic revenue reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Florida [Member] | Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Florida [Member] | Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Florida [Member] | Home Health [Member] | Infinity HomeCare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Lakeland, Florida [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Clearwater, Florida [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_AmedisysCIAMember', window );">Amedisys CIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CorporateIntegrityAgreementTerm', window );">Corporate integrity agreement term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember', window );">Compassionate Care Hospice CIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CorporateIntegrityAgreementTerm', window );">Corporate integrity agreement term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ActualClaimsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actual Claims Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ActualClaimsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CorporateIntegrityAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Integrity Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CorporateIntegrityAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ErrorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Error Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ErrorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FloridaZpicRevenueReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in revenue as a result of the Florida ZPIC audit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FloridaZpicRevenueReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IndemnificationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount to be reimbursed if and when certain assumed liabilities are paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IndemnificationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Numberofpatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Numberofpatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_LakelandFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_LakelandFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_AmedisysCIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_AmedisysCIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_CompassionateCareHospiceCIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399039190664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsurance', window );">Health insurance</a></td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WokersCompensation', window );">Workers&#8217; compensation</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiability', window );">Professional liability</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedInsuranceTotal', window );">Estimated Insurance Total</a></td>
<td class="nump">55.8<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedInsuranceLongTermPortion', window );">Less: long-term portion</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedInsuranceExcludingLongTermPortion', window );">Estimated Insurance Excluding Long Term Portion</a></td>
<td class="nump">$ 54.6<span></span>
</td>
<td class="nump">$ 53.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceExcludingLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated insurance liability, excluding long-term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceExcludingLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term portion of estimated insurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated insurance, total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional liability insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WokersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Workers' Compensation insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WokersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398964988152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DefinedContributionPlanEmployerMatchingContribution', window );">Employer match amount</a></td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram', window );">Employee contribution amount</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage', window );">Maximum percentage of employee salary eligible for employer match (percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">401(k) expense recognized</a></td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Percentage of Employee Salary Eligible for Employer Match</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan Employee Contribution For Employer Matching Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefinedContributionPlanEmployerMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer matching contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefinedContributionPlanEmployerMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399052404920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 23, 2020</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
<th class="th"><div>Jun. 04, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 181,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseAxis=amed_A2021StockRepurchaseProgramMember', window );">2021 Stock Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock repurchase program, expiration date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseAxis=amed_A2019StockRepurchaseProgramMember', window );">2019 Stock Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock repurchase program, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember', window );">KKR Share Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageofSharesOutstanding', window );">Percentage of Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DiscountedClosingStockPrice', window );">Discounted Closing Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageofClosingStockPrice', window );">Percentage of Closing Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,418,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DiscountedClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounted Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DiscountedClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageofClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageofClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageofSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageofSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Share Repurchase [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseAxis=amed_A2021StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseAxis=amed_A2021StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseAxis=amed_A2019StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseAxis=amed_A2019StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140398966290568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399038103480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 550,700<span></span>
</td>
<td class="nump">$ 544,100<span></span>
</td>
<td class="nump">$ 485,000<span></span>
</td>
<td class="nump">$ 491,700<span></span>
</td>
<td class="nump">$ 500,700<span></span>
</td>
<td class="nump">$ 494,600<span></span>
</td>
<td class="nump">$ 493,000<span></span>
</td>
<td class="nump">$ 467,300<span></span>
</td>
<td class="nump">$ 2,071,519<span></span>
</td>
<td class="nump">$ 1,955,633<span></span>
</td>
<td class="nump">$ 1,662,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,185,369<span></span>
</td>
<td class="nump">1,150,337<span></span>
</td>
<td class="nump">992,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">668,200<span></span>
</td>
<td class="nump">607,900<span></span>
</td>
<td class="nump">501,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,802<span></span>
</td>
<td class="nump">18,428<span></span>
</td>
<td class="nump">13,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,152<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,886,623<span></span>
</td>
<td class="nump">1,778,161<span></span>
</td>
<td class="nump">1,507,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,268<span></span>
</td>
<td class="nump">177,472<span></span>
</td>
<td class="nump">155,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Reportable Business Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,249,200<span></span>
</td>
<td class="nump">1,256,400<span></span>
</td>
<td class="nump">1,174,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,900<span></span>
</td>
<td class="nump">754,100<span></span>
</td>
<td class="nump">722,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307,200<span></span>
</td>
<td class="nump">297,200<span></span>
</td>
<td class="nump">276,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,400<span></span>
</td>
<td class="nump">1,057,000<span></span>
</td>
<td class="nump">1,001,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">199,400<span></span>
</td>
<td class="nump">172,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Reportable Business Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,100<span></span>
</td>
<td class="nump">617,200<span></span>
</td>
<td class="nump">410,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,600<span></span>
</td>
<td class="nump">335,100<span></span>
</td>
<td class="nump">212,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,400<span></span>
</td>
<td class="nump">137,500<span></span>
</td>
<td class="nump">84,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,000<span></span>
</td>
<td class="nump">474,200<span></span>
</td>
<td class="nump">297,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,200<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
<td class="nump">113,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member] | Reportable Business Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,200<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="nump">77,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,900<span></span>
</td>
<td class="nump">61,100<span></span>
</td>
<td class="nump">58,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="nump">73,600<span></span>
</td>
<td class="nump">71,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Other [Member] | Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,200<span></span>
</td>
<td class="nump">160,900<span></span>
</td>
<td class="nump">127,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,700<span></span>
</td>
<td class="nump">173,300<span></span>
</td>
<td class="nump">136,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (195,700)<span></span>
</td>
<td class="num">$ (173,300)<span></span>
</td>
<td class="num">$ (136,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399041917016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION Operating Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 550,700<span></span>
</td>
<td class="nump">$ 544,100<span></span>
</td>
<td class="nump">$ 485,000<span></span>
</td>
<td class="nump">$ 491,700<span></span>
</td>
<td class="nump">$ 500,700<span></span>
</td>
<td class="nump">$ 494,600<span></span>
</td>
<td class="nump">$ 493,000<span></span>
</td>
<td class="nump">$ 467,300<span></span>
</td>
<td class="nump">$ 2,071,519<span></span>
</td>
<td class="nump">$ 1,955,633<span></span>
</td>
<td class="nump">$ 1,662,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 45,100<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="nump">$ 34,700<span></span>
</td>
<td class="nump">$ 31,800<span></span>
</td>
<td class="nump">$ 27,700<span></span>
</td>
<td class="nump">$ 34,100<span></span>
</td>
<td class="nump">$ 33,700<span></span>
</td>
<td class="nump">$ 31,300<span></span>
</td>
<td class="nump">$ 183,608<span></span>
</td>
<td class="nump">$ 126,833<span></span>
</td>
<td class="nump">$ 119,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders - basic (usd per share)</a></td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 0.98<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 3.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders - diluted (usd per share)</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="nump">$ 5.52<span></span>
</td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140399041818776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 04, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Equity Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 7,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">181,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=amed_MedalogixMember', window );">Medalogix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Equity Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember', window );">KKR Share Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="nump">2,418,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageofSharesOutstanding', window );">Percentage of Shares Outstanding</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="nump">$ 181,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DiscountedClosingStockPrice', window );">Discounted Closing Stock Price</a></td>
<td class="nump">$ 73.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageofClosingStockPrice', window );">Percentage of Closing Stock Price</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember', window );">KKR Share Repurchase [Member] | KKR Consulting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageofSharesOutstanding', window );">Percentage of Shares Outstanding</a></td>
<td class="nump">14.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DiscountedClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounted Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DiscountedClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageofClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageofClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageofSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageofSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseAxis=amed_KKRShareRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amed_KKRConsultingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amed_KKRConsultingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,UR[2T97L&I8VP'V&1#,!IP@W7+I3A\.V$BMM@.&*_EL/+TE01[%!BP\,$:
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MFY8+<FB%(,>TC&!C>B+FKT73B-6D.?DO 1LCZI(@,8^=[G%QF+(XMKFX,.6
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M@>1H;_-G')[EB%^,7A^S#;D"9?M");?A">8QR[S^%S-F=!-4T!G8W" 9O6'
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M@M&2QGZX22B,]#*OEZD0@BY)M8F4JD'GFUH+L'7LX6Q[& +TK+W8BS,J2:-
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MM89L ZXKC*'P)Q JL<#$E<,];E[A9-T-^N((5$IK4RU-(S17N^[J4IX_>(%
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MZ2K[H!9WRX<_YDF)'O6"<FX5(T5G%\R3AUTQ_1EF9.#D?8B!$V[$<JD]<#5
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M@/LS8WSU@S:H_\KAV;\!4$L#!!0    ( $9 65*'5*Q=K@8  ' 1   9
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M7T/KP\0*#8Y$2J?-*:Y^Y;M_/3CU,?292#/8$/7F<^?E0J36S_9;!\?L$6=
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M3*>QCW?I<BW84MWED]0I:H#TH<$J'T@5HK),M(AV9BPV!4H8*]GM0\-&0BY
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MT29Q(@T"6#_@G05# $H<VSOZEB<VX8#8I_B%2A+ )LQU6.5]8I"2.(YPK(
M3PLJ"%#-I#(ZWXY1=&;+"6VL(,0"O.%H8+ME:Y\?4N@<#U\67&[2X=>CER%^
M=*TJK&3; ]]?$.Y.ZZ[9#T@+,<HG\:>6%#77W!2CST:2@E,0!Y"298J">+.#
MPV8EME_3;5F5E3P$K8; F'+W<Z?2<,Q.)VY8;>-=8:Q^+8S(N!L! _&;$E-M
M4$@KC@,$M\2T&X)>;TM"D6$3N&1?;5C)&M[/*JW5&US]YB9:4-#&2:A9"@^]
M^K'N<_U*'491[THDVPFPW5!U10F[%WJ&S$IN*2'#3"G+*]0]VF2*",24UPJ
M&RF%.GR&NFVWYKT+$"PL5UL@L 6E*ITH5)FUVI540/DKRY *T*$F%% <QZ&B
M^>4'*J%P_$+L)P=,=Z.J;:M6X6C[25C^U!+7RQ)05)Y1P'*I2$8I9FD>N1P9
M ,KP(;4407W+H=D0?!;HJEG,&<*.9V2F8@['I&D;-A,O2([#9Q6=OMB?^@VP
MXU+YA2!3:HX")JI2],XEB"]BM-@)]87D-/#>TG/WHQU:&-6.;8B_L;JI!"+W
M+=<$JET:0.4:P\C7Q/949E_%Q]F,X[;O)WHWUY<?/Z-,Y.@842(R; N;1TB<
MZ!9"&\/ES6Y10X56J<AWDJ0UG2F$A[6F&(&01J?9Y%XL?=-/&<%/6OP!N3UH
MZ&$#(H4>$LL3E;BH 795+UPX6MA264I<9:)T3'5*TZ5!5T/;;P5W0I 93VJV
M8_DKM[AA?Z2#1RWK-I' JSGL<4>26MVLYJHJE:(&D_45:560\HO*\2E7E"5&
M5W[DXF&W5M #1N1GMPD(7]5U?%/H^#/K>%/T5A&IV"D$N2D%N"93GPTG+ZFX
M')+$U+:.Z/,S-*/\;S@XFN ?FG3Z=XTMJ6NNG^:NI#.N/1_Z+6$GZ SYVV3(
M= *A<0<AWEP2FM2VDOGY&_^[_M73::ZOK\ WOYO%:2F3XQ!CVL(VX+;9VS]:
MK"+C,PIPBO.0F2J>$M#'H@Z6U2AHFQM_Q'9R[8L%,C.LWR?&:D!%Z#$X,MVL
MTF>US!U 5B5P2BG#P0DY27,(Q:A7&<.O+9USZO1%/UY_D,B\-:_EW$.Z'SY"
M]P*\I:*<"'03/0K1//&4STX?X[A.^6B#<KLY?3U!2T+SLJ/"6>8(LE-J:9+8
M]S&=9KS.J-[BXJ7(##2AC_/4=X\-4[4?YV6OV=K/ETD"=1^IE9_.T!JCDNP.
M"8"=W-!@VW++0)'-(#LEINB@%%#8>=R,:L)^T0GN*CQ1SB/-A:IL-(2](07:
M6I$IAW[,+JIJRB"Z)R&14<_%Q322'A6,AI^4W=>#;T YZ5-RR<)5 )]"Y03W
M;-;B#"M33FIQ8M'9>36ON7M%'EW4#PGGVQ;6< HITK)#[DW*BIW*J*D_K3E0
M<PM)WVB<5^L-JPS0%?0?:9F"B:P@)#J5E2A<:P87T,WM[!V]<M:7A')G^L7N
M4-E2K3S%BHSD! ;>24-HM^)2P9.4+U04V?U6WE/[^U8!)E0]\RT,L'!11^M^
M[]WE]>W;B]Y!6QN\(^MY-][BNZQ=2+RF /X@!CZ9K5JYD&:N6MOP;@.\DX"%
M=S6K*EV2-2.91GG*W! /PB"%^OE\;IZ'^%H.Z;F]H&*A&88C99P,>*HY)LJE
MK\K91^S/]* 5HF!K7EYR69M)]#E7$@"+491#D4=Z0=7@#];9"UK/XUT/I#11
MF2=2>UB$)T"+$-)GGV)78!?S FCR2(8231!<8ZH".V1S/S I@H_UAHY5A"(D
MC(]I()S02 #E/RNBH?\@=C.VH4C?5*$W-I:F3['V]7;\X/XJ<^:A&J!THW5-
M<3.BSC46>\/!67TN&>\:MH/+UB%Z'PYJR;;-F7N8J!)O#:\H4I&_Z(V16(!'
M8OF!FDG/]4;9/#I_K#P!8N= ,]2N?#BFP.OP%=&%Z@>$;^H<P,MZ 1=X>*[7
MY%HQ0A- [B?!X4M]8/;4X"8='^'0W%D?2:%EBF3%7*]D+K3@#2[J)X8XG&W,
M>8T*=;5W#XYW@*@XGSPK!&LHF1*"0=C,\C 4D/'O0"'>A,C#7!#/W9R48:U+
MB._@^]2GU0;/&RSV=\>@@?A(UN2K;MH<(FSSPHSJ*3_YX;3@LQDIJ^M&L3F=
M'0_&6S59*T!#I<<7:AOKM^I,2-,"[^\2YJDSP3\CT_%@N^+M=-+.IG<+H)L7
M I(ZX).6A5U)E&69#$Z8R5 /<FFU1&O- :8,C55$?DHY<^TQ3,[C"L($W@[B
MX2*\S+FA;LY1,2L.MFN^OUGEQJ)9NH.S:+IP22%5QO,.&P;%$@77<L5H#_,2
MNE*@(@_*N/,7/YG.GE=,% /0)<&F&!/WJ0*GIH"S&X7@N:6B5O%]0H-;Z!#G
MTS64\4-T3G./6%'>(4_):7W(_(<QN'=\BOZU7(PGT-,"J >948U*_2(&2JJ!
MGXR^-SZK9:^-M2TW;#]I/UNMXG=+*FT?T&[<4,AM6GT1@A@?N>7T]4$YD0_[
MJU$VXT/ZFPYO5>:"$I.SS4C+-T]+&2ON CCVZG[HR"/8L1XWJ]F-'\)GOBXB
M)ON/U GUMXU;G2]TWT&F[!"^<07=D/R)Y"JM%.U:Z\9/*)?FZB_B8I-8=2/4
M 9(+BVATQ?.U[X(*\SD:%RZVC8/F871UX?X_4?#'K-4T22E?T%:_?G?D]%QQ
M-&MX:+&R?E,4GMG*>I]J^J2%Q8J_4;)^M^N6=+;M.>?2BNO_F;S3Y150ZW!<
M^GD&-S_^_M%?.(94"1JM]2_H)=SN66Z-4-?ALWNH-T4K%B8NU-5ZNJKZ39##
MB2M_L]>0]5_%[9&_B*Z",]7,-6:1;_Z,NKBOK)7\E(,:/<EZX3&3Z36J1HC
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M@)1.:N]*1*?V:4C&6.5*"Z'F"%A@2Q@FD^_ 9=KZ@C,.;GY8, .MNO"Q2,A
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M$&@@&O8EJB[7A0;]W152'"IIR18"YEVRR1+'06= !]A $MR&Z2N9OH6M\$@
M$E<,9Q=7<:[[T; FNH/P-1M=I@'TA9KZQ^FL]D7U@?H;$F>ZM&)C[T+2OHE_
MNSR/9W[.+0.N^TW^W)_L)UWIA5FV!%#W3;J\BN>$(N7=.UU$&[';NFI+%TK
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M1\F) -]7UH;=1@P,+]S3?P%02P,$%     @ 1D!94@:57+[1!   G0L  !D
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MXW$-#$-\;S?2T@:LKXWQTX0,[&_R)_\ 4$L#!!0    ( $9 65*B*S*3.0,
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MICUOZGC3__G^_WL66%-+6(I"-NC<>U1/O$#8X!.*%L^WYTSS@JZH;@V6[HM
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M?F_ ^UMCZ##Q ;J_&?-_ %!+ P04    " !&0%E2LSZ+#&HN  "[F@  &0
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MG.;@8%-W/PQ9;&Q,$7; 9C!/G/U=KSB]*B3>QRD!\5(BP1!9I*A#Y*@]I[D
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MU)Z/O&RC;D4DRT^CY;S4"(EUU@K)%%LS@;G<[GGWO:EYL+$MN'^66G:ZEJR
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M%LT0!B.VCCXML$8@UY_C+E,/"?DWU:&CSU.A1)[0PJ 2K-YIT"4AGJS8\5?
M)[::!UO]]]<BXQ*W('-JI$I1*NV;?T&\#P(+^T'#*Q@$[0'=HFX[6H^+IPS:
M,?3[[= +>*%])#$B4:]@V"?N+2GM-RGMOSBE)];)S ?NUN*L5'!.L]![/C$T
MX(V[]S9QO@L:N6Y39K=K^X(PQYR0JA2U(Z/O9,I9-30B*=.)%'X(ZSN*L7N4
M;VQ,*RO35BU*L8EM^ .%L7!<2I4R>32$<Z3&L- J!9FQ)LQ\4,_1$BO[I)@
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MYK03-=69O%HX7?AS\%0[.E7[QP4*P@,3T/>9IGY1+UA!\\/(T3]02P,$%
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M6%8TS%'[ -HOE;)'PQ.T?P_#7U!+ P04    " !&0%E29$+B3[H&  "K%@
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M0(Z&O"2\"[M!2)!#;_YHA."W@0.,MLH NW6,P\$0.[UJ]&J86ZL%\HVK:$S
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MOR-%HR$YC*,7+GR?OM0:U6_M>4I7% ]SR!=SP-R?:EGM9VEP2(<Z/NFSX%I
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MQ<-1O!7Q M, >M$>Q&$<;L'K-1'W/%YO(][4P86TJ=*V,@A_#J?6&:J.O[:
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MN.W83R[.Q:/,<W+805(>N]OVT%[FW51V3Y@;9^D_Z_W-55UK:(NU83"C/L8
M'-S[E?7G+(YKPN((U@:%Z;1<4^\NH0WRO;R^418@"3_OE?2MJ;,WBS([97WB
MA7'U4;U:<+>IS*2M7VCMVG<OK$T=2]^]IA-N9'YOH+<5^Z#SACX3^M']'X(.
M0JB$ZF5]^[3]5\>L>L._7E[]G^0SUTBW8:E88*OOG8Q[3%?_>ZB^6%6X]_US
M9:W*W"W0'%!'"_#[0BG;?"$%[3^ +G\'4$L#!!0    ( $9 65(@DO!*4 8
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M%?V=T#* SG>&+K=?L(/3_V[V'U!+ P04    " !&0%E2V9&13P0%  !8#
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M(8\7/BG7VF'B'$<YB8)V;;+'7C$^%G$1"(RR) PXO87_]&&*-QB)<9CQ(-F
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MEO1O0F4=Z'PGI3DO+$#WMQO_#U!+ P04    " !&0%E2P>'6(I %  !B%P
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MVY2NUMQ= L=Z>4EJ5NJ<LZZ>6E<W@TK>-:@9F ED4*0TKO3'VI<?**1RR3Q
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ME<+!!8R*LUJ!S;7BD8D59.$E8..,IC&^(M@99V/G:F [IP6^401VQN[83*W
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M9EP_T;JTM0P4+[F@>0F6#')2;-[XK=1A"V![GP"<$N <"G!+@'LHP"L!WJ$
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M0F(N@15/5"CA*O'1?TI@ZRKK4LF^U"DQ,EZB=P8=]R,0AS@&ODXM7:?@Z[[
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M,^0G@A[T6^L-%8(F^G"/D90.U4#>WU(JCB=J@/)KS_@_4$L#!!0    ( $9
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MU;AL[N%SAPIM ,^WG*OGCGY!\P$U_0=02P,$%     @ 1D!94HTNG5W0 P
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M'Q"QB'6"4/]J=^Q6T+'S[-L)GGTN^[OL_9CH'316$,J_*W!K.6XMP:U=P'U
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M5[I[!1$;Z/T%YVHWB0_(^^'.OU!+ P04    " !&0%E220)U&"L#  #<"0
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M9QAABJ$V$(S^'G&*:6J0B,?W$M2I8AK'^O@)_1\KGL1LF,*I2+_P2"=#I^]
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M&FQ&;ICCYP*4!>#^2DKS,K$=J?D 97\ 4$L#!!0    ( $9 65*H""\5P (
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M*P@XI,8R4/R\P 0XMT0HX_>.TRM36F!UO&>_==[1RYQJF$C^@RW,>NCU/;*
M)<VY>93;S[#ST[%\J>3:_9)M$=O!X#371F8[,"K(F"B^]'57APH@:A\!Q#M
M_%Y L@,DSFBAS-F:4D-' R6W1-EH9+,#5QN'1C=,V']Q9A3N,L29T=W->'8S
M(Y?DE@DJ4B!W@$71Y'P*AC*N+W#K:38EYV<7Y(PP0>X9YUA_/0@,IK<D0;I+
M=5VDBH^DFD+JDR1JD3B,PP;XY-WPZ-,A/$#3I?.X=!X[ON28\\+HS_%<&X7=
M].L$9U)R)HZS?81S7T1NN<GCUR="M0;36*R"J>.8[%E[&75\]/52K4A33%S&
M'$ALEQ+;[Y+H[+><QK'5V"+C-,VSG%,#"S+.I#+L+[5'K4E\D2,**\HN$S]Y
M([\I*O+[S08ZI8'.AVK<(@),D]9.747L=]](;0A*_':STFZIM'M2Z217"H3!
M4Z,-Y1SO/J.)7!(YYVSE2JM)+A:@R++JJ;%;NG5]D=][8^(_00<F>J6)WDD3
M=U*L+@VHC&QL2^#-^T$'O;JXL-;P#4%''?1+!_V3#KY)K/ZA0,(9G3/.#&O6
MVJ^=NWK'U&/J#1-4+F;[*-Y3M<)N0!%+1(5^#^&J>&B*B9$;=U?/I<&;WPW7
M^#:#L@&XOY32["?V^B]?^]$_4$L#!!0    ( $9 65(K>L]F*0,  $X)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;*U6VT[C,!#]%2OB :2EN93>
M4%NI%- B@4!4[#ZL]L%-)HV%8V=ME\+?[]A)0RAIQ0,OB2\SQ^=XQAZ/-U(]
MZPS D-><"SWQ,F.*<]_7<08YU1U9@,"95*J<&NRJE:\+!31Q3CGWHR#H^SEE
MPIN.W=B#FH[EVG FX$$1O<YSJMXN@,O-Q N][< C6V7&#OC3<4%7L #S5#PH
M[/DU2L)R$)I)012D$V\6GL]'UMX9_&*PT8TVL4J64C[;SDTR\0)+"#C$QB)0
M_+W '#BW0$CC7X7IU4M:QV9[BW[MM*.6)=4PE_PW2TPV\88>22"E:VX>Y>8G
M5'IZ%B^67+LOV52V@4?BM38RKYR10<Y$^:>OU3XT',+^'H>H<HAV'<[V.'0K
MAZX36C)SLBZIH=.QDANBK#6BV8;;&^>-:IBP45P8A;,,_<ST]FJVN%J04[)8
M%P4'C(^AG,RISE(,,+D19:+8'3^^!$,9UR=H_;2X),=')^2(,$'N&.=HH,>^
M0486UX^KU2_*U:,]JX<1N9/"9)I<B022CP ^2JGU1%L]%]%!Q$N(.Z0;_B!1
M$ 4MA.9?=@]'!^ATZ^WM.KSNONT%3#%-_LR6VBA,V;\',,]JS#.'>;8'\[X
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M"SM-'6_SQXF1N^Q"O)0&KM?9< M?0%19 UA?2]C/^<3>L8MOJN&_4$L#!!0
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MX.%ZQS[PQEMC9E3CM>1_L=0L.\%E "G.:<[-1&[>X]:@IN-+)-?^%S;;NU$
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MJK6L1U4QPA4;(U=^;)I)8X<POUS:L1>5NV#/YU*:W<8]4 [2W:]02P,$%
M  @ 1D!94MJ:_K]R @  EP8  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N
M>&ULC97;3N,P$(9?Q8JX  ER3E-0&@G:A46B%-&RJ[UTTVEKX<1=VZ7P]FL[
M:905+N4F\=CSSS<S22;9CO%7L0:0Z+VDE1@X:RDW5YXGBC646+AL Y4Z63)>
M8JE,OO+$A@->&%%)O=#W>UZ)2>7DF=E[XGG&MI*2"IXX$MNRQ/SC!BC;#9S
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M4C(I%N>"AR(S!^C],RG5VXKIH/K48_0?4$L#!!0    ( $9 65)'G+HL/PD
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M^'[.F'A](Q_!WOXOP]G_ 5!+ P04    " !&0%E2FT188FL&   Q'@  &0
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MMP+)35D2\7(!!=^.'>R\WKBCRY6J;KB3T9HL80;J87TK],IMH^2T!"8I9TC
M8NR<X[,4&X-1_**PE3O7J$*9<_Y8+:[SL>-5&4$!F:I"$/WW!%,HBBJ2SN-O
M$]1I]ZR,N]>OT:\,O(:9$PE37ORFN5J-G<1!.2S(IE!W?/L-&J"HBI?Q0II?
MM&VTGH.RC52\;,PZ@Y*R^I\\-X78,>"XP^ W!G_?$'88@L80?-00-H;05*9&
M,75(B2*3D>!;)"JUCE9=F&(:M\:GK.K[3 G]E&J?FES_F/Z\N43WYW\N9^@K
MFO)RS1DP)1%?H'ORC&X%?Z*FR_,7]'TCJ,QIW;+C%!2AA3S1OH=9BHZ/3M 1
MH@S=K_A&$I;+D:MTBM5&;M:D<U&GXW>D@WUTPYE:273)<LC?!W U6POHOP)>
M^+T14\A.48"_(-_SO0,)33]LQ\,#]O3C]J2')FC;%9AX04>\Z48(W1U=Y8R7
M@)1N$#SK=X $]W@.#!94G9SU[!.V^X1FG[!CGRO(09#B4 -KX\ 8J[?*TR3$
ML:=+^[1;55OEA_Z^*K55. YW5.]RC]K<H][<9XHH0/K\H8)GAQGJ /'NOI[-
M8*O"Q$*P13[N(HA;@KB7H+O+J.WR(:S8RB7RK:)/;94_]"PN6X63J MLT((-
M>H]O"@O0:/FGSV_2;I1\]OPF%MA7WX^L*MFRH25*;1$..XLT;',?_N_Y'=H,
M(;80;%5H]]D614D7 ?;>OBI>+T-/H_N/<!/W?7OB*-YG.Z##01C'>W0'9/H[
M,, =?#M?3=S+=VUA'83!]ELPBH-HG\66A?I$!OLLMBQ(DFBXQ^+N# ,EB*49
MJB3*^(:I^K/9WFT'MW,SKNS=OZ@&.C-DO(6II\$;(I:4253 0H?T3@?Z)2CJ
M :M>*+XV(\><*SW F,N5'DI!5 +]?,&Y>EU4&[1C[N0?4$L#!!0    ( $9
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M\G'KO:R>'L$-6&:'%'U "+84A6_ +W 8LW(&?AKDS8B 3PM(@R0EGQGR%U
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M@+@4L/L[A.AI4#IHODVFOP!02P,$%     @ 1D!94A-H#>_P P  G \  !D
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MV0+DEA5HND.'=B.RT]/!EK (_?@F*=&=@)3_-#CDEP[YVB'_A$/CF#^C6P:
MQD3 E5K#<;I.JS)O)G(LK_6I*C]F&+9\OPH6FF&N56]\,LBOE_+KOR:?O)R2
M;R;"5AU7RC?#I ZO4KX9YEG.<=3>R&^4\AM&GL'+2A[P<HT]T42NPR06.^,2
M,+/YCH7KE4$X@W,M_SB;>13.XAS'%(9F&8;F;X3A]%(PLTFW6L=NY6$X@_.L
M5O5B.(.K6YYK"D.K#$/KLC \ JO4;88WT X(X\A#J2X!!H]N2H]NC)3?];U
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MA]&@[P5]=V@]U !R<T"N$="O#">"K(V6W8IEUT%N4&_8RPU[1L.S1\)6(2=
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MK"]W!,M$4POD^PVEXOE&?2#+/[F._@902P,$%     @ 1D!94M0&(:!# P
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M_L'QOJ6"PE*#'68A>,!L27A1 P@2NDEY8R4-W__0,<TCAOK>24E"!+(\<<K
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MND'^/J54;+ZHMU:W;[^?_Q]02P,$%     @ 1D!94BNO?>XE P  C@@  !D
M  !X;"]W;W)K<VAE971S+W-H965T.#(N>&ULE99MC]HX$,>_RBA7G5KIEI"$
MQSU V@5ZBU0H*O3ZXG0O3#* 5<>FMEFVW[[C))MFV8#:-Q#;,__YS3CV9'!2
M^JO9(UIX2H4T0V]O[>'6]TV\QY29ACJ@I)6MTBFS--0[WQPTLB1S2H4?-IL=
M/V5<>J-!-K?4HX$Z6L$E+C688YHR_?T>A3H-O<![GOC$=WOK)OS1X,!VN$+[
M^;#4-/)+E82G* U7$C1NA]Y=<#ON._O,X%^.)U-Y!I?)1JFO;C!+AE[3 :'
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M=/R,LMP;].S:5 YZ8JTYRV$JB5IG&96O0^!BT_=";[?PR%:I-@O^H%?0%<Q
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MH)V#/<^5PI/A @P_EO@/4$L#!!0    ( $9 65)T%7",R <  ) N   9
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M7G]NOI39IGX%]28KRVQ=?US*>"'S2J!^O\VR\O%+54'W$OK1OU!+ P04
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M\U^=T&Q7;L#6&64;NO)P"P-FO0+ KK]E&3V>% &:+S#]OP%02P,$%     @
M1D!94B:Q5R_, P  H@T  !D   !X;"]W;W)K<VAE971S+W-H965T.#@N>&UL
MM5=M;^(X$/XKHVA7:J4>L4,@L (D"IRNM]LN KJGT^H^N,& U<1F;:>TTOWX
MLY,0TA*RW$KE _'+/.-G/"^V>SLA']6&4@W/<<15W]EHO?WDNBK<T)BHAMA2
M;F960L9$FZY<NVHK*5FFH#AR/83:;DP8=P:]=&PJ!SV1Z(AQ.I6@DC@F\N6:
M1F+7=["S'YBQ]4;; 7?0VY(UG5-]OYU*TW,++4L64ZZ8X"#IJN\,\:<)[EA
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MJ*%JT25CV-OW.",-N^YZ/9B%<+UZ^X>97C!O"_;_)Y*_4$L#!!0    ( $9
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M/X>-/I84$UG(8+80C&9K>#>0A0SN92"X6D5G% :RD,&]_QEBTMFN@2QD<.^
MAIATMFL@"QFGW,?6FNT:<!,T]SXVB$FK[0:RD,%L(8Q)J^T&LI#!;"&,2:OM
M(V2A$;.%\+KT.<5$%AJQ__<&8+:&]Q&RT(C90L=W63ZG=!0366C$O1)TL-WR
M(.>DF,A"HQ-L1B"D%!-9:,2]$G04\[F<1#&1A4;,%L+;)FCJ,4(6&C%;Z/L;
M1INVIYCPSSB-A;K-R>7;-RNY3C*Y\M17E.KX,DZ7\T+4#_65>OVA5N]_7C^F
MJ:6.^9F;QZO]/R'W_^)\^Q]02P,$%     @ 1D!94L,EV4B4 @  WS,  !H
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $9 65* ( ]([P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $9
M65*97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 1D!94L?K"4K2!0  5Q@  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $9
M65(%VBA@; <  &L=   8              " @18.  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !&0%E2O=O+N7X#  "Q"P  &
M        @(&X%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 1D!94C,@21F7!@  S1H  !@              ("!;!D  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $9 65*>E8-9% ,  "X)   8
M              " @3D@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !&0%E2@W/[BB((  !D*@  &               @(&#(P  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 1D!94EKN?+/C"@
M>#$  !@              ("!VRL  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( $9 65)Z<[PLS1   #@N   8              " @?0V
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !&0%E2?,QJ
MSN@G   D@0  &               @('W1P  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 1D!94G^!?]9U"0  ;!<  !D
M ("!%7   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !&
M0%E2T<E3VW$-  #Q,   &0              @('!>0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $9 65*'5*Q=K@8  ' 1   9
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M970Q-BYX;6Q02P$"% ,4    " !&0%E2V>P0.S 1  #7-   &0
M    @(&>N   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M $9 65(DP4 #1!4  -9    9              " @07*  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 1D!94OC'8G'>!   [0H  !D
M             ("!@-\  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !&0%E2!I5<OM$$  "="P  &0              @(&5Y   >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $9 65+?7N7]CP8
M -4/   9              " @9WI  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 1D!94J(K,I,Y P  &0<  !D              ("!
M8_   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !&0%E2
MPU]@$> #  !R"   &0              @('3\P  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( $9 65*S/HL,:BX  +N:   9
M      " @>KW  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 1D!94C,5I NN!@  )!$  !D              ("!BR8! 'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !&0%E2YHXM@PT#   J!@
M&0              @(%P+0$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( $9 65)D0N)/N@8  *L6   9              " @;0P 0!X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 1D!94FE;LFZ\
M!0  * \  !D              ("!I3<! 'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !&0%E21WD2;.H$   .&0  &0
M@(&8/0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $9
M65*S:JH)+ 8  %43   9              " @;E" 0!X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 1D!94L)"$0O=!   +PP  !D
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M=#,U+GAM;%!+ 0(4 Q0    ( $9 65)Q$;U%6 ,  /D&   9
M  " @:YG 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M1D!94L'AUB*0!0  8A<  !D              ("!/6L! 'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !&0%E2/@&0T],"   9"   &0
M            @($$<0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( $9 65)QFM&[<04  &@8   9              " @0YT 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 1D!94MWKJ@RY P
M#A,  !D              ("!MGD! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !&0%E2RU6^4PP#   _"0  &0              @(&F
M?0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $9 65(6
M_#N..@,  /P(   9              " @>F  0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ 1D!94C+\L$$4!0  #Q4  !D
M     ("!6H0! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $9 65(N"+P'$08  /D9   9              "
M@:.7 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 1D!9
M4H-EN61O#P  +7D  !D              ("!ZYT! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " !&0%E2P[CT[?8#  !,#0  &0
M        @(&1K0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( $9 65*-+IU=T ,  !L/   9              " @;ZQ 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 1D!94DD"=1@K P  W D
M !D              ("!Q;4! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " !&0%E2F+ SE/P%  #%'P  &0              @($GN0$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( $9 65*)FD[>
MB (  $H&   9              " @5J_ 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ 1D!94K,FNN+#!0  #!@  !D
M ("!&<(! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !&
M0%E26G6X1]H"  #N"@  &0              @($3R $ >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( $9 65*^](1,+ ,  "T*   9
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M970V,2YX;6Q02P$"% ,4    " !&0%E2ID1A>V\#  ![#0  &0
M    @($RV@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M $9 65)S.8B*O ,  %\-   9              " @=C= 0!X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ 1D!94C.F8_U, P  5 L  !D
M             ("!R^$! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    " !&0%E2VIK^OW("  "7!@  &0              @(%.Y0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( $9 65+!JJH0^P0
M /8A   9              " @??G 0!X;"]W;W)K<VAE971S+W-H965T-C8N
M>&UL4$L! A0#%     @ 1D!94D><NBP_"0  US   !D              ("!
M*>T! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " !&0%E2
MFT188FL&   Q'@  &0              @(&?]@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;%!+ 0(4 Q0    ( $9 65*OE2EQ/0,  /(*   9
M      " @4'] 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%
M  @ 1D!94C<'J7;< @  % @  !D              ("!M0 " 'AL+W=O<FMS
M:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " !&0%E28#_@*4D#  !7"P
M&0              @('( P( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+
M 0(4 Q0    ( $9 65*)>8[!V 0  #H2   9              " @4@' @!X
M;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ 1D!94I^"#O!&
M P  $@L  !D              ("!5PP" 'AL+W=O<FMS:&5E=',O<VAE970W
M,RYX;6Q02P$"% ,4    " !&0%E2S4CJZ.L(   -,   &0
M@('4#P( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( $9
M65(J1R9.F ,  *<,   9              " @?88 @!X;"]W;W)K<VAE971S
M+W-H965T-S4N>&UL4$L! A0#%     @ 1D!94A-H#>_P P  G \  !D
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M=#@P+GAM;%!+ 0(4 Q0    ( $9 65)+<3CO60@   DO   9
M  " @9XR @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @
M1D!94BNO?>XE P  C@@  !D              ("!+CL" 'AL+W=O<FMS:&5E
M=',O<VAE970X,BYX;6Q02P$"% ,4    " !&0%E23?WXB-("  !R!P  &0
M            @(&*/@( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4
M Q0    ( $9 65)V7#Z)MP,  "D.   9              " @9-! @!X;"]W
M;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ 1D!94I.-0- < @
M9 0  !D              ("!@44" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX
M;6Q02P$"% ,4    " !&0%E2=!5PC,@'  "0+@  &0              @('4
M1P( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( $9 65(<
M]*S&A@0  (T1   9              " @=-/ @!X;"]W;W)K<VAE971S+W-H
M965T.#<N>&UL4$L! A0#%     @ 1D!94B:Q5R_, P  H@T  !D
M     ("!D%0" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"% ,4
M" !&0%E2=Z)"X5$"  !<#   #0              @ &36 ( >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( $9 65*7BKL<P    !,"   +              "
M 0]; @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $9 65)W @8]E@8  $DZ   /
M              "  ?A; @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !&
M0%E2PR792)0"  #?,P  &@              @ &[8@( >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !&0%E2C9S+JS0"  !6,@  $P
M            @ &'90( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     8 !@
+ %<:  #L9P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>338</ContextCount>
  <ElementCount>635</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>107</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2117103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120104 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2130106 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS</Role>
      <ShortName>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2133107 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2143108 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2150109 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2158110 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2167111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2171112 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2173113 - Disclosure - SHARE REPURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASE</Role>
      <ShortName>SHARE REPURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2175114 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2179115 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION</Role>
      <ShortName>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2182116 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2206202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2318302 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2321303 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/ACQUISITIONS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables</Role>
      <ShortName>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LEASES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2351308 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/INCOMETAXES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2359309 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2368310 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2376311 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2380312 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables</Role>
      <ShortName>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Recently Issued Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Recently Issued Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2414409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2415410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2416411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - ACQUISITIONS - Pro Forma Condensed Consolidated Statement of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails</Role>
      <ShortName>ACQUISITIONS - Pro Forma Condensed Consolidated Statement of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails</Role>
      <ShortName>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LEASESTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - LEASES - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESLeaseCostDetails</Role>
      <ShortName>LEASES - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - LEASES - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESOperatingLeaseDetails</Role>
      <ShortName>LEASES - Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - LEASES - Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESFinanceLeasesDetails</Role>
      <ShortName>LEASES - Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - LEASES - Supplemental Cashflow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails</Role>
      <ShortName>LEASES - Supplemental Cashflow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - LEASES- Weighted Average Remaining Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails</Role>
      <ShortName>LEASES- Weighted Average Remaining Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2442426 - Disclosure - LEASES - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESMaturitiesDetails</Role>
      <ShortName>LEASES - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2447429 - Disclosure - LONG-TERM OBLIGATIONS - Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2448430 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2449431 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2452432 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2453433 - Disclosure - INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails</Role>
      <ShortName>INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2454434 - Disclosure - INCOME TAXES - Income Tax Expense Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails</Role>
      <ShortName>INCOME TAXES - Income Tax Expense Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2455435 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2456436 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2457437 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2460438 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2461439 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2462440 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2463441 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2464442 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2465443 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2466444 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2469445 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2470446 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2472447 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2474448 - Disclosure - SHARE REPURCHASE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails</Role>
      <ShortName>SHARE REPURCHASE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2477449 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2478450 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2481451 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION Operating Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails</Role>
      <ShortName>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION Operating Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="amed-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2483452 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="amed-20201231.htm">amed-20201231.htm</File>
    <File>a202010-kexhibit1016.htm</File>
    <File>a202010-kexhibit1026.htm</File>
    <File>a202010-kexhibit211.htm</File>
    <File>a202010-kexhibit231.htm</File>
    <File>a202010-kexhibit311.htm</File>
    <File>a202010-kexhibit312.htm</File>
    <File>a202010-kexhibit321.htm</File>
    <File>a202010-kexhibit322.htm</File>
    <File>amed-20201231.xsd</File>
    <File>amed-20201231_cal.xml</File>
    <File>amed-20201231_def.xml</File>
    <File>amed-20201231_lab.xml</File>
    <File>amed-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amed-20201231_g1.jpg</File>
    <File>amed-20201231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amed-20201231.htm": {
   "axisCustom": 7,
   "axisStandard": 26,
   "contextCount": 338,
   "dts": {
    "calculationLink": {
     "local": [
      "amed-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amed-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "amed-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amed-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amed-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amed-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 943,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 19,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 25
   },
   "keyCustom": 161,
   "keyStandard": 474,
   "memberCustom": 66,
   "memberStandard": 38,
   "nsprefix": "amed",
   "nsuri": "http://www.amedisys.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.amedisys.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\")",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\")",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120104 - Disclosure - ACQUISITIONS",
     "role": "http://www.amedisys.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130106 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS",
     "role": "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS",
     "shortName": "DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:LesseeLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133107 - Disclosure - LEASES",
     "role": "http://www.amedisys.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:LesseeLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143108 - Disclosure - LONG-TERM OBLIGATIONS",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONS",
     "shortName": "LONG-TERM OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150109 - Disclosure - INCOME TAXES",
     "role": "http://www.amedisys.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158110 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171112 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173113 - Disclosure - SHARE REPURCHASE",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASE",
     "shortName": "SHARE REPURCHASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175114 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2179115 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION",
     "role": "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION",
     "shortName": "UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2182116 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2206202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318302 - Disclosure - NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") (Tables)",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321303 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)",
     "role": "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables",
     "shortName": "DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - LEASES (Tables)",
     "role": "http://www.amedisys.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - LONG-TERM OBLIGATIONS (Tables)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables",
     "shortName": "LONG-TERM OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ProvisionforIncomeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351308 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.amedisys.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ProvisionforIncomeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359309 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:InsuranceProgramsTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2368310 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:InsuranceProgramsTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2376311 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2380312 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)",
     "role": "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables",
     "shortName": "UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Recently Issued Accounting Pronouncements (Details)",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Recently Issued Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i2914b051b7f649fbb23140dd91cafcdb_I20190101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:NetServiceRevenueEpisodePaymentRateDuration",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:NetServiceRevenueEpisodePaymentRateDuration",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:CashBalanceAssociatedWithProviderReliefFund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:PercentageOfPatientReceivablesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:PercentageOfPatientReceivablesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "id56f149b375540d6ac65813b85c223fc_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "id56f149b375540d6ac65813b85c223fc_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i6001d3911d55430a8c080827cb5bcaff_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") (Details)",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i6001d3911d55430a8c080827cb5bcaff_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "id9cafc4be2f5437d9ca0b72a01385735_D20200301-20200301",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:BusinessAcquisitionProFormaInformationAseraCareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - ACQUISITIONS - Pro Forma Condensed Consolidated Statement of Income (Details)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
     "shortName": "ACQUISITIONS - Pro Forma Condensed Consolidated Statement of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:BusinessAcquisitionProFormaInformationAseraCareTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i8aea3ef0e7b14a82832a5ffa8397ab08_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i75707ab7adca4f98a7ec345287bc457d_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:PayrollTaxEscrow",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)",
     "role": "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
     "shortName": "DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:PayrollTaxEscrow",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - LEASES (Details)",
     "role": "http://www.amedisys.com/role/LEASESDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - LEASES - Lease Cost (Details)",
     "role": "http://www.amedisys.com/role/LEASESLeaseCostDetails",
     "shortName": "LEASES - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - LEASES - Operating Lease (Details)",
     "role": "http://www.amedisys.com/role/LEASESOperatingLeaseDetails",
     "shortName": "LEASES - Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - LEASES - Finance Leases (Details)",
     "role": "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
     "shortName": "LEASES - Finance Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i71d70551ae8f463895c999fdc4613768_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i71d70551ae8f463895c999fdc4613768_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - LEASES - Supplemental Cashflow Information (Details)",
     "role": "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails",
     "shortName": "LEASES - Supplemental Cashflow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - LEASES- Weighted Average Remaining Term and Discount Rate (Details)",
     "role": "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails",
     "shortName": "LEASES- Weighted Average Remaining Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442426 - Disclosure - LEASES - Maturities (Details)",
     "role": "http://www.amedisys.com/role/LEASESMaturitiesDetails",
     "shortName": "LEASES - Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i90dece5459db457b9caee4a934044bae_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "if7c937ebfcbb4487b42fa8461a09a162_I20201231",
      "decimals": "3",
      "lang": "en-US",
      "name": "amed:DebtInstrumentInterestRateatPeriodEnd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447429 - Disclosure - LONG-TERM OBLIGATIONS - Maturities of Debt (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Maturities of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i4332b377849d47079522cdb966f405aa_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448430 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i4332b377849d47079522cdb966f405aa_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449431 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amed:TotalLeverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452432 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:ProvisionforIncomeTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453433 - Disclosure - INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)",
     "role": "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails",
     "shortName": "INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:ProvisionforIncomeTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454434 - Disclosure - INCOME TAXES - Income Tax Expense Allocation (Details)",
     "role": "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails",
     "shortName": "INCOME TAXES - Income Tax Expense Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:IncomeTaxEffectsAllocatedToInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455435 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)",
     "role": "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails",
     "shortName": "INCOME TAXES - Reconciliation of Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456436 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)",
     "role": "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "ia733ca32dbec4462ac0839915fc3b59a_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457437 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460438 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amed:Percentageofownershipinsubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i5c385df453324adfaca85d0811925684_D20201001-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461439 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i5c385df453324adfaca85d0811925684_D20201001-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462440 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i4acfc20b2b5340aa84009558a940adbc_D20200101-20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "ia733ca32dbec4462ac0839915fc3b59a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463441 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "ia733ca32dbec4462ac0839915fc3b59a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464442 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "ia733ca32dbec4462ac0839915fc3b59a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i24d3940f86e248f5a619e4759d853c1e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465443 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Activity (Details)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "iaa4e0fb702ce4b66bd29cae8cd282e27_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i67aef9e5409443cc838400c94814e771_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466444 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "ic2ea695caf8744e68518d5aeff81f13c_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i767079f30664438f8d9be671a161fd0e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyReceivableNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469445 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:InsuranceProgramsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:HealthInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470446 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:InsuranceProgramsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:HealthInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:DefinedContributionPlanEmployerMatchingContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472447 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:DefinedContributionPlanEmployerMatchingContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474448 - Disclosure - SHARE REPURCHASE - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
     "shortName": "SHARE REPURCHASE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "ic8e83cf1d9574cf69c223d04622768aa_I20201223",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477449 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i5c385df453324adfaca85d0811925684_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478450 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
     "shortName": "SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i5c385df453324adfaca85d0811925684_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481451 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION Operating Activity (Details)",
     "role": "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails",
     "shortName": "UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION Operating Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i5c385df453324adfaca85d0811925684_D20201001-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483452 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "ib96bea9253ac4d8d90b0d2f79b7e9bb6_D20180101-20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20201231.htm",
      "contextRef": "i60a06c2491f9486f940fcffa0f09286b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 107,
   "tag": {
    "amed_A2019StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Stock Repurchase Program",
        "label": "2019 Stock Repurchase Program [Member]",
        "terseLabel": "2019 Stock Repurchase Program [Member]"
       }
      }
     },
     "localname": "A2019StockRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2021StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Stock Repurchase Program",
        "label": "2021 Stock Repurchase Program [Member]",
        "terseLabel": "2021 Stock Repurchase Program [Member]"
       }
      }
     },
     "localname": "A2021StockRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AcquiredNameOfBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Name Of Business [Member]",
        "label": "Acquired Name Of Business [Member]",
        "terseLabel": "Acquired Name of Business [Member]"
       }
      }
     },
     "localname": "AcquiredNameOfBusinessMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Names [Member]",
        "label": "Acquired Names [Member]",
        "terseLabel": "Acquired Names [Member]"
       }
      }
     },
     "localname": "AcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ActualClaimsPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual Claims Payment",
        "label": "Actual Claims Payment",
        "terseLabel": "Actual claims payment"
       }
      }
     },
     "localname": "ActualClaimsPayment",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AdditionalFundingDistributedToHealthcareProviders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Additional Funding Distributed To Healthcare Providers",
        "terseLabel": "Additional Funding Distributed To Healthcare Providers"
       }
      }
     },
     "localname": "AdditionalFundingDistributedToHealthcareProviders",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AdditionalPerformanceBasedAwardTargetShareAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional stock units authorized for achievement of targeted performance if target objective is surpassed to the point of achieving the projected maximum payout",
        "label": "Additional Performance Based Award Target share Amount",
        "terseLabel": "Additional Performance Based Award Target share Amount"
       }
      }
     },
     "localname": "AdditionalPerformanceBasedAwardTargetShareAmount",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_AlternativeMinimumTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Minimum Tax Credit [Member]",
        "label": "Alternative Minimum Tax Credit [Member]",
        "terseLabel": "Alternative Minimum Tax Credit [Member]"
       }
      }
     },
     "localname": "AlternativeMinimumTaxCreditMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmedisysCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amedisys CIA",
        "label": "Amedisys CIA [Member]",
        "terseLabel": "Amedisys CIA [Member]"
       }
      }
     },
     "localname": "AmedisysCIAMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizableAcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortizable acquired names",
        "label": "Amortizable acquired names [Member]",
        "terseLabel": "Amortizable acquired names [Member]"
       }
      }
     },
     "localname": "AmortizableAcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "label": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "terseLabel": "Amortization and impairment of operating lease right of use assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AsanaHospiceAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice Acquisition",
        "label": "Asana Hospice Acquisition [Member]",
        "terseLabel": "Asana Hospice Acquisition [Member]"
       }
      }
     },
     "localname": "AsanaHospiceAcquisitionMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AsanaHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice",
        "label": "Asana Hospice [Member]",
        "terseLabel": "Asana Hospice [Member]"
       }
      }
     },
     "localname": "AsanaHospiceMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AseraCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AseraCare Hospice Member",
        "label": "AseraCare Hospice [Member]",
        "terseLabel": "AseraCare Hospice [Member]"
       }
      }
     },
     "localname": "AseraCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AssetImpairmentChargesNetOfIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges, Net Of Income Taxes",
        "label": "Asset Impairment Charges, Net Of Income Taxes",
        "terseLabel": "Asset impairment charge, net of income taxes"
       }
      }
     },
     "localname": "AssetImpairmentChargesNetOfIncomeTaxes",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AssociatedHomecareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Associated Homecare [Member]",
        "label": "Associated Homecare [Member]",
        "terseLabel": "Associated Homecare [Member]"
       }
      }
     },
     "localname": "AssociatedHomecareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BringCareHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bring Care Home [Member]",
        "label": "Bring Care Home [Member]",
        "terseLabel": "Bring Care Home [Member]"
       }
      }
     },
     "localname": "BringCareHomeMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building And Leasehold Improvements [Member]",
        "label": "Building And Leasehold Improvements [Member]",
        "terseLabel": "Building and Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessAcquisitionClosingPaymentAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Closing Payment Adjustment",
        "label": "Business Acquisition Closing Payment Adjustment",
        "terseLabel": "Business Acquisition Closing Payment Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionClosingPaymentAdjustment",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a the AseraCare acquisition .",
        "label": "Business Acquisition, Pro Forma Information, AseraCare [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Financial Information, AseraCare"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationAseraCareTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for the Compassionate Care Hospice acquisition.",
        "label": "Business Acquisition, Pro Forma Information, Compassionate Care Hospice [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Financial Information, Compassionate Care Hospice"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationCompassionateCareHospiceTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_BusinessAcquisitionProFormaOperatingIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisition pro forma operating income loss",
        "terseLabel": "Operating income"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaOperatingIncomeLoss",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionTransactionCostsNetOfIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Transaction Costs, Net Of Income Taxes",
        "label": "Business Acquisition, Transaction Costs, Net Of Income Taxes",
        "terseLabel": "Transaction-related expenses for acquisitions, net of income taxes"
       }
      }
     },
     "localname": "BusinessAcquisitionTransactionCostsNetOfIncomeTaxes",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionWorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Working Capital Adjustment",
        "label": "Business Acquisition Working Capital Adjustment",
        "terseLabel": "Business Acquisition Working Capital Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionWorkingCapitalAdjustment",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Accrued Expenses",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Payroll and Employee Benefits",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating lease right of use assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Current Asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActDeferralOfEmployerShareSocialSecurityTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferral of the employer's share social security tax provided by the CARES Act",
        "label": "CARES Act Deferral Of Employer Share Social Security Tax",
        "terseLabel": "CARES Act Deferral Of Employer Share Social Security Tax"
       }
      }
     },
     "localname": "CARESActDeferralOfEmployerShareSocialSecurityTax",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures",
        "label": "CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures",
        "terseLabel": "CARES Act Provider Relief Funds Received by Unconsolidated Joint Ventures"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Utilized",
        "label": "CARES Act Provider Relief Funds Utilized",
        "terseLabel": "CARES Act Provider Relief Funds Utilized"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsUtilized",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19DeferralOfSocialSecurityTaxesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Deferral of Social Security Taxes",
        "label": "COVID-19 Deferral of Social Security Taxes [Member]",
        "terseLabel": "COVID-19 Deferral of Social Security Taxes [Member]"
       }
      }
     },
     "localname": "COVID19DeferralOfSocialSecurityTaxesMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_COVID19ExpensesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses incurred as a result of the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID19 Expenses Incurred",
        "terseLabel": "COVID19 Expenses Incurred"
       }
      }
     },
     "localname": "COVID19ExpensesIncurred",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19TextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID19 [Text Block]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\")"
       }
      }
     },
     "localname": "COVID19TextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_CallPremiumPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Call premium paid during the period",
        "label": "Call Premium Payment",
        "terseLabel": "Call premium payment"
       }
      }
     },
     "localname": "CallPremiumPayment",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CapYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Axis]",
        "label": "Cap Year [Axis]",
        "terseLabel": "Cap Year [Axis]"
       }
      }
     },
     "localname": "CapYearAxis",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_CapYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Domain]",
        "label": "Cap Year [Domain]",
        "terseLabel": "Cap Year [Domain]"
       }
      }
     },
     "localname": "CapYearDomain",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Fourteen Through Two Thousand Twenty One [Member]",
        "label": "Cap Year Two Thousand Fourteen Through Two Thousand Twenty One [Member]",
        "terseLabel": "Cap Year 2014 Through 2021 [Member]"
       }
      }
     },
     "localname": "CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandThirteenThroughTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Thirteen Through Two Thousand Twenty [Member]",
        "label": "Cap Year Two Thousand Thirteen Through Two Thousand Twenty [Member]",
        "terseLabel": "Cap Year 2013 Through 2020 [Member]"
       }
      }
     },
     "localname": "CapYearTwoThousandThirteenThroughTwoThousandTwentyMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CareInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Care Innovations [Member]",
        "terseLabel": "Care Innovations [Member]"
       }
      }
     },
     "localname": "CareInnovationsMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CashBalanceAssociatedWithProviderReliefFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Balance Associated with the CARES Act Provider Relief Fund",
        "label": "Cash Balance Associated With Provider Relief Fund",
        "terseLabel": "Cash Balance Associated With Provider Relief Fund"
       }
      }
     },
     "localname": "CashBalanceAssociatedWithProviderReliefFund",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of dividends or other distributions to noncontrolling interest holders.",
        "label": "Cash Distribution To Noncontrolling Interest",
        "negatedLabel": "Non-controlling interest distribution"
       }
      }
     },
     "localname": "CashDistributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of Need",
        "label": "Certificate of Need [Member]",
        "terseLabel": "Certificate of Need [Member]"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificatesOfNeedAndLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates Of Need And Licenses [Member]",
        "label": "Certificates Of Need And Licenses [Member]",
        "terseLabel": "Certificates of Need and Licenses [Member]"
       }
      }
     },
     "localname": "CertificatesOfNeedAndLicensesMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificatesOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates Of Need [Member]",
        "label": "Certificates Of Need [Member]",
        "terseLabel": "Certificates Of Need [Member]"
       }
      }
     },
     "localname": "CertificatesOfNeedMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CharityCare": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to charity care",
        "label": "Charity Care",
        "terseLabel": "Charity care"
       }
      }
     },
     "localname": "CharityCare",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ChristianCareatHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Christian Care at Home [Member]",
        "label": "Christian Care at Home [Member]",
        "terseLabel": "Christian Care at Home [Member]"
       }
      }
     },
     "localname": "ChristianCareatHomeMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ClearwaterFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clearwater, Florida [Member]",
        "label": "Clearwater, Florida [Member]",
        "terseLabel": "Clearwater, Florida [Member]"
       }
      }
     },
     "localname": "ClearwaterFloridaMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance to the Company's employee stock purchase plan",
        "label": "Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan",
        "terseLabel": "Common stock authorized for issuance under Employee Stock Purchase Plan (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_CompassionateCareHospiceCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice CIA",
        "label": "Compassionate Care Hospice CIA [Member]",
        "terseLabel": "Compassionate Care Hospice CIA [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceCIAMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice [Member]",
        "label": "Compassionate Care Hospice [Member]",
        "terseLabel": "Compassionate Care Hospice [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ComputerInventoryAndDataSecurityReportingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Inventory And Data Security Reporting",
        "label": "Computer Inventory And Data Security Reporting [Member]",
        "terseLabel": "Computer Inventory And Data Security Reporting [Member]"
       }
      }
     },
     "localname": "ComputerInventoryAndDataSecurityReportingMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConsolidatedInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges",
        "label": "Consolidated Interest Coverage Ratio",
        "terseLabel": "Consolidated interest coverage ratio"
       }
      }
     },
     "localname": "ConsolidatedInterestCoverageRatio",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Leverage Ratio",
        "label": "Consolidated Leverage Ratio",
        "terseLabel": "Consolidated Leverage Ratio"
       }
      }
     },
     "localname": "ConsolidatedLeverageRatio",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_CorporateIntegrityAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Integrity Agreement Term",
        "label": "Corporate Integrity Agreement Term",
        "terseLabel": "Corporate integrity agreement term (years)"
       }
      }
     },
     "localname": "CorporateIntegrityAgreementTerm",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple",
        "label": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple",
        "terseLabel": "Credit facility, maximum allowable consolidated leverage ratio multiple"
       }
      }
     },
     "localname": "CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_Creditfacilitymaximumallowableconsolidatedleverageratio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement",
        "label": "Credit facility maximum allowable consolidated leverage ratio",
        "terseLabel": "Credit facility maximum allowable consolidated leverage ratio"
       }
      }
     },
     "localname": "Creditfacilitymaximumallowableconsolidatedleverageratio",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than Equal to 3.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 2.00 to 1.0 but Greater Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than 3.00 to 1.0 but Greater Than Equal To 2.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentCarryingAmountExcludingFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "label": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "terseLabel": "Debt Instrument Carrying Amount Excluding Finance Leases"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountExcludingFinanceLeases",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "label": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "terseLabel": "Additional interest rate above Eurodollar Rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveEurodollarRate",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "label": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "terseLabel": "Additional interest rate above Federal Fund rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveFederalFundRate",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestRateatPeriodEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate at Period End",
        "label": "Debt Instrument Interest Rate at Period End",
        "terseLabel": "Debt Instrument Interest Rate at Period End"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateatPeriodEnd",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentNumberOfPeriodicPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, number of quarterly installments",
        "label": "Debt Instrument Number Of Periodic Payments",
        "terseLabel": "Number of quarterly installments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfPeriodicPayments",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_DebtInstrumentPeriodicPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the Term Loan that is required as periodic payments including both interest and principal payments",
        "label": "Debt Instrument Periodic Payment Percentage",
        "terseLabel": "Debt Instrument Periodic Payment Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentage",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtIssuanceCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for debt issuance costs.",
        "label": "Debt Issuance Costs Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_DeferredCompensationPlanLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan Liability",
        "label": "Deferred Compensation Plan Liability",
        "terseLabel": "Deferred compensation plan liability"
       }
      }
     },
     "localname": "DeferredCompensationPlanLiability",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredOperatingIncomeCARESAct": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred operating income as a result of the CARES Act in relation to the Novel Coronavirus Pandemic (\"COVID-19\")",
        "label": "Deferred Operating Income (CARES Act)",
        "terseLabel": "Deferred operating income (CARES Act)"
       }
      }
     },
     "localname": "DeferredOperatingIncomeCARESAct",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetDeferredSocialSecurityTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred social security taxes which are the result of the novel coronavirus pandemic (\"COVID-19\").",
        "label": "Deferred Tax Asset, Deferred Social Security Taxes",
        "terseLabel": "Deferred social security taxes (2)"
       }
      }
     },
     "localname": "DeferredTaxAssetDeferredSocialSecurityTaxes",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of intangible assets and the basis of intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses.",
        "label": "Deferred Tax Assets Goodwill And Intangible Assets",
        "terseLabel": "Deferred Tax Assets Goodwill And Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets1",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsLegalAndComplianceMatters": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from legal and compliance matters.",
        "label": "Deferred Tax Assets, Legal and Compliance Matters",
        "terseLabel": "Legal &amp; compliance matters"
       }
      }
     },
     "localname": "DeferredTaxAssetsLegalAndComplianceMatters",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the Provider Relief Fund Advance set up as a result of the novel coronavirus pandemic (\"COVID-19\").",
        "label": "Deferred Tax Assets, Provider Relief Fund Advance",
        "terseLabel": "Provider relief fund advance (1)"
       }
      }
     },
     "localname": "DeferredTaxAssetsProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax deferred expense compensation and benefits workers compensation",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from amortization of intangible assets.",
        "label": "Deferred Tax Liabilities, Amortization of Intangible Assets",
        "negatedTerseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAmortizationOfIntangibleAssets",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.",
        "label": "Deferred Tax Liabilities, Right of Use Assets",
        "negatedTerseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Percentage of Employee Salary Eligible for Employer Match",
        "label": "Defind Contribution Plan Maximum Annual Match Per Employee Salary Percentage",
        "terseLabel": "Maximum percentage of employee salary eligible for employer match (percent)"
       }
      }
     },
     "localname": "DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan Employee Contribution For Employer Matching Program",
        "label": "Defined Contribution Plan Employee Contribution For Employee Matching Program",
        "terseLabel": "Employee contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DefinedContributionPlanEmployerMatchingContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employer matching contribution.",
        "label": "Defined Contribution Plan Employer Matching Contribution",
        "terseLabel": "Employer match amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContribution",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DepreciationAndAmortizationForContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation And Amortization For Continuing Operations",
        "label": "Depreciation And Amortization For Continuing Operations",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortizationForContinuingOperations",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DetailsOfCertainBalanceSheetAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details Of Certain Balance Sheet Accounts [Abstract]",
        "terseLabel": "Details Of Certain Balance Sheet Accounts [Abstract]"
       }
      }
     },
     "localname": "DetailsOfCertainBalanceSheetAccountsAbstract",
     "nsuri": "http://www.amedisys.com/20201231",
     "xbrltype": "stringItemType"
    },
    "amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details of Certain Balance Sheet Accounts Disclosure [Text Block]",
        "terseLabel": "DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS"
       }
      }
     },
     "localname": "DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_DiscountedClosingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted Closing Stock Price",
        "label": "Discounted Closing Stock Price",
        "terseLabel": "Discounted Closing Stock Price"
       }
      }
     },
     "localname": "DiscountedClosingStockPrice",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Document And Entity Information [Abstract]",
        "label": "Document And Entity Information [Abstract]",
        "terseLabel": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.amedisys.com/20201231",
     "xbrltype": "stringItemType"
    },
    "amed_EastTennesseePersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "East Tennessee Personal Care [Member]",
        "label": "East Tennessee Personal Care [Member]",
        "terseLabel": "East Tennessee Personal Care [Member]"
       }
      }
     },
     "localname": "EastTennesseePersonalCareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent",
        "negatedTerseLabel": "Excess tax benefits from share-based compensation (1)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit Adjustment, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit Adjustment, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditAdjustmentPercent",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EmploymentTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Tax Credit [Member]",
        "label": "Employment Tax Credit [Member]",
        "terseLabel": "Employment Tax Credit [Member]"
       }
      }
     },
     "localname": "EmploymentTaxCreditMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_EpisodeOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health episode of care.",
        "label": "Episode Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Episode of care as episodic-based revenue, days"
       }
      }
     },
     "localname": "EpisodeOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_EpisodesInProgressThatBeginDuringReportingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in an episode of care.",
        "label": "Episodes In Progress That Begin During Reporting Period",
        "terseLabel": "Episodes in progress that begin during reporting period, days"
       }
      }
     },
     "localname": "EpisodesInProgressThatBeginDuringReportingPeriod",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_EquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment And Furniture [Member]",
        "label": "Equipment And Furniture [Member]",
        "terseLabel": "Equipment and Furniture [Member]"
       }
      }
     },
     "localname": "EquipmentAndFurnitureMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact Of Increase Decrease In Assets Of Equity Method Investment",
        "label": "Equity Impact Of Increase Decrease In Assets Of Equity Method Investment",
        "terseLabel": "Assets contributed to equity investment"
       }
      }
     },
     "localname": "EquityImpactOfIncreaseDecreaseInAssetsOfEquityMethodInvestment",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact Of Write Off Of Other Comprehensive Income",
        "label": "Equity Impact Of Write Off Of Other Comprehensive Income",
        "negatedTerseLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "EquityImpactOfWriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EquityImpactofRepurchaseofNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact of Repurchase of Noncontrolling Interest",
        "label": "Equity Impact of Repurchase of Noncontrolling Interest",
        "verboseLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "EquityImpactofRepurchaseofNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ErrorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Error Rate Percentage",
        "label": "Error Rate Percentage",
        "terseLabel": "Error rate (percent)"
       }
      }
     },
     "localname": "ErrorRatePercentage",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.",
        "label": "Estimated Amount Due Back To Medicare In Other Accrued Liabilities",
        "terseLabel": "Estimated amounts due back to Medicare"
       }
      }
     },
     "localname": "EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid",
        "label": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid",
        "terseLabel": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundAmountsToBeRepaid",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Funds Expected To Be Utilized",
        "label": "Estimated CARES Act Provider Relief Funds Expected To Be Utilized",
        "terseLabel": "Estimated CARES Act Provider Relief Funds Expected To Be Utilized"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundsExpectedToBeUtilized",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedFutureCOVID19RelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated expenses as a result of the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Estimated Future COVID19 Related Expenses",
        "terseLabel": "Estimated Future COVID19 Related Expenses"
       }
      }
     },
     "localname": "EstimatedFutureCOVID19RelatedExpenses",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedInsuranceExcludingLongTermPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated insurance liability, excluding long-term",
        "label": "Estimated Insurance Excluding Long Term Portion",
        "totalLabel": "Estimated Insurance Excluding Long Term Portion"
       }
      }
     },
     "localname": "EstimatedInsuranceExcludingLongTermPortion",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedInsuranceLongTermPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 2.0,
       "parentTag": "amed_EstimatedInsuranceExcludingLongTermPortion",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term portion of estimated insurance",
        "label": "Estimated Insurance Long Term Portion",
        "negatedTerseLabel": "Less: long-term portion"
       }
      }
     },
     "localname": "EstimatedInsuranceLongTermPortion",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedInsuranceTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 1.0,
       "parentTag": "amed_EstimatedInsuranceExcludingLongTermPortion",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated insurance, total",
        "label": "Estimated Insurance Total",
        "totalLabel": "Estimated Insurance Total"
       }
      }
     },
     "localname": "EstimatedInsuranceTotal",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedMedicareCapLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to the estimated Medicare CAP liability",
        "label": "Estimated Medicare Cap Liability",
        "terseLabel": "Estimated Medicare cap liability"
       }
      }
     },
     "localname": "EstimatedMedicareCapLiability",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "stimated Useful Lives Of Property And Equipment, table",
        "label": "Estimated Useful Lives Of Property And Equipment [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ExecutiveStockOptionExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Stock Option Exercise",
        "label": "Executive Stock Option Exercise [Member]",
        "terseLabel": "Executive Stock Option Exercise [Member]"
       }
      }
     },
     "localname": "ExecutiveStockOptionExerciseMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExtrapolatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extrapolated [Member]",
        "label": "Extrapolated [Member]",
        "terseLabel": "Extrapolated [Member]"
       }
      }
     },
     "localname": "ExtrapolatedMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_Fairvalueofshareofcommonstockpercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of a share of common stock, percentage",
        "label": "Fairvalueofshareofcommonstockpercentage",
        "terseLabel": "Fair value of share of common stock (percent)"
       }
      }
     },
     "localname": "Fairvalueofshareofcommonstockpercentage",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_FinanceLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of finance lease cost including amortization of ROU asset and interest expense",
        "label": "Finance Lease Cost",
        "terseLabel": "Finance Lease Cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FinanceLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance leases Table Text Block",
        "label": "Finance leases [Table Text Block]",
        "terseLabel": "Schedule of Finance Leases"
       }
      }
     },
     "localname": "FinanceLeasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FinancialInstrumentDetailsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instrument Details, table",
        "label": "Financial Instrument Details [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentDetailsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FirstThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the first threshold of therapy services required.",
        "label": "First Threshold Of Therapy Services Required",
        "terseLabel": "First threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "FirstThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "label": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "terseLabel": "Five Hundred Fifty Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "FiveHundredFiftyMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FleetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fleet Lease Member",
        "label": "Fleet Lease [Member]",
        "terseLabel": "Fleet Lease [Member]"
       }
      }
     },
     "localname": "FleetLeaseMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FloridaZpicRevenueReduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in revenue as a result of the Florida ZPIC audit",
        "label": "Florida Zpic Revenue Reduction",
        "terseLabel": "Florida Zpic revenue reduction"
       }
      }
     },
     "localname": "FloridaZpicRevenueReduction",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FrontierLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frontier Litigation",
        "label": "Frontier Litigation [Member]",
        "terseLabel": "Frontier Litigation [Member]"
       }
      }
     },
     "localname": "FrontierLitigationMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FundingForHealthcareProvidersIncludingHospitals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding For Healthcare Providers Including Hospitals",
        "terseLabel": "Funding For Healthcare Providers Including Hospitals"
       }
      }
     },
     "localname": "FundingForHealthcareProvidersIncludingHospitals",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements",
        "terseLabel": "Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements"
       }
      }
     },
     "localname": "FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act",
        "label": "Funding Received From CARES Act",
        "terseLabel": "Funding Received From CARES Act"
       }
      }
     },
     "localname": "FundingReceivedFromCARESAct",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program",
        "label": "Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program",
        "terseLabel": "Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program"
       }
      }
     },
     "localname": "FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundsReceivedFromProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Funds Received From Provider Relief Fund Advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "FundsReceivedFromProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_GoodwillDeductibleForIncomeTaxPurposesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Deductible For Income Tax Purposes, Period",
        "label": "Goodwill, Deductible For Income Tax Purposes, Period",
        "terseLabel": "Period of time goodwill is expected to be deductible for income tax purposes"
       }
      }
     },
     "localname": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_GovernmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy disclosure text block for government grants",
        "label": "Government Grants [Policy Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "localname": "GovernmentGrantsPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_HealthInsurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 1.0,
       "parentTag": "amed_EstimatedInsuranceTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health insurance, estimated liability",
        "label": "Health Insurance",
        "terseLabel": "Health insurance"
       }
      }
     },
     "localname": "HealthInsurance",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthInsuranceDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Insurance Deposits",
        "label": "Health Insurance Deposits",
        "terseLabel": "Health insurance deposits"
       }
      }
     },
     "localname": "HealthInsuranceDeposits",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.",
        "label": "Health Insurance Retention Limit",
        "terseLabel": "Health insurance retention limit"
       }
      }
     },
     "localname": "HealthInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthcareanalyticscompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare analytics company [Member]",
        "label": "Healthcare analytics company [Member]",
        "terseLabel": "Healthcare analytics company [Member]"
       }
      }
     },
     "localname": "HealthcareanalyticscompanyMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HeritageHealthcareInnovationFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heritage Healthcare Innovation Fund LP Member",
        "label": "Heritage Healthcare Innovation Fund LP [Member]",
        "terseLabel": "Heritage Healthcare Innovation Fund LP [Member]"
       }
      }
     },
     "localname": "HeritageHealthcareInnovationFundLPMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HistoricalCollectionRateFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Historical collection rate from Medicare.",
        "label": "Historical Collection Rate From Medicare",
        "terseLabel": "Historical collection rate from Medicare"
       }
      }
     },
     "localname": "HistoricalCollectionRateFromMedicare",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HomeHealthAndHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health And Hospice [Member]",
        "label": "Home Health And Hospice [Member]",
        "terseLabel": "Home Health And Hospice [Member]"
       }
      }
     },
     "localname": "HomeHealthAndHospiceMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Medicare [Member]",
        "label": "Home Health Medicare [Member]",
        "terseLabel": "Home Health Medicare [Member]"
       }
      }
     },
     "localname": "HomeHealthMedicareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health [Member]",
        "label": "Home Health [Member]",
        "terseLabel": "Home Health [Member]"
       }
      }
     },
     "localname": "HomeHealthMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareNonEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Non-Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareNonEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeStaffLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Staff LLC [Member]",
        "label": "Home Staff LLC [Member]",
        "terseLabel": "Home Staff LLC [Member]"
       }
      }
     },
     "localname": "HomeStaffLlcMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to Hospice room and board, general in-patient and other expenses",
        "label": "Hospice accruals",
        "terseLabel": "Hospice accruals (room and board, general in-patient and other)"
       }
      }
     },
     "localname": "HospiceAccruals",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HospiceMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Medicare [Member]",
        "label": "Hospice Medicare [Member]",
        "terseLabel": "Hospice Medicare [Member]"
       }
      }
     },
     "localname": "HospiceMedicareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareRevenueRateAccountedForRoutineCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.",
        "label": "Hospice Medicare Revenue Rate Accounted For Routine Care",
        "terseLabel": "Hospice Medicare revenue rate accounted for routine care"
       }
      }
     },
     "localname": "HospiceMedicareRevenueRateAccountedForRoutineCare",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice [Member]"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceNonMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Non-Medicare [Member]",
        "label": "Hospice Non-Medicare [Member]",
        "terseLabel": "Hospice Non-Medicare [Member]"
       }
      }
     },
     "localname": "HospiceNonMedicareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_IdahoandWyomingSelfReportMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idaho and Wyoming Self Report [Member]",
        "label": "Idaho and Wyoming Self Report [Member]",
        "terseLabel": "Idaho and Wyoming Self Report [Member]"
       }
      }
     },
     "localname": "IdahoandWyomingSelfReportMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_IncomeTaxEffectsAllocatedToGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Effects Allocated To Goodwill",
        "label": "Income Tax Effects Allocated To Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "IncomeTaxEffectsAllocatedToGoodwill",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncomeTaxEffectsAllocatedToInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect of items occuring during the period that have been charged or credited directly to interest expense",
        "label": "Income Tax Effects Allocated to Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "IncomeTaxEffectsAllocatedToInterestExpense",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IndemnificationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount to be reimbursed if and when certain assumed liabilities are paid",
        "label": "Indemnification Amount",
        "terseLabel": "Indemnification amount"
       }
      }
     },
     "localname": "IndemnificationAmount",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_InfinityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infinity HomeCare [Member]",
        "label": "Infinity HomeCare [Member]",
        "terseLabel": "Infinity HomeCare [Member]"
       }
      }
     },
     "localname": "InfinityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InsuranceProgramsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Programs Details, Table",
        "label": "Insurance Programs Table [Table Text Block]",
        "terseLabel": "Schedule of Insurance Programs"
       }
      }
     },
     "localname": "InsuranceProgramsTableTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_IntercityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intercity Home Care [Member]",
        "label": "Intercity Home Care [Member]",
        "terseLabel": "Intercity Home Care [Member]"
       }
      }
     },
     "localname": "IntercityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InternalAuditComplianceReviewMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Audit Compliance Review [Member]",
        "label": "Internal Audit Compliance Review [Member]",
        "terseLabel": "Internal Audit Compliance Review [Member]"
       }
      }
     },
     "localname": "InternalAuditComplianceReviewMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InternallyDevelopedComputerSoftware": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed AMS3 computer software",
        "label": "Internally Developed Computer Software",
        "terseLabel": "Internally developed computer software"
       }
      }
     },
     "localname": "InternallyDevelopedComputerSoftware",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_KKRConsultingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KKR Consulting [Member]",
        "terseLabel": "KKR Consulting [Member]"
       }
      }
     },
     "localname": "KKRConsultingMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_KKRShareRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KKR Share Repurchase [Member]",
        "label": "KKR Share Repurchase [Member]",
        "terseLabel": "KKR Share Repurchase [Member]"
       }
      }
     },
     "localname": "KKRShareRepurchaseMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LakelandFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lakeland, Florida [Member]",
        "label": "Lakeland, Florida [Member]",
        "terseLabel": "Lakeland, Florida [Member]"
       }
      }
     },
     "localname": "LakelandFloridaMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liability Maturity Table Text Block",
        "label": "Lease Liability Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lease Liability Maturity"
       }
      }
     },
     "localname": "LeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_LeaseTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease type",
        "label": "Lease type [Axis]",
        "terseLabel": "Lease type [Axis]"
       }
      }
     },
     "localname": "LeaseTypeAxis",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_LeaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Type",
        "label": "Lease Type [Domain]",
        "terseLabel": "Lease Type [Domain]"
       }
      }
     },
     "localname": "LeaseTypeDomain",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LegalAndOtherSettlements": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to legal and other settlements",
        "label": "Legal And Other Settlements",
        "terseLabel": "Legal settlements and other audits"
       }
      }
     },
     "localname": "LegalAndOtherSettlements",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LegalFeesNetOfIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Fees, Net Of Income Taxes",
        "label": "Legal Fees, Net Of Income Taxes",
        "terseLabel": "Legal fees, net of income taxes"
       }
      }
     },
     "localname": "LegalFeesNetOfIncomeTaxes",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations"
       }
      }
     },
     "localname": "LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LesseeLeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of operating and finance lease and maturity analysis of operating and finance lease liability.",
        "label": "Lessee, Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeLeasesTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LetterOfCreditFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the letters of credit, for the letters of credit",
        "label": "Letter Of Credit Fee",
        "terseLabel": "Letter of Credit Fee"
       }
      }
     },
     "localname": "LetterOfCreditFee",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_LettersofCreditmaximumcommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letters of Credit, maximum commitment",
        "label": "LettersofCreditmaximumcommitment",
        "terseLabel": "Letters of Credit, maximum commitment"
       }
      }
     },
     "localname": "LettersofCreditmaximumcommitment",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Additional Borrowing Capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "terseLabel": "Credit facility, maximum additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "label": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "terseLabel": "Indemnity receivable related to amounts withheld prior to August 2009"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LowUtilizationPaymentAdjustmentNumberOfVisits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the visit threshold for a low utilization payment adjustment.",
        "label": "Low Utilization Payment Adjustment Number Of Visits",
        "terseLabel": "Low utilization payment adjustment, maximum number of visits"
       }
      }
     },
     "localname": "LowUtilizationPaymentAdjustmentNumberOfVisits",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid",
        "terseLabel": "Maximum days to submit final bill from the date the request for anticipated payment was paid"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Start Of Period of Care",
        "terseLabel": "Maximum days to submit final bill from the start of period of care"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumPercentOwnershipForCostMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Cost Method Percent",
        "terseLabel": "Maximum ownership percentage for cost method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForCostMethodPercent",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MaximumPercentOwnershipForEquityMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Equity Method Percent",
        "terseLabel": "Maximum ownership percentage for equity method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForEquityMethodPercent",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MedalogixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medalogix",
        "label": "Medalogix [Member]",
        "terseLabel": "Medalogix"
       }
      }
     },
     "localname": "MedalogixMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Revenue [Member]",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare Revenue [Member]"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicarelicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare licenses [Member]",
        "label": "Medicare licenses [Member]",
        "terseLabel": "Medicare Licenses [Member]"
       }
      }
     },
     "localname": "MedicarelicensesMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MinimumDaysAccountsReceivableOutstandingFullyReserved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of days required before a patient accounts receivable must be outstanding to be fully reserved.",
        "label": "Minimum Days Accounts Receivable Outstanding Fully Reserved",
        "terseLabel": "Minimum days for accounts receivable outstanding to be fully reserved"
       }
      }
     },
     "localname": "MinimumDaysAccountsReceivableOutstandingFullyReserved",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MinimumPercentOwnershipForControllingInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.",
        "label": "Minimum Percent Ownership For Controlling Interest Percent",
        "terseLabel": "Minimum percent ownership for controlling interest (percent)"
       }
      }
     },
     "localname": "MinimumPercentOwnershipForControllingInterestPercent",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MorgantownWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Morgantown, West Virginia [Member]",
        "label": "Morgantown, West Virginia [Member]",
        "terseLabel": "Morgantown, West Virginia [Member]"
       }
      }
     },
     "localname": "MorgantownWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetOperatingLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss [Member]",
        "label": "Net Operating Loss [Member]",
        "terseLabel": "Net Operating Loss [Member]"
       }
      }
     },
     "localname": "NetOperatingLossMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetServiceRevenueEpisodePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Episode Payment Rate Duration",
        "terseLabel": "Net service revenue episode payment rate"
       }
      }
     },
     "localname": "NetServiceRevenueEpisodePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NetServiceRevenuePeriodOfCarePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue Period Of Care Payment Rate Duration",
        "terseLabel": "Net Service Revenue Period Of Care Payment Rate Duration"
       }
      }
     },
     "localname": "NetServiceRevenuePeriodOfCarePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NonCurrentSocialSecurityTaxesDeferredUnderCARESAct": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The non-current portion of Social Security Taxes deferred under the CARES Act as a result of the Novel Coronavirus Pandemic (\"COVID-19\")",
        "label": "Non-current Social Security Taxes (deferred under CARES Act)",
        "terseLabel": "Non-current social security taxes (deferred under CARES Act)"
       }
      }
     },
     "localname": "NonCurrentSocialSecurityTaxesDeferredUnderCARESAct",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_NonMedicareRevenueTermRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates",
        "label": "Non-Medicare Revenue Term Rates",
        "terseLabel": "Non-medicare revenue term rates"
       }
      }
     },
     "localname": "NonMedicareRevenueTermRates",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NonVestedStockAndStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non vested stock and stock units.",
        "label": "Non Vested Stock And Stock Units",
        "terseLabel": "Non-vested stock and stock units"
       }
      }
     },
     "localname": "NonVestedStockAndStockUnits",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_NonVestedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-Based Non-Vested Stock",
        "label": "Non-Vested Stock [Member]",
        "terseLabel": "Non-Vested Stock [Member]"
       }
      }
     },
     "localname": "NonVestedStockMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NonVestedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Vested Stock Units [Member]",
        "label": "Non Vested Stock Units [Member]",
        "terseLabel": "Non-Vested Stock Units [Member]"
       }
      }
     },
     "localname": "NonVestedStockUnitsMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Vested Stock Units - Service-Based and Performance-Based [Member]",
        "terseLabel": "Non-Vested Stock Units - Service-Based and Performance-Based [Member]"
       }
      }
     },
     "localname": "NonVestedStockUnitsServiceBasedAndPerformanceBasedMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NonVestedStockUnitsServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Vested Stock Units Service [Member]",
        "terseLabel": "Non-Vested Stock Units - Service-Based [Member]"
       }
      }
     },
     "localname": "NonVestedStockUnitsServiceMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NoncontrollingInterestRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest Repurchased",
        "label": "Noncontrolling Interest Repurchased",
        "terseLabel": "Noncontrolling Interest Repurchased"
       }
      }
     },
     "localname": "NoncontrollingInterestRepurchased",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NoncontrollingInterestSoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest sold",
        "label": "Noncontrolling interest sold [Member]",
        "terseLabel": "Noncontrolling interest sold [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestSoldMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NumberOfBeneficiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of beneficiaries who received services",
        "label": "Number of beneficiaries",
        "terseLabel": "Number of beneficiaries"
       }
      }
     },
     "localname": "NumberOfBeneficiaries",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of care centers sold during the period.",
        "label": "Number Of Care Centers Sold",
        "terseLabel": "Number of care centers sold"
       }
      }
     },
     "localname": "NumberOfCareCentersSold",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfClaimsSubmittedBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims submitted by subsidiary.",
        "label": "Number Of Claims Submitted By Subsidiary",
        "terseLabel": "Number of claims submitted by subsidiary"
       }
      }
     },
     "localname": "NumberOfClaimsSubmittedBySubsidiary",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfIndividualStatesSubjectToIncomeTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual states subject to income tax",
        "label": "Number of Individual States Subject To Income Tax",
        "terseLabel": "Number of individual states subject to income taxes"
       }
      }
     },
     "localname": "NumberOfIndividualStatesSubjectToIncomeTax",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_Numberofpatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients",
        "label": "Number of patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "Numberofpatients",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OigSelfDisclosureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OIG Self-Disclosure matters",
        "label": "OIG Self-Disclosure [Member]",
        "terseLabel": "OIG Self-Disclosure [Member]"
       }
      }
     },
     "localname": "OigSelfDisclosureMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OneHundredSeventyFiveMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "label": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "terseLabel": "One Hundred Seventy Five Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "OneHundredSeventyFiveMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OperatingCareCenters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of care centers owned by the entity as of the balance sheet date.",
        "label": "Operating Care Centers",
        "terseLabel": "Number of owned and operated care centers"
       }
      }
     },
     "localname": "OperatingCareCenters",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OperatingLeaseTermYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease term, years",
        "label": "Operating Lease Term Years",
        "terseLabel": "Operating lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseTermYears",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_OperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases Table Text Block",
        "label": "Operating leases [Table Text Block]",
        "terseLabel": "Schedule of Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_OrganizationAndNatureOfOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization And Nature Of Operations [Line Items]",
        "terseLabel": "Organization And Nature Of Operations [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfOperationsLineItems",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_OrganizationAndNatureOfOperationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization And Nature Of Operations [Table]",
        "terseLabel": "Organization And Nature Of Operations [Table]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfOperationsTable",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_OtherIntangibleAssetsAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions to Other Intangible Assets that occurred during the period",
        "label": "Other Intangible Assets Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "OtherIntangibleAssetsAdditions",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_OtherLongTermObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Obligations [Member]",
        "label": "Other Long Term Obligations [Member]",
        "terseLabel": "Other Long Term Obligations [Member]"
       }
      }
     },
     "localname": "OtherLongTermObligationsMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OtherMiscellaneousDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Miscellaneous Deposits",
        "label": "Other Miscellaneous Deposits",
        "terseLabel": "Other miscellaneous deposits"
       }
      }
     },
     "localname": "OtherMiscellaneousDeposits",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ParkersburgWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parkersburg, West Virginia [Member]",
        "label": "Parkersburg, West Virginia [Member]",
        "terseLabel": "Parkersburg, West Virginia [Member]"
       }
      }
     },
     "localname": "ParkersburgWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PatientLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to Patient liabilities",
        "label": "Patient Liability",
        "terseLabel": "Patient liability"
       }
      }
     },
     "localname": "PatientLiability",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PaymentsForRepurchaseOfNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of noncontrolling interests.",
        "label": "Payments For Repurchase Of Noncontrolling Interest",
        "negatedTerseLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PaymentsRelatedToTaxAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to tax asset",
        "label": "Payments related to tax asset",
        "terseLabel": "Payments related to tax asset"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxAsset",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PayorClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Class [Axis]",
        "label": "Payor Class [Axis]",
        "terseLabel": "Payor Class [Axis]"
       }
      }
     },
     "localname": "PayorClassAxis",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payor Class [Axis]",
        "label": "Payor Class [Domain]",
        "terseLabel": "Payor Class [Domain]"
       }
      }
     },
     "localname": "PayorClassDomain",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PayrollTaxEscrow": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll tax escrow",
        "label": "Payroll tax escrow",
        "terseLabel": "Payroll tax escrow"
       }
      }
     },
     "localname": "PayrollTaxEscrow",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of adjusted EBITDA that guarantor subsidiaries represent",
        "label": "Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries",
        "terseLabel": "Percentage of adjusted EBITDA that guarantor subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfPatientReceivablesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of patient receivables outstanding.",
        "label": "Percentage Of Patient Receivables Outstanding",
        "terseLabel": "Percentage of patient receivables outstanding"
       }
      }
     },
     "localname": "PercentageOfPatientReceivablesOutstanding",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent",
        "label": "Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries",
        "terseLabel": "Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfTotalReimbursementOfOutlierPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage at which total reimbursement is capped if cost of care is unusually costly.",
        "label": "Percentage Of Total Reimbursement Of Outlier Payment",
        "terseLabel": "Percentage of total reimbursement of outlier payment"
       }
      }
     },
     "localname": "PercentageOfTotalReimbursementOfOutlierPayment",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofClosingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Closing Stock Price",
        "label": "Percentage of Closing Stock Price",
        "terseLabel": "Percentage of Closing Stock Price"
       }
      }
     },
     "localname": "PercentageofClosingStockPrice",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Shares Outstanding",
        "label": "Percentage of Shares Outstanding",
        "terseLabel": "Percentage of Shares Outstanding"
       }
      }
     },
     "localname": "PercentageofSharesOutstanding",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageofownershipinsubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership in subsidiaries",
        "label": "Percentageofownershipinsubsidiaries",
        "terseLabel": "Percentage of ownership in subsidiaries"
       }
      }
     },
     "localname": "Percentageofownershipinsubsidiaries",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total combined voting power of the Company and our subsidiaries",
        "label": "Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries",
        "terseLabel": "Percentage of total combined voting power of the Company and subsidiaries"
       }
      }
     },
     "localname": "Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Performancebasedawardtargetshareamount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock units authorized for achievement of targeted performance",
        "label": "Performance Based Award Target Share Amount",
        "terseLabel": "Performance-based award, target number of units to be received (shares)"
       }
      }
     },
     "localname": "Performancebasedawardtargetshareamount",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_PeriodOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health period of care using PDGM",
        "label": "Period Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Period Of Care As Episodic Based Revenue Duration"
       }
      }
     },
     "localname": "PeriodOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_PersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personal Care [Member]",
        "label": "Personal Care [Member]",
        "terseLabel": "Personal Care [Member]"
       }
      }
     },
     "localname": "PersonalCareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PortionOfPatientAccountsReceivableDerivedFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.",
        "label": "Portion Of Patient Accounts Receivable Derived From Medicare",
        "terseLabel": "Portion of accounts receivable derived from Medicare"
       }
      }
     },
     "localname": "PortionOfPatientAccountsReceivableDerivedFromMedicare",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ProceedsFromBorrowingsUnderTermLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowings under the term loan.",
        "label": "Proceeds From Borrowings Under Term Loan",
        "terseLabel": "Proceeds from borrowings under term loan"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsUnderTermLoan",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProceedsReceivedFromLoanPartyOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Received From Loan Party Of Subsidiary",
        "label": "Proceeds Received From Loan Party Of Subsidiary",
        "terseLabel": "Proceeds Received From Loan Party Of Subsidiary"
       }
      }
     },
     "localname": "ProceedsReceivedFromLoanPartyOfSubsidiary",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 3.0,
       "parentTag": "amed_EstimatedInsuranceTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional liability insurance, estimated liability",
        "label": "Professional Liability",
        "terseLabel": "Professional liability"
       }
      }
     },
     "localname": "ProfessionalLiability",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiabilityInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.",
        "label": "Professional Liability Insurance Retention Limit",
        "terseLabel": "Professional liability insurance retention limit"
       }
      }
     },
     "localname": "ProfessionalLiabilityInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes [Member]",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable related to funds received from the government related to COVID-19",
        "label": "Provider Relief Fund Advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "ProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProvisionForLiabilityOnRegulatoryAudit": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Liability On Regulatory Audit",
        "label": "Provision For Liability On Regulatory Audit",
        "terseLabel": "Florida ZPIC audit, gross liability"
       }
      }
     },
     "localname": "ProvisionForLiabilityOnRegulatoryAudit",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProvisionforIncomeTaxesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for Income Taxes Table",
        "label": "Provision for Income Taxes [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Provision"
       }
      }
     },
     "localname": "ProvisionforIncomeTaxesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for the initial period of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for subsequent episodes of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of the overpayment made to the subsidiary.",
        "label": "Recovery Amount Of Overpayment Made To Subsidiary",
        "terseLabel": "Recovery amount of the overpayment made to the subsidiary"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiary",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of overpayment made to subsidiary including interest",
        "label": "Recovery Amount of Overpayment Made To Subsidiary Including Interest",
        "terseLabel": "Recovery amount of overpayment made to subsidiary including interest"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of over payment made to subsidiary including interest withheld",
        "label": "Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld",
        "terseLabel": "Recovery amount of over payment made to subsidiary including interest withheld"
       }
      }
     },
     "localname": "Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RefundTaxYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refund Tax Year",
        "label": "Refund Tax Year",
        "terseLabel": "Refund tax year"
       }
      }
     },
     "localname": "RefundTaxYear",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "amed_ResearchAndDevelopmentTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Credit [Member]",
        "label": "Research And Development Tax Credit [Member]",
        "terseLabel": "Research And Development Tax Credit [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_RevenueAdjustmentToMedicareRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.",
        "label": "Revenue Adjustment To Medicare Revenue",
        "terseLabel": "Revenue adjustment to Medicare revenue"
       }
      }
     },
     "localname": "RevenueAdjustmentToMedicareRevenue",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue by payor class as a percentage of total net service revenue",
        "label": "Revenue by payor class as a percentage of total net service revenue",
        "terseLabel": "Revenue by payor class as a percentage of total net service revenue"
       }
      }
     },
     "localname": "Revenuebypayorclassasapercentageoftotalnetservicerevenue",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RevolvingCreditFacilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility Total",
        "terseLabel": "Amount of revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityTotal",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RoseRockHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RoseRock Healthcare [Member]",
        "label": "RoseRock Healthcare [Member]",
        "terseLabel": "RoseRock Healthcare [Member]"
       }
      }
     },
     "localname": "RoseRockHealthcareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SafeguardZoneProgramIntegrityContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Safeguard Zone Program Integrity Contractor [Member]",
        "label": "Safeguard Zone Program Integrity Contractor [Member]",
        "terseLabel": "Safeguard Zone Program Integrity Contractor [Member]"
       }
      }
     },
     "localname": "SafeguardZoneProgramIntegrityContractorMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the Asana business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule Of Business Acquisitions Asana Hospice [Table Text Block]",
        "terseLabel": "Schedule Of Business Acquisitions, Asana Hospice"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule Of Business Acquisitions AseraCare Hospice [Table Text Block]",
        "terseLabel": "Schedule Of Business Acquisitions, AseraCare Hospice"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of Compassionate Care business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule Of Business Acquisitions Compassionate Care Hospice [Table Text Block]",
        "terseLabel": "Schedule Of Business Acquisitions Compassionate Care Hospice"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsCompassionateCareHospiceTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cares Act Provider Relief Funds",
        "label": "Schedule Of Cares Act Provider Relief Funds [Table Text Block]",
        "terseLabel": "Schedule Of Cares Act Provider Relief Funds"
       }
      }
     },
     "localname": "ScheduleOfCaresActProviderReliefFundsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash Cash Equivalents and Restricted Cash Table Text Block",
        "label": "Schedule of Cash Cash Equivalents and Restricted Cash [Table Text Block]",
        "terseLabel": "Schedule of Cash Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SecondThresholdOfServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the second threshold of therapy services required.",
        "label": "Second Threshold Of Services Required",
        "terseLabel": "Second threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "SecondThresholdOfServicesRequired",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_SecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Class Action Lawsuit [Member]",
        "label": "Securities Class Action Lawsuit [Member]",
        "terseLabel": "Securities Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Awards",
        "label": "Share-Based Awards [Member]",
        "terseLabel": "Share-Based Awards [Member]"
       }
      }
     },
     "localname": "ShareBasedAwardsMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based awards to any owner of 10% or more of our total combined voting power of us and our subsidiaries",
        "label": "Share Based Awards To More Than Ten Percent Owner [Member]",
        "terseLabel": "Share Based Awards to More Than Ten Percent Owner [Member]"
       }
      }
     },
     "localname": "ShareBasedAwardsToMoreThanTenPercentOwnerMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The calculated fair value of a stock-based compensation award",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value",
        "terseLabel": "Weighted Average Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_ShareRepurchaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Axis]",
        "label": "Share Repurchase [Axis]",
        "terseLabel": "Share Repurchase [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseAxis",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Share Repurchase [Axis]",
        "label": "Share Repurchase [Domain]",
        "terseLabel": "Share Repurchase [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseDomain",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareRepurchaseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Share Repurchase [Table]",
        "label": "Share Repurchase [Line Items]",
        "terseLabel": "Share Repurchase [Line Items]"
       }
      }
     },
     "localname": "ShareRepurchaseLineItems",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Table]",
        "label": "Share Repurchase [Table]",
        "terseLabel": "Share Repurchase [Table]"
       }
      }
     },
     "localname": "ShareRepurchaseTable",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_SocialSecurityTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social Security Tax",
        "label": "Social Security Tax [Member]",
        "terseLabel": "Social Security Tax [Member]"
       }
      }
     },
     "localname": "SocialSecurityTaxMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_StateTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Tax Credit [Member]",
        "label": "State Tax Credit [Member]",
        "terseLabel": "State Tax Credit [Member]"
       }
      }
     },
     "localname": "StateTaxCreditMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Shares Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401 (k) plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Value Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401 (k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental CashFlow Information and NonCash Activity for Leases Table Text Block",
        "label": "Supplemental CashFlow Information and NonCash Activity for Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental CashFlow Information and NonCash Activity for Leases"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SurrenderedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.",
        "label": "Surrendered Shares",
        "terseLabel": "Surrendered shares"
       }
      }
     },
     "localname": "SurrenderedShares",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SurrenderedSharesInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surrendered Shares In Shares",
        "label": "Surrendered Shares In Shares",
        "terseLabel": "Surrendered Shares In Shares"
       }
      }
     },
     "localname": "SurrenderedSharesInShares",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_SwingLineFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Line Facility included within Revolving Credit Facility",
        "label": "Swing Line Facility",
        "terseLabel": "Swing Line Facility"
       }
      }
     },
     "localname": "SwingLineFacility",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SwingLineLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Line Loan [Member]",
        "label": "Swing Line Loan [Member]",
        "terseLabel": "Swing Line Loan [Member]"
       }
      }
     },
     "localname": "SwingLineLoanMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward [Member]",
        "label": "Tax Credit Carryforward [Member]",
        "terseLabel": "Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Transition Tax Expense (Benefit), Net",
        "label": "Tax Cuts And Jobs Act Of 2017, Transition Tax Expense (Benefit), Net",
        "terseLabel": "Effect of Tax Cuts and Jobs Act of 2017, net of income taxes"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxExpenseBenefitNet",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TenetHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenet Healthcare [Member]",
        "label": "Tenet Healthcare [Member]",
        "terseLabel": "Tenet Healthcare [Member]"
       }
      }
     },
     "localname": "TenetHealthcareMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ThirdThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the third threshold of therapy services required.",
        "label": "Third Threshold Of Therapy Services Required",
        "terseLabel": "Third threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "ThirdThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_ThresholdOfIndividualsInDataBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold of number of individuals involved in a data breach",
        "label": "Threshold of Individuals in Data Breach",
        "terseLabel": "Threshold of individuals in data breach"
       }
      }
     },
     "localname": "ThresholdOfIndividualsInDataBreach",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_TotalCARESActProviderReliefFundsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total CARES Act Provider Relief Funds Received",
        "label": "Total CARES Act Provider Relief Funds Received",
        "terseLabel": "Total CARES Act Provider Relief Funds Received"
       }
      }
     },
     "localname": "TotalCARESActProviderReliefFundsReceived",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of debt to earnings before interest, taxes, depreciation and amortization.",
        "label": "Total Leverage Ratio",
        "terseLabel": "Consolidated leverage ratio"
       }
      }
     },
     "localname": "TotalLeverageRatio",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_TwoHundredMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Hundred Million Revolving Credit Facility [Member]",
        "label": "Two Hundred Million Revolving Credit Facility [Member]",
        "terseLabel": "200 Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "TwoHundredMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeOfIncomeTaxDeferralAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Income Tax Deferral",
        "label": "Type of Income Tax Deferral [Axis]",
        "terseLabel": "Type of Income Tax Deferral [Axis]"
       }
      }
     },
     "localname": "TypeOfIncomeTaxDeferralAxis",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_TypeOfIncomeTaxDeferralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Income Tax Deferral",
        "label": "Type of Income Tax Deferral [Domain]",
        "terseLabel": "Type of Income Tax Deferral [Domain]"
       }
      }
     },
     "localname": "TypeOfIncomeTaxDeferralDomain",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeofEquityMethodInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Axis]",
        "terseLabel": "Type of Equity Method Investment [Axis]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentAxis",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_TypeofEquityMethodInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Domain]",
        "terseLabel": "Type of Equity Method Investment [Domain]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentDomain",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnamortizableAcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unamortizable acquired names",
        "label": "Unamortizable acquired names [Member]",
        "terseLabel": "Unamortizable acquired names [Member]"
       }
      }
     },
     "localname": "UnamortizableAcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnamortizedDebtIssuanceCostAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected amortization period of debt issuance cost",
        "label": "Unamortized Debt Issuance Cost Amortization Period",
        "terseLabel": "Unamortized debt issuance costs, weighted average amortization period, years"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceCostAmortizationPeriod",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_UncertainTaxBenefitsInLongTermObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain Tax Benefits In Long Term Obligations",
        "label": "Uncertain Tax Benefits In Long Term Obligations",
        "terseLabel": "Reserve for uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxBenefitsInLongTermObligations",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_UnfavorableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfavorable [Member]",
        "terseLabel": "Unfavorable [Member]"
       }
      }
     },
     "localname": "UnfavorableMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnrecognizedTaxBenefitsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits [Axis]",
        "label": "Unrecognized Tax Benefits [Axis]",
        "terseLabel": "Unrecognized Tax Benefits [Axis]"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsAxis",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits Decreases Resulting From Change In Statutory Tax Rate",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Change In Statutory Tax Rate",
        "negatedTerseLabel": "Change in statutory tax rate (1)",
        "terseLabel": "Reduction in uncertain tax positions from change in enacted tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_UnrecognizedTaxBenefitsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits [Domain]",
        "label": "Unrecognized Tax Benefits [Domain]",
        "terseLabel": "Unrecognized Tax Benefits [Domain]"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDomain",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UsDepartmentOfJusticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Department of Justice",
        "label": "US Department of Justice [Member]",
        "terseLabel": "US Department of Justice [Member]"
       }
      }
     },
     "localname": "UsDepartmentOfJusticeMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WageAndHourLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wage And Hour Litigation [Member]",
        "label": "Wage And Hour Litigation [Member]",
        "terseLabel": "Wage and Hour Litigation [Member]"
       }
      }
     },
     "localname": "WageAndHourLitigationMember",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Interest Rate",
        "terseLabel": "Weighted-average interest rate for five year Term Loan (percent)"
       }
      }
     },
     "localname": "WeightedAverageInterestRate",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term and discount rate Table Text Block",
        "label": "Weighted average remaining lease term and discount rate [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Remaining Lease Term and Discount Rate"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_WokersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 2.0,
       "parentTag": "amed_EstimatedInsuranceTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workers' Compensation insurance, estimated liability",
        "label": "Wokers Compensation",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "WokersCompensation",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WorkersCompensationDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workers Compensation Deposits",
        "label": "Workers Compensation Deposits",
        "terseLabel": "Workers\u2019 compensation deposits"
       }
      }
     },
     "localname": "WorkersCompensationDeposits",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WorkersCompensationInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.",
        "label": "Workers Compensation Insurance Retention Limit",
        "terseLabel": "Workers' compensation insurance retention limit"
       }
      }
     },
     "localname": "WorkersCompensationInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write Off Of Other Comprehensive Income",
        "label": "Write Off Of Other Comprehensive Income",
        "negatedTerseLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "WriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_YearOfDeparture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year of departure from the company",
        "label": "Year of Departure",
        "terseLabel": "Year of departure"
       }
      }
     },
     "localname": "YearOfDeparture",
     "nsuri": "http://www.amedisys.com/20201231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r631",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r302",
      "r516",
      "r517",
      "r520",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity [Member]"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r176",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r196",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r176",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r196",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r209",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management [Member]"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r313",
      "r316",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r599",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r313",
      "r316",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r599",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r292",
      "r313",
      "r316",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r599",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r292",
      "r313",
      "r316",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r599",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r130",
      "r131",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r142",
      "r143",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Restatement Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r130",
      "r131",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r157",
      "r227",
      "r228",
      "r360",
      "r416",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r130",
      "r131",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r157",
      "r227",
      "r228",
      "r360",
      "r416",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r204",
      "r205",
      "r290",
      "r291",
      "r600",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r290",
      "r291",
      "r600",
      "r615",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r267",
      "r314",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_AZ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ARIZONA",
        "terseLabel": "Arizona [Member]"
       }
      }
     },
     "localname": "AZ",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONNECTICUT",
        "terseLabel": "Connecticut [Member]"
       }
      }
     },
     "localname": "CT",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida [Member]"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Illinois [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KENTUCKY",
        "terseLabel": "KENTUCKY"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts [Member]"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina [Member]"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS",
        "terseLabel": "Texas [Member]"
       }
      }
     },
     "localname": "TX",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201609Member": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.",
        "label": "Accounting Standards Update 2016-09 [Member]",
        "terseLabel": "ASU 2016-09 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201609Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r21",
      "r210",
      "r211"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Patient accounts receivable",
        "verboseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r16",
      "r557",
      "r578"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Health insurance"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued expenses:"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r258"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r53",
      "r54",
      "r55",
      "r582",
      "r609",
      "r613"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r125",
      "r126",
      "r128",
      "r455",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r125",
      "r126",
      "r128",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r413",
      "r414",
      "r415",
      "r416",
      "r537",
      "r538",
      "r539",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a tax deficiency associated with a share-based compensation plan other than an employee stock ownership plan (ESOP).",
        "label": "Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation",
        "negatedTerseLabel": "Tax deficit from stock options exercised and restricted stock vesting"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r318",
      "r320",
      "r373",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation": {
     "auth_ref": [
      "r281",
      "r286",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.",
        "label": "Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation",
        "terseLabel": "Tax benefit from stock options exercised and restricted stock vesting"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r320",
      "r349",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r73",
      "r105",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r105",
      "r487"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred debt issuance costs/debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r105",
      "r240",
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization",
        "terseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r105",
      "r255"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r117",
      "r184",
      "r191",
      "r198",
      "r222",
      "r449",
      "r456",
      "r474",
      "r555",
      "r577"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r51",
      "r117",
      "r222",
      "r449",
      "r456",
      "r474"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldUnderCapitalLeasesMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived property, plant or equipment assets held by a lessee through a capital lease arrangement.",
        "label": "Assets Held under Capital Leases [Member]",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "AssetsHeldUnderCapitalLeasesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r321",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]",
        "verboseLabel": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r312",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r312",
      "r315",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill deductible for income tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income attributable to Amedisys Inc."
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r431",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Acquisition, total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Business Combination, Integration Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquisition, other intangibles recorded"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r435",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r435",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r114",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r28",
      "r107"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r12",
      "r108",
      "r114",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r100",
      "r107",
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r100",
      "r475"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r266",
      "r563",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 60,000,000 shares authorized; 37,470,212 and 36,638,021 shares issued; and 32,814,278 and 32,284,051 shares outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r71",
      "r570",
      "r594"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r61",
      "r70",
      "r447",
      "r448",
      "r460",
      "r569",
      "r593"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r61",
      "r69",
      "r446",
      "r460",
      "r568",
      "r592"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r472",
      "r473",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r472",
      "r473",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of net services revenue provided by Medicare"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r200",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other Segment [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r79",
      "r535"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r409",
      "r419"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r409",
      "r419",
      "r421"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income tax expense/(benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r409",
      "r419"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r556",
      "r559",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Margin on Loans",
        "verboseLabel": "Basis spread on variable rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r17",
      "r278",
      "r559",
      "r576"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r486",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r42",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Frequency of periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r41",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Periodic principal payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r42",
      "r120",
      "r282",
      "r283",
      "r284",
      "r285",
      "r485",
      "r486",
      "r488",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Deferred debt issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r410",
      "r419"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r33",
      "r487"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r105",
      "r118",
      "r410",
      "r419",
      "r420",
      "r421"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred income tax expense/(benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r410",
      "r419"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOtherLossCarryforwards": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Other Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r405",
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other",
        "terseLabel": "Accrued payroll\u00a0&amp; employee benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r385",
      "r402"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "negatedTerseLabel": "Investment in partnerships"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.",
        "label": "Deferred Tax Liabilities, Tax Deferred Income",
        "negatedTerseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "401(k) expense recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r105",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r105",
      "r179"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "CAPITAL SOCK AND SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromJointVenturesCurrent": {
     "auth_ref": [
      "r47",
      "r122",
      "r517",
      "r519"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from an entity in which the reporting entity shares joint control with another party or group, due within 1 year (or 1 business cycle).",
        "label": "Due from Joint Ventures, Current",
        "terseLabel": "Due from joint ventures"
       }
      }
     },
     "localname": "DueFromJointVenturesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r72",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r144",
      "r146",
      "r151",
      "r152",
      "r153",
      "r157",
      "r158",
      "r571",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders - basic (usd per share)",
        "verboseLabel": "Net income attributable to Amedisys, Inc. common stockholders (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r72",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r146",
      "r151",
      "r152",
      "r153",
      "r157",
      "r158",
      "r571",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders - diluted (usd per share)",
        "verboseLabel": "Net income attributable to Amedisys, Inc. common stockholders (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r154",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r387",
      "r422"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax expense at U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r387",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r387",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r387",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other items, net (2)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r376",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "verboseLabel": "Recognized share-based compensation tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r387",
      "r422"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local income taxes, net of federal income tax benefit (1)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r387",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense weighted-average period for recognitions (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Share-based compensation, tax benefit recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefit from stock option exercise"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of plan compensation cost recognized during the period.",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "terseLabel": "Employee Stock Purchase Plan expense"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r128",
      "r131",
      "r140",
      "r143",
      "r161",
      "r226",
      "r281",
      "r286",
      "r357",
      "r358",
      "r359",
      "r415",
      "r416",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity method investment, aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r66",
      "r99",
      "r105",
      "r589"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Return on equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.",
        "label": "Equity Method Investments [Member]",
        "terseLabel": "Equity Method Investments [Member]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r29",
      "r99",
      "r114",
      "r221",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit for indemnification purposes and working capital price adjustments"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar [Member]"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r464",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r465",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r293",
      "r295",
      "r300",
      "r308",
      "r465",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r293",
      "r295",
      "r300",
      "r308",
      "r465",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r465",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r114",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r497",
      "r503",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance Lease, Interest Expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r496",
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current installments of obligations under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of obligations under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "terseLabel": "Finance Lease - Total undiscounted lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Finance Lease - Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "Finance Lease - 2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Finance Lease - 2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Finance Lease - 2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Finance Lease - 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Finance Lease - 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Finance Lease - Less: Imputed Interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r499",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Financing cash flow from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease ROU assets, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r497",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedTerseLabel": "Finance Lease, ROU Asset, Accumulated Amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r497",
      "r503",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Finance lease ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r510",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r509",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r241",
      "r244",
      "r247",
      "r251",
      "r536",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r241",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r247",
      "r536"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "(Gain) loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r231",
      "r232",
      "r554"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recorded during period",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r114",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r233",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "negatedTerseLabel": "Reduction in goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r235",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Adjustments related to acquisitions"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.",
        "label": "Health Care Organization, Revenue Net of Patient Service Revenue Provisions",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r105",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "negatedTerseLabel": "Write-off",
        "terseLabel": "Non-cash impairment charge for write-off of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r121",
      "r184",
      "r190",
      "r194",
      "r197",
      "r200"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r66",
      "r105",
      "r181",
      "r220",
      "r564",
      "r589"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in earnings from equity method investments",
        "terseLabel": "Equity in earnings from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r388",
      "r398",
      "r404",
      "r417",
      "r423",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r142",
      "r143",
      "r182",
      "r386",
      "r418",
      "r424",
      "r597"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense",
        "verboseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails",
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation": {
     "auth_ref": [
      "r418",
      "r425"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) for continuing operations, discontinued operations, other comprehensive income, and items charged (credited) directly to shareholders' equity.",
        "label": "Income Tax Expense (Benefit), Intraperiod Tax Allocation",
        "totalLabel": "Total income tax expense allocation"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r114",
      "r382",
      "r383",
      "r398",
      "r399",
      "r403",
      "r411",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r48",
      "r562",
      "r588"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of impact of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r153"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r243",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r243",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Indefinite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Intangible assets, net of accumulated amortization of $22,973 and $7,044"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r65",
      "r178",
      "r484",
      "r487",
      "r572"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r97",
      "r101",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating leases rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r511",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Lessee, Finance Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Operating Lease - Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Operating Lease - Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Operating Lease - 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Operating Lease - 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Operating Lease - 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Operating Lease - 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Operating Lease - 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Operating Lease - Less: Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Lessee, Operating Lease, Option to Terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Outstanding letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r117",
      "r192",
      "r222",
      "r450",
      "r456",
      "r457",
      "r474"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r117",
      "r222",
      "r474",
      "r561",
      "r585"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r117",
      "r222",
      "r450",
      "r456",
      "r457",
      "r474"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment Fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability under the revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r35",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r279",
      "r559",
      "r580"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-Term Obligations, Fiscal Year Maturity"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Current portion of long-term obligations",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term obligations, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r123",
      "r276"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r123",
      "r276"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r123",
      "r276"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r123",
      "r276"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r123",
      "r276"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted Average Interest Rate"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r42",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of former employees who filled a putative collective and class action complaint"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyReceivableCurrent": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Current",
        "terseLabel": "Settlement amount to be paid by Company's insurance carriers"
       }
      }
     },
     "localname": "LossContingencyReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivableNoncurrent": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Noncurrent",
        "terseLabel": "Indemnity receivable"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossOnSaleOfInvestments": {
     "auth_ref": [
      "r75",
      "r76",
      "r105",
      "r565",
      "r596"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of an investment.  A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.",
        "label": "Loss on Sale of Investments",
        "negatedTerseLabel": "Loss on sale of equity method investment",
        "terseLabel": "Loss on sale of equity method investment"
       }
      }
     },
     "localname": "LossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r49",
      "r117",
      "r222",
      "r474",
      "r560",
      "r584"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners (percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r100",
      "r103",
      "r106"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r57",
      "r60",
      "r67",
      "r106",
      "r117",
      "r130",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r150",
      "r184",
      "r190",
      "r194",
      "r197",
      "r200",
      "r222",
      "r474",
      "r566",
      "r590"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Amedisys, Inc.",
        "totalLabel": "Net income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r60",
      "r142",
      "r143",
      "r453",
      "r459"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r137",
      "r157",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r413",
      "r414",
      "r415",
      "r416",
      "r537",
      "r538",
      "r539",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r125",
      "r126",
      "r128",
      "r286",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAssumed1": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes assumed in noncash investing or financing activities.",
        "label": "Notes Assumed",
        "terseLabel": "Note payable issued for software licenses"
       }
      }
     },
     "localname": "NotesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r17",
      "r559",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes payable issued in acquisition"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Acquisition, number of care centers acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states with facilities"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Tax years open to examination"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r184",
      "r190",
      "r194",
      "r197",
      "r200"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r504",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment of operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails",
      "http://www.amedisys.com/role/LEASESOperatingLeaseDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LEASESOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LEASESOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r500",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedTerseLabel": "Operating cash flow from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LEASESOperatingLeaseDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r510",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r509",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Reportable Business Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "totalLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent [Abstract]",
        "terseLabel": "Other assets:"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r58",
      "r61",
      "r64",
      "r68",
      "r281",
      "r476",
      "r481",
      "r482",
      "r567",
      "r591"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other",
        "verboseLabel": "Other General and Administrative Expense"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations",
        "totalLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other long-term obligations:"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Financing Activity:"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r18",
      "r558",
      "r579"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of company stock",
        "terseLabel": "Purchase of company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Debt issuance costs",
        "terseLabel": "Payments of Financing Costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Shares withheld to pay taxes on non-cash compensation",
        "terseLabel": "Payments Related to Tax Withholding for Share-based Compensation"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r89",
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to Acquire Businesses, Gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Investments in equity method investees",
        "terseLabel": "Payments to Acquire Equity Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r292",
      "r294",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.",
        "label": "Pension Cost (Reversal of Cost)",
        "terseLabel": "Non-cash 401(k) employer match"
       }
      }
     },
     "localname": "PensionExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Other current assets:"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r229",
      "r230"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from sale of deferred compensation plan assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from borrowings under revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r92",
      "r352"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r57",
      "r60",
      "r98",
      "r117",
      "r130",
      "r142",
      "r143",
      "r184",
      "r190",
      "r194",
      "r197",
      "r200",
      "r222",
      "r446",
      "r452",
      "r454",
      "r459",
      "r460",
      "r474",
      "r573"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r114",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r257"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r259",
      "r586"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $95,024 and $96,137",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r114",
      "r259",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r302",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r516",
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related party transaction, amount of transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r302",
      "r516",
      "r517",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Cost incurred in related party transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r302",
      "r516",
      "r520",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r514",
      "r515",
      "r517",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments of long-term obligations",
        "terseLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayments of borrowings under revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r113",
      "r553",
      "r581"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r286",
      "r360",
      "r583",
      "r608",
      "r613"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r125",
      "r126",
      "r128",
      "r131",
      "r140",
      "r143",
      "r226",
      "r357",
      "r358",
      "r359",
      "r415",
      "r416",
      "r604",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r166",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]",
        "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r508",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r508",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of major classes of indefinite-lived intangible assets acquired showing attributes such as amounts and totals. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit.  Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.",
        "label": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r42",
      "r120",
      "r282",
      "r283",
      "r284",
      "r285",
      "r485",
      "r486",
      "r488",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Sources of Tax Effects"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r241",
      "r246",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Commitments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Goodwill and Other Intangible Assets Net"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r35",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Commitment Fee Under Credit Facilities"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested Performance-based Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, classified as other.",
        "label": "Schedule of Other Assets and Other Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Long-Term Obligations"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Unaudited Summarized Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r119",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Payor Class"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r184",
      "r187",
      "r193",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r184",
      "r187",
      "r193",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Income of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r321",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Purchase Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r327",
      "r340",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r397",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Uncertain Tax Positions"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Aggregate Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r171",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r207",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r173",
      "r174",
      "r184",
      "r188",
      "r194",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r206",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]",
        "verboseLabel": "Quarterly Financial Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period of equity-based awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Percentage of market value for purchases under Employee Stock Purchase Program (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Canceled, forfeited or expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled, forfeited or expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (usd per share)",
        "verboseLabel": "Non-vested stock granted, weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested, ending balance (shares)",
        "periodStartLabel": "Non-vested, beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested, ending balance (usd per share)",
        "periodStartLabel": "Non-vested, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Expected Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Risk Free Rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Risk Free Rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Equity-based awards, number of shares authorized (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Equity-based awards, shares available for grant (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average\u00a0Contractual Life\u00a0(Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled, forfeited or expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled, forfeited or expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (shares)",
        "verboseLabel": "Options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r329",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (shares)",
        "periodStartLabel": "Outstanding, beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average\u00a0Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r319",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Price per Employee Stock Purchase Plan share issued (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award",
        "terseLabel": "Contractual term of share-based award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r319",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r114",
      "r321",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r346",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exerciseable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted average contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Non-vested stock options ending balance (shares)",
        "periodStartLabel": "Non-vested stock options beginning balance (shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Non-vested stock options ending balance (usd per share)",
        "periodStartLabel": "Non-vested stock options beginning balance (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted average contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r505",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer Software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r171",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r207",
      "r237",
      "r260",
      "r261",
      "r262",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONOperatingActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r46",
      "r125",
      "r126",
      "r128",
      "r131",
      "r140",
      "r143",
      "r161",
      "r226",
      "r281",
      "r286",
      "r357",
      "r358",
      "r359",
      "r415",
      "r416",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r604",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r125",
      "r126",
      "r128",
      "r161",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r19",
      "r20",
      "r281",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Employee Stock Purchase Plan shares issued (shares)",
        "verboseLabel": "Issuance of stock - employee stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r19",
      "r20",
      "r281",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r281",
      "r286",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r19",
      "r20",
      "r281",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock - employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r281",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r281",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.",
        "label": "Stock Repurchase Program Expiration Date",
        "terseLabel": "Stock repurchase program, expiration date"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r25",
      "r26",
      "r117",
      "r217",
      "r222",
      "r474"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Amedisys, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r117",
      "r125",
      "r126",
      "r128",
      "r131",
      "r140",
      "r222",
      "r226",
      "r286",
      "r357",
      "r358",
      "r359",
      "r415",
      "r416",
      "r444",
      "r445",
      "r458",
      "r474",
      "r476",
      "r477",
      "r482",
      "r605",
      "r606"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, Stockholders Equity",
        "periodStartLabel": "Balance, Stockholders Equity",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r483",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r483",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r483",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Patient Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Shares repurchased, weighted average price per share (usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r45",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r45",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r20",
      "r281",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "SHARE REPURCHASE"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r45",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock at cost, 4,655,934 and 4,353,970 shares of common stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r281",
      "r286",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r133",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r413",
      "r414",
      "r415",
      "r416",
      "r537",
      "r538",
      "r539",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r381",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Uncertain tax benefits, ending balance",
        "periodStartLabel": "Uncertain tax benefits, beginning balance",
        "terseLabel": "Uncertain tax benefits accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued related to uncertain income tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in total valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r506",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles [Member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r145",
      "r153"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding (shares)",
        "totalLabel": "Weighted average number of shares outstanding \u2013 diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r144",
      "r153"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding \u2013 basic",
        "verboseLabel": "Weighted average shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Workers' Compensation Liability, Current",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "WorkersCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Write-off of deferred debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=75018788&loc=d3e30768-111565"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79507997-165333"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79507997-165333"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508013-165333"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508013-165333"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508029-165333"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508029-165333"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508043-165333"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508043-165333"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508057-165333"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL79508057-165333"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384995&loc=d3e23524-113945"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121593497&loc=SL77918431-209957"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r629": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r631": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r632": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r633": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r634": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r635": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r636": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0000896262-21-000045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000896262-21-000045-xbrl.zip
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MC,.]_Z*=U5F:)54&*X2_/(#GYQEHCOJO?WG]Q5<P(!@13 ,<QC2BNIU?PVR
M9&1IF^0TZ*6!]<2)69EJ45:PQ'/SHH(I0?V3V06@.4WFUYF!Q<A+D$"P,:Z,
MOBFZ*N&1[L7P9E,DLWSPO;A 2=5D\VP%[X$_T??1<V&IEA$HYMOFFKYID17P
M]"S)\2ES4]=6<-RJ\ MO\'WSLJV2*WQE>5O 1%]G*[R<%LJ^Q<XB?'MW7/PL
M?.L6/ Z&_C,^"F[**E@0)8$P_G# @8@-K966E9WHL@2!0Y4-PEK.?H*UASEV
MB[S,FL:8:)G<P40DM$MQ_.4*WPT2<T'_/%BM0&@R'M Y;K(ZVOKK7UZ^^NKB
MX+RF'[;=M?@ZN'.>U-?1K"S:6B2FA%=6?IFCA"[$[SNV$CKV16ND+RIYJG%J
M^&]U2U]I)PZD.R4#%2;&-!&(4'-MUP<W\PYLS@A5'5X3\SS1KH?_XE07*0@G
M/(LDS 3#P]\N%CRC^9W=C['L1-F4-/MG;0,?8*(CM_E )$!O@##@LL.@>/II
M!KH7RY3BZWK/V8E.2_Y[!.8%S*\?_Q;<N2S3#/2 2!+,ORD7VU%]G<#9S:\W
M]/+4+$Q5@>##ZT/INTZ:*"UAGHNRH3_!A]YF,(47^-UPQ:O=+P[\NL'SVB+'
MK1,(&"B:AI<)5#Q>35\;1_4*Q H'F.=V/G#_7\O5_&$9OUPOQD,&@E/3X!4U
MJ+:4M:2\I,;KZ5([65Y88 VKNSC*%B!9,%2<P\J=(*ODCFTF^/W,%&:!T@E+
M84 "4OPE/&=F_&]@E9/HO54_L+W@1*I;_ %U7"$?>%NV.:CA!+8*BZ6Z :Z#
M+=-6-'@KIK!03?(KOL\J UG]L;D8VN^5077*BLG/"KQO"<)+ BR3LDQ^S9;M
M,@)["]VS%1TZ<[<;2G!?,AP2+9 S!Y/5*I>K_--Q.<JVB6ZR,N=S@F;5_IW$
M?W0])V%S/-*FV]\ F^[H^)N3TQ-T>RZF,<=K9S3YT#/ZX/G;D_D3T\V=26*\
M_3G#'#9^Q=1"G8&G;0,&(Q^_H%J+WA&+_W5'[-TVZU_0C*"+P;LBZPP4&=[U
M=8GZ*H$G*Z,*M[$8F94[A?APC:U23[U2MV]F0Q2T.*DQ_Z];''@3Y2:I,<CS
MGU8'@,Z?P8>FT4U)KUR5M_ F^",>9O,\J6LV(,2"6? ;Y?/A'4//]*:;MZJR
M0M^Y 3MB-IT=\=G.%Z_TELAA4D& T-RCHVX*6^,Z8>,$MPA9!35*.=L5=!B*
ME>T.HOW].$+3*2LV0!CFTQ&&+W9V/]/",!4!\+J1#""TN%=L_(,W$[@Q<70.
M*J'*YA0@NT;'_?LB:[1S@YIET+-A$]>D/8UX>VWH>HQNYVAI%J+:$AX$J<,(
M;5:SC,E.# Q"T<3>EM,F)7E!L?)YT!GA+R#S"K5]GL&-B?P5S%R8B#A*Z@$+
M$>Y$KQH_]4[9XV!69W/C/OPVJR=BFZW=&.ET-D972ZI9G=#^B&XK%(4"G2]<
M[T55+KON;RB:?&Q:H3&U=\S'13+NRJ1V'+23E'DOG1T3#.SYESD3A:/;1=K;
M*#BU>Y]]58,?8ZIYQF%!]-^2=)D5&0R)#RJR*VH*"^#]YD:<F@2_80%#@SUH
MFEMC=.!!Q<"=2:77-1ZYUKKBYB;)\IWH,MB#],=8!S34W.3);0P6&CX2EI">
MB(%\-6%HP)DE'VS@E(H^ZKZDK&*8D;E9N8B)\_-*2@TY%=9].<Y=:G)S!:_=
MJK<[*B/XWN2JPJ&(Y\SZ,I4\'2P(6HC%' ]C"75T8QDXI?#X.)J!\U@8&!((
M)0K2+RW8C6R0.@ECL9&0FWNS6_[2O]J+A WC%!RZ #D.[]9WX62"#,U;91BK
M;8 :?9ZW%'& O\($S9NJ++)YQ-9T6WG=J?^*-K!$:G#&YK@D&.R,)>5BQZ1W
M'(W/&2Z+MF(CW\7"5/ +YDBB+11L7?-]&Z#,S724><?*(0]I.EK<.VT@4T<J
M]*\U^?B"ZU3WJN1$_Y<4L8>]TDM^NWPGR\>NOR69U64.^^7A^?('_>T/F]3/
M'S2G^Y_OO]G=>_4"W_)R+]I]]=>_O/KLJ]W7]!_,)E$D/*+_Y1^', #\O]>5
M'?PJN3(O9I5)?GZ1+&#K?IGDM\E=_<D'PAU,9@\O)K.']W=W]O0>/D3K_AU'
M/:>SE?_C=00/SV$[/>'$P6BF?SI<34:R.B'"0PSQ3T:BR!4M(AA2RDYH44C$
M@_(JUH 3QY1-8&5\...)TW=H.<24E\X6O2P&QES C'-FEL0+R?+P-HA[K?4P
MRJH3F\3?N#@KFC1RD/4L7S%VV>Q.S0(,?/H(^[%D_0P.@A]*?\>GDC].R>V!
MSW*)L>ODQCS1!TJZS;GB/N)JDYP#2Q:Z)LL$/ &P"FZOL_EU;._[J4VOEBJA
MHY)YB!AHLJ:E,=T-)<H699Z7M[ /_OJ7UY]_16(!JY"T.5F:>-K!_)8+OGTQ
MD 6BV+2;.!<\UK./_@9-_-BT^HF$7_@Y5H"%1.(B[H,H&ULE+4QL,@-A 1<+
MG!GX0-BA"*68F7_]*S<LZRFZL2WOF)(B/ N:+#L*^*"5J?"^X)-I.=N&OAM$
M),GQQ]M!5\)Z9!W\ 8Y<,FBR+W&R N\,O>PV-^3M5.:JS<6YWG*^2>R2<=[Y
MCBF6_LZ@(X)NE<O:7QL8YG5$O]5/YQ2W?SQ^KX!09.A!OO6Z7!K]K!A^4Z\D
MF$0+QY$Q4]W +VLORMZ7QWG85D ,\'G =[_&-X(8@SJD5/(BR7'M0'7-YVU%
MVWB9U;E)R"NC"!NED TA0@A6HL$6X7S?C,A)XM[865T%XJ'=1FEQ^-LQ.+1S
MN/IK1+;BICT$]ZQ%Q,#071:W S)>I+.R_#F<)"=E)2R[&RI(QBT8"8LVASG(
M<O0UX9MX-\)*)77), 8*NB2W>!UG7@AX4_94G!M-W:YP56H,%]AQ#']M;8H,
MKF /F2&'%HI$"B9B_%-19W43*,6AU_Y4SC!<M,++9["9&XL 46@@_G94TS>X
M,]1W(XBA7K#L2*Q @A#C'PIOQ,#"%2A(4JPV7 O/1TW/CK:\ O2PS+9V^DG_
M#0_" 7"\CF/]L<(H![Q"@YRR)<H_*T#Z^Z@6G!F.F.Q$!YA8,YUCF\P.PGD(
M("Z,05EM26<"!Z1F&  &H>T%F^%L((A1"3($FG%>&7P)OY?/S.#E[FD+0@A0
M6"YC, ;\-3 G-B#J<#T=N[(30CZ\)HC<28$JI:G*?#)&)LG/-1Q.ADZ%\,@/
MK81'"$ X&Y\Y$#;(%NR6+U^\VMO9_^S)H*?9GR0G0V\/9^;E&YP$.B9  ;.=
MPGEMK; 2BSY%D/I*1 >-3S*<V9*TR="]EUOI]M;+;;N$Q[_.6?8.YHVDKL9!
M2",8!%1 H&=!&.Y>8$8^5<::.VW<<2BX*U&9BR'#3]\^,W#22RZ";R6$)V7^
MQX\PL!KXK $#$Z?H-6(&0A-W%(] CA-Z5F!<.>R9>F1GS*3518O/$9^P8&.2
M8\.BPM.1T%V ZZ P.)R69&7C1H,#"E.#<QJS&@%Y0QK789\FIG]9P9C1&T&0
M*R=*9F*S;-O3]H_<K:]V=E\]W6Z=W':MQ6"1A;0IX8Z#'I.H4R::@)%DHAB[
M'<'H,F"J+4UUQ7]A.;'+&*:<ZR07BZ2N#>=H$ D)_@V(R* 8NFVIGN.U.IA/
M)5E"6!V6N$0?1C=Y=_C?1P(61?&%7?!3667-W1^\Q=Q@!=9-G^?Q]_1/=-4X
M_Z=4)/TWYPS:#4+\KT"!5.1AR$[1DT..W<@^C?T2C Y",D+R;K22KTWNW/CD
MZJJB5)O=L[8:X'X=!JH5C$DL1H#;"6B;,52UNQ;7"6@$3&P^[L/'/OI#J(HW
M.Y_O/:&JF)JN2&&-+;(9GEE2GF=OG_PKZW\MX;G7B/5051$H$N),S RL@37.
MR&7G!ZD@C\\BS<&%9%<"7\D.)0.R?43(XNSZ^YF>$6N$N!6C6"(HX&,YYP'?
MXL0L/*B\E*M:AQA?0WZX%<CN8;G(*A@7/1-D6^:.=6UN;M";@JFCZ;*3<)L0
M( '],$%STW9 5>G@A)3^>7F?!F!]!9.4(U):G&):!]!I:VX;7B7X+8]P ]RF
M/VO//"C1\]G+=6Y3]+Z:% B'#L&\I$+H%0X-JSIB&XJN$9%6TTF!H0G0Y!@K
M0\>Z<(8 QY9R%%0\Y>4I>/C(8V4JDOIG8_/6?-$V2AB_(UHE6>KLTE5;P;/9
M+,3( +SPPE8])1%O7JRA\@<0B.+/IK&E.A3+)A'O37^)X;IZ V3ZIRG)=)B\
M!$]K6@)\4A *.(_.$4O5&A</W?OB\S<$/:1B9!!=AIAAB1 :)_#?)T0F/%T1
M^PCXX#?@(YZQ$Q\I=N+GR:B?7B12PRVGHX."HFX%?@SLTB"_,G<7C93!@.9J
MFVNP;__%?I*%D2JP=Z<J[V50<SB(]K2)$;P2SW3O'8-A2O0,;+N[P#H8IV56
M\-@8*<A_PAR:L<;C"BU5PATN8O\!/ !O>/I'8=:"[B]=H"X8Y,SXM*ZL.SIH
M*T->FK4B,$@AWJ*MM9#YSN$+R6-'UYT GQ(75C:#CV14.-'EDA;@E[9L)+5P
M!U.]C-H5AD,HKV1'ZNV1FM[$E9EX)UHX+O<K R_*XH6++;K)L-^P-?P1YRV8
M4GMO9B]>*GB_#H5NJ_KN3+VME +>A[Z(CDH7>WVSO[7TG "V<EXE8+=WHN_*
M6SAFJUB>5&$N:BX9]$0#_)GL Q-55%K\"_B%V>+.8GUUD-Z&<X(4&DL"%^;>
MP*V"4+!YI)'TD1 Q6!2#1RW0(_([OB\LF=@ <S"?C#[NN3AJ0TQ+)?_'[L[N
M[A[6$>+BMQ3MPZ&J^KT'(%0G(P++R8C WNNN1Z Y12:P^AT>EFYP=@,6^RDA
MF/?97Y;,90KKS8<$KKHD"^S@.D@;RG!TB3XT%&X38@+E=(2B SLMP2  0\'R
MK$Q!,FP1IHI*<YZB9F :H7X4C8O+HX2WJ SU@*FT]7)[ ^1F-1VYZ2@36S R
M;8'!1 ,;L]J=VX"%_V7""U\G!+>;A-5@*_;K9*G+]GM(9\^1E;KQ>V0=X20=
MN4T?^X!'T$+!:.-H68(CCEP^19/K.^/[;TW&,-VQ"Z,')8,=E"%Y:T&AW[QI
M*?TJU$*U_D3'1.3]IO"K=Z(3#"<\:((PXX4.I)XIS+\9.,H71!^IAL4?SAC[
M#NC0BY XJK64\WJF/?;2;?&]NH'W^GN#0$A"T(/'>PF.?ZXO&L8G[>]O&8U/
M8B8HI/C";UZUC8D'QFNG/^E5+=0M BG@'8E^-Z(^QT&24JV*%]3M:E56*G24
MI#<9XW&2:'5]5R,:J6#.+4+#VFQ_91*<+QO9 ''H3^@&J+AJ.BJN4ZAY[$HU
MCB;"V9,-"O2;#5CE>DJK_&9/K_(435X7;D2M6Y5DY_J:(1^6]C9OYS3!0B![
MH&R >#23$8]NLM27KDU&0!P;0Z+#HQ)ZI6-D'%^+H+VL:,NV1I -45I5[0I/
M'V9KQLRJ*DQ[9-V43B\P>-CT2WQ<[0Y7_/6X+$NL7'%1 &L+/:9PZZD(]887
MS=J@6,K$@?<G%2$)\TLB(BM&2C;K)FG:FO/ML$K'2B'U5HQH7M2:^3R5!7QU
MRT2/5>UC?=_S&0"@36<G9,$["IBASH/5J/@V*T[)39FE%O><ENT,__ZX25$[
MQHV>9@)Y[SJ__STSTF$ZV8D.[JFQE;?9%Y@ 58,)N=$*+OX\G@7F ^GRX2++
MKQ$L+9)Y,E*(LF7=LB,B926' C&K_#6,D"LLYYZE$71(.:H3[1YM1;C;@Z.N
M4XN[8[-H3UG_+BN7/N4VMTE#%@4N/D8TL<6_6"=Y VR#=C*V03<&HM.YD[$.
M:/-<^"PY:KVP! =A52]?_598U63DXF8Z<A$&TX\M>]@$H:(.F<DHSU5R9VG4
M/&83=# S&1)R@C#8B@\-3;:5JFB7)X%>]Q@+SM92!./BX-Q#41P96<K/ML^-
M XI"%ZC9>?G9!LCA[73D\,W._N=*$+])LBIZQ\C:'W!)IB"+(ZD;!T&(Y4Q'
M*_\*^=:$9*/'8J&$::@(^:HL4\2N8!F4E__*2+#-@ILUY!GEE=',7=RR[(,U
M*"-7G6.1S*K2RIHYLEL*-)!R F,S*0'=H!P=-1<</BU*'N>:$698<NT_SQ'S
M)S:<N4!AD'>I_3G\-(J</G!Z-V"+_CJ=+1H>%=]D-=(]_-,D$\J@*>O[;^#L
M\!#O8(C/6&LW52^?L=;/6&L[FW=352_?HI(^IQ*\*:@7C_4A</!?_[+W9G?@
M?Y]9'CY0*>A)AY^-D1$8KKJ3S.O#.,FXAU) #NLZ\U#AI^93 ]-"B6&/;@T#
MTHG-:'7Y>(6UYYE(X,^5B"XHS/(T#?-^$%Q;\)K1=V7.U&%O=][N'.Z +P?/
MH#@K53N@=/R7N5/]O'1K._J+(X4*;[7][GH"%,I7*$]XZ?J'/I>??W@)*\HU
M9(KFUZQF/HELT54JCCR1I2W4([;+:"_DW#Q @CT,9IUXL*Q1Q6EE)%>PCLG0
M\>5UQO4WK%595<05)HSY5'U/*DZ*9/1G,**DUO1Q:09V4TL"C]D)+BM"$H@N
M]1FYC&F+/WK6L^S^%\ T"5$A/'^&<2#P."F9[-EC!BA $^(P!)\3*WH;$SZ&
MJM+=HX1U@TJ/X&O@-_D=_-2TY% +)YPPP8$$W9C<-Z;<V0!.V7]-QPKL %E.
M++-'] V]>@JVH&^Q,K_.\C2& 9B5_(C,I:G\#-8)46GBG^W/]'?WAU5)+)RP
M!7(Z>98DL:"07U /@D42_!-TA_LY35H8D?KCK KO+;$'2ZVOH,HJSFQC6PCL
M@GEC&&V%U577V6H3,%?)A%JDO0P\EF'HWY0$5CJ?!B'S(';6[X(BX;^PW8^-
M<G_>ZPQBK]?M+)?&-!+ #$DJ'=1C?S_HL=GC,U(-'+%555-BXU>)[C?,H*LI
MA'JQXVA+101UKTXNX!]:-O71"FVIIJH;"Q;V3S@AAA_(3!:2-:#$A8V:,F\+
MC8<SS"Y]KOAOYDENL)J4@EG1EM0Q8G>5'-<6MO2\RF;6%9G5,K5;//K1F1::
M.X4CT^RL(8F3K<QD[47_U!4MVP3M,6D=_<?>[FX,(AVS462_WZ52FLK0N0FV
M^"FHM/^FVDQLW!',UR;HH@DUI]L/\[OC$SL%A1143GT K51%^R][NFF@T^[,
MC&.V-T'^)M0/[U5HMTU'UMSA-Z+H*>@SOETV00PFU/VMHX:Z>+@)"<10696M
MN2)/W-*8,?7D,'KYOAX'&U?HG4RH^517I0QVCI^.1)E,JFS< +6&<;]4'3B9
MG--3C#;<PYY;; KOR@#*.#SN]E]N@EA-IQ]2ET"@@R:=ABPQ7;$K!27_@M',
M+#A8O$5<IM8$ZN$<NM#;#9"1"74V"CW[][YOP8NO$VRR,S'5@U%8%!FO<!"[
M-M:CUX95/1T4"Y4UJZGN3_7EU&T;KDHD6)W1),";U,Q$[YB&J0^^=F7K^YL@
MA1/J@] QIH8F>SHR.)!=T(*SM-(AI%6A7.QIJJN^O&&H9,[==Z*1S5C;HM2!
MKKE.*VZ"_$V'4!9.RH!MB1VD.PQ)'=],JZJL&XU+P@)TTH_=LI5NO]FA<I1.
M*?P6=3_& I5K4[SP_"U!)1?%PFPZS7:GL6FVQ/+"9HH7ME,UPLKY=PQ7Y\MP
MZ^@D\^.&PD<%#:<R>3D/J/"'!N,QHJL\X;2C"<9'^H%2<J]WL>4C)LA.Z-BA
M8ZIN<*Q2Z!7D_1PCFU2$=*4QP&'/<YIW6O=9>4.1U9NL:A@ZBCS?TL5KYJ*?
MG?H>X>RI-6</C9#9XH8F[Q;-]UC-,"U9[[JXMT:503J"^I&51K8<2KFB[EC7
MM]YR4=9(V>%]'S5(K=_YL&=LI=5'KYZQE?^.V,KAV90MM(.M*/$\<+T\ N))
MS!/?24ZLP,[H95LTX_U(>VJ/]K@JSY3#.C4+4R& 9*[(8=>3EXZ57BO=BRR&
M!">1D@8\#V&X6=[3:=04-:]+3#FW%7.,R-!JLTHDIT2A?:FJ7C^X@  +1[@)
MMMQTB-2[48]S;.^94:<(+ICZOLBF8]"!K&!/R)^-6>'R@YCC057W:8T:K!N9
ME^"\DF4FF\=F5LD!EL(O";@MT$JT7ZZS3'4GK+:W&R20O) [>E=L&Q!'<W1$
M<BR1A[<N3":$O*Z".:6B(+QQCHDM=E(V078GQ,+=\8,O#LZG(*E9[>6*E#"K
M2>DN)(@'T(:989M4R*WZS@IU=1DN9C+4R14;5SG1UP6-5"][<!X3%)I-;/.+
M! SYVCD5GO&5?5R$KJY'2]T]^D8"1O?>0EML$\1Y.B3&7;<Z9'6<@F2S#NX0
M<VN#P )8@^[(<)2W^14A.RB18;FVT_O0/*@@,]M>?"/KN9,)\2-W2(#\*DY1
ML@8;;3KIHB[<_]9R-2$JYNXA[-?PI,#\Y*1R^]H3D9R^2FCX:NH>\;]R@^#+
M.CU'1X->$J?HE1MM@HA-B-@YS+JI1/F$1,M:?#:Y-L3^ +Z#.+"8J:#@+3<S
MZ]7F5]H=&;YH$V1H0B3/737E6RA&!]3J$'E6)\*)Z6O64^&ZLCPDDK4G'T,U
M:'0H:M WQC5K)/9@U2JRBSJ*-J ")9D07717A!1%WU1D)AENK^L:($O\/^MT
M#Z*8"7?GR3G%4;A_77.:@%J'8S$( 651.Z$XJ0[AT]!'HT2&P^+U\D-+UZ/&
MTZ'ME,+W@Z-W)Z<G%Y?G!Y<G9Z?3F.:ULGAI@V.^7Y?K$C:4?!]L"4;9/%*!
M63T'JQV+\9 <SY8)PKDJE8;)-HODJI)Z$E\&NS7;]GE_;MY+O@,Z"=I'S; >
MTRSKJ##H-."+7-_/"IMD1](I6\H=[/=48=[3OW>^'=74<1=!"S6^@G**\W(9
M6(IV)!0 LGB%$)8C#TRW/7M-8$%8P\.SJ3LVJYAC0,I>BKES^JPLVEHUY\X<
M IH0AFNA$IRE+%J+D17CI&-%R]LD)4Y1SYJ86M-,^J);^X9+8& 6\@Q>D,A?
M,R)+BL,/Y"(UFR@AEPUO]$\-8U55=&.HXYHOK*5Q6"8FMM=.RX9R##3+1L^R
MG4]9EOJZ;'/L%.Y,/,P5YW<QUY"JAO#4MQYS.F8ISUUL2\SY-H%9YI.8=L@C
M)T8>=[6-(6V0K\HVE75?JC_?AOZ"0'?50^#X%MKN*MON_,;>/NC>=( (*I\/
M;[G%QL^<KY\[M*M\U:V=25M0BZ>)/5;Z3>1G+>:V\SL?O6Q<@HO+JZ5ZEQZ+
MZ:B;K,SMU#CW/ZPMZ^2R9&:OM;Z@9TNM\-V*+7 6AAB'3-P0H(VP&'AEYMDB
MFU.S @.;@U8FI.C?>1EW6O;91HLB<%P))JT0 Y(*2Q; 3F4+!WQM=*N];9"V
MGPWM-AZN3,B 6L-52&\ZE68]'4=7C:FX'40)V,WN/F\W[GP7)?DZNEQK;]D1
MLKM@IL#S1FB(%5GY VAU6,VVAHD=QBV&#2R-JWO7^4UI]]"'Z"O PTYTD.=A
MAP0MBIU6D*X)0MCO':$ATK$R=H5QG6>Z1RS@5SF(4L;97]%EH./JC+M04AT?
MGQ]=[:=Y2_2!TCE,23G1&-PI&E.N*07M0461^$>_+/@XKK3OSK*EM;O.S$*Q
M"YSY4@BX@M<@K'OO]7;G!RNMW5%RG1G'T;H]R5)O2:=%*_0NYZ.7BZJ%)-GO
MZN <$"'3/KJ+6\D*NG=P)<C]$KWF=8D^X150/[H/"E!($8$;1W>W%:5N7YE5
M-H^$:V37NEX[>-A^MM>Z)"^MF81?U<$1Q]W6+QHO3!BM'-:H4FR81)J AU+
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M!5>3I:#H8J'C$\B&MIZ5:U5?58C/):<3F_]&>8DG3\VBGI8BZ;0=<!."R"_
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M06ZVA2"(".O<"-?$0/'<<*P^MH/"O3F-H?X_JM.%(Z4C&Q5^6;%>ZY^YPQN
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M'!9>179C?<M6PL ]ZJOF&^QA5:BI;I(&BQUL/1!\+A\.GI[4-X3G2KJ!K^H
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MK%MWS\4;Q=>9PA>KCOX!4$L#!!0    ( $9 65(V$N\>#0L  '61   7
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M/*_=KH3F=32:JQ_C=#JY^!-02P,$%     @ 1D!94M2'GLT"!   (0P  !<
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M72\+EI+W:2IJKHVD+IDL?Z30(*S^_Y[$SY:UR(&<"RHS4]B,24BUD.H ],N
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M=SEV;3MZ76V>[O)LK_&3[U!+ P04    " !&0%E24Q^S'JH'  "$'@  %P
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M=E:0D'9N$W959AW8Z.C%V:C?8>^XA9HP0S%GMZ6>*1)C2J*I3+21T%BQU$!
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M67.E70BS(>V+].:@PV[NJ?YJY["?'AS;QE\-9OOPUGDN\;IK7P>[7#%N*'@
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MO]N#IJ]V!@?'OX3?Z.^'!^1+MV^A=>/:$,D55/%[7+;0X2]HDHT;C6"2;['
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MN$C@!KLSAT;<((I<.7?AP;58N K!(WDB<VGG#OBW+>L"UWO5.RS$W"/2M7;
M@]Y#HU!5ZPH!8WRA2E.EA1? -P9C*E%_<L0-1JAR >E(T/2$V$#@R@JX\R*C
M(^VPZRG/:Y]GSG2492C,<@JES98"NZPR.^!&>-U><WTP8")RWH3*GJC:/B_!
M+LC&E]3DVI;LTWT<2Q8-D8]O"I: /-Z7;H&7YD^!; ^FVC2Y:]6;8NE'MOKU
M,W+<P;Q*TUH[PZYAZA:NA3(6W]T>'+Q,"D:_UX!DL-Y_9DJ&"$'V/:%N!$</
M2'Z7X38@?@\7Y'H=I)IPLRQ +F]]1)'P@.;MT8#-''N)>\J;+<<3^NBK3?1U
M4?0=F\N#KV@N_39;+&(P6J68R_CU.%AEF_/D9U2EC>9A*1U' V&5-LM"X#^
M98&MIR7Z SQ+%$J-&Q<2\GDF^X@6P(=Q\(2_KHU9A#C]7DN([\.Y+E._.7G]
M4GO("^S,7*&6\*3KB5UWG4J"W1L07_9R,^+W#I5#H?2X[$N\W]TO=FF?Y<VF
M[0H[DBU9R04F&EHFY;.>;QH#3('[4+^C4!H,ZH*I"Q@?-O'*-&"X=3_[8F$?
M3=X%T#W3"/@(-B6?IO"*/^EHW!<%<)3E5.53<@A9\G%S8*.;S*:BRM6<,#J;
MJ)#+_%%PP)G_D_+1^92)$V6M*OQ!Z.G_Q\'H%>SH<YR]I42C(,W#26#_( K'
M_+M$S<'C4^G%B;KUK6]#GB!^2;>A5\XK0Z/%PRE@M<KY?"1++YV?=/K87H[_
MU,$SJF:SAE\N##?7 (-AIW<X=#<!5N._6"S<7!)T_"5!UXK-L9/CSDGO^>%>
M)UZ.=3WOP!\:F(J7;UJ#UF)"DSJC?O7 XL=&<=FTH82JOKW;O::O]H9'I[_Y
MW^#O1Z?C2Y_OH'+C5Q_&%?1P&URV4. S[1'\^>VO,[Q)OM@"+TG)ZP=*:[</
M8?]$A\,^8(^!G6IS9G0YD92QMTM<>Q_:H#_1%M\B ;8;8O]#V.-"S0V%7V]J
MW/6PM/M%XI8[R+5)3ZXQL4OW!\2C<)0TI8V+S56R>3SLK:;P!!E7V^>G/'=;
M^.PM:?,;[FS][?'Y?P%02P,$%     @ 1D!94BL(0.J<!   %0\  !<   !A
M,C R,#$P+6ME>&AI8FET,S(Q+FAT;=5766_;.!!^WU\Q=;!M EBGC\1' KBR
M@AK-QH:M;-NG!2W1-E%*U%)4'.VOWR%EISG6V "+;E,_"):&<WP?9X;#X9OQ
M-(B^S$+8J)3#[.;]U22 AN4XGUJ!XXRC,7R(?KN"MNUZ$$F2%4PQD1'N..%U
M QH;I?*^XVRW6WO;LH5<.]'<T:;:#A>BH':BDL;%4'_!)R7)Q2_#-Y8%8Q&7
M*<T4Q)(211,H"Y:MX5-"BZ]@6;M5@<@KR=8;!;[K>_!)R*_LEM1RQ12G%WL[
M0Z=^'SK&R7 IDNIBF+!;8,EY@Y$E\9+37O>L3;OM3B\F)&XEIQU_V5OY/1)W
M__ P2 >7USJ%JC@];Z0LLS94^^^W??NTDZO!EB5JT_=<]]>&67HQ7(E,H3^)
M^O7?VLPS8XK>*8MPML[Z!E*C5MV+8\&%[!^YYC?0$FM%4L:K_KN(I;2 :[J%
MN4A)]JY9X#98!95L52\LV%\48\+PS.NV#OD4[7"6T3T$S]=!AW<;MF0*6K[M
M/8[X(7 BUXA=B1RUT.R#V&,DF\H?%'P0SJ/)Y20819/I-4PO83:?7 >3V>@*
MPL]A<!--?@_Q,ZX(YYC+\\7-Z#J": K>&=S8"SNP81$&1MEK==SF00)>"^#1
M D;CZ2P*QX_@[$'TW*YF(?H0PF(T?S^Z#A?6]/-5^ 5&0:0EONOZ+]WE[PZQ
M_8\0)QG$(LMHK/L*;)G:@-I0&&5923C,:2ZD K&"44H35E1%$R99;,.Q7O3V
MZ,SWW4$@TIQDE7GS!B> =BZ%3,%SK8^P$M(8K"B10+,$>\V8QC1=4OGVR.NZ
M@Y;7U.W%?62R]KNWB#Z;,",EA_<V?"P+A"JV30@VC*X@O*-QJ=@MA>EJQ6(J
M=;3:U"ZL)FRHI,L*4*38J@(E(*W@:R:VG"9KVH2\E$5)D'J4/,C4FI(Z2).N
M0 H@B<AUOWRH\VBESHE=  LBER2CA36]X[2"46R(U#G11#E!>)VSP4O2HXL[
MF9,DP19M<;I2??_TA^7+L7<"$8+;9<:JY!RI1:HY0R?W^2/IGR635)\-A4;]
MA,UC@FDBP>L<)R?W=.$^2CS>T$QX%V](MJ9[SKQ>JXUL]09 LN2G8\RO&6,9
MUD)*3)UAR2F"*Q/\:L#OZ21,(I^YI(5FKJG%A'- -72.!8F"'*DLFD9KQ3*2
MQ?H[&DS,:* 9TJM*7A,O<BJ-S^))7=C_QN-2*"72^@1Z';UJC"R8HH%+NI0E
MD56=3WZG64\H+TF-C@E?D26G>^E2R(1*"V%PDA>TO_\SP(Z7<U+U66:",4J#
MQ_3HJ>16=Y:8\-V194ZO6KP;6%HXOW7;>F91.*BH9.]X-\[89IQQ5/)<UCNS
M>^YAL6M[]S+'V*[M(X("-_F\T6KL%7;ET/?S._ >#Q6Z0IZ"J./__S?:@'U[
MU#X=+,RSWN&GS?]^HU\ ?+>[)G=SA"(X2V"/X76R\FP:,:S\%Q)^)IP'SO7O
M"!=SXP=A/9Y)AAT\QQ;^#/#)<\2.:4$/&MS!"]"#YO?D#I6+^A+9EY03[>_9
MK>I;Y9@6YWY3(4LLGU(=5CDTN1^\HNV>]8717%TO_@902P,$%     @ 1D!9
M4H4/$E6G!   1@\  !<   !A,C R,#$P+6ME>&AI8FET,S(R+FAT;=57;6_;
M-A#^OE]Q=; V :PWOR6QW0"N7UICF6W8ZKI^&BB1LHE*I$K1<;1?OR-EIW&R
M8$&!KJT_")*/=[SGN1<>^R]&\V'X<3&&C<Y26+Q_<ST=0LWQO _-H>>-PA&\
M"W^_AI;K!Q J(@JNN10D];SQK :UC=9YU_-VNYV[:[I2K;UPZ1E3+2^5LF N
MU;1VU3?_X),1>O5+_X7CP$C&VXP)#;%B1#,*VX*+-7R@K/@$CK-?-91YJ?AZ
MHZ'A-P+X(-4G?D,JN>8Z95<'.WVO^NY[=I-^)&EYU:?\!CA]7>,MVO3]9D3/
MVRW68C2)&*-M%G4BVNY<))WXKP"=]'!YI5/H,F6O:QD7SH:9_;NMAGO>SG5O
MQZG>= /?_[5FEU[U$RDT[J=0OWJMS#PRIMFM=DC*UZ)K(=4JU8,XEJE4W1/?
M_GI&XB0DXVG9?17RC!4P8SM8RHR(5_4"P^ 43/&D6ECPOQGZA.[9SUWE\CG:
M2;E@!PA!PS@]OMWPB&MH-MS&L<?W@1.U1NQ:YJB%9N_Y'B/93'TGYX?C93B=
M3(>#<#J?P7P"B^5T-IPN!M<PF<X&^(IO\PFN&"\QEY>K]X-9".$<@@MX[Z[<
MH0NK\= J!\VV7W^2@!\%\& %@]%\$8Y'1W .("[]CF$A?#>&U6#Y9C ;KYSY
MG]?CCS 8AD;2\/UG1_F;0VS]*\2I@%@*P6+35V#']0;TAL% B"U)8<ERJ33(
M! 89H[PHBSI,1>S"J5GT\N2BT?![0YGE1)3V*^B= =J92)5!X#N_02*5-5@R
MHH )BKUFQ&*614R]/ DZ?J\9U$U[\8],5OL>+.*>=5C%4FMXZ\);+D0=QK<L
MWFI^P^ /'C-8*%9P:CH:$12&&\X2F'!!1,P1QCQ)<)$R.,PF>X?KL&&*126@
M2/.D!"TA*^&3D+N4T36K0[Y5Q9:@493<R^&*K,I]F\A "B!4YJ:3WM<Y6FFR
M9>_ BJB("%8X\]N4E3"(+<4F6^HH)PB\?=%[3N)T,,8YH12;MY.R1'<;Y]\M
MDTZ#,P@1W#YGDFV:(K5(=<IQD[O,4NSSEBMF3HW"H'[ YBG!!%(0M$_IV1U=
M&&J%!Q^:&=_&&R+6[,!9<-EL(5N7/1/WGXZQ1L48%U@E&;$5B,6H":ZD^*\%
M?Z"3<(5\YICGAKFZ$9,T!53#S3''49 CE47=:B5WN8\&J1T:;&7@JFU:$2]S
MINR>Q8.Z</^+QP@K46;5V?1C=+$1LF"+!B8L4ENBRBJ?&NUZ-;L\)S7:UGU-
MHI0=I)%4E"D'8:0D+UCW\-+#7IBGI.QR89VQ2KUC>LR\<F,Z2TS2_6%FS[5*
MO!]EFCC9=5IFFM$XPFAZV'@_Z+AVT/$T?2R[O' O_:?%OAO<R3QKN[*/" H,
M\NM:LW90V)=#MY'?0G \;I@*>0BB\O__#[0%^_*D==Y;V6<5X:-CX2[*ST"]
M#ZU-W!QQR)13. #X,2EY-*182KZ:@9\)Y-<<]]^0"\R:[T3$Z4)Q1)DCS$>
MSQXC]FQGNM?WGKPQW>N)#RY=N:QNG5W%4F)B\.@:]J6F;.?SOZB0" MKJY]6
M>6K4?_).MW]6-TQ[U[WZ!U!+ P04    " !&0%E2'6VCL,N7!  (EC  $0
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M:S*L4:'1B,\L;X>IB[VWE Y&_$LV\:@QL_<)M"[1EX)&00X^ E@552PY0D+
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M<"[+3<I&>D E0!8C' M\@J"UCZ)D::(MPJ!VN/@SI0]DNLMY65*4M99"A*(
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M]%RO63[H#D$+"^F5N]U&M7Q0KPHIY8';K _WWC0ZK:;3HZ, 4O@DYB5GD/G
MQKW2LD/Y@TZN#_\\BR^CF_!G.[?+7O5+VVM3Y[ARS76'H%6\6GG8=-OE@VJW
M+46UVNK4#_;>_"92D @743:6SW=0)/#/XG.PJT&P;Z>9_+>XK/G%[7A5T3@
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MBWQ3. OQ-:,8FGF\G,ZB&PQ6F!VB&!;'&, 9B2-8.ZX;/:#\C?DP4MI'])+
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M$E%[NBHH!RLQ=;-\ 'VP0^,^*1T"$H.GJS]!;Y8-=66'*\NO>)PZF&WL4PU
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MN:J%Q3/%R(7NF[R5B0<U&TCGK3'%Z?$0\GC,1?QL,>15P]3O?7%2?,5Y9_]
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MF9/7)>VZ4JJP"R9:1/6#N6^O!JCC<!<[P^X J45ZY=;8<Q=-']438;EX4W7
MUV'FD<2J4YQ\,O:30#DEA55-A4=Y?C*<QMSM>R1!T+MPPTPW(D 2'!5F+B^\
MZVL3DS %S"6["[[UJ1]JPHXEEC%;DZ*5K+=^0ONX=9)DJ?[/M^)@-*$"F"Z1
MV!0A72P2M.,[O+,S._235]GIZAH#I= =MH=R#M)$?T^FL59:6HWC\_5#Z+%6
MS2)-A3!!PT0%0G7-(?$6CPGRO#+<40<#!\<F%LC<"1\XON6TJ\@=$9SBZD#0
MD"C38!9>)?!'DCD$FT("O\2J IKCJ,H=32)JMX!^J^J;8ZK@R9#1[T9$FO/C
M#A"E*;2]Z8"HC>)G.[0ULL@PCXKPY)#%8(\=J]-) Z)_8,/<9N7F.@N%P6AG
M*[]368^4Y%_U;!U RGLWY7:XC=O*"[31?+F19)_HV&@>>HF&9+X^)%AR=URD
M&,?*(U;8) =_GX6Z?R /O//04?*3J^V3]Y<WF&>:)1QQYW:'%**P,&W*%POG
M=@AT:>"ZLJPX!,,.A_+,PC$<SUR*N.*\TRY1B2VHPEAHU?,+-3:*6\Q)+=S=
M\LG8V-0Q:=VI;(A.[Z30-K_07QOTEL&IZN^I/3:.6<K3%WH>=4E9L[%&X:G[
M3U3#!";VA44^O/O(KH'=TA+HCJ^Q0XSOW@W$NJ.9K#;!^F*6C]AX+K_,M@AG
MS&;)0KY16Q!%XQ$=%T$-04@ FR%?$86Z*2]+^<AZ58=SZ![4J(N;E%GW8GLJ
M=SU6]GE@@XGX7%^LEZ:-*!(%F)53R1]\)^QG(%-']9E9LJ;IUCH=)0M1<Q,&
M3RV[+5^;7HX.FOJI%BUD+.$RN-);K62]^-UQVE-P&K8#PQ9SNF/@1O!;I!:E
M"5M1*#*3,G%!O0<8*V25I\P6H1( [(CF'?XH09X[^"*?>L^L:>D[Y"]LR\,/
M!$O'S=A(6$S1+K3WTP$TI';F(4G-CQ=5Y$QGXPL-+"C7)6[]:3;EAIN< M*>
MUPK4Q!T*:JU=LLH(?LAU/YH"/E%8@>*G:LPL3<BC'AXSG/$944E*1C:IW:LN
M#Y&AU*$V9P4IJ"6WE>=9I U\@A)5"F!/<CC_.(\<V4*P2"C3+$C]&6<XBUJB
M6"8C,>I"\R9M$\H>-\"T0@ZIU8^2%T)BW$\XC*,\>]B-8$L3@.=+<0A[5TJ%
M.)QU'%HEZ:^LR!8Y%C./V]_JV%0AV#20G":N=6K-??_5?NW5?O_5O@__^N/X
M^)762@-V]^''&75+ZN%D,043TDVIL(2+<H',S#G9F69Y/*83_2SX3RF/QY%'
MAP3#_9.0K"CK>*T=.W9;%K(>*NB7ARA7+G))R!B+7VTV;X^52M*XM-D2C$,)
M534&TS0^+?0\Y4U!<<J]QW)," _G7FTKK(*^8%:#\DYF*6RP2(]'\0C5WHT;
MM3)(A7<B4<OG=%?"[8ES#E1=JI3O8G:'@1U+GI#J7<SP$=-+7JF90(;CE&;U
MT!((F.+?4F?:0N#GH3F53>'%AZ19MCKY>KHB5TF  "U]N)N0GS>SM,/<"SE,
M6U(5^Q\6D@\ZWEJR,XUB'$N-I?K$@0YS)>5%V>I(Y,KT:GYO9)35M]W:?-ZY
M'M/7QS?>:G(SKV([:RS4E-7I,971N6("CZ5I+G625 ]*P:A&4.R#3$8LP2X+
M^>4H'HM01\=*-*<=I+Q/^0VTG^*D@#; 1I09_,+.+%G,8"$/M*F;<0_FD7_+
M5H^=Y=D8LEO='KV/KX#CWM#[(7WRFX+I.(-Y@@V8C\-1++CG9G8_R:E0//JD
MFTJ$GZQ<76%RI0[P2@,$X:U1F4N/H/$FJ6QFXR&=<%RVY.09M4+W/GU# ^[4
M43Q[0C8\?1I1[W0,!BY#0 N TT><PRY:\!31@C[1@T/U +5G'(2Q]\896!8P
M&'&AGMCH!B))\@Z2&)KS$VJ,O[]WW#_<>V5!&%RJ8N1*<!PSSY:IGL!H%4 D
MA?R('ZO.SAF&('36/$=0[6N(*3QI*"F_R7.+T'F+4RP6T&NB'#N6&I Q#;?"
M80;@Q8+0>55Q?E,]?)D-"XW7A8'[WQJ3P;+6%4PX5=,*"'UH.-[P..@!*@JB
MY$ZFV5U+!/ %T$P';X1M=-@C=#+0PL!$"=FW?(%:,8,<#=Z5'0;E8H#*X()X
MS+9H:<(**V;H94CF??&'5DK! RG #69)JBS>@AU!?:WRH:/8-QD@M--"H+W"
M5"O5W0*<PBQFS%T>30#Z&%,/ =V76J?0]1Q!?O=4BFDARUWB =/HVW,'=)TS
M0SPF(KP25C'["&:D-\1_('V]RDOX!;CZ4]IJ214"B]DT7)!!I6C21*2]1G99
M8M?,,'U;O E#4C'?KH^,L#PXX MY2XV*4:]IQJN6=(HNRE)L78T!&:PO4+_3
MG:IUTHU3.ZP6S-AF!"TA[U&W8!I&P-$^5B-P8Y?FQM%PF+P!K'4VB80]T;G_
ML][@>& J@=15V-]$U;:81"*P/ST6JP4,C,[0C!Z*46@V08LL63,C2SC1C&S]
M5(Q&G%#2MH/'TZDYWR9QIDB$A!5S@1%"8K A.W5"PNNH2IK9,52!"-/*V+2#
M,5(,*XEV"O#9%:"6._E(C8W0AI]RN6LXE7J++!4F+*!]EZ84X/=<@2<76=P:
M@I-#U49Y2V1$!YM?%- '%-3.E2E'@PK#4A9;O&BLG:IC8D"9**;X&=U,/&/!
M(4NJ[(DQMLO=]:EE$45.K>@/.3E_9^2!8QFK'D71DKR>)_^558ST6I^4F1+
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M-UXSCQ,YQ6+*_;W^V>D>0U#.T<E-Z3OJ!W4M:!+/66_OU=;Q]_LUQULHP>8
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M-HG_]/(^WD2K?NR16)C;\ZWLMM\7DD;HS9T>C1?JY[\R N2BU[<$R+DR, ;
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MZ"<J8D=8O_]DX#8F=C$5_=NVE#0LI.)\-(X2W)CIVL)L(6D28V'U#/FY)"E
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M3_%G<SC3)'7HIQ*9@P6<8&U-D8)D_0![E2;Q(/IDOF!T_F,Z A$6LX'W$4S
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M2$&QI>2!B5JN05/G/ N3?=)ZDI;<I3K7  $R#8-_4<4#/UKKG*4<V''"^IG
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ML5Q,<\^\,O(3YZQF66UTKW0@[0"9XS=P'*<X$)$R)N@<H583Y&S5%5I.$8+
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M8Y;R@N8+;+=^]DG8_X>Z3;L)/7^-=:JU^92A>1,I.D@6J+LD:5V#*>B<JN#
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MXKAF,<P4(F3])-H1,<D[X$,LF>)2KGVQ.0><H4 Q1R>WJ=&#$__>VTV,K\S
M6OQ"MB3PSE_V=@^W=\$HS#)TK?FI2 1R,?#Z#FI\.SM(HZ>W/ ?.EKLCM?T:
M' QC>K'[K^*IZ*E9TJ[?]^8O12ZOK7/K%YDE9+5C$7M$0R(<_*"E](*>)>P&
M;7>QX(Z6+P<M>"+RI<F?8%69ZBA8]P8IQPP4R8 #9UL-MG$LY"54+6($!@4/
MI1]<08#T_&!_*+:1U@3MC44 7X?^Z#GLCW(8%I LF#-LF%&S+=4Z@K+$"KQB
M])F,B5L1&&LKA[6&*,.YVX[V/:4?@=+CS'Q)A=I8^)#%'.8>%^5 RFJEHJXN
M!K[3YD/#(E^HHNJI]Z=3#VL/40U0 _I5DZ'(5+<B'\=7!?_3EA!ZU/':R@5L
MYQ9CG7J*_2F2E<@8N&!8-D,_3*[BO):J?Q:.W0,QUB^+<]+R(\&";%JA,]\B
M82A'K#E+3#4JTZ'V ZD%*_FS3?#:,+H67Y9&%&.(J]UR(*AZQ<(Q(3@K. .U
MY%0=MV$356E\P!=K#JJY&#@8I!$6\2D"A<T/JH*U/G8#W 8@&M^>^D^]1NMW
M:%<=V=LL6*URB"8C/2\N+,X%]9V.).,<,%'H;OC]NEA/(/53'7W<[C%D/> [
MM3^'W]42@ST2YP/KI+; 1<Y:;K1]?X5=SU>YL*L_#-\8EC8!R2F- 0T.]L":
M971N!X0L#01 W.6D8J'W6:N($RS428<-&]*]!'M0HA$=7)4-HCR3\NOI\+!T
MH%9_[(PP_1EXZ+UGE$&J.JQ+>+;.A>%BSO$8K"M,'_9D>031Y+OT/0$>[5S\
MJX _(HPS8 BZ)\0#GP3LZ2=,(.?A]S1X:%</;2,JPBM*N#BGQN$T2>,R[4_$
M0U.#VK1]Y6!;RWI2/)Z64#^BNHYG7ORMI\@C^G0:*73-&3T]'I@>Y%2,L?"/
M\OT$!!%7AC#CXJHR0)'H%IG#GBK?_I1TX9])/MY5S9@O:553"Y1,E<P1V#"[
M!3S+RB1$L'ZNE=[@GJC.9"K8-VSM<)EIS=DA:KLSVK1%C!M5<<;]V& ,4=\$
MY9ZH0 5[8Q@ZTTMMC-(2U+3MY?I J (T>FVQ*E9 G22UYEM;%B.!DO8TW.TO
MAUHQB,]9MN;<6S:A(CK(=YIQ5F1-3BCXWJ^XAK:]>6%&9T80G'0AUMU&61'G
MMKY:$C9+JJ\ERI!192-5SR\L?A U>8;)*M@4DTD3XE=H1&FD+]AY4[K*:Y(U
M/OCG?2:9KO)T[0!V@1@)NTWGA44%R.NRR"3#ZG7^>;S?GF70(OQV=(1 8Y+6
M'<Z_DM)#NGH#.6Z1V6L]++:UH]YCW,T+TP]S.3\\'"3&'\L<$X8ADC:W]E=Q
M^0K#BH3UYHPH$L71=8Q @E('2>6XN?8'NV,K>$&(8N4:D ?!];+YHQ&P<JFS
M0Z9QW912$4F'?EFY,&V1C@$1_*<IB+"I(H"+6&>\5)D-*IA2<O*>>@C8G>5Y
MM^B9>"8[YC-#)Q)SFU2KF]:7HHZ5JN!P>+?4ZJ"2.@2B&D>_G+P]/5^$HE14
M<RZ?K!R:R#6V4"RT #>WVZ-'@I!:KM?;"F44EZ0D8R2\($#H3I0RQ1[43 K'
M);48T-'[IBR2(D.02;J(&FH&O+7/+- I&#]3[J;9CD[SZ*]--A<$UQ<$1O%B
MX#>@_0W>G11N#,L'R[S' MUYU-23HN0F).G7I+9!6#Z]&<LF\Z*AWG)&YJZE
M?8J!^H @V&()EH:.P23P>H:Y&<;Y9[ZL&:*5PVSR[Z:H]81@MIF0!H(ZD _'
M1R#E^;4H5[00A($4VK]5I T%89 !.(A9UV)0@6?5610(&5LI^IF%?!4HM)AP
M"A-OB5Q!ZEA]1'Q.,*I@GH:\3>UV59/6%C0",85BY(DA&+(3;+Q"Q(F10-<(
MRBA>R"]08-&P.8KD?(4/3:N) H[GP,E3 V345N1LI.CM\MEE]XW^Y!]_W(Y=
M(7=M><W+10>W2Z.QH/?ZC\'MH2> WV7!_[%OK?LJ&:OAP-B4_Q(E:04VGU$P
M>-12'>)IL("2I^.F&:A4>:$#](XQ4>E8(B3PB;T4"5U92G.[7E'5B@[,;&-D
MH@<%QFC![2X_:2=K([H2>)>W(X&L>%H]L_"MN;DL$-S5)&+GD$5%.%[4,T^D
M<J/D!]TRV)?2@T7'PW9$$L5*-8SQ.OKZ!8- NDNY'<LDMO+.M22Z#@NY]IY]
M:@@>N"I(@:=V= =L#BJ!8YH@$EU@N<6&E&^"KAFYF6#\?=PK(724[NE;@T&N
M>L4B?S!.JR!5N/#9=1DGIEKX>M)*NC'84"LH**BI4;GCGPZCI0J@P^65<&;0
M]\69*!E.*M$>)]*XW.C(5CH]GFXB(5B9$9KM-"W.#=[)YB)HX8I@9 NHYC@G
M.?&I];2;R&QAXQ,9HS97+(F[],SUT;-O&CVCWGWV-010T&NA-"4A-@#)^E#S
MPY(%B]AMT UI].\&CJ7!([D(WDCG42:!87<[SF, 4L;97/3U2 SEGHH/G# @
M@+$9AG_RQ$/+%5 0E?)%N2 S^]IC5WO\HJ\]_FY.C  C:=DQIR0X-S$.C0H9
M.GQ,M@@U6X+%<BD&U*3(>"@=NZR@R!!/@T!/T!2B\'S'.SBT1\/ >E'Y&&4Y
MW%_+BHL@B7$0H4^^9?U9"L_?J[@'IEN"8![%S!M')_B0&0,E2_ DF!K'M-;6
MJYYB#URAKH,C2HD8@N'HI<Q]1X\F&P:3=Q@_WA^FKI,X=3JD?_& <[\NQAJR
M"-\X15S1LF>#!S^XZ.@W/*W]LR$8RJK(<Y/UE'B< RF!>86>'#@D72E7H<E(
M:5XU9>SC^'+4>P&&%%$E&0NX)^C#NWUA3(5-5HZ0>5$5AV3 +KP4!4ATK2?;
M ]<B!XJ*2T*<:SXS=4JXMQ@N]2*O5(L2CW!68AOP21$%4=!*F!]^'K9@^'4]
M7@7$FZ@G_@-7$5(LAE W%V%A_'SB\>D_3MYM[;[JC^?#4DA1T(*IM$&ZQ(/Q
M@6/5D^=A$PFDQQ0<W '3D%635M$3S'U&'_CW3S#C9/$U3589'G*O%Q_E.<Y4
M/#<(ZX/U%A\PZ;Z[L_6WM03W\49(M5-\.%&=&=N5*/QZ=/'NZ._13XSU?,&E
MHA_Y^J=2V\+76&@3&L^F>;L!#2 .QCE\/3UXC04;&4'D\F35<6UR^)'!B0,J
M_@KJ\B>WD> 5J7:OB$*#IV7@M&;$,YI\F$+$2I>RB'4JJ*#N"HR:LE1KXI,'
MQ?BU!"06UEW&99()3FF8\_*6BV#HF@C%23%5M<4]Q%A[8*J%C1G21&I8[V6,
M@RW<5X$UGF6$W.RC^WLHX6+KMU?.(TI=-A86A*%*%TNA8;SXKK1NJ$I"WMQ4
M@X4:4F\@IDQ.(>AOQ&\ 8T2B:6[TU?^N:,)';H\E/(D!I#>AHIB0A!#3AXF+
M1AQ.8J-.#E?-ZC&5T 2#)%P2J\4NUE%;RF_;6H!VP:^(,Z.0^"F*QG&*T\YQ
M: -* _@M+4>CVK'B-U#P6@K1[$^2 A: =3\TJ/33?(:CVG'&@5Z! Q,* :2D
MU^NI#I;LY!!5!8TME#;R"W9%U(:>@1Q<36+"(ZUQRA1L*:)2TG.H8)\>JR@A
MK<H'^)V4-0V;N7LGE1?= #CL/F5BL,18/L35^+>AAG>VGVO7 #]+EMQ5C*#E
MB8(##H38^\$*!:]:.20HL8_=F@3(<)U?@TBQDXBUXM?W]))&8/+KAB?$^D^P
M60UW%Q"?RJ7T?&N\#0L3KVC*,!/7Y)<(@X='W#)8]\<R5_,DPO;J""]WA"=E
M$W#BL';J;8$40<9*2^.4!I5,PLYO(8P@QJ&#$<4RC%!+<PJ"AX.]PAV.=<(*
M)9^HYV#]P+VIM-B NAXS-C(!;VM3%.DVKF/%,CJNXOT/O)S;(7AKFAG^_?G.
M !:*_VN?L8#E4(@<ZI61NPB+\=%O)N:'4S,V)<\3H_-U _F8>_WU>#A=G52S
MHZJ\O@=M&7&G!-.&K<XEMUK_^ RQBC$CWT\%G4C9*6ZSCK^DYW9\ S5=N(X5
M$#E<Y4N+Q@P\"<:KHI;"9ZDSQ4=S@:I$9FF:N43.PX\*!E8/EJW#EP7^;K9H
M$:$%4)/@URPJ7 K+0X6 ,2J2N&0BS%T"P<-;04,$!'A9+SR9>XL#PRPQ4S8U
M$L.#@%C-8"X/^-5:KORMN?@,,IQ/SJ;;AP$/MS7E"&NG@WUDWF,'/IW.# X?
MBE0>K)]/@>I(^_*(1[P3P3P,)P<4.NSTI6P$^%7Y)8)..YXS,8$ILEV(?7 U
M90'X$9WZ1#T4X5;'I/Y5PC;KMZLZ",^?HB4]6S>H#^]?9*[Y_4%YZT[N#O+!
M)@G5%H@HTSX#4-$QN5M\?B.,>>1>1Y"WU:[R?P"7@3R?-C*<7NCD/Z@:^"^1
M>9/ZDJMX%//P,N0 ''C Q9IPL8ZCMO+$:[]RM['W0>_$VE6XK[B*LV?.M\V;
MJ8Q7<T\"HYA['*6F8U%XN?N[!%OL1D;R<$CY.QF<0'\U>#ONM>..O-TDVQ)6
M'3W%WXJQ7Y*LJ;A<"\2/E.4=AXKU)%"LN.:W<TR,/E,WUS'+P(&\"^,LD=LT
M]A"'ET48(J'BI@']T%-Y!? 5"VJ*07,_*\]TIB.MO<$=CT>1/"FPRA>]"FQ.
MP%HOQD>U3[4&/OJ9Z ZA&TI5-'(-\P(*5=_K! 4P39NIA@BZ_'1G7U-GA;02
M!$4\4CZ<&$R!F82[XSR\9V[<+<9IK2/W[F"U+14^745@>%^:_->3-'FU-TQ>
M["3/]W9V#@YV=E_NO-Q_=?@B?K7S\F#G<'3P/WM[3[R;;G[B=UO8]W*E"OL>
MIR/DY-/[C]'NV^TH^NW7\_<7I[_\X_V[Z.+3T8</T?'IQX_O?_UTL78>QZ_%
M+7W*&U?]!P_@X>(!?!3:[@%IS\Y/S]Z??SIYOWZT/*6&+3-JR)X :4_F>!5E
MQ2B6<9R_QM7D"DV%0?3)Y)@YHYG=((<SGN*,Y@FHE#GUWDGO%\Y7!3?QU8NH
MPM)V,#:,J=^T #LF)DZD\+UJO?1M7(.&/2^:2WCM+P7F7>,\OLUK7QX.7AT>
M^J^E$<@:)KL6(S!.P$JB,-@L'DD<AZS<A'1]L$Y0>..QOSHIB2I&8K"-I1 5
M-1SL#G=S4JGK)L163\*A@D47RW #?!=AJ0^2,4S(:I-&QU1J6GBFM:UK&=@!
MUU040YYQG&UQ7Q+]AU2:(B'\Q+D5'8Z=&1?'C^WT=,;Z -88XX)I*.L@&C:U
M&'V,E)!SI@-,'[I GO\1^S?%E)&'TZ<HU+SA+BH!.J#@Y<S9\"6L[MH-MN<P
MHTL=<-=O-<'Y9,@]RD_ZPOV]'5LMM"4A'I,$54#^E@PB$)/=-_".^A?3^G8/
M;MAA]-2[([BWFGM&2</_(Y^HMDP)!M\63A:/9Y5YK7]Y@SFG+)Z_3G-B/KKI
M37@^4&ABT '#X7(HZ'SPK\4>>/5J>^_Y*S0)ZA+^E^B+Q5K8)FOAQSI9_-VK
M[>>'NTM_N[-]W]\=[C^_UYTWK75W9_OEWJM^L=_[8G>W#W9?KLMBUVIGUVVQ
M^P>W>NR/)!59,H+L11G^7T_VGSA/C,H^7N_-OD2[H?V!E2!M\<N2]UN;)"^_
M9GF3RT<3LZT6DN^^X9-V\(.>W.K2CJ]GA;A*WX^SV5DG\X#V[WHKR+CYCG?@
M3$PX9HAC,.&^X\WH)4,O&7K)<#O)\!5[ '%O+\NBR9,M6>]H9,QX_$;\.,+:
MF=41@=Y%^C%WM"+@(7_VWBP$-6AOCK)X&$_C6W#'TGWX*MOL?<.]W(DZ=I02
MM(_#<=V[NB_%(^UM_98L11NQ<_MMZ$G[34B[N]N3=D-)2\"/>V^^$_H^L(9[
M3,+B4_Z*&'KS7L]]TXW=^T[.RO='V1<]93>4LJNMY>[LC(WI_];'WRH_8PEQ
M=2]%U/K6>S%UQWZM!]\>WI%CNQGC3Q4ZWS5][B=7>BKU5/I#5/KVNN%Q/95A
M&5>?[Q>/ZQE[DQA[(ZET5[>BI\]W=HKNFXQ9'_L__4^1/WJ^9?TX<_]^#NN:
MQAS6CS[W3(OT]%EIR;["5/KV2N&Q4Q3_+,K/O6*XZ\X=; Y+;R1]-D[P]%3Z
M,ZBTZ8'_8WC_N"CSM(_M_.DBOH\:]/3IZ;-"49T^Z/\UV__G>#JK)NFMFA9Z
M[OY#D:$5YNN-I$^O'5:;/H^N'38]YG\LF'ZCIN[#.WU<N:=/3Y]5E^XK3*4-
MB_L3S.)Q7!;PNSXM?.?]>[DYC+V1]+EG'T%/G^]%/6QZW/^=R>+KVX%1]'[I
M'VHNZ^,&/7UZ^JQ07*>/^M]$GM-)6O1*X<\.-ZPP.V\D??HNO=6FSZ,KA4T/
M]G^ MZ1)'\FYNV3O0SFK3:#G/7U6FCX;E(G9K!C_Z><LGA2/#[*W?BS=BYS5
MIL\&B9R-I$\?W?^3-_@G4Y27?4G_/23[71%2^T#! XOVGD"K3:!'C^3TX?T;
MC?[27!9YKQCZ:O[-HD^?@%EM^CRZ6MCT /])!C\KTOLA>'[7WF@/X;/:].FC
M.:M-GT>/YO1A_IO(<V;RO)IG5_%],1Z^:^;N"\57FSY[]YSUT!/H>]$.FQ[K
M/\F3-+YGC]9W[9+V-8&K39^[9ME[^JR#9%]A*FU6I/]\4B0F.JFR.$]ZY=#'
MDS>+/GV7UVK3Y]&5P\;'^XOK/IRS?MYH3Z4^XK_V]-FX4[19$?^+HNG!>_J8
M\N82J&_)6VWZ/+I^V/28_]_Z8;WKZ97V5.IC;VM/GXT[19L5^&?S_UW\N:C[
MK'#/W!M)I3[\O]KT>?13M.GA_[^9O&Y&G^=]=.?.UF5?TKG:!'KTZ$%/I>^1
M2IN5 _AD\MQ4E;D?P/-WS=D'=RT,76&FWD@"[?8$6G$"]9'_/VMK?RF:M.KK
M_>^S=:_ZF,%*TZ?OQUAM^CQZ3*</^]]L\7_I4\)])'G3Z+/;(R^M-H$>72UL
M>JC_8UQ5\6C25*:N>WB?/]VL[(,%#RS@[XKHV1/H@0FT0>70FQ7D_T=:7J8]
MK,]#6)4KS-,;2:!^Q,)JT^?1T[^;'NC_&,./^G!.'\[9+/H<]/19:?H\>C2G
M#_+?1)[?XVH"2ZU["/]>-6P:?39.]/14ZL/]]S'\R_F],=N^:Y_TK@4^?<S@
M8>G3Q]Q6FSZ/'M/IH_TWVOZFJJ,^Y'_OD'^/*K;:!.I#_JM-GT=7#QL?\D]'
MD_0R[D,[Z^>4]E3Z$]J">OKTIZB/_3O[/ZU&15ZEO7[H)<^&T:>O\5]M^CRZ
M9MCXH'^*< WW!6SKW=)-BEIN))7ZX-MJTV?C3M&&Q?YMW<\@>K=]O-VKB5X
M;19]-DX ]53J<P#W<02J"O]_-DO[,,^?70#4AQ%66P?W]%D'Z;["5+JC8M@[
MW'YQ*$MOT>I?356GX_DJ4>M34<?98RN)85$FIMP"??D:B5X569I$^.EKR/[[
M>W>%(KC3)JS*H?C.J+K[LJ?J!E+UGHV$?RY1-S]-455%4][/-?FN'>>^N'&U
MZ;-!&#<;29]'#SP]9'YB0>>K8_)MGG;_9WC:<Q^6DQ3-,#.A^NR7^,V72%;%
MCW4,5\&?27KUW_^'_L.'8%C^^-_V0.@OHS3YKR=I\FIOF+S829[O[>P<'.R
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MZ./1^=_>?XH^G)Y'Y^]_.KGX='[TZR>2TB_>7$3'IQ\_GOX:O?_[;R>?_CF
M*WXY^O3^773QZ?3X;S^?_O+N_3D\X-.G]^<7T=&O[Z*3BXO?X$=GOYT?_WQT
M\?XB.OT@]T87[X]_.S_Y='([N;1[0-K_,7;G8UQ^-J#!//6#"NKG(@.;I?K:
MXD5:O()7>9_S:I7$["EHT!&HWP+?7(P^1W49)_!X^'<],=&O1Q?OCOX>_905
M0U"R%R8SHSJ230%3SI1T%=Z#ZKB:3X=%1FI];^?-T<?W[[;I[Z#BC^"1X^B#
M&99-7,Z9X79?#:*]G;W= 3ZD--$U_@=D?EE\26&S33:/#EY*,?2$=QP?4IH1
MF(SXMZ*U^.WHTR2MHKR9#F%E<,'B74D!'Y>#;BG-K#05" _Z@GA4-_"![LZA
MR<TX':7PP^(ZEV>TWP=7C>*F,E$UB>%A$?PG&I?FWPT\%A8_,5D"EHON1U67
M!K8MCZ=&=V4XCRHS:DI0)7![8N(,WX0<5N"6L.V#Z^/EU+B(- =&2Y/&K>QZ
M4D23^,K0E>2\17417:&1!3])2UG><AVZ&F?M'7Z6@6\_*T#KS]?.8OG=,!60
MNQ(SRF#/@8YE-(O3!&@ZCT9Q-8D2^4HZ8@L,!9?CE41]Y3B/0Y SDH+>8+[,
M\"P"H6?QPJ.5;>!/X'&#%E0T;NJF--L1+!.>5S*+IJ \X9GPE-+4<<HKXBLC
M$Y.170VB=(RK&N!EXP8OAT<GYLIDQ0R-=EH6^';7]437/&RJ%"?N;4<?^&&P
M(6D%XK/RS7=\#JR>G@$WNO5?IUD&M\QP;<U,-@H^I<EJ/H@S4Y(TAL6-TSS.
MZ:#"DQ,RR@:P'[.TAA_A+N$/<0FS#(C+6VB&-6QK>96.X,# >4U+0]['((KA
MY09>#G]6S6@BE!B#?"CP9%:TDK=%S +H'=Q(OQG@.4]A<6 ,PL>FU0CVDU8R
M1>I@HQ(*2[ OS56<U]N@42)T;OD:?&;1U%4-B\-]@2,.*S0)[B!^=EVF(UH<
MK/T:A!5X1Z-T!A*2F$6? Y\KE ONQP7H,_A5\3#-TGK>S3MOT)7"OR<#$)_7
M0.42Y7-<XYOQ67B+H]33]!G^A#@,OYUXBMZ"VUK/V]S[-(4;@)^>[CX#-@9*
MC&,@*O(]O$G80'[F],L1$ <6%!W#B0(A>'0)@I28!@0;T(I.73$BKD[H+4.#
M>PX^9(/;&;.,K^&PX_.)KOH%^.;KH@%!S>S%JFA<%M-!]'3O&7YT8N!\PO[%
M)$]CV$1BR4MX CP<=BLBXR RX[&<R. - SGE.657X"$)N*RPJV S1\3$T=,8
M93_PL2%U<=,7P]Y5<#N0%5:21WO;._B^7?B#-G=_8<%Q!&9W.FVF498"01(D
M">S!7PYWX!=9A@:-_S5+OF'55<=94XXF<65(.+QGQKNPC+=VFN03B>XL*ZY)
M2M+ADE-9$7OXX9#K%,0N,*]5!W8OIF#)H8G1T+:(C=)EQB2P44C\>$0"'-\
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MH0>= #5W@1)1=S0AQV<\87ER6.W9@#^&,XX+>Y/D@JUYX<#T7SDP;QZ??7H
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M>$U[^\3UE6TUVN*B](>?/MRDWZD-;TB:<>D*Z8@('8 "X@;D)EI-M I/U<(
M92NDY)%'M[==>$SC [CUA?)4S>)]^6G.0!;[%,Z7'J#+V ,A E7W8 F7K%:F
M9U>3J5DOPZ+XWP.65UHMOS-H>9,1DY'S?UZ Z' O45+9C:;]OZ.&]==T]((!
M3:]Z5,9UJ]V?_MCE&F^[WYK^0!!4[7YQ'U1 N[?+]6(T%NW=;GFNO:M9M]J]
MWC-<+.V8Q9K%FL728ON;W;3?\#+TJ=WTLQL_->V?T+ [X^N.&1 Z!@AUNVN
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M8937<ZFE9;/@]8F I3Y8U66Q<H>JEP(#C/F=R,N)4"&NF/F"RY@*<?CTQ[W
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MR#%02=*QEG-H9@2N1\WL==92)- <1N#BL%DRJYS)6$QJY:.^T@Q#3M:8-QF
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M%$_B,,+Z 0!Q=19A6^UY2RH;8XHGHQC-U@&17SPJIP2(2A4#&CPP-C9BK67
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MNM.% =PZP*WIZ6JXT687]D)+(4-8AB/WR)$GWV?Z#Q5"^T6%T/ZD] W39[I
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MF;V<1M5E%GLR.O(0W/+2[NJ38I);Z#*%.DKF8#Q HPD#UUYVM3*U6$FS$>Z
M;F*F(G1:IV;F4NK36NPS/O%0":*U"XXF6(=H9/$)AK=K[&6S7EX*DE/FSB%-
M32;"]> ;GTSA;&UY"%N9O_!@&D84*@)#5(YQ(Q@ @X]I4T,A+H'L+O-(2T$!
MD!F-+4DMW<:\# <&TD6D)BT9B$CP*"-XC):A,JK)TH_(]XR$([QI9@I^T0-I
MWF+OT?B^>/'EZWO@GR'\0X>,1I$@(44!(Q%-U,^9PR^57S'#%2_&-RG*5HX6
M2K40#.?Q*>SF!YTC "!?@K.FP#[18*=S+D*K%X%"6T +S*P66L3-"K)!8*K
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M BT51U$H)5.4G+N$&PFZ2M%\2DR:)F&OL!^ 3I1,4Y)!2!8ULG+&).@"V%&
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M"2!E#%L+D#5X%"=3/0R."Q0@?@ =X$9PO;RXCL+,5KD'][$0>Z-RQ*Z2W;S
M\1,79N+.WXDGO9CH"%$$, OO0KD:WJKRM2J\T"H+Z;\2&7O#V?,!FT;<J(L[
M@?]_!(_8.R #E[T5CI@,1*1$=I.HOE%G-^%D"D3FLC@DNGW@"[O/*@F7=51
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M!+UA3/%[AN=CCS"6?"T'5+-'0 +D3-SB-A8)@(I[Y%;C-.,4@ZOC(FSSX[0
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M ?AF1^+ZY?8AY(Q2Y:"@(\7K*4<I2!M/44$LPOF8@#P.8(_,',]1BLT1?)P
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M/^";8U 6!F&AG$Z'5-&UP%9U[O" \^"7\3)"P#0-F.J]<+T!\2@!17D+D 1
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M-',[$)RP6"H!0U3+<58%SLAC(T3?<7T.%J6]QC2\2Z Y.F1*%RX+&B=HA_A
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MOZ=CJI350_.%).7;>7QP+!I?"J,#+==:3YQ22=RHNF2E,KV6TQ8HF[+Z5&0
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M_I"XCJNY?FQJCF-9IA=[D1]0Q]6)[NAQI-&O!Z@7Z(:I[^!TFF1$AOG_[*C
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M)^OHC\/K+]^.DJ/1AV_'?YQ^.][[;/_?S_WKX_/O^N'YOH'G@OU]]4S#=YS
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MB!>88(:[%O81"'R5:%& %0?4BTR#!HX%'-&FOFA=>\.V! ,[#OUE'%K%_/Q
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MT?G1Y9?SO_3#/XXN/Y\? 1P.]4-8Y\O>P/SRQ^EHKC+\_.*K9;B>H=M$U6D
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MT[T>'5XQW&5*EJAM*6J[LJ.R6"-=S@:"XAPP< 1;7 198N+:1A/+^6)=<WV
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M(X(8[AX,MSC:+DD;JHL&+OO*<)QY\.@0,FKMI*[F<]A6VKF^Q'OOJZ \WFI
M^:V?#.)\Z\Z[/*YO\_2TPG-R[,?YFT\F[6YQ#Q:,(^OM3Z.SINC_:IU/!AA7
M$:1\S%?Y:":\WSIV]/'1GH[B;\>CDWI'KV6E[SUC=N/=C>WP*%[F\:O&8*N-
M#HF_>@_/+YCS\M?-^/2C%\'(B[B%%W%E,6Y)/JEL695('@&M*>!,SF!DR#PX
M'TN..[OJB5Y5R>\&Z2#BGNZ\M3MPSSWC-L0]7X9[YC$:JZ0P3"IP;7\/6J?
M"ET@L&BDT-QK5[E'/G'7^XZ)>XA[NLP]]XRH$/=\$>Y9B)Y$P07/R4%$(=O\
MN 36I#;U0$HOE%.Q=3[(;OD]CV9!\4^SO^34\_6*_-M\'AV9]$9GT\G4#]N;
M>5SES9^DH/,;\X Y^4M3[9U;ZO#L-.3Q49FQU.1H;J^KC$7QWMLPUI7MQ%E&
M[CTV]ZA54+4><>\J@9G(>)+:*%=892S15S?TB-,NTRV"]SH3T@3O+PKON1A2
MW%7/0VMPJ6T=L\:"S:* MFB*89CM;%.1Z'/LTEY3@O?*X;W.;"S!^TO">W$*
MI%#1N!0KGFVN\&Y3('-24*+W(G#$(-4,WL;Q#L%[V^N@GPU.SIK.6'%&]K:M
MY?0:CTC4KB=O>MM#<G/CAS>]P\T\_A\N;WK!>Q1!7.I$O[*9#[72R<IJ ),T
M( I=E;D0$!*F$!CZG'++G*HM=->)?;::?;YTYI38YX[L,P\7%,E4PAQ!R6P
M66:->!"2]5I;;Y+4V/(7]Q_51NQ#[+-5N5-BG[NQST(TPY@LT<0$3H@$&$,
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M^<D_+YE[,)Q=P>R'_GGQ6A<$T8CIKW'?=H_.OWSQZ#OWQ##3GOZ+<^_B%U\
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M!AM9AFA-#"*;I+-9V0+495'1\9([(K='1FZ/>]?KII#;AX_D)A)F'[@#ZU,
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M#$7]GW(N*"W<;(*K#B)E4G7;H.I>_WBA[/9^8:X@1IF !:$ I9]5$R30.:G
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M&/*KE_"KWRS&,&,Q32@9,"Y;0*8U.)T\6(=91Z>E2/B1L*@68$N@WO'RRZ5
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MO<[:.\+TE\/T0J.0\[%H::$-0 *4]4- J: -4!;.N\ *[NR:OK77<P>$Z6W
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M/*>)2K2CE&DTW9--:>'SY,,%:RL(UFG[/U_D8%,#!RNQS3=^N_;];O5 ]8U
M]:73R_C+Q_C@]$3'DBL\M9G'&06PHHZ(1"8D3PJ9J8P;FM&METFQS8O^2+:G
MR]OW'$!8;DO4L_6#L_7E EM3)N.B !TD,3H#@Q]X6RJJ2!XSQ7,A#97WUY>H
MY^N-Y>L';C?6\_5#\_7!HKAV<9P:JQQ)C5"$4982X7)''*,Q,RS6L+.;R-=/
M/9+@+>AJX,]51.-"S2JXIJILM1V-K&]M[-N1R6!IFSZFL!%6QK('Y-=VVP[L
M]-!AWX3Z%],CUZV0:^$H=ZLRRYBT1!:T("S)8J)888GF2L94Y3:F?.ME*K"Y
MV%U"G[UG<W/Y^H>F*/5\?8]\/8]6* E(K M-DD(;PG+FB+0Z)<[Q/#,\YIG*
M\#"D;)OE?<3B:?+U#XU8]'Q]?WS=C6 DU*9,Y43!UF*7\H1(4Q1$JMSE3$N>
MQ7KKI=A.-X6KGWH$HVUG/*LLQBKJ<$7?RG@S#(Z;G[=P3;/"MC%;WZSP&W%L
MX=!WRH1@L(TDUXX!CBE-1&K![HC!SF!9GL0<SY7EQ39\NGO*9=^[]$D!PW<]
MB*4'AH<'ADYG8VJHL;$F&F >#!=."1<\!CO&:9:(-&-<@N&2I=MB36^F'AA^
M;F"X!Y.G!X8- H:.Y:/2-)6IT"3/BI2P@CNBK#&D$(6"#2ZHX S;&V\GXBX'
M-/6-C1^FL?';P4B.=-_8^$D,\JD;]8MIB8.JF@'M^M3$:CK6'Z/9!,20_6Q+
M/:@Z7X\G/LK8IREN0@"QF_> NW,8-N=-O6N]%_)VLGCA*-3,J<SE64S21&&N
M@[)$4IL2;:42UG C>(+EDC3=I#:,?0;31F<F]NS\?=EY;G/'W%+.54PTC;$1
M6N&(P!B#3(Q6>/9IEONC3_.D[V+^=-GYNX8+>W:^9W;NMD6+!5=,)<3DRA%F
MI"0\88)HW+28,\U2;(NV+;+[.@:H-XCO;E-,QY$]GPS'E];6WTSJ7FK^[)2?
M*RWQL1@5V(2E]^K=#JL6#C=-<E> I &$HCD>OI#G!!21E%A5%-IDJ;,\]:>N
M]PU8GS /_U!+HN?A;^+AN?E N5(TPY[GU ILH1P3)3)++.QA&ILD8]*;#PDO
M>AY^LCS\0\V'GH>_A8>[QZH8*GA>8!=EB38#F LBBW,\&(G10B@39V+K9;K-
M4K%!//S4XQ!'9[*$AUT,IF=G=FC01IC(RV@J/V.#Y5$$NT!\\F'WJ,6?*_RP
MZ05,[^U03JTY'A_+SW_@/HZ'N,)OQZ7?W%_!OC.O.KO7@]BM0.Q#UYA@3!H=
M9Y+06($B0N.8",XI2>*,6IDHFL8%]H/?9O>1(M#[,#>0Q7]$+5//X@_-XG-;
M(^-I)C5W1#L\_DW1A"B+[H/<49T9(:AD6/^09:L]47H.?PH<_B.JFGH.?V .
M[U@BP,9Q8@4C.5?8'Z70A-M"D!A()\\+ /A,^5;,Q5TJG!Y?X.)'\N<!VAEP
M53D>#C&%;P#\"(;)-#(#/-Y4S;[9[GBTGI%-LSO@'_,"DRY?=[;D> P[U]FX
MO7K?>GRZ%3XM'/@NI<[!T%"$YA2,#) ^1)I$$YJEH&XJE26IVWJ9;"?I78YT
MZ1V=F\O.W\/&Z-GY0=FY$[R@*J4Y*!D9Y8RPA.9$9DZ07'+.C5$)Z)K(SO&:
M &3/SD^!G;^'0=&S\T.R<_<@%P9:%G,I45I2PE@NB>#:$:&26,B<IEIRS\ZB
M[X_P ]*>U+@LQQ<P[@HXTM@R HH_CX;C;\QO>K0.CQ]G/"SWB?3(U(VG_MIN
MT0?<H6/8H-]A?WI0NA4H+1P/G_(L9XE1Q&BA,;\Z(UQ*2T#S$* Z\C31=!-;
M0_:^R\>7YM3S\T/Q\]QF2)Q-5<HY$6E< #\;2WC.#%%)&M,XLTPY@9W9LVV@
MO)Z?GRP_/W +YYZ5'XB5N_8"\&MAE2&Q20362A0@E3'DD"4&-I?G(+(W433_
M7-42*V9#:3^-AY\P%(&W^A[.I36#;SLAYM%Z.38L!+$V._-L7$X1J%Y;U3LV
M;@=4"R?)*R&8*5A.XA2/GZ/2$)D+3E)9&.R*E+$$PZ*<;:=WUSEZ=^7&,O(/
M*Y7H&?DNC#PW'IS.;2'2A,A$@/$ O$MX A8$8USG<6R5S?$<R3S=SGI&?L*,
M_,/J)7I&O@,C+X0:+&.YRXDJ$HN'24HBL]01ZM)4B5PY3C$1@/+[\ +T$8<;
M\^![.ZG3]OQQ+P]J.CQ:+\>FI2\U2#7?O$/7(]6W(]7"&?,QHXF0A20*! YA
M*J48%*6$2A K+,OR1/"MET5,U]H.?=KT4V#B[VDW]$Q\;TQ\V0DB*JX,34A,
MM2),VI1(S3@Q(D]3F[/42;0;XGBMNM$S\5-@XN]I,_1,?%],O'  ?:8=S0QQ
MN11@,]B$\*S@A">:P?>6*8WI231>:_P_Y?*&'QAI&(ST8"*'4==L&(Y'I\0G
M)XT5C$]^>V/71^O+> PFPN^P33TN?0,NP?B[%@(7"3,Q [W"4$>8+BCA+*'P
M266QXLXQJ@&7XFW8XLW(F^S=D4_$0.A9^"XLW$E**H2Q>/0TMQ0[J;&, -_"
MGZI(I+64<B>QZV.>LIZ#GR0'_RCKH.?@.W!PQSB(8Y;1/%4DL0:$<"S +D@9
M)855<5;D1<89<+!(MEG6%R]\%^Y#BIZW:M7C:MH?[O"#ZA266S(<NO9$F5>X
M+SWPW IX%@YCS(012:$,H=R""8#]5Y4$8T F@A:Q2 PO^OJ$Q\K"W]D&Z+GU
M8;BUH^C3/-:QQ!SE3! FM2"2<T442X35>2IEEFZ]Y&RUV6H?!'@*3/HC&B#U
M_'M'_CWH5@-:H73!B3#80$1@(6 <"Y*FUF22ILSERK=:I1O2I/#I1P#\P9V8
M&C0<6!<YF$HDS2=4^G\NE_^&>?Q] =1;6-CJO=5V\,D:3&!LMNN]WRW\>3?L
M50]*MP*ESCD,?^\F!Z<G*4!/PF)-,$J)00!0,0J3$*EC5>@BRV4:;[W,UR<8
M](G)3X6S[SD0L+:JL6?JAV/JRP6FM@6/X?^Q4UG&"*.I)++0%"N(,I50XRRS
M]V;;]UR]L5S]/6J5>ZY^,*X^6!35VK LT2HC!<?#T(&5"5<))YF4L<6*9D?Y
M)G+U4P\8O&N.;,.R@O$Y#. R'.;6APTV(VSP=@Q@U!RL=^A>C<_/QR-_A$P/
M2;>"I+V%@Q=$S'2N$Z(US0ACUA(E.".:T8)1D?$":QK[ ,)39^8'-AUZ9GXX
M9NYT1 4E,5-4D"S%-(3":<)-@H=""8HY"-RE?33PL3+SI@<:>I:^-Y;NEAVP
MQ#"K"\*Y G,A,YQP$0-?<^GR+(DSG6'9 4^V67R7-L=]T.$V5<H=6V&TT BX
M/5^ACS[\R*:HZR&I[]E\#^BTW[4>"FU-;*PA<:'!>M!&$= RP)@ 8#):"P&*
MXB8Z,WH7Y:.R'GJF?GBFGEL1@J<J9S0FL:":,&E2(@HK2*R53*D5/*%YS]2/
ME*F_LQ71\^]WXM^.R>"DTPF7@A0%GJ5JF2:2V8(8F7.;%@6H6G3K)<V3OA+A
M>W#<@9U&_J3G9[/*&C 0GD>3$%PSD;J,7).=%^$F?!I,!_9.E0IJ7!I;$ICN
M"]R1:CP<F*B9Y-/&JWLP+2J8+WRZA?L#MA=/AZGCI>;7RP^PRWNC-NERM]W5
M'M.^-<EI]T2*))9<(9+I@K T-D2D6H*UD2KGLL1*"IB6L&U1W$/R](UYZ!$Y
M/)\8+FQH>72/!@^?';5[4DC!;,I!I5%4XLEOCHBX$(1JDTB>TY1)M_4R38OM
M-%YM>O!M<8X>$S8>$[ZS;=/K"AN$#AW[Q]B84>JPL:O, !UXC&I"1F0*6J 6
MCJO"8)OF8IO=J:'"]P*&IQY/00/I&7!,:65EGX.!%#[!!V\W;0?KR?[?;/ )
M6 *[/,F1B=!+4 [T%*PH_/TN\9:?& 9_B,F$&(C_>S/?TO?M;N(/NR.S^$7G
MRG>P)F, S4 DKVNR>?-9#V>X3_#A3(Y.[7LYM6^<L[IW)=T.2C]TS2Z7IH(G
M8&QQYO$T9T3&H&UE*:4:!*7*K<*F=]O)G2K>;LN'C\A#_,2P94/-KAY1-AM1
M.J8;SXLTST ;DWB@)I."2"<RXD#%YIFU5N6@G!7Y=KK&/_UML:4>5C8>5C;>
M<NL!9J,!IAO],K#E"6@K:5R RN(TIJ04@O D8QGH+GFFDJV7>0XJRSUTT]L\
MX^^11<=>W=C"B^0T4O9T,!IAL&SLHHEGJ[X\YRJ<+$!'ES0URFK&\E3JF%,A
MDLQIJC(A3_9^K-K5@]RM0.[/A::_E*LX5HIHBN$PCBV%3,%)6I@LBPN= ]1M
MO13Y-A/]*<9/E\6+K(@+J0IIM&1.<%E835F6\D)IEA7&L_C=LOM[%O^N+#XW
ME&QA*,UD0>)$9819"H92800I\L0*IAC+-'JQX^TTO:\05\_B&\CBB2GB+$ND
MY8[EE(L,LZJ=T2Q/:)%SS^)%S^*/AL4[I@HUA3).6I((;?%<($>DYI(8:5)N
M4L6T8ELO>;Y-\U7O:G^ ^6:8)!:^OM(8>5@WSKI5^Y&P]C\/-_TG ^<Y:&S"
MT3C/&:/<<2.4S8M$)GGB3&P1SN]XR$H/Y]\/SO5"*P4GB[1 *TQC$S:9&-#8
M>$($=7%F$R>T Z.,TVV:K>8H/FW7=H^#/0[VSJDGC8-SRU7GG!;8K0YVKR L
M9X(('6>D4 FG*G<NU>R^G%,]#O8X^)AQL/?@/3$<[)CWP5-'$Y+:)"&,8?].
M73AB 1VUH87C6MV7!Z\/1]Z6=8NUK'LTFTR&%NM4Y3!Z/:CT<%S-P.I'$Q]9
M(WH['%]$>Z/ ?;!1+ZZ,/]Y@53K;16%#S'BFAG9EOZ[TC=Z'?_5G'N7/X,B*
M)A(@ ,CURLXT=ZYQ?_1JQY/4++[GN;Y-U?X[H+4#VZ<OW4YI^-AU(L59KF*:
M4L(3R@F+P7CB*=>D -N8QXEFNLBW7N;;:7Q?/J1'9![U4+0Y4]O03/ >BNX(
M19>=FOO8\3PUQ&6T(,S8@O ,]DBEK-!%;+A3=NNEV,Y3WD-1#T6/ HJ^9V/4
M'HKN!D4=5PIH/2[)F26Q-@:THJ(^Z4CC.:?:V+RP?.LEW<[2U1ZH_9$)W\N^
MU.-S&TWE9UMM1R,[19]):?%(M@K^&XX6N4-Q]5>L^B<(PK>?_U.!Z.]KN"+-
M'B/)]BC]#2A]O-NU71-0Z.,BS8B5-":,.D>4%9IDN'FY9()*M?4RB[>+],ZU
M?;?FCQ^<T-H#70]T/]0L[H'NKD WMXQ97KC,6$4R:BAA7%@B:&J)X0;6/]&.
M%O'6RU3<AS[: UT/=(\<Z+ZOT=T#W1V!KF-W)TK$PF24F-PDA&D;$U$H2G*:
M"ID76J<Z]6TWT^+./L#O!G3?*>S[?9CS]FD,!^,1":D,;>?ANN_<Y;<E,ZSF
MGBQMW-WB^S?MFG&G(3Z.4=Y3&L.WN9E^I+ Y&$]M-)&7$E=B4%4S&WQ.U=A-
M+V1IH^% VU&UVCG[AF@3YO93*R0W7(*GHI-\I\-+D7"K72#8<VN27A.YE2:R
M<$ZIT%SS/&:$4V;!Y"H,X8E3A(,^*1/G$H-]H^[W:,-;<<;C,+MZH/O9@.X[
M'>S: ]V=@&[N6\JL5%KB<4N&4ZPB9$1EO""I+G@2,QES=*+W0-<#70]T#W-:
M50]I]P%I'2]2;!-F\02J7"A#6)851#H6D\QEEKI<)U8D6R]9<L\NI(>%,V]U
M_W.*%BG\UPP^O?S_P3_-V#K/ L-T:LO[9I\DOHY_4N2?XS,;2:W'Y_#N2W3U
MC)"H(S2983!8$G!:RB&8UJ5/UYB>V<HB6_G*(8E]+NKSJ>"B:@I?^"/<=MH=
M69[W63.8G0S&-QE7 U\D4]JAG X^V5\N!F9ZUO!VY[YZK^+Y+5+!&&;3JV_9
ME"7.T\75Z/Z+PPUH(5)EBMCD8%,RACC$J<@*"3#%XDRS$PP8U3>=E<T4)O+4
M$E5:^1$8!F;X0@XOY&6U]<^%A3@?C)H190R&O#D+MN*<] NVN__F]=[1GT?;
MT=[!JYUH]^!U=/3AUZ.]UWN[[_?>'%U)6YLR_H/#XS='T?%A=/RO-]&KPX.C
MP]_W7N\>OWD=O=T[V#UXM;?[>W1T#%_LOSDXWOSIO+;:GBM;!JRER7:$#H]U
M-.W_"5^K$FAP968W)'6ZM?+$[SWI9">J58L#$._E0-^#=VA1>S@L3^5H\,47
M";YJ 17^V!V9=R7 [&CJ_SQT;QN$/6H!=NZR/X8Q_3H<ZX\_5NV@^ZW:\=^S
M@]_>?CPX_G4 ?) >_/V?S_M?WI\=_K&7'/S][^'AZ_=_'_[V@1W NT&%&-I_
MO;_\ZP\S42G+#_YX$__YQW^2_=_VLOWC/U.XYLO!;V^R/__^ .H*W//;/OOK
M&-YY?.;VX=G[Q_LG5 @#ZIPF+)66,"I3,(?BF"2IB9U2N7!Q$A3!P6AFS2Z:
MJ8Y;G60L5;G63%BKC*(%SV CE>..QUN1!65N@CQ8SBPP].[QA_=OHL.WT>&[
M-^]WC_> I[<[G U_>Y1Z]_[-$;!T^ *N7L_N"V2UQ"3P6SU4O_=A2Z\?[M+T
MC,DRP[%UAF!.QUPP)H \<Z-S+6B\B/KGLCP% 8'1A&S1SOE[5DT'[O('B<U=
MT*H'U64%4F"D=[8C&;T&)<$[\_6XG(S+L$+/IN-3"VI)&5T,IF?18%HMJB?5
M3%4#,Y#E +-.2^ML6<+7TW$$]]C!*))5A,9R&O_2OM'_G?S2?']AE[^9S:\9
ME\V7XUE9?_E\.QJ #A6=SX;3 ?%J47.D9XE:U!GFP9Y9.9R>;<,?U62@K6\?
M-K%E-1Z!*J5QFK!PG^"7*LQ,3N 1G\$8F=KA972EW3.:(58OF3ZQ+:CFRB8F
M!\B5%LC".*6=!$+*\R*YQIF=KK0,&(]0)(4M>#^H/KZS)7X!ZLC<$"+ISP9)
M7_:^G#B1YC33FNC42L)RRHA,<D&<%IERJ>2P\ELOBVS%E/G']BTW-:-):C-N
M@+\E$ZGE+@'DLXHEAG)GV36.NWY3;[JI]$1R#K)>65)HB><)<D7P&R*2+(D!
MBF%Q"]C4U7[Q__!L?;M]!5!G2B@I@%U9%@N1,,7R3$C+M2MR>XV?HM_7&^[K
M?GPB<V62(LM)9@PGC%M,2,XDH8D"C8[IQ&8Y[.MJ<\U_((P#X(- ^61!\,+Z
MEUB^$+ER?![M@QSQ"(XA: 145)D3X6D!MPSE4#6QF%0!6 X6CL^[6*]G;T<7
M-AI?C.#9>/L81(27:U?2%+[XI#88%@F+.F9X8:CC.F9%SJ51L1$B$YR!0"BR
M];T%]P[>+AS3?NA',!B=OH(7O?+OF7>!B7\R*D+'VHF-C2UB+8BB!D^42#D1
M<>Y(D<89)FS$5.-YZNEJ,ZN64HA&5Y(;P,9VE(.@!H2]K+XB'J[>\B)/N$DU
MJ(S6,9H[F=L$R"S5BMI$"MUO^3=L^2D],5*D#E":H'PE+%->(!1$&-ASEKM8
M2@U&)+_IE@<5L+O=7Q<<7V'RV$@G3&S!#F54*.7RE(LL+2BU<9*H?L=OO^/'
M("I0=Z-)DA*7<# V\XP1E4M*:*I=ECO*E#_I;E4%:)5Z$K:WN\=@?ERYQ=YL
MN)?NL)W-;4,77O$X=-ZC4.V-_C@;Z+,W8$1.+\/6VY]YN_^D)X(F-K>Q!A!7
M$@_0* BW!2.6,64*SE*A0(VGJWVY@A<\V&RPO6"91A]@2X'+PUI[OL9O7P]"
M2S7?.6H\A T9R)T5;\ #.J# 3M_5>CQ#U\'INW(\@H\ZN)?>@?FL+\._/[>#
MZ3\GG%JE0+R37.!IP50D!)1O15@<6VNTL#)QRQX8G9LTSP5E JP$^,"EDSJ1
M*LM J:=%L>Q@NL(?D[#O[)#Q3WPQF,+K] V<I.\M MGP,MHUXPF2^)R>HD6"
MNM+)O:G>I\-1]&\YFLGR,FH5<>3:5R%2%LG5&0-_CXPL315]F*#O*7JVM7OT
M8>LYJOPY22@H</4J?._=6S_%UJT<[8T BF9^HR(2O2I!0YE&OX^K"E[_['@,
MNDE$T_SY P__JX,%,PA%5.-&JZ+3V<# \(.-=6YE-2MQ$W08_# ,'N3I/#PY
MF,]R)SH$V\WO(<I<']@<5 C=?@<C,S 8"(W.Y">+?CS8S1(?8?WI>_A8M/VN
M#X-&-Z%[L4ET_SHL(Y*Z@SF"#?)_P 33X+?\"AL<?? F+DG232/S4/ 3^8J?
MAIH+%C\'2C\:G$^&L-;-C#O,C%35O7,3:-\.!^= 9:A$H.T@0;VPG[7U-(P=
M%(:>$*=C/Q?O+I9P5]W:KY3A! KLOQ#)(0AT[P\*VWENIV=C ],YO?37@^*G
M9T-O (1^#9&9TX7O$S@XKT^TF"LTI=7CT]&@X2C3NMKAA<.!5(,A_ :/PA>,
M9],*V#A2L@*^,P/@J]("-P/+'",GMMP-"NPXJL(^X<W2^TVJ.A?!IRYT=LR5
M<!/<WW:9L".)5X?S,[V^[4<C+RITW)>M0J:'L@PO6/-46+M1%=0[_%U.T7TS
M&T[Q<1*(P4[(;!+5RAX^/\P*AG@Z'IN+P7"(L[+S2<&/ 4D&G^R\]2(L*0Y%
MCD#L#-O5G9]HZ"/\K9<H2K+6083A 2O+X>4<TN#V\\$4Z.$ZJ!OC'(!4&G]4
M/?@+67D$;*&O)JN:\7UZ8?%+=9=4D$V%P&71GXA;B/Y78R#F@:YC4Z  O (%
M ,R%[<T"Q>AW/&&V>G"L_NH@9I4GZ^C<KYG%TW.F'4+T;!?@I &S!@E+/'>G
MK+EU!*-IR1G(5'GP&PX"%@+414,_60!+,+G\*Z?^1J^D 4,,$+2 :/U=8>MV
MP&C#8!WLG]\]> 0H%'5B5/UV__@:]+Z@FN!?TT+=93@0".=+QH[,X"<)SY@"
M5;P__! ^ VT@^W?&&$)]$3#=>71:6N0^A!S E@L[A$4YAU4]JS%W#,#ITP!L
M]-%>PC3:IL.15("P_IE^OF6)^%?K)+O&^%6%MUYN-^_U7HDA#"KL!'"_'?BH
MJFN+ !&V&[?0+WX!FQMJ<C<6APW;'/9E(@%_2@\Y]O,$JZ\61$0-N]T'=&SF
M%D"\HSV\%J!F)_K#1K"4IKG([_K_=O'4[RJ,'S6TK^XP)EW 3GH+9MM?WM45
MYVO90.%L$E"ND7>F4S;9DL3,D\T*6>+RXC-J]344IYE6_#1@/X'_E+BQ2P 4
MY,?"$UM%N+*?+*;H!8!'R>%=$1K555AV,_!JO1=;&N@(N:,&,&2#EL?\RMJA
M]6=7X?BW)E)_E*=^_=8]<GNK9D94)D">SBH<.$X23Z\&F@I;$*8$8D(/@=^#
MHG(*$T"*"@P#LQA-6R*H*7*9-'"5FETTL-*@A>MQ-0T$T:CK?OA^\$ BR'1
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MT]B_ZHRN<CP.7GTU!F[9#C65N@Q^CY%W8>!PZF=N(S&"/,:%!D8!!AK,O1]
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MZH=H*8+M4\>I41<$Q@'E00Z?^R6I_9QP<:3JQ?%NQX8<O)<$:6)]'D:PRP9
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M@"H3\EHK1+S&6_M;ZHQK75OX>/^9-:<A,#D,WYX-)FVQ0[/JO^_]>OC>&[.
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M.L,$W#93@41O)H-J#'\1G_QR!Y-MS5(]1<",';6FX,ZDJ6$FH9+&:5YD2<P
M0J7+>Y-MXP#SX%7'9!.&:<JH)47"!6%,Y41E+B=<Y$*P++86NTVM-K>X)5ZN
M!X['AI?W[7+K\6-@G77"I P3'9CO<)9S87F1*R!(9UQOL6TB?LPM-N6L-(4
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MH\!W<NK7;'[Q);H:YI)H:-%A"#OP3]0O_%N1[T#">]:KZ<S+'G0,RL_X6.N
M!*;/MYL1P<YX2IE.<8^KCR#)8'='8"=ZA\3D[++RN]M$4(!^JHFUP:GIOVG
MH(42E)V@'ED9K,2@7('B-)2CUF?2-?D\#7N$J2/%@=(PQG")]_DA#.1H)]I#
MH8I/"W(8]2G0X.!%\)4;VL\#$,3H9.U UPCD&\J]<CR2GP8E2'T@#V//06EZ
MMO7J\+][KTDB,-+]:O_(.V>1\C][0Q2YR UJIRD,?+Y),/CI#/<2U*G3X-XU
M=:2@<2Q/9C ]W9 !\&UY"JQQN1.][L!J/1)8N>5=;K8/!C)_;3"M+X.C6%D[
M@LVKIN7,.XP7U\I[D5H:@;L&-84HJV4=(O-$XM")9ORVSF!C_:.:96E<9S >
M^+TV[!O@#HYLC=@>,!WI%=4K[YP]#X$S>"8J0(.:8AO4P05H7N(];XW+VFO8
M2TLQGW^-A.WP KW5C-60[IP<O8^XD507(>4 AO#)KVJ@RNDU?+L<MT.1BI,8
MC&9^M]=]TX&K&B,RS"*:P#KZI!8/K< BOUP,S/2LR:3LW%6GN\7S6Z2JQL/9
M].I;.D"H?2+)#\+!/%]:K\Z_9^4\=^W4$@5\^Y%(!X-](8<7\K+:^N<BU@/0
M=Q=P<^9>K%<"]M^\WCOZ\V@[VCMXM1/M'KR.CC[\>K3W>F_W_=Z;HRMEVJ:,
M_P#TUJ/H^# Z_M<;X+&#H\/?]U[O'K]Y';W=.]@]>+6W^WMT= Q?[+\Y.-[\
MZ;P&082V2S"=:9ULM8X\ES@X&!A6"4%3'1OJ%+8A4ZD2W#&:Q8S%SJA@$L$]
MUNRB_R<S5+*$9@G#/N9)(CG<;U.A$ND<Q0R7]>])<N=2%2=,.M#B;<'3E&%N
MA!0B=R).EM_CDKAPML@XE2DK4B9C)7-%<PMV%W.QVWH4^M+NL),?T$B%QIRH
MDTDQ^<LGA445#!AC,5T%HG8.VPE@O]=8\;+1Z=!>$0+<]@Z7TJ?(U2+:V.'
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M%V'D[A-Z@L*2>IW/^_7LZ7@:6 7]EU5M$)R"8EH&-0/S1FZ4-G*_R2++F4Y
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M0=MA[87^2O-U7YSA&[CZ*#3LQ!7MF-KY!*P*5;(+)<6+2+?=5K7!:!8[!BT
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MC_U<KTQ#,3QC^FTK?:Q86''3^ FK_L:7W>;Q4F11!8Z=WCS2@0AY\X*OM&B
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MPF3@.S#)^ 0P%1B[=EQ$18]<W3-F[VK>&YW=C&AY++5#4$T#/A?>N=\[Z57
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M=]:&)AIT!JPM:W>P8:]OJ$J=;?]&]224:EN6S#HIJ:">FF1\0 PTKS55J=[
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MV#59:?'BM,N?#+/&-7Z_Y#YVG@5I7&:)E,DACG5")D%(*;$VQ!$7.:Y\K(=
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M4IS\6"@VT6TY<P@;SN/Z8!H+BDV#8LTQ%*.<&4<E1R'FXF4-L;\)\!W5)KE
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MTM7X+"%B[/7!)C+IX 0KY3UA?TCIQV#80^<D>V;GSU&XS&8V0"\&Q)_9W[R
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M=)XCH3\NQWV>%1@>*"UZ%G-8E--J[7[8;6U^??]M%^ZIWH#??X6_;8369N,
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M@#3(Y_[9WY;.?[OT^YM,5K/UK64/X$Z&*^=@T-B=!^A[9B%]4TV\S;-=\5W
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M7*%+OH&>;!2VS8:=]BE=X\).^X#%1#;!?\:246DP(A1V&^XB029IBFB0WHI
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MVVS?J]JWS/8CS#;;W-^3A#M!A$01_"W$C57(>$J1$%X[#F,?J,RS3:^?[3<
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M5DJYJ<7_#EJGA20^ ZEY7S[3')DAKTYH=GCC[(!%FSA-%D4I6 [8462U9P@
MGW@GB ">L+;1/^S&>)W0[ ZZ(QD)G=I)IU\L9Y80>W)>Z\9>'[[7;X%$91&"
M^>_WUJ_RDR&R7@N]U_&:7_WNL2$[S\90,X:3,FQ" 6@[FA=P(N*9;0,R%_GQ
M!0H#G+4ZH5?+P)ZU+'4[Q[6I)\@"CEH_T6$KA'CR]A5)ZL?S^K>#J)3120 ?
M\9$CKF)"5B6'%(M&6.RULGAMHW,R:@%:ZW=NA!GP"34#7)3"4)Z8M9*X(#1A
M,?H@DEB><?I4+G?&FU<',A_/P3(Y2;@$GH:,3SKWN";(:2F1H)Q&FL )L6EM
M(V6(N 9C_HS>#H#AG(%E >N20:8+4]LY :_J_-(BP8K'G['K6_!-,#7P=T;3
MWA06:*1VHRN!6/1:X /& /3IDG!E)<S?+JE5?N]-09%.[7FV=O#S7I'.E_O2
MG;7ZAQ.7+I^BN'[\Z=L#8)RE/I?7&EVAA,YIL"C,[Q@Q@,[EG]?*(95\^/)9
MS@Y;_A!^T>Z<%1 "-X6?3'TU33R"3?VA"4ZM;J]? U7),S:![7>?Y[GCN\]<
M_S&>Y_QHQ:@'[?;$-XI+#N>GN-BO)W>.><IML[HY)Q/L5"L,X,4/VQ[$VK>!
M!23NQ_C2;57!^$<3-!(W6\XPB,^-CGAD&@=-G!&)<QVMR^WK13!$1"M\^ 6"
M!GM>4?M?4WNXY^<#$RR-WE D@H[ [8U&-AF'HI.> D=SF(NU#2;5+'0"^S[O
ME?AT#%-XV#Z_PCZR4QD+<"AU9DHB"CR:0:&L+*!![9H-67X+[N_;&3=ZM=]R
MHA?%?S0_;;XK7I(_?A\AU6FW\P-TOU!H6[@7EU<::NWD%6V_T/J8^W5-P!C
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M=OI%7LMM T>+%+>Z7Z6'9PU<#TPU\J9V!5<+P=7G68*AG0H)?!Z4-*.Y2U]
M+B:) C?)8V(Q][E-A[E_GXY%U>$9U:][Q2K^P-RD4O'[^!";!UYBHCR-"#,K
M$ <41DXJC!0@L;("%%^E(M9Q;TKR6.H]Y"LSIQ)(R1V>8'MNI:_QV.3N*<#J
M_622XSTVA)?82?3!KE%% 3>/<R[IQ>4QT2KN]V1D?+(FQ:<\IMWTN1<W\V),
MKE)EOA<RW]]F&;K1#!.=$@K,8\2)H<@2&Y 2U&#!A.)$KVW0^^]65"' U57>
MI=/L2GD?0GG])/=F4G$EHD AYN+O1%EDA&=(IXA#B D':7)-Z55J&;,JT< G
MW&;,>9ZQ*#,QI)3M<2W-^T<#7S9,/2C'&*U,E0)Q%VCZ/LLKG$Y!48>13,(A
M;B)'+DB/<+)28TJTCBEO5M 5RH)XY;TIGAFOJ!1V28[ Y@%/(F(?')),4\2M
M4D@'+9'TG"=&I,).K9JRKDJP8@5V%M.5&-7]HQ6O>--A:32CJ*L\"5G5?L/"
M.+5]-FXIL4,;S?H!>#<"&R(1#7E/41*%7((_@FA"@Z6)<I<C%O<&JT4UX1F%
M,UZQ=B^-DU3:O52W8?/ <)AV!XX"UBGFEIF%RY"+NU''%8E*Z90C&DON@;#B
MFXG/8>.HVGQ:!HC],RH+LDP>][+!?.D1H=$:5(!^1[IV/DO7O$C6VD203%HA
M3JE%.@6!$@W:$<.HHWQM@U4;3"]93Y<>"*KT])YZ^G.R4Y\(-AAL&!+,<\03
M,<BYQ)'4QDBKI.$19Y=J68WZJKVD9>C?WF&GVT=%2>IE9I2_;"1: F.8*-K]
M]B)V.\'V#F?QJ5B;7*.[ J@[ M3%+)'01G.;A$$T$(<XLQ8Y'332'D<<?-1!
ML;6-7%V;T#]6*%!=[2JM.IFHE'6)K'_S@&D;-$D8*#YFB(>HD<7!(95TM$IH
MD1)>T=VD*N][%?.^5WCK[;XUH%Y,)^>'*N/R_%LYKR2'O::(;V7W%K-[9):D
M,J%#I#*A)/.)*$$5TEIHY(B.$FN%N:%K&YROL^6>B'H&/>]_P6\KI*R0<O5=
MA0HI[XB4>-)#L%[*% 1#0#)QKCN# 2 -@"9)C#L"?XT"E,1+*\WW]"AYBW;W
MJU7@OTAOF#XNW:MJ_$_5^-\^2-(;;PE# J85<9\HLH$K>,5=4@+\8.6?18W_
MS6$=_F[,W33*ACO]P[*_3]:%HL^%L^TBS[!W&&/9V:.3;BKV/^K1,=MJO>H"
M4'4!F!ELU07@AEKLFU<4K:K[7]7]?Z%U_U=OGW6VXONOB@+<.>_P17NIBSW\
MB_% E518F<2PE)PSG70P+DI%+)$D!1PGNT'?OG#1S)GJ%^*,GA[O;L$W_]KY
MN=_\3/)OZA>'K=TF/,'Q1]+XLL,:?VV?U[_LX,O?C)S1XWT8S_[9_M'[PT;S
M,_#XCQ=P?]$X\N=?MSZ3_2./P4G]N7_T\6*J7O/1/FE\.P">'C@+!L$Z1,2)
M5,@2S1'5(4G,C*74K6T8MLX?.O5XE=+7'O80P0N&LI>+9E8QYBVCP47/N:36
M8\V,(>#^,B>,S6BV>!FV"LWN@V;;DV<HA';@^1&*N,N9?)J(W/2"(RQXL,Q%
MK91<V]!\75>'*.ZV?S'QP'/BB*MRQ.(.HZR(_KM!MYL;  P;RLYK!+"<:AVO
M(N?[89COA^$"G \7JS(6"QF+C[/4UP=CL-<:14: ^E*CD'8$HPCO6LR#8X2M
M;3!<G<]XR;KZ,+RNTM5[Z>I4\7_")$LJ&J!SRB >=4ZJ=!(1R7%@S$EF^-H&
M54LC=M49C8>('4[PAS?P5J]7\].DHSJ_\:2LHM$Y\158W0&L/L\2"T.%2C(0
M) ('8F%H1$:3[(G**%-P@7*RMB&74%FT.JNQNNKZP,2B4M?[^P&;!Q)SZ9.5
MR%*:?0">D$E$("F#DEI81:)<VQ!R:5TZJOI?#]I9Z)=!BEL&]:I<VT>8H!<#
M]0_,S"J 7PC@]V?Y6' BDH =4CP"R%O*D>/:(Z829\9C$65<VS#+J_3^]#FW
MC[L/6J%EA98K0XPKM+RK][IYX CU*7", O<4Y=JX2'/MD(\F-^\FS&'P7#5;
M=B&ZEWDZ816SW1_RR,1D1<CJP,3T@8F= ^\5H98)4"9+$%<D(>M91,R00#"G
MPFA;(F7K9!##9BZSX@ K"89O)(>Y)397*O*8)"6\HIJ0V0,6#W:68:K.<GF*
MH77BVX,POD=Y\,#%=N=LO=:$-Z9K,X]31XM?=Z//FAUJ9ZW^(5SAM)M=N?YY
M<=OXWT'K-/=-?E,[B457>NO]X'C0+L8?XBG\NE5VJAK^/)^UN.$AYPUHPE6<
M.R)_=4N\W0'7MZ@ZU'&@R\4(>L6(YWXR/\Q]VR%?@:%I?Q8^',I*<;,IM!EJ
MO.  ":>=7BM_X6TWPO2U?L3AR8VAV9[XU1"$\?@GUL'H!OWK?S+O ,I3H)K&
M,[,S\?>P.PY>?(O(=:/]CFR"P;ZU[3-[WEO[U_09F]8)FIS U7GV*VGKY?FE
M^O;6SM[^WIO:3N/=>FVSL57;^_SGWL[6SN:GG>V]VYBD)QU_8[>YO5=K[M::
M_]ZNO=MM[.U^V-G:;&YOU=[O-#8;[W8V/]3VFO!&?;O17/W'&0%IR8=&:#I/
M/&<TN+20E@0;'-/$*,ZQ4TYYYX5PC$9J<22S%H(3)W40WGHC.=/!8AQP4I%(
M&ZD69FW1\V-S1_5+.U2=.ZO.G57GSJIS9]6YL^K<V=);#U>GSJI39X^^%W-#
M'\\_([C$<7/LDK[$QI[BZU8..6Z2^O&G]GYS'S>.ZF?[QW6\V_Q(&T7E%+CV
MEK\:?CQJ?Z]??+RH;WT^__K7/X>-HX^T?O%G:__BHVAL[;.B<LKQ>WCN*P?2
M:+$C'SC7',0X)9LW:QBRSA@D#.$Y]T\(SM8VQ,.WPGB&^S"O?9NEVD59?!>E
MPKE'P;FIHVI$.BYSE3R;>&XZ*#0RQD040F )L$_:9#/&/9L^7E6V\X26U.R$
MFKS*I.;?5HNO50BV# 2KSS(U\&:==<(B*VQ"G!&)M*(&<1P4\\1)&HOV-E?K
M??Y>)3B_!-5]! I2J>Z2G:S- U@A'CVV2&C/$!<YY=D;B8C@5!,O@A$L]QJ\
M>IKJ2=1V58)A3YKL?%T\K-@?7W)0K'(97ZK+^ A4JP+FA8#YXRRGH@1[C8E#
M8%MS+54ED L*(XJ#C"X1K[5<9CNR%Y:(7*'9ZT&S1V"?%9K=U4,$)%-4P@(
MB.6&]9SF<DR*!<0"O*D8E='$[!T^>%VY)<>XJFI,536FAT;!436FUDFO;]OM
MG E;Y*-,9IW"\\?9O-R[>0*OP#R^3 OX$'S^A1:N>2P3N#]+Z)V%9?8YT$*H
M1CP0AC0+#/@]3E(Q$K$*.=JB5JAVS2-Q]@IW5NG9GIAY5[AS+]R9.L4GL)$
M.PP9RT/>F D -]$CKUP*,A>UP'[5,*?:0?YP>81HL@CGG1C?"]^C6A6*].)*
M\#P66ODK27\RB@3&!(6@..)")&2MYD@GK")V0@A/<]_D>R?]5?O)JZNK#THK
M*EV]OT>S>< XT9%2BY36P"R$\\AA;A##3@M+G#)4+8595!O(#U$MZ]H#T%6M
MK*KZRTM@9!6V+X3MWV9YF%>4:&,P(C%*Q%,,2'L:$";$<!T3T58_P/9S52BK
M@LH**A^7$%=0>5>7=?/ !IFHPAB9H"SBU"FD0U%0$-Q5DIAFN6G:TO>V5Z9*
MUI7:,[>NQO'(3;SW!J>G[9CW3VW[G>T=OF]WSG9.4J=[7 Q\\R2 7Y@_V(3E
M^0%:\;[3K<I7S2E?]?$ 6($61CB@!KE1H'8$&9+Y0?#"<ZIB)/Q9]/N>E(F:
MA[6O)9"*6FLL%D5%)Q!)5'QJAZ)1*PHHQ5#K=XK:355#[ZJP2E589=%B%P"P
M1;6X_6B[O=KV22ZX5I59J<JLO((R*T^2298MV*F%-<M5',>V:;ITXS&8LD&W
ML(E%F<.K]1'!((Y/G;R]C?S=O=["G=(-;]OO;/DCK':NQYV>QG0J=3O'L]T9
M%@TSWW;7:^6T[O;1CWF/N-KQBT4.B-[)?;M]R>^_[7F1&OM"0AFG[<9%N[7?
M]'#M;_#]'9P_W]W:_EG_\@D^\P3^)^"]H\:[V8K?G]DN?+=Q <^Q]>EX_^A3
M]N,X^&\_O_[UF34N\O_:[1P6F3W(W=@\(-@PIX1!6B>'N/ ,V:@X\IAQ3J.*
M@=JU#:;GU*-XSB>Y*]QYJ;B3G,<T81FIY9P3Z02\C-A%G!155F?<(6:(.XNW
M&JAPYTZX,W4*W5+-O)4182L2XE)JY B.2"MO.4E<R'S0D8GJ&/JJL+QR%V$.
MRUM:1N+S[3?\I*1H<GOG[R[X=JU3VZXPZDX8]7&6&W$5 8QX#G8[@3BC FG)
M"'*:*FR]2I'1O"-^M774[6%J]8YN5.KZ<%RB4M<'<64V#[P)@13E;(*WB"<%
MKZ*T2'L9HU7,"Q_G)R<^B:JNVGGBE;[&:XC53G3(Z;B^A<^+ &W\Z0_MR;=8
M1'#+T.S$J9![Q6)7)>):Q55_$5>M#OL\";.>*0>R.]3*G9/MH4Z^[W1?>!?"
M1S+D?I9WLY@+@5N&@'M'Q+DGR'J@X9(SKP(&,^]-$9,4*W34H#H2M&2-7CKY
MKC3ZL31ZZMQ0T%308##H,#% S0U%VC&+6))$2A=R?V:@YD3>OP5S%?-[J+J3
MKS.TM^K\XR4G=S\65GV;91^."8&Y2$A$@"J.B4:&YEIFECA!A: R][PC2RO0
M7X7^5E"=GX1\5.J\5&=B\X [(K6F%#EK.:BRL4BG 'Z%E<Y* >Z%+XZT+:N?
M4!4:K$*#RP\-QC#P9168?F>RE78W]@;M(D14;,5VI[Y7!0NK8.'K"A8^\CY\
M#QX87DT=.?L003/C= QAK+[-#BAO8?U[GT:J^QXT=_(;Q4]VQUI;6?^%K/]V
M:?D+!K!#&T<?#Z+V00I)$0XA(DX$!C:?JY:H8),7B:;<;HNLD]5(-:JBB"NX
MAU^I^BJJ^ME8U8'I"X6]#AXI[\%I-Y8@+8E%R@++US8E0>Z]_U]%%ZOHXO.-
M+I8GG.%:/_MO+V*W$VSO< ZB375$&*%5!6</#V?GL\S%B8@]%A[Y:#7B5@=D
M/! 93Z5V!G/)>5C;^+__1U-"_UBA $85BUR]6&2E_*NM_#\GN0PAB3$M%"(F
MBMRDCR*3O$,B6 V('XE-;!45?[I.3&G)I^J[W+E*S"J6$MD<GJ<.K9YO=WJQ
M/&5]ISR^T9GLRS/:L!AEK9%\0-O;;O<\QW;*3_,A[>N#@.6UCSNAE6"=RJOG
M ]S=F+_?ZQ6)QNN+S^XCU^[Y4LQT#)L@</8;8-$Q3.7(S6K&[O'F2=B"B<\3
M\LGV8U6Q9ZIBS^<#QKD/03*D/2.(:Q&1C=*@Q,!/\B0ES,VSJ-@SDH2:+44!
M)'DH"T-9SU732QD/0X&H@4L>>X6J3=;J*;KH3)8;J671*WZ9S>9,,9^J;$]5
MMJ<JVU.VM[^B.56AGJI03U6H9VF^X*UL7.VW\UPVZ_>J $^U]WN/O=_[S<W*
MQE'F>B&+E!N?B)# 4/S;,.AF?;NY&,0OW13R3%V187U=VCCZ#O=XWVHT/:O3
M;;S?W&&[S8_G^Q>AO;OE<:.YP^O-?P[WK]37W:>[37B>+SLY1'*QW_QT6#_R
MHK'UGZ,&_<P;%Q])_>C;S\:7]T<SQ2&DQLP:'Y$P3"-.'$-&$X%,%"[!2FI5
M'/X8[^1<!A?N@HL/D*#T[-5FD=+3E=H\G=K4^_7S4FT:%YMGNQ\/DK):"ZD1
M"]0@;E(N58 #<L0X'[S$SN*L.N9&U:GV)A?:F[S?S#PO9'@ @SJYY5#APK)P
M8>+T%3%14D "0J5"/"J*C/0.*>(-=M2%D*;[0=[+G#Y JN>S5YH',*>5TBQ=
M:3[.&E,KN)(N.!2Q3(C;))!FA"(EN5-4L<"-R6<'R&V,:97-7V7S7Q/KF=JU
MJ)+TJT#-B\[<O3;MY620-Q>6TB^.+>1]3FXC_QV[?K)+***5[;R%[9PZ[N\H
MC5X;D%4*-),G3I&V,2(1+>;: /%)A1-Z->'^@0[[KYP)^)\'C515N''7YFD5
M;CPR;OA9SDVL"#81CY@,&'$<)=+.,F1X\(I')X!V3P6P7CEV5*&ZZAC!TU"J
M&R(0%3 N QC'A,JPF)PC"L48/.+*:*0%E\A0;RU-A%LKUS;$.GNL5. 5!\7J
M_,'*$JH*-1X2-;[-TBE!*2R^ML@0K!$7CB*78O;'B O8N)"2JI!CAD[=?(#A
M:OO;NV;/3_QN."3!8<RGG5XK7_AMT7&T]2,.DWR'6COQJV&*,![_Q+I>ISWH
M7_^3Z\Y</'92MR8S3&WB[V%W3#&_1>2ZT7Y'-L%@W]KVF3WOK?UK.AV[=8(F
M)W!UGOU*AF-Y;J2^O;6SM[_WIK;3>+=>VVQLU?8^_[FWL[6S^6EG>^\V1S.>
M=/R-W>;V7JVY6VO^>[OV;K>QM_MA9VNSN;U5>[_3V&R\V]G\4-MKPAOU[49S
M]1]GE-9<(M[H5, \\9S1_-(B<>*D#L);;R30Z6 Q#CBI2*2-5 MS\];@?8_)
M3%<*J]O^H O_K0[#3!V&V3]PUBJ2)$?!R]SC+"8$%C BRJ)E6E-)@GH6AV&&
M*YR[<LYOU7G=&9>7U:=:RW4JU%T.O$B^3L3M#GLL=(9$K&MN'N# B^0/<. %
M!BNN_WB9!UZN?O59'$(8[]05O.W#=&SIUP_YTN9C%&2[;C9>P[X]X"A9U!^Z
M];&<E]9A<N'G?Z:QDJNU&NX67KU:+G9>>:E+HC=J&+4UB VX<_,LMG_$.@SC
M\*447NA<['_99XV_MF$L^9K[N'[1.-K=VB'[1]_@W@T8Q^'A[M8_WQNMV9!)
MX_#KD<?[S;HHQG_T\0+NR>M'_[3@]V=U^I_ONW]M\\:7CQ2XXF2@E0D@W@%+
M! OH$=<T(&>)04(I[SF6C)+<EI(NK?+S(L?VGK(42X5S%<X]$,[-+7E=X=L2
M\>U\W"//1:><I(!ON1HVPQ89@1W2A'CC10S<TYP*?K7K[HK"VV/G%#X1[Z37
MNAZO+-?GZ>G6?K3=YEFG0J&%4&CJ?"=6C *KTLA+HA&GQ"*;!$=&)V>2H#(Y
M!F*_A%VIJBSORU?<7_&'2F'OJ+!CVF"YRTDF 5E&).)!"&2UE8ABK?+.!:>.
MKVW@.:5U7T_WKB=B!NQ.S. %)JVL"#,X[,980<U"4#-U6-5H98/U&%%O'>(Q
M1N14=( W$1O)P6_)9^Z(6I<K5/:RRC=;4=6]%3>H5/8N*CMF!U%JD;AB65LI
MXLER9&5,R L#2RBXIBQF=K!*W?)>2=R 5W&#56('[SN#;H4T"R'-QYGMF9@H
MYT@8I0%N+$5:1(%" L?$"N)E*OH(KY0C4@4.5D9S;ZJ!OPAEJ/3X+GH\9@Q2
MLFB]\TC(:'(VGD!&6((HP58E*0@7>&GE[:N8PJ*L050QA95B#:T?E7^R&-I\
MGF0-EB9KO,4H"9(;@V&"7*(*I<0L5SQ%GN3:AEPI_Z2***R,XBZ--%1J? <U
M'I,&8I4*G#D4B,J=O&U"#GN)L%>Y*"RC5*]D,ZS7$&IH'L9N+$YH50&'5:$.
MFWDY*N"Y$_!,E3,*VF )JX4 ?!CBCGID)?$H\ES:B,9()5W;X/??D:B"#B]1
M>Y?!'RI=OI<NCTD$)8:$*"DR"@.)($DA;8)%,O H<8PF*E]%'JXO\T/8NGBR
M2C_-3M^V04E']3)C&!Z /!UJROV+_]POC_V5(MS=^$D%8PO!V%1!("&BTHXK
MA$7$B,=$D8M:HIB"94I*S9A:VS#+RY)X+N=4*EU?J?R*2L<7U?'SB;+]4;$4
M/#(D E6AC"$M4JY;8$6@/DA8JUQ]_-Y[G=59C>7I8#9^;VL[QZ>#?M'V%VA[
M[/5?65#DMU5C'9\G*./V3P]?+5LW5_"T$#Q]FZ(@L-8V8H,<E0%QR>"5(P0E
MA5,NX&H(+-F&F,- ?J\"(I7F_H)#5!J[+(V=V$#QQ FJ04^3)8@[+9#62J&H
MN==<:>]-<8KC:EGV)]'8*N1Q&?*X4N9I?J#CE@QO6&>)P;J$SB!7;1H]1W6*
M?VD3M-HX_P0P?PTUJP!](4#_/G56QLA<9] @ZH1'G%&%='0!&4^HIH+Q8/7:
MAJ'K>+DNXA+TXWF4,ZF0LD+*%2'$%4XNBI-CXIN+.24,.(EM<(@'@Y&67B.6
M#(O6L>2QSI&T)0?+GQ F[UO&>KJU!U^_+/K9.@GQI/\6"3U!BJ^I;7USX>M2
MB UU0>$@*<:<8Z)S37FAK,&:8^'Y <&Y?N[,)1^[0+!>KSU0"=^1RF]%U\_E
M[]N=WJ"[0H5[OU^J>F/K&X/OXOVC *H.:GN\37=![?<O/H(ZMK]_/0*5;6ZR
MW7=7"O?B7-^^OO6IU:#[%U^//I[O-_=%_<M7N.9WOOOETS&H+*EO>3Y=N/>[
MV&WN'.AH@_2Y=KW%!G&O/'+$*F [VBC'?"#,ES@,@AS#9DZTH"8P$S@#S/5<
M*.FP(4PP'5SR43HS6^CWPV[C+]3<_E2O[?[Y8>>OS>;.;F/OVIZ>UU>"_O5]
MI\>I/=4X)B4\-EQ([T*0 4R'BSF[4;$'JQP]$KL]?QC#H!UW4Q; G9,>S$>Q
M=?-Z)?!;EKZ#8 T)B46DM16(<PE21X,">-$^4D4I+.I-Y:*OKY?\M-6C/W0
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M>.(IRL:.9G\8%GJ79[T1*PQ:#(.FNDHP;ZP(*J*D.,NU=A(R4ED4(U%$Q\3
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ME5Z.KUU!1P4=UT '32%H1I/2B7,E# X^6O (C$Q"ZSNPCFH3X"'18TP\1(S
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M$4_1(*.P1H[3_+81CM%KXHDK=8C@I5-?KYB76')"#2@F+ P3TM-HE":1IK3
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M+3/*$@2(R1'G!B-'G4+1*\X]+RV-,E_PUE[!I0'2*TI3S):BF*E5L0 #;%;
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M 7SG"D*36<QM4OB>2PN#_B3C_&)C5%N=UQ<MIE^QD];'=6OBW>DJSGSYS$V
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M+\:PZP]CF/1B'9>[Q,>N7/_U?.JD.S[=RT-_UL49/F_N U0($QA#P*PRI%B
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M?)"2K[VB4JWC^V\//+':I*9PLRG<7 I7[V8EF\+-IV(>9WC4N@)3(2G"FEO
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M$ >^%:Z/6$OC7(>MK3,S;EW+SW_QI+\5T8D"$ #C+'AB/!.!$X.QP)KI*Q
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M7-7S3!M7<8ZM)\:"45A%ZK$;'26>JGZV!^-,F#'_^>OA^'1G>+H78-QN>#"
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M\(G>X+3CO39B5P4L/DL^T<>R=PM\HI8%Y80CB#M8<U80 5B1"Q1 *#0E3N(
M]JY@ZXS>FWN^X9-8$=-PW8F[>]F'IOC\^=B(&29B'!.C-4F4$1!/<N60#J)
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M[:WFSA-"6+!0[(U;OZ3K:\-<FJ22@V1JP<"J3$LU4CU'M1<62A_2/\^;)/5
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MTLL2,4TJ5(F33$^4#.8JV8<-=SHQ_5("JN9H+]D.?(,QL?V@/0T1M)_H@@+
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M!'C4R%#ND0HAMRI7L0UC:HKWBU8;D<*N(P0&UM=*XE30.1<:J\+&!MY:^KS
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MQF N-0[! 4&/)'PFQ.6Z,-&=<8G#D,RG]/6^0/NR9V"]^+A<_C>8?N/@HP2
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MA6AXB(:':/@C2IS#1<-7T[;5T*9-,MD=+P0$3';U-=DI;YCL1@[MCASS-KN
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M39N$&<?S4 ;,J 5F4'6D&8HFG5N&JJIR>QTS=MA.>&(-28X+#=77</*)J?7
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MX&MR&/%=U-TDWSS!3S1QYK><0S?Z-$KSOO&&KSY^(&^3&O@NI2=[E![JBZA
M_0UU\+&6Q ,LS'YFQ&JY(P&:- 9-BBF#\_%AV*2P>W8^'AP&6HHM2>_NX:%4
M/F"I2$N<_^#VMD0V.%Z6N()?QW[Y8+-<\+H!^_"R#>J:IA>Y(3/[ 3CL 0YR
MI_G@D$E3#-10=E.@ANI1PQ]E:LW>]T$?E;DJAS%J%)N]4.K,#^-M6-"8-!J-
MJV=**4]]7]H^,4.O[#2?]>*7-]5&0_B%TO-/FZ"A@'IX/@^ 8,IN"@13/8*Y
M*5&3W0V'?YVL&K_[J]]"-Y>@R4&3@R;?H<EO/,=9H)ZW()F?3)65&BCR^BER
M\*W8T[?B6YG.!<-!O]3+D\MRG2N&W='XH3\H\P8%0*(1(/&6RFH(2'R+')OP
M7RQS)P^)#?<:I3=M*$P4M@KL"J@L0WX<QAVAV)+T[_OC+MQKE#+S4D%F<-LO
M$6*JE2T!" 9,(?F2F?@DP.Q2XSM[$_"E[*8-Q1>PA>QI"[DOU27DNGM_6:HU
MI"N@,O&IW[L>]@</_7LPAZR1%<$6&K@6F;/@<%9R%^@"[".Y58AM<\JBC-BO
MF)A3A]CAH>KG F, 8P!C[,<8%R6NR/V/7NGW+67&\O;OOZ]7C :\ %L%T$0^
M35SXD<EO6T;$_VF[X(%9>E, "0")JCAN]*^N[OM_E6VL*-5<<]F_^_$ 7J"
M$X 319PWR&3BDP7_U=H6\:(0O$&KT/07Y@Q0T2BH*'$IX@$,_NC>]A\>NNS0
M,>[>_.@/X:0.JA54ZR[5.O@;NR0,,?_=X%E$G"H>UE_E%Z]6:;@*:*0D@[>T
M(?36_SYZUH+^9QK.G"__#U!+ P04    " !&0%E2RZ=(B)@I   /SP$ $0
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MK.+->G-]#"W?MF0^ >;ZHW-JHD8X121M7GUH9N5O&9+R3MX(NK_X4_)$W)"
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M3?7^QA.2VW@<+(FW7;BV[Y/ 'Y&R-U&OT;68<SZV&IEK\F,E"AM1BHTT/B8
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MA8R0D^K_QA]LZ;:J(+5.(]SS,(II_:%UG;G<RJ-U2GT%<K_M]NWB] EA]7S
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MR:O&<F'S#;/+^S3T_DD\.G;);Y&?WKO7 V.97\VN&K;::B2Q7M6AJT?;92/
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M^R=\?6C(YI_X=7)]>?/>HOXT7M[^?5Y77IUMTU%17=U0 N:]+6<^]8>C\4P
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M6V638K/ \Q7L[UIZ?\;4;B+P*J%(?K_F6(B@-C+B\[6^?% L34ZHERB01(D
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MKG%@KJ%^5X_14K>EA(H+";;8<G0XFH!!F97)CT/_8Z'^Y<*F@(G&<X:13P:
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M2V+91. KGU5"@,V UA-("3^A\;-K"JRYSS /\/,_N8W,W__E_P-02P,$%
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M2J/F[E"TW6@F?Q*XGN)74'GKFY?96=G-:%2BBT8PMXEZVJ&!XZ,B00;<!G@
ME(NB1*2L;)#<<O]D8-7J1Q\G,3H0XPJM;GVGL9CZ99GPS>C+=,+3#?XDXGQ'
MA7SCR5N87#6I1Z/0X#Q:N5F@7Y4])<'21++F22E@P5!18\UI ^XXV5)-/2LX
MM/6UQ@+DV_ZP&4WC668Q*@O!E,7L97\\"VHISM.ZH)9?9J+K)4.]T(X32I/
MW5IRXAES1$"6CH&VR>L:/.MJ L?-Q8.H>05?M[Y"F2[!\]"KZT\^3L[S;S@A
M.,_Y/)]/KF!4-MP17)7LI,\PVYY[Y24R+$62'2LB,[A6)Y=(<IFE)&-BDK?:
MZ#8=^3C95%\)*RBS]?7&"K0/A70R'L-D?)YGWYLMRF?#SS"S_WHA,!UP>R>4
M9TID$540QA"7G>%&Q*1SNQO<W7!\-W2JJJ 5Y-KZAN(!]B9_@$_SB)<FKPD
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MHP,--5V*MT+:\9J+R3DXKRTD@WL?J(3@A(HDJ(Q>$P>C0HB)B5#GJOD15,?
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MTSH[R>*3UO_FPWX?I*FGB0Z+'4V1ONZ/QI-+U._XJADDI/@5"N33E_DR.?X
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M[. 9FDW9D@"&$Q9#UHE[&I9[N*\K9W+ON8<Z<:BNPJ8;47;M!]PQ)>9M/UN
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M6CJ""7'1A(L-!X?&&04@SCLT9%6P$=>>D)?;M75TS[$9SB.UI/:AM0H-/I^
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M;J7EG3VFVZBH[["DQ^]L.H>,PGMBC"MF,P@TT44F.ALA+17 Q=XK^?-[A.R
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M$:"*Y0Q<D."S)FB^&,NS<](VK-%^+<$=K1!K&]S11MU]Q_K\?>27GEY1P(9
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M%H^OHY(K[ 6/)7I04[*)7#4]OFV"G<;GZPK<3AYTU'H%DW^K?-QPXYQ(1&=
MLU3Q<GNI#8+'E#1:9<6K-!<\+AOV^'W'(D,;9?=M[MV,X#_N1@FMT(_P'<7Z
M\6;X'?X8WMZ6?" \%HO+LF:=6LO0L(%2>U8HM$Y+V0+F)8DFT0CEW:-A/D;[
ML4_]8G H:./C:;Q')W&1OH#2+>5],\PHTD+2W0Z, >T='I($0 <BH^;HP-!
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M<,&)#L#+21R)%RD1E;21- DJ7972KUOD>7;LZ0.7"E4OGHAU<S>;SOR\V=^
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MRS7C_K'.T'6I#NBX'AI;KZ*/__#XN/KM<5\@FXQ]K*?(UGI8>Y/4F4H EK2
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M&XAUZ/#D&+0TU(#IK_CT%74".,0F/USQ%3L!-!'C2CL!M$)@2Q'Y0]17L1,
MH]YHD)EHS4N%0^E)2((3\ *W%PX\QR;AZ^>!8J-. 'V V$9K53L!6,B"6X\F
MJX@XF:@9\;Z<"""Y<\D9)YI<M5Y2)X!6NM_:":"-XLZVG,/<-CA-#O_&H4^3
MR+]?"^OUY25G@H?((GCI=;"VU'/-RD;E+?A\2#;_1B%.GM)/C??HVEJB<T:#
MT?)(;#0&-[Q((0?PK$XOSF>7TB\X9!-<)CD[5+16B> 9(TG6G ?(.FMQJ3G*
MEQZ-W68-G#BEOPV++CJE7P6?C$&C2]A43E\EB)<ND.@" XH[L;ZT'*_GEM+?
MBJHG2^EOP[,+#GT>6)X=M[BI"2\$D66*GO-$&"2?8\I*KE_*G?MZ>F8I_>>Y
MG#JP[(+#C@>9@67H!Y*@$A2+01-;9NQ%E%9YX5SXE=+_:S4=D667&/+[L'H!
M6".B,^6B1A+TOM'Z-FB1@_..26],SA>60/?\4OK/<TUUX]IE!N N;=L43#;*
M1,(HYW@:JT"LT(;@[RMJF:5,7=BBNO*4_D2# JD<*C:E4KE%(&#@B%0LZ^1L
MCK1.0.YYZ>&"=LJ+N42JQL.+<HI;I"ADE9-BR9.H@1$9T/@**C#BC%4\^Z3T
MQ99@_95GU.\*.,/5W(J^%[6$VV9"YZR]<XD3DZD@D@*Z4T%)DK377 1M>9V^
MAF>C@5^+^3P7<TTB7_#=6H-,Z*3!AM+7S7J/_AO-Q(,,Q%AAO0-IJ+JPZK2_
M4OJO8D77)/(EWN\URX=V4K-H!8*7J2&2Y41"!'2<%!61XX8G\X55Z/B5TG_Y
M:[D:A2_S1G&_#DSDJ *6B7#E]I<E15SVFM!H)><\HC[.JS?,&:3TSY,Y7J0T
M7_'^%L^-/)Y\]:.XD':9&S#Y#+/Y%%Y\'=^-9H,DJ+!!.Z)<<>V8SL0B XGT
M6G&JA?!N[5IW2WY-VY$O:*_J=B]7'Y<:!GIOB2@9J*+<4@):H,J<8,1Q$7%'
M=C+:K"T+OWI6G\.U\4D0/\^Z$()9#3%%HE@Y@@&%=S098KQQ*H=$H4Y\TY75
MA6A%A)UU(=H <BDI]4WF]*LN1/NZ$*VX<HS<^D. OA02)Y&3+7UI,S"."YL;
MXJQ41!MM/'"#AU%ZWN1M51?B[+C;!M^Z=2'F&4\?8?)]&%>I>4YKZBP-Q.%1
M4MI^!.)SHL0&ZKBTUHOH&ODN^T8Z0U^E.IA[2@0<CL01:D<LA5OX5ZB&-9=K
ME=F)0E&A&(E,F5+P(I+@A49K.85H?$3]Q([TV2W!+UH= ;FMNU*_V;0W?_SQ
M]M,?K]]]^OCBW:N7-^\^O7WWM]?O7KY]_?&@#-D=G^LCZ[6IM&N9K,[3*,L/
M47@)N,J#BH$K'SUC.04V:"AW;[J=^QF'Y2#O_6A=/6^2?%W;&3AX(27E3AKN
MK8R9"^N 2I.9"KNT_70.O>G\G<?M8C;\#ETRP%M\OBX.NV>SADCV4B FB$"6
MY78E4)&=#5(%89C0;A<B3P;J9LW_/IY.7XY'LR%NW*,XA.G/6R!ODK,I6,*<
M8:7+&"_-^SRQP MQ6,BFRNW%=I&ZG>_SZ-QQ_H;:*R?4P )U ,H1IKPCDBHH
MP=>>1*MMPBDKSFFS<WOMR\<_CWM"\?&IVD5?%=)\'\_QQT*\FXQ&!"IMF#-.
M-<:HJ> $)Q500/R9*X%F6@*G-'"0X@B$W2#9Q1.B#@85+B=^1[U^GANC'V$V
M6USN+EY"YH8GI$_C^8O:>S^9_1AP%R7W.9,D0BG<7FKJE,MN:4$JK_#<;%1%
MJ#UAVDAY/>2IADV%AZLUIK^(<7+G;U_,7N+Q^P-_<_&^K!E0'E(F5!;13/;$
M43.OCI:%P3\1=5HS-9+N>HC3.Q85 I>63FZ)T?@=/OO;GQR?#CAP9P2ZLI(:
M*'ZF(=Y%2SRUV7!M(XM5&H3LD.EJR-&7WGL,@7E@/MUD)"F\1&E@,OTXODT#
M%U7T&NU(Y:PD4OI 0A"9,"-\H,E0SW0+J_/) !</;&_:>XJHZOE4^  1AM^+
MB_SR;C)!,0>26T&#"<1D)X@,(1+G2IZC$2)[0;/15;(;]PEV\:RH@L!3ANA.
M:_[E>/)MC-XYO$7&?IX,9S]>?)[ ?#/Z!).O XN;C^ X4Y&@Y+Y",8ZS(<",
M3-ZXX-;[1&Q9^WL&NGBT>]?F4Z1-)Z0_(3S3+[@CW>2WHS3\/DQHD4S?CE[Y
MF?]M CY^&4BC(,K$" .;2NQA(%Y:3H+."7TD0".6-P)[_UC7@7?/.GT*N>T$
M^7^"QP/I%7Q#]^1N @.7DT1K0A$G.,I27!4O''HIS#F1= Y@FN&[]N'K +.+
MMIXBYWHQQ7Z#$6HS#OT$YX@.IC7>9D&85)E($10)2E 2C=:4"THI;Q:QNO'S
MUX%B=\UMN./I]DR+)_[X.TQ^+&X.;O(-_N+;P@?XPR?X-/YX%Z;#A*+^& 2>
M>#(HGG"(G$0*$JMX($+AQ+VU*N?4".(6@UX'\+6TO($.W8([6@CZ=A1O[Q)J
MJ=@3>-3,!M9RHZ.3) 'SN"FI5(K;%UY;KQWU^?\O[UJ;V[J1[/?]%5O['1.\
M'U6[6\7(<J)96_)*\J9FOK#P:-BLD4@/2?DQOWX;?,@215*7)"XE,E-3B2(G
M%^>>TQ?H!AK=0?K:]O$$Q9_.8';388D%;;W9]SC4O/&]VQ'"O.V-QY!^_?'
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M/&F%T,3$NKEDY;H4)\&@"Q5#I#R$-N: YA"/R+]H29>*F^@K^HQ,4<YS2QM
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MFV>O\F\SS"\_W^GQN\[&>J1S2V\'W\?03Z5@72_]UW_TE 9T9S&,H!PD93F
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M1SZ6'R<I3D_P(B8F0Q $?)1$FAA)",H1D!8Y0;A F_45W6+P8[.*MOFO?:B
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M,@C+HV,ZMW/MY5@N'VSC -27IH4$O,=Y9TW _*DO'VRDUMHL]&VH;OWR ;#
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MD3H32Z'@"UNVA _VZ.:XVV98D_<QQE3R5##CV3G*>IIT >Z)<+#*[P&$% [
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M@U%0G>C-)77N?C3R?[."BP-_TR#.P+\ 4$L#!!0    ( $9 65(0N]K2!5T
M /5L   4    86UE9"TR,#(P,3(S,5]G,BYJ<&?LNW587-^V);HK:'!W"Q((
M[NX$"T&#.P&"NQ5:2(#@ 8($#^X$=W=W=PT.A3N/W^WW^KUS[^GN<V]WGW[]
M?;WJ&W_MM5>ML>:><\PY=]7SW/,:@/%!2E8* (% @.'+!WA>!"0 !#@X>#A8
M!'@X>$0$!$0D3&2DUZ^1<-$Q4# )<(D("7 )\(G):-\0D]*0XA-0,E/2T+UC
M8&0@HF#A8*%GIZ5GH/]K$1 "(B+2:R0<9&0<>A("$OI_]WAN S 108.O5&!
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M\D<E#.1;!P96)1GB;STOH;;HBF>F(?4K?H/7GH.-O;],CL3W?0\BX)0\0K$
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M-[RS7LJQ#?3PG@BX>_6OY'5@9D,(;6'&?9D9:QES1YS@& E$\9OB?)^>'+U
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MR^Z?1W&&>/*W$4K.[/-5 U-SZ!*[("NUOK.A&7V&"3RLZS&JV/KENQSVRJI
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M]]V'S73!"-UL$H4K[=F$?Z!PD>7F5YD[-%9X37584A-L-L6%63MSFG\R;*M
M>RO,T,"R@(M[XN0PY$?)LA.LD15484YW(BDI0_NA+ *)$:O$&SNHH@PTJ,@A
M4]/B+K6ZHZ3[.MF)Y/-;"59>E!AN'>PW%^TC]E)&-T4O19[!#8+X[].(+$N>
M!>\M'T>:#IWXX,.)SC<H0VS1;WGYB"L7Z@S@P3!ZTT]4J1)=/BB-$U7O#.MK
M(%1="CWO!"?F:=ZBJ5IC'BG7!O)N<H(NA&!]V140FAV@#PRG*3(%I*49N#I@
M@Z.P(;-(Q1/W77K?&]+3/T[EIU,?=9U:=KX\5#SXX("6^QU0N(\$)WI)Z-DG
M.( ,C]B)BB_0],"CRJLH+ M,0Y.3UA!(LCK[ ]4I^V([,$;)NACS64(PFUE!
M$:[^STR.8J PG%1<<!#CZT2CZS?63V91';[\J'(ZD\YA<,U3)T8UU:Y(%8U>
MQ8I4""U6[.1D8-N=#3JF2VR&@77\P=KH(-FV?F2_2T$UTQN#-5/-V2=,(9JO
M$#?O3&X1MN&/PB0W-$Y1"+LDE\] B(G@,[!9!3+6AD9&9' B0Y@ZJV[/NG-2
M:OEZ^!.G_2])'509A:G!GDHMW(-<W35C<H/N,*(A42?X/2)$5<+D-YPVO5^K
MWE3&]22C#U[<6JJ=2@?BU!N@F ^8$#ARWK38E0T. Z:6K=C.>NQ0PQ#YNSJX
MMS7-E8A;5_"R";2G61]N4C,,Y.P; H=S(]\ .^=J%38K39(<FV2752U8IPN(
M'6"(G#+F$+@BW/K.H5LA"3X*FR]*MER"=I7!.L!M-M(<9M1+#^K(P(2@Z8UU
M(FI!69VRH$OJ\>IX(-B*6H(FTB'P&%SV9DR8,H)%;=S.M.'T,NNQ@6"[:7(C
MM=0VBPDC^8CQ+)XBN]1Q=]X\F>!6]D[#X+0YOGI=3TXJE,%3L69^V#*6J2&=
M=DB\T1^:8L;;-\(_FR9]&MPCFZ-I$0&EYV.LNEVO\\<_O1 45" EJ+/?.B:D
M=550D.W/0"Y_D)PJ4Z&MF+;6,KW/'>W4CCB&=T@I,#ACD/6RRU_>P\>SWTVC
ML]J=M5SMS PS3?QS(A5;CMQ[?=":Z2OX<S32EKKZ[*(,7T_JS^.;XVH]_M$!
MPB=,+--((=='*PV-X-XTBLEC&_+..YN*8U3SR0-L*=7P\,$MQTV$8W]X;ZMQ
MN@QTNLH;EPV9$\[%GJK3[I+E9,8H^A#FIIE/WYWH;95$Y@T]M]2K5N"AZEDT
MB_LM[\H3CFBW%G-Y8Z9,4LME*@O$1H1D8*AG,\9%2>@?^)NCB\E.NMV&[L"O
MEB<0YV-3MGZ^#XSTK)%7M#D=Z9@OE9F^%%RNB]GJJKEZ\H3Y/KHMGAPIRR=<
M/?]R^\0-LLP"GE6)I3WOXMM:M]JG6RRXQW>0=7VP?.OLKNNLP>5U@]<SL&KR
M5UUAK'TCT(FG>4\>S)GLY7Q6_%G71TZ7YX&.!>49,(68/59L]I]Y1:S.-]@E
MU]HNW;::K#:2]S:ZNH^XEZED^E+5U/B/S##H\!K[K^!@=N/(X%(IL>**K@'P
M "[-WWOE.CP;D)O0Y=8P'!52[<WO.17*1U4K)RVIV8Y4M--V"*^53+@_K,>%
M XI:+T/+"RIF9C*>8F%Y&G>AF91UI833EX@'I+YEX TZ[P_K_(_\_=?_Q&[B
M_WB @C?1<>=O.#IC]F>A<KQHT9*P%+;QT@)J8H(HL5.G#&B04 ^;W#@+=[=L
M2Z@L4W9"+7?/\OMX>ZEV?0V4SG?Q!._J?F^+E1B0[<XV/ /^)U7+W)/RS4FF
MP**ES$?'4G<@JNYQ^K>H(>^QX/'L.DM(21,';HK;E8J<4[:>!7:WBP,54SCV
M!U)8Q:J?@M5PXC5CX"V0*-E09(54&3&"%%#TKH]J2MWG;]YEJ:L,<$Y.#'&F
M:4M1P>D6&:)X;[<C1,X5AJS?$_PHMO'PC>EB>E@S28F]OHN1?3"'40@=>>JL
M>@;2:I^!&];T9R LZQYM\LEC]1E8ZX \,?MRFA>?' HHWAY GH& UR^3&D1^
M'XG\*7D&GE!HGX&-W9<BZY^PA(6_^8+K5U9VRJ**:R &] ST*FZK0OYFF;VL
MSBM*]>]<N]$_&$06__3#\!*NCID\??'EW/W_!87_]A*)7R+,-.5 5$7\98X@
M(/T![.,B_3>+)'F)?#;50M;_B?NAZ+'%R]<A.O41#6&+[G\?,\8,DR"2J2/F
MQ(&$B\7];F+@E/_5';FMP8>F2A75![[MOE:WHQ1;Y*U3&.CKHD3.ZO]7-]\5
MU=3WK1L,BM)!Z46$ $J5CO1. E*E]RX0(/30I$IO A(4I"B]@R3T*H06"+T3
M(("@]":@HEQ^Y_Y?_O><<>_;N7?<A_6TQUAC[;F^;\YO[CWGA)^SE%[]Z+H&
M]+R^!EQ9/ISWSS^=O09< ^[<OP8<^Q(4JKX,LUT,&S._>4JO<PU 3_R)=;D&
MR,*N 4>V\M< .@5&T?^F39YG.^^OI;N\ WF5P^TG%!BXRJX!_[;KE,/1GZ0)
M46_4;O^.85KM]J.(G;NK@P5D4KS2_V:RU'^W.&#B4T/7OUO]?[%? 1GC_PM;
MD(R/LO11C9(0I:B2)TD]Y6";VI%D2UE<D62S3%.)H%*WN0,H_R]2 ]YUP[DX
MT5PJ5#6%B3BEB9J5<R>&.:T)6S0D(FX];$"1&0_/72!*,H::!!U&B3ZD7E'U
MJUH0G5*_KV#*G?Z(3S6*?O-N-_B]KK^<<2US-F#[/MIL_<J:,;20,S<_!ILJ
MNTGOV:^02GE:Y"VG&./V6'* NU$$)@,I"\CH9]RTHCU.S2B9=TY;,>N(7%Q6
M.J5]R[(WB,YZ3$",&3_A'<]1F5JUBC43O[GBIY$+U?;OI,GJ1>[P-DD'E6TS
MK#>(A=UR9MPJ%R\L6\+=:'XOZ+,HW>8(I[C[KWV39RQ#G=:B/F0#-D7SDR2D
MBK'OW:'X',P 8O8+] *5\/*$\2OPZJ.= \_'*.J31P,*\S51BL?+K=4Y4*F8
M'%CQI?NL4:Q!OIXB$M1I<JH7^3.X#MPKN0>6,<H<B+B2]JOJK= L*6MYK01(
M,0;G#('ZK#AM4EYX+9I"K(22B/VSUCJ JC/Y^E-NSXWYM]Q'3J14M\1_RC0O
M) RTA'/;,!PJ, OVA;&X,CZ8E4J-#E%D+>5?!,T&\1=101Z<?V\IS3,-=5I
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M@_'0[6F@LA^?-V=ONIE*FHG4_9;88752=>6$F<DSC"R=9N.4;YM?(Q*5I/Y
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M\"A*!$NP%I2'V.T)NGT8EV714L\?POJ$Y-ZFR6; Z=>V/B;[S]M?G?35[E
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M9Q-0J6G+(<>_>QDU&2[UW]LU^O_K*COPL&E (79.G->:HDG3,;S1X&E2A%T
M@"!="P!1M7/Y*W;46!O&@LA<MV3]=6#QT_]\[AC"L4;M6='W : S;H0#/- S
MI0WEF8!=Z87AES3/,HRFTD"MC7>[^ZL(B$ V1^I*7FD?=.]T_.,L:)3-YD0/
M*5S6?YLT_Y:M1TC"]U[^Q$66?8D,M+NMXQ),\^W=EX;:#!&E%;\V-.)%I'$
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M)ZXPCW=I0?0[5P+>,Z7B_H@^RRUJ4Y&W=A"G47BO9AMC<O70G!_P 15A^O0
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M2P<O3XB13ST+%',76#]54RP;]<@RDS8S-_=(YX^K:VM)EB#R-5[L?48,H#E
MZA*1K"=".R36U5+7C1L[6J<XIFK<N*"\_LWID^H.CAG#NB/=>[R91@,,]*->
M9DC6)\?6$7[FK_27S+MND/LZ98)/#E=:12?H^EF]4RU%<CP:NY%>F*IQ_NLQ
ML-=/A]AR$2HU6O(>_SL.M5&Y",'OJ\T.(5:P0QJTJIEJ@V\())V'F!+/W+^D
M4GT/J@I]-,=G/X&"K%R@@_P_DM8M@(]R_*B(?-B8U":+J')QQ^'@"Y['P.U#
MPN_7 .CT63Q2BWU'UFH5#?]LM6,WT^<TX-LS/G8!YC.X>YK;G=N^^0=HN+?'
M=_;-C$5NEL3D_:(:F.-N\;NO.< 6;M!%Y?_U*I/_8Q7*]<+_ %!+ P04
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M?D"?;A8?>L1NDIYLC+8FY]6RTD?;^K;@,J^*+"\S_CN=+^6,^"&+N<#0\ZB
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MVW*L81MX+7B#$;.V45U [=)T/4F>42U:%\AM&[I.VNP1YJA]Z%NS@B>A]-.
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M^Q0[(C##W(P;G",Y,%WLNHSZHY$2#%+,Q H@EZ1BUO&H/&.%Q3;UV+U\6C&
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MGSW)@BW&17:]RQ&P5: "6LOI#%DS_G6#UL#\NX)IS>&H2VRF)'7'P,?1<,G
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M35G*[$FNTMUI?V==5C[GV3QKRLVWI8L_Y+0^+V^>F3'F$\K4_BD.0S5%41A
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MI?R[I,7MM\4LH2%&)";0Y[Y0%,A3R'P=(XE)&'IQDB!I59K LO^I<>"6_Q&
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M50H:><%*8%W3[V8H'"T8WC&>([&ZZ??I*MN/!4H'2=RDG?&(VT*K#;*V>6^
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MCB2]#4ULZS <8ZP)?P:8O,OR7%_8,CJOT^R<7LI@A,]",BPQQ0(*CX80>41
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M0R2Q!PD.*,2IC!"+. D"H_-/H]ZFMEINRJOF6R,P*)7$?2HK'47;8(5SB>'
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MVHPV+T,?Y>Q.R:O>C(S4VJ4/ML/DX'62Z)W2\?J@=SHSK]=3S3BYR)=R8+[
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M2N7Y.*:A:M.4B#" R/4I)+X30-\)J4AXXF)J5JGY8(BI\4$I(:"5<)U.QX_
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MHQ61$(J ^1 AAT*<E/\441+1B,?$,/?^Y%A3(\5:5%#*"K:$!7\H<0V#RMI
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M!ID:=2D95:Q@(R7XXU/VC-.%H6MV%$\]ANJ+TL L=$EIMEJ4]/-=M?O#.2O
MCQ>&E_P\5L:$TP:&35(Y.LZHQ-&FZ3XYM%[;(:JX>EX5_/: ?U4%4?"\FLV9
MY[B4>%3 R'-#B%Q*(8G] %)/A(F@R$N0?E_[UJ&F2@9U%S*5F]D(;,@+&C"W
MLX-=\ ;FB%%Q,P@4MH;?6)ECIW&T%!>LA4AK2'#[$\:+!M;29"<06.^.CC'
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M0(\'"0T8IZZC%?)Q;J"I,9P2M=R 5,*"C;1=FM"UX:MQR&L)M8$)K 3L<GC
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MWXN<"<'+STK)6Z(%V 147%4A%I6C9.8AAH)8$!@$*-*6FX2$!RF4<2(#&?%
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M%W6@:<S,HS3F/(U@$$3:ZQKJEBX1@B(-$/%CWV/8*/_"<+RIL4TK[DX+ ]L
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M0I]"1Y@/T\[P5.'>J>NA(TP/-T=T-4"?DUY6NU6^J7]=R[9\5QMA& 8L2K"
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M!A&27/<L#B!29C4DV/>A^GRCF'DI8Y%5DR.30:?V:3<R@[708$OJ$R+GC2;
M"_5IH"^@1YGV"H4!Q%@@B$.6IDQ(Z5,^4U8[S=]K"K8''VX2_O>*%&JRYR];
MQL^(TV!FE[J&=F".=O!BVP>%6D#D--[39-QQ0SDMD'@5I6ES[PEGC76Y'S*_
MEI=U-=BBBOB\S2L#4B<$J#7ICOR:44HB74<'<AHJF@I]#BE6MI^/$)6>C$6
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MM'+[ZU'&+=1^4,M7==D/7]GO"[]:,!VM+3Z)^K]7BS:QKRGSWK:'T?GUD=K
M>2()H/1C"5$0,4@8#Z&0'$O/3R@51E4M^@P^-5:H3[;F^>(>JN$>[1UMO6;
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MPHA('WL)8Q@9M3,]-M#4J+"6%33"GH%*7%VPL178[$L_BF\W);I$;6AW<&_
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M3Y#X' 4>@S**$42QU.6T.8%^$'@\3D*.T]3X1,)BX*D9XEIT4,NN:PK#5GH
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M1R**<>*'5LT'N@:;VEYI7<UT6UCP>RMNS]JO;\)LMDJX F]@7N^-6^]2L%V
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M0>(1'GN(A>9)_I:#S^TK-.SN&_S)\]KNOH"L:_#GDLL[RN:/'_ZIRR(6(_8
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M#K@UC7A:"F'TN67-Y_9"E/$^/2TX+(105G*A>]S37>%;4]@FO&<[.R91TC'
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MO&[I_RW7:OL*$$S_N"N+]4K^MLX?Y*^N=$>"DM/B;J7SEW'3.5S]=J>5[9_
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MWA4/)%_I-5PU[+U;J2/DGYCDV%SD>).<HXMFE)Q=K]AN0D]521. M<4Y=_]
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MCM>:5-OC<JF'DS0.?9B*-%4&)(8ID_]B%!,AG7"!F5'!1J?1Y\9?6_G!C@)
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M2#(1IE$BK/89>\::V\K5BBJA!%MA@9+V2OWN;5'?G[/@K.$V"V(,!.+("]
M^%G'* R0&3(6T3?<I#$' [T/8PLFM[CF,=3Y79,RP>MZJ3FLB=%JVN+LMKBI
M[WGY#9?U\\+/0HR\+()1ED00A3R&.,4<"H9('$1AXIE59W4:?6Z<LQ6Y6<V;
MG8M"R0L>E<"VZ0TV,V&:X# 2OJ.G.'1R@ZW@5^WN'KC>HJVE!]]ZT79(<G!
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MRY,R[U>W/'V92[9EZSE<4^FT5;ILYKMEH0)67;8G^Y]U<XIHD88DB9(L@VF
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MNJ[+G*R;7>>Z .^[66HG;HP#6 ,A/.1^]:4B3;JI/1!^ASO?0SWV D__7?%
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MU[W2"?C]7 7\7NO@T*'.JP$39>O*&A?^"1U;+?*-)@M0ZP*T,J"KS42>KN'
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MO\D!%6!3B"IA>[O65^D'=C^67.IVB_FV.B?3#],7B,H"_8\2R*J0;$96H%0
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M?H-RW3*0#'G6*1"@120&11*L5"1:+:C27(DZ(WV?4=+Q#>O^VMT^MV$'4?<
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M*(V:5^DLWCHGW;>Y[Q7XZZ&@^_X,RT3H+2X\1N&N^^X-M$-GSD=%@@QX:/$
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MB8DC7T) <5U*PSA#)5!0VE6I(&I&7M]&N1P(D7MKJJ<(7)\$9_['\AC(R("
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M,&RDVAF9=)V.+XVHZQ9N^X/@J>UJ72.]AQF_:Y:09& A$&9S&78B%7$V1J+
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MA*"SKB.4C0H:O1!-YG\^0=.P-73-W(Z^M#!>0&W:67CK?6U6KT5M8F%\G9F
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M/V'YCM2W"=9+B#8R@I4SF9PG[AD0!?2E%6A9<0YMDXL\VX+U)IF8 X99W'U
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M8O27Y=5J%H-0/)5$!I-*1"22Z12Y BS,HW-!$YU=0+3N=OK^TKT@=&_9G25
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M%Y<^,&:LQ/MM2P?E>/Q@V9Y0<ZB8=R=[C,GS<T#3AS^7-RFZEM4&T@)R\,3
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MWN><FW1E[;YMRUZB_7';EGWXW %2[C45"585G7P!43M%J!!,M>PC>",3G9K
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MFXKP#%R(UV%5N\Q]P9_Q,LPOCG4F'GS<V&[%T_L]@8.A&*;BN  AC2$;$&O
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M,>2H(?I,IEO@DB[>$*&4K+,P O/ H.OP-;M$SR%27K9G>0?ZZ<6FU))^>7/
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M%U?7$KJX6/Y9JQQF6@>C)-WYAN< BMDZ@29[,%(9D5@R43>)00S86W]O,>,
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MVVO;!&+L0-_?+8^^"9!62EZ]?_/V3@?XO^I?<>:]]5;0-<9C%L31H, S'8C
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M<')$?05KH#@W9,-K'DA(2EG,ZZW]GG#?'OU\3^'<-M*9MLJJOH5]>(5A]J]
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M5.2ULREFLHW*<XA&9F"%8S3*,0S-'(T7E^JWT4!OH-F%X9O#Q]_ 9X*7RV3
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M7(79M_M)Y4HD+D0$:WT= U/3<0J13U&[B$%*)G*S))86-M/[Q>PK@?0513:
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M:70Q,#$V+FAT;5!+ 0(4 Q0    ( $9 65*>89GKR 8  +,E   8
M      "  =91  !A,C R,#$P+6ME>&AI8FET,3 R-BYH=&U02P$"% ,4
M" !&0%E2-A+O'@T+  !UD0  %P              @ '46   83(P,C Q,"UK
M97AH:6)I=#(Q,2YH=&U02P$"% ,4    " !&0%E2U(>>S0($   A#   %P
M            @ $69   83(P,C Q,"UK97AH:6)I=#(S,2YH=&U02P$"% ,4
M    " !&0%E24Q^S'JH'  "$'@  %P              @ %-:   83(P,C Q
M,"UK97AH:6)I=#,Q,2YH=&U02P$"% ,4    " !&0%E2YY!;?KP'  "8'@
M%P              @ $L<   83(P,C Q,"UK97AH:6)I=#,Q,BYH=&U02P$"
M% ,4    " !&0%E2*PA ZIP$   5#P  %P              @ $=>   83(P
M,C Q,"UK97AH:6)I=#,R,2YH=&U02P$"% ,4    " !&0%E2A0\25:<$  !&
M#P  %P              @ 'N?   83(P,C Q,"UK97AH:6)I=#,R,BYH=&U0
M2P$"% ,4    " !&0%E2'6VCL,N7!  (EC  $0              @ '*@0
M86UE9"TR,#(P,3(S,2YH=&U02P$"% ,4    " !&0%E2RZ=(B)@I   /SP$
M$0              @ '$&04 86UE9"TR,#(P,3(S,2YX<V102P$"% ,4
M" !&0%E2PRM&"F(U  #G, ( %0              @ &+0P4 86UE9"TR,#(P
M,3(S,5]C86PN>&UL4$L! A0#%     @ 1D!94HOKT98MN@  #=4' !4
M         ( !('D% &%M960M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M $9 65)$_MD^(0L  "\,   4              "  8 S!@!A;65D+3(P,C Q
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( $9 65(0N]K2!5T  /5L   4
M      "  =,^!@!A;65D+3(P,C Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( $9
M65(7DH^*X=D! / S$P 5              "  0J<!@!A;65D+3(P,C Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " !&0%E2/OA4M'T; 0 %V@P %0
M    @ $>=@@ 86UE9"TR,#(P,3(S,5]P<F4N>&UL4$L%!@     0 !  . 0
' ,Z1"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
